"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03739671","Vitamin D Supplementation and Effects on Mood in Emergency Medicine Residents",,"Active, not recruiting","No Results Available","Seasonal Mood Disorder","Drug: Vitamin D","Effect of vitamin D on resident mood","Lakeland Health","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","14","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MMMC#1580","October 1, 2018","March 31, 2019","March 2021","November 14, 2018","null","November 14, 2018","Lakeland Regional Healthcare, Saint Joseph, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03739671"
2,"NCT03738943","Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults",,"Not yet recruiting","No Results Available","Receptor Blockade","Drug: Adenosine Triphosphate|Drug: Acetylcholine|Drug: Sodium Nitroprusside|Drug: Adenosine Diphosphate|Drug: Adenosine Monophosphate|Drug: Uridine Triphosphate|Drug: Adenosine|Drug: Vitamin B 6","Vascular Conductance","Colorado State University","All","18 Years to 30 Years   (Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","17-7430H","January 5, 2019","June 1, 2021","June 1, 2021","November 12, 2018","null","November 12, 2018","","","https://ClinicalTrials.gov/show/NCT03738943"
3,"NCT03738852","Mechanisms for Restoration of Hypoglycemia Awareness",,"Not yet recruiting","No Results Available","Type1 Diabetes Mellitus","Device: insulin pump closed loop|Drug: Insulin","Brain glucose levels","Yale University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Sherwin.10.29.2018","November 30, 2018","February 28, 2019","November 30, 2023","November 12, 2018","null","November 14, 2018","","","https://ClinicalTrials.gov/show/NCT03738852"
4,"NCT03738306","Mézières Method in People With Low Back Pain.",,"Not yet recruiting","No Results Available","Low Back Pain, Mechanical","Other: Mezieres Method|Other: Conventional Physiotherapy","Roland Morris Questionnaire|Owestry Disability Questionnaire|Posture|Trunk Range of movement","Universidad de la Sabana|Universidad Ramón Llull","All","19 Years to 64 Years   (Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","ENF-26-2018","February 2019","February 2020","February 2021","November 12, 2018","null","November 12, 2018","","","https://ClinicalTrials.gov/show/NCT03738306"
5,"NCT03738176","The Efficacy of Topical Sesame Oil Versus Topical Triamcinolone on Oral Lichen Planus and Salivary Level of Oxidative Stress Biomarker [MDA]","(MDA)","Not yet recruiting","No Results Available","Oral Lichen Planus","Drug: Sesame Oil|Drug: triamcinolone in orabase","pain intensit measure|reduction of clinical signs measure|Salivary level of oxidative stress biomarker (MDA)","Mona Taha Mohammed MD|Cairo University","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2:5:1","December 16, 2018","November 16, 2019","December 30, 2019","November 12, 2018","null","November 12, 2018","","","https://ClinicalTrials.gov/show/NCT03738176"
6,"NCT03738059","The Lowest Effective Dose of Dexmedetomidine in Attenuating the Hemodynamic Responses During Skull Pin Insertion in Patients Undergoing Elective Craniotomy",,"Recruiting","No Results Available","Skull Pin Insertion","Drug: Dexmedetomidine Injection [Precedex]|Other: normal saline 0.9%","arterial blood pressure change|heart rate change","Assiut University","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","17300238","November 15, 2018","March 2019","March 2019","November 12, 2018","null","November 14, 2018","Assiut governorate, Assiut, Egypt","","https://ClinicalTrials.gov/show/NCT03738059"
7,"NCT03736343","Impulsivity and Alcohol Response","IDEA","Not yet recruiting","No Results Available","Alcohol Use Disorder (AUD)|Subjective Response to Alcohol (SR)","Drug: Alcohol|Other: Placebo","Subjective Effects of Alcohol Scale|Perceived Impairment Scale|Facets of Impulsivity|Subjective Effects of Alcohol - Biphasic Alcohol Effects|Alcohol Reward","University of Florida|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","All","21 Years to 30 Years   (Adult)","Early Phase 1","20","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","IRB201801192 - N|1T32AA02587701A1","January 2019","April 2020","April 2020","November 9, 2018","null","November 9, 2018","UF Health, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT03736343"
8,"NCT03735095","Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer",,"Not yet recruiting","No Results Available","Locally Advanced Lung Carcinoma|Non-Small Cell Lung Carcinoma|Small Cell Lung Carcinoma|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8","Drug: Porfimer Sodium|Procedure: Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy","Incidence of adverse events that are >= grade 4 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 4.0|Tumor response rate|Progression-free survival (PFS) assessed using modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","6","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 279415|NCI-2018-01969|P30CA016056","November 15, 2018","October 1, 2019","November 15, 2020","November 8, 2018","null","November 14, 2018","Roswell Park Cancer Institute, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT03735095"
9,"NCT03734848","Bilateral Ultrasound Guided Pectoralis Nerve Block Induces Hemodynamic Stability With Reducing Systemic Stress Response for Off-pump Coronary Artery Bypass Graft",,"Completed","No Results Available","Analgesic Effects|Systemic Stress Response|Hemodynamic Stability","Drug: Bilateral Ultrasound Guided Pectoralis Nerve Block.","Changes in Heart rate.|changes in mean arterial blood pressure and cardiac indices.|changes in cardiac indices.|changes in Plasma levels of adrenocorticotropic hormone(ACTH) .|changes in Plasma levels of cortisol hormone|changes in sufentanil consumption","Tanta University","All","45 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","TantaS","January 2016","January 2018","November 2018","November 8, 2018","null","November 8, 2018","Ahmed Said Elgebaly, Tanta, Egypt","","https://ClinicalTrials.gov/show/NCT03734848"
10,"NCT03734653","Testosterone Therapy in Castration Resistant Prostate Cancer",,"Not yet recruiting","No Results Available","Prostate Cancer|Castration-Resistant Prostate Cancer","Drug: Transdermal Testosterone|Drug: Standard of Care, Enzalutamide","Feasibility of the Administration of Transdermal Testosterone Alternating with Enzalutamide|Safety of the Administration of Transdermal Testosterone Alternating with Enzalutamide|Prostate Specific Antigen (PSA) Response Rate|Time to Radiographic Progression|Time to PSA Progression|Maximum Decrease in PSA|Physical Function Change|Patient Activation|Reported Fatigue|Patient Mood and Depression Evaluation|Bone Health|Body Composition|Quality of Life Assessment|Change in Hormones|Self-Reported Physical Function|Energy Expenditure|Change in Max Repetition|Change in Spontaneous Physical Activity and Sedentary Time|PSA Response in this Cohort of Patients vs Historical Cohorts","University of Colorado, Denver|Cancer League of Colorado, Inc","Male","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-0821.cc","December 2018","August 2024","August 2025","November 8, 2018","null","November 12, 2018","University of Colorado Hospital, Aurora, Colorado, United States","","https://ClinicalTrials.gov/show/NCT03734653"
11,"NCT03731221","Pectoral Fascial Plane and Serratus Anterior Plane Blocks With Bupivacaine v. Liposomal Bupivacaine",,"Not yet recruiting","No Results Available","Video Assisted Thoracic Surgery","Drug: Bupi HCI and lipo bupi|Drug: Bupi HCI","Overall benefit of analgesia score","The Cleveland Clinic","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","192","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","18-981","November 5, 2018","December 2020","December 2020","November 6, 2018","null","November 6, 2018","","","https://ClinicalTrials.gov/show/NCT03731221"
12,"NCT03730649","Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure",,"Not yet recruiting","No Results Available","Skin Aging","Drug: Sulforaphane (broccoli sprout extract)|Radiation: UV or visible light","keratin 16 presence as determined by immunofluorescence assay|keratin 17 presence as determined by immunofluorescence assay|keratin 16 fold change as determined by Reverse Transcription Polymerase Chain Reaction (RT-PCR)|keratin 17 fold change as determined by RT-PCR|keratin expression changes as determined by RT-PCR","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00184806","December 2018","September 2024","September 2024","November 5, 2018","null","November 5, 2018","Cutaneous Translational Research Program, Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03730649"
13,"NCT03730064","Brain Imaging to Understand the Role of Inflammation in N-Acetyl Cysteine (NAC) Treatment of Bipolar Depression",,"Recruiting","No Results Available","Bipolar Disorder|Depression","Drug: N-acetyl cysteine (NAC)","Montgomery Asberg Depression Rating Scale","Martin Lan|New York State Psychiatric Institute","All","18 Years to 60 Years   (Adult)","Early Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","7580","November 1, 2018","November 1, 2019","November 1, 2019","November 5, 2018","null","November 5, 2018","Columbia University Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03730064"
14,"NCT03729310","Comparison of Two Steroid Nasal Implants Following Endoscopic Sinus Surgery for Chronic Rhinosinusitis",,"Not yet recruiting","No Results Available","Chronic Sinusitis|Rhinosinusitis","Device: Propel 'implant'|Drug: Triamcinolone|Device: Nasopore","Change from Pre-operative score in Patient's nasal endoscopy, as measured by Perioperative Sinus Endoscopy (POSE) Scores|Change from Pre-operative score in Patient's nasal endoscopy, as measured by the Lund-Kennedy Endoscopic Score.|Change from Pre-operative score in Patient's sinonasal quality of life, as measured by SNOT-22 (Sino-nasal outcome test)","Weill Medical College of Cornell University","All","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","1802018943","November 23, 2018","September 24, 2019","February 5, 2020","November 2, 2018","null","November 2, 2018","Teresa Valderrama, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03729310"
15,"NCT03728569","Skin Barrier Dysfunction and the Role of Skin Barrier Restoration",,"Recruiting","No Results Available","Cutaneous Inflammation","Other: Vanicream Moisturizing Skin Cream|Other: Vanicream Cleansing Soap","Change in skin hydration status in aged and young subjects","University of Michigan","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","45","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HUM00138533 / Derm 719","May 16, 2018","October 2019","October 2019","November 2, 2018","null","November 2, 2018","University of Michigan, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03728569"
16,"NCT03728322","iHSCs With the Gene Correction of HBB Intervent Subjests With β-thalassemia Mutations",,"Not yet recruiting","No Results Available","Thalassemia","Biological: iHSCs treatment group","Occurrence of treatment related adverse events as assessed by CTCAE v4.0","Allife Medical Science and Technology Co., Ltd.","All","2 Years to 60 Years   (Child, Adult)","Early Phase 1","12","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HBB HSC-01","January 2019","January 2020","January 2021","November 2, 2018","null","November 5, 2018","","","https://ClinicalTrials.gov/show/NCT03728322"
17,"NCT03728296","A Study of Autologous Induced Islet Body With Type 1 Diabetes",,"Not yet recruiting","No Results Available","Type 1 Diabetes","Biological: islet body","Occurrence of treatment related adverse events as assessed by CTCAE v4.0","Allife Medical Science and Technology Co., Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","20","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","islet body-01","January 2019","January 2020","January 2021","November 2, 2018","null","November 2, 2018","","","https://ClinicalTrials.gov/show/NCT03728296"
18,"NCT03727776","Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)",,"Not yet recruiting","No Results Available","Proliferative Vitreoretinopathy","Drug: Adrenocorticotropic Hormone","Change in mean aqueous levels of albumin in post-operative PVR patients receiving subcutaneous injections of H.P. Acthar®|Change in mean aqueous levels of TGF-B in post-operative PVR patients receiving subcutaneous injections of H.P. Acthar®|Change in mean aqueous levels of interleukin-1B (IL-1B) in post-operative PVR patients receiving subcutaneous injections of H.P. Acthar®|Change in mean grade of aqueous cell in post-operative PVR patients receiving subcutaneous injections of H.P. Acthar®|Change in mean grade of flare in post-operative PVR patients receiving subcutaneous injections of H.P. Acthar®|Change in best-corrected visual acuity as measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) score in post-operative PVR patients receiving subcutaneous injections of H.P. Acthar®|Percentage of post-operative PVR patients receiving subcutaneous injections of H.P. Acthar® who develop recurrent retinal detachment|Percentage of post-operative PVR patients receiving subcutaneous injections of H.P. Acthar® who develop macular edema","Johns Hopkins University|Mallinckrodt","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB00179012","December 1, 2018","January 1, 2021","April 1, 2021","November 1, 2018","null","November 1, 2018","Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03727776"
19,"NCT03727646","Nicotinamide Riboside in LVAD Recipients","PilotNR-LVAD","Recruiting","No Results Available","Heart Failure，Congestive|Heart Failure New York Heart Association Class IV|Mitochondrial Alteration","Dietary Supplement: Nicotinamide riboside","Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)|Effect of NR on whole blood NAD+ levels|Effect of NR on mitochondrial respiration (Seahorse assay) in isolated peripheral blood mononuclear cells (PBMCs)|Between-group comparison of whole blood NAD+ levels|Between-group comparison of mitochondrial respiration in PBMCs","University of Washington|American Heart Association","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","STUDY00005431","September 26, 2018","February 26, 2019","July 26, 2019","November 1, 2018","null","November 1, 2018","University of Washington, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03727646"
20,"NCT03726814","A Clinical Study of iEPC Intervent Subjects With Cerebral Hemorrhagic Stroke",,"Not yet recruiting","No Results Available","Stroke, Ischemic","Biological: EPC treatment group","Incidence of Treatment Emergent AE","Allife Medical Science and Technology Co., Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","12","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EPC-BJYY-01","December 2018","December 2018","December 2020","November 1, 2018","null","November 1, 2018","","","https://ClinicalTrials.gov/show/NCT03726814"
21,"NCT03726645","The Effect of Fecal Microbiota Transplantation in Ankylosing Spondylitis (AS) Patients.","ASGUT","Enrolling by invitation","No Results Available","Ankylosing Spondylitis","Other: Fecal microbiota transplantation","The effect of FMT (fecal microbiota transplantation) on the clinical activity of ankylosing spondylitis (AS) as assessed by change in BASDAI (Bath Ankylosing Spondylitis Disease Activity Index).|The effect of FMT on the clinical activity of AS as assessed by change in BASFI (Bath Ankylosing Spondylitis Functional Index).|The effect of FMT on the clinical activity of AS as assessed by change in MASES (Maastricht Ankylosing Spondylitis Enthesitis Score).|The effect of FMT on C-reactive protein (CRP) concentration.|The effect of FMT on erythrocyte sedimentation rate (ESR) level.|The effect of FMT on gut wall inflammation as assessed by change in fecal calprotectin (F-calpro) level.|The effect of FMT on gut microbiota composition in AS patients.|Association between specific intestinal pathogens and disease activity as assessed by BASDAI score.|Association between specific intestinal pathogens and disease activity as assessed by CRP concentration.|Association between gut wall cytokine expression and disease activity as assessed by BASDAI score.|Association between gut wall inflammasome activity and disease activity as assessed by BASDAI score.|Association between gut wall cytokine expression and disease activity as assessed by CRP concentration.|Association between gut wall inflammasome activity and disease activity as assessed by CRP concentration.|Association between F-Calpro level and disease activity as assessed by BASDAI score.|Association between F-Calpro level and disease activity as assessed by CRP concentration.|The effect of FMT on gut wall permeability as assessed by blood zonulin concentration.|The effect of FMT on gut wall bacterial penetrance as assessed by lipopolysaccharide (LPS) concentration.|The effect of FMT on gastrointestinal symptoms as assessed by GSRS (The Gastrointestinal Symptom Rating Scale).","Hospital District of Helsinki and Uusimaa","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HospitalDHU/Rheumatology","October 24, 2018","April 2020","April 2020","October 31, 2018","null","October 31, 2018","Hospital District of Helsinki and Uusimaa, Department of Rheumatology, Helsinki, Uusimaa, Finland","","https://ClinicalTrials.gov/show/NCT03726645"
22,"NCT03725865","A Clinical Study of iNSC Intervent Cerebral Hemorrhagic Stroke",,"Not yet recruiting","No Results Available","Stroke, Ischemic","Biological: Induction of neural stem cells","Incidence of Treatment Emergent AE","Allife Medical Science and Technology Co., Ltd.","All","30 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","12","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","iNSC-81NK-01","March 2019","March 2019","March 2019","October 31, 2018","null","October 31, 2018","","","https://ClinicalTrials.gov/show/NCT03725865"
23,"NCT03724409","Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases",,"Recruiting","No Results Available","Neuroendocrine Tumors","Drug: [90]Y-DOTATOC","Change in liver enzymes|Change in platelet counts|Change in absolute neutrophil count|90Y-DOTATOC distribution","Sandeep Laroia|National Institutes of Health (NIH)|Holden Comprehensive Cancer Center|National Cancer Institute (NCI)|University of Iowa","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201805910|P50CA174521","October 11, 2018","December 2025","December 2025","October 30, 2018","null","October 30, 2018","The Holden Comprehensive Cancer Center, Iowa City, Iowa, United States","","https://ClinicalTrials.gov/show/NCT03724409"
24,"NCT03722303","Lipografting Versus Steroid Injections for Treatment of Carpal Tunnel Syndrome",,"Recruiting","No Results Available","Carpal Tunnel Syndrome","Other: Fat Injection|Drug: Steroid Injection","Functional Outcome Score|Score on the Michigan Hand Questionnaire (MHQ)|Score on the Brigham Women's Carpal Tunnel Questionnaire","Columbia University|Orthopaedic Scientific Research Foundation","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AAAK4700","December 19, 2016","December 2019","December 2019","October 26, 2018","null","October 29, 2018","Columbia University Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03722303"
25,"NCT03719105","INDUCTION CHEMO-IMMUNOTHERAPY FOLLOWED BY CONSOLIDATION WITH REDUCED TOXICITY CONDITIONING AND ALLOGENEIC STEM CELL TRANSPLANT IN ADVANCED STAGE MATURE NON-ANAPLASTIC T-CELL OR NK LYMPHOMA/LEUKEMIA IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS",,"Not yet recruiting","No Results Available","NK-Cell Lymphoma|NK-Cell Leukemia|Peripheral T Cell Lymphoma","Drug: Methotrexate, ifosfamide, dexamethasone, etoposide, pegasparagase,|Drug: pralatraxate, cyclophosphamide, doxorubicin, prednisone, brentuximab vedotin","overall response rate|event free survival","New York Medical College|University of Alabama at Birmingham","All","1 Year to 31 Years   (Child, Adult)","Early Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NYMC 575","November 1, 2018","December 31, 2022","December 31, 2023","October 25, 2018","null","October 25, 2018","","","https://ClinicalTrials.gov/show/NCT03719105"
26,"NCT03719001","Effect of Changing Physiological Conditions on Myogenic Oscillations: Pilot Study",,"Recruiting","No Results Available","Vascular Diseases","Drug: Phenylephrine|Drug: Dexmedetomidine|Drug: Clevidipine|Other: tetanic stimulus|Other: Increased venous pressure|Drug: Calcium Chloride","myogenic oscillations","University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PT1802","October 23, 2018","October 1, 2020","October 1, 2020","October 25, 2018","null","October 26, 2018","University of California San Francisco, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT03719001"
27,"NCT03718650","Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer",,"Not yet recruiting","No Results Available","Pancreatic Cancer|Resectable Pancreatic Cancer","Drug: Pimonidazole|Procedure: Surgical Resection","Radiosensitivity Index and Degree of Pimonidazole Staining|Correlative Biomarkers","H. Lee Moffitt Cancer Center and Research Institute|Varian Medical Systems","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MCC-19599","January 1, 2019","January 1, 2021","January 1, 2022","October 24, 2018","null","October 24, 2018","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States","","https://ClinicalTrials.gov/show/NCT03718650"
28,"NCT03718390","Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules in Healthy Adults",,"Active, not recruiting","No Results Available","Gastric Retention|Healthy","Drug: Formulation A|Drug: Formulation B|Drug: Formulation C|Drug: Formulation D|Drug: Formulation E|Procedure: Endoscopy|Procedure: Magnetic Resonance Imaging","Gastric retention assessed by Magnetic Resonance Imaging (MRI)|Safety and tolerability of four LYN-PLT modified release capsules and a placebo capsule collected from Adverse Event (AE) reporting based on spontaneous reports|Safety and tolerability of four LYN-PLT modified release capsules and a placebo capsule collected from Adverse Event (AE) reporting based on changes in examinations pre (Day 1) and post dosing (Days 4 and 7)|Safety and tolerability of four LYN-PLT modified release capsules and a placebo capsule collected from Adverse Event (AE) reporting based on post dosing evaluation of bowel movements for blood|Safety and tolerability of four LYN-PLT modified release capsules and a placebo capsule collected from Adverse Event (AE) reporting|Gastric retention assessed by abdominal ultrasound (U/S)|Confirm esophageal clearance of several MR capsules and a placebo capsule|Physical Feature of Recovered Formulation Components","Lyndra Inc.","All","18 Years to 40 Years   (Adult)","Early Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","LYN-PLT-C-001|ACTRN12618000991213|CM8818","June 25, 2018","September 15, 2018","October 20, 2018","October 24, 2018","null","October 24, 2018","CMAX, Adelaide, South Australia, Australia","","https://ClinicalTrials.gov/show/NCT03718390"
29,"NCT03711825","Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules Containing Memantine Hydrochloride in Healthy Adults",,"Active, not recruiting","No Results Available","Alzheimer Disease|Gastric Retention|Healthy","Drug: LYN-057|Procedure: Imaging Assessment (MRI)|Procedure: Imaging Assessment (U/S)","Gastric retention by imaging assessment by MRI|Gastric retention by imaging assessment by abdominal U/S|Safety and tolerability of a single dose of LYN-057 extended release capsule|Memantine HCl pharmacokinetics - Maximum Plasma Concentration (Cmax)|Memantine HCl pharmacokinetics - Time after administration of maximum plasma concentration (Tmax)|Memantine HCl pharmacokinetics - Area Under the Curve (AUC)|Physical features of recovered formulation components","Lyndra Inc.","All","18 Years to 40 Years   (Adult)","Early Phase 1","8","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LYN-057-C-002|ACTRN12618001426279|CM8718","September 10, 2018","October 1, 2018","November 15, 2018","October 19, 2018","null","October 19, 2018","CMAX, Adelaide, South Australia, Australia","","https://ClinicalTrials.gov/show/NCT03711825"
30,"NCT03709667","Exercise in Methamphetamine Use Disorder Upregulation and Neural Function",,"Not yet recruiting","No Results Available","Methamphetamine Abuse","Behavioral: EX|Behavioral: CON","Striatal D2/3 Binding Potential (BPND) Upregulation|Sustained attention|Working memory|Declarative memory|Selective attention|Inhibitory control - stop signal task|Inhibitory control - reversal learning|Reward-based decision-making|Resting state functional connectivity|Task-based brain activity (functional magnetic resonance imaging) - balloon analog risk|Task-based brain activity (functional magnetic resonance imaging - stop signal|Decision making under risk and ambiguity|Loss Aversion|Motor Function","University of California, Los Angeles","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-000496","November 15, 2018","April 30, 2023","April 30, 2023","October 17, 2018","null","October 18, 2018","","","https://ClinicalTrials.gov/show/NCT03709667"
31,"NCT03709381","Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study",,"Recruiting","No Results Available","Adrenal Insufficiency|Osteopenia, Osteoporosis|Steroid Suppression of ACTH Secretion","Drug: Low Dose Cosyntropin (ACTH) stimulation test|Drug: High Dose Cosyntropin (ACTH) stimulation test","Difference between VEGF levels at baseline and the peak VEGF level after low dose cosyntropin administration in healthy children and adolescents|Difference between VEGF levels at baseline and the peak VEGF level after high dose cosyntropin administration in healthy children and adolescents","Nationwide Children's Hospital","All","9 Years to 17 Years   (Child)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB17-00194","October 1, 2017","October 2018","June 2019","October 17, 2018","null","October 18, 2018","Nationwide Children's Hospital, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03709381"
32,"NCT03708627","Bimatoprost as a Treatment for Graves' Orbitopathy",,"Recruiting","No Results Available","Graves Ophthalmopathy","Drug: Bimatoprost Ophthalmic","Reduction in periorbital fat causing improvement in proptosis","University of Washington","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","3","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","STUDY00003194","November 1, 2017","May 2019","June 2019","October 17, 2018","null","October 18, 2018","University of Washington, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03708627"
33,"NCT03707938","Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer",,"Not yet recruiting","No Results Available","Advanced Lung Carcinoma|ALK Gene Rearrangement|Non-Small Cell Lung Carcinoma|Recurrent Non-Small Cell Lung Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8","Drug: Brigatinib|Procedure: Local Consolidation Therapy","Incidence of adverse events|Progression-free survival (PFS)|Overall survival (OS)|Time to progression of non-local consolidative therapy (LCT) lesion","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","24","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-0598|NCI-2018-02099|P30CA016672","March 31, 2019","January 28, 2023","January 28, 2023","October 16, 2018","null","October 16, 2018","M D Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03707938"
34,"NCT03707795","Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study","TRANSLATE","Recruiting","No Results Available","Familial Amyotrophic Lateral Sclerosis","Drug: Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days","Betamethasone plasma levels|Protein carbonyl plasma levels|Superoxide dismutase plasma levels|Peroxide plasma levels|Glutathione disulfide plasma levels|Glutathione plasma levels","University of Kentucky","All","20 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","17-0159-F6A","August 21, 2017","December 31, 2018","December 31, 2018","October 16, 2018","null","October 16, 2018","University of Kentucky Medical Center, Lexington, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT03707795"
35,"NCT03707600","State and Trait Mediated Response to TMS in Substance Use Disorder",,"Not yet recruiting","No Results Available","Nicotine Dependence","Device: TMS","Subjective and behavioral task report and changes in MRI BOLD signal","National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)","Early Phase 1","180","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","999918148|18-DA-N148","November 20, 2018","December 30, 2022","December 29, 2023","October 16, 2018","null","November 15, 2018","National Institute on Drug Abuse, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03707600"
36,"NCT03705832","Ginger's Therapeutic Potential in Asthma","GINGER","Not yet recruiting","No Results Available","Asthma","Drug: Ginger Extract|Drug: Placebo","Methacholine Challenge Test|Change in Serum Cytokines|Change in Eosinophilia|Change in Fractional Exhaled Nitric Oxide (FeNO)|Score on the Asthma Control Test (ACT)|Score on Juniper mini-Asthma specific Quality of Life (Mini AQLQ-J)","Emily DiMango, MD|National Center for Complementary and Integrative Health (NCCIH)|Columbia University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","36","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AAAR8427|R61AT009989","November 2018","November 2020","December 2021","October 15, 2018","null","October 15, 2018","Columbia University Asthma Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03705832"
37,"NCT03705819","Exploratory Evaluation of [11C]-NOP46",,"Not yet recruiting","No Results Available","Chronic Pain","Drug: [11C]-NOP46|Radiation: PET/CT scan","Uptake ratio for site with pain is >1|Occurrence of Physiologic Effects of Single Micro-dose of [11C]-NOP46","Akiva Mintz|Columbia University","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","AAAQ8138","November 2018","October 2019","May 2020","October 15, 2018","null","October 29, 2018","","","https://ClinicalTrials.gov/show/NCT03705819"
38,"NCT03705637","Liposomal Bupivicaine for Skin Graft Donor Sites in Burn Patients",,"Not yet recruiting","No Results Available","Burns|Postoperative Pain","Drug: Exparel","Morphine milligram equivalents (MME) administered after receiving Exparel|Length of hospital stay","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","70","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","MGH2018P001992","November 30, 2018","August 30, 2019","September 30, 2019","October 15, 2018","null","October 15, 2018","","","https://ClinicalTrials.gov/show/NCT03705637"
39,"NCT03703453","REBOA in Non-traumatic Cardiac Arrest",,"Not yet recruiting","No Results Available","Cardiac Arrest","Device: ER-REBOA catheter","Feasibility of aortic occlusion|Change in systolic blood pressure after aortic occlusion|Change in diastolic blood pressure after aortic occlusion|Change in end tidal carbon dioxide after aortic occlusion|Neurologic function at 30 days","Yale University|University of California, Davis","All","18 Years to 79 Years   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Yale","October 20, 2018","October 20, 2020","October 20, 2020","October 12, 2018","null","October 12, 2018","","","https://ClinicalTrials.gov/show/NCT03703453"
40,"NCT03702218","Hepatitis C Positive Donor Into Hepatitis C Negative Recipients",,"Not yet recruiting","No Results Available","Hepatitis C","Drug: Direct Acting Antivirals","SVR after receiving an organ from a donor previously exposed to Hepatitis C after treatment direct-acting antiviral drugs.","University of Maryland","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HP-00083009","October 31, 2018","May 31, 2019","December 31, 2019","October 11, 2018","null","November 2, 2018","University of Maryland Medical Center, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03702218"
41,"NCT03701087","Effect of Vitamin D Intake in Pregnancy to Prevent Recurrence of Gestational Diabetes",,"Recruiting","No Results Available","Vitamin D Intake in First Trimester and Incidence of Gestational Diabetes Recurrence","Drug: Vitamin D","incidence of gestational diabetes recurrence","Kasr El Aini Hospital","Female","18 Years to 38 Years   (Adult)","Early Phase 1","430","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","assistant professor","August 2, 2018","February 2, 2020","April 2, 2020","October 9, 2018","null","October 9, 2018","Kasr El Ainy, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03701087"
42,"NCT03695926","Assessment of [18F]MNI-1054 as a Marker for LSD1",,"Recruiting","No Results Available","Healthy Volunteers (HV)","Drug: [18F]MNI-1054","Average and standard deviation across subjects of the variability ((test - retest) / average(test, retest) ) as well as the intraclass correlation (ICC).","Invicro","All","18 Years to 50 Years   (Adult)","Early Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","[18F]MNI-1054","August 9, 2018","September 1, 2019","September 1, 2019","October 4, 2018","null","October 11, 2018","Invicro, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03695926"
43,"NCT03695887","A Pilot Trial of Disposable Nitrous Oxide Canisters in Providing Pain Control During Burn Dressing Changes",,"Not yet recruiting","No Results Available","Burns|Pain, Acute","Drug: Nitrous Oxide Inhalant Product","Burn Specific Pain Anxiety Scale|Visual Analogue Scale for pain|Visual Analogue Scale for anxiety","University of Manitoba","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","nitrousoxide","December 1, 2018","December 1, 2020","December 1, 2021","October 4, 2018","null","October 4, 2018","University of Manitoba, Winnipeg, Manitoba, Canada","","https://ClinicalTrials.gov/show/NCT03695887"
44,"NCT03694834","Window of Opportunity Study of Pembrolizumab in Early Stage, High Grade Obesity-driven Endometrial Cancer",,"Not yet recruiting","No Results Available","Endometrial Cancer|Uterine Cancer","Drug: Pembrolizumab|Procedure: Hysterectomy","Change in the number of Tumor Infiltrating Lymphocytes|Number of patients who experience Adverse Events after one dose of Pembrolizumab|Change in number of Tumor Infiltrating Lymphocytes by endometrial cancer sub-types|Correlation of Programmed Cell Death-1 (PD-1) Expression with TILs|Correlation of Immune and Obesity/Inflammation EC Signatures with TILs|Correlation of Microbiota Profiles with TILs|Overall Response Rate of Pembrolizumab with Paclitaxel and Carboplatin","UNC Lineberger Comprehensive Cancer Center|Merck Sharp & Dohme Corp.","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","LCCC 1739","December 2018","May 1, 2020","May 1, 2022","October 3, 2018","null","October 3, 2018","","","https://ClinicalTrials.gov/show/NCT03694834"
45,"NCT03692767","Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma",,"Not yet recruiting","No Results Available","Refractory B-Cell Lymphoma","Biological: Anti-CD22 CAR NK Cells","Occurrence of treatment related adverse events as assessed by CTCAE v4.0","Allife Medical Science and Technology Co., Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","9","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CD22 CAR NK-BJZL-01","November 2018","November 2020","November 2021","October 2, 2018","null","October 2, 2018","","","https://ClinicalTrials.gov/show/NCT03692767"
46,"NCT03692663","Study of Anti-PSMA CAR NK Cell in Castration-Resistant Prostate Cancer",,"Not yet recruiting","No Results Available","Castration-resistant Prostate Cancer","Biological: anti-PSMA CAR NK cells","Occurrence of treatment related adverse events as assessed by CTCAE v4.0","Allife Medical Science and Technology Co., Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","9","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PSMA CAR NK-ZGZYZL-01","December 2018","December 2020","December 2021","October 2, 2018","null","October 2, 2018","","","https://ClinicalTrials.gov/show/NCT03692663"
47,"NCT03692637","Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer",,"Not yet recruiting","No Results Available","Epithelial Ovarian Cancer","Biological: anti-Mesothelin Car NK Cells","Occurrence of treatment related adverse events as assessed by CTCAE v4.0","Allife Medical Science and Technology Co., Ltd.","Female","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Mesothelin Car NK-HNRM-01","November 2018","November 2020","November 2021","October 2, 2018","null","October 2, 2018","","","https://ClinicalTrials.gov/show/NCT03692637"
48,"NCT03692221","Mesenchymal Stem Cells for Lumbar Degenerative Disc Disease",,"Not yet recruiting","No Results Available","Disc Degeneration","Drug: MSC Treatment group 1 (low dose)|Drug: MSC Treatment group 2 (high dose)|Other: Healthy Control (no treatment)","Rate of treatment related adverse events|Changes in Pain -Visual Analogue Scale (VAS) for back pain|Changes in Pain - Oswestry Disability Index (ODI) scores over time|changes in Quality of life - Short form Health Survey 36 (SF-36)|changes in MRI monitoring of transplant site","Salim M Hayek|University Hospitals Cleveland Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","014924/0012/A002","November 1, 2018","September 30, 2021","September 30, 2022","October 2, 2018","null","October 31, 2018","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03692221"
49,"NCT03691350","Bronchoscopy in Determining the Effect of E-Cigarette Smoking on Biomarkers in the Lungs",,"Recruiting","No Results Available","Cigarette Smoker|Current Every Day Smoker","Procedure: Bronchoscopy with Bronchoalveolar Lavage|Drug: Cigarette|Other: Electronic Cigarette|Other: Laboratory Biomarker Analysis|Drug: Nicotine Replacement|Other: Questionnaire Administration","Changes in cell counts and cytokines|Changes in fractional exhaled nitric oxide (FeNO) levels|Changes in messenger (m) ribonucleic acid (RNA) and microRNA (miRNA) gene expression analyzed using sequencing|Changes in deoxyribonucleic acid (DNA) gene methylation|Changes in the microbiome in BAL cells and saliva|Changes in untargeted metabolomics using mass spectrometry","Ohio State University Comprehensive Cancer Center|National Institute on Drug Abuse (NIDA)|National Cancer Institute (NCI)","All","21 Years to 45 Years   (Adult)","Early Phase 1","160","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","OSU-18044|NCI-2018-00283|U01DA045530|P30CA016058","September 17, 2018","April 1, 2020","April 1, 2020","October 1, 2018","null","October 3, 2018","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03691350"
50,"NCT03691311","Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer","D-BIOMARK","Recruiting","No Results Available","Breast Neoplasm Female|Stage I Breast Cancer|Stage II Breast Cancer|Hormone Receptor Negative Neoplasm|Hormone Receptor Positive Tumor","Drug: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]","Antiproliferative and/or pro-apoptotic activity of denosumab|Correlation between antiproliferative activity of denosumab and Rank/RankL expression|Differential antiproliferative activity of denosumab among the different phenotypes of breast cancers.|Differential antiproliferative activity of denosumab among pre and post menopausal patients|Safety of denosumab and biopsy procedures in terms of Frequency of adverse events (CTCAE V4.)","Institut Català d'Oncologia|Amgen","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ICO 13-001|2016-002678-11|20119112","July 5, 2018","July 5, 2019","February 5, 2020","October 1, 2018","null","October 1, 2018","Institut Català d'Oncologia - L'Hospitalet, L'Hospitalet De Llobregat, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT03691311"
51,"NCT03690544","Apremilast for RAS",,"Not yet recruiting","No Results Available","Recurrent Aphthous Stomatitis","Drug: Apremilast 30mg","Improvement in duration of RAS lesions|Percentage change in number of RAS lesions|Improvement in duration of the remission period between ulcer episodes|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Discontinuation of study participants|Frequency of clinically significant changes in vital signs and/or laboratory findings","Mayo Clinic|Celgene","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-002914","September 30, 2018","September 30, 2019","December 15, 2019","October 1, 2018","null","October 1, 2018","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT03690544"
52,"NCT03690310","Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma",,"Not yet recruiting","No Results Available","Refractory B-Cell Lymphoma","Biological: Anti-CD19 CAR NK Cells","Occurrence of treatment related adverse events as assessed by CTCAE v4.0","Allife Medical Science and Technology Co., Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","9","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CD19 CAR NK-BJZL-01","November 2018","November 2020","November 2021","October 1, 2018","null","October 1, 2018","","","https://ClinicalTrials.gov/show/NCT03690310"
53,"NCT03688464","Treatment of Nighttime Pruritus in Atopic Dermatitis",,"Not yet recruiting","No Results Available","Atopic Dermatitis","Drug: Melatonin|Drug: Diphenhydramine|Drug: Placebos","POEM (Patient Oriented Eczema Measure)|EASI score|5D Pruritus survey|ESS-CHAD|Actigraphy","University of Nebraska|Children's Hospital and Medical Center, Omaha, Nebraska","All","2 Years to 12 Years   (Child)","Early Phase 1","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","197-18-FB","April 1, 2019","May 30, 2019","June 30, 2019","September 28, 2018","null","November 14, 2018","","","https://ClinicalTrials.gov/show/NCT03688464"
54,"NCT03687814","Low FODMAP Plus PEG 3350 for the Treatment of Patients With Irritable Bowel Syndrome-Constipation",,"Not yet recruiting","No Results Available","Irritable Bowel Syndrome Characterized by Constipation","Other: Low FODMAP diet/PEG 3350|Other: sham diet/PEG 3350","Improvement of abdominal pain as measured by 11-point numerical rating scale|Bloating|abdominal discomfort|Mean number of SBMs per day|Mean weekly number of spontaneous complete bowel movements|Composite endpoint: Full responder was defined as a patient with >3 SBM per week, an increase of ≥1 SBM per week and >30% pain reduction.|stool consistency|Straining|IBS-QOL|HADS score|WPAI questionnaire|Sleep Assessment questionnaire","University of Michigan","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","HUM00139784","October 1, 2018","August 1, 2020","August 1, 2020","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687814"
55,"NCT03687021","Clinical Study on Endometrial Receptivity",,"Not yet recruiting","No Results Available","Endometrial Receptivity;RNA; Progesterone","Drug: Progesterone","endometrial receptivity measured by pathology|endometrial receptivity measured by immunohisochemistry|endometrial receptivity measured by Ribose Nucleic Acid （RNA）|endometrial receptivity measured by scanning electron microscope","Peking Union Medical College Hospital","Female","18 Years to 40 Years   (Adult)","Early Phase 1","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","yuqi03029","October 10, 2018","October 10, 2018","November 10, 2018","September 27, 2018","null","September 27, 2018","Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03687021"
56,"NCT03686748","Two Point Discrimination","TPD","Recruiting","No Results Available","Ehlers-Danlos Syndrome (EDS)|Complex Regional Pain Syndrome (CRPS)|Amplified Musculoskeletal Pain Syndrome (AMPS)|Low Back Pain|Fibromyalgia|Chronic Widespread Pain","Behavioral: Two-point discrimination training|Behavioral: One-point discrimination training","Change in spatial extent of pain from baseline visit to final visit|Change in pain ratings from baseline visit to final visit|Change in pain-related disability from baseline visit to final visit|Change in two point discrimination threshold from baseline visit to final visit","Children's Hospital Medical Center, Cincinnati","All","10 Years to 17 Years   (Child)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CIN_TPD_001","July 21, 2018","July 17, 2021","July 16, 2023","September 27, 2018","null","September 27, 2018","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States","""Informed Consent Form: Healthy Control"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT03686748/ICF_000.pdf|""Informed Consent Form: Patient Population"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT03686748/ICF_001.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT03686748/Prot_002.pdf","https://ClinicalTrials.gov/show/NCT03686748"
57,"NCT03686501","D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562",,"Recruiting","No Results Available","Healthy Male Volunteers","Drug: PF-06412562","Evaluate D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562, Using Positron Emission Tomography (PET) with Ligand [18F]MNI-968","Invicro","Male","20 Years to 55 Years   (Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","[18F] MNI-968","July 6, 2018","August 2019","August 2019","September 27, 2018","null","September 27, 2018","Invicro, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03686501"
58,"NCT03686202","Feasibility Study of Microbial Ecosystem Therapeutics (MET-4) to Evaluate Effects of Fecal Microbiome in Patients on ImmunOtherapy","MET4-IO","Not yet recruiting","No Results Available","All Solid Tumors","Biological: MET-4","Cumulative relative abundance of immunotherapy-responsiveness associated species at day 12 of MET-4|Changes in relative abundance of immunotherapy-responsiveness associated MET-4 strains between baseline and approximately day 12|Number of participants with treatment-related adverse events assessed by CTCAE v.5.0|Cumulative relative abundance of immunotherapy-responsiveness associated species at later MET-4 or control time points (approximately 24 weeks and/or 1-2 weeks following the end of treatment).|Changes in relative abundance of immunotherapy-responsiveness associated MET-4 strains between baseline and later MET-4 or control timepoints (approximately 24 weeks and/or 1-2 weeks following the end of treatment)|Bacterial taxonomic diversity between baseline and follow-up samples","University Health Network, Toronto|NuBiyota","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","65","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MET4-IO-001","December 1, 2018","December 1, 2020","December 1, 2023","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03686202"
59,"NCT03685175","Effect of Cardiotoxic Anticancer Chemotherapy on the Metabolism of [1-13C]Pyruvate in Cardiac Mitochondria","HPCardiotox","Recruiting","No Results Available","Breast Neoplasms","Drug: Formal study using hyperpolarized 13C-pyruvate injection|Drug: Feasible study using hyperpolarized 13C-pyruvate injection","Detect subclinical anthracycline induced cardiotoxicity using hyperpolarized carbon-13 pyruvate","University of Texas Southwestern Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","110","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","STU 072016-058","July 1, 2018","March 2022","March 2022","September 26, 2018","null","October 15, 2018","UT Southwestern - Advanced Imaging Research Center, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT03685175"
60,"NCT03684980","Study of Voraxaze in Patients With Central Nervous System Lymphoma",,"Not yet recruiting","No Results Available","Central Nervous System Lymphoma","Drug: Voraxaze|Drug: Methotrexate|Drug: Rituximab|Drug: leucovorin","number of patients that have significant reduction of serum methotrexate levels","Memorial Sloan Kettering Cancer Center|University of Alabama at Birmingham","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-410","November 2018","October 2019","October 2019","September 26, 2018","null","November 8, 2018","Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03684980"
61,"NCT03682172","Effect of Glucagon-like Peptide 2 on Gallbladder Motility After a Meal in Young, Healthy Male Subjects",,"Active, not recruiting","No Results Available","Effect of Glucagon-like Peptide 2 on Gallbladder Motility","Drug: GLP-2 (1pmol/kg/min)|Drug: GLP-2 (10pmol/kg/min)|Drug: Placebo","Gallbladder ejection fraction (EF%)|Glucagon|Gastric emptying|Time to maximum gallbladder EF%","Steno Diabetes Center","Male","18 Years to 35 Years   (Adult)","Early Phase 1","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","H-17037571","May 1, 2018","August 30, 2018","August 31, 2019","September 24, 2018","null","September 24, 2018","Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, Hellerup, Region Hovedstaden, Denmark","","https://ClinicalTrials.gov/show/NCT03682172"
62,"NCT03682094","Impact of Probiotics on Oral Microbiota in Older Adults With Dysphagia",,"Recruiting","No Results Available","Dysphagia","Drug: VSL#3","Change in Oral microbiota profiles- bacterial diversity|Eating Assessment Test (EAT-10)|Functional Oral Intake Scale (FOIS) Score|Kayser-Jones Brief Oral Health Status Examination (BOHSE)|Change in Resting Swallow Frequency Rate|Change in Residual Mucosal Saliva (RMS)|Change in Amount of Saliva Produced","University of Wisconsin, Madison","All","65 Years to 99 Years   (Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-0428","August 13, 2018","August 31, 2019","August 31, 2019","September 24, 2018","null","September 24, 2018","University of Wisconsin-Madison, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT03682094"
63,"NCT03682081","Interventions for Patients With Alzheimer's Disease and Dysphagia",,"Recruiting","No Results Available","Dementia|Dysphagia","Device: Isometric tongue strengthening|Drug: Biotene","Change in Lingual Pressures at the Anterior and Posterior Tongue Locations|Change in Perceived Swallow Effort|Change in Penetration-Aspiration Scale scores|Change in Functional Oral Intake Scale (FOIS) scores|Change in Swallowing Quality of Life (Swal-QOL) scale|Change in Amount of saliva produced|Change in number of hospital admissions and readmissions as well as pneumonia incidence|Change in Caregiver Burden Scale|Change in 6-item Caregiver Activity Survey (CAS)","University of Wisconsin, Madison","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","76","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-0835","October 1, 2018","September 1, 2023","September 1, 2023","September 24, 2018","null","September 24, 2018","University of Wisconsin-Madison, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT03682081"
64,"NCT03681769","Developing Brain Stimulation as a Treatment for Chronic Pain in Opiate Dependent",,"Recruiting","No Results Available","Chronic Pain|Opiate Dependence|Lower Back Pain","Device: iTBS to the left dlPFC|Device: Sham iTBS to the left dlPFC|Device: cTBS to the mPFC|Device: Sham cTBS to the mPFC","Decrease in Quantitative Pain Testing Following Active TMS Compared to Sham|Reductions in Patient Reported Pain and Discomfort","Medical University of South Carolina","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00078668","October 2018","July 2020","July 2021","September 24, 2018","null","October 11, 2018","Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT03681769"
65,"NCT03681704","the Integrated Traditional Chinese and Western Medicine Treat Early Stage DKD",,"Not yet recruiting","No Results Available","Diabetic Nephropathy Type 2","Drug: HuangQi Decoction|Drug: HuangQi Decoction placebo","ACR","Shanghai University of Traditional Chinese Medicine|Shanghai Jiao Tong University Affiliated Sixth People’s Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","144","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","17401970500-a","October 2018","September 2021","September 2021","September 24, 2018","null","September 24, 2018","Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03681704"
66,"NCT03681249","the Integrated Traditional Chinese and Western Medicine Treat Middle Stage DKD",,"Recruiting","No Results Available","Diabetic Nephropathy Type 2","Drug: ShenqiDihuang Decoction|Drug: ShenqiDihuang Decoction placebo","24H urine total protein","Shanghai University of Traditional Chinese Medicine|Shanghai Jiao Tong University Affiliated Sixth People’s Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","144","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","17401970500-b","November 2, 2018","September 2021","September 2021","September 24, 2018","null","November 9, 2018","Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03681249"
67,"NCT03681197","Metformin Use and Clinical Pregnancy Rate in Women With Unexplained Infertility",,"Recruiting","No Results Available","Infertility","Drug: Metformin|Drug: Placebo|Drug: Clomiphene Citrate","Clinical pregnancy rate","Elham Raafat|Ain Shams University","Female","20 Years to 35 Years   (Adult)","Early Phase 1","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","1982","June 15, 2018","November 2018","December 2018","September 21, 2018","null","September 21, 2018","Elham Raafat Mohamed, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03681197"
68,"NCT03680885","Validating a New Non-invasive Approach to Testing Lidocaine Effectiveness",,"Not yet recruiting","No Results Available","ADHD|Controls","Drug: Lidocaine gel|Drug: Placebo|Drug: Injected lidocaine","Taste sensation after lidocaine or placebo|Ability to feel pressure and discomfort after injection of lidocaine into the cheek","PhenoSolve, LLC|Jacobi Medical Center","All","18 Years to 49 Years   (Adult)","Early Phase 1","20","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","2018-271","September 30, 2018","June 30, 2019","July 30, 2019","September 21, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03680885"
69,"NCT03679845","Study to Assess Sarilumab in Halting Progression of Morphea",,"Not yet recruiting","No Results Available","Morphea, Plaque Form","Drug: Sarilumab","Change in morphea|Change in PGA-A during treatment period","Massachusetts General Hospital|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018P002128","October 2018","October 2019","October 2019","September 20, 2018","null","September 20, 2018","","","https://ClinicalTrials.gov/show/NCT03679845"
70,"NCT03679377","Mandibular Slotplates",,"Not yet recruiting","No Results Available","Craniofacial Abnormalities","Device: Mandibular slotplate","Feasebility of the slotprinciple|Inclination of the screws","Universitair Ziekenhuis Brussel","All","12 Years to 50 Years   (Child, Adult)","Early Phase 1","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","Mandi slot plates v 1.0","October 1, 2018","December 31, 2018","March 1, 2019","September 20, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03679377"
71,"NCT03678389","Feasibility of Endosphenoidal Coil Placement for Imaging of the Sella During Transsphenoidal Surgery",,"Not yet recruiting","No Results Available","Pituitary Neoplasm","Device: ENDOSPHENOIDAL COIL","Feasibility of using ESC as a clinical tool during transsphenoidal surgery.Feasibility will be assessed by the time added to a standard TSSprocedure.|Evaluate whether the use of ESC causes local trauma, bleeding, burns or other unanticipated safety issues during TSS.","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","180133|18-N-0133","November 20, 2018","November 30, 2019","November 30, 2019","September 19, 2018","null","November 15, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03678389"
72,"NCT03678012","Evaluation of Anti-biofilm Effects of Ferumoxytol (Feraheme) Using an in Situ Biofilm Demineralization Model",,"Completed","No Results Available","Dental Caries","Drug: Ferumoxytol/Hydrogen peroxide|Drug: Hydrogen Peroxide|Drug: Water","Biofilm Analyses-cell viability|Biofilm Analysis-extracellular polysaccharides|Assessment of Enamel Demineralization by Means of Surface Microhardness Test (SMH)","University of Pennsylvania|Indiana University","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1802077294","June 7, 2018","August 16, 2018","August 16, 2018","September 19, 2018","null","September 19, 2018","Oral Health Research Institute, Indianapolis, Indiana, United States|University of Pennsylvania, School of dental medicine, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03678012"
73,"NCT03677479","Evaluation of Post-extraction Socket Preservation With Camelline Versus Bovine Deproteinized Xenograft",,"Not yet recruiting","No Results Available","Socket Preservation","Procedure: socket preservation procedure","patient-reported outcome|ridge contour changes","Cairo University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","PER123","October 2018","February 2020","August 2020","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677479"
74,"NCT03676725","Assessing the Frequency of Lidocaine Ineffectiveness in the General Population",,"Not yet recruiting","No Results Available","General Population","Drug: Lidocaine gel","Frequency of lidocaine ineffectiveness in the general population (without ADHD)","PhenoSolve, LLC|Jacobi Medical Center","All","13 Years to 49 Years   (Child, Adult)","Early Phase 1","100","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2018-272","September 30, 2018","June 30, 2019","July 30, 2019","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03676725"
75,"NCT03675659","Intra-articular Magnesium Sulfate for Tmj Dysfunction",,"Recruiting","No Results Available","Temporomandibular Joint Disorders|Temporomandibular Sprain","Drug: intra-articular injection","estimation of pain: Visual Analog Scale","Cairo University","Female","20 Years to 40 Years   (Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","CD5618","September 9, 2017","November 2019","November 2019","September 18, 2018","null","September 21, 2018","Atef, Giza, Egypt","","https://ClinicalTrials.gov/show/NCT03675659"
76,"NCT03675022","Effect of Dupilumab on Sleep Apnea in Patients With Rhinosinusitis",,"Not yet recruiting","No Results Available","Sleep Apnea|Rhinosinusitis Chronic","Drug: Dupilumab","Percent change in apnea-hypopnea index (AHI) after 16 weeks of dupilumab therapy|Effect of 16 weeks of dupilumab on sleep architecture total sleep time|Effect of 16 weeks of dupilumab on sleep architecture sleep stage percentages|Effect of 16 weeks of dupilumab on sleep architecture arousal index|Effect of 16 weeks of dupilumab on sleep architecture oxygen saturation|Epworth Sleepiness Score (ESS)|Pittsburgh Sleep Quality Index (PSQI)|Functional Outcomes of Sleep Quality (FOSQ)|Subjective sleep quality [visual analog scale(VAS)]|Effect of 16 weeks of dupilumab on nasal resistance with catheter|Effect of 16 weeks of dupilumab on nasal resistance with mask","Brigham and Women's Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018P001031","October 2018","July 2020","July 2020","September 18, 2018","null","October 2, 2018","","","https://ClinicalTrials.gov/show/NCT03675022"
77,"NCT03673215","The Tolerability，Safety，PK/PD Study of rhTPO in the Patients With Liver Function Impairment",,"Recruiting","No Results Available","Liver Cirrhosis","Drug: Recombinant human thrombopoietin|Drug: Placebo|Drug: recombinant human thrombopoietin|Drug: placebo","Safety and tolerability as assessed by the collection of adverse events|AUC[0-24]of rhTPO|AUC [0-t] of rhTPO|AUC [0-∞]of rhTPO|Cmax of rhTPO|tmax of rhTPO|t1/2 of rhTPO|MRT for rhTPO|Kel of rhTPO|Vd of rhTPO|CL/F of rhTPO|Immunogenicity of rhTPO|Change of Platelet count (PLT)","Shenyang Sunshine Pharmaceutical Co., LTD.","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","58","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","3SBio-TPO-106","June 28, 2018","July 31, 2019","December 31, 2019","September 17, 2018","null","September 17, 2018","302 Military Hospital of China, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03673215"
78,"NCT03672539","Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome",,"Recruiting","No Results Available","CD33 Positive|High Risk Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia","Drug: Gemtuzumab Ozogamicin|Drug: Liposome-encapsulated Daunorubicin-Cytarabine|Other: Quality-of-Life Assessment","Overall response rate|Incidence and severity of all adverse events assessed using Common Toxicity Criteria version 4.0|Response and patient's clinical characteristics|Event-free survival|Overall survival","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-0235|NCI-2018-01812|P30CA016672","November 7, 2018","June 30, 2020","June 30, 2020","September 14, 2018","null","November 9, 2018","M D Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03672539"
79,"NCT03672305","Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC",,"Not yet recruiting","No Results Available","Primary Hepatocellular Carcinoma","Biological: c-Met/PD-L1 CAR-T cell injection","The efficacy of c-Met/PD-L1 CAR-T cells in the treatment of HCC|the incidence of treatment-emergent adverse events of c-Met/PD-L1 T cell injection in the treatment of HCC|The amplification and persistence of c-Met/PD-L1 CAR-T cell in the subjects varied with time","The Second Hospital of Nanjing Medical University","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JGZNO1","October 1, 2018","October 30, 2019","October 30, 2019","September 14, 2018","null","September 18, 2018","","","https://ClinicalTrials.gov/show/NCT03672305"
80,"NCT03671720","Personalized Vaccine Generated by Autologous Dendritic Cells Pulsed With Autologous Whole Tumor Cell Lysate Treat Advanced Solid Tumor Patients With High Tumor Mutation Burden",,"Recruiting","No Results Available","Advanced Cancer|Metastatic Cancer","Biological: personalized DC vaccine","Treatment-related adverse events|Objective response rate (ORR)|Progression-free survival of the participants(PFS)|Overall survival of the participants(OS)|The changes in immune-response specific patient-reported outcomes(irPRO)|The changes in patient self-reported quality of life","Capital Medical University|Duke University","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCL DC Vaccine for TMB-High","September 11, 2018","September 30, 2019","December 30, 2020","September 14, 2018","null","September 14, 2018","Capital Medical University Cancer Center/Beijing Shijitan Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03671720"
81,"NCT03671525","Cognitive Effects of Nimodipine in Patients With Schizophrenia",,"Recruiting","No Results Available","Schizophrenia|Schizo Affective Disorder","Drug: Nimodipine|Drug: Placebo oral capsule","Brain activity as assessed by BOLD fMRI|Changes in Visual Learning and Memory Score|Changes in Auditory Learning and Memory Score|Changes in Global Neurocognitive effect as assessed by the Global Neurocognitive Assessment (GNA)|Effect of CACNA1C genotype on cognitive performance measures|Broader genetic associations with cognitive performance","Johns Hopkins University","All","18 Years to 55 Years   (Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","IRB00168634","October 5, 2018","October 2019","October 2019","September 14, 2018","null","November 8, 2018","Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03671525"
82,"NCT03665753","Comparison of IV 10, 20, and 30mg for Renal Colic Pain in the ED",,"Recruiting","No Results Available","Pain|Renal Colic","Drug: Ketorolac","Pain assessed with visual analogue scale (VAS)|Adverse Effects","Tehran University of Medical Sciences","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","165","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","9521307004","August 5, 2017","September 15, 2019","September 15, 2019","September 11, 2018","null","September 11, 2018","IKCH, Tehran, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT03665753"
83,"NCT03665675","Donor CMV Specific CTLs in Treating CMV Reactivation or Infection in Participants Who Have Undergone Stem Cell Transplant or Solid Organ Transplant",,"Not yet recruiting","No Results Available","Allogeneic Hematopoietic Stem Cell Transplantation Recipient|Cytomegalovirus|Donor|Solid Organ Transplantation Recipient","Biological: Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes","Incidence of adverse events defined by the National Cancer Institute Common Terminology Criteria for Adverse Events 4.0|Feasibility defined as identifying a suitable donor within 4 weeks and meeting minimum T cell doses in the final product|Antiviral activity defined as response to viral load|Persistence of infused CTLs as measured by T cell gene rearrangement and effects on clinical signs of viral infection|Overall survival|Risk for chronic GVHD|Systemic infections|Secondary graft failure|Effects of cytomegalovirus (CMV) specific-CTL on viral loads assessed by weekly reverse transcriptase-polymerase chain reaction|Viral reactivations|Clinical response to CTL infusions|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0"".","Sumithira Vasu|National Cancer Institute (NCI)|Ohio State University Comprehensive Cancer Center","All","Child, Adult, Older Adult","Early Phase 1","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-17199|NCI-2018-01412|P30CA016058","October 1, 2018","December 31, 2021","December 31, 2021","September 11, 2018","null","September 11, 2018","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03665675"
84,"NCT03665636","Anaplerotic Therapy Using Triheptanoin for Patients With Glycogen Storage Disease Type I",,"Not yet recruiting","No Results Available","Glycogen Storage Disease Type I","Drug: Triheptanoin","Blood glucose level|Dietary intake|Liver steatosis assessment|Liver size assessment|Laboratory metabolic control markers|Other laboratory metabolic control markers","Areeg El-Gharbawy|Ultragenyx Pharmaceutical Inc|University of Pittsburgh","All","1 Month to 65 Years   (Child, Adult, Older Adult)","Early Phase 1","5","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO17090545","December 2018","May 2019","June 2019","September 11, 2018","null","November 5, 2018","UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03665636"
85,"NCT03664401","A Clinical Trial to Evaluate Kerecis Oral™ Compared to Autogenous Free Gingival Graft (AFGG) Tissue to Augment Gingival Soft Tissue and Wound Healing",,"Completed","No Results Available","Mucogingival Deformity - Insufficient Keratinized Tissue","Device: Kerecis Oral™|Other: Free Gingival Graft","Change in KT width from time of surgery to 3 months post-surgery|Probing depth|Papillary height and widht|Horizontal recession|Subject completed discomfort questionaire|Bleeding on probing","Kerecis Ltd.|Tufts University School of Dental Medicine","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","6","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","01-GING-001-Kerecis Oral","September 1, 2016","September 1, 2017","December 1, 2017","September 10, 2018","null","September 13, 2018","","","https://ClinicalTrials.gov/show/NCT03664401"
86,"NCT03662477","Effect of NK Cell Immunotherapy on Advanced Lung Adenocarcinoma Adenocarcinoma With EGFR Mutation",,"Recruiting","No Results Available","NK Cell Mediated Immunity","Biological: NK cells","Clinical response|Detection of immune function|Analysis of tumor biomarker CEA and CA125 levels in serum","Shenzhen Fifth People's Hospital","All","35 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Shenzhen Fifth Hospita","January 1, 2018","July 1, 2019","July 1, 2019","September 7, 2018","null","September 7, 2018","Shenzhen Luohu Hospital, Shenzhen, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03662477"
87,"NCT03661892","Pilot, Syndros, Decreasing Use of Opioids in Breast Cancer Subjects With Bone Mets",,"Not yet recruiting","No Results Available","Bone Metastases|Breast Cancer|Pain","Drug: Syndros","Need for opiate pain medication|Change in pain|Change in quality of life|Change in bone modulation","University of Arizona","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","29387|NCI-2018-01916","November 30, 2018","September 30, 2019","September 30, 2019","September 7, 2018","null","November 7, 2018","University of Arizona, Tucson, Arizona, United States","","https://ClinicalTrials.gov/show/NCT03661892"
88,"NCT03661684","Effect of Short Course of Glucocorticoid in Patients With Diabetes Mellitus(DM) Type 2",,"Completed","No Results Available","Diabetes|Hyperglycemia Steroid-induced","Drug: Prednisone","AUC for glucose during OGTT|HOMA index|AUC for Insulin during OGTT","John H. Stroger Hospital","All","18 Years to 50 Years   (Adult)","Early Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","JHStrogerHEndoSteroid01","June 3, 2016","April 1, 2017","July 1, 2017","September 7, 2018","null","September 7, 2018","","","https://ClinicalTrials.gov/show/NCT03661684"
89,"NCT03661554","BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma","BCMA CAR-T","Recruiting","No Results Available","Relapsed and Refractory Multiple Myeloma","Biological: BCMA CAR-T Cells","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","The Pregene (ShenZhen) Biotechnology Company, Ltd.|Henan Cancer Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","15","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRG 1801","April 10, 2018","October 30, 2018","November 30, 2018","September 7, 2018","null","September 7, 2018","Pregene Shenzhen Biotechnology Co., Ltd., Shenzhen, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03661554"
90,"NCT03661125","SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis","SCRIPT","Not yet recruiting","No Results Available","Parkinson Disease Psychosis","Drug: Saracatinib|Drug: Placebo Oral Tablet","Difference between study drug and placebo in BOLD activity in the ventral visual stream during visual recognition vs. the control task measure using fMRI|Difference between study drug and placebo in BOLD activity in the occipito-temporal region during the visual processing task (Kanisza illusion)|Change in Mismatch negativity (MMN) in microvolts (mV) and connectivity with the posterior cingulate hub of the default mode network","King's College London|AstraZeneca|King's College Hospital NHS Trust","All","40 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","247303","December 1, 2018","September 1, 2021","September 1, 2021","September 7, 2018","null","September 25, 2018","Mitul Mehta, London, Camberwell, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT03661125/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT03661125/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03661125"
91,"NCT03660748","Safety and Efficacy of MET-3 in Obese Human Subjects",,"Recruiting","No Results Available","Obesity","Biological: MET-2","Effect of MET-3 on the Incremental Area under the glucose curve (2 hrs) in obese subjects|Incidence of Treatment-Emergent Adverse Events","NuBiyota|Glycemic Index Laboratories, Inc","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MET-3 101","October 1, 2018","September 1, 2019","September 1, 2019","September 7, 2018","null","October 5, 2018","GI Labs, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03660748"
92,"NCT03658655","Dental Medullary Mesenchymal Stem Cells in Treatment of Type 2 Diabetes",,"Recruiting","No Results Available","Type2 Diabetes","Biological: Dental pulp mesenchymal stem cells","Total daily insulin|HbAlc","CAR-T (Shanghai) Biotechnology Co.,Ltd.","All","45 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","24","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KTLC001","June 1, 2018","September 1, 2019","September 30, 2019","September 5, 2018","null","September 5, 2018","Changhai hospital, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03658655"
93,"NCT03658109","Lidocaine Infusion or Quadratus Lumborum Block and Intrathecal Morphine, Versus Intrathecal Morphine Alone",,"Not yet recruiting","No Results Available","Gynecologic Cancer","Drug: Lidocaine Bolus Infusion|Procedure: QL block|Drug: Saline Bolus Infusion|Procedure: Simulated QL block","PACU Post-operative opioid consumption|Length of PACU admittance to time of readiness for discharge from PACU|PACU Sedation Scores|Length of hospital stay|Ambulation on POD 0 and POD1|Return to bowel function|Total Opioid Dose Utilized During Surgery|Presence or Absence of Patient Controlled Analgesia|Time to First Opioid Use|Average PACU Pain Score|Post Operative Pain Scores|Average PACU opioid consumption|Post-operative opioid consumption","University of Alabama at Birmingham","Female","18 Years to 69 Years   (Adult, Older Adult)","Early Phase 1","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","56789013","November 1, 2018","July 1, 2019","October 1, 2019","September 5, 2018","null","September 17, 2018","","","https://ClinicalTrials.gov/show/NCT03658109"
94,"NCT03657602","Immediate Postpartum Insertion of Contraceptive Intrauterine Devices",,"Not yet recruiting","No Results Available","Contraception","Drug: Skyla Intrauterine System|Drug: Mirena Intrauterine System","Expulsion of intrauterine contraception|Discontinuation of intrauterine contraception","University of Oklahoma","Female","18 Years to 49 Years   (Adult)","Early Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","9588","November 2018","September 2020","December 2020","September 5, 2018","null","October 12, 2018","","","https://ClinicalTrials.gov/show/NCT03657602"
95,"NCT03655756","pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma",,"Recruiting","No Results Available","Cutaneous Melanoma, Stage III|Cutaneous Melanoma, Stage IV","Biological: IFx-Hu2.0","Safety; defined as four of the six patients enrolled having no grade-3 or higher treatment-related adverse events as assessed by CTCAE v5.0.|Feasibility; defined as the ability to treat at least five of the six patients enrolled without dose-limiting toxicity.|Objective response rate (ORR) determined using standard criteria.","Morphogenesis, Inc.|H. Lee Moffitt Cancer Center and Research Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","6","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CM 2017-01","August 2018","February 2019","August 2019","August 31, 2018","null","August 31, 2018","H. Lee Moffitt Cancer Center, Tampa, Florida, United States","","https://ClinicalTrials.gov/show/NCT03655756"
96,"NCT03655704","Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study","BRD4i","Not yet recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: Apabetalone","Change in Pulmonary Vascular Resistance (PVR), dyn·s·cm−5","Steeve Provencher|Laval University","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","BRD4i-apabetalone-PAH","November 2018","May 2020","August 2020","August 31, 2018","null","November 12, 2018","Peter Lougheed Centre 3500 26 Ave NE, Calgary, Alberta, Canada|Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Québec, Canada","","https://ClinicalTrials.gov/show/NCT03655704"
97,"NCT03655275","Effects of Platelet-rich Plasma Prolotherapy of Temporomandibular Joint Subluxation",,"Recruiting","No Results Available","Temporomandibular Joint Disorders","Biological: PRP prolotherapy|Biological: Saline prolotherapy","Patients' subjective pain experience|Frequency of luxation|Maximum mouth opening|Joint sounds","Abdelrahman Soliman Alateyh|Cairo University","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMJ prolotherapy","August 24, 2018","September 30, 2018","May 30, 2019","August 31, 2018","null","August 31, 2018","Faculty of Oral and Dental Medicine, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03655275"
98,"NCT03655197","Lipidome and Microbiome Profile of the Eye in Rosacea",,"Recruiting","No Results Available","Rosacea|Ocular Rosacea|Cutaneous Rosacea","Drug: Doxycycline","Lipidome Change in Diversity|Microbiome Change in Diversity|Lipidome Change in Quantity|Microbiome Change in Quantity","University of California, Davis","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","1138313","November 2, 2017","November 2, 2018","November 2, 2018","August 31, 2018","null","August 31, 2018","University of California-Davis, Department of Dermatology, Sacramento, California, United States","","https://ClinicalTrials.gov/show/NCT03655197"
99,"NCT03653494","the Clinicaltrail of the Effection Which of Phrenic Block Using in Non-intubated Video-assisted Thoracoscopic Surgery",,"Enrolling by invitation","No Results Available","Phrenic Nerve Paralysis","Procedure: phrenic block|Procedure: no phrenic block","the volume of anesthetic drugs|the time to get out of bed after surgery|the cost of hospitalization","Shenzhen People's Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","daizhongliang-02","October 1, 2018","December 31, 2018","December 31, 2018","August 31, 2018","null","August 31, 2018","Shenzhen People's Hospital, Shenzhen, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03653494"
100,"NCT03651895","Metformin to Reduce Airway Glucose in COPD Patients",,"Not yet recruiting","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: Metformin|Drug: Placebo","Sputum Glucose Concentration|Nasal Glucose Concentrations|Sputum bacterial load|Sputum inflammatory markers|Quality of life score|Lung function","Imperial College London","All","40 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P74536","September 1, 2018","February 28, 2020","August 31, 2020","August 29, 2018","null","September 6, 2018","","","https://ClinicalTrials.gov/show/NCT03651895"
101,"NCT03651583","Examining the Efficacy of Kiko Exercises on the Prevention of Migraine Headaches",,"Completed","No Results Available","Migraine Headache","Behavioral: Kiko exercises-combines breathing and movement","Change in Migraine Frequency and Severity from Baseline|Change in number of headache free days|Change in number of migraine free days|Change in overall quality of life|Subject satisfaction with Kiko training","Regional Clinical Research","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Kiko Protocol 01","January 2006","May 2006","May 2006","August 29, 2018","null","August 29, 2018","Endwell Family Physicians, Endwell, New York, United States","","https://ClinicalTrials.gov/show/NCT03651583"
102,"NCT03649815","Feasibility and Outcomes of a Digital Health Support for the Schizophrenia Spectrum",,"Completed","No Results Available","Schizophrenia Spectrum and Other Psychotic Disorders","Combination Product: App4Independence","Symptomatology|Recovery Process Engagement|Treatment Adherence","Centre for Addiction and Mental Health","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","38","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","84-2016","April 18, 2017","May 8, 2018","May 8, 2018","August 28, 2018","null","August 28, 2018","Centre for Addiction and Mental Health, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03649815"
103,"NCT03649529","Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy",,"Recruiting","No Results Available","Malignant Melanoma","Biological: GPA-TriMAR-T","safety （Incidence of treatment-related adverse events as assessed by CTCAE v4.03）|Complete response rate[CR] （Complete response rate per the revised International Working Group (IWG) Response Criteria）|Partial response rate [PR] （Partial response rate per the revised International Working Group (IWG) Response Criteria）|Duration of Response （The time from response to relapse or progression）|Progression Free Survival （The time from the first day of treatment to the date on which disease progresses.）|Overall Survival （The number of patient alive, with or without signs of cancer）","Timmune Biotech Inc.|The Second Affiliated Hospital of Hainan Medical University","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","6","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","T2018-7","September 27, 2018","September 15, 2021","January 1, 2022","August 28, 2018","null","October 25, 2018","The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China","","https://ClinicalTrials.gov/show/NCT03649529"
104,"NCT03649438","131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma",,"Not yet recruiting","No Results Available","Relapsed Neuroblastoma|Metastatic Pheochromocytoma","Drug: 131 I-Metaiodobenzylguanidine|Drug: Potassium Iodide|Drug: G-csf","Number of patients who receive 131 I-MIBG|Disease Outcome|Incidence of hematologic toxicities|Incidence of hepatic toxicities|Incidence of thyroid toxicities|Improvement of pain symptoms|Improvement of fatigue","University of Texas Southwestern Medical Center","All","Child, Adult, Older Adult","Early Phase 1","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU 052018-010","September 4, 2018","December 31, 2021","December 31, 2021","August 28, 2018","null","August 28, 2018","The University of Texas Southwestern Medical Center, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT03649438"
105,"NCT03647917","A Pilot Study on the Use of Platelet Rich Plasma (PRP) for Facial and Hand Skin Rejuvenation","PRP","Not yet recruiting","No Results Available","Skin Aging of Face and Hands","Biological: Platelet Rich Plasma","Wrinkle Severity Rating Scale (WSRS)|Hand Grading Scale","Mayo Clinic","Female","45 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","17-005431","October 1, 2018","August 1, 2019","November 1, 2019","August 27, 2018","null","August 27, 2018","Mayo Clinic in Florida, Jacksonville, Florida, United States","","https://ClinicalTrials.gov/show/NCT03647917"
106,"NCT03647657","177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer",,"Not yet recruiting","No Results Available","Thyroid Cancer, Medullary","Drug: 177Lu-PP-F11N|Drug: Sacuitril","Tumor radiation doses|Kidney radiation doses|Organ radiation doses|In-vivo stability|Autoradiography","University Hospital, Basel, Switzerland|Krebsforschung Schweiz, Bern, Switzerland|Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland|University Hospital, Zürich|University Hospital Freiburg","All","18 Years to 64 Years   (Adult)","Early Phase 1","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2018-00972","December 2018","June 2020","October 2020","August 27, 2018","null","November 7, 2018","","","https://ClinicalTrials.gov/show/NCT03647657"
107,"NCT03647514","Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast Cancer",,"Not yet recruiting","No Results Available","Breast Cancer","Drug: Abraxane|Drug: Xeloda","ORR(CR+PR)|Side Effects.|Event Free Survival(DFS)|Overall Survival(OS)","Zhejiang Cancer Hospital","Female","18 Years to 60 Years   (Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","dingxwyh01","October 1, 2018","September 30, 2020","September 30, 2020","August 27, 2018","null","August 27, 2018","","","https://ClinicalTrials.gov/show/NCT03647514"
108,"NCT03647280","The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast Cancer",,"Not yet recruiting","No Results Available","Breast Cancer","Drug: Abraxane|Drug: Epirubicin","ORR(CR+PR)|Side Effects.|Event Free Survival(DFS)|Overall Survival(OS)","Zhejiang Cancer Hospital","Female","18 Years to 60 Years   (Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","dingxwyh02","October 1, 2018","September 30, 2020","September 30, 2020","August 27, 2018","null","August 27, 2018","","","https://ClinicalTrials.gov/show/NCT03647280"
109,"NCT03647202","Food Effects on Milademetan Pharmacokinetics in Healthy Participants",,"Completed","No Results Available","Food Effects on Pharmacokinetics","Drug: Milademetan Treatment A|Drug: Milademetan Treatment B|Drug: Milademetan Treatment C","Maximum plasma concentration (Cmax) of milademetan|Area under the plasma concentration-time curve (AUC) extrapolated to infinity (AUCinf) for milademetan|Time to teach maximum plasma concentration (Tmax) of milademetan|AUC from time 0 to the time of last measurable concentration (AUClast) for milademetan|Lag time (tlag) for milademetan|Terminal elimination half-life (t½) of milademetan|Apparent total body clearance (CL/F) of milademetan clearance (CL/F),|Apparent volume of distribution (Vz/F) of milademetan","Daiichi Sankyo, Inc.","All","18 Years to 55 Years   (Adult)","Early Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","DS3032-A-U115","August 16, 2018","September 13, 2018","September 13, 2018","August 27, 2018","null","September 28, 2018","Covance Clinical Research Unit, Inc., Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT03647202"
110,"NCT03643627","A Study of SYNT001 in Healthy Volunteers",,"Completed","No Results Available","Healthy","Drug: SYNT001|Drug: Placebo","assessment of safety data (counts and percentages of adverse events)|Pharmacokinetics (serum concentration of SYNT001)|Pharmacodynamics","Syntimmune, Inc.","Male","18 Years to 55 Years   (Adult)","Early Phase 1","31","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SYNT-101","August 17, 2016","April 13, 2017","April 13, 2017","August 23, 2018","null","August 24, 2018","Clinical Pharmacology of Miami, Miami, Florida, United States","","https://ClinicalTrials.gov/show/NCT03643627"
111,"NCT03642496","Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies",,"Not yet recruiting","No Results Available","B-Cell Malignancies","Biological: Low dose ET019002- T Cells|Biological: Middle dose ET019002- T Cells|Biological: High dose ET019002- T Cells","Maximum Tolerated Dose|Tmax of serum cytokine levels|Time to baseline for serum cytokine levels|Toxicity profile of ET019002T-cell treatment|Rate of disease response|Progression free survival(PFS)|Time to baseline for B cell level","First Affiliated Hospital Xi'an Jiaotong University|Eureka Therapeutics Inc.","All","6 Years to 80 Years   (Child, Adult, Older Adult)","Early Phase 1","18","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XJTU1AF2018LSL-C003","August 19, 2018","August 19, 2020","September 20, 2020","August 22, 2018","null","August 23, 2018","","","https://ClinicalTrials.gov/show/NCT03642496"
112,"NCT03641248","Bioavailability and Pharmacokinetic Measures of H. Procumbens Extract",,"Not yet recruiting","No Results Available","Osteoarthritis, Knee","Drug: Enteric coated Devil's Claw|Drug: Non-enteric coated Devil's Claw","Maximal concentration level of Devil's Claw metabolites, Cmax (ng/ml)|Time to reach Cmax (h)|Determination of terminal half-life of Devil's Claw, t 1/2 (h)|Change in plasma levels of harpagoside|Change in plasma levels of harpagide|Change in plasma levels of verbascoside|Change in levels of 8-p-coumarylharpagide","University of Missouri-Columbia","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","2010425|0090861","November 2018","January 2019","June 2019","August 21, 2018","null","August 21, 2018","Univ of Missouri Health Care Center, Columbia, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03641248"
113,"NCT03638999","NSAIDs Stent Study",,"Recruiting","No Results Available","Ureteral Stent Placement|Kidney Stone","Drug: Ketorolac Trometamol 30Mg/1mL Injection|Drug: Normal saline","Analog Pain Scale, 0 - 10 rating of pain - Stent insertion Day 1|Analog Pain Scale, 0 - 10 rating of pain - Stent removal|Analog Pain Scale, 0 - 10 rating of pain - Follow-up Visit","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","201804199","July 31, 2018","October 2020","October 2021","August 20, 2018","null","October 2, 2018","Washington University, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03638999"
114,"NCT03637842","Lorcaserin for Cannabis Use Disorder",,"Not yet recruiting","No Results Available","Cannabis Use Disorder","Drug: Lorcaserin|Drug: Placebo oral capsule","Self-report of cannabis use (episodes per day through ecological momentary assessment)|Timeline Follow Back; days of abstinence from cannabis|Urine toxicology|4 Choice Serial Response Test of Impulsivity","New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA)","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","90","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","7662","November 30, 2018","July 30, 2023","December 31, 2023","August 20, 2018","null","October 31, 2018","Columbia Substance Treatment and Research Service, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03637842"
115,"NCT03633474","Defining the Immune Response to Nasopharyngeal Colonisation by the Commensal Neisseria Lactamica","Lac-7","Recruiting","No Results Available","Meningitis, Bacterial","Biological: N. lactamica|Other: PBS only","To measure host T-cell and B-cell memory responses and plasma B-cell responses in blood to experimentally-induced nasopharyngeal colonisation with N. lactamica.|Determine if N. lactamica-specific CD4+ T-cell memory responses detected in blood cross-react with N. meningitidis.","University of Southampton|University Hospital Southampton NHS Foundation Trust","All","18 Years to 45 Years   (Adult)","Early Phase 1","65","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Lactamica-7","September 1, 2018","September 1, 2019","September 1, 2020","August 16, 2018","null","November 7, 2018","NIHR Southampton Clinical Research Facility, Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT03633474"
116,"NCT03632759","Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D",,"Recruiting","No Results Available","Type 1 Diabetes Mellitus","Drug: Liraglutide|Drug: Golimumab","Proportion of individuals with peak MMTT stimulated C-peptide >0.017 pmol/mL.","Carla Greenbaum, MD|Juvenile Diabetes Research Foundation|Benaroya Research Institute","All","18 Years to 50 Years   (Adult)","Early Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB18-044","August 15, 2018","April 2020","June 2020","August 15, 2018","null","October 9, 2018","Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Benaroya Research Institute, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03632759"
117,"NCT03632044","Evaluation of Trigeminal Nerve Blockade",,"Enrolling by invitation","No Results Available","Mouth Abnormalities|Cleft Palate|Birth Defect","Drug: Ropivacaine|Other: Sham Comparator","Change in time to oral intake following palatoplasty for cleft palate|Change in amount of opioids following palatoplasty for cleft palate|Change in length of hospitalization following palatoplasty for cleft palate","University of Florida","All","3 Months to 5 Years   (Child)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","IRB201801011","December 15, 2018","September 2020","December 2020","August 15, 2018","null","October 30, 2018","UF Health, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT03632044"
118,"NCT03631667","Ultralow Dose PAH Binary Mixture Study",,"Not yet recruiting","No Results Available","Environmental Exposure","Drug: [14C]-benzo[a]pyrene|Drug: [14C]-benzo[a]pyrene plus phenanthrene","Plasma and urine 14C-BaP and 14C-BaP metabolite levels after oral dose|Peak plasma concentration of 14C-BaP Cmax|Time at highest plasma concentration of 14C-BaP Tmax|Area under plasma concentration of 14C-BaP versus time curve AUC|Rate of elimination of 14C-BaP|Metabolites of 14C-BaP in plasma|Metabolites of 14C-BaP in urine","Oregon State University|National Institute of Environmental Health Sciences (NIEHS)|Lawrence Livermore National Laboratory|Pacific Northwest National Laboratory","All","21 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","7","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","LPI-8554","November 1, 2019","December 1, 2020","December 1, 2022","August 15, 2018","null","August 21, 2018","","","https://ClinicalTrials.gov/show/NCT03631667"
119,"NCT03631251","Using Honest Placebos to Improve Pain Management in Hand Surgery Patients",,"Not yet recruiting","No Results Available","Hand or Wrist Surgery","Drug: Open Placebo","Enrollment Percentage|Retention Rate|Placebo Intake|Numeric Pain Rating Scale|Pain Interference Short Form 4a, 4-item PROMIS questionnaire|Pain bothersomeness single-item questionnaire","Brown University|Rhode Island Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00000556","August 17, 2018","December 25, 2018","January 3, 2019","August 15, 2018","null","August 15, 2018","","","https://ClinicalTrials.gov/show/NCT03631251"
120,"NCT03631043","Personalized Vaccine in Treating Participants With Smoldering Multiple Myeloma",,"Not yet recruiting","No Results Available","Smoldering Plasma Cell Myeloma","Procedure: Biopsy Specimen Radiography|Biological: Vaccine Therapy","Feasibility assessed by the proportion of participants for whom the vaccine is successfully developed and ready to administer|Incidence of adverse events|Intensity and longevity of antigen specific T-cell mediated immune responses to the neoantigen vaccine|Time to progression|Duration of response|Clinical benefit rate (minor response or better) assessed by the modified International Myeloma Working Group criteria for multiple myeloma|Overall survival","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-0345|NCI-2018-01614|P30CA016672","January 31, 2019","September 30, 2022","September 30, 2022","August 15, 2018","null","November 14, 2018","M D Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03631043"
121,"NCT03630250","Challenge of the Nasopharynx With Neisseria Lactamica Expressing the Meningococcal Protein Neisseria Adhesin A (NadA)","NadA-Lac4","Recruiting","No Results Available","Meningitis, Bacterial|Neisseria Infection","Biological: N. lactamica","Establish the effect of the nasal inoculation of healthy volunteers with a genetically modified strain of Neisseria lactamica expressing NadA by measuring respiratory rate.|Establish the effect of the nasal inoculation of healthy volunteers with a genetically modified strain of Neisseria lactamica expressing NadA by measuring body temperature.|Establish the effect of the nasal inoculation of healthy volunteers with a genetically modified strain of Neisseria lactamica expressing NadA by measuring heart rate.|Establish the effect of the nasal inoculation of healthy volunteers with a genetically modified strain of Neisseria lactamica expressing NadA by measuring blood pressure.|To measure the NadA specific immunity in healthy volunteers following nasal inoculation with Neisseria lactamica expressing NadA","University of Southampton|University Hospital Southampton NHS Foundation Trust","All","18 Years to 45 Years   (Adult)","Early Phase 1","88","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NadA-Lac4","October 18, 2018","September 1, 2019","September 1, 2020","August 14, 2018","null","November 7, 2018","NIHR Southampton Clinical Research Facility, Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT03630250"
122,"NCT03627520","A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Sulfatinib",,"Completed","No Results Available","Healthy","Drug: [14C]Sulfatinib","To investigate the area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration (AUCt) of total radioactivity of [14C] Sulfatinib|To investigate the Maximum observed plasma concentration (Cmax) of total radioactivity of [14C] Sulfatinib|To investigate the time to Cmax (peak time, Tmax) of total radioactivity of [14C] Sulfatinib|To investigate Half-life (t1/2) of total radioactivity of [14C] Sulfatinib|To obtain mass balance data after a single oral dose of [14C] Sulfatinib|To observe the safety of healthy volunteers after a single oral dose of [14C]Sulfatinib.","Hutchison Medipharma Limited","Male","18 Years to 50 Years   (Adult)","Early Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2017-012-00CH1","April 2, 2018","July 1, 2018","July 1, 2018","August 13, 2018","null","August 13, 2018","Hutchison Medipharma Ltd., Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03627520"
123,"NCT03626727","Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia",,"Recruiting","No Results Available","Hypersomnia|Narcolepsy|Traumatic Brain Injury","Drug: Sodium Oxybate Oral Solution [Xyrem]","Change in Subjective Daytime Sleepiness|Change in Sleep Duration|Change in Clinical Condition|Change in Subjective Daytime Sleepiness (ESS)|Change in Nocturnal Sleep Quality (Frequency of nocturnal awakenings)|Change in Nocturnal Sleep Quality (Duration of nocturnal awakenings)|Change in Nocturnal Sleep Quality (Subjective amount of sleep)|Change in Nocturnal Sleep Quality (Frequency of sleep walking)|Change in Nocturnal Sleep Quality (Frequency of hypnagogic hallucinations)|Change in Nocturnal Sleep Quality (Change in Pittsburgh Sleep Quality index) scores)|Change in Nocturnal Sleep Quality (actigraphy)|Change in Global Functioning","Brigham and Women's Hospital","All","18 Years to 64 Years   (Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-P-002884","November 12, 2018","October 1, 2020","December 31, 2020","August 13, 2018","null","November 14, 2018","Brigham and Women's Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03626727"
124,"NCT03626714","Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study",,"Active, not recruiting","No Results Available","Organ Transplant Rejection|Psoriasis","Drug: Sustained Release Injectable Tacrolimus","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Individual blood concentration-time curve - Cmax|Individual blood concentration-time curve - tmax|Individual blood concentration-time curve - AUC|Individual blood concentration-time curve - t1/2","Auritec Pharmaceuticals|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 45 Years   (Adult)","Early Phase 1","8","Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RTB-010|U44AI069674","October 16, 2018","February 28, 2019","June 30, 2019","August 13, 2018","null","November 9, 2018","Worldwide Clinical Trials, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT03626714"
125,"NCT03625518","Mode of Induction in Fetal Growth Restriction and Its Affects on Fetal and Maternal Outcomes",,"Not yet recruiting","No Results Available","Fetal Growth Retardation|Induction of Labor Affected Fetus / Newborn","Drug: prostaglandins E2|Device: intracervical balloon catheter combined with pitocin","mode of delivery|composite neonatal outcome","Tel-Aviv Sourasky Medical Center","Female","18 Years to 50 Years   (Adult)","Early Phase 1","280","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0114-18","September 2018","July 2020","January 2021","August 10, 2018","null","August 10, 2018","Lis Maternity Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel","","https://ClinicalTrials.gov/show/NCT03625518"
126,"NCT03625128","18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls",,"Active, not recruiting","No Results Available","Alzheimer's Disease|Cortical Basal Syndrome|Frontotemporal Dementia|Progressive Supranuclear Palsy|Vascular Cognitive Impairment","Drug: F-18","The primary outcome measures are to evaluate the dosimetry of novel radiotracer 18F-PM-PBB3 in human.|Optimal scanning time for brain imaging using 18F-PM-PBB3 .","Chang Gung Memorial Hospital","All","20 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201700982A0","January 2, 2018","August 3, 2018","August 3, 2018","August 10, 2018","null","August 10, 2018","Chang Gung Memorial Hospital,Linkou, Taoyuan City, Guishan Dist, Taiwan","","https://ClinicalTrials.gov/show/NCT03625128"
127,"NCT03624101","Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations",,"Not yet recruiting","No Results Available","Cystic Fibrosis","Drug: Tezacaftor/Ivacaftor","lung function","University of Alabama at Birmingham","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-300001363","November 1, 2018","November 1, 2020","November 1, 2021","August 9, 2018","null","August 21, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT03624101"
128,"NCT03623984","Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers",,"Not yet recruiting","No Results Available","Neuroendocrine Carcinoma of Pancreas|Carcinoid","Drug: Gallium Dotatate","Comparison of intraoperative findings to preoperative PET scan findings|Determine threshold levels of gallium dotatate uptake in order to determine tumor involvement","University of Alabama at Birmingham","All","19 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-300001980","November 1, 2018","November 1, 2019","November 1, 2020","August 9, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03623984"
129,"NCT03623711","A Prediction Study of Multiple Indexes of the Effect of Different Mechanisms of Antidepressants Treatment on Depression",,"Recruiting","No Results Available","Major Depressive Disorder|Depression, Unipolar","Drug: Escitalopram|Drug: Duloxetine|Drug: Bupropion|Other: Healthy control","change of functional magnetic resonance imaging (fMRI) after medication","Yuqi Cheng|Kunming Medical University","All","18 Years to 60 Years   (Adult)","Early Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","81660237","August 20, 2018","December 31, 2019","December 31, 2020","August 9, 2018","null","August 9, 2018","The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China","","https://ClinicalTrials.gov/show/NCT03623711"
130,"NCT03620552","18F-S16 PET/CT in Healthy Volunteers and Patients With Neurodegenerative Dementia",,"Recruiting","No Results Available","Neurodegenerative Dementia","Drug: 18F-S16","Semiquantitative assessment of lesions and biodistribution|Blood pressure|Pulse|Respiration frequency|Temperature|Serum alanine aminotransferase|Serum albumin|Serum creatinine|Adverse events collection","Oriental Neurosurgery Evidence-Based-Study Team","All","40 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","S16AD2018","August 20, 2017","October 20, 2018","February 20, 2019","August 8, 2018","null","August 8, 2018","PET/CT center,Tianjin Medical University General Hospital, Tianjin, Tianjin, China","","https://ClinicalTrials.gov/show/NCT03620552"
131,"NCT03620201","M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients With Stage II-III HER2/Neu Positive (HER2+) Breast Cancer (BC)",,"Recruiting","No Results Available","Malignant Neoplasm of Breast","Drug: M7824 - patients with Stage II or III HER2+ breast cancer|Drug: Chemotherapy","change in tumor-infiltrating lymphocytes (TIL) percentage pre and post M7824 therapy|Adverse Events (AE) with M7824 Therapy|Pathological Response with M7824 Therapy","M.D. Anderson Cancer Center|EMD Serono","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-0502|NCI-2018-01184","August 3, 2018","December 2018","December 2018","August 8, 2018","null","November 6, 2018","MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03620201"
132,"NCT03616353","IMpact of Perineural Hydrodissection Over Alternative Therapies in Patients With Carpal Tunnel Syndrome","IMPACTS","Not yet recruiting","No Results Available","Carpal Tunnel Syndrome","Procedure: Perineural Hydrodissection|Procedure: Corticosteroid Injection","Change in Boston Carpal Tunnel Questionnaire (BCTQ)|Change in Ultrasonographic Measurement|Change in Electromyographic Measurement- Amplitude|Change in Electromyographic Measurement- Motor Conduction Velocity|Change in Electromyographic Measurement- Sensory Conduction Velocity|Change in Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire|Change in Visual Analog Scale (VAS) for Pain","Leslie Witton|Hamilton Health Sciences Corporation","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1","October 15, 2018","June 30, 2020","June 30, 2020","August 6, 2018","null","October 4, 2018","","","https://ClinicalTrials.gov/show/NCT03616353"
133,"NCT03616262","""Efficacy of Botulinum Toxin Injection in Reducing Limb Pain in Patients With Complex Regional Pain Syndrome""",,"Recruiting","No Results Available","Complex Regional Pain Syndrome","Drug: Botox + Lidocaine|Drug: Lidocaine alone","Reduction in the VAS score will be the primary outcome measure.|Quality of Life as a measure of function with pain.|Disability|Thermography|Goniometry|Algometry|Modified VAS Score|Electrical Impedence Myography","VA Connecticut Healthcare System|Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","20","U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","VACHS","July 2016","December 2019","December 2019","August 6, 2018","null","August 6, 2018","VA Connecticut Healthcare System, West Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03616262"
134,"NCT03615378","Maintenance Dosing of Vitamin D in Crohn's Disease",,"Not yet recruiting","No Results Available","Crohns Disease|Vitamin D Deficiency","Dietary Supplement: 5000 IU D3|Dietary Supplement: 1000 IU D3|Dietary Supplement: Placebo","Vitamin D serum level Vitamin D sufficiency|Time to Vitamin D Insufficiency","Cedars-Sinai Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Pro50335","July 30, 2018","June 30, 2019","June 30, 2020","August 3, 2018","null","August 3, 2018","","","https://ClinicalTrials.gov/show/NCT03615378"
135,"NCT03615248","Effectiveness of a Mobile Health Intervention in Improving the Technique of Inhaled Medications Among Children With Asthma",,"Not yet recruiting","No Results Available","Asthma|Asthma in Children","Device: BreatheSuite","Does the given mobile health intervention improve inhaler technique in children aged 10-18?|To compare the Asthma Control Questionnaire scores before and after use of BreathSuite","Memorial University of Newfoundland","All","10 Years to 18 Years   (Child, Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","MemorialUN001","September 10, 2018","December 10, 2018","February 10, 2019","August 3, 2018","null","August 7, 2018","","","https://ClinicalTrials.gov/show/NCT03615248"
136,"NCT03614455","Pharmacokinetics (PK) Drug Interaction Study of Milademetan and Itraconazole or Posaconazole in Healthy Participants",,"Completed","No Results Available","Pharmacokinetics","Drug: Milademetan|Drug: Itraconazole|Drug: Posaconazole","Maximum plasma concentration (Cmax) of milademetan|Area under the plasma concentration-time curve extrapolated to infinity (AUCinf) of milademetan|Time to reach maximum plasma concentration (Tmax) of milademetan|Area under the plasma concentration-time curve from time 0 to the time of last measurable concentration (AUC0-t) for milademetan|Terminal elimination half-life (t½) of milademetan|Apparent total body clearance (CL/F) of milademetan|Apparent volume of distribution (Vz/F)","Daiichi Sankyo, Inc.","All","18 Years to 55 Years   (Adult)","Early Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","DS3032-A-U107","July 13, 2018","October 1, 2018","October 1, 2018","August 3, 2018","null","November 12, 2018","Covance Clinical Research Unit, Inc., Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT03614455"
137,"NCT03613259","Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma",,"Not yet recruiting","No Results Available","Stage II Adult Soft Tissue Sarcoma|Stage IIA Adult Soft Tissue Sarcoma|Stage IIB Adult Soft Tissue Sarcoma|Stage IIC Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma","Drug: Fluorothymidine F-18|Other: Laboratory Biomarker Analysis|Procedure: Positron Emission Tomography","Change in Fluorothymidine F-18 mean standardized uptake value (SUV) as response to therapy.|Change in Fluorothymidine F-18 peak SUV as response to therapy|Fluorothymidine F-18 mean SUV correlation with pathology mitotic index|Fluorothymidine F-18 peak SUV correlation with pathology mitotic index|Fluorothymidine F-18 peak SUV correlation with enhancement by MRI|Volume of T2 enhanced MRI","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","STUDY00016373|NCI-2017-00833|SOL-16169-LX|P01CA042045|P30CA069533","August 2018","December 1, 2021","June 1, 2022","August 3, 2018","null","August 3, 2018","OHSU Knight Cancer Institute, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT03613259"
138,"NCT03612713","Influence of Medication on Functional Connectivity",,"Recruiting","No Results Available","Prescription Drug Abuse (Not Dependent)","Drug: Oxycodone Medication First|Drug: Placebo First","Change in functional connectivity following oxycodone administration","Yale University|National Institute on Drug Abuse (NIDA)","All","18 Years to 30 Years   (Adult)","Early Phase 1","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","20000 20857|1R21DA045969-01","October 30, 2018","September 2020","September 2020","August 2, 2018","null","November 2, 2018","Magnetic Resonance Research Center at The Anlyan Center Yale School of Medicine, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03612713"
139,"NCT03612401","Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. Mirabegron","SCIMYR","Enrolling by invitation","No Results Available","Spinal Cord Injuries|Neurogenic Bladder|Cognitive Change","Drug: Mirabegron","Change in cognitive measure - Logical Memory I (Immediate) - baseline and post treatment with mirabegron|Change in cognitive measure of memory (SLUMS) - baseline and post treatment with mirabegron|Change in cognitive measure of executive function (Stroop test) - baseline and post treatment with mirabegron|Change in cognitive measure of executive function (SDMT) - baseline and post treatment with mirabegron|Change in memory and executive function (TEXAS) - baseline and post treatment with mirabegron|Change in Neurogenic Bladder Symptom Score (NBSS) - baseline and post treatment with mirabegron|Change in Neurogenic Bowel Dysfunction Score (NBD) - baseline and post treatment with mirabegron|Change in cognitive measure - Logical Memory II (Delayed) - baseline and post treatment with mirabegron","The University of Texas Health Science Center at San Antonio","All","60 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC20180376H","November 26, 2018","October 31, 2019","October 31, 2020","August 2, 2018","null","November 14, 2018","South Texas Veterans Health Care System, Audie L. Murphy Hospital, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT03612401"
140,"NCT03612323","Comparison Between Intraligamentary Piroxicam and Articaine",,"Not yet recruiting","No Results Available","Pulpitis - Irreversible","Drug: Intra-ligamentary Piroxicam|Drug: Intra-ligamentary Articaine","Alleviation of post-operative pain severity|Intra-operative pain during access cavity preparation and instrumentation which will be measured ny Numerical Rating Scale (NRS)","Cairo University","All","18 Years to 60 Years   (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Piroxicam_Articaine","November 2018","May 2019","August 2019","August 2, 2018","null","August 2, 2018","","","https://ClinicalTrials.gov/show/NCT03612323"
141,"NCT03609190","A Multimodal Neuroimaging Study of Brain Activation Patterns Under Ketamine",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Drug: Ketamine|Drug: Placebo","Change in functional reactivity to emotional stimuli|Change in glutamate concentrations in prefrontal cortex|Change in resting-state functional connectivity","Psychiatric University Hospital, Zurich","All","20 Years to 60 Years   (Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","E-31/2008","January 2015","December 2018","December 2018","August 1, 2018","null","August 1, 2018","","","https://ClinicalTrials.gov/show/NCT03609190"
142,"NCT03608592","Human Umbilical Cord Mesenchymal Stem Cells (MSCs) Therapy in ARDS","ARDS","Not yet recruiting","No Results Available","Acute Respiratory Distress Syndrome","Biological: umbilical cord derived mesenchymal stem cells (UCMSCs) suspension|Biological: normal saline","Infusion associated events|Ventilation free days(VFDs)|Oxygenation index(OI) changes|Lung injury score(LIS)|Positive end expiratory pressure(PEEP)|Plateau pressure(Pplat)|Driving pressure|Static compliance","Sun Yat-sen University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QHJH201804","August 2018","August 2020","December 2020","August 1, 2018","null","August 1, 2018","","","https://ClinicalTrials.gov/show/NCT03608592"
143,"NCT03607331","Auricular Concha Electro-acupuncture for the Treatment of Depression",,"Not yet recruiting","No Results Available","Depression|Depressive Symptom|Depressive Disorder","Device: Auricular vagus nerve stimulation|Drug: Citalopram","17 Item Hamilton Depression Rating Scale (HAMD-17) Score Change|14 Item Hamilton Anxiety Scale (HAMA-14) Score Change|NE(ng/L)|5-HT(ng/L)|DA(ng/L)|Cortisol(ng/L)|ACTH(ng/L)|GABA(ng/L)|Glutamate(ng/L)|BDNF(ng/L)|bFGF(ng/L)","China Academy of Chinese Medical Sciences","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","106","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ChinaACMS-5","August 15, 2018","April 1, 2019","June 1, 2019","July 31, 2018","null","July 31, 2018","","","https://ClinicalTrials.gov/show/NCT03607331"
144,"NCT03606707","Efficacy of Fluoroscopic Guided Atlantoaxial Joint Injection on Head and Neck Pain and Sleep Quality in RA Patients",,"Recruiting","No Results Available","Pain, Head|Sleep Disturbance","Drug: Steroids","neck pain|neck disability|sleep quality","Assiut University","All","20 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Atlantoaxial injection in RA","June 1, 2018","July 15, 2018","August 1, 2018","July 31, 2018","null","July 31, 2018","Manal Hassanien, Assiut, Assuit, Egypt|Assiut governorate, Assiut, Egypt","","https://ClinicalTrials.gov/show/NCT03606707"
145,"NCT03606473","Brain Mechanisms in Young Adults","MHP","Recruiting","No Results Available","Cocaine-Related Disorders","Drug: d-amphetamine|Radiation: [C-11]NPA","Percent change in Binding potential (BPnd)","Gale Richardson|National Institute on Drug Abuse (NIDA)|University of Pittsburgh","All","25 Years to 30 Years   (Adult)","Early Phase 1","30","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PRO17080203","January 24, 2018","January 1, 2022","January 1, 2022","July 30, 2018","null","July 30, 2018","University of Pittsburgh, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03606473"
146,"NCT03605901","Dosing of Methadone for Spine Surgery",,"Not yet recruiting","No Results Available","Pain, Postoperative","Drug: Standard dosing of methadone|Drug: Aliquots of methadone titrated to apnea","Change in opioid requirement for complex spine surgery patients","University of Florida","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","IRB201700673","November 2018","September 2020","December 2020","July 30, 2018","null","October 11, 2018","UF Health, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT03605901"
147,"NCT03604744","Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin","LSD-psilo","Not yet recruiting","No Results Available","Healthy","Drug: LSD|Drug: Psilocybin","Altered states of consciousness|Subjective effects assessed by VAS|Subjective effects assessed by AMRS scales|Psychotomimetic effects|Mystical-type experiences assessed by SCQ|Mystical-type experiences assessed by MS scales|Effects on emotion processing|Autonomic effects assessed by heart rate|Autonomic effects assessed by blood pressure|Autonomic effects assessed by body temperature","Matthias Liechti|University Hospital, Basel, Switzerland","All","25 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","BASEC 2018-00985","December 1, 2018","April 1, 2020","April 1, 2020","July 27, 2018","null","August 10, 2018","","","https://ClinicalTrials.gov/show/NCT03604744"
148,"NCT03604367","Gait Mate: Examining Neural Networks Engaged During Lower Extremity Movement in the MRI",,"Recruiting","No Results Available","Stroke|Motor Activity","Device: GAITRite assessment","fMRI protocols will measure neural function activity during active bipedal movement in healthy volunteers","Medical University of South Carolina|MUSC Center for Biomedical Research Excellence (COBRE) in Stroke Recovery","All","21 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","72777","February 1, 2018","November 2018","May 2019","July 27, 2018","null","July 27, 2018","Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT03604367"
149,"NCT03604289","Angiotensin 1-7 in Obesity Hypertension",,"Not yet recruiting","No Results Available","Obesity|Hypertension","Drug: Angiotensin-(1-7)|Drug: Saline","Change in brachial artery diameter with reactive hyperemia|Heart Rate Variability|Circulating catecholamines|Change in coronary blood velocity to the cold pressor test|Change in systolic and diastolic blood pressure to the cold pressor test|Change in muscle sympathetic nerve activity to the cold pressor test","Amy Arnold|American Heart Association|Milton S. Hershey Medical Center","All","18 Years to 60 Years   (Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","STUDY00008170|18POST33960087","January 2019","June 2020","June 2021","July 27, 2018","null","October 25, 2018","Penn State College of Medicine, Hershey, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03604289"
150,"NCT03603730","Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis",,"Recruiting","No Results Available","Dyspepsia|Gastroparesis","Device: taVNS","Neuroimaging|Electrogastrography (EGG)|Electrocardiography (ECG)|Respiration|Skin Conductance Levels (SCL)","Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2010P000440","October 2018","September 2020","October 2020","July 27, 2018","null","October 3, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03603730"
151,"NCT03601585","Evaluation of the Effectiveness of Fibrous Foods, Sugar-free Gomes and Rolly Brush® in the Dental Biofilm Removal",,"Completed","No Results Available","Self Cleaning","Device: Comparison of dental biofilm removal.","Plaque index","Federal University of São Paulo","All","18 Years to 26 Years   (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Device Feasibility","self-cleaning","March 15, 2018","June 19, 2018","June 19, 2018","July 26, 2018","null","July 26, 2018","Periodontics Clinic, Department of Dentistry, Diamantina, Minas Gerais, Brazil","","https://ClinicalTrials.gov/show/NCT03601585"
152,"NCT03601338","Low Molecular Weight Heparin in Pregnancies With Unexplained Stillbirths",,"Recruiting","No Results Available","Unexplained Stillbirth","Drug: Bemiparin|Other: multivitamins and routine antenatal follow up","Stillbirth|Early neonatal death|Low birth weight|Preterm labor|Pre-eclampsia|major abruptio placenta","Hawler Medical University","Female","15 Years to 44 Years   (Child, Adult)","Early Phase 1","152","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HawlerMU2.7","August 1, 2015","December 1, 2019","December 31, 2019","July 26, 2018","null","August 6, 2018","Hawler Medical University, Erbil, Kurdistan Region, Iraq","","https://ClinicalTrials.gov/show/NCT03601338"
153,"NCT03600623","Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer",,"Recruiting","No Results Available","Locally Advanced Pancreatic Cancer|Borderline Pancreatic Inoperable Cancer|Pancreatic Cancer","Drug: Folfirinox|Drug: Gemcitabine nab-Paclitaxel","Number of participants with adverse events as a measure of safety and tolerability|Progression-free survival|Overall survival|Rate of preoperative chemotherapy + radiotherapy completion|Proportion of participants undergoing surgery after preoperative chemoradiation therapy","University of Alabama at Birmingham","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB160830003 (UAB 1632)","December 7, 2016","July 2020","July 2021","July 25, 2018","null","July 25, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT03600623"
154,"NCT03599726","Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil",,"Recruiting","No Results Available","Parkinson Disease","Drug: Donepezil|Drug: Placebo","Oxygenated Hemoglobin levels in the prefrontal cortex while walking (microM).|Stride time variability of gait (%).|Gait speed (m/s)|Stride length (m)|Turning velocity (degrees/s)|Turning duration (s)","Oregon Health and Science University|Medical Research Foundation, Oregon","All","50 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","eIRB 17805","July 30, 2018","December 30, 2018","January 1, 2019","July 25, 2018","null","July 25, 2018","Oregon Health & Science University, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT03599726"
155,"NCT03599206","ONES Grant: CXCL10/CXCR3 Regulation of Ozone-Induced Epithelial Permeability",,"Recruiting","No Results Available","Environmental and Genetic Factors on Lung Function","Drug: Ozone|Other: Filtered Air","Change in Ozone (O3) induced epithelial permeability, as measured by the level of clara cell secretory protein (ng/mL)|Change in Ozone (O3) induced epithelial permeability, as measured by albumin level (ug/mL)|Change in Ozone O3 induced alterations in gene expression of airway epithelial cells, and bronchoalveolar lavage cells|Change in Ozone O3 induced alterations in bronchoalveolar lavage cytokines and growth factors","Duke University","All","18 Years to 45 Years   (Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other","Pro00088966","September 20, 2018","August 2020","August 2020","July 25, 2018","null","October 16, 2018","Duke Asthma, Allergy, and Airway Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03599206"
156,"NCT03597230","Per-operative Exploration of the Peri-pancreatic Lymphatic Pathways During Pancreatic Surgical Resection",,"Recruiting","No Results Available","Pancreatic Resection","Other: Dye","Lymph node areas colored by the diffusion of the blue patente","CHU de Reims","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PO18091","July 10, 2018","January 2019","January 2019","July 24, 2018","null","July 24, 2018","Chu Reims, Reims, France","","https://ClinicalTrials.gov/show/NCT03597230"
157,"NCT03596775","Effect of Dexmedetomidine on Emergence Agitation and Postoperative Behavior Changes in Children",,"Not yet recruiting","No Results Available","Emergence Agitation","Drug: Dexmedetomidine|Drug: saline","Incidence of EA as assessed by the Pediatric Anesthesia Emergence Delirium (PAED) scale|Pain scores as assessed by the Face, Legs, Activity, Cry, Consolability (FLACC) scale|Rescue analgesia and sedative drug consumption|Incidence of adverse events|Post-hospitalization negative behaviour changes as assessed by the Post Hospitalisation Behaviour Questionnaire (PHBQ) scale","Xuzhou Medical University","All","2 Years to 7 Years   (Child)","Early Phase 1","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","XYFY-2018-0061","September 1, 2018","June 1, 2019","July 1, 2019","July 24, 2018","null","September 7, 2018","The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China","","https://ClinicalTrials.gov/show/NCT03596775"
158,"NCT03594630","Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer",,"Not yet recruiting","No Results Available","Rectal Adenocarcinoma|Stage II Rectal Cancer AJCC v8|Stage IIA Rectal Cancer AJCC v8|Stage IIB Rectal Cancer AJCC v8|Stage IIC Rectal Cancer AJCC v8|Stage III Rectal Cancer AJCC v8|Stage IIIA Rectal Cancer AJCC v8|Stage IIIB Rectal Cancer AJCC v8|Stage IIIC Rectal Cancer AJCC v8","Drug: Chemotherapy|Other: Patient Observation|Other: Questionnaire Administration|Procedure: Resection of Rectum","Overall organ preservation rate|Local tumor regrowth rate|Time to surgery or death|Decision quality assessment determined by European Organization for Treatment and Research of Cancer Quality of Life Questionnaire (EORTC-QLQ30+CR29)|Overall survival (OS)|Regression-free survival (RFS)|Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Surgical success rates|Radiographic Findings|Pathologic Findings","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","120","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-0549|NCI-2018-01142|P30CA016672","January 18, 2019","January 2020","January 2020","July 20, 2018","null","November 2, 2018","M D Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03594630"
159,"NCT03594565","The Use of Topical Nasal Steroids for Skin Reactions to Continuous Glucose Monitoring System, Among Children and Youth With Type 1 Diabetes Mellitus: Case Series",,"Completed","No Results Available","T1DM|Hypersensitivity","Drug: Fluticasone Propionate","Difference in skin irritation before and after regular application of nsFP according to the modified Draize scale.|Change in BMI SDS|Change in height SDS 6 months after nsFP use|Change in mean glucose 6 months after nsFP use|Change in glycated hemoglobin 6 months after nsFP use","Assaf-Harofeh Medical Center","All","1 Year to 20 Years   (Child, Adult)","Early Phase 1","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","0277-16-ASF","March 2016","June 2017","June 2018","July 20, 2018","null","July 20, 2018","","","https://ClinicalTrials.gov/show/NCT03594565"
160,"NCT03592329","Vagus Nerve Stimulation and Stress Reduction Training for Migraine",,"Not yet recruiting","No Results Available","Migraine","Behavioral: Stress Reduction Training A|Device: active tVNS|Behavioral: Stress Reduction Training B|Device: sham tVNS","Brain activity changes in migraine patients in response to treatment|Brain inflammation changes in migraine patients in response to treatment|Brain activity differences between Migraine patients and healthy controls|Brain inflammation differences between Migraine patients and healthy controls","Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","P01AT009965","February 2019","July 2023","July 2023","July 19, 2018","null","July 19, 2018","Anthinoula A. Martinos Center, Charlestown, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03592329"
161,"NCT03592121","Study to Investigate the Effect of AB-101 in Breast Cancer Survivors",,"Recruiting","No Results Available","Sexual Dysfunction|Sexual Arousal Disorder|Sexual Dysfunction, Physiological|Breast Cancer|Nipple Disorder|Neuropathy|Cancer of Breast","Drug: AB-101|Drug: Placebo","Delayed Orgasm|Vaginal Dryness","Applied Biology, Inc.","Female","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","RJ-101-RCT-001","July 9, 2018","November 12, 2019","November 12, 2019","July 19, 2018","null","October 5, 2018","Southern CA Center for Sexual Health and Survivorship Medicine, Newport Beach, California, United States","","https://ClinicalTrials.gov/show/NCT03592121"
162,"NCT03591757","Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR)",,"Enrolling by invitation","No Results Available","Transthyretin Amyloidosis|Amyloidosis, Leptomeningeal, Transthyretin-Related","Drug: Tolcapone","Change in plasma TTR stabilization|Change in CSF TTR stabilization|Changes in plasma TTR stabilization|Tolcapone Concentration in CSF|Tolcapone Concentration in Serum","Boston University|Corino Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-37757","October 2018","February 2019","March 2019","July 19, 2018","null","October 12, 2018","Amyloidosis Center, Boston Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03591757"
163,"NCT03591614","Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma",,"Not yet recruiting","No Results Available","Monoclonal Gammopathy|Smoldering Myeloma|Myeloma","Biological: DKK1","Number of patients with dose limiting toxicity|Average time of progression-free survival|Average time of overall survival|Average time to progression|Best overall response|Clinical Benefit Response","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE1A16","December 2018","August 2019","August 2020","July 19, 2018","null","July 19, 2018","University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03591614"
164,"NCT03590821","Timed Aspirin Chronobiome",,"Recruiting","No Results Available","Healthy","Drug: Aspirin 81 mg|Drug: Celecoxib 200mg capsule","Blood pressure [mmHg]|Mean arterial pressure (MAP)","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","829532","November 1, 2018","May 31, 2020","May 31, 2021","July 18, 2018","null","October 3, 2018","Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03590821"
165,"NCT03589898","Study of Neuroimaging Biomarkers of Social Cognition Deficits in Adolescents (Age 13-17) With Autism Spectrum Disorder and Effects of Gabapentin",,"Recruiting","No Results Available","Autism Spectrum Disorder","Drug: Gabapentin","Cortical GABA in Anterior Cingulate Cortex|Cortical GABA in Occipital Cortex|Cortical Glx in Anterior Cingulate Cortex|Cortical Glx in Occipital Cortex","University of Massachusetts, Worcester|National Institute of Mental Health (NIMH)|Johns Hopkins University","All","13 Years to 17 Years   (Child)","Early Phase 1","70","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","H00012656|1K23MH113008-01A1","September 14, 2017","June 1, 2021","June 1, 2021","July 18, 2018","null","July 19, 2018","University of Massachusetts Medical School, Worcester, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03589898"
166,"NCT03587961","Personalized Theratyping Trial",,"Not yet recruiting","No Results Available","Cystic Fibrosis","Drug: Symdeko","spirometry","University of Alabama at Birmingham","All","6 Years and older   (Child, Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-300001867","January 1, 2019","January 1, 2020","January 1, 2021","July 16, 2018","null","October 29, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT03587961"
167,"NCT03587376","Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)",,"Completed","No Results Available","Alzheimer Disease","Drug: Atabecestat","Number of Participants with Atabecestat-Specific T-cell Mediated Inflammatory Immune Response|Participants T-cell Receptor (TCR) Sequencing","Janssen Research & Development, LLC","All","50 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","9","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","CR108462|54861911ALZ0002|2018-000403-17","May 30, 2018","August 23, 2018","August 23, 2018","July 16, 2018","null","October 15, 2018","Ziekenhuis Hoge Beuken, Hoboken, Belgium|Hôpital Fernand Widal, Paris, France|CTC North GmbH & Co. KGim Spectrum am UKE, Hamburg, Germany|Fundacion Ace, Barcelona, Spain|Minnesmottagningen, M51, Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT03587376"
168,"NCT03585725","A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma",,"Recruiting","No Results Available","Follicular Lymphoma|Mantle Cell Lymphoma","Drug: Ribavirin","Number of participants who receive treatment for at least 3 months, have peripheral blood samples collected at baseline and monthly while on treatment, and have levels of BCL-t or cyclin D1, respectively, obtained from their peripheral blood samples|Number of participants with treatment-related Serious Adverse Events as assessed by the CTCAE v4.0|Number of participants who achieve a response to ribavirin treatment based on PET/CT or CT|Average change in BCL2-t or Cyclin D1 cfDNA levels","Weill Medical College of Cornell University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1709018594","September 26, 2018","January 2020","January 2020","July 13, 2018","null","November 14, 2018","Weill Cornell Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03585725"
169,"NCT03584724","Assessment of the Anti-inflammatory Effects of Norflo Oro in Acute Relapses of HLA-B27 Associated Autoimmune Uveitis",,"Not yet recruiting","No Results Available","Uveitis","Drug: Norflo Oro|Drug: Placebo for Norflo Oro","The reduction of the mean number of relapses per patient between the year before treatment and the study period.|The improvement of side effects due to HLA-B27-associated uveitis","Eye Pharma|Bascom Palmer Eye Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","7","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Norflo-Oro-16","September 2018","May 2019","July 2019","July 12, 2018","null","July 12, 2018","Bascom Palmer Eye Institute, Miami, Florida, United States","","https://ClinicalTrials.gov/show/NCT03584724"
170,"NCT03584438","iTBS Methods and Motor Cortex Excitability",,"Recruiting","No Results Available","Motor Activity","Device: Real iTBS|Device: Sham iTBS","Effects of theta burst stimulation protocols of LTP-like and LTD-like stimulation on change in motor cortex excitability","Medical University of South Carolina|MUSC Center for Biomedical Research Excellence in Stroke Recovery","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","68775","May 26, 2018","November 2019","May 2020","July 12, 2018","null","July 23, 2018","Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT03584438"
171,"NCT03584425","Imaging Laterality in Chronic Stroke Patients",,"Recruiting","No Results Available","Stroke|Motor Cortex; Lesion","Diagnostic Test: Rasch modified version of the Fugl-Meyer Motor assessment|Diagnostic Test: Anatomical image acquisition|Diagnostic Test: Functional MRI task and acquisition","Compare the ratio of gluatamte and gaba concentrations within the contralesional primary motor cortex|Quantify the relationship between neural activity and motor performance using the Rasch modified version of the Fugl-Meyer motor assessment battery to acquire three aspects of motor performance for all individuals in both groups.","Medical University of South Carolina|MUSC Center for Biomedical Research Excellence in Stroke Recovery","All","21 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","31250","December 15, 2014","November 2022","May 2023","July 12, 2018","null","July 23, 2018","Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT03584425"
172,"NCT03583866","Adiposity and Endothelin Receptor Function","END-RF","Recruiting","No Results Available","Hypertension","Drug: Candesartan|Drug: Placebo","Percentage Change in Flow-Mediated Dilation (FMD)","Augusta University|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 40 Years   (Adult)","Early Phase 1","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1148277|5P01HL069999","May 21, 2018","June 2020","June 2021","July 12, 2018","null","July 12, 2018","Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03583866"
173,"NCT03582605","Antibiotics Prior to Mini-screw Implant Insertion",,"Recruiting","No Results Available","Inflammation at Mini-screw Insertion Site|Mobility, Mini-screw","Drug: Amoxicillin|Drug: Placebo oral capsule","Mini-screw implant success or failure","St. Louis University","All","12 Years and older   (Child, Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","29379","August 7, 2018","August 2019","October 2019","July 11, 2018","null","September 13, 2018","Saint Louis University Center for Advanced Dental Education, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03582605"
174,"NCT03582553","Safety and Pharmacokinetics of an Extract of Naringenin","Citrus","Completed","No Results Available","Safety Issues|Pharmacokinetics","Dietary Supplement: Naringenin|Other: Placebo","Incidence of treatment-emergent adverse events following a single dose of a citrus extract of naringenin|Measurement of area under the serum naringenin concentration versus time curve at 150 and 600 mg doses|Measurement of maximal concentration of serum naringenin at 150 and 600 mg doses|Measurement of time to peak concentration of serum naringenin at 150 and 600 mg doses|Measurement of half life of naringenin at 150 and 600 mg doses|Measurement of apparent oral clearance of naringenin at 150 and 600 mg doses|Measurement of concentration of serum naringenin at 300 and 900 mg doses","Pennington Biomedical Research Center|Louisiana Clinical and Translational Science Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","2018-011","May 25, 2018","September 28, 2018","September 28, 2018","July 11, 2018","null","November 6, 2018","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT03582553"
175,"NCT03580590","Efficacy of Oral Diltiazem on the Intraoperative Bleeding in Functional Endoscopic Sinus Surgery",,"Not yet recruiting","No Results Available","Hypotension on Induction","Drug: oral Diltiazem|Drug: IV Tranexamic Acid|Drug: Placebo Oral Tablet","Estimated Blood Loss|The Boezaart and van der Merwe intraoperative surgical field scale|Incidence of hypotension|total consumption of propofol|Heart Rate|End Tidal CO2","Assiut University","All","18 Years to 60 Years   (Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Oral diltiazem in FESS","September 1, 2018","November 1, 2019","January 1, 2020","July 9, 2018","null","July 9, 2018","","","https://ClinicalTrials.gov/show/NCT03580590"
176,"NCT03580525","Nicotine Delivery Rate and Its Abuse Potential: Impact of Menthol",,"Not yet recruiting","No Results Available","Nicotine Dependence","Drug: Nicotine saline infusion 0.00mcg/kg/s|Drug: Nicotine infusion 0.24mcg/kg/s|Drug: Nicotine infusion 0.096mcg/kg/s|Drug: Nicotine infusion 0.048 mcg/kg/s|Drug: Nicotine infusion 0.024mcg/kg/s","Peak Changes on items of the Drug Effects Questionnaire (DEQ)","Yale University","All","18 Years to 30 Years   (Adult)","Early Phase 1","70","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","HIC: 2000023289","December 1, 2018","August 1, 2020","December 1, 2020","July 9, 2018","null","October 22, 2018","","","https://ClinicalTrials.gov/show/NCT03580525"
177,"NCT03579953","Nicotine TMS EFT Smoking Pilot Study",,"Recruiting","No Results Available","Smoking|Nicotine Dependence|Addiction|Smoking, Cigarette","Device: Real cTBS|Device: Sham cTBS","Changes in craving after a single session of cTBS|Changes in delayed discounting after a single session of cTBS","Medical University of South Carolina","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","74722","May 22, 2018","May 2019","May 2019","July 9, 2018","null","July 23, 2018","Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT03579953"
178,"NCT03579446","Levorphanol as A Second Line Opioid in Reducing Pain in Participants With Cancer",,"Not yet recruiting","No Results Available","Malignant Neoplasm|Metastatic Malignant Neoplasm|Pain","Drug: Hydrocodone|Drug: Hydromorphone Hydrochloride|Drug: Levorphanol|Drug: Morphine Sulfate|Drug: Oxycodone|Drug: Oxymorphone Hydrochloride|Other: Questionnaire Administration","Proportion of successful opioid rotation (OR) from morphine equivalent daily dose (MEDD) to levorphanol|Opioid rotation ratio (ORR)|Change of Exercise Self-Efficacy Scale (ESES) pain score|Incidence of levorphanol related side effects|Personalized pain goal (PPG)","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","86","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2017-0925|NCI-2018-01139|P30CA016672","October 31, 2018","January 16, 2019","January 16, 2019","July 6, 2018","null","October 16, 2018","M D Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03579446"
179,"NCT03578432","Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy",,"Recruiting","No Results Available","Salivary Gland Dysfunction|Xerostomia|Head and Neck Cancer","Drug: Everolimus|Other: Laboratory Biomarker Analysis|Other: Survey Administration","Percent recovery of salivary gland function|Change of saliva flow rates|Saliva protein composition|Total score obtained on Xerostomia Visual Analog Scale survey|Total score obtained on Xerostomia Inventory Survey","University of Arizona|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","16","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","PHXB-17-0072-70-15|NCI-2018-00492|CRAD001XUA274T|P30CA023074","May 4, 2018","June 1, 2019","June 1, 2020","July 6, 2018","null","July 12, 2018","The University of Arizona Cancer Center, Phoenix, Arizona, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT03578432/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03578432"
180,"NCT03578224","Contrast-Enhanced Ultrasound Identification of Sentinel Nodes in Esophageal Cancer",,"Recruiting","No Results Available","Esophagus","Procedure: Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA)|Procedure: Contrast-Enhanced Ultrasound|Procedure: Fine-Needle Aspiration|Drug: Sonazoid (Perflubutane)","Accuracy rate of traditional endoscopic ultrasonography (EUS) with suspicious node biopsy and lymphosonography for sentinel node identification|Number of nodes identified","Sidney Kimmel Cancer Center at Thomas Jefferson University|National Cancer Institute (NCI)|Thomas Jefferson University","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F.235|R21CA218946","September 6, 2018","April 2020","April 2021","July 6, 2018","null","October 9, 2018","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03578224"
181,"NCT03577730","Caffeine and Neurologic Recovery Following Surgery and General Anesthesia",,"Recruiting","No Results Available","Pain, Postoperative","Drug: Caffeine Citrate|Drug: Dextrose Water","Cumulative opioid consumption: Postoperative opioid consumption, oral morphine equivalents (mg)|Acute pain (patient-reported) as assessed by Visual Analogue Scale|Acute pain (observer-reported) as assessed by Behavioral Pain Scale|Time until anesthetic emergence|Depressive symptoms as assessed by Hospitalized Anxiety and Depression Scale (HADS-D)|Anxiety symptoms as assessed by Hospitalized Anxiety and Depression Scale (HADS-A)|Cognitive Function as assessed by Trail Making Test|Positive Affect as assessed by PANAS (Positive and Negative Affect Schedule)|Negative Affect as assessed by PANAS (Positive and Negative Affect Schedule)","University of Michigan","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HUM00135919","July 10, 2018","June 11, 2020","July 11, 2020","July 4, 2018","null","July 11, 2018","Michigan Medicine, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03577730"
182,"NCT03577262","A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic Density",,"Recruiting","No Results Available","Healthy|Alzheimer Disease","Other: [11C]-UCB-J","Measure [11C]-UCB-J plasma radioactivity levels in plasma over time|Measure concentration of radioactivity as a function of time according to pre-defined brain regions","Rodin Therapeutics|QPS Netherlands B.V.|University Medical Center Groningen|VU University Medical Center","All","55 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","20","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","RDN-NI-001","July 23, 2018","February 20, 2019","March 20, 2019","July 4, 2018","null","November 9, 2018","VU Medical Center, Dept. Radiology and Nuclear Medicine, Amsterdam, Netherlands|QPS Netherlands B.V., Groningen, Netherlands|University Medical Center Groningen, Nuclear Medicine and Molecular Imaging, Groningen, Netherlands","","https://ClinicalTrials.gov/show/NCT03577262"
183,"NCT03576781","Developing rTMS Treatment Strategies for Pain in Opiate Dependence",,"Recruiting","No Results Available","Pain|Chronic Pain|Opioid Dependence|Opioid Use","Device: Real iTBS|Device: Sham iTBS|Device: Real cTBS|Device: Sham cTBS","iTBS to the left DLPFC vs. cTBS to the left MPFC|Changes in pain threshold|Changes in opiate pain and craving inventory","Medical University of South Carolina|South Carolina Clinical & Translational Research Institute (SCTR)","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","61328","February 9, 2017","December 2019","December 2019","July 3, 2018","null","July 23, 2018","Medical University of South Carolina, Charleston, South Carolina, United States|Ralph H Johnson Veterans Medical Center, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT03576781"
184,"NCT03576664","Effects of Sleep Deprivation and Adrenergic Inhibition on Glymphatic Flow in Humans",,"Recruiting","No Results Available","Sleep Deprivation|Sleep Wake Disorders|Sleep","Drug: Carvedilol 25mg|Drug: Placebo oral capsule","Measure the change in functional Magnetic Resonance Imaging (fMRI)-detected glymphatic flow in wakefulness and sleep at baseline|Measure and compare functional Magnetic Resonance Imaging (fMRI)-detected glymphatic flow in baseline sleep and in sleep-deprived sleep|Measure and compare fMRI-detected glymphatic flow in placebo and carvedilol condition|Correlate fMRI-detected glymphatic flow with simultaneous detected EEG sleep slow wave activity|Measure EEG slow wave activity during Magnetic Resonance imaging and compare Carvedilol with placebo to see how sleep is affected by the treatment|Measure if fMRI-detected glymphatic flow correlates with subjective sleepiness ratings|Measure fMRI-detected glymphatic flow and whether it correlates with cognitive performance before and after MR imaging|Measure fMRI-detected glymphatic flow and whether correlates with changes in cognitive performance from before to after MR imaging|Measure whether Carvedilol improves sleepiness after the MR scan compared to placebo|Measure whether Carvedilol improves cognitive performance (measurement: psychomotor vigilance test) after the MR scan compared to placebo|Measure whether fMRI-detected glymphatic flow is spatially correlated with simultaneous EEG NREM slow wave activity|Measure whether fMRI-detected glymphatic flow correlates with simultaneous NREM EEG activity|Measure whether fMRI-detected glymphatic flow is positively correlated with sleep driven structural changes in T2 and diffusion weighted (DWI) images|Measure whether Carvedilol modulates nocturnal recovery sleep (measurement: EEG slow wave activity) after sleep deprivation|Measure whether the psychomotor vigilance test is modulated by carvedilol|Measure whether the visual attention (measurement: Theory of Visual Attention task) is modulated by carvedilol|Measure whether the visual attention (measurement: Theory of Visual Attention task) is modulated by sleep-deprivation|Measure whether emotional memory performance (measurement: emotional word pair task) is modulated by carvedilol|Measure whether emotional memory performance (measurement: emotional word pair task) is modulated by sleep-deprivation","Gitte Moos Knudsen|Center for translational Neuroscience, University of Copenhagen, Denmark|Danish Center for Sleep Medicine, Rigshospitalet, Denmark|Rigshospitalet, Denmark","All","18 Years to 35 Years   (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","sleepgf|H-16045933","June 25, 2018","April 1, 2019","April 1, 2019","July 3, 2018","null","July 3, 2018","Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT03576664"
185,"NCT03575949","Dual-Time Point (DTP) FDG PET CT for the Post-Treatment Assessment of Head and Neck Tumors Following Definitive Chemoradiation Therapy",,"Recruiting","No Results Available","Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites|Head and Neck Primary Squamous Cell Carcinoma","Drug: FDG|Procedure: PET/CT Scan|Procedure: FDG PET/CT Scan","Optimal FDG PET Imaging Time","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2017-0826","June 15, 2018","December 2019","December 2019","July 3, 2018","null","July 13, 2018","MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03575949"
186,"NCT03575598","Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study","SNOW","Recruiting","No Results Available","Squamous Cell Carcinoma, Head And Neck|Squamous Cell Carcinoma Mouth|Squamous Cell Carcinoma of the Oral Cavity","Drug: Sitravatinib|Biological: Nivolumab","Pharmacodynamic effects with biomarker analyses|Immune effects with biomarker analyses|Toxicities as per NCI CTCAE v5.0|Rate of completion of surgery within the initially planned window|Rate of post-operative complications|Rate of disease progression as per RECIST v1.1 during the pre-operative treatment period|Pathologic treatment effect in tumor and/ or lymph nodes|Rate of nodal extracapsular extension and positive margins|Analysis of plasma Sitravatinib concentration before and after Nivolumab therapy","University Health Network, Toronto|Mirati Therapeutics Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SNOW-001","August 30, 2018","August 30, 2020","August 30, 2020","July 2, 2018","null","September 5, 2018","Princess Margaret Cancer Centre, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03575598"
187,"NCT03574870","Wearable Sensor for Biometrics During Locoregional Therapy for Head and Neck Cancer","FITBIT","Recruiting","No Results Available","Cancer of Head and Neck","Device: wearable sensor","Number of participants who could wear the device more than 90% of the time, of 23 hours a day, daily|Daily data acquisition rate|Changes in daily steps taken|Changes in heart rate|Changes in sleep habits|Volume of intravenous fluids|Days of inpatient hospitalization|Changes in pain level|Number of emergency department visits.|Utilization of pain medication|Physical and mental well-being|Sleep quality","University of Texas Southwestern Medical Center","All","18 Years to 120 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","STU 102016-059","October 30, 2017","October 2018","October 2020","July 2, 2018","null","July 2, 2018","University of Texas Southwestern Medical Center, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT03574870"
188,"NCT03574220","Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer",,"Not yet recruiting","No Results Available","Non Small Cell Lung Cancer","Drug: Pembrolizumab|Radiation: Stereotactic body radiotherapy","Percent of patients tolerant to study drug|Duration of Distant metastases free survival (DMFS)|Duration of Disease Free Survival|Duration of Overall Survival|Duration of Local control","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE7516","December 2018","March 2022","March 2027","June 29, 2018","null","October 5, 2018","Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03574220"
189,"NCT03574207","Targeted Transcranial Magnetic Stimulation to Improve Hippocampal-dependent Declarative Memory Abilities",,"Not yet recruiting","No Results Available","Mild Cognitive Impairment|Memory Loss","Device: Transcranial magnetic stimulation","Changes in memory performance measured with the number of studied face-word associations recalled|Changes in intrinsic functional connectivity between the target brain region stimulated with rTMS and other brain regions.","University of Nebraska|National Institute of General Medical Sciences (NIGMS)","All","19 Years and older   (Adult, Older Adult)","Early Phase 1","70","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","096-18-FB","July 2018","July 2020","July 2021","June 29, 2018","null","July 4, 2018","","","https://ClinicalTrials.gov/show/NCT03574207"
190,"NCT03574051","the Microbiota Are Associated With Iodine-131 Therapy and Hypothyroidism",,"Recruiting","No Results Available","Microbiota","Drug: Probiotic","The number of patients with improved side effects","First Affiliated Hospital of Harbin Medical University","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Yunwei Wei 2018 -05-21","May 1, 2018","May 1, 2020","May 1, 2022","June 29, 2018","null","July 16, 2018","First affiliated hospital of Harbin medical university, Harbin, Heilongjiang, China","","https://ClinicalTrials.gov/show/NCT03574051"
191,"NCT03573349","Glutamate MRS During Ketamine Infusion",,"Not yet recruiting","No Results Available","Major Depressive Disorder|Treatment Resistant Depression","Drug: Ketamine","Change in glutamate and correlation with change in depression symptoms measured with MADRAS","Mayo Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-011373","November 2018","August 2019","December 2019","June 29, 2018","null","November 7, 2018","Mayo Clinic in Rochester, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT03573349"
192,"NCT03573258","Dietary Fibers and Satiety in Bariatric Patients","FIBAR","Recruiting","No Results Available","Bariatric Surgery Candidate","Dietary Supplement: Fiber or Placebo (depending on the randomization)","food intake|fermentation|Appetite ratings on hunger, fullness and satiety|short chain fatty acid levels|gut hormones|glucose metabolism","University of Zurich|Dr. Robert E. Steinert, PhD","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","ID 2017-02287","June 1, 2018","February 2021","December 2022","June 29, 2018","null","July 16, 2018","University Hospital Zurich, Zürich, Zurich, Switzerland","","https://ClinicalTrials.gov/show/NCT03573258"
193,"NCT03572283","Bethanechol Prior to Pancreatic Surgery",,"Recruiting","No Results Available","Pancreas Cancer","Drug: Bethanechol","Change in cell proliferation by Ki-67 expression in tumor cells|Number of Adverse Events","Columbia University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","AAAR6735","April 8, 2018","October 19, 2019","December 19, 2019","June 28, 2018","null","June 28, 2018","Columbia University Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03572283"
194,"NCT03571282","Safety and Effectiveness of Intravitreal Conbercept for Exudative Circumscribed Choroidal Haemangioma",,"Recruiting","No Results Available","Circumscribed Choroidal Haemangioma","Drug: conbercept","Best-corrected visual acuity|Central foveal thickness","Sun Yat-sen University","All","15 Years to 90 Years   (Child, Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018KYPJ081","June 6, 2018","June 6, 2019","June 6, 2019","June 27, 2018","null","June 27, 2018","Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03571282"
195,"NCT03571100","Comfort and Antimicrobial Efficacy of Chlorhexidine vs Betadine for Intravitreal Injections",,"Recruiting","No Results Available","Age-related Macular Degeneration|Diabetic Vascular Diseases|Proliferative Retinopathy|Retina Vein Occlusion","Drug: Chlorhexidine|Drug: Povidine-Iodine","Patient Comfort|Culture of conjunctiva for bacteria","MidAtlantic Retina|Wills Eye","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","18-692E","May 7, 2018","May 6, 2019","May 6, 2019","June 27, 2018","null","June 27, 2018","MidAtlantic Retina, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03571100"
196,"NCT03570372","Internet-based Treatment for Adults With Autism Spectrum Disorder (iALMA)","iALMA","Not yet recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Internet-based treatment for adults with autism spectrum|Behavioral: Psychoeducation about autism spectum disorder","Change in life quality|Change in depressive and anxiety symptoms|Change in knowledge of ASD|Subjective experience of ICBT|Content of communication|Correlation between schizotypal traits using SPQ and effect in quality of Life using BBQ","Örebro County Council","All","16 Years to 55 Years   (Child, Adult)","Early Phase 1","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","17RS4920","August 1, 2018","May 30, 2020","May 30, 2020","June 27, 2018","null","June 27, 2018","Region Örebro County, Örebro, Örebro County, Sweden","","https://ClinicalTrials.gov/show/NCT03570372"
197,"NCT03568994","Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)","ATACC AML","Recruiting","No Results Available","Acute Myeloid Leukemia","Drug: Atovaquone|Drug: Cytarabine|Drug: Daunorubicin|Drug: Etoposide|Drug: Gemtuzumab Ozogamicin","Plasma Concentrations|Dose Omission Frequency|Time to Achieve Steady State","Baylor College of Medicine|Texas Children's Hospital|William Marsh Rice University","All","1 Month to 20 Years   (Child, Adult)","Early Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-42691","July 10, 2018","July 2020","January 2021","June 25, 2018","null","November 6, 2018","John Hopkins Medicine, Baltimore, Maryland, United States|Baylor College of Medicine, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03568994"
198,"NCT03567707","Vaginal Microbiome Exposure and Immune Responses in C-section Infants",,"Not yet recruiting","No Results Available","Allergic Diseases|Asthma","Biological: C-section -Vaginal seeding|Drug: C-section - Placebo Seeding|Other: standard care","Presence of Sensitization to at Least One Food Allergen at 12 months of age - by Treatment Group|Occurrence of Adverse Events (AEs) -by Treatment Group|Presence of Sensitization to at Least One Aeroallergen at 12 months of age - by Treatment Group|Level of Allergen-Specific Atopy at 12 months of age - by Treatment Group|Level of Combined Allergen-Specific Atopy at 12 Months of Age - by Treatment Group|Number of Food Allergens and Aeroallergens Each Infant is Sensitized to at 12 Months of Age-by Treatment Group|Severity of Atopic Dermatitis - by Treatment Group","National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)","Female","18 Years to 45 Years   (Adult)","Early Phase 1","120","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","DAIT ITN079AD|ACTIVATE","November 2018","July 2020","July 2021","June 25, 2018","null","November 14, 2018","Icahn School of Medicine at Mount Sinai, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03567707"
199,"NCT03566225","Pioglitazone Versus Metformin as First Treatment in Infertile Women With Polycystic Ovary Syndrome",,"Not yet recruiting","No Results Available","Pioglitazone","Drug: Pioglitazone|Drug: Metformin|Drug: Clomiphene Citrate","Clinical pregnancy rate","Ain Shams University","Female","20 Years to 35 Years   (Adult)","Early Phase 1","400","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","AinShamaU","June 25, 2018","November 25, 2018","December 25, 2018","June 25, 2018","null","June 25, 2018","","","https://ClinicalTrials.gov/show/NCT03566225"
200,"NCT03566147","Treatment of RP and LCA by Primary RPE Transplantation",,"Recruiting","No Results Available","Leber Congenital Amaurosis, Retinitis Pigmentosa","Biological: Human primary Retinal Pigment Epithelial (HuRPE) cells","best-corrected visual acuity (BCVA)","Eyecure Therapeutics Inc.|Beijing Tongren Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","30","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TR-RPE-RP/LCA","August 1, 2018","December 31, 2019","March 31, 2020","June 21, 2018","null","August 9, 2018","Beijing Tongren Hospital, Beijing, China","","https://ClinicalTrials.gov/show/NCT03566147"
201,"NCT03564782","Examining Bioactivity of PVSRIPO in Triple Negative Breast Cancer",,"Recruiting","No Results Available","Triple Negative Breast Cancer","Biological: PVSRIPO","Change in tumor infiltrating immune cells","Istari Oncology, Inc.|Duke University|United States Department of Defense","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","6","Industry|Other|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Pro00085352|W81XWH-16-1-0354","November 15, 2018","July 2021","December 2021","June 21, 2018","null","October 24, 2018","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03564782"
202,"NCT03563235","Clinical Study on Treatment of Postmenopausal Osteoporosis (Kidney Deficiency and Blood Stasis Syndrome) With Xulin Jiangu Granules","CSOPOPWXJG","Not yet recruiting","No Results Available","Postmenopausal Osteoporoses","Drug: Xulin Jiangu granules|Drug: Calcitriol capsules","Bone density（BMD）","Fujian Academy of Traditional Chinese Medicine","Female","50 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2018R1035-4","September 1, 2018","September 30, 2021","December 31, 2021","June 20, 2018","null","June 20, 2018","Fujian Academy of Trational Chiness Medicine, Fuzhou, Fujian, China","","https://ClinicalTrials.gov/show/NCT03563235"
203,"NCT03562793","Communication and Activation in Pain to Enhance Relationships and Treat Pain With Equity","COOPERATE","Recruiting","No Results Available","Pain","Behavioral: Communication and Activation in Pain to Enhance Relationships and Treat Pain with Equity (COOPERATE)","Patient Activation|Communication Self-Efficacy (Perceived Efficacy in Patient-Physician Interactions--PEPPI)|Pain Intensity and Interference (Brief Pain Inventory)|Depression (PHQ8)|Anxiety|Pain Coping","VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","250","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IIR 17-032","October 1, 2018","May 1, 2021","June 30, 2022","June 19, 2018","null","October 5, 2018","Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis, Indiana, United States","","https://ClinicalTrials.gov/show/NCT03562793"
204,"NCT03561376","Zinc Oxide Versus Petrolatum Following Skin Surgery",,"Not yet recruiting","No Results Available","Surgical Incision|Surgery--Complications|Surgical Wound|Surgical Site Infection|Scar|Hypertrophic Scar","Drug: Topical zinc oxide vs. petrolatum post-surgical scars","POSAS (patient and observer scar assessment score)|Percentage of epidermal linear seal|POSAS (patient and observer scar assessment score) change between 8 weeks and six months|Change in % epidermal linear seal between weeks 1 and 4 post-operative|Surgical site infection","University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO17110516","September 1, 2018","November 15, 2018","December 15, 2018","June 19, 2018","null","August 9, 2018","UPMC Dermatology Clinics: Falk and St. Margaret, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03561376"
205,"NCT03560960","Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease","DTAD","Enrolling by invitation","No Results Available","Alzheimer Disease|Mild Cognitive Impairment","Drug: Pramlintide challenge test","Plasma Aβ and t-tau changes|Plasma inflammatory changes|Plasma metabolic changes in blood|Change in MMSE|Change in CDR|Change in NAB|Change in WMS-III Logical Memory|Change in CLOX paradigm|Change in Trailmaking Test Part B|Change in Controlled Oral Word Association Test","Boston University","All","60 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","240","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","H-37432","August 6, 2018","June 2023","June 2023","June 19, 2018","null","August 16, 2018","Indiana University Alzheimer Disease Center, Indianapolis, Indiana, United States|BU Alzheimer Disease Center, Boston, Massachusetts, United States|Memory Center VA Boston Healthcare, Jamaica Plain, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03560960"
206,"NCT03560934","Tetrahydrocannabinol (THC) and Sleep",,"Not yet recruiting","No Results Available","Sleep|THC|Marijuana|Cannabis","Drug: Dronabinol","Sleep Stages|Psychomotor Vigilance|Blood Pressure|Heart Rate|Endothelial Function|Sleep Cardiac Data|Sleep Beat-By-Beat Blood Pressure|Buschke Selective Reminding Test (SRT)|Victoria Stroop Test|Necker Cube Test|Subjective sleepiness/alertness|Caloric Intake","Oregon Health and Science University","All","21 Years to 34 Years   (Adult)","Early Phase 1","14","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB00018052","September 1, 2018","February 1, 2020","February 1, 2022","June 18, 2018","null","June 18, 2018","","","https://ClinicalTrials.gov/show/NCT03560934"
207,"NCT03559764","Study of BCMA CAR-T in Multiple Myeloma",,"Not yet recruiting","No Results Available","Relapsed and Refractory Multiple Myeloma","Biological: Anti-BCMA CAR T cells","The safety of CAR T is evaluated to determine if CRS occurred","Allife Medical Science and Technology Co., Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","20","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BCMA CAR T-HNRM-01","June 2018","February 2020","May 2020","June 18, 2018","null","June 18, 2018","","","https://ClinicalTrials.gov/show/NCT03559764"
208,"NCT03559556","Treating Arteriovenous Malformation With Stereotactic Radiosurgery Using CT Angiography for Treatment Planning",,"Not yet recruiting","No Results Available","Arteriovenous Malformations","Other: CT angiography","To evaluate whether target(s) based on CT angiogram can accurately and precisely identify the target nidus as well as an interventional cerebral arteriography.|To analyze and compare dosimetric parameters: planning target volume|To analyze and compare dosimetric parameters: volume of the brain that receives at least 12 Gray of radiaton (V12)|To evaluate the total time it takes to perform the additional CT angiograms and compare it to the duration of the interventional procedure.","University of Texas Southwestern Medical Center","All","10 Years to 120 Years   (Child, Adult, Older Adult)","Early Phase 1","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","STU 042018-100","December 2018","July 2020","December 2022","June 18, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03559556"
209,"NCT03557684","Leucine for Depression Study (L-DEP)",,"Recruiting","No Results Available","Depression","Dietary Supplement: leucine|Other: PO placebo|Biological: lipopolysaccharide (LPS)|Other: IV placebo","Change in depressed mood from baseline|Change in depressive symptoms from baseline|Change in feelings of social disconnection from baseline|Change in fatigue from baseline|Change in confusion from baseline|Change in cognitive function from baseline","University of California, Los Angeles|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","90","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","R21MH113915","September 1, 2018","July 31, 2020","July 31, 2020","June 15, 2018","null","October 16, 2018","UCLA Cousins Center for Psychoneuroimmunology, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT03557684"
210,"NCT03556930","Simulated Radiotherapy Treatment Assisted With Pediatric Radiation Oncology With Movie Induced Sedation Effect Technique",,"Not yet recruiting","No Results Available","Childhood Cancer","Device: AlignRT system (VisionRT LTD, UK)","To investigate the feasibility of applying PROMISE for pediatric radiotherapy by analyzing overall treatment time|To determine overall PROMISE radiotherapy treatment efficiency|To quantify PROMISE radiotherapy treatment dose deviation","University of Texas Southwestern Medical Center","All","4 Years to 10 Years   (Child)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","STU 042018-088","December 2018","July 2019","July 2021","June 14, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03556930"
211,"NCT03555851","Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy",,"Recruiting","No Results Available","Leukemia, Not Otherwise Specified|Leukemia, Other","Drug: Cyclophosphamide|Other: Specimen collection","Incidence of acute GVHD|Incidence of chronic GVHD|Cy exposure|Toxicities","Carolinas Healthcare System","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCI-HEM-HCT-PTCY-001","July 13, 2018","October 2020","October 2020","June 14, 2018","null","July 18, 2018","Levine Cancer Institute, Charlotte, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03555851"
212,"NCT03554707","SGT-53 in Children With Recurrent or Progressive CNS Malignancies",,"Not yet recruiting","No Results Available","Childhood CNS Tumor","Genetic: SGT-53|Radiation: Radiation|Drug: Irinotecan|Drug: Temozolomide|Drug: Bevacizumab","Incidence of Adverse Events|Response Rate|Duration of Response|Overall Survival|Progressive-Free Survival (PFS)|Characterization of Phenotype of Patients|Feasibility of Droplet PCR Assays to Monitor for Tumor Burden","SynerGene Therapeutics, Inc.","All","1 Year to 21 Years   (Child, Adult)","Early Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SGT53-00-1","September 2018","September 2019","March 2020","June 13, 2018","null","August 17, 2018","Children's National Medical Center, Washington, District of Columbia, United States","","https://ClinicalTrials.gov/show/NCT03554707"
213,"NCT03548727","Pseudo-Simultaneous Imaging of Tumor Hypoxia and Proliferation in HNC Patients Using PET/CT",,"Not yet recruiting","No Results Available","Head and Neck Cancer","Diagnostic Test: PET/CT Imaging","Simultaneous Imaging of tumor hypoxia and proliferation|Repeatability of FLT","Weill Medical College of Cornell University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1703018046","November 1, 2018","October 30, 2019","October 30, 2019","June 7, 2018","null","October 10, 2018","","","https://ClinicalTrials.gov/show/NCT03548727"
214,"NCT03547622","Galantamine and CBT4CBT Pilot",,"Recruiting","No Results Available","Methadone or Buprenorphine Detoxoxification","Drug: MAT taper with galantamine|Drug: MAT taper with placebo","Change in methadone/buprenorphine dose for successful completion of taper|Clinical Opioid Withdrawal Scale (COWS)|Substance Use Calendar","Yale University","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","20000 21868","May 1, 2018","May 2019","May 2019","June 6, 2018","null","June 6, 2018","APT Foundation, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03547622"
215,"NCT03546829","Randomized Pilot Trial of Antimicrobial Therapy and Stereotactic Body Radiation Therapy in Early-stage Non-small Cell Lung Cancer",,"Recruiting","No Results Available","Early Stage Non-Small Cell Lung Cancer","Drug: Vancomycin|Radiation: Stereotactic Body Radiation Therapy (SBRT)","Th1 immune response measured by cytokine expression (IFN gamma).","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 08517","April 24, 2018","April 24, 2020","December 24, 2020","June 5, 2018","null","June 5, 2018","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03546829"
216,"NCT03546556","18-FLT PET/MR Imaging to Predict Graft Failure and GVHD in Bone Marrow Transplant Patients",,"Recruiting","No Results Available","Graft Vs Host Disease","Drug: Fluorothymidine (FLT)","Overall FLT-PET Bone Marrow Signal|Overall FLT-PET Signal Intensity within Host Secondary Lymphoid Sites|Overall Long-Term FLT-PET Bone Marrow Signal|Overall Long-Term FLT-PET Signal Intensity within Host Secondary Lymphoid Sites|Differences in FLT Uptake in Autologous HSCT and Allogeneic HSCT Patients|Strength of FLT-PET Signal and Transfusion Independence|Strength of the FLT-PET Signal and Bone Marrow Cellularity|Strength of FLT-PET Signal and Transfusion Independence (Long Term)|Strength of FLT-PET Signal and Bone Marrow Cellularity (Long Term)|Isolated/Asymmetric Foci of Increased FLT|Strength of FLT-PET signal and MRI Findings|Overall FLT-PET Signal Intensity and Acute Graft Versus Host Disease","UNC Lineberger Comprehensive Cancer Center","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","LCCC 1714","January 1, 2017","January 2019","June 2019","June 5, 2018","null","June 5, 2018","Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03546556"
217,"NCT03546478","99mTc Labelled Affibody SPECT/CT Imaging for Breast Cancer HER2 Characterization",,"Completed","No Results Available","Breast Cancer","Biological: 99mTc-ABH2","T/B|Adverse events collection","Peking Union Medical College Hospital","Female","29 Years to 76 Years   (Adult, Older Adult)","Early Phase 1","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CaiJ","June 24, 2015","May 24, 2017","May 18, 2018","June 5, 2018","null","June 5, 2018","Peking Union Medical College Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03546478"
218,"NCT03545139","Clinical & Radiographic Evaluation of Neo MTA Versus White MTA in Revascularization of Non-Vital Immature Permanent Teeth",,"Not yet recruiting","No Results Available","Nonvital Tooth","Biological: NeoMTA nusmile|Biological: White MTA","Discoloration/ Staining potential|Pain on biting|Pain on percussion|Sinus or fistula, recurrent swelling|Root lengthening","Cairo University","All","7 Years to 15 Years   (Child)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","NeoMTA in Revascularization","June 2019","September 2020","September 2021","June 4, 2018","null","July 31, 2018","","","https://ClinicalTrials.gov/show/NCT03545139"
219,"NCT03544385","Effect of Ocular Hygiene on Scleral Lens Wear",,"Recruiting","No Results Available","Scleral Contact Lenses","Drug: Ringers Solution|Drug: Placebo - Concentrate","length of scleral lens wear","University of Houston","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","STUDY00000851","May 18, 2018","July 25, 2018","October 25, 2018","June 1, 2018","null","June 1, 2018","University of Houston- College of Optometry, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03544385"
220,"NCT03544359","MRI Study of Noninvasive Transcranial Electrical Stimulation in Tinnitus",,"Not yet recruiting","No Results Available","Tinnitus, Subjective","Device: Transcranial electrical stimulation (tES)","Changes in brain function (functional connectivity)|Tinnitus loudness ratings","Northwestern University|National Institute on Deafness and Other Communication Disorders (NIDCD)","All","18 Years to 55 Years   (Adult)","Early Phase 1","35","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","STU00207056|R21DC015880","August 2018","August 2021","August 2021","June 1, 2018","null","June 1, 2018","","","https://ClinicalTrials.gov/show/NCT03544359"
221,"NCT03543969","Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma",,"Recruiting","No Results Available","Melanoma (Skin)|Skin Cancer|Skin Melanoma|Skin Carcinoma","Drug: Vemurafenib|Drug: Cobimetinib","8 Week Completion Rate|Time to Treatment Failure|Objective Tumor Response Rate","H. Lee Moffitt Cancer Center and Research Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-19441","May 23, 2018","September 2020","September 2021","June 1, 2018","null","October 3, 2018","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States","","https://ClinicalTrials.gov/show/NCT03543969"
222,"NCT03542812","L-citrulline and Pulmonary Hypertension Associated With Bronchopulmonary Dysplasia",,"Not yet recruiting","No Results Available","Infant,Premature|Bronchopulmonary Dysplasia|Pulmonary Hypertension","Drug: L-Citrulline","Plasma L-citrulline levels following administration of a single dose of L-citrulline|Evaluate ability to achieve target trough L-citrulline plasma level|Evaluate incidence of feedings being stopped following L-citrulline administration|Evaluate incidence of hypotension developing following L-citrulline administration|Urinary nitrite and nitrate levels will be measured in subjects enrolled into Group 3.","University of Utah","All","up to 3 Months   (Child)","Early Phase 1","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other","97293","December 1, 2018","June 30, 2020","June 30, 2021","May 31, 2018","null","October 12, 2018","University of Utah Health, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT03542812"
223,"NCT03542695","64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy",,"Not yet recruiting","No Results Available","Breast Carcinoma|Calcification","Procedure: Computed Tomography|Drug: Copper Cu-64-DOTA-alendronate|Other: Pharmacokinetic Study|Procedure: Positron Emission Tomography","Maximum standardized uptake value (SUVmax) of 64Cu-DOTA-alendronate in evaluating tumor size and calcifications|Uptake of 64Cu-DOTA-alendronate on positron emission tomography (PET) scan compared to histology after mastectomy","City of Hope Medical Center|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","6","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18112|NCI-2018-00890","December 7, 2018","December 7, 2020","December 7, 2020","May 31, 2018","null","October 23, 2018","City of Hope Medical Center, Duarte, California, United States","","https://ClinicalTrials.gov/show/NCT03542695"
224,"NCT03541720","18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma",,"Recruiting","No Results Available","Neuroblastoma|Pheochromocytoma","Drug: 18F-DA","Adverse event rate|The frequency of localization of 18F-DA in different organs.|max SUV from 18F-DA and 123I-mIBG PET","St. Jude Children's Research Hospital","All","1 Year and older   (Child, Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","FLOPET|NCI-2018-01306","November 2018","January 1, 2020","July 1, 2020","May 30, 2018","null","November 7, 2018","St. Jude Children's Research Hospital, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT03541720"
225,"NCT03540966","Effects of Camouflage on the Life Quality of Patients With Vitiligo",,"Recruiting","No Results Available","Quality of Life","Combination Product: CapulinTM|Other: Chinese version of the vitiligo life quality index, VLQI-C","Chinese version of the vitiligo life quality index, VLQI-C|VASI Scoring Criteria|Vitiligo European Task Force assessment, VETFa","Xijing Hospital","All","18 Years to 64 Years   (Adult)","Early Phase 1","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","XJPF-LCY-V201804","January 1, 2018","January 2019","January 2020","May 30, 2018","null","May 30, 2018","Xijing Hospital, Xi'an, Shaanxi, China","","https://ClinicalTrials.gov/show/NCT03540966"
226,"NCT03539068","Online and Shared Decision-Making Interventions to Engage Service Men and Women in Post-Deployment Mental Health Care","eSDM","Active, not recruiting","No Results Available","PTSD|Depression|Substance Use Disorder|Traumatic Brain Injury","Behavioral: WEB-ED+ Treatment Arm","VA mental health treatment engagement validated by VA electronic medical record review.|Shared Decision Making Interface between VA clinician and Veteran validated by VA electronic medical record review","VA Office of Research and Development","All","Child, Adult, Older Adult","Early Phase 1","2000","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","IIR 16-096","June 1, 2018","May 28, 2021","May 30, 2022","May 28, 2018","null","August 16, 2018","Iowa City VA Health Care System, Iowa City, IA, Iowa City, Iowa, United States","","https://ClinicalTrials.gov/show/NCT03539068"
227,"NCT03537482","APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies",,"Recruiting","No Results Available","Hematologic Malignancies","Drug: APG-2575","Maximum Tolerated Dose (MTD)|Maximum plasma concentration (Cmax)|Area under the plasma concentration versus time curve (AUC)|Anti-tumor effects of APG-2575","Ascentage Pharma Group Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","90","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APG-2575","August 7, 2018","June 15, 2019","June 15, 2020","May 25, 2018","null","August 31, 2018","Mayo Clinic, Scottsdale, Arizona, United States|Mayo Clinic, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States|MDACC, Houston, Texas, United States|Linear Clinical Research, Nedlands, Western Australia, Australia|St. Vincent Hospital, Melbourne, Australia","","https://ClinicalTrials.gov/show/NCT03537482"
228,"NCT03537469","Neuromodulation With Low Frequency-Pulsed Electromagnetic Fields",,"Completed","No Results Available","Electromagnetic Fields|Neuronal Plasticity|Transcranial Magnetic Stimulation","Device: CTU Mega 20 real device|Device: CTU Mega 20 sham device","Cortical Excitability change across time","Azienda Ospedaliera Spedali Civili di Brescia","All","18 Years to 35 Years   (Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","NP-2322","March 10, 2016","July 1, 2016","July 10, 2016","May 25, 2018","null","May 28, 2018","","","https://ClinicalTrials.gov/show/NCT03537469"
229,"NCT03536208","Biological Effect of Warfarin on Pancreatic Cancer",,"Not yet recruiting","No Results Available","Pancreatic Cancer","Drug: Warfarin","Determine change in AXL pathway|Assess adverse events|Effect of warfarin on tissue markers|Antitumor effect","University of Texas Southwestern Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU 022018-090","December 2018","June 2020","June 2021","May 24, 2018","null","August 15, 2018","","","https://ClinicalTrials.gov/show/NCT03536208"
230,"NCT03534115","NAC Prevents Toxicity of Teeth Bleaching",,"Completed","No Results Available","Removal of Toxicity From Dental Bleaching","Dietary Supplement: NAC|Dietary Supplement: Placebo","inhibition of pain|white lesion in gingiva","University of California, Los Angeles","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","41","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","14-001368","December 4, 2014","October 26, 2017","October 26, 2017","May 23, 2018","null","May 23, 2018","","","https://ClinicalTrials.gov/show/NCT03534115"
231,"NCT03533556","Effects of L-theanine and Caffeine on Attention and Attention-related Brain Activity of Children With Attention Deficit Hyperactivity Disorder",,"Not yet recruiting","No Results Available","Attention Deficit Hyperactivity Disorder","Dietary Supplement: L-theanine|Dietary Supplement: Caffeine|Dietary Supplement: L-theanine-Caffeine Combination|Other: Placebo","Differences of fMRI blood oxygen level dependent (BOLD) responses of the brain in response to Stop Signals of an SSRT recorded following administration of each treatment and the placebo|Differences of fMRI blood oxygen level dependent (BOLD) responses of the brain in a Go-NoGo CPT recorded following administration of each treatment and the placebo|Differences of resting state fMRI functional connectivity recorded following administration of each treatment and the placebo|Differences of cerebral blood flow measured following administration of each treatment and the placebo|Differences of delay discounting following administration of each treatment and the placebo|Differences of stop signal delay following administration of each treatment and the placebo|Differences of reaction times of correct Go responses in a Go-NoGo CPT following administration of each treatment and the placebo|Differences of commission errors in the Go-NoGo CPT following administration of each treatment and the placebo|Differences of performance in Flanker Inhibitory Control and Attention Test following administration of each treatment and the placebo|Differences of performance in Dimensional Change Card Sort Test following administration of each treatment and the placebo|Differences of performance in Pattern Comparison Processing Speed Test following administration of each treatment and the placebo|Differences of post- vs. pre-treatment change of STAI-CH State Scale following administration of each treatment and the placebo","Texas Tech University|Texas Tech University Health Sciences Center","Male","8 Years to 17 Years   (Child)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IRB2017-767","May 14, 2018","August 31, 2018","December 31, 2018","May 23, 2018","null","May 24, 2018","Texas Tech University - Department of Human Development and Family Studies, Lubbock, Texas, United States","","https://ClinicalTrials.gov/show/NCT03533556"
232,"NCT03532334","Comparison of 133Xe Scintigraphy With 19F MRI",,"Withdrawn","No Results Available","Lung Diseases","Diagnostic Test: Perfluorinated Gas/Oxygen Mixture","Efficacy of 19F MRI compared to 133 Xenon Scintigraphy","Hal C Charles|Duke University","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Pro00089045","April 4, 2018","December 2019","December 2019","May 22, 2018","null","July 24, 2018","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03532334"
233,"NCT03529825","Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation",,"Recruiting","No Results Available","Microbial Colonization","Drug: Rifaximin","Alterations to microbiome diversity in children treated with rifaximin compared to the historical cohort.|Rates of BSI pathogen infection/colonization frequency during the treatment period compared to the historical cohort.|Transplant related mortality (TRM)|Number of patients with Acute GVHD|Number of patients with Chronic GVHD including overlap syndrome|Number of patients with other Infections|Number of patients with relapse free survival at 1 year|Overall number of patients survived at 1 year","Emory University","All","2 Years to 21 Years   (Child, Adult)","Early Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00101158","July 18, 2018","May 2020","May 2020","May 18, 2018","null","September 26, 2018","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03529825"
234,"NCT03529019","Nutrition in Patient With Critical Limb Ischemia","NutriVasc","Recruiting","No Results Available","Critical Limb Ischemia|Malnutrition|Nutritional Supplements","Drug: Ensure Surgery Immunonutrition Shake|Drug: Ensure Enlive Advanced Nutrition Shake","Change in serum albumin levels|Change in prealbumin levels|Change in transferrin levels|Change in C-reactive protein levels|Change in Hand grip strength","Boston Medical Center|Vascular & Endovascular Surgery Society|Abbott","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","H-37324","October 2, 2018","December 2019","December 2020","May 18, 2018","null","October 16, 2018","Boston Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03529019"
235,"NCT03528070","A Clinical Study of Tranilast in the Treatment of Sarcoidosis",,"Not yet recruiting","No Results Available","Sarcoidosis","Drug: Tranilast","Changes in the size of the pulmonary nodule by ultrasound|Changes of the forced vital capacity(FVC)","The First Affiliated Hospital with Nanjing Medical University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","56","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FirstNanjingMUMH Hou","May 2018","May 2020","December 2020","May 17, 2018","null","May 17, 2018","","","https://ClinicalTrials.gov/show/NCT03528070"
236,"NCT03527316","Effect of Methylenedioxymethamphetamine (MDMA) (Serotonin Release) on Fear Extinction","MFE","Not yet recruiting","No Results Available","Healthy","Drug: MDMA|Drug: Placebo","Fear extinction measured by Skin conductance response|Fear extinction measured by Fear-potentiated startle|Plasma concentration of Oxytocin|Subjective effects measured by Visual analog scales|Autonomic effects measured by Blood pressure|Autonomic effects measured by Hearth rate|Autonomic effects measured by Body temperature|Subjective effects measured by State-trait anxiety inventory for state (STAI-S)|Plasma concentration of MDMA","University Hospital, Basel, Switzerland","Male","18 Years to 50 Years   (Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","BASEC 2017-01947","January 2019","August 2019","August 2019","May 17, 2018","null","November 7, 2018","Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland","","https://ClinicalTrials.gov/show/NCT03527316"
237,"NCT03527056","Pilot Study Using Oral Capsule FMT to Decolonize GI CRE",,"Not yet recruiting","No Results Available","Enterobacteriaceae Infections|Fecal Microbiota Transplantation","Biological: Fecal Microbiota Transplantation","Proportion of participants with CRE decolonization at day 10 (+/- 3 days) after fecal transplant|Proportion of participants with an adverse event through day 10 (+/- 3 days) after FMT|Proportion of participants with CRE decolonization at month 1 (+/-5 days) after FMT|Proportion of participants with CRE infection at day 10 (+/-3 days) and month 1 (+/-5 days) after FMT|Proportion of participants with an adverse event, severe adverse event, or adverse events of special interest through month 1 (+/-5 days) after FMT.|Proportion of participants with a severe adverse event at month 6 (+/-14 days) after FMT.|Proportion of participants with microbial engraftment assessed by microbiome disruption index (MDI) (MDI-community and MDI-species) measured by 16s ribosomal RNA at time of enrollment, day 10 (+/-3 days) and month 1 (+/-5 days) after FMT","Zachary A. Rubin, MD|OpenBiome|Finch Research and Development LLC.|University of California, Los Angeles","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-001946","September 2018","July 2019","July 2019","May 16, 2018","null","May 16, 2018","","","https://ClinicalTrials.gov/show/NCT03527056"
238,"NCT03526185","A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes",,"Recruiting","No Results Available","Metastatic Melanoma","Drug: Tumor Infiltrating Lymphocytes","Adverse Events|Serious Adverse Events|Objective response rate to TIL","Yale University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2000020477","February 6, 2018","December 1, 2019","December 1, 2019","May 16, 2018","null","May 16, 2018","Yale New Haven Hospital, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03526185"
239,"NCT03525561","Acetazolamide and Exercise Performance at Altitude",,"Recruiting","No Results Available","Hypoxia|Exercise Performance|Cognitive Function|Dexterity","Drug: Acetazolamide Pill|Drug: Placebo pill","Endurance exercise performance","United States Army Research Institute of Environmental Medicine","All","18 Years to 45 Years   (Adult)","Early Phase 1","10","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","M-10729","October 10, 2018","October 2020","October 2020","May 15, 2018","null","October 15, 2018","Natick Soldier Systems Center, Natick, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03525561"
240,"NCT03525509","Epidural Methadone in Healthy Volunteers",,"Recruiting","No Results Available","Pain, Acute","Drug: Methadone hydrochloride|Drug: Morphine Sulfate","Selective segmental analgesia for heat pain - methadone|Selective segmental analgesia for heat pain - morphine|Selective segmental analgesia for pressure pain - methadone|Selective segmental analgesia for pressure pain - morphine","simon.haroutounian|Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","13","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","201802099","June 4, 2018","May 31, 2019","August 31, 2019","May 15, 2018","null","June 5, 2018","Washington University in St. Louis, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03525509"
241,"NCT03520569","Effect of Hyperglycemia on Microvascular Perfusion in Healthy Adults",,"Recruiting","No Results Available","Vascular Stiffness|Insulin Sensitivity","Drug: Octreotide|Drug: Insulin|Drug: Dextrose 20% solution","Change in Flow Mediated Dilation (FMD) between baseline and after 2 hour insulin clamp|Change in Augmentation Index between baseline and after 2 hour insulin clamp|Change in Pulse Wave Velocity (PWV) between baseline and after 2 hour insulin clamp","University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 35 Years   (Adult)","Early Phase 1","22","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","19948|T32DK007646","November 15, 2017","December 2022","December 2022","May 9, 2018","null","May 9, 2018","University of Virginia, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03520569"
242,"NCT03519308","A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Micoenvironment in Resectable Pancreatic Cancer",,"Recruiting","No Results Available","Pancreatic Cancer","Drug: Nivolumab|Drug: Nab-Paclitaxel|Drug: Gemcitabine|Drug: Paricalcitol","Numer of Adverse Events","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 22217","August 4, 2017","April 4, 2019","August 4, 2019","May 8, 2018","null","May 8, 2018","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03519308"
243,"NCT03519022","Behavioral Effects of Drugs: Inpatient (35)","BED IN 35","Recruiting","No Results Available","Cocaine Use Disorder","Drug: Cocaine|Drug: Placebo oral capsule|Drug: Methylphenidate","Reinforcing Effects of Cocaine Following Placebo Maintenance.|Reinforcing Effects of Cocaine Following Duloxetine Maintenance.|Reinforcing Effects of Cocaine Following Methylphenidate Maintenance.|Reinforcing Effects of Cocaine Following Methylphenidate and Duloxetine Maintenance.|Adjective Rating Scale-Sedative|Adjective Rating Scale-Stimulant|Drug Effect Questionnaire|Heart rate|Blood pressure|Temperature|Side effects|Delay Discounting Task|Attentional Bias|Inhibitory Control","Craig Rush|National Institute on Drug Abuse (NIDA)|University of Kentucky","All","18 Years to 55 Years   (Adult)","Early Phase 1","32","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Basic Science","43500","June 1, 2018","May 2019","May 2019","May 8, 2018","null","July 10, 2018","University of Kentucky Medical Center, Lexington, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT03519022"
244,"NCT03516656","Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin",,"Recruiting","No Results Available","Deep Vein Thrombosis|Pulmonary Embolism|Venous Thromboembolism","Drug: Standard heparin dose|Drug: Real time heparin dose adjustment","Percentage of Anti-Xa Levels Within Target Range (0.1-0.35 IU/mL)|Number of Rate Adjustments","University of Utah","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB_00107294","March 23, 2018","March 1, 2019","October 1, 2019","May 4, 2018","null","May 4, 2018","University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT03516656"
245,"NCT03515941","Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers","GABLE","Recruiting","No Results Available","Gastrointestinal Cancer","Drug: Oxaliplatin|Drug: Capecitabine|Drug: Leucovorin|Drug: 5-fluorouracil|Radiation: radiation","Proportion of patients who complete the recommended therapy from each arm|Time to recurrence","Brandon G. Smaglo|Baylor College of Medicine","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-40682","May 31, 2018","October 8, 2022","January 1, 2027","May 4, 2018","null","June 26, 2018","Baylor Clinic, Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Baylor St. Lukes Medical Center, Houston, Texas, United States|Harris Health System- Smith Clinic, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03515941"
246,"NCT03514121","FPA150 in Patients With Advanced Solid Tumors","FPA150-001","Recruiting","No Results Available","Breast Cancer|Ovarian Cancer|Endometrial Cancer|Urothelial Cancer|Advanced Solid Tumors","Biological: FPA150","For Phase 1a, to determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of FPA150|For Phase 1a, number of participants with adverse events as assessed by the latest version of CTCAE|For Phase 1b, number of participants with adverse events as assessed by the latest version of CTCAE at the maximum tolerated dose (MTD) and/or recommended dose (RD) of FPA150|Area under serum concentration-time curve of FPA150 in day*µg/mL|Maximum serum concentration of FPA150 in µg/mL|Trough serum concentration of FPA150 in µg/mL|Clearance of FPA150 in mL/day/kg|Terminal Half-Life of FPA150 in day|Volume of distribution (mL/kg) of FPA150|Incidence of treatment emergent anti-FPA150 antibody response (levels in serum)|Pharmacodynamic profile of FPA150","Five Prime Therapeutics, Inc.","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","268","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FPA150-001","March 27, 2018","January 2023","January 2024","May 2, 2018","null","October 18, 2018","Honor Health, Scottsdale, Arizona, United States|UCLA, Los Angeles, California, United States|Sarcoma Oncology Research Center, Santa Monica, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT03514121"
247,"NCT03513770","Autonomic Control of the Circulation and the Venous Distension Reflex",,"Recruiting","No Results Available","Blood Pressure","Drug: Ketorolac Tromethamine|Other: Control","Muscle Sympathetic Nerve Activity (MSNA)|Blood pressure in mmHg|Heart rate in beats per minute|Vein size with MRI","Milton S. Hershey Medical Center","All","21 Years to 35 Years   (Adult)","Early Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","STUDY00006585","July 12, 2017","July 2019","July 2020","May 2, 2018","null","May 2, 2018","Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03513770"
248,"NCT03512873","A Clinical Study of Tranilast in the Treatment of Scleredema Diabeticorum",,"Not yet recruiting","No Results Available","Scleredema Adultorum","Drug: Tranilast","Measure the volume change of skin lesions by ultrasound","The First Affiliated Hospital with Nanjing Medical University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","56","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MH Hou","June 2018","June 2020","December 2020","May 1, 2018","null","May 1, 2018","","","https://ClinicalTrials.gov/show/NCT03512873"
249,"NCT03512223","Intravenous and Perineural Dexamethasone for Brachial Plexus Block in Hand Surgery",,"Not yet recruiting","No Results Available","Hand Surgery","Drug: Dexamethasone","Duration of anesthetic blockade|Duration of motor block|Patient satisfaction on a scale of 0-10 (0=not satisfied at all 10=very satisfied) of pain management|48-hour postoperative units of oral morphine consumption|the incidence of nausea and/or vomiting within 48 hour of the block|• Rebound pain on a scale of 0-10 (0=no pain 10=worst possible pain), which is the worst level of pain experienced within the 2 hours after the block wore off","Ohio State University","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","2017H0244","December 1, 2018","March 31, 2020","March 31, 2021","April 30, 2018","null","August 14, 2018","","","https://ClinicalTrials.gov/show/NCT03512223"
250,"NCT03511196","Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer",,"Recruiting","No Results Available","Prostate Cancer|Stage IV Prostate Cancer|Advanced Prostate Cancer|Adenocarcinoma of the Prostate","Drug: Adaptive Androgen Deprivation Therapy (ADT)|Drug: Abiraterone|Drug: Prednisone","Rate of Participant Retention|Median Time to Progression From the First Dose of Androgen Deprivation Therapy (ADT)|Median Time to Radiographic Progression From the First Dose of ADT","H. Lee Moffitt Cancer Center and Research Institute","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-19367","May 17, 2018","June 2021","June 2022","April 27, 2018","null","October 5, 2018","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States","","https://ClinicalTrials.gov/show/NCT03511196"
251,"NCT03510572","Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain",,"Recruiting","No Results Available","Healthy Volunteer|Alzheimer Disease|Frontotemporal Dementia|Parkinson Disease","Drug: [18F]PI-2620","Cross-sectional [18F]PI-2620 Imaging Results|.Assess the rate of change of tau deposition as measured by [18F]PI-2620 uptake (SUVR) over time|Correlation between standard uptake value ratio (SUVR) of [18F]PI-2620 positron emission computed tomography and neuropsychiatric test scores|Correlation between standard uptake value ratio (SUVR) of [18F]PI-2620 positron emission computed tomography and indices of structural MRI","Asan Medical Center|Korea Health Industry Development Institute","All","40 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PI-18001","June 4, 2018","July 2019","July 2019","April 27, 2018","null","October 15, 2018","Asan Medical Center, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03510572"
252,"NCT03508817","Atropine 0.01% Eye Drops in Myopia Study","AIMS","Recruiting","No Results Available","Myopia, Progressive","Drug: Atropine Sulfate 0.01% Eye Drops","The primary outcome is progression of myopia|change in axial length","Sultan Qaboos University|Christian Medical College, Vellore, India","All","6 Years to 15 Years   (Child)","Early Phase 1","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MREC 1473","October 1, 2018","January 1, 2022","January 1, 2022","April 26, 2018","null","September 6, 2018","Sultan Qaboos University, Muscat, Oman","","https://ClinicalTrials.gov/show/NCT03508817"
253,"NCT03507608","Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression",,"Not yet recruiting","No Results Available","Prostate Cancer","Drug: Flutamide|Other: Placebo","time to DNA double strand break","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","Male","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J1851|IRB00167697","January 1, 2019","July 1, 2023","July 1, 2025","April 25, 2018","null","November 6, 2018","SKCCC at Johns Hopkins, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03507608"
254,"NCT03507374","PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis",,"Not yet recruiting","No Results Available","Stroke|Intracranial Atherosclerosis|Intraplaque Hemorrhage","Drug: Alirocumab|Drug: Placebo","Vessel Wall MRI|Post-Contrast Plaque Enhancement","University of Utah|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00104839","October 2018","September 28, 2020","September 28, 2021","April 25, 2018","null","August 23, 2018","","","https://ClinicalTrials.gov/show/NCT03507374"
255,"NCT03502967","Imaging of Traumatic Brain Injury Metabolism Using Hyperpolarized Carbon-13 Pyruvate","HPTBI","Enrolling by invitation","No Results Available","Traumatic Brain Injury","Drug: Hyperpolarized [1-13C] Pyruvate|Drug: Hyperpolarized [2-13C] Pyruvate","[1-13C]lactate-to-H13CO3- ratio from [1-13C]pyruvate or [2-13C]lactate-to-[5-13C]glutamate ratio from [2-13C]pyruvate","University of Texas Southwestern Medical Center","All","18 Years to 60 Years   (Adult)","Early Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","STU 072017-009","June 1, 2018","October 31, 2019","October 31, 2020","April 19, 2018","null","August 1, 2018","UT Southwestern - Advanced Imaging Research Center, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT03502967"
256,"NCT03498300","Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibodies Response After Its Single Dose of Tdap Vaccine in Thai Pregnant Women",,"Active, not recruiting","No Results Available","Pertussis|Pregnancy Related","Biological: Tdap vaccine","Seroprevalence of Bordetella pertussis antibodies in Thai pregnant women|Anti-pertussis antibodies response after its single dose of reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine (Tdap) in Thai pregnant women","Mahidol University","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","SI 089/2018","May 9, 2018","September 5, 2018","April 2019","April 13, 2018","null","October 9, 2018","Nalat Sompagdee, Bangkok Noi, Bangkok, Thailand","","https://ClinicalTrials.gov/show/NCT03498300"
257,"NCT03498235","Effects of Sevoflurane and Propofol on Optic Nerve Sheath Diameter During Laparoscopic Gynecologic Surgery",,"Enrolling by invitation","No Results Available","Laparoscopic Gynecologic Surgery","Drug: Sevoflurane|Drug: Propofol","Changes of ultrasonographic optic nerve sheath diameter|Analyzed whether mean arterial pressure influence the change of ONSD based on 110 patients in two groups.|Analyzed whether airway pressure influence the change of ONSD based on 110 patients in two groups.|Analyzed whether urine volume influence the change of ONSD based on 110 patients in two groups.|Analyzed whether blood loss influence the change of ONSD based on 110 patients in two groups.|Analyzed whether fluid volume influence the change of ONSD based on 110 patients in two groups.","Obstetrics & Gynecology Hospital of Fudan University","Female","18 Years to 60 Years   (Adult)","Early Phase 1","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","V2018-2","March 1, 2018","July 2018","August 2018","April 13, 2018","null","April 13, 2018","Obstetrics & Gynecology Hospital of Fudan University, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03498235"
258,"NCT03498131","Melatonin in Patients With Multiple Sclerosis (MS).",,"Recruiting","No Results Available","Relapsing Remitting Multiple Sclerosis","Drug: 3 mg Melatonin|Drug: 5 mg Melatonin","Changes in urine melatonin levels|Modified Fatigue Impact Scale (MFIS)|Serum melatonin level|Multiple Sclerosis Impact Scale-29 (MSIS-29)|Pittsburgh Sleep Quality Index (PSQI)|Relapse Rate|Patient Determined Disease Steps - Performance Scale (PDDS-PS)","Providence Health & Services","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2017000005","May 9, 2018","March 2021","March 2022","April 13, 2018","null","May 15, 2018","Providence MS Center, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT03498131"
259,"NCT03497819","Autologous CARTmeso/19 Against Pancreatic Cancer",,"Active, not recruiting","No Results Available","Pancreatic Cancer","Biological: CARTmeso CART19","The Percentage of Adverse Events (AEs) ≥ grade 3 assessed through MedDra and CTCAE v4.03 [Time frame: from infusion to 3 month afterward]|Overall Response Rate defined as any improvement measured by imaging following RECIST 1.1 [Time Frame: Day 14 and 1 month after infusion]","First Affiliated Hospital of Wenzhou Medical University","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","YXA-meso19","October 1, 2017","October 31, 2019","October 31, 2020","April 13, 2018","null","April 13, 2018","First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China","","https://ClinicalTrials.gov/show/NCT03497819"
260,"NCT03497442","Treatment of Asian Flushing Syndrome With Topical Alpha Agonists",,"Recruiting","No Results Available","Flushing|Alcohol-Related Disorders|Aldehyde Dehydrogenase Deficiency","Drug: Brimonidine Tartrate|Drug: Placebo Vehicle Gel","Clinician Erythema Score|Patient Erythema Self Assessment|Delayed Clinician Erythema Score|Delayed Patient Erythema Self Assessment","University of California, San Francisco","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17-23964","July 12, 2018","February 2019","March 2019","April 13, 2018","null","October 25, 2018","UC, San Francisco, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT03497442"
261,"NCT03497117","19F MRI of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation",,"Recruiting","No Results Available","Cystic Fibrosis","Device: Lung Clearance Index|Drug: MRI with PFP","Whole lung ventilation defect volume (VDV)|The wash-in kinetics of PFP|Ventilation defect percent (VDP) correlation with LCI|Ventilation defect percent (VDP) correlation with FEV1","University of North Carolina, Chapel Hill|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","16","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","15-0239|2P30DK065988-11","August 25, 2015","June 30, 2020","December 1, 2020","April 13, 2018","null","April 13, 2018","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03497117"
262,"NCT03494881","Mepolizumab for the Treatment of Chronic Spontaneous Urticaria",,"Not yet recruiting","No Results Available","Chronic Spontaneous Urticaria","Drug: Nucala","Mean UAS score 7|Mean reduction in ISS and UCT","Mayo Clinic|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-009322","October 1, 2018","October 15, 2019","October 15, 2019","April 11, 2018","null","August 15, 2018","Mayo Clinic in Florida, Jacksonville, Florida, United States","","https://ClinicalTrials.gov/show/NCT03494881"
263,"NCT03492996","A Mass Balance Study of LCB01-0371 After a Single Oral LCB01-0371 Dose With a [14C]LCB01-0371-microtrace",,"Not yet recruiting","No Results Available","Healthy","Drug: LCB01-0371 dose with a [14C]-LCB01-0371-tracer dose","Assess the AME of LCB01-0371","LegoChem Biosciences, Inc","Male","19 Years to 46 Years   (Adult)","Early Phase 1","4","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCB01-0371-17-1-06","September 1, 2018","October 15, 2018","December 20, 2018","April 10, 2018","null","April 10, 2018","","","https://ClinicalTrials.gov/show/NCT03492996"
264,"NCT03492762","PET Imaging CCR2 in Lung Inflammation",,"Recruiting","No Results Available","Lung Inflammation","Drug: 64Cu-DOTA-ECL1i","Whole body effective dose (in rems/mCi) from an injection of 64Cu-DOTA-ECL1i|Differences in whole-lung standard uptake value (SUV) at 30 and 60 min between healthy volunteers and participants who smoke|Radiation doses (in rems/mCi) to critical organs","Washington University School of Medicine","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","20171192","February 27, 2018","December 30, 2019","December 30, 2019","April 10, 2018","null","April 11, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03492762"
265,"NCT03492736","Effects of Melatonin in Untreated Obstructive Sleep Apnea",,"Not yet recruiting","No Results Available","Obstructive Sleep Apnea","Dietary Supplement: Melatonin|Other: Placebo","PHQ-9 score|Reactive Hyperemia Index","Naomi Deacon|University of California, San Diego","All","30 Years to 60 Years   (Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","180013","April 2018","April 2020","April 2020","April 10, 2018","null","April 20, 2018","","","https://ClinicalTrials.gov/show/NCT03492736"
266,"NCT03492164","Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Pancreatic Cancer",,"Recruiting","No Results Available","Pancreatic Cancer","Drug: [18F]FluorThanatrace ([18F]FTT)","Number of Adverse Events","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 42217","March 20, 2018","March 20, 2021","December 20, 2021","April 10, 2018","null","April 10, 2018","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03492164"
267,"NCT03491267","Study to Determine Effect of Gentle Wounding to Stimulate Hair Follicle Neogenesis",,"Enrolling by invitation","No Results Available","Central Centrifugal Cicatricial Alopecia (CCCA)","Drug: Retinoic acid|Device: Laser|Drug: Sham treatment|Device: Sham treatment","Hair follicle neogenesis as counted by in vivo scanning confocal microscopy","Johns Hopkins University","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","IRB00105061","January 1, 2018","December 31, 2025","December 31, 2025","April 9, 2018","null","April 9, 2018","Johns Hopkins School of Medicine, Dermatology Department, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03491267"
268,"NCT03491098","The Efficacy of Nasal Steroids in Treatment of Otitis Media With Effusion: Acomparative Study","Efficacy","Not yet recruiting","No Results Available","Otitis Media With Effusion","Drug: Mometasone Furoate spray|Drug: prednisolone sodium phosphate 15mg|Drug: hypertonic sea water solution spray","Clinical examination:Hearing loss|Clinical examination:Nasal obstruction|Full E.N.T history","Muteea Mubark Salmen Bakuwiri|Assiut University","All","4 Years to 12 Years   (Child)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","The Efficacy of Nasal Steroids","May 15, 2018","April 30, 2019","March 1, 2020","April 9, 2018","null","April 18, 2018","","","https://ClinicalTrials.gov/show/NCT03491098"
269,"NCT03490708","A Clinical Study of Tranilast in the Treatment of Mucinoses",,"Not yet recruiting","No Results Available","Mucinoses","Drug: Tranilast","Measure the volume change of skin lesions by ultrasound","The First Affiliated Hospital with Nanjing Medical University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","56","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Mucinoses MH Hou","April 2018","June 2022","December 2022","April 6, 2018","null","April 6, 2018","","","https://ClinicalTrials.gov/show/NCT03490708"
270,"NCT03489590","19F MRI to Evaluate Regional Ventilation in Healthy Subjects and Subjects With Cystic Fibrosis",,"Recruiting","No Results Available","Cystic Fibrosis","Drug: PFP","Obtain technically sufficient 19F MRI images|Determine the reproducibility of ventilation assessments in the adult cystic fibrosis (CF) population.|Compare quantitative and qualitative image measures of lung ventilation using 19F MRI imaging to spirometric values.","University of North Carolina, Chapel Hill","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","14-0509","July 1, 2015","June 30, 2020","December 1, 2020","April 5, 2018","null","April 5, 2018","The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03489590"
271,"NCT03489161","Feasibility of the Utilization of Buprenorphine in the Emergency Room to Treat Clinical Opioid Withdrawal",,"Recruiting","No Results Available","Drug Overdose|Opioid Withdrawal|Opioid-use Disorder","Drug: Buprenorphine","Recruitment rates|Acceptability of transferral to outpatient clinic (MOTIVATE)|Feasibility of 5-Trial Delay Discounting","Virginia Commonwealth University","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM20012543","August 1, 2018","October 1, 2018","October 1, 2018","April 5, 2018","null","September 11, 2018","Virginia Commonwealth University, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03489161"
272,"NCT03485560","Revitalization of Damaged Skin Due to Chronic Skin Diseases",,"Not yet recruiting","No Results Available","Chronic Eczema|Psoriasis|Atopic Dermatitis","Combination Product: ACE CSD","Regeneration of the damaged skin lesion|Flare control","Ace Cells Lab Limited","All","Child, Adult, Older Adult","Early Phase 1","200","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACEcsd","May 1, 2018","November 1, 2018","January 1, 2019","April 2, 2018","null","April 2, 2018","ACE cells Lab Europe Doo, Belgrade, Serbia|ACE Cells Lab Limited, Nottingham, Nottinghamshire, United Kingdom","","https://ClinicalTrials.gov/show/NCT03485560"
273,"NCT03482960","Comparison of 129Xe MRI With 19F MRI in CF Lung Disease",,"Recruiting","No Results Available","Cystic Fibrosis","Drug: Hyperpolarized Xenon gas|Drug: PFP","Volume of unventilated lung area after a single 129Xe inhalation and after each inhalation cycle with PFP|Signal-to-noise (SNR) of each modality|Rate constant describing wash-in and wash-out of PFP|Correlation between VDP identified by each modality and spirometry and Lung Clearance Index (LCI)","University of North Carolina, Chapel Hill|Cystic Fibrosis Foundation Therapeutics","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","17-2569|XePFP2017","May 29, 2018","October 2019","April 2020","March 29, 2018","null","May 31, 2018","The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03482960"
274,"NCT03482440","Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia",,"Recruiting","No Results Available","Preeclampsia","Drug: Salsalate Oral Tablet|Drug: Placebo Oral Tablet","change in endothelial function following salsalate treatment compared to placebo treatment|change in inflammatory response to ang II compared to baseline","Penn State University","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","32","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","HL138133","August 23, 2017","August 2021","March 2023","March 29, 2018","null","March 29, 2018","Pennsylvania State University, State College, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03482440"
275,"NCT03481920","A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer",,"Recruiting","No Results Available","Pancreatic Ductal Adenocarcinoma|Pancreatic Cancer","Drug: PEGylated Recombinant Human Hyaluronidase (PEGPH20)|Drug: Avelumab","Determine ORR as per RECIST v1.1 criteria|To assess the safety of this combination in patients with PDAC.|Determine OS (OVERALL SURVIVAL)|Determine PFS (PROGRESSION FREE SURVIVAL)|Changes in CA 19,9 leves","PH Research, S.L.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PH1603","January 10, 2018","January 2019","August 2019","March 29, 2018","null","March 29, 2018","Hospital Universitario Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT03481920"
276,"NCT03481205","Ischemic Conditioning by Aircrews for Refractory Occlusions","ICARO","Not yet recruiting","No Results Available","Acute Stroke","Device: Ischemic conditioning device","Feasibility","University of Iowa","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","201712791","June 1, 2018","June 1, 2019","August 1, 2019","March 29, 2018","null","March 29, 2018","","","https://ClinicalTrials.gov/show/NCT03481205"
277,"NCT03480594","Effect of Fatty Liver on TCA Cycle Flux and the Pentose Phosphate Pathway","HPFFF","Not yet recruiting","No Results Available","Fatty Liver","Drug: Hyperpolarized [13C] Pyruvate Injection","Bicarbonate:lactate ratio|Labeled glycerol fraction","University of Texas Southwestern Medical Center","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","082017-019","May 1, 2018","December 31, 2020","December 31, 2020","March 29, 2018","null","March 29, 2018","","","https://ClinicalTrials.gov/show/NCT03480594"
278,"NCT03479671","Low Dose Fat-Induced Insulin Resistance",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2|Insulin Resistance|Insulin Sensitivity","Drug: Intralipid, 20% Intravenous Emulsion","Insulin Sensitivity","University of Pennsylvania","All","18 Years to 35 Years   (Adult)","Early Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","829352","February 2019","December 2019","January 2020","March 27, 2018","null","October 17, 2018","","","https://ClinicalTrials.gov/show/NCT03479671"
279,"NCT03479203","Acute Effects of E-Cigarette Aerosol Inhalation",,"Recruiting","No Results Available","Endothelial Dysfunction|Biochemical Markers","Drug: Electronic Cigarette Aerosol","Changes in serum protein levels (micrograms) of inflammatory biomarkers (HMGB-1, RAGE, ICAM, CRP) in non-smoking healthy subjects before and after electronic cigarette aerosol inhalation.|Aortic pulse-wave velocity (meters/second)|Femoral artery flow-mediated dilation (% fractional change in cross-sectional area)|Washout time (seconds)|Upslope (%HbO2/seconds)|Overshoot (%HbO2)|Breath hold index (meters/seconds^2)","University of Pennsylvania|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 35 Years   (Adult)","Early Phase 1","39","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","828195|R01HL139358","May 22, 2018","February 2020","February 2021","March 27, 2018","null","June 12, 2018","University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03479203"
280,"NCT03478878","Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation",,"Recruiting","No Results Available","Reticular Pseudodrusen (RPD)|Age-Related Macular Degeneration (AMD)","Drug: Vitamin A Palmitate","Measurement of change in dark adaptation times as measured by the AdaptDx and Medmont pre-and post-vitamin A palmitate supplementation.|Changes in LLVA and changes in patient reported outcomes as measured by the LLQ.","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","10","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","180068|18-EI-0068","May 14, 2018","April 30, 2019","August 22, 2019","March 27, 2018","null","July 4, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03478878"
281,"NCT03478865","Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation",,"Recruiting","No Results Available","AMD","Drug: Vitamin A palmitate","Measurement of dark adaptation as measured by AdaptDX and Medmont comparing pre- and post-vitamin A palmitate supplementation.|Changes in LLVA and changes in patient reported outcomes as measured by the LLQ.","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","10","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","180067|18-EI-0067","April 20, 2018","April 30, 2019","August 22, 2019","March 27, 2018","null","July 4, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03478865"
282,"NCT03478618","Comparison of Different Protocols of Fluid Therapy in Severe Preeclamptic Patients Under Spinal Anesthesia",,"Not yet recruiting","No Results Available","Hypotension Drug-Induced","Drug: Lactated Ringer","incidence of hypotension","Assiut University","Female","18 Years to 40 Years   (Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","haemodynamics in preeclampsia","March 2018","March 2019","April 2019","March 27, 2018","null","March 27, 2018","","","https://ClinicalTrials.gov/show/NCT03478618"
283,"NCT03478085","Near-Infrared Spectroscopy-Guided Exercise Training in Peripheral Arterial Disease",,"Completed","No Results Available","Peripheral Arterial Disease","Other: Oxygen guided exercise therapy","Pain Free Walking Time in Minutes|Total Treadmill Walking Time in Minutes","Augusta University","All","40 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","13GRNT1693006","June 1, 2013","May 31, 2016","May 31, 2016","March 27, 2018","null","March 27, 2018","","","https://ClinicalTrials.gov/show/NCT03478085"
284,"NCT03477162","Metformin Pharmacology in Human Cancers: A Proof of Principle Study",,"Recruiting","No Results Available","Thoracic Neoplasm","Drug: Metformin","Tumor concentration of Metformin|Concentration of Metformin in adipose tissue|Concentration of Metformin in tumor-adjacent normal tissue|Concentration of Metformin in plasma.|Concentration of Metformin in whole blood.|AMPK activity alterations.","Dartmouth-Hitchcock Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D17188","May 15, 2018","December 31, 2018","December 31, 2018","March 26, 2018","null","May 23, 2018","Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States","","https://ClinicalTrials.gov/show/NCT03477162"
285,"NCT03477110","Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma",,"Recruiting","No Results Available","Glioblastoma","Drug: Temozolomide|Radiation: Radiation Therapy|Device: NovoTTF-200A Device|Procedure: Tumor Treating Fields Therapy","NovoTTF-200A device discontinuation rate due to skin toxicity|Progression-free survival|Overall survival|Event-free survival","Sidney Kimmel Cancer Center at Thomas Jefferson University|NovoCure Ltd.|Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","35","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17P.346","May 4, 2018","March 17, 2019","March 2020","March 26, 2018","null","May 24, 2018","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03477110"
286,"NCT03476564","Effects of Pentoxifylline and Vitamin E on Pregnancy Rate in Infertile Women Treated by ICSI:",,"Not yet recruiting","No Results Available","Infertility, Female","Drug: pentoxifylline|Drug: Vit E","clinical pregnancy rate.|clinical pregnancy rate","Benha University|El Galaa Teaching Hospital|Benha University Hospital","Female","20 Years to 39 Years   (Adult)","Early Phase 1","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","BenhaU1","May 1, 2018","September 1, 2018","September 1, 2018","March 26, 2018","null","March 26, 2018","El Galaa Teaching hosptial, Cairo, Ghamra, Egypt","","https://ClinicalTrials.gov/show/NCT03476564"
287,"NCT03475693","A Cohort Study Evaluating the Efficacy of PO Magnesium in the Treatment of Acute Traumatic Brain Injury in Adolescents",,"Recruiting","No Results Available","Concussion Post Syndrome","Drug: Magnesium Oxide|Drug: Acetaminophen|Drug: Zofran ODT 4 MG Disintegrating Oral Tablet","Change in symptom severity score|Adverse events in the emergency department","Lakeland Health|Michigan State University","All","12 Years to 18 Years   (Child, Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","MMMC#1571","September 1, 2017","July 2019","November 2019","March 23, 2018","null","June 7, 2018","Lakeland Regional Healthcare, Saint Joseph, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03475693"
288,"NCT03474718","Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia",,"Not yet recruiting","No Results Available","Androgenic Alopecia","Biological: Platelet-rich Plasma Left Side|Biological: Platelet-rich Plasma Right Side","Change in Severity of Alopecia Tool (SALT) from baseline|Change in Hair Count (number of hairs/0.65cm^2)|Change in Hair Density (number of hairs/cm^2)","Wake Forest University Health Sciences","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00045844","February 22, 2019","May 1, 2020","May 1, 2020","March 22, 2018","null","May 18, 2018","Wake Forest University Baptist Health, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03474718"
289,"NCT03473730","Daratumumab in Patients With Metastatic Renal Cell Carcinoma (MRCC) or Muscle Invasive Bladder Cancer",,"Recruiting","No Results Available","Malignant Neoplasms of Urinary Tract","Drug: Daratumumab","Adverse Events of Daratumumab Determined by CTCAE v4.03|Rate of Surgical Delay in Bladder Cohort Defined as Delay Greater than 4 weeks from Planned Intervention|Pathologic Response of Daratumumab in Bladder Cohort|Best Objective Response Rate (ORR) of Daratumumab in Renal Cohort Estimated Using RECIST v1.1 criteria.|Progression Free Survival (PFS) of Daratumumab in Renal Cohort","M.D. Anderson Cancer Center|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-0688|NCI-2018-00800","May 29, 2018","March 2019","March 2020","March 22, 2018","null","July 16, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03473730"
290,"NCT03473691","Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer","Breast50","Withdrawn","No Results Available","Triple Negative Breast Cancer","Drug: Glembatumumab Vedotin","Incidence of Adverse Events (AEs)|Proportion of patients who complete the 4 cycles of GV within 15 weeks of the first dose of GV (without dose limiting adverse events).|Number of discontinuations due to AEs|Efficacy|Growth Differentiation Factor-11 (GDF11) expression in the tumor|Glycoprotein-NMB (gpNMB) expression in the tumor","University of Virginia|Celldex Therapeutics","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TBDBreast50","May 1, 2018","May 1, 2018","May 1, 2018","March 22, 2018","null","June 1, 2018","","","https://ClinicalTrials.gov/show/NCT03473691"
291,"NCT03473093","Oral Pregabalin Effect to the Intravenous Morphine in Multiple Fracture Ribs",,"Not yet recruiting","No Results Available","Fracture; Rib, Multiple","Drug: Pregabalin 150mg|Drug: Morphine","decrease pain|I.C.U stay time","Assiut University","All","18 Years to 50 Years   (Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","pain in multiple fracture ribs","March 2018","March 2019","April 2019","March 22, 2018","null","March 23, 2018","","","https://ClinicalTrials.gov/show/NCT03473093"
292,"NCT03471585","Effects of THC on Emotional Memory Retrieval","TARE","Completed","No Results Available","Healthy","Drug: THC|Drug: Placebo oral capsule","Emotional Memory|DRM Memory|Addiction Research Centre Inventory Marijuana Scale|Visual Analog Scales|Drug Effects Questionnaire|Physiological Measure 1|Physiological Measure 2","University of Chicago","All","18 Years to 35 Years   (Adult)","Early Phase 1","23","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","IRB16-1132","February 15, 2017","October 4, 2017","October 4, 2017","March 20, 2018","null","March 20, 2018","University of Chicago, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT03471585"
293,"NCT03471364","Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash",,"Recruiting","No Results Available","Skin Burning Sensation|Skin Rash","Drug: Ketoconazole|Other: Laboratory Biomarker Analysis|Other: Placebo|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Proportion of patients who report an improvement in skin rash assessed by Skindex-16|The change from baseline in total score and subscales for incidence of skin toxicity as measured by the Skindex-16|The change from baseline in the total score and subscales of the incidence of skin toxicity as measured by the Skin Toxicity Assessment Tool (STAT)|Incidence of adverse events for ketoconazole","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MC17C1|NCI-2018-00355|P30CA015083","August 22, 2018","March 15, 2020","March 15, 2020","March 20, 2018","null","September 21, 2018","Mayo Clinic, Rochester, Minnesota, United States|Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States|Regions Cancer Care Center, Saint Paul, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT03471364"
294,"NCT03470038","The Interaction Between NGF-induced Muscle Sensitivity and Acute Exercise-induced Ischemia",,"Recruiting","No Results Available","Muscle Hypersensitivity|Pain Response|Healthy Subjects","Drug: NGF/Isotonic saline","Muscle sensitivity|Ischemic-induced pain intensity|NGF-induced pain in intensity|Combined NGF and ischemic pain intensity|Functional muscle pain|Muscle pain diary","Aalborg University","All","18 Years to 55 Years   (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","N-2017-0007_S2","March 15, 2018","May 15, 2018","June 15, 2018","March 19, 2018","null","March 19, 2018","Aalborg University, Aalborg, Denmark","","https://ClinicalTrials.gov/show/NCT03470038"
295,"NCT03469492","Investigating the Role of the Polyol Pathway in the Central Nervous System Production of Fructose",,"Recruiting","No Results Available","Hyperglycaemia (Diabetic)","Drug: Insulin|Behavioral: exercise|Dietary Supplement: Dietary counseling","HbA1C|gluthathione|plasma glucose|plasma fructose|plasma insulin","Yale University","All","18 Years to 60 Years   (Adult)","Early Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1602017151","January 18, 2018","January 2020","January 2020","March 19, 2018","null","May 17, 2018","The Anylan Center, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03469492"
296,"NCT03469284","MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)",,"Not yet recruiting","No Results Available","Diseases of Oral Cavity Salivary Glands and Jaws","Drug: Methylene Blue (MB) 0.025%|Drug: Methylene Blue (MB) 0.05%|Drug: Methylene Blue (MB) 0.1%|Behavioral: Study Phone Calls","Reduction in Pain Scores Measured by Numeric Rating Scale (NRS)|Mean Change in Oral Functioning Scores","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-1051|NCI-2018-00822","November 2018","November 2020","November 2021","March 19, 2018","null","September 14, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03469284"
297,"NCT03468582","123I Radiolabeled 3BNC117",,"Recruiting","No Results Available","Human Immunodeficiency Virus","Combination Product: 123I radiolabeled 3BNC117","Absorbed dose per Organ mGy/MBq|total number of lesions","University of Lausanne Hospitals","All","18 Years to 55 Years   (Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2010-01003","February 8, 2018","February 7, 2019","February 7, 2019","March 16, 2018","null","April 10, 2018","Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland","","https://ClinicalTrials.gov/show/NCT03468582"
298,"NCT03468543","Study Determining Gastric-Retentive and Modified Release Properties of Prototype Capsules in Healthy Subjects",,"Terminated","No Results Available","Gastric Retention|Healthy","Drug: Memantine Hydrochloride MR Prototype Capsule Formulation A|Drug: Memantine Hydrochloride MR Prototype Capsule Formulation B|Drug: Memantine Hydrochloride MR Prototype Capsule Formulation C|Drug: Memantine Hydrochloride MR Prototype Capsule Formulation D|Drug: Memantine Hydrochloride MR Prototype Capsule Formulation E|Procedure: Magnetic Resonance Imaging","Gastric Retention by Magnetic Resonance Imaging (MRI)","Lyndra Inc.","All","18 Years to 60 Years   (Adult)","Early Phase 1","3","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","QCL117924|2017-000982-61","July 26, 2017","September 18, 2017","September 18, 2017","March 16, 2018","null","March 16, 2018","Quotient Sciences (formerly Quotient Clinical), Ruddington, Nottingham, United Kingdom","","https://ClinicalTrials.gov/show/NCT03468543"
299,"NCT03468140","Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation",,"Not yet recruiting","No Results Available","End Stage Liver Disease","Drug: Eculizumab|Other: No intervention","Degree of Hepatocellular Injury|Alanine transaminase (ALT) recovery time|Seven-day peak post-transplant (GCT)|Gamma-glutamyl transpeptidase (GCT) recovery time|International Normalized Ratio (INR) recovery time|Seven-day peak post-transplant creatinine","Yale University|Ochsner Health System|Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2000021373","November 15, 2018","December 31, 2019","December 31, 2020","March 16, 2018","null","October 22, 2018","","","https://ClinicalTrials.gov/show/NCT03468140"
300,"NCT03468049","Effect of Allium Cepa in the Management of Shoulder Pain Post Stroke",,"Not yet recruiting","No Results Available","Stroke","Biological: Topical App. of Allium Cepa Extract|Biological: Phonophoresis of Allium Cepa Extract|Biological: Raw Mashed Allium Cepa Application|Other: Standard Physiotherapy Group (SPG)","Stroke Impact Scale","Bayero University Kano, Nigeria|Physiotherapy Associates","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","HMohammed","April 2018","August 2018","December 2018","March 16, 2018","null","April 4, 2018","","","https://ClinicalTrials.gov/show/NCT03468049"
301,"NCT03467191","Behavioral Alcohol Responses (BAR) Study",,"Recruiting","No Results Available","Alcohol Drinking|Alcohol Use Disorder|Alcohol Intoxication|Alcohol; Harmful Use|Alcoholism|Binge Drinking","Drug: Alcohol|Other: Placebo","Change from Baseline Alcohol Use at 12-months|Change from Baseline Alcohol Use Disorder Symptoms at 12-months|Subjective Responses to Alcohol|Social Bonding|Mood|Alcohol Use","Carnegie Mellon University|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|University of Pittsburgh|Penn State University","All","21 Years to 29 Years   (Adult)","Early Phase 1","400","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","STUDY2017_00000346|R01AA025936","February 13, 2018","May 31, 2022","May 31, 2022","March 15, 2018","null","April 25, 2018","Carnegie Mellon University, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03467191"
302,"NCT03466242","IN Dexmedetomidine for Procedural Sedation in Pediatric Closed Reductions for Distal Forearm Fractures",,"Not yet recruiting","No Results Available","Conscious Sedation|Distal Radius Fracture","Drug: Dexmedetomidine|Drug: Ketamine","Evaluate the sedative effects of intranasal Dexmedetomidine in children undergoing conscious sedation for closed distal forearm fracture reduction compared to intravenous Ketamine|Evaluate the analgesic effects of intranasal Dexmedetomidine in children undergoing conscious sedation for closed distal forearm fracture reduction compared to intravenous Ketamine|Compare each sedation technique for time to sedation onset|Compare each sedation technique for length of sedation|Compare each sedation technique for length of ED stay|Compare each sedation technique for need for additional doses of medications for analgesia or sedation|Compare each sedation technique for Vital sign abnormalities|Compare each sedation technique for need for respiratory interventions|Compare each sedation technique for rate of vomiting|Compare each sedation technique for procedural success rate|Compare each sedation technique for patient family satisfaction","Phoenix Children's Hospital","All","2 Years to 18 Years   (Child, Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-193","May 1, 2018","April 1, 2019","May 1, 2019","March 15, 2018","null","March 15, 2018","Phoenix Children's Hospital, Phoenix, Arizona, United States","","https://ClinicalTrials.gov/show/NCT03466242"
303,"NCT03465943","Different Preloads for Prevention of Hypotension in Patients Undergoing Elective CS Under Intrathecal Anesthesia",,"Not yet recruiting","No Results Available","Hypotension Drug-Induced","Drug: Ringer|Drug: Voluven","Incidence of hypotension|Perfusion index|Heart rate|Urine output","Assiut University","Female","18 Years to 40 Years   (Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Hypotension in elective CS","March 2018","March 2019","April 2019","March 15, 2018","null","March 15, 2018","","","https://ClinicalTrials.gov/show/NCT03465943"
304,"NCT03465917","Physiological Study of the Efficacy and Mechanistic Effects of Alcohol Renal Denervation",,"Recruiting","No Results Available","Hypertension","Combination Product: Renal Denervation","Renal sympathetic activity|Blood pressure|Muscle sympathetic activity|Vascular function|Vascular stiffness","University of Texas Southwestern Medical Center|National Institute of Neurological Disorders and Stroke (NINDS)","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","5","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","STU 112014-023","March 1, 2018","February 2019","February 2019","March 14, 2018","null","March 14, 2018","The Institute for Exercise and Environmental Medicine, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT03465917"
305,"NCT03465774","Indwelling Pleural Catheters Versus Indwelling Pleural Catheters Plus Doxycycline",,"Recruiting","No Results Available","Malignant Neoplasms of Respiratory and Intrathoracic Organs","Behavioral: Surveys|Drug: Fentanyl|Drug: Doxycycline","Time to Indwelling Pleural Catheter (IPC) Removal|Fluid Recurrence after Indwelling Pleural Catheter (IPC) Removal|Symptom Burden Determined by Patient Self Assessment Form","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","208","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-0973|NCI-2018-00630","March 8, 2018","December 2019","December 2020","March 14, 2018","null","April 20, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03465774"
306,"NCT03463408","Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma",,"Recruiting","No Results Available","Sarcoma","Drug: nivolumab|Drug: ipilimumab","Adverse Event evaluation","University of Rochester","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","USAR17101","July 17, 2018","August 1, 2024","August 1, 2025","March 13, 2018","null","September 5, 2018","James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States","","https://ClinicalTrials.gov/show/NCT03463408"
307,"NCT03459794","Ivermectin and Human Immunity",,"Active, not recruiting","No Results Available","Ivermectin","Drug: Ivermectin|Other: Placebo","Changes in cytokine levels|Changes in gene expression|Complete Blood counts","University of Georgia","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","STUDY00005069","February 12, 2018","April 9, 2018","November 30, 2018","March 9, 2018","null","October 10, 2018","University of Georgia, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03459794"
308,"NCT03459729","Antitumor B KAC-α PK Study",,"Not yet recruiting","No Results Available","Squamous Cell Carcinoma of the Oral Cavity","Dietary Supplement: Antitumor B KAC-α","Antitumor B KAC-α in blood samples.|Antitumor B KAC-α in saliva.|Antitumor B KAC-α accumulation in tumor tissue specimen.","Medical College of Wisconsin","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","IIT-WONG-ATB","April 1, 2018","May 1, 2019","May 1, 2020","March 9, 2018","null","March 9, 2018","Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT03459729"
309,"NCT03457025","Effect of Adjuvant Hyperbaric Oxygen Therapy on Bells Palsy Outcome",,"Not yet recruiting","No Results Available","Bell Palsy","Drug: Oral Corticosteroids|Drug: Oral antivirals|Device: Hyperbaric Oxygen Therapy","Change in the percentage of subjects that return to baseline facial function 1 year following the onset of paralysis Standard of Care Group|Change in the percentage of subjects that return to baseline facial function 1 year following the onset of paralysis Standard of Care + Hyperbaric Oxygen Therapy on Bells Palsy (HBOT) Group|Short Form 36 (SF-36) Score Standard of Care Group|Short Form 36 (SF-36) Score Standard of Care + HBOT|Facial Clinimetric Evaluation Scale (FaCE) Score Standard of Care Group|Facial Clinimetric Evaluation Scale (FaCE) Score Standard of Care + HBOT|Facial Disability Index (FDI) Score Standard of Care Group|Facial Disability Index (FDI) Score Standard of Care + HBOT","New York University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","17-01740","December 2018","June 2020","June 2020","March 7, 2018","null","October 5, 2018","New York University School of Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03457025"
310,"NCT03456570","The Efficacy of Progestins in Treatment of Functional Ovarian Cyst",,"Not yet recruiting","No Results Available","Functional Ovarian Cyst|Progesterone","Drug: Dydrogesterone 10 mg|Drug: Placebo Oral Tablet","disappearance of cyst","Assiut University","Female","18 Years to 44 Years   (Adult)","Early Phase 1","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","Progestins and ovarian cyst","May 1, 2018","May 1, 2020","September 1, 2020","March 7, 2018","null","March 7, 2018","","","https://ClinicalTrials.gov/show/NCT03456570"
311,"NCT03454295","Easing Psychosocial Burden for Informal Caregivers",,"Recruiting","No Results Available","Glioblastoma","Behavioral: Focus Group|Behavioral: Meaning-Centered Psychotherapy for Cancer Caregivers / MCP-C|Behavioral: Enhanced Usual Care / EUC","Feasibility of Meaning-Centered Psychotherapy for Cancer Caregivers (MCP-C) delivered to caregivers of participants with GBM|Acceptability of Meaning-Centered Psychotherapy for Cancer Caregivers (MCP-C) delivered to caregivers of participants with GBM","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","18-075","February 12, 2018","August 2019","August 2019","March 5, 2018","null","October 24, 2018","Memorial Sloan Kettering Commack (Consent only), Commack, New York, United States|Memoral Sloan Kettering Westchester (Consent only), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03454295"
312,"NCT03454243","Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors","TITAN","Terminated","No Results Available","Advanced or Metastatic Solid Tumors","Drug: RXDX-106","Dose Limint Toxicities (DLT)|Maximum Tolerated Dose (MTD)|Recommended Phase 2 Dose (RP2D)|Objective Response Rate (ORR)|Duration of Response|Overall Survival (OS)|Progression-Free Survival (PFS)|Maximum observed plasma concentration (Cmax)|Time of maximum observed plasma concentration (Tmax)|AUC throughout dosing interval (AUCτ)","Ignyta, Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","1","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RXDX-106-01","February 15, 2018","June 5, 2018","June 5, 2018","March 5, 2018","null","September 17, 2018","START, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT03454243"
313,"NCT03451435","N-Acetyl Cysteine Protects Pulpal Stem Cells in Endodontic Revascularization","NAC","Not yet recruiting","No Results Available","Endodontic Disease","Drug: N acetyl cysteine","Change of Root length","University of California, Los Angeles","All","6 Years to 18 Years   (Child, Adult)","Early Phase 1","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","17-001024","June 15, 2018","June 15, 2019","June 15, 2019","March 1, 2018","null","May 11, 2018","","","https://ClinicalTrials.gov/show/NCT03451435"
314,"NCT03451123","FET-PET/MRI for Surgical Assessment of Pediatric Brain Tumors",,"Recruiting","No Results Available","Pediatric Brain Tumors","Drug: FET PET/MRI","Percentage of patients whose surgical plan change with FET-PET/MRI compared to MRI alone.|Percentage of patients who have residual tumor after surgery detected with FET-PET/MRI","University of Alabama at Birmingham","All","6 Years to 18 Years   (Child, Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","R17-077","April 23, 2018","February 2021","February 2021","March 1, 2018","null","May 15, 2018","UAB Advanced Imaging Facility, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT03451123"
315,"NCT03449459","Prevention of Acute Exacerbation in Subjects With COPD by Bacterial Decolonization in Lower Respiratory Tract","PAEAN","Not yet recruiting","No Results Available","Chronic Obstructive Pulmonary Disease (COPD)","Dietary Supplement: oral probiotics|Drug: aerosol inhaled amikacin|Biological: combined vaccination","Time to the first COPD exacerbation|Colonization of potential pathogenic bacteria in induced sputum|Microbiome in induced sputum|Forced Expiratory Volume in 1 Second|COPD Assessment Test(CAT) Score|modified Medical Research Council(mMRC) scale|serum C-reactive protein(CRP) levels|interleukin(IL)-6 in induced sputum|IL-8 in induced sputum|IL-1β in induced sputum|Number of Patients With Adverse Events, Serious Adverse Events, and Death","Shanghai Zhongshan Hospital|The First Affiliated Hospital of Guangzhou Medical University|Ruijin Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","144","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","B2017-197R|2017YFC1309303","December 2018","December 2020","December 2020","February 28, 2018","null","November 15, 2018","The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, Shanghai, China|Shanghai Zhongshan Hospital, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03449459"
316,"NCT03448016","[C-11]NOP-1A and Alcohol Use Disorder",,"Recruiting","No Results Available","Alcohol Use Disorder","Radiation: [C-11]|Drug: NOP-1A","[C-11]NOP-1A VT","Rajesh Narendran|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|University of Pittsburgh","All","18 Years to 55 Years   (Adult)","Early Phase 1","80","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PRO16030103 & PRO13080387|R01AA025247","May 27, 2016","December 31, 2022","December 31, 2022","February 27, 2018","null","September 6, 2018","University of PIttsburgh PET Facility, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03448016"
317,"NCT03447743","Re-entry XR-NTX for Rural Women With Opioid Use Disorder",,"Not yet recruiting","No Results Available","Opioid Dependence","Drug: XR-NTX community location","Study enrollment|Opioid relapse","University of Kentucky","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","R34DA045856-01","April 1, 2019","March 31, 2021","March 31, 2021","February 27, 2018","null","April 13, 2018","","","https://ClinicalTrials.gov/show/NCT03447743"
318,"NCT03446651","Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure",,"Not yet recruiting","No Results Available","Heart Failure","Drug: Lysine Chloride|Other: Placebo","Change in Blood Volume|Change in log NTpro-BNP|Change in Serum Creatinine|Change in Cystatin C|Change in Chloride|Change in Bicarbonate","Yale University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","2000022001","July 2018","September 2023","March 2024","February 27, 2018","null","June 26, 2018","","","https://ClinicalTrials.gov/show/NCT03446651"
319,"NCT03445858","Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults",,"Recruiting","No Results Available","Childhood Solid Tumor|Childhood Lymphoma|Relapsed Cancer|Refractory Cancer|Adult Solid Tumor|Adult Lymphoma","Drug: Pembrolizumab|Drug: Decitabine|Radiation: Hypofractionated Index Site Radiation","Feasibility of administering Pembrolizumab in combination with Decitabine and hypofractionated index radiation|Identification of treatment related toxicities and tolerability|Define anti-tumor efficacy of treatment combination of pembrolizumab, decitabine, and hypofractionated index radiation (per irRECIST criteria)","Children's Hospital Medical Center, Cincinnati","All","12 Months to 40 Years   (Child, Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pembro_BT_1603","February 12, 2018","May 12, 2022","May 12, 2022","February 26, 2018","null","November 1, 2018","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03445858"
320,"NCT03445702","Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2|Metformin Adverse Reaction","Drug: Metformin|Drug: Placebo","Lactate to pyruvate ratio|Genomic testing","St. Louis University|Washington University School of Medicine","All","40 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Screening","25319","October 2018","September 2019","December 2019","February 26, 2018","null","October 2, 2018","Saint Louis University, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03445702"
321,"NCT03445611","Parabens Flocculation on the Anti Inflammatory Effects of Corticosteroid Injections for Total Knee Arthroplasty","5160373","Not yet recruiting","No Results Available","Osteoarthritis, Knee","Drug: corticosteroid solution with lidocaine containing parabens.|Drug: corticosteroid solution with lidocaine containing no paraben","WOMAC-Western Ontario and McMaster Universities Osteoarthritis Index|VAS-Visual Analogue Scale","Loma Linda University","All","19 Years to 89 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","5160373","May 15, 2018","March 15, 2019","May 30, 2019","February 26, 2018","null","February 26, 2018","Loma Linda University Health, Department of Orthopaedic Surgery, Loma Linda, California, United States","","https://ClinicalTrials.gov/show/NCT03445611"
322,"NCT03445104","Effect of Huperzine A on Cognitive Function and Perception of Effort During Exercise",,"Completed","No Results Available","Cognitive Enhancement During Exercise","Other: Huperzine A|Other: Placebo","Digit span|Verbal Fluency|Category Fluency|Stroop Effect Test","St. Louis University","All","18 Years to 60 Years   (Adult)","Early Phase 1","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","28661","January 16, 2018","April 5, 2018","April 5, 2018","February 26, 2018","null","May 31, 2018","Allied Health Professional Building, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03445104"
323,"NCT03443882","Bioavailability of Astaxanthin Formulations",,"Active, not recruiting","No Results Available","Healthy Volunteers","Dietary Supplement: Astaxanthin","plasma level","Algatechnologies Ltd.","All","21 Years to 50 Years   (Adult)","Early Phase 1","10","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","01 2018 ver1","March 25, 2018","September 25, 2018","September 25, 2018","February 23, 2018","null","July 3, 2018","Bert W. Strassburger Lipid Center, Sheba Medical Center,, Tel Hashomer, Israel","","https://ClinicalTrials.gov/show/NCT03443882"
324,"NCT03440970","Mechanism and Effects of Manipulating Chloride Homeostasis in Stable Heart Failure",,"Not yet recruiting","No Results Available","Decompensated Heart Failure","Drug: Lysine Chloride|Other: Placebo","Change in Blood Volume|Change in log NTpro-BNP|Change in Serum Creatinine|Change in Cystatin C|Change in Chloride|Change in Bicarbonate","Yale University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","125","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","2000022016","July 2018","March 2023","September 2023","February 21, 2018","null","June 26, 2018","","","https://ClinicalTrials.gov/show/NCT03440970"
325,"NCT03439865","Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis",,"Not yet recruiting","No Results Available","Chronic Rhinosinusitis (Diagnosis)","Drug: Ivacaftor|Drug: standard of care treatment","Improvement in quality of life measures","University of Alabama at Birmingham|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-300000168|5R01HL133006-02","July 2019","July 2021","July 2022","February 20, 2018","null","March 5, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT03439865"
326,"NCT03437824","Effects of Vitamin B12 Treatment in Singers",,"Recruiting","No Results Available","Vitamin B 12 Deficiency","Drug: Cyanocobalamin|Drug: Placebo","Evaluation of the Ability to Sing Easily (EASE) - Change|Singing Voice Handicap Index-10 (SVHI-10) - Change|0-10 Visual Analog Scale (VAS) - Change|Vocal Fold Swelling (Bastian et al., 2009) - Change|Voice Fatigue Index (VFI) - Change|Short Warwick-Edinburgh Mental Wellbeing Scale (SWEMWBS) - Change|Patients Health Questionnaire-9 for Depression - Change","University of Southern California","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","APP-16-06647","October 1, 2017","July 1, 2020","July 1, 2021","February 19, 2018","null","February 19, 2018","Keck Medicine of USC - Downtown Los Angeles, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT03437824"
327,"NCT03437759","MSC-Exos Promote Healing of MHs","MSCs","Recruiting","No Results Available","Macular Holes","Biological: exosomes derived from mesenchymal stem cells (MSC-Exo)","Macular holes closure|Best corrected visual acuity(BCVA)","Tianjin Medical University","All","up to 80 Years   (Child, Adult, Older Adult)","Early Phase 1","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2015KY-05","March 1, 2017","May 30, 2018","December 30, 2018","February 19, 2018","null","May 18, 2018","Tianjin Medical University Hospital, Tianjin, China","","https://ClinicalTrials.gov/show/NCT03437759"
328,"NCT03436342","Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma",,"Not yet recruiting","No Results Available","Multiple Myeloma|Lymphoma","Drug: 68Ga-Pentixafor","SUVmax|Diagnostic value|Incidence of emergency events during the study|Tumor burden assessement|Diagnostic value in special type of multiple myeloma|CXCR4 expression and SUV|Overall Survival|Disease Free Survival|Disease Specific Survival","Peking Union Medical College Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PekingUMCHCXCR4","June 1, 2018","March 1, 2020","December 1, 2020","February 16, 2018","null","May 4, 2018","Department of Nuclear Medicine, Peking Union Medical College Hopital, Chinese Academy of Medical Science, Beijing, China","","https://ClinicalTrials.gov/show/NCT03436342"
329,"NCT03436160","Study Assessing Pharmacokinetics and Bioavailability of Three Novel Triazine Compounds",,"Recruiting","No Results Available","Malaria","Drug: WR826647|Drug: WR909388|Drug: WR909390","Pharmacodynamic parameters of Carbon-14 radio labeled (14C) WR826647, WR909388, and WR909390|Bioavailability of Carbon-14 radio labeled (14C) WR826647, WR909388, and WR909390","U.S. Army Medical Research and Materiel Command|Walter Reed Army Institute of Research (WRAIR)","All","19 Years to 50 Years   (Adult)","Early Phase 1","18","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","S-15-45","August 10, 2018","November 3, 2018","October 2019","February 16, 2018","null","August 16, 2018","Celerion, Lincoln, Nebraska, United States","","https://ClinicalTrials.gov/show/NCT03436160"
330,"NCT03435939","Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240",,"Not yet recruiting","No Results Available","Cystic Fibrosis","Drug: Losartan","Improvement of mucociliary clearance ( MCC) and cough clearance (CC)|Improvement on pulmonary function tests (in %predicted)|Improvement on pulmonary function tests (in L)|Decrease of inflammatory markers|Nasal cytokine changes","University of Miami|University of North Carolina","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","20170522","January 10, 2019","January 10, 2020","March 10, 2020","February 16, 2018","null","October 11, 2018","University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03435939"
331,"NCT03433898","This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer",,"Recruiting","No Results Available","Neoplasms","Drug: BI 754091|Drug: BI 754111","Part I: Maximum tolerated dose (MTD) of BI 754091|Part I: Number of patients experiencing dose limiting toxicities (DLTs) during the MTD evaluation period (first cycle of treatment)|Part II: MTD of the BI 754091 plus BI 754111 combination|Part II: Number of patients experiencing DLTs during the MTD evaluation period (first cycle of treatment)|Part III: Objective response (OR) - confirmed complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumours (RECIST) Version 1.1 as assessed by the Investigator|Part I: Cmax: maximum measured concentration of BI 754091 in plasma|Part I: AUC0-504: area under the concentration-time curve of BI 754091 in plasma|Part II: Cmax: maximum measured concentration of BI 754091 and BI 754111 in plasma|Part II: AUC0-504: area under the concentration-time curve of BI 754091 and BI 754111 in plasma|Part III: Duration of response|Part III: Disease control|Part I - Objective response (OR)|Part II - Objective response (OR)","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","164","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1381-0004","February 23, 2018","April 18, 2021","April 18, 2021","February 15, 2018","null","November 14, 2018","National Cancer Center Hospital, Tokyo, Chuo-ku, Japan","","https://ClinicalTrials.gov/show/NCT03433898"
332,"NCT03433378","To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris",,"Completed","No Results Available","Acne Vulgaris","Drug: Tretinoin cream, 0.05%|Drug: RETIN-A® (tretinoin) cream, 0.05%|Drug: Vehicle of the test product","Demonstration of Bioequivalence","Taro Pharmaceuticals USA","All","12 Years to 40 Years   (Child, Adult)","Early Phase 1","700","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TRTC 1623","August 4, 2017","January 26, 2018","January 26, 2018","February 14, 2018","null","May 18, 2018","Catawba Research, LLC, Charlotte, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03433378"
333,"NCT03432572","Investigating Oral Agents for Urine Staining to Facilitate Intraoperative Observation of Ureteral Jets",,"Not yet recruiting","No Results Available","Ureteral Injury","Drug: Pyridium|Drug: Riboflavin|Drug: Thiamine","urine discoloration on cystoscopy","Texas Tech University Health Sciences Center","Female","21 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic","L18-072","November 1, 2018","December 1, 2018","March 1, 2019","February 14, 2018","null","November 2, 2018","","","https://ClinicalTrials.gov/show/NCT03432572"
334,"NCT03430934","Non-invasive Fluorescent Imaging System for Imaging Mohs Tumor",,"Recruiting","No Results Available","Skin Cancer","Combination Product: NAVI mapping with Indocyanine green","Near Infra-Red Navigation (NAVI) System for Mohs Tumor Mapping","University of Missouri-Columbia","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","2009753","July 1, 2018","December 1, 2020","December 1, 2020","February 13, 2018","null","October 12, 2018","University of Missouri Health Care, Columbia, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03430934"
335,"NCT03430596","a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics",,"Not yet recruiting","No Results Available","Extrapyramidal Syndrome","Drug: Pramipexole|Drug: Trihexyphenidyl hydrochloride","The change of SAS BARS AIMS from baseline|The change of PANSS CDSS CGI-S from baseline","Shanghai Mental Health Center","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","17411970300","February 2018","September 2018","June 2019","February 13, 2018","null","February 13, 2018","Shanghai Mental Health Center, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03430596"
336,"NCT03430050","Progesterone for Cannabis Withdrawal",,"Recruiting","No Results Available","Cannabis Use Disorder|Cannabis Withdrawal","Drug: Progesterone|Drug: Placebo","Salivary Progesterone|Cannabis withdrawal","Medical University of South Carolina|National Institute on Drug Abuse (NIDA)|National Institutes of Health (NIH)","Female","18 Years to 45 Years   (Adult)","Early Phase 1","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","65954|5K24DA038240-03","October 16, 2017","July 31, 2019","July 31, 2019","February 12, 2018","null","February 12, 2018","Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT03430050"
337,"NCT03429634","Balloon-Stent Kissing Technique Versus Jailed Wire Technique for the Coronary Bifurcation Lesions",,"Completed","No Results Available","Coronary Artery Disease","Procedure: Balloon-Stent Kissing technique|Procedure: Jailed Wire technique","Perioperative major adverse cardiovascular (MACE) events （%）|long-term clinical outcomes（%）","Dalian University","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","89","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","DalianU","January 1, 2013","May 1, 2016","July 1, 2017","February 12, 2018","null","February 12, 2018","Dept. of Cardiology, Affiliated Zhongshan hospital of Dalian University, Dalian, Liaoning, China","","https://ClinicalTrials.gov/show/NCT03429634"
338,"NCT03429140","Early Anti-inflammatory Treatment in Patients With Acute ACL Tear and Painful Effusions","HEALR","Active, not recruiting","No Results Available","Anterior Cruciate Ligament","Drug: Gel-One|Other: Saline Placebo","Change in KOOS score over time|Change in CTX-II pre and post surgery","Mary Ireland|University of Kentucky","All","14 Years to 33 Years   (Child, Adult)","Early Phase 1","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","16-0662-F6A","April 6, 2017","December 31, 2021","December 31, 2021","February 12, 2018","null","August 28, 2018","UK Healthcare at Turfland, Lexington, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT03429140"
339,"NCT03427554","To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris",,"Completed","No Results Available","Acne Vulgaris","Drug: Tretinoin cream 0.1%|Drug: RETIN-A® Cream|Drug: Vehicle of the test product","Demonstration of Bioequivalence","Taro Pharmaceuticals USA","All","12 Years to 40 Years   (Child, Adult)","Early Phase 1","455","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","TRTC 1622","August 21, 2017","January 26, 2018","January 26, 2018","February 9, 2018","null","May 18, 2018","Catawba Research, LLC, Charlotte, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03427554"
340,"NCT03427463","Comparison of 0.1 and 0.05mg Intrathecal Morphine for Post-cesarean Analgesia.",,"Recruiting","No Results Available","Cesarean Section","Drug: receiving 0.1 mg IT morphine|Drug: recieving 0.05 mg IT morphine","Time to first narcotic rescue dose in the first 24 hours posto cesarean delivery.|time to first ambulation|opiate consumption|subjective pain rating using visual analogue scales (VAS)|presence of opiate side effects (nausea, vomiting, and pruritus)|overall patient satisfaction with pain control","Medical University of South Carolina","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Pro00072393","January 16, 2018","February 1, 2020","February 1, 2020","February 9, 2018","null","February 9, 2018","Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT03427463"
341,"NCT03427021","A Randomized Study to Establish the Efficacy of Oral Ice Exposure During Oxaliplatin Infusion in Preventing Oral Cold Sensitivity",,"Recruiting","No Results Available","GI Patients on Oxaliplatin Containing Regimen","Drug: Oxaliplatin","overall intraoral cold sensitivity score","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 28216","February 1, 2017","February 1, 2020","February 1, 2021","February 9, 2018","null","August 21, 2018","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03427021"
342,"NCT03426969","HLA-Haploidentical SCT+ Post SCT Cy for Advanced Myelofibrosis",,"Recruiting","No Results Available","Myelofibrosis","Drug: Melphalan|Drug: Fludarabine|Radiation: Total Body Irradiation (TBI)|Procedure: Stem Cell Infusion|Drug: Cyclophosphamide|Drug: Tacrolimus|Drug: Mycophenolate Mofetil|Drug: G-CSF","Toxicities of HLA-Haploidentical SCT+ Post SCT Cy for Advanced Myelofibrosis scored using the NCI Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (NCI) version 4.03.|Time to neutrophil recovery defined as the first of 3 measurements on different days when the patient has an absolute neutrophil count of ≥500/ýL after conditioning.|Time to Platelet Recovery|Graft Failure-Free Survival (GFS)|Overall Survival (OS)|Progression Free Survival (PFS)|Cumulative Incidence of Relapse/Progression (CIR)|Non-Relapse Mortality (NRM)|Cumulative Incidence of Acute GvHD|Cumulative Incidence of Chronic GvHD:","M.D. Anderson Cancer Center","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-0375|NCI-2018-00910","January 31, 2018","November 2019","November 2020","February 8, 2018","null","July 23, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03426969"
343,"NCT03426540","Intravitreal Conbercept After Vitrectomy",,"Active, not recruiting","No Results Available","Early Proliferative Diabetic Retinopathy","Drug: Conbercept","best corrected visual acuity|postoperative complications|central retinal thickness","Tianjin Medical University Eye Hospital","All","28 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2016KY-09","January 1, 2017","March 30, 2018","July 30, 2018","February 8, 2018","null","May 16, 2018","","","https://ClinicalTrials.gov/show/NCT03426540"
344,"NCT03424746","Chelation Therapy in Diabetic Patients With Critical Limb Ischemia","TACT-PAD","Recruiting","No Results Available","Critical Limb Ischemia|Peripheral Arterial Disease","Drug: disodium EDTA","Improvement in vascular flow parameters|Wound Evaluation|Peripheral Artery Questionnaire","Mt. Sinai Medical Center, Miami","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","14-36-H-07","August 2015","June 2019","December 2019","February 7, 2018","null","February 7, 2018","Mount Sinai Medical Center, Miami Beach, Florida, United States","","https://ClinicalTrials.gov/show/NCT03424746"
345,"NCT03423810","Assessing a Dose‐Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients",,"Recruiting","No Results Available","Polycystic Kidney Diseases","Drug: Hydralazine","Change in polycystin-1 (PC1)|Change in mucin-like protocadherin (MUPCDH)|Circulating methylated RASAL1 levels","University of Kansas Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","STUDY00141337|UL1TR002366","April 23, 2018","February 15, 2019","May 15, 2019","February 6, 2018","null","April 27, 2018","University of Kansas Medical Center, Kansas City, Kansas, United States","","https://ClinicalTrials.gov/show/NCT03423810"
346,"NCT03421756","Stem Cell Transplant in Patients With Severe Sickle Cell Disease",,"Recruiting","No Results Available","Sickle Cell Disease","Drug: Alemtuzumab|Radiation: Total Body Irradiation|Drug: Sirolimus","Treatment Success|Engraftment|Probability of developing acute GVHD after HSCT.|Probability of developing chronic GVHD after HSCT.|Graft failure or Relapse|Discontinuation of Immunosuppressive therapy|Sickle cell disease related organ damage|Lymphocyte subsets|Changes in monthly transfusions after HSCT|Changes in the annual frequency of SCD-related hospitalization after|Quality of life measures|Transplant-related mortality|Opioid independence|MDC, whole blood and CD3 Lineage","Kathleen Dorritie|University of Pittsburgh","All","18 Years to 40 Years   (Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-097","March 29, 2018","February 15, 2022","February 15, 2023","February 5, 2018","null","May 14, 2018","UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03421756"
347,"NCT03421613","3VM1001 Cream for the Treatment of Pain Associated With Post Herpetic Neuralgia (PHN)","PHN","Completed","No Results Available","Treatment of PHN","Drug: 3VM1001|Other: Placebo","The time averaged mean in a standard 100 mm visual analog scale (VAS).|Adverse Events, serious adverse events, and study discontinuation|Patient Global Expression of change Scale (PGIC) from baseline (day 0) to the end of each study period.|Change in Patient Global Assessment of Treatment Satisfaction from baseline to the end of each study phase.|Use of Rescue medication","CDA Research Group, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","3VM0416","March 6, 2017","March 30, 2018","May 4, 2018","February 5, 2018","null","July 10, 2018","Medex Healthcare Research, Inc., Chicago, Illinois, United States|Medex Healthcare Reasearch, Inc., New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03421613"
348,"NCT03420287","Evaluation of MPM Prepared From Allogenic Bone Graft in Alveolar Cleft Closure: A Prospective Randomized Clinical Trial",,"Not yet recruiting","No Results Available","Cleft; Alveolar Process","Combination Product: MPM Prepared From Allogenic Bone Graft|Other: Autogenous bone","Oro-nasal Fistula|C.T analysis of secondary bone grafts|Donor site long standing pain","Cairo University","All","6 Years and older   (Child, Adult, Older Adult)","Early Phase 1","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CEBD-CU-2018-01-02","April 2018","April 2019","April 2019","February 2, 2018","null","February 12, 2018","","","https://ClinicalTrials.gov/show/NCT03420287"
349,"NCT03419858","The Role of Opioidergic Systems in Breathing Based Analgesia",,"Completed","No Results Available","Pain","Behavioral: Mindfulness Meditation|Behavioral: Placebo Meditation|Behavioral: Slow-Breathing|Drug: Naloxone|Other: Saline","Change in Visual Analog Scale Pain intensity and Unpleasantness ratings as a function of each respective cognitive manipulations and activation in response to naloxone and/or saline.|Respiration Rate Measures|State Anxiety Inventory|Pain Catastrophizing Scale (PCS)|Cohen Perceived Stress Scale (CPS)|Treatment Effectiveness Scale|Attitude Toward Treatment Scale (ATTS)|Center for Epidemiological Studies Depression Scale (CES-D)|Stress-Level Visual Analogue Scale|Naloxone Symptom Assessments","Wake Forest University Health Sciences","All","18 Years to 55 Years   (Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","IRB00040519","March 13, 2017","June 27, 2017","June 27, 2017","February 2, 2018","null","February 12, 2018","Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03419858/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03419858"
350,"NCT03416452","Gait Disorders in Parkinson's Disease",,"Recruiting","No Results Available","Parkinson's Disease","Device: vibratory cueing device|Device: Mobile Gait Trainer","To examine the relative phase variability or coherence between oscillating axial and appendicular components of gait in PD + FOG, compared to PD-FOG and healthy controls.|Changes in Stride length","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","NIH","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","180050|18-N-0050","November 19, 2018","October 31, 2019","October 31, 2019","January 31, 2018","null","November 14, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03416452"
351,"NCT03415165","Efficacy of Green Tea Buccal Tablets in Oral Lichen Planus",,"Recruiting","No Results Available","Oral Lichen Planus","Drug: green tea buccal tablet|Drug: Corticosteroids Topical","size of the lesion|visual analogue score","Cairo University","All","17 Years to 80 Years   (Child, Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","161187","January 3, 2018","January 30, 2019","January 30, 2019","January 30, 2018","null","February 13, 2018","Cairo University, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03415165"
352,"NCT03414632","Transthyretin Cardiac Amyloidosis in HFpEF",,"Recruiting","No Results Available","Heart Failure With Preserved Ejection Fraction","Drug: 99mTc-PYP","Prevalence of TTR-CA","Mayo Clinic|Pfizer","All","60 Years and older   (Adult, Older Adult)","Early Phase 1","300","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","17-003021","December 1, 2017","September 2019","September 2019","January 30, 2018","null","January 30, 2018","Mayo Clinic in Rochester, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT03414632"
353,"NCT03414359","A Study Comparing 3% Chloroprocaine Versus 2 % Lidocaine/ Epinephrine/ Bicarbonate/ Fentanyl for Epidural Anesthesia in Elective Cesarean Delivery",,"Recruiting","No Results Available","Surgical Anesthesia, Cesarean Section","Drug: 2% Lidocaine|Drug: 3% Chloroprocaine","The onset time to surgical anesthesia","University of Arkansas","Female","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","207313","February 15, 2018","January 1, 2019","January 1, 2019","January 29, 2018","null","February 22, 2018","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States","","https://ClinicalTrials.gov/show/NCT03414359"
354,"NCT03414112","The Impact of Oxytocin on the Neurobiology of Anorexia Nervosa",,"Recruiting","No Results Available","Anorexia Nervosa","Biological: Intranasal oxytocin","Test meal|fMRI measures","University of Minnesota - Clinical and Translational Science Institute|Klarman Foundation","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","00001809","September 25, 2018","February 1, 2019","February 1, 2019","January 29, 2018","null","October 15, 2018","University of Minnesota - Dept of Psychiatry, Minneapolis, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT03414112"
355,"NCT03411330","Safety and Efficacy of Addition of Hyaluronidase to Lidocaine and Bupivacaine in Scalp Nerves Block in Elective Craniotomy Operations, Comparative Study",,"Completed","No Results Available","Addition of Hyalase to Local Anesthetic in Scalp Block","Drug: Hyaluronidase|Drug: Lidocaine|Drug: Bupivacaine","Post-operative pain evaluation|Haemodynamic Measures|Interleukin 6 measurement|Intraoperative rescue dose of opioid|Time of first analgesic request|Haemodynamic effects","Cairo University|Mohamed, Ahmed A., M.D.|Tarek Ahmed Radwan|Mohamed Mahmoud Mohamed|Hatem Abdellatif Mohamed|Badawy Mohammed Al-Kholy","All","18 Years to 60 Years   (Adult)","Early Phase 1","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","N-58/2017","January 24, 2017","April 22, 2018","April 24, 2018","January 26, 2018","null","April 27, 2018","Ahmed Abdalla Mohamed, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03411330"
356,"NCT03411252","Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study",,"Recruiting","No Results Available","Achalasia","Drug: Mirabegron 50 MG|Drug: Placebo","Changes in lower esophageal sphincter pressures|Eckardt Achalasia Score (EAS)","Thomas Jefferson University|Astellas Pharma Inc","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17P.054","February 15, 2018","December 15, 2018","December 15, 2018","January 26, 2018","null","January 29, 2018","Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03411252"
357,"NCT03410654","Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.",,"Recruiting","No Results Available","Kidney Transplant; Complications","Drug: Tacrolimus, Extended Release, (Envarsus Xr)","cognitive assessment at baseline|cognitive improvement from baseline|MoCA cognitive assessment|NIH Toolbox cognitive test","Yale University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2000022307","October 24, 2018","November 2019","February 2020","January 25, 2018","null","November 2, 2018","Yale New Haven Transplantation Center, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03410654"
358,"NCT03409796","Assessment of Immune Activation and Tolerance in Celiac Disease",,"Recruiting","No Results Available","Celiac Disease","Dietary Supplement: Gluten","Change From Baseline in Small Intestine Histology|Correlation Coefficient Between Gluten-specific Blood T Cells and Standard CeD Histological Assessments|Change From Baseline in Blood T Cells After Gluten Challenge","Takeda","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","TIMP-GLIA-5001|U1111-1202-6708","April 24, 2018","January 28, 2019","January 28, 2019","January 24, 2018","null","June 13, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03409796"
359,"NCT03407859","Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL",,"Enrolling by invitation","No Results Available","Therapy Related Leukemia","Biological: Sequential Treatment With different CART","Adverse events that Are related to treatment|Estimate 2 year overall survival(OS) after infusion of CD19-CART and sequential treatment|Estimate relapse rate after infusion of CD19-CART and sequential treatment|Estimate 2 year progression free survival after infusion of CD19-CART and sequential treatment","Zhujiang Hospital|Nanfang Hospital of Southern Medical University","All","18 Years to 60 Years   (Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-XYNK-002","January 18, 2016","December 31, 2020","December 31, 2021","January 23, 2018","null","March 19, 2018","Southern Medical University Zhujiang Hospital, Guangdong, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03407859"
360,"NCT03407781","IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Lower Grade Glioma",,"Recruiting","No Results Available","Glioma","Drug: 68Ga-BBN-IRDye800CW","Standardized uptake value of 68Ga-BBN-IRDye800CW in PET imaging of lower grade gliomas|The sensitivity and specificity of intraoperative IRDye800CW-BBN fluorescence","Deling Li|Peking Union Medical College Hospital|National Institute for Biomedical Imaging and Bioengineering (NIBIB)|Key laboratory of molecular imaging Chinese Academy of Sciences|Beijing Tiantan Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","BTHospital-N-008|ZIAEB000073","January 1, 2016","December 30, 2018","December 30, 2018","January 23, 2018","null","January 23, 2018","Beijing Tiantan Hospital, Beijing, China","","https://ClinicalTrials.gov/show/NCT03407781"
361,"NCT03407716","Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors",,"Not yet recruiting","No Results Available","Cancer Survivor|Stage I Breast Cancer AJCC v7|Stage I Colon Cancer AJCC v6 and v7|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage II Breast Cancer AJCC v6 and v7|Stage II Colon Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIA Colon Cancer AJCC v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIB Colon Cancer AJCC v7|Stage IIC Colon Cancer AJCC v7|Stage III Breast Cancer AJCC v7|Stage III Colon Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIA Colon Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIB Colon Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IIIC Colon Cancer AJCC v7","Drug: American Ginseng|Other: Laboratory Biomarker Analysis|Other: Placebo|Other: Questionnaire Administration","Change in general subscale of the Multidimensional Fatigue Symptom Inventory- Short Form (MFSI-SF)|Change in MFSI-SF emotional subscale|Change in MFSI-SF general subscale|Change in MFSI-SF mental subscale|Change in MFSI-SF physical subscale|Change in MFSI-SF vigor subscale|Change in the single item numeric analogue fatigue question|Fatigue as measured by the National Institutes of Health (NIH) Patient-Reported Outcomes Measurement Information System (PROMIS) score|Fatigue as measured by the NIH PROMIS score|Incidence of adverse events as reported by the patient in a Ginseng Symptom Experience Diary|Perceived treatment efficacy as measured by the Subject Global Impression of Change","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","48","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","MC16C2|NCI-2017-02494|P30CA015083","November 28, 2018","March 1, 2022","March 1, 2022","January 23, 2018","null","March 16, 2018","Mayo Clinic in Arizona, Scottsdale, Arizona, United States","","https://ClinicalTrials.gov/show/NCT03407716"
362,"NCT03407001","Lesion Detection in Cirrhotic Patients With Contrast Enhanced Ultrasound and the Accuracy of Contrast Enhanced Ultrasound Li-RADS for Hepatocellular Carcinoma (HCC) Diagnosis",,"Recruiting","No Results Available","Diseases of Liver|Hepatocellular Carcinoma","Procedure: Ultrasound|Drug: Lumason","Accuracy of contrast enhanced ultrasound (CEUS) utilizing contrast agent compared to B-mode non-contrast enhanced ultrasound for liver lesion detection, including hepatocellular carcinoma (HCC), in cirrhotic US patients","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","150","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2017-0691|1R01CA195524","January 12, 2018","September 30, 2021","September 30, 2022","January 23, 2018","null","March 19, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03407001"
363,"NCT03406429","rTMS as a Treatment for PPA",,"Not yet recruiting","No Results Available","Logopenic Variant Primary Progressive Aphasia|Non-Fluent Primary Progressive Aphasia","Device: Active rTMS|Device: SHAM rTMS","Language Assessment Battery","Brigham and Women's Hospital|Massachusetts General Hospital","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2017P002319","March 1, 2018","January 1, 2020","January 1, 2021","January 23, 2018","null","January 23, 2018","","","https://ClinicalTrials.gov/show/NCT03406429"
364,"NCT03404596","Applying mHealth to Tobacco-related Health Disparities","Time2Quit","Recruiting","No Results Available","Smoking Cessation","Drug: Nicotine Patch|Behavioral: Counseling|Behavioral: Smartphone|Other: AutoSense","Rate of Smoking Lapse|Rate of Stress","H. Lee Moffitt Cancer Center and Research Institute|National Institute on Minority Health and Health Disparities (NIMHD)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","35","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MCC-19002|R00MD010468","July 10, 2018","December 2019","December 2020","January 19, 2018","null","September 18, 2018","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States","","https://ClinicalTrials.gov/show/NCT03404596"
365,"NCT03403634","Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver",,"Recruiting","No Results Available","Metastatic Carcinoma in the Liver|Recurrent Colorectal Carcinoma|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7","Drug: Celecoxib|Other: Laboratory Biomarker Analysis|Biological: Recombinant Interferon Alfa-2b|Drug: Rintatolimod","Change in tumor-infiltrating lymphocytes (TILs) in the colorectal cancer lesions|Incidence of adverse events according to Common Terminology Criteria for Adverse Events version 4.0|Objective response rate (ORR) assessed by Response Evaluation Criteria in Solid Tumors version (RECIST) 1.1|Overall survival|Progression free survival","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 52917|NCI-2017-02471|P30CA016056","March 27, 2018","December 1, 2018","December 1, 2019","January 18, 2018","null","November 14, 2018","Roswell Park Cancer Institute, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT03403634"
366,"NCT03402230","Broccoli Sprout/Broccoli Seed Extract Supplement in Decreasing Toxicity in Heavy Smokers",,"Recruiting","No Results Available","Current Every Day Smoker|Tobacco Smoking","Drug: Broccoli Sprout/Broccoli Seed Extract Supplement|Other: Laboratory Biomarker Analysis|Other: Questionnaire Administration","Change in urinary excretion of the mercapturic acid of benzene|Changes in the urinary excretion of the mercapturic acids of acrolein and crotonaldehyde|Urinary excretion of the mercapturic acids of tobacco carcinogens|Change in the NRF2 target gene transcripts|Detoxification of tobacco carcinogens|Systemic study agent exposure","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","61","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NCI-2017-02406|N01-CN-2012-00031|1711022046|UAZ2017-09-02|N01CN00031|P30CA023074","February 20, 2018","November 30, 2020","November 30, 2020","January 18, 2018","null","November 14, 2018","The University of Arizona Medical Center-University Campus, Tucson, Arizona, United States","","https://ClinicalTrials.gov/show/NCT03402230"
367,"NCT03401541","25-Hydroxyvitamin D Pharmacokinetic Study",,"Recruiting","No Results Available","Vitamin D Deficiency|Fat Malabsorption","Drug: Calcifediol|Drug: Calciferol","Change in Serum vitamin D status|Change in 25-Hydroxyvitamin D Status|Serum Calcium Levels|Serum Phosphorus Levels|Serum Albumin Levels|Serum Creatinine levels|Serum intact parathyroid hormone levels","Boston University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","H-37167","October 1, 2018","March 2019","May 2019","January 17, 2018","null","October 11, 2018","Solomon Carter Fuller Mental Health Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03401541"
368,"NCT03401047","Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome","CRM009","Recruiting","No Results Available","Polycystic Ovary Syndrome","Drug: Estradiol","Estradiol-induced change in 24-hour urinary LH excretion|Estradiol-induced change in 24-hour urinary FSH excretion","University of Virginia","Female","18 Years to 30 Years   (Adult)","Early Phase 1","37","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","19692","November 30, 2017","April 1, 2025","December 1, 2025","January 17, 2018","null","July 2, 2018","University of Virginia Clinical Research Unit, Charlottesville, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT03401047/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03401047"
369,"NCT03400501","Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin",,"Recruiting","No Results Available","Type 1 Diabetes Mellitus","Drug: Insulin Degludec|Drug: Insulin Glargine","Lower beta hydroxybutyrate levels|Control of HbA1c levels|Measure of beta hydroxybutyrate levels between the 2 groups.","Yale University","All","8 Years to 18 Years   (Child, Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2000020909","October 1, 2017","August 2019","February 2020","January 17, 2018","null","June 27, 2018","Yale University, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03400501"
370,"NCT03395847","A Study of Pembrolizumab Monotherapy or in Combination With Other Agents in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma",,"Recruiting","No Results Available","Diseases of Oesophagus Stomach and Duodenum|Advanced Gastroesophageal Adenocarcinoma","Drug: Pembrolizumab","Overall Response Rate (ORR) of Intravenous Administration of Pembrolizumab or Pembrolizumab plus Ramucirumab|Duration of Response (DOR) of Intravenous Administration of Pembrolizumab or Pembrolizumab plus Ramucirumab|Exploratory Biomarkers of Intravenous Administration of Pembrolizumab or Pembrolizumab plus Ramucirumab|Adverse Events of Intravenous Administration of Pembrolizumab or Pembrolizumab plus Ramucirumab","M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-0905|NCI-2018-00946","February 9, 2018","February 2022","February 2022","January 10, 2018","null","July 25, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03395847"
371,"NCT03395756","Depot Medroxyprogesterone Acetate as Emergency Contraception",,"Not yet recruiting","No Results Available","Emergency Contraception|Contraception","Drug: Depot-Medroxyprogestereone Acetate","Ovulation|Ovulation Suppression|Ovulatory dysfunction","University of Southern California|Society of Family Planning","Female","18 Years to 39 Years   (Adult)","Early Phase 1","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HS-17-01006","June 2018","March 2019","May 2019","January 10, 2018","null","May 3, 2018","","","https://ClinicalTrials.gov/show/NCT03395756"
372,"NCT03395496","Comparison of Biodentine and MTA Pulpotomies in the Primary Molar Teeth 3 Year Follow up",,"Completed","No Results Available","Pulpotomy|Dental Caries","Drug: Biodentine|Drug: ProRoot (Aggregate)","Total success rate","Istanbul University","All","7 Years to 15 Years   (Child)","Early Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2017-24692","May 1, 2013","May 1, 2016","May 30, 2016","January 10, 2018","null","January 10, 2018","Istanbul University, Istanbul, Turkey","","https://ClinicalTrials.gov/show/NCT03395496"
373,"NCT03395028","GCSF Adjunct Therapy for Biliary Atresia","BA_GCSF","Enrolling by invitation","No Results Available","Biliary Atresia","Drug: Granulocyte Colony-Stimulating Factor","Dose determination GCSF","Holterman, Ai-Xuan, M.D.|T Rose Clinical, Inc.|Children's National Health System|Prometheus USA, Ltd. Co.","All","up to 180 Days   (Child)","Early Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CR00005169|IND 119679-0007","January 15, 2018","December 31, 2018","January 31, 2019","January 9, 2018","null","February 21, 2018","Children's National Medical Center, Washington, District of Columbia, United States","","https://ClinicalTrials.gov/show/NCT03395028"
374,"NCT03393364","Pain Management in Outpatient Urologic Procedures",,"Recruiting","No Results Available","Urologic Diseases","Drug: Oxycodone|Drug: Ketorolac","Pain control|Number of pills used","University Hospitals Cleveland Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-17-31","April 1, 2018","June 2018","November 2018","January 8, 2018","null","May 2, 2018","University Hospitals, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03393364"
375,"NCT03392623","DNA Methylation in Malar Melasma and Its Change by Sunscreen, Retinoic Acid and Niacinamide.",,"Completed","No Results Available","Melasma","Drug: Retinoic acid|Device: colorimetry measurement|Drug: sunscreen|Drug: Niacinamide","improve in the level of DNA methylated|improve in the clinical severity of melasma","Universidad Autonoma de San Luis Potosí","Female","18 Years to 50 Years   (Adult)","Early Phase 1","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","71-15","January 1, 2015","January 1, 2016","December 1, 2016","January 8, 2018","null","January 9, 2018","","","https://ClinicalTrials.gov/show/NCT03392623"
376,"NCT03392181","PET/MRI for the Staging of Newly Diagnosed Prostate Cancer",,"Recruiting","No Results Available","Prostate Cancer","Drug: 18F-DCFPyL","PET/MR versus mp-MRI for the Staging of Newly Diagnosed Prostate Cancer","Northwestern University|Progenics Pharmaceuticals, Inc.","Male","18 Years to 89 Years   (Adult, Older Adult)","Early Phase 1","48","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NU 17U12|STU00205957|NCI-2018-00059","June 8, 2018","May 1, 2023","June 1, 2023","January 5, 2018","null","June 13, 2018","Northwestern University, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT03392181"
377,"NCT03388970","Vitamin K1 in the Treatment of Spontaneous Intracerebral Hemorrhage",,"Enrolling by invitation","No Results Available","Intracerebral Haemorrhage in Cerebellum","Drug: Vitamin K 1|Drug: normal saline","The volume of cerebral hemorrhage|The Activated Partial Thromboplastin Time（s）at certain time post onset|The condition of Platelet level at certain time post onset|The condition of GCS scale post(3-15) at certain time post onset|The prothrombin time(s) at certain time post onset|The Fibrinogen (g/L)at certain time post onset|The Thrombin Time(s) at certain time post onset","HUANG XIANJIAN|Shenzhen Second People's Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HUANGXIANJIAN20170608","August 1, 2017","October 31, 2018","July 1, 2019","January 3, 2018","null","January 4, 2018","Shenzhen second people's hospital, Shenzhen, Guangdong, China|The fifth people's hospital of Longgang District, Shenzhen, Shenzhen, Guangdong, China|Baoan District central hospital of Shenzhen, Shenzhen, Guangdong, China|Shajing hospital of Baoan District ,Shenzhen, Shenzhen, Guangdong, China|The second People's hospital of Longgang District, Shenzhen, Shenzhen, Guangdong, China","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03388970/SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03388970/ICF_001.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03388970/Prot_002.pdf","https://ClinicalTrials.gov/show/NCT03388970"
378,"NCT03388814","Speeding Recovery From Pain and Opioid Use",,"Not yet recruiting","No Results Available","Pain, Postoperative|Breast Cancer|Opioid Use|Surgery","Drug: Local infiltration of bupivacaine|Drug: Pectoralis Nerve block","Modeled worst pain intensity using the numeric rating scale (NRS)|Area under the curve of the numeric rating scale (NRS)|Opioid use|Length of stay for hospitalization|Readmission rates","Wake Forest University Health Sciences","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","IRB00047335","November 2018","June 2020","June 2020","January 3, 2018","null","August 15, 2018","Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03388814"
379,"NCT03388788","Body Weight, Sleep, and Heart Health",,"Recruiting","No Results Available","Cardiovascular Risk Factor|Circadian Dysregulation|Obesity","Radiation: PET Imaging|Behavioral: Circadian Study Protocol|Drug: 11C-Meta-Hydroxyephedrine (mHED)|Drug: 11C-CGP12177|Drug: O15-water","Blood Pressure|Heart Rate|Epinephrine|Norepinephrine|Cortisol|Aldosterone|Endocannabinoid|Heart Rate Variability (HRV)|malondialdehyde (MDA) adducts|Flow Mediated Dilation (FMD)|Tumor Necrosis Factor alpha (TNF-alpha)|Coronary blood flow|Norepinephrine reuptake transport|Beta-adrenergic receptor density|Dual Emission X-ray Absorbance (DEXA) Body composition","Oregon Health and Science University","All","35 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","28","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB00017489","May 1, 2018","May 31, 2020","May 31, 2021","January 3, 2018","null","July 17, 2018","Oregon Health & Science University, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT03388788"
380,"NCT03387553","HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer",,"Recruiting","No Results Available","Breast Cancer|Breast Cancer Female|Breast Cancer, Male|Invasive Breast Cancer|HER2-positive Breast Cancer|HER2 Positive Breast Carcinoma|Stage II Breast Cancer|Stage III Breast Cancer","Biological: Dendritic Cell Vaccine (DC1)|Drug: Neoadjuvant Chemotherapy|Procedure: Curative Surgery","Expansion Phase Schedule Selection by Week 4|Pathologic Complete Response (pCR) Rate|Recurrence Free Survival (RFS)","H. Lee Moffitt Cancer Center and Research Institute|United States Department of Defense","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","24","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-19337","April 6, 2018","March 2021","March 2022","January 2, 2018","null","August 24, 2018","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States","","https://ClinicalTrials.gov/show/NCT03387553"
381,"NCT03385148","The Clinical Application of 68Ga Labeled ssDNA Aptamer Sgc8 in Healthy Volunteers and Colorectal Patients",,"Recruiting","No Results Available","Colorectal Cancer","Drug: 68Ga-Sgc8","diagnosis effecacy","Xijing Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","70","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","KY20162077-2","January 1, 2017","December 15, 2017","December 30, 2019","December 28, 2017","null","December 28, 2017","Xijing Hospital Nuclear Medicine Department, Xi'an, Shaanxi, China|Xijing Hospital, Xi'an, Shaanxi, China","","https://ClinicalTrials.gov/show/NCT03385148"
382,"NCT03385005","Evaluating Neuromuscular Stimulation for Restoring Hand Movements",,"Recruiting","No Results Available","Healthy Volunteers|Spinal Cord Injury Cervical|Spinal Cord Injury at C5 Level|Spinal Cord Injury at C5-C7 Level|Physical and Rehabilitation Medicine","Device: Participants will receive neuromuscular electrical stimulation via an investigational (not FDA approved) neuromuscular stimulator.","The primary outcome of the study is to determine the feasibility of achieving refined hand movements through electrical stimulation of the muscles within the forearm, as assessed by visual inspection.|The primary outcome of the study is to determine the feasibility of achieving refined hand movements through electrical stimulation of the muscles within the forearm, as assessed by force sensors.","Northwell Health","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","17-0070","September 15, 2017","December 31, 2018","March 31, 2019","December 28, 2017","null","March 6, 2018","Northwell Health's The Feinstein Institute for Medical Research, Manhasset, New York, United States","","https://ClinicalTrials.gov/show/NCT03385005"
383,"NCT03384537","Antimicrobial Effect of Tropolone Containing Versus Tropolone Free Mouthwash",,"Not yet recruiting","No Results Available","Dental Diseases","Combination Product: Listerine total care zero|Combination Product: Chlorhexidine Mouthwash (0.2%).","Bacterial count.","Cairo University","All","18 Years to 45 Years   (Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","CEBC-CU-2017-11-45","June 1, 2018","December 1, 2018","June 1, 2019","December 27, 2017","null","January 5, 2018","","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03384537/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03384537"
384,"NCT03384420","Mitochondrial-enriched Autologous CD34+ Cells for Non-inherited Mitochondrial Disorders","MNV-BLD-1","Not yet recruiting","No Results Available","Mitochondrial Diseases|Pearson Syndrome","Biological: CD34+ cells enriched with MNV-BLD","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 following MNV-BM-BLD infusion.|Percent of mitochondrial engraftment, per participant, compared to baseline, by serial qPCR in peripheral blood performed monthly.","Sheba Medical Center|Minovia Therapeutics Ltd.","All","Child, Adult, Older Adult","Early Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3428-16-SMC","February 1, 2018","January 1, 2020","January 1, 2021","December 27, 2017","null","December 27, 2017","","","https://ClinicalTrials.gov/show/NCT03384420"
385,"NCT03383133","Studies of Sulfur Metabolism in Humans",,"Not yet recruiting","No Results Available","Metabolic Side Effects of Drugs","Drug: SULT Allosteric Inhibition","Acetaminophen and Dehydroepiandrosterone Conjugates","Albert Einstein College of Medicine, Inc.","Male","61 Years to 61 Years   (Adult)","Early Phase 1","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2017-8685","January 2018","March 2018","April 2018","December 26, 2017","null","December 27, 2017","","","https://ClinicalTrials.gov/show/NCT03383133"
386,"NCT03382834","Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors",,"Active, not recruiting","No Results Available","HIV Infections","Drug: Tamoxifen|Drug: Vorinostat|Drug: Antiretroviral drugs","Frequency of new Grade 3 or greater adverse events that are considered definitely, probably, or possibly related to study treatment|Change in cell-associated HIV-1 RNA in resting CD4+ T cells from baseline|Single copy HIV-1 RNA levels|Total HIV-1 DNA levels","National Institute of Allergy and Infectious Diseases (NIAID)","Female","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","30","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACTG A5366|38190","April 26, 2018","September 30, 2019","June 30, 2023","December 26, 2017","null","October 9, 2018","Alabama CRS, Birmingham, Alabama, United States|UCLA CARE Center CRS, Los Angeles, California, United States|Ucsf Hiv/Aids Crs, San Francisco, California, United States|Harbor-UCLA CRS, Torrance, California, United States|University of Colorado Hospital CRS, Aurora, Colorado, United States|Whitman-Walker Health CRS, Washington, District of Columbia, United States|The Ponce de Leon Center CRS, Atlanta, Georgia, United States|Northwestern University CRS, Chicago, Illinois, United States|Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States|New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Greensboro CRS, Greensboro, North Carolina, United States|Cincinnati Clinical Research Site, Cincinnati, Ohio, United States|Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States|Puerto Rico AIDS Clinical Trials Unit CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT03382834"
387,"NCT03382574","Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy",,"Not yet recruiting","No Results Available","BRCA1 Gene Mutation|BRCA2 Gene Mutation|Fallopian Tube Carcinoma|Ovarian Carcinoma|Premenopausal","Biological: Denosumab|Other: Laboratory Biomarker Analysis|Procedure: Salpingo-Oophorectomy","Ki67 proliferation index fallopian tube fimbrial epithelial cells assessed using immunohistochemistry (IHC)|Ki67 proliferation index in ovarian surface epithelium and endometrium assessed using IHC|Other tissue-based biomarkers in the fimbrial end of the fallopian tube, ovarian surface epithelium, and endometrium assessed by IHC|Gene expression profiling of RANK, cell proliferation, cell cycle progression, and inflammation pathways|Serum biomarkers including progesterone, estradiol, and denosumab drug levels|Change in serial serum C-terminal telopeptide (CTX) levels|Toxicity profile and frequency of adverse effects in premenopausal BRCA1/2 mutation carriers","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NCI-2017-02314|N01-CN-2012-00034|MDA2017-09-03|N01CN00034|P30CA016672","October 22, 2018","September 20, 2019","September 20, 2019","December 26, 2017","null","October 22, 2018","Moffitt Cancer Center, Tampa, Florida, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|Weill Medical College of Cornell University, New York, New York, United States|M D Anderson Cancer Center, Houston, Texas, United States|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel","","https://ClinicalTrials.gov/show/NCT03382574"
388,"NCT03382184","Fractional Photothermolysis for Hair Follicle Induction",,"Active, not recruiting","No Results Available","Alopecia","Device: Fraxel Dual laser|Device: Halo laser","Hair regrowth by dermoscopy|Hair regrowth by optical coherence tomography (OCT).|Quality of Life","University of California, Irvine|Beckman Laser Institute","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-3385","October 20, 2017","November 1, 2019","November 1, 2019","December 22, 2017","null","July 16, 2018","University of California, Irvine, Department of Dermatology, Dermatology Clinical Research Center, Hewitt Hall, Irvine, California, United States","","https://ClinicalTrials.gov/show/NCT03382184"
389,"NCT03381807","Human Amniotic Epithelial Cell in Treatment of Refractory Severe Intrauterine Adhesion",,"Not yet recruiting","No Results Available","Intrauterine Adhesion","Biological: hAECs","changes of Endometrial thickness|changes of Menstrual blood volume|pregnancy rate","Second Affiliated Hospital, School of Medicine, Zhejiang University|Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China","Female","20 Years to 45 Years   (Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-080","March 1, 2018","March 1, 2020","March 1, 2021","December 22, 2017","null","December 22, 2017","","","https://ClinicalTrials.gov/show/NCT03381807"
390,"NCT03380936","Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients",,"Recruiting","No Results Available","Kidney Transplant Rejection","Drug: Tacrolimus Extended Release Oral Tablet [Envarsus]|Other: Plasma Exchange and IVIG (Intravenous Immunoglobulin )","Change in Acute Inflammatory Histologic Parameters|Change in MDRD GFR (Modification of Diet in Renal Disease Glomerular Filtration Rate)|Change in Donor-Specific Antibody (DSA) Mean Fluorescence Intensity (MFI) Level|Change in serum creatinine|Graft Survival|Patient Survival|Evaluation of Adverse Events","University of Colorado, Denver|Veloxis Pharmaceuticals","All","18 Years to 79 Years   (Adult, Older Adult)","Early Phase 1","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-1812","December 2018","November 2020","November 2021","December 21, 2017","null","October 12, 2018","University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States","","https://ClinicalTrials.gov/show/NCT03380936"
391,"NCT03379649","Platelet Rich Plasma for Patients With Recurrent Implantation Failure",,"Not yet recruiting","No Results Available","Infertility","Combination Product: Platelet rich plasma|Combination Product: Placebo","Live birth rate|Pregnancy","Stanford University","Female","18 Years to 45 Years   (Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","43265","January 2018","July 2018","December 2018","December 20, 2017","null","December 21, 2017","Stanford Fertility and Reproductive Health, Sunnyvale, California, United States","","https://ClinicalTrials.gov/show/NCT03379649"
392,"NCT03378297","IMPACT: A Non-randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC","IMPACT","Recruiting","No Results Available","Ovarian Cancer","Drug: Metformin|Drug: Acetylsalicylic acid|Drug: Olaparib|Drug: Letrozole","Changes in the expression of biomarkers","Haukeland University Hospital","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","143","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2017/1168","May 4, 2018","June 1, 2020","June 1, 2020","December 19, 2017","null","May 9, 2018","Helse Bergen HF, Haukeland University Hospital, Bergen, Norway|Oslo University Hospital, Oslo, Norway|Helse Stavanger HF, Stavanger University Hospital, Stavanger, Norway","","https://ClinicalTrials.gov/show/NCT03378297"
393,"NCT03378102","Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation",,"Not yet recruiting","No Results Available","Allogeneic Hematopoietic Stem Cell Transplantation","Biological: IFN-gamma-secreting HAdV antigen specific T cells","Number of patients with severe adverse events|Number of patients with viral response|Number of patients with clinical response|Time from enrollment to T cell product infusion|Time from peripheral mononuclear cell collection to T cell product infusion","Case Comprehensive Cancer Center","All","3 Months and older   (Child, Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CASE4Z17","December 2018","March 2020","March 2021","December 19, 2017","null","October 19, 2018","University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03378102"
394,"NCT03378063","Stem Cells for Bronchopulmonary Dysplasia",,"Recruiting","No Results Available","Bronchopulmonary Dysplasia","Drug: transplantation of mesenchymal stem cell|Drug: no transplantation of mesenchymal stem cell","death|Bayley Scales of Infant Development","Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Children's Hospital of Chongqing Medical University|Chongqing Maternal and Child Health Hospital","All","1 Month to 3 Months   (Child)","Early Phase 1","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","stem cell for BPD","November 1, 2017","December 30, 2022","December 30, 2022","December 19, 2017","null","December 19, 2017","Department of Pediatrics, Daping Hospital, Research Institute of Surgery, Third Military Medical University, Chongqing, Chongqing, China","","https://ClinicalTrials.gov/show/NCT03378063"
395,"NCT03377543","Sleep and Inflammatory Resolution Pathway",,"Recruiting","No Results Available","Inflammatory Response|Inflammation|Sleep|Sleep Restriction","Drug: Aspirin|Drug: Placebo","Inflammatory Resolution Markers|Inflammatory Markers","Beth Israel Deaconess Medical Center","All","18 Years to 60 Years   (Adult)","Early Phase 1","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","2017P000484","June 6, 2018","April 1, 2022","April 1, 2023","December 19, 2017","null","June 7, 2018","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03377543"
396,"NCT03376971","Real-Time Optical Biopsy in Improving Lung Cancer Diagnosis in Patients Undergoing Lung Biopsy",,"Recruiting","No Results Available","Lesion|Lung Cancer|Diagnoses Disease","Procedure: Biopsy|Other: Laboratory Biomarker Analysis","Diagnosis of ex vivo tissue samples for lung cancer or benign lesions using optical microscopy|Imaging of ex vivo tissue samples using an endoscopic instrument","University of Arizona|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","200","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1706540415|NCI-2017-02088|P30CA023074","July 26, 2017","May 1, 2021","November 1, 2021","December 19, 2017","null","December 19, 2017","The University of Arizona, Tucson, Arizona, United States","","https://ClinicalTrials.gov/show/NCT03376971"
397,"NCT03376581","The Utility of Platelet Rich Plasma in Hair Loss",,"Active, not recruiting","No Results Available","Androgenetic Alopecia","Procedure: Platelet rich plasma","Hair density to measure the efficacy of treatment|Hair count (number of hairs/0.65 cm2)|Terminal hair density|Anagen hair percentage|Telogen hair percentage|Anagen/telogen ratio|Changes in hair structure, diameter, and blood flow","University of California, Irvine","All","18 Years to 95 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-3239","November 28, 2017","October 2018","December 2018","December 18, 2017","null","July 16, 2018","University of California, Irvine, Department of Dermatology, Dermatology Clinical Research Center, Hewitt Hall, Irvine, California, United States","","https://ClinicalTrials.gov/show/NCT03376581"
398,"NCT03371992","Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC","NO3DEXPL","Enrolling by invitation","No Results Available","Non Small Cell Lung Cancer","Drug: Nivolumab|Diagnostic Test: 3D-EX|Other: Evaluation of Response by RECIST","Evaluation of target lesions by RECIST","Nilogen Oncosystems|Henry Ford Health System","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","NO88352235","March 9, 2018","August 2018","August 2018","December 13, 2017","null","April 5, 2018","Henry Ford Health Systems, Detroit, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03371992"
399,"NCT03371420","PET Imaging of Subjects Using 124I-PU-AD",,"Recruiting","No Results Available","Lymphoma|Solid Malignancy|Alzheimer Disease|Myeloma","Drug: PU-AD|Device: PET Scan|Other: Blood Draws","Pharmacokinetic profile of 124I-PU-AD: area under the curve (AUC)|Pharmacokinetic profile of 124I-PU-AD: maximum plasma concentration (Cmax)|Pharmacokinetic profile of 124I-PU-AD: trough plasma concentration (Cmin)|Pharmacokinetic profile of 124I-PU-AD: plasma half-life (T1/2)|Pharmacokinetic profile of 124I-PU-AD: time to maximum plasma concentration (Tmax)|Incidence of adverse events","Samus Therapeutics, Inc.|Memorial Sloan Kettering Cancer Center|Weill Medical College of Cornell University|Rockefeller University","All","21 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","10","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PU-AD-00-001","April 2016","April 2018","August 2018","December 13, 2017","null","December 13, 2017","Memorial Sloan Kettering, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03371420"
400,"NCT03368352","Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude.",,"Recruiting","No Results Available","Altitude Hypoxia|Ventilation|Sleep|Oxidative Stress|Neurocognitive Dysfunction","Dietary Supplement: Melatonin|Other: Hypoxia","Neurocognitive function|Endothelial function|Lipid peroxidation in serum|Hypercapnic hypoxic ventilatory sensitivity","University of California, San Diego","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","170200","July 4, 2017","June 1, 2018","June 1, 2018","December 11, 2017","null","January 18, 2018","UCSD Sleep Lab, San Diego, California, United States","","https://ClinicalTrials.gov/show/NCT03368352"
401,"NCT03367663","The Effect of Prednisone on Atherogenesis as Studied in the Macrophage Foam Cell Formation Model System.",,"Not yet recruiting","No Results Available","Atherosclerosis|Dyslipidemias|Diabetes","Drug: Prednisone 20 Mg|Drug: Prednisone 40 Mg","Serum atherogenicity","Prof. Tony hayek MD|Rambam Health Care Campus","Male","18 Years to 50 Years   (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","0254-17-RMB","December 2017","June 2018","December 2018","December 11, 2017","null","December 11, 2017","","","https://ClinicalTrials.gov/show/NCT03367663"
402,"NCT03366844","Breast Cancer Study of Preoperative Pembrolizumab + Radiation",,"Recruiting","No Results Available","Breast Cancer","Drug: Pembrolizumab|Radiation: RT Boost","Number of patients who do not necessitate a delay in standard of care treatment after receiving the investigational combination of preoperative Pembrolizumab and radiation|Changes in Tumor Infiltrating Lymphocytes (TIL)|Pembrolizumab-related adverse events|Immune-related adverse events|Invasive disease-free survival after preoperative radiation and Pembrolizumab","Stephen Shiao|Cedars-Sinai Medical Center","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIT2017-07-HO-PembroRT","December 22, 2017","December 30, 2018","December 30, 2018","December 8, 2017","null","May 18, 2018","Cedars-Sinai Medical Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT03366844"
403,"NCT03361800","Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC",,"Recruiting","No Results Available","Breast Cancer|Invasive Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer","Drug: Entinostat","Decrease in Ki-67 mRNA following treatment with entinostat across TNBC breast cancers|mRNA gene expression changes following treatment with entinostat, across TNBC|Changes in the proliferation signature by mRNA expression following treatment with entinostat across TNBC|Differential kinome activation before and after treatment with entinostat across TNBC|Correlation of mutation and/or copy number variations by whole exome sequencing (WES) with mRNA gene expression changes and reduction of proliferation signature following treatment with entinostat across TNBC.|Correlation of protein lysine hyperacetylation in peripheral blood and tumor from pre- and post-entinostat treated TNBCs|Percentage of participants with treatment related adverse events","UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","LCCC 1639|P50CA058223","January 22, 2018","January 15, 2019","February 15, 2019","December 5, 2017","null","August 15, 2018","Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03361800"
404,"NCT03360708","Vaccine Therapy and Cytokine-Induced Killer Cells in Treating Patients With Recurrent Glioblastoma",,"Not yet recruiting","No Results Available","Giant Cell Glioblastoma|Recurrent Glioblastoma|Recurrent Gliosarcoma","Biological: Cytokine-Induced Killer Cells|Other: Laboratory Biomarker Analysis|Biological: Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine","Incidence of significant toxicity, defined as a dose limiting toxicity (DLT) that is possibly, probably, or definitely related to treatment as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Clinical benefit rate|Duration of response|Feasibility|Overall response rate|Overall survival|Progression-free survival|Time to response","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC1772|NCI-2017-02159|P30CA015083","November 30, 2018","December 1, 2022","December 1, 2022","December 4, 2017","null","April 18, 2018","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT03360708"
405,"NCT03358563","Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer",,"Recruiting","No Results Available","Prostate Cancer","Drug: Docetaxel|Drug: Degarelix|Drug: Bicalutamide","Change in pCR rates|Change in PSA|PSA Recurrence|Safety and tolerability of combination ADT and docetaxel measured by CTCAE v.4.0","University of Wisconsin, Madison|United States Department of Defense|National Cancer Institute (NCI)","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|U.S. Fed|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UW17009|P30CA014520|2017-0606","January 5, 2018","January 2019","January 2020","November 30, 2017","null","May 17, 2018","University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT03358563"
406,"NCT03356964","Step Down FSH Approach and Late Follicular Phase in Progesterone Level","FSH","Recruiting","No Results Available","Progesterone Resistance","Drug: follicle stimulating hormone","Impact of dose reduction in recFSH for IVF on the progesterone level.","IVI Middle East Fertility Clinic|Merck Serono International SA","Female","18 Years to 40 Years   (Adult)","Early Phase 1","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1612-ABU-084-HF","November 23, 2017","January 2019","February 2019","November 29, 2017","null","April 13, 2018","IVI Middle East Fertilty Clinic, Abu Dhabi, United Arab Emirates","","https://ClinicalTrials.gov/show/NCT03356964"
407,"NCT03356457","Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 Diabetes",,"Recruiting","No Results Available","Hyperglycaemia (Diabetic)","Drug: Dichloroacetate|Drug: Placebo oral capsule","• Measurement of hormone changes during hypoglycemia|cognitive function","Yale University","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2000020041","November 30, 2017","November 30, 2020","November 30, 2020","November 29, 2017","null","December 12, 2017","Yale New Haven Hospital, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03356457"
408,"NCT03352232","Hyperbaric Oxygen and Manipulative Therapies to Regain Function Post Stroke","HBOT/OMT","Recruiting","No Results Available","Stroke|Motor Dysfunction|Chronic Stroke|Ischemic Stroke","Combination Product: HBOT and OMT","National Institute of Health Stroke Score (NIHSS) 0-5 or Modified Rankin Score (mRS) 0-2|Beck Depression Inventory|Wolf Motor Score|Rivermead Extended Activities of Daily Living (EADL) scale|Medical Outcomes 36 Item|Functional Independence Measure (FIM)","Abington Memorial Hospital|Philadelphia College of Osteopathic Medicine","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-063","February 3, 2018","January 2021","January 2021","November 24, 2017","null","April 9, 2018","Abington Memorial Hospital, Abington, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03352232"
409,"NCT03349775","Cardiometabolic Disease and Pulmonary Hypertension",,"Recruiting","No Results Available","Obesity","Drug: Metformin|Drug: Placebo","Pulmonary vascular hemodynamics (rest)|Pulmonary vascular hemodynamics (exercise)|Effect on pulmonary artery endothelial cell phenotypes","Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)","All","30 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","75","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","2017P001020|1R01HL134893-01A1","November 27, 2017","September 1, 2022","September 1, 2024","November 22, 2017","null","October 29, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03349775"
410,"NCT03349606","Cocaine Use Disorder and Cortical Dopamine",,"Recruiting","No Results Available","Cocaine Dependence","Drug: d-amphetamine|Radiation: [C-11]FLB 457","Percent change in Binding potential (BPnd)","University of Pittsburgh|National Institute on Drug Abuse (NIDA)","All","18 Years to 40 Years   (Adult)","Early Phase 1","30","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PRO10030625|R01DA026472|PRO14080588","June 2, 2010","December 31, 2020","December 31, 2020","November 21, 2017","null","September 6, 2018","University of PIttsburgh PET Facility, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03349606"
411,"NCT03348384","[11C]NOP-1A and Cocaine Use Disorders",,"Recruiting","No Results Available","Cocaine Use Disorder","Radiation: [C-11]|Drug: NOP-1A","[C-11]NOP-1A VT","University of Pittsburgh|National Institute on Drug Abuse (NIDA)","All","18 Years to 50 Years   (Adult)","Early Phase 1","80","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PRO14080588|R01DA026472","October 30, 2014","December 31, 2021","December 31, 2021","November 20, 2017","null","September 6, 2018","University of Pittsburgh, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03348384"
412,"NCT03347864","68Ga-NOTA-RM26 PET/CT in Breast Tumor Patients",,"Recruiting","No Results Available","Breast Tumor","Drug: 68Ga-NOTA-RM26","Standardized uptake value of 68Ga-NOTA-RM26 in breast tumor|Adverse events collection","Peking Union Medical College Hospital","Female","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PekingUMCH-NM15","October 2016","October 2018","October 2018","November 20, 2017","null","November 20, 2017","Peking Union Medical College Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03347864"
413,"NCT03347331","[18F]-F13640 as a New Brain Radiopharmaceutical","F13640","Not yet recruiting","No Results Available","Neurological Pathology|Healthy Subjects","Drug: [18F]F13640","Binding potentials","Hospices Civils de Lyon","Male","20 Years to 45 Years   (Adult)","Early Phase 1","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","69HCL16-0770","December 1, 2017","December 1, 2019","December 1, 2019","November 20, 2017","null","November 20, 2017","","","https://ClinicalTrials.gov/show/NCT03347331"
414,"NCT03347097","PD1-PIK Cell Therapy for Patients With Glioblastoma Multiforme",,"Recruiting","No Results Available","Glioblastoma Multiforme","Drug: pd-1-pik","Number of Adverse Events related to pd-1-pik cell infusion|Treatment Responses Rate|Overall Survival Rate|Progression-free Survival Rate","Huashan Hospital|Shanghai Cell Therapy Research Institute","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KY2017-241","January 1, 2017","January 2019","March 2019","November 20, 2017","null","August 14, 2018","Huashan hospital, Fudan University, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03347097"
415,"NCT03346681","N-Acetyl-cysteine in Early Acute Respiratory Distress Syndrome","NARDS","Recruiting","No Results Available","Acute Respiratory Distress Syndrome","Drug: N-acetyl cysteine","Ventilator days|Mortality|ICU days|P/F ratio|Use of ""rescue"" maneuvers","Palmetto Health","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PalmettoHealth","February 1, 2018","December 2018","May 2019","November 17, 2017","null","April 10, 2018","Palmetto Health Richland, Columbia, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT03346681"
416,"NCT03346668","Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia",,"Recruiting","No Results Available","Scarring Alopecia|Frontal Fibrosing Alopecia|Lichen Planopilaris|Central Centrifugal Cicatricial Alopecia|Central Centrifugal Scarring Alopecia","Drug: Topical gabapentin","Neurogenic inflammation-QOL|Neurogenic inflammation-Short Form (36) Health Survey|Neurogenic inflammation- Visual Analog pain Scale|Safety and efficacy of topical 6% gabapentin -Medication side Effects|Safety and efficacy of topical 6% gabapentin -Blood levels|Safety and efficacy of topical 6% gabapentin -Adverse Events","University of Minnesota - Clinical and Translational Science Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1308M40801","January 28, 2016","May 1, 2019","May 30, 2019","November 17, 2017","null","May 31, 2018","University of Minnesota, Minneapolis, Minnesota, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT03346668/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03346668"
417,"NCT03346252","The Effect of Botulinum Toxin A on Headache Attributed to TMD",,"Recruiting","No Results Available","Secondary Headache Disorder","Drug: Botulinum Toxin type A","Reduction in number of Headaches Attributed to TMD (HA)|Reduction in Headache Impact Test-6 score (HIT-6)|Pressure Pain Threshold|Graded Chronic Pain Scale (GCPS), 1 and 6 months score|Jaw Functional Limitation Scale|Migraine Disability Assessment/ HA-TMD","State University of New York at Buffalo","Female","18 Years to 74 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00000054","May 8, 2017","September 30, 2018","September 30, 2018","November 17, 2017","null","November 17, 2017","University at Buffalo, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT03346252"
418,"NCT03341715","Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHN",,"Not yet recruiting","No Results Available","Familial Alcoholism Vulnerability","Drug: Mavoglurant (AFQ056)|Other: Placebo","MRI Monetary Incentive Delay (MID) task|MRI Alcohol Cue Reactivity (ACR) task","Yale University","All","18 Years to 35 Years   (Adult)","Early Phase 1","14","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","HHC-2017-0172","January 17, 2018","October 31, 2018","November 30, 2018","November 14, 2017","null","January 9, 2018","Hartford Hospital, Hartford, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03341715"
419,"NCT03339700","Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia",,"Recruiting","No Results Available","Acute Lymphoblastic Leukemia, Adult","Drug: Gemcitabine|Drug: Busulfan|Drug: Cyclophosphamide|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation","Disease Free Survival|Overall Survival","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","All","18 Years to 60 Years   (Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INCMNSZ REF 2235","September 15, 2017","September 30, 2018","December 30, 2018","November 13, 2017","null","November 13, 2017","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico","","https://ClinicalTrials.gov/show/NCT03339700"
420,"NCT03338777","Suicide Plus Immune Gene Therapy for Advanced Melanoma","IGTM-101","Recruiting","No Results Available","Melanoma","Biological: Suicide plus immunogene therapy","Safety reported as the number of treatment-related adverse events as assessed by CTCAE v4.03","Hospital Italiano de Buenos Aires|Instituto de Oncología Ángel H. Roffo|Agencia Nacional de Promoción Científica y Tecnológica, Argentina|National Council of Scientific and Technical Research, Argentina|Facultad de Medicina. Universidad de Buenos Aires","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2082","March 13, 2017","March 13, 2019","September 13, 2019","November 9, 2017","null","November 9, 2017","Hospital Italiano, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina","","https://ClinicalTrials.gov/show/NCT03338777"
421,"NCT03336372","Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients",,"Recruiting","No Results Available","Molluscum Contagiosum","Drug: Picato","Complete clearance at Week 4|Partial clearance at Week 4|Percentage of subjects who sustain complete clearance of MCs in the treatment area at Week 24|Percentage of subjects who clear MCs outside of the treatment area at Week 24","Center for Clinical Studies, Texas|LEO Pharma","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIS-Picato-1386","December 20, 2017","July 1, 2018","December 15, 2018","November 8, 2017","null","January 26, 2018","Center for Clinical Studies, Houston, Texas, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/72/NCT03336372/ICF_001.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/72/NCT03336372/Prot_002.pdf","https://ClinicalTrials.gov/show/NCT03336372"
422,"NCT03335670","Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors",,"Recruiting","No Results Available","Neuroendocrine Tumors","Drug: [68Ga]Pentixafor","Determine biodistribution (pharmacokinetic parameters) of [68Ga]Pentixafor in patients with neuroendocrine tumors (NETs)|Determine the repeatability of [68Ga]Pentixafor uptake in known neuroendocrine tumor lesions|Compare standardized uptake values of [68Ga]Pentixafor and [68Ga]DOTATATE in known neuroendocrine tumor lesions|Correlate the uptake of [68Ga]Pentixafor and [68Ga]DOTATATE (NetSpot) in known neuroendocrine tumor lesions with expression of receptors (CXCR4 and SSTR2) in biopsy tissue samples.","Yusuf Menda|National Cancer Institute (NCI)|National Institutes of Health (NIH)|Holden Comprehensive Cancer Center|University of Iowa","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201708705|P50CA174521","November 3, 2017","October 1, 2019","December 31, 2020","November 8, 2017","null","January 9, 2018","Holden Comprehensive Cancer Center, Iowa City, Iowa, United States","","https://ClinicalTrials.gov/show/NCT03335670"
423,"NCT03334500","Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer",,"Recruiting","No Results Available","Prostate Cancer","Device: [18F]FluorThanatrace ([18F]FTT)|Drug: PARP-1","Number of adverse events","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 13817","July 14, 2017","July 14, 2020","July 14, 2021","November 7, 2017","null","November 7, 2017","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03334500"
424,"NCT03333369","Exceptional Experiences (EE), Salience & Dopaminergic Neurotransmission",,"Completed","No Results Available","Healthy|Schizotypal Personality","Drug: 200 mg levodopa/50 mg benserazide|Drug: Dextrose","intrinsic functional connectivity|Schizotypy","University of Zurich|Swiss Federal Institute of Technology","Male","20 Years to 60 Years   (Adult)","Early Phase 1","65","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","DA_EE_Salience","May 15, 2014","August 13, 2015","August 13, 2015","November 6, 2017","null","November 6, 2017","Collegium Helveticum, ETH & Universität Zürich, Zürich, Switzerland","","https://ClinicalTrials.gov/show/NCT03333369"
425,"NCT03333148","Preoperative Oral ImmunoNuTrition to Improve Surgical Outcomes for IBD Patients (PINT)","PINT","Not yet recruiting","No Results Available","Inflammatory Bowel Diseases","Drug: Nestle IMPACT Immunonutrition|Other: Arm B- Standard of Care","The occurrence of any postoperative complications after surgery|Detection of the differences in the markers of inflammation interleukin-1-β (IL-1β)|Detection of the differences in the markers of inflammation Interleukin 6 (IL-6)|Detection of the differences in the markers of inflammation tumor necrosis factor (TNF-α)|Detection of the differences in the markers of inflammation CRP|Detection of the differences in the markers of inflammation nutritional status albumin|Detection of the differences in the markers of inflammation pre-albumin","University of Alabama at Birmingham","All","19 Years and older   (Adult, Older Adult)","Early Phase 1","252","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB -170222002","November 12, 2018","November 12, 2020","May 1, 2021","November 6, 2017","null","October 29, 2018","","","https://ClinicalTrials.gov/show/NCT03333148"
426,"NCT03330704","Small-Volume, Patient-Specific, Balanced Hypertonic Fluid Protocol Validation",,"Not yet recruiting","No Results Available","Cerebral Edema|Saline Solution, Hypertonic","Drug: 3% Sodium Chloride|Drug: 23.4% Sodium Chloride|Drug: 8.4% Sodium Bicarbonate","Total volume of intravenous hypertonic fluid administered to the patient|Urine output","Stanford University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","IRB-43653","December 8, 2017","February 8, 2018","April 30, 2018","November 6, 2017","null","November 6, 2017","Stanford University Hospital, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT03330704"
427,"NCT03329235","Intraosseous With Intra-articular Injection of Platelet Rich Plasma in Treatment of Knee Osteoarthritis",,"Completed","No Results Available","Osteoarthritis, Knee","Drug: PRP|Drug: HA","WOMAC scores","Cangzhou Central Hospital","All","40 Years to 73 Years   (Adult, Older Adult)","Early Phase 1","86","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Cangzhou Central Hospital","January 1, 2015","June 30, 2015","January 1, 2017","November 1, 2017","null","November 1, 2017","","","https://ClinicalTrials.gov/show/NCT03329235"
428,"NCT03328312","Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium",,"Not yet recruiting","No Results Available","Incidence of Postoperative Residual Curarization","Drug: Sugammadex|Drug: neostigmine+atropine|Drug: neostigmine+atropine+sugammadex","Incidence of postoperative residual curarization (PORC)|Time|Bradycardia|Residual blockade","Iuliu Hatieganu University of Medicine and Pharmacy","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Early Phase 1","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","36325348/2017","December 1, 2017","March 1, 2018","June 1, 2018","November 1, 2017","null","November 1, 2017","","","https://ClinicalTrials.gov/show/NCT03328312"
429,"NCT03326050","Comparison Between Rifampicin and Gemifloxacin and Ciprofloxacin in Treatment of Rhinoscleroma",,"Not yet recruiting","No Results Available","Rhinoscleroma","Drug: Gemifloxacin|Drug: Ciprofloxacin|Drug: Rifampicin","clinical examination., nasal crustation,|clinical examination purulent secretions|• Full ENT history","Assiut University","All","18 Years to 45 Years   (Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","rhinoscleroma","February 2018","September 1, 2018","October 2018","October 30, 2017","null","February 13, 2018","Asmaa Ahmed, Assiut, Egypt","","https://ClinicalTrials.gov/show/NCT03326050"
430,"NCT03323567","A Comparison of Collagen, Lidocaine and Saline, in Trigger Points in Masseter Muscle.",,"Completed","No Results Available","Temporomandibular Disorder","Drug: MD Muscle GUNA collagen|Drug: Lidocaine 2% Injectable Solution|Drug: Saline Solution, Hypertonic","sEMG reduction of masseter muscle in TMD patients","Medical University of Silesia","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","43","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Silesian UM","January 10, 2016","October 4, 2017","October 12, 2017","October 27, 2017","null","January 4, 2018","Department of TMD and Orthodontics Silesian Medical University, Zabrze, Poland","","https://ClinicalTrials.gov/show/NCT03323567"
431,"NCT03322423","Evaluation of Two Marketed Multifocal Contact Lenses",,"Completed","No Results Available","Visual Performance","Device: Multifocal Contact Lens 1|Device: Multifocal Contact Lens 2|Device: Spherical Contact Lens 2","Visual Performance|Vision and Handling","Johnson & Johnson Vision Care, Inc.","All","40 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","78","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CR-5860","September 11, 2017","November 4, 2017","November 4, 2017","October 26, 2017","null","December 14, 2017","Golden Vision, Sarasota, Florida, United States|ABQ Eye Care, Albuquerque, New Mexico, United States|Sacco Eye Group, Vestal, New York, United States|West Bay Eye Associates, Warwick, Rhode Island, United States|Botetourt Eyecare, LLC, Salem, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03322423"
432,"NCT03321136","Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)","LDR","Recruiting","No Results Available","Healthy","Drug: LSD|Drug: Placebo","Altered states of consciousness|Subjective effects|Psychotomimetic effects|Mystical-type experiences|Autonomic effects","Matthias Liechti|University Hospital, Basel, Switzerland","All","25 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","BASEC-2017-01348","November 28, 2017","March 2019","March 2019","October 25, 2017","null","November 29, 2017","University Hospital, Basel, Switzerland","","https://ClinicalTrials.gov/show/NCT03321136"
433,"NCT03321045","PET Imaging With 89Zr-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness",,"Recruiting","No Results Available","Breast Cancer","Drug: [89Zr]-Df-Trastuzumab|Diagnostic Test: PET/MRI Imaging","Investigate the use of [89Zr]-Df-Trastuzumab as a HER2 imaging agent","University of Alabama at Birmingham","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB-170220004","November 21, 2017","January 2022","January 2022","October 25, 2017","null","January 23, 2018","The Kirklin Clinic, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT03321045"
434,"NCT03318978","Benzo[a]Pyrene Ultralow Dose-Response Study",,"Recruiting","No Results Available","Environmental Exposure","Drug: [14C]-benzo[a]pyrene","Plasma and urine benzo[a]pyrene and metabolite levels after oral dose|Peak plasma concentration Cmax|Time at highest plasma concentration Tmax|Area under plasma concentration versus time curve AUC|Rate of elimination|Metabolites in plasma|Metabolites in urine","Oregon State University|National Institute of Environmental Health Sciences (NIEHS)|Lawrence Livermore National Laboratory|Pacific Northwest National Laboratory","All","21 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","7","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","LPI-8233","April 17, 2018","December 2019","November 2022","October 24, 2017","null","October 18, 2018","Clinical Research Facility, 407 Linus Pauling Science Center, Oregon State University, Corvallis, Oregon, United States","","https://ClinicalTrials.gov/show/NCT03318978"
435,"NCT03317730","Pilot Trial of Microsphere Oxycodone (Xtampza ER) for Pain Management in Patients Receiving Radiotherapy for Locally Advanced Head and Neck Cancer","RAD 1702","Recruiting","No Results Available","Locally Advanced Head and Neck Cancer","Drug: Xtampza ER","Feasibility of Xtampza ER during radiotherapy (RT) for locally advanced head and neck cancer (LAHNC).|Determine Pain Control (at time of enrollment)|Determine Pain Control (weekly during RT)|Determine Pain Control (at follow-up)|Access Toxicity|Access Quality of Life","University of Alabama at Birmingham","All","19 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-300000574","May 1, 2018","October 2019","December 2019","October 23, 2017","null","May 22, 2018","Hazelrig-Salter Radiation Oncology Center, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT03317730"
436,"NCT03316963","Neostigmine For Snoring During DISE",,"Recruiting","No Results Available","Snoring","Drug: Neostigmine Methylsulfate","Change in decibel sound after injection of neostigmine|Change in soft palate motion after injection of neostigmine","Emory University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00096770","November 14, 2017","August 2019","August 2019","October 23, 2017","null","August 20, 2018","Raj C. Dedhia, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03316963"
437,"NCT03316274","Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma",,"Recruiting","No Results Available","Kaposi Sarcoma|HIV/AIDS|Immunosuppression","Drug: Intra-lesional injection of nivolumab","Safety and tolerability as assessed by Common Terminology Criteria for Adverse Events version 4 (CTCAE v. 4)|The changes in frequency of circulating activated T cells in the skin KS lesions as determined by immunohistochemistry and flow cytometry|The changes in number of circulating activated T cells in the skin KS lesions as determined by immunohistochemistry and flow cytometry|The changes in frequency of circulating activated T cells in the peripheral blood as determined by flow cytometry|The changes in number of circulating activated T cells in the peripheral blood as determined by flow cytometry|The changes in PD-1 expression as determined by immunohistochemistry in lesions|The changes in PD-L1 expression as determined by immunohistochemistry in lesions","University of California, San Francisco|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other|Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC17872","April 15, 2018","December 2018","June 2019","October 20, 2017","null","May 2, 2018","Zuckerberg San Francisco General Hospital, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT03316274"
438,"NCT03315065","19F Thoracic Radiotherapy for Lung Cancer",,"Recruiting","No Results Available","Lung Cancer","Drug: Perfluorinated Gas/Oxygen Mixture","Number of study patients consented (maximum 8)in order to result in 5 patients successfully completing both 19F functional MR imaging data sets|Proportion of study patients that successfully return for a re-assessment 19F MRI scan after completing radiotherapy.","Hal C Charles|Duke University","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Pro00084472","February 16, 2018","August 28, 2019","December 1, 2019","October 19, 2017","null","September 27, 2018","Duke University Medical Center - Cancer Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03315065"
439,"NCT03314259","Prophylactic Alpha-blockers in the Prevention of Urinary Retention Post Inguinal Hernia Repair",,"Not yet recruiting","No Results Available","Urinary Retention|Inguinal Hernia","Drug: Tamsulosin|Drug: Placebo Oral Tablet","Post operative urinary retention","National University Hospital, Singapore|National University, Singapore","Male","41 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2016/00295-SRF0001","December 1, 2017","December 1, 2018","June 1, 2019","October 19, 2017","null","October 19, 2017","","","https://ClinicalTrials.gov/show/NCT03314259"
440,"NCT03313934","Platelet Rich Fibrin for Tear Trough Rejuvenation",,"Not yet recruiting","No Results Available","Tear Trough Hollowing, Under Eye Bags","Combination Product: Hyaluronic Acid Filler and Platelet Rich Fibrin (PRF)|Combination Product: Hyaluronic Acid Filler and Saline","Overall Tear Trough Rejuvenation|Improvement of Facial Rhytids","Rejuva Medical Aesthetics","All","20 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","20171835","November 2017","November 2018","November 2018","October 18, 2017","null","October 18, 2017","Rejuva Medical Aesthetics, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT03313934"
441,"NCT03311958","Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance",,"Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Nivolumab, IV, 240 mg","Evaluation of the rate of conversion from positive to negative ctDNA in nivolumab treated patients|To evaluate adverse events in patients on nivolumab as maintenance drug in post-induction, post-salvage and post-autologous transplant setting|Relapse free survival (RFS-ctDNA) for nivolumab treated patients|Proportion of patients who are able to convert from ctDNA positive to ctDNA negative after nivolumab treatment|To compare the ctDNA results of Clonoseq and Neolabs platform","Fox Chase Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM-110","May 15, 2018","April 15, 2019","April 15, 2021","October 17, 2017","null","May 18, 2018","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03311958"
442,"NCT03309865","Evaluating the Combined Effect of Vedolizumab and Semi-Vegetarian Diet on Ulcerative Colitis.",,"Withdrawn","No Results Available","Ulcerative Colitis|Dietary Modification","Dietary Supplement: semi-vegetarian diet|Drug: Vedolizumab Injection","Clinical response at week 6|Clinical response at week 14","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB 17-005613","December 25, 2017","August 31, 2018","December 31, 2018","October 16, 2017","null","September 26, 2018","Mayo Clinic Florida, Jacksonville, Florida, United States","","https://ClinicalTrials.gov/show/NCT03309865"
443,"NCT03309696","Regulating Homeostatic Plasticity and the Physiological Response to rTMS",,"Recruiting","No Results Available","Tinnitus","Device: tDCS|Device: rTMS","Change in cortical excitability - the local mean field potential","University of Arkansas","All","21 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","206326","November 16, 2017","October 30, 2019","October 30, 2019","October 13, 2017","null","November 20, 2017","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States","","https://ClinicalTrials.gov/show/NCT03309696"
444,"NCT03303235","Intravenous Versus Intramuscular Administration of Methylergonovine for Uterine Contraction in Cesarean Sections",,"Not yet recruiting","No Results Available","Uterine Atony|Uterine Tone Disorders|Postpartum Hemorrhage","Drug: Methylergonovine","Time to achieve ""adequate"" uterine tone|Dose that achieves ""adequate"" uterine tone|Need for additional uterotonic agents|Frequency of side effects of methylergonovine|Need for vasopressors|Estimated blood loss|Computed blood loss","Johns Hopkins University","Female","Child, Adult, Older Adult","Early Phase 1","4000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","IRB00120873","November 2018","October 2020","December 2020","October 5, 2017","null","October 4, 2018","Johns Hopkins Hospital, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03303235"
445,"NCT03302416","CRF - Nociceptin Receptor Interactions",,"Recruiting","No Results Available","Healthy","Drug: Hydrocortisone|Radiation: [C-11]NOP-1A","[C-11]NOP-1A volume of distribution expressed relative to total plasma concentration","University of Pittsburgh|National Institute on Drug Abuse (NIDA)","All","18 Years to 40 Years   (Adult)","Early Phase 1","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PRO16030242|R21DA042633","June 1, 2016","June 1, 2019","June 1, 2019","October 5, 2017","null","September 6, 2018","University of Pittsburgh, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03302416"
446,"NCT03301532","Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1D",,"Enrolling by invitation","No Results Available","GLUT1DS1","Drug: Triheptanoin","Ketosis|EEG|Seizure rate|Glycemia","University of Texas Southwestern Medical Center|National Institute of Neurological Disorders and Stroke (NINDS)","All","30 Months to 35 Years   (Child, Adult)","Early Phase 1","15","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU 102015-091|R01NS094257-01A1","June 5, 2018","July 5, 2021","July 5, 2023","October 4, 2017","null","November 5, 2018","UTexasSouthwestern, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT03301532"
447,"NCT03300687","First in Human Safety Study of FX-322 in Adults Undergoing Cochlear Implantation",,"Completed","No Results Available","Hearing Loss","Drug: FX-322|Drug: Placebo","Incidence of treatment-emergent adverse events (Safety and Tolerability) of FX-322.|Plasma Pharmacokinetics|Cochlear Perilymph Pharmacokinetics","Frequency Therapeutics","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","9","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Other","FX-322-103","May 30, 2017","December 12, 2017","January 18, 2018","October 3, 2017","null","April 12, 2018","Royal Victoria Eye and Ear Hospital, Melbourne, Victoria, Australia","","https://ClinicalTrials.gov/show/NCT03300687"
448,"NCT03299803","Depression in Men With Physical Disabilities",,"Not yet recruiting","No Results Available","Depression","Behavioral: Men's Healing Pathways","Center for Epidemiologic Studies Depression Measure","Oregon Health and Science University","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R15NR016362","December 2017","December 2018","December 2018","October 3, 2017","null","October 13, 2017","","","https://ClinicalTrials.gov/show/NCT03299803"
449,"NCT03297489","Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer",,"Recruiting","No Results Available","Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma|Stage I Ovarian Cancer|Stage IA Ovarian Cancer|Stage IB Ovarian Cancer|Stage IC Ovarian Cancer|Stage II Ovarian Cancer|Stage IIA Ovarian Cancer|Stage IIB Ovarian Cancer|Stage IIC Ovarian Cancer|Stage III Ovarian Cancer|Stage IIIA Ovarian Cancer|Stage IIIB Ovarian Cancer|Stage IIIC Ovarian Cancer|Stage IV Ovarian Cancer","Procedure: Diagnostic Microscopy|Drug: Fluorescein Sodium Injection|Other: Laboratory Biomarker Analysis","Fluorescein within the tumor vessels|Identification of tumor vessels|Tumor vessel diameter|Vessel density|Blood flow velocity of the tumor vessels|Tissue penetration of fluorescein","Roswell Park Cancer Institute|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","24","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","I 43717|NCI-2017-01459|P30CA016056","November 6, 2017","May 15, 2019","May 15, 2020","September 29, 2017","null","June 21, 2018","Roswell Park Cancer Institute, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT03297489"
450,"NCT03297112","Contrast-Enhanced Subharmonic Ultrasound Imaging in Improving Characterization of Adnexal Masses in Patients Undergoing Surgery",,"Active, not recruiting","No Results Available","Adnexal Mass","Drug: Perflutren Lipid Microspheres|Procedure: Contrast-Enhanced Subharmonic Ultrasound Imaging","Characterization of adnexal masses compared to standard ultrasound and contrast enhanced magnetic resonance imaging (MRI)|Risk of malignancy index","Sidney Kimmel Cancer Center at Thomas Jefferson University|National Institutes of Health (NIH)|Lantheus Medical Imaging|Thomas Jefferson University","Female","21 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","16F.394","August 1, 2017","September 4, 2018","August 2019","September 29, 2017","null","October 9, 2018","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03297112"
451,"NCT03296852","Study: SONAS Ultrasound for Detecting Stroke SONAS Ultrasound for Detecting Stroke",,"Active, not recruiting","No Results Available","Stroke, Acute","Diagnostic Test: SONAS Ultrasound Device|Drug: Lumason","Blood brain barrier impairment by extravasation of Gadolinium into the brain tissue","University of California, Los Angeles|BURL Concepts Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","16-001538","April 19, 2018","September 26, 2018","January 20, 2019","September 28, 2017","null","October 11, 2018","UCLA Medical Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT03296852"
452,"NCT03296436","A Pilot Study to Assess the Efficacy of NEOX® CORD 1K® in the Treatment of Complex Diabetic Wounds",,"Not yet recruiting","No Results Available","Vascular Ulcer (Arterial or Venous Including Diabetic Ulcers Not Located on the Foot)|Diabetic Foot Ulcer|Diabetic Foot|Diabetic Foot Infection|Diabetic Foot Ulcer Mixed","Biological: NEOX® CORD 1K®","complete ulcer closure|NEOX CORD 1K applications|ulcer surface area|number of days to complete wound closure|Mean cost to closure|recurrent ulcer-related complications","Johns Hopkins University","All","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00145403","January 2019","October 2019","October 2019","September 28, 2017","null","October 9, 2018","","","https://ClinicalTrials.gov/show/NCT03296436"
453,"NCT03295916","Stereotactic Body Radiotherapy for Patients With Breast Cancer Oligometastasis","STOMP","Not yet recruiting","No Results Available","Breast Cancer","Radiation: Stereotactic Body Radiotherapy","Technical feasibility of planning SBRT to multiple sites|Toxicity: Incidence of treatment-emergent adverse events [safety and tolerability] as assessed by CTCAE 4.0|Feasibility of patient accrual: Successful accrual of 30 patients to study|Local Control: CT scan or MRI as assessed by RECIST criteria 1.1|Progression Free Survival (PFS)|Overall Survival (OS)|Quality of Life defined by EORTC Quality of Life Questionnaire core-30","Juravinski Cancer Center|Toronto Sunnybrook Regional Cancer Centre","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3764","October 1, 2017","October 1, 2019","April 1, 2020","September 28, 2017","null","September 28, 2017","","","https://ClinicalTrials.gov/show/NCT03295916"
454,"NCT03295903","Cannabinoid Supplementation on Vascular and Cognitive Function",,"Not yet recruiting","No Results Available","Diet Modification","Dietary Supplement: Cannabidiol supplement","Circulating cannabidiol and nitric oxide markers|Vascular function|Height|Weight|Body mass index|Systolic blood pressure|Diastolic blood pressure|Heart rate|Respiration|Medical History Questionnaire|Gastrointestinal Distress Questionnaire|Anxiety Questionnaire|Cognitive performance|Exercise performance","University of British Columbia|Lexaria Bioscoence Corp|Mitacs","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","H17-01957","October 2017","July 2019","August 2019","September 28, 2017","null","September 28, 2017","University of British Columbia, Kelowna, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03295903"
455,"NCT03295695","PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient",,"Not yet recruiting","No Results Available","Breast Cancer|Breast Cancer, Female|Breast Cancer, Male|Breast Neoplasms","Diagnostic Test: Fluoro-D-glucose-positron Emission Tomography|Biological: 2-deoxy-2-[18F]fluoro-D-glucose (FDG)|Diagnostic Test: Echocardiogram","Cardiac Ejection Fraction (EF)|Concordance Between FDG-RBC PET-CT and Echocardiogram","H. Lee Moffitt Cancer Center and Research Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","MCC-19220","March 2019","March 2020","March 2021","September 28, 2017","null","November 7, 2018","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States","","https://ClinicalTrials.gov/show/NCT03295695"
456,"NCT03295240","The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma",,"Recruiting","No Results Available","Mantle Cell Lymphoma|Lymphoma","Drug: BR-I (bendamustine, rituximab, ibrutinib)|Drug: VEN (Venetoclax)","Maximum tolerated dose|Treatment related toxicity evaluated using CTCAE v4.0","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-216","September 20, 2017","September 20, 2019","September 20, 2019","September 27, 2017","null","November 9, 2018","Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memoral Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan - Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering @ Rockville, Rockville Centre, New York, United States","","https://ClinicalTrials.gov/show/NCT03295240"
457,"NCT03294564","Cognitive, Emotional, and Neural Responses to Acute Inflammation",,"Active, not recruiting","No Results Available","Healthy","Biological: Typhoid Vi Polysaccharide Vaccine|Biological: Placebo","Inflammatory markers elicited by the typhoid vaccine|Threat sensitivity between groups|Reward sensitivity between groups","University of California, San Francisco|National Institute of Mental Health (NIMH)","Male","30 Years to 60 Years   (Adult)","Early Phase 1","24","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","14-13204|K01MH109871","January 1, 2018","December 2018","December 2018","September 27, 2017","null","July 23, 2018","San Francisco Veterans Affairs Medical Center, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT03294564"
458,"NCT03292822","Effects of (Licochalcone A) and Paclitaxel on Human Oral Squamous Cell Carcinoma Cell Line",,"Not yet recruiting","No Results Available","Squamous Cell Carcinoma","Dietary Supplement: Licochalcone A|Drug: Paclitaxel","Apoptosis","Cairo University","All","Child, Adult, Older Adult","Early Phase 1","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CEBD-CU-2017-09-26","November 1, 2017","September 1, 2018","April 1, 2019","September 26, 2017","null","September 26, 2017","Cairo University, Cairo, Egypt","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT03292822/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03292822"
459,"NCT03292445","Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation","CIRM","Recruiting","No Results Available","Immune Tolerance","Procedure: Immune tolerance after kidney transplant|Drug: Donor blood stem cells and T cells","Reduction of dependence on immunosuppressive drugs to prevent graft rejection.|Incidence of rejection episodes requiring corticosteroid therapy|Incidence of graft loss.","Samuel Strober|California Institute for Regenerative Medicine|Stanford University","All","18 Years to 60 Years   (Adult)","Early Phase 1","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","40442","February 14, 2017","February 14, 2020","February 14, 2024","September 25, 2017","null","September 25, 2017","Stanford University Medical Center, Palo Alto, California, United States","","https://ClinicalTrials.gov/show/NCT03292445"
460,"NCT03292146","Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study",,"Recruiting","No Results Available","Bone Density|Bone Loss|Anorexia Nervosa|Eating Disorder|Atypical Anorexia Nervosa","Drug: Denosumab 60 MG [Prolia]|Drug: Placebo Injection","Change in bone density","Massachusetts General Hospital|Amgen","Female","20 Years to 60 Years   (Adult)","Early Phase 1","75","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2017P000529","October 25, 2017","May 2020","May 2020","September 25, 2017","null","September 17, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03292146"
461,"NCT03291990","5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme",,"Recruiting","No Results Available","Glioblastoma Multiforme","Drug: Temozolomide","Rate of change of lymphopenia|Percentage change in Cluster of differentiation 4 (CD4) count (antigen found on helper T cells)|Rate of change of lymphocytes|Rate of survival|Rate of change in serious adverse events","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","46","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","J1745|IRB00129314","October 1, 2017","October 1, 2020","October 1, 2021","September 25, 2017","null","November 6, 2018","Sibley Hospital, Washington, District of Columbia, United States|Suburban Hospital, Washington, District of Columbia, United States|SKCCC at Johns Hopkins (East Baltimore), Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03291990"
462,"NCT03291379","Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies","VEROnA","Recruiting","No Results Available","Carcinoma, Hepatocellular|Metastatic Colorectal Cancer","Drug: BTG-002814 (vandetanib-eluting radiopaque beads)","Adverse events (AEs) related to treatment with BTG-002814 using the National Cancer Institute- Common Terminology Criteria for Adverse Events- Version 4.0 (NCI-CTCAE v4.0)|Concentration of vandetanib and N-desmethyl vandetanib in plasma following treatment with BTG-002814|Concentration of vandetanib and N-desmethyl vandetanib in resected liver tissue following treatment with BTG-002814|BTG-002814 distribution|Evaluation of histopathological features|Assessment of changes in blood flow","Biocompatibles UK Ltd","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BTG-002814-01","May 17, 2017","January 2019","January 2019","September 25, 2017","null","October 18, 2018","University College London Hospital, Bloomsbury, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT03291379"
463,"NCT03291353","Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia",,"Recruiting","No Results Available","Refractory Acute Myeloid Leukemia","Drug: pembrolizumab","Adverse event assessment|Response Rate (RR)|Overall survival","Michael Boyiadzis|Merck Sharp & Dohme Corp.|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-056","October 17, 2017","August 19, 2019","August 19, 2022","September 25, 2017","null","December 11, 2017","UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03291353"
464,"NCT03290430","End Nicotine Dependence Clinic",,"Recruiting","No Results Available","Smoking Cessation","Behavioral: Group Counseling|Behavioral: Individual Counseling|Behavioral: Phone Counseling|Behavioral: Video Counseling|Behavioral: Texting support|Drug: Nicotine Replacement Therapy","Rate of 24 hour smoking abstinence across intervention|Rate of 7-day smoking abstinence across intervention|Rate of 28-day smoking abstinence across intervention|Average intervention rating|Sessions completed|Study Retention|Nicotine Replacement Therapy (NRT) Completed","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CASE3Z17","January 9, 2018","January 2021","July 2021","September 21, 2017","null","March 14, 2018","Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03290430"
465,"NCT03288298","Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line",,"Not yet recruiting","No Results Available","Tongue Neoplasms|Carcinoma","Drug: luteolin|Drug: nano-luteolin","gene expression of Caspase 3 to detect apoptosis|cell viability","Cairo University","All","Child, Adult, Older Adult","Early Phase 1","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CEBD-CU-2017-09-23","November 1, 2017","September 1, 2018","April 1, 2019","September 20, 2017","null","September 20, 2017","","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT03288298/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03288298"
466,"NCT03287050","Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma",,"Recruiting","No Results Available","Urothelial Carcinoma","Drug: Pembrolizumab|Radiation: SBRT","The percentage of subjects who receive 4 doses of pembrolizumab and at least one session of treatment of SBRT|The number of grades 3-5 drug related adverse events (AEs)|The percentage of patients that respond to treatment|Progression free survival (PFS) time","University of Michigan Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMCC 2017.069|HUM00135161","January 23, 2018","March 1, 2020","November 1, 2021","September 19, 2017","null","March 7, 2018","University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03287050"
467,"NCT03285971","Real-Time Decision Support for Improving Intraoperative Cerebral Perfusion Pressure",,"Recruiting","No Results Available","Cerebral Hypoperfusion","Other: Electronic CPP pager alert","Mean Cerebral Perfusion Pressure (CPP, mmHg)|Mortality (incidence, %)|Postoperative Stroke (incidence, %)|Myocardial Infarction (incidence, %)|Congestive Heart Failure (incidence, %)|Cardiac Dysrythmias (incidence, %)|Acute Respiratory Distress Syndrome, ARDS (incidence, %)|Acute Kidney Injury, AKI (incidence, %)","University of Michigan","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","HUM117828","September 25, 2017","December 31, 2020","December 31, 2020","September 18, 2017","null","May 4, 2018","Michigan Medicine - University of Michigan, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03285971"
468,"NCT03285282","Evaluation of Thoracolumbar Interfascial Plane Block for Postoperative Analgesia After Herniated Lumbar Disc Surgery",,"Recruiting","No Results Available","Postoperative Analgesia After Disc Surgery","Procedure: Thoracolumber interfascial plane block","Visual Analogue Score|Total morphine consumption","Ain Shams University","All","21 Years to 60 Years   (Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","123/2017","May 8, 2017","October 2017","November 2017","September 18, 2017","null","September 18, 2017","Faculty of medicine, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03285282"
469,"NCT03284268","Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma","RTB","Recruiting","No Results Available","Retinoblastoma, Recurrent","Genetic: VCN-01","Incidence of Treatment-Emergent Adverse Events|Tumor response|VCN-01|Immune response","Fundació Sant Joan de Déu","All","1 Year to 12 Years   (Child)","Early Phase 1","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FSJD-RTB-2015","September 6, 2017","September 25, 2019","November 25, 2019","September 15, 2017","null","May 17, 2018","Hospital Sant Joan de Déu, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT03284268"
470,"NCT03282461","A Microdose Evaluation Study of ABY-029 in Head and Neck Oncology Surgery",,"Enrolling by invitation","No Results Available","Head and Neck Cancer","Drug: ABY-029","Signal detection|Correlation of spatial patterns of EGFR expression","Dartmouth-Hitchcock Medical Center|Dartmouth College","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D17064","January 25, 2018","June 1, 2019","December 31, 2019","September 14, 2017","null","May 1, 2018","Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States","","https://ClinicalTrials.gov/show/NCT03282461"
471,"NCT03282110","Comprehensive Acupuncture for Depressive Disorder With Comorbid Psychogenic Pain",,"Not yet recruiting","No Results Available","Depression; Psychoneurotic|Pain","Device: ta-VNS|Other: Electro-acupuncture|Drug: Citalopram","Montgomery-Asberg Depression Rating Scale Change|SF-McGill Pain Questionnaire|SF-36 Health Survey Questionnaire|Pittsburgh Sleep Quality Index|Hamilton Anxiety Rating Scale(HAMA)","China Academy of Chinese Medical Sciences","All","18 Years to 50 Years   (Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ChinaACMS-3","November 30, 2017","June 30, 2018","June 30, 2019","September 13, 2017","null","November 7, 2017","","","https://ClinicalTrials.gov/show/NCT03282110"
472,"NCT03280589","Pranayama Practice on the Autonomic Nervous System","PYAMA","Recruiting","No Results Available","Pranayama Effect on Autonomic Nervous System|Respiration Variability Effect on Nervous System","Other: Sheetali/Sheekari Pranayama|Other: Sitting Quietly|Other: Deep breathing","Change in Heart Rate Variability (HRV)|Change in EEG","National University of Natural Medicine","All","25 Years to 55 Years   (Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PYAMA","August 15, 2017","December 15, 2018","December 15, 2018","September 12, 2017","null","September 12, 2017","National University of Natural Medicine, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT03280589"
473,"NCT03279393","PPG Project 3 - PET/MRI of the Brain-hematopoiesis-atherosclerosis Axis in PTSD Patients",,"Recruiting","No Results Available","PTSD|Trauma|Healthy","Drug: fluorodeoxyglucose (FDG)-PET/MRI","Atherosclerotic burden in PTSD using PET/MRI|Degree of brain fear circuit activation|Level of circulating HPSCs|Level of circulating immune cells|Level of soluble inflammation biomarkers","Zahi Fayad|Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health (NIH)|Icahn School of Medicine at Mount Sinai","All","30 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","240","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","GCO 15-0893 P3|1P01HL131478","November 28, 2017","February 28, 2022","February 28, 2022","September 12, 2017","null","September 21, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03279393"
474,"NCT03278990","Scalable Interventions to Increase PrEP Adherence: Value Affirmation and Future Selves","SIIPA","Not yet recruiting","No Results Available","HIV Prevention","Behavioral: Value Affirmation and Future Selves Combination","PrEP Adherence|HIV contraction|Sexual Risk Behavior 1: Partners|Sexual risk behavior 2: Condomless sex|STI contraction","Nichole Ben Itzhak|Allegheny Singer Research Institute|Gilead Sciences|University of Pittsburgh|Pittsburgh AIDS Task Force|Center for Inclusion Health|Central Outreach|BI Development, LLC","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","170","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","IN-US-276-4221","November 1, 2017","October 31, 2018","March 31, 2019","September 12, 2017","null","September 12, 2017","Center for Inclusion Health, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03278990"
475,"NCT03277456","A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1",,"Completed","No Results Available","Human Volunteers","Biological: MVA-NP+M1","Measure of local reactogenicity following intramuscular injection of MVA-NP+M1|Measure of systemic reactogenicity following intramuscular injection of MVA-NP+M1|Measure the occurrence of adverse events following intramuscular injection of MVA-NP+M1|Assessment of safety laboratory assessments following intramuscular injection of MVA-NP+M1|Serious Adverse Events that occur during the study","Vaccitech Limited|University of Oxford","All","18 Years to 50 Years   (Adult)","Early Phase 1","6","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","FLU008","September 18, 2017","November 2, 2017","November 2, 2017","September 11, 2017","null","November 14, 2017","Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford, Oxfordshire, United Kingdom","","https://ClinicalTrials.gov/show/NCT03277456"
476,"NCT03276832","Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma",,"Recruiting","No Results Available","Metastatic Melanoma|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7","Drug: Imiquimod|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab","Duration of response|Incidence of adverse events graded using Common Terminology Criteria for Adverse Events version 4.0|Overall survival|Progression free survival|Tumor response rate defined as percentage of patients whose objective disease status meets the criteria for Response Evaluation Criteria in Solid Tumors (RECIST) criteria for partial or complete response on two consecutive disease evaluations|Biomarker changes during treatment","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC1578|NCI-2017-01591|P30CA015083","December 20, 2017","February 15, 2021","February 15, 2021","September 8, 2017","null","December 22, 2017","Mayo Clinic in Florida, Jacksonville, Florida, United States","","https://ClinicalTrials.gov/show/NCT03276832"
477,"NCT03275974","Glutamine PET Imaging Colorectal Cancer",,"Recruiting","No Results Available","RAS Wild Type|Stage IV Colorectal Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer","Biological: Carbon C 11 Glutamine|Biological: Fluorine F 18 L-glutamate Derivative BAY94-9392|Procedure: Positron Emission Tomography","Pet imaging|Gene expression|Change in tumor size (e.g., long-axis diameter, tumor volume)|Plasma levels of Gln, Glu, cystine, and substrates and metabolites related to glutaminolysis and amino acid transport|Progression free survival|Overall survival","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","VICC GI 1781|NCI-2017-01543","October 17, 2017","November 2021","November 2022","September 8, 2017","null","November 14, 2017","Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT03275974"
478,"NCT03275896","Evaluation of the Efficacy of Descemet Membrane Transplantation for the Treatment of Fuchs' Endothelial Dystrophy",,"Recruiting","No Results Available","Fuchs' Endothelial Dystrophy","Other: Descemet Membrane Transplantation","Central Endothelial Cell Density|Visual acuity","Singapore National Eye Centre","All","21 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R1366/52/2016","September 2016","December 2020","December 2020","September 8, 2017","null","September 8, 2017","Singapore National Eye Centre, Singapore, Singapore","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT03275896/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT03275896/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03275896"
479,"NCT03275857","Cisplatin in Castration Resistant Prostate Cancer",,"Recruiting","No Results Available","Prostate Cancer","Drug: Cisplatin","Response to dosing differences of Cisplatin from lab and scan results|Toxicity observed with dosing differences of Cisplatin","University of Rochester|Roswell Park Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","37","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UGUP-17050","September 21, 2018","January 2020","January 2021","September 8, 2017","null","October 17, 2018","Wilmot Cancer Institute, Rochester, New York, United States","","https://ClinicalTrials.gov/show/NCT03275857"
480,"NCT03274700","The Use of Tamsulosin in Treatment of (10-15 mm) Lower Ureteric Stones in Adults With Non-emergent Symptoms",,"Not yet recruiting","No Results Available","Ureteric Stone","Drug: Tamsulosin.|Drug: Placebo.","Theraputic effect of tamsulosin as assessed by number of cases of expulsed ureteric stones.","Assiut University","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","tamsulosin in ureteric stones","October 1, 2017","September 2018","October 2018","September 7, 2017","null","September 7, 2017","","","https://ClinicalTrials.gov/show/NCT03274700"
481,"NCT03272568","Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers",,"Recruiting","No Results Available","Hemophilia|Menstrual Flow Excessive","Drug: Recombinant FVIII Fc fusion product Eloctate|Drug: Recombinant FIX Fc fusion product Alprolix|Device: Patient-operated diagnostic device for anemia AnemoCheck.","Reduction in menstrual bleeding measured by the Pictorial Bleeding Assessment Chart (PBAC).|Change in Patient-Reported Outcomes Measurement Information Systems (PROMIS-43) score.|Change in Short Form 36 (SF-36) score.|Change in Menorrhagia Impact Questionnaire (MIQ) score.|Number of hypersensitivity reactions.|Accuracy of hemoglobin levels detection by Anemocheck.|Change in FVIII level after the first dose of Eloctate.|Change in FIX level after the first dose of Alpolix.","Emory University|Bioverativ Therapeutics Inc.","Female","14 Years to 55 Years   (Child, Adult)","Early Phase 1","16","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00095067","February 14, 2018","July 31, 2019","September 30, 2019","September 5, 2017","null","March 12, 2018","Emory University Hospital Clinical Research Network, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03272568"
482,"NCT03271983","Pharmacokinetics of Metronidazole Dermal Products",,"Not yet recruiting","No Results Available","Bioequivalence","Drug: Metronidazole gel 1|Drug: Metronidazole gel 2|Drug: Metronidazole cream","PK parameters","University of Maryland|Food and Drug Administration (FDA)","All","18 Years to 45 Years   (Adult)","Early Phase 1","12","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HP-00071790","December 1, 2018","September 30, 2019","December 31, 2019","September 5, 2017","null","October 24, 2018","General Clinical Research Center (GCRC) at the University of Maryland Medical Center, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03271983"
483,"NCT03270332","Effect of Inhaled Albuterol in Pulmonary Hypertension",,"Recruiting","No Results Available","Pulmonary Hypertension","Drug: albuterol first then placebo|Drug: placebo first then albuterol","Mean Pulmonary Artery Pressure|Pulmonary Vascular Resistance","University of Miami","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20170552","October 12, 2017","December 2018","March 30, 2019","September 1, 2017","null","October 18, 2018","Pulmonary Human Research Laboratory, University of Miami, Miller School of Medicine, Miami, Florida, United States","","https://ClinicalTrials.gov/show/NCT03270332"
484,"NCT03268525","The Effect of Local Anesthesia on Postoperative Pain in Vaginal Hysterectomy",,"Recruiting","No Results Available","Pain, Postoperative","Drug: Marcaine 0.5 % Injectable Solution|Drug: Sodium Chloride 0.9%","Pain at movement|pain at rest","Wolfson Medical Center","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","0156-17-WOMC","January 1, 2018","December 30, 2018","December 30, 2018","August 31, 2017","null","May 9, 2018","Wolfson medical center, H̱olon, Israel","","https://ClinicalTrials.gov/show/NCT03268525"
485,"NCT03268213","Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate Colitis","FMT","Recruiting","No Results Available","Clostridium Difficile Infection|Ulcerative Colitis|Indeterminate Colitis","Biological: Fecal Microbial Transplantation","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|To measure the effect of fecal microbial transplantation on microbial diversity in healthy donor stools compared to pre-FMT, 1 week post FMT, and 12 weeks post-FMT recipient stools.|To measure the effect of fecal microbial transplantation on microbial composition in healthy donor stools compared to pre-FMT, 1 week post FMT, and 12 weeks post-FMT recipient stools.|To measure the effect of fecal microbial transplantation on microbial function using shotgun DNA metagenomic in healthy donor stools compared to pre-FMT, 1 week post FMT, and 12 weeks post-FMT recipient stools.|To measure the effect of fecal microbial transplantation on microbial function using bacterial metatranscriptomic sequencing|To measure the effect of fecal microbial transplantation on microbial function using targeted metabolomic assays.|Determine if FMT causes a statistically significant change in recipient fecal calprotectin levels|Determine number of C. difficile recipients who have recurrent C. difficile within a year after fecal microbial transplant","Stony Brook University","All","1 Year and older   (Child, Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","479696","November 2013","June 30, 2022","June 30, 2023","August 31, 2017","null","June 1, 2018","Stony Brook University Hospital, Stony Brook, New York, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT03268213/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03268213"
486,"NCT03267238","Fecal Microbial Transplantation in Patients With Crohn's Disease",,"Recruiting","No Results Available","Crohn Disease","Biological: Fecal Microbial Transplantation","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.|To measure the effect of fecal microbial transplantation on microbial diversity in healthy donor stools compared to pre-FMT, 1 week post FMT, and 12 weeks post-FMT recipient stools.|To measure the effect of fecal microbial transplantation on microbial composition in healthy donor stools compared to pre-FMT, 1 week post FMT, and 12 weeks post-FMT recipient stools.|To measure the effect of fecal microbial transplantation on microbial function using shotgun DNA metagenomic in healthy donor stools compared to pre-FMT, 1 week post FMT, and 12 weeks post-FMT recipient stools.|To measure the effect of fecal microbial transplantation on microbial function using bacterial metatranscriptomic sequencing|To measure the effect of fecal microbial transplantation on microbial function using targeted metabolomic assays.|Determine if FMT causes a statistically significant change in recipient fecal calprotectin levels","Stony Brook University","All","7 Years and older   (Child, Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","973349","June 16, 2017","June 30, 2022","June 30, 2023","August 30, 2017","null","May 21, 2018","Stony Brook University Hospital, Stony Brook, New York, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03267238/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03267238"
487,"NCT03267173","Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.",,"Recruiting","No Results Available","Pancreatic Cancer|CAR","Drug: Chimeric antigen receptor T cell","Number of patients with tumor response|Number of patients with adverse event","First Affiliated Hospital of Harbin Medical University|Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","Male","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Yunwei Wei","June 15, 2017","June 2019","June 2019","August 30, 2017","null","August 30, 2017","Harbin Medical University, Harbin, Heilongjiang, China","","https://ClinicalTrials.gov/show/NCT03267173"
488,"NCT03266900","A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival","RESECT","Recruiting","No Results Available","Bladder Cancer|Bladder Urothelial Carcinoma","Procedure: re-TURBT|Drug: 6 weeks BCG instillation","5 year Progression Free Survival|Clinical Measures - These include recurrence free survival (in the bladder), time to cystectomy, and metastases-free survival as measured over time from intervention to 5-years post-intervention.|Survival Measures - These include disease specific survival and overall survival as measured over time from intervention to 5-years post-intervention.|Perioperative Safety Measures - These include rate of major complications as defined by the Clavien-Dindo classification as grade 3, 4, and 5.|Mean Change of Patient FACT BI Scores - This includes prospective collection with a validated BCa HRQOL instruments performed at each patient visit.","University Health Network, Toronto|Bladder Cancer Canada|Canadian Urological Association Scholarship Fund|Canadian Urological Oncology Group","All","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-5305.0","November 16, 2017","July 2018","July 2023","August 30, 2017","null","March 2, 2018","University Health Network, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03266900"
489,"NCT03264430","Adding Ketamine to Low Dose Bupivacaine in Saddle Block for Perianal Surgery",,"Active, not recruiting","No Results Available","Perianal Fistula|Hemorrhoids","Drug: Ketamine|Drug: bupivacaine","- Duration of saddle block|Evaluation of the need of supplemental analgesia","Esam Eldin Mohamed Abdalla|Assiut University","All","18 Years to 55 Years   (Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","17100219","January 1, 2017","October 31, 2018","December 31, 2018","August 29, 2017","null","January 17, 2018","","","https://ClinicalTrials.gov/show/NCT03264430"
490,"NCT03263780","High Resolution PET-MRI Before Prostate Cancer HIFU",,"Recruiting","No Results Available","Prostate Cancer","Drug: 18F-Fluciclovine","Number of biopsy-proven cancers that standard imaging (mpMRI) would have missed compared with high resolution diffusion-weighted imaging (DWI) PET-hrMRI on mapping MRI.|Negative biopsy rate|Rate of high grade cancer","Timothy J. Daskivich|Blue Earth Diagnostics|Cedars-Sinai Medical Center","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","IIT2016-19-DASKIVICH-18F","December 7, 2017","December 2020","December 2020","August 28, 2017","null","August 22, 2018","Cedars-Sinai Medical Center, Los Angeles, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT03263780/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03263780"
491,"NCT03263533","HDAC Inhibitor Augmentation to Clozapine",,"Recruiting","No Results Available","Schizophrenia","Drug: Vorinostat Oral Capsule Group 1|Drug: Vorinostat Oral Capsule Group 2","Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)|Change in clinical cognitive symptoms during adjunctive vorinostat therapy in schizophrenia patients treated with clozapine","Virginia Commonwealth University","All","18 Years to 60 Years   (Adult)","Early Phase 1","6","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HM20007977","December 1, 2018","December 31, 2018","July 31, 2019","August 28, 2017","null","October 26, 2018","Virginia Commonwealth University, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03263533"
492,"NCT03261570","Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS",,"Recruiting","No Results Available","Postural Orthostatic Tachycardia Syndrome (POTS)|POTS|Orthostatic Intolerance","Drug: Pyridostigmine|Drug: Digoxin|Drug: Placebo","Cardiovagal Baroreflex during orthostatic stress|Cognitive ability during orthostatic stress|Cardiac output measure by inert gas breathing technique|Arterial blood pressure, and mean arterial pressure defined by the time average blood pressure over the cardiac cycle|Heart rate|systemic vascular resistance defined by the ratio of mean arterial pressure to cardiac output","New York Medical College|National Institutes of Health (NIH)","Female","15 Years to 30 Years   (Child, Adult)","Early Phase 1","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","1R01HL134674-01A1","July 1, 2017","June 30, 2021","September 1, 2021","August 25, 2017","null","July 19, 2018","New York Medical College/Bradhurst building, Hawthorne, New York, United States","","https://ClinicalTrials.gov/show/NCT03261570"
493,"NCT03258281","Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus After Elective Percutaneous Coronary Intervention","ISS-DMII","Recruiting","No Results Available","Diabetes Mellitus, Type 2|Dyslipidemia Associated With Type II Diabetes Mellitus|Percutaneous Coronary Intervention","Drug: Evolocumab|Drug: Placebo","Absolute difference in ADP-stimulated P-selectin expression|Absolute differences in unstimulated and ADP-stimulated p-selectin and GPIIb/IIIa receptor expression and unstimulated CD36, and LOX-1|Absolute differences in lipid profile including LDL-C, oxLDL, fibrinogen|Prevalence of high on-clopidogrel platelet reactivity by the VerifyNow P2Y12 assa","Inova Health Care Services","All","Child, Adult, Older Adult","Early Phase 1","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","17-2639","May 1, 2018","July 1, 2019","December 1, 2019","August 23, 2017","null","August 22, 2018","Inova Fairfax Hospital, Falls Church, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03258281"
494,"NCT03255941","Clinical Study of Depo Provera Comparing Lay Health Workers and Clinically-trained Health Workers",,"Recruiting","No Results Available","Contraception","Drug: DMPA|Drug: Sayana Press","Proportion of lay providers versus proportion of clinic providers that appropriately screen women for contraceptive use|Proportion of lay providers versus proportion of clinic providers that demonstrate appropriate injection technique.|Proportion of clients providers who report satisfaction with the services received from the provider|Proportion of clients who report satisfaction with DMPA","FHI 360|Aga Khan University|Jhpiego|United States Agency for International Development (USAID)","Female","15 Years to 49 Years   (Child, Adult)","Early Phase 1","342","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","4798-CHS-ERC-17","March 19, 2018","October 2018","December 2018","August 21, 2017","null","June 14, 2018","Aga Khan University, Karachi, Sindh, Pakistan","","https://ClinicalTrials.gov/show/NCT03255941"
495,"NCT03255915","PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study)","PrEP-Pod-IVR","Recruiting","No Results Available","HIV Prevention","Drug: Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC)|Other: Placebo","Safety of Vaginal IVRs releasing TDF-FTC by reports of Adverse Events|Characterization of pharmacokinetics of TDF-FTC released by an IVR - plasma|Characterization of pharmacokinetics of TDF-FTC released by an IVR - vagina|Characterization of pharmacokinetics of TDF-FTC released by an IVR - rectum|Acceptability of IVR assessed via computer assisted self interviews|Acceptability of IVR assessed via in depth interviews|Adherence|Acceptability of IVR assessed via in depth interviews - male partners","Oak Crest Institute of Science|The Miriam Hospital|Johns Hopkins University|University of California, Los Angeles|University of California, San Diego|Vanderbilt University|The University of Texas Medical Branch, Galveston|National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID)","Female","18 Years to 45 Years   (Adult)","Early Phase 1","10","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","17-0131|1U19AI113048-01","October 9, 2018","September 2019","December 2019","August 21, 2017","null","October 8, 2018","University of Texas Medical Branch, Galveston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03255915"
496,"NCT03255031","Ketogenic Diet (KD) in Alcoholism",,"Recruiting","No Results Available","Alcoholism","Dietary Supplement: Ketogenic Diet (KD)|Dietary Supplement: Standard American (SA) Meals and Shakes","To assess ketogenic diet on withdrawal ratings (CIWA) and Benzodiazepine use during withdrawal in the first week of detoxification.|To assess ketogenic diet on brain function (during rest and activation assessed with fMRI), neurochemistry (assessed with MRS) and structure (assessed with MRI).|To assess ketogenic diet on NP performance.|To determine if ketogenic diet improves: 1. sleep. 2. mood. 3. alcohol craving.","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","100","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","170152|17-AA-0152","October 24, 2017","December 31, 2025","December 31, 2025","August 21, 2017","null","October 2, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03255031"
497,"NCT03254290","Color Stability of NeoMTA Pulpotomized Primary Teeth",,"Not yet recruiting","No Results Available","Dental Caries Extending to Pulp","Biological: NeoMTA|Biological: Formocresol","Color stability","Texas A & M University Baylor College Of Dentistry","All","30 Months to 9 Years   (Child)","Early Phase 1","15","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","TexasAMBaylor","October 1, 2017","June 30, 2018","June 30, 2018","August 18, 2017","null","August 18, 2017","","","https://ClinicalTrials.gov/show/NCT03254290"
498,"NCT03253276","Effect of Obeticholic Acid on Transport of Bile Acids in PBC Examined by 11C-cholyl-sarcosine PET/CT",,"Recruiting","No Results Available","Primary Biliary Cirrhosis","Drug: Obeticholic acid|Drug: Placebos","Effect of OCA on bile flow","University of Aarhus","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","OCAPBC","May 19, 2016","January 20, 2018","March 31, 2018","August 17, 2017","null","August 22, 2017","Susanne Keiding, Aarhus, Denmark","","https://ClinicalTrials.gov/show/NCT03253276"
499,"NCT03251872","PARP-1 Inhibition in Pulmonary Arterial Hypertension",,"Recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: Olaparib","Change in pulmonary vascular resistance (PVR) at week 16","Laval University","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PARP1","October 25, 2018","December 2019","December 2019","August 16, 2017","null","November 12, 2018","Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Québec, Canada","","https://ClinicalTrials.gov/show/NCT03251872"
500,"NCT03250520","Application of Palliative Treatment in Children With Brain Stem Glioma and Recurrent High-grade Tumors in the Central Nervous System With the Nanomaterial NPt-Ca",,"Active, not recruiting","No Results Available","Brain Tumor, Pediatric, Brainstem Glioma|Brain Tumor, Pediatric, Recurrent","Drug: Platinum acetylacetonate (1% wt) supported by sol-gel technology functionalized titania","Change in the quality of life using the PedsQL Cancer Module©|Change in tumor size","Hospital Infantil de Mexico Federico Gomez","All","5 Years to 14 Years   (Child)","Early Phase 1","8","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","HIM 2017-072","September 1, 2017","February 28, 2020","February 28, 2021","August 15, 2017","null","October 5, 2018","Hospital Infantil de Mexico Federico Gomez, DF, Mexico","","https://ClinicalTrials.gov/show/NCT03250520"
501,"NCT03249194","Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients",,"Recruiting","No Results Available","Kidney Transplant|Hepatitis C","Drug: Direct acting Anti-Viral Therapy using Epclusa or Zepatier","Sustained Virologic Response (SVR)|Graft and Patient Survival|Sustained Virologic Response (SVR) Follow Up 1|Sustained Virologic Response (SVR) Follow Up 2|Liver Disease","Virginia Commonwealth University","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM20010320","August 17, 2017","June 30, 2019","June 30, 2022","August 15, 2017","null","June 8, 2018","Virginia Commonwealth University, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03249194"
502,"NCT03248947","Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075","Pharm-OUD-Care","Recruiting","No Results Available","Opioid Use Disorder","Drug: buprenorphine/naloxone|Other: Pharmacist-administered buprenorphine/naloxone maintenance care","Recruitment rate|Treatment retention|Opioid and other substance use|Medication compliance|Treatment fidelity|Treatment satisfaction|Participant safety|Pharmacists' use of the Prescription Drug Monitoring Program (PDMP)|Pharmacists' use of electronic health records (EHRs)|Use of the EHR to compare treatment outcome measures","Duke University|National Institute on Drug Abuse (NIDA)|The EMMES Corporation","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","70","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00083544|UG1DA040317","March 28, 2018","March 2019","March 2019","August 15, 2017","null","April 6, 2018","Duke Outpatient Clinic, Durham, North Carolina, United States|Josefs Pharmacy, Durham, North Carolina, United States|Changes by Choice, Durham, North Carolina, United States|Clinic Pharmacy, Durham, North Carolina, United States|Carolina Performance, Raleigh, North Carolina, United States|Health Park Pharmacy, Raleigh, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03248947"
503,"NCT03248713","Glucocorticoid Antagonist Treatment for Tobacco Use Disorder",,"Recruiting","No Results Available","Nicotine Dependence","Drug: Mifepristone|Drug: Placebo","Minnesota Nicotine Withdrawal Symptom Checklist (M-NWSC)","Yale University","Male","18 Years to 55 Years   (Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Health Services Research","MS053","November 29, 2017","September 1, 2019","December 1, 2019","August 14, 2017","null","January 11, 2018","Veterans Affairs Hospital, West Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03248713"
504,"NCT03248466","PRG Combined With Autologous BMMSCs for Treatment of Diabetic Foot Ulcer",,"Recruiting","No Results Available","Diabetic Foot Ulcer","Biological: PRG combined with BMMSCs transplantation","Amputation rate|hospital stay|Wound healing time|Transcutaneous oxygen partial pressure","Third Military Medical University","All","20 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","endocrine department of TMMU","August 30, 2017","January 1, 2020","July 1, 2020","August 14, 2017","null","August 14, 2017","Southwest Hospital of the Third Military Medical University, Chongqing, Chongqing, China|Endocrine Department, the First Affiliated Hospital of the Third Military Medical University, Chongqing, Chongqing, China","","https://ClinicalTrials.gov/show/NCT03248466"
505,"NCT03246282","Feasibility of Polychromatic Light Emitting Diode System to Reduce Pain",,"Suspended","No Results Available","Pain","Device: UVL1000 Treatment Station|Drug: Normal Saline 0.9% Infusion Solution Bag|Device: Peripheral Catheterization","The use of polychromatic light therapy delivered through an intravascular catheter to assess the change in self-reported VAS pain score.","John W. Reeves, MD|White Clover Research Foundation|White Clover Wellness and Research Center","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","150","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","UVL_P001","February 8, 2017","December 31, 2018","December 31, 2018","August 11, 2017","null","November 14, 2017","White Clover Wellness and Research Center, Shreveport, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT03246282"
506,"NCT03245970","Impedance Cardiography to Decrease the Risk of Preeclampsia",,"Recruiting","No Results Available","Chronic Hypertension Complicating Pregnancy (Diagnosis)|Preeclampsia","Drug: Labetalol Hydrocholoride 200 mg orally every 12 hours|Drug: Nifedipine 60 mg orally daily|Drug: Atenolol 25 mg daily","Rates of preeclampsia in chronically hypertensive pregnant women","High Risk Obstetrical Consultants","Female","18 Years to 51 Years   (Adult)","Early Phase 1","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","4222","April 24, 2017","April 24, 2018","April 24, 2019","August 10, 2017","null","August 10, 2017","HIgh Risk Obstetrical Consultants, Knoxville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT03245970"
507,"NCT03245554","Clinical Research on Teratment of Gastrointestinal Cancer in the Preoperative by Propranolol",,"Not yet recruiting","No Results Available","Gastrointestinal Cancer","Drug: Propranolol","Tumor size will be measured.","Central South University","All","18 Years to 60 Years   (Adult)","Early Phase 1","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017 PROP/CSU/GC","May 1, 2018","September 1, 2020","September 1, 2020","August 10, 2017","null","April 9, 2018","Institute of Clinical Pharmacology, Changsha, Hunan, China","","https://ClinicalTrials.gov/show/NCT03245554"
508,"NCT03244176","Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study","AvR-CHOP","Recruiting","No Results Available","Lymphomas Non-Hodgkin's B-Cell","Drug: Avelumab","Immune-related toxicity|Response Rate|Failure Free Survival|Overall Survival|Overall Toxicity of Treatment","Austin Health|Merck KGaA","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","28","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MS100070-0068","July 21, 2017","February 2021","July 2025","August 9, 2017","null","August 10, 2017","Austin Health, Heidelberg, Victoria, Australia","","https://ClinicalTrials.gov/show/NCT03244176"
509,"NCT03243630","Effects of Flavors on Nicotine Reinforcement in Smokers",,"Recruiting","No Results Available","Nicotine Dependence","Drug: IV nicotine|Drug: Menthol flavor|Drug: green apple|Drug: green apple and menthol","The reinforcing drug effects will be measured with the drug effects questionnaire (DEQ).","Yale University","All","18 Years to 30 Years   (Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Health Services Research","2000021591","April 23, 2018","April 1, 2020","July 1, 2020","August 9, 2017","null","June 28, 2018","Veterans Affairs, West Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03243630"
510,"NCT03243032","Pre-Emptive Analgesia in Dental Implant Surgery",,"Withdrawn","No Results Available","Pain, Postoperative","Drug: Ibuprofen 600 mg|Drug: Local anesthetic Group 1|Drug: Placebo oral capsule|Drug: Local anesthetic Control","Post-operative pain as measured by numerical rating scale|Total pain medication consumption between test and control|Time duration to take first pain medication between test and control|Post-operative pain with anterior versus posterior site of surgery|Post-operative pain as it correlates with the duration of the surgical procedure|Pre-surgical anxiety correlated with post-surgical pain|Complications following surgery","Satheesh Elangovan|University of Iowa","All","18 Years to 64 Years   (Adult)","Early Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","201707814","October 6, 2017","November 6, 2017","November 6, 2017","August 8, 2017","null","October 12, 2018","Univerity of Iowa College of Dentsitry Dental Clinics, Iowa City, Iowa, United States","","https://ClinicalTrials.gov/show/NCT03243032"
511,"NCT03242161","Development of LabPatch-alcohol as a Noninvasive Skin Patch to Detect Blood Alcohol Concentrations",,"Recruiting","No Results Available","Alcohol Intoxication","Diagnostic Test: LabPatch-alcohol","Interstitial and Blood Alcohol Concentrations","Mclean Hospital","All","21 Years to 50 Years   (Adult)","Early Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","2017P001502","January 1, 2018","October 1, 2019","October 1, 2020","August 8, 2017","null","March 29, 2018","McLean Hospital, Belmont, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03242161"
512,"NCT03241719","Novel Strategies to Improve Immunomodulation and Non-invasive Clinical Monitoring in VCA",,"Recruiting","No Results Available","Amputation, Traumatic|Amputation;Traumatic;Old|Face Injury|Face; Deformity|Abdominal Wall Defect","Drug: IL-2","Number of regulatory T cells|Number of episodes of rejection|T-cell alloreactivity measured by ELISPOT|Steroid dose|Mycophenolate dose","Brigham and Women's Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017P000590","October 17, 2017","August 31, 2019","December 31, 2019","August 7, 2017","null","July 19, 2018","Brigham and Women's Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03241719"
513,"NCT03240068","Angiotensin-(1-7) in Peripheral Arterial Disease",,"Active, not recruiting","No Results Available","Peripheral Arterial Disease","Drug: Angiotensin 1-7|Drug: Saline","Leg Blood Flow|Inflammatory Markers|Blood Pressure|Heart Rate","Milton S. Hershey Medical Center","All","21 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","6189","September 1, 2017","December 31, 2019","December 31, 2019","August 4, 2017","null","June 8, 2018","Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03240068"
514,"NCT03239561","Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants",,"Completed","No Results Available","Alzheimer Disease","Drug: [18F]MNI-1020","Standardized Uptake Value Ratio (SUVR) of [18F]MNI-1020|Plasma Concentration of 18F]MNI-1020 in AD Participants Compared With age Matched Healthy Participants|Number of Participants With Adverse Events|Distribution of tau (Using [18F]MNI-1020) Compared to Amyloid Beta (Using Florbetapir) in Participants With Probable AD","Janssen Research & Development, LLC","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CR108349|64326067EDI0001","September 6, 2017","April 30, 2018","April 30, 2018","August 4, 2017","null","September 12, 2018","Molecular NeuroImaging, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03239561"
515,"NCT03238365","Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck",,"Recruiting","No Results Available","Lip, Oral Cavity and Pharynx|Larynx","Biological: Nivolumab|Drug: Tadalafil|Procedure: Therapeutic Conventional Surgery","Change in immune cell polarization (Th1/Th2; M1/M2) in peripheral blood and tumor specimens using multiplex cytokine analysis|Prevalence of intratumoral immune cell populations","Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17P.210","August 10, 2017","December 16, 2019","December 16, 2020","August 3, 2017","null","March 27, 2018","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT03238365"
516,"NCT03237702","Decipher Lethal Prostate Cancer Biology - Urine Metabolomics",,"Recruiting","No Results Available","Significant Prostate Cancer|Urine Metabolomics|Cancer Screening","Dietary Supplement: Multi-Carotenoids","Change of urine metabolomics","National Taiwan University Hospital","Male","30 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","750","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","201705040MIPB","August 1, 2017","April 30, 2020","April 30, 2020","August 2, 2017","null","January 18, 2018","Department of Urology, National Taiwan University Hospital, Taipei, Taiwan","","https://ClinicalTrials.gov/show/NCT03237702"
517,"NCT03237689","Effects of Glucocorticoids on Cognition in HIV-infected Women","MsSCORE","Recruiting","No Results Available","Hiv","Drug: Hydrocortisone|Drug: Placebo Oral Tablet","Hopkins Verbal Learning Test-Revised assesses total learning|Hopkins Verbal Learning Test-Revised assesses verbal memory|Wechsler Adult Intelligence Scale IV Letter-Number Sequencing assesses working memory condition|Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Line Orientation Task assesses visuospatial abilities|Trail Making Test Part A assesses processing speed/attention|Trail Making Test Part B assesses mental flexibility|Comalli Stroop Test, Trial 1 assesses processing speed/attention|Comalli Stroop Test, Trial 2 assesses processing speed/attention|Comalli Stroop Test, Trial 3 assesses behavioral inhibition|Liver function as assessed by aspartate aminotransferase (AST) levels|Liver function as assessed by alanine transaminase (ALT) levels|Liver function as assessed by alkaline phosphatase levels|renal function assessed by creatinine levels|metabolic function assessed by glucose levels|metabolic function assessed by hemoglobin A1c (HbA1c)","Johns Hopkins University|National Institute of Mental Health (NIMH)","Female","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","148","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","IRB00145327|R01MH113512","November 20, 2017","May 31, 2022","August 31, 2022","August 2, 2017","null","August 16, 2018","Johns Hopkins University School of Medicine, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03237689"
518,"NCT03237533","Treatment Modalities of Oral Lichen Planus","OLP","Recruiting","No Results Available","Oral Lichen Planus","Drug: Dexamethasone","healing of lesions","University of Faisalabad","All","Child, Adult, Older Adult","Early Phase 1","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","123456789","June 1, 2017","December 1, 2017","December 31, 2017","August 2, 2017","null","August 2, 2017","The university of Faisalabad, Faisalābād, Punjab, Pakistan","","https://ClinicalTrials.gov/show/NCT03237533"
519,"NCT03237364","Iraq- Afghanistan War Lung Injury Using 19F MRI (DIAL1001006)",,"Recruiting","No Results Available","Constrictive Bronchiolitis|Iraq-Afganistan War Lung Injury Syndrome","Diagnostic Test: Perfluorinated Gas/Oxygen Mixture","Lung Ventilatory Heterogeneity defined by parametric imaging with 19F perfluorinated gas/oxygen mixtures","Hal C Charles|Duke University","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Pro00076112","August 19, 2017","March 30, 2019","April 15, 2019","August 2, 2017","null","November 7, 2018","Duke Image Analysis Laboratory, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03237364"
520,"NCT03237117","Effect of Growth Hormone on Uterine Receptivity in Women With RIF in an Oocyte Donation Program",,"Recruiting","No Results Available","Female Infertility","Biological: Growth Hormone (GH)","Pregnancy rate|live birth rate|live delivery rate|ongoing pregnancy rate|implantation rate|ongoing implantation rate|miscarriage rate","Competence Centre on Health Technologies|Universidad de Granada","Female","18 Years to 51 Years   (Adult)","Early Phase 1","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","MarGen","January 1, 2010","December 31, 2017","December 31, 2017","August 2, 2017","null","August 2, 2017","University of Granada, Granada, Spain","","https://ClinicalTrials.gov/show/NCT03237117"
521,"NCT03236467","Neurohormonal Benefits of Exercise in Fibromyalgia and PTSD","EXFMPTSD","Recruiting","No Results Available","FM and PTSD","Behavioral: Progressive Exercise Training","Fibromyalgia Impact Questionnaire-Revised|Clinician Administered PTSD Scale -5","VA Office of Research and Development|VA Boston Healthcare System","All","18 Years to 60 Years   (Adult)","Early Phase 1","36","U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D2395-P|1I21RX002395-01A1","January 1, 2018","December 31, 2020","December 31, 2020","August 2, 2017","null","November 8, 2018","VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03236467"
522,"NCT03235869","Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma",,"Withdrawn","No Results Available","Cutaneous T Cell Lymphoma","Drug: Durvalumab|Radiation: Radiation Therapy","The percentage of patients that respond to treatment|The percentage of patients that completely respond to treatment|Time to response|Duration of overall response|Progression free survival time|Time to next treatment","University of Michigan Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMCC 2017.079|HUM00131550","March 1, 2018","March 1, 2023","March 1, 2023","August 1, 2017","null","March 15, 2018","University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03235869"
523,"NCT03232632","Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.","AMYLCAR","Recruiting","No Results Available","Cardiac Amyloidosis","Drug: PET with 18 F-Flutemetamol","ratio C/M|SUV measures","University Hospital, Toulouse","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","13 199 02","March 15, 2017","December 2017","January 2018","July 28, 2017","null","July 28, 2017","University Hospital Toulouse, Toulouse, France","","https://ClinicalTrials.gov/show/NCT03232632"
524,"NCT03232164","PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer",,"Recruiting","No Results Available","Prostate Cancer|Prostate Neoplasm","Drug: 18F-DCFPyL PET","18F-DCFPyL PSMA-based PET and multi-parametric MRI with DWI for sub-study #1: Primary Prostate Cancer|Evaluate 18F-DCFPyL PSMA-based PET for localization for sub-study #2: Biochemical Recurrence|Compare detectability of 18F-DCFPyL for sub-study #3: Metastatic Androgen-Resistant Prostate Cancer|Sub-study #1: Detection of local-nodal and distant metastatic disease (PET|Sub-study #1: Correlation of 18F-DCFPyL PET and MRI|Sub-study #1: Specificity of 18F-DCFPyL|Sub-study #1: Low-dose CT versus MRI derived PET SUV|Sub-study #2: Detection of local-nodal and distant metastatic disease (pelvic)|Sub-study #2: Dedicated pelvic 18F-DCFPyL PET/MRI with dynamic PET acquisition and multi-parametric MRI|Sub-study #3: Contribution of whole body MRI DWI|Sub-study #3: Quantitative accuracy|Sub-study #3: Quantitative reproducibility","University of Wisconsin, Madison|National Cancer Institute (NCI)","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","36","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","UW16062|P30CA014520|2016-0883","February 2, 2017","July 31, 2019","July 31, 2020","July 27, 2017","null","July 9, 2018","University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT03232164"
525,"NCT03230981","Age-dependency of Cornea Biomechanics Using OCT Vibrography",,"Not yet recruiting","No Results Available","Cornea","Device: Optical imaging of the cornea in healthy subjects","Number of subjects to successfully complete OCT Vibrography without serious unanticipated adverse events related to application of the device.|Validation of OCT Vibrography data by means of Brillouin microscopy measurements of the in-vivo cornea","Massachusetts General Hospital|Massachusetts Eye and Ear Infirmary","All","18 Years to 79 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","2017P000867","September 1, 2017","September 1, 2019","September 1, 2019","July 27, 2017","null","July 27, 2017","","","https://ClinicalTrials.gov/show/NCT03230981"
526,"NCT03229512","Topical Sildenafil as Pre-Treatment for Hand-Foot Skin Reaction",,"Recruiting","No Results Available","Hand Foot Skin Reaction","Drug: Sildenafil","Evidence of hand-foot skin reaction|Adverse events due to 1% sildenafil cream","Northwestern University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","JNC052716","April 11, 2017","December 2018","December 2018","July 25, 2017","null","November 14, 2018","Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT03229512"
527,"NCT03228732","The Effects of Fluoxetine and/or DHEA",,"Recruiting","No Results Available","Type 1 Diabetes Mellitus","Drug: Placebo Oral Tablet|Drug: Fluoxetine|Drug: DHEA|Drug: Fluoxetine and DHEA","Change in the level of catecholamines in plasma","University of Maryland","All","18 Years to 50 Years   (Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","HP-00075896","December 19, 2017","December 10, 2020","December 10, 2020","July 25, 2017","null","January 11, 2018","University of Maryland, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03228732"
528,"NCT03228524","D-aspartate and Therapeutic Exercise","DAsp&TerapEx","Recruiting","No Results Available","Brain Injuries","Drug: D-Aspartate|Behavioral: Therapeutic exercise|Drug: Placebo Oral Tablet","quality of life|FIM|stroke|disability|parkinson|depression|neuronal plasticity|locomotion and posture|deglutition|Cognition","Neuromed IRCCS","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Neuromed","November 22, 2017","July 1, 2018","December 1, 2022","July 25, 2017","null","November 27, 2017","IRCCS Neuromed, Pozzilli, Isernia, Italy","","https://ClinicalTrials.gov/show/NCT03228524"
529,"NCT03228303","Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia",,"Not yet recruiting","No Results Available","Chronic Myeloid Leukemia","Drug: Nilotinib 150 MG [Tasigna]|Drug: Imatinib 400mg","Nilotinib vs imatinib in patients with newly diagnosed CML-CP: Overall survival rate in years|Nilotinib vs imatinib in patients with newly diagnosed CML-CP: Cholesterol level in mg|Nilotinib vs imatinib in patients with newly diagnosed CML-CP: Heart state by assessment by ECG|Nilotinib vs imatinib in patients with newly diagnosed CML-CP: Free survival rate in years","Assiut University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Jgmaxwell","December 1, 2017","July 30, 2020","August 1, 2020","July 24, 2017","null","October 10, 2017","","","https://ClinicalTrials.gov/show/NCT03228303"
530,"NCT03227978","PCL (Poly-ε-caprolactone) Mesh Pleurodesis",,"Not yet recruiting","No Results Available","PCL Pleurodesis","Combination Product: PCL mesh pleurodesis","blood pressure and temperature|pain scale","National Taiwan University Hospital","All","18 Years to 50 Years   (Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1060006968","August 1, 2017","July 31, 2018","July 31, 2019","July 24, 2017","null","July 24, 2017","","","https://ClinicalTrials.gov/show/NCT03227978"
531,"NCT03225092","Platelet-rich Plasma Injections for Persistent Medial Knee Pain After Total Knee Arthroplasty",,"Enrolling by invitation","No Results Available","Knee Pain Chronic|Pes Anserinus Bursitis|Status-Post Total Knee Arthroplasty","Biological: Ultrasound-guided platelet rich plasma injection","Knee Society Score|The Hospital for Special Surgery (HSS) Knee Score|Visual Analog Scale (VAS) for Pain","Ohio State University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017H0153","July 18, 2017","June 2019","September 2019","July 21, 2017","null","July 21, 2017","The Ohio State University Wexner Medical Center, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03225092"
532,"NCT03224871","A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.",,"Recruiting","No Results Available","METASTATIC NON-SMALL CELL LUNG CANCER","Drug: Intralesional IL-2|Drug: Nivolumab|Drug: Pembrolizumab|Radiation: Radiotherapy","Dose limiting toxicity (DLT)|Disease free survival","University of California, Davis","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1032095|UCDCC#269","August 11, 2017","July 30, 2020","July 30, 2020","July 21, 2017","null","March 19, 2018","UC Davis Medical Center, Sacramento, California, United States","","https://ClinicalTrials.gov/show/NCT03224871"
533,"NCT03224819","Study of AMG 673 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia",,"Recruiting","No Results Available","Acute Myeloid Leukemia","Drug: AMG 673","Subject incidence and grade of adverse events|Dose limiting toxicities (DLTs)|Pharmacokinetic parameter - half-life|Pharmacokinetic parameter - steady state|Pharmacokinetic parameter - Concentration|Pharmacokinetic parameter - Volume of distribution|Pharmacokinetic parameter - Clearance of AMG 673","Amgen","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20160377","September 7, 2017","March 22, 2020","March 22, 2020","July 21, 2017","null","November 8, 2018","Research Site, Birmingham, Alabama, United States|Research Site, Duarte, California, United States|Research Site, Houston, Texas, United States|Research Site, Melbourne, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, München, Germany","","https://ClinicalTrials.gov/show/NCT03224819"
534,"NCT03223987","Influence of a Food Supplement on the Gut Microbiome in Healthy Obese Women",,"Recruiting","No Results Available","Overweight","Dietary Supplement: Strath® Kräuterhefe Original (liquid)","Quantitative difference in microbiome composition.|BMI","Bio-Strath AG|Zentrum für Adipositas- und Stoffwechselmedizin Winterthur GmbH","Female","25 Years to 35 Years   (Adult)","Early Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Care Provider)|Primary Purpose: Basic Science","BS2016.1","May 11, 2017","October 15, 2018","March 15, 2019","July 21, 2017","null","July 18, 2018","Center for Obesity and Metabolism Adimed - Zentrum für Adipositas- und Stoffwechselmedizin Winterthur GmbH Lagerhausstrasse 9, Winterthur, Kanton Zurich, Switzerland","","https://ClinicalTrials.gov/show/NCT03223987"
535,"NCT03221998","The Effect of Timing of Intravenous Paracetamol Administration on Post-surgical Pain",,"Not yet recruiting","No Results Available","Obesity, Morbid","Drug: IV paracetamol|Drug: IV saline (NaCl 0.9 %)","measuring of Visual Analogue pain Scale,|measuring of Cytokine levels|Total consumption of opiates after surgery|Respiratory post-operative complication while in ward|septic post-operative complication while in ward|Cardiovascular post-operative complication while in ward|Gastrointestinal post-operative complication while in ward|urinary trak post-operative complication while in ward|post-operative pruritus while in ward|post-operative hospitalization|Respiratory post-operative complication while recovering in post anesthesia care unit|septic post-operative complication while recovering in post anesthesia care unit|Cardiovascular post-operative complication while recovering in post anesthesia care unit|Gastrointestinal post-operative complication while recovering in post anesthesia care unit|urinary retention post-operative complication while recovering in post anesthesia care unit|post-operative pruritus while recovering in post anesthesia care unit|post-operative stay in post anesthesia care unit","Soroka University Medical Center","All","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","sor17ybyrctil","July 2017","March 2019","March 2020","July 19, 2017","null","July 25, 2017","","","https://ClinicalTrials.gov/show/NCT03221998"
536,"NCT03221855","Use of Domperidone to Increase Milk Production in Mothers With Newborns in Neonatology",,"Completed","No Results Available","Breastfeeding","Drug: Domperidone|Drug: Placebo","Increase the production of breast milk of nursing mothers who are with their newborns admitted to the neonatal. Milk production measured by volume (ml) for 10 days.","Hospital de Clinicas de Porto Alegre","Female","18 Years to 40 Years   (Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13-0197","March 2013","December 2015","March 2016","July 19, 2017","null","July 19, 2017","Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil","","https://ClinicalTrials.gov/show/NCT03221855"
537,"NCT03219801","Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Systemic Lupus Erythematosus",,"Not yet recruiting","No Results Available","Systemic Lupus Erythematosus","Biological: mesenchymal stem cells","The change of Complement levels(C3 and C4) in peripheral blood|Erythrocyte sedimentation rate|C-reactive protein|adverse reaction","Hebei Medical University","All","14 Years to 60 Years   (Child, Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17277787D-SLE","August 1, 2017","December 30, 2018","December 30, 2019","July 18, 2017","null","July 18, 2017","the First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China","","https://ClinicalTrials.gov/show/NCT03219801"
538,"NCT03219047","The EXPLORE Trial: Study Evaluating Xenografts to Personalize Therapies (PDX) in Relapsed Mantle Cell Lymphoma to Optimize Response",,"Not yet recruiting","No Results Available","Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic|Mantle Cell Lymphoma","Drug: Investigator's Choice Drug Therapy|Procedure: Xenograft|Drug: Xenograft Developed Drug Therapy|Drug: Ibrutinib","Feasibility of Using Personalized Treatment Guided by a PDX-based Platform in Participants with Relapsed Lymphoma|Objective Response Rate (ORR) of Using Personalized Treatment Guided by a PDX-based Platform in Participants with Relapsed Lymphoma|Toxicity of Using Personalized Treatment Guided by a PDX-based Platform in Participants with Relapsed Lymphoma","M.D. Anderson Cancer Center|Cancer Prevention Research Institute of Texas","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-0051|2015-RP160019-Y1|NCI-2018-01117","January 2019","September 2020","September 2020","July 17, 2017","null","October 31, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03219047"
539,"NCT03217942","Spread of Muscle Hyperalgesia and Pain in a Low Dose NGF-induced Pain Model",,"Completed","No Results Available","Hyperalgesia|Healthy Subjects","Drug: NGF","Muscle sensitivity|Pressure-induced referred pain|Activity-induced muscle soreness|Pain intensity|Muscle soreness Diary|Activity-induced muscle soreness Diary","Aalborg University","All","18 Years to 55 Years   (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","N-2017-0007","July 1, 2017","October 1, 2017","October 1, 2017","July 14, 2017","null","January 11, 2018","Aalborg University, Aalborg, Denmark","","https://ClinicalTrials.gov/show/NCT03217942"
540,"NCT03216954","Influence of n-Acetylcysteine Maintenance on Alcohol Effects",,"Recruiting","No Results Available","Alcohol Use Disorder","Drug: Alcohol|Drug: Placebos|Drug: N-acetyl cysteine","Reinforcing Effects|Visual Analog Scales of Alcohol Effects|Breath Alcohol Level|Systolic blood pressure|Diastolic blood pressure|Heart rate","William Stoops|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|University of Kentucky","All","21 Years to 55 Years   (Adult)","Early Phase 1","25","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Basic Science","BED IN 34|R21AA026129","September 15, 2017","September 14, 2019","December 14, 2019","July 13, 2017","null","June 25, 2018","University of Kentucky, Lexington, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT03216954"
541,"NCT03215940","Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)",,"Recruiting","No Results Available","Chronic Pain, Widespread","Drug: Delta-9-Tetrahydrocannabinol|Drug: Cannabidiol|Drug: Placebos","Brain Changes|Improvement in pain relief","University of Utah","All","18 Years to 50 Years   (Adult)","Early Phase 1","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB_00103451","February 1, 2018","December 2018","February 2019","July 12, 2017","null","August 27, 2018","University Of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT03215940"
542,"NCT03215095","RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers",,"Recruiting","No Results Available","Thyroid Cancer","Drug: Durvalumab (Medi4736)|Radiation: Radioiodine (RAI)","number of patients with Dose-Limiting Toxicity (DLTs)|Best Overall Response","Memorial Sloan Kettering Cancer Center|AstraZeneca|MedImmune LLC","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","11","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-218","July 10, 2017","July 2019","July 2019","July 12, 2017","null","October 23, 2018","Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States","","https://ClinicalTrials.gov/show/NCT03215095"
543,"NCT03214939","Autologous Antigen-activated Dendritic Cells in the Treatment of Patients With Colorectal Cancer",,"Recruiting","No Results Available","Colorectal Cancer","Biological: Immunotherapy based on dendritic cells","Сytotoxicity|Parameters of peripheral blood|Immune status indicators|The content of immunosuppressive populations|Interrogation of the patient using a visual analogue scale|Relapse-free period","Research Institute of Fundamental and Clinical Immunology","All","30 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Colorectal cancer lysate DC","September 27, 2016","September 2019","September 2019","July 12, 2017","null","July 12, 2017","RIFCI, Novosibirsk, Russian Federation","","https://ClinicalTrials.gov/show/NCT03214939"
544,"NCT03211130","Using SystemCHANGE™ to Enhance Medication Adherence in Older Adult Stroke Survivors",,"Not yet recruiting","No Results Available","Stroke, Ischemic","Behavioral: SystemCHANGE™|Behavioral: Attention-Control","Acceptability and feasibility|Social Support|Perceived Health|Personal Systems Behaviors|Medication Adherence","University of Missouri, Kansas City|Saint Luke's Health System","All","65 Years and older   (Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Dissertation","October 2017","January 2018","March 2018","July 7, 2017","null","July 13, 2017","","","https://ClinicalTrials.gov/show/NCT03211130"
545,"NCT03211013","Study of the Effects of Oxytocin on Attentional Bias and Startle in PTSD",,"Recruiting","No Results Available","Posttraumatic Stress Disorder","Drug: Oxytocin|Drug: Placebos","Change in attentional bias|Change in startle response -heart rate","Palo Alto Veterans Institute for Research","Male","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","WOS0022ADM","July 10, 2017","February 28, 2019","July 31, 2019","July 7, 2017","null","April 18, 2018","VA Palo Alto Health Care System, Menlo Park, California, United States","","https://ClinicalTrials.gov/show/NCT03211013"
546,"NCT03209115","Influence of Calcium Hydroxide Chlorhexidine Combination vs. Calcium Hydroxide as an Intra Canal Medicaments in Retreatment Cases","med","Not yet recruiting","No Results Available","Postoperative Flare up","Drug: combination of calcium hydroxide and chlorhexidine|Drug: Calcium Hydroxide","Postoperative flare up (pain and swelling ) will be measured as below after 7 days from first visit postoperative pain","Cairo University","All","20 Years to 50 Years   (Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Hind","July 8, 2017","September 8, 2017","July 8, 2018","July 6, 2017","null","July 6, 2017","","","https://ClinicalTrials.gov/show/NCT03209115"
547,"NCT03208712","Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy",,"Terminated","No Results Available","Urothelial Carcinoma","Drug: Atezolizumab|Drug: Radium-223","Percent of Patients that respond to Treatment|Median Overall Survival Time|Median Progression Free Survival Time|Number of Patients with Complete Response|Change in QOL Score From Baseline","University of Michigan Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMCC 2017.023|HUM00126822","November 1, 2017","August 2, 2018","August 2, 2018","July 5, 2017","null","October 24, 2018","University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03208712"
548,"NCT03206112","Loss of Depotentiation in Focal Dystonia",,"Recruiting","No Results Available","Focal Dystonia|Healthy Volunteers","Other: PAS25-cTBS150","MEP amplitude immediately after the PAS25-cTBS150 (depotentiation) protocol|MEP amplitudes","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","170123|17-N-0123","September 20, 2017","December 31, 2019","December 31, 2019","July 2, 2017","null","June 27, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03206112"
549,"NCT03205670","Tissue-engineered Construct Based on Buccal Mucosa Cells and Matrix From Collagen and Polylactoglycolide Fibers",,"Enrolling by invitation","No Results Available","Urethral Stricture","Procedure: Urethroplasty with a tissue-engineered construct","Serious adverse events|Serious adverse reactions|Retrograde urethrography|Voiding cystourethrography|Pericatheter urethrography|Biopsy|Urodynamic changes via uroflowmetry - 1|Urodynamic changes via uroflowmetry - 2|Urodynamic changes via uroflowmetry - 3|Urodynamic changes via uroflowmetry - 4|Quality of life monitoring - 1|Quality of life monitoring - 2","I.M. Sechenov First Moscow State Medical University","Male","18 Years to 78 Years   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SU-IRM-2017-0001","June 1, 2017","June 1, 2022","June 1, 2022","July 2, 2017","null","August 8, 2018","Sechenov University, Moscow, Russian Federation","","https://ClinicalTrials.gov/show/NCT03205670"
550,"NCT03205605","Effect of Heat on Oxybutynin Release and Absorption From Oxybutynin Products",,"Recruiting","No Results Available","Heat Effect","Drug: oxybutynin","PK parameter","University of Maryland|Food and Drug Administration (FDA)","All","18 Years to 45 Years   (Adult)","Early Phase 1","12","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","HP-00070850","January 2, 2018","January 31, 2019","February 28, 2019","July 2, 2017","null","October 24, 2018","General Clinical Research Center (GCRC) at the University of Maryland Medical Center, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03205605"
551,"NCT03205553","Direct Peritoneal Resuscitation in Gastroschisis",,"Recruiting","No Results Available","Gastroschisis","Other: Standard of Care Treatment Group|Drug: Investigational Treatment Group","Reduction in inflammatory markers","University of Arkansas","All","up to 6 Months   (Child)","Early Phase 1","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","206573","February 1, 2018","December 2019","December 2019","July 2, 2017","null","August 1, 2018","Arkansas Childrens Hospital, Little Rock, Arkansas, United States","","https://ClinicalTrials.gov/show/NCT03205553"
552,"NCT03204305","Brain Imaging of Cannabinoid Receptors",,"Recruiting","No Results Available","Cannabis Use Disorder|Cannabis Dependence, Continuous","Drug: 11C-OMAR|Drug: Cannabis","Non-displaceable binding potential (BPND)|Peak Marijuana Withdrawal Discomfort Score","Johns Hopkins University|National Institute on Drug Abuse (NIDA)","Female","18 Years to 45 Years   (Adult)","Early Phase 1","20","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","IRB00101744|R21DA043963","September 14, 2017","May 31, 2019","May 31, 2020","July 2, 2017","null","February 12, 2018","Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03204305"
553,"NCT03204266","Oral Supplementation to Enhance Recovery Pilot Study",,"Recruiting","No Results Available","Malignant Neoplasms of Urinary Tract","Drug: Arginine recovery supplement|Dietary Supplement: Omega-3 Fatty Acids","Determination if novel immunonutrition regimen is able to be implemented with adequate compliance in Radical Cystectomy (RC) patients: Participant Compliance|Determination if Poor Recovery is Associated With the Use Immunonutrition Before and After Radical Cystectomy (RC): Length of Hospital Stay>7 Days|Determination if Poor Recovery is Associated With the Use Immunonutrition Before and After Radical Cystectomy (RC): Postoperative Infections|Determination if Poor Recovery is Associated With the Use Immunonutrition Before and After Radical Cystectomy (RC): Hospital Readmissions|Determination if Poor Recovery is Associated With the Use Immunonutrition Before and After Radical Cystectomy (RC): Deaths within 90 days of Cystectomy|Decrease in Inflammatory Response of Serum Interleukin-6 Levels After Radical Cystectomy (RC) postoperative day 1","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","46","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2017-0117","August 16, 2017","August 2019","August 2019","June 29, 2017","null","January 17, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03204266"
554,"NCT03202537","Effectiveness of Physiologic Testing in PPI Non-Responders",,"Enrolling by invitation","No Results Available","Gastro Esophageal Reflux","Drug: dexlansoprazole","number of patients able to successfully withdraw from PPI treatment","Northwestern University|Washington University School of Medicine|Vanderbilt University","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","240","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","STU00204123","July 1, 2017","October 1, 2021","March 31, 2022","June 28, 2017","null","August 21, 2018","Northwestern Memorial Health Care, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT03202537"
555,"NCT03202511","Assessment of a New ""Boosting"" Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers",,"Active, not recruiting","No Results Available","Pre-Exposure Prophylaxis","Drug: Probenecid Oral Tablet|Drug: Tenofovir disoproxil fumarate/Emtricitabine","Geometric mean ratio (GMR) of plasma exposure (AUC)|Geometric mean ratio (GMR) of peripheral blood mononuclear cell (PBMC) exposure (AUC)|Number of subjects demonstrating changes in urinary markers of proximal tubulopathy|Number of subjects demonstrating changes serum markers of proximal tubulopathy","Indiana University","Male","18 Years to 55 Years   (Adult)","Early Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","1705315090","June 23, 2017","July 2, 2018","July 2, 2018","June 28, 2017","null","March 16, 2018","Indiana University Clinical Research Center at University Hospital, Indianapolis, Indiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT03202511/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03202511"
556,"NCT03199612","Hemolysis With Continuous Flow Pumps",,"Not yet recruiting","No Results Available","Thrombosis|Hemolysis","Drug: Sildenafil|Drug: Placebo Oral Tablet","Change in platelet activation and aggregation (aggregometry)|Change in P-Selectin levels|Change in CD 40 ligand (L) levels|Change in Glycoprotein (GP) IIB/IIIA receptor levels|Change in Platelet cGMP levels","Montefiore Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2016-7404","December 1, 2018","June 30, 2022","August 30, 2022","June 27, 2017","null","March 23, 2018","","","https://ClinicalTrials.gov/show/NCT03199612"
557,"NCT03199482","Effect of Pretreatment Dexamethazone on Pain and Success of Nerve Block",,"Not yet recruiting","No Results Available","Postoperative Pain","Drug: Dexamethasone Oral Tablet|Drug: Placebo","Postoperative pain|success of inferior alveolar nerve block","Cairo University","All","20 Years to 50 Years   (Adult)","Early Phase 1","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","kinda","July 12, 2017","October 12, 2017","July 7, 2018","June 27, 2017","null","June 27, 2017","Faculty of Dentistry, Cairo, Manyal, Egypt","","https://ClinicalTrials.gov/show/NCT03199482"
558,"NCT03199274","Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer",,"Recruiting","No Results Available","Hepatocellular Carcinoma","Procedure: Yttrium-90 Microsphere Radioembolization|Drug: Perflutren Protein-Type A Microspheres|Procedure: Dynamic Contrast-Enhanced Ultrasound Imaging","Treatment response to yttrium Y-90 radioembolization measured using the modified Response Evaluation Criteria in Solid Tumors|Tumor perfusion measured by contrast-enhanced ultrasound between ultrasound-triggered microbubble destruction pulses","Sidney Kimmel Cancer Center at Thomas Jefferson University|National Cancer Institute (NCI)|Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","52","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17F.222","July 1, 2017","December 12, 2019","January 1, 2020","June 26, 2017","null","January 29, 2018","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03199274"
559,"NCT03197961","Pharmacokinetics and Pharmacodynamics of DMPA With HIV PrEP","DynamoPrEP","Completed","No Results Available","HIV/AIDS|Contraception","Combination Product: tenofovir/emtricitabine|Drug: DMPA","Tenofovir and emtricitabine levels in the female genital tract, blood, and rectum|Ex vivo HIV replication in cervical tissue and cervicovaginal fluid","Jessica Tarleton|University of Pittsburgh","Female","18 Years to 45 Years   (Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other","PRO17010089","November 17, 2017","April 18, 2018","April 18, 2018","June 23, 2017","null","May 3, 2018","Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03197961"
560,"NCT03197389","Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early ER/PR Negative Breast Cancer.",,"Recruiting","No Results Available","Breast Cancer|Triple Negative Breast Cancer|Hormone Receptor Negative Neoplasm","Drug: Pembrolizumab","PD-1 expression|Increase in the amount of TILs|PD-L1 expression","Universitaire Ziekenhuizen Leuven","All","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","34","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","MK 3475-318","January 18, 2018","December 2018","December 2018","June 23, 2017","null","October 11, 2018","University Hospitals Leuven, Leuven, Belgium","","https://ClinicalTrials.gov/show/NCT03197389"
561,"NCT03197012","Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor",,"Recruiting","No Results Available","Neuroendocrine Tumor","Drug: 90Y-DOTA-TOC|Drug: 68Ga-DOTA-TOC","Overall Response Rate (ORR)|Incidence of Treatment-Related Adverse Events [Safety]|Change in SUVmax between pre-treatment IV 68Ga-DOTA-TOC PET and treatment IA 68Ga-DOTA-TOC.|Correlation between uptake on IA 68Ga-DOTA-TOC PET/CT compared to 24-hour post-treatment IA 90Y-DOTA-TOC PET/MRI.","Thomas Hope|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC# 17455","July 1, 2017","July 1, 2020","July 1, 2021","June 23, 2017","null","August 1, 2017","UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT03197012"
562,"NCT03195205","Identification to Elimination in HCV-Infected Individuals",,"Recruiting","No Results Available","Hepatitis C","Diagnostic Test: OraQuick HCV Rapid Antibody Test","Positivity rates|Linked to care|Treatment","TruCare Internal Medicine & Infectious Disease|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","3000","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","GSI-2016-09-APR","June 1, 2017","December 2019","June 2020","June 22, 2017","null","April 27, 2018","TruCare Internal Medicine & Infectious Diseases, DuBois, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03195205"
563,"NCT03193463","Intratumorally-Administered Topotecan Using CED in High Grade Glioma Undergoing Stereotactic Biopsy",,"Recruiting","No Results Available","Glioma","Drug: Topotecan (<=8cc)|Drug: Topotecan (>8cc)|Device: Cleveland Multiport Catheter|Diagnostic Test: Magnetic Resonance Imaging (MRI)|Drug: Lower Does Topotecan","Number of intra-operative catheter related complications|Number of post-operative catheter related complications|Number of catheter related complications after catheter removal|Change in the spatial distribution of intratumorally-administered topotecan at serial timepoints using a gadolinium-based contrast agent, as determined by MRI scan|Changes in the spatial distribution of intratumorally-administered topotecan associated with changes in the infusion rate, as determined by MRI scan|Changes in the spatial distribution of intratumorally-administered topotecan at serial timepoints using volumetric magnetic resonance imaging, as determined by MRI scan|Changes in the spatial distribution of intratumorally-administered topotecan at serial timepoints using three-dimensional image reconstruction, as determined by MRI scan|Changes in the spatial distribution of intratumorally-administered topotecan associated with changes in the infusion concentration, as determined by MRI scan|Changes in the spatial distribution of intratumorally-administered topotecan associated with changes in the infusion duration, as determined by MRI scan|Number of Participants with response as measured by the Response Assessment in Neuro-Oncology (RANO) Criteria|Safety as measured by the common terminology criteria for adverse events (CTCAE)","Michael Vogelbaum, MD, PhD|Infuseon Therapeutics, Inc.|Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INFT1317","November 3, 2017","December 2019","December 2020","June 20, 2017","null","January 25, 2018","Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03193463"
564,"NCT03191084","Examine the Feasibility of a Standardized Field Test for Marijuana Impairment: Laboratory Evaluations",,"Recruiting","No Results Available","Marijuana Impairment","Drug: Low Dose THC Marijuana|Drug: High Dose THC Marijuana|Drug: Placebo Marijuana","Marijuana induced performance changes on Cogstate 1-back/2-back task.|Marijuana induced performance changes on Cogstate Card Learning.|Marijuana induced performance changes on Cogstate Groton Maze Learning task.|Marijuana induced performance changes on Cogstate Social/Emotional Cognition task.|Marijuana induced performance changes on Alertmeter.|Marijuana induced performance changes on the Time Estimation Task.|Marijuana induced performance changes on the Stop Signal Reaction Time task.|Marijuana induced performance changes on the Critical Tracking Task.|Marijuana induced performance changes on the ANAM Pursuit Tracking Task.|Marijuana induced performance changes on the Finger to Nose Task.|Marijuana induced performance changes on the One Leg Stand Task.|Marijuana induced performance changes on the Line Walking/Months Backwards Task.|Marijuana induced performance changes on the Time Reproduction Task.|Change in concentration of THC/metabolites in blood samples.|Change in concentration of THC/metabolites in oral fluid tested using Draeger Drug Detection Kits.|Change in concentration of THC/metabolites in oral fluid tested using Quantisal Oral Fluid Collection devices.|Change in performance on simulated driving Road Tracking Task.|Change in performance on simulated driving Car Following Task.|Change in performance on simulated driving Gap Acceptance Task.","Yale University|National Highway Traffic Safety Administration|Hartford Hospital|Montana State University|Maastricht University|The Mind Research Network|National Institute on Drug Abuse (NIDA)","All","20 Years to 40 Years   (Adult)","Early Phase 1","28","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","HHC-2016-0261","December 1, 2017","June 2018","June 2018","June 19, 2017","null","February 5, 2018","Olin Neuropsychiatry Research Center, Hartford, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03191084"
565,"NCT03190954","Brain Dopaminergic Signaling in Opioid Use Disorders",,"Recruiting","No Results Available","Normal Physiology|Opioid-Related Disorders","Other: Placebo|Drug: Methylphenidate","To assess whether the balance between D1R and D2R in striatum is disrupted in participants with an opioid use disorder (OUD) who are being treated with an opioid medication (MAT+) and does who are not (MAT-).|To assess the impact of disruptions on striatal D1R to D2R availability on: DA release; Function of brain reward and control networks; Behavior.|To assess if DA increases as achieved with oral MP influence the brain functional measures.","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","240","NIH","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","170114|17-AA-0114","August 17, 2017","December 31, 2024","December 31, 2024","June 19, 2017","null","October 24, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03190954"
566,"NCT03190681","Motivation and Methylphenidate","MBB_MPH","Not yet recruiting","No Results Available","Motivation|Apathy|Impulsive Behavior","Drug: Ritalin 10Mg Tablet","coefficient of sensitivity to reward|coefficient of sensitivity to effort|coefficient of sensitivity to punishment|coefficient of sensitivity to delay","Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years to 50 Years   (Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Basic Science","C13-08","July 1, 2017","September 30, 2017","September 30, 2018","June 19, 2017","null","June 19, 2017","Centre d'investigation clinique, Institut du Cerveau et de la Moelle, Paris, France","","https://ClinicalTrials.gov/show/NCT03190681"
567,"NCT03189706","Pilot Study of Chemoimmunotherapy for High-Risk Neuroblastoma",,"Recruiting","No Results Available","Neuroblastoma (NB)","Drug: Irinotecan|Drug: temozolomide|Biological: Hu3F8|Drug: GM-CSF","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","Memorial Sloan Kettering Cancer Center|Y-Mabs, Inc","All","Child, Adult, Older Adult","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-251","June 12, 2017","June 2019","June 2019","June 16, 2017","null","September 6, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03189706"
568,"NCT03189485","Tau PET Imaging in the NACC Study Cohort","TPI","Enrolling by invitation","No Results Available","Normal Controls","Drug: the radiotracer 18F-AV-1451","Examine uptake of 18F-AV-1451 in the medial temporal lobe (MTL) and its relationship with high-resolution structural and functional MRI measures of MTL subregions.|Determine relationship to clinical, cognitive, and other biomarker data","University of Pennsylvania|National Institutes of Health (NIH)|National Institute on Aging (NIA)","All","60 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","825944|R01AG055005","November 22, 2017","May 31, 2022","May 31, 2022","June 16, 2017","null","January 23, 2018","UPenn, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03189485"
569,"NCT03188276","The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAs",,"Completed","No Results Available","Chronic Hepatitis C","Drug: Ledipasvir-Sofosbuvir|Drug: Daclatasvir-Sofosbuvir","Changes of the frequency of CD14+CD11b+CD33+HLA-DR-/low MDSCs|Changes of the frequency of CD14+HLA-DR-/low M-MDSCs|Changes of the frequency of CD3+CD4+ T cells|Changes of the frequency of CD3+CD8+ T cells|Changes of the frequency of CD3CD56+ NK cells|Changes of the frequency of NKG2A in CD3CD56+ NK cells|Changes of the frequency of NKp30 in CD3CD56+ NK cells|Changes of the frequency of NKp46 in CD3CD56+ NK cells","Third Affiliated Hospital, Sun Yat-Sen University","All","18 Years to 76 Years   (Adult, Older Adult)","Early Phase 1","52","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Effect of DAAs on MDSCs and NK","February 1, 2016","May 1, 2017","May 1, 2017","June 15, 2017","null","June 15, 2017","","","https://ClinicalTrials.gov/show/NCT03188276"
570,"NCT03186547","Satisfaction Of Adult Patients With Gummy Smile Treated By Botulinum Toxin A Injection",,"Not yet recruiting","No Results Available","Gummy Smile Due to Hypermobile Upper Lip","Drug: Botulinum Toxin A Injection|Procedure: Modified Lip Repositioning Surgery","Patient satisfaction and postoperative side effects|Improvement of gingival display upon smiling|Lower face esthatics: a) upper lip length b) upper lip- vermillion length c) interlabial gap|Lower face esthatics: d)nasolabial angle|stability of gummy smile correction.","Cairo University","All","18 Years to 30 Years   (Adult)","Early Phase 1","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CEBD-CU-2017-06-02","June 2017","June 2018","June 2018","June 14, 2017","null","June 20, 2017","","","https://ClinicalTrials.gov/show/NCT03186547"
571,"NCT03185169","GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors","GSM","Terminated","No Results Available","Genitourinary Abnormality|Breast Cancer Female|Vaginal Abnormality|Urinary Tract Infections|Dyspareunia|Dysuria","Combination Product: Replens and coconut oil","Improvement of GSM signs and/or symptoms|Sexual health of breast cancer survivors who are sexually active who are enrolled in this study","Alta Bates Summit Medical Center","Female","Child, Adult, Older Adult","Early Phase 1","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GSM","November 18, 2016","July 23, 2018","July 23, 2018","June 14, 2017","null","July 25, 2018","Alta Bates Summit Medical Center, Berkeley, California, United States","","https://ClinicalTrials.gov/show/NCT03185169"
572,"NCT03184155","Prevention of Coronary Microvascular Dysfunction Post-PCI by Intracoronary Nicardipine",,"Not yet recruiting","No Results Available","Coronary Artery Disease","Drug: Nicardipine|Drug: Sterile Saline","Change in Index of Microcirculatory Resistance (IMR)|Post-Procedure myocardial Infarction (PMI)|Major Adverse Cardiac Event","Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","17D.172","December 2018","July 2019","July 2020","June 12, 2017","null","September 19, 2018","Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03184155"
573,"NCT03183570","Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis Using PET/CT",,"Recruiting","No Results Available","Idiopathic Pulmonary Fibrosis","Drug: [18F]FP-R01-MG-F2","SUV max comparison : IPF versus Healthy Lung|Time Activity Measurements|Incidence of Study Completion (Safety and Tolerability)","Stanford University|Pliant Therapeutics","All","60 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB Protocol: 40450","November 8, 2017","May 15, 2019","May 15, 2020","June 12, 2017","null","March 6, 2018","Stanford University, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT03183570"
574,"NCT03182959","Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer",,"Recruiting","No Results Available","HNSCC|Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma|Tobacco-Related Carcinoma|Carcinoma in Situ|Dysplasia|Hyperplasia|Premalignant Lesion","Drug: Avmacol®","Determine whether Avmacol® results in acute and/or sustained induction of NRF2 target gene transcripts in the oral mucosa of patients who have been curatively treated for a tobacco-related HNSCC.|Determine whether NRF2 target protein expression is upregulated by Avmacol® in the oral mucosa.|Evaluate for a dose-response relationship between Avmacol® dose and quantitative change in candidate NRF2 pathway biomarkers in oral mucosa.|Evaluate oral mucosa for quantitative modulation of NRF2-independent biomarkers of sulforaphane (SF) chemopreventive efficacy, as defined in parallel preclinical models.|Evaluate biomarkers of Avmacol® activity in PBMCs gene expression|Evaluate biomarkers of Avmacol® activity in PBMCs flow cytometry|Evaluate biomarkers of Avmacol® activity in PBMCs functional assays of T cells and NK cells|Evaluate cytokine biomarkers of Avmacol® activity in serum, including IL8.|Measurement of serum albumin-bound SF using isotope dilution mass spectrometry.|Measure urinary metabolites of SF during administration of two doses of Avmacol®.|Description of safety profile in accordance with NCI CTCAE v.4.|Description of the proportion of patients with HNSCC primary tumors harboring genomic alteration of NRF2.|Description of the proportion of patients with HNSCC primary tumors harboring genomic alteration of NRF2 related genes.","University of Arizona|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","36","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1612032762|5P50CA097190","April 24, 2017","December 31, 2019","December 31, 2019","June 9, 2017","null","November 20, 2017","The University of Arizona Cancer Center, Tucson, Arizona, United States","","https://ClinicalTrials.gov/show/NCT03182959"
575,"NCT03179956","Impact of Ribociclib on Head and Neck Squamous Cell Cancer",,"Recruiting","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: Ribociclib","Treatment with a CDK4/6 inhibitor, Ribociclib, decreases pRB1 levels in patients with SCCHN of the oral cavity, oropharynx and larynx.|Change in pre-treatment to post-treatment levels of Ki67 in tissue samples from patients|Change in pre-treatment to post-treatment levels of ERK1/2 in tissue samples from patients|Change in pre-treatment to post-treatment levels of phosphorylated-ERK1/2 in tissue samples from patients|Change in pre-treatment to post-treatment levels of p16 in tissue samples from patients","Fox Chase Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","29","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HN-089","April 12, 2018","December 2019","March 2020","June 7, 2017","null","May 17, 2018","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03179956"
576,"NCT03179449","In Vivo Characterization of Macrophages in Pediatric Patients With Malignant Brain Tumors Using Ferumoxytol-enhanced MRI",,"Recruiting","No Results Available","Childhood Brain Neoplasm","Diagnostic Test: Diagnostic (ferumoxytol-enhanced MRI)|Procedure: Surgery|Drug: Ferumoxytol|Other: Tissue Analysis","Iron concentration measurements|Macrophages on histopathology","Michael Iv|National Cancer Institute (NCI)|Stanford University","All","2 Years and older   (Child, Adult, Older Adult)","Early Phase 1","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PEDSBRNCNS0008|NCI-2017-00959|P30CA124435|IRB-39245","July 1, 2017","July 1, 2019","July 1, 2019","June 7, 2017","null","September 7, 2018","Stanford University, School of Medicine, Palo Alto, California, United States","","https://ClinicalTrials.gov/show/NCT03179449"
577,"NCT03176550","Peripheral Stimulation Neural Response",,"Completed","No Results Available","Stroke","Device: Transcutaneous electrical nerve stimulation","Change in Action Research Arm Test (ARAT)|Change in Finger Fractionation|Change in Modified Ashworth Scale (MAS)|Resting State EEG","University of California, San Francisco|VA Office of Research and Development","All","Child, Adult, Older Adult","Early Phase 1","8","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-123462","August 1, 2014","April 30, 2015","April 30, 2015","June 5, 2017","null","June 5, 2017","","","https://ClinicalTrials.gov/show/NCT03176550"
578,"NCT03176043","Patient Controlled Fluid Administration",,"Recruiting","No Results Available","Dehydration (Physiology)|Thirst; Due to Deprivation of Water|Plasma Osmolality Increased|Hypovolemia","Procedure: IV Fluid Administration","Volume of Fluid Administered|Change in body mass|Change in urine specific gravity|Change in plasma osmolality","University College, London","Male","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","9339/001","August 1, 2016","August 2017","August 2017","June 5, 2017","null","June 5, 2017","Institute of Sport Exercise & Health, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT03176043"
579,"NCT03175380","Biological Samples Obtained by Leukapheresis Induced by Two BCG Vaccinations in BCG-naïve Healthy Adults in the US","(A-051)","Active, not recruiting","No Results Available","Tuberculosis","Biological: bacillus Calmette-Guérin","Biological samples","Aeras","All","18 Years to 55 Years   (Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","A-051","August 8, 2017","January 10, 2019","January 10, 2019","June 5, 2017","null","October 2, 2018","Saint Louis University, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03175380"
580,"NCT03174977","Pharmacokinetics Distribution of Raltegravir by PET/MR",,"Recruiting","No Results Available","HIV-1-infection","Drug: 18F-Raltegravir","Number of patients with microdose (<2.5 millicurie; mCi) 18F-Raltegravir-related adverse events as measured by clinical observation during single intravenous dose administration and PET/MR imaging|Whole-body distribution (coronal through pelvis) of radiolabeled 18F-Raltegravir as determined by PET-MR scanning and quantification of radiographic regions of interest (ROI) immediately following and up to 4 hours after drug administration.","University of California, San Francisco|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","15-17586","April 1, 2018","November 1, 2018","January 1, 2019","June 5, 2017","null","May 2, 2018","University of California, San Francisco, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT03174977"
581,"NCT03173430","Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma",,"Recruiting","No Results Available","Multiple Myeloma","Drug: Blinatumomab","Number of Adverse Events","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 56416","May 27, 2017","November 27, 2018","November 27, 2019","June 1, 2017","null","June 1, 2017","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03173430"
582,"NCT03168737","Test-Retest of (18)F-Fluoroazomycin Arabinoside ([18F]FAZA) PET-CT of Solid Tumors",,"Recruiting","No Results Available","Malignant Neoplasms of Independent (Primary) Multiple Sites","Drug: [18F]FAZA|Procedure: PET-CT Scan","Optimal Imaging Time After Injection of (18)F-Fluoroazomycin Arabinoside to Detect Hypoxia in Solid Tumors in Group A|Optimal Imaging Time After Injection of (18)F-Fluoroazomycin Arabinoside to Detect Hypoxia in Solid Tumors in Group B","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","2016-0847|NCI-2018-01196","September 22, 2017","September 2019","September 2019","May 30, 2017","null","October 5, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03168737"
583,"NCT03167216","Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction",,"Recruiting","No Results Available","Chronic Prostatitis With Chronic Pelvic Pain Syndrome","Drug: Cromolyn Sodium|Drug: Cetirizine Hydrochloride","Mast cell tryptase levels in expressed prostatic secretions|NIH-CPSI score|AUA-SI score","Northwestern University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Male","21 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","STU00202831|2R01DK083609-06A1","August 1, 2017","June 30, 2020","June 30, 2021","May 25, 2017","null","August 31, 2017","Northwestern Medical Faculty Foundation, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT03167216"
584,"NCT03167138","Micro-Fragmented Adipose Tissue (Lipogems®) Injection for Chronic Shoulder Pain in Persons With Spinal Cord Injury",,"Recruiting","No Results Available","Shoulder Pain|Shoulder Impingement Syndrome|Rotator Cuff Impingement Syndrome|Rotator Cuff Tendinitis|Rotator Cuff Syndrome of Shoulder and Allied Disorders|Spinal Cord Injuries","Biological: Autologous micro-fragmented adipose tissue|Device: Lipogems system","Numerical Rating Scale|Wheelchair User's Shoulder Pain Index (WUSPI)|Patient Global Impression of Change|Brief Pain Inventory interference items (BPI-I7)|Physical Examination of the Shoulder Score (PESS)","Kessler Foundation","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R-957-17","July 14, 2017","December 30, 2019","December 30, 2019","May 25, 2017","null","August 8, 2018","Kessler Institute for Rehabilitation, West Orange, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT03167138"
585,"NCT03165929","Oral Flurbiprofen Spray for Mucosal Graft Harvesting at the Palatal Area",,"Completed","No Results Available","Surgery, Oral","Drug: Flurbiprofen|Drug: placebo","complete epithelization|patients' discomfort|postoperative swelling|changes in patients' feeding habits|burning sensation","Gazi University","All","18 Years to 60 Years   (Adult)","Early Phase 1","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","36290600/66","May 2016","February 2017","March 2017","May 24, 2017","null","May 24, 2017","","","https://ClinicalTrials.gov/show/NCT03165929"
586,"NCT03165500","Comparative Evaluation of Three Anxiety Control Protocols in Third Molar Extraction",,"Completed","No Results Available","Anxiety Disease","Drug: Diazepam|Drug: Midazolam|Drug: Nitrous Oxide + Oxygen Gas|Procedure: Third molar extraction","Assessment of blood pressure change|Assessment of heart rate change|Assessment of oxygen saturation change","Universidade Estadual Paulista Júlio de Mesquita Filho","All","18 Years to 30 Years   (Adult)","Early Phase 1","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Universidade Estadual Paulista","December 23, 2015","December 20, 2016","May 4, 2017","May 24, 2017","null","May 24, 2017","","","https://ClinicalTrials.gov/show/NCT03165500"
587,"NCT03164486","First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide",,"Recruiting","No Results Available","Breast Carcinoma|Colorectal Carcinoma|Lung Carcinoma|Metastatic Malignant Neoplasm in the Breast|Metastatic Malignant Neoplasm in the Colon|Metastatic Malignant Neoplasm in the Lung|Metastatic Malignant Neoplasm in the Rectum|Pancreatic Carcinoma","Drug: 18F-αvβ6-BP","Assessment of safe administration of 18F-αvβ6-BP|Measurement of 18F-αvβ6-BP accumulation in tumors|Level of αvβ6-BP expression in tumors","University of California, Davis|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","27","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","970652|NCI-2017-00411|CCHO028|P30CA093373","November 2016","June 2019","June 2020","May 23, 2017","null","March 2, 2018","University of California Davis Comprehensive Cancer Center, Sacramento, California, United States","","https://ClinicalTrials.gov/show/NCT03164486"
588,"NCT03163368","Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors",,"Recruiting","No Results Available","Brain Metastases","Radiation: Neoadjuvant stereotactic radiosurgery|Procedure: Neurosurgical resection","Maximum tolerated dose (MTD)|Adverse events|Describe preliminary rates of image-complete resection|Describe preliminary rates of local tumor control|Describe preliminary rates of intracranial control|Describe preliminary rates of progression-free survival|Describe preliminary rates of leptomeningeal spread|Describe preliminary rates of rate of salvage treatment","Cedars-Sinai Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIT2016-18-Shiao-NeoAdSRS","May 9, 2017","January 1, 2019","June 1, 2019","May 23, 2017","null","May 25, 2018","Cedars-Sinai Medical Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT03163368"
589,"NCT03163212","Safety and Tolerability of Lactoferrin/FOS in Very Low Birth Weight Infants",,"Not yet recruiting","No Results Available","Safety Issues|Tolerance|Very Low Birth Weight Infant","Dietary Supplement: Lactoferrin/FOS","Definitely related study solution serious adverse event|Day after birth to reach 120ml/kg of enteral feeds|Number of days not receiving any feedings after lactoferrin/FOS administration","University of Virginia|The Gerber Foundation","All","up to 14 Days   (Child)","Early Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19804","June 2017","December 2017","June 2018","May 22, 2017","null","May 22, 2017","","","https://ClinicalTrials.gov/show/NCT03163212"
590,"NCT03162731","Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer",,"Recruiting","No Results Available","Larynx|Lip, Oral Cavity and Pharynx","Biological: Nivolumab|Biological: Ipilimumab|Radiation: Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy|Radiation: Volume Modulated Arc Therapy","Incidence of adverse events assessed using Common Terminology Criteria for Adverse Events version 4.03","Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17P.082","May 11, 2017","November 2021","January 2022","May 22, 2017","null","October 9, 2018","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03162731"
591,"NCT03160404","Zolpidem or Exercise for Insomnia?",,"Not yet recruiting","No Results Available","Chronic Insomnia","Drug: Zolpidem|Behavioral: Exercise","Change from baseline polysomographic sleep recording to first night and 6 weeks|Change from baseline actigraphy sleep recording to first night and 6 weeks|Change from baseline sleep diary recording to first night and 6 weeks|Change from baseline prior sleep anxiety to first night and 6 weeks|Change from baseline insomnia severity to 12 weeks|Change from baseline sleep quality to 6 weeks|Change from baseline mood to 6 weeks|Change from baseline quality of life to 6 weeks|Change from baseline serum serotonin to first night and 6 weeks|Change from baseline cortisol to first night and 6 weeks|Change from baseline Effort Exercise test to 6 weeks","Universidade Federal de Goias","All","30 Years to 60 Years   (Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1.986.600","October 20, 2018","July 2019","December 2020","May 19, 2017","null","August 14, 2018","Hospital Padre Thiago, jATAÍ, GO, Brazil","","https://ClinicalTrials.gov/show/NCT03160404"
592,"NCT03159936","Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)",,"Recruiting","No Results Available","Discoid Lupus Erythematosus|Systemic Lupus Erythematosus","Biological: Tofacitinib citrate","Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)","Tufts Medical Center|Pfizer","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DLE","April 3, 2017","April 2018","April 2019","May 19, 2017","null","May 19, 2017","Tufts Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03159936"
593,"NCT03158883","Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients",,"Recruiting","No Results Available","Metastatic Non-small Cell Lung Cancer (NSCLC)","Drug: Avelumab|Radiation: Stereotactic ablative radiotherapy (SAR)","Overall Response Rate|Overall Survival (OS)|Progression-Free Survival (PFS)|Disease Control Rate (DCR)|Duration of Stable Disease|Duration of Overall Response|Confirmation|Immune Related Response Criteria|Evaluation of Best Overall Response","University of California, Davis|EMD Serono","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","26","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1054028|UCDCC#270","May 17, 2017","June 1, 2020","June 1, 2021","May 18, 2017","null","March 27, 2018","UC Davis, Sacramento, California, United States","","https://ClinicalTrials.gov/show/NCT03158883"
594,"NCT03156673","Treatment of COPD by Autologous Transplantation of Bronchial Basal Cells",,"Recruiting","No Results Available","Chronic Obstructive Pulmonary Disease","Biological: bronchial basal cells","Forced expiratory volume in one second (FEV1)|Forced vital capacity (FVC)|Diffusion capacity of CO (DLCO)|The ratio of forced expiratory volume in the first one second to the forced vital capacity (FEV1/FVC)|Maximum mid-expiratory flow (MMF)|Maximum voluntary ventilation (MVV)|6-minute-walk test (6MWT)|Modified medical research council (MMRC) chronic dyspnea scale|St. George's respiratory questionnaire (SGRQ) scale","First Affiliated Hospital of Shantou University Medical College|Regend Therapeutics|Tongji University","All","40 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017112","April 1, 2017","December 31, 2021","June 30, 2022","May 17, 2017","null","May 17, 2017","the First Affiliated Hospital of Shantou University Medical College, Shantou, Guang Dong, China","","https://ClinicalTrials.gov/show/NCT03156673"
595,"NCT03155204","Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With A Reference Product",,"Completed","No Results Available","Healthy","Drug: tiotropium pMDI","Peak Plasma Concentration (Cmax)|Adverse events|Area Under the Plasma Concentration vs Time Curve (AUC)","3M","All","18 Years to 55 Years   (Adult)","Early Phase 1","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CSP-07-000039","April 25, 2017","January 21, 2018","March 19, 2018","May 16, 2017","null","July 4, 2018","3M Health Care, Loughborough, United Kingdom","","https://ClinicalTrials.gov/show/NCT03155204"
596,"NCT03154476","Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study","SiFALD","Recruiting","No Results Available","Cirrhosis|Congenital Heart Disease","Drug: Sildenafil|Drug: Placebo","Change in liver stiffness as measured by magnetic resonance elastography (MRE)","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","16-008985","July 5, 2017","June 2019","June 2019","May 16, 2017","null","September 11, 2017","Mayo Clinic in Rochester, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT03154476"
597,"NCT03154411","A Microdose Evaluation Study of ABY-029 in Primary Sarcoma",,"Recruiting","No Results Available","Primary Soft-tissue Sarcoma","Drug: ABY-029","Signal detection|Correlation of spatial patterns of EGFR expression|molecular uptake and ABY-029 concentration","Dartmouth-Hitchcock Medical Center|Dartmouth College","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D16143","August 30, 2017","December 1, 2018","December 31, 2018","May 16, 2017","null","March 30, 2018","Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States","","https://ClinicalTrials.gov/show/NCT03154411"
598,"NCT03153800","Autologous Bronchial Basal Cells Transplantation for Treatment of CRD Including COPD, BE and PF",,"Recruiting","No Results Available","Chronic Respiratory Disease","Biological: bronchial basal cells","Forced expiratory volume in one second (FEV1)|Diffusion capacity of CO (DLCO)|The ratio of forced expiratory volume in the first one second to the forced vital capacity (FEV1/FVC)|Maximum mid-expiratory flow (MMF)|Maximum voluntary ventilation (MVV)|Forced vital capacity (FVC)|6-minute-walk test (6MWT)|Modified medical research council (MMRC) chronic dyspnea scale|St. George's respiratory questionnaire (SGRQ) scale|Imaging of lung by high resolution computed tomography (HR-CT)","Regend Therapeutics|The First Affiliated Hospital of Soochow University","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","30","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017042","April 5, 2017","April 4, 2019","October 4, 2019","May 15, 2017","null","August 31, 2018","The First Affiliated Hopsital of Soochow University, Suzhou, Jiang Su, China","","https://ClinicalTrials.gov/show/NCT03153800"
599,"NCT03153670","MRI in Patients With Deep Brain Stimulation (DBS)",,"Recruiting","No Results Available","Neuro-Degenerative Disease","Other: functional magnetic resonance imaging","Brain areas engaged with deep brain stimulation","University Health Network, Toronto|Manish Ranjan, Functional Neurosurgery, University Health Network|Alexandre Boutet, Neurosurgery, University Health Network","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","14-8255","January 1, 2017","July 1, 2019","July 1, 2020","May 15, 2017","null","May 30, 2017","Toronto Western Hospital, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03153670"
600,"NCT03153410","Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas",,"Recruiting","No Results Available","Pancreatic Cancer","Drug: Cyclophosphamide|Drug: GVAX|Drug: Pembrolizumab|Drug: IMC-CS4","CD8 T cell density in the primary tumor after neoadjuvant administration of combination immunotherapy by immunohistochemistry (IHC)|Number of participants experiencing study drug-related toxicities|Overall survival (OS)|Disease free survival (DFS)|Objective response rate (ORR) by immune-related RECIST criteria (irRC)|Surgical resectability rate of borderline resectable pancreatic cancer (BRPC)|Pathologic response rate of patients with BRPC|Progression free survival (PFS)","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Merck Sharp & Dohme Corp.|Eli Lilly and Company","All","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J1766|IRB00130267","September 7, 2018","September 2020","September 2020","May 15, 2017","null","November 6, 2018","Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03153410"
601,"NCT03151772","Bioavailability of Disulfiram and Metformin in Glioblastomas","INSIDE","Recruiting","No Results Available","Glioblastoma","Drug: Disulfiram|Drug: Metformin","Bioavailabilty disulfiram|Bioavailabilty of metformin","Sahlgrenska University Hospital, Sweden","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","1144-16","January 29, 2018","February 2019","June 2019","May 12, 2017","null","February 16, 2018","Sahlgrenska University Hospital, Göteborg, Sweden","","https://ClinicalTrials.gov/show/NCT03151772"
602,"NCT03151174","Effects of Vitamin D Supplementation on Strength, Bone Density, and Injury Risk in Collegiate Athletes",,"Completed","No Results Available","Vitamin D Deficiency","Drug: Vitamin D 10000 UNT|Drug: Vitamin D 5000 UNT","Strength|Femur Bone Density|Spine Bone Density|Injury Occurence","Virginia Polytechnic Institute and State University","All","18 Years to 30 Years   (Adult)","Early Phase 1","68","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","17-009","April 29, 2017","May 15, 2018","June 1, 2018","May 12, 2017","null","June 29, 2018","Virginia Tech, Blacksburg, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03151174"
603,"NCT03147092","Matão Controlling Hypertension (MatCH Study): Rationale and Design","MatCH","Not yet recruiting","No Results Available","Hypertension|Blood Pressure","Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,|Drug: Atenolol|Drug: Losartan potassium 50mg|Drug: Clonidine","Number of hypertensive subjects with BP controlled during follow-up|Correlation of BP control with demographics|Correlation of BP control with risk factors|Correlation of BP end organ disease","Centro Neurológico de Pesquisa e Reabiitação, Brazil","All","40 Years and older   (Adult, Older Adult)","Early Phase 1","15000","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMinelli","February 1, 2018","June 30, 2020","June 30, 2021","May 10, 2017","null","November 21, 2017","","","https://ClinicalTrials.gov/show/NCT03147092"
604,"NCT03147053","Efficacy and Safety of Jiedu Tongluo Granules for Post-stroke Depression",,"Recruiting","No Results Available","Post-stroke Depression","Drug: Jiedu Tongluo granules|Drug: Placebo","Change of 17-item Hamilton Depression Scale( HAMD-17) From Baseline|Change of Barthel Index (BI) From Baseline|Change of National Institute of Health stroke scale（NIHSS）From Baseline|The stroke diagnosis and evaluation criteria of Traditional Chinese Medicine（TCM）from baseline","Xiyuan Hospital of China Academy of Chinese Medical Sciences","All","45 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","XiyuanH","April 27, 2017","December 2017","March 2018","May 10, 2017","null","May 10, 2017","Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China","","https://ClinicalTrials.gov/show/NCT03147053"
605,"NCT03146572","Primary Care and Parenting",,"Active, not recruiting","No Results Available","Parenting|Knowledge, Attitudes, Practice|Development, Child","Behavioral: Sit Down and Play|Other: Handout","Change in Parental Knowledge|Change in participation in cognitively stimulating activities|Change in parenting self-efficacy","University of Illinois at Chicago|Society of Developmental and Behavioral Pediatrics","All","6 Months to 12 Months   (Child)","Early Phase 1","61","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","SDBP","April 3, 2017","February 11, 2018","June 3, 2019","May 10, 2017","null","November 2, 2018","University of Illinois at Chicago, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT03146572"
606,"NCT03145259","Evaluation of Bioavailability of Diclofenac Dermal Products",,"Recruiting","No Results Available","Bioavailability","Drug: Diclofenac Epolamine Patch|Drug: diclofenac sodium solution","pharmacokinetic|tape stripping of skin","University of Maryland|Food and Drug Administration (FDA)","All","18 Years to 45 Years   (Adult)","Early Phase 1","12","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","HP-00067047","April 19, 2017","December 31, 2018","January 31, 2019","May 9, 2017","null","October 24, 2018","General Clinical Research Center (GCRC) at the University of Maryland Medical Center, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03145259"
607,"NCT03145207","PK and DPK of Lidocaine Dermal Products",,"Active, not recruiting","No Results Available","Heat Effect","Drug: Lidocaine patch","Measurement of maximum serum concentration (Cmax)","University of Maryland|Food and Drug Administration (FDA)","All","18 Years to 45 Years   (Adult)","Early Phase 1","12","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","HP-00067033","December 14, 2016","December 31, 2018","January 31, 2019","May 9, 2017","null","November 14, 2018","General Clinical Research Center (GCRC) at the University of, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03145207"
608,"NCT03144778","Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO)",,"Recruiting","No Results Available","Malignant Neoplasms of Oropharynx","Drug: Durvalumab|Drug: Tremelimumab|Behavioral: Questionnaire|Procedure: Surgery|Drug: Chemotherapy|Radiation: Radiation Therapy","Change of CD8+ Tumor Infiltrating Lymphocytes of Durvalumab Single Agent or Combined with Tremelimumab|Adverse Events of Durvalumab Single Agent or Combined with Tremelimumab|Objective Response Rate (ORR) of Durvalumab Single Agent or Combined with Tremelimumab","M.D. Anderson Cancer Center|AstraZeneca|Stiefel, a GSK Company","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","28","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-0805|NCI-2018-01199","July 12, 2017","July 2020","July 2020","May 9, 2017","null","November 5, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03144778"
609,"NCT03144115","Does Oxytocin Modulate Rewarding Effects in Women and Fluctuating Across the Menstrual Cycle",,"Completed","No Results Available","Healthy","Drug: Oxytocin|Drug: Placebos","Oxytocin effect on neural activity as assessed via fMRI towards reward between fertility and luteal phases","University of Electronic Science and Technology of China","Female","18 Years to 25 Years   (Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","UESTC-neuSCAN-22","October 2016","June 2018","July 2018","May 8, 2017","null","October 29, 2018","University of Electronic Science and Technology of Chia, Chengdu, Sichuan, China","","https://ClinicalTrials.gov/show/NCT03144115"
610,"NCT03143920","Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder","HBOTCICrUTI","Recruiting","No Results Available","Chronic Interstitial Cystitis|Painful Bladder Syndrome|Recurrent Urinary Tract Infection","Combination Product: Hyperbaric Oxygen Therapy-","HBOT acceptance|HBOT adherence|Pre and post treatment symptom survey for the chronic interstitial cystitis study group.|Post treatment incidence of recurrent urinary tract infection.|Pre and post treatment symptom survey fro the chronic interstitial cystitis study group. The patient's overall rating of improvement of symptoms (PORIS) will be used.|Time of occurrence of recurrent urinary tract infection.","University of California, San Diego","Female","35 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HBOTurology.2017","November 1, 2017","June 1, 2020","October 30, 2020","May 8, 2017","null","November 14, 2018","Hillcrest Hosptial, San Diego, California, United States","","https://ClinicalTrials.gov/show/NCT03143920"
611,"NCT03143270","A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer",,"Recruiting","No Results Available","Liver Cancer","Drug: Drug Eluting Bead Transarterial Chemoembolization|Drug: Nivolumab","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","14","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-087","April 28, 2017","April 2019","April 2019","May 8, 2017","null","September 11, 2018","Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Abramson Cancer Center at University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03143270"
612,"NCT03140397","Oral Bioavailability and Bioactivity of Prenylflavonoids From Hops",,"Completed","No Results Available","Safety After Oral Intake|Pharmacokinetics After Oral Intake|Immune Cells Activity","Dietary Supplement: Placebo|Dietary Supplement: 6-prenylnaringenin|Dietary Supplement: 8-prenylnaringenin","Mean area under the curve (AUC) of plasma concentration vs. time of total 6-prenylnaringenin [nmol/L*h]|Mean area under the curve (AUC) of plasma concentration vs. time of total 8-prenylnaringenin [nmol/L*h]|Mean maximum plasma concentration (Cmax) of total 6-prenylnaringenin [nmol/L]|Mean maximum plasma concentration (Cmax) of total 8-prenylnaringenin [nmol/L]|Time to reach maximum plasma concentration (Tmax) of total 6-prenylnaringenin [h]|Time to reach maximum plasma concentration (Tmax) of total 8-prenylnaringenin [h]|Cumulative urinary excretion of total 6-prenylnaringenin [nmol/g creatinine]|Cumulative urinary excretion of total 8-prenylnaringenin [nmol/g creatinine]|Cell count (dead cells/ml and living cells/ml) of PBMCs after 6-PN administration|Cell count (dead cells/ml and living cells/ml) of PBMCs after 8-PN administration|Cell viability of PBMCs after 6-PN administration|Cell viability of PBMCs after 8-PN administration|Serum aspartate transaminase activity [U/L]|Serum alanine transaminase activity [U/L]|Serum gamma-glutamyl transferase activity [U/L]|Serum alkaline phosphatase activity [U/L]|Serum bilirubin|Serum uric acid [mg/dL]|Serum creatinine [mg/dL]|Serum total cholesterol [mg/dL]|Serum HDL cholesterol [mg/dL]|Serum LDL cholesterol [mg/dL]|Serum triacylglycerols [mg/dL]|LDL/HDL cholesterol ratio|Serum cystatin C [mg/mL]|Glomerular filtration rate [mL/min]|Serum glucose [mg/dL]|Hemoglobin [g/dL]|Mean corpuscular hemoglobin concentration [g/dL]|Mean corpuscular hemoglobin [pg]|Mean corpuscular volume [fL]|Hematocrit [%]|Erythrocytes [/pL]|Thrombocytes [/nL]|Leucocytes [/nL]|Segmented granulocytes [%]|Lymphocytes [%]|Monocytes [%]|Basophil granulocytes [%]|Eosinophil granulocytes [%]","University of Hohenheim|Universität Tübingen","All","18 Years to 45 Years   (Adult)","Early Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","HS-PF1-2016","January 2016","April 2017","December 31, 2017","May 4, 2017","null","March 30, 2018","University of Hohenheim, Stuttgart, Baden-Württemberg, Germany|Eberhard Karls University Tuebingen, Tübingen, Baden-Württemberg, Germany","","https://ClinicalTrials.gov/show/NCT03140397"
613,"NCT03140293","Pain Perception During Chorionic Villus Sampling",,"Completed","No Results Available","Chorionic Villi Sampling","Drug: Lidocaine injection|Drug: Gebauer Ethyl Chloride Spray","Visual Analog Scale (VAS) Pain perception scores VAS ()|Verbal Rating Scale (VRS)","Angela Bianco|Icahn School of Medicine at Mount Sinai","Female","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 14-1425","September 2016","May 23, 2017","May 23, 2017","May 4, 2017","null","October 25, 2017","Icahn School of Medicine at Mount Sinai, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03140293"
614,"NCT03136263","Oxytocin and Cognitive Control in Adult ADHD",,"Recruiting","No Results Available","Attention Deficit/Hyperactivity Disorder","Drug: Oxytocin nasal spray|Drug: Placebo nasal spray","Stop-signal task|AX-CPT|Category switch task|Global/local task|Simon task","Massachusetts General Hospital","Male","18 Years to 55 Years   (Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","2017P000123","December 14, 2017","June 2019","June 2019","May 2, 2017","null","September 10, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03136263"
615,"NCT03136029","Exercise and NO in HFrEF",,"Recruiting","No Results Available","Heart Failure With Reduced Ejection Fraction","Dietary Supplement: Antioxidant|Dietary Supplement: Tetrahydrobiopterin (BH4)|Other: Exercise training","Blood Flow","VA Office of Research and Development|University of Utah","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","140","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","F1311-R","June 1, 2018","May 31, 2021","March 31, 2023","May 2, 2017","null","July 25, 2018","VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT03136029"
616,"NCT03135873","Mastiha Treatment for Obese With NAFLD Diagnosis","MAST4HEALTH","Recruiting","No Results Available","Non Alcoholic Fatty Liver Disease","Dietary Supplement: Mastiha|Dietary Supplement: Placebo","LIF score|NAFLD/NASH-related laboratory markers|Anthropometric characteristics|Genetic profile|Metabolomic profile|Metagenomic profile|Epigenetic profile","Harokopio University|Fondazione C.N.R./Regione Toscana ""G. Monasterio"", Pisa, Italy","All","18 Years to 67 Years   (Adult, Older Adult)","Early Phase 1","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MAST4HEALTH (691042)","March 8, 2017","December 2018","December 2019","May 1, 2017","null","August 2, 2018","Harokopio University, Athens, Attica, Greece","","https://ClinicalTrials.gov/show/NCT03135873"
617,"NCT03135860","Effect iNO on Functional Respiratory Imaging in Subjects With WHO Group 3 Pulmonary Hypertension With COPD on Oxygen",,"Terminated","No Results Available","COPD|Pulmonary Hypertension|Chronic Obstructive Pulmonary Disease","Drug: Inhaled Nitric Oxide 30mcg/kg IBW/hr","change in lobar blood volume at total lung capacity with iNO and the change in lobar blood volume with iNO after 4 weeks of treatment with iNO as measured by HRCT.|Blood vessel % and density on lobar level|• Blood vessel % and density on lobal level compared among patients with emphysema, chronic bronchitis or combined emphysema and chronic bronchitis as assessed by HRCT|Total lung volume at TLC|Lobar volumes at TLC|Internal airflow distribution based on lobar expansion|Airway volume down to generation 8-10 at TLC|Computational Fluid Dynamics (CFD)-based resistance on lobar level|Ventilation/perfusion (V/Q) matching|Spirometry|Change from baseline 6MWD; Borg CR10 Dyspnea and Leg Fatigue Score ; PRO|Change from baseline to 4 weeks of treatment and two weeks of withdrawal","Bellerophon","All","40 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","7","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PULSE-COPD-007","October 2016","August 21, 2017","August 21, 2017","May 1, 2017","null","September 18, 2017","Antwerp University Hospital, Edegem, Belgium","","https://ClinicalTrials.gov/show/NCT03135860"
618,"NCT03134339","The Effect of Nicotine Delivery Rate on Reinforcement",,"Completed","No Results Available","Nicotine","Drug: Nicotine saline 0.00mcg/kg/s|Drug: Nicotine 0.24 mcg/kg/s|Drug: Nicotine 0.048 mcg/kg/s|Drug: Nicotine 0.024 mcg/kg/s","Peak Change on items of the Drug Effects Questionnaire (DEQ)","Yale University","All","18 Years to 30 Years   (Adult)","Early Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","1609018390","January 5, 2017","January 29, 2018","January 29, 2018","April 28, 2017","null","October 22, 2018","VA Hospital, West Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03134339"
619,"NCT03132467","Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 Antibody (Tremelimumab) in HR+/HER2- Breast Cancer",,"Recruiting","No Results Available","Breast Cancer|Hormone Receptor Positive, HER2 Negative Breast Cancer","Drug: Tremelimumab|Drug: Durvalumab|Procedure: Core Breast Tumor Biopsy","Feasibility of Enrolling Participants with Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor negative (HER2-) Breast Cancer to Trial with Durvalumab Plus Tremelimumab|Safety of Tremelimumab plus Durvalumab in Participants with Early Stage HR+/HER2- Breast Cancer: Adverse events recorded according to CTCAE 4.03","M.D. Anderson Cancer Center|AstraZeneca","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-0902|NCI-2018-01189","June 13, 2017","June 2019","June 2019","April 27, 2017","null","November 14, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03132467"
620,"NCT03131934","Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant","ITREC","Not yet recruiting","No Results Available","Post-transplant Lymphoproliferative Disease|Transplant-Related Hematologic Malignancy","Biological: Autologous EBV-CTL transduced with vector SFG-CNA12|Biological: Autologous EBV-CTL transduced with control vector SFG-CNA8|Procedure: Leucapheresis","Toxicity at 6 weeks post infusion|Persistence and frequency of circulating EBV CTL|Disease response|Relapse rate|Disease free survival|Organ graft Rejection","University College, London|bluebird bio","All","1 Year to 70 Years   (Child, Adult, Older Adult)","Early Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCL/16/0529","February 1, 2019","June 30, 2020","May 15, 2025","April 27, 2017","null","October 16, 2018","","","https://ClinicalTrials.gov/show/NCT03131934"
621,"NCT03130517","Efficacy of Intravenous Immunoglobulin in Management of Rh and ABO Incompatibility Disease","IVIG","Not yet recruiting","No Results Available","Haemolysis Neonatal","Drug: intravenous immunoglobulin","To measure duration of phototherapy|duration of hospital stay","Assiut University","All","up to 30 Days   (Child)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","assuit university 66","July 1, 2017","December 31, 2018","December 31, 2018","April 26, 2017","null","June 27, 2017","","","https://ClinicalTrials.gov/show/NCT03130517"
622,"NCT03130153","Topical Analgesic Versus Saline Mouth Rinses in Post Extraction Healing",,"Completed","No Results Available","Tooth Extraction Site Healing","Drug: Aspirin Powder|Drug: Normal saline","Healing of the extraction socket","Aga Khan University","All","20 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","3425-Sur-ERC-14","January 1, 2016","July 15, 2017","December 31, 2017","April 26, 2017","null","June 28, 2018","Aga Khan University, Karachi, Sind, Pakistan","","https://ClinicalTrials.gov/show/NCT03130153"
623,"NCT03128866","Reducing Blood Loss in Hemipelvectomy Surgery With the Use Tranexamic Acid (TXA)",,"Recruiting","No Results Available","Malignant Neoplasms of Bone and Articular Cartilage|Pelvic Tumor","Drug: Tranexamic Acid","Total Perioperative Blood Loss","M.D. Anderson Cancer Center","All","Child, Adult, Older Adult","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-0650|NCI-2018-01178","May 19, 2017","May 2021","May 2021","April 25, 2017","null","August 13, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03128866"
624,"NCT03125811","Value of Ondansetron Medication vs Inhaled Isopropyl Therapy in the Emergency Department (VOMIITED)","VOMIITED","Recruiting","No Results Available","Nausea|Vomiting","Other: Inhaled Isopropyl Alcohol (IPA)|Drug: Oral Dissolvable Tablet Zofran (ondansetron)","Change in Nausea Severity|Emesis Event","Texas Tech University Health Sciences Center, El Paso","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","E17005","July 17, 2017","March 1, 2019","March 1, 2019","April 24, 2017","null","March 15, 2018","Texas Tech University Health Sciences Center El Paso, El Paso, Texas, United States|University Medical Center, El Paso, Texas, United States","","https://ClinicalTrials.gov/show/NCT03125811"
625,"NCT03122756","Effect of Intravenous Dexamethasone Before Spinal Anesthesia on Post-cesarean Section Pain",,"Recruiting","No Results Available","Cesarean Section","Drug: Dexamethasone|Other: Normal Saline","change in post-cesarean pain|sensory recovery|motor recovery|nausea|vomiting|shivering","Ain Shams Maternity Hospital|Ain Shams University","Female","20 Years to 40 Years   (Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IVD-SA-CS","August 1, 2017","October 2018","October 2018","April 21, 2017","null","August 14, 2018","Ain Shams Maternity Hospital, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03122756"
626,"NCT03122639","Endothelial Function in Obstructive Sleep Apnea",,"Recruiting","No Results Available","Obstructive Sleep Apnea of Adult","Drug: Atorvastatin 10mg|Drug: Placebo","Change in proportion of CD59 on the endothelial cell (EC) surface (the percent [%] of the total cellular CD59 protein that is expressed on the endothelial cell surface).|MAC deposition on EC surface (measurement unit is fluorescent area quantified as micrometer square).","Columbia University|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","245","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","AAAR0444","September 1, 2017","June 30, 2021","August 30, 2021","April 21, 2017","null","January 30, 2018","Columbia University Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03122639"
627,"NCT03122197","Study of Letrozole in Recurrent Gliomas",,"Recruiting","No Results Available","Brain Tumor","Drug: Letrozole Oral Tablet","Overall Letrozole AUC in tumor tissue.|Adverse Events|Progression free Survival|Overall Survival","University of Cincinnati","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","UCCI-BN-16-01","May 16, 2017","April 2019","June 2019","April 20, 2017","null","October 1, 2018","University of Cincinnati, Cincinnati, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03122197"
628,"NCT03120468","Topiramate Augmenting Strategies for the Treatment of Alcohol Use Disorder",,"Recruiting","No Results Available","Alcoholism","Drug: Topiramate and N-Acetyl Cysteine|Drug: Topiramate and Placebo","Cognitive side effects|Percent Heavy Drinking Days (PHDD)|Drinks per Drinking Day|Percentage of Days Abstinent|Obsessive compulsive drinking scale (OCDS)|Drinking Inventory of Consequence (DrInC) scale|Clinical Global Improvement (CGI) scale","Nassima Ait-Daoud Tiouririne|University of Virginia","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","19422","May 1, 2017","April 2018","April 2018","April 19, 2017","null","June 19, 2017","UVA Center for Leading Edge Addiction Research, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03120468"
629,"NCT03119558","PET/MRI Evaluation of Cardiac Amyloid",,"Recruiting","No Results Available","Cardiac Amyloidosis","Drug: 18F‑Florbetaben (Neuraceq®) PET/MRI","Number of participants with 18F‑Florbetaben (Neuraceq®) uptake on Fused PET/MRI Images","Stanford University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB-35049","May 26, 2016","August 2019","August 2020","April 18, 2017","null","April 12, 2018","Stanford University, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT03119558"
630,"NCT03117517","Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome",,"Completed","No Results Available","Polycystic Ovarian Syndrome","Drug: Metformin|Drug: Metformin, Pioglitazone","Cytokines, Chemokines|Hormonal profiles|Insulin resistance|Demographic parameters","Khyber Medical University Peshawar","Female","20 Years to 40 Years   (Adult)","Early Phase 1","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment","Protocol KMU/CTU/2016/02","March 20, 2017","August 29, 2017","March 7, 2018","April 18, 2017","null","March 8, 2018","Mardan Medical Complex, Mardan, Khyber Pukhtunkhwah, Pakistan","","https://ClinicalTrials.gov/show/NCT03117517"
631,"NCT03116659","CTCL Directed Therapy",,"Recruiting","No Results Available","Lymphoma, T-Cell, Cutaneous","Drug: Doxycycline|Drug: Imiquimod","Pilot assessment of response.","James J. Peters Veterans Affairs Medical Center","All","30 Years to 89 Years   (Adult, Older Adult)","Early Phase 1","8","U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAN-15-028","February 1, 2018","December 30, 2018","March 2019","April 17, 2017","null","August 7, 2018","James J Peters Bronx Veterans Affairs Medical Center, Bronx, New York, United States","","https://ClinicalTrials.gov/show/NCT03116659"
632,"NCT03114865","A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance",,"Recruiting","No Results Available","Acute Lymphoblastic Leukemia|B-cell Non Hodgkin Lymphoma|Pre B-Cell Acute Lymphoblastic Leukaemia","Drug: Blinatumomab|Drug: Dexamethasone","Overall survival at two years post first treatment cycle|Non-Relapse Mortality|Progression-free survival|Disease-free Survival|Overall Survival|Minimal Residual Disease","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Amgen","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J1713|IRB00125679","September 5, 2017","May 2020","May 2020","April 14, 2017","null","October 22, 2018","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03114865"
633,"NCT03113058","""Treatment of Active HBV With γδT Cells"" Clinical Trial Protocol",,"Not yet recruiting","No Results Available","Adoptive Treatment for Hepatitis B With γδT Cells","Combination Product: Adoptive transfer of γδT cells","DNA copy number|Negative conversion rate of HbeAg","Jinan University Guangzhou|Guagnzhou Qiaokang Hospital","All","18 Years to 45 Years   (Adult)","Early Phase 1","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GDT-HBV-01-QK","May 2, 2017","October 5, 2018","November 1, 2018","April 13, 2017","null","April 21, 2017","Guagnzhou Qiaokang Hospital, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03113058"
634,"NCT03113019","Autologous Antigen-activated Dendritic Cells in the Treatment of Patients With Breast Cancer","BC-LDC","Active, not recruiting","No Results Available","Breast Cancer","Biological: Immunotherapy based on dendritic cells","Сytotoxicity|Parameters of peripheral blood|Immune status indicators|The content of immunosuppressive populations|Interrogation of the patient using a visual analogue scale|Relapse-free period","Research Institute of Fundamental and Clinical Immunology","Female","28 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Breast Cancer Lyzate DC","February 11, 2014","February 11, 2017","September 11, 2017","April 13, 2017","null","April 13, 2017","","","https://ClinicalTrials.gov/show/NCT03113019"
635,"NCT03112044","Lung Transplant HCV, Pilot Study",,"Recruiting","No Results Available","Lung Transplant Infection|Hepatitis C","Drug: Sofosbuvir-velpatasvir (400 mg/100 mg)|Device: Ex Vivo Lung Perfusion (EVLP)","Safety of transplantation from HCV positive donors to HCV negative recipients|Incidence of HCV transmission|Correlation between viral loads and recipient infection|Time to viremia development|HCV cure rates","Marcelo Cypel|University Health Network, Toronto|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UHNTID006","September 19, 2017","April 3, 2018","December 31, 2018","April 13, 2017","null","September 25, 2017","University Health Network Toronto General Hospital, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03112044"
636,"NCT03111173","Can Conventional ECG Technology Capture Fetal Cardiac Activity?",,"Recruiting","No Results Available","Fetal Monitoring","Device: Holter Device","Successful extraction of fetal ECG from the maternal abdominal ECG signal","University of Washington|University of Toronto","Female","18 Years to 55 Years   (Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","STUDY00001556","June 2, 2017","June 2019","June 2019","April 12, 2017","null","October 16, 2018","University of Washington, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03111173"
637,"NCT03109873","Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer",,"Active, not recruiting","No Results Available","Larynx|Lip|Oral Cavity|Pharynx","Radiation: External Beam Radiation Therapy|Drug: Metformin Hydrochloride|Other: Placebo","Cytokine/chemokine profile|Mucositis assessed using WHO classification|Objective response rate|Exosome profile|Incidence of toxicities","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","16D.639","January 5, 2017","April 4, 2018","June 2020","April 12, 2017","null","April 24, 2018","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03109873"
638,"NCT03107884","Role of Metformin on Muscle Health of Older Adults",,"Recruiting","No Results Available","Atrophy|Insulin Resistance","Drug: Metformin|Drug: Placebo","Muscle size","University of Utah","All","60 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","93579","July 1, 2017","July 1, 2019","July 1, 2021","April 11, 2017","null","March 15, 2018","University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT03107884"
639,"NCT03107520","Intraoperative Contrast-Enhanced Ultrasound Evaluation of Blood Flow After Surgical Hip Reduction for DDH",,"Recruiting","No Results Available","Developmental Dysplasia of the Hip","Diagnostic Test: Intraoperative contrast-enhanced ultrasound (CEUS)|Drug: Lumason","Visualization of epiphyseal vascularity in the femoral head|Comparison of CEUS and Post-Operative Imaging","Children's Hospital of Philadelphia|Bracco Diagnostics, Inc","All","up to 24 Months   (Child)","Early Phase 1","35","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","16-013583","May 22, 2017","April 2019","April 2020","April 11, 2017","null","June 28, 2018","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03107520"
640,"NCT03106935","Recurrent Pregnancy Loss and Thyroid Disease",,"Enrolling by invitation","No Results Available","Recurrent Pregnancy Loss","Drug: Levothyroxine","Gestational week at delivery|Newborn birth weight|APGAR Score at birth|Number of clinical pregnancy at 6-8 weeks (defined as the presence of a gestational sac, with or without a yolk sac or fetal pole)|Number of ongoing pregnancy at 12 weeks (defined as the presence of a fetal heartbeat)|Number of miscarriage (defined as loss of pregnancy before 28 weeks of gestation).","Second Affiliated Hospital of Soochow University","Female","18 Years to 39 Years   (Adult)","Early Phase 1","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","The Second Affiliated Hospital","July 2015","December 2017","June 2018","April 11, 2017","null","April 12, 2017","Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China","","https://ClinicalTrials.gov/show/NCT03106935"
641,"NCT03106766","Six Months Evaluation of Next Science Acne Creams on Facial Acne in Adult Females.",,"Terminated","No Results Available","Acne Vulgaris","Drug: Acne cream 2X|Drug: Acne cream 1X","Reduction in Lesion Count|Inflammatory Lesion count over time|Non-inflammatory acne lesion over time|Investigator Global Assessment over time|Treatment Areas over time|Quality of Life over time","Next Science TM|Skin Laser & Surgery Specialists","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","2","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CSP-004","March 27, 2017","August 14, 2017","August 14, 2017","April 10, 2017","null","August 30, 2017","Skin Laser & Surgery Specialists of NY & NJ, Hackensack, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT03106766"
642,"NCT03106363","Combined Alcohol and Cannabis Effects on Skills of Young Drivers",,"Recruiting","No Results Available","Psychomotor Impairment","Drug: delta 9 tetrahydrocannabinol|Drug: placebo delta 9 tetrahydrocannabinol|Drug: Alcohol|Drug: Placebo alcohol","Psychomotor impairment: Standard deviation of lateral position|Psychomotor impairment: Mean speed, standard deviation of speed, and maximum speed|Psychomotor impairment: Minimum time to collision and brake latency|Psychomotor impairment: Number of collisions|Subjective alcohol and cannabis effects|Cognitive testing|Breath alcohol content|Blood concentration for delta 9 tetrahydrocannabinol, carboxy-tetrahydrocannabinol, and 11 hydroxy tetrahydrocannabinol.|Urine cannabinoids corrected for creatinine|Vital signs","Centre for Addiction and Mental Health|Canadian Institutes of Health Research (CIHR)|Health Canada","All","19 Years to 25 Years   (Adult)","Early Phase 1","70","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","123-2015","July 4, 2017","December 2019","January 2020","April 10, 2017","null","September 27, 2018","Centre for Addiction and Mental Health, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03106363"
643,"NCT03105661","Use of Impedance Cardiography to Decrease the Risk of Pre-eclampsia in Obese Patients",,"Recruiting","No Results Available","Obesity, Morbid|Preeclampsia","Drug: Labetalol Hydrochloride 200 mg|Drug: NIFEdipine 60 mg|Drug: Atenolol 25 mg","Rates of preeclampsia in morbidly obese pregnant women","University of Tennessee Graduate School of Medicine","Female","18 Years to 51 Years   (Adult)","Early Phase 1","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","4226","April 4, 2017","March 4, 2019","March 4, 2020","April 10, 2017","null","September 14, 2018","University of Tennessee Medical Center, Knoxville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT03105661"
644,"NCT03105375","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose Study",,"Completed","No Results Available","Healthy Volunteers","Drug: Single ascending dose of X842|Drug: Multiple ascending dose of X842|Drug: Losec","Occurrence and frequency of AEs, changes in laboratory parameters, vital signs and physical examination after single and multiple doses of X842. Summary statistics will be applied.|Measurement of the PK profile (Cmax)|Measurement of the PK profile (t1/2)|Measurement of the PD profile (intragastric pH)","Cinclus Pharma AG","All","18 Years to 60 Years   (Adult)","Early Phase 1","39","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CX842A2101","February 21, 2017","October 12, 2017","October 12, 2017","April 7, 2017","null","November 7, 2017","Clinical Trial Consultants, Uppsala, Sweden","","https://ClinicalTrials.gov/show/NCT03105375"
645,"NCT03103594","Comparison of the Treatment of Refractory Bladder Pain Syndrome With DMSO and DMSO With Botulinum Toxin A",,"Completed","No Results Available","Bladder Pain Syndrome","Drug: DMSO|Drug: Botox","Pain Score","University of Pennsylvania|Society for Urodynamics and Female Urology","Female","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","821084","August 2015","August 2016","April 2017","April 6, 2017","null","June 9, 2017","","","https://ClinicalTrials.gov/show/NCT03103594"
646,"NCT03102177","Effect of Age, Weight and Sex on Levothyroxine Pharmacokinetics",,"Completed","No Results Available","Hypothyroidism Primary","Drug: Administration of stable Isotope labeled levothyroxine","CL/F|V/F|t-half|CL/F analysed by age groups|V/F analysed by age groups|t-half by age groups","Georgetown University","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2010-572","May 31, 2011","November 30, 2013","July 26, 2016","April 5, 2017","null","April 6, 2017","","","https://ClinicalTrials.gov/show/NCT03102177"
647,"NCT03101540","Cytokines, PUFA Tissue Concentrations and Treatment Selection in Antenatal MDD",,"Terminated","No Results Available","Major Depressive Disorder in Pregnancy","Drug: Omega-3 PUFA supplementation","Hamilton Rating Scale for Depression (HAM-D)|Montgomery-Asberg Depression Scale (MADRS)|Edinburgh Postnatal Depression Scale (EPDS)|Beck Depression Scale (BDI)","William Coryell|University of Iowa","Female","18 Years to 50 Years   (Adult)","Early Phase 1","27","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201102756","August 2011","May 2014","May 2014","April 5, 2017","null","April 28, 2017","","","https://ClinicalTrials.gov/show/NCT03101540"
648,"NCT03101527","Open Trial Determining Antidepressant Effects of Omega-3 Supplementation During Pregnancy",,"Terminated","No Results Available","Major Depressive Disorder in Pregnancy","Drug: Omega-3 PUFA supplementation","The Hamilton Rating Scale for Depression (HAM-D)|Montgomery-Asberg Depression Scale (MADRS)|Edinburgh Postnatal Depression Scale (EPDS)|Beck Depression Scale (BDI)","William Coryell|University of Iowa","Female","18 Years to 50 Years   (Adult)","Early Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201002781","May 2011","February 2012","February 2012","April 5, 2017","null","April 28, 2017","","","https://ClinicalTrials.gov/show/NCT03101527"
649,"NCT03100123","AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study","APPLE","Recruiting","No Results Available","Antiphospholipid Syndrome in Pregnancy|Pregnancy Loss","Drug: Aspirin 81 mg|Drug: Low-molecular-weight heparin","Feasibility|Essential Documents|Eligibility|Consent|Withdrawals/Loss to Follow-up|Crossover Rate|Study Drug Compliance|Non-consent","Ottawa Hospital Research Institute","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTO 0807","November 6, 2017","November 6, 2019","January 2020","April 4, 2017","null","November 21, 2017","McMaster University Medical Centre, Hamilton, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03100123"
650,"NCT03099980","Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa",,"Recruiting","No Results Available","Hidradenitis Suppurativa","Biological: secukinumab","Hidradenitis Suppurativa Clinical Response (HiSCR)","Tufts Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAIN457AUS03T","July 11, 2016","August 2018","January 2019","April 4, 2017","null","March 15, 2018","Tufts Medical Center, Department of Dermatology, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03099980"
651,"NCT03099564","Pembrolizumab Plus Y90 Radioembolization in HCC Subjects",,"Recruiting","No Results Available","Hepatocellular Carcinoma","Drug: Pembrolizumab|Device: Y90 radioembolization","Progression free survival (PFS)|Assess Safety - toxicities as defined by the NCI CTCAE v4|Time to progression (TTP)|Objective response rate (ORR)|Estimate overall survival (OS)","Autumn McRee, MD|Merck Sharp & Dohme Corp.|Hoosier Cancer Research Network","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCRN GI15-225","March 28, 2017","July 2018","January 2020","April 4, 2017","null","June 18, 2018","Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|University of Washington/Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03099564"
652,"NCT03095469","Effects of Dexmedetomidine on Patients With Coronary Heart Disease After Percutaneous Coronary Intervention","EODOPWCHD","Not yet recruiting","No Results Available","Heart Injuries","Drug: Dexmedetomidine|Drug: 0.9%NaCl solution","the incidence of myocardial infarction type 4a (MI4a)|post-procedural cardiac function|major adverse cardiac events(MACEs)|systemic inflammatory markers","First Affiliated Hospital Xi'an Jiaotong University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","XJTU1AF-CRF-2016T-09","August 20, 2017","November 30, 2017","December 31, 2017","March 29, 2017","null","June 9, 2017","the 1st affiliated hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China","","https://ClinicalTrials.gov/show/NCT03095469"
653,"NCT03095404","Intravenous Lidocaine for Post-Operative Pain Control in Patients Undergoing Bariatric Bowel Surgery",,"Not yet recruiting","No Results Available","Bariatric Surgery Candidate","Drug: Low Dose Lidocaine|Drug: High Dose Lidocaine","Evaluation of an intravenous lidocaine dosing schedule using 1mg/kg or 2mg/kg adjusted body weight|Amount of intraoperative narcotics used post-surgery|Pain scores|Enhancement of gastrointestinal recovery|Post-operative nausea and vomiting|Patient satisfaction|Time of rescue analgesia|Length of stay in recovery room|Length of hospital stay","McMaster University|St. Joseph's Healthcare Hamilton","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","2198","September 1, 2018","December 31, 2019","February 28, 2020","March 29, 2017","null","September 7, 2017","","","https://ClinicalTrials.gov/show/NCT03095404"
654,"NCT03094897","Clinic Study of 18F-Al-NOTA-MATBBN in Cancer Diagnostics",,"Not yet recruiting","No Results Available","Breast Neoplasms|Prostatic Neoplasms","Drug: 18F-Al-NOTA-MATBBN PET/CT|Device: PET/CT","Standardized uptake value of 18F-Al-NOTA-MATBBN in malignant lesions|Adverse events collection","Wuxi No. 4 People's Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Wuxi4PH","April 20, 2017","December 31, 2020","December 31, 2020","March 29, 2017","null","April 13, 2017","","","https://ClinicalTrials.gov/show/NCT03094897"
655,"NCT03093506","Effects of Micro-dose and Low-dose Recombinant Human Erythropoietin on Mitochondrial Function and Cognitive Performance",,"Completed","No Results Available","Human Volunteers","Drug: Low-dose rhEpo|Drug: Micro-dose rhEpo|Other: Placebo Control","Maximal oxygen-flux (picomol/second)|Sum of speed-score and accuracy-score in the RAVEN-test|Number of correctly found fields in the NUFI-test|Rating of the interviews on a scale from -3 to +3 according to experienced change in ability to concentrate","Bispebjerg Hospital","Male","18 Years to 45 Years   (Adult)","Early Phase 1","25","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","H-1-2011-098","September 2011","December 2011","December 2011","March 28, 2017","null","March 28, 2017","Copenhagen University Hospital Bispebjerg, Department of Anaesthesiology, Copenhagen, Kbh NV, Denmark","","https://ClinicalTrials.gov/show/NCT03093506"
656,"NCT03090893","Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients",,"Withdrawn","No Results Available","Antithrombin Deficiency Type 2","Drug: ATryn continuous infusion","Percentage of time within the serum AT level target range of 80-100%","Mayo Clinic|rEVO Biologics","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","15-001713","June 1, 2018","June 2019","June 2019","March 27, 2017","null","September 10, 2018","","","https://ClinicalTrials.gov/show/NCT03090893"
657,"NCT03090776","Prevention of Post Mastectomy With Intraoperative Ketamine",,"Not yet recruiting","No Results Available","Pain, Postoperative|Post-Mastectomy Chronic Pain Syndrome","Drug: Ketamine|Other: Placebo saline","postmastectomy pain","Brigham and Women's Hospital|National Institutes of Health (NIH)|National Institute of General Medical Sciences (NIGMS)","Female","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2016P002521|K23GM110540","May 1, 2017","May 1, 2019","May 1, 2020","March 27, 2017","null","March 28, 2017","","","https://ClinicalTrials.gov/show/NCT03090776"
658,"NCT03090048","Vitamin A and Azithromycin for Acne Vulgaris",,"Not yet recruiting","No Results Available","Acne Vulgaris","Drug: Vitamin A|Drug: Azithromycin","Measurement (dimensions) of acne lesions","Manchanda Medical Clinic","All","12 Years to 45 Years   (Child, Adult)","Early Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","Tawar -1","October 1, 2018","February 28, 2019","May 31, 2019","March 24, 2017","null","August 16, 2018","Manchanda Mc, Surrey, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT03090048"
659,"NCT03090009","Microbiome Shift in Peri-mucositis by Anti-inflammatory Drugs",,"Not yet recruiting","No Results Available","Peri-implant Mucositis","Drug: Flurbiprofen|Drug: Placebo Oral Tablet","Change in the Microbiome|change in periodontal probing depth|change in bleeding on probing|change in Suppuration","Polak David|Hadassah Medical Organization","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","0674-16-HMO","April 2017","April 2019","April 2020","March 24, 2017","null","March 31, 2017","Hadassah Medical Organization, Jerusalem, Israel","","https://ClinicalTrials.gov/show/NCT03090009"
660,"NCT03089567","Comparison of the Salivary Levels of Streptococcus Mutans in Pediatric Patients With Early Childhood Caries After the Application of Silver Diamine Fluoride or 5% Sodium Fluoride Varnish",,"Not yet recruiting","No Results Available","Dental Caries","Drug: Sodium Fluoride|Drug: Silver diamine fluoride","Salivary levels of Streptococcus mutans","Yale University","All","2 Years to 6 Years   (Child)","Early Phase 1","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SMAHEN","June 15, 2017","June 15, 2018","July 15, 2018","March 24, 2017","null","March 24, 2017","","","https://ClinicalTrials.gov/show/NCT03089567"
661,"NCT03088306","Improving Pain and Reducing Opioid Use (IPaRO) in Lumbar Spine Surgery Patients","IPaRO","Completed","No Results Available","Lumbar Spinal Stenosis|Lumbar Spinal Instability|Lumbar Spine Degeneration","Drug: Standard analgesia use [Oxygen]|Drug: Standard analgesia use [Hydromorphone]|Drug: Standard analgesia use [Volatile Anesthesia]|Drug: Standard analgesia use [Fentanyl]|Drug: Multi-modal pain management [Acetaminophen + Gabapentin]|Drug: Multi-modal pain management [Fentanyl]|Drug: Multi-modal pain management [Intravenous Ketamine]|Drug: Multi-modal pain management [Valium + Gabapentin]","Number of participants undergoing lumbar spine surgery with complete follow-up|Patient controlled analgesia (PCA) pump use|Opioid medication use|Patient Reported Outcomes Measurement Information System (PROMIS) Pain|PROMIS Physical Function|PROMIS Fatigue|PROMIS Anxiety|PROMIS Depression|PROMIS Sleep Disturbance|PROMIS Satisfaction with Social Roles|Health status (Medical Outcome Study Short Form 12, version 2)|Oswestry Disability Index (ODI)","Johns Hopkins University|North American Spine Society","All","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","49","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","IRB00113816","July 1, 2017","May 31, 2018","August 31, 2018","March 23, 2017","null","October 16, 2018","Johns Hopkins University School of Medicine, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03088306"
662,"NCT03087968","Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124",,"Withdrawn","No Results Available","Severe Alcoholic Hepatitis","Drug: GS-4997|Drug: Prednisolone|Device: HepQuant SHUNT Test|Drug: Placebo","To compare the change in (DSI ) Disease Severity Index between GS-4997 treatment and placebo arms|Secondary Outcome 1|Secondary Outcome 2|Secondary Outcome 3|Secondary Outcome 4","HepQuant, LLC","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Diagnostic","HepQuant-002-2124","July 31, 2016","September 13, 2017","September 13, 2017","March 23, 2017","null","September 15, 2017","Southern California Research Center, Coronado, California, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|Liver Institute of Virginia, Newport Newes, Virginia, United States|Liver Institute of Virginia, Richmond, Virginia, United States|VCU Health System, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03087968"
663,"NCT03085654","Multiple Dose Effect of Oxytocin on Males With High or Low Trait Anxiety",,"Completed","No Results Available","Healthy","Drug: Oxytocin nasal spray|Drug: Placebo nasal spray","Changes between acute and chronic administration of oxytocin on amygdala activity as assessed by fMRI|Changes between acute and chronic administration of oxytocin on amygdala connectivity as assessed by fMRI|Interaction of acute and chronic treatment effects with trait anxiety on neural activity|Interaction of acute and chronic treatment effects with trait anxiety on neural connectivity|Effects of oxytocin on arousal ratings of emotional stimuli (acute and changes with chronic treatment)|Effects of oxytocin on valence ratings of emotional stimuli (acute and changes with chronic treatment)|Interaction of treatment effects on valence ratings with trait anxiety (acute and changes with chronic treatment)|Interaction of treatment effects on arousal ratings with trait anxiety (acute and changes with chronic treatment)","University of Electronic Science and Technology of China","Male","18 Years to 30 Years   (Adult)","Early Phase 1","147","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","UESTC-neuSCAN_10","March 3, 2017","March 31, 2018","April 30, 2018","March 21, 2017","null","October 29, 2018","school of life science and technology, University of Electronic Science and Technology of China, Chengdu, Sichuan, China","","https://ClinicalTrials.gov/show/NCT03085654"
664,"NCT03085056","Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer",,"Recruiting","No Results Available","Anaplastic Thyroid Cancer","Drug: Trametinib|Drug: Paclitaxel","Progression-Free Survival (PFS)","Memorial Sloan Kettering Cancer Center|Novartis","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-055","March 15, 2017","March 2019","March 2019","March 21, 2017","null","April 5, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03085056"
665,"NCT03084029","The Neural Basis of Oxytocin's Effects on Empathy",,"Completed","No Results Available","Healthy","Drug: Oxytocin|Drug: Placebo","Neural processing of empathy as assessed using fMRI|Behavioral ratings of subjective experienced empathy processing","University of Electronic Science and Technology of China","All","18 Years to 30 Years   (Adult)","Early Phase 1","72","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","UESTC-neuSCAN-03","January 2016","June 2017","September 2017","March 20, 2017","null","February 6, 2018","School of Life Science and Technology,University of Electronic Science and Technology, Chengdu, Sichuan, China","","https://ClinicalTrials.gov/show/NCT03084029"
666,"NCT03083353","Enhancing Cue Exposure Treatment for Smoking Reduction With Isradipine",,"Suspended","No Results Available","Nicotine Dependence","Drug: Isradipine|Behavioral: CET|Drug: Placebos","Craving Intensity to Smoking Cues|Abstinence: Number of abstinence days","University of Texas at Austin","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","2016-09-0150","January 2020","January 2022","January 2022","March 20, 2017","null","August 6, 2018","University of Texas at Austin, Austin, Texas, United States","","https://ClinicalTrials.gov/show/NCT03083353"
667,"NCT03083132","Modafinil for Freezing of Gait (FOG) in Parkinson's Disease (PD)",,"Enrolling by invitation","No Results Available","Parkinson Disease","Drug: modafinil 50mg|Drug: Placebo oral capsule","FOG-Q","University of Arkansas","All","50 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","206341","June 13, 2017","April 30, 2019","October 2019","March 17, 2017","null","July 16, 2018","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States","","https://ClinicalTrials.gov/show/NCT03083132"
668,"NCT03082768","Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects",,"Completed","No Results Available","Healthy Volunteers","Drug: [18F]MNI-968","Tracer uptake will be evaluated in regions of interest for analysis of regional [18F]MNI-968 binding/uptake and expressed in SUV by using established methods for normalization for 7 HV subjects.","Molecular NeuroImaging","All","18 Years to 50 Years   (Adult)","Early Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","[18F]MNI-968","March 3, 2017","March 1, 2018","March 1, 2018","March 17, 2017","null","March 6, 2018","Molecular NeuroImaging, LLC, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03082768"
669,"NCT03080051","Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain",,"Completed","No Results Available","Progressive Supranuclear Palsy|Alzheimer Disease|Healthy Volunteers","Drug: [18F]MNI-952|Drug: [18F]Florbetapir","Tracer uptake will be evaluated in regions of interest for analysis of regional [18F]MNI-952 binding/uptake and expressed in SUV by using established methods for normalization for 2 PSP, 2 AD, and 2 HV subjects.","Molecular NeuroImaging","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","[18F]MNI-952","August 2016","March 6, 2017","March 6, 2017","March 15, 2017","null","October 6, 2017","Molecular NeuroImaging, LLC, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03080051"
670,"NCT03079921","Adrenergic System in Islet Transplantation","Aim 1 Islets","Recruiting","No Results Available","Type1diabetes|Hypoglycemia|Hypoglycemia Unawareness","Drug: Phentolamine|Drug: Propranolol|Drug: Placebo","C-PEPTIDE suppression during hyperinsulinemia euglycemia.|GLUCAGON activation during hyperinsulinemia hypoglycemia.|EPINEPHRINE during hyperinsulinemia hypoglycemia.|Rates of ENDOGENOUS GLUCOSE PRODUCTION during hyperinsulinemia hypoglycemia.|AUTONOMIC SYMPTOMS during hyperinsulinemia","University of Pennsylvania|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","21 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","45","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","826386|2R01DK091331-06","January 20, 2017","December 2019","December 2020","March 15, 2017","null","August 24, 2018","University of Pennsylvania - Institute for Diabetes, Obesity and Metabolism, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03079921"
671,"NCT03078309","The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients",,"Recruiting","No Results Available","Retinitis Pigmentosa|Retinal Degeneration|Cannabis","Drug: cannabis","Electroretinogram (ERG) - acivity of the neural retina mixed cone-rod response, cone flicker, rod response|Electroretinogram (ERG) - acivity of the neural retina cone flicker latency|Visual acuity|Titmus stereo eye movements|Eye movements|Intra ocular pressure|Macular thickness (OCT)","Hadassah Medical Organization|Hebrew University of Jerusalem","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","0007-17-HMO","September 2018","August 2020","August 2020","March 13, 2017","null","August 2, 2018","Hadassah Medical Center, Jerusalem, Israel","","https://ClinicalTrials.gov/show/NCT03078309"
672,"NCT03076684","Gender Differences in the Metabolic Effects of Uric Acid",,"Recruiting","No Results Available","Hyperuricemia","Other: low-fructose diet|Drug: Allopurinol","vessel stiffness","University of Missouri-Columbia","All","40 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2007093","March 3, 2017","May 2019","December 2019","March 10, 2017","null","April 4, 2018","University of Missouri, Columbia, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03076684"
673,"NCT03073395","Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer",,"Recruiting","No Results Available","Prostate Cancer|Renal Cancer","Drug: [68Ga]P16-093","Uptake of [68Ga]P16-093 in metastatic prostate and renal cancer|Radiation dosimetry of [68Ga]P16-093 in patients with a history of prostate cancer","Five Eleven Pharma, Inc.","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","511-0003-A","July 21, 2017","November 2018","February 2019","March 8, 2017","null","August 4, 2017","University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03073395"
674,"NCT03071328","INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Prostate Cancer",,"Recruiting","No Results Available","Metastatic Castration-resistant Prostate Cancer (mCRPC)","Drug: Isovue-M 200","Percent of iodinated contrast enhancement within the metastasis on post-injection CT|Percent of tumor CD155 membrane expression in metastatic bone, liver, or lymph node specimens.","Duke University","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","Pro00078508","January 8, 2018","August 31, 2019","August 31, 2019","March 6, 2017","null","February 14, 2018","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03071328"
675,"NCT03071224","Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein",,"Recruiting","No Results Available","Alzheimer Disease|Healthy Volunteers","Drug: [18F] MNI-946|Drug: [18F]Florbetapir","To determine the longitudinal change in tau burden (including SUVR and tau distribution metrics) compared to baseline in AD subjects and in similarly aged HV subjects.","Invicro","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","[18F] MNI-946","June 2016","June 2019","June 2019","March 6, 2017","null","July 11, 2018","Invicro, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03071224"
676,"NCT03070613","Investigating the Use of Fluorescent Lectins to Identify Dysplasia and Cancer During Endoscopy and Surgery",,"Enrolling by invitation","No Results Available","Colorectal Cancer|Colorectal Neoplasms|Colorectal Polyp","Drug: Fluorescent Lectin Application","Signal to background ratios of identified colonic lesions under white light and under fluorescence|Number of dysplastic and cancerous lesions identified under white light and under fluorescence|Number of dysplastic and cancerous lesions identified under white light and fluorescence in different subgroups|Resection margin of of lesions undergoing TEMS resection under white light and under fluorescence.","University of Oxford","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","R37106","April 23, 2017","March 1, 2018","March 1, 2018","March 3, 2017","null","July 18, 2017","Thomas Barnes, Oxford, Oxfordshire, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, United Kingdom","","https://ClinicalTrials.gov/show/NCT03070613"
677,"NCT03070561","Evaluating Peanut Immunotherapy Dissolving Film in Healthy Subjects",,"Completed","No Results Available","Peanut Allergy|Immunotherapy|Pharmacokinetics","Biological: sublingual film with peanut extract","Measurement of elimination half life (T1/2) of the Ara H2 in sublingual placement|Measurement of elimination half life (T1/2) of the Ara H2 in buccal placement|Measurement of elimination half life (T1/2) of the Ara H2 in vestibular placement","Johns Hopkins University|National Institutes of Health (NIH)","All","3 Years to 30 Years   (Child, Adult)","Early Phase 1","9","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","JHU NA_00072576","January 14, 2014","May 2015","May 2015","March 3, 2017","null","March 3, 2017","Johns Hopkins Hospital, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03070561"
678,"NCT03070054","LIA in Hip Arthroscopy Patients",,"Enrolling by invitation","No Results Available","Pain","Drug: 20ml 0.25% bupivacaine-epinephrine","PACU pain scores","University of Utah","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","90371","June 2016","June 2021","June 2021","March 3, 2017","null","June 6, 2018","University of Utah Orthopaedic Center, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT03070054"
679,"NCT03069781","The Effects of 17β-estradiol on Skeletal Muscle",,"Withdrawn","No Results Available","Muscle Atrophy","Drug: 17β-estradiol|Drug: Polycose","Muscle protein synthesis and breakdown rates|Muscle size|Muscle strength","McMaster University","Male","18 Years to 30 Years   (Adult)","Early Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","REB-2919","May 2017","May 2018","August 14, 2018","March 3, 2017","null","August 16, 2018","McMaster Univeristy, Hamilton, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03069781"
680,"NCT03068910","Hyperandrogenemia and Altered Day-night LH Pulse Patterns","CRM008","Recruiting","No Results Available","Hyperandrogenism|Polycystic Ovary Syndrome|Puberty","Drug: Micronized progesterone|Drug: Spironolactone|Drug: Placebo","Luteinizing hormone (LH) pulse frequency","University of Virginia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","10 Years to 17 Years   (Child)","Early Phase 1","32","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","18489|P50HD028934","July 2016","April 2025","December 2025","March 3, 2017","null","July 2, 2018","University of Virginia Clinical Research Unit, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03068910"
681,"NCT03067974","Intranasal Ketamine for Pediatric Procedural Sedation: a Feasibility Study",,"Recruiting","No Results Available","Failed Moderate Sedation During Procedure|Ketamine Adverse Reaction","Drug: Ketamine Hcl 100Mg/Ml Inj","Successful procedural sedation","University of Arizona","All","2 Years to 7 Years   (Child)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1705414419","September 21, 2017","December 2019","December 2019","March 1, 2017","null","October 25, 2017","Banner Univsersity Medical Center Tucson, Tucson, Arizona, United States","","https://ClinicalTrials.gov/show/NCT03067974"
682,"NCT03067467","Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)","HPCIM","Not yet recruiting","No Results Available","Brain Tumor Adult","Drug: Hyperpolarized 13C-Pyruvate|Drug: Gadolinium","13C-pyruvate Metabolic Product Ratio","University of Texas Southwestern Medical Center","All","18 Years to 60 Years   (Adult)","Early Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","STU 012017-070","May 1, 2018","December 31, 2020","December 31, 2020","March 1, 2017","null","April 13, 2018","","","https://ClinicalTrials.gov/show/NCT03067467"
683,"NCT03065998","Double Blind Placebo Control Opipramol-Baclofen Treatment for Addiction",,"Recruiting","No Results Available","Drug Abuse","Drug: Opipramol|Drug: Baclofen","Decreased craving","Ministry of Health, Israel","All","18 Years to 60 Years   (Adult)","Early Phase 1","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","066-2017 MOH","March 2017","January 2018","January 2019","February 28, 2017","null","February 28, 2017","Retorno rehabilitation center, Bet Shemesh, Israel","","https://ClinicalTrials.gov/show/NCT03065998"
684,"NCT03064282","Prostatic Hyperplasia Treatment and Cancer Prevention",,"Not yet recruiting","No Results Available","Prostatic Hyperplasia","Other: Placebo|Drug: papaverine","Laboratory tests to measure regression of symptoms","Manchanda Medical Clinic","Male","50 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Tawar - 2","October 30, 2018","May 30, 2019","July 1, 2019","February 27, 2017","null","August 15, 2018","","","https://ClinicalTrials.gov/show/NCT03064282"
685,"NCT03063736","Entolimod, an Adjuvant for Vaccine Augmentation",,"Active, not recruiting","No Results Available","Substance Use Disorders","Drug: Entolimod|Biological: Td Vaccine","Adverse events associated with entolimod augmentation.|Antibody titer comparison with entolimod augmentation of Td vaccine","Baylor College of Medicine","Male","18 Years to 40 Years   (Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","H-39354","December 8, 2017","March 9, 2018","December 2019","February 24, 2017","null","September 21, 2018","Baylor College of Medicine, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03063736"
686,"NCT03062488","Emergence Agitation and Pain Scores in Pediatrics When Comparing Single-modal vs Multi-modal Analgesia for ENT Surgery",,"Completed","No Results Available","Emergence Agitation|Pain","Drug: IV acetaminophen|Drug: Fentanyl|Drug: PO acetaminophen","Emergence agitation as measured by standardized scale PAED|Post Operative Pain","Nemours Children's Clinic|University of Central Florida","All","24 Months to 7 Years   (Child)","Early Phase 1","142","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB1074554","October 3, 2017","July 11, 2018","July 11, 2018","February 23, 2017","null","July 26, 2018","Nemours Children's Specialty Care, Jacksonville, Florida, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT03062488/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT03062488/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03062488"
687,"NCT03060356","Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)",,"Recruiting","No Results Available","Malignant Melanoma|Breast Cancer","Biological: T cells modified with RNA anti -cMET CAR","Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 in melanoma and breast cancer subjects|Objective overall response rate by clinical exam for visible cutaneous tumors|Objective overall response rate by radiologic imaging using RECIST 1.1|Estimate the activity of RNA CART-cMET in subjects who receive at least 1 dose of cells by objective response rate using RECIST 1.1 criteria|Estimate the activity of RNA CART-cMET in subjects who receive at least 1 dose of cells by objective response rate using pathological evaluation of resected or biopsied tissue","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 11916, 825376","December 21, 2016","August 2018","August 2019","February 23, 2017","null","November 9, 2017","University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03060356"
688,"NCT03060343","Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC)",,"Recruiting","No Results Available","Non-small Cell Lung Cancer","Biological: Zeushield Cytotoxic T Lymphocytes","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Number of Z-CTLs in peripheral blood samples after infusion|Objective response rate (ORR)|Progression free survival (PFS)|Time to tumor progression (TTP)|Overall survival (OS)","Yu Fenglei|Hunan Zhaotai Yongren Biotech Co. Ltd.|Hunan Yongren Medical Innovation Co. Ltd.|Second Xiangya Hospital of Central South University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Z-NSCLC-01","November 28, 2016","November 28, 2018","November 28, 2019","February 23, 2017","null","February 23, 2017","Second Xiangya Hospital of Central South University, Changsha, Hunan, China","","https://ClinicalTrials.gov/show/NCT03060343"
689,"NCT03059979","The Effect of High Dose Methylprednisolone on Nailfold in Early Systemic Sclerosis ( SSc )",,"Recruiting","No Results Available","Systemic Sclerosis|Raynaud Phenomena","Drug: Methylprednisolone|Other: sodium chloride","the change in capillary density from baseline|change in selected biomarkers: the interferon signature in peripheral blood from baseline|change in nail fold capillary changes other than capillary density and giant capillaries from baseline|change in modified Rodnan skin score (mRSS) from baseline|presence of puffy fingers from baseline|presence of synovitis from baseline|presence of tendon friction rubs from baseline|fulfilling EULAR/ACR ( American College of Rheumatology )classification from baseline criteria for SSc from baseline|pulmonary function tests from baseline|presence of interstitial lung disease from baseline|suspicion of pulmonary hypertension from baseline|Change in physical function from baseline|general health score from baseline|Change in 36-Item Short Form Survey (SF-36) total score from baseline|Change in Scleroderma Health Assessment Questionnaire (SHAQ)total score from baseline|Change in EQ-5D is a standardised instrument for use as a measure of health outcome. (EQ5D) total score from baseline|Change in gastrointestinal tract ( GIT ) total score from baseline","Radboud University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HHaE","January 2017","January 2020","January 2020","February 23, 2017","null","April 17, 2018","Radboudumc, Rheumatology department, Nijmegen, Gelderland, Netherlands","","https://ClinicalTrials.gov/show/NCT03059979"
690,"NCT03059940","Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer",,"Recruiting","No Results Available","Smoking Cessation","Behavioral: Questionnaires|Procedure: Low Dose Computed Tomography Scan|Other: Shared Decision Making + Video|Behavioral: Cessation Counseling|Behavioral: Quitline|Behavioral: Pharmacotherapy Discussion|Drug: Nicotine Patch|Drug: Anti-Smoking Drug|Behavioral: Tobacco Treatment Program|Other: Carbon Monoxide (CO) Level Test","Smoking Abstinence Rate","M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Pfizer","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","1260","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2016-0626|R01-CA 2027078-01|NCI-2018-01219","June 16, 2017","June 2022","June 2023","February 23, 2017","null","July 16, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03059940"
691,"NCT03059888","Trial of Orencia in Patients With Myasthenia Gravis",,"Recruiting","No Results Available","Myasthenia Gravis","Drug: Abatacept Injection","Subjective Composite Score of Myasthenia Gravis (MG) Severity|Objective Composite Score of Myasthenia Gravis (MG) Severity|Muscle Strength (Dynamometry)|Myasthenia Gravis Composite Score (MGC)|Myasthenia Gravis Quality of Life-15 (MG QOL15) Score|Acetylcholine Receptor (AChR) or Muscle-Specific Kinase (MuSK) Antibody Concentrations","Johns Hopkins University|Bristol-Myers Squibb","All","16 Years to 85 Years   (Child, Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00100059","April 12, 2017","January 2019","January 2019","February 23, 2017","null","September 28, 2018","Johns Hopkins University, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03059888"
692,"NCT03059498","PECS Block: Plasma Bupivacaine Level",,"Completed","No Results Available","Nerve Blocks","Procedure: Unilateral PECS I and II block|Procedure: Bilateral PECS I and II block|Drug: Bupivacaine","Peak plasma bupivacaine concentration|Bupivacaine mean concentration|Standard deviations of plasma bupivacaine concentrations|Rates of block success|Rates of adequate ultrasound success of appropriate separation of the muscular layers for each block.|Rates of symptoms of local anesthetic systemic toxicity","Wake Forest University Health Sciences","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00042325","June 6, 2017","November 15, 2017","November 15, 2017","February 23, 2017","null","August 9, 2018","Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03059498"
693,"NCT03059316","The Effects of Nitroglycerin Versus Labetalol on the Perfusion During Hypotensive Anesthesia",,"Completed","No Results Available","Controlled Hypotension for Nasal Surgeries","Combination Product: Massimo device|Drug: Nitroglycerin drug|Drug: Labetalol","perfusion index|serum lactate level|surgical feild score","Cairo University","All","18 Years to 45 Years   (Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","N-53-2016","June 10, 2016","April 10, 2017","April 21, 2017","February 23, 2017","null","July 19, 2017","","","https://ClinicalTrials.gov/show/NCT03059316"
694,"NCT03058965","Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain",,"Recruiting","No Results Available","Alzheimer Disease|Healthy Volunteers|Progressive Supranuclear Palsy","Drug: [18F]MNI-958|Drug: [18F]Florbetapir|Drug: DaTscan","Tracer uptake will be evaluated in regions of interest for analysis of regional [18F]MNI-958 binding/uptake and expressed in SUV by using established methods for normalization for 3 AD, 3 PSP, and 3 HV subjects.","Molecular NeuroImaging","All","50 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","[18F]MNI-958","November 2016","November 2018","November 2018","February 23, 2017","null","March 6, 2018","Molecular NeuroImaging, LLC, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03058965"
695,"NCT03057535","Impact of NaHCO3- on Exercise Hyperpnea",,"Completed","No Results Available","Pulmonary Ventilation","Drug: Sodium Bicarbonate|Drug: Sodium Chloride","Ventilatory equivalent to carbon dioxide (V̇E/V̇CO2) at its lowest point (""nadir"") during exercise|Partial pressure of carbon dioxide in the arterialized capillary blood (PacCO2)","McGill University","All","18 Years to 40 Years   (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","A02-M19-15B","May 2015","April 2016","September 2016","February 20, 2017","null","February 20, 2017","McGill University, Department of Kinesiology & Physical Education, Clinical Exercise & Respiratory Physiology Laboratory, Montreal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT03057535"
696,"NCT03056014","Antioxidant Use in Diabetes to Reduce Oxidative Stress",,"Not yet recruiting","No Results Available","Ameliorating Oxidative Stress in Type 1 Diabetes","Drug: N-acetyl cysteine|Dietary Supplement: omega 6 Fish oil ( PUFA)|Dietary Supplement: Placebo","Change from baseline in level of oxidative stress with varying doses of NAC at 2 weeks.|Change from baseline in level of oxidative stress with varying doses of omega 6 fish oil(PUFA) at 2 weeks.","University of Maryland","Female","18 Years to 44 Years   (Adult)","Early Phase 1","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","HP-00067782","May 2018","June 2018","June 2020","February 16, 2017","null","February 5, 2018","","","https://ClinicalTrials.gov/show/NCT03056014"
697,"NCT03055546","Effects of Intranasal Oxytocin on Emotion Regulation",,"Recruiting","No Results Available","Healthy","Drug: Oxytocin|Drug: Placebo","Oxytocin effects on neural activity during emotion regulation task|Oxytocin effects on heart rate variability during emotion regulation task|Oxytocin effects on behavior response during emotion regulation task|Oxytocin effects on heart rate variability during resting-state|Oxytocin effects on neural activity during resting-state","University of Electronic Science and Technology of China","Male","18 Years to 30 Years   (Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","UESTC-neuSCAN-11","February 2016","December 2018","March 2019","February 16, 2017","null","October 29, 2018","School of Life Science and Technology, University of Electronic Science and Technology, Chengdu, Sichuan, China","","https://ClinicalTrials.gov/show/NCT03055546"
698,"NCT03051646","Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis",,"Completed","No Results Available","Fatigue|Overheating","Drug: Acetylsalicylic acid|Drug: Placebo Oral capsule","Increased time to exhaustion|Exercise-induced body temperature increase","Columbia University|National Multiple Sclerosis Society","All","18 Years to 60 Years   (Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AAAQ1758","January 13, 2017","May 10, 2017","May 10, 2017","February 14, 2017","null","May 18, 2017","Columbia University Medical Center, MS Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03051646"
699,"NCT03050515","Fecal Microbiota Transplantation for the Treatment of Recurrent Urinary Tract Infections",,"Recruiting","No Results Available","Recurrent Urinary Tract Infection","Biological: Fecal Microbiota Transplantation","Change in frequency of culture proven urinary tract infections following fecal transplant|Efficacy of fecal transplant in transforming recurrent urinary tract infection bacteria profile to that of pan-sensitive organisms on urine culture specimens|Change in the gut microbiome following fecal transplantation measured via 16s sequencing of stool samples","University of California, Irvine","Female","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-3541","February 5, 2018","June 2019","June 2019","February 13, 2017","null","March 22, 2018","UCI Women's Healthcare Center, Orange, California, United States","","https://ClinicalTrials.gov/show/NCT03050515"
700,"NCT03049293","Measurement of Midazolam Levels in Follicular Fluid",,"Recruiting","No Results Available","Midazolam Overdose","Drug: Midazolam","Midazolam values measured by the time from the injection of Midazolam to the oocyte aspiration .","IVI Middle East Fertility Clinic","Female","18 Years to 38 Years   (Adult)","Early Phase 1","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1610-ABU-074-HF","June 20, 2017","October 2020","November 2020","February 10, 2017","null","November 8, 2018","IVI Middle East Fertilty Clinic, Abu Dhabi, United Arab Emirates","","https://ClinicalTrials.gov/show/NCT03049293"
701,"NCT03049111","Screening Inhaled Allergen Challenge for Dermatophagoides Farinae","MiteScreen","Recruiting","No Results Available","Asthma","Biological: Der f","Decline of FEV1 during the late phase response|Levels of IL-1β in induced sputum|Sputum granulocytes|Mucins in sputum|Maximum drop in FEV1 during the late phase response|Airway hyper-responsiveness|Exhaled nitric oxide (eNO) levels","University of North Carolina, Chapel Hill|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 45 Years   (Adult)","Early Phase 1","100","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16-2131|1R01HL135235-01A1","November 20, 2017","March 2022","March 2022","February 9, 2017","null","June 15, 2018","UNC Center for Environmental Medicine, Asthma and Lung Biology, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03049111"
702,"NCT03048929","Inflammation and Threat Sensitivity in PTSD","K01","Not yet recruiting","No Results Available","Posttraumatic Stress Disorder","Biological: Typhoid Vi Polysaccharide Vaccine|Biological: Placebo","Neural activity to threat as assessed with functional magnetic resonance imaging|Threat sensitivity","University of California, San Francisco|National Institute of Mental Health (NIMH)","All","30 Years to 60 Years   (Adult)","Early Phase 1","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","15-18367|K01MH109871","November 1, 2018","April 2020","April 2020","February 9, 2017","null","May 2, 2018","San Francisco Veterans Affairs Medical Center, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT03048929"
703,"NCT03044977","Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors",,"Recruiting","No Results Available","Neuroendocrine Tumor, Malignant|Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting","Drug: 90Y-DOTA-3-Tyr-Octreotide|Drug: 131I-MIBG","glomular filtration rate (eGFR)|urine protein|platelet count decreased|absolute neutrophil count decreased|Progression free survival (PFS)|Overall survival (OS)","David Bushnell|National Institutes of Health (NIH)|National Cancer Institute (NCI)|Holden Comprehensive Cancer Center|University of Iowa","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","20","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201608857|P50CA174521-02","May 7, 2017","December 31, 2020","December 31, 2022","February 7, 2017","null","April 17, 2018","Holden Comprehensive Cancer Center, Iowa City, Iowa, United States","","https://ClinicalTrials.gov/show/NCT03044977"
704,"NCT03042091","Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery",,"Recruiting","No Results Available","Colorectal Neoplasms|Diverticulitis|Inflammatory Bowel Diseases|Surgical Site Infection","Drug: Polyethylene Glycol|Drug: Neomycin|Drug: Metronidazole Hydrochloride|Procedure: Therapeutic Conventional Surgery","Incidence of post-operative surgical site infection (SSI) including superficial/incisional, deep, and organ space, anastomotic dehiscence and leak|Incidence of post-operative clostridium difficile infection|Incidence of adynamic ileus|Incidence of cardiopulmonary complications|Incidence of urinary tract infection|Length of hospital stay|Incidence of mortality","Thomas Jefferson University","All","19 Years and older   (Adult, Older Adult)","Early Phase 1","224","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","16D.204","September 2016","October 2020","October 2021","February 3, 2017","null","August 22, 2018","Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03042091"
705,"NCT03041740","Fluid Filled Lung Oxygenation Assistance Trial","FFLOAT","Recruiting","No Results Available","Bronchopulmonary Dysplasia","Drug: Perfluorooctylbromide(PFOB)","Number of PFOB participants with no treatment-related adverse events as assessed by CTCAE v4.03 toxicity Scale.|Pulmonary Artery Pressure Response to PFOB","Children's Hospital of Philadelphia|ADAGP Charitable Foundation dba Auto Dealers CARing for Kids Foundation","All","up to 6 Months   (Child)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-008686","June 27, 2017","December 2019","January 2021","February 3, 2017","null","October 15, 2018","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03041740"
706,"NCT03039491","Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults",,"Recruiting","No Results Available","HIV Lipodystrophy|Aging","Biological: Pneumococcal polysaccharide vaccine 23 valent|Biological: 13 valent conjugated pneumococcal vaccine","Antibody response|opsonophagocytic antibody activity|PPS-specific B cell phenotype|Expression of TACI on PPS-specific B cells|Expression of BAFFR on PPS-specific B cells|Expression of BCMA on PPS-specific B cells|Expression of CD40 on PPS-specific B cells|Expression of cluster of differentiation 21 (CD21) on PPS-specific B cells|Expression of CD21 on PPS-specific B cells|Serum interleukin-6 (IL-6)|Serum BAFF|Serum APRIL|Serum IL-10|Serum IL-1(RA)|Serum IL-1(B)|Serum IL-8|Serum TNFalpha","Medical University of South Carolina","All","21 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MUSC vaccine study","September 1, 2015","March 30, 2019","June 30, 2019","February 1, 2017","null","June 18, 2018","Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT03039491"
707,"NCT03039413","Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy",,"Recruiting","No Results Available","Bladder Urothelial Carcinoma|Urothelial Carcinoma","Drug: Copper Cu 64 TP3805|Procedure: Positron Emission Tomography|Procedure: Computed Tomography","Feasibility of Cu-64-TP3805 to detect UC as determined by post-surgical histology|Blood clearance defined as the point at which radioactivity decreases to 50% of the initial value|Radioactivity internalization of copper Cu 64 TP3805 as analyzed in centrifuged urine samples","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","16G.500","September 28, 2016","March 15, 2021","January 30, 2022","February 1, 2017","null","November 24, 2017","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03039413"
708,"NCT03037944","Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri","LNG-IUDvsCOCs","Recruiting","No Results Available","Adenomyosis","Drug: Yasmin|Device: Metraplant-E","Measurement of pain by pain measurement score|Number of bleeding days","Ain Shams Maternity Hospital","Female","30 Years to 45 Years   (Adult)","Early Phase 1","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","ASAD0316","March 1, 2016","December 1, 2017","December 1, 2018","January 31, 2017","null","January 31, 2017","Ain Shams University - Maternity Hospital, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03037944"
709,"NCT03035838","Importance of Substance P in Intracranial Pressure Elevation Following Traumatic Brain Injury","NK1","Not yet recruiting","No Results Available","Traumatic Brain Injury","Drug: Fosaprepitant","Reduction in intracranial pressure|Improvement in brain tissue oxygen tension|Improvement in lactate/pyruvate ratio on microdialysis monitoring","Arun Gupta|Cambridge University Hospitals NHS Foundation Trust|University of Cambridge","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","212176","October 2019","December 2020","April 2021","January 30, 2017","null","October 11, 2018","","","https://ClinicalTrials.gov/show/NCT03035838"
710,"NCT03032367","TASK-002: Bioequivalence of Bedaquiline 400mg Administered in Crushed Form Compared to Tablet Form in Healthy Male and Female Adults Under Fed Conditions (BDQ Crush Study)",,"Completed","No Results Available","Tuberculosis","Drug: bedaquiline","Bioequivalence of bedaquiline 4 x 100mg given to healthy adult males and females orally in tablet form compared to crushed form","International Maternal Pediatric Adolescent AIDS Clinical Trials Group|US National Institute of Allergy and Infectious Diseases|US National Institute of Child Health and Human Development|National Institute of Mental Health (NIMH)","All","18 Years to 55 Years   (Adult)","Early Phase 1","24","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","TASK-002","November 10, 2016","December 9, 2016","January 11, 2017","January 26, 2017","null","July 28, 2017","TASK Clinical Research Centre, Bellville, Western Cape, South Africa","","https://ClinicalTrials.gov/show/NCT03032367"
711,"NCT03030079","Electrical Stimulus Therapy for Chronic Phantom Limb Pain",,"Recruiting","No Results Available","Phantom Limb Pain","Device: High intensity electrical stimulation","Use of electrical stimulus medium frequency alternating current for short term decreased Phantom Limb Pan|Assess the effectiveness of reducing chronic phantom limb pain long term.","University of Colorado, Denver|Hanger Clinic: Prosthetics & Orthotics","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-1063","January 2017","December 2018","December 2018","January 24, 2017","null","May 10, 2018","Children's Hospital Colorado Research Institute, Aurora, Colorado, United States","","https://ClinicalTrials.gov/show/NCT03030079"
712,"NCT03027674","Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud",,"Completed","No Results Available","Raynaud Phenomenon Due to Trauma|Raynaud Disease|System; Sclerosis|Lupus Erythematosus, Systemic|Dermatomyositis|Ultrasound Therapy; Complications","Drug: 10% nifedipine cream|Drug: 5% sildenafil cream","Improvement of blood flow in the digital arteries (peak systolic velocity ) of the dorsal arterial arch of the proximal nail fold of the index, middle and thumb fingers of both hands|Improvement of the diameter (mm) of the dorsal arterial arch of the proximal nail fold of the of the index, middle and thumb fingers of both hands.","Pontificia Universidad Catolica de Chile","All","13 Years to 99 Years   (Child, Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","16-234","August 2016","August 2016","August 2016","January 23, 2017","null","January 23, 2017","Department of Dermatology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile., Santiago, RM, Chile","","https://ClinicalTrials.gov/show/NCT03027674"
713,"NCT03027466","Integrating Use of Self-Affirmation Content Into a Mobile App to Promote Quit Attempts With Text-Based Smoking Cessation Intervention Messaging",,"Not yet recruiting","No Results Available","Number of Quit Attempts","Behavioral: Self-affirmation induction","number of quit attempts|self-reported smoking status|number of smoke-free days|type of tobacco products","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","5000","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","999917039|17-C-N039","January 6, 2017","September 20, 2019","September 20, 2019","January 23, 2017","null","October 4, 2018","National Cancer Institute (NCI), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03027466"
714,"NCT03027388","Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma",,"Not yet recruiting","No Results Available","Astrocytoma, Grade IV|Glioblastoma Multiforme|Giant Cell Glioblastoma","Drug: LB-100","Drug Level in tumor tissue","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","20","NIH","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","170037|17-C-0037","January 5, 2017","August 30, 2020","August 30, 2020","January 23, 2017","null","October 9, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03027388"
715,"NCT03027206","Respiratory Physiotherapy Change Premature Pain With Pneumonia","RPCPPWP","Completed","No Results Available","Premature|Pneumonia|Pain|Physiotherapy","Other: Vibration technique|Other: Acceleration of expiratory flow","Evaluation of the parameters of the pain profile scale in preterm infants at different times","Amazon University|Fundação Santa Casa de Misericórdia do Pará (FSCMPA)","All","up to 28 Days   (Child)","Early Phase 1","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","1.690.842","June 2015","July 2016","November 2016","January 23, 2017","null","January 23, 2017","","","https://ClinicalTrials.gov/show/NCT03027206"
716,"NCT03025399","Clinical Study of Tang Wang Prescription Intervene Diabetic Non-proliferative Retinopathy",,"Not yet recruiting","No Results Available","Diabetic Non-proliferative Retinopathy|Type2 Diabetes","Drug: Tangwang prescription|Drug: Placebo","the changes of degree of retinal microvascular lesions before and after treatment (no, mild non proliferative phase, moderate non proliferative phase, severe non proliferative phase, proliferative phase)|Change of the number of micro hemangioma of diabetic retinopathy|Change of the number of microvascular bleeding of diabetic retinopathy|Change of the number of microvascular leakage of diabetic retinopathy|Degree of change of macular edema of diabetic retinopathy,analysis of measured values of the shortest distance from the margin of edema and the retinal thickness in macular region before and after medication|Change of Vision (analysis of visual acuity before and after medication using EDTRS international visual acuity chart)","Fengmei Lian|Guang'anmen Hospital of China Academy of Chinese Medical Sciences|The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine|Hubei Hospital of Traditional Chinese Medicine|Zhengzhou City Hospital of Traditional Chinese Medicine|Baodin City Hospital of Traditional Chinese Medicine|zi bo wanjie cancer hospital|Shijiazhuang City Hospital of Traditional Chinese Medicine|Zouping Country Hospital of Traditional Chinese Medicine","All","30 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","384","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2015Tangwang Prescription","February 2017","May 2019","May 2020","January 19, 2017","null","January 20, 2017","","","https://ClinicalTrials.gov/show/NCT03025399"
717,"NCT03022565","Vorinostat in Patients With Class 2 High Risk Uveal Melanoma",,"Recruiting","No Results Available","Uveal Melanoma","Drug: Vorinostat","Degree of transformation from a class 2 phenotype into a cell phenotype that resembles normal melanocytes.|Proportion of patients whose tumors transformed from a class 2 phenotype into a cell phenotype that resembles normal melanocytes.|Toxicity During Protocol Therapy|Tumor size before and after Vorinostat therapy|Recurrence-free survival (RFS)|Overall survival (OS)|Disease Specific Survival (DSS)","University of Miami|University of Miami Sylvester Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20160653","December 2018","December 2020","December 2025","January 16, 2017","null","September 7, 2018","University of Miami, Miami, Florida, United States","","https://ClinicalTrials.gov/show/NCT03022565"
718,"NCT03021421","Comparison of Two Regional Technics In Knee Artroplasty","CTRTIKA","Completed","No Results Available","Postoperative Analgesia|Anesthesia; Functional","Procedure: intratechal (subarachnoidal )injection|Procedure: lombar plexus and sciatic nerve injection","Postoperative VAS values|Perioperative Heart Rate|Perioperative Mean Arterial Pressure","T.C. ORDU ÜNİVERSİTESİ","All","50 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","OrduU","January 2015","June 2015","July 2015","January 13, 2017","null","January 13, 2017","","","https://ClinicalTrials.gov/show/NCT03021421"
719,"NCT03020524","Autologous CD4 T-Cells in HIV (C34-CXCR4)",,"Recruiting","No Results Available","Hiv","Biological: Autologous CD4 T-Cells","The number of subjects with treatment related adverse events|Compare the percentage of enriched modified cells C34-CXCR4 modifiec T- cells|Compare the change between CD4 count|Compare viral set point log 10 HIV RNA level|Evaluate cell mediated response (immunogenicity) using flow cytometry","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","9","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","826035","January 2017","January 2019","December 2019","January 13, 2017","null","August 3, 2018","University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03020524"
720,"NCT03020433","Novel Brain Stimulation Therapies in Stroke Guided Expressions of Plasticity",,"Recruiting","No Results Available","Stroke|Cerebrovascular Disorders|Nervous System Diseases|Brain Diseases|Cardiovascular Diseases|Vascular Diseases|Central Nervous System Diseases","Device: rTMS Contralesional M1|Device: rTMS Contralesional PMC|Device: rTMS Ipsilesional PMC|Device: rTMS sham at Ipsilesional M1","Aim 1: Change in time (seconds) to perform functional reaching|Aim 2:Change in plasticity evoked with rTMS.","The Cleveland Clinic","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","16-128|16GRNT27720019","March 2016","December 2017","December 2017","January 13, 2017","null","January 13, 2017","Cleveland Clinic Foundation, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03020433"
721,"NCT03020017","NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery",,"Active, not recruiting","No Results Available","Gliosarcoma|Recurrent Glioblastoma","Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Targeted Molecular Therapy","Incidence of Adverse Events|Drug concentration in blood after drug administration|Biodistribution of NU-0129 in tumor tissue|Feasibility of giving NU-0129 as a standard treatment","Northwestern University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","8","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 16C01|STU00203790|P30CA060553|NCI-2016-02007","May 4, 2017","July 2019","July 2022","January 13, 2017","null","August 22, 2018","Northwestern University, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT03020017"
722,"NCT03019822","Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing","LAM","Completed","No Results Available","Healthy","Drug: LSD|Drug: MDMA|Drug: Amphetamine|Drug: Placebo","Emotional enhancement as determined by fMRI|fMRI brain activity|Resting State fMRI|Effect Modulation by personality traits (assessed with questionnaires),|Effect Modulation by amygdala reactivity to fear (assessed in the fMRI)|Effect Modulation by genetic polymorphisms (determined by genotyping of each subject)","University Hospital, Basel, Switzerland","All","25 Years to 50 Years   (Adult)","Early Phase 1","28","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","BASEC 2016-01827","February 1, 2017","August 11, 2018","September 4, 2018","January 13, 2017","null","October 15, 2018","University Hospital Basel, Basel, Basel Stadt, Switzerland","","https://ClinicalTrials.gov/show/NCT03019822"
723,"NCT03016832","Clinical Trial of HuangKui Capsule to Treat Diabetic Kidney Disease",,"Recruiting","No Results Available","Diabetic Kidney Disease","Drug: Placebo drug that simulates Irbesartan tablets|Drug: irbesartan tablets|Drug: Placebo drug that simulates HuangKui capsule|Drug: HuangKui Capsule","ACR|24-hour urinary protein|PCR|Glomerular filtration rate|TCM syndromes Efficacy endpoint|High sensitivity C","Jiangsu Famous Medical Technology Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","414","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SZCT-2016-01","January 2017","May 2018","December 2018","January 11, 2017","null","July 5, 2017","Jiangsu Province Hospital of TCM, Nanjing, Jiangsu, China","","https://ClinicalTrials.gov/show/NCT03016832"
724,"NCT03014895","A Single Intravenous Dose Study of E3112 in Japanese Healthy Adult Male Subjects",,"Completed","No Results Available","Healthy Male Volunteers","Drug: Placebo|Drug: E3112","Peak concentration (Cmax) of E3112|Time to peak concentration (Tmax) of E3112|Area under the curve (AUC)|Half-life of elimination (t1/2) of E3112|Clearance of E3112|Volume of distribution (Vd) of E3112|Number of participants with any serious adverse event and any non-serious adverse event|Number of participants with an abnormal, clinically significant hematology parameter value|Number of participants with an abnormal, clinically significant blood chemistry parameter value|Number of participants with an abnormal, clinically significant urine value|Number of participants with an abnormal, clinically significant vital sign measurement|Number of participants with an abnormal, clinically significant electrocardiogram (ECG) measurement|Number of participants with an abnormal, clinically significant physical examination measurement","EA Pharma Co., Ltd.|Eisai Inc.","Male","20 Years to 44 Years   (Adult)","Early Phase 1","29","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","E3112/CP1","January 25, 2017","June 12, 2017","November 22, 2017","January 9, 2017","null","November 14, 2018","EA Pharma Trial Site, Toshima, Tokyo, Japan","","https://ClinicalTrials.gov/show/NCT03014895"
725,"NCT03012958","Utility of Lung Clearance Index Score as a Noninvasive Marker of Deployment Lung Disease","LCI","Active, not recruiting","No Results Available","Bronchiolitis|Pneumonitis|Dyspnea","Other: Lung clearance index (LCI)","LCI parameters in symptomatic deployers compared to normal adults to determine whether LCI is an early marker of lung injury.|Correlation between LCI score and the clinical characteristics of the population of deployers.","National Jewish Health","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","400","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","HS-2851","July 2014","January 2019","January 2019","January 6, 2017","null","April 20, 2018","National Jewish Health, Denver, Colorado, United States","","https://ClinicalTrials.gov/show/NCT03012958"
726,"NCT03010241","The Multi-Centric Clinical Study of Chinese Medicine Intervention on Diabetes Distal Symmetric Polyneuropathy.",,"Not yet recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: Tangbi (prescription)|Drug: Placebo","The clinical symptoms and signs of patients were recorded by Michigan Diabetic Neuropathy Score(MDNS), and the changes of Michigan Diabetic Neuropathy Score(MDNS) were compared between the two groups before and after medication|nerve conduction velocity changes The changes in nerve conduction velocity of each nerve were compared before and after taking medicine.|Clinical symptoms and signs change The clinical symptoms and signs of the patients were compared before and after taking the medicine.","Guang'anmen Hospital of China Academy of Chinese Medical Sciences|The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine|Zhengzhou City Hospital of Traditional Chinese Medicine|the first affiliated hospital of Liaoning university of traditional Chinese medicine|Hebei Yiling Hospital|Hubei Hospital of Traditional Chinese Medicine","All","30 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","188","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2016Tangbi Prescription","January 2017","November 2019","May 2020","January 5, 2017","null","January 5, 2017","","","https://ClinicalTrials.gov/show/NCT03010241"
727,"NCT03009864","The Multi-Center Clinical Study of Tang Shen Prescription on Type 2 Diabetic Kidney Disease in Early Stage",,"Not yet recruiting","No Results Available","Diabetic Kidney Disease","Drug: Tangshen Prescription|Drug: Placebos","changes of albumin-to-creatinine ration|number of participants of diabetic kidney disease in macroalbuminuria stage|number of participants whose microalbuminuria excretion rate < 20ug/min|change of GFR|the rate of doubling the baseline with serum creatinine value","Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Anhui Provincial Hospital of Traditional Chinese Medicine|Zhengzhou City Hospital of Traditional Chinese Medicine|Shijiazhuang City Hospital of Traditional Chinese Medicine|Baoding City Hospital of Traditional Chinese Medicine|Hubei Hospital of Traditional Chinese Medicine|Changchun Hospital of Traditional Chinese Medicine|Xingtai City Hospital of Traditional Chinese Medicine|Medicine Zibo Wanjie Tumor Hospital|Zouping Country Hospital of Traditional Chinese Medicine|She Country Hospital of Traditional Chinese Medicine|Beijing Hospital of TCM|Baishi Hospital","All","30 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","632","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","201507001-11Tangshen","January 2017","September 2019","May 2020","January 4, 2017","null","January 4, 2017","Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03009864"
728,"NCT03009266","Ischemic Memory Imaging With Myocardial Contrast Echocardiography",,"Recruiting","No Results Available","Myocardial Ischemia","Drug: Sonazoid","Dose optimization|Detection of Ischemia","Oregon Health and Science University","All","19 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00016794","July 7, 2018","December 2019","December 2019","January 4, 2017","null","August 23, 2018","OHSU, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT03009266"
729,"NCT03009149","Effects of Aerobic Exercise on CD4 Count,Viral Load,Selected Psycho-social Trait",,"Enrolling by invitation","No Results Available","HIV","Other: Aerobic exercise","CD4 count|Effects of aerobic exercise on psycho-social|viral load change duo to aerobic exercise","Mekelle University","All","30 Years to 40 Years   (Adult)","Early Phase 1","58","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","ERC0771/2016","November 2016","January 2017","February 2017","January 4, 2017","null","January 4, 2017","","","https://ClinicalTrials.gov/show/NCT03009149"
730,"NCT03006510","Hypoglycemia Prediction Model",,"Not yet recruiting","No Results Available","Hypoglycemia","Other: Hypoglycemia prediction alert","The proportion of patients (in each group) who ultimately have a hypoglycemic event","University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","6500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Prevention","16-20565","January 2017","January 2018","July 2018","December 30, 2016","null","December 30, 2016","","","https://ClinicalTrials.gov/show/NCT03006510"
731,"NCT03004534","A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide",,"Recruiting","No Results Available","Breast Cancer Female","Drug: darolutamide","Explore/Define Molecular Alterations in Core Tissue Tumor Samples Following Darolutamide Administration|Number of participants with treatment-related adverse events as assessed by CTCAE v4.03","Translational Research in Oncology|Bayer","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TRIO030|2016-004151-79|HC6-24-c 201058","September 5, 2017","February 2019","April 2019","December 29, 2016","null","October 8, 2018","UCLA, Los Angeles, California, United States|Valley Breast Care and Women's Health Center, Los Angeles, California, United States|Torrance Memorial Physician Network, Cancer Care Associates, Redondo Beach, California, United States|Central Coast Medical Oncology, Santa Maria, California, United States|UF Health Cancer Center - Orlando Health, Orlando, Florida, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|McGill University Hospital, Montreal, Quebec, Canada|(CIUSSS) de l'Est-de-l'Île-de-Montréal - l'Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Centre Hospitalier Affilie Universitaire De Quebec - Hospital Du Saint-Sacrement, Quebec City, Quebec, Canada|Universitatsklinikum Erlangen, Erlangen, Germany|Interdisziplinares Onkologisches Zentrum, Muenchen, Germany|Department of Women's Health, Tubingen, Germany","","https://ClinicalTrials.gov/show/NCT03004534"
732,"NCT03001752","Immediate Implants Inserted Through Open Flap, Open Flap and Bone Grafting and Flapless Techniques","ETPEI-RCT","Not yet recruiting","No Results Available","Isolated Premolar Edentulous Site","Device: Open flap immediate implant|Device: Open flap immediate implant and bone grafting|Device: Flapless immediate implant","Marginal Bone Loss measured through CT Cone Beam|Alveolar Bone Dimensional Reduction assessed through CT Cone Beam|Pain and Discomfort measured through questionaire|Intra-operatory or post-operatory complications assessed through intra-operatory observation and post-intervention check-ups.|Time needed to perform surgical intervention","University of Bari","All","20 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","4987","January 2017","September 2017","September 2017","December 23, 2016","null","December 28, 2016","","","https://ClinicalTrials.gov/show/NCT03001752"
733,"NCT03001349","68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors",,"Active, not recruiting","No Results Available","Meningioma|Metastatic Well Differentiated Neuroendocrine Neoplasm|Multiple Endocrine Neoplasia Type 1|Neuroendocrine Neoplasm|Somatostatin Positive Neoplastic Cells Present|Von Hippel-Lindau Syndrome","Procedure: Computed Tomography|Drug: Gallium Ga 68-Edotreotide|Procedure: Positron Emission Tomography","Incidence of adverse events as measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4 (CTCAE v4)","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Older Adult","Early Phase 1","100","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2016-0030|NCI-2018-01894|P30CA016672","May 16, 2017","December 31, 2019","December 31, 2020","December 23, 2016","null","September 24, 2018","M D Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03001349"
734,"NCT03001271","Acute Effect of Agiotensin-(1-7) in Healthy and Hypertensive Subjects","Ang-(1-7)","Active, not recruiting","No Results Available","Hypertension","Drug: Angiotensin 1-7|Other: Placebo","Absence of adverse effects after Ang-(1-7) acute administration|Blood Pressure Changes after Ang-(1-7) administration|Ang-(1-7) effects on Blood Pressure Variability|Heart Rate Changes after Ang-(1-7) administration|Ang-(1-7) effects on Heart Rate Variability","Instituto de Cardiologia do Rio Grande do Sul","All","18 Years to 60 Years   (Adult)","Early Phase 1","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","4576/10","January 2014","February 2017","March 2017","December 23, 2016","null","December 23, 2016","","","https://ClinicalTrials.gov/show/NCT03001271"
735,"NCT02998775","Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding",,"Completed","No Results Available","Hepatic Impairment; Renal Impairment","Drug: Plasma Sampling","Number of participants with any serious adverse event and any non-serious adverse event","Eisai Inc.","All","18 Years to 79 Years   (Adult, Older Adult)","Early Phase 1","54","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","E7080-A001-010","December 2, 2016","July 8, 2017","July 8, 2017","December 20, 2016","null","September 7, 2018","Orlando Clinical Research Center, Inc., Orlando, Florida, United States|DaVita Clinical Research, Minneapolis, Minnesota, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT02998775"
736,"NCT02996643","Ultrasound-Assisted Brace Casting for AIS",,"Completed","No Results Available","Scoliosis; Adolescence","Device: Ultrasound Assisted Group","In-brace Cobb angle|Number of adjustments","University of Alberta","All","10 Years to 18 Years   (Child, Adult)","Early Phase 1","34","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Pro000028133","January 2012","March 2016","March 2016","December 19, 2016","null","December 19, 2016","Medicine and Dentistry, Edmonton, Alberta, Canada","","https://ClinicalTrials.gov/show/NCT02996643"
737,"NCT02995083","Intra-articular Injections for Knee Osteoarthritis: A Single Blinded Prospective Randomized Trial",,"Withdrawn","No Results Available","Symptomatic Osteoarthritis of the Knee","Drug: 40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine|Drug: Normal Saline 10 ml|Drug: Air 10 ml","Mean change in Western Ontario and McMaster Universities Arthritis Index score (WOMAC)|Mean change in Knee injury and Osteoarthritis Outcome Score (KOOS)|Mean change in International Knee Documentation Committee (IKDC) score|Mean change in Visual Analogue Scale (VAS)|Mean change in Short Form 12 (SF-12) score|Mean change in The Lysholm Knee score|Mean change in use of rescue medication","Rush University Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","16090902","June 2017","January 2018","January 2018","December 16, 2016","null","December 18, 2017","","","https://ClinicalTrials.gov/show/NCT02995083"
738,"NCT02994875","Functional Magnetic Resonance Imaging of N-acetylcysteine in Cocaine Dependence",,"Recruiting","No Results Available","Cocaine Dependence","Dietary Supplement: N-acetylcysteine|Other: Placebo","Change in neural network engagement measured using functional magnetic resonance imaging","Yale University","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1510016617","May 2016","May 2022","May 2022","December 16, 2016","null","January 9, 2018","Yale University School of Medicine, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02994875"
739,"NCT02994550","Influence of FSH/LH Ratio in Controlled Ovarian Stimulation",,"Not yet recruiting","No Results Available","Sub-Fertility","Drug: FSH/LH","Pregnancy achievement","Hospital de Cruces","Female","35 Years to 40 Years   (Adult)","Early Phase 1","300","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CEIC E14/30","January 2017","June 2017","January 2018","December 16, 2016","null","December 16, 2016","","","https://ClinicalTrials.gov/show/NCT02994550"
740,"NCT02993640","Optimization of Hepatic Hemodynamics During Liver Surgery",,"Completed","No Results Available","Portal Blood Pressure|Liver Surgery|Hepatic Hemodynamics","Drug: vasopressin + nitro","Portal and hepatic venous flow after vasopressin and nitroglycerine infusion|Pressure in the hepatic and portal veins after vasopressin and nitrovasopressin infusion|lactate in the splanchnic circulation","Sahlgrenska University Hospital, Sweden","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","EPN879-13","September 2016","March 20, 2017","March 20, 2017","December 15, 2016","null","November 8, 2018","","","https://ClinicalTrials.gov/show/NCT02993640"
741,"NCT02992678","Pentoxifylline for the Prevention of PEP",,"Recruiting","No Results Available","Pancreatitis","Drug: Pentoxifylline|Drug: Placebo","Acute Pancreatitis|The prophylaxis effect of pentoxifylline on post-ERCP pancreatitis in higher risk patients","Anhui Provincial Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","pentoxifylline-001","December 2016","June 2017","September 2017","December 14, 2016","null","December 14, 2016","Department of General Surgery, Anhui Provincial Hospital Affiliated with Anhui Medical University, HeFei, Anhui, China","","https://ClinicalTrials.gov/show/NCT02992678"
742,"NCT02992509","IVES for Treatment of UUI and OAB",,"Completed","No Results Available","Urinary Bladder, Overactive|Urinary Incontinence, Urge","Device: EMED detruset(TM) intravesical electrical stimulation","Reduction in incontinence","Loma Linda University","Female","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","17","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5130321","December 2014","November 2015","null","December 14, 2016","null","January 4, 2017","Loma Linda University Health, Loma Linda, California, United States","","https://ClinicalTrials.gov/show/NCT02992509"
743,"NCT02992015","Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma",,"Recruiting","No Results Available","Diffuse Intrinsic Pontine Glioma","Drug: Gemcitabine","PK testing levels of gemcitabine, its metabolite difluorodeoxyuridine (dFdU), and gemcitabine necleotides in peripheral blood and DIPG tissue","University of Colorado, Denver|Children's Hospital Colorado","All","3 Years to 17 Years   (Child)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","15-1621.cc","September 23, 2016","September 2019","December 2019","December 14, 2016","null","August 22, 2018","Children's Hospital Colorado, Aurora, Colorado, United States","","https://ClinicalTrials.gov/show/NCT02992015"
744,"NCT02991833","Developing Of A New Incontinence Care Product",,"Completed","No Results Available","Incontinence-associated Dermatitis|Nursing Care","Other: A New Incontinence Care Product|Other: Diaper","A New Incontinence Care Product associated dermatitis|Diaper associated dermatitis","Ege University","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","EGE.0.20.05.00/BOY/1718/99Z","November 2014","April 2015","July 2015","December 14, 2016","null","October 30, 2017","Ege University, Izmir, Turkey","","https://ClinicalTrials.gov/show/NCT02991833"
745,"NCT02991404","Single Injection Adductor Canal Block Versus Continuous Adductor Canal Infusion for Total Knee Arthroplasty",,"Completed","No Results Available","Total Knee Arthroplasty|Pain, Postoperative|Adductor Canal Block","Procedure: Multimodal Peripheral Nerve Block Injection|Procedure: Single Shot Adductor Canal Block|Drug: Initial Bolus|Drug: Continuous infusion","Pain scores|total opioid consumption","Wake Forest University Health Sciences","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","IRB00041950","February 17, 2017","November 15, 2017","November 15, 2017","December 13, 2016","null","April 5, 2018","Wake Forest Baptist Hospital, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02991404"
746,"NCT02990013","AvenovaTM as a Sterile Skin Preparation Agent",,"Not yet recruiting","No Results Available","Cleaning Product Causing Toxic Effect","Device: Avenova|Drug: Povidone-iodine 5% solution|Drug: 4% chlorhexidine|Drug: Isopropyl alcohol","Compare the efficacy of Avenova to other standard of care cleansing agents","University of Miami","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","20160881","December 2018","December 2019","January 2020","December 12, 2016","null","April 6, 2018","University of Miami Bascom Palmer Eye Institute, Miami, Florida, United States","","https://ClinicalTrials.gov/show/NCT02990013"
747,"NCT02989571","The Effects of Increased IV Hydration on Nulliparous Women Undergoing an Induction of Labor",,"Recruiting","No Results Available","Labor; Forced or Induced, Affecting Fetus or Newborn","Drug: Intravenous normal saline administered at 250ml/hr|Drug: Intravenous normal saline administered at 125ml/hr","Delivery within 24 hours (yes or no)|Length of labor (hours of duration)|Epidural use (yes or no)|Oxytocin use (yes or no)|Mode of Delivery (vaginal delivery, operative vaginal delivery, or cesarean)|Indication for operative or cesarean delivery (e.g. Nonreassuring fetal tracing, arrest of labor, other)|Maternal infectious or other morbidity (Yes or No)|Total amount of IV fluids administered (numerical value in milliliters)|Amount of additional oral fluids taken during labor (numerical value in milliliters)|Birth weight (numerical value in grams)|Neonatal weight at 72 hours of life (numerical value in grams)|NICU admission (Yes or No)|Need for treatment of jaundice (yes or no)|NICU length of stay (numerical value expressed in days)","MemorialCare Health System","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","628-15","November 2016","June 2019","June 2019","December 12, 2016","null","March 22, 2018","Long Beach Memorial Medical Center, Long Beach, California, United States","","https://ClinicalTrials.gov/show/NCT02989571"
748,"NCT02989233","Impact of Three Different Education Methods on Oral Hygiene",,"Completed","No Results Available","Oral Hygiene","Other: Non-surgical periodontal treatment","Theoretical Test Application|Gingival index|Plaque index|Bleeding on probing","Umut BALLI|Bulent Ecevit University","All","8 Years to 13 Years   (Child)","Early Phase 1","144","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","36290600/93","January 2014","December 2014","December 2014","December 12, 2016","null","December 13, 2016","","","https://ClinicalTrials.gov/show/NCT02989233"
749,"NCT02989129","Trial of Quercetin in the Treatment and Prevention of Chemotherapy-induced Neuropathic Pain in Cancer Patients",,"Withdrawn","No Results Available","Polyneuropathies and Other Disorders of the Peripheral Nervous System|Chemotherapy Induced Neuropathic Pain","Behavioral: Questionnaires|Drug: Quercetin","Change in Neuropathic Pain Intensity","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-0287","April 2018","April 2020","April 2020","December 12, 2016","null","April 18, 2018","","","https://ClinicalTrials.gov/show/NCT02989129"
750,"NCT02986607","Corticosteroid Rhythms in Hypoparathyroid Patients",,"Recruiting","No Results Available","Hypoparathyroidism|Hyperparathyroidism","Drug: parathyroid hormon 1-84","Corticosteroid secretion in hypoparathyroid patients","University of Bergen|Haukeland University Hospital","All","18 Years to 60 Years   (Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2015/871","March 2016","January 2018","June 2018","December 8, 2016","null","October 27, 2017","Haukeland University Hospital, Bergen, Norway","","https://ClinicalTrials.gov/show/NCT02986607"
751,"NCT02985346","Efficacy of Bone Marrow Mesenchymal Stem Cell in Pulmonary Hemosiderosis",,"Not yet recruiting","No Results Available","Idiopathic Pulmonary Hemosiderosis","Biological: Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis","Complete remission","Sun Yat-sen University","All","1 Month to 18 Years   (Child, Adult)","Early Phase 1","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WTan","January 2017","December 2020","null","December 7, 2016","null","December 7, 2016","","","https://ClinicalTrials.gov/show/NCT02985346"
752,"NCT02983422","Effects of Aminophylline on Renal Function and Urine Volume of AKI Patient",,"Not yet recruiting","No Results Available","Acute Kidney Injury","Drug: aminophylline|Drug: frusemide|Drug: normal saline","serum creatinine|urine volume|Serum cystatin-C|Urine β_2-microglobulin|dose of norepinephrine|blood pressure|central venous pressure","Shanghai Jiao Tong University Affiliated Sixth People’s Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","SSH-ICU-017","December 2016","June 2017","July 2017","December 6, 2016","null","December 6, 2016","","","https://ClinicalTrials.gov/show/NCT02983422"
753,"NCT02982902","T Cell Therapy of Opportunistic Cytomegalovirus Infection",,"Recruiting","No Results Available","Cytomegalovirus Infections|Hematopoietic Stem Cell Transplant|Opportunistic Infections","Biological: CMV specific adoptive t-cells","Incidence of adverse events|Eradication rate of opportunistic CMV infections|response rate","Case Comprehensive Cancer Center","All","3 Months and older   (Child, Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CASE1Z16","December 2016","March 2019","March 2020","December 6, 2016","null","February 5, 2018","University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02982902"
754,"NCT02982551","Insulin Modulation of fMRI Connectivity in Healthy Adults",,"Withdrawn","No Results Available","Healthy Volunteers","Drug: Insulin|Other: Taste Task|Other: Magnetic Resonance Imaging|Drug: Dextrose","fMRI BOLD Response in Brain","University of Pittsburgh","All","21 Years to 30 Years   (Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PRO15040502","January 1, 2016","December 2017","December 2017","December 5, 2016","null","December 4, 2017","Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02982551"
755,"NCT02981914","Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation",,"Recruiting","No Results Available","Classical Hodgkin Lymphoma|B-cell Non-Hodgkin Lymphoma|Acute Myeloid Leukemia|Myelodysplastic Syndromes","Drug: Pembrolizumab","Number of patients with adverse events|Time between initial response and subsequent disease progression or relapse|Time between first documentation of complete remission (CR) or partial remission (PR) (by IRC) to the first documentation of disease progression or death by any cause|Time between the start of therapy to death from any cause.","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB16-1195","March 7, 2017","February 2020","February 2020","December 5, 2016","null","April 18, 2018","University of Chicago, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT02981914"
756,"NCT02981329","Fetal Hemoglobin Induction Treatment Metformin","FITMet","Recruiting","No Results Available","Sickle Cell Anemia|Sickle Cell Disease|Hemoglobin Disorder|Hemoglobin Disease; Sickle-Cell, Thalassemia","Drug: Metformin|Behavioral: Questionnaires","Change in Fetal Hemoglobin (HbF) Percentage (SCA) or Change in Total Hemoglobin (Hb) (NTDT)|Change in Laboratory Values|Impact on Quality of Life|Variability of Hemoglobin Response","Baylor College of Medicine|Pfizer","All","12 Years to 40 Years   (Child, Adult)","Early Phase 1","64","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-38457 Metformin","March 2, 2017","November 2019","November 2022","December 5, 2016","null","July 11, 2018","Texas Children's Hospital, Houston, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02981329"
757,"NCT02979327","Cardiovascular Effects of Adderall in Healthy Adults.",,"Recruiting","No Results Available","Hemodynamics|Cardiovascular System","Drug: Adderall capsule|Drug: Placebo capsule","Change in blood pressure|Change in heart rate|Change in plasma catecholamines","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","16-004743","June 1, 2018","June 1, 2019","June 1, 2019","December 1, 2016","null","June 18, 2018","Mayo Clinic in Rochester, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02979327"
758,"NCT02978196","99m-Tc Labeled Anti-PD-L1 VHH for Diagnostic Imaging of Non-Small Cell Lung Cancer",,"Recruiting","No Results Available","Non-Small Cell Lung Cancer","Procedure: PD-L1 expression detection in Lung tumour tissue","Visual Assessment of NSCLC in 99m-Tc labeled anti-PD-L1 VHH SPECT/CT Scan|Semiquantitative Assessment of Lung Lesions in 99m-Tc labeled anti-PD-L1 VHH SPECT/CT Scan|PD-L1 expression levels|Adverse Drug Reaction Report|New tumor detection","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Nanomab Technology Limited","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2016KY220","February 15, 2018","February 2019","April 2019","November 30, 2016","null","June 15, 2018","Shanghai General Hospital, Shanghai, China|Shanghai General Hospital, Shanghai, China","","https://ClinicalTrials.gov/show/NCT02978196"
759,"NCT02976441","Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas",,"Withdrawn","No Results Available","Astrocytoma|Brainstem Glioma|Ependymoma|Mixed Glioma|Oligodendroglioma|Optic Nerve Glioma","Radiation: Radiation therapy|Drug: Temozolomide|Procedure: Stem cell collection|Procedure: Stem cell infusion","Efficacy of lymphocyte stem cell harvesting and reinfusion in patients as measured by the number of patients from whom 1-5x10e6 lymphocyte stem cells are collected and successfully reinfused without an adverse event|Number of lymphocyte stem cells that can be harvested from this patient population|Proportion of patients who have an increase in lymphocyte of ≥300 cells/mm^3 after autologous stem cell reinfusion.|Duration of lymphocyte rise following stem cell reinfusion|Changes in lymphocyte subtypes following collection and reinfusion|Changes in series of cytokine levels following collection and reinfusion|Safety and toxicities with stem cell collection and reinfusion as measured by grade and frequency of adverse events","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-x135","January 2017","February 2018","February 2018","November 29, 2016","null","February 20, 2017","","","https://ClinicalTrials.gov/show/NCT02976441"
760,"NCT02974699","Role of Gastrointestinal Microbes on Digestion of Resistant Starch and Tryptophan Availability to Humans",,"Recruiting","No Results Available","Type II Diabetes","Dietary Supplement: Potato Starch (Bob's Red Mill)|Dietary Supplement: Pregelatinized Starch (Resource ThickenUp)","Plasma Amino Acid Levels|Change in Plasma Amino Acid Levels","Wayne State University","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","110116M1F","January 2017","December 2017","null","November 28, 2016","null","May 4, 2017","Wayne State University, Detroit, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02974699"
761,"NCT02973633","Diffusion MRI in Heart Failure",,"Recruiting","No Results Available","Heart Failure|Myocardial Infarction|Left Ventricular Hypertrophy","Device: Diffusion Tensor MRI (DTI)|Drug: Gadolinium DOTA Meglumine","Myofiber Helix Angle|Correlation of Myofiber Helix Angle and Strain","Massachusetts General Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","160","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","2016P001898","June 30, 2017","December 2020","December 2020","November 25, 2016","null","June 13, 2018","Massachusetts General Hospital, Charlestown, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02973633"
762,"NCT02972762","Anesthesia Depth's Influence on Postoperative Delirium",,"Enrolling by invitation","No Results Available","Femur Head Necrosis","Drug: Diprivan","postoperative delirium score(with The Confusion Assessment Method)|final data analysis|postoperative pain score(with visual analogue scale)|intraoperative awareness","Xiangya Hospital of Central South University","All","60 Years and older   (Adult, Older Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","XiangyaH","November 2016","December 2018","December 2018","November 23, 2016","null","December 15, 2017","Xiangya hospital of CSU, Changsha, Hunan, China","","https://ClinicalTrials.gov/show/NCT02972762"
763,"NCT02971410","Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma",,"Withdrawn","No Results Available","Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma","Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment|Drug: Simvastatin","Change in free light chain ratios|Change in M-protein level measured using electrophoresis|DOR|Incidence of toxicities evaluated according to National Cancer Institute CTCAE version 4.0|OR including stringent complete remission (CR), CR, Partial Remission (PR), and very good PR|Overall survival|PFS|QoL assessed using a survey designed by European Organization for Research and Treatment of Cancer (EORTC)|Response in patients who did and did not receive zoledronic acid with therapy|Time to first response|Time to next therapy|TTP","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00040660|NCI-2016-01465|CCCWFU 26216|P30CA012197","April 2017","November 2021","November 2021","November 23, 2016","null","July 2, 2018","Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02971410"
764,"NCT02970448","Expedited Laser Interstitial Thermal Therapy + Chemoradiation For Newly Diagnosed High Grade Gliomas",,"Recruiting","No Results Available","High Grade Glioma","Procedure: LITT|Radiation: Radiation therapy|Drug: Temozolomide","Study safety as determined by the number of patients who experience pre-specified adverse events|Number of patients with adjustments to radiation plan to account for post-LITT tissue distortion","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE4316","May 18, 2017","January 2020","January 2020","November 22, 2016","null","September 6, 2018","Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02970448"
765,"NCT02970032","Evaluation of Anti-Xa Levels in Surgery Patients Receiving Fixed Dose Heparin",,"Active, not recruiting","No Results Available","Deep-Venous Thrombosis|Pulmonary Embolism|Venous Thromboembolism","Drug: Real time heparin dose adjustment|Drug: Standard heparin dose","Percentage of anti-Xa levels within target range (0.1-0.35 IU/mL)","University of Utah","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB_00095514","November 10, 2016","September 10, 2017","December 8, 2017","November 21, 2016","null","October 26, 2017","Univeristy of Utah Hospital, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02970032"
766,"NCT02969759","Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis","Fibro-ALS","Not yet recruiting","No Results Available","Sporadic Amyotrophic Lateral Sclerosis","Other: Skin Biopsy","Kinetics of fibroblast growth|Mitochondrial metabolism|Protéic metabolism|stress in senescence answer","University Hospital, Angers","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2016/36","November 2016","November 2017","November 2019","November 21, 2016","null","November 23, 2016","","","https://ClinicalTrials.gov/show/NCT02969759"
767,"NCT02968446","Effect of Vitamin D After Application With Valchlor",,"Recruiting","No Results Available","Skin Irritation","Dietary Supplement: 4 placebo|Dietary Supplement: 4 Vitamin D|Drug: Valchlor","Change in skin erythema|Change in skin thickness|Change in TNF-alpha expression|Change in iNOS expression","University Hospitals Cleveland Medical Center|National Institutes of Health (NIH)|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","28","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","09-16-36C|U01AR064144-01|CASE3416","November 17, 2016","December 15, 2018","December 15, 2018","November 18, 2016","null","November 20, 2017","University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02968446"
768,"NCT02967861","Effect of Pranayama on Periodontal Health",,"Completed","No Results Available","Chronic Periodontitis","Behavioral: Pranayama|Procedure: Scaling and root planing","Clinical efficacy of pranayama in chronic periodontitis patients from baseline to 3 months|Microbiological efficacy of pranayama in chronic periodontitis patients from baseline to 3 months|Efficacy of pranayama on nuclear factor-kappa B (NF-kB) in chronic periodontitis patients|Efficacy of pranayama on perosxisome proliferator-activated receptor (PPAR)-γ in chronic periodontitis patients","Meenakshi Ammal Dental College and Hospital","All","30 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","MAHER-MU-002-IEC/2016","January 2016","July 2016","July 2016","November 18, 2016","null","November 18, 2016","","","https://ClinicalTrials.gov/show/NCT02967861"
769,"NCT02966730","Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy",,"Recruiting","No Results Available","Follicular Lymphoma|Follicular Lymphoma, Grade 1|Follicular Lymphoma, Grade 2|Follicular Lymphoma Grade IIIa","Drug: Ibrutinib","Rate of conversion from FDG-PET positive to negative","Memorial Sloan Kettering Cancer Center|Fox Chase Cancer Center|Pharmacyclics LLC.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-396","November 2016","November 2019","November 2019","November 17, 2016","null","October 8, 2018","Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan - Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT02966730"
770,"NCT02964182","Concomitant Use of Very Low Nicotine Content Cigarettes and e-Cigarettes",,"Recruiting","No Results Available","Mental and Behavioral Disorders Due to Use of Tobacco","Procedure: Carbon Monoxide (CO) Testing|Behavioral: Questionnaires|Behavioral: Smartphone Assessments|Other: Urine Sample|Drug: Usual Brand (UB) Cigarettes|Other: Very Low Nicotine Content Cigarettes (VLNCC)|Drug: VLNCC and e-cigs (VLNCC+ECIG)","Effects of Dual Use of VLNCCC and ECIG on Nicotine Abuse Liability Among Daily Smokers (DS)|Effects of Dual Use of VLNCCC and ECIG on Nicotine Abuse Liability Among Intermittent Smokers (ITS)","M.D. Anderson Cancer Center|National Institute on Drug Abuse (NIDA)","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","480","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","2015-0638|R01DA042526","October 26, 2017","October 2020","October 2020","November 16, 2016","null","October 5, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02964182"
771,"NCT02963181","Effects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic Hypotension",,"Recruiting","No Results Available","Hypotension, Orthostatic|Hypertension|Autonomic Nervous System Diseases","Drug: Yohimbine|Drug: Melatonin","Investigation into the integrity of post-ganglionic sympathetic nerves in idiopathic NOH|Effects of melatonin on supine hypertension in persons with neurogenic orthostatic hypotension|Effects of melatonin on supine hypertension in patients with neurogenic orthostatic hypotension|Serum markers of sympathetic activation|Carotid artery diameter|Sympathetic nerve activation using microneurography|Orthostatic symptoms based on standard autonomic symptom questionnaires|Sleep quality assessment using Epworth Sleepiness Scale|Urine and Saliva melatonin levels","Lawson Health Research Institute","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","010788","March 1, 2018","August 2019","August 2019","November 15, 2016","null","March 9, 2018","University Hospital, London, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02963181"
772,"NCT02957734","Full Occlusal Rehabilitation for Patients With Severe Tooth Wear Using Indirect Composite Restorations","NTWP","Active, not recruiting","No Results Available","Tooth Wear|Dental Restoration Failure|Dental Restoration Wear","Procedure: Rehabilitation of severely worn dentitions","Surival of indirect composite restorations in patients treated for severe tooth wear","Radboud University|3M ESPE","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","22","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NTWP-LAVA2016","January 2016","December 2018","July 2019","November 8, 2016","null","April 20, 2018","Radboud University Medical Center, Nijmegen, Gelderland, Netherlands","","https://ClinicalTrials.gov/show/NCT02957734"
773,"NCT02956941","Effect of Behavior Change Communication About Improved Micronutrient Intake on Nutritional Status and Academic Performance of School Age Children in Meskan District, Gurage Zone, South Ethiopia","BCC","Unknown status","No Results Available","Child Nutrition Disorders","Behavioral: BCC on Essential Nutrition and Hygiene Actions (ENHAs)","Linear growth as assessed by mean change in height for age z score","Jimma University","All","10 Years to 15 Years   (Child)","Early Phase 1","376","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","4088/08|4086/2016","October 2016","January 2017","April 2017","November 7, 2016","null","November 11, 2016","Jimma University, Jimma, Oromia, Ethiopia","","https://ClinicalTrials.gov/show/NCT02956941"
774,"NCT02956538","Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using Thalidomide",,"Unknown status","No Results Available","Crohn Disease","Drug: Thalidomide|Drug: placebo(for thalidomide)","difference CDAI between thalidomide group and placebo group|difference SES-CD score between thalidomide group and placebo group|difference CDAI between different thalidomide dosage group|difference SES-CD score between different thalidomide dosage group","Sixth Affiliated Hospital, Sun Yat-sen University","All","18 Years to 50 Years   (Adult)","Early Phase 1","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","E2016022","October 2016","October 2018","October 2018","November 7, 2016","null","November 7, 2016","Department of Gastroenterology, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT02956538"
775,"NCT02956148","Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers","LONGPDE10","Completed","No Results Available","Huntington's Disease","Radiation: Radioligand [18F]MNI-659","The longitudinal changes of PDE10A enzyme availability in the caudate, putamen, and globus pallidus of Huntington's Disease Gene Expansion Carriers by comparison of the follow-up and initial PET measurements.","CHDI Foundation, Inc.","All","18 Years to 73 Years   (Adult, Older Adult)","Early Phase 1","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CHDIKI1401","September 6, 2015","March 10, 2017","March 10, 2017","November 7, 2016","null","September 6, 2018","The Memory Clinic, Rigshopitalet, Copenhagen, Denmark|Leiden University Medical Center, Department of Neurology, Leiden, Netherlands|University of Oslo, Nevrologisk poliklinikk, Oslo, Norway|Skane Universitetssjukhus Lund, Neurologiska kliniken, Lund, Sweden|Karolinska Universitetssjukhus, Huddinge, Stockholm, Sweden|Karolinska University Hospital, Stockholm, Sweden|Uppsala University Hospital, Uppsala, Sweden","","https://ClinicalTrials.gov/show/NCT02956148"
776,"NCT02955849","A Trial of China Laser and Surgery Study Glaucoma in Rural China",,"Active, not recruiting","No Results Available","Glaucoma","Device: SLT laser","Intraocular pressure|Visual quality of life|Satisfaction score|Cataract surgery|Allocated treatment","Sun Yat-sen University","All","Child, Adult, Older Adult","Early Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SLT in rural China","September 2016","October 2018","February 2019","November 4, 2016","null","November 4, 2016","Blindness Preventment and Treatment Department, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT02955849"
777,"NCT02955524","Topical Anesthesia and Intra-arterial Chemotherapy for Retinoblastoma","TOPIAC","Withdrawn","No Results Available","Hemodynamic Instability","Drug: Tetracaine 0.5%|Drug: Lidocaine hydrochloride ophthalmic gel 3.5%","Decrease in systolic Blood Pressure|Drop in end-tidal C02|Decrease in lung compliance|Decrease in oxygen saturation|Cardiac arrythmia|Recovery from Trigeminal-cardiac event","University of Miami","All","8 Weeks and older   (Child, Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20161001","March 2018","June 2020","December 2020","November 4, 2016","null","April 20, 2018","","","https://ClinicalTrials.gov/show/NCT02955524"
778,"NCT02954250","Mindfulness Based Cognitive Therapy for Depression and Cognitive Inhibition in Suicide",,"Unknown status","No Results Available","Depression, Anxiety","Behavioral: Mindfulness Based Cognitive Therapy","Fulfillment of initial recruitment goals (first 20 patients)|Decreases in HAM-D Scale|Improvement in the Stroop task performances","Lady Davis Institute","All","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IUSMD-16-17","September 2016","July 2017","July 2018","November 3, 2016","null","November 3, 2016","Douglas Mental Health University Institute, Montreal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT02954250"
779,"NCT02953275","Synergistic Effect of Vedolizumab and Pentoxifylline",,"Recruiting","No Results Available","Crohn Disease","Drug: vedolizumab|Drug: Pentoxifylline|Drug: placebo","proportion of patients in clinical remission|number of new major and minor infections|number of episodes of nephrotoxicity|number of episodes of hepatotoxicity|number of episodes of myelosuppression","University of Miami|Takeda","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20160543","April 13, 2017","December 1, 2018","April 1, 2019","November 2, 2016","null","September 3, 2018","University of Miami Crohn's and Colitis Center, Miami, Florida, United States","","https://ClinicalTrials.gov/show/NCT02953275"
780,"NCT02950753","Does Intravenous Lactated Ringer Solution Raise Measured Serum Lactate?",,"Completed","No Results Available","Hyperlactatemia","Drug: Lactated Ringer Solution|Drug: Normal Saline","Change in lactate level of the LR group compared to the NS group.|Change in bicarbonate level of the LR group compared to the NS group|Change in chloride level of the LR group compared to the NS group","University Medical Center of Southern Nevada","All","18 Years to 64 Years   (Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","EM 2016.10","January 4, 2017","May 5, 2017","June 1, 2017","November 1, 2016","null","June 14, 2017","University Medical Center of Southern Nevada, Las Vegas, Nevada, United States","","https://ClinicalTrials.gov/show/NCT02950753"
781,"NCT02948296","Charleston ARC Clinical Project 4- Cortical rTMS as a Tool to Change Craving and Brain Reactivity to Alcohol Cues","ARC4","Recruiting","No Results Available","Alcohol Dependence","Device: medial prefrontal cortex|Device: dorsolateral prefrontal cortex|Device: sham stimulation","Percent signal change in the cortex directly stimulated|Changes in neurochemistry","Medical University of South Carolina","All","21 Years to 40 Years   (Adult)","Early Phase 1","66","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","ARC4","January 2016","October 2021","October 2021","October 28, 2016","null","July 23, 2018","Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT02948296"
782,"NCT02944318","The Movement Program for an Active and Healthy Lifestyle in Adolescents",,"Unknown status","No Results Available","Adolescent Behavior","Behavioral: The Movement Program","Change from baseline in weekly time in moderate-to-vigorous physical activity at 10 months|Change from baseline in the daily time using TV/computer/cellular/video games at 10 months|Change from baseline in the healthy eating score at 10 months|Change from baseline in the body mass index at 10 months|Change from baseline in the waist circumference at 10 months|Change from baseline in the quality of life score at 10 months|Change from baseline in the sleepiness score at 10 months|Change from baseline in the academic performance score at 10 months|Change from baseline in the body image score at 10 months","Kelly Samara da Silva|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Universidade Federal de Santa Catarina","All","12 Years to 15 Years   (Child)","Early Phase 1","1400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1.259.910","March 2014","December 2017","November 2018","October 25, 2016","null","October 25, 2016","Kelly Samara da Silva, Florianopolis, Santa Catarina, Brazil","","https://ClinicalTrials.gov/show/NCT02944318"
783,"NCT02944097","Bioavailability of Resveratrol From Vineatrol30 Extract Incorporated Into Micelles",,"Completed","No Results Available","Safety After Oral Intake|Pharmacokinetics After Oral Intake","Dietary Supplement: Vineatrol 30 native powder|Dietary Supplement: Vineatrol 30 micelles","Mean area under the curve (AUC) of plasma concentration vs. time of total trans-resveratrol [nmol/L*h]|Mean area under the curve (AUC) of plasma concentration vs. time of total trans-epsilon-viniferin [nmol/L*h]|Mean maximum plasma concentration (Cmax) of total trans-resveratrol [nmol/L]|Mean maximum plasma concentration (Cmax) of total trans-epsilon-viniferin [nmol/L]|Time to reach maximum plasma concentration (Tmax) of total trans-resveratrol [h]|Time to reach maximum plasma concentration (Tmax) of total trans-epsilon-viniferin [h]|Cumulative urinary excretion of total trans-resveratrol [nmol/g creatinine]|Cumulative urinary excretion of total trans-epsilon-viniferin [nmol/g creatinine]|Serum aspartate transaminase activity [U/L]|Serum alanine transaminase activity [U/L]|Serum gamma-glutamyl transferase activity [U/L]|Serum alkaline phosphatase activity [U/L]|Serum bilirubin|Serum uric acid [mg/dL]|Serum creatinine [mg/dL]|Serum total cholesterol [mg/dL]|Serum HDL cholesterol [mg/dL]|Serum LDL cholesterol [mg/dL]|Serum triacylglycerols [mg/dL]|LDL/HDL cholesterol ratio|Serum cystatin C [mg/mL]|Glomerular filtration rate [mL/min]|Serum glucose [mg/dL]","University of Hohenheim","All","18 Years to 35 Years   (Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","HS-VM-2015","March 2015","May 2015","February 2017","October 25, 2016","null","May 3, 2017","University of Hohenheim, Stuttgart, Baden-Württemberg, Germany","","https://ClinicalTrials.gov/show/NCT02944097"
784,"NCT02944084","Absorption and Excretion Kinetics of the Bioactive Ingredients of Rice Bran Extract",,"Completed","No Results Available","Safety After Oral Intake|Pharmacokinetics After Oral Intake","Dietary Supplement: Rice bran extract|Dietary Supplement: Porridge in water|Dietary Supplement: Porridge in milk","Mean area under the curve (AUC) of plasma concentration vs. time of total alfa, beta, gamma and delta tocopherols and tocotrienols [nmol/L*h]|Mean area under the curve (AUC) of plasma concentration vs. time of total ferulic acid [nmol/L*h]|Mean area under the curve (AUC) of plasma concentration vs. time of total gamma-oryzanol [nmol/L*h]|Mean maximum plasma concentration (Cmax) of total total alfa, beta, gamma and delta tocopherols and tocotrienols [nmol/L]|Mean maximum plasma concentration (Cmax) of total ferulic acid [nmol/L]|Mean maximum plasma concentration (Cmax) of total gamma-oryzanol [nmol/L]|Time to reach maximum plasma concentration (Tmax) of total alfa, beta, gamma and delta tocopherols and tocotrienols [h]|Time to reach maximum plasma concentration (Tmax) of total ferulic acid [h]|Time to reach maximum plasma concentration (Tmax) of total gamma-oryzanol [h]|Cumulative urinary excretion of total Vitamin E metabolites [nmol/g creatinine]|Cumulative urinary excretion of total ferulic acid [nmol/g creatinine]|Cumulative urinary excretion of total gamma-oryzanol [nmol/g creatinine]|Serum aspartate transaminase activity [U/L]|Serum alanine transaminase activity [U/L]|Serum gamma-glutamyl transferase activity [U/L]|Serum alkaline phosphatase activity [U/L]|Serum bilirubin|Serum uric acid [mg/dL]|Serum creatinine [mg/dL]|Serum total cholesterol [mg/dL]|Serum HDL cholesterol [mg/dL]|Serum LDL cholesterol [mg/dL]|Serum triacylglycerols [mg/dL]|LDL/HDL cholesterol ratio|Glomerular filtration rate [mL/min]|Serum glucose [mg/dL]","University of Hohenheim|German Federal Ministry of Economics and Technology","All","18 Years to 35 Years   (Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HS-RBE-2016","April 2016","June 2016","April 2017","October 25, 2016","null","May 3, 2017","University of Hohenheim, Stuttgart, Baden-Württemberg, Germany","","https://ClinicalTrials.gov/show/NCT02944084"
785,"NCT02942212","Health Literacy and Smoking Cessation in Low-SES Diverse Smokers - Project HALT II",,"Not yet recruiting","No Results Available","Smoking Cessation","Behavioral: Questionnaire|Behavioral: In-Depth Interviews|Other: Breath Test|Drug: Nicotine Patches|Behavioral: Advice plus Phone Counseling|Behavioral: Advice plus Counseling Sessions|Behavioral: Self Assessment Questionnaires","Efficacy of Helping Adults with Health Literacy Trouble (HALT) versus Standard Treatment (ST) in Facilitating Abstinence from Smoking in Low Health Literacy (HL) Smokers","M.D. Anderson Cancer Center","All","25 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2016-0267","October 2018","October 2021","October 2021","October 24, 2016","null","July 12, 2018","Literacy Advance of Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02942212"
786,"NCT02940769","Neurobiological Effects of Light on MDD",,"Suspended","No Results Available","Major Depressive Disorder","Device: light glasses|Device: sham glasses (placebo)","salivary cortisol levels|salivary melatonin levels","University of Michigan","All","18 Years to 60 Years   (Adult)","Early Phase 1","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","PRITZ1","September 4, 2014","October 2022","October 2022","October 21, 2016","null","February 6, 2018","University of Michigan, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02940769"
787,"NCT02940483","Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma","5-AZA","Recruiting","No Results Available","Brain Tumor Recurrent","Drug: 5-Azacytidine","Number of patients with grade 3 through grade 5 new neurological adverse events that are related to study drug, graded according to NCI CTCAE Version 4.0","The University of Texas Health Science Center, Houston","All","1 Year to 21 Years   (Child, Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC-MS-16-0739","December 2016","December 2019","January 2020","October 21, 2016","null","October 11, 2018","UTHealth & Children's Memorial Hermann Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02940483"
788,"NCT02939352","The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues","addictionTBS","Completed","No Results Available","Alcoholism|Cocaine Addiction|Drug Addiction","Device: Real continuous Theta Burst Stimulation|Device: Sham continuous Theta Burst Stimulation","Percent Blood Oxygen-Level Dependent (BOLD) signal change in the Medial Prefrontal Cortex (MPFC)|Self reported craving|Percent Blood Oxygen-Level Dependent (BOLD) signal change in the Striatum","Medical University of South Carolina","All","25 Years to 55 Years   (Adult)","Early Phase 1","49","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","30506","September 2014","December 2015","December 2015","October 20, 2016","null","July 23, 2018","Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT02939352"
789,"NCT02939339","Theta Burst TMS as a Tool to Change Smoking Behavior",,"Completed","No Results Available","Smoking|Addiction","Device: continuous theta burst stimulation (real)|Device: continuous theta burst stimulation (sham)","Percent BOLD signal change in the MPFC","Medical University of South Carolina","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","00042165","October 2015","August 1, 2017","August 1, 2017","October 20, 2016","null","July 23, 2018","Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT02939339"
790,"NCT02939313","Cortical rTMS as a Tool to Change Brain Reactivity to Alcohol Cues","ARC4","Recruiting","No Results Available","Alcohol Dependance","Device: medial prefrontal cortex|Device: dorsolateral prefrontal cortex|Device: sham","Percent signal change in the MPFC|Percent signal change in the DLPFC|Change in craving score|Change in glutmate concentration|Change in GABA concentration","Medical University of South Carolina|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","All","21 Years to 40 Years   (Adult)","Early Phase 1","66","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","00030506|P50AA010761","January 2016","October 2021","October 2021","October 20, 2016","null","July 23, 2018","Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT02939313"
791,"NCT02937376","Effects of N-acetyl Cystein (NAC) Supplementation in G6PD Deficient Individuals After Acute Exercise",,"Not yet recruiting","No Results Available","G6PD Deficiency","Drug: N-acetyl cystein|Other: Placebo","Change in redox status after exercise|Body composition|Blood pressure","University of Thessaly","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UTH_G6PD 2","February 2019","June 2019","November 2019","October 18, 2016","null","May 3, 2018","Department of Physical Education & Sport Science of the University of Thessaly, Trikala, Karyes, Greece","","https://ClinicalTrials.gov/show/NCT02937376"
792,"NCT02933736","Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients",,"Recruiting","No Results Available","Glioblastoma Multiforme|Meningioma","Drug: Ribociclib","Plasma Exposure|CSF Penetration|Brain Accumulation of Ribociclib","St. Joseph's Hospital and Medical Center, Phoenix|Novartis","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","48","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHX-16-0116-80-12","October 2016","December 2018","April 2019","October 14, 2016","null","January 6, 2017","Barrow Brain and Spine, Phoenix, Arizona, United States","","https://ClinicalTrials.gov/show/NCT02933736"
793,"NCT02932852","Autologous Adipose-Derived Adult Stem Cell Transplantation for Corneal Diseases","A-ADAS-CT-CD","Unknown status","No Results Available","Hereditary Corneal Dystrophy|Keratoconus","Procedure: Lipoaspiration|Procedure: Transplantation","Vision recovery (Corrected Distance Visual Acuity)|Corneal Thickness|Topopgraphy|Anterior segment Optical Coherence Tomography|Slit Lamp Observation|refraction measurement","Vissum, Instituto Oftalmológico de Alicante|Reviva Pharmaceuticals|Hospital Universitario La Paz|LASER VISION CENTER IN LIBANON|OPTICA GENERAL IN LIBANON","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTP-007/15","November 2015","April 2017","null","October 13, 2016","null","October 13, 2016","Optica General, Saida, Lebanon","","https://ClinicalTrials.gov/show/NCT02932852"
794,"NCT02929797","Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer","AKT","Recruiting","No Results Available","Pancreatic Ductal Adenocarcinoma","Biological: CD8+NKG2D+ AKT Cell|Drug: Gemcitabine","Disease-free survival|Overall Survival|immune indices|Quality of life","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","72","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CD8+NKG2D+ AKT","August 2016","August 2017","August 2019","October 11, 2016","null","October 11, 2016","Shanghai General Hospital, Shanghai, Shanghai, China|Shanghai General Hospital, Shanghai, China","","https://ClinicalTrials.gov/show/NCT02929797"
795,"NCT02929225","Effectiveness of Probiotics to Treat End Stage Renal Disease",,"Completed","No Results Available","Kidney Failure, Chronic","Drug: Bifid Triple Viable Capsules|Other: placebo","Gut microbiota|plasma detection of bacterial genomic DNA,plasma and fecal metabolomics|plasma concentrations of inflammatory biomarkers(hs-C reactive protein,Interleukin(IL)-6,tumor necrosis factor(TNF)-α,endotoxin)|Gastrointestinal Symptom Rating Scale (GSRS),SF-36","First Affiliated Hospital Xi'an Jiaotong University","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","XJTU1AF-CRS-2016-015","December 2016","January 30, 2018","March 30, 2018","October 11, 2016","null","August 8, 2018","First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China","","https://ClinicalTrials.gov/show/NCT02929225"
796,"NCT02928991","Fludarabine Based RIC for Bone Marrow Failure Syndromes",,"Recruiting","No Results Available","Bone Marrow Failure Syndromes","Other: MRD-BMT with Fludarabine-based RIC for Acquired AA|Other: MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia|Other: MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia","Rate of graft failure|Time to neutrophil engraftment|Transplant-related mortality|Rate of overall survival|Rate of disease free survival","Children's Hospital of Philadelphia","All","up to 22 Years   (Child, Adult)","Early Phase 1","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-011465|14BT057","April 2015","April 2020","April 2020","October 10, 2016","null","November 1, 2017","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02928991"
797,"NCT02927626","Yang Yin Fu Zheng Therapy in HBV Associated Hepatocellular Carcinoma","YYFZTIHBVHCC","Unknown status","No Results Available","Hepatocellular Carcinoma","Drug: Yang Yin Fu Zheng therapy|Drug: Routine medical care","Survival rate|Objective response rate|quality of life(QOL)","Beijing Ditan Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","132","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BeijingDH","August 2016","June 2018","null","October 7, 2016","null","October 7, 2016","Zhiyun Yang, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT02927626"
798,"NCT02925676","Evaluation of the Hypoglycaemia Alarm Device Hyposafe H02",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1","Device: hyposafe H02","sensitivity|Positive predictive value|Number of adverse events|overall sensitivity|overall positive predictive value|sensitivity during insulin-induced hypoglycaemia|positive predictive value for insulin-induced hypoglycaemia|Change in EEG quality (power in alpha frequency band) over time|Change in impedance (kOhm) over time|Device complaints|Mean glucose level at the time of a hypoglycaemia alarm|Number of adverse device effects|Feasibility of using hyposafe H02 on a daily basis based on diary|Development in discomfort over time based on questionnaires|Link strength between the implant and the external device (Volt)|User satisfaction based on questionnaire|Mean number of hours of use per hyposafe H02 device|Percentage of correct key press in response to hypoglycaemia alarm|Alarm fatigue based on interview|User experience in an everyday context based on interview","UNEEG Medical A/S","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Pilot 2 Diabetes","September 2016","December 2018","December 2018","October 6, 2016","null","October 18, 2017","Odense University Hospital, Odense, Denmark","","https://ClinicalTrials.gov/show/NCT02925676"
799,"NCT02919176","Brown Fat Activation Study",,"Recruiting","No Results Available","Obese|Metabolic Syndrome","Drug: Mirabegron|Drug: Pioglitazone|Drug: Mirabegron and Pioglitazone","Change in beige adipose tissue|Change in brown adipose tissue|Change in insulin sensitivity|Change in body mass index|Change in glucose tolerance","Philip Kern|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Kentucky","All","35 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","75","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16-0642-F1V","September 1, 2016","December 1, 2019","December 1, 2020","September 29, 2016","null","June 25, 2018","Center for Clinical and Translational Science, Lexington, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT02919176"
800,"NCT02918682","A Multi-component Intervention in Frail Community-dwelling Older People","MIF","Not yet recruiting","No Results Available","Frail Elderly|Exercise Therapy|Physical Therapy Techniques","Other: Exercise","strength muscle evaluation|Balance|gait|functional performance","University of Sao Paulo","All","65 Years and older   (Older Adult)","Early Phase 1","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","932.043","December 2016","December 2018","June 2019","September 29, 2016","null","September 29, 2016","","","https://ClinicalTrials.gov/show/NCT02918682"
801,"NCT02915276","The Effectiveness of Blastocentesis Versus Trophectoderm Biopsy",,"Unknown status","No Results Available","Abnormal Karyotype","Procedure: Blastocentisis|Procedure: Trophectoderm biopsy","Number of blastocyst with genomic DNA present in the blastocoelic cavity","Center for Reproductive an Genetic Health","All","18 Years to 50 Years   (Adult)","Early Phase 1","250","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","blatocentesesJBNKL2016","October 2016","March 2017","May 2017","September 27, 2016","null","September 27, 2016","Kalliopi Loutradi, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02915276"
802,"NCT02911831","IV Tranexamic Acid Prior to Hysterectomy",,"Recruiting","No Results Available","Hysterectomy|Blood Loss, Surgical","Drug: Tranexamic Acid|Drug: Sodium Chloride","Intra-operative blood loss|Change in hemoglobin, postoperative from baseline|Need for blood transfusion|Length of hospital stay|Length of operative procedure|Rates of postoperative thromboembolic events|Incidence of drug-related adverse events|Health care cost","Northwestern University","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","248","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","STU00203110","November 2016","January 2020","April 2020","September 22, 2016","null","July 17, 2018","Northwestern University - Northwestern Medicine, Lavin Family Pavillion, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT02911831"
803,"NCT02910804","IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Glioblastoma",,"Recruiting","No Results Available","Glioblastoma","Drug: 68Ga-BBN-IRDye800CW|Device: PET/NIRF|Procedure: PET/NIR fluorescent imaging-guided surgery","Standardized uptake value of 68Ga-BBN-IRDye800CW in PET imaging of GBM|Margin assessment of positive tumors in NIRF fluorescent-guided surgery","Beijing Tiantan Hospital|Peking Union Medical College Hospital|National Institute for Biomedical Imaging and Bioengineering (NIBIB)|Key laboratory of molecular imaging Chinese Academy of Sciences","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","BTHospital-N-005|ZIAEB000073","November 2015","December 2018","December 2018","September 22, 2016","null","January 18, 2018","Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT02910804"
804,"NCT02906956","Music and Adherence Home Programs Post Stroke",,"Completed","No Results Available","Stroke","Behavioral: Preferred music playlist","Number of sessions of practice|Duration of sessions of practice|Number of minutes of practice|Intensity of practice|Canadian Occupational Performance Measure|Motor Activity Log|Western Aphasia Battery - Revised|Cognitive Linguistic Quick Test","Duquesne University","All","40 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#2016/06/18","September 2016","August 2017","August 2017","September 20, 2016","null","May 31, 2018","Duquesne University Speech, Hearing, Language Clinic, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02906956"
805,"NCT02905773","Postoperative Pain After the Removal of Root Canal Filling Material",,"Completed","No Results Available","Postoperative Pain","Other: root canal therapy|Other: root canal retreatment","postoperative pain after non-surgical endodontic retreatment using modified visual analog scale","TC Erciyes University","All","Child, Adult, Older Adult","Early Phase 1","135","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","232/2015","March 2015","May 2016","May 2016","September 19, 2016","null","September 20, 2016","","","https://ClinicalTrials.gov/show/NCT02905773"
806,"NCT02905110","Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Brain Tumors",,"Recruiting","No Results Available","Brain Tumor Recurrent","Drug: Methotrexate|Drug: Etoposide|Procedure: Ommaya Reservoir","Number of patients with grade 3 through grade 5 new neurological adverse events that are related to study drug, graded according to NCI CTCAE Version 4.0","The University of Texas Health Science Center, Houston","All","1 Year to 21 Years   (Child, Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC-MS-16-0639","October 2016","November 2020","November 2020","September 19, 2016","null","October 24, 2018","UTHealth & Children's Memorial Hermann Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02905110"
807,"NCT02903030","Probiotics for Quality of Life in Autism Spectrum Disorders",,"Completed","No Results Available","Autism Spectrum Disorders|Anxiety","Drug: Maltose (placebo)|Drug: Visbiome Extra Strength","Change in Gastrointestinal (GI) Module of the Pediatric Quality of Life Inventory (PedsQL) (Varni et al., 2001; (Varni, Burwinkle, & Seid, 2006; Varni et al, 2014)|Change in Target Symptom Rating (Arnold et al, 2003)|Change in Parent Anxiety Checklist--ASD (Scahill, Lecavalier, Bears, & Aman, 2015)|Change in The Aberrant Behavior Checklist (ABC) (Aman et al., 1985a, 1985b)|Change in Social Responsiveness Scale (SRS) (Costantino et al., 2003)|Change in Children's Sleep Habits Questionnaire (CSHQ) (Owens, Spirito, & Mcguinn, 2000)|Change in The Parenting Stress Index Short Form (PSI) (Abidin,1995)","Ohio State University|Autism Treatment Network|Autism Speaks","All","3 Years to 12 Years   (Child)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2016H0174","August 2016","December 1, 2017","December 1, 2017","September 16, 2016","null","December 14, 2017","Ohio State University Wexner Medical Center, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02903030"
808,"NCT02901925","A Microdose Evaluation Study of ABY-029 in Recurrent Glioma","ABY-029","Recruiting","No Results Available","Glioma","Drug: ABY-029","signal detection|diagnostic accuracy of ABY-029 detection|molecular uptake","Dartmouth-Hitchcock Medical Center|Dartmouth College","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D16107","December 2016","March 2019","September 2019","September 15, 2016","null","March 5, 2018","Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States","","https://ClinicalTrials.gov/show/NCT02901925"
809,"NCT02900469","Presurgical Trial of Denosumab in Breast Cancer",,"Recruiting","No Results Available","Breast Cancer","Biological: denosumab|Procedure: Surgery","Pharmacodynamic markers of RANKL inhibition determination|Frequency of RANK and RANKL protein expression (by IHC) in operable breast cancer using Immunohistochemical analyses (IHC)","New York University School of Medicine","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","s14-01311","October 2016","June 2019","June 2019","September 14, 2016","null","November 14, 2018","NYU Perlmutter Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02900469"
810,"NCT02898792","Remifentanil in Adults With OSA","AROSA","Completed","No Results Available","Apnea, Sleep","Drug: Targeted infusion of remifentanil","The relationship between remifentanil concentration and miotic effect","Washington University School of Medicine","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","77","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","201605158","September 16, 2016","May 2, 2018","May 2, 2018","September 13, 2016","null","October 4, 2018","Washington University St Louis School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02898792"
811,"NCT02896907","Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery",,"Active, not recruiting","No Results Available","Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma","Drug: Oxaliplatin|Drug: Irinotecan Hydrochloride|Drug: Leucovorin Calcium|Drug: Fluorouracil|Dietary Supplement: Ascorbic Acid","Incidence of adverse events as determined by CTCAE version 4.03|Change in quality of life as defined by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16D.347","October 18, 2016","March 22, 2018","January 1, 2019","September 12, 2016","null","March 27, 2018","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02896907"
812,"NCT02891863","Low Energy Therapy to Convert Ventricular Tachycardias","LEVER","Terminated","Has Results","Ventricular Tachycardia","Device: LEVER Acute Study System","System and Procedure Related Adverse Events|Conversion Efficacy of Low Energy VT Therapies","Boston Scientific Corporation","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","9","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91003730","September 2015","March 2016","March 2016","September 8, 2016","July 17, 2017","July 17, 2017","Royal Adelaide Hospital, Adelaide, Australia","","https://ClinicalTrials.gov/show/NCT02891863"
813,"NCT02891538","Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients",,"Recruiting","No Results Available","Colon Cancer","Drug: Epigallocatechin gallate (EGCG)","Change in methylation from baseline when compared to the control arm","The University of Texas Health Science Center at San Antonio","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CTMS 16-0085|16-446H","January 31, 2017","November 2019","November 2019","September 7, 2016","null","September 20, 2018","UT Health San Antonio, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT02891538"
814,"NCT02890524","Tokushima Night Guard for Recurrent Aphthous Stomatitis",,"Recruiting","No Results Available","Aphthous Stomatitis","Device: night guard|Device: placebo night guard","number of developed aphthous stomatitis|days until healing","University of Tokushima","All","Child, Adult, Older Adult","Early Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Tokushima #2053","July 2014","March 2018","March 2018","September 7, 2016","null","May 3, 2017","Tada Dental Clinic, Kakogawa, Hyogo, Japan|Tokushima University Hospital, Tokushima, Japan","","https://ClinicalTrials.gov/show/NCT02890524"
815,"NCT02887768","Epicardial Infarct Repair Using CorMatrix®-ECM: Clinical Feasibility Study","EIR","Completed","No Results Available","Acute Coronary Syndrome|Heart Failure","Device: Epicardial Infarct Repair with CorMatrix-ECM|Procedure: Coronary Artery Bypass Grafting Surgery","The number of patients in which the study intervention is successfully completed|The number of patients in which the target myocardium can be successfully identified at the time of surgery|The number of patients in which regional myocardial function and tissue characteristics are successfully measured by CMR|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","University of Calgary|CorMatrix Cardiovascular, Inc.","All","35 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REB14-1715","January 2016","July 2017","October 2017","September 2, 2016","null","October 30, 2017","University of Calgary, Calgary, Alberta, Canada","","https://ClinicalTrials.gov/show/NCT02887768"
816,"NCT02887430","Foot Reflexology Therapy and Non-specific Low Back Pain",,"Unknown status","No Results Available","Low Back Pain","Other: foot reflexology therapy","mean time in days to the recovery of pain|demographic information|side effects of treatment|health-related quality of life","Universiti Sultan Zainal Abidin","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening","UHREC/2016/2/011","September 2016","October 2016","February 2017","September 2, 2016","null","September 8, 2016","","","https://ClinicalTrials.gov/show/NCT02887430"
817,"NCT02885649","Enzalutamide Before Surgery in Treating Patients With Kidney Cancer",,"Recruiting","No Results Available","Clear Cell Renal Cell Carcinoma|Stage I Renal Cell Cancer","Drug: Enzalutamide|Other: Laboratory Biomarker Analysis|Procedure: Nephrectomy","Cell proliferation|Tumor apoptosis as measured by annexin|Incidence of adverse events (AEs) as assessed by Common Terminology Criteria for Adverse Events version 4|Tumor size as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1","Rutgers, The State University of New Jersey|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","081604|NCI-2016-01113|P30CA072720","December 5, 2017","January 2020","January 2020","August 31, 2016","null","August 9, 2018","Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT02885649"
818,"NCT02885272","Dual Time Point FDG PET-MR Imaging Optimization for the Evaluation of Glioblastoma",,"Recruiting","No Results Available","Malignant Neoplasms, Eye|Glioblastoma|Malignant Neoplasms, Brain|Malignant Neoplasms, Central Nervous System","Drug: FDG|Procedure: PET/CT|Procedure: MRI","Optimal FDG Positron Emission Tomography-Magnetic Resonance (PET-MR) Imaging Time Point","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2016-0261|NCI-2016-01971","October 2016","October 2019","October 2020","August 31, 2016","null","January 29, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02885272"
819,"NCT02879903","Prevalence of Porphyromonas Gingivalis Fimbrial Subunit Genotype in Smokers and Nonsmokers After Periodontal Therapy",,"Unknown status","No Results Available","Chronic Periodontitis","Procedure: Periodontal treatment|Procedure: Microbiological collect|Procedure: Questionnaire","Change from baseline Bleeding on Probe to 3 months|Change from Baseline Plaque Index to 3 months|Change from Baseline Pocket Probing Depth to 3 months|Change from Baseline Gingival Recession to 3months|Change from Baseline Clinical Attachment level to 3 months|Change from Baseline Biofilm to 3 months|Change from baseline Age to 3 months|Change from Baseline Cigarette consumption to 3 months","Universidade Federal Fluminense","All","27 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CAAE: 53022216.0.0000.5626","August 2016","October 2016","December 2016","August 26, 2016","null","August 30, 2016","","","https://ClinicalTrials.gov/show/NCT02879903"
820,"NCT02879721","Expression and Function of the Renin-Angiotensin System in the Esophagus",,"Completed","No Results Available","Barrett's Esophagus","Drug: Candesartan|Drug: Enalapril","Change in expression of proteins associated with inflammation, proliferation and cancer development|Change in regulation of potential new biomarkers associated with esophageal cancer","Göteborg University|Sahlgrenska University Hospital, Sweden","All","20 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","33","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","233-09","October 2009","December 2012","December 2012","August 26, 2016","null","August 26, 2016","Dept. of Gastrosurgical Research and Education, Inst. Clinical Sciences, Sahlgrenska University Hospital, Gothenburg, Sweden","","https://ClinicalTrials.gov/show/NCT02879721"
821,"NCT02879136","TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease","TAME-PD","Recruiting","No Results Available","Parkinson's Disease, Idiopathic","Drug: Methylphenidate|Other: Physical Therapy|Drug: Atomoxetine","Balance Evaluation|Change in gait","Shnehal Patel|The Cleveland Clinic","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","16-277","December 2016","December 2019","December 2020","August 25, 2016","null","June 27, 2018","Cleveland Clinic, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02879136"
822,"NCT02878538","A Pilot of the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive Impairment",,"Withdrawn","No Results Available","Mild Cognitive Impairment","Drug: Deferiprone|Other: Placebo phase","Efficacy of deferiprone therapy on ""d"" scores in Mild Cognitive Impairment (MCI)|Explore deferiprone's longitudinal effect on ""d"" and dementia conversion","The University of Texas Health Science Center at San Antonio","All","65 Years to 80 Years   (Older Adult)","Early Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other","P30AG044271|HSC20160395H","January 2018","April 2022","April 2023","August 25, 2016","null","February 6, 2018","University of Texas Health Science Center, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT02878538"
823,"NCT02877784","Screening in Oculopharyngeal Muscular Dystrophy",,"Recruiting","No Results Available","Oculopharyngeal Muscular Dystrophy","Device: Iowa Oral Performance Instrument|Drug: Capsaicin|Device: Electrical Impedance Myography (EIM)|Procedure: Videofluoroscopic swallowing study|Other: Swallowing Related Quality of Life Questionnaire|Other: Functional Oral Intake Scale|Other: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised|Other: Eating Assessment Tool-10|Other: Communicative Effectiveness Survey|Other: The Center for Neurologic Studies Bulbar Function Scale","Kinematic Swallowing Measurements will be used to analyze a normal movement of swallowing|The IOPI will be used to measure Lingual strength and endurance|The nebulizer with cough protocol will be used to measure reflexive cough|Global disease progression as confirmed by the ALS Functional Rating Scale-Revised (ALSFRS-R)|Participant perception of swallowing impairment as confirmed by Swallowing Quality of Life Questionnaire (SWAL-QOL)|Dietary intake as confirmed by Functional Oral Intake Scale (FOIS)|Participant perception of swallowing related symptoms as confirmed by The Eating Assessment Tool 10 (EAT-10)|Participant perception of communication abilities as confirmed by Communication Effectiveness Survey|Bulbar function confirmed by the Center for Neurologic Studies Bulbar Function Scale (CNS-BFS)","University of Florida","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB201601374","October 2016","June 2019","June 2019","August 24, 2016","null","June 25, 2018","University of Florida, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT02877784"
824,"NCT02876770","Melatonin Supplementation and Performance","MSP","Terminated","No Results Available","Motor Activity","Dietary Supplement: Experimental: Melatonin|Dietary Supplement: Placebo","Hooper's index score|handgrip strength (in Kg)|Blood lactate (µmol/l)|reaction time (in secondes)|vigilance score|squat jump (in centimeters)|agility (in secondes)|anaerobic capacity (In watts)|glucose level (µmol/l)|Rating of perceived exertion score","kais|University of Sfax","Male","20 Years to 23 Years   (Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CNMSS1","December 2012","January 2013","January 2013","August 24, 2016","null","August 24, 2016","","","https://ClinicalTrials.gov/show/NCT02876770"
825,"NCT02876705","Spatiotemporal Patterns of Pain During Exercise",,"Completed","No Results Available","Pain","Other: Exercise","Changes of pain location during exercise measured through pain drawings, body maps, or manikins.","Institut Nacional d'Educacio Fisica de Catalunya","All","18 Years to 30 Years   (Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","INEFC-Psychobiological","September 2016","October 2016","October 2016","August 24, 2016","null","October 11, 2016","INEFCatalunya, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT02876705"
826,"NCT02874820","I2PETPG - Imidazoline2 Binding Sites in a Group of Participants Diagnosed With AD","I2PETPG","Completed","No Results Available","Alzheimer Disease","Radiation: [11C]BU99008|Drug: Idazoxan","Density and distribution of Imidazoline 2 binding sites using either Total Volume of Distribution (VT) or Binding Potential (BP)","Imperial College London|GlaxoSmithKline","Male","50 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","2","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16HH3243|MR/L01307X/1","July 2016","March 2017","July 2017","August 22, 2016","null","March 7, 2018","Centre for Neuropsychopharmacology; Division of Brain Sciences; Imperial College London; Burlington Danes Building; Hammersmith Hospital campus; 160 Du Cane Road, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02874820"
827,"NCT02873299","High-Frequency Repetitive Transcranial Magnetic Stimulation of the Right Dorsolateral Prefrontal Cortex in PTSD","rTMS","Completed","No Results Available","PTSD, Post Traumatic Stress Disorder","Other: 10 Hz rTMS of the right dorsolateral prefrontal cortex|Other: 20 Hz rTMS of the right dorsolateral prefrontal cortex","Clinician Administered PTSD Scale , CAPS|Posttraumatic Stress Disorder Checklist, PCL","United States Naval Medical Center, San Diego","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","37","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NMCSD.2011.0025","April 2012","October 2014","October 2014","August 19, 2016","null","August 22, 2016","NMCSD, San Diego, California, United States","","https://ClinicalTrials.gov/show/NCT02873299"
828,"NCT02872519","PET Imaging of Ovarian Carcinoma With 18F-FSPG",,"Withdrawn","No Results Available","Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer","Drug: (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG)|Procedure: Positron Emission Tomography|Other: Laboratory Biomarker Analysis","Lesion (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) PET standard uptake values|Number of lesions detected by(S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) PET|Number of lesions detected by (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) PET imaging before and after neoadjuvant chemotherapy treatment|Immunohistochemistry evaluation of xC- and CD 44 of resected malignant ovarian cancer with a measurement of strength of staining from 0-3.|Proportion of patients whose surgical resection by novel imaging classification changed following validation by histological confirmation|Proportion of patients whose response to chemotherapy changed by Response Evaluation Criteria in Solid Tumors criteria|Conditional predictive models of imaging performance and agreement","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","All","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","VICC GYN 15142","June 2018","August 2019","August 2020","August 19, 2016","null","June 6, 2018","","","https://ClinicalTrials.gov/show/NCT02872519"
829,"NCT02872025","Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)",,"Recruiting","No Results Available","Carcinoma, Intraductal, Noninfiltrating","Drug: Pembrolizumab","Maximum tolerated dose (MTD)|Dose-limiting toxicities (DLTs)|Percentage of patients who demonstrate an increase (baseline vs. post intralesional injection) in intralesional CD8+ T cells (treated vs. untreated participants) as measured using multiplex immunofluorescence on FFPE tissue sections","Laura Esserman|Merck Sharp & Dohme Corp.|University of California, San Francisco","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","48","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16704","December 12, 2016","March 2019","September 2019","August 18, 2016","null","June 21, 2018","University of California, San Francisco, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT02872025"
830,"NCT02871349","Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response",,"Recruiting","No Results Available","Autism Spectrum Disorder","Drug: Propranolol|Drug: Placebo|Device: Magnetic Resonance Imaging (MRI)","Change in General Social Outcomes Measure (GSOM) Assessment|Change in Social Responsiveness Scale (SRS-2)|Change in score on Anagrams test|Change in Semantic fluency test results|Change Clinical Global Impression surveys|Change in Autism Impact Measure (AIM)|Change in Clinical Evaluation of Language Fundamentals (CELF-5) assessment|Change in Vineland Adaptive Behavior Scales (VABS-2) assessment|Change in score on Aberrant Behavior Checklist (ABC)|Change in gastrointestinal symptomology","University of Missouri-Columbia|United States Department of Defense","All","7 Years to 24 Years   (Child, Adult)","Early Phase 1","96","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2005213","August 2016","September 2020","September 2020","August 18, 2016","null","July 16, 2018","Thompson Center for Autism & Neurodevelopmental Disorders, Columbia, Missouri, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02871349/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT02871349"
831,"NCT02869984","Clinical Trial Assessing 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Anterior Resection Syndrome",,"Unknown status","No Results Available","Anterior Resection Syndrome","Drug: Ramosetron","low anterior resection syndrome score|Quality of Life score","Seoul National University Hospital|Dong-A ST","Male","19 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1604-095-755","August 2016","October 2018","null","August 17, 2016","null","August 17, 2016","","","https://ClinicalTrials.gov/show/NCT02869984"
832,"NCT02869009","Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke","ATAMIS","Recruiting","No Results Available","Ischemic Stroke","Drug: clopidogrel|Drug: Aspirin","Early neurological deterioration assessed as change of NIHSS|new clinical vascular events (ischemic stroke/hemorrhagic stroke/TIA/myocardial infarction/vascular death)|Changes in National Institute of Health stroke scale scores|moderate to severe bleeding events|Total mortality|Adverse events/severe adverse events","General Hospital of Shenyang Military Region","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","3000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","k2016-06","November 2016","September 2018","December 2018","August 16, 2016","null","May 31, 2018","General Hospital of Shenyang Military Region, Shenyang, Liaoning, China","","https://ClinicalTrials.gov/show/NCT02869009"
833,"NCT02868424","Treatment of Age-related Macular Degeneration by Fetal Retinal Pigment Epithelial Cells Transplantation",,"Active, not recruiting","No Results Available","Age Related Macular Degeneration|Macular Degeneration|AMD","Drug: fRPE cells","Number of subjects with adverse events|Assessment of standardized ETDRS acuity testing|Assessment of visual function changes|Assessment of systemic condition","The First Affiliated Hospital with Nanjing Medical University","All","50 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JSPH-fRPE-001","February 13, 2016","August 2018","December 2018","August 16, 2016","null","June 16, 2017","The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China","","https://ClinicalTrials.gov/show/NCT02868424"
834,"NCT02866435","Identifying the Brain Substrates of Hypoglycemia Unawareness in Type 1 Diabetes",,"Recruiting","No Results Available","Hypoglycemia","Drug: Insulin|Drug: Glucose|Drug: Potassium phosphate","Change from baseline (i.e., normal glucose levels) functional connectivity, measured as a dimensionless correlation coefficient of MRI signals among brain areas, at hypoglycemia|Change from baseline (i.e., normal glucose levels) cerebral blood flow, measured in ml/min/100g, at hypoglycemia","University of Minnesota - Clinical and Translational Science Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","25007","November 2016","September 2019","December 2019","August 15, 2016","null","October 11, 2018","University of Minnesota, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02866435"
835,"NCT02866305","Study Designed to Optimize the Treatment of Primary Pneumothorax","TOPP","Recruiting","No Results Available","Primary Spontaneous Pneumothorax|Pleural Disease","Procedure: VATS bullectomy and mechanical pleuradesis.|Procedure: Chest tube insertion|Drug: Epidural|Radiation: High-resolution Computer Tomography","Time to ipsilateral recurrence|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Length of hospital stay|Pain according to NRS scale reported at discharge, at 4 weeks, 1 year, 5 years and 10 years.","Odense University Hospital|Danish Medical Association|Danmarks Lungeforening","All","18 Years to 40 Years   (Adult)","Early Phase 1","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TOPP2009","March 2009","December 2017","December 2024","August 15, 2016","null","August 16, 2016","Research Unit at the cardiothoracic departement at the University Hospital of Odense, Odense, Fyn, Denmark|Research Unit at the Cardiothoracic Department at the University Hospital of Skejby, Århus, Midtjylland, Denmark|Research Unit at the Cardiothoracic Department af Ålborg Hospital, Ålborg, Nordjylland, Denmark","","https://ClinicalTrials.gov/show/NCT02866305"
836,"NCT02864550","Oral Doxycycline for the Prevention of Syphilis in Men Who Have Sex With Men",,"Not yet recruiting","No Results Available","Syphilis|Sexually Transmitted Infections","Drug: Doxycycline|Other: Placebo","Number of new (incident) syphilis cases|Frequency of adverse events and discontinuations|Number of new (incident) cases of any bacterial sexually transmitted infection (i.e. syphilis, gonorrhoea, or chlamydia)|Number of doses of study medication taken per week|Increase in minimum inhibitory concentration (MIC) of either Staphylococcus aureus or Streptococcus pneumoniae to tetracyclines.","British Columbia Centre for Disease Control","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","288","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","BritishCCDC2","November 2016","March 2020","May 2020","August 12, 2016","null","August 12, 2016","British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT02864550"
837,"NCT02864121","Oncogenous HPV DNA Integration (Intégration De l'ADN Des HPV Oncogènes)","IDAHO","Recruiting","No Results Available","Abnormal Cytology","Other: all patients included in IDAHO study","presence of high-risk papillomavirus in the analysis of cervical smear|integration of genome of high-risk papillomavirus detected in cervical smear according molecular combing|presence and severity of cervical lesion according to results of cervical smear, colonoscopy and histological analysis","CHU de Reims","Female","25 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","3500","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","PI15088","December 2015","December 2021","March 2022","August 11, 2016","null","August 11, 2016","Chu de Reims, Reims, France","","https://ClinicalTrials.gov/show/NCT02864121"
838,"NCT02858336","CaREFREE Study (Calorie Restriction, Environment and Fitness: Reproductive Effects Evaluation Study)",,"Recruiting","No Results Available","Normal Physiology|Healthy","Behavioral: NEA|Behavioral: DEA","The primary outcome measure will be change in daytime LH pulse frequency following 5 days of neutral energy availability as compared to LH pulse frequency following 5 days deficient energy availability. LH pulse frequency will be derived from 2 ...|Change in hormone measures (LH, FSH, estradiol, and progesterone from daily urine samples and blood spots, total cycle, follicular and luteal phase length during the cycle following NEA or DEA|Change in leptin, ghrelin, adiponectin, insulin, and glucose in response to standardized breakfast, lunch, and snack|Change in cortisol, TSH, TT3, and fT4","National Institute of Environmental Health Sciences (NIEHS)|National Institutes of Health Clinical Center (CC)","Female","18 Years to 28 Years   (Adult)","Early Phase 1","150","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Screening","160157|16-E-0157","August 5, 2016","July 1, 2021","July 1, 2021","August 8, 2016","null","September 5, 2018","NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02858336"
839,"NCT02857218","Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Stage IIB-IIIC Esophageal Cancer",,"Recruiting","No Results Available","Stage IIB Esophageal Cancer AJCC v7|Stage III Esophageal Cancer AJCC v7|Stage IIIA Esophageal Cancer AJCC v7|Stage IIIB Esophageal Cancer AJCC v7|Stage IIIC Esophageal Cancer AJCC v7","Drug: Ferumoxytol|Procedure: Magnetic Resonance Imaging","Practical feasibility assessed by successful accrual objectively, as a percentage of all subjects enrolled|Technical feasibility of ultrasmall superparamagnetic iron oxide (USPIO) - magnetic resonance imaging (MRI) of the chest|Accuracy of USPIO - MRI|Reason for accrual failure|Report location and enhancement patterns on USPIO - MRI|Sensitivity and specificity of MRI imaging for all lymph nodes|Sensitivity and specificity of PET/CT imaging","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","7","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00012071|NCI-2016-01093|P30CA069533","April 27, 2018","December 31, 2018","June 30, 2019","August 5, 2016","null","August 21, 2018","OHSU Knight Cancer Institute, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT02857218"
840,"NCT02856750","Efficacy of Gabapentin vs. Placebo for Adjuvant Pain Control Following Acute Rib Fractures",,"Completed","No Results Available","Acute Pain","Drug: Gabapentin","Average Daily Pain Score|Narcotic requirements|pulmonary function","Denver Health and Hospital Authority|University of Colorado, Denver","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","16-1170","October 2016","October 23, 2018","October 23, 2018","August 5, 2016","null","October 26, 2018","Denver Health Medical Center, Denver, Colorado, United States","","https://ClinicalTrials.gov/show/NCT02856750"
841,"NCT02855697","Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer","MOLTO","Recruiting","No Results Available","Ovarian Cancer","Drug: Olaparib|Drug: Cediranib|Drug: Platinum-based Chemotherapy","To determine the feasibility of administering a second course of maintenance olaparib for more than 6 months (26 weeks) to participants with recurrent platinum-sensitive HGS/EOC who have been previously treated with olaparib.|Impact of multi-maintenance olaparib treatment on time to first subsequent therapy (TFST) in participants with platinum sensitive recurrent BRCAm HGS/EOC.|Impact of multi-maintenance olaparib treatment on time to second subsequent therapy (TSST) in participants with platinum sensitive recurrent BRCAm HGS/EOC.|Progression-free survival (PFS) for each course of chemotherapy followed by olaparib","Rozalia Lubiatowska|The Christie NHS Foundation Trust","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15_DOG01_142","May 26, 2017","January 31, 2019","December 2020","August 4, 2016","null","May 2, 2018","The Christie NHS Foundation Trust, Manchester, United Kingdom","","https://ClinicalTrials.gov/show/NCT02855697"
842,"NCT02853942","Autologous Adipose Mesenchymal Stem Cell Transplantation in the Treatment of Patients With Hemifacial Spasm",,"Unknown status","No Results Available","Injury of Facial Nerve, Unspecified Side, Initial Encounter","Biological: Autologous adipose stem cell therapy|Drug: Mecobalamin","House-Brackmann facial nerve grading scale","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","XH-16-012","October 2016","October 2017","December 2017","August 3, 2016","null","August 9, 2016","","","https://ClinicalTrials.gov/show/NCT02853942"
843,"NCT02853799","Comparison of the Effects of Intermittent and Continuous Enteral Feeding on Glucose-Insulin Dynamics in Critically Ill Medical Patients",,"Unknown status","No Results Available","Glucose-insulin Dynamics","Other: Comparison of the Effects of Intermittent and Continuous Enteral Feeding on Glucose-Insulin Dynamics in Critically Ill Medical Patients|Dietary Supplement: Osmolite 1.2 cal/ml Enteral Feeds","Mean glucose concentrations mg/dl|Number of Episodes of feeding intolerance","San Antonio Military Medical Center","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","20","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","x5tjqsc6","August 2016","August 2017","October 2017","August 3, 2016","null","August 3, 2016","","","https://ClinicalTrials.gov/show/NCT02853799"
844,"NCT02852473","Impact of Continuous Positive Airway Pressure on Breathing Motion Amplitude",,"Completed","No Results Available","Cancer","Other: Continuous Positive Airway Pressure","Change in Breathing Motion Characteristics at High CPAP Setting|Change in Breathing Motion Characteristics at Lower CPAP Setting","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16-001685","July 2016","September 2016","September 2016","August 2, 2016","null","October 14, 2016","Mayo Clinic in Rochester, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02852473"
845,"NCT02851914","SSRIs vs. TCAs for Depression in ALS Patients",,"Recruiting","No Results Available","Depression|Amyotrophic Lateral Sclerosis","Drug: Tricyclic Antidepressants (""TCA"")|Drug: Selective Serotonin Uptake Inhibitors (""SSRI"")","BDI-II|ANCOVA","St. Louis University","All","25 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","22974","July 21, 2015","December 2018","December 2018","August 2, 2016","null","February 12, 2018","Monteleone Hall, Saint Louis University, 1438 South Grand Blvd., Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02851914"
846,"NCT02851368","Near Infrared Fluorescence Imaging With Indocyanine Green","NIFI-ICG","Completed","No Results Available","Solitary Pulmonary Nodules","Device: near infrared fluorescence imaging (NIFI)|Drug: Indocyanine Green","Visibility in situ, white light|Visibility in situ, fluorescence|Nodule malignancy|Visibility ex vivo, white light|Visibility ex vivo, fluorescence","University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","UPCI 15-205","November 2016","November 2017","November 2017","August 1, 2016","null","November 21, 2017","Department of Cardiothoracic Surgery, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02851368"
847,"NCT02851056","Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)",,"Recruiting","No Results Available","Multiple Myeloma","Biological: Survivin Vaccine|Procedure: Autologous Hematopoietic Cell Transplantation|Biological: Prevnar 13|Drug: Granulocyte-colony Stimulating Factor","Rate of Complete Response (CR)|Number of Participants With Treatment Emergent Adverse Events|Number of Participants With Improved Immunologic Response","H. Lee Moffitt Cancer Center and Research Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-18346","August 26, 2016","September 2019","September 2020","August 1, 2016","null","September 5, 2018","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States","","https://ClinicalTrials.gov/show/NCT02851056"
848,"NCT02850276","Autonomic Neuropathy, GI Motility, and Inflammation in HIV","ANGI","Completed","No Results Available","HIV Disease","Drug: Pyridostigmine","vagal sub-score|Gastric Emptying (GE T 1/2)|Blood Pressure|Heart Rate|Hydrogen Breath Test|the Composite Autonomic Symptom Score (COMPASS)|Medical Outcomes Study Questionnaire","Icahn School of Medicine at Mount Sinai|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","76","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 14-1454|1R21DK105917-01A1","November 2015","June 1, 2018","June 1, 2018","July 29, 2016","null","August 13, 2018","Icahn School of Medicine at Mount Sinai, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02850276"
849,"NCT02849639","The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression","INCREASE","Recruiting","No Results Available","Alzheimer's Disease|Dementia","Other: Placebo|Other: Medication Therapy Management (MTM)|Drug: Scopolamine patch","Medication Appropriateness Index scale|Cognitive Reserve: Trail Making Test B with and without the scopolamine patch|Cognitive Reserve: Montreal Cognitive Assessment|Cognitive Reserve: California Verbal Learning test|Perceived Health Status","Daniela Moga|National Institute on Aging (NIA)|University of Kentucky","All","65 Years to 101 Years   (Older Adult)","Early Phase 1","90","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","16-0375-F2L INCREASE|1R01AG054130-01","April 4, 2017","March 2021","March 2021","July 29, 2016","null","May 2, 2018","University of Kentucky, Lexington, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT02849639"
850,"NCT02847377","A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC","IMKRUN 2","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Other: Injection of [18F]-ODS2004436 radiotracer","Evaluation of sensibility of [18F] ODS2004436|Evaluation of specificity of [18F] ODS2004436","Centre Georges Francois Leclerc","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IMK RUN 2","September 27, 2016","September 27, 2016","March 27, 2019","July 28, 2016","null","August 9, 2018","CGFL, Dijon, France","","https://ClinicalTrials.gov/show/NCT02847377"
851,"NCT02847000","p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer",,"Active, not recruiting","No Results Available","Metastatic Pancreatic Adenocarcinoma","Drug: Tetrahydrouridine|Drug: Decitabine","DNMT1 protein level decreases with an effect size of 1|Clinical Response as measured by RECIST 1.1 guidelines|Best Overall Response|Duration of Response|Duration of stable disease|Overall Survival|Progression-Free Survival","Yogen Saunthararajah|Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE2216","December 20, 2016","October 25, 2017","December 2018","July 27, 2016","null","November 5, 2018","University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02847000"
852,"NCT02846935","p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies",,"Recruiting","No Results Available","T-cell Lymphoma|Aggressive B-cell Lymphoma|Non-Hodgkin's Lymphomas|Indolent B-cell Lymphoma","Drug: Decitabine|Drug: Tetrahydrouridine","Objective Response by Revised Response Criteria for Malignant Lymphoma|Complete Response|Partial Response|Stable Disease|Progressive Disease|Duration of response|Disease-free survival|Disease-specific survival|Progression-free survival|Time to progression|Time to treatment failure","Yogen Saunthararajah|Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE1416","April 25, 2017","August 2020","August 2021","July 27, 2016","null","May 4, 2018","Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02846935"
853,"NCT02845544","Influence of Pilates-based Exercises on Postural Balance",,"Completed","No Results Available","Sedentary Lifestyle","Other: Pilates-based exercises","Static and dynamic postural balance with body mass displacement tracking|Surface Electromyography of the abdominal and low-back muscles","Universidade Federal de Pernambuco","All","18 Years to 30 Years   (Adult)","Early Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","PAOM0012016","May 2016","July 2016","August 2016","July 27, 2016","null","September 8, 2016","Laboratory of Kinesiology and Functional Evaluation in Federal University of Pernambuco, Recife, Pernambuco, Brazil","","https://ClinicalTrials.gov/show/NCT02845544"
854,"NCT02844803","Study of Metformin and S. Baicalensis Combination Therapy in Type 2 Diabetes Mellitus Patients",,"Unknown status","No Results Available","Diabetes Mellitus","Drug: Combination of Metformin + S. Baicalensis|Drug: Combination of Metformin + Placebo","Change of serum glucose level after 8 weeks from baseline","Namyi Gu|DongGuk University","All","20 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","S.baicalensis-Metformin","July 2016","June 2017","null","July 26, 2016","null","August 3, 2016","Dongguk University Ilsan Hospital, Goyang, Gyeonggi, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02844803"
855,"NCT02844621","Effect of Proton Pump Inhibitors on Gut Microbiota and Systemic Inflammation in Older Adults",,"Completed","No Results Available","Healthy Volunteers","Drug: Omeprazole","Change in fecal microbiota diversity following omeprazole use|Change in interleukin inflammatory markers following omeprazole use|Change in tumor necrosis factor-alpha following omeprazole use|Change in insulin-like growth factor-1 due following omeprazole use","The University of Texas Health Science Center at San Antonio","All","60 Years and older   (Adult, Older Adult)","Early Phase 1","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HSC20160114H","May 2016","December 2016","December 2016","July 26, 2016","null","January 20, 2017","First Outpatient Research Unit, Medical Arts and Research Center, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT02844621"
856,"NCT02842398","Independent Walking Speed and Crossing a City Street",,"Completed","No Results Available","Balance Problems|Cerebral Palsy","Behavioral: Balance Master|Behavioral: Customary Care","Change in gait velocity after intervention|Weight","Blythedale Children's Hospital","All","5 Years to 21 Years   (Child, Adult)","Early Phase 1","71","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Balance_Master","November 2010","January 2016","January 2016","July 22, 2016","null","May 18, 2018","Blythedale Children's Hospital, Valhalla, New York, United States","","https://ClinicalTrials.gov/show/NCT02842398"
857,"NCT02838667","Prevention and Early Detection and Intervention of Post-Coronary Artery Bypass Grafting Surgery (CABG) Acute Kidney Injury (AKI)",,"Unknown status","No Results Available","Acute Renal Injury|Preventive Measures","Procedure: Standard of Care plus Nephrology Care","Perfusion pressures (mean arterial pressure) ≥ 65-70 mmHg","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","2300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","16-003845","July 2016","June 2017","August 2017","July 20, 2016","null","July 22, 2016","Mayo Clinic in Rochester, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02838667"
858,"NCT02837861","Early and Adequate Protein Feeding Post-Traumatic Injury","EMS","Recruiting","No Results Available","Protein Feeding in Post-traumatic Injury Patients","Drug: Routine Nutritional Support plus supplemental IV amino acids|Other: Routine Nutritional Support","Nitrogen balance and Catabolic Index|Metabolomics Profiles","Peter Burke|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Boston Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","H-34322|1R21DK108145-01A1","March 7, 2017","December 31, 2020","January 31, 2021","July 20, 2016","null","October 24, 2018","Boston Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02837861"
859,"NCT02837614","Evaluation of Preoperative Submucosal Dexamethasone in Third Molar Surgery",,"Completed","No Results Available","Impacted Third Molar Tooth","Drug: dexamethasone acetate|Drug: submucosal dexamethasone injection|Procedure: Third molar surgery|Drug: Amoxicillin and paracetamol","Assessment of pain|Trismus|Facial Swelling","Sun Yat-sen University","All","18 Years to 40 Years   (Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SunYat","October 2015","January 2016","March 2016","July 19, 2016","null","July 19, 2016","","","https://ClinicalTrials.gov/show/NCT02837614"
860,"NCT02837432","The Effect of Cortisol Administration on Neural Correlates of Emotion in Depression",,"Recruiting","No Results Available","Depression","Drug: Hydrocortisone acetate|Drug: Placebo","Sadness-induced subgenual cingulate activity as measured by functional magnetic resonance imaging.","Stanford University","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","19771","July 2016","July 2020","July 2020","July 19, 2016","null","July 21, 2017","Department of Psychiatry and Behavioral Sciences, 401 Quarry Road, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT02837432"
861,"NCT02836288","Study of Oral Ketamine Versus Placebo for Treating Depression in Patients Undergoing Treatment for Cancer",,"Completed","No Results Available","Cancer|Depression","Drug: Ketamine|Other: Placebo","Proportion of patients pre-screened that were potentially eligible for study participation.|Proportion of patients that were potentially eligible who were approached.|Proportion of approached patients that decline study participation and why.|Proportion of approached patients that agreed to participate|Proportion of approached that were randomized.|Proportions of patients discontinuing prematurely from study treatment for any reason, including side effects attributed to ketamine or side effects attributed to placebo, documenting reasons for dropout.|Proportion of patients evaluable.|Adverse events related to study treatment.|Patient-reported Frequency, Intensity and Burden of Side Effects (FIBSER) scores.|Treatment expectancy and satisfaction as measured by the credibility/expectancy questionnaire (CEQ).","Scott A. Irwin, MD, PhD|Icahn School of Medicine at Mount Sinai|Cedars-Sinai Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IIT2015-23-IRWIN-KETTREAT","December 20, 2016","May 29, 2018","May 29, 2018","July 19, 2016","null","November 6, 2018","Cedars-Sinai Medical Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02836288"
862,"NCT02831374","Effectiveness of Platelet Rich Plasma in Wound Healing",,"Completed","No Results Available","Impacted Third Molar Tooth","Drug: Local anesthesia|Procedure: surgical extraction of impacted third molar|Biological: Preparation of PRP gel|Procedure: Placing platelet Rich plasma and suturing|Procedure: Suturing|Drug: Postoperative medication","Assessment of pain|Assessment of facial swelling|Assessment of trismus|Assessment of soft tissue healing|Assessment of bone healing","Linyi People's Hospital","All","18 Years to 50 Years   (Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LinyiPH","October 2015","March 2016","March 2016","July 13, 2016","null","July 13, 2016","","","https://ClinicalTrials.gov/show/NCT02831374"
863,"NCT02830776","Topical Bimatoprost for Chemical Blepharoplasty",,"Active, not recruiting","No Results Available","Dermatochalasis","Drug: bimatoprost 0.03% ophthalmic solution","Graded improvement in dermatochalasis|Improved patient satisfaction","Tulane University|Allergan","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","14","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","833277-1","November 2016","April 30, 2017","June 30, 2017","July 13, 2016","null","May 2, 2017","Tulane Department of Dermatology, New Orleans, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT02830776"
864,"NCT02828605","Virtual Interactive Platform (VIP) Transplant Research Study",,"Unknown status","No Results Available","Transplant Patients","Device: Virtual Interactive Platform (VIP) Transplant","Time to travel from home to Yale New Haven Hospital|Cost to travel from home to Yale New Haven Hospital|Patient Satisfaction with Care|Physician Satisfaction with Care","Yale University","All","10 Years to 80 Years   (Child, Adult, Older Adult)","Early Phase 1","8","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","JosephZinter071116","July 2016","September 2016","December 2016","July 11, 2016","null","July 11, 2016","","","https://ClinicalTrials.gov/show/NCT02828605"
865,"NCT02828033","Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss",,"Recruiting","No Results Available","Autoimmune Neurosensory Hearing Loss (ANSHL)","Drug: Rilonacept","Improvement in hearing in comparison to baseline values|Pt reported evaluation of auditory acuity|Vertigo evaluation|Tinnitus evaluation|Quality of Life assessment","Stanley Cohen|Regeneron Pharmaceuticals|Metroplex Clinical Research","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Rilonacept IIS 1604","February 1, 2017","March 2018","March 2018","July 11, 2016","null","September 13, 2017","Metroplex Clinical Research Center, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT02828033"
866,"NCT02826382","Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041",,"Recruiting","No Results Available","Prostate Cancer|Bone Metastases","Drug: [68Ga]P15-041","Time course of uptake of [68Ga]P15-041 in bone metastases|Time course of whole body distribution of [68Ga]P15-041","Five Eleven Pharma, Inc.","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","511-0001-A","September 20, 2016","December 2018","December 2018","July 11, 2016","null","February 7, 2018","University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02826382"
867,"NCT02826343","New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD)",,"Recruiting","No Results Available","Pulmonary Disease, Chronic Obstructive","Drug: Xenon129 MRI imaging|Drug: Gadolinium MRI|Drug: Advair (250mcg/50mcg) one puff twice a day","Improvement in pulmonary airflow physiology detected by Xenon129 MRI|Improvement in pulmonary gas exchange physiology detected by Xenon129 MRI|Improvement in clinical pulmonary function test|St. George's Respiratory Questionnaire|Baseline Dyspnea Index|Transition Dyspnea Index|Chronic Respiratory Questionnaire|BODE score|GOLD Stage","University of Virginia|National Institutes of Health (NIH)","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18667","May 2016","June 2018","June 2018","July 11, 2016","null","October 19, 2017","University of Virginia, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT02826343"
868,"NCT02825095","Management of Malignant Pleural Effusion - Indwelling Pleural Catheter or Talc Pleurodesis",,"Unknown status","No Results Available","Pleural Effusion, Malignant|Lung Neoplasms","Procedure: Talc Pleurodesis|Procedure: Indwelling Pleural Catheter|Procedure: chest ultrasound|Drug: Local anesthesia|Procedure: Chest Tube","change in Quality of Life|procedure and admissions","Rambam Health Care Campus","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0371-15rmb","August 2016","May 2017","August 2017","July 7, 2016","null","July 7, 2016","","","https://ClinicalTrials.gov/show/NCT02825095"
869,"NCT02825056","Postoperative Hemodynamics Comparison After High Spinal Block With or Without Intrathecal Morphine.",,"Unknown status","No Results Available","Vasoplegia","Drug: Bupivacaine|Drug: Bupivacaine + Morphine","incidence of Vasoplegia|Mechanical ventilation duration.|Time to extubation|Requirement of postoperative analgesia based on VAS|Spirometry performance|incidence of awareness under anesthesia","Postgraduate Institute of Medical Education and Research","All","18 Years to 60 Years   (Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","NK/2676/DM/397","July 2016","June 2017","June 2017","July 7, 2016","null","July 7, 2016","","","https://ClinicalTrials.gov/show/NCT02825056"
870,"NCT02824991","Ultrasonography Detection of Local Twitch Response During Dry Needling","US-DN","Completed","No Results Available","Healthy Participants","Procedure: detection of local twitch response intensities during dry needling","Size of local twitch responses to Dry Needling with Ultrasonomiography","University of Malaga|University of Chile","null","18 Years to 35 Years   (Adult)","Early Phase 1","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CH-Sp-01","January 2016","March 2016","April 2016","July 7, 2016","null","October 4, 2016","","","https://ClinicalTrials.gov/show/NCT02824991"
871,"NCT02824393","Experimental Autologous Mesenchymal Stem Cell Therapy in Treatment of Chronic Autoimmune Urticaria",,"Completed","No Results Available","Urticaria|Autoimmune Diseases|Immune System Diseases|Skin Diseases","Biological: Autologous mesenchymal stem cell","Change from baseline in weekly urticaria activity scores.|Follow-up of the mesenchymal stem cell treatment-related side effects according to World Health Organisation (WHO) Toxicity Grading Scale for Determining The Severity of Adverse Events.|The changes in the ratios of peripheral blood cluster of differentiation 4 (CD4) T cell subsets.|The changes in ratios of peripheral blood inflammatory and anti-inflammatory cytokines.|The changes in the levels of peripheral blood anti-FcεRI autoantibody","Celal Bayar University|The Scientific and Technological Research Council of Turkey|Acıbadem Labcell","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TUBITAK-1001-215S612","March 3, 2017","May 15, 2018","July 15, 2018","July 6, 2016","null","July 18, 2018","Celal Bayar University, Medical School, Manisa, Turkey","","https://ClinicalTrials.gov/show/NCT02824393"
872,"NCT02823847","Non Invasive Oral Cancer Screening Among HIV Infected Individuals",,"Recruiting","No Results Available","Malignant Neoplasms of Mesothelial and Soft Tissue|Human Immunodeficiency Virus","Behavioral: Screening Interview|Device: Carbon Monoxide Test|Behavioral: Self-Help Materials|Procedure: Visual Oral Screening Examination|Procedure: Direct Fluorescent Oral Visualization Examination|Procedure: Oral Biopsy","Positive Predictive Value for Premalignant and Malignant oral lesions (PMOL)","M.D. Anderson Cancer Center|Baylor College of Medicine|The University of Texas Health Science Center, Houston","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","2015-1030","July 2016","July 2019","July 2019","July 6, 2016","null","January 17, 2018","Bering Omega/Houston Area Community Services, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02823847"
873,"NCT02823691","The MetNET-2 Trial","MetNET-2","Recruiting","No Results Available","Neuroendocrine Tumors","Drug: Lanreotide and Metformin","incidence of SAEs and AEs|time to progression (TTP) to Lanreotide ATG 120 mg in combination with Metformin|symptomatic responses to Lanreotide ATG 120 mg in combination with Metformin in symptomatic patients|biochemical responses to Lanreotide ATG 120 mg in combination with Metformin","Melani Cecilia|National Cancer Institute, Milan","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NationalCIMilan","April 2016","April 2022","April 2022","July 6, 2016","null","July 6, 2016","NationalCIMilan, Milan, Italy","","https://ClinicalTrials.gov/show/NCT02823691"
874,"NCT02823665","The Effects of Bariatric Surgeries on Glucose Metabolism",,"Recruiting","No Results Available","Post Bariatric Surgery|Gastric Bypass|Sleeve Gastrectomy|Hypoglycemia After Gastric Bypass","Drug: Exendin-(9-39)|Drug: Atropine","Insulin levels measured after nutrient ingestion","The University of Texas Health Science Center at San Antonio|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other","20180070H|1R01DK105379-01","July 2015","July 2022","July 2022","July 6, 2016","null","May 18, 2018","South Texas Veterans Health Care System, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT02823665"
875,"NCT02823314","Effectiveness of Medical Taping Concept in Cancer Patients",,"Unknown status","No Results Available","Cancer-related Problem/Condition","Device: Cure Tape™ covering T 7 and T 8 dermatomes|Device: Cure Tape™ away from dermatomes T 7 and T 8","Difference between Number of times you have vomited during the first 24 hours after the first chemotherapy session and after the second chemotherapy session|Difference between nausea after the first chemotherapy session and after the second chemotherapy session|Difference between Intensity of nausea in the experience of the participant after the first chemotherapy session and after the second chemotherapy sessionintervention and pre-intervention|Difference between Quality of life post-intervention and pre-intervention","Universidad Miguel Hernandez de Elche|Hospital Universitario San Juan de Alicante","Female","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","16/308","June 2016","October 2016","June 2017","July 6, 2016","null","July 6, 2016","Hospital de San Juan, Sant joan DÁlacant, Alicante, Spain","","https://ClinicalTrials.gov/show/NCT02823314"
876,"NCT02820883","A Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults",,"Completed","No Results Available","Staphylococcus Aureus Infection","Biological: Staphylococcus aureus vaccine (60µg/per protein)|Biological: Staphylococcus aureus vaccine (30µg/per protein)|Biological: Staphylococcus aureus vaccine (15µg/per protein)","Occurrence of solicited adverse reactions after vaccination.|Occurrence of unsolicited adverse reactions after vaccination.|Occurrence of serious adverse events after the vaccination.|Changes of the laboratory examinations after vaccination.","Jiangsu Province Centers for Disease Control and Prevention|Chengdu Olymvax Biopharmaceuticals Inc.|Third Military Medical University","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","JSVCT027a","June 2016","August 2016","August 2016","July 1, 2016","null","September 12, 2016","Taixing county disease control and prevention, Taixing, Jiangsu, China","","https://ClinicalTrials.gov/show/NCT02820883"
877,"NCT02817945","Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging",,"Recruiting","No Results Available","Lung Cancer","Drug: 68Ga-NOTA-3P-TATE-RGD","Standardized uptake value of 68Ga-NOTA-3PTATE-RGD in lung cancer","Peking Union Medical College Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PUMCHNM13","June 1, 2016","December 1, 2019","December 31, 2019","June 29, 2016","null","November 5, 2018","Peking Union Medical College Hospitall, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT02817945"
878,"NCT02817698","Imaging the Neurochemistry of Drug Addiction With PET",,"Recruiting","No Results Available","Smoking|Cannabis","Drug: cannabis","Change in dopamine levels at baseline and after drug of dependence administration as confirmed by PET images.|Change in beta endorphin levels at baseline and after drug of dependence administration as confirmed by PET images.","Yale University","All","18 Years to 55 Years   (Adult)","Early Phase 1","90","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","1604017594","November 29, 2017","September 2021","September 2021","June 29, 2016","null","March 15, 2018","Connecticut Mental Health Center, New Haven, Connecticut, United States|Yale Magnetic Resonance Research Center, New Haven, Connecticut, United States|Yale PET Center, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02817698"
879,"NCT02816957","Benefits of Nigella Sativa in Children With Beta Thalassemia Major","Nigella","Unknown status","No Results Available","Nigella Sativa With Beta Thalassemia Major","Drug: nigella sativ","malondialdehyde|cluster of differentation4 and 8(CD4 and CD8)|total antioxidant|Serum iron|total iron binding capacity|serum ferritin|complete blood count","Tanta University","All","3 Years to 18 Years   (Child, Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","30794l03l16","June 2016","June 2017","June 2017","June 29, 2016","null","April 26, 2017","Faculty of Medicine- Tanta University, Tanta, Gharbia, Egypt","","https://ClinicalTrials.gov/show/NCT02816957"
880,"NCT02815215","Efficacy Analysis of Minimally Invasive Carroll's Technique in Treatment of Congenital Idiopathic Clubfoot",,"Recruiting","No Results Available","Congenital Clubfoot","Procedure: Minimally Invasive Carroll's Technique|Procedure: Ponseti method","Dimeglio classification system|Pirani scoring system","LiMing|Hunan Children's Hospital|Shenzhen Children's Hospital|Guangzhou Women and Children's Medical Center|Children's Hospital of Chongqing Medical University","All","up to 4 Years   (Child)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHChongqingMU","June 2016","December 2016","December 2019","June 28, 2016","null","June 28, 2016","Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China","","https://ClinicalTrials.gov/show/NCT02815215"
881,"NCT02814695","Yeast Cells as Antioxidant-Producing Probiotics","Probiotics","Completed","No Results Available","Infertility, Male","Dietary Supplement: Vit E 1|Dietary Supplement: Vit E 2|Dietary Supplement: Vit E 3|Dietary Supplement: YE 1|Dietary Supplement: YE 2|Dietary Supplement: YE 3|Dietary Supplement: Vit C 1|Dietary Supplement: Vit C 2|Dietary Supplement: Vit C 3","Number of motile sperms in prepared semen sample per high power field (HPF)|Number of progressively-motile sperms in prepared semen sample per HPF|Number of Vital sperms in prepared semen sample per HPF|level of oxidative stress (OS) By Oxisperm Kit","Benha University|Hawaa Fertility Center|Zagazig University","Male","22 Years to 35 Years   (Adult)","Early Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","HAWAA-001","August 2015","April 2016","May 2016","June 28, 2016","null","January 4, 2017","","","https://ClinicalTrials.gov/show/NCT02814695"
882,"NCT02814474","Effects of Experimental Hyperketonemia on Myocardial Metabolism",,"Completed","No Results Available","Healthy Volunteers","Other: Na-3-hydroxybutyrate|Other: Saline","Myocardial Glucose uptake|Myocardial Fatty Acid Metabolism|Myocardial Blood Flow|Insulin sensitivity","University of Aarhus|Aarhus University Hospital","All","50 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","1-10-72-104-14","October 2014","June 2016","June 2016","June 27, 2016","null","July 4, 2016","Department of Nuclear Medicine & PET Center, Aarhus University Hospital, Aarhus, Denmark|Medical Research Laboratories, Aarhus, Denmark","","https://ClinicalTrials.gov/show/NCT02814474"
883,"NCT02812719","Treatment of Melasma With Glycolic Acid-Salicylic Acid Peel Versus Glycolic Acid Peel",,"Withdrawn","No Results Available","Melasma","Drug: Glycolic acid peel alone|Drug: Glycolic and salicylic acid peel","Change in pigmentation|Change in pigmentation score|Improvement of melasma|Adverse events assessment","Boston Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","H-33976","July 2018","December 2018","February 2019","June 24, 2016","null","June 26, 2018","","","https://ClinicalTrials.gov/show/NCT02812719"
884,"NCT02811627","Predicting Treatment Response to Memantine in Autism Using Magnetic Resonance Spectroscopy",,"Recruiting","No Results Available","Autism Spectrum Disorder","Drug: Memantine|Device: Magnetic Resonance Imaging","Clinical Global Impressions - Improvement|Social Responsiveness Scale|General Social Outcomes Measure|Aberrant Behavior Checklist","University of Missouri-Columbia","All","16 Years and older   (Child, Adult, Older Adult)","Early Phase 1","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2004983HS","June 2016","December 2018","December 2018","June 23, 2016","null","February 6, 2018","University of Missouri, Columbia, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02811627/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02811627"
885,"NCT02810756","Study With Improved Solubility Pazopanib",,"Completed","No Results Available","Pharmacokinetics of Pazopanib","Drug: New Pazopanib formulation","Plasma concentration|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Area under the plasma concentration versus time curve (AUC)","The Netherlands Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","N16PZN","September 15, 2016","August 28, 2017","August 28, 2017","June 23, 2016","null","September 11, 2017","Netherlands Cancer Institute, Amsterdam, North Holland, Netherlands","","https://ClinicalTrials.gov/show/NCT02810756"
886,"NCT02810548","Evaluation of Platelets Rich Fibrin and Nanohydroxyapatite in the Treatment of Intrabony Defects",,"Unknown status","No Results Available","Bony Defects","Procedure: OFD alone|Drug: Platelet rich Fibrin|Drug: Nanohydroxyapatite","Changes in Gingival crevicular fluid (GCF)|Changes in Gingival index|Changes in level of attachment loss|Changes in probing pocket depth","King Abdulaziz University","All","20 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","032-16","August 2016","December 2016","null","June 23, 2016","null","June 23, 2016","King Abdelaziz University. Faculty of dentistry, Jeddah, Saudi Arabia","","https://ClinicalTrials.gov/show/NCT02810548"
887,"NCT02806817","ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism",,"Recruiting","No Results Available","Breast Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Early-Stage Breast Carcinoma","Drug: ME-344|Drug: Bevacizumab|Other: Normal saline","Reduction of FDG uptake|SDH (succinate dehydrogenase) levels staining|Toxicity profile: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0|Ki67 changes|Cleaved caspase-3 changes","Centro Nacional de Investigaciones Oncologicas CARLOS III|Fundación CRIS","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CNIO-BR-009|2015-005457-12","July 2016","August 2018","January 2019","June 21, 2016","null","September 14, 2017","Hospital Reina Sofía, Córdoba, Cordoba, Spain|Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|Complejo Hospitalario Universoitario A Coruña, A Coruña, Spain|H. Arnau de Vilanova Lleida, Lleida, Spain|Hospital de la Princesa, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|H. Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Clínica Quirón, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT02806817"
888,"NCT02806739","Soy Supplementation and Gestational Diabetes",,"Completed","No Results Available","Gestational Diabetes","Dietary Supplement: Soy Group (Soy Protein + Isoflavones)|Dietary Supplement: Control Group (Minimize Soy Intake)","Number of Participants With Adverse Events That Are Related to Treatment|Effects of Soy Intake on Triglycerides (TG)|Effects of Soy Intake on Total Cholesterol (TC)|Effects of Soy Intake on High-density Lipoprotein Cholesterol (HDL-C)|Effects of Soy Intake on Free Fatty Acid (FFA)|Effects of Soy Intake on Fasting Glucose|Effects of Soy Intake on Fasting Insulin|Effects of Soy Intake on Hemoglobin A1c (HbA1c)|Effects of Soy Intake on C-reactive Protein (CRP)","University of Massachusetts, Boston|University of Massachusetts, Worcester|Tufts University|Hallmark Health System","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","UL1TR000161","January 2013","September 2016","September 2016","June 21, 2016","null","October 27, 2016","Tufts Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02806739"
889,"NCT02805868","Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis",,"Withdrawn","No Results Available","Myelofibrosis|Polycythemia Vera|Primary Myelofibrosis|Thrombocytopenia","Procedure: Bone Marrow Aspiration and Biopsy|Other: Laboratory Biomarker Analysis|Biological: Siltuximab","Incidence of Adverse Events|Clinical Improvement (CI): changes in symptoms|Clinical Improvement (CI): splenomegaly|Clinical Improvement (CI): Anemia response|Overall Response Rate (ORR)","Northwestern University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 16H01|STU00202680|P30CA060553|NCI-2016-00685","June 2016","February 2019","null","June 20, 2016","null","October 24, 2016","","","https://ClinicalTrials.gov/show/NCT02805868"
890,"NCT02804620","From Clinic to Community Study","C2C","Unknown status","No Results Available","Peer Support|Diabetes Self-management","Behavioral: Peer-led, Empowerment-based Approach to Self-management efforts in Diabetes","Change in HbA1c%|ApoB","University of British Columbia|Canadian Diabetes Association","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","228","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","H14-02419","October 2014","September 2017","September 2017","June 17, 2016","null","June 17, 2016","Vancouver Coastal Health, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT02804620"
891,"NCT02803125","Improving Psychosocial Functioning in Older Veterans With PTSD",,"Recruiting","No Results Available","Posttraumatic Stress Disorder","Behavioral: Psychosocial intervention|Behavioral: Support group control","Change in the Quality of Life Inventory (QOLI)|Change in the Inventory of Psychosocial Functioning|Change in the Veterans Rand 12-item Health Survey","VA Office of Research and Development","Male","60 Years and older   (Adult, Older Adult)","Early Phase 1","124","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","D1832-W","November 14, 2017","November 30, 2020","November 30, 2021","June 16, 2016","null","October 24, 2018","VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02803125"
892,"NCT02802748","Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)",,"Completed","No Results Available","Breast Cancer","Drug: Oral Vinorelbine|Drug: Letrozole","Changes in the expression of the PAM50 proliferation signature upon treatment in patients defined as Luminal by PAM50|Changes in the expression of the PAM50 proliferation signature upon treatment in patients defined as Luminal by IHC and separately, in patients defined as either Luminal A or Luminal B by PAM50.|Changes in % of Ki67-positive cells (per IHC) upon treatment|Changes in the expression of angiogenic gene signature upon treatment|Changes in the expression of immune-response-related gene signature upon treatment|Changes in the expression of breast cancer related genes (contained in a 560 gene Custom CodeSet) upon treatment|Objective Response Rate (ORR) according to RECIST v1.1, assessed by ultrasound.|Safety profile","SOLTI Breast Cancer Research Group|Pierre Fabre Laboratories","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SOLTI-1501|2015-004714-24","July 2016","January 2018","January 2018","June 16, 2016","null","September 20, 2018","Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital de León, León, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitari Sant Joan de Reus, Reus, Spain|Clínica Quirón Sagrado Corazón, Sevilla, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain","","https://ClinicalTrials.gov/show/NCT02802748"
893,"NCT02802696","Transfusion-Associated Circulatory Overload Best Eliminated With Lasix",,"Completed","No Results Available","Transfusion-associated Circulatory Overload","Drug: Furosemide|Drug: Normal Saline","Number of patients enrolled|Proportion of patients screened meeting eligibility criteria|Proportion of eligible patients consenting to participate|Proportion of patient receiving the allocated treatment|Proportion of treated patients completing follow-up assessment|Proportion of patient in which blinding was maintained throughout study|Vital Signs|Positive end-expiratory pressure|Inspiratory oxygen|Incidence of TACO within 6 hours from completion of transfusion|Severity of TACO-graded as per the Public Health Agency of Canada's Transfusion Transmitted Injuries Surveillance System|Validation of TACO as per criteria adopted from the US Center for Disease Control|Change in plasma brain natriuretic peptide(BNP)|Net fluid balance at 24 hours from start of transfusion- all intravenously-administered fluids (including the transfused blood product and the study intervention)|Proportion of patients developing hyponatremia or hypokalemia by Day 1|Proportion of patients developing hypotension|Proportion of patients developing acute kidney injury|Need for increased supplemental oxygen is defined as any increase in oxygen flow ≥ 1 L/hr or (fraction of inspired oxygen)FiO2 ≥ 5% of 1 hour duration or longer, prompted by either patient symptoms or a fall in oxygen saturation(SpO2) ≥ 5%|Need for inotropic support is defined as the initiation of a continuous infusion of dopamine, dobutamine, epinephrine, or norepinephrine|Need for additional diuretic or vasodilatory therapy is defined by the prescription of non-study furosemide, hydrochlorothiazide, metolazone, or either transdermal or intravenous nitroglycerin|Occurrence of acute coronary syndrome or new arrhythmia|Mortality during hospital stay|Length of hospital stay","Sunnybrook Health Sciences Centre|University Health Network, Toronto|Canadian Blood Services","All","65 Years and older   (Older Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","16-5032","June 2016","March 17, 2017","April 15, 2017","June 16, 2016","null","June 26, 2017","Canadian Blood Services, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02802696"
894,"NCT02802098","Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer",,"Recruiting","No Results Available","Metastatic Breast Cancer|Bevacizumab-alone Maintenance Treatment Progression","Drug: Durvalumab|Drug: Bevacizumab","Changes Immunodynamics factors: kynurenine, prostaglandin, tryptophan levels|T-cell exhaustion parameters|T-cell exhaustion reversion|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","Centro Nacional de Investigaciones Oncologicas CARLOS III|Fundación CRIS","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CNIO-BR-008|2015-005609-34","May 2016","May 2018","December 2018","June 16, 2016","null","September 14, 2017","Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|H. Arnau de Vilanova Lleida, Lleida, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Clínica Quirón, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT02802098"
895,"NCT02795663","Deep Brain Stimulation and Parkinson's Disease","SCP TCI NIRS","Completed","No Results Available","Parkinson Disease","Device: NIRS EEG HR recording","Study of local cortical hemodynamic change (oxy-Hb, deoxy-Hb, and total Hb)|Study of QUIP score (QUIP scale)|Comparison of local cortical hemodynamic changes (oxy-Hb, deoxy-Hb, and total Hb) with the localisation of the contact use for STN-DBS stimulation|Comparison of local cortical hemodynamic changes (oxy-Hb, deoxy-Hb, and total Hb) with intensity of STN-DBS stimulation|Study of local cortical hemodynamic changes (oxy-Hb, deoxy-Hb, and total Hb) with intensity of NonSTN-DBS stimulation|Study of delayed discounting task (DDT) score","Centre Hospitalier Universitaire, Amiens","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PI2013_843_0016","September 1, 2014","December 2017","December 2017","June 10, 2016","null","August 10, 2018","CHU Amiens, Amiens, France","","https://ClinicalTrials.gov/show/NCT02795663"
896,"NCT02795351","Induction of Migraine Aura With Sildenafil",,"Recruiting","No Results Available","Migraine With Aura","Drug: Sildenafil|Drug: Placebo","Aura and migraine like headache|Markers of endothelial function in blood|Migraine without aura","Herlev Hospital","All","18 Years to 50 Years   (Adult)","Early Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","H-15008491","June 2015","March 2019","March 2019","June 10, 2016","null","October 23, 2018","Department of Neurology, Herlev-Gentofte Hospital, Herlev, Denmark","","https://ClinicalTrials.gov/show/NCT02795351"
897,"NCT02794675","Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Head and Neck Cancer",,"Recruiting","No Results Available","Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma","Drug: Cesium 131","Median disease free survival (DFS)","Case Comprehensive Cancer Center","All","19 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE5315","December 21, 2016","January 2019","January 2019","June 9, 2016","null","November 12, 2018","University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02794675"
898,"NCT02790385","Negative Pressure Wound Therapy - A Multi-Centered Randomized Control Trial","NPWT","Recruiting","No Results Available","to See Whether Negative Pressure Wound Therapy Decreases Wound Infections.","Device: Negative Pressure Wound Therapy|Other: Standard Gauze Treatment","Wound Infection|Time for wound closure|Cosmetic results|Caregiver/parental satisfaction|Wound dehiscence|Foreign body reaction","University of British Columbia","All","8 Years to 21 Years   (Child, Adult)","Early Phase 1","870","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","H13-03020","July 2014","July 2019","July 2019","June 3, 2016","null","June 3, 2016","BC Children's Hospital, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT02790385"
899,"NCT02789579","The Preventive Infection Role of One Week Antibiotics Before Minimally Invasive Upper Tract Lithotomy",,"Recruiting","No Results Available","Complication of Surgical Procedure","Drug: levofloxacin|Drug: Nitrofurantoin|Drug: cefuroxime","Evidence of clinically urinary tract infection confirmed by laboratory examination or urine bacterial culture.|Evidence of clinically urosepsis confirmed by laboratory examination, urine bacterial culture, and vital signs","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","All","16 Years to 75 Years   (Child, Adult, Older Adult)","Early Phase 1","150","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","XH-16-010","September 2016","December 2018","December 2018","June 3, 2016","null","May 11, 2018","Department of Pharmacy, Xinhua Hospital, Shanghai Jiaotong University School of Medicine.Kongjiang Road 1665,, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT02789579"
900,"NCT02789150","Outcomes of Renal Function in Hepatorenal Syndrome (HRS) Determined By Comparison of Target Mean Arterial Pressure (MAP) of 65 - 70 Mmhg Versus ≥ 85 Mmhg",,"Completed","No Results Available","Hepatorenal Syndrome","Drug: Norepinephrine (Levophed)","Urine output|serum creatinine|Cardiac events|ischemic events","University of Louisville","All","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14.1190","January 2015","January 11, 2018","January 11, 2018","June 2, 2016","null","January 16, 2018","University of Louisville, Louisville, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT02789150"
901,"NCT02789085","ANS Effects of ULF-TENS Stimulation in Patients With and Without TMD",,"Unknown status","No Results Available","TEMPOROMANDIBULAR JOINT DISEASES","Device: ULF TENS stimulation","Between groups difference in ANS activity, expressed as heart rate (HR), as assessed by computed polygraph|Between groups difference in ANS activity, expressed as heart rate variability parameters (HRV, DET, RR), as assessed by computed polygraph|Between groups difference in ANS activity, expressed as EMG of suprahyoid muscles, as assessed by computed polygraph|Between groups difference in ANS activity, expressed as breathing rate, as assessed by computed polygraph|Between groups difference in ANS activity, expressed as skin conductance, as assessed by computed polygraph|Between groups difference in ANS activity, expressed as skin temperature, as assessed by computed polygraph|Between groups difference in ANS activity, expressed as total antioxidant capacity (TAC), as assessed by ELISA|Between groups difference in ANS activity, expressed as serum total pro-oxidant activity (TPA) assessed by ELISA|Between groups difference in ANS activity, expressed as serum and salivary noradrenaline, as assessed by ELISA|Between groups difference in ANS activity, expressed as salivary alpha-amylase, assessed by ELISA.","University of L'Aquila","Female","25 Years to 35 Years   (Adult)","Early Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Screening","45423/30.12.2015","November 2013","December 2015","null","June 2, 2016","null","June 3, 2016","Dental Clinic, University of L'Aquila, St. Salvatore Hospital,, L'Aquila, Italy","","https://ClinicalTrials.gov/show/NCT02789085"
902,"NCT02786329","Anesthesia and Postoperative Outcome in Colorectal Cancer Patients",,"Recruiting","No Results Available","Colorectal Cancer","Drug: TIVA+lidocaine|Drug: Sevoflurane+lidocaine|Drug: TIVA+placebo|Drug: Sevoflurane+placebo","Survival after TIVA vs sevoflurane anesthesia in patients operated for colorectal cancer|Incidence of recurrences:|Morphine consumption during the first 24 postoperative hours|Severity of postoperative pain - verbal response pain (VRPS) score in recovery room and during the first 48 hrs postoperatively|Resumption of bowel function|Length of hospital stay|Postoperative chronic pain","Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor|Prof. Dr. I. Chiricuta Institute of Oncology","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","450","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","53/14.03.2016","June 2016","December 2019","December 2021","June 1, 2016","null","August 8, 2018","Clinica ATI, str Croitorilor nr 19-21, Cluj-napoca, Cluj, Romania|Institutul Oncologic Prof Dr Ion Chiricuta, Cluj-Napoca, Cluj, Romania","","https://ClinicalTrials.gov/show/NCT02786329"
903,"NCT02784847","A Pilot Trial of Triheptanoin for the Preventive Treatment of Migraine","TRIMI","Unknown status","No Results Available","Migraine","Drug: Triheptanoin","Change in monthly migraine days|Change in mean attack severity|Change in mean attack duration|Number of patients who have at least a 50% reduction in monthly migraine days","University Hospital of Liege","Female","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UX007","June 2016","November 2016","November 2016","May 27, 2016","null","May 27, 2016","","","https://ClinicalTrials.gov/show/NCT02784847"
904,"NCT02780791","Maturation of Follicles After Transplantation of Ovarian Tissue Into the Pelvic Wall and the Ovary","Ovartrans","Enrolling by invitation","No Results Available","Infertility|Ovarian Failure, Premature","Other: Transplantation into pelvic wall|Other: Transplantation into the ovary","Comparison of follicle maturation in transplanted tissue between pelvic wall and ovary|Duration of cycle, measured in weeks|Number of study participants with pregnancy|Number of study participants with life-birth after pregnancy|Determination of hormone levels after transplantation, concerning the concentration of estradiol, progesterone, LH, FSH|Sonographic measurement of the endometrium wall, measured in mm","University Hospital Inselspital, Berne","Female","18 Years to 49 Years   (Adult)","Early Phase 1","25","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-OVARTRANS","September 10, 2017","March 2019","March 2020","May 23, 2016","null","May 4, 2018","Universitätsfrauenklinik, Abteilung für Gynäkologische Endokrinologie und Reproduktionsmedizin, Bern, BE, Switzerland","","https://ClinicalTrials.gov/show/NCT02780791"
905,"NCT02780648","Respiratory-gated Stereotactic Body Radiation Therapy for Adenocarcinoma of the Pancreas or Periampullary Region",,"Recruiting","No Results Available","Pancreatic Neoplasms","Radiation: Stereotactic Body Radiation","Acute toxicity rates of grade 3 gastrointestinal and hematologic toxicities (as raw percentage)|Late toxicity rates of grade 3 gastrointestinal and hematologic toxicities (as raw percentage)|Overall survival rates|Progression-free survival rates|Metastasis-free survival rates|Patient self-report of pain control|Patient self-report of quality of life","Susannah Ellsworth|Indiana University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IUSCC-0565|1601638414","May 1, 2016","October 1, 2019","October 1, 2019","May 23, 2016","null","March 27, 2018","Indiana University Health Hospital, Indianapolis, Indiana, United States|Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Indiana University Health Methodist Hospital, Indianapolis, Indiana, United States","","https://ClinicalTrials.gov/show/NCT02780648"
906,"NCT02774512","Predictive Biomarkers of Biological Activity and Efficacy of Nilotinib on ZAK Target in Non-metastatic Colon Cancer","ZAK-0","Withdrawn","No Results Available","Colon Cancer","Drug: Nilotinib","ZAK expression level by immunohistochemistry on frozen material (surgical specimen) by Western blot and on paraffinembedded tissues section using an immunohistochemistry approach|Efficacy of the 7day nilotinib treatment based on histological response as measured with tumour regression grade|Efficacy of the 7day nilotinib treatment based on histological response as measured with the proportion of tumour necrosis|Efficacy of the 7day nilotinib treatment based on histological response as measured with the type of tumour necrosis|Incidence of Treatment Emergent Adverse Events as assessed by CTCAE v4.0 as assessed by CTCAE v4.0|Postoperative complications as assessed by Dindo and Clavien classification|Maximum Plasma Concentration [Cmax] of nilotinib .|Half-life of nilotinib","Institut Bergonié|Novartis Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","IB 2015-03","May 2016","November 2017","November 2017","May 17, 2016","null","October 6, 2017","Institut Bergonié, Bordeaux, France","","https://ClinicalTrials.gov/show/NCT02774512"
907,"NCT02772068","Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a",,"Active, not recruiting","No Results Available","Heart Failure, Congestive","Drug: Istaroxime|Other: Exercise","Change in cardiac filling pressures (pulmonary capillary wedge pressure) during exercise with Istaroxime|Change in cardiac relaxation time (isovolumic relaxation time) during exercise with Istaroxime","University of Texas Southwestern Medical Center","All","60 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","STU 042013-039","September 2015","May 2018","May 2018","May 13, 2016","null","May 2, 2018","The Institute for Exercise and Environmental Medicine, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT02772068"
908,"NCT02772016","Therapeutic Effect of Colla Corii Asini on Improving Anemia and Hemoglobin Composition in Pregnant Women With Thalassemia",,"Unknown status","No Results Available","Thalassemia","Drug: Colla corii asini","Hemoglobin(Hb)|Adult hemoglobin(HbA)|Fetal hemoglobin(HbF)|Minor adult hemoglobin(HbA2)|Serum iron(SI)|Serum ferritin(SF)|Adverse effect","Yanfang Li|The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine","Female","20 Years to 35 Years   (Adult)","Early Phase 1","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TH-1","March 2015","May 2016","null","May 13, 2016","null","May 13, 2016","the first affiliated hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT02772016"
909,"NCT02769260","Comparison of Biofilm Characteristics Between an in Situ Biofilm Model of Supragingival Plaque and Natural Teeth",,"Unknown status","No Results Available","Biofilm|Dental Plaque","Other: Toothbrushing","Bacterial viability|Bacterial diversity|Biofilm thickness","University of Santiago de Compostela","All","20 Years to 45 Years   (Adult)","Early Phase 1","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Pyro-Biofilm","September 2015","May 2016","June 2016","May 11, 2016","null","May 11, 2016","Univeristy of Santiago de Compostela, Faculty of Dentistry, Santiago de Compostela, Galicia/ A Coruña, Spain","","https://ClinicalTrials.gov/show/NCT02769260"
910,"NCT02768688","MRI of Glymphatic Clearance During Anesthetic Sedation",,"Completed","No Results Available","Glymphatic Flow","Other: Brain connectivity and physiology|Drug: Dexmedetomidine","Glymphatic clearance from the human brain","University of Pennsylvania","All","20 Years to 40 Years   (Adult)","Early Phase 1","17","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","819962","July 2014","February 9, 2017","December 2017","May 11, 2016","null","January 25, 2018","University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02768688"
911,"NCT02768441","Dexamphetamine Sustained Release Pharmacokinetics and Clinical Validation of Dried Blood Spots",,"Completed","No Results Available","Cocaine Addiction","Drug: Dexamphetamine","Area under the Curve (AUC) of dexamphetamine|Maximum plasma concentration (Cmax) of dexamphetamine|Half life (T 1/2) of dexamphetamine","The Netherlands Cancer Institute","All","25 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAM001DFM","November 1, 2016","June 1, 2017","June 1, 2017","May 11, 2016","null","June 2, 2017","AMC, Amsterdam, Netherlands","","https://ClinicalTrials.gov/show/NCT02768441"
912,"NCT02768389","Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma",,"Suspended","No Results Available","Glioblastoma|Brain Tumor","Drug: Bevacizumab|Behavioral: Modified Atkins Diet","Number of subjects following Modified Atkins Diet|Number of subjects with ketosis|Correlation of blood sugar levels by compliance level|Correlation of ketosis values by compliance level|Correlation of ketosis values by tumor response|Correlation of blood sugar levels by tumor response","Case Comprehensive Cancer Center|University of Cincinnati|OhioHealth Research Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE10314","September 6, 2016","December 2018","February 2019","May 11, 2016","null","September 27, 2018","University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive cancer Center, Cleveland, Ohio, United States|OhioHealth Research and Innovation Institute, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02768389"
913,"NCT02767362","A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium",,"Recruiting","No Results Available","Endometrial Cancer","Drug: Atorvastatin","Absolute difference score","UNC Lineberger Comprehensive Cancer Center|Wilma Williams Education and Clinical Research for Endometrial Cancer Award","Female","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC 1514","November 2015","November 2019","November 2020","May 10, 2016","null","September 24, 2018","University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02767362"
914,"NCT02766517","Biomarker Study in Participants With Migraine",,"Completed","No Results Available","Migraine Disorders","Drug: Capsaicin","The Capsaicin-Induced Dermal Blood Flow (DBF)|Plasma Calcitonin Gene-Related Peptide (CGRP) Levels","Eli Lilly and Company","All","Child, Adult, Older Adult","Early Phase 1","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16235|I5Q-MC-S001","September 28, 2016","January 1, 2017","January 1, 2017","May 9, 2016","null","February 3, 2017","Arizona Research Center, Phoenix, Arizona, United States|Pharmacology Research Institute, Newport Beach, Encino, California, United States|Parexel Early Phase Unit at Glendale, Glendale, California, United States|Pharmacology Research Institute, Newport Beach, Los Alamitos, California, United States|Pharmacology Research Institute, Newport Beach, Newport Beach, California, United States|Medical Center for Clinical Research, San Diego, California, United States|California Clinical Trials, San Diego, California, United States|Avail Clinical Research LLC, Deland, Florida, United States|Psychiatric Inst of Florida-Clinical Neuroscience Solutions, Orlando, Florida, United States|PharmaSite Research Inc, Baltimore, Maryland, United States|PAREXEL-Phase 1 Baltimore Harbor Hospital Center, Baltimore, Maryland, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|CNS Health Care, Memphis, Tennessee, United States|Northwest Clinical Research Center, Bellevue, Washington, United States","","https://ClinicalTrials.gov/show/NCT02766517"
915,"NCT02766270","CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas",,"Recruiting","No Results Available","Grade II/III Glioma","Drug: Temozolomide|Radiation: Radiotherapy","Overall survival (OS)|Progression free survival(PFS)|The incidence and severity of adverse events associated with treatment with RT alone and combined with temozolomide chemotherapy; according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0.","Beijing Tiantan Hospital|Beijing Neurosurgical Institute|Beijing Shijitan Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CFMD 2016-2-1073","September 26, 2016","December 2017","December 2018","May 9, 2016","null","January 20, 2017","Beijing Tiantan Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT02766270"
916,"NCT02765113","Two Different Surgical Methods of Blepharospasm",,"Unknown status","No Results Available","Blepharospasm","Procedure: Facial nerve combing|Procedure: Facial and Trigeminal nerve combing","Improvement of symptoms in patients with blepharospasm|Incidence of facial numbness|Incidence of facial paralysis","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","XH-16-008","May 2016","December 2017","December 2017","May 6, 2016","null","May 6, 2016","","","https://ClinicalTrials.gov/show/NCT02765113"
917,"NCT02764060","The Effect of Tongue Cleaning in Periodontitis Patients",,"Completed","No Results Available","Periodontitis|Tongue Coating","Device: Tongue scraper|Device: Toothbrush","Extension of the tongue coating|Bacterial load measured by culturing methods|Bacterial load measured by means of qPCR|Bacterial composition of unstimulated saliva (measured with the aid of culturing methods)|Bacterial composition of unstimulated saliva (measured with qPCR)|Experience of the subject of tongue coating related factors measured using a questionnaire","Universitaire Ziekenhuizen Leuven","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","s54161","January 2011","January 2015","January 2015","May 6, 2016","null","May 6, 2016","UZLeuven, Leuven, Belgium","","https://ClinicalTrials.gov/show/NCT02764060"
918,"NCT02759510","Cardiac Output Changes in Cesarean Section",,"Unknown status","No Results Available","Cardiac Output,Low|Hemodynamic Instability|Obstetrical Complication of Anesthesia","Drug: Norepinephrine|Drug: Phenylephrine","cardiac output|systolic blood pressure|heart rate|Apgar score|Umbilical cord arterial blood pH/BE/Lac|umbilical plasma catecholamine concentration","RenJi Hospital","Female","18 Years to 40 Years   (Adult)","Early Phase 1","106","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Renji-2016035k","June 2016","June 2016","June 2017","May 3, 2016","null","May 3, 2016","","","https://ClinicalTrials.gov/show/NCT02759510"
919,"NCT02757521","Nitrous TRD Bipolar Depression",,"Recruiting","No Results Available","Treatment- Resistant Bipolar Disorder|Bipolar Disorder|Bipolar Depressive Disorder","Drug: Nitrous Oxide|Drug: Placebo","Change in MADRS (Montgomery Asberg Depression Rating Scale)|Hamilton Depression Rating Scale-17 item (Ham-D17)|Young Mania Rating Scale (YMRS) to assess emergence of mania/hypomania","Washington University School of Medicine|Stanley Medical Research Institute|PPD","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","64","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","201509128","November 2015","October 2020","March 2021","May 2, 2016","null","November 7, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02757521"
920,"NCT02757261","Evaluation of Muscle Activity, Bite Force and Salivary Cortisol in Children With Bruxism","Bruxism","Unknown status","No Results Available","Sleep Bruxism","Device: Laser|Device: Occlusal splint|Device: Placebo laser","Change in ELECTROMYOGRAPHIC EVALUATION OF MASTICATORY AND TRAPEZIUS MUSCLES|Change in Bite force|Change in Salivary cortisol","University of Nove de Julho","All","6 Years to 8 Years   (Child)","Early Phase 1","76","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","1.333.636","June 2016","October 2016","March 2017","May 2, 2016","null","May 2, 2016","","","https://ClinicalTrials.gov/show/NCT02757261"
921,"NCT02756884","Safety and Preliminary Efficacy of Adipose Derived Stem Cells and Low Frequency Ultrasound in PAD",,"Completed","No Results Available","Peripheral Arterial Disease","Biological: LoFU and aADSC|Biological: adipose derived stem cells","Safety measured by incidence of adverse events|Efficacy of stem cells in improving ABI|Efficacy of stem cells in improving 6MWT|Efficacy of stem cells in improving the TcPO2|Efficacy of stem cells in improving Quality of Life using EQ-5D 5L questionnaire|Efficacy of stem cells in improving Quality of Life using the VascuQol questionnaire","Arkansas Heart Hospital|SonaCare Medical","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","12","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AHH-2015-10","June 3, 2015","August 7, 2018","August 7, 2018","April 29, 2016","null","September 5, 2018","Arkansas Heart Hospital, Little Rock, Arkansas, United States|Arkansas Site Management Services LLC, Little Rock, Arkansas, United States","","https://ClinicalTrials.gov/show/NCT02756884"
922,"NCT02753309","A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer",,"Recruiting","No Results Available","Bladder Cancer","Drug: Sirolimus","Percentage change in systemic (whole blood) gamma-delta T cells frequency|Percentage change in systemic (whole blood) gamma-delta T cell proliferation in response to BCG-specific antigens|Percentage change in systemic (whole blood) Ag85 peptide-specific CD4 and CD8 T lymphocytes measured using human IFN-gamma release.","The University of Texas Health Science Center at San Antonio","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC20160162H","June 2016","December 2018","December 2018","April 27, 2016","null","July 10, 2018","University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT02753309"
923,"NCT02753101","[18F]FTC-146 PET/MRI in Healthy Volunteers and in CRPS and Sciatica",,"Completed","No Results Available","Complex Regional Pain Syndrome|Sciatica","Drug: [18F]-FTC-146","Biodistribution of [18F]FTC-146|Dosimetry of [18F]FTC-146|Incidence of Adverse Events","Stanford University|University of Mississippi Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","32231","February 9, 2016","February 9, 2017","February 16, 2017","April 27, 2016","null","March 5, 2018","Stanford University, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT02753101"
924,"NCT02750176","Rehabilitation: Closed-Chain Exercises for Rotator Cuff Tears","CERCT","Completed","No Results Available","Full Thickness Rotator Cuff Tear","Other: Closed chain exercises","Feasibility - recruitment|Patient Specific Functional Scale (PSFS)|Penn Shoulder Score (Penn)|Feasibility - retention|Quick Disabilities of the Arm Shoulder Hand (QDASH) scale|Global Rating of Change (GRoC) scale|Numeric Pain Rating Scale (NPRS)|American Shoulder and Elbow Surgeon Patient-report (ASES) scale|Shoulder pain-free active elevation range of motion|Shoulder elevation strength|Shoulder external rotation strength|Patient Acceptable Symptom State (PASS) score","University of Southern California","All","40 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS-15-00771","April 2016","July 2018","July 2018","April 25, 2016","null","October 25, 2018","Clinical Biomechanics Orthopedic and Sports Outcomes Research Laboratory, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02750176"
925,"NCT02749513","Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients",,"Recruiting","No Results Available","Esophageal Cancer","Drug: Itraconazole","Inhibition of Hedgehog pathway signaling as measured by real-time PCR.|Inhibition of VEGFR2 pathway signaling as measured by Western blot","Dallas VA Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","15-084","January 2016","December 2018","null","April 25, 2016","null","July 26, 2017","Dallas VA Medical Center, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT02749513"
926,"NCT02749240","A Feasibility (Pilot) Study of an Innovative Non-pharmacological Intervention Program in at Risk Youth",,"Recruiting","No Results Available","At Risk Youth","Other: Youth Empowerment Seminar, YES!","Number of potential participants approached per month.|Number (proportion) of participants who are successfully screened.|Number (proportion) of successfully screened participants who enroll.|Rate of participant retention.|Rate of adherence to study protocol.|Proportion of planned ratings that are completed.|Intervention cost per case|Completeness of final data for analysis.|Length of time to collect all data.|Quality of all collected data.|Determining if YOU is willing to conduct the study as per study protocol.|Assess if it is safe to apply the intervention.|Community integration questionnaire|Global Appraisal of Individual Needs- Substance Problem Scale (GAIN-SPS)|Colorado Symptom Index|demographic, service and housing history (DSSH)","Lawson Health Research Institute","All","16 Years to 25 Years   (Child, Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","107708","June 2016","December 31, 2018","December 31, 2018","April 22, 2016","null","June 21, 2018","London Health Sciences Centre, London, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02749240"
927,"NCT02748798","Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders",,"Not yet recruiting","No Results Available","Lung Transplant|Lung Resection|Lung Cancer|Asthma|Cystic Fibrosis|Chronic Obstructive Pulmonary Disease|Emphysema|Mesothelioma|Asbestosis|Pulmonary Embolism|Interstitial Lung Disease|Pulmonary Fibrosis|Bronchiectasis|Seasonal Allergies|Cold Virus|Lung Infection|Pulmonary Hypertension|Pulmonary Dysplasia|Obstructive Sleep Apnea","Drug: HP 3He|Drug: HP 129Xe|Drug: PFP|Drug: SF6|Device: 129Xe Small and Large Human Lung Coil|Device: 3He Human Lung Coil|Device: PFP and SF6 Human Lung Coil","Signal to Noise Ratio|Correlation with PFTs","Thunder Bay Regional Research Institute|Thunder Bay Regional Health Sciences Centre|St. Joseph's Care Group|Lakehead University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","160","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RP-312-07112014","September 2018","September 2020","September 2020","April 22, 2016","null","August 22, 2018","Thunder Bay Regional RI, Thunder Bay, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02748798"
928,"NCT02747290","68Ga-NOTA-BBN-RGD PET/CT in Prostate Cancer Patients",,"Unknown status","No Results Available","Prostate Cancer","Drug: 68Ga-NOTA-BBN-RGD","Standardized uptake value of 68Ga-NOTA-BBN-RGD in prostate cancer|Adverse events collection","Peking Union Medical College Hospital|National Institute for Biomedical Imaging and Bioengineering (NIBIB)","Male","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PUMCHNM011|ZIAEB000073","July 2014","July 2017","null","April 21, 2016","null","April 21, 2016","Peking Union Medical College Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT02747290"
929,"NCT02744729","99mTc-3PRGD2 SPECT/CT in Esophagus Cancer Patients",,"Unknown status","No Results Available","Esophageal Cancer","Drug: 99mTc-3PRGD2","Visual Assessment of Esophagus Lesions in 99mTc-3PRGD2 SPECT/CT Scan|Semiquantitative Assessment of Esophagus Lesions in 99mTc-3PRGD2 SPECT/CT Scan|18F-FDG PET/CT Scan|Laboratory Values|Adverse events collection|Contrast-enhanced CT","First Affiliated Hospital of Fujian Medical University","All","30 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","FirstAHFujian","October 2015","February 2018","June 2018","April 20, 2016","null","August 9, 2016","Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China","","https://ClinicalTrials.gov/show/NCT02744729"
930,"NCT02744053","Multimodality Breast Imaging for the Assessment of Tumor Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients",,"Recruiting","No Results Available","Breast Cancer|Malignant Neoplasm of Breast","Procedure: Dynamic Contrast Enhanced Molecular Resonance Imaging (DCE-MRI)|Procedure: Tc99m Sestamibi Molecular Breast Imaging (MBI)|Drug: 99mTc Sestamibi","Assessment of Response to Neoadjuvant Chemotherapy (NAC) Using Tc99m Sestamibi Molecular Breast Imaging (MBI) and Dynamic Contrast Enhanced Molecular Resonance Imaging (DCE-MRI)","M.D. Anderson Cancer Center|GE Healthcare|Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2015-0816|NCI-2016-00715","November 2016","November 2020","November 2020","April 20, 2016","null","November 6, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02744053"
931,"NCT02743299","Investigation of a Novel Turbine-driven Ventilator for Use in Cardiopulmonary Resuscitation",,"Completed","No Results Available","Cardiac Arrest|Hyperventilation","Device: Handivent Ventilator","Respiratory rate|Tidal volume|Peak Inspiratory pressure","University of Utah","All","Child, Adult, Older Adult","Early Phase 1","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00063298","April 2013","June 2013","April 2016","April 19, 2016","null","August 10, 2016","","","https://ClinicalTrials.gov/show/NCT02743299"
932,"NCT02742168","99mTc-3PRGD2 SPECT/CT in Breast Cancer Patients",,"Recruiting","No Results Available","Breast Cancer","Radiation: 99mTc-3PRGD2","Visual Assessment of Breast Lesions in 99mTc-3PRGD2 SPECT/CT Scan|Semiquantitative Assessment of Breast Lesions in 99mTc-3PRGD2 SPECT/CT Scan|Adverse events collection|Mammography and/or ultrasound|18F-FDG PET/CT scan|carbohydrate antigen 153","First Affiliated Hospital of Fujian Medical University","All","20 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","FirstAHFujian2","January 2016","December 2020","March 2021","April 18, 2016","null","April 18, 2016","Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China","","https://ClinicalTrials.gov/show/NCT02742168"
933,"NCT02741063","Oxytocin Effect on Attentional Bias Towards Emotional Expression Faces in Individuals With High and Low Autistic Traits: A Functional Magnetic Resonance Imaging (fMRI) Study",,"Recruiting","No Results Available","Healthy","Behavioral: screen low autistic subjects|Behavioral: screen high autistic subjects|Drug: oxytocin|Drug: placebo","attentional bias toward emotional expression faces|brain activity during RSVP task","University of Electronic Science and Technology of China","Male","18 Years to 30 Years   (Adult)","Early Phase 1","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","UESTC-neuSCAN-19","May 2016","June 2019","September 2019","April 18, 2016","null","October 29, 2018","China, Sichuan, Chengdu, Sichuan, China","","https://ClinicalTrials.gov/show/NCT02741063"
934,"NCT02740192","Pain Control After Total Knee Arthroplasty: Is There Benefit In Adding Single Shot Adductor Canal Block to Existing Multimodal Pain Regimen and Periarticular Injection Protocol?",,"Unknown status","No Results Available","Pain","Procedure: Adductor Canal Block|Procedure: Periarticular Injection|Drug: Ropivacaine|Drug: Bupivacaine","Post-operative pain level (Visual Analog Scale)|Knee flexion and extension ROM (Range of Motion)|Distance Walked (meters)|Pain with Ambulation (VAS)|Pain Medication Intake|Time to discharge readiness","Henry Ford Health System","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","10221","April 2016","December 2016","December 2016","April 15, 2016","null","April 15, 2016","Henry Ford Hospital, Detroit, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02740192"
935,"NCT02740101","The Role of Oxytocin in Modulating the Effects of Social Feedback on Achieving Personal Goals",,"Completed","No Results Available","Healthy","Drug: oxytocin treatment|Drug: placebo treatment","Rating of Encouragement after receiving specific social feedback|Rating of Likeability after receiving specific social feedback","University of Electronic Science and Technology of China","Male","18 Years to 30 Years   (Adult)","Early Phase 1","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","UESTC-neuSCAN-14","November 2014","August 2015","October 2015","April 15, 2016","null","March 6, 2017","school of life science and technology, University of Electronic Science and Technology of China, Chengdu, Sichuan, China","","https://ClinicalTrials.gov/show/NCT02740101"
936,"NCT02740049","In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma",,"Completed","No Results Available","Asthma","Drug: VR588","Cytokine production epithelial cell supernatant|Cell Viability Assay|JAK/STAT signal activation","Imperial College London|Vectura Limited","All","18 Years to 79 Years   (Adult, Older Adult)","Early Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","15IC2844","January 27, 2016","October 19, 2016","October 19, 2016","April 15, 2016","null","March 10, 2017","Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02740049"
937,"NCT02738905","Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease",,"Active, not recruiting","No Results Available","End Stage Renal Disease","Drug: Rifaximin","Change in serum TMAO levels|Change in fecal bacterial species|Change in fecal bacterial colony numbers","Jason Stubbs, MD|American Heart Association|University of Kansas Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00004204","July 2016","January 2018","July 2018","April 14, 2016","null","October 19, 2017","University of Kansas Medical Center, Kansas City, Kansas, United States|Westwood Dialysis Center, Westwood, Kansas, United States","","https://ClinicalTrials.gov/show/NCT02738905"
938,"NCT02735798","64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets",,"Withdrawn","No Results Available","Brain Metastases|Documented Her2 Overexpression|Advanced Solid Tumor|Neurologically Stable","Drug: MM-302|Drug: Trastuzumab","MM-302 drug penetration into the brain|Adverse event|Overall response rate|Progession-free survival|CNS response rate|Systemic response rate|Adverse Event","Pamela Munster|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15952","April 2016","June 2017","June 2018","April 13, 2016","null","May 4, 2017","","","https://ClinicalTrials.gov/show/NCT02735798"
939,"NCT02735356","Topical Itraconazole in Treating Patients With Basal Cell Cancer",,"Active, not recruiting","No Results Available","Skin Basal Cell Carcinoma","Drug: Itraconazole|Other: Placebo","Percentage change of GLi levels in treated vs untreated tumors|Change in BCC tumor size","Jean Yuh Tang|National Cancer Institute (NCI)|Stanford University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","9","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SKIN0030|NCI-2016-00452|P30CA124435","May 5, 2016","July 28, 2018","January 31, 2019","April 12, 2016","null","November 1, 2018","Stanford Cancer Institute, Palo Alto, California, United States","","https://ClinicalTrials.gov/show/NCT02735356"
940,"NCT02733744","Fecal Microbiota Transplantation After HSCT",,"Completed","No Results Available","Bone Marrow Transplantation","Biological: Fecal Microbiota Transplantation (FMT)","Feasibility measured by number of participants able to ingest 15 FMT capsules over a 2-day period|Progression Free Survival|Overall Survival|Cumulative Incidence Of aGVHD|Non-Relapse Mortality Rate|Number of participants with treatment-related adverse events","Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-023","May 2016","December 2016","December 2017","April 11, 2016","null","December 22, 2017","Massachusetts general Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02733744"
941,"NCT02732171","PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer",,"Recruiting","No Results Available","Breast Cancer","Other: Plasma/Buffy Coat|Other: Serum|Other: Bone Marrow Aspirate","Number of disseminated tumor cells","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","600","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Screening","UPCC 28115","April 2016","April 2019","null","April 8, 2016","null","January 16, 2017","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02732171"
942,"NCT02731586","Effect on Allogenic Mesenchymal Stem Cells on Osseointegration of Dental Implants","MSC&IMPLANTS","Enrolling by invitation","No Results Available","Edentulous Alveolar Ridge","Drug: Allogenic Mesenchymal stem cells","Determination of Implant Stability with RFA","Sri Sai College of Dental Surgery and Research Centre","All","18 Years to 64 Years   (Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","SSCDS-IMP-201601","January 2016","December 2017","March 2018","April 7, 2016","null","October 6, 2017","Sri Sai College Of Dental Surgery and Research Centre, Vikarabad, Telangana State, India","","https://ClinicalTrials.gov/show/NCT02731586"
943,"NCT02729415","Point-of-Care Adipose-derived Cells for Hair Growth","ASVF-2016","Active, not recruiting","No Results Available","Androgenetic Alopecia","Procedure: Stromal Vascular Fraction Cells (SVF Cells) Injection|Procedure: Liposuction|Other: Hair Measurements","Incidence of treatment-emergent adverse events|Growth of new hair from baseline to 6 weeks, 3 months and 6 months|Change in hair thickness from baseline to 6 weeks, 3 months and 6 months","University of Florida","All","18 Years to 60 Years   (Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB201600420|ASVF-2016","October 2016","July 2019","July 2019","April 6, 2016","null","September 27, 2018","University of Florida, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT02729415"
944,"NCT02729194","Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma",,"Active, not recruiting","No Results Available","Carcinoma, Renal Cell","Drug: Pazopanib|Other: Low Fat Diet","Number of Grade 3 or 4 Adverse Events|Number of Dose Reductions|Duration of Treatment|Mean Total Dose|Number of Patients that Respond to Treatment (Overall Response) with Pazopanib Administered Along with a Low Fat Diet|Number of Patients with Complete Response|Number of Patients with Partial Response|Progression-Free Survival Time","University of Michigan Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMCC 2016.013|HUM00111682","June 2016","September 2017","April 2020","April 6, 2016","null","October 18, 2017","University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02729194"
945,"NCT02728830","A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers",,"Recruiting","No Results Available","Gynecologic Neoplasms|Epithelial Ovarian Cancer|Uterine Endometrial Cancer|Fallopian Tube Cancer|Peritoneal Cancer","Drug: Pembrolizumab","Fold change in tumor Immune Infiltrates|Toxicity Profile: Frequency and severity of adverse events as assessed by CTCAE","AA Secord|Merck Sharp & Dohme Corp.|Duke University","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00068544","June 2016","November 2019","April 2020","April 5, 2016","null","June 19, 2018","Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Duke Cancer Institute, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02728830"
946,"NCT02728271","Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome",,"Terminated","No Results Available","Churg-Strauss Syndrome","Biological: HPC cell infusion","number of patients with adverse events during treatment|hematologic recovery|graft failure rate|resolution of eosinophilia","Mounzer Agha|University of Pittsburgh","All","18 Years to 60 Years   (Adult)","Early Phase 1","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-146","April 2016","July 22, 2016","August 20, 2016","April 5, 2016","null","August 1, 2017","","","https://ClinicalTrials.gov/show/NCT02728271"
947,"NCT02726542","Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents",,"Recruiting","No Results Available","NAFLD","Drug: somatropin","Change in hepatic fat|Change in aspartate aminotransferase (AST)|Change in alanine aminotransferase (ALT)|Change in gamma glutamyl transferase|Change in visceral adipose tissue","Massachusetts General Hospital","All","18 Years to 29 Years   (Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016p-000657","May 3, 2017","September 2019","September 2019","April 1, 2016","null","October 22, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02726542"
948,"NCT02724202","Curcumin in Combination With 5FU for Colon Cancer",,"Unknown status","No Results Available","Metastatic Colon Cancer","Drug: Curcumin|Drug: 5-flurorouracil","Determine the safety using curcumin in patients with metastatic colon cancer; where toxicities will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.|Overall Response|Evidence of altered biomarker status (circulating DNA methylation status, miRNA profile) at 8 weeks post-treatment according to RECIST version 1.1 and survival criteria.|Duration of response|Duration of progression free survival|Duration of overall survival|Duration of Quality of Life","Baylor Research Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","014-143","March 2016","March 2018","March 2018","March 31, 2016","null","April 1, 2016","Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT02724202"
949,"NCT02723760","99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients","TRGDRA","Recruiting","No Results Available","Rheumatoid Arthritis","Drug: 99mTc-3PRGD2","99mTc-3PRGD2 SPECT/CT scan|X-ray radiography and/or CT(computed tomograph) and/or MRI(magnetic resonance imaging)|99mTc-MDP bone scan|18F-FDG PET/CT|Serum rheumatoid factor (RF)|Serum antinuclear antibodies (ANAs)|Erythrocyte sedimentation rate (ESR)|Adverse events collection","First Affiliated Hospital of Fujian Medical University","All","20 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","FAHFMUNM001","November 2015","December 2019","May 2020","March 30, 2016","null","March 30, 2016","Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China","","https://ClinicalTrials.gov/show/NCT02723760"
950,"NCT02720341","VIT-ARMin Virtual, Intensified and Patient-tailored Robotic Arm Therapy With the Exoskeleton Robot ARMin","VIT-ARMin","Unknown status","No Results Available","Stroke|Spinal Cord Injury|Healthy","Device: ARMin","Intrinsic Motivation Inventory (IMI) questionaire|performance tests (kinematic and kinetic data) in virtual reality on the ARMin robot (time in msec)|performance tests (kinematic and kinetic data) in virtual reality on the ARMin robot (position in cm)|performance tests (kinematic and kinetic data) in virtual reality on the ARMin robot ( force in Nm)|muscle strength in Nm|questionaire on interaction, time and effort|EMG for muscle activity (time and electric potential)|EMG for muscle activity (time in sec)|EMG for muscle activity (electric potential in V)|detection thresholds (time)|detection thresholds (position in cm)","Prof. Robert Riener|Swiss Federal Institute of Technology","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","420","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VIT-ARMin","April 2015","January 2018","January 2018","March 25, 2016","null","March 30, 2016","Labor für Sensomotorische Systeme, ETH Zürich, Balgrist Campus, Zürich, Switzerland","","https://ClinicalTrials.gov/show/NCT02720341"
951,"NCT02719795","Pectoral Nerves Blocks for Chronic Pain","PNBCP","Recruiting","No Results Available","Breast Neoplasms","Drug: Ropivacaine|Drug: Normal saline","The incidence of chronic postoperative pain for 3 months after modified radical mastectomy surgery|Postoperative Numerical Rating scale (NRS) score for pain","First Affiliated Hospital Xi'an Jiaotong University","Female","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","XJTU1AF-CRS-2016-003","April 2016","December 2018","February 2019","March 25, 2016","null","February 17, 2017","First Affiliated Hosipital of Xi'an Jiaotong Univercity, Xi'an, Shaanxi, China","","https://ClinicalTrials.gov/show/NCT02719795"
952,"NCT02719587","Dietary Supplementation With Low-Dose Omega-3 Reduces Salivary TNF-α Levels in Patients With Chronic Periodontitis",,"Completed","No Results Available","Chronic Periodontitis","Procedure: Placebo|Procedure: Omega-3|Procedure: SRP","change in levels of salivary TNF alpha|change in levels of salivary SOD","İlker KESKINER|Ondokuz Mayıs University","All","30 Years to 50 Years   (Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","1491-831-09/1539","April 2009","December 2009","January 2010","March 25, 2016","null","March 25, 2016","","","https://ClinicalTrials.gov/show/NCT02719587"
953,"NCT02718885","Gut Microbiome Mediated Effects of Inulin Supplementation on Mineral and Bone Metabolism in Hemodialysis Patients",,"Completed","No Results Available","Bone Diseases, Endocrine|Nutritional and Metabolic Diseases","Dietary Supplement: Inulin|Dietary Supplement: Maltodextrin","Mineral metabolism|Bone biomarkers|Gut-microbiota derived metabolites|Gut microbiome","University of Illinois at Urbana-Champaign|Renal Research Institute","All","20 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","16035","May 2016","December 2017","July 2018","March 24, 2016","null","August 2, 2018","University of Illinois at Urbana-Champaign, Urbana, Illinois, United States","","https://ClinicalTrials.gov/show/NCT02718885"
954,"NCT02716337","Target Versus Standard Human Milk Fortification in Very Low Birth Weight Preterm Infants",,"Completed","No Results Available","Postnatal Growth Failure of Preterm Infants|Human Milk Fortification","Dietary Supplement: Addition of human milk fortifiers according to human milk analysis","Daily growth velocity (g/kg/day)|weekly weight increase (g/week)|weekly length increase (cm/week)|head circumference increase (cm/week)","Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","All","Child, Adult, Older Adult","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Target HM fortification","October 2014","March 2015","null","March 23, 2016","null","March 23, 2016","","","https://ClinicalTrials.gov/show/NCT02716337"
955,"NCT02716077","Early FDG PET in Melanoma",,"Recruiting","No Results Available","Clinical Stage III Nodal or Intransit Disease or Resectable Stage IV Melanoma","Radiation: FDG PET/CT imaging","disease-free survival","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Other","UPCC 11615","March 2016","March 2023","null","March 23, 2016","null","October 5, 2018","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02716077"
956,"NCT02715583","C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer",,"Recruiting","No Results Available","Prostate Cancer Patients","Drug: 11C-Acetate|Drug: Ra-223 therapy","Number of adverse events","Abramson Cancer Center of the University of Pennsylvania","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Treatment","UPCC 02816","March 2016","March 2019","null","March 22, 2016","null","September 28, 2018","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02715583"
957,"NCT02714439","Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley",,"Active, not recruiting","No Results Available","Malignant Neoplasms of Female Genital Organs","Drug: Proflavine|Procedure: High-Resolution Microendoscopy (HRME)","Diagnostic Accuracy of the High-Resolution Microendoscopy (HRME)","The University of Texas Medical Branch, Galveston|M.D. Anderson Cancer Center|The University of Texas Health Science Center, Houston|William Marsh Rice University","Female","21 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","150","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","0014-0302|NCI-2016-00729","October 25, 2016","July 2020","July 2020","March 21, 2016","null","October 17, 2018","University of Texas Medical Branch Cancer Stop McAllen Clinic, McAllen, Texas, United States","","https://ClinicalTrials.gov/show/NCT02714439"
958,"NCT02711891","Topical Loperamide Gel for Pain Reduction During Repeat Finger Lancing","Loperamide","Completed","No Results Available","Pain","Drug: Loperamide|Drug: Drug, placebo gel","Pain - Numeric Rating Scale|Pain - comparative pain scale|Reported numeric pain rating and sensitivity to touch and pressure in the lanced finger site.|Change in heart rate from baseline during the lance procedure|Safety- number of participants with treatment related adverse events as assessed by the CTCAE V.4|Safety - number of participants with treatment related adverse gastrointestinal disorders using the CTCAE V. 4 with focus on abdominal pain, constipation and diarrhea","Rush University Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","13091401-IRB02|IND 122919","March 2015","December 2015","December 2015","March 17, 2016","null","March 17, 2016","","","https://ClinicalTrials.gov/show/NCT02711891"
959,"NCT02710162","Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS)",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Device: Micro Mouth Pressure Meter|Device: Iowa Oral Performance Instrument|Device: Electrical Impedance Myography|Drug: Capsaicin|Procedure: Videofluoroscopic Swallowing Study|Procedure: Pulmonary Function Testing|Other: Swallowing Related Quality of Life Questionnaire|Other: Functional Oral Intake Scale|Other: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised|Other: Eating Assessment Tool-10|Other: Communicative Effectiveness Survey|Other: The Center for Neurologic Studies Bulbar Function Scale","The Penetration-aspiration scale will be used to measure swallowing function|The IOPI will be used to measure Lingual strength and endurance|The oral pneumatograph will be used to measure voluntary cough function|The nebulizer with cough protocol will be used to measure reflexive cough|Global disease progression as confirmed by the ALS Functional Rating Scale-Revised (ALSFRS-R)|Participant perception of swallowing impairment as confirmed by Swallowing Quality of Life Questionnaire (SWAL-QOL)|Dietary intake as confirmed by Functional Oral Intake Scale (FOIS)|Participant perception of swallowing related symptoms as confirmed by The Eating Assessment Tool 10 (EAT-10)|Participant perception of communication abilities as confirmed by Communication Effectiveness Survey|Bulbar function confirmed by the Center for Neurologic Studies Bulbar Function Scale (CNS-BFS)","University of Florida","All","21 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB201600163","April 2016","December 19, 2017","December 19, 2017","March 16, 2016","null","December 21, 2017","University of Florida, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT02710162"
960,"NCT02710110","Respiratory Strength Training in Persons With Amyotrophic Lateral Sclerosis (ALS)",,"Active, not recruiting","No Results Available","Amyotrophic Lateral Sclerosis","Device: PowerLung trainer|Device: Micro Mouth Pressure Meter|Procedure: Pulmonary Function Testing|Procedure: Videofluoroscopic swallowing study|Other: Swallowing Quality of Life Questionnaire|Device: Iowa Oral Pressure Instrument|Drug: Capsaicin","Maximum Expiratory Pressure will be measured between the groups for a change from baseline to month 3|Maximum Inspiratory Pressure will be measured between the groups for a change from baseline to month 3|Pulmonary function to measure the forced vital capacity (FVC) between the groups for a change from baseline to month 3|Sniff Nasal Inspiratory Pressure will be measured between the groups for a change from baseline to month 3|Pulmonary function to measure the peak expiratory flow (PEF) will be measured between the groups for a change from baseline to month 3|Pulmonary function to measure the forced expiratory volume (FEV1) will be measured between the groups for a change from baseline to month 3|The Penetration-aspiration scale will be used to measure swallowing function|Lingual strength will be measured between the groups for a change from baseline to month 3|Lingual endurance will be measured between the groups for a change from baseline to month 3|Voluntary cough function will be measured between the groups for a change from baseline to month 3|Reflexive cough will be measured between the groups for a change from baseline to month 3","University of Florida|ALS Association","All","21 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IRB201501172","April 2016","November 30, 2017","March 2020","March 16, 2016","null","April 5, 2018","UF Health Shands, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT02710110"
961,"NCT02707523","Prospective Pilot Clinical Trial of Azithromycin Treatment In RSV-Induced (Respiratory Syncytial Virus - Induced) Respiratory Failure In Children",,"Recruiting","No Results Available","Respiratory Syncytial Virus","Drug: Azithromycin 10 mg|Drug: Azithromycin 20mg|Drug: Placebo","Compare the mean serum AZM levels to the lungs while subjects hospitalized between the three arms of the study at day 1|Compare the mean oxygenation support between the three study arms|Compare the mean MOSF scores between the three study arms|Compare the mean tracheal aspirate AZM levels while subjects hospitalized between the three arms of the study at day 1|Compare the mean nasal AZM levels while subjects hospitalized between the three arms of the study|Compare the mean serum AZM levels to the lungs while subjects hospitalized between the three arms of the study on day 2, if still hospitalized|Compare the mean serum AZM levels to the lungs while subjects hospitalized between the three arms of the study on day 3, if still hospitalized|Compare the mean serum AZM levels to the lungs while subjects hospitalized between the three arms of the study on day 5, if still hospitalized|Compare the mean serum AZM levels to the lungs while subjects hospitalized between the three arms of the study on day 7, if still hospitalized|Compare the mean serum AZM levels to the lungs while subjects hospitalized between the three arms of the study on day 14, if still hospitalized|Compare the mean serum AZM levels to the lungs while subjects hospitalized between the three arms of the study on day 21, if still hospitalized|Compare tracheal aspirate AZM levels while subjects hospitalized between the three arms of the study at day 2|Compare tracheal aspirate AZM levels while subjects hospitalized between the three arms of the study at day 3 if still hospitalized|Compare the mean tracheal aspirate AZM levels while subjects hospitalized between the three arms of the study at day 5 if still hospitalized|Compare the mean tracheal aspirate AZM levels while subjects hospitalized between the three arms of the study at day 7 if still hospitalized|Compare the mean tracheal aspirate AZM levels while subjects hospitalized between the three arms of the study at day 14 if still hospitalized|Compare the mean tracheal aspirate AZM levels while subjects hospitalized between the three arms of the study at day 21 if still hospitalized|Compare the mean nasal AZM levels while subjects hospitalized between the three arms of the study, at 3 days if not discharged|Compare the mean nasal AZM levels while subjects hospitalized between the three arms of the study, at 5 days if not discharged|Compare the mean nasal AZM levels while subjects hospitalized between the three arms of the study, at 7 days if not discharged|Compare the mean nasal AZM levels while subjects hospitalized between the three arms of the study, at 14 days if not discharged|Compare the mean nasal AZM levels while subjects hospitalized between the three arms of the study, at 21 days if not discharged","University of Alabama at Birmingham","All","up to 16 Years   (Child)","Early Phase 1","48","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","FWA00005960","January 2016","April 30, 2019","April 30, 2020","March 14, 2016","null","March 8, 2018","UAB, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT02707523"
962,"NCT02707315","A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer",,"Unknown status","No Results Available","Pancreas Cancer|Pancreatic Cancer|Adenocarcinoma of the Pancreas|Pancreas Adenocarcinoma|Pancreatic Adenocarcinoma","Drug: Gemcitabine|Radiation: Stereotactic Radiosurgery","percentage of subjects who successfully undergo pancreaticoduodenectomy|Overall Survival|Tumor response per RECIST 1.1|Quality of Life|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","The Cooper Health System","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-169","January 2013","December 2016","null","March 14, 2016","null","March 14, 2016","MD Anderson Cancer Center at Cooper, Camden, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT02707315"
963,"NCT02707211","Anti-oxLDL IgM Antibodies as a Novel Therapy for Metabolic Lipid Diseases",,"Unknown status","No Results Available","Lipid Metabolism, Inborn Errors","Biological: Anti-oxLDL IgM antibody","The level of inflammation|Levels of lysosomal enzymes|the level of cholesterol metabolism","Universitaire Ziekenhuizen Leuven","All","2 Years to 64 Years   (Child, Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pfizer-Prevenar13-2015","June 2016","February 2017","February 2017","March 14, 2016","null","March 15, 2016","UZ Leuven, Leuven, Vlaams-brabant, Belgium","","https://ClinicalTrials.gov/show/NCT02707211"
964,"NCT02705547","Rosuvastatin (Crestor) in Friedreich Ataxia",,"Completed","No Results Available","Friedreich Ataxia","Drug: Rosuvastatin","Change in ApoA-1 serum protein levels from baseline to Week 12 visit|Change in frataxin levels from baseline to Week 12 visit|Change in platelet metabolism from baseline to Week 12 visit","Children's Hospital of Philadelphia|Friedreich's Ataxia Research Alliance","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-012659","May 2016","August 4, 2017","August 4, 2017","March 10, 2016","null","January 10, 2018","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02705547"
965,"NCT02704494","Resveratrol's Effects in Diabetic Nephropathy","ReDNeph","Completed","No Results Available","Diabetic Nephropathy","Drug: Resveratrol|Drug: Placebo|Drug: Losartan","Urine albumin level|Serum creatinin|Fasting blood sugar (FBS)|Glycosylated hemoglobin (A1C)|Liver aminotransferases (ALT and AST)|Serum insulin level|Number of patients with adverse events","Shiraz University of Medical Sciences","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","93-01-49-9028","March 2016","February 2017","February 2017","March 10, 2016","null","October 5, 2017","Shahid Motahhari Clinic, Shiraz University of Medical Sciences, Shiraz, Fars, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT02704494"
966,"NCT02704299","The Study of Surgery,Chemotherapy and Autologous T Cells-Based Immunotherapy for Advanced Gastric Cancer.",,"Unknown status","No Results Available","Gastric Cancer.","Biological: Autologous T cells-Based Immunotherapy","Progression-Free-Survival(PFS)|Incidences of adverse events or serious adverse events","Cellular Biomedicine Group Ltd.|Beijing Cancer Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","36","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CBMG-TCM-GC-1.1","March 2016","June 2018","September 2018","March 10, 2016","null","March 11, 2016","","","https://ClinicalTrials.gov/show/NCT02704299"
967,"NCT02704052","Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose",,"Recruiting","No Results Available","Deep Venous Thrombosis|Pulmonary Embolus|Venous Thromboembolism","Drug: Real time enoxaparin dose adjustment|Drug: Standard enoxaparin dose","Venous thromboembolism|Re-operative hematoma","University of Utah","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","300","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB_00086103","March 2016","December 2018","March 2019","March 9, 2016","null","October 19, 2018","University of Utah Hospitals, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02704052"
968,"NCT02701127","Molecular Effects of Vitamin B3 (Niacinamide) in Acute Kidney Injury",,"Completed","No Results Available","Acute Kidney Injury","Drug: Oral niacinamide, 1 gram daily|Drug: Oral niacinamide, 3 gram daily|Drug: Placebo","Changes from baseline in serum metabolite profile of niacinamide|Changes from baseline in urine metabolite profile of niacinamide","Beth Israel Deaconess Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","55","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other","2016P000028","March 2016","February 2017","July 2017","March 8, 2016","null","March 8, 2018","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02701127"
969,"NCT02699918","Impact of Obstructive SAS on Metastatic Potential of Cutaneous Melanoma","MELA-SAS","Withdrawn","No Results Available","Melanoma With a Breslow's Thickness ≥ 1mm|Obstructive Sleep Apnea Syndrome","Procedure: nocturnal oximetry","Ratio of metastasis confirmed by thoraco-abdominal-pelvic or cerebral CT in patients subgroups with or without sleep apnea syndrome|Ratio of a positive status of the sentinel lymph node confirmed by histological measurements in patients subgroups with or without sleep apnea syndrome|In the subgroup of patients with sleep apnea syndrome, ratio of patients with metastatic evolution according to the CPAP treatment adherence","AGIR à Dom","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","Agiradom","December 1, 2015","April 1, 2016","October 1, 2016","March 7, 2016","null","February 1, 2017","Grenoble University Hospital, Grenoble, France","","https://ClinicalTrials.gov/show/NCT02699918"
970,"NCT02699138","Obstructive Sleep Apnea and Arousal Threshold in Patients With Post-traumatic Stress Disorder",,"Suspended","No Results Available","Sleep Apnea, Obstructive; Post-Traumatic Stress Disorders","Drug: Trazodone|Drug: Placebo|Device: Epiglottic catheter","Respiratory arousal threshold|Apnea hypopnea index","University of California, San Diego","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","UCSD151424","October 2015","December 2018","December 2019","March 4, 2016","null","February 7, 2017","University of California San Diego, San Diego, California, United States","","https://ClinicalTrials.gov/show/NCT02699138"
971,"NCT02697318","Evaluation of a New Method for Instilling Eye Drops",,"Completed","No Results Available","Ophthalmic Solutions|Glaucoma","Drug: Timolol maleate 0.5% ophthalmic solution","Intraocular Pressure","University of Waterloo","All","21 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other","21282","May 2016","September 2017","January 7, 2018","March 3, 2016","null","January 23, 2018","University of Waterloo, Waterloo, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02697318"
972,"NCT02697201","Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D)","DYNAMMO-T2D","Recruiting","No Results Available","Insulin Resistance","Drug: Intralipid|Drug: Saline","Effects of lipid infusion on mitochondrial fission|Effects of lipid infusion on mitochondrial function|Insulin sensitivity","Pennington Biomedical Research Center","All","18 Years to 45 Years   (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","15-1311","July 2016","February 2021","February 2021","March 3, 2016","null","July 25, 2018","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT02697201"
973,"NCT02696707","An Integrated Consent Model Study to Compare Two Standard of Care Schedules for Monitoring Cardiac Function in Patients Receiving Trastuzumab for Early Stage Breast Cancer","OTT 15-05","Unknown status","No Results Available","Breast Cancer","Procedure: LVEF 3 month|Procedure: LVEF 4 month","LVEF results","Ottawa Hospital Research Institute","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","20150777-01H","June 2016","March 2018","March 2018","March 2, 2016","null","September 16, 2016","The Ottawa Hospital, Ottawa, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02696707"
974,"NCT02695706","Clinical Study, Opened, of Cutaneous Acceptability of a Topic Product in Normal Conditions of Use",,"Unknown status","No Results Available","Diabetes","Device: Laboratoires Mercurochrome Reparador","Skin acceptability through the self perception of patients.|Instrumental Performance Measures","LM Farma Indústria e Comércio Ltda.","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","LM Farma","April 2016","April 2016","July 2016","March 1, 2016","null","March 3, 2016","","","https://ClinicalTrials.gov/show/NCT02695706"
975,"NCT02695641","Reduction of Plasma Free VEGF-A Using Low-dose Bevacizumab in Hemodialysis Patients",,"Unknown status","No Results Available","End Stage Renal Disease|Hemodialysis Vascular Access Failure","Drug: 1.25mg bevacizumab|Drug: 2.50mg bevacizumab","Change in Serum concentration of bevacizumab (nM)|Change in plasma free VEGF-A levels (pg/ml)|Safety Profile/ Adverse Events (NCI-CTCAE v. 4.0) monitoring","Mayo Clinic","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","15-007414","April 2016","August 2016","November 2016","March 1, 2016","null","March 1, 2016","Mayo Clinic in Rochester, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02695641"
976,"NCT02694783","Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-Cells",,"Recruiting","No Results Available","Leukoencephalopathy","Biological: PyVST|Other: No Intervention","Treatment related serious adverse events|JCV DNA titer in cerebrospinal fluid|Clinical outcomes|Survival|MRI outcomes","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","72","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","160072|16-N-0072","February 27, 2016","December 1, 2020","December 1, 2020","March 1, 2016","null","August 22, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02694783"
977,"NCT02692313","Dose Response of Epinephrine","Epineprhine","Recruiting","No Results Available","Diabetes Complications","Drug: Epinephrine|Other: Saline infusion","Flow mediated dilation (FMD) of the brachial artery","University of Maryland|Vanderbilt University","All","18 Years to 55 Years   (Adult)","Early Phase 1","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","HP-00068487","June 2016","December 2018","December 2018","February 26, 2016","null","January 11, 2018","University of Maryland, Baltimore, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02692313"
978,"NCT02691897","Melatonin's Effects on Treatment Of Diabetes Mellitus","METOD","Enrolling by invitation","No Results Available","Diabetes Mellitus","Drug: Melatonin|Drug: Placebo","Fasting blood sugar (FBS)|HbA1c|Serum Insulin|Weight (Body mass index)|Waist circumference|Serum aminotransferases|Number of patients with adverse events","Shiraz University of Medical Sciences","All","20 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CT-93-7817","March 2016","November 2017","December 2017","February 25, 2016","null","October 4, 2017","Shahid Motahhari Clinic, Shiraz University of Medical Sciences, Shiraz, Fars, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT02691897"
979,"NCT02691169","Integrated 18F-labelled PSMA Project",,"Active, not recruiting","No Results Available","Prostate Cancer","Drug: 18F-DCFPyL","Number of participants with [F-18]-DCFPyL-related adverse events as assessed by CTCAE v4.0|Extent of baseline disease on [F-18]-DCFPyL imaging compared to extent of baseline disease on conventional imaging in each participant as assessed by counting the total number of lesions on imaging prior to starting hormonal therapy|Treatment response on [F-18]-DCFPyL imaging using EORTC criteria will be compared with treatment response on clinical follow-up according to PCWG2 criteria.","St. Joseph's Healthcare Hamilton","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","JNMP-01","April 2016","December 2017","December 2017","February 25, 2016","null","October 9, 2017","St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02691169"
980,"NCT02690987","Gut Hormones in Obesity, Nicotine and Alcohol Dependence","GHADD","Recruiting","No Results Available","Obesity|Smoking Cessation|Alcoholism","Drug: Exenatide|Biological: Desacyl ghrelin|Biological: Saline","Functional MRI measure of brain activation during cigarette, alcohol and food picture evaluation task|Functional MRI measure of brain activation during anticipation of winning monetary reward (monetary incentive delay task)|Functional MRI measure of brain activation during negative emotional reactivity task|Functional MRI measure of brain activity in salience resting state network|Functional MRI measure of brain activity in limbic resting state network|Functional MRI measure of brain activity in default mode resting state network","Imperial College London","All","18 Years to 60 Years   (Adult)","Early Phase 1","95","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","15/LO/1041|MR/M007022/1","August 2015","October 2018","October 2018","February 24, 2016","null","December 22, 2017","Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, Hammersmith Hospital, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02690987"
981,"NCT02689843","Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS","AntiPCO","Completed","No Results Available","Polycystic Ovary Syndrome","Drug: Cyproterone compound + Spironolactone|Drug: Metformin|Drug: Pioglitazone","Serum C3 level|Serum C4 level|Serum high-sensitive CRP (C-reactive protein)|Serum total Testosterone level|Serum free Testosterone level|Serum Dehydroepiandrosterone sulfate (DHEAS) level|Serum follicle stimulating hormone (FSH) level|Serum luteinizing hormone (LH) level|Fasting Blood Sugar (FBS)|Fasting Serum Insulin level|Serum homocysteine level|Serum high sensitive C-reactive protein (hs-CRP)|Number of patients with adverse events","Shiraz University of Medical Sciences","Female","18 Years to 35 Years   (Adult)","Early Phase 1","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CT-P-9145-4025","February 1, 2017","October 30, 2017","December 30, 2017","February 24, 2016","null","September 25, 2018","Shahid Motahhari Clinic, Shiraz University of Medical Sciences, Shiraz, Fars, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT02689843"
982,"NCT02685124","Metabolomic Approach to Evaluate the Effect of Orange Juice Intake in Healthy Humans (METABORANGE).","METABORANGE","Completed","No Results Available","Healthy Volunteers","Dietary Supplement: Orange juice","Qualitative changes in urinary metabolome will be evaluated by Gas Chromatography coupled to Mass Spectrometry (GC-MS) and Liquid Chromatography coupled to Mass Spectrometry (LC-MS).|Changes in the antioxidant enzymes will be evaluated in serum samples in different time points.|Changes in the miRNAs expression will be evaluated in plasma samples in different time points.|Qualitative and quantitative changes in fecal metabolome will be evaluated by an untargeted metabolomic approach based on Nuclear Magnetic Resonance spectroscopy (NMR).","University of Sao Paulo","All","20 Years to 45 Years   (Adult)","Early Phase 1","21","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CEP FCF 1097907","September 2015","October 2015","February 2016","February 18, 2016","null","February 18, 2016","","","https://ClinicalTrials.gov/show/NCT02685124"
983,"NCT02684747","Detecting Autologous Transfusion by Measuring Alterations in the Dynamics of Red Blood Cell Maturation and Recycling",,"Completed","No Results Available","Blood Transfusion, Autologous|Blood Doping","Other: Autologous Transfusion|Other: Control - Normal Saline (Placebo)","Hematocrit|Hemoglobin|Reticulocyte count|Mean corpuscular volume","University of Utah|Sports Medicine Research and Testing Laboratory|Partnership for Clean Competition","All","18 Years to 35 Years   (Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","83533","February 2016","May 5, 2018","May 5, 2018","February 18, 2016","null","May 14, 2018","University of Utah Center for Clinical & Translational Science, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02684747"
984,"NCT02683850","Influence of an Omega-3 SPM Supplement on Quality of Life",,"Completed","No Results Available","Chronic Pain","Dietary Supplement: Omega-3 SPM™ softgel","Quality of Life through PROMIS-43|Quality of Life ACPA","National University of Natural Medicine|Metagenics, Inc.","All","20 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","44","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","091515-B","January 2016","July 2016","July 2016","February 17, 2016","null","September 2, 2016","National University of Natural Medicine, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT02683850"
985,"NCT02683824","Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers",,"Recruiting","No Results Available","Healthy Subject|Pancreatic Carcinoma","Diagnostic Test: Computed Tomography|Other: Laboratory Biomarker Analysis|Diagnostic Test: PET/MRI scan|Drug: [18F]FP-R01-MG-F2","Biodistribution of [18F]FP-R01-MG-F2 (%ID/g)|Biodistribution of [18F]FP-R01-MG-F2 (SUV)|Dosimetry of [18F]FP-R01-MG-F2 (rem/mCi)|Dosimetry of [18F]FP-R01-MG-F2 (mSv/MBq)","Sanjiv Sam Gambhir|National Cancer Institute (NCI)|Stanford University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PANC0020|NCI-2015-01887|4593|P30CA124435","January 12, 2016","December 2018","December 2019","February 17, 2016","null","September 7, 2018","Stanford University, School of Medicine, Palo Alto, California, United States","","https://ClinicalTrials.gov/show/NCT02683824"
986,"NCT02680548","Pilot RCT of Efficacy of Perineural Local Anesthetics and Steroids for Chronic Post-traumatic Ankle and Foot Pain","PREPLANS","Completed","No Results Available","CHRONIC POST-TRAUMATIC NEUROPATHIC PAIN IN ANKLE AND FOOT","Drug: 0.9% saline|Drug: 0.25% bupivacaine hydrochloride injectable suspension USP|Drug: 4mg/cc methylprednisolone acetate injectable suspension USP","Enrollment and retention of participants (SEE DESCRIPTION)|Central tendency (mean) and spread (standard deviation) of Numerical Rating Score (NRS) ratings of Foot and Ankle pain|Change in scores of Pain Catastrophizing Score (PCS)|Change in scores of Dolores Neuropathique (DN4)|Change in scores of Neuropathic Pain Symptom Inventory (NPSI)|Change in scores of anxiety component scores on the Hospital Anxiety and Depression Scale (HADS)|Change in scores of depression scores on the Patient Health Questionnaire-9 (PHQ-9)|Change in scores of Brief Pain Inventory interference with activities (BPI-I)|Change in scores of Short Form-12 (SF-12)|Change in scores of Lower Extremity Function Score (LEFS)|Evaluate the impact of study interventions on requirement for opioids (measured as average daily oral morphine equivalents in mg) and neuropathic medications (average daily doses of gabapentin and/or amitriptyline in mg)|Change in pre- and post-intervention levels of blood glucose and blood pressure|Measure incidence of infections at the injection site, skin discoloration or atrophy at the injection site, fractures, and evidence of myopathy","University Health Network, Toronto","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","8","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15-9584-A","November 2015","December 2017","December 2017","February 11, 2016","null","May 3, 2018","Toronto Western Hospital, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02680548"
987,"NCT02679781","Nasal Versus Oral Midazolam Sedation in Routine Pediatric Dental Care",,"Recruiting","No Results Available","Conscious Sedation","Drug: oral midazolam|Drug: nasal midazolam","patient acceptability and tolerance to oral or nasal midazolam administration|Behavior during dental treatment","Hadassah Medical Organization","All","2 Years to 6 Years   (Child)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","0678-15-HMO-CTIL","March 28, 2017","December 2019","December 2020","February 10, 2016","null","March 9, 2018","Hadassah Medical Organization, Jerusalem, Israel","","https://ClinicalTrials.gov/show/NCT02679781"
988,"NCT02679586","Imaging Biomarker for Early Detection of Treatment Efficacy During Breast Cancer Neoadjuvant Chemotherapy",,"Completed","No Results Available","Breast Cancer","Device: Diffusion weighted MRI","Percent change in apparent diffusion coefficient between baseline and 8-11 days after chemotherapy|Change in relative tumor volume with increasing apparent diffusion coefficient between baseline and 8-11 days of chemotherapy|Change in relative tumor volume with decreasing apparent diffusion coefficient between baseline and 8-11 days of chemotherapy","University of Michigan Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","UMCC 2006.010|HUM00003392","June 2006","March 2013","null","February 10, 2016","null","February 11, 2016","University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02679586"
989,"NCT02679274","Cycled Testosterone Therapy to Improve Physical Function in Frail Nursing Home Residents",,"Unknown status","No Results Available","Aging","Drug: Placebo|Drug: Testosterone","Body Composition|Muscle Strength","The University of Texas Medical Branch, Galveston","All","60 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","15-0176","December 2015","August 2017","August 2017","February 10, 2016","null","February 20, 2017","Gulf Health Care Center, Texas City, Texas, United States","","https://ClinicalTrials.gov/show/NCT02679274"
990,"NCT02679183","Medically-Graded Honey Supplementation Formula To Preterm Infants","Honey","Completed","No Results Available","Prebiotics|Honey|Premature Infants|Intestinal Microbiota","Dietary Supplement: Medically-Graded Honey|Other: Premature Milk Formula","The presence of Bifidobacterium bifidum and Lactobacillus spp in Stool|CD4 and CD8 concentration in the serum|Change in Weight (gram)|Change in crown-heel length (cm)|Change in head circumference (cm)","Cairo University","All","up to 3 Weeks   (Child)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","100904","January 2011","March 2014","March 2014","February 10, 2016","null","February 10, 2016","","","https://ClinicalTrials.gov/show/NCT02679183"
991,"NCT02671552","Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery",,"Withdrawn","No Results Available","Renal Cell Carcinoma","Drug: Perflutren Protein-Type A Microspheres|Procedure: Dynamic Contrast-Enhanced Ultrasound Imaging","Sensitivity - Ability of contrast-enhanced ultrasound to successfully evaluate the cryoablation of renal cell carcinoma|Specificity - Ability of contrast-enhanced ultrasound to successfully evaluate the cryoablation of renal cell carcinoma|Accuracy - Ability of contrast-enhanced ultrasound to successfully evaluate the cryoablation of renal cell carcinoma|Positive predictive value - Ability of contrast-enhanced ultrasound to successfully evaluate the cryoablation of renal cell carcinoma|Negative predictive value - Ability of contrast-enhanced ultrasound to successfully evaluate the cryoablation of renal cell carcinoma","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","12P.615|2012-84|NCI-2015-01470","January 24, 2013","December 4, 2014","December 4, 2014","February 2, 2016","null","November 17, 2017","Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02671552"
992,"NCT02670941","Aromatherapy for Chemotherapy-induced Symptoms",,"Recruiting","No Results Available","Chemotherapy Symptoms","Drug: Ginger|Drug: Lavender|Drug: Orange|Drug: Jojoba","Mean change in severity in symptoms|change in mean peak severity for nausea across all three cycles|change in mean peak severity for vomiting across all three cycles|change in mean peak severity for anxiety/distress across all three cycles|change in mean peak severity for pain across all three cycles|change in mean peak severity for fatigue across all three cycles|change in mean peak severity for sleep difficulties across all three cycles|change in mean peak severity for lack of appetite across all three cycles|the number of participants who found the aromatherapy acceptable","University of Rochester","All","21 Years to 89 Years   (Adult, Older Adult)","Early Phase 1","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","RSRB57258","January 2016","July 2019","July 2019","February 2, 2016","null","October 24, 2017","University of Rochester Medical Center, Wilmot Canter Center, Rochester, New York, United States","","https://ClinicalTrials.gov/show/NCT02670941"
993,"NCT02669563","An Exploratory Study of 18F-Labeled Hydroxyphenethylguanidines in Heart Failure Patients",,"Completed","No Results Available","Cardiomyopathy","Drug: [18F]4F-MHPG|Drug: [18F]3F-PHPG|Drug: [13N]ammonia|Drug: [11C]HED","Composite measures based on radiotracer tissue uptake ratios (heart-to-lung ratio, heart-to-liver ratio, heart-to-blood ratio) and rates of metabolism in plasma (half-time, minutes) of [18F]4F-MHPG and [18F]3F-PHPG in patients with heart failure.|Quantitative measures of regional cardiac sympathetic nerve density in patients with heart failure using tracer kinetic analyses.|Number of study participants with adverse events as a measure of safety and tolerability following intravenous administration of [18F]4F-MHPG or [18F]3F-PHPG.","University of Michigan","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HUM00105110","December 2015","August 2016","December 2016","February 1, 2016","null","February 27, 2017","University of Michigan, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02669563"
994,"NCT02669225","Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy People",,"Completed","No Results Available","Normal Physiology","Radiation: [18F]florbetaben","Differences in the mean retention of [18F]florbetaben|For the results obtained with the MRI scan","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","22","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","160059|16-AA-0059","January 29, 2016","July 11, 2018","July 11, 2018","February 1, 2016","null","October 9, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02669225"
995,"NCT02666859","Virtual Reality Prosthetic Training and Rehabilitation",,"Recruiting","No Results Available","Amputation of Upper Limb","Device: Virtual Reality","Joint Angle Range of Motion|Movement Symmetry","University of South Florida|U.S. Army Medical Research and Materiel Command|Telemedicine & Advanced Technology Research Center","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","30","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00016934","January 2016","March 2019","December 2019","January 28, 2016","null","September 18, 2018","University of South Florida, Tampa, Florida, United States","","https://ClinicalTrials.gov/show/NCT02666859"
996,"NCT02664233","Connecting Smartphones With Electronic Health Record to Facilitate Behavioral Goal Monitoring in Diabetes Care",,"Completed","No Results Available","Diabetes Mellitus, Type 2|Obesity","Behavioral: Mobile and connected health","Change in HbA1c levels from baseline to 3 months|Change in weight measures from baseline to 3 months|Usability of the connected interface technology as indicated by a System Usability Scale","The University of Texas Health Science Center, Houston|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","HSC-SN-14-1027","June 2015","August 2016","August 2016","January 26, 2016","null","November 1, 2016","University of Pittsburgh, Pittsburgh, Pennsylvania, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02664233"
997,"NCT02660814","Chemerin and Interleukin-6 Levels of Gingival Crevicular Fluid in Obese Individuals Following Periodontal Treatment",,"Completed","No Results Available","Obesity|Periodontitis","Other: Non-surgical periodontal treatment|Other: Gingival crevicular fluid collection","Chemerin|Probing pocket depth|Clinical attachment level|Gingival index|Plaque index|Bleeding on probing|Interleukin-6","Umut BALLI|Bulent Ecevit University","All","32 Years to 53 Years   (Adult)","Early Phase 1","72","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2014-115-17/06.","July 2014","May 2015","May 2015","January 21, 2016","null","January 22, 2016","","","https://ClinicalTrials.gov/show/NCT02660814"
998,"NCT02659904","The Quantitative Changes in Palatal Donor Sites Thickness After Free Gingival Graft Harvesting",,"Completed","No Results Available","Healthy|Gingival Recession","Other: Less than 2 mm remaining palatal tissue thickness|Other: 2 mm or more remaining palatal tissue thickness","Change in remaining palatal tissue thickness","İlker KESKINER|Ondokuz Mayıs University","All","18 Years to 35 Years   (Adult)","Early Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2015/103","February 2015","December 2015","January 2016","January 21, 2016","null","January 21, 2016","","","https://ClinicalTrials.gov/show/NCT02659904"
999,"NCT02659241","A Pilot Study of Induction Wee1 Inhibition in Ovarian Cancer",,"Recruiting","No Results Available","Ovarian Cancer|Fallopian Tube Cancer|Peritoneum Cancer","Drug: AZD1775","Molecular Results of AZD1775","M.D. Anderson Cancer Center|AstraZeneca","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0519|NCI-2016-00118","February 2016","February 2020","February 2021","January 20, 2016","null","June 21, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02659241"
1000,"NCT02659163","An Integrated Closed-loop Feedback System for Pediatric Cardiometabolic Disease","STRIVE","Not yet recruiting","No Results Available","Obesity|Health Behavior","Behavioral: mHealth wristband|Behavioral: mHealth scale|Behavioral: EMA|Behavioral: mHealth app|Behavioral: Health Behavior Feedback|Behavioral: Integrated closed-loop feedback system","BMI, Child|Health Behaviors Index, Child and Adult|BMI, Adult","Massachusetts General Hospital|Massachusetts Institute of Technology","All","6 Years to 12 Years   (Child)","Early Phase 1","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","R21HS024001","October 2017","October 2018","October 2018","January 20, 2016","null","September 1, 2017","","","https://ClinicalTrials.gov/show/NCT02659163"
1001,"NCT02657109","Influence of a Rehabilitation in Valve Replacement on Heart Rate Variability and Oxidative Stress",,"Unknown status","No Results Available","Cardiac Valve Disease","Other: physical therapy procedure","Heart Rate Variability|Oxidative stress|Hospitalization time evaluation","Universidade Metodista de Piracicaba","All","18 Years to 60 Years   (Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","37/2014","September 2014","March 2015","July 2017","January 15, 2016","null","October 26, 2016","Hospital de Clínicas Gaspar Viana, Belém, Pará, Brazil","","https://ClinicalTrials.gov/show/NCT02657109"
1002,"NCT02655471","Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection",,"Recruiting","No Results Available","HTLV-I Infections|Tropical Spastic Paraparesis","Drug: ""Raltegravir"" and ""Zidovudine""","Measure of proviral load|Measure of Disability Scale","Universidad Peruana Cayetano Heredia|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","65384","July 1, 2017","June 2018","June 2019","January 14, 2016","null","November 22, 2017","Instituto de Medicina Tropical Alexander von Humboldt, Lima, Peru","","https://ClinicalTrials.gov/show/NCT02655471"
1003,"NCT02653833","The Study of Skeletal Muscle Blood Flow in Becker Muscular Dystrophy",,"Recruiting","No Results Available","Muscular Dystrophy","Drug: Tadalafil 20 MG|Other: beetroot juice extract","Change in Skeletal Muscle Blood Flow|Change in Measured Functional Sympatholysis|Change in Measured Flow Mediated Dilation (FMD)","Cedars-Sinai Medical Center","Male","18 Years to 45 Years   (Adult)","Early Phase 1","19","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Pro00041688","December 2015","December 2017","December 2017","January 12, 2016","null","March 6, 2017","Cedars-Sinai Medical Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02653833"
1004,"NCT02653638","Blood Brain Flow and Exercise",,"Recruiting","No Results Available","Cerebrovascular Circulation","Other: Control|Drug: Indomethacin","Cerebral Vasodilator Responses|Blood Pressure","University of Wisconsin, Madison|National Institutes of Health (NIH)","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","90","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2015-0331|CVR-AAA4385","February 2016","June 2019","June 2019","January 12, 2016","null","July 6, 2018","Gymnasium-Natatorium, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT02653638"
1005,"NCT02653196","A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors",,"Terminated","No Results Available","Neuroepithelial Tumor|Solid Tumor|Allogeneic Hematopoietic Stem Cell Transplantation","Procedure: Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy|Drug: Keratinocyte Growth Factor|Drug: Alemtuzumab|Drug: Thiotepa|Drug: Etoposide|Drug: Fludarabine|Drug: Melphalan|Drug: Tacrolimus|Drug: Cyclosporine A|Drug: Mycophenolate mofetil","Progression-Free Survival|Overall Survival|Transplant Related Mortality|Engraftment|Regimen Related Toxicity|Time to Immune Reconstitution","Montefiore Medical Center|Children's Hospital Los Angeles|Nationwide Children's Hospital","All","up to 60 Years   (Child, Adult)","Early Phase 1","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-3856","September 2015","August 2017","August 2017","January 12, 2016","null","August 17, 2017","The Children's Hospital at Montefiore, The Bronx, New York, United States","","https://ClinicalTrials.gov/show/NCT02653196"
1006,"NCT02652455","Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma",,"Active, not recruiting","No Results Available","Melanoma (Skin)|Skin Cancer","Drug: Nivolumab|Procedure: Surgery to Remove Tumor for Growth of TIL|Drug: CD137|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: TIL Infusion|Drug: Interleukin-2","Occurrence of Study Related Adverse Events","H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb|Prometheus Inc.|Iovance Biotherapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","11","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-18377","March 2, 2016","August 2019","August 2020","January 11, 2016","null","August 2, 2018","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States","","https://ClinicalTrials.gov/show/NCT02652455"
1007,"NCT02652286","Pulmonary Artery Harmonic Ace+7 Energy Sealing in VATS Lobectomy",,"Completed","No Results Available","Lung Cancer","Device: HARMONIC ACE+7","All patients will be assessed for effective intra-operative pulmonary arterial branch vessel sealing. It will be measured visually by the presence or lack of vessel sealing failure","Centre hospitalier de l'Université de Montréal (CHUM)|Centre de Recherche du Centre Hospitalier de l'Université de Montréal","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CE 15.270","January 2016","April 2016","April 2016","January 11, 2016","null","April 19, 2016","CHUM-Notre Dame Hospital, Montreal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT02652286"
1008,"NCT02650726","Purified Anthocyanins Supplementation and High-Density Lipoprotein (HDL) Function",,"Completed","No Results Available","Diabetes Mellitus，Type 2","Dietary Supplement: Anthocyanin|Other: Placebo","HDL-associated PON1 activity|The anti-oxidative ability of HDL|anti-inflammatory ability of HDL|endothelium-dependent flow-mediated dilatation (FMD)","Sun Yat-sen University","All","40 Years to 60 Years   (Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","ZXYZM-4","November 2014","September 2015","November 2015","January 8, 2016","null","January 8, 2016","Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Department of Nutrition, School of Public Health, Sun Yat-Sen University (Northern Campus), Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT02650726"
1009,"NCT02646319","Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations",,"Active, not recruiting","No Results Available","Advanced Malignant Neoplasm|Cervical Squamous Cell Carcinoma|Endometrial Carcinoma|Malignant Uterine Neoplasm|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Head and Neck Carcinoma|Recurrent Malignant Neoplasm|Recurrent Ovarian Carcinoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Solid Neoplasm|Stage III Bladder Cancer|Stage III Prostate Cancer|Stage III Renal Cell Cancer|Stage IIIA Breast Cancer|Stage IIIA Cervical Cancer|Stage IIIA Ovarian Cancer|Stage IIIB Breast Cancer|Stage IIIB Cervical Cancer|Stage IIIB Ovarian Cancer|Stage IIIC Breast Cancer|Stage IIIC Ovarian Cancer|Stage IV Breast Cancer|Stage IV Ovarian Cancer|Stage IV Prostate Cancer|Stage IV Renal Cell Cancer|Stage IVA Bladder Cancer|Stage IVA Cervical Cancer|Stage IVB Bladder Cancer|Stage IVB Cervical Cancer","Other: Laboratory Biomarker Analysis|Drug: Nanoparticle Albumin-Bound Rapamycin|Other: Quality-of-Life Assessment","Proportion of confirmed responses, evaluated using the RECIST v1.1|Clinical benefit rate defined as the proportion of patients with a confirmed response or stable disease (complete response+partial response+stable disease) divided by the total number of evaluable patients|Incidence of adverse events, using the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0|Survival time|Time to disease progression","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","2","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC1313|NCI-2015-02151|P30CA015083","January 2016","September 5, 2017","May 2019","January 5, 2016","null","June 5, 2018","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02646319"
1010,"NCT02644590","The Effect of Melatonin on Early Signs of Hypertension in Teenagers With Diabetes Mellitus Type 1",,"Unknown status","No Results Available","Diabetes Mellitus, Type 1|Hypertension","Drug: Melatonin","blood pressure monitoring , pre and post treatment with melatonin","Sheba Medical Center","All","12 Years to 21 Years   (Child, Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","311080","February 2016","September 2016","February 2017","January 1, 2016","null","January 1, 2016","","","https://ClinicalTrials.gov/show/NCT02644590"
1011,"NCT02644044","Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study","ITMTXPMS","Unknown status","No Results Available","To Evaluate the Effect of Therapy With IT MTX on the Disease Course of Patients With Progressive MS","Drug: Intrathecal methotrexate","The change in disability ( Multiple Sclerosis Functional Composite (MSFC)|Safety and tolerability (adverse events)|Changes in brain MRI measurements|Laboratory measurements","Tel-Aviv Sourasky Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0166-15-TLV","January 2016","December 2017","January 2018","December 31, 2015","null","December 31, 2015","","","https://ClinicalTrials.gov/show/NCT02644044"
1012,"NCT02643927","Efficacy of 8 vs 4 Sessions Mindfulness-based Programs in a Non-clinical Population",,"Completed","No Results Available","Healthy Subjects","Behavioral: standard 8-weeks MBSR|Behavioral: 4-week shortened MBSR","Hospital Anxiety and Depression Scale (HADS)|Hospital Anxiety and Depression Scale (HADS) change from baseline|Mindful Attention Awareness Scale (MAAS)|Five Facets Mindfulness Questionnaire (FFMQ)|Self-Compassion Scale (SCS)|The Positive and Negative Affect Scale (PANAS)|Connor-Davidson Resilience Scale (10-item CD-RISC)","Hospital Miguel Servet","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","99","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PI12/00134","February 2013","April 2013","October 2013","December 31, 2015","null","January 1, 2016","","","https://ClinicalTrials.gov/show/NCT02643927"
1013,"NCT02642523","Natriuretic Peptides and Metabolic Risk in Obesity",,"Withdrawn","No Results Available","Obesity|Hyperinsulinemia","Drug: Nesiritide|Drug: Insulin|Other: Saline","Change in natriuretic peptide levels|Change in glycerol levels|Change in free fatty acid levels|Change in triglyceride levels|Change in energy expenditure assessed by indirect calorimetry","Vanderbilt University Medical Center","All","18 Years to 50 Years   (Adult)","Early Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","151768","null","February 2017","February 2017","December 30, 2015","null","November 6, 2017","","","https://ClinicalTrials.gov/show/NCT02642523"
1014,"NCT02642211","IOP Changes Associated With SICS and Phako",,"Completed","No Results Available","Cataract|Glaucoma","Procedure: cataract surgery","Intraocular pressure lowering|Angle anatomy","Robin, Alan L., M.D.","All","40 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","SICS_Phaco_1","January 2014","September 2015","September 2015","December 30, 2015","null","January 7, 2016","","","https://ClinicalTrials.gov/show/NCT02642211"
1015,"NCT02641522","Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes",,"Completed","Has Results","Type 1 Diabetes","Drug: Siltuximab","Percent Change From Baseline in IL-6 Stimulated Intracellular p-STAT3 at Week 12","Carla Greenbaum, MD|Janssen Research & Development, LLC|Benaroya Research Institute","All","18 Years to 45 Years   (Adult)","Early Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","EMU-002","March 8, 2016","March 16, 2017","March 16, 2017","December 29, 2015","October 8, 2018","November 2, 2018","Benaroya Research Institute, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT02641522/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02641522"
1016,"NCT02640976","Poor Ovarian Stimulation Response in In Vitro Fertilization (IVF) Program",,"Completed","No Results Available","Infertility","Drug: Human menopausal gonadotrophin (HMG)|Drug: GnRH antagonist Cetrorelix|Drug: Human chorionic gonadotrophin (hCG)","number of oocytes collected|Detection of the single nucleotide polymorphisms ESR2(+1730G>A) (rs4986938), FSHR p.Thr307Ala (c.919A>G, rs6165) and FSHR p.Asn680Ser (c.2039A>G, rs6166) SNPs will be performed using the TaqMan system by real-time polymerase chain reaction (PCR)","Cairo University","Female","25 Years to 35 Years   (Adult)","Early Phase 1","216","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","BC (705)","June 2013","June 2015","August 2015","December 29, 2015","null","December 29, 2015","","","https://ClinicalTrials.gov/show/NCT02640976"
1017,"NCT02638519","HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Other: Traditional Proton fMRI|Other: Hyperpolarized Xenon-129 fMRI|Drug: Hyperpolarized Xenon-129|Device: 1H-129Xe Dual-Tuned Quadrature Head Coil","Signal-to-Noise Ratio (SNR)|P-Value","Thunder Bay Regional Research Institute|Lakehead University|Thunder Bay Regional Health Sciences Centre","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","RP-307-08312015","June 2016","June 2019","June 2019","December 23, 2015","null","August 9, 2018","Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02638519"
1018,"NCT02636959","A Postoperative Study on HVSI vs LVSI Treatment of Chronic Rhinosinusitis",,"Unknown status","No Results Available","Rhinosinusitis","Other: saline irrigation","Change of preoperative from postoperative CT endoscopic photo scans used to evaluate different saline irrigation treatment volumes in patients with chronic rhinosinusitis.|Change of preoperative from postoperative sinus surgery regarding quality of life based on SNOT-22 questionnaire.|Change of preoperative from postoperative sinus surgery regarding quality of life based on the Nasal and Sinus Symptoms Score questionnaire.","University of British Columbia","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","H15-02550","December 2015","March 2017","June 2017","December 22, 2015","null","May 20, 2016","Vancouver General Hospital/Otolaryngology Clinic, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT02636959"
1019,"NCT02636790","Early Versus Late Surgical Wait Times",,"Not yet recruiting","No Results Available","Rhinosinusitis","Procedure: Surgery wait time","Questionnaire relating to demographics.|Change relating to personal costs over 1 year following surgery.|Change to the quality of life over 1 year following surgery based on the WPAI-SHP questionnaire.|Change to the quality of life over 1 year following surgery based on the SNOT-22 questionnaire.|Change to the quality of life over 1 year following surgery based on the EQ5-D questionnaire.","University of British Columbia","All","19 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","H15-02020","September 2018","December 2019","June 2020","December 22, 2015","null","May 8, 2018","UBC - Department of Surgery Division of Otolaryngology - Head and Neck Surgery, Vancouver, British Columbia, Canada|UBC, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT02636790"
1020,"NCT02632149","Trial to Assess Vagus Nerve Stimulation Therapy in Children With Lennox-Gastaut Syndrome",,"Unknown status","No Results Available","Lennox-Gastaut Syndrome","Device: PINS Vagus Nerve Stimulator","Changes in seizure frequency from baseline to the seizure count evaluation period 6 month|Changes in seizure frequency from baseline to the seizure count evaluation period|Change from Baseline in the Engel and McHugh description|Overall WISC Score in Patients from Baseline","Beijing Pins Medical Co., Ltd|Qilu Hospital of Shandong University|Qingdao University|Linyi People's Hospital|Yantai Yuhuangding Hospital","All","3 Years to 14 Years   (Child)","Early Phase 1","31","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PINS-017","October 2016","October 2017","null","December 16, 2015","null","October 11, 2016","Qilu Hospital of Shandong University, Jinan, Shandong, China|JiNing First People's Hospital, JiNing, Shandong, China|Linyi People's Hospital, Linyi, Shandong, China|The Affiliated Hospital of Qingdao University, QingDao, Shandong, China|Yantai Yuhuangding Hospital, Yantai, Shandong, China","","https://ClinicalTrials.gov/show/NCT02632149"
1021,"NCT02630030","Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma",,"Completed","No Results Available","Glioblastoma","Drug: Ixazomib","Concentration of ixazomib in tumor tissue|Concentration of ixazomib in blood and plasma samples|Incidence of adverse events after single dose administration of ixazomib, assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03","Emory University|Takeda","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","3","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB00083003|NCI-2015-01682|X16071|Winship3017-15","March 2016","July 2018","July 2018","December 15, 2015","null","August 15, 2018","Emory University/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02630030"
1022,"NCT02629497","Role of 12-lipoxygenase in Platelet Reactivity and Type 2 Diabetes Mellitus",,"Active, not recruiting","No Results Available","Thrombosis|Type 2 Diabetes Mellitus","Dietary Supplement: Primrose oil|Dietary Supplement: Fish Oil","platelet reactivity|fatty acid incorporation|Oxylipin production","University of Michigan|National Heart, Lung, and Blood Institute (NHLBI)","Female","21 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","88","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","HL 114405|R01HL114405|ODS","November 2015","June 2017","May 2019","December 14, 2015","null","May 31, 2018","University of Michigan, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02629497"
1023,"NCT02629120","High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease",,"Suspended","No Results Available","X-Linked Chronic Granulomatious Disease","Drug: Campath|Drug: Busulfan|Other: allogeneic peripheral blood allograft infusion|Drug: cyclophosphamide","Reduced incidence of graft failure or rejection (Engraftment as defined by >20% engraftment by oxidase positive neutrophils in at least 95% of participants by Day 100)|Same or reduced rate of acute Graft versus Host Disease of <20% in subjects who will be receiving a high stem cell dose in combination with post cyclophosphamide.|Establish stable mixed chimerism.|Improve rapidity of immune reconstitution.","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","4 Years to 65 Years   (Child, Adult, Older Adult)","Early Phase 1","12","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","160032|16-I-0032","December 10, 2015","December 31, 2025","December 31, 2030","December 14, 2015","null","November 2, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02629120"
1024,"NCT02628080","Atovaquone as Tumour HypOxia Modifier","ATOM","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Atovaquone","Percentage change in reduction of hypoxia by atovaquone|Reduction of perfusion by atovaquone|Replacement of hyp-PET-CT imaging with serological markers of hypoxia|Reproducibility","University of Oxford","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OCTO-073","May 2016","November 2017","February 2019","December 11, 2015","null","April 13, 2017","Churchill Hospital, Oxford, Oxfordshire, United Kingdom","","https://ClinicalTrials.gov/show/NCT02628080"
1025,"NCT02624258","Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma",,"Recruiting","No Results Available","Hodgkin Lymphoma","Biological: CD19 RNA redirected autologous T-cells (RNA CART19 cells)","Incidence of Treatment-Emergent Adverse Events, defined as NCI CTCAE V4 > Grade 3","University of Pennsylvania|Children's Hospital of Philadelphia","All","18 Years to 24 Years   (Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14BT055, 821157","November 2015","July 2019","December 2019","December 8, 2015","null","October 15, 2018","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02624258"
1026,"NCT02623582","CD123 Redirected Autologous T Cells for AML",,"Terminated","No Results Available","Relapsed or Refractory Acute Myeloid Leukemia","Biological: Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes|Drug: Cyclophosphamide","Number of Adverse Events","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","7","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","823175 - UPCC 04415","December 2015","August 26, 2016","November 18, 2016","December 7, 2015","null","October 17, 2017","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02623582"
1027,"NCT02622750","Triple-branch Stent Graft Placement and Total-arch Replacement for the Treatment of Acute DeBakey I Aortic Dissection","TBSGPATART","Recruiting","No Results Available","Acute Aortic Dissection","Procedure: triple-branched stent graft|Procedure: four-branched Dacron graft","the occluded rate of false lumen by the CTA|the survive rate by the questionnaire|complication by the datum of case|reoperation rate by the datum of case|the growth rate of thoracic descending aorta by the CTA|security index by the datum of case|life quality by the questionnaire","Liang-Wan Chen MD|Xinqiao Hospital of Chongqing|RenJi Hospital|First Affiliated Hospital of Zhongshan Medical University|Longyan City First Hospital|The First City Hospital, ZhanZhou|Fujian Medical University","All","20 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CLW2015AD2","November 1, 2016","November 30, 2018","March 31, 2019","December 4, 2015","null","November 17, 2017","the Department of Cardiovascular Surgery, FuZhou, Fujian, China","","https://ClinicalTrials.gov/show/NCT02622750"
1028,"NCT02621944","Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia",,"Recruiting","No Results Available","Hypoxic Ischemic Encephalopathy","Drug: Melatonin|Other: Magnetic Resonance Imaging|Other: Pharmacokinetics|Behavioral: Neurological Outcome Assessment|Behavioral: Generalized Motor Assessment","To identify the maximum tolerated dose of Melatonin|Bayley-III Index Scores (Cognitive, Language, and Motor) will be used for neurological outcome assessment|Peak Plasma Concentration (Cmax) of Melatonin 0.5 mg/kg.|Number of participants with treatment-related adverse events as assessed by MedDRA ??? This is something the PI/Team needs to agree on which one to use.|Peak Plasma Concentration (Cmax) of Melatonin 3 mg/kg.|Peak Plasma Concentration (Cmax) of Melatonin 5 mg/kg.|Bayley-III Index Scores Subscales (Receptive and Expressive Language, Fine and Gross Motor) will be used for neurological outcome assessment|Generalized Motor Assessment (GMA)|Evaluation of The Impact of Melatonin using Magnetic Resonance Image (MRI)","University of Florida|Thrasher Research Fund","All","up to 6 Hours   (Child)","Early Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB201500886","November 2016","March 2019","January 2021","December 4, 2015","null","February 16, 2018","University of Florida, Gainesville, Florida, United States|Florida Hospital for Children, Orlando, Florida, United States","","https://ClinicalTrials.gov/show/NCT02621944"
1029,"NCT02619721","Clinical Trial of Sacral Neuromodulation for Treatment of Refractory Overactive Bladder (OAB)",,"Unknown status","No Results Available","Refractory Overactive Bladder","Device: PINS SNS","Changes in voiding frequency from baseline to the voiding frequency evaluvation period 6 month","Beijing Pins Medical Co., Ltd|Beijing Hospital","All","16 Years and older   (Child, Adult, Older Adult)","Early Phase 1","7","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PINS-016","October 2015","November 2017","February 2018","December 2, 2015","null","October 11, 2016","Beijing Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT02619721"
1030,"NCT02619448","Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC",,"Recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: Carboplatin|Drug: Paclitaxel|Radiation: 70 Gy in 20 fractions over 4 weeks","Toxicity as measured using the National Cancer Institute's Common Terminology Criteria for Adverse Events|Radiographic response as measured by PET/CT|Local progression as measured by PET/CT|Regional progression as measured by PET/CT|Distant progression as measured by PET/CT|Time to overall progressions as measured by PET/CT|Overall survival as determined by patient contact","State University of New York - Upstate Medical University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","665895","December 2014","December 2023","December 2025","December 2, 2015","null","May 4, 2018","SUNY Upstate Medical University, Syracuse, New York, United States","","https://ClinicalTrials.gov/show/NCT02619448"
1031,"NCT02617498","Spray Diathermy Versus Harmonic Scalpel Technique for Hepatic Parenchymal Transection","LDLT","Completed","No Results Available","End Stage Liver Disease","Device: harmonic scalpel|Device: spray mode diathermy","the amount of blood loss|operative time|number of ligation used,|extent of necrosis at the cut surface","Mansoura University","All","10 Years to 50 Years   (Child, Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","hepatic transection","April 2013","April 2015","November 2015","December 1, 2015","null","March 22, 2016","","","https://ClinicalTrials.gov/show/NCT02617498"
1032,"NCT02615353","Preventing Diabetes in Latino Youth",,"Recruiting","No Results Available","Obesity|Diabetes","Behavioral: Intensive Lifestyle Intervention|Other: Usual Care Control","Glucose Tolerance|Quality of Life|Body Composition","Arizona State University|Phoenix Children's Hospital|St. Vincent de Paul Medical and Dental Clinic|Valley of the Sun YMCA, Arizona|University of Washington|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","12 Years to 16 Years   (Child)","Early Phase 1","120","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1R01DK107579-01","January 2016","October 2020","December 2021","November 26, 2015","null","June 28, 2017","Arizona State University, Phoenix, Arizona, United States","","https://ClinicalTrials.gov/show/NCT02615353"
1033,"NCT02614599","Neurocognitive and Neurobiological Improvement in ADHD Children With High Protein Diet","BrainProtein","Completed","No Results Available","ADD|ADHD","Drug: BP22042013|Dietary Supplement: Low carbohydrate diet","Changes Related Potential Recording after 3 months of dietary approach|Quantitative Electroencephalogram|Behavior","Spanish Foundation for Neurometrics Development|PronoKal Foundation|Child Health Foundation","All","7 Years to 13 Years   (Child)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","BrainProteins","June 2015","November 2015","November 2015","November 25, 2015","null","November 25, 2015","Pronokal Foundation, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT02614599"
1034,"NCT02611219","Deconditioning in Transplant",,"Completed","No Results Available","Hematopoietic and Stem Cell Transplant","Other: General Health Module-Baseline Adolescent-Self Report (13-18 years)|Other: General Health Module-Follow Up Adolescent-Self Report (13-18 years)|Other: General Health Module-Baseline Parent Report-Adolescent (13-18 years)|Other: General Health Module-Follow Up Parent Report-Adolescent (13-18 years)|Other: General Health Module-Baseline Parent Report-School Age (5-12 years)|Other: General Health Module-Follow Up Parent Report-School Age (5-12 years)|Other: Demographic Data Form|Other: SCT Daily Activity Log|Other: The Functional Independence Measure for Children|Other: Manual Muscle Testing|Other: 3-Minute Step Test|Other: HSCT Module-Follow Up Adolescent-Self Report (13-18 years)|Other: HSCT Module-Follow Child-Self Report (5-12 years)|Other: HSCT Module-Follow Up Parent Report-adolescent (13-18 years)|Other: HSCT Module-Follow Up Parent Report-School Age (5-12 years)","Recruitment and retention of participants throughout the study|Number of participants who achieve 6 hours out of bed through the 6 week clinic visit|Quality of life as measured by General Health Module questionnaires","Washington University School of Medicine","All","7 Years to 17 Years   (Child)","Early Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","201406031","March 2015","April 2016","April 2016","November 20, 2015","null","May 27, 2016","Washington University School of Medicine, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02611219"
1035,"NCT02610270","Erythrocyte Omega-3 Fatty Acid Content in Elite Athletes","O3Sport","Completed","No Results Available","Healthy","Dietary Supplement: 2 Gums|Dietary Supplement: 3 Gums","fatty acid levels at the membrane of the red blood cells|Impregnation in relation to dosage administrated to the athletes|Different level of impregnation of the red blood cells in relation to dosage and weight of the athletes|Different level of impregnation of the red blood cells in relation to dosage and different previous omega 3 index of the athletes|Different level of impregnation of the red blood cells in relation to dosage and different sex of the athletes|Different level of impregnation of the red blood cells in relation to dosage and different age of the athletes","Centre d'Alt Rendiment","All","Child, Adult, Older Adult","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CAR-2","June 2014","January 2015","April 2015","November 20, 2015","null","November 20, 2015","","","https://ClinicalTrials.gov/show/NCT02610270"
1036,"NCT02608736","Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid","GAMA","Completed","No Results Available","Head and Neck Squamous Cell Carcinoma","Drug: Valproic Acid|Drug: Placebo","Changes in protein or histone acetylation|Incidence of Treatment-Emergent Adverse Events|Change in DNA methyltransferases expression. (DNMT)","Barretos Cancer Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","BarretosCH - Head and Neck","December 2015","December 2016","July 2017","November 20, 2015","null","February 1, 2018","Barretos Cancer Hospital, Barretos, São Paulo, Brazil","","https://ClinicalTrials.gov/show/NCT02608736"
1037,"NCT02608528","Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy",,"Recruiting","No Results Available","Non-Small Cell Lung Cancer (NSCLC)","Radiation: [18F]fluoroglucose(FDG)","Number of inflammatory changes within the tumor","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Basic Science","UPCC 15515","September 2015","September 2019","null","November 18, 2015","null","October 8, 2018","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02608528"
1038,"NCT02606292","Photoacoustic Endoscopy of Barrett's Esophagus",,"Completed","No Results Available","Barrett Esophagus","Procedure: Photoacoustic endoscopy|Procedure: Endoscopic ultrasound (standard of care)|Procedure: Endoscopic surgery (standard of care)","Feasibility of PA endoscopic imaging as an alternative real-time noninvasive tool for evaluation of Barrett's esophagus as measured by the agreement between the PA imaging system and the standard esophageal biopsy for diagnosing Barrett's epithelium|Sensitivity and specificity of PA endoscopic imaging for identification of Barrett's epithelium compared to esophageal biopsy","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201204145","August 2014","August 2016","August 2016","November 17, 2015","null","September 29, 2016","Washington University School of Medicine, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02606292"
1039,"NCT02605746","Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis",,"Recruiting","No Results Available","Glioblastoma|Brain Metastases","Drug: ceritinib 750mg","Plasma Concentration|Cerebrospinal Concentration|Intratumoral Concentration|Tumor Tissue|Tumor Cells in M-Phase|Double Strand DNA|Tissue Concentration","St. Joseph's Hospital and Medical Center, Phoenix|Novartis|Wayne State University|Translational Genomics Research Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","48","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","PHX15BN068","November 2015","June 2017","September 2017","November 16, 2015","null","December 13, 2016","Barrow Brain and Spine, Phoenix, Arizona, United States","","https://ClinicalTrials.gov/show/NCT02605746"
1040,"NCT02605655","Clinical Trial of Chinese Formula AMP-1915 on Metabolic Syndrome",,"Completed","No Results Available","Metabolic Syndrome X","Drug: AMP-1915|Other: Placebo","Fasting blood glucose (FBG)|Plasma lipid levels|Plasma Insulin concentration|Body weight|Plasma HbA1c","Shanghai University of Traditional Chinese Medicine","All","40 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ShanghaiUTCM-01","June 2014","December 2014","April 2015","November 16, 2015","null","January 7, 2016","","","https://ClinicalTrials.gov/show/NCT02605655"
1041,"NCT02604862","Imaging FIB ONE in the Human Lung Using Endomicroscopy","FIB ONE","Recruiting","No Results Available","Fibrosis|Lung Cancer","Other: FIB ONE","The measurement of FIB ONE fluorescence intensity in the lung|The biological relationship between fibrosis and the intensity of the FIB ONE signal","University of Edinburgh|NHS Lothian","All","16 Years and older   (Child, Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","FIB ONE","May 2016","September 2018","September 2018","November 16, 2015","null","February 20, 2018","Royal Infirmary Edinburgh, Edinburgh, United Kingdom","","https://ClinicalTrials.gov/show/NCT02604862"
1042,"NCT02604134","Medical Management of Caries in the Primary Dentition Using Silver Nitrate",,"Enrolling by invitation","No Results Available","Dental Caries","Procedure: Prophylaxis|Drug: Fluoride varnish|Drug: Silver Nitrate","Change in baseline Caries Experience and activity (Incidence of caries in primary teeth)|Caries activity in primary teeth","Arwa Owais|Delta Dental of Iowa|University of Iowa","All","2 Years to 11 Years   (Child)","Early Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","201406792","July 2014","July 2019","July 2019","November 13, 2015","null","October 17, 2018","UIowa, Iowa City, Iowa, United States","","https://ClinicalTrials.gov/show/NCT02604134"
1043,"NCT02604069","Detection of Flap Ischemia Using Interstitial Glucose Monitor",,"Unknown status","No Results Available","Free Tissue Flaps","Device: Continuous Glucose Monitor","Temporal correlation between interstitial glucose measurements and flap ischemia|Incidence of minor side effects related to device|Incidence of major adverse effects related to the device|Incidences of technical issues related to the device","Hamilton Health Sciences Corporation|Thoma, Achilleas|Jiayi Hu|Matthew McRae","Female","Child, Adult, Older Adult","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CGM-2015-10","November 2015","February 2016","null","November 13, 2015","null","November 13, 2015","Juravinski Hospital, Hamilton, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02604069"
1044,"NCT02602977","the Influence of Remote Ischemic Preconditioning on Inflammation During Human Endotoxemia","RISPENDO","Completed","No Results Available","Autoimmune Diseases|Infection","Other: Multiple-dose Remote Ischemic Preconditioning|Other: Single-dose Remote Ischemic Preconditioning|Biological: LPS infusion","Plasma TNF-α concentration following LPS administration|circulating cytokines (including but not limited to IL-6, IL-10, IL-1RA)|Hemodynamic parameters|body temperature|subjective symptom scores|kidney injury markers in urine - TIMP2*IGFBP7","Radboud University","Male","18 Years to 35 Years   (Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","RISPENDO","October 2015","March 2016","March 2016","November 11, 2015","null","April 4, 2016","Radboud University Medical Centre, Intensive Care, Nijmegen, Netherlands","","https://ClinicalTrials.gov/show/NCT02602977"
1045,"NCT02602522","Danshen-Jiang-Fu Granule Prepared by Danshen From Different Producing Areas for Primary Dysmenorrhea",,"Recruiting","No Results Available","Primary Dysmenorrhea|Traditional Chinese Medicine","Drug: Shandong Danshen-Jiang-Fu Granule|Drug: Sichuan Danshen-Jiang-Fu Granule","Visual Analogue Scale on the pain of dysmenorrhea|Cox Menstrual Symptom Scale|Daily Symptom Scale|The change on the index of uterine artery doppler ultrasound","Zhong Wang|China Academy of Chinese Medical Sciences","Female","14 Years to 25 Years   (Child, Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DS-V3.0","November 2015","July 2018","null","November 11, 2015","null","November 30, 2017","Changzhou TCM hospital, Changzhou, Jiangsu, China","","https://ClinicalTrials.gov/show/NCT02602522"
1046,"NCT02602158","13C Trioctanoate Breath Test as a Measurement of Gastric Fat Volume Emptying","13CTriOBT","Completed","No Results Available","Healthy","Dietary Supplement: Octanoic acid (1-13C, 99%)|Dietary Supplement: TRIOCTANOIN (1,1,1-13C3, 99%)","Half emptying time (T50) [min] as determined from 13CO2 recovery curves in breath using the exponential beta function|The T50 [min] of MRI fat volume emptying|Correlation of MRI T50 [min] and breath test T50 [min|The maximum secretion volume [ml]|Spatial heterogeneity of gastric content will be assessed using a variogram approach","University of Zurich","All","18 Years to 50 Years   (Adult)","Early Phase 1","32","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","KEK-Nr. 2015-0450","October 2015","April 2016","April 2016","November 11, 2015","null","July 22, 2016","University Hopsital Zurich, Zurich, Switzerland","","https://ClinicalTrials.gov/show/NCT02602158"
1047,"NCT02597205","The Adherence and Knowledge Exchange Heart and Stroke Medicines Study","TAKEmeds","Completed","No Results Available","Myocardial Infarction","Behavioral: physician-facing app and patient-facing messages","Medical adherence change|Change in diet|Change in exercise|Change in smoking habit","Duke Kunshan University|Population Health Research Institute|Fudan University|Hainan Provincial Nongken General Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","190","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2014HHSC0016","May 2015","December 2015","June 2016","November 5, 2015","null","August 27, 2018","Hainan Nongken General Hospital, Haikou, Hainan, China|Shanghai Xietu Street Community Healthcare Center, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT02597205"
1048,"NCT02596776","Cold Induced Changes in White Adipose",,"Recruiting","No Results Available","Obese|Normal Body Weight|Prediabetes|Metabolic Syndrome","Procedure: Fat biopsy|Drug: Propranolol and fat biopsy|Other: heavy water and fat biopsy","WAT changes during repeated exposure to cold temperatures|WAT changes following Propranolol dosing|In vivo measurement of adipose lipolysis and triglyceride (TG) turnover","Philip Kern|National Institutes of Health (NIH)|University of Kentucky","Female","35 Years to 60 Years   (Adult)","Early Phase 1","90","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","15-0663","March 2016","December 2019","December 2019","November 4, 2015","null","May 8, 2018","University of Kentucky Medical Center Center for Clinical and Translational Science, Lexington, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT02596776"
1049,"NCT02595723","Phenytoin for Memory Impairment Secondary to Megestrol",,"Completed","No Results Available","Cognitive Impairment","Drug: Phenytoin|Drug: Megestrol Acetate|Drug: Placebo","Rey Auditory Verbal Learning Test (RAVLT)|Digit Span Backwards|The Sternberg Memory Task (SMT)|The Running Memory Continuous Performance Task (RMCPT)","University of Texas Southwestern Medical Center|The Rogosin Institute","All","18 Years to 50 Years   (Adult)","Early Phase 1","22","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","032015-004","July 2015","November 2016","December 2016","November 3, 2015","null","December 29, 2016","UT Southwestern Medical Center, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT02595723"
1050,"NCT02593929","Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer",,"Withdrawn","No Results Available","Head and Neck Squamous Cell Carcinoma","Drug: ruxolitinib","baseline and/or pharmacodynamic biomarkers of response to ruxolitinib based upon association with change in tumor size|preliminary efficacy of neoadjuvant ruxolitinib in patients with operable HNSCC as determined by quantitative ΔTumor size|the tolerability of brief neoadjuvant exposure to ruxolitinib as determined by the number of participants with treatment related adverse events as assessed by CTCAE v4.0|the effect of ruxolitinib on the tumoral Ki-67 proliferation index|additional candidate biomarkers of ruxolitinib response or resistance in HNSCC patients as determined by quantitative ΔTumor size","University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCI 14-207","January 2017","January 2018","null","November 2, 2015","null","June 8, 2017","","","https://ClinicalTrials.gov/show/NCT02593929"
1051,"NCT02593682","The Role of Orexin in Human Panic Disorder",,"Unknown status","No Results Available","Panic Disorder","Drug: suvorexant|Drug: placebo","Change in orexin levels (blood) +1 minute|Change in orexin levels (blood) +5 minutes|Change in orexin levels (blood) +15 minutes|Change in orexin levels (blood) +60 minutes","University of California, San Francisco","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","2015078","May 2016","June 2017","June 2017","November 2, 2015","null","May 16, 2016","UCSF Fresno Medical Education Program, Fresno, California, United States","","https://ClinicalTrials.gov/show/NCT02593682"
1052,"NCT02593643","Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.",,"Completed","No Results Available","Major Depressive Disorder|Bipolar I Disorder|Bipolar II Disorder|Bipolar Depression|Suicidal Ideation","Drug: Ketamine|Drug: Midazolam|Other: Treatment as usual (TAU)","Montgomery-Aspberg Depression Rating Scale (MADRS)|Clinical Global Impression of Severity/Improvement (CGI-S, CGI-I)|Scale of Suicidal Ideation (SSI)|Columbia-Suicide Severity Rating Scale (CSSRS)","Sunnybrook Health Sciences Centre","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","361-2013","January 2016","April 2017","April 2017","November 2, 2015","null","July 26, 2017","Sunnybook Health Sciences Centre, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02593643"
1053,"NCT02591654","MRI and PET to Assess Pembrolizumab Response","MPAK","Recruiting","No Results Available","Malignant Melanoma, Metastatic","Drug: Pembrolizumab|Drug: FLT PET","Prevalence of lesion detection (sensitivity)|Difference in lesion metrics|Change in patient response (immunoscore)|Change in patient response (expression levels)|Change in RECIST Index","Yvonne Saenger|Merck Sharp & Dohme Corp.|Columbia University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAO2558","October 2015","November 2022","November 2024","October 29, 2015","null","January 25, 2018","Columbia University, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02591654"
1054,"NCT02591173","Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure",,"Recruiting","No Results Available","Autonomic Nervous System Disorders|Pure Autonomic Failure|Shy-Drager Syndrome|Orthostatic Hypotension, Dysautonomic","Drug: Angiotensin-(1-7)|Drug: Saline","Blood Presure|Heart Rate|Cardiac Output|Stroke Volume|Systemic Vascular Resistance|Renin Activity|Angiotensin Peptides|Aldosterone","Vanderbilt University|Vanderbilt University Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","22","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","151461","February 2016","December 2019","December 2019","October 29, 2015","null","July 26, 2018","Vanderbilt University, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT02591173"
1055,"NCT02591147","Silver Diamine Fluoride Pilot Study (SDF)","SDF","Recruiting","No Results Available","Dental Caries","Drug: Silver Diamine Fluoride 38%|Drug: Group 2 (Placebo)","Caries Progression|Incidence of caries in all other teeth in the study subject","Justine Kolker|University of Iowa","All","21 Years to 64 Years   (Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Health Services Research","201509831","October 2016","December 2020","December 2020","October 29, 2015","null","August 29, 2018","University of Iowa, Iowa City, Iowa, United States","","https://ClinicalTrials.gov/show/NCT02591147"
1056,"NCT02590458","Feasibility of Short Breast MRI (SBMRI) for Screening Patients at High Risk for Breast Cancer",,"Active, not recruiting","No Results Available","Breast Cancer","Procedure: Short Breast MRI (SBMRI)|Behavioral: Questionnaire","Sensitivity of SBMRI for Detecting Breast Cancer in High Risk Participants","M.D. Anderson Cancer Center|GE Healthcare","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","131","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","2015-0243|NCI-2015-02031","October 26, 2015","October 2020","October 2020","October 29, 2015","null","May 9, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02590458"
1057,"NCT02589106","Anisotropic Textile Braces for Adolescent Idiopathic Scoliosis",,"Enrolling by invitation","No Results Available","Scoliosis","Device: Anisotropic Textile Braces","Progression of the spinal curve|Posture improvement","The Hong Kong Polytechnic University","Female","10 Years to 14 Years   (Child)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GRF2016","January 2017","December 2019","December 2020","October 28, 2015","null","November 6, 2017","The Hong Kong Polytechnic University, Hong Kong, China","","https://ClinicalTrials.gov/show/NCT02589106"
1058,"NCT02587741","Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens","CORRECT","Recruiting","No Results Available","Diabetic Retinopathy","Drug: Metformin|Drug: Lantus|Drug: Novomix30","The incidence of diabetic retinopathy|cardiovascular events|renal failure|glucose fluctuation|oxidative stress","Third Affiliated Hospital, Sun Yat-Sen University","All","30 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Third SunYetSan","July 2015","July 2023","July 2025","October 27, 2015","null","October 27, 2015","the third affiliated hospital of Sun yet-san university, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT02587741"
1059,"NCT02583789","Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon",,"Recruiting","No Results Available","Raynaud's Phenomenon","Drug: oral treprostinil|Drug: Placebo","Change in Raynaud's Condition Score|Change in number of Raynaud's Phenomenon attacks|Change in duration of Raynaud's Phenomenon attacks|Reduction of ulcer burden among secondary Raynaud's Phenomenon patients","Brigham and Women's Hospital|United Therapeutics","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2015P001879","May 2016","July 2018","July 2018","October 22, 2015","null","August 2, 2017","Brigham and Women's Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02583789"
1060,"NCT02583529","Neurogenic Overactive Bladder Treatment on Parkinson's Disease Through Back Tibial Nerve Electrostimulation","NOVTPD","Unknown status","No Results Available","Overactive Bladder|Parkinson Disease","Device: Back Tibial Nerve Electrostimulation|Device: Placebo Electrostimulation","Voiding diary|Hoehn and Yahr Disability Stage of scale|King's Health Questionnaire","Tatiane Gomes de Araujo|Hospital de Clinicas de Porto Alegre","Female","40 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","14-0554","July 2014","December 2016","December 2017","October 22, 2015","null","October 22, 2015","Tatiane Gomes de Araujo, Porto Alegre, Rio Grande do Sul, Brazil","","https://ClinicalTrials.gov/show/NCT02583529"
1061,"NCT02582008","Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy",,"Recruiting","No Results Available","Current Smoker|Head and Neck Squamous Cell Carcinoma|Hypopharyngeal Squamous Cell Carcinoma|Laryngeal Squamous Cell Carcinoma|Nasopharyngeal Carcinoma|Oral Cavity Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma","Drug: Bupropion Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Nicotine Replacement|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Drug: Varenicline","Proportion of patients who are not smoking|Levels of depression and anxiety as measured by Hamilton Rating Scale-Depression questionnaire|Proportion of patients who are not smoking at 6 months post RT or CRT|Proportion of patients who develop mucositis and mucositis-related pain evaluated by Common Terminology Criteria for Adverse Events|Proportion of patients who experience smoking relapse among patients who quit smoking|QOL as measured by MD Anderson Inventory","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00035113|NCI-2015-01714|CCCWFU # 98415|CCCWFU 98415|P30CA012197","January 2016","January 2019","January 2020","October 21, 2015","null","July 4, 2018","Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT02582008"
1062,"NCT02580604","PTH And Calcium Responses to Exercise in Older Adults Experiment 2 (PACE Sr. 2)",,"Recruiting","No Results Available","Osteoporosis","Drug: Calcium Chloride/Calcium Gluconate|Drug: Placebo","Change in Parathyroid Hormone (PTH)|Change in C-telopeptide (CTX)|Change in Total Calcium (Ca)","University of Colorado, Denver","Female","60 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","28","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","15-0878|UL1TR001082","November 2015","December 2018","December 2018","October 20, 2015","null","October 11, 2018","University of Colorado Hospital, Aurora, Colorado, United States","","https://ClinicalTrials.gov/show/NCT02580604"
1063,"NCT02577575","Adult Oxytocin Study","OT","Completed","No Results Available","Schizophrenia|Oxytocin|Social Cognition","Drug: Oxytocin|Drug: Saline Nasal Spray","Improvement in social cognition task performance|Pre-morbid IQ Questionnaire (AmNART)|Experiences in Close Relationships-Relationship Structures (ECR-RS) Questionnaire|Childhood Trauma Questionnaire (CTQ)|Emotional Quotient Scale (EQS)|Kinsey Scale|Change in Working Memory capacity|Change in Auditory Perception correctness|Change in Auditory Perception reaction time","University of California, San Francisco|San Francisco Veterans Affairs Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","120","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","10-01508","August 2010","November 2015","November 2015","October 16, 2015","null","October 19, 2018","San Francisco Veterans Affairs Medical Center, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT02577575"
1064,"NCT02575235","Clinical Trial to Assess the Preventive Effects of Cetylpyridinium Chloride on Sarcopenia","CPC2","Unknown status","No Results Available","Sarcopenia","Drug: CPC|Drug: placebo","Change from baseline in procollagen type III N-terminal peptide|Change from baseline in IGF-1|Change from baseline in TGF-β1|Change from baseline in Myostatin|Change from baseline in TNF-α|Change from baseline in IL-1|Change from baseline in FABP3|Change from baseline in MCP-1|Change from baseline in Skeletal muscle index|Change from baseline in SPPB|Change from baseline in Grip strength","Seoul National University Hospital","All","60 Years and older   (Adult, Older Adult)","Early Phase 1","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","SNUHRM-CPC2","October 2015","August 2016","August 2016","October 14, 2015","null","October 14, 2015","Seoul National University College of Medicine, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02575235"
1065,"NCT02568709","Oxytocin MEG Study","MEG","Completed","No Results Available","Schizophrenia|Oxytocin|Magnetoencephalography (MEG)|Social Cognition","Drug: Oxytocin|Drug: Saline Nasal Spray","Change in MEG neural activation patterns|Change in performance on Facial Recognition Task|Change in performance on International Affective Picture System (IAPS) task|UCLA Loneliness Scale|Experiences in Close Relationships-Relationship Structures (ECR-RS) Questionnaire|Childhood Trauma Questionnaire (CTQ)|Parental Bonding Instrument (PBI)|Emotional Quotient Scale (EQS)|Fagerstom Nicotine Dependence Test|Quality of Life Scale (QLS)|Social Functioning Scale (SFS)","University of California, San Francisco","Male","18 Years to 40 Years   (Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12-08411","February 2012","December 2016","December 2016","October 6, 2015","null","October 19, 2018","University of California, San Francisco, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT02568709"
1066,"NCT02568033","Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer",,"Unknown status","No Results Available","Non Small Cell Lung Cancer","Drug: Pemetrexed|Drug: Carboplatin|Drug: Cisplatin|Drug: Docetaxel|Drug: Paclitaxel|Radiation: stereotactic radiosurgery","Disease free progression|Toxicity (Treatment related side effects)","The Cooper Health System","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-130","October 2013","October 2017","October 2017","October 5, 2015","null","January 31, 2017","MD Anderson Cancer Center at Cooper, Camden, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT02568033"
1067,"NCT02567032","Adult Study Oxytocin - Behavioral","ASO-Behavioral","Recruiting","No Results Available","Schizophrenia|Oxytocin|Social Cognition|Psychotic Disorders","Drug: Oxytocin|Drug: Saline Nasal Spray","Change in Social Cognition Task Performance|Physiological Measurements|Questionnaire","University of California, San Francisco|San Francisco Veterans Affairs Medical Center","Male","18 Years to 45 Years   (Adult)","Early Phase 1","300","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","10-02262","October 2010","November 2020","December 2020","October 2, 2015","null","June 4, 2018","San Francisco Veterans Affairs Medical Center, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT02567032"
1068,"NCT02566356","Adult Study Oxytocin - fMRI","ASO-fMRI","Unknown status","No Results Available","Schizophrenia|Oxytocin|Social Cognition|Functional Magnetic Resonance Imaging (fMRI)","Drug: Oxytocin|Drug: Saline Nasal Spray","Change in fMRI neural activation patterns|Quality of Life Scale (QLS)|Social Functioning Scale (SFS)|UCLA Loneliness Scale|Experiences in Close Relationships - Relationship Structures (ECR-RS)|Parental Bonding Instrument (PBI)|Premorbid IQ test (AmNART)|Childhood Trauma Questionnaire (CTQ)|Emotional Quotient Scale (EQS)|Kinsey Scale|Socioeconomic Status (SES)","University of California, San Francisco|San Francisco Veterans Affairs Medical Center","Male","18 Years to 50 Years   (Adult)","Early Phase 1","72","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12-09654","September 2012","August 2016","null","October 2, 2015","null","May 24, 2016","San Francisco Veterans Affairs Medical Center, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT02566356"
1069,"NCT02565264","Effect of Plasma Derived Exosomes on Cutaneous Wound Healing",,"Enrolling by invitation","No Results Available","Ulcer","Other: plasma-derived exosomes","Ulcer size (length, mm)|Ulcer size (width, mm)|Ulcer size (depth, mm)|Pain of cutaneous wounds (Visual Analog Score for pain)","Kumamoto University","All","Child, Adult, Older Adult","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012","September 2015","March 2019","March 2019","October 1, 2015","null","August 28, 2018","Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan","","https://ClinicalTrials.gov/show/NCT02565264"
1070,"NCT02563171","Gingival Crevicular Fluid Vaspin and Omentin Levels in Obese Patients With Chronic Periodontitis",,"Completed","No Results Available","Obesity|Periodontitis","Other: non surgical periodontal treatment|Other: Gingival crevicular fluid collection","Biochemical parameters (Vaspin and omentin)|Tumor necrosis factor alfa|Probing pocket depth|Clinical attachment level|Gingival index|Plaque index|Bleeding on probing","Umut BALLI|Bulent Ecevit University","All","30 Years to 49 Years   (Adult)","Early Phase 1","76","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2014-115-17/06","July 2014","May 2015","May 2015","September 30, 2015","null","September 30, 2015","","","https://ClinicalTrials.gov/show/NCT02563171"
1071,"NCT02560376","68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis",,"Unknown status","No Results Available","Insulinoma|Nesidioblastosis","Drug: 68Ga-NOTA-exendin-4","Standardized uptake value of 68Ga-NOTA-exendin-4 PET/CT in Diagnosis of Insulinoma and Nesidioblastosis|Adverse events collection","Peking Union Medical College Hospital|National Institute for Biomedical Imaging and Bioengineering (NIBIB)","All","6 Years to 70 Years   (Child, Adult, Older Adult)","Early Phase 1","100","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PUMCHNM12|ZIAEB000073","February 2014","December 2016","December 2016","September 25, 2015","null","September 25, 2015","Peking Union Medical College Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT02560376"
1072,"NCT02558998","Improving Clinical Trial Awareness in NSCLC: Pilot Testing A Novel Healthcare IT Platform for Incorporating Education at the Point of Care",,"Recruiting","No Results Available","Non-Small Cell Lung Carcinoma (NSCLC)","Other: Survey","Number of patient who completed surveys","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","120","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","UPCC 34514","March 2015","March 2019","null","September 24, 2015","null","October 5, 2018","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02558998"
1073,"NCT02558751","Pneumonia Vaccine in Aging HIV Positive Individuals",,"Completed","No Results Available","Pneumococcal Infection","Biological: 23-valent pneumococcal polysaccharide vaccine|Biological: 13-valent pneumococcal conjugate vaccine","Antibody response measured by ELISA (ug/ml)|Opsonophagocytic antibody activity measured by opsonophagocytic assay (OPA titer)|B cell phenotype of PPS-specific B cells expressing CD27+IgM+: flowcytometry (%)|Serum C-reactive protein (ng/ml)|Flow cytometry : percentage cells expressing BAFF-R on surface (%)|B cell phenotype of PPS-specific B cells expressing CD27IgM: flowcytometry (%)|Serum IL-6 level (pg/ml)|Serum sCD27 (U/ml)|Serum sCD30 (U/ml)|Serum BAFF concentration (pg/ml)|Serum TACI concentration (pg/ml)|Serum BCMA concentration (pg/ml)|Flow cytometry : percentage cells expressing CD40 on surface (%)|Flow cytometry : percentage cells expressing CD21 on surface (%)|Flow cytometry : percentage cells expressing TACI on surface (%)","University of Toledo Health Science Campus|National Institute on Aging (NIA)","All","50 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","51","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R01AG045973","July 2013","June 2015","June 2015","September 24, 2015","null","September 24, 2015","The University of Toledo-Health Science Campus, Toledo, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02558751"
1074,"NCT02558062","Microdosing of BAC ONE to the Distal Lung","BAC ONE","Recruiting","No Results Available","Bacterial Respiratory Infections","Other: BAC ONE administration","The measurement of BAC ONE fluorescence intensity in the distal lung","University of Edinburgh|NHS Lothian","All","16 Years and older   (Child, Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","BAC ONE","May 2016","December 2018","December 2018","September 23, 2015","null","February 20, 2018","Royal Infirmary Edinburgh, Edinburgh, United Kingdom","","https://ClinicalTrials.gov/show/NCT02558062"
1075,"NCT02557958","Chronic Obstructive Pulmonary Disease Transcription Factor and Cytokine Study",,"Active, not recruiting","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: Azithromycin|Drug: Placebo","Inflammatory markers|transcription factor changes|Lung function changes","New York University School of Medicine","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","19","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","09-0769","January 2009","December 2018","December 2020","September 23, 2015","null","March 30, 2018","","","https://ClinicalTrials.gov/show/NCT02557958"
1076,"NCT02554695","Osteoclast Inhibition and Bone Formation",,"Completed","No Results Available","Bone Loss|Aging","Drug: placebo|Drug: denosumab","Gene expression changes in bone cells|Osteoclast-osteoblast coupling factor changes","Mayo Clinic","Female","25 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","81","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","15-002313","October 20, 2015","October 25, 2016","October 25, 2016","September 18, 2015","null","January 5, 2018","Mayo Clinic in Rochester, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02554695"
1077,"NCT02554344","Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs)",,"Unknown status","No Results Available","Cervical Intraepithelial Neoplasia","Drug: Curcumin","Determine the safety and feasibility using curcumin in patients with CIN3 where toxicities will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.|Regression Rate|Overall Response|Pathologic Response|Rate of patients in which p65, phosphorylated p65, and acetylated p65 play a role in the persistence of CIN.|Evaluation of patients with CIN3 for the presence of high-risk HPV.","Baylor Research Institute","Female","21 Years and older   (Adult, Older Adult)","Early Phase 1","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","015-074","March 2016","January 2017","January 2017","September 18, 2015","null","March 17, 2016","Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT02554344"
1078,"NCT02553447","Cholecalciferol in Treating Patients With Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency",,"Recruiting","No Results Available","Chronic Lymphocytic Leukemia|Non-Hodgkin Lymphoma|Untreated Chronic Lymphocytic Leukemia|Vitamin D Deficiency","Dietary Supplement: Cholecalciferol|Other: Laboratory Biomarker Analysis","Progression-free survival|Incidence of adverse events and serious events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Overall survival","University of Nebraska|National Cancer Institute (NCI)","All","19 Years and older   (Adult, Older Adult)","Early Phase 1","312","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","556-15|NCI-2015-01502|P30CA036727","October 19, 2015","August 28, 2019","August 28, 2022","September 17, 2015","null","July 27, 2018","University of Nebraska Medical Center, Omaha, Nebraska, United States","","https://ClinicalTrials.gov/show/NCT02553447"
1079,"NCT02553005","Evaluation of the Effect of Acupuncture on Hand Pain, Functional Deficits and Health Related Quality of Life in Patients With Rheumatoid Arthritis",,"Unknown status","No Results Available","Acupuncture","Procedure: Acupuncture","gene expression profiles (Assessment by microarray)|Quality of life (Assessment by SF-36 scale)|Cortisol levels in blood|Interleucines levels in blood|hand pain (Assessment by algometry)|hand strength (Assessment by dynamometry)","University of Coimbra","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Coimbra","May 2015","October 2015","June 2017","September 17, 2015","null","September 29, 2015","Faculty of Medicine - University of Coimbra, Coimbra, Portugal","","https://ClinicalTrials.gov/show/NCT02553005"
1080,"NCT02550327","Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer",,"Recruiting","No Results Available","Pancreatic Adenocarcinoma","Drug: Nab-paclitaxel|Drug: Gemcitabine|Drug: Cisplatin|Drug: Anakinra","Disease Free Survival (DFS)|Overall Survival (OS)|Quality of Life|Toxicities and Adverse Events will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.","Baylor Research Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","015-198","January 2016","September 2018","September 2018","September 15, 2015","null","October 1, 2018","Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT02550327"
1081,"NCT02548936","Efficacy and Safety of Simvastatin-ezetimibe Combination Therapy Among Patients With SLE",,"Unknown status","No Results Available","Atherosclerosis","Drug: Ezetimibe+Simvastatin Drug Combination","The change of carotid intima media thickness over 12 months|The rate of abnormal elevated alanine aminotransferase (ALT)|The rate of abnormal elevated alanine aminotransferase|The rate of abnormal elevated creatine kinase (CK)|The rate of abnormal elevated creatine kinase","Peking Union Medical College Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","pumch-sleas","April 2015","October 2016","December 2016","September 14, 2015","null","September 14, 2015","Peking Union Medical College Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT02548936"
1082,"NCT02546752","Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine",,"Completed","No Results Available","Human Papilloma Virus Infection Type 11|Human Papilloma Virus Infection Type 16|Human Papilloma Virus Infection Type 18|Human Papilloma Virus Infection Type 6|Cervical Cancer","Other: THEO","Outcome Measure 1: Difference Between Average HPV Vaccine Series Initiation and Completion Rates|Outcome Measure 1: Relative Difference in Time of Appointment","Regenstrief Institute, Inc.|Merck Sharp & Dohme Corp.","All","11 Years to 17 Years   (Child)","Early Phase 1","1306","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","Merck - 20","September 2015","May 2016","May 2016","September 11, 2015","null","May 25, 2016","Eskenazi Health Outpatient Care Center, Indianapolis, Indiana, United States|Eskenazi Health Center Blackburn, Indianapolis, Indiana, United States|Eskenazi Health Center Forest Manor, Indianapolis, Indiana, United States|Eskenazi Health West 38th Street, Indianapolis, Indiana, United States|Eskenazi Health Pecar, Indianapolis, Indiana, United States","","https://ClinicalTrials.gov/show/NCT02546752"
1083,"NCT02546206","Probiotic Yoghurt Effect on Experimental Gingivitis",,"Completed","No Results Available","Gingivitis","Dietary Supplement: Probiotic Yoghurt|Dietary Supplement: Natural Yoghurt","Bleeding on probing|Gingival Index|Plaque Index","Marmara University","All","16 Years to 26 Years   (Child, Adult)","Early Phase 1","51","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","MAR-2011-10-11/14","November 2011","May 2012","May 2012","September 10, 2015","null","September 10, 2015","Marmara University, Faculty of Dentistry, Department of Periodontology, Istanbul, Sisli/Nisantasi, Turkey","","https://ClinicalTrials.gov/show/NCT02546206"
1084,"NCT02540512","Acupuncture for Pain in the Emergency Department",,"Withdrawn","No Results Available","Musculoskeletal Pain|Pain","Procedure: Auricular Acupuncture|Device: Acupuncture|Procedure: Placebo Acupuncture|Drug: hydrocodone / acetaminophen 5mg/325mg|Drug: Placebo Pill","Pain Intensity Measure (VAS score 0-10)|Recurrence of Pain (VAS score 0-10)|Medication Usage|Past Trauma History","Loma Linda University","All","18 Years to 89 Years   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","15063","July 27, 2017","September 2017","September 2017","September 4, 2015","null","July 28, 2017","","","https://ClinicalTrials.gov/show/NCT02540512"
1085,"NCT02538484","Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects",,"Recruiting","No Results Available","Breast Cancer","Drug: Letrozole|Dietary Supplement: Fish Oil","Change in levels of aromatase target gene.|Change in serum levels of PGE2 (prostaglandin E2).","Andrew Brenner|The University of Texas Health Science Center at San Antonio","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CTMS# 15-2100","April 2016","September 2019","December 2019","September 2, 2015","null","October 26, 2018","Houston Methodist Cancer Center at Texas Medical Center, Houston, Texas, United States|Mays Cancer Center, UT Health San Antonio, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT02538484"
1086,"NCT02538146","Effect of Acetyl-L-carnitine on Chronic Pancreatitis",,"Terminated","No Results Available","Chronic Pancreatitis","Dietary Supplement: acetyl-L-carnitine 1000mg 2X per day for 3 months","Pain score|Well Being|Generalized anxiety disorder 7-item (GAD-7) Scoring|Patient Depression Questionnaire Scoring|Inflammatory Markers","Karin High|University of Kentucky","All","20 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","UKentucky","August 2015","October 2016","October 2016","September 2, 2015","null","March 10, 2017","University of Kentucky Center for Clinical and Translational Science, Lexington, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT02538146"
1087,"NCT02536352","Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being",,"Recruiting","No Results Available","Preterm Birth|Preterm Labor|Bacteremia|Preterm Premature Rupture of Fetal Membranes","Drug: Prenatal vitamin-mineral containing 3 mg fluoride|Dietary Supplement: Prenatal vitamin-mineral containing 0 mg fluoride","Length of gestation|Birth weight|Birth length|Preterm birth|Preterm premature rupture of membranes (PPROM)","Johns Hopkins University","Female","18 Years to 55 Years   (Adult)","Early Phase 1","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","IRB00038838","October 2015","October 2019","October 2019","August 31, 2015","null","October 1, 2018","Johns Hopkins Hospital, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02536352"
1088,"NCT02535455","Acceptance and Compassion to Enhance Self-care Pilot","ACES Pilot","Unknown status","No Results Available","HIV/AIDS|Substance Use Disorder","Behavioral: ACES Pilot","Change from baseline antiretroviral adherence to post intervention follow up visits|Change from baseline engagement in HIV-related Care (number of HIV-related health visits scheduled and attended) to follow up visits.|Change from baseline viral load to final follow up visit.|Change in substance use|Change in baseline sexual risk behaviors to research visit after face-to-face intervention component (approximately 5 weeks post-baseline) and research visit after text-message component (approximately 11 months post-baseline).|Change in HIV and Abuse Related Shame (HARSI)|Change in depression (CES-D)|Change in Self-Compassion (Self-Compassion Scale)|Change in mindfulness (Five Facet Mindfulness Questionnaire)","University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A118121","August 2015","February 2016","February 2016","August 28, 2015","null","August 28, 2015","","","https://ClinicalTrials.gov/show/NCT02535455"
1089,"NCT02534376","Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal",,"Recruiting","No Results Available","Prostate Cancer","Drug: ezetimibe 10mg-simvastatin 40mg","Growth of Gleason grade 3 prostate cancer|Growth of benign prostate glands|Growth of high grade prostate cancer (e.g. Gleason grade 4/5)","Cedars-Sinai Medical Center|Roswell Park Cancer Institute","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","70","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00040945","September 2015","February 2019","February 2020","August 27, 2015","null","September 10, 2018","Cedars Sinai Medical Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02534376"
1090,"NCT02533076","The Functional Consequences of the CTNS-deletion for the TRPV1-receptor in Cystinosis Patients",,"Completed","No Results Available","Cystinosis","Other: Challenge agent: capsaicin|Other: Challenge agent: placebo|Device: Mechanical stimulation with Von Frey filaments|Device: Temperature sensitivity measurement with Advanced Thermal Stimulation","Change from baseline of the dermal blood flow response to topical applied capsaicin at 10, 20, 30, 40, 50 and 60 minutes, measured with Laser Doppler Imaging and expressed in % change to baseline|Change from baseline of the skin sensitivity response after topical applied capsaicin at 10, 20, 30, 40, 50 and 60 minutes, measured with the Numerical rating scale and skin sensitivity to mechanical stimulation, measured with Von Frey filaments.|Temperature sensitivity (detection and pain threshold), measured with Advanced Thermal stimulation and expressed in degrees Celsius.","Universitaire Ziekenhuizen Leuven","All","8 Years and older   (Child, Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CCP13-3302-CYST","November 2014","July 2015","July 2015","August 26, 2015","null","August 26, 2015","Centre for Clinical Pharmacology, UZ Leuven, Leuven, Vlaams-Brabant, Belgium","","https://ClinicalTrials.gov/show/NCT02533076"
1091,"NCT02531360","Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies",,"Completed","No Results Available","Alzheimer's Disease (AD)|Progressive Supranuclear Palsy (PSP)|Cortical Basal Syndrome (CBS)|Frontal Temporal Dementia (FTD)","Drug: [18F]MNI-815 (MNI-815)","Brain uptake of [18F]MNI-815","Molecular NeuroImaging|Piramal Imaging SA","All","50 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","7","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","MNI-815","May 2015","July 2016","August 2016","August 24, 2015","null","December 16, 2016","Molecular NeuroImaging, LLC, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02531360"
1092,"NCT02529202","Dexmedetomidine Pharmacokinetics in Neonates During Therapeutic Hypothermia",,"Completed","No Results Available","Hypoxic-ischemic Encephalopathy","Drug: Dexmedetomidine","Pharmacokinetic (PK) parameter of area under the curve (AUC)|Pharmacokinetic (PK) parameter of clearance|Pharmacokinetic (PK) parameter of terminal half-life|Pharmacokinetic (PK) of volume of distribution|Efficacy of dexmedetomidine at preventing shivering|Safety of dexmedetomidine in neonatal subjects. (composite outcome will include: adverse events, physical examination findings, and vital signs)","Seattle Children's Hospital","All","up to 1 Day   (Child)","Early Phase 1","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15647","March 2016","November 2016","January 2017","August 20, 2015","null","January 12, 2017","Seattle Children's Hospital, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT02529202"
1093,"NCT02529150","WISER After Ovarian Cancer - Exercise Pilot Study",,"Unknown status","No Results Available","Ovarian Cancer","Behavioral: Exercise","Number of adverse events","Abramson Cancer Center of the University of Pennsylvania","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Supportive Care","UPCC 38814","May 2015","December 2015","null","August 20, 2015","null","January 15, 2016","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02529150"
1094,"NCT02527252","Craniosacral Therapy in Patients With Chronic Low Back Pain",,"Completed","No Results Available","Low Back Pain|Musculoskeletal Manipulations","Other: Craniosacral therapy|Other: Classic Massage","Roland-Morris Disability Questionnaire (RMQ)|Oswestry Low Back Pain Disability Index (ODI).|10-point Numerical Pain Rating Scale|Tampa Scale of Kinesiophobia (TSK)|Isometric endurance of trunk flexor muscles|Lumbar mobility in flexion|Hemoglobin Oxygen Saturation|Systolic Blood Pressure|Diastolic Blood Pressure|Hemodynamic (Cardiac Index)|Insterticial Liquid Biochemical Estimation","Universidad de Almeria","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","UAL-472","July 2015","October 2015","November 2015","August 18, 2015","null","January 11, 2017","Universidad de Almeria, Almería, Spain","","https://ClinicalTrials.gov/show/NCT02527252"
1095,"NCT02526368","A Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer","pyruvate","Recruiting","No Results Available","Prostate Cancer","Drug: Pyruvate (13C)","Difference in peak lactate/pyruvate conversion with histologic grade of prostate cancer|Safety As measured by Adverse Events|Optimal cut-off value of lactate/pyruvate that accurately detects primary Gleason 4 component cancer.","University of California, San Francisco","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","15557","March 22, 2016","December 2019","December 2020","August 18, 2015","null","October 23, 2018","University of California, San Francisco, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT02526368"
1096,"NCT02524236","Effect of 50 and 100 IU Doses of Botox A Toxin Injection in BPH Patients.",,"Completed","No Results Available","Benign Prostatic Hyperplasia","Drug: Botox injection in the prostate","IPSS score improvement|Urinary flow rate","Beni-Suef University","Male","50 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1 Urology","August 2015","November 2016","November 2016","August 14, 2015","null","February 20, 2017","Beni - Suef University, Beni Suef, Egypt","","https://ClinicalTrials.gov/show/NCT02524236"
1097,"NCT02520882","68Ga-NOTA-Aca-BBN(7-14) PET/CT in Patients With Primary Gliomas",,"Unknown status","No Results Available","Glioma","Drug: 68Ga-NOTA-Aca-BBN|Device: PET/CT","Standardized uptake value of 68Ga-NOTA-Aca-BBN(7-14) in primary glioma|Adverse events collection","Peking Union Medical College Hospital|National Institute for Biomedical Imaging and Bioengineering (NIBIB)","All","3 Years to 70 Years   (Child, Adult, Older Adult)","Early Phase 1","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PUMCHNM11|ZIAEB000073","January 2015","December 2017","December 2017","August 13, 2015","null","April 7, 2017","Peking Union Medical College Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT02520882"
1098,"NCT02517502","Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy",,"Active, not recruiting","No Results Available","Cognitive Dysfunction","Drug: DHA|Drug: Placebo","Number of potentially eligible subjects who consent to participate in the study.|Number of enrolled subjects who complete all cognitive assessments at all three defined timepoints.|Number of enrolled subjects who take at least 70% of prescribed study agent.|Number of subjects reporting serious adverse events|Change in Cognitive Ability-General Concerns Questionnaire|Change in Cognitive Ability-Abilities Questionnaire|Change in Quality of Life Questionnaire|Level of Physical Activity Questionnaire|Change in Cognitive Function test|Measurement of Cognitive Function Mobile Cognitive Assessment Battery (MCAB) Questionnaire","Carol Fabian, MD|DSM Nutritional Products, Inc.|University of Kansas Medical Center","Female","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","STUDY00002415","July 2015","June 2018","December 2018","August 7, 2015","null","January 17, 2018","Decatur Memorial Hospital, Decatur, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States","","https://ClinicalTrials.gov/show/NCT02517502"
1099,"NCT02515240","Immune Response to Pneumococcal Vaccination in HIV Infected Individuals",,"Completed","No Results Available","Pneumococcal Infection","Biological: PPV23","Antibody activity and response by opsonophagocytic assay (OPT) and ELISA (ug/ml)|Polysaccharide-specific B cell phenotype: percentage naive or memory B cell distribution flow cytometry|Flow cytometry : percentage cells expressing tumor necrosis factor receptors on surface","University of Toledo Health Science Campus|National Institutes of Health (NIH)","All","19 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","124","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HIV PPV23|5R01AI081558","July 2010","June 2014","March 2015","August 4, 2015","null","August 7, 2015","The University of Toledo-Health Science Campus, Toledo, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02515240"
1100,"NCT02514876","Foresight Intracardiac Echocardiography (ICE) System",,"Completed","No Results Available","Atrial Fibrillation","Device: Foresight ICE System","Successful transseptal puncture during atrial fibrillation ablation procedure under the guidance of study device","Conavi","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","EXT-001","September 2015","April 8, 2016","May 5, 2016","August 4, 2015","null","April 24, 2017","Southlake Regional Health Centre, Newmarket, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02514876"
1101,"NCT02514837","Microwave Radiometry for the Diagnosis and Monitoring of Breast Cancer","RTM","Unknown status","No Results Available","Breast Cancer","Device: RTM","Sensitivity of the RTM device|Predictability of the method","University of Edinburgh","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","300","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RTM 2015","September 2015","February 2016","February 2016","August 4, 2015","null","August 4, 2015","","","https://ClinicalTrials.gov/show/NCT02514837"
1102,"NCT02511197","68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis",,"Unknown status","No Results Available","Pulmonary Fibrosis, Unspecified","Drug: 68Ga-NOTA-PRGD2|Device: PET/CT","Visual assessment of lung lesions|Semiquantitative assessment of lung lesions|Adverse events collection|Routine blood test|Serum albumin|Routine urine test","Peking Union Medical College Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PUMCHNM10","May 2015","December 2017","December 2017","July 29, 2015","null","April 6, 2017","Peking Union Medical College Hospital, Beijing, China","","https://ClinicalTrials.gov/show/NCT02511197"
1103,"NCT02511028","In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging",,"Enrolling by invitation","No Results Available","Multiple Sclerosis","Drug: Ferumoxytol","Change in gradient-echo T2*-weighted signal in an iron-rich brain structure, the globus pallidus","National Institutes of Health Clinical Center (CC)|National Institute of Neurological Disorders and Stroke (NINDS)","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","13","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","150156|15-N-0156","July 28, 2015","June 30, 2019","June 30, 2019","July 29, 2015","null","August 9, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02511028"
1104,"NCT02508584","Personalized Immunotherapeutic for Antibiotic-resistant Infection",,"Enrolling by invitation","No Results Available","Infection|Immune Deficiency|Hypogammaglobulinemia|Septic Arthritis|Mycoplasma Hominis","Biological: anti-mycoplasma hominis antibodies","Presence or absence of mycoplasma hominis cultured from joint and wound fluid|Patency of fistula as assessed by clinical exam|Pain reduction as measured by pain scale and amount of pain medication required","Brigham and Women's Hospital","Male","Child, Adult, Older Adult","Early Phase 1","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015P001027","April 12, 2016","December 2017","December 2017","July 27, 2015","null","February 1, 2017","Brigham and Women's Hosptial, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02508584"
1105,"NCT02506894","Fetal Middle Cerebral Artery Doppler in Preterm Births Receiving Magnesium Sulfate for Neuroprotection",,"Completed","No Results Available","Preterm Birth","Drug: Magnesium Sulfate|Other: 0.9% sodium chloride solution","changes in fetal middle cerebral artery Doppler indices|maternal adverse effects of magnesium sulfate","Cairo University","Female","20 Years to 40 Years   (Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Mgso4 for neuroprotection","July 2015","November 2015","November 2015","July 23, 2015","null","February 1, 2016","Cairo University, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT02506894"
1106,"NCT02506335","Liver Function Measured by HepQuant-SHUNT in the Prediction of Outcomes in Patients With Heart Disease",,"Completed","No Results Available","Liver Disease|Cardiovascular Disease","Drug: Cholate testing","Liver Function","Northwestern University|University of Colorado, Denver","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","STU00100794","September 1, 2015","May 1, 2018","May 1, 2018","July 23, 2015","null","August 22, 2018","","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02506335/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02506335"
1107,"NCT02505516","BLADDER CANCER SCREENING AMONG DIABETIC PATIENTS",,"Completed","No Results Available","Bladder Cancer|Diabetes","Other: metformin","Number of diabetic patients on metformin therapy","UFUOMA MILLER FAKPOR|University of Cape Coast","All","25 Years to 86 Years   (Adult, Older Adult)","Early Phase 1","150","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Screening","021","June 2013","January 2014","February 2014","July 22, 2015","null","July 22, 2015","Universty of Capecoast, Cape Coast, Ghana","","https://ClinicalTrials.gov/show/NCT02505516"
1108,"NCT02505295","Selenium and Ischemic Stroke Outcome",,"Unknown status","No Results Available","Ischemic Stroke","Drug: Selenium|Drug: normal saline","National Institutes of Health Stroke Scale(NIHSS)|modified Rankin Scale (MRS)|Barthel index","Mazandaran University of Medical Sciences","All","20 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1421","July 2015","December 2015","July 2016","July 22, 2015","null","July 22, 2015","Athena Sharifi Razavi, Sari, Mazandaran, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT02505295"
1109,"NCT02503813","Does Venous pCO2 Increase by 20 mmHg or More During Apnea Challenge Test?",,"Unknown status","No Results Available","Brain Death","Procedure: venous blood gas","Change in venous blood CO2 during apnea challenge test|Change in End Tidal CO2 during apnea challenge test","MemorialCare Health System","All","Child, Adult, Older Adult","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","504-15","July 2015","July 2017","July 2017","July 21, 2015","null","July 21, 2015","Long Beach Memorial and Miller Children's & Women's Hospital Long Beach, Long Beach, California, United States","","https://ClinicalTrials.gov/show/NCT02503813"
1110,"NCT02501837","The Influence of Oxytocin on Pair-bonding and Emotion Regulation",,"Completed","No Results Available","Healthy","Drug: Syntocinon-Spray","Neural response to photographs of the partner|Neural response during the regulation of food craving|Attractiveness ratings of all stimuli|Arousal ratings of all stimuli|Food craving ratings","University Hospital, Bonn","Female","18 Years to 45 Years   (Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","OXT_BOND","July 2014","June 2015","June 2015","July 17, 2015","null","July 17, 2015","Department of Psychiatry, University of Bonn, Bonn, Germany","","https://ClinicalTrials.gov/show/NCT02501837"
1111,"NCT02500459","Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection",,"Recruiting","No Results Available","Brain Tumor|High Grade Glioma","Drug: topotecan|Device: Cleveland Multiport Catheter","Summary of number of adverse events by grade - A measure of treatment safety|The number of patients with abnormal hematology lab reports|The number of patients with abnormal clinical chemistry lab reports|The number of patients with abnormal coagulation lab reports","Michael Vogelbaum, MD, PhD|Infuseon Therapeutics, Inc.|Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INFT1315","July 6, 2015","December 2018","December 2019","July 16, 2015","null","January 25, 2018","Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02500459"
1112,"NCT02498886","IHAT Absorption Kinetics",,"Completed","No Results Available","Iron-deficiency Anemia","Dietary Supplement: IHAT|Dietary Supplement: Ferrous sulphate","Relative bioavailability value of IHAT versus ferrous sulphate|Serum iron|Transferrin saturation|Pathogen Growth|Plasma iron","Medical Research Council","Female","18 Years to 45 Years   (Adult)","Early Phase 1","34","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","1422","August 2015","March 2016","March 2016","July 15, 2015","null","February 6, 2017","MRC Unit The Gambia, Keneba, West Kiang, Gambia","","https://ClinicalTrials.gov/show/NCT02498886"
1113,"NCT02498522","Effect of Metformin on Early Pregnancy Loss in Pregnant Women With Polycystic Ovarian Syndrome","MIP","Completed","Has Results","Polycystic Ovary Syndrome","Drug: Metformin","Miscarriage Rate","Ain Shams University","Female","25 Years to 35 Years   (Adult)","Early Phase 1","166","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Metformin in pregnancy","August 2015","February 2016","March 2016","July 15, 2015","May 19, 2016","May 19, 2016","Faculty of Medicine, Ain Shams University, Cairo, Al Qahirah, Egypt","","https://ClinicalTrials.gov/show/NCT02498522"
1114,"NCT02498379","PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis (Volunteer - BioD and Safety Study)",,"Completed","No Results Available","Atherosclerosis","Drug: Cu[64]-25%CANF-Comb","Biodistribution, dosimetry and safety of Cu[64]-25%CANF-Comb in normal healthy adult volunteers.","Washington University School of Medicine","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201409006V","October 2014","April 2015","April 2015","July 15, 2015","null","April 28, 2016","Washington University in St.Louis, St.Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02498379"
1115,"NCT02497833","Retinoic Acid Supplementation and Subjects With Hypercholesterolemia",,"Completed","No Results Available","Hypercholesterolemia","Dietary Supplement: retinoic acid|Other: placebo","PON1 activity|Lp-PLA2 activity","Sun Yat-sen University","All","25 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ZXYZM-2","November 2014","May 2015","May 2015","July 15, 2015","null","July 15, 2015","Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Department of Nutrition, School of Public Health, Sun Yat-Sen University (Northern Campus), Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT02497833"
1116,"NCT02494674","Using Bite Counter for Weight Loss: A One-month Usability Trial to Test the Effectiveness of Using the Bite Counter","Bites","Completed","No Results Available","Obesity","Behavioral: Bite Counter tracking","Body Weight (kg)|Energy intake (kilocalories)","University of South Carolina","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00036795","July 2015","August 2015","November 2015","July 10, 2015","null","February 29, 2016","University of South Carolina, Columbia, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT02494674"
1117,"NCT02493959","Degradation of the Anorexic Hormone Peptide YY",,"Completed","No Results Available","Healthy","Biological: PYY1-36 infusion|Biological: PYY1-36 + sitagliptin|Biological: PYY3-36 infusion|Biological: placebo","PYY3-34 concentration|Half-lives of PYY1-36 and PYY3-36","Hvidovre University Hospital|University of Copenhagen","Male","18 Years to 50 Years   (Adult)","Early Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","STKBM-PI14","May 2014","July 2015","July 2015","July 10, 2015","null","July 10, 2015","Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark","","https://ClinicalTrials.gov/show/NCT02493959"
1118,"NCT02491164","Exploratory Study of Intrapulmonary Microdosing of Gram-negative Optical Imaging Detection Probe","BAC TWO","Recruiting","No Results Available","Respiratory Infections","Other: BAC TWO|Device: FE and Cellvizio viewer software","Imaging parameters of BAC TWO in the distal lung","University of Edinburgh|NHS Lothian","All","16 Years and older   (Child, Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","BAC TWO","April 2016","June 2018","June 2018","July 7, 2015","null","February 20, 2018","Royal Infirmary Edinburgh, Edinburgh, United Kingdom","","https://ClinicalTrials.gov/show/NCT02491164"
1119,"NCT02490930","A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma",,"Completed","No Results Available","Glioblastoma|Anaplastic Astrocytoma","Drug: Fingolimod","Incidence of severe infection attributable to fingolimod-induced lymphopenia|Total lymphocyte counts (TLC)","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","J14168|IRB00055036","July 2015","September 2017","September 2017","July 7, 2015","null","September 13, 2017","The Johns Hopkins University, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02490930"
1120,"NCT02488018","Investigation of the Glycemic Index of Ethiopian Honey",,"Completed","Has Results","Hyperglycemia, Postprandial","Biological: Provision of experimental honey","Examine Effect of Monofloral Honey Types on Glycemic Index of Health Human Subjects","Addis Ababa University","All","20 Years to 24 Years   (Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Honey-1","June 2015","November 2015","February 2016","July 2, 2015","December 28, 2016","December 28, 2016","","","https://ClinicalTrials.gov/show/NCT02488018"
1121,"NCT02486510","Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication","CHEMOMAR","Terminated","No Results Available","HIV-1 Infection","Drug: Maraviroc","number of resting memory CD4+ T cells latently infected with replicative HIV-1, expressed as IUPM|Proviral DNA (copies/million cells)|Effector T cells producing HIV-1 specific gamma interferon (cells/mm3)|Levels of HIV-1 antibodies|Percentage of CD4+ and CD8+ cells with immune activation markers","Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","7","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHEMOMAR","July 2012","December 2015","December 2015","July 1, 2015","null","December 18, 2015","Hospital Universitario Ramon Y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT02486510"
1122,"NCT02486458","Long-term Release of Fluoride Formed on Enamel by Fluoride Gel or Varnish to Biofilm Fluid",,"Completed","No Results Available","Dental Caries","Drug: 5% sodium fluoride varnish|Drug: 1.23% sodium fluoride acidic gel","Change in fluoride concentration in enamel days after fluoride application|Change in fluoride concentration in dental biofilm fluid days after fluoride application|Change in fluoride concentration in whole biofilm days after fluoride application","University of Campinas, Brazil","All","18 Years to 30 Years   (Adult)","Early Phase 1","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","FOPBioq005","April 2015","December 2015","December 2016","July 1, 2015","null","May 9, 2017","Unochapecó, Chapecó, Santa Catarina, Brazil","","https://ClinicalTrials.gov/show/NCT02486458"
1123,"NCT02486367","Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR)",,"Recruiting","No Results Available","Aortic Stenosis|Inflammation|Thrombosis","Drug: Clopidogrel|Drug: Ticagrelor","Platelet reactivity|Inflammatory monocyte proportion","University Hospitals Cleveland Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","UH IRB # 06-14-33","June 2015","December 2018","December 2018","July 1, 2015","null","May 1, 2018","UH Cleveland Medical Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02486367"
1124,"NCT02485886","68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary Fibrosis",,"Unknown status","No Results Available","Idiopathic Pulmonary Fibrosis","Drug: 68Ga-BMV101","Visual and semiquantitative assessment of lesions|Blood pressure|Pulse|Respiration frequency|Temperature|Routine blood test|Routine urine test|Serum alanine aminotransferase|Serum albumin|Serum creatinine|Adverse events collection","Peking Union Medical College Hospital|Stanford University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PUMCHNM09","January 2015","December 2017","December 2017","June 30, 2015","null","April 7, 2017","Peking Union Medical College Hospital, Beijing, China","","https://ClinicalTrials.gov/show/NCT02485886"
1125,"NCT02485145","The Analgesic Activity of a Topical Formulation in Patients With Osteoarthritis of the Hands",,"Unknown status","No Results Available","Osteoarthritis of the Hands","Drug: A/B|Drug: Placebo|Drug: B/A","100 mm Visual Analog Scale|Australia/Canadian Osteoarthritis Index|Composite Pharmacokinetics|Use of rescue medication","Transdermal Therapeutics, Inc.|Albert Einstein College of Medicine, Inc.|Montefiore Medical Center","All","40 Years to 79 Years   (Adult, Older Adult)","Early Phase 1","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","54321","July 2015","December 2015","March 2016","June 30, 2015","null","June 30, 2015","","","https://ClinicalTrials.gov/show/NCT02485145"
1126,"NCT02484053","Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders",,"Completed","No Results Available","Hematologic Disorders|Oncologic Disorders|Rheumatologic Disorders","Drug: Rituximab","To determine the safety of rapid infusion rituximab in a pilot group of adolescent patients for hematologic, oncologic, and rheumatologic disorders.|To determine the incidence of infusion-related reactions with the administration of rapid infusion rituximab","Baylor College of Medicine|Texas Children's Hospital","All","1 Year to 19 Years   (Child, Adult)","Early Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-35628 Rituximab","June 2015","January 2017","January 2017","June 29, 2015","null","July 11, 2018","Texas Children's Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02484053"
1127,"NCT02481609","NAC Trial for Anosmia",,"Completed","No Results Available","Anosmia","Drug: N-acetyl cysteine (NAC)","Change in the Smell Identification Test score|Change in Sino-Nasal Outcome Test (SNOT-20) score","University of Miami","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","29","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20130996","July 2014","December 1, 2017","December 1, 2017","June 25, 2015","null","March 20, 2018","University of Miami, Miller School of Medicine, Clinical Research Building, Miami, Florida, United States","","https://ClinicalTrials.gov/show/NCT02481609"
1128,"NCT02478814","Protein Requirements In Active Populations",,"Active, not recruiting","No Results Available","Increased Metabolic Requirement|Healthy","Dietary Supplement: Amino Acid Intake","13CO2 (carbon dioxide) excretion (μmol/kg/h)|13C-Phenylalanine Oxidation (μmol/kg/h)","University of Toronto|Ajinomoto Co., Inc.","Male","18 Years to 35 Years   (Adult)","Early Phase 1","7","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IAAO-YM","April 2015","June 2016","December 2017","June 23, 2015","null","May 2, 2017","","","https://ClinicalTrials.gov/show/NCT02478814"
1129,"NCT02478801","Protein Requirements in Endurance-trained Athlete","EP","Completed","No Results Available","Increased Metabolic Requirement|Healthy","Dietary Supplement: amino acids intake","13CO2 (carbon dioxide) excretion (μmol/kg/h)|[13C]phenylalanine oxidation (μmol/kg/h)","University of Toronto|Ajinomoto Co., Inc.","Male","18 Years to 35 Years   (Adult)","Early Phase 1","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IAAO-E","March 2015","January 2016","May 2016","June 23, 2015","null","June 16, 2016","","","https://ClinicalTrials.gov/show/NCT02478801"
1130,"NCT02476734","FDG-PET/CT Imaging as Early Predictor of DP",,"Active, not recruiting","No Results Available","Lymphoma","Biological: CART-19 autologous T-cells|Radiation: FDG-PET/CT","NUmber of Adverse Events","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","9","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 12914","August 2014","February 2016","August 2018","June 19, 2015","null","March 14, 2018","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02476734"
1131,"NCT02474849","Pharmacokinetic Study Comparing Nicotine Delivery From E-cigarettes and a Conventional Cigarette in Healthy Subjects",,"Completed","No Results Available","Healthy Volunteers","Other: Use electronic cigarette or smoke conventional cigarette","Plasma nicotine concentration (Cmax)|Plasma nicotine concentration (Tmax)|Plasma nicotine concentration (AUC0-60)|Change in heart rate|Number of puffs taken|Duration of puffs taken|Subjective measurement of product satisfaction","British American Tobacco (Investments) Limited|LA Clinical Trials","All","21 Years to 55 Years   (Adult)","Early Phase 1","18","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","BAT4215006","June 2015","August 2015","August 2015","June 18, 2015","null","September 15, 2015","Los Angeles Clinical Trials, Burbank, California, United States","","https://ClinicalTrials.gov/show/NCT02474849"
1132,"NCT02473406","Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Necrotising Acute Pancreatitis",,"Recruiting","No Results Available","Pancreatitis, Acute Necrotizing","Drug: Thymosin Alpha 1|Drug: physiological saline","Occurrence of pancreatic infection:","Weiqin Li|The First Affiliated Hospital of Nanchang University|Zhejiang Provincial People’s Hospital|Nantong people's Hospital|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Nanjing University School of Medicine","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","510","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","TRACE trial","March 27, 2018","June 30, 2019","December 30, 2019","June 16, 2015","null","November 15, 2018","Department of SICU, Research Institute of General Surgery Jinling Hospital, Nanjing, Jiangsu, China, Nanjing, Jiangsu, China|Jinling Hospital, Nanjing, Jiangsu, China","","https://ClinicalTrials.gov/show/NCT02473406"
1133,"NCT02469259","The Effects of Oxytocin on Startle Hyperreactivity in Patients With AUD and PTSD","POP","Unknown status","No Results Available","Stress Disorders, Post-Traumatic|Alcoholism","Drug: Oxytocin|Other: Placebo","Social Perception measured by score on the Reading the Eyes in the Mind Test|Alcohol Approach Bias measured by score on the Approach Avoidance Task|Startle Hyperactivity measured by heart rate change score in response to startle stimuli","University of California, San Francisco","All","18 Years to 55 Years   (Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","15-16676","February 2016","August 2016","August 2016","June 11, 2015","null","May 12, 2016","San Francisco Veterans Affairs Medical Center, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT02469259"
1134,"NCT02469129","PET Imaging of PARP Activity in Cancer",,"Recruiting","No Results Available","Cancer","Drug: [18F]FluorThanatrace","Whole body effective dose and doses to critical organs (in rems) of a 10 millicurie (mCi) injection of [18F]FTT|[18F]FTT maximum standard uptake value (SUV) in tumors|Distribution volume ratio (DVR) of [18F]FTT in tumors by Logan plot analysis|PARP enzyme activity|% positive poly(ADP)ribosylated (PAR) cells by immunohistochemistry","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201410102","March 2015","July 2020","July 2020","June 11, 2015","null","July 23, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02469129"
1135,"NCT02468492","Pilot Synovial Fluid Molecular/Stem Cell Response to PRP in Knee Osteoarthritis: Clinical & Imaging Outcome Correlation",,"Completed","No Results Available","Knee Osteoarthritis","Biological: Platelet Rich Plasma|Other: Normal Saline","Biochemical Molecular Outcomes|Clinical Outcomes|Imaging Outcomes","Hunter Holmes Mcguire Veteran Affairs Medical Center|Foundation for Physical Medicine and Rehabilitation","All","40 Years and older   (Adult, Older Adult)","Early Phase 1","18","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","IRB #01979/FDA IDE#15944","September 2014","November 2015","November 2015","June 10, 2015","null","August 16, 2017","Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT02468492"
1136,"NCT02467803","Shoulder Functional Outcomes of Patients With Proximal Humerus Fractures: Comparison of Two Different Treatment Protocol",,"Unknown status","No Results Available","Humeral Fracture","Other: Scapula mobilization|Other: Shoulder ROM exercises","Constant Score","Hacettepe University","All","30 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","GO13/55","June 2015","January 2016","null","June 10, 2015","null","June 10, 2015","","","https://ClinicalTrials.gov/show/NCT02467803"
1137,"NCT02467738","Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck Cancer",,"Active, not recruiting","No Results Available","Recurrent Head and Neck Carcinoma","Radiation: Brachytherapy|Drug: Cesium-131|Procedure: Conventional surgery","Disease free survival (DFS)|Incidence of toxicity|Recurrence rate|Overall survival|Complication rate|Adverse event rate","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15D.067|2014-112","March 17, 2015","November 6, 2019","January 2020","June 10, 2015","null","August 21, 2018","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02467738"
1138,"NCT02467400","Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism",,"Active, not recruiting","No Results Available","Osteoporosis, Age-Related","Drug: Atenolol|Drug: Nebivolol|Drug: Propranolol|Drug: placebo","Ratio of serum bone formation to bone resorption marker","Mayo Clinic","Female","50 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","165","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","14-004305","July 2015","October 26, 2017","December 2018","June 10, 2015","null","January 5, 2018","Mayo Clinic in Rochester, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02467400"
1139,"NCT02466828","qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia.",,"Completed","No Results Available","Glioblastoma|Hypoxia","Drug: Feraheme®","Oxygen saturation in GBM with qBOLD MRI and its correlation with histological markers of tissue hypoxia and angiogenesis|Oxygen saturation in GBM with qBOLD MRI and its correlation with targeted intraoperative oxygen measurement","Sunnybrook Health Sciences Centre|St. Michael's Hospital, Toronto","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","127-2014","March 2015","April 2018","April 2018","June 9, 2015","null","April 18, 2018","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02466828"
1140,"NCT02465749","Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa",,"Not yet recruiting","No Results Available","Retinitis Pigmentosa","Drug: Continuous oxygen|Device: blue light-absorbing sunglasses|Drug: Compound thrombosis capsule sig: 1.5g/tid|Drug: Ginkgo biloba pills sig: 300mg/tid;|Drug: Vitamin B sig: 10mg/tid|Drug: Vitamin AD sig: 1 tablet/tid","the percentage of patients preserved 80% of the initial visual acuity at 5 years follow-up.|ERG b-wave mean values|Change of visual field|Fundus changes of fluorescence fundus angiography|Retinal vessel oxygen saturation|intra-ocular pressure|blood pressure|Finger pulse oxygen saturation|the mutant genes of retinitis pigmentosa","Sun Yat-sen University|Zhujiang Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Guangzhou Jeeyor Medical Research Co.,Ltd.","All","18 Years to 60 Years   (Adult)","Early Phase 1","404","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZOC20150503","May 2015","June 2025","June 2025","June 8, 2015","null","June 8, 2015","State Key Laboratory of Ophthalmology,Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT02465749"
1141,"NCT02463994","A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC",,"Active, not recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: MPDL3280A|Radiation: Hypofractionated Radiotherapy","The number of participants that respond to a combination of HIGRT and MPDL3280A (PD-L1)","University of Michigan Cancer Center|University of Washington","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMCC 2015.005|HUM00100387","October 2015","July 2020","July 2020","June 8, 2015","null","March 7, 2018","The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|University of Washington, Seattle, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT02463994"
1142,"NCT02463383","Effect of PPARγ2 Polymorphism and NSAIDs on Acute Alcohol-induced Changes in Serum Estrogens Among Post-menopausal Women","EPPNASE","Completed","No Results Available","Breast Cancer","Drug: Ibuprofen Tab 400 MG|Drug: Placebo tab","Serum estrone sulphate (pmol/l)|Serum estrone (pmol/l)|Serum SHBG (nmol/l)|Serum ethanol (g/l)|Serum metabolomics (relative metabolite intensity)|Urine metabolomics (relative metabolite intensity)","Professor Lars Ove Dragsted|Technical University of Denmark|University of Copenhagen","Female","50 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","25","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","M215","September 2013","October 2014","December 2015","June 4, 2015","null","December 12, 2017","Department of Nutrition, Exercise and Sports, University of Copenhagen, Frederiksberg, Denmark","","https://ClinicalTrials.gov/show/NCT02463383"
1143,"NCT02463305","Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD)",,"Recruiting","No Results Available","Colitis, Ulcerative","Drug: Creatine monohydrate|Other: Placebo","Improvement in endoscopic assessment of mucosal inflammation in ulcerative colitis.|Clinical response in ulcerative colitis disease activity.|Intestinal permeability|Patient symptom severity|Colonic inflammation|Creatine kinase modulation|Clinical remission of ulcerative colitis disease activity.|Creatine modulation","University of Colorado, Denver","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","13-3054|UL1TR001082","April 2016","December 2019","December 2019","June 4, 2015","null","October 26, 2017","University of Colorado Hospital, Denver, Colorado, United States","","https://ClinicalTrials.gov/show/NCT02463305"
1144,"NCT02460705","Fecal Microbiota Transplant for Inflammatory Bowel Disease",,"Completed","No Results Available","Inflammatory Bowel Disease","Drug: Biologically active human fecal material, OpenBiome","Clinical improvement of IBD|Efficacy of FMT treatment","University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","59","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-16617","June 2015","December 20, 2016","November 4, 2017","June 2, 2015","null","June 21, 2018","UCSF Division of Gastroenterology at Mount Zion, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT02460705"
1145,"NCT02460107","Botulinum Toxin Type A for Neuropathic Pain in Patients With Diabetic Peripheral Polyneuropathy","BTXADMPPNP","Terminated","No Results Available","Neuralgia","Biological: Botulinum toxin type A|Other: Normal saline","Pain intensity using numeric rating scale|Quality of life using WHOQOL","Catholic University of Korea Saint Paul's Hospital|Medy-Tox","All","20 Years and older   (Adult, Older Adult)","Early Phase 1","9","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CatholicUKSPH","May 2015","November 30, 2016","December 31, 2016","June 2, 2015","null","August 8, 2017","St. Paul's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02460107"
1146,"NCT02459600","Comparison of Refraction Measurments in Children Under General Anesthesia, With and Without Cycloplegic Drops",,"Unknown status","No Results Available","General Anesthesia","Other: instulling cyclopentolate drops in the eye","difference in refraction results with and without cyclopentolate drops under general anesthesia","Soroka University Medical Center","All","1 Year to 12 Years   (Child)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","SOR026014CTIL","May 2015","May 2016","May 2016","June 2, 2015","null","June 2, 2015","Soroka, Beer Sheva, Israel","","https://ClinicalTrials.gov/show/NCT02459600"
1147,"NCT02457988","The Cirrhosis Outpatient Optimization, Readmission & Safety Study","Vivify","Terminated","No Results Available","Cirrhosis","Device: Vivify Kit","Number of 30-day readmissions between intervention and control group|Number of emergency room visits between the two study groups for ED visits within 30 days post discharge. (composite measure)|Blood pressure control|Weight compliance|Medication compliance","University of California, Los Angeles","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","COORS","April 2015","October 2017","March 2018","May 29, 2015","null","October 26, 2017","UCLA Center for Inflammatory Bowel Diseases, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02457988"
1148,"NCT02456311","Pulmonary Artery Harmonic Ace+7 Energy Sealing in Open Lobectomy",,"Completed","No Results Available","Lung Cancer","Device: HARMONIC ACE+7","Effective intra-operative pulmonary arterial branch vessel sealing measured by presence or lack of vessel sealing failure (binary outcome: yes/no).","Centre hospitalier de l'Université de Montréal (CHUM)|Centre de Recherche du Centre Hospitalier de l'Université de Montréal","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CE 14.380","May 2015","October 2015","October 2015","May 28, 2015","null","November 26, 2015","Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT02456311"
1149,"NCT02454426","Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease",,"Withdrawn","No Results Available","Major Depressive Disorder|Coronary Artery Disease","Drug: Vortioxetine","Severity of depressive episodes measured using the Montgomery-Asberg Depression Rating Scale (MADRS)","Thomas Jefferson University|Takeda","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TakedaHRV","April 2016","June 2016","June 2016","May 27, 2015","null","August 25, 2016","Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02454426"
1150,"NCT02452216","Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS",,"Completed","No Results Available","Brain Injury|Central Nervous System Degenerative Disorder|Central Nervous System Infectious Disorder|Central Nervous System Vascular Malformation|Hemorrhagic Cerebrovascular Accident|Ischemic Cerebrovascular Accident|Primary Brain Neoplasm|Brain Cancer|Brain Tumors","Drug: Ferumoxytol|Other: Tissue Analysis|Procedure: Magnetic Resonance Imaging","Obtain measurements of iron concentration (indicative of ferumoxytol uptake) on T2*-weighted MR images.|Determine the number of macrophages in resected/biopsied samples at histopathology.","Michael Iv|Stanford University","All","2 Years and older   (Child, Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","BRNCNS0007|NCI-2015-00435|26570","June 10, 2015","January 12, 2017","January 12, 2017","May 22, 2015","null","August 31, 2017","Stanford University Hospitals and Clinics, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT02452216"
1151,"NCT02450942","18F-FDS PET/CT in Healthy Volunteers and Patients With Suspected Infection",,"Unknown status","No Results Available","Enterobacteriaceae Infections","Drug: 18F-FDS","Visual and semiquantitative assessment of lesions and biodistribution|Blood pressure|Pulse|Respiration frequency|Temperature|Routine blood test|Routine urine test|Serum alanine aminotransferase|Serum albumin|Serum creatinine|Adverse events collection","Peking Union Medical College Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PUMCHNM08","January 2015","January 2018","March 2018","May 21, 2015","null","April 7, 2017","Peking Union Medical College Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT02450942"
1152,"NCT02450201","MRI With C13 Pilot Study Prostate Cancer",,"Terminated","No Results Available","Prostate Cancer","Drug: Pyruvate","Difference in peak lactate/pyruvate ratio|Pyruvate area under the curve (AUC)|Lactate area under the curve (AUC)|Safety As measured by Adverse Events","University of California, San Francisco","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","125518","October 12, 2016","January 17, 2017","January 17, 2017","May 21, 2015","null","October 23, 2018","University of California, San Francisco, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT02450201"
1153,"NCT02449577","Identification of Biomarkers for Acute Intake of Beer and Alcohol and Acute Effects on Plasma and Insulin Response","METABEER","Completed","No Results Available","Alcohol Consumption|Insulin Resistance","Other: Beverage sequence ABCD|Other: Beverage sequence CADB|Other: Beverage sequence DACB|Other: Beverage sequence CBAD|Other: Beverage sequence ABDC|Other: Beverage sequence DABC|Other: Beverage sequence DCAB|Other: Beverage sequence DBCA|Other: Beverage sequence ADCB|Other: Beverage sequence BADC|Other: Beverage sequence ACDB","Area under the curve (AUC) for glucose|Area under the curve for insulin|Plasma concentration of fatty acid ethyl esters (FAEE)|Blood level of ethanol|Plasma beer metabolites (metabolic profiling with NMR and mass spectrometry).|Urinary content of paraaminobenzoic acid (PABA)|Urinary content of ethyl glucuronide (EtG) and ethyl sulphate (EtS)|Blood content of ethyl glucuronide (EtG) and ethyl sulphate (EtS)|Urinary content of acetaldehyde (ethanal)|Urinary compounds of beer metabolites|Blood pressure|Body fat mass and body fat percentage|Urinary creatinine","University of Copenhagen|Carlsberg Breweries A/S","All","18 Years to 60 Years   (Adult)","Early Phase 1","19","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","M212","May 2013","June 2013","June 2013","May 20, 2015","null","May 20, 2015","Department of Nutrition, Exercise and Sports, University of Copenhagen, Frederiksberg C, Denmark","","https://ClinicalTrials.gov/show/NCT02449577"
1154,"NCT02448732","Exploratory Clinical Trials of ACM-1 in the Treatment of Ophthalmological Neovascular Diseases",,"Unknown status","No Results Available","Neovascularization, Pathologic","Drug: ACM-1","fluorescence fundus angiography|intra-ocular pressure|optical coherence tomography|Retinal Oximetry|blood pressure|ocular inflammatory response|morphological changes of the anterior segment|Corneal Endothelium Cell Counter|adverse event|morphological changes of the posterior segment","Sun Yat-sen University","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Sun Yat-sen Un","December 2014","April 2016","June 2016","May 19, 2015","null","May 20, 2015","State Key Laboratory of Ophthalmology,Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT02448732"
1155,"NCT02448030","Effects of Functional Electrical Stimulation on Metaboreflex Activation in Healthy Individuals",,"Unknown status","No Results Available","Reduction of Blood Flow","Other: Functional electric stimulation|Other: Isometric exercise","Forearm and calf blood flow change|Maximum muscle strength|Peripheral vascular resistance","Hospital de Clinicas de Porto Alegre","All","35 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","14-0359","March 2015","December 2015","March 2016","May 19, 2015","null","May 20, 2015","Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil","","https://ClinicalTrials.gov/show/NCT02448030"
1156,"NCT02447224","Pilot Trial of Antibiotics Versus Surgery for Treating Acute Appendicitis",,"Completed","No Results Available","Acute Uncomplicated Appendicitis","Drug: 1 gm IV ertapenem at enrollment|Drug: 1 gm IV ertapenem at Day 2 and oral metronidazole and cefdinir to complete 10 days|Procedure: Appendectomy","Major Complications|Recurrent appendicitis|QOL outcomes","Olive View-UCLA Education & Research Institute|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","5 Years and older   (Child, Adult, Older Adult)","Early Phase 1","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1R21DK102048","March 2015","October 2015","December 31, 2017","May 18, 2015","null","April 10, 2018","Olive View-UCLA Medical Center, Sylmar, California, United States","","https://ClinicalTrials.gov/show/NCT02447224"
1157,"NCT02447055","Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma",,"Withdrawn","No Results Available","Multiple Myeloma|Myeloma-Multiple","Biological: Tocilizumab|Drug: Melphalan|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Tacrolimus|Drug: Mycophenolate mofetil|Drug: Filgrastim","Safety and tolerability of regimen as measured by grade and frequency of adverse events|Cumulative incidence and severity of acute GvHD|Cumulative incidence and severity of chronic GvHD|Non-relapse mortality (NRM)|Progression-free survival (PFS)|Overall survival (OS)|Time to neutrophil engraftment|Time to platelet engraftment","Washington University School of Medicine","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201508102","December 2015","June 2016","June 2016","May 18, 2015","null","July 12, 2016","","","https://ClinicalTrials.gov/show/NCT02447055"
1158,"NCT02446431","Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence","Metronomic","Recruiting","No Results Available","Solid Tumor","Drug: Bevacizumab|Drug: Cyclophosphamide|Drug: Valproic Acid|Drug: Temsirolimus","5 year Event Free Survival|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Site(s) of relapse|Composite Cost of Treatment|Fatigue scores on the PedsQL Fatigue Scale|Pain scores on the Present Functioning Scale|Quality of Life scores on the PedsQL Quality of Life Scale","Miller Children's & Women's Hospital Long Beach|Children’s Hospital of Orange County","All","12 Months to 31 Years   (Child, Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","001","July 2014","July 2024","July 2029","May 18, 2015","null","May 18, 2015","Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States|Children's Hospital Orange County, Orange, California, United States","","https://ClinicalTrials.gov/show/NCT02446431"
1159,"NCT02445781","Differing Levels of Hypoglycemia",,"Recruiting","No Results Available","Hypoglycemia","Device: Glucose clamp","Flow mediated vasodilation of brachial artery measurements (mean maximum % change)","University of Maryland|Vanderbilt University","All","18 Years to 55 Years   (Adult)","Early Phase 1","32","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","00064405","July 2015","December 2018","December 2018","May 15, 2015","null","January 11, 2018","University of Maryland, Baltimore, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02445781"
1160,"NCT02445066","A Pilot Study to Examine the Effects of Vitamin D Supplementation on Mitochondrial Bioenergetics in Older Adults",,"Completed","No Results Available","Low 25-hydroxyvitamin D Concentrations","Dietary Supplement: Vitamin D3","Respirometric profiling|Lower extremity muscle power|Physical performance|Grip strength","Wake Forest University Health Sciences","All","65 Years to 89 Years   (Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00028235","October 2014","August 2017","August 2017","May 15, 2015","null","August 15, 2018","Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02445066"
1161,"NCT02444364","Effects of DPP-4 Inhibition on Calcium and Bone Metabolism in Type 2 Diabetes Mellitus",,"Withdrawn","No Results Available","Type 2 Diabetes","Drug: Sitagliptin","Change in Bone Turnover","University of Missouri-Columbia","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MERCK-200379","May 2015","January 2016","January 2016","May 14, 2015","null","June 1, 2017","University of Missouri-Columbia: Diabetes Center, Columbia, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02444364"
1162,"NCT02443727","The Role of Oxytocin in the Perception of Faces",,"Completed","No Results Available","Healthy","Drug: Syntocinon (synthetic oxytocin)|Other: Placebo","Functional Magnetic Resonance Imaging (fMRI) Data|Eye movements data|Implicit Attitudes toward infants|Theory of mind","Rodrigo Cardenas|U.S. National Science Foundation|Penn State University","null","18 Years to 25 Years   (Adult)","Early Phase 1","71","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","STUDY00001225","April 2015","December 2015","September 2016","May 14, 2015","null","May 31, 2017","","","https://ClinicalTrials.gov/show/NCT02443727"
1163,"NCT02442843","Non Invasive Brain Stimulation for PTSD",,"Completed","No Results Available","Posttraumatic Stress Disorder (PTSD)","Device: Active tDCS|Device: Sham tDCS","Functional Connectivity changes as assessed by fMRI images|Symptomatic changes as assessed by structured questionnaires (PCL-C)|Symptomatic changes as assessed by structured questionnaires (CAPS)|Symptomatic changes as assessed by structured questionnaires (Hamilton Depression Rating Scale)|Symptomatic changes as assessed by structured questionnaires (State-trait anxiety inventory)|Cognitive changes as assessed by Neuropsychological testing","University of Michigan|National Institute of Mental Health (NIMH)","Male","18 Years to 88 Years   (Adult, Older Adult)","Early Phase 1","18","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HUM00089481|1R21MH102539-01","May 2015","August 1, 2017","August 1, 2017","May 13, 2015","null","August 31, 2018","University of Michigan Neuropsychology Section, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02442843"
1164,"NCT02442739","Ketamine for Preventing Depression in Patients Undergoing Treatment for Pancreatic or Head and Neck Cancers",,"Withdrawn","No Results Available","Head and Neck Cancer|Pancreatic Cancer|Depression","Drug: Ketamine|Other: Placebo","Proportion of patients pre-screened that were potentially eligible for study participation.|Proportion of patients that were potentially eligible who were approached.|Proportion of approached patients that decline study participation and why.|Proportion of approached patients that agreed to participate.|Proportion of approached that were randomized.|Proportion of patients discontinuing prematurely from study treatment for any reason, including side effects attributed to ketamine or side effects attributed to placebo, documenting reasons for dropout.|Proportion of patients that are evaluable|Treatment-related adverse events|Patient-reported tolerability questionnaire (FIBSER)|Treatment expectancy and satisfaction as measured by the credibility/expectancy questionnaire (CEQ).","Cedars-Sinai Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IIT2015-22-IRWIN-KETPREVE|1R21CA197023-01A1","August 15, 2016","November 3, 2017","November 3, 2017","May 13, 2015","null","November 6, 2018","Cedars-Sinai Medical Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02442739"
1165,"NCT02442544","Prebiotic Fiber Supplement in T1DM Children",,"Active, not recruiting","No Results Available","Type 1 Diabetes","Dietary Supplement: Prebiotic|Dietary Supplement: Placebo","Glycemic control (serum hemoglobin A1c)|Gut microbiota composition (mRNA in stool)|Glycemic control (as measured by serum hemoglobin A1c)","University of Calgary","All","8 Years to 17 Years   (Child)","Early Phase 1","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OFSDM1","September 2015","June 2018","June 2018","May 13, 2015","null","May 2, 2018","Alberta Children's Hospital, Calgary, Alberta, Canada","","https://ClinicalTrials.gov/show/NCT02442544"
1166,"NCT02442466","Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma",,"Terminated","No Results Available","Melanoma","Drug: Endothelin Receptor B inhibitor BQ788|Drug: PBS","Tumour response by size measurement and histological examination|Measuring changes in tumor cell proliferation by histological analyses using Ab staining|Evaluation of changes in mRNA as well as protein expression levels of Endothelin Receptor B by PCR and Ab staining|Evaluation of changes in blood vessels formation by histological examination using Ab staining|Evaluation of changes in immune cell infiltration by histological examination using Ab staining","MelCure SA|California Institute of Technology|University of Bern|Universitaire Ziekenhuizen Leuven","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","5","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)","MelCure","May 2011","May 2012","null","May 13, 2015","null","May 20, 2015","","","https://ClinicalTrials.gov/show/NCT02442466"
1167,"NCT02441270","Evaluation of the Immunological Effects of a Combined Treatment With Radiation and Cyclophosphamide in Metastasized Breast Cancer Patients",,"Unknown status","No Results Available","Radiotherapy|Immunology","Drug: Cyclophosphamide|Radiation: Stereotactic body radiotherapy","Identification of the immunological effects, in peripheral blood and tumor biopsies, of the combined treatment with radiation and cyclophosphamide|Evaluation of the clinical/radiographical response of irradiated metastases|Evaluation of the response of non-irradiated metastases (the so-called ""abscopal effect"").","University Hospital, Ghent","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC 2015/0204","April 2015","October 2016","null","May 12, 2015","null","May 12, 2015","University Hospital - Radiotherapy Department, Ghent, Belgium","","https://ClinicalTrials.gov/show/NCT02441270"
1168,"NCT02439580","Effect of Annona Muricata Leaves on Colorectal Cancer Patients and Colorectal Cancer Cells",,"Completed","No Results Available","Colorectal Cancer","Dietary Supplement: Annona muricata extract|Dietary Supplement: Placebo","Nutritional Status|Cytotoxicity","Indonesia University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","406/H2.F1/ETIK/2013","October 2013","June 2014","October 2014","May 12, 2015","null","May 14, 2015","","","https://ClinicalTrials.gov/show/NCT02439580"
1169,"NCT02431273","Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women",,"Completed","No Results Available","Human Immunodeficiency Virus (HIV) Prophylaxis","Drug: TDF IVR|Drug: TDF-FTC IVR|Drug: TDF-FTC-MVC IVR","Safety of the Single, Dual and Triple ARV IVRs.|Pharmacokinetics of the Single, Dual and Triple ARV IVRs.|Acceptability of the IVRs.","Auritec Pharmaceuticals|The University of Texas Medical Branch, Galveston|Oak Crest Institute of Science|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","18 Years to 45 Years   (Adult)","Early Phase 1","6","Industry|Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ARV-IVR 01|2R44HD075636-02","June 2015","December 2016","December 2016","May 1, 2015","null","February 2, 2017","University of Texas Medical Branch, Galveston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02431273"
1170,"NCT02428361","Fecal Microbiota Transplant (FMT) for Pouchitis",,"Active, not recruiting","No Results Available","Pouchitis","Drug: Biologically active human fecal material, OpenBiome","Clinical improvement of pouchitis|Mucosal healing","Najwa Elnachef|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-15859","May 28, 2015","April 9, 2018","March 4, 2019","April 28, 2015","null","October 18, 2018","UCSF Division of Gastroenterology at Mount Zion, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT02428361"
1171,"NCT02427763","Microbiological and Epithelial Evaluation Related to the Use of Orthodontic Thermoplastic Device",,"Completed","No Results Available","Malocclusion|Orthodontic Appliance Complication","Device: hours of use (Essix)|Other: collect saliva|Other: collect biofilm|Other: collect epithelium","change in the amount of bacterias streptococcus mutans and lactobacillus sp. that adhere to thermoplastic device|change in the amount of bacterias streptococcus mutans that adhere to biofilm od the teeth|change in the amount of bacterias lactobacillus sp. that adhere to upper teeth|change in the amount of bacterias streptococcus mutans in the saliva|change in the amount of bacterias lactobacillus sp. in the saliva|Check any change in the epithelium","Universidade Positivo","All","16 Years to 40 Years   (Child, Adult)","Early Phase 1","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","luiza2014","October 2014","December 2014","March 2015","April 28, 2015","null","April 28, 2015","Universidade Positivo, Curitiba, PR, Brazil","","https://ClinicalTrials.gov/show/NCT02427763"
1172,"NCT02426853","Ultraviolet (UV) Photography in Adolescents",,"Active, not recruiting","No Results Available","Cancer Prevention","Behavioral: Questionnaires|Other: Photos|Behavioral: Pamphlets","Sun Protection Behavior Composite Score","M.D. Anderson Cancer Center","All","12 Years to 14 Years   (Child)","Early Phase 1","293","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2014-1037|NCI-2015-00764","April 2015","April 2019","April 2019","April 27, 2015","null","September 25, 2018","Houston Independent School District, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02426853"
1173,"NCT02424435","Methylprednisolone Treatment of Friedreich Ataxia",,"Completed","No Results Available","Friedreich Ataxia","Drug: Methylprednisolone","Change in the Timed 25 Foot Walk (T25FW) Score|Change in the Friedreich Ataxia Rating Scale (FARS) Score|Change in The 1-Minute Walk Distance|Change in the Change in the 9-Hole Peg Test (9HPT) Time","Children's Hospital of Philadelphia|Friedreich's Ataxia Research Alliance","All","5 Years and older   (Child, Adult, Older Adult)","Early Phase 1","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-011801","June 2015","December 2017","April 2018","April 23, 2015","null","May 23, 2018","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02424435"
1174,"NCT02424201","Comparative Study on the Effects of Sublingual Misoprostol in Addition to Standard AMTSL in Low Risk Parturients in LASUTH, Ikeja.",,"Unknown status","No Results Available","Primary Postpartum Haemorrhage","Drug: Misoprostol|Drug: vitamin c","mean blood loss|number of participants with untowards effects","Lagos State University","Female","15 Years to 45 Years   (Child, Adult)","Early Phase 1","660","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","LagosSU","June 2015","December 2015","February 2016","April 22, 2015","null","April 30, 2015","","","https://ClinicalTrials.gov/show/NCT02424201"
1175,"NCT02423252","Effects of a Psycho-cognitive Nursing Intervention on Patients' Outcomes in Critical Illness",,"Unknown status","No Results Available","Critical Illness|Stress|Inflammatory Response","Behavioral: Massage, Relaxation, Guided imagery and music listening.|Other: No Intervention","Change in Pain intensity [10-point numeric rating scale (NRS) scale]|Change in Pain intensity [Behavioral pain scale (BPS) scale]|Change in Pain intensity [critical-care pain observation tool (CPOT) scale]|Change in Systolic blood pressure (SBP)|Change in self reported Relaxation/calm levels (self- reported, 10 points NRS scale)|Change in Plasma Neuropeptide Y level|Change in Plasma Neuropeptide oxytocin level|Change in Plasma Neuropeptide beta-endorphin level|Change in Plasma Neuropeptide acetylcholine level|Change in Diastolic blood pressure (DAP)|Change in Mean arterial pressure (MAP)|Change in Heart rate (HR)|Change in Respiration rate (RR)|Change in Temperature (TMP)|Sequential organ failure assessment (SOFA) scores|Multiple organ disfunction syndrome (MODS) scores|Self reported quality of Sleep [10-point numeric rating scale (NRS) scale]|Change in Self reported anxiety level [10-point numeric rating scale (NRS) scale]|Change in Self reported fear level [10-point numeric rating scale (NRS)|Change in Self reported optimism level [10-point numeric rating scale (NRS)|Change in Self reported distress level [10-point numeric rating scale (NRS)]|Richmond agitation-sedation scale (RASS) score|Change in Plasma levels of Inflammatory marker Interleukin-6|Change in Plasma levels of Inflammatory marker Interleukin-8|Change in Plasma levels of Inflammatory marker soluble fas ligand (sfas)|Change in Plasma inflammatory marker levels High mobility group box-1 (HMGB-1)]|assessment of psychological distress (ICUESS: Intensive Care Unit Environmental Stressor Scale, self-assessment in a 1-10 numerical analogue scale).|Assessment of symptoms of post traumatic stress disorder (PTSD) using DTS (Davidson Trauma Scale)|assessment of quality of life using Short Form 36 version2 scale (SF36v2)|Exploration of lived experience of critical illness (phenomenological interviews)","Dr Elizabeth Papathanassoglou|Nicosia General Hospital|Cyprus University of Technology","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","EX 043 - EP1|EX 043 EPPSY-13","March 2015","November 2015","May 2016","April 22, 2015","null","April 22, 2015","Nicosia General Hospital, Nicosia, Cyprus","","https://ClinicalTrials.gov/show/NCT02423252"
1176,"NCT02421575","Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance",,"Terminated","No Results Available","Prostate Carcinoma","Drug: Hydroxychloroquine|Other: Laboratory Biomarker Analysis","Change in markers of autophagy in prostate tumor (Group I)|Levels of markers of autophagy in prostate tumor (Group II)|Distribution of autophagic activity in prostate cancer tissue|Autophagic activity, assessed by beclin-1 levels|Levels of markers of apoptosis in tumor tissue|Clinical activity, as assessed by PSA levels|Number of CTCs in blood samples","Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","4","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","121102|NCI-2014-02216|0220110278|P30CA072720","July 2012","February 26, 2016","February 26, 2016","April 20, 2015","null","February 2, 2017","Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT02421575"
1177,"NCT02420977","Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer",,"Not yet recruiting","No Results Available","Advanced Prostate Cancer","Drug: Pelvic DCFPyL PET-MRI fusion or PET/MRI","Response rate differences|Biomarker changes|Metabolic tumor uptake changes|Gene expression changes|Nodal metastatic disease changes|All cause DCFPyL PET-MRI fusion or PET/MRI toxicity","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)","Male","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","24","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","J1560|IRB00065395|1U01CA183031-01A1","February 1, 2019","February 1, 2021","February 1, 2023","April 20, 2015","null","November 7, 2018","The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02420977"
1178,"NCT02420665","Use of High-Resolution Microendoscopy (HRME) in Patients With Cervical Dysplasia",,"Active, not recruiting","No Results Available","Cervical Cancer","Drug: Proflavine|Device: HRME Imaging|Behavioral: Phone Call|Procedure: Colposcopy|Drug: Acetic Acid","Concordance Between the Diagnosis Using HRME Imaging and the Most Severe Histologic Diagnosis ( Concordance rate monitored using method described by Thall et al. (1995))","M.D. Anderson Cancer Center|National Cancer Institute (NCI)|National Institutes of Health (NIH)","Female","21 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2014-0368|HHSN261200800001E|1R01CA186132|NCI-2015-00681","September 23, 2015","September 2025","September 2025","April 20, 2015","null","October 19, 2018","Lyndon B. Johnson General Hospital, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02420665"
1179,"NCT02419170","Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)",,"Withdrawn","No Results Available","Carcinoma, Non-Small-Cell-Lung|Non-Small Cell Lung Cancer|Nonsmall Cell Lung Cancer","Procedure: Standard of care surgery|Procedure: Apheresis|Drug: Cyclophosphamide|Biological: Personalized mature dendritic cell vaccine","Immunological response as measured by increased numbers of peptide specific CD8+ T cells as calculated by the tetramer assay|Safety and tolerability of vaccine as measured by adverse events experienced and graded by NCI CTCAE Version 4.0|Time to progression (TTP)","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-x043","July 2016","October 2019","October 2023","April 17, 2015","null","July 18, 2016","","","https://ClinicalTrials.gov/show/NCT02419170"
1180,"NCT02416674","Vascularized Composite Allotransplantation for Treatment of Abdominal Wall Defects",,"Recruiting","No Results Available","Abdominal Wall Defect","Procedure: abdominal wall transplantation|Drug: Immunosuppressive Agents","allograft survival|immune rejection episodes|infections|donation of abdominal wall","Brigham and Women's Hospital","All","18 Years to 60 Years   (Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013P002556","March 2015","February 2019","February 2025","April 15, 2015","null","July 19, 2018","Brigham and Women's Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02416674"
1181,"NCT02414932","Ketamine for Depression Relapse Prevention Following ECT","KEEP-WELL","Completed","No Results Available","Depression","Drug: Ketamine|Drug: Midazolam","Recruitment rate|Depression relapse rate","St Patrick's Hospital, Ireland|Health Research Board, Ireland","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","SPUH 05/14|2014-004262-14","April 2015","April 7, 2017","April 7, 2017","April 13, 2015","null","June 14, 2017","St Patrick's University Hospital, Dublin, Ireland","","https://ClinicalTrials.gov/show/NCT02414932"
1182,"NCT02413502","Leukapheresis Sampling for Immune Responses After BCG Vaccination in BCG-naïve Healthy Adults in the US",,"Completed","No Results Available","Tuberculosis","Biological: BCG","Immune response measured by Intracellular cytokine staining (ICS)","Aeras|University of Rochester","All","18 Years to 55 Years   (Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","A-046","May 2015","September 2015","October 2015","April 10, 2015","null","October 9, 2015","","","https://ClinicalTrials.gov/show/NCT02413502"
1183,"NCT02412995","The Effects of Sea Buckthorn and Strawberry on Postprandial Glycaemia, Insulinemia and Appetite","OPUS-WP3C","Completed","No Results Available","Insulin Sensitivity|Glucose Intolerance","Other: Meal sequence 1-2-3|Other: Meal sequence 1-3-2|Other: Meal sequence 2-3-1|Other: Meal sequence 2-1-3|Other: Meal sequence 3-1-2|Other: Meal sequence 3-2-1","Glycemia Area under the plasma glucose concentration curve, concentration curve.|Insulin response Area under the plasma insulin concentration curve|Appetite scores (visual analogue scale)|urine metabolic profile|plasma metabolic profile (metabolic profiling by UPLC-QTOF)|Meal perception VAS questionnaire|Incremental area under the plasma glucose concentration curve|Glycemic profile (calculated as the time in minutes during which the blood glucose concentration is above baseline concentration divided by the incremental peak value of blood glucose)|Incremental insulin response Incremental area under the plasma insulin concentration curve.","University of Copenhagen|Nordea-fonden","Male","20 Years to 50 Years   (Adult)","Early Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","M208","October 2012","November 2012","February 2015","April 9, 2015","null","April 9, 2015","Department of Nutrition, Exercise and Sports, University of Copenhagen, Frederiksberg C, Denmark","","https://ClinicalTrials.gov/show/NCT02412995"
1184,"NCT02412137","Effect of Compliance Counseling on Brace Success in Patients With Idiopathic Scoliosis",,"Completed","No Results Available","Adolescent Idiopathic Scoliosis","Other: Counseled cohort","Brace Progress Report","Texas Scottish Rite Hospital for Children","All","up to 18 Years   (Child, Adult)","Early Phase 1","245","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","112007-014","December 2007","March 2015","March 2015","April 8, 2015","null","April 15, 2015","","","https://ClinicalTrials.gov/show/NCT02412137"
1185,"NCT02411643","Molecular Effects of Topical Calcipotriene on Morphea",,"Terminated","Has Results","Morphea|Localized Scleroderma","Drug: topical calcipotriene 0.005% ointment","Change of Gene Expression From Skin Biopsy|Quality of Life|Modified Localized Scleroderma Skin Score|Change of Appearance of Skin Biopsy","Northwestern University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","STU00101294","March 2015","April 2016","April 2016","April 8, 2015","September 13, 2018","September 13, 2018","Northwestern University Feinberg School of Medicine, Department of Dermatology, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT02411643"
1186,"NCT02410980","Assessing the Effects of Tretinoin Cream on Human Skin With Optical Imaging Technologies",,"Completed","No Results Available","Collagen Fibril Alteration","Drug: Tretinoin cream 0.1%","Skin Collagen/Elastin ratio over time - Change from baseline in sun exposed, and non sun exposed skin areas.","University of California, Irvine|Unilever R&D|Beckman Laser Institute University of California Irvine","Female","45 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NIH/LAMMP-Unilever-2014-1508","August 2015","December 2016","December 2016","April 8, 2015","null","March 7, 2017","Beckman Laser Institute Medical Clinic, Irvine, California, United States","","https://ClinicalTrials.gov/show/NCT02410980"
1187,"NCT02409784","PET Study of Cerebral Metabolism of 11C-acetoacetate and 18F-FDG in Patients Under Moderate Ketosis",,"Completed","Has Results","Healthy","Dietary Supplement: Ketogenic diet","Mean in Cerebral Metabolic Rate of Acetoacetate Before or After 4 Days of Ketogenic Diet|Mean in Cerebral Metabolic Rate of Glucose Before or After 4 Days of Ketogenic Diet","Université de Sherbrooke","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","13-214","March 2014","January 2015","January 2015","April 7, 2015","April 6, 2018","April 6, 2018","","","https://ClinicalTrials.gov/show/NCT02409784"
1188,"NCT02409758","Comprehensive Voice Rehabilitation Program Compared With Vocal Function Exercises","Voicetherapy","Completed","No Results Available","Dysphonia","Behavioral: Voice therapy","Improvement of the vocal quality (assessed by two self assessment questionnaires)|Perceptual auditory analysis (assessed by 3 senior SLP)|Improvement of larynx (evaluation by blind assessor)","Federal University of São Paulo","All","18 Years to 50 Years   (Adult)","Early Phase 1","106","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2010/15166-3","January 2011","December 2011","August 2012","April 7, 2015","null","April 7, 2015","","","https://ClinicalTrials.gov/show/NCT02409758"
1189,"NCT02405559","Lymphatic Occlusion Pressure in Lower Limb",,"Unknown status","No Results Available","Lymphatic Function","Drug: Indocyanine Green","Lymph flow active or not, depending on the pressure applied","Centre Hospitalier Universitaire Saint Pierre","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Ly-Occl-Pressure-2","May 2015","December 2015","December 2015","April 1, 2015","null","April 1, 2015","CHU St-Pierre - Lymphology Clinic of Brussels, Brussels, Belgium","","https://ClinicalTrials.gov/show/NCT02405559"
1190,"NCT02405403","Microglial Activation Role In ALS (MARIA)","MARIA","Withdrawn","No Results Available","Amyotrophic Lateral Sclerosis","Drug: [18F]DPA-714 PET","Concentration of cytokines in cerebrospinal fluid (pg/mL)|Fixation and distribution of [18F]DPA-714 (Binding Potential BP)","University Hospital, Tours","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PHAO-13-PC/MARIA","March 2015","September 2016","March 2017","April 1, 2015","null","May 31, 2017","University Hospital, Tours, France","","https://ClinicalTrials.gov/show/NCT02405403"
1191,"NCT02402569","Multi-electrodes Set for Deep Brain Stimulation in Parkinson Disease","SIV2","Recruiting","No Results Available","Parkinson Disease","Device: 32 channels Deep Brain Stimulator","Safety, as measured by Number of Participants with Adverse Events|Neurologic evaluation","University Hospital, Grenoble","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","SIV2","December 2014","December 2019","December 2021","March 30, 2015","null","May 4, 2018","CLINATEC, Grenoble, France","","https://ClinicalTrials.gov/show/NCT02402569"
1192,"NCT02402348","Pilot Study of Metformin in HNSCC to Investigate the Effects of MF, Tumor Genotype and MF-genotype Interactions, on Tumor Metabolism and Anoikis",,"Terminated","No Results Available","Cancer of Head and Neck","Drug: Metformin","Tumor cell death estimated by percentage","West Virginia University|West Virginia Clinical and Translational Science Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","WV011614","December 2014","August 2016","August 2016","March 30, 2015","null","February 8, 2017","West Virginia University Hospitals - Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States","","https://ClinicalTrials.gov/show/NCT02402348"
1193,"NCT02400463","A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome",,"Recruiting","No Results Available","Hemophagocytic Syndrome (HPS)","Drug: Ruxolitinib","Number of Patients Alive at 2 Months|Percentage of Patients with a Response to Treatment with Ruxolitinib|Duration of Response|Progression Free Survival Time","University of Michigan Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMCC 2014.112|HUM00092921","September 2015","November 2018","November 2018","March 27, 2015","null","February 6, 2018","University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02400463"
1194,"NCT02398383","Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes",,"Unknown status","No Results Available","Cystic Fibrosis|Cystic Fibrosis Related Diabetes","Other: Oral Glucose Tolerance Test|Other: Mixed Meal Tolerance Test|Other: Hypoglycemic Clamp","Glucagon levels|C-peptide levels|Epinephrine levels|Norepinephrine levels|Hypoglycemia unawareness scores|GLP-1 and GIP levels","Yale University","All","12 Years to 45 Years   (Child, Adult)","Early Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","1409014580","March 2015","January 2018","January 2018","March 25, 2015","null","July 29, 2016","Yale New Haven Hospital, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02398383"
1195,"NCT02398045","Developing Computerised CBT for Adults With OCD","CCBT","Unknown status","No Results Available","Obsessive-compulsive Disorder","Other: Computerised CBT for OCD","Change in Y-BOCS-OCD|Psychiatric Diagnostic Screening Questionnaire|DSM-IV OCD SCID|Patient Health Questionnaire|Generalised anxiety disorder assessment|Work and social adjustment scale|Expectation for treatment success and credibility|demographic variables|Obsessive-compulsive inventory","Institute of Psychiatry, London|South London and Maudsley NHS Foundation Trust","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCBT-1111|658-PAHTLZB","October 2015","October 2017","December 2017","March 25, 2015","null","August 30, 2016","Centre for Anxiety Disorders and Trauma, London, United Kingdom|South London and Maudsley NHS Trust, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02398045"
1196,"NCT02396303","Carbetocin Versus Oxytocin in Caesarean Section for the Control of Postpartum Haemorrhage",,"Unknown status","No Results Available","Postpartum Haemorrhage","Drug: Carbetocin","Estimated blood loss after cesarean section","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","Female","Child, Adult, Older Adult","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","67365","June 2015","October 2015","November 2015","March 24, 2015","null","March 24, 2015","BSMMU, Dhaka, Bangladesh","","https://ClinicalTrials.gov/show/NCT02396303"
1197,"NCT02394054","Vasopressin and the Social Brain",,"Completed","No Results Available","Social Psychology","Drug: Intranasal vasopressin|Drug: Intranasal placebo","Changes in neural brain activity, as observed by fMRI, when observing others during social inclusion vs. exclusion|Ratings of empathic concern after witnessing social exclusion in a friend or a stranger|Altruism and punishment as measured by number of points given to excluders and those excluded|Changes in neural brain activity, as observed by fMRI, while attempting to detect deception|Accuracy of deception detection as measured by self-report|Changes in neural brain activity, as observed by fMRI, when viewing images of primary caregivers versus strangers|Changes in brain neural activity, observed by fMRI, in response to a reading comprehension task|Performance on a memory test of reading comprehension as measured by percentage of questions answered correctly","University of California, Los Angeles","All","18 Years to 30 Years   (Adult)","Early Phase 1","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","11-003565-3","January 2015","July 2016","July 2016","March 20, 2015","null","August 10, 2017","UCLA Department of Psychology, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02394054"
1198,"NCT02393456","Oxytocin and the Social Brain",,"Completed","No Results Available","Social Psychology","Drug: Intranasal oxytocin|Drug: Intranasal placebo","Changes in neural brain activity, as observed by fMRI, when observing others during social inclusion vs. exclusion|Ratings of empathic concern after witnessing social exclusion in a friend or a stranger|Altruism and punishment as measured by number of points given to excluders and those excluded|Changes in neural brain activity, as observed by fMRI, while attempting to detect deception|Accuracy of deception detection as measured by self-report|Changes in neural brain activity, as observed by fMRI, when viewing images of primary caregivers versus strangers","University of California, Los Angeles","All","18 Years to 30 Years   (Adult)","Early Phase 1","161","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","11-003565-2","January 2015","July 2016","July 2016","March 19, 2015","null","August 10, 2017","UCLA Department of Psychology, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02393456"
1199,"NCT02393443","Oxytocin and Learning for Teaching",,"Completed","No Results Available","Social Psychology","Drug: Intranasal oxytocin|Drug: Intranasal placebo","Changes in brain neural activity, observed by fMRI, in response to a reading comprehension task|Performance on a memory test of reading comprehension as measured by percentage of questions answered correctly","University of California, Los Angeles","All","18 Years to 30 Years   (Adult)","Early Phase 1","161","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","11-003565-1","January 2015","July 2016","July 2016","March 19, 2015","null","August 10, 2017","UCLA Department of Psychology, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02393443"
1200,"NCT02393339","Pre-operative Analgesics for Postoperative Pain Relief After Dental Treatment",,"Recruiting","No Results Available","Pain, Postoperative|Analgesia","Drug: paracetamol|Drug: placebo","Postoperative pain, as measured by Wong-Baker Facial Rating Pain Scale ,after routine dental treatment","Hadassah Medical Organization","All","5 Years to 12 Years   (Child)","Early Phase 1","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","0638-14-HMO-CTIL","February 1, 2017","December 2019","December 2020","March 19, 2015","null","March 9, 2018","Hadassah Medical Organization, Jerusalem, Israel","","https://ClinicalTrials.gov/show/NCT02393339"
1201,"NCT02393027","Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999","LBT 999","Terminated","No Results Available","Idiopathic Parkinson Disease","Drug: [18F] LBT-999 PET","Binding potential of [18F] LBT-999|DAT striatal density by estimating the LBT-999 distribution volume|presence of lipophilic metabolites","University Hospital, Tours","All","45 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PHAO14-MJR / LBT-999","March 2015","November 2016","May 2017","March 19, 2015","null","May 30, 2017","University Hospital, Tours, France","","https://ClinicalTrials.gov/show/NCT02393027"
1202,"NCT02392039","Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma",,"Terminated","No Results Available","Lymphoma","Drug: Pegfilgrastim|Drug: Loratadine|Other: Placebo|Behavioral: Questionnaires","Bone Pain Related Quality of Life (QOL) Measured by FACT-Bone Pain (FACT-BP) Questionnaire","M.D. Anderson Cancer Center|Amgen","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","1","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2014-0880|NCI-2015-00592","December 14, 2015","April 4, 2018","April 4, 2018","March 18, 2015","null","May 31, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02392039"
1203,"NCT02391766","Group Intervention Empowerment Dementia",,"Unknown status","No Results Available","Empowerment|Self Efficacy|Quality of Life","Behavioral: empowerment|Behavioral: usual care","patients' HRQoL (15D)|caregivers' psychological well-being (GHQ-12)|caregivers sense of competence (SCQ).|spousal caregivers' HRQoL (RAND-36)","Universidad Nacional de Rosario","All","56 Years to 79 Years   (Adult, Older Adult)","Early Phase 1","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","PGIED01|´GIED01","September 2014","September 2015","October 2015","March 18, 2015","null","March 18, 2015","Faculty of Psychology, Rosario, Santa Fe, Argentina","","https://ClinicalTrials.gov/show/NCT02391766"
1204,"NCT02391428","The Correlation Between Blood omega3 and ADHD",,"Unknown status","No Results Available","Attention Deficit Hyperactivity Disorder (ADHD)","Procedure: blood test|Dietary Supplement: omega3 capsules","blood omega3|ADHD Symptoms","Ayelet Omer Armon|Ziv Hospital","All","6 Years to 14 Years   (Child)","Early Phase 1","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","ZIV-0019-14|Ziv","April 2015","September 2015","April 2016","March 18, 2015","null","March 19, 2015","","","https://ClinicalTrials.gov/show/NCT02391428"
1205,"NCT02390726","Fecal Microbiota Transplant in the Treatment of Ulcerative Colitis","FMTUC","Active, not recruiting","No Results Available","Ulcerative Colitis, Active Moderate","Biological: Fecal Microbiota Transplant|Biological: Placebo","Asses Endoscopic Stages of the Colon Pre/Post FMT|Asses Biologic Inflammatory Markers|Review and Track Patient reported Outcomes via Validated Questionnaires|Change in metagenomic sequencing in Stool samples after FMT treatment","University of Vermont","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","15373","December 2015","December 2017","September 2018","March 17, 2015","null","July 9, 2018","The University of Vermont Medical Center, Burlington, Vermont, United States","","https://ClinicalTrials.gov/show/NCT02390726"
1206,"NCT02390479","Gingival Crevicular Fluid Levels of Sclerostin, Osteoprotegerin (OPG) and RANKL in Health, Disease and After Treatment",,"Completed","No Results Available","Periodontitis","Other: non surgical periodontal treatment","Biochemical parameters (Sclerostin levels, RANKL/OPG ratio )|Probing pocket depth|Probing pocket depth and clinical attachment level|Gingival index|Plaque index|Bleeding on probing","Umut BALLI|Bulent Ecevit University","All","25 Years to 49 Years   (Adult)","Early Phase 1","54","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","2013-112-01/10","December 2013","October 2014","October 2014","March 17, 2015","null","September 30, 2015","","","https://ClinicalTrials.gov/show/NCT02390479"
1207,"NCT02389738","Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration",,"Unknown status","No Results Available","Blood Brain Barrier Defect","Drug: Regadenoson|Drug: Temozolomide|Device: Microdialysis catheter","change in AUC0-18 of the temozolomide concentration (AUC-T) in brain interstitium before and after Regadenoson infusion|Evaluation of relationaship between cognitive/mood disorders and expression of biochemical markers post-op day 1","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","J14155","February 2015","July 2016","December 2016","March 17, 2015","null","November 25, 2015","Johns Hopkins Hospital, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02389738"
1208,"NCT02386852","Ginseng and Ginkgo Biloba Effects on Cognition as Modulated by Cardiovascular Reactivity",,"Completed","No Results Available","Blood Pressure|Cognition","Drug: Placebo|Drug: Ginseng|Drug: Ginkgo Biloba","Cognitive performance as modulated by either ginseng or ginkgo biloba|Cardiovascular reactivity as a result of ginseng or ginkgo biloba intake","Sunway University","All","18 Years to 30 Years   (Adult)","Early Phase 1","48","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Sunway-979","March 2014","November 2014","November 2014","March 12, 2015","null","March 13, 2015","Department of Psychology, Sunway University, Bandar Sunway, Selangor, Malaysia","","https://ClinicalTrials.gov/show/NCT02386852"
1209,"NCT02385877","Clinical Translation of 18F-Labeled Hydroxyphenethylguanidines",,"Completed","No Results Available","Autonomic Peripheral Nervous System Diseases","Drug: [18F]4F-MHPG|Drug: [18F]3F-PHPG","Composite measure based on radiotracer tissue uptake ratios (heart-to-lung ratio, heart-to-liver ratio, heart-to-blood ratio) and rates of metabolism in plasma (half-time, in minutes) of [18F]4F-MHPG and [18F]3F-PHPG in healthy subjects.|Radiation Dose|Number of Adverse Events","University of Michigan","All","18 Years to 55 Years   (Adult)","Early Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HUM00088601","March 2015","August 2016","August 2016","March 11, 2015","null","July 2, 2017","University of Michigan, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02385877"
1210,"NCT02385357","Effect of a Protein-enriched Drink on Muscle Function","SPORTEUS","Unknown status","No Results Available","Contracture","Dietary Supplement: Protein-enriched drink","Isometric muscle strength|Muscle soreness of lower limbs self-reported by a visual anagogic scale and with an algometer score.|Power output assessed with the 30sec. Wingate anaerobic test|Creatine kinase|Urine Creatinine|Resting metabolic rate|Time limit (time that the participant is able to run 90% of his determined maximum aerobic velocity)","Puleva Biotech|Universidad de Granada","Male","18 Years to 40 Years   (Adult)","Early Phase 1","12","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Puleva","February 2015","December 2015","December 2015","March 11, 2015","null","March 11, 2015","Biosearch Life, Granada, Spain","","https://ClinicalTrials.gov/show/NCT02385357"
1211,"NCT02384551","Dietary Carbohydrate and GERD in Veterans","DietGERD","Recruiting","No Results Available","Gastroesophageal Reflux Disease|Obesity","Other: Dietary Carbohydrate","Gastroesophageal pH|GERD symptoms|GERD medication use","VA Office of Research and Development","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","200","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CLNB-006-14S","January 25, 2016","January 31, 2020","December 31, 2020","March 10, 2015","null","August 2, 2018","Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT02384551"
1212,"NCT02384473","Real-Time Contrast-Enhanced Ultrasonography and Shear Wave Elastography in Predicting Treatment Response in Patients With Soft Tissue Sarcoma",,"Active, not recruiting","No Results Available","Adult Soft Tissue Sarcoma|Bone Sarcoma|Retroperitoneal Sarcoma","Procedure: Real-Time CEUS|Procedure: SWE|Drug: Definity Suspension for Injection|Device: Philips Shear Wave Elastography","Inter-reader agreement for sequential contrast-enhanced ultra sound for evaluating treatment response as determined by kappa coefficient","University of Southern California|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","11S-14-1|NCI-2014-02579|HS-14-00792|P30CA014089","December 24, 2014","December 24, 2019","December 24, 2020","March 10, 2015","null","August 9, 2018","USC Norris Comprehensive Cancer Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02384473"
1213,"NCT02383043","Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer",,"Completed","No Results Available","Active Cocaine Users","Drug: Cocaine|Drug: Sustained Release d-Amphetamine","Number of Injections of self-administered cocaine","Joshua A. Lile, Ph.D.|University of Kentucky","All","21 Years to 45 Years   (Adult)","Early Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","R01DA033364-02","February 1, 2015","April 5, 2018","April 5, 2018","March 9, 2015","null","October 10, 2018","Laboratory of Human Behavioral Pharmacology, Lexington, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT02383043"
1214,"NCT02382029","Acupuncture Versus Clonazepam in Burning Mouth Syndrome","ACUCLONBMS","Completed","No Results Available","Burning Mouth Syndrome","Drug: Clonazepam|Other: acupuncture","Pain intensity|The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) Pain Scale|Cognitive function|Depression|Quality of life","University of Zagreb","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","UZagreb","March 2014","November 2014","November 2014","March 6, 2015","null","March 6, 2015","","","https://ClinicalTrials.gov/show/NCT02382029"
1215,"NCT02380209","An Early Phase Clinical Trial to Evaluate the Feasibility of CEST MRI in Patients With Early Stage Breast Cancer",,"Terminated","No Results Available","Breast Cancer","Other: CEST MRI","pH measurement of the tumor will be measured by the CEST MRI.|Correlate tumor pH as estimated by CEST MRI with protein and RNA based markers for acidosis and hypoxia.","University of Arizona","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1406349968","August 2014","August 2016","August 2016","March 5, 2015","null","October 27, 2016","Arizona Cancer Center at UMC North, Tucson, Arizona, United States","","https://ClinicalTrials.gov/show/NCT02380209"
1216,"NCT02379988","Prone Breath Hold Technique to Decrease Cardiac and Pulmonary Doses in Women Receiving Left Breast Radiotherapy",,"Active, not recruiting","No Results Available","Breast Cancer","Radiation: Verify radiation dose to heart and lung","The radiation dose in Gy to the heart and lung using two radiation techniques.|Changes in the mean dose to the heart and lungs with prone breath hold.|Heart volume receiving 20 Gy, maximum dose to left ventricle/LAD artery.|Relative volumes of lung receiving 20 Gy.","University of Arizona","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1409500149","November 6, 2014","December 2018","December 2019","March 5, 2015","null","February 5, 2018","Radiation Oncology Department at the University of Arizona Heath Network, Tucson, Arizona, United States","","https://ClinicalTrials.gov/show/NCT02379988"
1217,"NCT02378792","Clinical Trial of Vagus Nerve Stimulation for Treatment of Refractory Epilepsy","VNSRE","Unknown status","No Results Available","Refractory Epilepsy","Device: Vagus Nerve Stimulation","Changes in seizure frequency from baseline to the seizure count evaluvation period 6 month|Changes in seizure frequency from baseline to the seizure count evaluvation period|Overall Quality of Life in Epilepsy-31 (QOLIE-31) Score in Patients With Baseline & at Least One Post-baseline QOLIE Assessment|Changes in the Number of Anti-epileptic Drugs Prescribed|Changes from Basline in the Engel and McHugh description|Changes from Basline in 24 hour ECG description","Beijing Pins Medical Co., Ltd|Beijing Tiantan Hospital","All","6 Years to 60 Years   (Child, Adult)","Early Phase 1","300","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","PINS-012","August 2014","October 2017","December 2017","March 4, 2015","null","October 12, 2016","Beijing Tiantan Hospital, Beijing, Beijing, China|The first hospital of jilin university, Changchun, Jilin, China|The general of shenyang military, Shenyang, Liaoning, China|Qilu hospital of shandong university, Jinan, Shandong, China|The second affiliated hospital zhejiang university school of medicine, Hangzhou, Zhejiang, China","","https://ClinicalTrials.gov/show/NCT02378792"
1218,"NCT02374931","18F-FES PET/CT in Imaging Patients With Desmoid Tumors",,"Active, not recruiting","No Results Available","Deep Fibromatosis/Desmoid Tumor|Familial Adenomatous Polyposis","Drug: F-18 16 Alpha-Fluoroestradiol|Procedure: Positron Emission Tomography|Procedure: Computed Tomography|Other: Laboratory Biomarker Analysis","Standard uptake value (SUV) measured as percent injected dose per cc|IHC staining intensity in tissue samples","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","3","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","VICC SAR 1458|NCI-2015-00081|P30CA068485","April 2015","July 2017","December 2018","March 2, 2015","null","April 11, 2018","Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT02374931"
1219,"NCT02373254","NSAIDS Versus Opioids in Acute SER II Ankle Fractures",,"Completed","No Results Available","Ankle Fracture","Drug: Ibuprofen|Drug: Acetaminophen/hydrocodone","fracture healing as measured by radiographic evaluation|pain level improvement as measured by VAS score|functional improvement as measured by AAOS score","University of California, Davis","All","18 Years to 60 Years   (Adult)","Early Phase 1","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","656916","January 2015","October 2015","October 2015","February 26, 2015","null","July 14, 2017","University of California Davis, Sacramento, California, United States","","https://ClinicalTrials.gov/show/NCT02373254"
1220,"NCT02372318","Single-dose of Nalmefene to Modulate Neural Alcohol Cue Reactivity","NALCUE","Terminated","No Results Available","Alcoholism","Drug: Nalmefene|Drug: Placebo","Difference in cue-induced brain activation between two fMRI scans (randomization to an intake of nalmefene (18 mg) or placebo).","Central Institute of Mental Health, Mannheim|Lundbeck GmbH, Ericusspitze 2, 20457 Hamburg","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","23","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","37","April 2015","May 2016","May 2016","February 26, 2015","null","July 2, 2017","Zentralinstitut für Seelische Gesundheit, Mannheim, Germany","","https://ClinicalTrials.gov/show/NCT02372318"
1221,"NCT02370862","Transdermal Administration of a Prokinetic Agent for Bowel Evacuation in Persons With SCI",,"Completed","No Results Available","Spinal Cord Injury|Neurogenic Bowel","Drug: Neostigmine and Glycopyrrolate","Biological Responses to Study Drugs (quantified by the presence and strength of biological responses (changes in bowel sounds, heart rate and airway resistance and bowel movement occurrence)|Safety of Study Medication (quantified through monitoring of side effects during study visits and through patient self report as measured by the Treatment Satisfaction Questionnaire)","James J. Peters Veterans Affairs Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","28","U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KOR-13-02","February 2013","December 2016","December 2016","February 25, 2015","null","March 7, 2017","James J. Peters VA Medical Center, Bronx, New York, United States","","https://ClinicalTrials.gov/show/NCT02370862"
1222,"NCT02369523","Multimodal Pain Management Following Primary TKA",,"Terminated","No Results Available","Pain","Drug: Exparel|Drug: Ropivacaine cocktail (PIC)|Drug: Bupivacaine","Time to Discharge Readiness","University of Utah","All","40 Years and older   (Adult, Older Adult)","Early Phase 1","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","74975","September 2014","April 2017","April 2017","February 24, 2015","null","August 31, 2017","University of Utah Orthopaedic Center, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02369523"
1223,"NCT02369432","Exploratory Study of the Cutaneous Penetration of Biodegradable Polymeric Microparticles in Atopic Dermatitis","MicroIskin","Terminated","No Results Available","Atopic Dermatitis","Drug: Biodegradable and biocompatible polymeric microparticles containing a fluorochrome applied to the skin followed by a skin biopsy","Assessment of the penetration beyond the stratum corneum in human skin (fluorochrome contained in the particle will be detected by confocal microscopy)|Assessment of the quantity of fluorescence (assessed by number of pixels on pictures taken with confocal microscopy)","Centre Hospitalier Universitaire de Besancon|University of Franche-Comté","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","API/2012/32","February 20, 2015","October 3, 2017","October 3, 2017","February 24, 2015","null","October 13, 2017","Regional University Hospital, Besançon, France","","https://ClinicalTrials.gov/show/NCT02369432"
1224,"NCT02368561","Treatment of Insertional Achilles Tendinopathy by Hyaluronic Acid Injection",,"Unknown status","No Results Available","Insertional Achilles Tendinitis","Drug: Injection of Hyaluronic Acid -"" SYNVISC"" (hylan G-F 20)","Change in the VISA-A questionnaire score|The sonographic signs","Meir Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MMC140082CTIL","March 2015","January 2016","July 2016","February 23, 2015","null","February 23, 2015","","","https://ClinicalTrials.gov/show/NCT02368561"
1225,"NCT02366065","Does Oral Acetaminophen Lower Intraocular Pressure?",,"Completed","No Results Available","Glaucoma","Drug: Acetaminophen","Lowering Eye Pressure","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CIR00006973","January 2015","May 2016","May 2016","February 19, 2015","null","June 7, 2016","Johns Hopkins - The Wilmer Eye Institute, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02366065"
1226,"NCT02365909","Study Evaluating Sphenopalatine Ganglion Block (SPGB) for Treatment of Postdural Puncture Headache (PDPH)","PDPH","Terminated","No Results Available","Postdural Puncture Headache","Drug: 0.5% bupivacaine|Drug: normal saline","Headache verbal pain score","University of Arkansas","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","203684","June 29, 2015","August 30, 2016","August 30, 2016","February 19, 2015","null","September 18, 2017","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States","","https://ClinicalTrials.gov/show/NCT02365909"
1227,"NCT02363478","Long Term Effect of Buspirone on Esophageal Function and Esophageal Symptoms in Patients With Systematic Sclerosis (SSc)",,"Completed","Has Results","Systemic Sclerosis","Drug: buspirone","Changes From Baseline in Manometric Parameters: i) Amplitude of Contractions at the Distal Part of the Esophagus and ii) Resting and Residual (Lower Esophageal Pressure) LES Pressure and IRP (Integrated Relaxation Pressure) at Week 4|Changes From Baseline in Manometric Parameters: Duration of Contractions at the Distal Part of the Esophagus at Week 4|Changes From Baseline in Manometric Parameters: Velocity of Contractions at the Distal Part of the Esophagus at Week 4|Changes in the Severity of Esophageal Symptoms at Week 4","Laikon General District Hospital, Athens","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Laikon 181/21-02-2014","December 2014","September 2015","September 2015","February 16, 2015","October 24, 2016","October 24, 2016","Academic Department of Gastroenterology, Laikon GH, Athens, Greece","","https://ClinicalTrials.gov/show/NCT02363478"
1228,"NCT02362529","Biomarkers of Neuroinflammation and Anti-Inflammatory Treatments in Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Minocycline|Drug: Placebo|Drug: Celecoxib","Translocator total distribution volume (TSPO VT): Treatment Effect of Minocycline in MDE Subjects|Translocator total distribution volume (TSPO VT): Difference between MDE and healthy subjects|Change in Hamilton Depression Rating Scale Score","Centre for Addiction and Mental Health","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","115","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","REB056/2014","February 2015","June 2019","July 2019","February 13, 2015","null","July 21, 2017","Centre for Addiction and Mental Health, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02362529"
1229,"NCT02361775","Paravertebral Catheters for VATS Procedures",,"Completed","No Results Available","Acute Pain","Device: Paravertebral catheter|Device: opioid iv pca|Drug: Ropivacaine|Device: Elastomeric Pump","Maximum NRS Pain score|total opioid use|length of stay","University of Minnesota - Clinical and Translational Science Institute","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1201M09227","July 2012","October 2014","October 2014","February 12, 2015","null","February 12, 2015","","","https://ClinicalTrials.gov/show/NCT02361775"
1230,"NCT02361177","Role of Oxytocin in Telling and Detecting Lies",,"Withdrawn","No Results Available","Dyssocial Behavior","Drug: Oxytocin","Unethical behavior","University of Texas at Austin|Harvard University","Male","18 Years to 30 Years   (Adult)","Early Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","2013-11-0033","January 2016","April 2016","April 2016","February 11, 2015","null","June 13, 2016","","","https://ClinicalTrials.gov/show/NCT02361177"
1231,"NCT02359578","Determining Occlusion Pressure in Lymphatic Vessels","Occlusion","Completed","No Results Available","Determination of the Occlusion Pressure in Lymphatic Vessels","Drug: Indocyanine Green","Lymph flow active or not depending on the pressure applied","Centre Hospitalier Universitaire Saint Pierre","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","LY-OCCL-PRESSURE-1","August 2014","November 2014","January 2015","February 10, 2015","null","February 13, 2015","CHU St-Pierre, Brussels, Belgium","","https://ClinicalTrials.gov/show/NCT02359578"
1232,"NCT02358915","A Two-step Training Paradigm for Voluntary Control of the Peri-auricular Muscles",,"Completed","No Results Available","Non-disabled Volunteers|Lacking Voluntary Control of Ear Muscles","Device: FastStart neuromuscular electrical stimulator","The surface EMG signal amplitude of the auricular muscles at the maximum voluntary contraction|The computer game performance score","University of Southern California","All","18 Years to 64 Years   (Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","HS-14-00672","February 2015","August 2016","August 31, 2016","February 9, 2015","null","April 5, 2017","University of Southern California-Health Sciences Campus, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02358915"
1233,"NCT02358759","Management of Abnormally Fertilized Zygotes? InVitro Correction of 3PN",,"Completed","No Results Available","Infertility","Procedure: Correction of abnormally fertilized oocytes","Normal Embryos Developed|Day 3 embryo available for blastomer biopsy|5 chromosomes FISH study","Ahmad Mustafa Mohamed Metwalley|Al Baraka Fertility Hospital","All","20 Years to 45 Years   (Adult)","Early Phase 1","22","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","AlBarakaSD3","June 2014","September 2015","September 2015","February 9, 2015","null","January 12, 2016","Al Baraka Fertility Hospital, Manama, Adliyah, Bahrain|Ibn Sina IVF Center- Ibn Sina Hospital, Sohag, Egypt","","https://ClinicalTrials.gov/show/NCT02358759"
1234,"NCT02357836","Neoadjuvant Itraconazole in Non-small Cell Lung Cancer",,"Recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: Itraconazole","Change in Pharmacodynamics (assessed by changes in tumor tissue microvessel density [MVD])","University of Texas Southwestern Medical Center|United States Department of Defense","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU 122014-038","June 2015","June 2019","June 2019","February 6, 2015","null","August 15, 2018","UT Southwestern Medical Center, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT02357836"
1235,"NCT02357225","A Pilot Study of Pyridostigmine in Pompe Disease",,"Terminated","No Results Available","Pompe Disease","Drug: Pyridostigmine Bromide","Change in skeletal muscle function (6 Minute Walk Test)(QMT)|Change in respiratory function (maximal inspiratory pressure, maximal expiratory pressure, and vital capacity)|Change in quality of life [short form 36 (SF-36)]|Evaluate the acute effects of pyridostigmine on neuromuscular junction transmission (Single-fiber EMG)","University of Florida","All","8 Years to 60 Years   (Child, Adult)","Early Phase 1","2","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB201200154","August 2015","January 1, 2018","January 1, 2018","February 6, 2015","null","May 15, 2018","University of Florida Clinical Research Center, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT02357225"
1236,"NCT02356653","Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC","ExpMACs","Recruiting","No Results Available","Leukemia|Inborn Errors of Metabolism|Bone Marrow Failure Syndromes|Immunodeficiencies|Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome","Device: Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)","Overall Survival|Graft versus Host Disease|Graft Failure","Children's Hospital of Philadelphia","All","up to 30 Years   (Child, Adult)","Early Phase 1","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-010286|12BT125","December 2013","January 2020","January 2020","February 5, 2015","null","January 24, 2018","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02356653"
1237,"NCT02355756","Biomarker Development for Future PAC1 Antagonists With Maxadilan",,"Completed","No Results Available","Healthy Volunteers","Drug: Maxadilan|Drug: Placebo","Change in dermal blood flow induced by intradermal injections of maxadilan, compared to baseline and placebo for different doses, time point and in terms of reproducibility over time (i.e. inter-period reproducibility).|Changes in vital signs.|Changes in ECG.|Change in laboratory safety tests.|Change in physical examination.|Tolerability of intradermal injections of maxadilan in healthy male subjects. Assessed using the Numerical rating scale-11 for pain.|Change in dermal blood flow induced by intradermal injections of maxadilan, compared to baseline and placebo in terms of reproducibility between arms (i.e. inter-arm reproducibility.","Universitaire Ziekenhuizen Leuven","Male","18 Years to 45 Years   (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCP14-3301-PAC1","January 2015","April 2015","April 2015","February 4, 2015","null","July 10, 2015","Centre for Clinical Pharmacology, UZ Leuven, Leuven, Vlaams-Brabant, Belgium","","https://ClinicalTrials.gov/show/NCT02355756"
1238,"NCT02353078","The Effect of Sucralfate Slurry in Patients With Eosinophilic Esophagitis","EoE","Completed","No Results Available","Eosinophilic Esophagitis","Drug: Sucralfate|Procedure: Intraluminal Impedance|Device: Intraluminal Impedance","The Effectiveness of Sucralfate treatment in patient's with EoE|Measuring Mucosal impedance","Mayo Clinic","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","3","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-008661","January 2015","December 2016","December 2016","February 2, 2015","null","October 11, 2017","Mayo Clinic in Rochester, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02353078"
1239,"NCT02352025","S-equol in Women With Triple Negative Breast Cancer",,"Recruiting","No Results Available","Breast Cancer","Drug: S-equol","Proliferation Rate of Triple Negative Breast Cancer","The University of Texas Health Science Center at San Antonio","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTMS 14-2018|HSC20150231H","April 15, 2015","January 31, 2019","July 31, 2019","January 30, 2015","null","September 5, 2018","CTRC (Cancer Therapy and Research Center) at UTHSCSA, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT02352025"
1240,"NCT02348541","CollaGUARD Adhesion Barrier",,"Completed","No Results Available","Hysteroscopic Adhesiolysis","Device: CollaGUARD","Feasibility of using CollaGUARD in hysteroscopic adhesiolysis: Surgeon completed questionnaire|Number of de novo adhesion and adhesion reformation|Change in severity of adhesions|Degradation of CollaGUARD","Innocoll","Female","18 Years to 45 Years   (Adult)","Early Phase 1","9","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","INN-CG-001","December 2014","September 2015","September 2015","January 28, 2015","null","June 13, 2016","Sint Lucas Andreas Ziekenhuis, Amsterdam, Netherlands|Spaarne Ziekenhuis, Hoofddorp, Netherlands","","https://ClinicalTrials.gov/show/NCT02348541"
1241,"NCT02347293","Over-night Effect of Dietary Fiber on Glucose Metabolism and Satiety",,"Completed","No Results Available","Obesity|Metabolic Syndrome","Other: High levels of indigestible carbohydrates|Other: Low levels of indigestible carbohydrates","Blood Glucose, levels of glucose in blood|Insulin, levels of insulin in blood|Appetite hormones, levels of Peptide YY (PYY) in blood|Markers of colonic fermentation, levels of hydrogen in breath|Inflammation markers, levels of Interleukin-6 (IL-6) in blood|Subjective satiety, as measured by VAS","Lund University","All","20 Years to 35 Years   (Adult)","Early Phase 1","21","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Dnr2013/241b","October 2014","May 2015","May 2015","January 27, 2015","null","May 27, 2015","Medicon Village, Lund, Sweden","","https://ClinicalTrials.gov/show/NCT02347293"
1242,"NCT02346500","Ultrasound-Guided Photoselective Vaporization of the Prostate",,"Completed","No Results Available","Benign Prostatic Hyperplasia","Device: Transrectal Ultrasound","Measurement of prostate volume.|Measurement of the prostate cavity.|Recording patient-completed questionnaires (International Prostate Symptom Score (IPSS).|Measurement of complications from the procedure including rectal injury.","Johns Hopkins University","Male","40 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NA_00052503","December 2012","November 26, 2016","November 26, 2016","January 27, 2015","null","September 18, 2018","Johns Hopkins Hospital, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02346500"
1243,"NCT02344758","Gluten-free Diet Monitoring in Urine",,"Completed","No Results Available","Celiac Disease","Device: Non-invasive lateral flow test for monitoring gluten intake|Behavioral: gluten-free diet (GFD)|Behavioral: gluten-containing diet","Usual gluten-containing diet for healthy individuals|Usual gluten-free diet for celiac patients (home diet not modified for this trial)","University of Seville|Instituto Hispalense de Pediatría|Hospitales Universitarios Virgen del Rocío","All","3 Years and older   (Child, Adult, Older Adult)","Early Phase 1","134","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment","CELIFLUID1","April 2013","July 2013","December 2013","January 26, 2015","null","January 26, 2015","Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Seville, Seville, Spain","","https://ClinicalTrials.gov/show/NCT02344758"
1244,"NCT02343783","A Study to Evaluate Use of Induced Skin Blisters in Adult Participants With Atopic Dermatitis, Allergic Asthma and Atopic Healthy Participants",,"Completed","No Results Available","Dermatitis, Atopic|Asthma|Healthy","Other: Allergic Skin Reaction (ASR) Testing and Skin Blister Induction","Cell Concentration in Suction Skin Blister Fluid After Allergic Skin Reaction (ASR) Induction with D. Pteronyssinus (House Dust Mite [HDM]), Alternaria alternata, or Aspergillus fumigatus Allergens|Cell Concentration in Suction Skin Blister Fluid After ASR Induction with D. Pteronyssinus (House Dust Mite), Alternaria alternata, or Aspergillus fumigatus Allergens|Levels of Inflammatory Mediators in Suction Skin Blister Fluid After ASR Induction with D. Pteronyssinus (House Dust Mite), Alternaria alternata, or Aspergillus fumigatus Allergens|Success Percentage of Repeated Skin Blister Induction and Blister Fluid Aspiration|Cell Concentration in Suction Skin Blister Fluid After ASR Induction with Non-protease Allergens|Levels of Inflammatory Mediators in Suction Skin Blister Fluid After ASR Induction with Non-protease Allergens","Janssen Research & Development, LLC","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","46","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR106398|NOCOMPOUNDNAP0005","January 2015","September 2015","September 2015","January 22, 2015","null","October 6, 2015","Antwerp, Belgium|Merksem, Belgium|Berlin, Germany|Hamburg, Germany|Hannover, Germany|Kiel, Germany|Mönchengladbach, Germany","","https://ClinicalTrials.gov/show/NCT02343783"
1245,"NCT02341703","Ovulation Induction in Clomiphene Citrate Resistant PCO Women",,"Completed","No Results Available","Polycystic Ovary Syndrome|Infertility","Drug: letrozole-metformin|Drug: letrozole-metformin-pioglitazone|Radiation: transvaginal ultrasound|Other: laboratory investigations","ovulation rate|pregnancy rate","Cairo University","Female","20 Years to 40 Years   (Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","University Hospital","February 2015","July 2015","July 2015","January 19, 2015","null","July 28, 2015","faculty of medicine, Cairo University, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT02341703"
1246,"NCT02341222","BP as a Super-light Mesh and as a New Fixation Device for General Surgery -DM108/2008-B","DM108/2008-B","Unknown status","No Results Available","Hernia","Device: BP self-standing felt device|Device: PR Parietene mesh device","bio-compatibility by liver performance (by SGOT(Serum Glutamic Oxaloacetic Transaminase)|cancer cell viability if exposed to BP|bio-compatibility by kidney performance (by BUN and blood creatinine, and creatinine clearance)|bio-compatibility by marrow biologic performance (by CBC(Complete Blood Count)","University of Roma La Sapienza|University of Sannio|P Consentino Appialab Veterinary Reseach Labaratory|Catholic University of the Sacred Heart|E D'Amore Istituto Superiore Sanità","Female","2 Months to 4 Months   (Child)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","DM108/2008-B","January 2008","August 2015","December 2015","January 19, 2015","null","January 19, 2015","National Health Institute (ISS Istituto Superiore di Sanità), Viale Regina Elena 299, Rome, Roma, Italy","","https://ClinicalTrials.gov/show/NCT02341222"
1247,"NCT02338375","Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product","Cartistem","Unknown status","No Results Available","Osteochondral Lesion of Talus","Biological: Cartistem","evaluate the efficacy of adding allogenic umbilical cord blood-derived stem cell product(Cartistem®) by American Orthopaedic Foot and Ankle Society(AOFAS) HINDFOOT/ANKLE SCALE|evaluate the efficacy of adding allogenic umbilical cord blood-derived stem cell product(Cartistem®) by 100-mm VAS(Visual Analogue Scale)","Samsung Medical Center","All","20 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2012-10-078","December 2012","August 2015","December 2015","January 14, 2015","null","January 14, 2015","Samsung Medical Center, Gangnam-Gu, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02338375"
1248,"NCT02338037","Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors",,"Active, not recruiting","No Results Available","Metastatic Malignant Neoplasm in the Adult Brain|Primary Brain Tumor","Procedure: Therapeutic Conventional Surgery|Procedure: Biopsy|Drug: Eribulin Mesylate|Procedure: Microdialysis|Other: Pharmacological Study","Time of maximum concentration observed (Tmax) for eribulin mesylate|Maximum concentration observed (Cmax) for eribulin mesylate|Area under the curve (AUC) for eribulin mesylate|Half-life (t1/2) for eribulin mesylate|Ratio of AUC of eribulin mesylate in dialysate to plasma|Toxicity profile of eribulin mesylate graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Clinical benefit rate defined as tumor response on brain MRI results","City of Hope Medical Center|National Cancer Institute (NCI)|Eisai Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","8","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14312|NCI-2014-02391","May 19, 2015","September 2019","September 2019","January 14, 2015","null","October 9, 2018","City of Hope Medical Center, Duarte, California, United States","","https://ClinicalTrials.gov/show/NCT02338037"
1249,"NCT02337257","Periodontal and Cardiometabolic Responses to Vitamin D Intervention in African Americans With Periodontal Disease","GumD","Unknown status","No Results Available","Periodontal Disease|Vitamin D Deficiency","Drug: Cholecalciferol|Drug: Placebo","Change in Periodontal Disease Activity|Change in Cardiometabolic Risk Factors|Change in Blood Myeloid Dendritic Cells","Augusta University","All","18 Years to 60 Years   (Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Pro00001693","April 2014","September 2015","December 2015","January 13, 2015","null","January 13, 2015","Georgia Prevention Institute, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02337257"
1250,"NCT02337114","Recovery Enhancement From Traumatic Brain Injury Using Acceptance and Commitment Therapy - a Pilot Study.","REACT","Completed","No Results Available","Brain Injuries, Traumatic","Behavioral: Acceptance and Commitment Therapy|Behavioral: Treatment as Usual","Acceptability of ACT as measured by focus-group discussions with clients and staff; number of participants withdrawing from study|Suitability of ACT as measured by Acceptance and Action Questionnaire - Acquired Brain Injury|Feasibility of ACT as measured by focus-group discussions with clients and staff; number of participants considering intervention satisfactory/appropriate|Suitability of ACT, as measured by Hospital Anxiety and Depression Scale|Suitability of ACT as measured by the Motivation for Traumatic Brain Injury Rehabilitation Questionnaire|Suitability of ACT as measured by Awareness Questionnaire","University of Glasgow|Brain Injury Rehabilitation Trust","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","47","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14/WS/1152","January 2015","September 2015","September 2015","January 13, 2015","null","December 10, 2015","Brain Injury Rehabilitation Trust, Glasgow, United Kingdom","","https://ClinicalTrials.gov/show/NCT02337114"
1251,"NCT02336841","Self-Help And Recovery Guide in Eating Disorders","SHARED","Unknown status","No Results Available","Anorexia Nervosa","Other: Treatment as usual + Recovery MANTRA|Other: Treatment as usual + feedback","Changes in body weight at the end of the intervention|Changes in eating disorder symptoms at the end of the intervention and follow-up","King's College London","All","16 Years and older   (Child, Adult, Older Adult)","Early Phase 1","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","159490","January 2015","December 2016","October 2017","January 13, 2015","null","January 13, 2015","King's College London, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02336841"
1252,"NCT02335866","Platelet-Rich Fibrin in the Treatment of Multiple Gingival Recessions",,"Completed","No Results Available","Gingival Recessions","Procedure: test groups|Procedure: Control groups","Complete root coverage|Gingival recession depth|Keratinized tissue width|Pain scores","Necmettin Erbakan University","All","18 Years to 60 Years   (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014/10","January 2014","January 2014","August 2014","January 12, 2015","null","January 12, 2015","NEU Dental School, Konya, Turkey","","https://ClinicalTrials.gov/show/NCT02335866"
1253,"NCT02335515","The Gastric Residence Time (GRT) of Soctec Capsule After a Standardized Breakfast",,"Unknown status","No Results Available","Healthy","Device: Soctec","To assess the gastric residence time (GRT) of the Soctec Capsule after a standardized breakfast.","SkyePharma AG|University of Zurich","Male","18 Years to 50 Years   (Adult)","Early Phase 1","15","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SKY1049#10600-1-001","September 2014","October 2014","March 2015","January 9, 2015","null","January 9, 2015","","","https://ClinicalTrials.gov/show/NCT02335515"
1254,"NCT02334917","Comparison of Fast-Absorbing Sutures for Mohs Surgery",,"Unknown status","No Results Available","Cicatrix","Procedure: Surgical wound closure with superficial absorbable sutures","The Stony Brook Scar Evaluation Scale (SBSES) score (cosmetic outcome)|The Wound Evaluation Scale (WES) score (cosmetic outcome)|The Visual Analogue Scale (VAS) score (cosmetic outcome)","University of British Columbia","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","H14-02604","January 2015","June 2015","June 2015","January 8, 2015","null","January 8, 2015","","","https://ClinicalTrials.gov/show/NCT02334917"
1255,"NCT02331979","Improving Bladder Function in SCI by Neuromodulation",,"Unknown status","No Results Available","Spinal Cord Injury","Device: Electromagnetic Neuromodulation","Urine flow and volume","University of California, Los Angeles","Male","18 Years to 45 Years   (Adult)","Early Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-000932","September 2015","October 2018","October 2018","January 6, 2015","null","January 27, 2016","University of California, Los Angeles, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02331979"
1256,"NCT02331706","IFN-DLI for Relapsed Acute Leukemia After Allo-SCT",,"Completed","No Results Available","Leukemia","Drug: Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily","Number of Adverse Events|overall survival|disease-free survival","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 09414","December 2014","November 11, 2016","November 11, 2017","January 6, 2015","null","August 22, 2018","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02331706"
1257,"NCT02328859","Virtual Reality Rehabilitation for Individuals With Lower Limb Amputation",,"Completed","No Results Available","Transtibial Amputation","Other: Virtual Reality Gait Training|Other: Treadmill Gait Training","Change from Baseline in Knee Joint Symmetry at 6 weeks|Change from Baseline in Gait Speed (m/s) at 6 weeks|Change from Baseline in Gait Variability at 3 weeks and 6 weeks|Change from Baseline in Trunk Lean on the Prosthetic versus Non-Prosthetic Side of the Body (measured in degrees) at 6 weeks.|Postural sway parameters - Swept Area - measured in meters x meters|Berg Balance Scale - clinical evaluation - scored on a scale of 0 -4 with a maximum score of 56|Dynamic Gait Index - A four-point ordinal scale, ranging from 0-3 with a maximum score of 24.|Four Square Step Test - the time it takes to step in four squares backwards, sideways and forward. Measured in seconds.|Postural sway parameters - Mediolateral excursion of the center of mass measured in millimeters|Postural sway parameters - Anteroposterior excursion of the center of mass measured in millimeters","VA Office of Research and Development","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","4","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A1598-P","April 1, 2016","June 23, 2017","June 27, 2017","December 31, 2014","null","June 28, 2017","Providence VA Medical Center, Providence, RI, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT02328859"
1258,"NCT02326168","PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer",,"Completed","No Results Available","Bladder Cancer","Drug: Bacillus Calmette-Guerin (BCG)","BCG response|PPD conversion","The University of Texas Health Science Center at San Antonio","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","140005","October 2013","October 2015","October 2015","December 25, 2014","null","January 25, 2017","The University of Texas Health Science Center, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT02326168"
1259,"NCT02326103","Randomised Open-label Multicenter Study Evaluating Ciprofloxacin in Severe Alcoholic Hepatitis",,"Completed","No Results Available","Alcoholic Hepatitis|Alcoholic Cirrhosis","Drug: Ciprofloxacin|Drug: Placebo","Death at 28 days|Death at 3 months|Death at 6 months|Early reduction in serum bilirubin level|Surrogate markers of liver function","Helsinki University","All","18 Years to 64 Years   (Adult)","Early Phase 1","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HELSINKIU","April 2015","January 2017","January 2017","December 25, 2014","null","January 19, 2017","University Hospital of Helsinki, Helsinki, Finland","","https://ClinicalTrials.gov/show/NCT02326103"
1260,"NCT02325999","Endoscopic Submucosal Dissection Combine With Laparoscopic Regional Lymph Node Dissection for Early Gastric Cancer",,"Recruiting","No Results Available","Early Gastric Cancer","Procedure: ESD AND LRLD","DFS","Beijing Friendship Hospital","All","Child, Adult, Older Adult","Early Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","ESDLD2013|BeijingFHMH2013","December 2013","December 2018","December 2019","December 25, 2014","null","December 25, 2014","The capital health research and development of special, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT02325999"
1261,"NCT02324036","The EMPATHy Toolkit: Helping Diabetes Patients Overcome Barriers to Medication Adherence","EMPATHy","Completed","No Results Available","Diabetes Mellitus, Type 2","Device: EMPATHy Toolkit|Behavioral: Coached Care","Development of a contextualized plan of care (assessed by analyzing an audio recording of the medical visit)|Attainment of concrete behavioral goal (assessed in a two-week follow-up phone call to the patient)|Discussion of a contextual factor in the visit (assessed from audio recordings of the visit)|Improvement in ""red flag"" outcome (assessed from the patient's medical record as the change in the measured value of the outcome measure identified as a high priority outcome)","University of California, Irvine","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","190","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2014-1442","December 2014","June 2015","August 2015","December 24, 2014","null","December 2, 2015","Health Policy Research Institute, Irvine, California, United States","","https://ClinicalTrials.gov/show/NCT02324036"
1262,"NCT02323841","Feasibility Study: Conservative Treatment in Cervical Cancer",,"Unknown status","No Results Available","Stage IB1 Cervical Cancer","Procedure: conservative treatment","pregnancy rate|disease free survival|Overall survival","Catholic University of the Sacred Heart","Female","18 Years to 40 Years   (Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","12650/13","March 2014","March 2014","March 2015","December 24, 2014","null","December 24, 2014","Giovanni Scambia, Rome, Italy","","https://ClinicalTrials.gov/show/NCT02323841"
1263,"NCT02323828","High Resistant Starch (RS) Cookies and Appetite Control","RS","Completed","No Results Available","Metabolic Syndrome","Dietary Supplement: High RS cookies|Dietary Supplement: Placebo","Consumption of RS on appetite regulation","Catholic University of the Sacred Heart","All","20 Years to 24 Years   (Adult)","Early Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","24238/14","January 2013","March 2013","June 2013","December 24, 2014","null","January 27, 2016","","","https://ClinicalTrials.gov/show/NCT02323828"
1264,"NCT02323217","I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers","I2PETHV","Completed","No Results Available","Healthy Volunteers|Alzheimer Disease|Molecular Imaging","Radiation: [11C]BU99008|Drug: Idazoxan|Drug: Isocarboxazid","Density and distribution of Imidazoline 2 binding sites using either Total Volume of Distribution (VT) or Binding Potential (BP)|Intra- and Inter-Subject Variability in brain expression of Imidazoline 2 binding sites, measured using coefficient of variability (%COV), determined from either Total Volume of Distribution (VT) or Binding Potential (BP).|Peripheral distribution of Imidazoline 2 binding sites using either Total Volume of Distribution (VT) or Binding Potential (BP)","Imperial College London|GlaxoSmithKline","Male","40 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","14HH2250|MR/L01307X/1","January 2015","February 2016","July 2016","December 23, 2014","null","August 18, 2016","Centre for Neuropsychopharmacology; Division of Brain Sciences; Imperial College London; Burlington Danes Building; Hammersmith Hospital campus; 160 Du Cane Road, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02323217"
1265,"NCT02320006","Effect of Acupuncture on Incomplete Fallopian Tube Obstructive Infertility: Study Protocol for Trial",,"Unknown status","No Results Available","Female Infertility Due to Occlusion of Fallopian Tube","Other: acupuncture","tubal patency rate|pregnancy rate","Li Liu|First Affiliated Hospital of Heilongjiang Chinese Medicine University","Female","22 Years to 42 Years   (Adult)","Early Phase 1","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","FirstHeilongjiang","December 2014","December 2016","null","December 19, 2014","null","December 19, 2014","LiLiu, Harbin, Heilongjiang, China","","https://ClinicalTrials.gov/show/NCT02320006"
1266,"NCT02319915","Evaluation of the Pharmacokinetic Profile of Tranexamic Acid, After Injection in a Knee Neo-articulation.",,"Completed","No Results Available","Knee Prosthesis","Drug: Tranexamic Acid|Drug: Adrenalin","The pharmacokinetic profile of tranexamic acid|Knee diameter|Net weight of the compresses|Size of the blood stain on the band aid|Blood loss","Brugmann University Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","CHUB-PTGexacyl-001","February 18, 2015","March 14, 2017","March 14, 2017","December 18, 2014","null","January 19, 2018","CHU Brugmann, Brussels, Belgium","","https://ClinicalTrials.gov/show/NCT02319915"
1267,"NCT02319889","Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma",,"Terminated","No Results Available","Stage I Non-Small Cell Lung Cancer|Stage II Non-Small Cell Lung Cancer","Radiation: Stereotactic Body Radiotherapy|Drug: Carboplatin|Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation","Number of participants with prohibitive dose limiting toxicities|1 year progression free survival (PFS)","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","3","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE2514|NCI-2014-02276|CASE 2514|P30CA043703","February 2, 2016","July 6, 2016","January 19, 2017","December 18, 2014","null","February 1, 2017","University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02319889"
1268,"NCT02319356","Does Dietary Nitrate Supplementation Improve Aerobic Performance",,"Unknown status","No Results Available","Colorectal Cancer","Dietary Supplement: Beetroot juice|Dietary Supplement: Placebo beetroot juice","anaerobic threshold (AT)|maximal oxygen uptake (VO2Max)","Royal Surrey County Hospital NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","163841","March 2015","June 2015","June 2015","December 18, 2014","null","December 18, 2014","","","https://ClinicalTrials.gov/show/NCT02319356"
1269,"NCT02318433","Intra-Articular Dexamethasone to Prevent Post-Traumatic Osteoarthritis: A Pilot Study",,"Unknown status","No Results Available","Distal Radius Fracture|Osteoarthritis","Drug: Dexamethasone|Drug: Saline","PTOA incidence|Functional assessment|Patient-rated evaluations","Mayo Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","14-004033","December 2014","December 2016","December 2017","December 17, 2014","null","January 1, 2016","Mayo Clinic in Rochester, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02318433"
1270,"NCT02317341","Effect of Ketamine on Fatigue Following Cancer Therapy",,"Recruiting","No Results Available","Cancer|Fatigue|Ketamine","Drug: Ketamine|Drug: Placebo (saline)|Drug: Midazolam|Drug: Midazolam(placebo)","Change in fatigue score|Cognition, muscle strength, depression|Cytokines, neurotrophins, metabolic mark","National Institute of Nursing Research (NINR)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","150037|15-NR-0037","December 13, 2014","May 1, 2019","May 1, 2019","December 16, 2014","null","August 9, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02317341"
1271,"NCT02317211","Purified Anthocyanins Supplementation in Type 2 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus，Type 2","Dietary Supplement: Anthocyanin|Dietary Supplement: placebo","Glycemic Control|Biomakers related to oxidative stress|Blood lipids","Sun Yat-sen University|Shaoguan University","All","25 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","ZXYZM-1","February 2014","September 2014","September 2014","December 15, 2014","null","November 17, 2015","","","https://ClinicalTrials.gov/show/NCT02317211"
1272,"NCT02316834","Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","POSITION","Active, not recruiting","No Results Available","Fallopian Tube Serous Adenocarcinoma|High Grade Ovarian Serous Adenocarcinoma|Ovarian Mass|Primary Peritoneal Serous Adenocarcinoma|Stage III Fallopian Tube Cancer AJCC v7|Stage III Ovarian Cancer AJCC v6 and v7|Stage III Primary Peritoneal Cancer AJCC v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7","Other: Laboratory Biomarker Analysis|Drug: BMN 673","Change in deoxyribonucleic acid (DNA) copy number|Change in ribonucleic acid (RNA) protein expression|Overall survival|Tumor response|Tumor volume|Apoptosis|Completion Rate of BMN 673 to determine feasibility|Incidence of adverse events|Proportion of patients that exhibit an increase (or decrease) in RNA protein expression greater than 50%|Change in DNA copy number|Change in RNA protein expression","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-0474|NCI-2014-02608|P30CA016672|P50CA083639","June 2, 2015","June 1, 2019","June 1, 2020","December 15, 2014","null","September 24, 2018","M D Anderson Cancer Center, Houston, Texas, United States|The Woman's Hospital of Texas, Houston, Texas, United States|MD Anderson Regional Care Center-Katy, Houston, Texas, United States|MD Anderson Regional Care Center-Bay Area, Nassau Bay, Texas, United States|MD Anderson Regional Care Center-Sugar Land, Sugar Land, Texas, United States|MD Anderson Regional Care Center-The Woodlands, The Woodlands, Texas, United States","","https://ClinicalTrials.gov/show/NCT02316834"
1273,"NCT02316795","Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma",,"Completed","No Results Available","Breast Cancer|Cancer of Breast|Cancer of the Breast|Melanoma|Malignant Melanoma","Procedure: Sentinel lymph node biopsy|Device: Goggle-based device with light-emitting diodes (LED)|Drug: Indocynanine Green","Ability for the imaging device to identify the sentinel lymph node (SLN) during the SLN biopsy procedure compared to standard of care gamma-probe identification of the SLN","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201302102","February 2014","June 2015","December 2015","December 15, 2014","null","December 18, 2015","Washington University School of Medicine, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02316795"
1274,"NCT02316210","Optimization of Onpulse Technology for Patients With Post Surgical or Vascular Oedema","TURBO","Completed","No Results Available","Oedema|Neuropathy","Device: electrical stimulation","Observable foot twitch in response to stimulation with Digitimer DS7A|adverse events|oedema|patient rated tolerability questionnaire","Firstkind Ltd","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","FKD-TURB-001","May 2014","September 2015","September 2015","December 12, 2014","null","March 9, 2016","BMI Harbour hospital, Poole, Dorset, United Kingdom","","https://ClinicalTrials.gov/show/NCT02316210"
1275,"NCT02313363","Patient-Centered Smartphone-Based Diabetes Care",,"Completed","No Results Available","Type 2 Diabetes Mellitus","Device: patient-centered smartphone-based diabetes care system","change of HbA1c|change of fasting plasma glucose|change of lipid profile|change of body weight|change of the scores of Summary of Diabetes Self-Care Activities (SDSCA)","Seoul National University Hospital","All","20 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","H-1301-075-459","December 2013","March 2014","March 2014","December 10, 2014","null","December 10, 2014","","","https://ClinicalTrials.gov/show/NCT02313363"
1276,"NCT02312635","Augmentation of Cognitive Training in Children With TBI With D-Cyloserine","DCS","Unknown status","No Results Available","Traumatic Brain Injury","Drug: D-Cycloserine|Behavioral: Cogmed Working Memory Training","Cogmed Working Memory Training Program|Wide Range Assessment of Memory & Learning-2","University of California, Los Angeles","All","11 Years to 18 Years   (Child, Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1R21HD076418-01A1","December 2012","September 2016","December 2016","December 9, 2014","null","December 9, 2014","University of California, Los Angeles, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02312635"
1277,"NCT02311374","Human Brain Mapping of the Apparent Diffusion Coefficient (ADC) During Sleep and Wakefulness",,"Completed","No Results Available","Brain Mapping","Other: Brain connectivity and physiology","Apparent diffusion coefficient and electroencephalography will be measured during the period just prior to falling asleep and during sleep for each study participants.","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","18 Years to 45 Years   (Adult)","Early Phase 1","40","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","150031|15-AA-0031","December 5, 2014","May 11, 2018","May 11, 2018","December 8, 2014","null","November 5, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02311374"
1278,"NCT02308969","Neuronal Correlates of Altered States of Consciousness","5HT2A-fMRI","Completed","No Results Available","Healthy","Drug: LSD|Drug: Placebo","fMRI brain activity|Physiological effects (Association of alterations in consciousness and autonomic nervous system reactions (blood pressure, heart rate, pupil size)|Plasma hormone levels (Associations of alterations in consciousness with plasma hormone levels)","University Hospital, Basel, Switzerland","All","25 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","24","Other","Interventional","Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","EKNZ 2014-344","December 2014","September 2015","September 2015","December 5, 2014","null","September 25, 2015","University Hospital, Basel, Switzerland","","https://ClinicalTrials.gov/show/NCT02308969"
1279,"NCT02307435","Allogenic Mesenchymal Stem Cell for Bone Defect or Non Union Fracture","AMSC","Unknown status","No Results Available","Non Union Fracture|Metaphyseal Fibrous Defect","Biological: MSC","cell viability|lower extremity functional score|disabilities of arm shoulder and hand","Indonesia University","All","19 Years to 30 Years   (Adult)","Early Phase 1","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ISMMSC001","August 2014","December 2017","December 2017","December 4, 2014","null","December 4, 2014","University of Indonesia, Jakarta Pusat, Jakarta, Indonesia|Faculty of Medicine, University of Indonesia, Propinsi DKI Jakarta, Jakarta, Indonesia","","https://ClinicalTrials.gov/show/NCT02307435"
1280,"NCT02306473","The Leaky Lung Test",,"Completed","No Results Available","Asthma|Allergy|Reactive Airway Disease|Lung Diseases, Obstructive","Drug: Mannitol","Airway permeability index (Urinary clearance of mannitol overtime)|Absorption of mannitol (Absorption and clearance of mannitol from the bloodstream)","University of Rochester|National Institutes of Health (NIH)|Pharmaxis|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","100","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","RSRB00043414|R01HL122424","October 2015","December 1, 2017","December 1, 2017","December 3, 2014","null","January 4, 2018","University of Rochester Medical Center, Rochester, New York, United States","","https://ClinicalTrials.gov/show/NCT02306473"
1281,"NCT02304978","Prognostic Value of Tissue Factor (TF) in Blood t in Colorectal Cancer in Adults","TF","Recruiting","No Results Available","Colorectal Cancer","Biological: Group CRC|Biological: Group control","TNM primary colorectal tumor stage|TF (blood levels of soluble TF)|TF intratumoral (blood levels of TF intratumoral)|E- selectin and CRP|ACE|Interaction plate / tumor cell","University Hospital, Lille","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2008-09/0908|2009-A00264-53","June 22, 2009","June 2020","June 2020","December 2, 2014","null","April 24, 2018","Service de Chirurgie Digestive et de transplantation Hôpital Claude HURIEZ, Lille, France","","https://ClinicalTrials.gov/show/NCT02304978"
1282,"NCT02304432","Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine","DCS","Completed","Has Results","Schizophrenia|Bipolar Disorder","Drug: D-cycloserine|Drug: DCS or placebo","Positive and Negative Symptom Scores|Brief Psychiatric Rating Scale (BPRS) Scores|Clinical Global Impression (CGI) Severity Scores|Mania Symptom Scores|Depression Symptom Scores|Neurocognitive Function|Brain Glycine/CR Ratio|Auditory Evoked Potentials in Latency (Msec)|Auditory Evoked Potentials in Amplitude (Degrees Measured in Microvolts)|Auditory Evoked Potentials in Gamma Oscillations (the Power Spectrum is Measured in Microvolts Squared)|Auditory Evoked Potentials - P50 Ratio (P50 S2/S1) (Amplitude)","Mclean Hospital|University of Minnesota - Clinical and Translational Science Institute","All","34 Years to 62 Years   (Adult)","Early Phase 1","2","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1R21MH105732","September 27, 2015","September 30, 2016","July 31, 2017","December 2, 2014","September 19, 2017","September 19, 2017","","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02304432/ICF_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02304432/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02304432/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02304432"
1283,"NCT02304211","Intra-Arterial Microdosing: Proof-of-Concept in Humans","IAM-POC","Completed","No Results Available","Healthy","Drug: Insulin","Glucose Plasma Levels|18F-FDG Uptake as measured with Positron Emission Tomography (PET) imaging|Potassium Plasma Levels|Lactic Acid Plasma Levels","Duke University","Male","18 Years to 40 Years   (Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Pro00056933","December 2014","July 2015","July 2015","December 1, 2014","null","December 23, 2016","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02304211"
1284,"NCT02300740","Pharmacokinetic Analysis of Nicotinamide Riboside",,"Completed","No Results Available","Healthy Participants","Dietary Supplement: Nicotinamide riboside","Serum nicotinamide riboside|serum concentrations of metabolites of nicotinamide riboside|area under the curve for serum nicotinamide riboside|calculation of halftime of serum nicotinamide riboside|calculation of C-max of serum nicotinamide riboside|calculation of t-max of serum nicotinamide riboside","Aarhus University Hospital|University of Copenhagen","Male","18 Years to 30 Years   (Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","45141","December 2014","February 2015","null","November 25, 2014","null","February 27, 2015","Medical Research Laboratories, Aarhus University Hospital, Aarhus, Denmark","","https://ClinicalTrials.gov/show/NCT02300740"
1285,"NCT02297997","Preventive Effects of Cetylpyridinium Chloride on SarcopeniaStudy",,"Unknown status","No Results Available","Sarcopenia","Drug: cetylpyridinium chloride|Drug: Placebo","Change from baseline in procollagen type III N-terminal peptide|Change from baseline in myostatin|Change from baseline in TNF-α|Change from baseline in IL-6|Change from baseline in urinary creatinine|Change from baseline in CRP|Change from baseline in Hemoblobin|Change from baseline in Albumin|Change from baseline in Vitamin D","Seoul National University Hospital","All","60 Years and older   (Adult, Older Adult)","Early Phase 1","65","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","SNUHRM","November 2014","November 2015","November 2015","November 21, 2014","null","December 3, 2014","","","https://ClinicalTrials.gov/show/NCT02297997"
1286,"NCT02297646","Influencing Factors on Training Efficacy in Healthy Adults","CHO","Completed","No Results Available","Health Status|Maximal and Submaximal Parameters of Physical Performance","Behavioral: Endurance Training","Maximum oxygen consumption (VO2max)|Numerous serum parameters from venous blood (LDL, HDL, Cholesterol, Triglycerides)|Resting heart rate|Resting blood pressure|Body fat (Skinfold thickness)|Ventilatory anaerobic threshold (VT)","Saarland University","All","30 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","23","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Saarland University - CHO","August 2012","December 2013","December 2013","November 21, 2014","null","November 21, 2014","Institute of Sports and Preventive Medicine, Saarland University, Saarbrücken, Saarland, Germany","","https://ClinicalTrials.gov/show/NCT02297646"
1287,"NCT02297243","Sinopsys Lacrimal Stent Indicated for Sinus Irrigation","SLS","Completed","No Results Available","Ethmoid Sinusitis","Device: Sinopsys Lacrimal Stent","SNOT - 20|Patency will be confirmed post procedure with passive flow through the SLS lumen by instilling 2-4 drops of sterile saline into the stented medial fornix and observing drainage.|Safety: Incidence and occurrence of anticipated and unanticipated adverse events|Lund-MacKay CT Scores|Lund-Kennedy Nasal Endoscopy Scores","Sinopsys Surgical","All","22 Years and older   (Adult, Older Adult)","Early Phase 1","9","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SLS-US-02","March 2015","February 2016","February 2016","November 21, 2014","null","February 12, 2016","Stanford University, Stanford, California, United States|Front Range ENT, Greeley, Colorado, United States|Advanced ENT and Allergy, Louisville, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT02297243"
1288,"NCT02296437","Transcranial Direct Current Stimulation (tDCS) and Cognitive Task in Depression","tDCS + CT","Recruiting","No Results Available","Depression","Other: Transcranial direct current stimulation combined with cognitive training","Montgomery and Asberg Depression Rating Scale (MADRS)","The University of New South Wales|Icahn School of Medicine at Mount Sinai","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HC14216","November 2014","November 2019","null","November 20, 2014","null","October 17, 2017","University of New South Wales, Sydney, New South Wales, Australia","","https://ClinicalTrials.gov/show/NCT02296437"
1289,"NCT02295956","Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer",,"Active, not recruiting","No Results Available","Pancreatic Cancer","Behavioral: Questionnaires|Other: Exercise|Other: Nutrition Counseling|Behavioral: Phone Calls|Other: Booklet","Feasibility of Prehabilitation Program Among Pancreatic Patients","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","75","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2014-0702|NCI-2014-02531","February 2, 2015","February 1, 2020","February 1, 2021","November 20, 2014","null","January 24, 2018","University of Houston, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02295956"
1290,"NCT02295293","The Effects of Rhus Coriaria L. on Serum Lipid Levels of Patients With Hyperlipidemia","SomaghLipid","Completed","No Results Available","Hyperlipidemias","Drug: Rhus Coriaria L. (Rhus)|Drug: Placebo","Serum total cholesterol level|Serum triglyceride level|Serum HDL-cholesterol level|Serum LDL-cholesterol level|Fasting Blood Sugar (FBS)|Serum creatinin level|Serum ALT level|Serum AST level|Serum alkaline phosphatase level|Number of patients with adverse events","Shiraz University of Medical Sciences","All","20 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CT-P-92-5581","December 2014","April 2015","May 2015","November 20, 2014","null","June 7, 2016","Shahid Motahhari Clinic, Shiraz University of Medical Sciences, Shiraz, Fars, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT02295293"
1291,"NCT02293486","Study of Pomegranate Juice in the Modulation of Oxidative Stress Markers in Endurance-based Athletes",,"Completed","No Results Available","Oxidative Stress","Dietary Supplement: Pomegranate juice","Protein carbonyls levels changes in plasma|Malondialdehyde levels changes in plasma|Blood biochemical parameters changes in plasma|C-reactive protein levels changes in plasma|Soluble E-selectin levels changes in plasma","Universidad Miguel Hernandez de Elche|Vitalgrana Pomegranate SL","Male","18 Years to 50 Years   (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GRA 01","August 2012","December 2012","February 2013","November 18, 2014","null","November 18, 2014","","","https://ClinicalTrials.gov/show/NCT02293486"
1292,"NCT02292888","Can Changes in Velocity Time Integral Serve as a Sensitive Indicator for Monitoring Changes in Stroke Volume ?",,"Unknown status","No Results Available","Ischemic Heart Disease","Other: Passive Leg Raising (PLR) test","Whether a change in Doppler VTI before and after passive leg raising test (PLR) correctly reflects changes in stroke volume measured by CCO PA catheter","Fortis Hospital, India","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Screening","FortisH","December 2014","December 2015","null","November 17, 2014","null","November 18, 2014","","","https://ClinicalTrials.gov/show/NCT02292888"
1293,"NCT02292342","An Investigation of the Dose-dependent Vascualr Effects of (-)-Epicatechin in Healthy Men",,"Completed","No Results Available","Vasodilation","Dietary Supplement: Water|Dietary Supplement: Epicatechin 0.1 mg/kg|Dietary Supplement: Epicatechin 0.5 mg/kg|Dietary Supplement: Epicatechin 1.0 mg/kg","Flow mediated dilatation|Laser Doppler Imaging with Iontophoresis|Plasma (-)-epicatechin metabolites|Plasma nitrate/nitrite","University of Reading","Male","18 Years to 40 Years   (Adult)","Early Phase 1","21","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","EpicatechinStudy","May 2014","February 2016","May 2016","November 17, 2014","null","May 30, 2016","Department of Food and Nutritional Sciences, Reading, Berkshire, United Kingdom","","https://ClinicalTrials.gov/show/NCT02292342"
1294,"NCT02289235","The Effects of Ginger on Nonalcoholic Fatty Liver Disease","GinLiv","Unknown status","No Results Available","Fatty Liver","Drug: Ginger|Drug: Placebo","Change in ALT (liver transaminases) level|Change in grade of fatty liver in sonography by use of Saverymuttu Scoring System|Change in AST (liver transaminases) level|Change in Gama GT (γ-glutamyl transpeptidase) levels|Number of patients with adverse events","Shiraz University of Medical Sciences","All","20 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CT-P-9364-6254","November 2014","November 2016","February 2017","November 13, 2014","null","February 24, 2016","Shahid Motahhari Clinic, Shiraz University of Medical Sciences, Shiraz, Fars, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT02289235"
1295,"NCT02287285","Determinants of Diabetes Remission After Gastric Bypass Surgery",,"Active, not recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: Exendin9","Beta Cell Sensitivity (BCS)|Insulin Secretion Rate (ISR) after OGTT|Insulin Secretion Rate (ISR) after GGI|Maximal Beta Cell Function","Blandine Laferrere|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Columbia University","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","25","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAO1360|1R01DK098056-01A1|1F32DK113747-01A1","October 2014","August 2017","October 2018","November 10, 2014","null","May 18, 2018","New York Obesity Research Center, Columbia University, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02287285"
1296,"NCT02287168","Effect of Peritoneal Lavage on Surgery-induced Positive Peritoneal Cytology in Gastric Cancer Patients",,"Completed","No Results Available","Gastric Adenocarcinoma|Gastric Cancer","Procedure: pre-gastrectomy peritoneal washing cytology|Procedure: post-gastrectomy peritoneal washing cytology|Procedure: post-lavage peritoneal washing cytology","elimination|dissemination","Bezmialem Vakif University","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","34","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GastCancPerLav2014","October 2014","December 2015","December 2015","November 10, 2014","null","March 29, 2016","Bezmialem Vakif University Faculty of Medicine Dept of General Surgery, Istanbul, Turkey|Mustafa Hasbahceci, Istanbul, Turkey","","https://ClinicalTrials.gov/show/NCT02287168"
1297,"NCT02285738","Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis",,"Recruiting","No Results Available","Solid Tumor|Cancer","Drug: Aspirin|Drug: Simvastatin|Other: Observation","Change in average sP-selectin levels|Frequency of major bleeding complications or clinically significant non-bleeding complications per patient|Change in average Platelet Factor 4|Change in average CD40 ligand|Change in average serum thromboxane B2|Change in average serum VEGF|Change in average serum angiopoietin-2|Change in average serum hepatocyte growth factor|Change in average serum PECAM|Change in average serum PDGF|Change in average plasma F1.2|Change in average plasma TAT complexes|Change in average plasma D-dimer|Change in the number of thrombotic events","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CASE8Y14","December 30, 2014","December 2018","December 2018","November 7, 2014","null","October 4, 2018","Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02285738"
1298,"NCT02285491","Local Anesthetic Injection Into Both Angles of the Rectus Sheath Incision",,"Completed","No Results Available","Postoperative Cesarean Delivery Pain","Drug: 10ml of bupivacaine 0.5%|Drug: Placebo","Pain assessment during rest and ambulation by visual analogue scale","Ain Shams Maternity Hospital","Female","20 Years to 40 Years   (Adult)","Early Phase 1","225","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","els7680","November 2014","November 2015","November 2015","November 7, 2014","null","February 9, 2016","Ain Shams Maternity Hospital, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT02285491"
1299,"NCT02284815","Can Gluten-free Diet Prevent the Destruction of Beta-cells During Remission?",,"Unknown status","No Results Available","Diabetes Mellitus, Type 1","Dietary Supplement: Glutenfree diet","C-peptide change from baseline to 12 months follow-up|Insulin Adjusted HbA1c change from baseline to 12 months follow-up|Insulin per kg from baseline to 12 months follow-up|Microbiota (feces samples) change from baseline to 6 months follow-up|Immune system (Th1 and Th2 cytokines) change from baseline to 12 months follow-up","Herlev Hospital","All","2 Years to 18 Years   (Child, Adult)","Early Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DIRECT-2011-119","March 2012","June 2015","August 2015","November 6, 2014","null","November 6, 2014","","","https://ClinicalTrials.gov/show/NCT02284815"
1300,"NCT02282917","Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma",,"Active, not recruiting","No Results Available","Vestibular Schwannoma|Meningioma|Acoustic Neuroma|Neurofibromatosis Type 2","Drug: AR-42","Expression levels of phospho-Akt (p-AKT) and p16INKA after 3 weeks of oral AR-42|Biological effects onPI3K (including levels of p-AKT, total AKT, p-PRAS-40, total PRAS-40, p-S6 ribosomal protein, and p-4E-BP-1)|Biological effects on tumor proliferation (as assessed by Ki-67 proliferation index), etc.|The utility of HR23B as a biomarker for sensitivity of VS and meningiomas|Gene sequencing (tumor and germ-line DNA)|Audiometric changes by conventional pure tone and speech discrimination testing|Volumetric tumor reduction by magnetic resonance imaging.|Steady-state plasma and intra-tumoral concentrations of AR-42","Massachusetts Eye and Ear Infirmary|Johns Hopkins University|Mayo Clinic|Stanford University|Ohio State University|Nationwide Children's Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-078H","September 2015","October 2018","October 2018","November 5, 2014","null","September 21, 2018","Stanford University, Stanford, California, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts Eye and Ear, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02282917"
1301,"NCT02282904","Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide",,"Active, not recruiting","No Results Available","Chronic Granulomatous Disease","Drug: Pre-Transplant Conditioning Medications|Other: Haploidentical Cellular Infusion|Drug: Post-Trasnplant Medications|Radiation: Total Body Irradiation","To use a subablative conditioning regimen followed by post-transplant cyclophosphamide to attain an engraftment rate of 100% with no occurrence of acute Grade 3 or higher GvHD (graft versus host disease).|Stable Chimerism as indicated by 30-50% myeloid engraftment and 50% lymphoid engraftment as assessed by 1 year post transplant|Immune reconstitution levels with DHR as a marker of normal neutrophil function by 1 year post transplant.","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","2 Years to 65 Years   (Child, Adult, Older Adult)","Early Phase 1","12","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","150007|15-I-0007","November 4, 2014","March 1, 2022","March 1, 2023","November 5, 2014","null","November 2, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02282904"
1302,"NCT02282072","PINS Stimulator System for Deep Brain Stimulation of the Nucleus Accumbens to Treat Severe Opioid Addiction",,"Not yet recruiting","No Results Available","Opioid Addiction","Device: Deep brain stimulation：PINS Stimulation System","Schedule for the Assessment of Negative Symptoms (SANS)|Chronic Hunger Scale|Beck Depression Inventory|Buss & Perry Aggression Questionnaire","Beijing Pins Medical Co., Ltd|Beijing Tiantan Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","PINS-003","December 2016","September 2018","December 2018","November 4, 2014","null","October 14, 2016","Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT02282072"
1303,"NCT02280109","Comparison of Tenofovir Vaginal Gel and Film Formulations","FAME-05","Completed","No Results Available","Healthy|HIV","Drug: Tenofovir Gel|Drug: Tenofovir Film","Plasma tenofovir concentration-time curve (AUC0-72) for each product (film and gel) 0 thru 72 hours after dosing|PBMC tenofovir diphosphate concentration-time curve (AUC0-72) for each product (film and gel) 0 thru 72 hours after dosing|Cervical tissue tenofovir maximum concentration (Cmax) at 5 hours|Cervical tissue tenofovir maximum concentration (Cmax) at 72 hours|Cervical tissue tenofovir diphosphate maximum concentration (Cmax) at 5 hours|Cervical tissue tenofovir diphosphate maximum concentration (Cmax) at 72 hours|Cervicovaginal fluid tenofovir maximum concentration (Cmax) at 5 hours|Cervicovaginal fluid tenofovir maximum concentration (Cmax) at 72 hours|Rectal fluid tenofovir maximum concentration (Cmax) at 5 hours|Rectal fluid tenofovir maximum concentration (Cmax) at 72 hours|All adverse clinical and laboratory events|Cumulative HIV p24 protein concentration from 0 to 15 days post ex-vivo infection of explant cervical tissue collected at 5 hours after dosing with tenofovir gel or film|Cumulative HIV p24 protein concentration from 0 to 15 days post ex-vivo infection of explant cervical tissue collected at 72 hours after dosing with tenofovir gel or film","CONRAD|National Institute of Allergy and Infectious Diseases (NIAID)","Female","18 Years to 45 Years   (Adult)","Early Phase 1","10","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","DAIDS-ES #12015|U19AI082639","November 2014","December 2015","null","October 31, 2014","null","January 28, 2016","Johns Hopkins University School of Medicine Division of Clinical Pharmacology, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02280109"
1304,"NCT02279992","Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases","LevitraCarbo","Terminated","No Results Available","Glioma|Brain Neoplasms|Brain Metastasis","Drug: Vardenafil|Drug: Carboplatin","Concentration of intratumoral carboplatin in tumor tissue and serum samples|Safety and tolerability of vardenafil in combination with carboplatin using common terminology criteria for adverse events (CTCAE) version 3.0","Cedars-Sinai Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","7","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSMC IIT: Levitra Carboplatin|Pro00017009","March 27, 2012","October 13, 2013","February 11, 2016","October 31, 2014","null","September 11, 2017","Cedars-Sinai Medical Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02279992"
1305,"NCT02278510","Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma",,"Completed","No Results Available","Malignant Glioma|WHO Grade III or IV Recurrent Glioma","Drug: Topotecan|Drug: Gadolinium DTPA|Device: Cleveland Multiport Catheter","Spatial distribution of topotecan|Number of catheter- and/or drug-related complications|Objective response rate of subjects given topotecan|Median progression-free survival of HGG subjects given topotecan|Median overall survival of HGG subjects given topotecan|Proportion of progression free HGG subjects given topotecan","Michael Vogelbaum, MD, PhD|Infuseon Therapeutics, Inc.|Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","3","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INFT1314|NCI-2014-02248","December 9, 2014","November 10, 2015","November 10, 2015","October 30, 2014","null","March 31, 2017","Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02278510"
1306,"NCT02278328","MEG Study of STX209",,"Active, not recruiting","No Results Available","Autism Disorder","Drug: STX209|Drug: placebo","Responsiveness (sensitivity to change) of MEG measures to acute administration of STX209 at 2 dose levels.","Timothy Roberts|Simons Foundation|Clinical Research Associates, LLC|Children's Hospital of Philadelphia","Male","14 Years to 17 Years   (Child)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","14-010857","February 2016","January 1, 2019","August 2019","October 30, 2014","null","October 22, 2018","Children's Hospital of Phladelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02278328"
1307,"NCT02277808","Which Apparatus for Inhaled Pentamidine?",,"Unknown status","No Results Available","Healthy","Drug: 500mg Amikacine (Amukin®) diluted in 4mL NaCl (0,9%)|Device: Respirgard II|Device: Isoneb®","Amikacine urinary dosage","Cliniques universitaires Saint-Luc- Université Catholique de Louvain","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Nebulizers for pentamidine","December 2013","October 2014","null","October 29, 2014","null","October 29, 2014","Clinique universitaire Saint-Luc, Brussels, Belgium","","https://ClinicalTrials.gov/show/NCT02277808"
1308,"NCT02277522","CD19 Redirected Autologous T Cells for Hodgkin Lymphoma",,"Terminated","No Results Available","Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis","Biological: RNA anti-CD19 CAR T cells","Number of Adverse Events","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 04414, 820840","October 2014","November 2016","June 27, 2017","October 29, 2014","null","November 9, 2017","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02277522"
1309,"NCT02277457","Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations",,"Withdrawn","No Results Available","Non-Small Cell Lung Cancer","Radiation: PET-Adaptive RT|Drug: Erlotinib|Drug: Crizotinib","Time to Progression From the Initiation of Study Treatment For ALK + and EGFR + Patients|Time to Death From Initiation of Study Treatment For ALK + and EGFR + Patients|The Number of Patients Experiencing Pneumonitis and Esophagitis|The Number of Patients Experiencing Grade 3 or Higher Toxicities","University of Michigan Cancer Center|Augusta University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMCC 2014.117|HUM00094166","September 2015","June 2021","null","October 29, 2014","null","June 24, 2016","University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02277457"
1310,"NCT02276677","Oxytocin Effects on Food Motivation Pathways",,"Completed","No Results Available","Overweight and Obesity","Drug: Oxytocin|Drug: Placebo","Change in functional magnetic resonance imaging activation of food motivation brain regions|Change in hormone levels (cholecystokinin, glucagon-like peptide-1)","Massachusetts General Hospital","Male","18 Years to 45 Years   (Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","SPID 1127","October 2014","May 2015","May 2015","October 28, 2014","null","February 8, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02276677"
1311,"NCT02274571","Raising Insulin Sensitivity in Post Menopause","RISE","Completed","No Results Available","Menopause","Drug: TSEC (Tissue-selective estrogen complexes)|Other: Placebo","2-step hyperinsulinemic clamp at 90 mg/dl glucose with resting metabolic rate measure|Metabolic rate|Body Composition","Pennington Biomedical Research Center","Female","50 Years to 60 Years   (Adult)","Early Phase 1","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","PBRC 2014-039","September 2015","April 11, 2017","April 11, 2017","October 24, 2014","null","December 15, 2017","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT02274571"
1312,"NCT02272556","Investigating the Role of the Polyol Pathway in the Central Nervous System",,"Recruiting","No Results Available","Hyperglycemia","Other: Brain MRS during hyperglycemic clamp|Other: Analysis of Metabolites in cerebrospinal fluid","Metabolite Measurements by MRS|Hunger Ratings|Satiety Ratings|Cognitive State","Yale University","All","18 Years to 55 Years   (Adult)","Early Phase 1","45","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","1408014461","February 2015","November 2018","November 2019","October 23, 2014","null","January 11, 2018","Yale University, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02272556"
1313,"NCT02271165","Subcutaneous Immunoglobulin (Hizentra) in Patients With Dermatomyositis: A Proof of Concept Study",,"Terminated","No Results Available","Dermatomyositis","Drug: Immunoglobulin (Hizentra)","The primary outcome is a change in strength (based on MRC sumscores) from baseline (enrollment) to the mean change at weeks 16, 20, 24 and 28.|The main secondary outcome is the preference of the participant for SCIg compared with IVIg","Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","2","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13P.192","November 2014","March 2, 2017","March 2, 2017","October 22, 2014","null","May 16, 2018","Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02271165"
1314,"NCT02270619","Sleep Health, Inflammation, and Emotion Study","SHINE","Recruiting","No Results Available","Depression","Biological: Endotoxin|Behavioral: Partial sleep deprivation|Other: Placebo|Other: Uninterrupted sleep","Change in depressive symptoms from baseline|Change in fatigue from baseline|Change in pain from baseline|Anhedonia","University of California, Los Angeles","Female","60 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","K23AG049085","October 2014","October 2019","January 2020","October 21, 2014","null","October 16, 2018","UCLA Cousins Center for Psychoneuroimmunology, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02270619"
1315,"NCT02269540","A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A)",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Sertraline|Drug: Citalopram|Drug: N-acetylcysteine (NAC)|Drug: Existing depression medication treatment","MAO-A distribution volume with positron emission tomography|Hamilton Depression Rating Scale Score|Magnetic Resonance Spectroscopy (n-acetylaspartate and glutathione levels)|Blood markers of monoamine oxidase-A fragment level and glutathione level","Centre for Addiction and Mental Health","All","18 Years to 49 Years   (Adult)","Early Phase 1","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","137/2013","October 2014","June 2018","July 2018","October 21, 2014","null","February 14, 2018","Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02269540"
1316,"NCT02268565","Preventing the Inflammatory Response to Experimentally-induced Insomnia Symptoms",,"Completed","No Results Available","Insomnia","Drug: Aspirin|Drug: Placebo","Inflammation|Pain sensitivity","Beth Israel Deaconess Medical Center","All","18 Years to 35 Years   (Adult)","Early Phase 1","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","2014P000269","October 2014","October 2016","December 2016","October 20, 2014","null","March 15, 2017","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02268565"
1317,"NCT02265861","Response of VEGF and AT-II to HCG in PCOS",,"Completed","No Results Available","Polycystic Ovary Syndrome","Drug: HCG","Levels of vascular endothelial growth factor(VEGF) and angiotensin-Ⅱ(AT-Ⅱ)","Nanjing University School of Medicine","Female","21 Years to 35 Years   (Adult)","Early Phase 1","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","NanjingUSMwy","January 2010","June 2012","December 2012","October 16, 2014","null","October 16, 2014","","","https://ClinicalTrials.gov/show/NCT02265861"
1318,"NCT02263417","A Randomized Controlled Trail Comparing Subthalamic and Pallidal Deep Brain Stimulation for Dystonia",,"Recruiting","No Results Available","Dystonia","Device: Deep Brain Stimulation (DBS) of Gpi|Device: Deep Brain Stimulation (DBS) of STN","Burke-Fahn-Marsden Scale (BFM)|Quality of life (SF-36)|Psychiatric assessment (HADS-D and PANSS)","Beijing Pins Medical Co., Ltd|Peking Union Medical College Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","PINS-005","July 2015","December 2018","December 2018","October 13, 2014","null","October 11, 2016","Peking union medical college hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT02263417"
1319,"NCT02263404","PINS Stimulator System to Treat Severe Anorexia Nervosa",,"Not yet recruiting","No Results Available","Anorexia Nervosa","Device: Deep Brain Stimulation","Eating Disorder Related Preoccupations and Rituals|Hamilton Depression Rating Scale|Health Survey Short Form (SF-36)","Beijing Pins Medical Co., Ltd|Beijing Tiantan Hospital","All","20 Years to 60 Years   (Adult)","Early Phase 1","16","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PINS-004","December 2016","December 2018","December 2018","October 13, 2014","null","October 14, 2016","","","https://ClinicalTrials.gov/show/NCT02263404"
1320,"NCT02261857","3D-Printed CPAP Masks for Children With Obstructive Sleep Apnea",,"Recruiting","No Results Available","Sleep Apnea, Obstructive|Craniofacial Abnormalities|Pediatric Disorder","Device: Personalized continuous positive airway pressure (CPAP) mask","Change in CPAP Compliance at 1 month|Change in CPAP Leak Rate at 1 month|Change in residual AHI on CPAP at 1 month|Change in time spent in large leak on CPAP at 1 month|Change in Quality of Life via OSA-18 questionnaire|Safety outcomes: Comfort at baseline|Safety outcomes: Comfort at 1 month|Safety outcomes: Skin reaction at 1 month|Change in Quality of Life via PSQ questionnaire|Safety outcomes: durability at 1 month|Safety outcomes: Skin reaction at 12 months|Safety outcomes: Durability at 12 months","Glenn Green|American Academy of Otolaryngology-Head and Neck Surgery Foundation|University of Michigan","All","1 Year to 18 Years   (Child, Adult)","Early Phase 1","5","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HUM00078727","September 2013","January 2019","January 2019","October 10, 2014","null","July 2, 2018","University of Michigan, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02261857"
1321,"NCT02260856","A Randomized Controlled Trial of Leg Length Discrepancy Techniques",,"Recruiting","No Results Available","Leg Length Discrepancy","Device: Tantalum Beads & Injector|Procedure: Percutaneous Drill Epiphysiodesis|Procedure: Percutaneous Screw Epiphysiodesis","Failure of Epiphysiodesis|Change in Physeal Growth|Time to Baseline Pain|Quality of Life|Length of Hospital Stay|Time to full weight-bearing|Need for Splint or Cast|Days Until Return to Sports|Need for Secondary Surgery|Physical Activity Level|Complications|Medical Costs|Operative Outcomes|Radiographic Assessments","Hospital for Special Surgery, New York|Boston Children’s Hospital|The Hospital for Sick Children","All","7 Years to 18 Years   (Child, Adult)","Early Phase 1","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","2014-174","June 2015","June 2019","June 2020","October 9, 2014","null","October 10, 2018","Boston Children's Hospital, Boston, Massachusetts, United States|Hospital for Special Surgery, New York, New York, United States|Hospital for Sick Children, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02260856"
1322,"NCT02259686","Cardiovascular Effects of Apelin In Healthy Volunteers",,"Completed","No Results Available","Healthy","Drug: Apelin 1mg subcutaneous|Drug: Apelin 1mg intravenous|Drug: Apelin 5mg subcutaneous|Drug: Apelin 5mg intravenous|Drug: Apelin 10 mg subcutaneous","Change in cardiac output between different methods of apelin administration.|Change in blood pressure between different methods of apelin administration.|Change in apelin concentrations between the different methods of administration","University of Edinburgh|NHS Lothian","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","14","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","Apelin2014","November 2014","May 2015","May 2015","October 8, 2014","null","June 1, 2015","Clinical Research Facility University of Edinburgh, Edinburgh, United Kingdom|Wellcome Trust Clinical Research Facility. Western General Hospital, Edinburgh, United Kingdom","","https://ClinicalTrials.gov/show/NCT02259686"
1323,"NCT02259309","Immune Modulation by Misoprostol",,"Completed","No Results Available","Gynecological Infection","Drug: Misoprostol - buccal|Drug: Misoprostol - vaginal","Comparison of misoprostol drug levels in patients after vaginal and buccal administration|Comparison of cytokine and chemokine levels in patients after vaginal and buccal administration|Determination of immune cell activation state after vaginal and buccal administration|Sequencing of 16S rRNA gene for microbial ecology studies after vaginal and buccal administration","Vanderbilt University|Gynuity Health Projects","Female","18 Years to 45 Years   (Adult)","Early Phase 1","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","140667","November 2014","July 2015","November 2015","October 8, 2014","null","January 14, 2016","Vanderbilt University Medical Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT02259309"
1324,"NCT02259049","The Effects of L-Tyrosine on 24 Hour Blood Pressure and Heart Rate in Parkinson's Disease",,"Completed","No Results Available","Blood Pressure","Dietary Supplement: L-tyrosine|Dietary Supplement: Sugar Pill","Blood Pressure|Heart Rate","New York Institute of Technology","All","40 Years to 84 Years   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","BHS-1056","October 2014","September 2015","September 2015","October 8, 2014","null","January 20, 2016","New York Institute of Technology, Old Westbury, New York, United States","","https://ClinicalTrials.gov/show/NCT02259049"
1325,"NCT02258061","Optimal Cardiac Resynchronization Therapy Pacing Rate",,"Completed","No Results Available","Cardiac Resynchronization Therapy|Heart Failure|Bi-ventricular Pacing|Sympathetic Activity|Quality of Life","Procedure: DDD-80|Procedure: DDD-60","N-terminal pro-brain natriuretic peptide|Autonomic nerve function|Peak oxygen consumption (pVO2)|Self-perceived quality of life","Rigshospitalet, Denmark","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","H-3-2011-034","August 2011","June 2013","June 2013","October 7, 2014","null","October 7, 2014","Rigshospitalet, University hospital of Copenhagen, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT02258061"
1326,"NCT02256865","Hormonal Mechanisms of Sleep Restriction",,"Active, not recruiting","No Results Available","Insulin Resistance","Drug: Ketoconazole|Drug: Hydrocortisone|Drug: Testosterone|Drug: Placebo for ketoconazole|Drug: Placebo for hydrocortisone|Drug: Placebo for testosterone","Insulin Sensitivity|Disposition index|C-peptide glucose dose-response|Lapses on Psychomotor Vigilance Task|Karolinska Sleepiness Scale|Urinary Catecholamines|Heart Rate Variability|Free Fatty Acid Concentrations|Inflammatory marker panel|Computerized cognitive testing|Bone turnover panel|Food cravings,|Assessment of mood states.|Food intake|Hunger measurement","Los Angeles Biomedical Research Institute","Male","22 Years to 45 Years   (Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","30068-01","October 2014","November 2017","October 2019","October 6, 2014","null","February 2, 2018","Los Angeles Biomedical Research Institute, Torrance, California, United States","","https://ClinicalTrials.gov/show/NCT02256865"
1327,"NCT02254642","Effects of Ischemic Preconditioning After Aortic Clamping",,"Not yet recruiting","No Results Available","Vascular Surgery|Ischemia-reperfusion|Ischemia Preconditioning","Procedure: Ischemic preconditioning during aortic clamping|Procedure: Procedure/Surgery: usual surgery","Myocardial damage measured by troponin level > 0.4 microgr/L (day 1)|Renal damage|Muscle weakness|Lung damage|Myocardial damage measured by troponin level > 0.4 microgr/L","University Hospital, Strasbourg, France","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","5831","November 2016","July 2020","July 2020","October 2, 2014","null","October 20, 2016","Service de Chirurgie Vasculaire, CH Jean Minjoz, Besancon, France|Service de Chirurgie Vasculaire, CHU le Bocage, Dijon, France|Service de Chirurgie vasculaire et transplantation rénale, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France|Service de Chirurgie Vasculaire, Hôpitaux Privés de Metz, Site de Mercy, Vantoux, France","","https://ClinicalTrials.gov/show/NCT02254642"
1328,"NCT02254395","PINS Stimulator System for Deep Brain Stimulation to Treat Obesity",,"Not yet recruiting","No Results Available","Obesity","Device: Deep Brain Stimulation","Body Weight|Body Mass Index (BMI)|Food Intake","Beijing Pins Medical Co., Ltd|Beijing Tiantan Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","8","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","PINS-010","December 2016","December 2018","December 2018","October 1, 2014","null","October 14, 2016","","","https://ClinicalTrials.gov/show/NCT02254395"
1329,"NCT02253498","The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Tourette Syndrome",,"Not yet recruiting","No Results Available","Tourette Syndrome","Device: deep brain stimulation (DBS)","Modified Rush Video Rating Scale (mRVRS)|Tourette Syndrome Symptom List (TSSL)|SF-36","Beijing Pins Medical Co., Ltd|Beijing Tiantan Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","PINS-009","December 2016","December 2018","December 2018","October 1, 2014","null","October 14, 2016","","","https://ClinicalTrials.gov/show/NCT02253498"
1330,"NCT02253472","The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Obsessive-Compulsive Disorder",,"Not yet recruiting","No Results Available","Obsessive-Compulsive Disorder","Device: Deep Brain Stimulation","Yale-Brown obsessive-compulsive psychiatrists rating scale(Y-BOCS)|Hamilton anxiety scale (HAMD)","Beijing Pins Medical Co., Ltd|Beijing Tiantan Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","30","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","PINS-008","December 2016","December 2018","December 2018","October 1, 2014","null","October 14, 2016","","","https://ClinicalTrials.gov/show/NCT02253472"
1331,"NCT02253355","PINS Stimulator System for Patients With Treatment Resistant Depression",,"Not yet recruiting","No Results Available","Treatment-Resistant Depression","Device: Deep Brain Stimulation","Changes in the Hamilton Depression Rating Scale-17|The incidence of all adverse events","Beijing Pins Medical Co., Ltd|Beijing Tiantan Hospital","All","20 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","20","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","PINS-006","December 2016","December 2018","December 2018","October 1, 2014","null","October 14, 2016","","","https://ClinicalTrials.gov/show/NCT02253355"
1332,"NCT02253004","Induction of Migraine Aura With Cilostazol",,"Completed","No Results Available","Migraine With Aura|Stroke","Drug: Cilostazol|Drug: Placebo","Aura|Migraine|Endothelial response","Herlev Hospital","All","18 Years to 50 Years   (Adult)","Early Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","H-3-2013-166|2013-004188-29","September 2014","August 2015","August 2015","October 1, 2014","null","August 21, 2015","Herlev Hospital, Dept Neurology, Herlev, Denmark","","https://ClinicalTrials.gov/show/NCT02253004"
1333,"NCT02252809","Effect of Anti-Inflammatory Agents on Biological Responses to Endotoxin Inhalation in Healthy Subjects",,"Completed","No Results Available","Innate Immunity","Drug: adalimumab|Drug: methylprednisolone","sputum cells count","Brugmann University Hospital","All","18 Years to 49 Years   (Adult)","Early Phase 1","51","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","FXT-01","November 2008","April 2009","July 2009","September 30, 2014","null","September 30, 2014","","","https://ClinicalTrials.gov/show/NCT02252809"
1334,"NCT02251626","Assessing Bioavailability of CoQ10 Supplementation in Burn Patients","CoQ10","Unknown status","No Results Available","Burn Injury","Dietary Supplement: coenzyme Q10|Dietary Supplement: Placebo","Coenzyme Q10 Content in Peripheral Blood Mononuclear Cells|Plasma Coenzyme Q10 Concentration|Plasma Mitochondrial DNA Concentration|Plasma cytokine concentrations","Massachusetts General Hospital|Kaneka Pharma America LLC","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","2013P001111","April 2014","April 2017","June 2017","September 29, 2014","null","September 15, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02251626"
1335,"NCT02250053","Exercise and Colon Cancer",,"Unknown status","No Results Available","Stage II Colon Cancer|Stage III Colon Cancer","Other: Exercise","1. The biological efficacy of aerobic exercise on soluble intercellular adhesion molecule-1 (sICAM-1), and soluble vascular adhesion molecule-1 (sVCAM-1) prognostic biomarkers.|Exercise adherence, quantified as the percentage of total dose completed relative to the total dose prescribed during the six-month study;|Visceral adipose tissue and anthropometric measures at baseline and six-months;|Fasting insulin measured at baseline and six-months;|Circulating tumor cells measured at baseline and six-months.","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","39","Other","Interventional","Primary Purpose: Treatment","UPCC 10214","December 2015","January 2016","null","September 26, 2014","null","September 1, 2016","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02250053"
1336,"NCT02246517","The Effect of N2O on Chronic Neuropathic Pain Patients","N2O","Unknown status","No Results Available","Neuropathic Pain","Drug: N2O|Drug: Oxygen","change in adult pain as measured by visual Analog Scale for Pain (VAS Pain)|change in adult pain as measured by Short-Form McGill Pain Questionnaire (SF-MPQ)","Tel-Aviv Sourasky Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TASMC-14-SB-0318-CTIL","September 2014","December 2015","null","September 22, 2014","null","September 22, 2014","Pain Medicine Unit, Tel Aviv, Israel","","https://ClinicalTrials.gov/show/NCT02246517"
1337,"NCT02244840","Anal Resting Pressure After Bidet, Compared to Sitz Bath","Bidet(2)","Completed","Has Results","Anorectal Disorders","Device: Electronic bidet|Device: Sitz bath","Anal Resting Pressure Change|Convenience","Seoul National University Hospital|Coway Research and Development Center","All","20 Years to 40 Years   (Adult)","Early Phase 1","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0620113700","December 2011","April 2014","April 2014","September 19, 2014","October 3, 2014","October 3, 2014","Seoul National University Hospital, Seoul, Jongro-gu, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02244840"
1338,"NCT02243982","Predictive and Diagnostic Value of Tau and Beta-amyloid Markers in the Dementia of Parkinson's Disease",,"Completed","No Results Available","Parkinson's Disease|Parkinson-Dementia Syndrome","Other: [F18]-FDDNP","Relative Volume of Distribution of [F18]-FDDNP in non-demented patients with Parkinson's disease (PDND), demented patients with Parkinson's disease (PDD) and controls.|Concentration ( pg/mL) of beta-amyloid, tau and phospho-tau in cerebrospinal fluid (CSF) of non-demented patients with Parkinson's disease (PDND), demented patients with Parkinson's disease (PDD) and controls.|Number of patients without dementia at baseline that switch to dementia at 18 months follow-up","Fundacion Clinic per a la Recerca Biomédica","All","60 Years and older   (Adult, Older Adult)","Early Phase 1","28","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PI1080236","March 2010","June 2011","December 2012","September 18, 2014","null","September 18, 2014","Hospital Clinic, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT02243982"
1339,"NCT02243631","Effect of Probenecid on Synovial Fluid ATP Levels in CPPD",,"Recruiting","No Results Available","Calcium Pyrophosphate Deposition Disease","Drug: Probenecid","ATP levels in synovial fluid","VA Office of Research and Development","All","21 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","40","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMMA-022-13F","October 15, 2014","September 30, 2019","September 30, 2019","September 18, 2014","null","October 3, 2018","Clement J. Zablocki VA Medical Center, Milwaukee, WI, Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT02243631"
1340,"NCT02241109","Predicting Aortic Stenosis Progression by Measuring Serum Calcification Propensity","PASP","Unknown status","No Results Available","Aortic Valve Sclerosis|Aortic Valve Stenosis|Stenosis Progression|Valvular Heart Disease","Other: no intervention","Progression of peak aortic jet velocity over one year (m/s per year)|Progression of peak aortic jet velocity >20% in one year|Combined endpoint: death, hospitalizations, aortic-valve replacement, heart failure, angina, syncope","University Hospital Inselspital, Berne","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","087/14","September 2014","January 2016","February 2017","September 16, 2014","null","December 10, 2015","Dep. of Cardiology, Bern University Hospital, Bern, Switzerland","","https://ClinicalTrials.gov/show/NCT02241109"
1341,"NCT02240615","The Sinopsys Lacrimal Stent for Lacrimal System Repair in Epiphora",,"Completed","No Results Available","Epiphora","Device: Sinopsys Lacrimal Stent","Relief of epiphora, determined by both 1) the Investigator assessment of the patency/function of the Sinopsys Lacrimal Stent ( and 2) the subject's self-assessment of tearing.|Measurement of device insertion success|Evaluation of all safety","Sinopsys Surgical","All","22 Years and older   (Adult, Older Adult)","Early Phase 1","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SLS-US-01","October 2014","February 2016","February 2016","September 15, 2014","null","February 12, 2016","Stanford University, Stanford, California, United States|University of Colorado Health Sciences Center, Aurora, Colorado, United States|Center for Sight, Sarasota, Florida, United States|Eye Care Specialists, Kingston, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02240615"
1342,"NCT02240329","Assessment of Dystussia in Traumatic Brain Injury",,"Completed","Has Results","TBI|Brain Injury","Behavioral: Neuropsychological Testing and Measures of TBI severity|Behavioral: Respiratory measures|Drug: Capsaicin cough sensitivity testing","Average Urge to Cough (UTC) Following Administration of 200 Micro Mole Capsaicin Solution Concentration|Number of Coughs in Response to Stimulation With 200 Micro Moles Capsaicin in Solution","University of Florida|United States Department of Defense","All","18 Years to 60 Years   (Adult)","Early Phase 1","4","Other|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","217-2012","March 2013","June 2015","June 2015","September 15, 2014","October 28, 2015","October 28, 2015","University of Florida, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT02240329"
1343,"NCT02238379","Intranasal Oxytocin Administration and the Neural Correlates of Social and Non-Social Visual Perception",,"Completed","Has Results","Social Perception","Drug: Oxytocin|Other: Placebo","Amplitude Social|Amplitude Non-Social|Latency Social|Latency Non-Social|Depression|Smoking|Anxiety|Stress|Early Experience|Number of Participants Endorsing Substance Use|Number of Participants Testing Positive for Alcohol Use Following a Breathalyzer","Yale University|Anna Freud Centre","Female","18 Years to 64 Years   (Adult)","Early Phase 1","26","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","1309012677","September 2014","December 2015","December 2015","September 12, 2014","May 25, 2017","January 17, 2018","Yale Child Study Center, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02238379"
1344,"NCT02237287","Combination of Taliderm® and Vacuum-assisted Closure (VAC) for Treatment of Pressure Ulcers",,"Terminated","No Results Available","Wounds|Pressure Ulcer","Other: wound dressing with VAC and sNAG without antiaggregation|Procedure: wound dressing with VAC|Drug: wound dressing with VAC and sNAG under Antiaggregation","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Wound surface area increase, respectively decrease as a measure of the effect of the studied devices on pressure ulcer healing|Wound Healing characteristics","University Hospital, Basel, Switzerland|Marine Polymer Technologies, Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2010-MD-0007","February 2011","August 2012","August 2012","September 11, 2014","null","September 29, 2015","University Hospital Basel, Basel, Switzerland|Swiss Paraplegic Centre Nottwil, Nottwil, Switzerland","","https://ClinicalTrials.gov/show/NCT02237287"
1345,"NCT02236754","Evaluation of 18F-FP-DTBZ Pancreatic PET Scanning as a Tool to Measure Beta Cell Mass",,"Withdrawn","No Results Available","Healthy Volunteers|Diabetes Mellitus, Type 1","Drug: 18F-FP-DTBZ|Radiation: PET Scanning","Mean BPND (non-displaceable binding potential)","Columbia University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","0","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","AAAJ5709|R01DK077493-03","July 2013","January 30, 2017","March 1, 2017","September 11, 2014","null","February 1, 2017","Naomi Berrie Diabetes Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02236754"
1346,"NCT02234193","Reducing Side-effects of Autologous Skin Tissue Harvesting",,"Unknown status","No Results Available","Scar","Device: Micro biopsy|Procedure: Lidocaine with epinephrine","Evaluation of Efficacy - Change from baseline scarring at 8 weeks|Assessing Subject Side-effects - Change from baseline side-effects at 8 weeks|Pain assessment - Visual Analog Scale (VAS) - Change from baseline pain at 8 weeks","Massachusetts General Hospital","All","18 Years to 50 Years   (Adult)","Early Phase 1","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2014P000120","June 2016","July 2017","December 2017","September 9, 2014","null","June 14, 2016","Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02234193"
1347,"NCT02233868","Brain Inflammation and Function in Alcoholism",,"Recruiting","No Results Available","Alcoholism","Device: MRI|Drug: C-11PBR28|Drug: F-18FDG","To assess if there is inflammation in the brain of alcoholics as measured with [11C]PBR28 and to determine if it recovers with 3 weeks of detoxification.|To assess the impact of neuroinflammation on brain function (assessed with PET and 18FDG and with MRI for fMRI with task activation and for functional connectivity).|To determine if the NP variables correlate with neuroinflammation.|To determine if the measure of neuroinflammation predicts relapse in AD participants in the 3 month follow-up period.","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","30 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","144","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","140192|14-AA-0192","September 6, 2014","December 31, 2022","December 29, 2023","September 9, 2014","null","October 17, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02233868"
1348,"NCT02233829","Dopamine Rhythms in Health and Addiction",,"Suspended","No Results Available","Cocaine Abuse","Drug: Methylphenidate|Drug: C-11 Raclopride","To assess if there are diurnal rhythms in DA signaling and in reward brain circuits and to determine if these are disrupted in cocaine addiction.|To determine if differences in measures of DA signaling between morning and evening correlate with circadian typology.|To determine if measures of DA signaling correlate with measures of spontaneous motor activity and with sleeping patterns.|To assess if DA signaling correlates with reactivity of brain regions to exposure of drug and with functional connectivity of the reward network and to assess if the reactivity of reward network shows circadian variability.","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","21 Years to 55 Years   (Adult)","Early Phase 1","112","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","140187|14-AA-0187","September 6, 2014","December 30, 2022","December 30, 2022","September 9, 2014","null","September 10, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02233829"
1349,"NCT02233647","Phendimetrazine and Cocaine",,"Completed","Has Results","Cocaine Use Disorder","Drug: Cocaine|Drug: Placebo","Peak Systolic Pressure|Peak Diastolic Pressure|Peak Heart Rate|Peak Temperature|Peak Score on Sedative Subscale of the Adjective Rating Scale|Peak Score on Stimulant Subscale of the Adjective Rating Scale|Peak Ratings of ""Active, Alert, Energetic"" on the Visual Analog Scale|Peak Ratings of ""Any Effect"" on the Visual Analog Scale|Peak Ratings of ""Bad Effect"" on the Visual Analog Scale|Peak Ratings of ""Euphoric"" on the Visual Analog Scale|Peak Ratings of ""Good Effect"" on the Visual Analog Scale|Peak Ratings of ""High"" on the Visual Analog Scale|Peak Ratings of ""Irregular/Racing Heartbeat"" on the Visual Analog Scale|Peak Ratings of ""Like Drug"" on the Visual Analog Scale|Peak Ratings of ""Nauseated/Queasy/Sick to Stomach"" on the Visual Analog Scale|Peak Ratings of ""Nervous/Anxious"" on the Visual Analog Scale|Peak Ratings of ""Willing to Pay For"" on the Visual Analog Scale|Peak Ratings of ""Performance Impaired"" on the Visual Analog Scale|Peak Ratings of ""Performance Improved"" on the Visual Analog Scale|Peak Ratings of ""Restless"" on the Visual Analog Scale|Peak Ratings of ""Rush"" on the Visual Analog Scale|Peak Ratings of ""Shaky/Jittery"" on the Visual Analog Scale|Peak Ratings of ""Sluggish/Fatigued/Lazy"" on the Visual Analog Scale|Peak Ratings of ""Stimulated"" on the Visual Analog Scale|Peak Ratings of ""Willing to Take Again"" on the Visual Analog Scale|Peak Ratings of ""Talkative/Friendly"" on the Visual Analog Scale","William Stoops|National Institute on Drug Abuse (NIDA)|University of Kentucky","All","18 Years to 55 Years   (Adult)","Early Phase 1","11","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Basic Science","BED (IN) 29","September 2014","December 2015","December 2015","September 8, 2014","September 15, 2016","September 27, 2017","University of Kentucky Laboratory of Human Behavioral Pharmacology, Lexington, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT02233647"
1350,"NCT02233504","Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)",,"Active, not recruiting","No Results Available","High Risk MDS or AML Patients","Drug: Exjade® (deferasirox, ICL670)","Number of Adverse Events","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Treatment","UPCC 40413","August 2014","October 2017","October 2019","September 8, 2014","null","July 19, 2018","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02233504"
1351,"NCT02228655","An Exploratory Study to Evaluate FMX-8 to Treat Anemia in CKD",,"Terminated","No Results Available","Anemia in Chronic Kidney Disease","Drug: FMX-8","Change in hemoglobin concentration","FerruMax Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","2","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FX-C-888","October 2014","April 2015","July 2015","August 29, 2014","null","February 2, 2016","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02228655"
1352,"NCT02228031","Oxytocin, Emotions and Mirror Neurons",,"Completed","No Results Available","Social Cognition|Expressed Emotion","Drug: Oxytocin|Other: Placebo","EEG mu rhythm suppression","University of Maryland","Male","18 Years to 30 Years   (Adult)","Early Phase 1","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","HP-00059904","October 2014","August 2016","August 2016","August 28, 2014","null","August 15, 2017","Child Development Lab, University of Maryland, College Park, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02228031"
1353,"NCT02226029","Quantitative MR Methods for Lipid Emulsions","Q-MRemulsion","Completed","No Results Available","Healthy","Other: Lipid emulsion","Fat fraction [%] of GI content|Distal fat fraction [%]","University of Zurich","All","18 Years to 50 Years   (Adult)","Early Phase 1","22","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","KEK-ZH-Nr. 2014-0185|SNF #146409","August 2014","December 2014","March 2015","August 26, 2014","null","April 9, 2015","Division of Gastroenterology and Hepatology, University Hopsital Zurich, Zurich, Switzerland","","https://ClinicalTrials.gov/show/NCT02226029"
1354,"NCT02225132","Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease",,"Completed","No Results Available","Sickle Cell Disease","Drug: Hydroxyurea","Maximal HbF level achieved after initiating/continuing HU as compared to an average of the 3 HbF levels obtained during the run-in period.|Number of hospitalizations for pain crises and acute chest syndrome as compared to the 1 year prior to HU initiation or dose increase.","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","15 Years to 99 Years   (Child, Adult, Older Adult)","Early Phase 1","15","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","140172|14-H-0172","August 23, 2014","May 24, 2018","May 24, 2018","August 26, 2014","null","September 5, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02225132"
1355,"NCT02223117","Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)",,"Completed","No Results Available","Healthy","Biological: Thrombosomes|Biological: Placebo","Number of Participants with Adverse Events as a Measure of Safety Evaluation|Standard Hematology, Coagulation and Platelet Immunology Assessment","Cellphire, Inc.|Department of Health and Human Services","All","18 Years to 45 Years   (Adult)","Early Phase 1","15","Industry|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2011-1","September 2014","July 21, 2016","July 21, 2016","August 22, 2014","null","December 13, 2017","Bloodworks Northwest, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT02223117"
1356,"NCT02222935","Effectiveness of Balance Training in Chronic Low Back Pain Patients","CLB","Unknown status","No Results Available","Chronic Low Back Pain","Behavioral: Balance Exercise Training|Behavioral: Routine Back exercise program","Starr Edward Balance Test|Berg Balance Scale|Visual Analogue score","Baskaran Chandrasekaran|PSG Hospitals","All","25 Years to 45 Years   (Adult)","Early Phase 1","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PSG02","June 2014","December 2014","December 2014","August 22, 2014","null","August 22, 2014","PSG Hospitals, Department of Physical Medicine Rehabilitation, Coimbatore, Tamilnadu, India","","https://ClinicalTrials.gov/show/NCT02222935"
1357,"NCT02221830","Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)","PHP3","Recruiting","No Results Available","Preeclampsia","Drug: Oxytocin|Drug: Placebo","Evaluation of Postpartum hematocrit|Primary postpartum hemorrhage|Estimated blood loss at delivery|Postpartum blood loss","University of Colorado, Denver","Female","13 Years to 45 Years   (Child, Adult)","Early Phase 1","124","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","13-2738|UL1TR001082","February 2015","September 2018","December 2018","August 20, 2014","null","May 10, 2018","University of Colorado Clinical and Translational Research Center, Aurora, Colorado, United States","","https://ClinicalTrials.gov/show/NCT02221830"
1358,"NCT02221726","Study to Assess Adhesion Quality and Wear of Placebo JNJ-35685-AAA-G-023 Transdermal System in Healthy Adults",,"Completed","No Results Available","Healthy","Drug: JNJ-35684-AAA-023: Size 1; small patch|Drug: JNJ-35684-AAA-023: Size 2; large patch","Visual Grading United States Food and Drug Administration (FDA) Scale Score|Adhesion Area Calculated by Digital Image Analysis|Total Adhesion Score Calculated by Visual Grading Grid System|Number of Participants With Adverse Events (AEs) and Serious AEs","Janssen Research & Development, LLC","Male","18 Years to 55 Years   (Adult)","Early Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR105188|FENPAI1024","August 2014","August 2014","August 2014","August 20, 2014","null","September 15, 2014","Cypress, California, United States","","https://ClinicalTrials.gov/show/NCT02221726"
1359,"NCT02221193","Comparing Site Specific Mouth Disinfection With Commercial Oral Mouth Rinse With Traditional Oral Maouth Disinfection",,"Completed","No Results Available","Oral Odor (Halitosis)|The Study Want to Know if Site Specific Mouth Rinsing With Oral Mouth Disinfectants Can be Better Than Paonoral Mouth Rinsing","Other: traditional mouth rinsing and site-specific mouth rinsing (crossover)","viable anaerobic and aerobic bacterial counts|assessment of oral odor|volatile sulfur compounds (VSCs) levels","Al-Baha University","Male","17 Years to 65 Years   (Child, Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","0568677142","July 2013","August 2013","September 2013","August 20, 2014","null","August 20, 2014","","","https://ClinicalTrials.gov/show/NCT02221193"
1360,"NCT02220023","Dynamic Assessment of Right Ventricular Function With Inhaled Nitric Oxide During Cardiac MRI","iNO","Completed","No Results Available","Pulmonary Vascular Disorder","Drug: INOmax Inhalation","Right ventricular ejection fraction (RVEF) before and after inhaled nitric oxide exposure|Pulmonary flow|Pulmonary perfusion|Estimates of pulmonary vascular resistance|Pulmonary transit time|Pulmonary artery compliance","Vanderbilt University|Mallinckrodt|Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","17","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","140068","July 2014","February 2017","February 2017","August 19, 2014","null","February 13, 2017","Vanderbilt University Medical Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT02220023"
1361,"NCT02218905","Normative Values and Forming Regression Equations for One Minute Sit to Stand Test in Healthy Normal Indian Population","1minSTS","Unknown status","No Results Available","Human Healthy Volunteers","Behavioral: Sit to stand test","Number of repetitions of sit ups within 60 seconds|heart rate recovery (in seconds)|blood pressure (mmHg)|saturation (%)|Heart rate (beats/ min)","Baskaran Chandrasekaran|PSG Hospitals","All","30 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","196","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","13/311","August 2014","December 2015","December 2015","August 18, 2014","null","September 1, 2014","PSG Hospitals, Coimbatore, Tamilnadu, India","","https://ClinicalTrials.gov/show/NCT02218905"
1362,"NCT02216513","Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage",,"Terminated","No Results Available","Subarachnoid Hemorrhage","Drug: desferrioxamine (DFO)|Drug: placebo","delayed cerebral ischemia (DCI)|Clinical outcome at discharge","Brigham and Women's Hospital|Dr. Jeffrey Thomas Stroke Shield Foundation","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2014P001400","September 2014","June 2015","July 2015","August 15, 2014","null","July 21, 2015","Brigham and Women's Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02216513"
1363,"NCT02214862","2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism","[F18]-FDDNP","Completed","No Results Available","Progressive Supranuclear Palsy|Multi-System Atrophy|Parkinsonism","Drug: [F18]-FDDNP","To assess the Relative Volume of Distribution of [18F]-FDDNP in individuals with unclassifiable parkinsonism, and to try to correlate their eventual clinical diagnosis with baseline PET findings.|to assess the uptake of [18F]-FDDNP in cases clinically defined of progressive supranuclear palsy and multi-system atrophy|To assess the ability to detect in vivo underlying tau pathology in unclassifiable parkinsonism by means of PET -[18F]-FDDNP.","Fundacion Clinic per a la Recerca Biomédica","All","40 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","PI11/02031","March 2013","December 2015","February 2016","August 12, 2014","null","February 4, 2016","Hospital Clinic, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT02214862"
1364,"NCT02214199","Effectiveness of Cervicothoracic Manipulative Treatment in Unilateral Shoulder Impingement Syndrome: A Randomized Controlled Trial.",,"Completed","No Results Available","Shoulder Pain|Manual Theapy|Exercises Therapy","Other: Manipulative Therapy Techniques|Other: Home Exercises","Disability Questionnaire Arm, Shoulder and Hand (DASHe)|Shoulder Disability Questionnaire|Hawkins-Kennedy Test|Neer Test.|Range of Motion|Visual Analogue Scale","Universidad de Almeria|Andaluz Health Service","All","18 Years to 55 Years   (Adult)","Early Phase 1","92","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","21/2013","August 2014","May 2015","December 2015","August 12, 2014","null","April 21, 2016","Universidad de Almeria, Almería, Spain","","https://ClinicalTrials.gov/show/NCT02214199"
1365,"NCT02214095","Glucosamine Periodontal Adjunctive Therapy",,"Terminated","No Results Available","Chronic Periodontitis","Drug: glucosamine sulphate|Drug: lactose capsules","gingival crevicular fluid IL-1β level|probing depth|clinical attachment level|gingival index|plaque index","Ain Shams University","All","35 Years to 48 Years   (Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","randomized clinical trial","January 2012","February 2013","February 2013","August 12, 2014","null","August 12, 2014","Ainshams University, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT02214095"
1366,"NCT02212210","Maternal Epidural Steroids and Hyperthemia",,"Terminated","No Results Available","Fever|Labor Pain|Complication of Anesthesia During Pregnancy, Unspecified","Drug: Methylprednisolone|Drug: Normal saline","Rate of maternal fever|Rate of funisitis","Medical University of South Carolina","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","135","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Goodier_Epidural_Steroids","February 2012","April 2014","October 2015","August 8, 2014","null","August 29, 2017","Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT02212210"
1367,"NCT02212054","A Trial on Treatments of Hirschsprung Allied Disease",,"Unknown status","No Results Available","Complications of Treatment|Complication of Surgical Procedure|Megacolon, Not Hirschsprung","Behavioral: conservative|Procedure: operative","the change of defecation frequency|stool pattern|controlling stool ability|complications","Tongji Hospital","All","1 Year to 14 Years   (Child)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","101","August 2013","August 2014","January 2015","August 8, 2014","null","August 8, 2014","Department of Pediatric Surgery, Wuhan, Hubei, China","","https://ClinicalTrials.gov/show/NCT02212054"
1368,"NCT02210117","Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery",,"Active, not recruiting","No Results Available","Clear Cell Renal Cell Carcinoma|Metastatic Renal Cell Cancer|Stage IV Renal Cell Cancer AJCC v7","Biological: Bevacizumab|Procedure: Biopsy|Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Procedure: Metastasectomy|Biological: Nivolumab|Procedure: Therapeutic Conventional Surgery","Incidence of adverse events, defined any grade 3 or higher adverse event that is possibly, probably, or definitely related to any therapy received on this protocol|Immunological changes in tumor tissues and peripheral blood|Objective response rates|Duration of response|Progression-free survival|Overall survival","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","105","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-0715|NCI-2014-01857|P30CA016672","November 25, 2014","November 30, 2019","November 30, 2020","August 6, 2014","null","September 18, 2018","M D Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02210117"
1369,"NCT02207179","Breast Cancer Margin Delineation Using Polarization Subtraction Imaging Technology",,"Unknown status","No Results Available","Breast Cancer","Device: LumaScan Image Guided Surgery","Tumor areas shown on LumaScan images are the same as those shown on subsequent en-face pathology images.|Pathologist interpretation of LumaScan images (blinded) are similar to those of histopathology images.|Surgeons interpretation of LumaScan images (blinded) are similar to those of histopathology images.|Time for each margin and bi-valved image acquisition in the operating room","LumaMed|University of Wisconsin, Madison","Female","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","40","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LM010","January 2014","September 2015","November 2015","August 4, 2014","null","March 31, 2015","University of Wisconsin, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT02207179"
1370,"NCT02207140","Effect of Multi-species Probiotic HOWARU® Restore, on Gut Microbiota of Elderly",,"Completed","No Results Available","Elderly|Probiotics|Clostridium Difficile|Gut Microbiota|Fecal Metabolome","Dietary Supplement: HOWARU Restore","Fecal Clostridium difficile numbers|fecal microbial composition","Gabriella C. van Zanten|University of Copenhagen","All","75 Years and older   (Older Adult)","Early Phase 1","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","DKID H-1-2014-051|H-1-2014-051","October 2014","May 2016","May 2016","August 4, 2014","null","June 21, 2016","Department of Food Science, Food Microbiology, Faculty of Science, University of Copenhagen, Frederiksberg C, Denmark","","https://ClinicalTrials.gov/show/NCT02207140"
1371,"NCT02207010","A Phase 0 Study of AZD1775 in Recurrent GBM Patients",,"Active, not recruiting","No Results Available","Glioblastoma|GBM","Biological: AZD1775","Plasma concentration of AZD1775 following single dose of AZD1775|Intratumoral concentration of AZD1775|Degree of CDC2 (Tyr15) phosphorylation in tissue|Number of GBM cells in M-phase of cell cycle (PH3)|Presence of double-strand DNA damage (γH2AX).","St. Joseph's Hospital and Medical Center, Phoenix|The Ben & Catherine Ivy Foundation|American Society of Clinical Oncology|Barbara Ann Karmanos Cancer Institute|Translational Genomics Research Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","BBTRC 001","July 2014","December 2017","May 2018","August 1, 2014","null","January 6, 2017","Barrow Neurological Institute at St. Joseph's Hospital Medical Center, Phoenix, Arizona, United States","","https://ClinicalTrials.gov/show/NCT02207010"
1372,"NCT02204943","Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer",,"Completed","No Results Available","Bone Metastatic Castration-Resistant Prostate Cancer","Device: Biomarker analysis|Drug: Administration of radium-223","Proportion of patients who overexpress alkaline phosphatase (ALP) in Circulating Tumor Cells (CTCs) at each time point|Change in biomarkers of epithelial plasticity and osteomimicry expressed in the bone metastases of men with bone metastatic CRPC","Duke University|Bayer","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Pro00053925","May 6, 2015","July 31, 2017","July 31, 2017","July 31, 2014","null","June 8, 2018","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02204943"
1373,"NCT02202499","Translating Extinction Research to Improve Pharmacotherapy for Tobacco Dependence",,"Active, not recruiting","No Results Available","Smoking Cessation|Tobacco Dependence","Drug: Varenicline|Other: Counseling and Support Materials|Other: Laboratory Assessments","Rate of Participant Retention|Client Satisfaction Questionnaire (CSQ) Results|Rate of Intervention Adherence","H. Lee Moffitt Cancer Center and Research Institute|James and Esther King Biomedical Research Program|Pfizer","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","86","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MCC-17654","July 17, 2014","December 11, 2015","March 31, 2018","July 29, 2014","null","August 9, 2017","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States","","https://ClinicalTrials.gov/show/NCT02202499"
1374,"NCT02198872","Aquatic and Land Aerobic Training, Cardiorespiratory and Metabolic Variables in Cardiorespiratory Diseases",,"Unknown status","No Results Available","Arteriosclerosis, Coronary","Other: Exercise, Aerobic (Water based)|Other: Land Group","Change in autonomic system modulation|Change in body composition","Universidade Metodista de Piracicaba","Male","50 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","03/13|190729/2011-2","September 2014","July 2015","February 2018","July 24, 2014","null","July 24, 2014","Universidade Metodista de Piracicaba, Piracicaba, São Paulo, Brazil","","https://ClinicalTrials.gov/show/NCT02198872"
1375,"NCT02197182","LUXSOL(TM) Topical Cream for the Treatment of Symptomatic Bacterial Vaginosis; A Proof of Concept Study",,"Terminated","No Results Available","Bacterial Vaginosis (BV)","Drug: LUXSOL copper containing cream|Drug: Metronidazole gel","Presence or absence of bacterial vaginosis at the end of the study","CDA Research Group, Inc.","Female","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDA 0801","June 2014","March 2015","March 2015","July 22, 2014","null","April 5, 2018","Harper University Hospital Department of Infectious Diseases, Detroit, Michigan, United States|Temple University Hospital Department of OB/GYN, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02197182"
1376,"NCT02193425","Reliability of the Human Brain Connectome",,"Recruiting","No Results Available","Functional Connectivity","Drug: F-18FDG|Device: MRI","The overaching goal of this study is to quantify the reproducibility of multiple measures of brian functional connectivity (FC) during resting conditions and during task performance.|To assess the dynamic properties and energy requirements of the human brain connectome as ewll as the effects of physiologic noise, gender and aging on measures of brain functional connectivity at rest and druing task performance.","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","21 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","180","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","140144|14-AA-0144","July 16, 2014","March 22, 2021","March 31, 2021","July 17, 2014","null","October 17, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02193425"
1377,"NCT02193256","Varenicline + Prazosin for Heavy Drinking Smokers",,"Completed","No Results Available","Cigarette Smoking|Alcohol Use Disorders","Drug: Varenicline|Drug: Prazosin|Drug: Placebo","Effect of prazosin on sleep disturbance caused by varenicline prior to quitting smoking|Effect of prazosin on sleep disturbance caused by varenicline during smoking cessation","Yale University|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","5","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","K05AA014715","July 2014","January 2015","June 2015","July 17, 2014","null","May 13, 2016","Yale University School of Medicine, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02193256"
1378,"NCT02192996","Probiotic Supplementation to Improve the GUT Microbiota of Very Low Birth Weight Preterm, a Pilot Study",,"Completed","No Results Available","Other Preterm Infants|NEC","Dietary Supplement: Probiotic","changes in microbiological counts in feces of preterm infants|concentration of immunological parameters on feces|concentration of immunological parameters on plasma samples","Hospital Universitario La Paz|Universidad Complutense de Madrid","All","up to 1 Week   (Child)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","HULP3551|Universidad Complutense Madrid","December 2012","February 2013","July 2014","July 17, 2014","null","July 17, 2014","Hospital Universitario La Paz, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT02192996"
1379,"NCT02192125","REWIRE - Rehabilitative Wayout In Responsive Home Environments, A Pilot Trial","REWIRE","Completed","No Results Available","Stroke","Device: REWIRE-System","Proof of concept|Quality of life","University of Zurich|University of Milan|Ecole Polytechnique Fédérale de Lausanne|University of Oxford|University of Padua|Swiss Federal Institute of Technology|Ab.Acus Srl|Fundación Pública Andaluza Progreso y Salud|Technogym SpA|Fundació Privada Barcelona Digital Centre Tecnològic (BDIGITAL)|University Hospital, Zürich|JSI Research & Training Institute, Inc.|Hospitales Universitarios Virgen del Rocío","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","17","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-061","January 2014","July 2015","July 2015","July 16, 2014","null","September 15, 2015","Cerneo, Vitznau, Luzern, Switzerland","","https://ClinicalTrials.gov/show/NCT02192125"
1380,"NCT02192086","Goal Directed Fluid Administration for Kidney Transplantation",,"Completed","No Results Available","End Stage Renal Disease","Other: goal directed fluid therapy|Other: Control Group","Effect of Plethysmography Directed Fluid Administration Tranplanted Kidney|Pleth Variability","Medical University of South Carolina","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Fluid Kidney Transplants","August 2012","July 2014","July 2014","July 16, 2014","null","April 10, 2018","","","https://ClinicalTrials.gov/show/NCT02192086"
1381,"NCT02190279","18F-DCFBC PET/CT in Prostate Cancer",,"Completed","No Results Available","Prostatic Neoplasms|Prostate Cancer","Drug: 18F DCFBC","To assess the ability of 18F-DCFBC to identify sites of localized, recurrent and metastatic prostate cancer","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Male","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","116","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","140140|14-C-0140","July 12, 2014","December 31, 2017","January 11, 2018","July 15, 2014","null","September 27, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02190279"
1382,"NCT02185456","Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis","BV-LbRC","Unknown status","No Results Available","Bacterial Vaginosis","Drug: 750 mg metronidazole/ 200 mg miconazole vaginal suppository|Drug: Standard of care","Diagnosis of bacterial vaginosis|Relative quantity of Lactobacillus among total vaginal bacteria","Wayne State University|National Institute of Allergy and Infectious Diseases (NIAID)","Female","18 Years to 55 Years   (Adult)","Early Phase 1","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","R21AI111103-01","September 2014","January 2016","March 2016","July 9, 2014","null","November 7, 2014","WSU Tolan Park Medical Building 3901 Chrysler Service Drive, Suite 4A, Detroit, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02185456"
1383,"NCT02184832","Dietary Intake of Tryptophan and Metformin Response",,"Completed","No Results Available","Metformin Response|Fasting Glucose|Tryptophan Concentration|Metformin Concentration|Diet Tolerability","Drug: Metformin|Other: Low tryptophan diet|Other: High tryptophan diet","change in fasting glucose|change in tryptophan concentration","Massachusetts General Hospital","All","20 Years to 40 Years   (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2014P001226","August 2014","March 2016","March 2016","July 9, 2014","null","March 16, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02184832"
1384,"NCT02183948","Effect of Oxytocin on Masked Facial Expressions: an fMRI Study",,"Completed","No Results Available","Facial Expressions","Drug: Oxytocin|Drug: Placebo","Number of participants with neuro activity to facial expressions","University of Electronic Science and Technology of China","All","18 Years to 29 Years   (Adult)","Early Phase 1","86","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","UESTC-SCAN-01","June 2014","December 2014","December 2014","July 8, 2014","null","March 7, 2017","","","https://ClinicalTrials.gov/show/NCT02183948"
1385,"NCT02183753","Effects of Wood Smoke Particles on Influenza-induced Nasal Inflammation in Normal Volunteers","Woodsies","Completed","No Results Available","Response of Viral Infection to Woodsmoke","Other: wood smoke|Other: clean air","IL-13","University of North Carolina, Chapel Hill|Environmental Protection Agency (EPA)|National Institute of Environmental Health Sciences (NIEHS)","All","18 Years to 40 Years   (Adult)","Early Phase 1","39","Other|U.S. Fed|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","13-3076|5R01ES013611-09","July 2014","March 2015","April 2015","July 8, 2014","null","June 11, 2015","center for envionmental medicine asthma an lung biology at the EPA, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02183753"
1386,"NCT02181478","Intra-Osseous Co-Transplant of UCB and hMSC",,"Recruiting","No Results Available","Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndromes|Myelofibrosis|Relapsed Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Relapsed Chronic Lymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Lymphoid Malignancies|Chronic Myelogenous Leukemia","Drug: cyclophosphamide|Drug: fludarabine phosphate|Radiation: total-body irradiation|Drug: cyclosporine|Drug: mycophenolate mofetil|Procedure: umbilical cord blood transplantation|Procedure: mesenchymal stem cell transplantation","Number of patients with BM cellularity failure: Measure of feasibility|Number of patients with ANC failure without evidence of disease: Measure of feasibility|Number of patients with hematopoietic recovery without evidence of donor umbilical cord blood engraftment: Measure of feasibility|Incidence of toxicities assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Rate of neutrophil recovery|Rate of platelet recovery|Median time of neutrophil recovery|Median time of platelet recovery","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE1Z14|NCI-2014-01316|P30CA043703","July 22, 2015","November 2018","November 2018","July 4, 2014","null","February 28, 2018","Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02181478"
1387,"NCT02172651","Study to Identify Transcriptional Targets of Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases Receiving Preoperative Vitamin D Supplementation.",,"Recruiting","No Results Available","Stage, Colon Cancer|Stage I-III Colon Cancer|Stage IV Colon Cancer With Resectable Liver Metastases","Drug: Vitamin D3","VDR Binding Sites|RNA transcriptome|Number of Participants with Serious and Non-Serious Adverse Events","Dana-Farber Cancer Institute|National Cancer Institute (NCI)|Pharmavite","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","14-091|P50CA127003-06A1","July 2014","June 2019","May 2020","June 24, 2014","null","August 14, 2018","Dana-Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02172651"
1388,"NCT02169687","High Intensity Focused Ultrasound Device in Patients With Autonomous Hyperfunctioning Thyroid Nodules",,"Terminated","No Results Available","Autonomous Hyperfunctioning Thyroid Nodules","Device: HIFU","Proportion of patient with TSH normalization / increase|Number of patients with TSH normalization / increase|Changes of FT3 and FT4|Change in the volume nodule|Number of adverse events","Theraclion|Groupe Hospitalier Pitie-Salpetriere|Hôpital Saint Louis Paris","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","2","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIFU/F/02.01/Protocol V0","June 2006","October 2007","October 2007","June 23, 2014","null","June 23, 2014","Hôpital Pitié Salpetrière, Paris, France","","https://ClinicalTrials.gov/show/NCT02169687"
1389,"NCT02168959","Continuous Femoral Nerve Block With a Tibial Plateau Fracture",,"Completed","No Results Available","Tibial Plateau Fracture","Drug: bupivacaine","Postoperative Pain Score and patient satisfaction|Long-term Pain Control","University of Utah","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","56481","February 2013","December 2014","December 2014","June 20, 2014","null","March 14, 2016","University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02168959"
1390,"NCT02168790","Safety Study of a Sutureless Amniotic Membran Transplantation to Treat Ocular Surface Disorders (Expanded Access)","AmnioClip","Completed","No Results Available","Corneal Ulcers|Corneal Melting","Device: Amniotic membrane ring","Slit lamp investigation of the inflammation status of the conjunctiva","Klinikum Chemnitz gGmbH|Technische Universität Dresden","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SKC002AR01","February 2011","August 2011","August 2013","June 20, 2014","null","June 20, 2014","Klinikum Chemnitz gGmbH, Chemnitz, Saxony, Germany","","https://ClinicalTrials.gov/show/NCT02168790"
1391,"NCT02163122","Cat Pilot Study - Environmental Exposure Chamber (EEC) vs. Nasal Allergen Challenge (NAC)",,"Completed","No Results Available","Hypersensitivity, Immediate","Procedure: Nasal Allergen Challenge|Other: Environmental Exposure Chamber|Biological: Cat allergen (FelD1)","NAC Total Nasal Symptom Score (TNSS) Area under the Curve (AUC)|EEC TNSS AUC|TNSS AUC with NAC|TNSS AUC with EEC|Peak TNSS Score","National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","24","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","DAIT ITN061AD","January 2015","June 2016","June 2016","June 13, 2014","null","September 12, 2017","Inflamax Research Inc., Mississauga, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02163122"
1392,"NCT02157831","Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors",,"Completed","No Results Available","Solid Tumors","Biological: CP-870,893","Number of Adverse Events","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Treatment","UPCC 10904","July 2005","February 2008","February 2008","June 6, 2014","null","August 17, 2018","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02157831"
1393,"NCT02157038","Neuromuscular Mechanisms Underlying Poor Recovery From Whiplash Injuries",,"Active, not recruiting","No Results Available","Whiplash Associated Disorders|WAD|Whiplash","Device: Pedometer|Device: MRI","MRI to assess the changes in markers of altered cervical spinal cord physiology and muscle degeneration.|Neck Disability Index (NDI) Questionnaire|Coping Strategy Questionnaire-C|Pain Management Inventory (PMI) Questionnaire|Tampa Questionnaire|Post-traumatic Diagnostic Scale (PDS) Questionnaire|Impact of Events Scale Questionnaire|Center for Epidemiological Studies - Depression Scale Questionnaire|Hospital Anxiety and Depression Scale Questionnaire|Traumatic Injuries Distress Scale and a Symptom Index|Prediction of Post-MVC Chronic Axial Pain Assessment|Follow-Up Data Collection Form for clinical prediction|Pedometer: wear for 2 consecutive weeks|RNA and DNA blood collection|Strength and reflex testing in the lower leg","Northwestern University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","100","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","STU00090769","July 2014","July 2018","July 2019","June 5, 2014","null","October 26, 2017","Northwestern University, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT02157038"
1394,"NCT02155777","Why do Oral Contraceptives Prevent Ovarian Cancer?",,"Recruiting","No Results Available","Ovarian Cancer Risk|Risk-reducing Surgery|Fallopian Tube Fimbriae|Ovarian Cortical Inclusion Cysts","Drug: OrthoNovum 1/35","Differences in cell proliferation as measured by Ki67 immunohistochemical analysis in the fallopian tube fimbriae of women on the OC arm compared to women on the no treatment arm.|Cell proliferation as measured by Ki67 immunohistochemical analysis in ovarian cortical inclusion cysts of women on the OC arm compared to women on the no treatment arm.","University of Southern California|National Cancer Institute (NCI)","Female","30 Years to 45 Years   (Adult)","Early Phase 1","28","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","OC Prevention|1R21CA178571-01","June 2014","June 2018","June 2018","June 4, 2014","null","April 4, 2017","USC Keck School of Medicine, Los Angeles, California, United States|University of Michigan, Ann Arbor, Michigan, United States|UBC BC Cancer Agency, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT02155777"
1395,"NCT02153450","Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer",,"Recruiting","No Results Available","Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage I-III Pancreatic Cancer","Drug: metformin hydrochloride|Radiation: stereotactic radiosurgery","Dose-limiting toxicity (DLT) rate scored according to the National Cancer Institute Common Toxicity Criteria version 4|Clinical response rate using the revised Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1|Progression-free survival using the revised RECIST version 1.1|Overall survival","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE4213|NCI-2014-01172|CASE 4213|P30CA043703","May 8, 2015","December 2018","December 2018","June 3, 2014","null","November 14, 2018","University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02153450"
1396,"NCT02152410","Acupuncture Versus IV Morphine in the Treatment of Acute Pain in ED","AcuMoPE","Completed","No Results Available","Renal Colic","Device: acupuncture|Drug: Morphine","pain relief by VAS|side effects|number of patients completing the treatment","University of Monastir|Emergency NGO Onlus","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","48003/12","April 2012","April 2013","April 2014","June 2, 2014","null","June 20, 2016","university of Monastir, Monastir, Non-US/Canada, Tunisia|Fattouma Bourguiba University Hospital, Monastir, Tunisia","","https://ClinicalTrials.gov/show/NCT02152410"
1397,"NCT02151552","Assessing NOS Uptake With PET Imaging in Lung Inflammation",,"Completed","No Results Available","Lung Inflammation","Drug: Endotoxin (E. coli O:113, Reference Endotoxin)|Drug: [18F](+/-)NOS","Distribution volume ratio (DVR), determined by Logan plot analysis, in the right middle lobe|Change in DVR in right middle lobe|Mean Hounsfield units (HU), measure of density on CT images, in right middle lobe and lingula|Change in HU in right middle lobe and lingula|Bronchoalveolar lavage (BAL) cell counts (including total nucleated and neutrophil counts)|Number and percent of iNOS-stained BAL cells by flow cytometry|Number and percent of 3-nitrotyrosine-stained cells on biopsy|Change in exhaled nitric oxide (ENO) levels|Regional PBF and EVLW in right middle lobe and lingula|Number of iNOS positive cells from brushing cytospins","Washington University School of Medicine|Doris Duke Charitable Foundation","All","19 Years to 44 Years   (Adult)","Early Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","DDCF 2010060-201403017","May 2014","February 2018","February 2018","May 30, 2014","null","July 23, 2018","Washington University School of Medicine / Barnes-Jewish Hospital, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02151552"
1398,"NCT02150655","Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women","RVMM","Completed","No Results Available","Vulvovaginal Candidiasis|Bacterial Vaginosis","Biological: Lactobacillus GR-1 and Lactobacillus RC-14 oral capsules|Biological: Placebo","maintenance of healthy vaginal microbiota|Reduction of environmental toxins in blood by lactobacilli","Western University, Canada","Female","18 Years to 55 Years   (Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","102886","September 2012","September 2013","December 2013","May 30, 2014","null","May 30, 2014","Nyamata District Hospital, Nyamata, East Province, Rwanda","","https://ClinicalTrials.gov/show/NCT02150655"
1399,"NCT02149927","Neural Mechanisms of Sevoflurane Induced Anesthesia: an EEG fMRI Study in Healthy Volunteers",,"Completed","No Results Available","Anesthesia|Drug Effects","Drug: Sevoflurane","Changes of information processing (entropy) in EEG and functional connectivity (BOLD ICA and small group network architecture) in fMRI during sevoflurane anesthesia at states awake, 2vol%, 3vol% and EEG endpoint burst suppression|Assessment of the brain network structure during recovery in EEG and fMRI","Technische Universität München","Male","18 Years to 35 Years   (Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","56012/12","June 2013","December 2013","January 2014","May 29, 2014","null","May 29, 2014","Klinikum rechts der Isar, Munich, Bayern, Germany","","https://ClinicalTrials.gov/show/NCT02149927"
1400,"NCT02149901","Water and Sudafed in Autonomic Failure",,"Active, not recruiting","No Results Available","Shy-Drager Syndrome|Multiple System Atrophy","Drug: Pseudoephedrine + 480 ml water|Drug: Pseudoephedrine + 50 ml water|Other: Placebo + 480 ml water (optional)|Other: Placebo + 50 ml water (optional)","The primary outcome measure in each Aim will be the peak increase in systolic blood pressure after pseudoephedrine or placebo relative to baseline (delta SBP).|Change in diastolic blood pressure relative to baseline|Change in heart rate relative to baseline|Absolute systolic blood pressure after treatment|Absolute diastolic blood pressure after treatment|area under the curve for systolic blood pressure from baseline to 135 minutes post-treatment|Peak plasma norepinephrine concentration after treatment","Vanderbilt University|National Heart, Lung, and Blood Institute (NHLBI)|National Center for Advancing Translational Science (NCATS)|Vanderbilt University Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","35","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","140547|P01HL056693|UL1TR000445","October 2014","December 2019","December 2019","May 29, 2014","null","March 27, 2018","Vanderbilt University, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT02149901"
1401,"NCT02148094","Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) for Sex Workers in India","PrEP-India","Completed","No Results Available","HIV Infection","Drug: Truvada","Sustained uptake and adherence to oral PrEP among female sex workers|Identification of female sex workers willing to take PrEP|Oral HIV PrEP as part of a combined prevention package delivered safely for female sex workers|Effective delivery of oral HIV PrEP demonstrated in context of National Targeted Interventions","University of Manitoba|World Health Organization|DMSC|Ashodaya Samithi","Female","18 Years to 49 Years   (Adult)","Early Phase 1","1325","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","B2014:050","January 2016","April 30, 2018","June 30, 2018","May 28, 2014","null","October 11, 2018","Ashodaya Samithi clinic, Mysore, Karnataka, India|DMSC Clinic, Kolkata, West Bengal, India","","https://ClinicalTrials.gov/show/NCT02148094"
1402,"NCT02147392","Assessment of [11C]ER176 to Image Translocator Protein in Brain and Whole Body of Healthy People",,"Completed","No Results Available","Pharmacokinetics|Adult","Drug: [11C]ER-176","The identifiability and time stability of distribution volume calculated with compartmental modeling and evaluate the genotype sensitivity of [11C]ER-176|Whole-body biodistribution and dosimetry of [11C]ER-176.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","16","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","140117|14-M-0117","May 14, 2014","June 16, 2016","June 16, 2016","May 26, 2014","null","July 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02147392"
1403,"NCT02146053","Questionnaire to Assess Gastrointestinal Symptoms of Oral Iron.",,"Completed","No Results Available","Anemia|Constipation|Diarrhea|Abdominal Pain|Heartburn|Side Effect","Dietary Supplement: ferrous sulfate|Dietary Supplement: Placebo","gastrointestinal symptoms","Medical Research Council|King's College London","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","Symptoms KCL","March 2004","December 2004","December 2004","May 23, 2014","null","February 6, 2017","King's College London, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02146053"
1404,"NCT02144688","COMO: Cognition Study With HIV+ Patients (CTNPT 015)","COMO","Terminated","No Results Available","HIV - Human Immunodeficiency Virus|Cognitive Symptoms","Drug: Change in antiretrovirals","Changes in neurocognitive functioning over 6 months","Marie-Josée Brouillette|Fonds de la Recherche en Santé du Québec|CIHR Canadian HIV Trials Network|McGill University Health Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTNPT 015","June 2011","March 2016","March 2016","May 22, 2014","null","March 16, 2016","Montreal Chest Institute - Chronic Viral Illness Service - McGill University Health Centre (MUHC), Montreal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT02144688"
1405,"NCT02144623","Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia","PREVAIL","Completed","No Results Available","Chronic Lymphocytic Leukemia","Drug: Valproate","Levels of CD20 protein and messengerRNA in response to treatment with valproate in patients with chronic lymphatic leukemia.|Translational blood samples.","Lund University Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Version 1.2","January 2015","February 2016","February 6, 2017","May 22, 2014","null","March 3, 2017","Lund University Hospital, Department of Oncology, Lund, Sweden","","https://ClinicalTrials.gov/show/NCT02144623"
1406,"NCT02144584","Memantine for Enhanced Stroke Recovery",,"Recruiting","No Results Available","Ischemic Stroke|Upper Extremity Weakness","Drug: Memantine XR|Drug: Placebo (for memantine)","Fugl-Meyer Assessment|Adverse events|Adverse Events|Motor Activity Log (MAL)|Ten Meter Walk Test|Stroke Impact Scale (SIS)|Cancellation Tests|Cancellations Tests|Grip Strength Test|Montreal Cognitive Assessment (MoCA©)","University of Utah","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00068751","January 2014","November 2018","December 2018","May 22, 2014","null","August 14, 2018","University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02144584"
1407,"NCT02142543","The Effect of 2-DeNT Oral Topical Powder on Minor Recurrent Aphthous Ulcer",,"Completed","No Results Available","Minor Recurrent Aphthous Stomatitis Lesions","Drug: 2-DeNT powder|Drug: Placebo Comparator","Ulcer size|Erythema","Texas A&M University","All","12 Years to 55 Years   (Child, Adult)","Early Phase 1","23","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BCDOrtho1|2011-23-BCD","March 2012","December 2012","December 2012","May 20, 2014","null","June 6, 2014","Texas A&M Baylor College of Dentisry, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT02142543"
1408,"NCT02142114","Assessment of Comfort Level Following an Intravitreal Injection by 30 or 32 Gauge Needles",,"Unknown status","No Results Available","Pain","Device: Eye injection by 30 or 32 gauge needle","Pain assessment.|Intraocular pressure assessment","Retina Health Center|California Retina Consultants|Genentech, Inc.","All","Child, Adult, Older Adult","Early Phase 1","200","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research","ML29182","May 2014","July 2016","July 2016","May 20, 2014","null","December 21, 2015","Retina Health Center, Fort Myers, Florida, United States","","https://ClinicalTrials.gov/show/NCT02142114"
1409,"NCT02141620","n-Acetylcysteine and Cocaine",,"Completed","Has Results","Cocaine Abuse|Cocaine Dependence","Drug: Cocaine|Drug: n-Acetylcysteine|Drug: Placebo","Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative|Peak Score on Sedative Subscale of the Adjective Rating Scale|Peak Score on Stimulant Subscale of the Adjective Rating Scale|Peak Ratings of ""Active, Alert, Energetic"" on the Visual Analog Scale|Peak Ratings of ""Any Effect"" on the Visual Analog Scale|Peak Ratings of ""Bad Effects"" on the Visual Analog Scale|Peak Ratings of ""Euphoric"" on the Visual Analog Scale|Peak Ratings of ""Good Effects"" on the Visual Analog Scale|Peak Ratings of ""High"" on the Visual Analog Scale|Peak Ratings of ""Irregular/Racing Heartbeat"" on the Visual Analog Scale|Peak Ratings of ""Like Drug"" on the Visual Analog Scale|Peak Ratings of ""Nauseous"" on the Visual Analog Scale|Peak Ratings of ""Nervous/Anxious"" on the Visual Analog Scale|Peak Ratings of ""Willing to Pay For"" on the Visual Analog Scale|Peak Ratings of ""Performance Impaired"" on the Visual Analog Scale|Peak Ratings of ""Performance Improved"" on the Visual Analog Scale|Peak Ratings of ""Restless"" on the Visual Analog Scale|Peak Ratings of ""Rush"" on the Visual Analog Scale|Peak Ratings of ""Shaky/Jittery"" on the Visual Analog Scale|Peak Ratings of ""Sluggish/Fatigued/Lazy"" on the Visual Analog Scale|Peak Ratings of ""Stimulated"" on the Visual Analog Scale|Peak Ratings of ""Willing to Take Again"" on the Visual Analog Scale|Peak Ratings of ""Talkative/Friendly"" on the Visual Analog Scale|Peak Diastolic Blood Pressure|Peak Systolic Blood Pressure|Peak Heart Rate|Peak Temperature","University of Kentucky|National Institute on Drug Abuse (NIDA)","All","18 Years to 55 Years   (Adult)","Early Phase 1","15","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Basic Science","R21DA035376","May 2014","April 2016","April 2016","May 19, 2014","October 6, 2016","January 4, 2017","University of Kentucky Laboratory of Human Behavioral Pharmacology, Lexington, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT02141620"
1410,"NCT02139839","Exploratory Study to Evaluate the Effects of the Probiotics L. Rhamnosus GR-1 and L. Reuteri RC-14",,"Completed","No Results Available","Vaginosis, Bacterial","Other: Lactobacillus capsules|Drug: Placebo gelatin pill","Change from baseline Nugent Score (arbitrary units) after treatment versus Change from baseline Nugent Score after placebo|Percent Lactobacilli abundance|Change in presence of metabolites|Change in cytokine/chemokine levels|Change in global host gene expression|Change in self-reported vaginal symptoms","Kimberly-Clark Corporation|Lawson Health Research Institute|Western University, Canada|Integrated Research Inc.","Female","40 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","14","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","500-10-0002","September 2012","March 2013","May 2013","May 15, 2014","null","May 15, 2014","Dorli Herman, London, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02139839"
1411,"NCT02139371","Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography",,"Completed","No Results Available","Breast Cancer|Prostate Cancer|Urinary Bladder Cancer","Other: Injection of 64Cu-DOTA-AE105","Biodistribution|Dosimetry|Expression of UPAR in tumor tissue|Quantitative uptake of UPAR in tumor tissue","Rigshospitalet, Denmark","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2013-574","May 2014","October 2014","October 2014","May 15, 2014","null","December 12, 2014","Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT02139371"
1412,"NCT02138630","Capsaicinoid Ingestion, Human Metabolism and Exercise (Phase 2)",,"Unknown status","No Results Available","Metabolism|Exercise","Dietary Supplement: Capsaicin|Dietary Supplement: Placebo","Performance|Substrate Use","University of Prince Edward Island|OmniActive Health Technologies","All","18 Years to 45 Years   (Adult)","Early Phase 1","15","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)","OAHTCAPX-003-2014-2","June 2014","January 2016","January 2016","May 14, 2014","null","September 17, 2015","UPEI, Charlottetown, Prince Edward Island, Canada","","https://ClinicalTrials.gov/show/NCT02138630"
1413,"NCT02137967","Sodium Hypochlorite Pulpotomies in Primary Molars: Comparison With Conventional 20% Formocresol Pulpotomies",,"Unknown status","No Results Available","Dental Pulp Disease","Procedure: NaOCl pulpotomy|Procedure: FC pulpotomy|Drug: 2.5% NaOCl|Drug: 20% Formocresol","Change of Clinical Findings|Change of Radiographic Findings","National Taiwan University Hospital","All","30 Months to 9 Years   (Child)","Early Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","201105091RB","August 2011","September 2014","June 2016","May 14, 2014","null","May 14, 2014","Pediatric dental department, National Taiwan University Hospital, Taipei, Taiwan","","https://ClinicalTrials.gov/show/NCT02137967"
1414,"NCT02137135","Menstrual Phase and Postoperative Pain",,"Completed","No Results Available","Acute Postoperative Pain|Chronic Postoperative Pain","Other: HAD scale|Other: The SF 12 test|Other: Visual analogue score","Persistent surgical pain after laparoscopic cholecystectomy assessed by VAS scale|The anxiety and depression was evaluated with Hospital anxiety and depression scale.","Adnan Menderes University","Female","18 Years to 60 Years   (Adult)","Early Phase 1","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","SARI-05","August 2012","November 2013","November 2013","May 13, 2014","null","May 13, 2014","Adnan Menderes University Medical Faculty, Anesthesiology and Reanimation Department, Aydin, Turkey","","https://ClinicalTrials.gov/show/NCT02137135"
1415,"NCT02135965","Testing Potential Synergistic Effects of Albuterol and Caffeine on Metabolic Rate","CALM","Completed","No Results Available","Healthy Volunteers","Drug: 2mg of Albuterol|Drug: 4mg of Albuterol|Drug: 100mg of Caffeine|Drug: 200mg of Caffeine|Drug: Albuterol 2mg & Caffeine 100mg|Drug: Albuterol 2mg and Caffeine 200mg|Drug: Albuterol 4mg and Caffeine 100mg|Drug: Albuterol 4mg and Caffeine 200mg","A change is being assessed for the combination of Albuterol and Caffeine on Metabolic rate.|Respiratory Quotient (RQ)|Pulse rate|Blood Pressure|Temperature|Safety Assessments (lab, adverse events, physical exams and electrocardiograms)","Pennington Biomedical Research Center","All","18 Years to 50 Years   (Adult)","Early Phase 1","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","PBRC 28026","April 2009","August 2011","August 2011","May 12, 2014","null","December 18, 2015","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT02135965"
1416,"NCT02135432","TOPIC Trial for COPD",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease","Drug: Ivacaftor|Drug: Placebo","Change in COPD as Measured by the Sweat Analysis in Each Group|Change in COPD as Measured by Nasal Potential Difference|Number of Adverse Events Experienced by the Ivacaftor Subjects and Placebo Subjects.|Change in COPD as Measured by Change in Percentage of FEV1 as Measured in Each Group","University of Alabama at Birmingham","All","40 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","F140319002|TOPIC Trial","May 2015","October 2015","November 2015","May 12, 2014","February 24, 2017","February 24, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT02135432"
1417,"NCT02135068","Preventing Hypoglycemia During Exercise With Proactive Snacking on Closed Loop",,"Completed","No Results Available","Type 1 Diabetes","Device: Medtronic MiniMed Closed Loop (CL) System|Other: Snacking","Nadir blood glucose levels during exercise|Episodes of hypoglycemia (blood glucose <60mg/dL) during exercise|Mean reduction in blood glucose during exercise|Mean time blood glucose in target during exercise|Mean time blood glucose levels are in target during the overnight period|Mean glucose values|Mean 24- hour glucose levels|insulin delivery during CL therapy|Incremental meal-related glucose Area Under the Curve|Nadir glucose levels following the meals|Area under the curve meal-related plasma insulin level excursion following meals|Nadir glucose levels overnight|Mean absolute relative difference (MARD) for each sensor|Mean daytime and nighttime glucose values","Yale University","All","13 Years to 44 Years   (Child, Adult)","Early Phase 1","15","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1403013588","January 2015","June 2016","December 2016","May 9, 2014","null","January 27, 2017","Yale University School of Medicine, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02135068"
1418,"NCT02134288","Belatacept for Renal Transplant Recipients With Delayed Graft Function",,"Recruiting","No Results Available","Delayed Graft Function","Drug: Belatacept|Drug: Everolimus","Time to recover from Delayed Graft Function|Percent patients reaching recovery (defined above) by 14 days and 3 months.|Hospital length of stay (days) from date of transplant to discharge|Number of dialysis treatments|Number of biopsies|Biopsy proven acute rejection events|Patient and graft survival|Number of hospital readmissions|Detection of DSA (Luminex)|Incidence and type of infection|Measured or estimated creatinine clearance.|Banff score of rejection episodes and immune suppression treatment/management of rejection|Immune suppression drug levels (everolimus or sirolimus, cyclosporine, or mycophenolate as clinically monitored).","Von Visger, Jon, MD|Bristol-Myers Squibb|Ohio State University","All","18 Years to 60 Years   (Adult)","Early Phase 1","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IM103-336|2013H0312","April 2014","December 2017","December 2017","May 9, 2014","null","January 24, 2017","The Ohio State Universtiy Wexner Medical Center, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02134288"
1419,"NCT02132338","Evaluation of the Educational Program of Diabetes Mellitus: Focus on Empowerment",,"Unknown status","No Results Available","Type 2 Diabetes Mellitus","Behavioral: The Education Health Program","Glycated hemoglobin level before and after intervention|level of knowledge about diabetes mellitus|diabetes mellitus empowerment for self-care|tests such as cholesterol|tests such as fasting glucose|body mass index","Federal University of Minas Gerais","All","30 Years and older   (Adult, Older Adult)","Early Phase 1","191","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CAAE 22372013.2.000.5149","June 2014","June 2015","November 2017","May 7, 2014","null","May 7, 2014","Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil","","https://ClinicalTrials.gov/show/NCT02132338"
1420,"NCT02131779","Men's Prostate Awareness Church Training","M-PACT","Unknown status","No Results Available","Prostate Cancer","Behavioral: Men's Workshops|Behavioral: Co-Educational Workshops","Informed Decision making for Prostate Cancer Screening|Theory-based measures, prostate cancer knowledge, and prostate cancer screening","University of Maryland","All","40 Years to 69 Years   (Adult, Older Adult)","Early Phase 1","480","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Screening","12-0095|American Cancer Society","July 2010","December 2014","June 2015","May 6, 2014","null","May 6, 2014","University of Maryland School of Public Health, College Park, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02131779"
1421,"NCT02130778","Natriuretic Effect of GLP-1in Healthy Non Obese Subjects",,"Completed","No Results Available","Sodium Excretion by Urination","Drug: Synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline|Other: 500 ml 0.9% saline","Evidence of the positive effect on natriuresis (level of sodium in urin sample) following the of GLP1 infusion","Clinical Hospital Centre Zagreb|Merck Sharp & Dohme Corp.","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","15","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","UHCZagreb","April 2014","October 2015","October 2015","May 5, 2014","null","December 14, 2015","University Hospital Centre, Zagreb, Croatia|University hospital Centre Zagreb, Zagreb, Croatia","","https://ClinicalTrials.gov/show/NCT02130778"
1422,"NCT02124824","Contribution of Endothelin-1 to Exercise Intolerance in Heart Failure",,"Recruiting","No Results Available","Heart Failure","Drug: BQ-123","Blood Flow","VA Office of Research and Development|University of Utah","All","45 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","40","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","F1418-P","September 1, 2014","September 1, 2018","September 1, 2019","April 28, 2014","null","May 1, 2018","VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02124824"
1423,"NCT02122289","Muco Smartphone Exacerbation","MUSE","Completed","No Results Available","Cystic Fibrosis","Device: Application of Smartphone|Other: No application Smartphone","Frequency of exacerbation|Satisfactory status and compliance","University Hospital, Montpellier","All","14 Years to 25 Years   (Child, Adult)","Early Phase 1","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","9172","April 2014","May 2015","January 2016","April 24, 2014","null","April 12, 2016","CRCM, Giens, France|CRCM, Montpellier, France","","https://ClinicalTrials.gov/show/NCT02122289"
1424,"NCT02120677","Topical Itraconazole in the Treatment of Basal Cell Carcinoma",,"Recruiting","No Results Available","Basal Cell Carcinoma","Drug: Itraconazole","Downregulation in glucagon-like immunoreactivity (GLI) expression|Incidence, timing, and severity of treatment adverse events","Johns Hopkins University","All","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NA_00077461","May 2014","June 2018","December 2018","April 23, 2014","null","September 6, 2018","Johns Hopkins School of Medicine, Department of Dermatology, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02120677"
1425,"NCT02117115","Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation","GVHD","Completed","No Results Available","Myelodysplastic Syndromes|Leukemia, Myeloid, Acute|Leukemia, Myelogenous, Chronic|Multiple Myeloma","Radiation: Dynamic contrast-enhanced computed tomography|Drug: Ioversol","Incidence of contrast related nephropathy|Incidence of contrast allergic reaction|Correlation between CT risk scores and occurrence of acute GVHD","Washington University School of Medicine","All","20 Years to 60 Years   (Adult)","Early Phase 1","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","201404063","June 2014","October 2014","May 2015","April 17, 2014","null","June 11, 2015","Washington University School of Medicine, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02117115"
1426,"NCT02115945","Femoral and Epidural Block After Total Knee Arthroplasty",,"Completed","No Results Available","Acute Postoperative Pain|Chronic Postoperative Pain","Other: DN4 test|Other: The SF 12 test|Other: HAD scale|Other: Visual analogue score|Procedure: femoral block|Procedure: epidural block","Persistent surgical pain after total knee arthroplasty assessed by VAS scale|The anxiety and depression was evaluated with Hospital anxiety and depression scale.","Adnan Menderes University","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","SARI-01","February 2013","March 2014","March 2014","April 16, 2014","null","April 16, 2014","Adnan Menderes University Medical Faculty, Anesthesiology and Reanimation Department, Aydın, Turkey","","https://ClinicalTrials.gov/show/NCT02115945"
1427,"NCT02115828","A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy",,"Completed","Has Results","Prostate Cancer","Drug: Vismodegib","The Proportion of mCRPC Patients Treated With Vismodegib Who Achieve a Pharmacodynamic (PD) Response in Tumor Biopsies|GLI1 Expression|Progression-free Survival (PFS)|AKT1 Expression in Tumor Biopsies|The Effect of Vismodegib on PSA Responses","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J1423|NA_00093427","April 2014","April 2016","April 2016","April 16, 2014","July 20, 2018","July 20, 2018","Johns Hopkins Hospital, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02115828"
1428,"NCT02114957","Pharmacokinetics of Decursin/Decursinol Angelate (CognIQTM)",,"Completed","No Results Available","Healthy","Dietary Supplement: 800mg dietary supplement CognIQTM (4 capsules) by oral at hour 0","Area under the plasma concentration versus time curve (AUC) of decursin, decursinol angelate (DA) and decursinol|vital signs, plasma biochemistry and blood cell counts of subjects after consumption the study herb","Texas Tech University Health Sciences Center","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","A12-3742","January 2013","April 2013","null","April 15, 2014","null","April 15, 2014","Clinical Research Unit, School of Medicine, Texas Tech University Health Sciences Center, Amarillo, Texas, United States","","https://ClinicalTrials.gov/show/NCT02114957"
1429,"NCT02113657","T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer",,"Active, not recruiting","No Results Available","Prostate Cancer","Drug: Ipilimumab","Impact of Ipilimumab on T Cell Responses to prostate cancer neoantigens in both primary tumor and metastatic sites in men with metastatic CRPC","M.D. Anderson Cancer Center|Bristol-Myers Squibb|Stand Up To Cancer|High Impact Clinical Research Support Program","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-0444|NCI-2014-01205|SUC2CR-AACR-DT10","August 20, 2014","August 2019","August 2020","April 14, 2014","null","November 14, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02113657"
1430,"NCT02109861","Microdose Study of Melphalan, Bortezomib and Dexamethasone","Phase-0-MM","Unknown status","No Results Available","Multiple Myeloma","Drug: Melphalan|Drug: Bortezomib|Drug: Dexamethasone","Change from baseline in gene expression at 15, 30, 60, 120 minutes upon microdose drug exposure.","Henrik Gregersen|Aalborg Universitetshospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","KFE2011.06|2011-003791-37","January 2014","December 2015","December 2015","April 10, 2014","null","December 8, 2015","Department of Haematology, Aalborg University Hospital, Aalborg, Denmark","","https://ClinicalTrials.gov/show/NCT02109861"
1431,"NCT02109614","Early Aortic Valve Lipoprotein(a) Lowering Trial","EAVaLL","Unknown status","No Results Available","Aortic Stenosis and Lipoprotein(a) Levels","Drug: Extended release Niacin|Drug: Placebo Comparator","Calcium score progression by cardiac CT in individuals randomized to niacin as compared to those randomized to placebo|Mean change in Lp(a) levels between treatment arms","George Thanassoulis|Jewish General Hospital|Laval University|Quebec Heart Institute|McGill University Health Center","All","50 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","238","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","A00-M105-13A","May 2014","January 2017","September 2017","April 10, 2014","null","September 13, 2016","MUHC - Montreal General Hospital, Montreal, Quebec, Canada|MUHC - Royal Victoria Hospital, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT02109614"
1432,"NCT02108457","[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers",,"Active, not recruiting","No Results Available","Gynecologic Cancer","Radiation: [18F]Fluorothymidine (FLT) PET/CT Imaging","Number of Adverse Events","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","17","Other","Interventional","Primary Purpose: Treatment","UPCC 28813","February 2014","January 2017","null","April 9, 2014","null","July 31, 2017","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02108457"
1433,"NCT02106286","Effects of Beta-blockade on Cardiopulmonary Exercise Testing",,"Completed","No Results Available","Abdominal Aortic Aneurysm Patients Under Surveillance","Drug: Bisoprolol","Change in oxygen uptake","Michelle Mossa|Aintree University Hospitals NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","55","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","11/NW/0810","February 2011","December 2013","December 2013","April 8, 2014","null","April 8, 2014","Aintree University Hospitals, Liverpool, United Kingdom","","https://ClinicalTrials.gov/show/NCT02106286"
1434,"NCT02099240","Patients Response to Early Switch To Oral:Osteomyelitis Study","PRESTO:Osteo","Recruiting","No Results Available","Osteomyelitis","Drug: oral antibiotics|Procedure: intravenous antibiotics","Clinical Failures|Evaluation of adverse events related to the use of antibiotics|Cost of care from the hospital perspective","Julio Ramirez|University of Louisville","All","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","456","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14.0185","April 2014","September 2019","September 2019","March 28, 2014","null","March 8, 2018","University of Louisville, Louisville, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT02099240"
1435,"NCT02097953","Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin",,"Completed","No Results Available","Drug Interactions|Pharmacokinetics","Drug: Daptomycin|Drug: Rifampin","Daptomycin total, renal, and non-renal clearance|Daptomycin Volume of Distribution|Daptomycin Elimination Rate Constant|Daptomycin Free and Total Peak Concentrations|Daptomycin Free and Total 24 hour Concentrations|Daptomycin Free and Total Area Under the Concentration-Time Curve (AUC) from 0 to 24 hours|Daptomycin Free and Total AUC from 0 to Infinity|Percent Protein Binding of Daptomycin|P-glycoprotein Polymorphism|Number of Participants with Adverse Events","University of Utah|Cubist Pharmaceuticals LLC","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00069136","May 2014","June 2015","July 2016","March 27, 2014","null","December 12, 2016","University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02097953"
1436,"NCT02093988","Topical Tranexamic Acid in Major Paediatric Spine Deformity Surgery: A Randomized Controlled Trial",,"Unknown status","No Results Available","Spinal Deformity, Paediatric Surgery, Tranexamic Acid","Drug: Topical TXA|Drug: Intravenous TXA","Volume of Blood Loss|Complications (reporting)","University of British Columbia","All","8 Years to 21 Years   (Child, Adult)","Early Phase 1","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","H14-00595","August 2015","February 2017","February 2017","March 21, 2014","null","December 2, 2015","BC Children's Hospital, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT02093988"
1437,"NCT02093481","Effects of Dietary Fibre on Glucose Metabolism and Satiety",,"Completed","No Results Available","Obesity|Metabolic Syndrome","Other: Test meal|Other: Reference|Other: Priming|Other: No priming","Blood glucose|Insulin|Appetite hormones|Markers of colonic fermentation and inflammation|Subjective satiety","Lund University","All","20 Years to 35 Years   (Adult)","Early Phase 1","19","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Dnr2013/241","February 2014","June 2014","June 2014","March 21, 2014","null","June 26, 2014","Applied Nutrition and Food Chemistry, Lund Univeristy, Lund, SE, Sweden","","https://ClinicalTrials.gov/show/NCT02093481"
1438,"NCT02091817","The Effect of Oxytocin on Face Perception",,"Suspended","No Results Available","Healthy|Congenital Prosopagnosia","Drug: Oxytocin|Drug: Placebo","Memory performance|Mood measurement","Soroka University Medical Center|Ben-Gurion University of the Negev","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","sor010712ctil|ISF, 384/10","November 2013","December 2016","December 2017","March 19, 2014","null","July 2, 2015","Soroka medical center, Beer Sheva, Israel","","https://ClinicalTrials.gov/show/NCT02091817"
1439,"NCT02091219","Effects of Vitamin D3 Versus 25OHD3 on Mineral Metabolism and Immune Function",,"Recruiting","No Results Available","Vitamin D Deficiency","Drug: Vitamin D|Drug: 25(OH)D3","Change in total serum 25D|Change in serum free 25D|Change in serum total 1,25D|Change in total free 1,25D|Change in serum calcium|Change in urinary calcium|Change in serum iPTH|Change in serum bone turnover markers|Change in markers of immune function","University of California, Los Angeles|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","35","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","UL1TR000124-1954|1P50AR063020-01|UL1TR000124","June 2014","June 2019","December 2019","March 19, 2014","null","October 11, 2018","UCLA Clinical and Translational Research Center (CTRC), Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02091219"
1440,"NCT02089386","Tamoxifen to Treat Barrett's Metaplasia",,"Terminated","No Results Available","Barrett Metaplasia","Drug: Tamoxifen|Procedure: Endoscopy","Extent of Barrett's involvement and changes in histology|Changes in SOX2 and CDX2 expression|Tolerance of tamoxifen|Changes in the length of Barrett's esophagus involvement","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","201404013","July 9, 2014","June 21, 2016","June 21, 2016","March 17, 2014","null","March 13, 2017","Washington University School of Medicine, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02089386"
1441,"NCT02088866","Commercial Lidocaine Patch as a Treatment for Ear-ringing",,"Completed","No Results Available","Tinnitus","Drug: Transdermal Lidocaine","Tinnitus Functional Index (TFI) change at 4 week intervals up to a maximum time frame of 12 weeks","University of California, Davis","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","515576","March 2014","August 2015","September 2015","March 17, 2014","null","May 30, 2017","UC Davis Department of Otolaryngology, Sacramento, California, United States","","https://ClinicalTrials.gov/show/NCT02088866"
1442,"NCT02083926","Ketamine Infusion for Social Anxiety Disorder",,"Unknown status","No Results Available","Social Anxiety Disorder","Drug: Ketamine|Drug: Saline","Visual Analog Scale (VAS) of Anxiety States|Anxiety Severity|Depression Severity|Clinical Global Impressions|Brief Psychiatric Rating Scale, Positive Symptom Subscale (BPRS-PS)|Clinician-Administered Dissociative States Scale|Self-Statement During Public Speaking Scale (SPSS)|Impromptu Speech Behavioral Assessment Test|Attention Bias|SAD Severity|Positive and Negative Affect Symptoms|State-Trait Anxiety Inventory","Yale University|Patterson Trust Awards Program in Clinical Research","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1310012947","March 2014","March 2018","March 2018","March 11, 2014","null","July 12, 2016","Connecticut Mental Health Center, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02083926"
1443,"NCT02083692","Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling",,"Completed","No Results Available","Head and Neck Squamous Cell Cancer","Drug: Metformin","Change in TOMM20 and MCT4 expression from tumor cells from date of biopsy and date of surgery","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","13D.458","September 2013","May 2016","null","March 11, 2014","null","October 19, 2016","Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02083692"
1444,"NCT02083510","Apolipoprotein CIII Reduction Via Colchicine",,"Completed","No Results Available","Hypertriglyceridemia|Gout|Pericarditis","Drug: Colchicine","Reduction in ApoCIII levels|Reduction of triglycerides and very low density lipoprotein (VLDL) levels|Measurement of Apolipoprotein A and Apolipoprotein B via Vertical Auto Profile (VAP)","Scripps Translational Science Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","13-6293|1UL1TR001114-01","February 2014","May 2014","May 2014","March 11, 2014","null","May 30, 2014","Scripps Translational Science Institute, La Jolla, California, United States","","https://ClinicalTrials.gov/show/NCT02083510"
1445,"NCT02081924","Reproductive Hormones During Sustained Administration of Kisspeptin","KisspeptPump","Recruiting","No Results Available","Fertility Disorders|Hypothalamic Dysfunction","Other: Kisspeptin|Other: Saline","The effect of sustained administration of the hormone kisspeptin on luteinising hormone pulsatility in participants with reduced fertility.|To determine whether there is a difference in luteinising hormone pulsatility between normal fertility participants and reduced fertility participants when given sustained administration of the hormone kisspeptin.","Imperial College London","All","18 Years to 60 Years   (Adult)","Early Phase 1","76","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)","13/LO/1807","March 2014","December 2018","February 2019","March 7, 2014","null","September 1, 2016","Imperial College NHS Healthcare Trust, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02081924"
1446,"NCT02080416","Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors",,"Terminated","No Results Available","Non-Hodgkin Lymphoma|Hodgkin Lymphoma|Kaposi Sarcoma|Gastric Cancer|Nasopharyngeal Cancer|EBV|Castleman Disease","Drug: Nelfinavir","Lytic activation of viral gene expression by NFV|Serial assessment of methylation of viral DNA|Serial assessment of viral copy number in plasma|Tolerability of high-dose nelfinavir|Tumor regression and response","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J13174|NA_00092477","July 2014","February 2016","February 2016","March 6, 2014","null","June 10, 2016","The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02080416"
1447,"NCT02079961","Distribution of Fortified Yoghurt in Senegal to Decrease Children's Anemia and Improve Milk Supply",,"Completed","No Results Available","Anemia|Iron-Deficiency","Dietary Supplement: Micronutrient-fortified yoghurt|Behavioral: BCC","Prevalence of anemia in children 24-59 months after receiving iron fortified yoghurt during a one year intervention|Frequency of milk supply by pastoralist during one year intervention","Agnes LePort|GRET|Cellule de Lutte contre la Malnutrition|Universite Gaston Berger|International Food Policy Research Institute","All","24 Months to 59 Months   (Child)","Early Phase 1","471","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","EC CRP4 Senegal","January 2013","February 2014","March 2014","March 6, 2014","null","March 6, 2014","IFPRI, Dakar, Senegal","","https://ClinicalTrials.gov/show/NCT02079961"
1448,"NCT02078037","Systemic Normothermia in Intracerebral Hemorrhage (ICH)","SNICH","Completed","No Results Available","Intracerebral Hemorrhage","Device: Arctic Sun cooling device|Other: Standard of Care","MRI measurement of relative perihematomal edema (% change of perihematomal edema)|Structured telephone interview of functional and cognitive outcome|Serum cytokine measurement with inflammatory cytokine protein array","The Cleveland Clinic","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","13-1407","March 2014","April 2016","April 2016","March 5, 2014","null","January 10, 2017","Cleveland Clinic, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02078037"
1449,"NCT02077998","Oxaliplatin in Treating Patients With Metastatic Breast Cancer",,"Completed","No Results Available","Stage IV Breast Cancer","Radiation: carbon C 14 oxaliplatin|Drug: oxaliplatin|Other: laboratory biomarker analysis","Threshold at which oxaliplatin-DNA adducts predict response to therapy|Response rate assessed using Response Evaluation Criteria in Solid Tumors (RECIST)|Progression-free survival|Overall survival|Overall toxicity from both the carbon C 14 oxaliplatin microdose and the full dose oxaliplatin chemotherapy evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|PK parameters including maximum concentration (Cmax), half-life (t1/2), and area under the curve (AUC) from both micro- and therapeutic- dosing in the same patients|Levels of oxaliplatin-DNA adducts in tumor and PBMC|Repair of oxaliplatin-DNA monoadducts in PBMCs|Messenger ribonucleic acid (mRNA) expression levels of ERCC1","University of California, Davis|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","1","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCDCC#237|457404|P30CA093373|NCI-2013-01747","May 2015","May 2015","December 2015","March 4, 2014","null","January 9, 2018","UC Davis Comprehensive Cancer Center, Sacramento, California, United States","","https://ClinicalTrials.gov/show/NCT02077998"
1450,"NCT02077543","Multicenter Safety Trial Assessing an Innovative Tumor Molecular and Cellular Print Medical Device in Glioma","ProTool","Recruiting","No Results Available","Glioma : Oligodendroglioma or Astrocytoma","Device: Brain Tissue Imprint - Medical Device (ProTool)","Clinical examination : neurologic deficiency, allergic reaction, infections, pain, headaches, others adverse events... Postoperative MRI evaluation : no hematoma|Molecular measurements in intra-operative cellular samples : transcriptome, micro-RNA, proteome and cellular cultur analysis","University Hospital, Grenoble|MEDIMPRINT|Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","150","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","ProTool","October 2013","June 2019","November 2019","March 4, 2014","null","October 19, 2018","Angers University Hospital, Angers, France|Henri Mondor University Hospital, Creteil, France|CLINATEC, Grenoble, France|Grenoble University Hospital, Grenoble, France|Sainte-Anne Hospital, Paris, France","","https://ClinicalTrials.gov/show/NCT02077543"
1451,"NCT02072720","Angiogenic Factor Expression During Fractionated Irradiation",,"Recruiting","No Results Available","Primary Esophageal Carcinoma","Drug: Bevacizumab","Change of VEGF mRNA expression in tumor biopsies|Change of VEGFR2 phosphorylation with IHC|Changes of mRNA expression of other pro-angiogenic factors|Changes in protein expression of pro-angiogenic factors|Changes in vascular parameters in the tumor tissue to asses ongoing angiogenesis","VU University Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013/340","February 2014","December 2017","December 2017","February 26, 2014","null","March 20, 2017","VU university medical center, Amsterdam, Noord-Holland, Netherlands","","https://ClinicalTrials.gov/show/NCT02072720"
1452,"NCT02072447","Absolute Bioavailability of YH4808 With Accelerator Mass Spectrometry(AMS)-Based Microdose Study",,"Completed","No Results Available","Gastroesophageal Reflux Disease","Drug: YH4808 PO and [14C]-YH4808 IV","Absolute bioavailability (Fpo)","Seoul National University Hospital","Male","20 Years to 45 Years   (Adult)","Early Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Microdose_01(YH4808-110(I))","March 2014","April 2014","April 2014","February 26, 2014","null","April 21, 2014","Seoul National University Hospital, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02072447"
1453,"NCT02070393","Breast-Sparing Proton Therapy for Hodgkin's Disease","Breast Sparing","Terminated","No Results Available","Hodgkins Disease","Radiation: Proton","Comparative DVH data for delivered proton plan and accompanying photon plan for target volume and normal tissues.|Treatment toxicity and disease control of proton therapy for the treatment of pediatric Hodgkin's Lymphoma.","Indiana University","Female","10 Years to 30 Years   (Child, Adult)","Early Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","IUHPTC-01","September 2011","February 2015","February 2015","February 25, 2014","null","February 4, 2015","Indiana University Health Proton Therapy Center, Bloomington, Indiana, United States","","https://ClinicalTrials.gov/show/NCT02070393"
1454,"NCT02070068","A Pilot Dosing and Timing Study to Optimize Imaging When Utilizing Endoscopic Fluorescence Imaging System During Laparoscopic Biliary and Hepatic Operations",,"Completed","No Results Available","Biliary Anatomy","Device: PINPOINT System","Ease of Identification of Biliary Anatomy as Scored by the Surgeon (1-5 scale)","University of California, Los Angeles|Novadaq Technologies Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","38","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PP LBH 01","January 2014","November 2014","November 2014","February 24, 2014","null","December 2, 2014","Ronald Reagan UCLA Medical Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02070068"
1455,"NCT02069080","Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor",,"Terminated","No Results Available","Cancer","Drug: 64-Cu-plerixafor","Uptake of 64Cu-plerixafor in the target lesion(s) of subjects expressing CXCR4 versus the uptake of 64Cu-plerixafor in the surrounding non-tumor tissues.|64Cu-plerixafor SUV in the target lesion(s) versus the level of CXCR4 expression detected via immunohistochemical staining.|Human-absorbed doses of 64Cu-plerixafor|The incidence and severity of adverse events (AEs) by dose group.","National Institute of Allergy and Infectious Diseases (NIAID)|Lombardi Comprehensive Cancer Center|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","2","NIH|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","140050|14-I-0050","February 20, 2014","July 10, 2018","July 10, 2018","February 21, 2014","null","July 12, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02069080"
1456,"NCT02066818","Injectable Lidocaine Versus Lidocaine/Tetracaine Patch for the Incision and Drainage of Skin Abscesses",,"Completed","No Results Available","Cutaneous Abscess|Pain","Drug: Lidocaine/tetracaine patch|Drug: 1% lidocaine","Change in VAS pain score over time","East Carolina University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","ECUEM-Synera","January 2008","January 2010","January 2010","February 20, 2014","null","February 20, 2014","","","https://ClinicalTrials.gov/show/NCT02066818"
1457,"NCT02066792","Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder",,"Completed","No Results Available","Social Anxiety Disorder","Drug: D-Cycloserine|Drug: Placebo|Behavioral: Cognitive Behavioral Therapy","Short- and Long-Term Improvements in Social Anxiety Severity","University of Texas at Austin|Rush University Medical Center|Boston University|Southern Methodist University","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","173","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R34MH099318","April 2014","July 1, 2018","July 1, 2018","February 20, 2014","null","October 11, 2018","Rush University Medical Center, Chicago, Illinois, United States|Boston University, Boston, Massachusetts, United States|University of Texas at Austin, Austin, Texas, United States","","https://ClinicalTrials.gov/show/NCT02066792"
1458,"NCT02065609","89ZrTrastuzumab Breast Imaging With Positron Emission Tomography",,"Completed","No Results Available","Breast Cancer","Drug: 89Zr-Trastuzumab Human Dosimetry and Safety|Drug: HER2 Positive Lesion Detection and Safety","Number of Participants with Adverse Events as a Measure of Safety and Tolerability after 89Zr-Trastuzumab Administration","Washington University School of Medicine|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","67","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201307037|R21CA182945","February 2014","December 31, 2017","null","February 19, 2014","null","October 3, 2018","Washington University School of Medicine @ Barnes-Jewish Hospital, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02065609"
1459,"NCT02063841","Digestive Endoscopy Suite Radiation Controlling Protective Strategies","D-ERCP","Completed","No Results Available","Radiation Exposure","Device: lead-free protective drape containing bismuth and antimony (RADPAD®)|Device: sterile identical sham drape","Amount of radiation exposure|Estimate cumulative annual radiation risk","Yale University","All","45 Years to 50 Years   (Adult)","Early Phase 1","2","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","1210010994.Jamidar","August 2013","November 2013","November 2013","February 14, 2014","null","August 20, 2015","Endoscopy Center, Smilow Cancer Center, Yale New Haven Hospital, New Have, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02063841"
1460,"NCT02063737","SleepTrackTXT Feasibility and Pilot Study","SleepTrackTXT","Completed","Has Results","Fatigue","Behavioral: Text-message assessments only|Behavioral: Text-message interventions for high level fatigue","Self-Reported Fatigue at End of Shift Work|Attitude One Subscale of the Sleep Fatigue and Alertness Behavior (SFAB) Tool|Attitudes Two Subscale of the Sleep Fatigue and Alertness Behavior Tool|Normative Beliefs Scale One Subscale of the SFAB|Normative Beliefs Scale Two Subscale of the SFAB|Self Efficacy Subscale of the SFAB|Knowledge-one Subscale of SFAB|Knowledge-two Subscale of the SFAB|Importance Subscale of SFAB|Environmental Constraints One Subscale of the SFAB|Environmental Constraints Two Subscale of the SFAB|Environmental Constraints Three Subscale of the SFAB|Habits Subscale of the SFAB|Intentions Subscale of the SFAB","University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PRO13120428","January 2014","June 2014","June 2014","February 14, 2014","July 13, 2015","August 5, 2015","University of Pittsburgh Department of Emergency Medicine School of Medicine, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02063737"
1461,"NCT02062255","Impact of COX2 on Sera Biomarkers From Obese Subjects",,"Completed","No Results Available","Breast Cancer Survivors","Drug: Aspirin|Dietary Supplement: Omega 3 FFA","Biomarker levels|BMI","The University of Texas Health Science Center at San Antonio","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","126","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CTRC 13-0041|HSC20130426H","October 2013","April 2016","April 2016","February 13, 2014","null","October 26, 2016","Cancer Therapy and Research Center at UTHSCSA, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT02062255"
1462,"NCT02061722","[PETDE10] Imaging of PDE10A Enzyme Levels in Huntington's Disease Gene Expansion Carriers and Healthy Controls With PET.","PEARL-HD","Completed","No Results Available","Huntington's Disease","Radiation: PET Imaging with [18F]MNI-659","The primary outcome measure will be the distribution volume (VT) in the striatum (caudate and putamen), globus pallidus, and ventral striatum estimated using kinetic and graphical analysis. Thalamus, cortex and cerebellum will also be examined.","CHDI Foundation, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","90","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CHDIKI1201/PET-HD-PDE10A","January 2013","May 2016","May 2016","February 13, 2014","null","June 1, 2016","The Memory Clinic, Rigshopitalet, Copenhagen, Denmark|Leiden University Medical Center, Department of Neurology, Leiden, Netherlands|University of Oslo, Nevrologisk poliklinikk, Oslo, Norway|Skane Universitetssjukhus Lund, Neurologiska kliniken, Lund, Sweden|Karolinska Universitetssjukhus, Huddinge, Stockholm, Sweden|Karolinska University Hospital, Stockholm, Sweden|KTA Karolinska Trial Alliance, Stockholm, Sweden|Neurologkliniken Akademiska sjukhuset, ing 85, Uppsala, Sweden","","https://ClinicalTrials.gov/show/NCT02061722"
1463,"NCT02058966","Pilot Study of Entacapone for Methamphetamine Abuse",,"Completed","No Results Available","Methamphetamine Dependence","Drug: Entacapone|Drug: Methamphetamine|Drug: Placebo","Interest, Mood elevation, and Reward|Cognition","Oregon Health and Science University|Portland VA Medical Center","All","18 Years to 45 Years   (Adult)","Early Phase 1","29","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","8874|1004805|3986","June 2014","June 2016","June 2016","February 11, 2014","null","January 4, 2017","Oregon Health & Science University, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT02058966"
1464,"NCT02058784","Study to Evaluate the Food Effect of Single-dose Bioavailability of Pracinostat in Healthy Adult Subjects","HVFE","Completed","No Results Available","Healthy Volunteers|Moderate to Heavy Smokers|Non-smokers","Drug: pracinostat","Assess the effect of food on a single-dose PK of pracinostat in nonsmoking healthy adult subjects|Evaluate the safety and tolerability of a single-dose of pracinostat under fasted and fed conditions in healthy nonsmoking and smoking adult subjects","Helsinn Healthcare SA|Celerion","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","MEI-006","February 2014","March 2014","March 2014","February 10, 2014","null","February 23, 2017","Celerion, Tempe, Arizona, United States","","https://ClinicalTrials.gov/show/NCT02058784"
1465,"NCT02052479","Insulin Differences Between African-American and Caucasian Female Adolescents With Polycystic Ovary Syndrome (PCOS)",,"Unknown status","No Results Available","Polycystic Ovary Syndrome|PCOS","Other: Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT)","Insulin Secretion|Insulin Sensitivity/Resistance","Nationwide Children's Hospital","Female","12 Years to 18 Years   (Child, Adult)","Early Phase 1","30","Other","Interventional","Primary Purpose: Diagnostic","297013","January 2014","June 2015","June 2015","February 3, 2014","null","February 3, 2015","Clinical Research Center at The Ohio University Wexner Medical Center / Nationwide Children's Hospital, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02052479"
1466,"NCT02052167","Human Factors Study of Methotrexate Prefilled Pen (50 mg/mL) in Patients With Juvenile Idiopathic Arthritis",,"Completed","No Results Available","Juvenile Idiopathic Arthritis","Device: methotrexate prefilled pen","Evaluation of test case scenarios with observation and performance measures","medac GmbH|PPD","All","2 Years to 20 Years   (Child, Adult)","Early Phase 1","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","MC-MTX.16/HF Children","April 2014","August 2014","August 2014","January 31, 2014","null","March 29, 2018","Children's Mercy Hospital & Clinics, Kansas City, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02052167"
1467,"NCT02051595","The Effects of Modified Ultrafiltration on Vancomycin Levels During Cardiopulmonary Bypass in Cardiac Surgery",,"Completed","Has Results","Infection","Other: Vancomycin concentrations","Circulating Vancomycin Concentration","University of Florida","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","201300857","April 2014","April 2015","April 2015","January 31, 2014","July 21, 2015","September 14, 2015","UF Health, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT02051595"
1468,"NCT02051569","Serotonin and Everyday Social Interaction",,"Completed","No Results Available","Social Behaviour","Dietary Supplement: Tryptophan","quarrelsome behaviour|interpersonal behaviour|affect|perceptions of others|social cognitions","University of Groningen","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","NL451-09-013 / 2","August 2012","January 2014","January 2014","January 31, 2014","null","January 31, 2014","","","https://ClinicalTrials.gov/show/NCT02051569"
1469,"NCT02051530","Mood, Serotonin and Social Interaction",,"Completed","No Results Available","Mood|Social Behavior","Dietary Supplement: tryptophan depletion","Empathic Accuracy|Behavioral mimicry|Emotional Prosody (EP)|blood|heart rate variability","University of Groningen","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","NL451-09-013","April 2012","March 2014","March 2014","January 31, 2014","null","January 30, 2015","University Center Psychiatry, Groningen, Netherlands","","https://ClinicalTrials.gov/show/NCT02051530"
1470,"NCT02047539","Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis",,"Recruiting","No Results Available","Clinical High Risk for Psychosis","Drug: Aspirin|Drug: Placebo","Scale of Prodromal Symptoms (SOPS)","Yale University","All","19 Years to 35 Years   (Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","1401013288","January 2015","March 2018","March 2018","January 28, 2014","null","January 16, 2018","PRIME Research Clinic, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02047539"
1471,"NCT02046694","A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL",,"Recruiting","No Results Available","Acute Lymphoblastic Leukemia (ALL)","Drug: Allopurinol","Absolute neutrophil count|Feasibility of the addition of allopurinol to ALL maintenance therapy|Safety of the addition of allopurinol to ALL maintenance therapy|Effects of allopurinol on liver function tests|Alteration of 6-MP metabolism through the addition of allopurinol","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","up to 30 Years   (Child, Adult)","Early Phase 1","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J1357|NA_00084984","January 2014","July 2020","September 2021","January 28, 2014","null","September 11, 2018","Johns Hopkins Hospital, Baltimore, Maryland, United States|Texas Children's Cancer and Hematology Centers, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02046694/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02046694"
1472,"NCT02045056","Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease",,"Active, not recruiting","No Results Available","Preclinical Alzheimer's Disease","Drug: Gemfibrozil|Drug: Placebo","Safety|microRNA-107 levels|beta-amyloid levels|Free and cued selective reminding test (FCSRT)|Paired associates learning (PAL)","Gregory Jicha, 323-5550|University of Kentucky","All","65 Years to 90 Years   (Older Adult)","Early Phase 1","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","R01AG042419","May 2014","June 30, 2018","June 2019","January 24, 2014","null","October 16, 2018","University of Kentucky, Lexington, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT02045056"
1473,"NCT02042430","Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",,"Active, not recruiting","No Results Available","Stage III Fallopian Tube Cancer AJCC v7|Stage III Ovarian Cancer AJCC v6 and v7|Stage III Primary Peritoneal Cancer AJCC v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7","Drug: Epacadostat|Other: Laboratory Biomarker Analysis|Procedure: Therapeutic Conventional Surgery","Number of participants with an increase in CD8+ T cells|Change in number and character of tumor infiltrating lymphocytes|Change in gene signatures as assessed by microarray analysis|Change in character of the cellular content of PBMCs and ascites fluid, determined by multiparameter flow cytometry|Change in fluid transcriptomes in PBMC and ascites|Change in ongoing and nascent anti-tumor response antigens associated with ovarian cancer, including NY-ESO-1, PRAME and mesothelin|Change in memory viral responses, including influenza A|Change in chronic viral responses, including cytomegalovirus|Incidence of adverse events, assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Kyn/Trp ratios|Changes in IDO1 expression by IHC","National Cancer Institute (NCI)","Female","19 Years and older   (Adult, Older Adult)","Early Phase 1","17","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2013-02483|CITN-05 OVARIAN IDO|ICD 10033159|ICD 10016180|ICD 10026669|CITN-05|P30CA015704|U01CA154967","December 31, 2013","March 31, 2016","null","January 22, 2014","null","August 28, 2018","University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Roswell Park Cancer Institute, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT02042430"
1474,"NCT02042222","Novel Dose Escalation to Predict Treatment With Hydroxyurea","NDEPTH","Recruiting","No Results Available","Sickle Cell Disease","Drug: Hydroxyurea","Time to patients reaching the maximum tolerated dose (MTD) of the medication|Safety Analysis","Baylor College of Medicine|Texas Children's Hospital|Children's Hospital Medical Center, Cincinnati","All","1 Year to 16 Years   (Child)","Early Phase 1","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-32003 NDEPTH|NDEPTH","October 2013","October 2018","October 2019","January 22, 2014","null","July 11, 2018","Texas Children's Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02042222"
1475,"NCT02042196","Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women","SHAPE2","Active, not recruiting","No Results Available","Menopause|Aging","Drug: KUVAN|Drug: Placebo|Drug: Cetrotide|Drug: Climara|Drug: Placebo transdermal patch","Change in brachial artery flow-mediated dilation|Change in carotid artery compliance and endothelial cell protein expression","University of Colorado, Denver|National Heart, Lung, and Blood Institute (NHLBI)","Female","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","06-0537 SHAPE2|R56HL114073-06A1","December 2013","December 2018","December 31, 2018","January 22, 2014","null","July 25, 2018","University of Colorado Denver, Aurora, Colorado, United States","","https://ClinicalTrials.gov/show/NCT02042196"
1476,"NCT02039648","The Influence of Rumex Acetosa L on the Intraoral Colonization With Porphyromonas Gingivalis","RPG-I","Completed","No Results Available","Periodontitis","Other: Rumex acetosa L. extract|Other: Placebo","change of the intraoral prevalence of Porphyromonas gingivalis|change of the Approximal Plaque Index|change of the Sulcular Bleeding Index|change of the cytopathological appearance of the mucosal tissue","Heinrich-Heine University, Duesseldorf","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NRW 300262502","March 2012","April 2013","April 2013","January 17, 2014","null","January 17, 2014","Department od Operative Dentistry, Periodontics and Endodontics, Duesseldorf, Germany","","https://ClinicalTrials.gov/show/NCT02039648"
1477,"NCT02038595","The Norepinephrine Transporter: A Novel Target for Imaging Brown Adipose Tissue",,"Completed","No Results Available","Brown Adipose Tissue","Radiation: PET imaging","detection of brown adipose tissue based on PET imaging","Yale University|New York University School of Medicine","All","18 Years to 30 Years   (Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","DK090764","September 2012","December 2013","December 2013","January 16, 2014","null","July 20, 2015","Yale University, New haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02038595"
1478,"NCT02037035","Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling",,"Active, not recruiting","No Results Available","Depression","Drug: Ketamine","Glutamate Metabolism","Yale University|National Institute of Mental Health (NIMH)|American Psychiatric Association","All","21 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","36","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","1305011972","July 2013","July 2019","July 2019","January 15, 2014","null","August 23, 2018","Yale Depression Research Program, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02037035"
1479,"NCT02033447","Magnetic Nanoparticle Thermoablation-Retention and Maintenance in the Prostate:A Phase 0 Study in Men","MAGNABLATE I","Completed","No Results Available","Prostate Cancer","Other: Magnetic Nanoparticle Injection","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|The anatomical distribution of magnetic nanoparticles","University College London Hospitals","Male","Child, Adult, Older Adult","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","13/0257|National Institute for Health","December 2013","January 2015","January 2015","January 10, 2014","null","May 10, 2017","University College London Hospital, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02033447"
1480,"NCT02031367","Efficacy of Platelet Rich Plasma vs. Corticosteroid Injections for Treating Greater Trochanteric Pain Syndrome",,"Unknown status","No Results Available","Greater Trochanteric Pain Syndrome","Drug: Triamcinolone Acetonide|Other: Platelet Rich Plasma","Pain|Functional outcomes","C.R.Darnall Army Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","GTPS PRP VS Steroid","March 2014","December 2016","December 2016","January 9, 2014","null","January 9, 2014","Carl R. Darnall Army Medical Center, Ft. Hood, Texas, United States","","https://ClinicalTrials.gov/show/NCT02031367"
1481,"NCT02029118","Acupoint Application in Patients With Stable Angina Pectoris (AASAP)","AASAP","Unknown status","No Results Available","Stable Angina Pectoris","Drug: Herbal plaster ( styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech)|Device: acupoint|Drug: Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn.","Change from Baseline Number of angina attacks at 12 weeks|Change from Baseline the severity of angina ( VAS score) at 12 weeks|Change from Baseline the dosage of nitroglycerin at 12 weeks|Seattle Angina Questionnaire|self-rating anxiety scale|Self-rating Depression Scale","Chengdu University of Traditional Chinese Medicine","All","35 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2011SZ0302.2","October 2012","May 2015","August 2015","January 7, 2014","null","September 9, 2014","Affiliated hospital of Chengdu University of TCM, Chengdu, Sichuan, China","","https://ClinicalTrials.gov/show/NCT02029118"
1482,"NCT02029053","Preliminary Study of a Vaginal Lubrication Ring to Treat the Symptoms of Vaginal Dryness",,"Completed","No Results Available","Menopausal and Perimenopausal Disorder, Unspecified|Atrophic Vaginitis","Device: Vaginal Lubrication Ring for Vaginal Dryness","Vaginal lubrication/moisturization|Comfort and fit of intravaginal ring","J3 Bioscience, Inc.|University of Utah","Female","35 Years and older   (Adult, Older Adult)","Early Phase 1","21","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","67709","January 2014","May 2014","May 2014","January 7, 2014","null","December 15, 2015","University of Utah Health Sciences Center, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02029053"
1483,"NCT02026869","Vaginal Administration of Metformin in PCOS Patients.","VMPCO","Unknown status","No Results Available","PCOS","Drug: Metformin","Ovulation rates|Therapeutic drug level","Assiut University","Female","20 Years to 35 Years   (Adult)","Early Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Vaginal Metformin- Ahmed Nasr","January 2013","June 2013","February 2014","January 3, 2014","null","January 3, 2014","Women's Health Hospital, Assiut, Egypt","","https://ClinicalTrials.gov/show/NCT02026869"
1484,"NCT02025582","Kinesio Taping Effectiveness on Idiopathic Toe Walking",,"Completed","No Results Available","Idiopathic Toe Walking","Device: Kinesio Tape of the Ankle","Change in Ankle Joint Range of Motion|Advanced gait analysis - Change in kinetics","Mayo Clinic","All","3 Years to 10 Years   (Child)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-003848","December 2013","March 2016","March 2016","January 1, 2014","null","April 22, 2016","Mayo Clinic in Rochester, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02025582"
1485,"NCT02025348","Explore the Performance of IntelliCap.",,"Completed","No Results Available","Plasma Concentration|Pharmacokinetic Profile","Drug: IntelliCap","In vivo performance|Pharmacokinetic parameters","AstraZeneca","Male","18 Years to 50 Years   (Adult)","Early Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D1840M00044","January 2014","March 2014","March 2014","January 1, 2014","null","January 27, 2016","Research Site, Merthyr Tydfil, United Kingdom","","https://ClinicalTrials.gov/show/NCT02025348"
1486,"NCT02024997","Improving Pancreas Radiotherapy Plans Using Respiration-driven Anatomic Deformation: A Pilot Study",,"Completed","No Results Available","Pancreatic Cancer","Other: Magnetic Resonance Imaging (MRI)","Compare magnetic resonance (MR) in different breath-hold phases to quantify respiration induced anatomic changes|Modeling the feasibility of the dose escalation using respiration induced anatomic changes","Cedars-Sinai Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IIT2012-07-YANG-MRIRESP","January 2013","September 2014","null","December 31, 2013","null","October 30, 2014","Cedars-Sinai Medical Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02024997"
1487,"NCT02023931","Broccoli Sprout Extracts in Healthy Volunteers: A Pilot Study of Nrf2 Pathway Modulation in Oral Mucosa","BSE","Completed","No Results Available","Healthy Subject","Drug: Broccoli Sprout Extract (BSE)","Determine the modulation of the Nrf2 pathway in response to short term exposure to three BSE regimens|Estimate modulation of Nrf2 pathway markers in PBMCs and metabolites of SFN in urine","Julie E. Bauman, MD, MPH|National Cancer Institute (NCI)|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","13-079|5P50CA097190-09","March 2014","April 2014","January 2015","December 30, 2013","null","November 13, 2017","Eye and Ear Institute, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center (University of Pittsburgh Cancer Institute), Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02023931"
1488,"NCT02023450","Testing of HIV Protease Inhibitors to Suppress Inflammation and Improve Cardio Pulmonary Hemodynamics in Subjects With Pulmonary Arterial Hypertension",,"Unknown status","No Results Available","Pulmonary Arterial Hypertension","Drug: saquinavir and ritonavir","HMGB1 level|TNF、IL-1Β、IL-6、NT-ProBNP and CRP level|NYHA/WHO functional class|Brog respiration class|PA pressure and total right heart function measured by echocardiography","The Third Xiangya Hospital of Central South University|Xiangya Hospital of Central South University","All","18 Years to 60 Years   (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HPI-PAH-0","December 2013","December 2014","July 2015","December 30, 2013","null","September 8, 2014","Xiangya hospital, Changsha, Hunan, China","","https://ClinicalTrials.gov/show/NCT02023450"
1489,"NCT02021214","Effects of Methylphenidate (Ritalin®) on the Neural Basis of Anxiety",,"Completed","No Results Available","PTSD","Drug: Methylphenidate|Drug: Placebo","Changes in blood oxygenation level-dependent BOLD signal responses|Changes in BOLD signal responses|Changes in skin conductance response|Latency and accuracy during a interoceptive stimulus task","University of California, San Diego","Male","18 Years to 40 Years   (Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","131297","March 2014","October 2014","October 2014","December 27, 2013","null","December 3, 2014","UCSD Psychiatry Clinical Research, San Diego, California, United States","","https://ClinicalTrials.gov/show/NCT02021214"
1490,"NCT02020837","A Pilot Study Assessing the Effect of Lymphaticovenous Micro-Anastomosis in the Treatment of Postmastectomy Lymphedema",,"Terminated","Has Results","Lymphedema|Post Mastectomy","Procedure: Lymphaticovenous Micro-Anastomosis","Changes Relative to Baseline in the Volume of the Affected Limb at 3 and 6 Months From Surgery","University of Arkansas","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202676","September 2014","December 3, 2015","July 2017","December 25, 2013","April 9, 2018","June 27, 2018","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States","","https://ClinicalTrials.gov/show/NCT02020837"
1491,"NCT02019355","Actinic Keratosis Study","AK","Completed","No Results Available","Actinic Keratosis","Drug: 5-fluorouracil 5% cream|Drug: Calcipotriol 0.005% ointment|Drug: Vaseline","percentage of change in the number of actinic keratoses from baseline|complete and partial (>75%) clearance of actinic keratoses|Composite score of erythema, itching and skin pain after topical 5-fluorouracil+calcipotriol vs. 5-fluorouracil alone treatment of actinic keratoses|Induction of TSLP expression in keratinocytes by calcipotriol|differences in response to topical 5-fluorouracil+calcipotriol vs. 5-fluorouracil alone between the four anatomical sites","Washington University School of Medicine","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","132","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","201303070","October 2013","March 2015","March 2015","December 24, 2013","null","May 19, 2016","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02019355"
1492,"NCT02014987","Running Related Injury Among Novice Runners",,"Unknown status","No Results Available","Treatment Error|Overuse Injury","Behavioral: Training programmes","Running related injury","Northern Orthopaedic Division, Denmark|University of Aarhus","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","160","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","N-20130035","July 2013","January 2016","January 2016","December 19, 2013","null","April 10, 2015","Sten Rasmussen, Aalborg, Northern Jutland, Denmark","","https://ClinicalTrials.gov/show/NCT02014987"
1493,"NCT02012647","Subthalamic Deep Brain Stimulation (DBS) in Parkinson's Disease",,"Completed","No Results Available","Parkinson's Disease","Procedure: Transcranial Magnetic Stimulation (TMS)|Procedure: Motor Physiology Testing","Motor Cortex Excitability|Relation between Unified Parkinson's Disease Rating Scale outcomes and physiological measures|Transcallosal Pathway Excitability|Physiological Measures","University of Florida","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","21-2013|40115065-2","August 2013","March 2016","June 2016","December 16, 2013","null","June 13, 2016","University of Florida, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT02012647"
1494,"NCT02012465","Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients",,"Completed","No Results Available","Lymphoma|Diabetes Mellitus, Type 2|Hyperglycemia","Biological: Insulin protocol","Incidence of hyperglycemia|Incidence of severe hyperglycemia|Incidence of hypoglycemia|Incidence of severe hypoglycemia|Remission of primary oncologic diagnosis at one year","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201306071","September 2013","May 2015","May 2015","December 16, 2013","null","May 7, 2018","Washington University in St. Louis, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02012465"
1495,"NCT02011477","Hypoalgesic Effects Neural Mobilization Techniques","NM","Completed","No Results Available","Hyperalgesia","Other: Neural Glide|Other: Neural stretching","Pressure pain threshold assessment","Josue Fernandez Carnero|Universidad Autonoma de Madrid|Universidad Rey Juan Carlos","All","18 Years to 30 Years   (Adult)","Early Phase 1","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CSEULS-PI-001/2013","March 2013","October 2013","November 2013","December 13, 2013","null","December 13, 2013","Centro superior de Estudios Universitarios La Salle, Madrid, Aravaca, Spain","","https://ClinicalTrials.gov/show/NCT02011477"
1496,"NCT02009566","Healthy Volunteer Visibility Study of Micromachined Tags for the Detection of Surgical Sponges",,"Withdrawn","No Results Available","Injury Due to Foreign Object Accidentally Left in Body During Surgical Operation","Radiation: Abdominal radiographs with microfabricated tags","Validate the CAD (computer aided detection) system","University of Michigan","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HUM00063233","July 2013","April 2015","August 2015","December 12, 2013","null","February 29, 2016","University of Michigan Hospital, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02009566"
1497,"NCT02005588","Treatment of Iron Deficiency Anemia With Pregnancy",,"Completed","No Results Available","Iron Deficiency Anemia of Pregnancy","Drug: amino acid chelated iron|Drug: iron salt (ferrous fumarate)","change in hemoglobin level|the occurence of side effects (abdominal colics, constipation, or metallic taste)|change in serum ferritin level","Cairo University","Female","20 Years to 40 Years   (Adult)","Early Phase 1","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ferrot2013|nerhado pharmaceutical company","December 2013","June 2015","July 2015","December 9, 2013","null","July 28, 2015","faculty of medicine, Cairo University, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT02005588"
1498,"NCT02003456","Initial Human Validation of Simultaneous Dual-Tracer Cardiac PET Imaging",,"Completed","No Results Available","Ischemic Heart Disease|Myocardial Infarction","Drug: Cardiac PET scan w/18F-Fluorodeoxyglucose and rubidium-82","Equivalence of Images from Rest Rubidium-82 Perfusion PET Obtained Separately versus Simultaneously|Equivalence of Quantitative Estimates of Global Myocardial Blood Flow using Rubidium-82 Perfusion PET Obtained Separately versus Simultaneously|Equivalence of Images from FDG PET Obtained Separately versus Simultaneously","University of Michigan","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HUM00080193","December 2013","August 2014","August 2014","December 6, 2013","null","February 23, 2017","University of Michigan Hospital, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02003456"
1499,"NCT01996527","3T MRI Biomarkers of Glioma Treatment Response",,"Terminated","No Results Available","Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor","Device: 3-Tesla magnetic resonance imaging|Device: CEST-MRI|Device: DW-MRI|Device: DCE-MRI|Device: DSC-MRI|Drug: IV administration of gadolinium-containing contrast agent","Best Response|Progression Free Survival (PFS)","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","7","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","VICC NEU 1268|NCI-2013-02195|P30CA068485","May 2012","November 23, 2015","January 1, 2016","November 27, 2013","null","April 17, 2017","Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT01996527"
1500,"NCT01992718","What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography",,"Completed","No Results Available","Uterine Bleeding|Uterine Fibroids|Adenomyosis","Procedure: Evaluation of MRI, US for pelvic and uterine conditions|Procedure: Patient preference between MRI and Ultrasound","Diagnostic accuracy of MRI and ultrasound elastography for distinguishing adenomyosis and fibroids|Patient preference between ultrasound and MRI","University of Michigan|Association of University Radiologists|GE Radiology Research Academic Fellowship","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","49","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HUM00076620","November 2013","March 2018","March 2018","November 25, 2013","null","May 31, 2018","University of Michigan Hospital, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT01992718"
1501,"NCT01992705","Borderline Pancreas Study: FOLFIRINOX +SBRT","GCC 1324","Recruiting","No Results Available","Resectable Pancreatic Cancer","Other: Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable|Drug: -Oxaliplatin 85 mg/m2 IV on Day 1|Drug: -Irinotecan 180 mg/m2 IV on Day 1|Drug: -5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours","Rate of downstaging to resectability in patients with borderline resectable pancreatic cancer receiving FOLFIRINOX and SBRT as preoperative therapy.|Survival status (disease-free-survival vs. overall survival) time to recurrence and site of recurrence in patients with borderline resectable pancreatic cancer receiving preoperative FOLFIRINOX followed by SBRT","University of Maryland","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HP-00055716","March 2014","December 2018","December 2020","November 25, 2013","null","July 11, 2018","University of Maryland Medical Center, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01992705"
1502,"NCT01991600","A Pilot Study to Assess the Influence of Dietary Organic Acids on Iron Absorption.",,"Completed","No Results Available","Iron Deficiency Anaemia","Dietary Supplement: ferrous sulphate|Dietary Supplement: ferric iron oxide-organic acid (Fe-OA)","Iron Bioavailability|Iron absorption","Medical Research Council","Female","18 Years to 45 Years   (Adult)","Early Phase 1","71","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","6129","May 2006","May 2010","May 2010","November 25, 2013","null","November 25, 2013","MRC Human Nutrition Research, Cambridge, Cambridgeshire, United Kingdom","","https://ClinicalTrials.gov/show/NCT01991600"
1503,"NCT01991574","Effect of the Consumption of Ferric Hydroxide Adipate on Urinary Phosphorus Excretion.",,"Completed","No Results Available","Healthy|Chronic Kidney Diseases","Drug: Calcium acetate|Dietary Supplement: Iron Hydroxide Adipate|Drug: Placebo","urinary phosphate|iron absorption","Medical Research Council","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","6320","April 2009","October 2009","October 2009","November 25, 2013","null","February 6, 2017","MRC Human Nutrition Research, Cambridge, Cambridgeshire, United Kingdom","","https://ClinicalTrials.gov/show/NCT01991574"
1504,"NCT01990495","Exercise to Prevent Muscle Mass and Functional Loss in Elderly Dialysis Patients","PERFECT","Recruiting","No Results Available","Chronic Kidney Disease","Other: Exercise training|Other: Usual Care","Maximal oxygen uptake|Biopsy of the quadriceps muscle.|Quality of life|Cardiovascular risk status","VA Office of Research and Development","All","55 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","46","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E0915-R","November 1, 2013","September 30, 2019","September 30, 2019","November 21, 2013","null","November 14, 2018","VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States","","https://ClinicalTrials.gov/show/NCT01990495"
1505,"NCT01989078","Losartan for Sickle Cell Kidney Disease","SCD-Losartan","Completed","No Results Available","Sickle Cell Disease","Drug: Losartan","Change in albumin/creatinine ratio (ACR)|Change in glomerular filtration rate (GFR)|Change in renal plasma flow (RPF)|Change in glomerular permeability (GP)","Emory University","All","9 Years and older   (Child, Adult, Older Adult)","Early Phase 1","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00056125","December 2012","December 2016","December 2016","November 20, 2013","null","July 17, 2017","Grady Health Systems, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01989078"
1506,"NCT01988883","Modafinil and Cognitive Function in POTS",,"Active, not recruiting","No Results Available","Postural Tachycardia Syndrome","Drug: Placebo|Drug: Modafinil|Drug: Propranolol","Visual Attention Performance Speed|Executive Function|Blood Pressure|Heart Rate","Vanderbilt University|Vanderbilt University Medical Center","All","18 Years to 60 Years   (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","131371|5UL1TR000445-07","October 2014","June 2019","June 2019","November 20, 2013","null","July 27, 2018","Vanderbilt University, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT01988883"
1507,"NCT01988116","Effects of Vitamin D Replacement on Hormones Regulating Iron Metabolism in Individuals With Chronic Kidney Disease",,"Completed","No Results Available","Chronic Kidney Disease|Anemia of Chronic Disease","Drug: Oral Calcitriol 0.5 mcg once daily for 6 weeks|Drug: Placebo","Change in serum hepcidin levels|Change in soluble hemojuvelin|Change in other indices of iron metabolism|Change in serum hemoglobin","University of Alabama at Birmingham","All","19 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","F130725013","October 2013","June 2015","June 2015","November 20, 2013","null","August 24, 2015","University of Alabama, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT01988116"
1508,"NCT01987206","Feasibility Study of PID Versus MPC and HMS",,"Completed","No Results Available","Type 1 Diabetes Mellitus","Device: MPC control algorithm|Device: PID control algorithm","time spent in safe blood glucose range|glucose level extremes and need for outside intervention","Sansum Diabetes Research Institute|Juvenile Diabetes Research Foundation|University of California, Santa Barbara","All","21 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","2013-11 C2T","July 2014","August 2015","August 2015","November 19, 2013","null","July 22, 2016","Sansum Diabetes Research Institute, Santa Barbara, California, United States","","https://ClinicalTrials.gov/show/NCT01987206"
1509,"NCT01987167","Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis","ACHTAR","Completed","No Results Available","Optic Neuritis","Drug: ACTHAR","Neuro-protection|Preservation of retinal nerve fiber layer.","Neuro-Ophthalmologic Associates, PC|Mallinckrodt","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-330|ACTHAR","November 2013","December 2016","December 2016","November 19, 2013","null","August 22, 2017","Neuro Ophthalmology, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01987167"
1510,"NCT01985750","Understanding the Importance of Plasticity in the Brain Mechanisms of Dyspnoea Perception",,"Recruiting","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: d-cycloserine|Drug: placebo","BOLD signal changes|Grey matter volume","University of Oxford|National Health Service, United Kingdom","All","45 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","OX-KP001","November 2013","December 2018","February 2020","November 15, 2013","null","October 12, 2018","Oxford Centre for Clinical Magnetic Resonance Imaging, Oxford, Oxfordshire, United Kingdom","","https://ClinicalTrials.gov/show/NCT01985750"
1511,"NCT01985646","A Trial on Conservative Treatment for Infants' Hirschsprung Disease",,"Completed","No Results Available","Hirschsprung Disease","Procedure: surgery treatment|Behavioral: anal dilation|Behavioral: colonic lavage|Drug: oral probiotic","the change of defecation frequence|stool pattern|controlling defecation ability|complications","Tongji Hospital","All","up to 3 Months   (Child)","Early Phase 1","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","001|20090302","October 2009","November 2011","null","November 15, 2013","null","November 15, 2013","","","https://ClinicalTrials.gov/show/NCT01985646"
1512,"NCT01982734","Improved Oral Bioavailability of Curcumin Incorporated Into Micelles",,"Completed","No Results Available","Pharmacokinetics of New Curcumin Formulations|Safety of New Curcumin Formulations","Dietary Supplement: curcumin","Area under the plasma concentration versus time curve (AUC) of total curcumin [nmol/L*h]|Area under the plasma concentration versus time curve (AUC) of total demethoxycurcumin [nmol/L*h]|Area under the plasma concentration versus time curve (AUC) of total bisdemethoxycurcumin [nmol/L*h]|Maximum plasma concentration (Cmax) of total curcumin [nmol/L]|Maximum plasma concentration (Cmax) of total demethoxycurcumin [nmol/L]|Maximum plasma concentration (Cmax) of total bisdemethoxycurcumin [nmol/L]|Time to reach maximum plasma concentration (Tmax) of total curcumin [h]|Time to reach maximum plasma concentration (Tmax) of total demethoxycurcumin [h]|Time to reach maximum plasma concentration (Tmax) of total bisdemethoxycurcumin [h]|Serum aspartate transaminase activity [U/L]|Serum alanine transaminase activity [U/L]|Serum gamma-glutamyl transferase activity [U/L]|Serum alkaline phosphatase activity [U/L]|Serum bilirubin [mg/dL]|Serum uric acid [mg/dL]|Serum creatinine [mg/dL]|Serum total cholesterol [mg/dL]|Serum HDL cholesterol [mg/dL]|Serum LDL cholesterol [mg/dL]|Serum triacylglycerols [mg/dL]","University of Hohenheim|German Federal Ministry of Education and Research","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","23","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","051113-HS2","November 2012","April 2013","April 2013","November 13, 2013","null","October 25, 2016","University of Hohenheim, Stuttgart, Baden-Württemberg, Germany","","https://ClinicalTrials.gov/show/NCT01982734"
1513,"NCT01981733","Improving Lower Limb Blood Flow in Healthy Adult Volunteers","THRIVE-1","Completed","No Results Available","Deep Vein Thrombosis","Device: geko","Changes in blood flow and volume, together with microcirculatory velocity were measured","Queen Mary University of London","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Masking: None (Open Label)|Primary Purpose: Basic Science","THRIVE-1","March 2005","April 2012","null","November 11, 2013","null","November 11, 2013","St. Bartholomew's Hospital, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT01981733"
1514,"NCT01981356","Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis","ACT-IP","Completed","Has Results","Psychotic Disorders","Behavioral: Acceptance and Commitment Therapy|Other: Treatment as Usual (TAU)","Brief Psychiatric Rating Scale (Overall & Gorham, 1962)|Frequency, Believability, and Distress Symptom Scale (Gaudiano & Herbert, 2006)|Acceptance and Action Questionnaire - II (Bond et al.., 2011)|Positive and Negative Affect Scale (Watson et al., 1988)|Cost of Stay|Barriers and Facilitators to Implementation|Experimental Treatment Feasibility|Experimental Treatment Acceptability|Experimental Treatment Safety","VA Office of Research and Development","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","18","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PPO 13-132","September 2014","April 2015","April 2015","November 11, 2013","April 14, 2016","April 14, 2016","VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States","","https://ClinicalTrials.gov/show/NCT01981356"
1515,"NCT01980823","Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer",,"Recruiting","No Results Available","Breast Cancer|Breast Tumors|Cancer of Breast","Drug: Metformin|Drug: Atorvastatin|Procedure: Breast surgery","Change in tissue levels of the proliferation marker Ki-67","Columbia University","Female","21 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAM2306","October 2013","April 2018","April 2018","November 11, 2013","null","December 13, 2017","Columbia University Medical Center - Herbert Irving Cancer Center, Manhattan, New York, United States","","https://ClinicalTrials.gov/show/NCT01980823"
1516,"NCT01979328","Geko™ Plaster Cast Study, Deep Vein Thrombosis (DVT) Prophylaxis","THRIVE-III","Completed","No Results Available","Deep Vein Thrombosis","Device: geko|Device: Plaster cast","Blood flow|microcirculatory blood flow","University Hospital Southampton NHS Foundation Trust","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","THRIVE-III","March 2012","May 2012","null","November 8, 2013","null","November 8, 2013","Southampton University Hospital, Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT01979328"
1517,"NCT01979003","A Pilot Study to Determine the Efficacy of Fluorescein Visualization of the Uterus in Detecting Endometrial Cancer Invasion",,"Active, not recruiting","No Results Available","Endometrial Cancer","Drug: Fluorescein","Efficacy of using fluorescein dye to determine depth of invasion compared to using frozen section and final pathology.","University of Arkansas","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","202459","September 2014","September 2019","September 2019","November 8, 2013","null","October 23, 2018","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States","","https://ClinicalTrials.gov/show/NCT01979003"
1518,"NCT01972906","Moxibustion for Primary Dysmenorrhea",,"Completed","No Results Available","Primary Dysmenorrhea","Device: moxibustion|Drug: Ibuprofen Sustained Release Capsules","change from baseline in menstrual pain intensity measured by VAS at 6 months|Laboratory index-1|Cox Menstrual Symptom Scale Cox Menstrual Symptom Scale|Laboratory Index-2|Laboratory Index-3|Laboratory Index-4|Laboratory Index-5|Laboratory Index-6","Chengdu University of Traditional Chinese Medicine","Female","13 Years to 35 Years   (Child, Adult)","Early Phase 1","152","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2011SZ0302","February 2012","February 2014","June 2014","October 31, 2013","null","December 2, 2014","Affiliated hospital of Chengdu University of TCM, Chengdu, Sichuan, China","","https://ClinicalTrials.gov/show/NCT01972906"
1519,"NCT01970514","Safety Study of ARO Spinal System as an Adjunct to Lumbar Decompression",,"Unknown status","No Results Available","Lumbar Disc Prolapse With Radiculopathy","Device: ARO Spinal System","Safety profile compared to historical controls and improvement in leg and back pain|Oswestry Disability Index (ODI) improvement is superior to historical control|VAS back pain improvement is superior to historical control|VAS leg pain improvement is superior to historical control,","ARO Medical","All","18 Years to 55 Years   (Adult)","Early Phase 1","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARO-01","April 2012","July 2015","July 2015","October 28, 2013","null","January 14, 2015","Aarhus University Hospital, Aarhus, Denmark","","https://ClinicalTrials.gov/show/NCT01970514"
1520,"NCT01968876","Is a Smartphone Application Effective as an Oral Medication Adherence Aid",,"Terminated","No Results Available","Hypertension|Diabetes|Dyslipidemia","Other: Medication Adherence Smartphone App","Change from baseline in number of pills taken over number of pills prescribed at 4 weeks|Change from baseline in number of pills taken over number of pills prescribed at 12 weeks","University of Arkansas","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","202266","October 30, 2013","November 14, 2017","November 14, 2017","October 24, 2013","null","November 20, 2017","Internal Medicine Clinic North; University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Remedy Drug, Little Rock, Arkansas, United States|Internal Medicine Clinic West; University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States","","https://ClinicalTrials.gov/show/NCT01968876"
1521,"NCT01968629","24hr Imaging Of HCC After EOVIST",,"Withdrawn","No Results Available","Hepatocellular Carcinoma","Drug: Eovist","Calculate the percent absolute enhancement of HCCs following Eovist administration at multiple phases","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","13-386","December 2013","July 2015","July 2015","October 24, 2013","null","September 23, 2015","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01968629"
1522,"NCT01967927","Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial Pressure to Increase Translation of Solid Tumor Therapy",,"Active, not recruiting","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: 18F-MISO","To estimate the mean and standard deviation of the decrease in interstitial fluid pressure in tumors within 72 hours after GRID treatment.","University of Arkansas","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","138725","December 2013","June 2020","July 2020","October 23, 2013","null","July 18, 2018","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States","","https://ClinicalTrials.gov/show/NCT01967927"
1523,"NCT01967381","Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse",,"Completed","No Results Available","Methamphetamine Abuse|Methamphetamine Dependence","Drug: Methamphetamine (Desoxyn®)","Reinforcing Effects|Subjective Effects|Physiological and Side Effects","University of Kentucky|National Institute on Drug Abuse (NIDA)","All","18 Years to 55 Years   (Adult)","Early Phase 1","24","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Basic Science","R01DA033394","October 2013","September 2018","September 2018","October 22, 2013","null","September 14, 2018","University of Kentucky Medical Center, Lexington, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT01967381"
1524,"NCT01966367","CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation",,"Recruiting","No Results Available","Bone Marrow Failure Syndrome|Severe Aplastic Anemia|Severe Congenital Neutropenia|Amegakaryocytic Thrombocytopenia|Diamond-Blackfan Anemia|Schwachman Diamond Syndrome|Primary Immunodeficiency Syndromes|Acquired Immunodeficiency Syndromes|Histiocytic Syndrome|Familial Hemophagocytic Lymphocytosis|Lymphohistiocytosis|Macrophage Activation Syndrome|Langerhans Cell Histiocytosis (LCH)|Hemoglobinopathies|Sickle Cell Disease|Sickle Cell-beta-thalassemia","Biological: CD34 Stem Cell Selection Therapy","Incidence of acute graft versus host disease (GVHD)|Incidence of primary graft failure|Survival Rate|Time to neutrophil and platelet engraftment|Time to immune reconstitution|Incidence of infectious complications|Incidence of secondary graft failure","Diane George, MD|Columbia University","All","up to 40 Years   (Child, Adult)","Early Phase 1","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAL0156","March 2013","December 2019","December 2019","October 21, 2013","null","July 17, 2017","Morgan Stanley Children's Hospital, New York-Presbyterian, Columbia University, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01966367"
1525,"NCT01965730","Dosing of Amicar and Measure of Fibrinolysis by TEG During Cardiac Surgery","EACA","Terminated","No Results Available","Aortic Disease","Drug: epsilon-aminocaproic acid (EACA)","degree of fibrinolysis as measured by thromboelastography","University of Pennsylvania","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","8","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","816724","January 2013","June 2014","June 2014","October 18, 2013","null","November 8, 2017","University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01965730"
1526,"NCT01962909","Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer",,"Terminated","No Results Available","Pancreatic Ductal Adenocarcinoma","Drug: PTP-01","Ability of PTP-01 to detect pancreatic ductal adenocarcinoma|Biodistribution and Binding Characteristics of PTP-01|Clearance of PTP-01|Safety and Tolerability of PTP-01","University of Virginia","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","16678","November 2013","January 2016","January 2016","October 14, 2013","null","March 18, 2016","University of Virginia, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01962909"
1527,"NCT01962649","A Pilot Study of Optical Molecular Imaging for Percutaneous Biopsy of Hepatocellular Carcinoma Using Indocyanine Green",,"Completed","No Results Available","Hepatocellular Carcinoma","Biological: ICG|Device: Optical molecular imaging","Measurement of fluorescence intensity within focal hepatic lesions","Massachusetts General Hospital|Radiological Society of North America","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","13-314","October 2013","April 2014","April 2014","October 14, 2013","null","April 25, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01962649"
1528,"NCT01959477","Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant",,"Completed","No Results Available","Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Grade III Lymphomatoid Granulomatosis|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Childhood Anaplastic Large Cell Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage I Childhood Large Cell Lymphoma|Stage I Childhood Lymphoblastic Lymphoma|Stage I Childhood Small Noncleaved Cell Lymphoma|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage IA Mycosis Fungoides/Sezary Syndrome|Stage IB Mycosis Fungoides/Sezary Syndrome|Stage II Adult Hodgkin Lymphoma|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Childhood Anaplastic Large Cell Lymphoma|Stage II Childhood Hodgkin Lymphoma|Stage II Childhood Large Cell Lymphoma|Stage II Childhood Lymphoblastic Lymphoma|Stage II Childhood Small Noncleaved Cell Lymphoma|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IIA Mycosis Fungoides/Sezary Syndrome|Stage IIB Mycosis Fungoides/Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Childhood Anaplastic Large Cell Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage III Childhood Small Noncleaved Cell Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IIIA Mycosis Fungoides/Sezary Syndrome|Stage IIIB Mycosis Fungoides/Sezary Syndrome|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Childhood Anaplastic Large Cell Lymphoma|Stage IV Childhood Hodgkin Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Stage IV Childhood Small Noncleaved Cell Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Stage IVA Mycosis Fungoides/Sezary Syndrome|Stage IVB Mycosis Fungoides/Sezary Syndrome|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia","Drug: busulfan|Drug: etoposide|Drug: cyclophosphamide|Procedure: peripheral blood stem cell transplantation|Procedure: autologous hematopoietic stem cell transplantation","Feasibility of performing real-time TDM, determined by the proportion of enrolled patients who are able to have an area under curve (AUC) for busulfan calculated|Incidence of adverse events including mucositis, liver toxicity, seizures, and pulmonary toxicity, graded using NCI CTCAE version 4.0|Proportion of patients who would not have achieved desired busulfan level with weight-based busulfan dosing","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","2 Years and older   (Child, Adult, Older Adult)","Early Phase 1","33","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE1412|NCI-2013-01829|CASE 1412|P30CA043703","March 2014","January 2015","April 2015","October 10, 2013","null","August 13, 2015","Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01959477"
1529,"NCT01957956","Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma",,"Active, not recruiting","No Results Available","Giant Cell Glioblastoma|Glioblastoma|Gliosarcoma","Other: Laboratory Biomarker Analysis|Biological: Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine|Drug: Temozolomide","Incidence of significant toxicity, defined as grade 3 or higher adverse event that is possibly, probably, or definitely related to treatment measured using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Change in immunologic correlates|Clinical benefit rate|Duration of response|Overall response rate|Time to response","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","21","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC1272|NCI-2013-01743|P30CA015083","November 11, 2013","November 16, 2016","November 15, 2018","October 8, 2013","null","August 14, 2018","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01957956"
1530,"NCT01955759","Atrial Fibrillation and By-pass Surgery",,"Unknown status","No Results Available","Patients With Coronary Artery Disease Scheduled for by Pass Surgery","Drug: Amiodarone tab 200 mg x 3|Drug: rosuvastatin 20 mg tab x1|Drug: beta blockers Bisoprolol in adjusted dose","atrial fibrillation","Heart Center BH Tuzla","All","Child, Adult, Older Adult","Early Phase 1","260","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","0115/09 - (2013)","December 2013","December 2014","February 2015","October 7, 2013","null","December 17, 2013","Heart Center BH, Tuzla, TK, Bosnia and Herzegovina","","https://ClinicalTrials.gov/show/NCT01955759"
1531,"NCT01954459","Warming up to Sensors: Does Site Warming Improve Continuous Glucose Monitor Performance?",,"Terminated","No Results Available","Type 1 Diabetes","Device: Insupatch|Device: Continuous glucose sensor","Point accuracy of the continuous glucose monitor plus Insupatch (CGM+IP) by mean absolute relative difference (MARD) calculation of sensors with and without IP use.","Yale University","All","8 Years to 44 Years   (Child, Adult)","Early Phase 1","11","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","1306012208","September 2013","June 2016","June 2016","October 1, 2013","null","October 3, 2016","Yale University School of Medicine, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01954459"
1532,"NCT01951508","Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study",,"Completed","No Results Available","Healthy|Substance-related Disorder|Mood Disorder","Drug: Methylphenidate|Drug: Modafinil|Drug: MDMA|Drug: Placebo","Effect on amygdala and striatum BOLD signal responses to emotional stimuli|Effects on cognitive performance and associated BOLD signal changes in frontal areas|Subjective effects|Neuroendocrine effects|Empathy and social behavior|Physiological effects of methylphenidate, modafinil, and MDMA|Genetic Polymorphisms|Pharmacokinetics of methylphenidate, modafinil, and MDMA","University Hospital, Basel, Switzerland","All","18 Years to 45 Years   (Adult)","Early Phase 1","24","Other","Interventional","Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","EK 36/13","October 2013","December 2014","December 2014","September 26, 2013","null","January 21, 2016","University Hospital Basel, Basel, Basel-Stadt, Switzerland","","https://ClinicalTrials.gov/show/NCT01951508"
1533,"NCT01950585","Hydroxyurea in Pulmonary Arterial Hypertension",,"Withdrawn","No Results Available","Pulmonary Hypertension","Drug: Hydroxyurea","The change in concentration of CD34+ circulating progenitors from baseline to 6 months (24 weeks (+/- 7 days)) on hydroxyurea.","National Heart, Lung, and Blood Institute (NHLBI)|The Cleveland Clinic|National Institutes of Health Clinical Center (CC)","All","18 Years to 110 Years   (Adult, Older Adult)","Early Phase 1","0","NIH|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","130203|13-H-0203","September 6, 2013","October 23, 2014","October 23, 2014","September 25, 2013","null","November 2, 2018","","","https://ClinicalTrials.gov/show/NCT01950585"
1534,"NCT01945099","Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy",,"Completed","No Results Available","Type 1 Diabetes","Device: ePID closed loop system|Drug: hyaluronidase|Drug: Lispro-PH20","Peak post-prandial venous glucose levels obtained after breakfast, lunch, and dinner between CL alone and CL+PH20preRx and CL+INS-PH20|Peak post-prandial insulin levels following meals","Eda Cengiz|Yale University","All","12 Years to 40 Years   (Child, Adult)","Early Phase 1","13","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIC 1307012334","September 2013","December 2015","July 2016","September 18, 2013","null","January 25, 2017","Yale University School of Medicine, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01945099"
1535,"NCT01944423","Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine","DCS/PSRT","Active, not recruiting","No Results Available","Nicotine Addiction|Panic Attack","Drug: d-cycloserine|Drug: Pill Placebo|Drug: Nicotine replacement therapy|Behavioral: Panic and Smoking Reduction Treatment","Smoking Status","University of Texas at Austin","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R34DA034658","October 2013","October 2018","October 2018","September 17, 2013","null","July 6, 2018","University of Texas at Austin, Austin, Texas, United States","","https://ClinicalTrials.gov/show/NCT01944423"
1536,"NCT01940926","68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis","GRGDRA","Unknown status","No Results Available","Rheumatoid Arthritis","Drug: 68Ga-BNOTA-PRGD2","Semiquantitative assessment (Standardized Uptake Values = SUVs) of lesion|Number of participants with adverse events as a measure of safety","Peking Union Medical College Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PUMCHNM07","February 2012","November 2017","December 2017","September 12, 2013","null","April 7, 2017","Peking Union Medical College Hospital, Beijing, China","","https://ClinicalTrials.gov/show/NCT01940926"
1537,"NCT01940718","Androgen Regulation of Priapism in Sickle Cell Disease",,"Withdrawn","No Results Available","Priapism|Sickle Cell Disease|Hypogonadism","Drug: Transdermal Androgel","change in frequency of priapism episodes|change in quality of life|change in quality of erections|change in EF","Johns Hopkins University","Male","18 Years to 50 Years   (Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NA_00076088","March 2014","January 2016","January 2016","September 12, 2013","null","January 19, 2017","Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01940718"
1538,"NCT01940302","Dietary Supplement of LEHEL for the Patients With Type 2 Diabetes",,"Completed","No Results Available","Type 2 Diabetes","Dietary Supplement: LEHEL multi-nutrients supplement","Metabolic Control","Shaoguan University|Sun Yat-sen University","All","25 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","71","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SGU-03|2012BAD33B10","June 2013","December 2013","March 2014","September 12, 2013","null","May 12, 2014","Shaoguan University, Shaoguan, Guangdong, China","","https://ClinicalTrials.gov/show/NCT01940302"
1539,"NCT01940263","Purified Anthocyanin and Nonalcoholic Fatty Liver Disease",,"Completed","No Results Available","Nonalcoholic Fatty Liver Disease","Dietary Supplement: Anthocyanin|Dietary Supplement: Placebo","Biomarkers related to oxidative stress|Biomarkers related to inflammation","Shaoguan University|Sun Yat-sen University","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","63","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","SGU-02|81372994","June 2013","January 2014","June 2014","September 12, 2013","null","August 1, 2014","Shaoguan University, Shaoguan, Guangdong, China","","https://ClinicalTrials.gov/show/NCT01940263"
1540,"NCT01939652","Restrictive Versus Standard Fluid Regime in Elective Minilaparotomy Abdominal Aortic Aneurysm Repair",,"Completed","No Results Available","Abdominal Aortic Aneurysm > 5.5 cm Effect of a Restricted Intravenous Fluid Regime on Complications and Hospital Stay After the Minilaparotomy AAA Repair.","Procedure: Restrictive VS Standard Fluid Regime|Drug: Drag: Crystalloids and Colloids","Number of major and minor complications|ICU and duration of Hospital stay|In-hospital mortality, 30-days mortality|Fluid balance (daily and cumulative)","University Clinical Center Tuzla","All","Child, Adult, Older Adult","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UKCTUZLA","February 2009","July 2013","July 2013","September 11, 2013","null","September 11, 2013","","","https://ClinicalTrials.gov/show/NCT01939652"
1541,"NCT01936831","High-Dose Isoniazid Among Adult Patients With Different Genetic Variants of INH-Resistant Tuberculosis (TB)",,"Recruiting","No Results Available","Tuberculosis","Drug: Isoniazid|Dietary Supplement: Vitamin B6","Daily decline in log10 Colony-forming unit (CFU) per mL sputum from baseline to Day 7 of study treatment (Groups 1 and 2)|Daily log10 CFU per mL sputum and TTD from baseline to Day 7 of study treatment; area under the time-concentration curve (AUC) for INH; MIC of M. tuberculosis isolates against INH (Group 1 for CFU and TTD, Group 3 for TTD only)|Grade 2 or higher drug-related adverse clinical or laboratory events (all groups)|Daily decline in TTD from baseline to day 7 of study treatment (all groups)|Steady state Pharmacokinetic (PK) parameters measured from PK sampling at Day 6|INH minimum inhibitory concentration (MIC) against M. tuberculosis isolates as determined by phenotypic drug susceptibility testing (DST) based on spot sputum collected at Step 1 Day 0 (all groups)|AUC/MICs which reach 50% of the mean EBA0-7(CFU) and EBA0-7(TTD) among Group 2 participants (Group 1 CFU and TTD, Group 3 TTD only) with MIC will be determined from spot sputum collected at Step 1 Day 0, AUC will be measured from Day 6 PK sampling|EBA measured by early- (EBA0-2) and late-phase (EBA2-7) individual-based parameter estimates from nonlinear mixed effect models when the number of phases is the same for every dosing cohort (all groups)|EBA measured by individual-based parameter estimates from linear or nonlinear mixed effect models when the number of phases differs between every dosing cohort|Mean EBA measured by ratio of the following areas: numerator = AUC of observed log10 CFU over 7 days and denominator = baseline log10 CFU for every dosing cohort in Groups 1 and 2|Daily decline in TTD from baseline to Day 7 of study treatment for every cohort in Group 1 and Group 2","AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","265","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACTG A5312|UM1AI068636","July 2014","February 27, 2019","February 27, 2019","September 6, 2013","null","September 19, 2018","TASK Applied Science CRS (31718), Bellville, South Africa","","https://ClinicalTrials.gov/show/NCT01936831"
1542,"NCT01935830","LAAM-HAART PET Imaging",,"Completed","No Results Available","Healthy Volunteers","Radiation: [11c] LAAM|Drug: Ritonavir|Drug: Efavirenz","cerebral [11C]LAAM distribution volume","Washington University School of Medicine","All","18 Years to 50 Years   (Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","201307040","August 2013","August 2015","September 2015","September 5, 2013","null","December 13, 2017","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT01935830"
1543,"NCT01935765","Sleep Apnea in Type 1 Diabetes","DIASOM","Unknown status","No Results Available","Type 1 Diabetes, Sleep Apnea Syndrome","Other: Polysomnography|Other: Evaluation of the autonomous nervous system|Other: Clinical examination of the sleep|Other: Clinical examination of diabetology|Other: Biological dosages|Other: Electrocardiogram (ECG)|Other: Carotid echography|Other: Blood pressure","Compare the prevalence of sleep apnea syndrome by polysomnography between type 1 diabetic patients and healthy volunteers|Precise if glycemic balance as defined by glycosylated hemoglobin<7% during the last three months is associated or not to sleep apnea syndrome|Precise if the presence of an autonomic neuropathy (positive at 2 tests) is associated or not to sleep apnea syndrome|Compare the patients with or without sleep apnea regarding consequences especially cardiovascular markers and coagulation factors|Determine if the presence of sleep apnea syndrome has an impact upon quality of life and diabetes complications, micro or macroangiopathy|Precise clinical symptoms in DT1 patients with Sleep apnea syndrome","Assistance Publique - Hôpitaux de Paris|Ministry of Health, France","All","18 Years to 60 Years   (Adult)","Early Phase 1","145","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","P111009","September 2013","June 2016","September 2016","September 5, 2013","null","May 29, 2015","Véronique Viot-Blanc, Paris, Ile de France, France","","https://ClinicalTrials.gov/show/NCT01935765"
1544,"NCT01934959","A Trial on Probiotics in Preventing Hirschsprung's Disease Associated Entercolitis",,"Completed","No Results Available","Probiotics|Hirschsprung's Disease Associated Enterocolitis","Drug: Bifico","Probiotics Prevent Hirschsprung's Disease Associated Entercolitis","Tongji Hospital|Anhui Provincial Hospital","All","1 Month to 13 Years   (Child)","Early Phase 1","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Tongji","January 2008","January 2010","null","September 4, 2013","null","September 4, 2013","","","https://ClinicalTrials.gov/show/NCT01934959"
1545,"NCT01934868","Prolotherapy Versus Epidural Steroid Injections (ESI) for Lumbar Pain Radiating to the Leg",,"Recruiting","No Results Available","Sciatica|Spinal Stenosis of Lumbar Region|Degeneration of Lumbar or Lumbosacral Intervertebral Disc","Drug: prolotherapy solution of 20% dextrose|Drug: Epidural Steroid Injection","Numerical Rating Scale|Oswestry Back Disability Questionnaire Score","Hadassah Medical Organization|Reuth Medical Center","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0309-13-HMO-CTIL","November 2013","December 2018","December 2019","September 4, 2013","null","February 28, 2018","Pain Unit, Hadassah Medical Center, Jerusalem, Israel","","https://ClinicalTrials.gov/show/NCT01934868"
1546,"NCT01933269","FACBC for Head and Neck Cancers",,"Withdrawn","No Results Available","Cancers of the Head and Neck","Drug: FACBC","The presence of FACBC radiotracer uptake in Head and neck tumors on PET scans","Emory University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00062214","May 2015","February 1, 2018","February 1, 2018","September 2, 2013","null","February 5, 2018","","","https://ClinicalTrials.gov/show/NCT01933269"
1547,"NCT01932658","Autologous Hematopoietic Stem Cell Transplantation for Crohn's Disease Treatment","HSCT","Withdrawn","No Results Available","Crohn's Disease","Biological: Hematopoietic stem cell transplantation","The primary outcome to be measured is safety and clinical benefit of lymphoablation followed by autologous HSCT rescue in therapy refractory Crohn's disease.|Disease remission","University of California, Los Angeles","All","7 Years to 70 Years   (Child, Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCLA-001836|IRB#12-001836","February 2014","March 2016","March 2017","August 30, 2013","null","April 15, 2016","UCLA Center for Inflammatory Bowel Diseases, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01932658"
1548,"NCT01929798","Crossover Feasibility Study of Portable AP Device With Zone-MPC and HMS and Adapted I:C and Basal Insulin","DP3","Completed","No Results Available","Type 1 Diabetes Mellitus","Device: portable Artificial Pancreas","time spent in safe blood glucose range|glucose level extremes and need for outside intervention","Sansum Diabetes Research Institute|University of Virginia|Mayo Clinic|University of California, Santa Barbara|University of Padova","All","21 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","36","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","DP301","November 2013","November 2014","November 2014","August 28, 2013","null","October 21, 2015","Sansum Diabetes Research Institutute, Santa Barbara, California, United States","","https://ClinicalTrials.gov/show/NCT01929798"
1549,"NCT01925391","The Measurement of Intraocular Pressure in Normal Children Under General Anesthesia With and Without Nitrous Oxide and Anesthetic Eye Drops","IOP","Completed","No Results Available","Glaucoma|Intraocular Pressure|Anesthesia","Drug: Tono-pen XL Applanation tonometer + Ocu-film +","Measurement of intraocular pressure in nonglaucomatous children under Nitrous oxide/Oxygen/topical anesthesia and Nitrous oxide/Sevoflurane/oxygen/Topical anesthesia.","University of Miami","All","1 Year to 18 Years   (Child, Adult)","Early Phase 1","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","20120451","January 2013","May 2014","May 2014","August 19, 2013","null","June 16, 2014","University of Miami Bascom Palmer Eye Hospital, Miami, Florida, United States|Bascom Palmer Eye Hospital, Miami, Florida, United States","","https://ClinicalTrials.gov/show/NCT01925391"
1550,"NCT01925287","Oral Bioavailability of Curcumin From Micronized Powder and Liquid Micelles in Healthy Young Women and Men",,"Completed","No Results Available","Pharmacokinetics of Novel Curcumin Formulations|Safety of Novel Curcumin Formulations","Dietary Supplement: curcumin","Area under the plasma concentration versus time curve (AUC) of total curcumin [nmol/L*h]|Area under the plasma concentration versus time curve (AUC) of total demethoxycurcumin [nmol/L*h]|Area under the plasma concentration versus time curve (AUC) of total bisdemethoxycurcumin [nmol/L*h]|Maximum plasma concentration (Cmax) of total curcumin [nmol/L]|Maximum plasma concentration (Cmax) of total demethoxycurcumin [nmol/L]|Maximum plasma concentration (Cmax) of total bisdemethoxycurcumin [nmol/L]|Time to reach maximum plasma concentration (Tmax) of total curcumin [h]|Time to reach maximum plasma concentration (Tmax) of total demethoxycurcumin [h]|Time to reach maximum plasma concentration (Tmax) of total bisdemethoxycurcumin [h]|Serum aspartate transaminase activity [U/L]|Serum alanine transaminase activity [U/L]|Serum gamma-glutamyl transferase activity [U/L]|Serum alkaline phosphatase activity [U/L]|Serum bilirubin [mg/dL]|Serum uric acid [mg/dL]|Serum cystatin C [mg/L]|Glomerular filtration rate [mL/min]|Serum creatinine [mg/dL]|Serum total cholesterol [mg/dL]|Serum HDL cholesterol [mg/dL]|Serum LDL cholesterol [mg/dL]|Serum triacylglycerols [mg/dL]","University of Hohenheim|German Federal Ministry of Education and Research","All","18 Years to 35 Years   (Adult)","Early Phase 1","23","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","01EA1334AHS1","October 2011","July 2013","July 2013","August 19, 2013","null","October 25, 2016","University of Hohenheim, Stuttgart, Germany","","https://ClinicalTrials.gov/show/NCT01925287"
1551,"NCT01923220","Safety and Efficacy of HO/02/02 20µg vs. SoC (Aloe Vera) to Reduce Radiation Dermatitis","ARD","Unknown status","No Results Available","Breast Cancer","Drug: HO/02/02 20µg|Other: Aloe Vera Jel","Number of patients using HO/02/02 20µg that developed grade 1-4 radiation dermatitis during adjuvant radiation therapy for breast cancer compared to SoC (Aloe Vera) commonly used as standard of care treatment.|Frequency and severity of adverse events reported by the patients and assessed clinically by NCI CTC v2.0","HealOr","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HO-ARD-01-2012","September 2013","September 2014","December 2014","August 15, 2013","null","August 15, 2013","The Chaim Sheba Medical Center, Ramat Gan, Israel","","https://ClinicalTrials.gov/show/NCT01923220"
1552,"NCT01920412","Feasibility and Safety Study of LAmbre Left Atrial Appendage Occluder",,"Completed","No Results Available","Atrial Fibrillation|Stroke","Device: LAmbre Left Atrial Appendage(LAA) Occluder","The feasibility end-point|The composite safety and efficacy end-point","Lifetech Scientific (Shenzhen) Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","LA-AP-01","October 2012","October 2013","September 2014","August 12, 2013","null","August 7, 2018","Prince of Wales Hospital, Hong Kong, China","","https://ClinicalTrials.gov/show/NCT01920412"
1553,"NCT01919619","Lenalidomide and Ipilimumab Post Allo or Auto Stem Cell Transplantation (SCT)",,"Recruiting","No Results Available","Blood And Marrow Transplantation|Leukemia|Lymphoma","Drug: Lenalidomide|Drug: Ipilimumab","Toxicity Rate","M.D. Anderson Cancer Center","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-0947|NCI-2013-02213","November 2013","November 2019","November 2019","August 9, 2013","null","July 18, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01919619"
1554,"NCT01918683","TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients",,"Recruiting","No Results Available","Hepatocellular Carcinoma Within Milan Criteria for Liver Tranplantation","Radiation: TACE transarterial chemoembolization|Radiation: stereotatic body radiotherapy (SBRT)","Progression Free Survival","Abramson Cancer Center of the University of Pennsylvania|Loyola University|Oregon Health and Science University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Primary Purpose: Treatment","UPCC 16213","July 2013","July 2019","July 2019","August 8, 2013","null","June 27, 2018","Loyola University Medical Center, Maywood, Illinois, United States|Oregon Health & Science University, Portland, Oregon, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01918683"
1555,"NCT01917123","The Effect of L-Citrulline Malate on Ankle Brachial Index Among Patients With Coronary Heart Disease",,"Unknown status","No Results Available","Coronary Heart Disease","Drug: L-Citrulline malate","Brachial Index","Masih Daneshvari Hospital|Shahid Beheshti University of Medical Sciences","All","16 Years to 70 Years   (Child, Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","f-91-128","August 2013","March 2014","March 2014","August 6, 2013","null","August 6, 2013","National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Masih Daneshvari Hospital, Tehran, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT01917123"
1556,"NCT01916122","Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status",,"Recruiting","No Results Available","Breast Cancer","Drug: Fluorestradiol (FES)|Procedure: PET/CT Imaging","FES PET/CT scanning","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","13-071","August 2013","August 2020","August 2020","August 5, 2013","null","August 3, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01916122"
1557,"NCT01913119","A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK/T-cell Lymphoma","Ro-ENKTL","Completed","No Results Available","Histologically Proven Extranodal NKTcell Lymphoma","Drug: Romidepsin","Rate of overall disease control including CR, PR, and SD|Number of participants with adverse events|Time to progression|overall survival","Samsung Medical Center|Celgene Corporation","All","20 Years to 79 Years   (Adult, Older Adult)","Early Phase 1","16","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-10-059","July 2013","July 2013","July 2013","July 31, 2013","null","July 31, 2013","National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Korea Cancer Center Hospital, Nowon-gu, Seoul, Korea, Republic of|Severance Hospital, Seodaemun-gu, Seoul, Korea, Republic of|Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01913119"
1558,"NCT01911247","Preoperative Window Study of Metformin for the Treatment of Endometrial Cancer",,"Completed","No Results Available","Endometrial Cancer","Drug: Metformin","Change in Ki-67 mean levels between pre-metformin treatment endometrial biopsies and post-metformin treatment hysterectomy specimens","UNC Lineberger Comprehensive Cancer Center|National Institutes of Health (NIH)|National Cancer Institute (NCI)","Female","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","28","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC1102|1K23CA143154-01A1","May 2011","February 2013","February 2013","July 30, 2013","null","July 30, 2013","Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01911247"
1559,"NCT01909401","Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation",,"Completed","No Results Available","Liver Transplantation","Drug: boceprevir","Number of individuals who can remain HCV RNA undetected 6 months post orthotopic liver transplant after receiving peginterferon, ribavirin, and boceprevir.|Safety and efficacy of peginterferon, ribavirin, and boceprevir in patients with genotype I undergoing orthotopic liver transplant for cirrhosis and/or hepatocellular carcinoma.","Indiana University|Merck Sharp & Dohme Corp.","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","1","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1301010500","June 2013","July 2014","July 2014","July 26, 2013","null","July 24, 2014","Indiana University School of Medicine - IUHealth-University Hospital, Indianapolis, Indiana, United States","","https://ClinicalTrials.gov/show/NCT01909401"
1560,"NCT01909141","Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS",,"Completed","Has Results","Polycystic Ovary Syndrome|Infertility","Drug: induction of ovulation using letrozole-pioglitazone-metformin|Drug: induction of ovulation using clomiphene citrate-pioglitazone-metformin|Radiation: transvaginal ultrasound|Other: body mass index (BMI) calculation|Other: day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone|Other: pretreatment blood urea and serum creatinine|Other: serum estradiol (E2) on day 12|Other: serum progesterone on day 21|Other: blood urea and serum creatinine every month","Ovulation Rate|Number of Follicles>18mm.|Endometrial Thickness|Pregnancy Rate","Cairo University","Female","20 Years to 40 Years   (Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","fem2013","August 2013","February 2014","April 2014","July 26, 2013","March 2, 2015","October 20, 2015","Cairo University, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT01909141"
1561,"NCT01909037","Exploratory Non Comparative Study to Evaluate the Efficacy of Highly Bioavailable Curcumin (Flexofytol) in Patients With Knee Osteoarthritis",,"Completed","No Results Available","Knee Osteoarthritis","Dietary Supplement: Flexofytol (bio-optimized curcumin)","Serum levels of biomarkers of cartilage metabolism and inflammation|Pain and the global patient assessment of disease activity using a Visual Analog Scale (VAS)","Tilman S.A.|Bioxtract SA","All","45 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","22","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TILFLEXFY 002","March 2012","December 2012","December 2012","July 26, 2013","null","June 23, 2015","Citadelle Hospital, Liege, Belgium","","https://ClinicalTrials.gov/show/NCT01909037"
1562,"NCT01908309","Contrast-inDuced nephRotoxicity as Assessed by the KIdney Load-to-DAmage RElationship","DrKILDARE","Completed","No Results Available","Contrast Induced Acute Kidney Injury","Drug: Iobitridol 350|Drug: Iodixanol 320","Slope of LDR (as assessed by serum cystatin-C changes)|Slope of LDR (as assessed by serum creatinine changes)","Azienda Sanitaria Locale 9, Grosseto","All","20 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","K-3","April 2013","October 2014","October 2014","July 25, 2013","null","June 23, 2015","Misericordia Hospital, ASL 9, Grosseto, Italy","","https://ClinicalTrials.gov/show/NCT01908309"
1563,"NCT01907165","Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide",,"Completed","No Results Available","Glioblastoma","Drug: Temozolomide|Drug: Disulfiram|Dietary Supplement: Copper gluconate","Pharmacological effect of disulfiram in GBM patients|Local tumor control probabilities|Time to tumor progression","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","21","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201308038","October 10, 2013","November 10, 2016","February 9, 2018","July 24, 2013","null","July 20, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT01907165"
1564,"NCT01906346","Impact of a Non-Drug Choice on Cocaine Reinforcement",,"Completed","No Results Available","Cocaine Dependence","Drug: Cocaine|Drug: Placebo","Number of injections of self-administered cocaine|Visual Analog Scale Subjective Effects Questionnaire|Physiological Effects|Side Effects Questionnaire","Joshua A. Lile, Ph.D.|University of Kentucky","All","21 Years to 45 Years   (Adult)","Early Phase 1","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","R01DA033364-01","January 2014","June 2015","June 2015","July 24, 2013","null","March 10, 2017","Laboratory of Human Behavioral Pharmacology, Lexington, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT01906346"
1565,"NCT01905696","The Role of S-nitrosohemoglobin in Regulating Systemic Blood Flow During Hypoxia and Normoxia",,"Terminated","No Results Available","Focus is Determination of the Role of SNO-Hb in Forearm Blood Flow Regulation","Drug: Oral N-acetylcysteine","Forearm blood flow","Duke University","All","18 Years to 40 Years   (Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Pro00041312","March 2013","August 2013","August 2013","July 23, 2013","null","December 29, 2016","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01905696"
1566,"NCT01904695","Causal Inference Research of Resistant Hypertension Treatment With Chinese Approach in a Cohort Study",,"Completed","No Results Available","Primary Hypertension|Hypertension, Resistant to Conventional Therapy","Drug: Herbs|Drug: Antihypertensive drugs","Systolic (SBP) and diastolic (DBP) blood pressure reductions|Cardiac event|Death incident|Scores for symptoms and signs","China Academy of Chinese Medical Sciences|Guang'anmen Hospital of China Academy of Chinese Medical Sciences","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","192","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","81202846","August 2013","October 2015","December 2015","July 22, 2013","null","September 7, 2016","Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT01904695"
1567,"NCT01903122","Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions",,"Completed","No Results Available","Dry Mouth","Drug: Cevimeline","bioequivalence determined by statistical comparison Cmax comparison of the pharmacokinetic parameters","Roxane Laboratories|West-Ward Pharmaceutical","All","18 Years to 45 Years   (Adult)","Early Phase 1","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CEVI-C30-PVFS-1","February 2009","February 2009","February 2009","July 19, 2013","null","January 23, 2018","Novum Pharmaceutical Research Services, Las Vegas, Nevada, United States","","https://ClinicalTrials.gov/show/NCT01903122"
1568,"NCT01903109","Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions",,"Completed","No Results Available","Dry Mouth","Drug: Cevimeline","bioequivalence determined by statistical comparison Cmax","Roxane Laboratories|West-Ward Pharmaceutical","All","18 Years to 45 Years   (Adult)","Early Phase 1","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CEVI-C30-PVFD-1","February 2009","February 2009","February 2009","July 19, 2013","null","January 23, 2018","Novum Pharmaceutical Research Services, Las Vegas, Nevada, United States","","https://ClinicalTrials.gov/show/NCT01903109"
1569,"NCT01901679","Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women",,"Completed","No Results Available","Obesity","Drug: Celebrex","To determine whether oral administration of Celebrex to obese women will reduce the PGE-M in urine","Rockefeller University","Female","40 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PHO-0807","July 2013","August 2014","August 2014","July 17, 2013","null","November 6, 2014","The Rockefeller University, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01901679"
1570,"NCT01895829","Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI",,"Active, not recruiting","No Results Available","Head and Neck Cancer","Procedure: Magnetic Resonance Imaging (MRI)|Drug: Ferumoxytol","Feasibility of Using Ferumoxytol with Magnetic Resonance Imaging (MRI)","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2012-1127|NCI-2013-02182","September 2013","September 2019","September 2019","July 11, 2013","null","October 16, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01895829"
1571,"NCT01894451","Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy",,"Active, not recruiting","No Results Available","Inflammatory Breast Carcinoma","Drug: 89Zr-bevacizumab|Procedure: FDG-PET/CT|Procedure: MRI scan|Procedure: Tumor biopsies","Quality Control Standards for Radiopharmamceuticals and Number of Successfully Acquired 89Zr-bevacizumab-PET/CT scans|Number of related adverse events after the intravenous administration of 89Zr-bevacizumab.|Biodistribution of 89Zr-bevacizumab and individual organ and effective dose of 89Zr-bevacizumab|Amount of 89Zr-bevacizumab uptake in IBC tumor and measures of tumor angiogenesis in research biopsy specimens.|Changes in tumor uptake of 89Zr-bevacizumab and FDG during and after preoperative chemotherapy and response in primary IBC tumor MRI.|To correlate the changes in tumor uptake on 89Zr-bevacizumab-PET/CT with standard imaging response using MRI and FDG-PET/CT","Dana-Farber Cancer Institute|National Cancer Institute (NCI)","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","13-147","June 2015","October 2019","October 2020","July 10, 2013","null","February 7, 2018","Brigham and Womens Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01894451"
1572,"NCT01891136","Oral Peanut Immunotherapy for Peanut Allergic Patients","PnOIT","Completed","No Results Available","Peanut Hypersensitivity","Drug: Peanut protein","The percentage of peanut-allergic patients achieving clinical desensitization to peanut, assessed after up to five years of OIT.|Clinical desensitization will be measured with an oral peanut challenge conducted while on OIT therapy.|Changes in number of antigen-specific lymphocytes.|Changes in function of antigen-specific lymphocytes.","University of North Carolina, Chapel Hill","All","1 Year to 16 Years   (Child)","Early Phase 1","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-2298","April 2004","November 2014","December 2014","July 2, 2013","null","June 25, 2015","UNC Chapel Hill, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01891136"
1573,"NCT01889147","Microdose and First-In-Human (FIH) Study of Recombinant Human Placental Alkaline Phosphatase (hRESCAP)",,"Completed","No Results Available","Healthy","Biological: hRESCAP|Biological: Placebo","Evaluate the peak plasma concentration of hRESCAP after microdose administration of hRESCAP|In the ascending dose study increased dosages of of hRESCAP will be supplied till finally the therapeutic dose.","TNO|Alloksys Life Sciences B.V.","Male","18 Years to 45 Years   (Adult)","Early Phase 1","4","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","CHDR1220","June 2013","July 2013","October 2013","June 28, 2013","null","October 24, 2013","Centre for Human Drug Research, Leiden, South-Holland, Netherlands","","https://ClinicalTrials.gov/show/NCT01889147"
1574,"NCT01888952","Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)",,"Completed","Has Results","Advanced B-cell Lymphoid Malignancies","Drug: Prednisone|Drug: Roflumilast","Total Number of Adverse Events.","Anand B. Karnad|The University of Texas Health Science Center at San Antonio","All","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTRC 13-0013|HSC20130307H","July 2013","January 2015","January 2015","June 28, 2013","February 27, 2017","February 27, 2017","Ctrc @ Uthscsa, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT01888952"
1575,"NCT01884805","Feasibility of Measurement of Optical Aberrations in Hyperopia by Using an Adaptive Optics Visual Simulator (AOVIS-I)","HyperVOPTICA","Unknown status","No Results Available","Hyperopia","Device: Monocular Adaptive Optics Visual Simulator (AOVIS-I)","Measurement of optical aberrations|Reproductibility of the measures|Quantitative measurement of optical aberrations","University Hospital, Toulouse|Centre de Référence National du Kératocône","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","12 483 03","March 2013","September 2016","September 2016","June 24, 2013","null","May 9, 2016","University Hospital, Toulouse, Toulouse, Midi-Pyrenees, France","","https://ClinicalTrials.gov/show/NCT01884805"
1576,"NCT01882634","Screening Programme for Abdominal Aortic Aneurysm by Hand-Held-Ultrasonography in Primary Health Care","BarcelonAAA","Completed","No Results Available","Abdominal Aortic Aneurysm","Device: Ultrasound (Trademark:VScan; Manufacturer:General Electric)","The prevalence of abdominal aortic aneurysm detected by a hand-held ultrasound in Primary Care|Associated risk factors to abdominal aortic aneurysm","Consorci d'Atenció Primària de Salut de l'Eixample|Medtronic","Male","60 Years and older   (Adult, Older Adult)","Early Phase 1","1010","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","CP041192","June 2013","October 2014","October 2014","June 20, 2013","null","November 6, 2014","Primary Care Center Les Corts, Barcelona, Catalonia, Spain|Primary Care Center Casanova, Barcelona, Catalonia, Spain|Primary Care Center Comte Borrell, Barcelona, Catalonia, Spain","","https://ClinicalTrials.gov/show/NCT01882634"
1577,"NCT01881971","Statins for Pulmonary and Cardiac Complications of Chronic HIV - Coordinating Center","SPARC","Completed","No Results Available","HIV Seropositivity","Drug: Placebo|Drug: Rouvastatin calcium","change in inflammatory markers - hsCRP|effect of rosuvastatin on pulmonary and cardiac status by use of cIMT/FMD/ Vascular studies are a measure of preclinical atherosclerosis and predicts future cardiovascular events and mortality","Alison Morris|University of Pittsburgh","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","23","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","PRO12100503|RFA-HL-12-034","May 2013","November 2015","January 2016","June 20, 2013","null","October 13, 2017","University of California, Los Angelos, Los Angeles, California, United States|University of California, SF, San Francisco, California, United States|University of Pittsburgh department of medicine division of Pulmonary, Allergy and Critical Care medicine, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01881971"
1578,"NCT01881919","Effect of Quercetin Supplements on Healthy Males: a Four-Week Randomized Cross-Over Trial",,"Completed","No Results Available","Hyperuricemia|Gout|Kidney Calculi|Diabetes|Cardiovascular Disease","Dietary Supplement: Treatment|Dietary Supplement: Control","Risk of getting hyperuricemia assessed by the measure of plasma uric acid.|Kidney excretion of uric acid: urinary uric acid level|Blood pressure|Blood glucose|Metabolomic and metabonomic profiling of blood plasma","University of Leeds","Male","19 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","22","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","MEEC12-019","February 2013","April 2014","November 2014","June 20, 2013","null","March 24, 2015","School of Food Science and Nutrition, Leeds, West Yorkshire, United Kingdom","","https://ClinicalTrials.gov/show/NCT01881919"
1579,"NCT01881776","Continuous Interscalene Block Results in Superior Recovery Throughout the First Postoperative Week",,"Completed","Has Results","Postoperative Pain|Adverse Effects","Procedure: ISB","Patients With Pain: Numerical Rating Scale (NRS-11(0-10): 0:no Pain and 10:Severe/Worst Pain) ≥ 4|Time-to-first Pain|The Number of Patients Consume ≥1 Dose of Analgesics","St. Luke's-Roosevelt Hospital Center|Baxter Healthcare Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","71","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","10142","August 2011","June 2012","June 2012","June 20, 2013","June 4, 2014","June 4, 2014","St Luke's Roosevelt Hospital Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01881776"
1580,"NCT01881139","Impact of Exercise Training on Cardiac Function in Man",,"Completed","No Results Available","Cardiovascular Disease","Behavioral: exercise training","change of cardiac function at baseline to exercise training for 3 months|change of lipoprotein at baseline to exercise training for 3 months|change of heart rate at baseline to exercise training for 3 months|Change of body weight at baseline to exercise training for 3 months|change of cardiac troponin frome baseline to exercise training for 3 months|Change of blood pressure from baseline to exercise training for 3 months","No. 150 Central Hospital of the Chinese People Liberation Army","Male","18 Years to 22 Years   (Adult)","Early Phase 1","46","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","150CTSX002","December 2012","May 2013","May 2013","June 19, 2013","null","June 19, 2013","No. 150 Central hospital of Chinese People's Liberation Army, Luoyang, Henan, China","","https://ClinicalTrials.gov/show/NCT01881139"
1581,"NCT01881048","Window of Opportunity Study Targeting the Inflammatory Milieu",,"Active, not recruiting","No Results Available","Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer","Dietary Supplement: Omega-3 fatty acid|Drug: Celecoxib","Change in mean Ki-67 index in patients receiving either omega-3 fatty acid or celecoxib for 1 or more weeks as compared to controls","University of Colorado, Denver","Female","18 Years to 50 Years   (Adult)","Early Phase 1","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08-0104.cc|NCI-2011-02967","December 8, 2009","January 14, 2014","October 2019","June 19, 2013","null","November 15, 2018","University of Colorado Cancer Center, Aurora, Colorado, United States","","https://ClinicalTrials.gov/show/NCT01881048"
1582,"NCT01880749","Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas",,"Active, not recruiting","No Results Available","Neurofibromatosis Type 2|Vestibular Schwannomas|Meningiomas","Drug: RAD001","Proportions of VS and meningiomas after exposure to RAD001","New York University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","12-02808","June 2013","December 2018","December 2019","June 19, 2013","null","July 4, 2018","New York University School of Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01880749"
1583,"NCT01878942","Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study",,"Completed","No Results Available","Healthy","Drug: Placebo|Drug: LSD","Subjective / psychological effects of LSD|Physiological effects of LSD|Endocrine response of LSD|Pharmacokinetics of LSD|Effect of LSD on prepulse inhibition|Tolerability of LSD|Long-term psychological effects of LSD|Genetic Polymorphisms|Effects on social cognition and empathy","University Hospital, Basel, Switzerland","All","25 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","EK 279/12","June 2013","February 2014","December 2014","June 17, 2013","null","January 21, 2016","University Hospital Basel, Basel, Basel-Stadt, Switzerland","","https://ClinicalTrials.gov/show/NCT01878942"
1584,"NCT01878708","A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma",,"Terminated","No Results Available","T-Cell Lymphoma|Relapsed T-Cell Lymphoma|Refractory T-Cell Lymphoma","Drug: PEG-L-asparaginase|Drug: Dexamethasone acetate","Overall response rate (complete + partial response) in evaluable patients.|Duration of response for patients with PR or CR|Grade 2 and above attributable toxicity of treatment.|Progression-free survival.|Complete remission (CR) rate.|Partial remission (PR) rate.|The stable disease (SD) rates in this population and in the intent-to-treat population|Progressive disease (PD) rate.|Stable disease (SD) rate.|Overall survival","Dana-Farber Cancer Institute|Leadiant Biosciences, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","2","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-165","July 2013","February 2017","February 2017","June 17, 2013","null","March 6, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01878708"
1585,"NCT01878643","Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit",,"Completed","No Results Available","Respiratory Infection|Bacterial Resistance|Respiratory Failure","Drug: vancomycin or gentamicin|Drug: Placebo","Eradication of multi-drug resistant bacteria|Clinical Pulmonary Infection Score (CPIS)","Stony Brook University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","47","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20033799","December 2001","December 2002","December 2002","June 17, 2013","null","June 17, 2013","University Hospital Medical Center, STony Brook, New York, United States","","https://ClinicalTrials.gov/show/NCT01878643"
1586,"NCT01875666","Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib",,"Active, not recruiting","No Results Available","Breast Neoplasms","Drug: Trastuzumab|Drug: pertuzumab|Drug: lapatinib","difference in kinome activation pre and post treatment|predictability in kinome activation","UNC Lineberger Comprehensive Cancer Center|Genentech, Inc.|Susan G. Komen Breast Cancer Foundation|GlaxoSmithKline","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","LCCC 1214","September 2013","December 2016","March 2019","June 12, 2013","null","November 2, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|IU Simon Cancer Center, Indianapolis, Indiana, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|MD Anderson, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01875666"
1587,"NCT01872585","Program for Caregivers Involved With Mental Health Services",,"Completed","No Results Available","Mental Illness","Behavioral: Mentalization based therapy","Maternal reflective functioning|Coding Interactive Behavior|Maternal parenting stress|Maternal depression|Maternal global psychiatric distress","Yale University","Female","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","K02DA023504","April 2012","June 2014","June 2014","June 7, 2013","null","November 8, 2016","West Haven Mental Health Clinic, West Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01872585"
1588,"NCT01872533","Effect of 10-day Overnight Hypoxia Treatment on Whole Body Insulin Sensitivity (SLEEP HIGH Study)","SLEEP HIGH","Completed","No Results Available","Insulin Resistance","Other: Hypoxia Exposure","Change in Insulin sensitivity|Change in oxygen tension in adipose tissue|Glucose uptake in myotubes|Change in gene and protein expression","Pennington Biomedical Research Center","Male","20 Years to 45 Years   (Adult)","Early Phase 1","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PBRC 11009","July 2011","September 2012","May 2013","June 7, 2013","null","December 2, 2015","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT01872533"
1589,"NCT01869361","Indomethacin for Tocolysis",,"Not yet recruiting","No Results Available","Preterm Labor","Drug: Indomethacin|Drug: Placebo","delivery within 48 hours|delivery within 7 days|delivery before 37 weeks|Maternal and Fetal Complications","MetroHealth Medical Center","Female","16 Years to 50 Years   (Child, Adult)","Early Phase 1","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB13-00533","June 1, 2019","June 2021","December 2021","June 5, 2013","null","July 17, 2018","MetroHealth Medical Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01869361"
1590,"NCT01868087","Impact Advanced Recovery® for Radical Cystectomy (RC) Patients: a Pilot Study",,"Completed","No Results Available","Bladder Cancer|Radical Cystectomy|Urinary Bladder Neoplasms|Surgery","Dietary Supplement: Boost Plus®|Dietary Supplement: Impact Advanced Recovery®","Immune and Inflammation Response|preservation of body weight and fat free mass (FFM)|count of infections after surgery|hospital readmission rate","Jill Hamilton-Reeves, PhD RD LD|American Cancer Society, Inc.|Nestlé|University of Kansas Medical Center","Male","40 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","13730","July 2013","March 2016","March 2016","June 4, 2013","null","April 7, 2016","University of Kansas Medical Center, Kansas City, Kansas, United States","","https://ClinicalTrials.gov/show/NCT01868087"
1591,"NCT01867593","MET-PET for Newly Diagnosed Glioblastoma",,"Completed","No Results Available","Glioblastoma","Device: C-11 methionine PET","Effect of C-11 methionine PET on progression free survival|Evaluate for discordance in tumor volumes|Compare pre-radiation and follow-up C-11 methionine PET imaging in predicting sites of failure|Compare pre-radiation and follow-up C-11 methionine PET in predicting occurrence of pseudoprogression","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","13-018","January 2014","September 2016","September 2016","June 4, 2013","null","October 13, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01867593"
1592,"NCT01867320","Raltegravir for HAM/TSP",,"Completed","No Results Available","HTLV-I Infection","Drug: Raltegravir","Reduction of HTLV-1 Proviral load in HAM/TSP patients","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","19","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","130135|13-N-0135","May 21, 2013","September 25, 2018","September 25, 2018","June 4, 2013","null","September 27, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01867320"
1593,"NCT01866917","Study of TAP and Laparoscopic and Robotic Gynecologic Procedures and Obese Women",,"Unknown status","No Results Available","Pain","Drug: Ropivacaine 0.5% 20cc injectate bilaterally","Pain","Montefiore Medical Center","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12-11-397","April 2013","April 2014","null","June 3, 2013","null","June 3, 2013","Moses Medical Center, Bronx, New York, United States","","https://ClinicalTrials.gov/show/NCT01866917"
1594,"NCT01866462","Pilot Study of the Effect of MN-504 Cobiotic Formulation on the Efficacy and Tolerability of Metformin",,"Completed","No Results Available","Type 2 Diabetes","Other: NM504","Metformin Tolerance|Fasting Blood Glucose|GI Symptoms|GI Stool Profile|Weight Loss","NuMe Health|Pennington Biomedical Research Center","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","10","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","ProCo Metformin","May 2013","July 2014","July 2014","May 31, 2013","null","July 24, 2014","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT01866462"
1595,"NCT01866254","Use of Intrathecal Hydromorphone in Elective Cesarean Deliveries",,"Active, not recruiting","No Results Available","Pain","Drug: Hydromorphone|Drug: Morphine","Change in Pain Scores|Number of Participants with Adverse Events (AEs)","Grace Shih, MD|Masimo Corporation|University of Kansas Medical Center","Female","18 Years to 40 Years   (Adult)","Early Phase 1","45","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","13527","May 2013","December 4, 2017","December 4, 2018","May 31, 2013","null","April 4, 2018","University of Kansas Medical Center, Kansas City, Kansas, United States","","https://ClinicalTrials.gov/show/NCT01866254"
1596,"NCT01865591","Feasibility Study of Renal Denervation for the Treatment of Resistant Hypertension","SoundITV","Unknown status","No Results Available","Uncontrolled Hypertension","Device: Ultrasound-based Renal Denervation","Major adverse events|Change from baseline in office blood pressure measurement|Change from baseline in ambulatory 24-hour blood pressure measurement|Change from baseline in renal artery dimensions|Change from baseline in creatinine|Adverse events and device complications","Sound Interventions, Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SITV-CL-0001","April 2012","July 2013","null","May 31, 2013","null","May 31, 2013","Na Homolce Hospital, Prague, Czech Republic","","https://ClinicalTrials.gov/show/NCT01865591"
1597,"NCT01864083","FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients",,"Completed","No Results Available","Breast Cancer","Procedure: Positron Emission Tomography (PET)|Drug: Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC)|Procedure: Positron emission mammography (PEM) When available|Procedure: MR","assess the diagnostic accuracy|ability of FACBC PET and PEM to determine therapeutic response to neoadjuvant chemotherapy","Memorial Sloan Kettering Cancer Center|GE Healthcare","Female","21 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","11-177","May 2013","August 29, 2017","August 29, 2017","May 29, 2013","null","August 31, 2017","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01864083"
1598,"NCT01863576","Effects of Omega-3 Supplementation on the Cytokine and Lipid Profiles in Patients With Chronic Chagas Cardiomyopathy",,"Completed","No Results Available","Chagas Cardiomyopathy","Dietary Supplement: Omega-3|Dietary Supplement: Placebo Comparator","Cytokine profile|Lipid profile","Evandro Chagas Institute of Clinical Research|Andrea Silvestre de Sousa, MD PhD|Alejandro Marcel Hasslocher, MD MSc PhD student|Andrea Pereira de Souza, PhD|Claudia Santos de Aguiar Cardoso, MSc|Patricia Dias de Brito, PhD|Pedro Emmanuel Alvarenga Americano do Brasil, MD PhD|Roberta Olmo Pinheiro, PhD|Roberto Magalhães Saraiva, MD PhD|Sergio Salles Xavier, MD PhD|Paula Simplicio da Silva, MSc PhD student","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Health Services Research","0037.0.009.000-10","March 2013","January 2014","December 2015","May 29, 2013","null","September 9, 2016","Evandro Chagas Institute of Clinical Research, RJ, Br, Brazil","","https://ClinicalTrials.gov/show/NCT01863576"
1599,"NCT01861340","Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma",,"Completed","No Results Available","Myeloma","Drug: Lenalidomide, Dexamethasone, and MEDI-551","The effect of Lenalidomide, dexamethasone and Medi-551 on multiple myeloma cancer stem cells (CSCs).|The safety of Medi-551 when combined with Lenalidomide and dexamethasone.","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|MedImmune LLC","All","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","J1340|NA_00081182","May 2014","April 2016","July 2016","May 23, 2013","null","September 10, 2018","The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01861340"
1600,"NCT01860378","Vouchers to Promote Tdap Vaccination",,"Completed","No Results Available","Whooping Cough","Other: Full price|Other: $5 off","Rate of Tdap Vaccination|Proportion of all vouchers that are redeemed","Children's Hospital of Philadelphia|Robert Wood Johnson Foundation|University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","149","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","13-010045","July 2013","March 2014","March 2015","May 22, 2013","null","April 3, 2015","Karabots Primary Care Center - The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01860378"
1601,"NCT01860313","Mental Health Training for Elementary Teachers Through Tele-education and Its Impact on the School Atmosphere",,"Completed","No Results Available","Mental Disorders","Behavioral: Web-based interactive education|Behavioral: Text and Video-based education","Knowledge in Child and Adolescents Mental Health, beliefs and attitudes in Child Mental Health","University of Sao Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo|Conselho Nacional de Desenvolvimento Científico e Tecnológico","All","Child, Adult, Older Adult","Early Phase 1","213","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","573974/2008-0","January 2010","December 2011","July 2012","May 22, 2013","null","May 22, 2013","","","https://ClinicalTrials.gov/show/NCT01860313"
1602,"NCT01859442","The Effect of Cancer Therapies and Exercise on Mitochondrial Energetics and Fitness",,"Completed","No Results Available","Locally Advanced Rectal Cancer","Procedure: Structured responsive interval exercise training programme|Other: Sham group","Exponential rate constant of post-chemoradiotherapy and post-exercise phosphocreatine recovery.|Alterations in mitochondrial energetics post-chemoradiotherapy and exercise","Michelle Mossa|University of Liverpool|Aintree University Hospitals NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","11/H1002/12c","January 2012","July 2013","October 2013","May 22, 2013","null","May 6, 2014","Aintree University Teaching Hospitals NHS FT, Liverpool, Merseyside, United Kingdom","","https://ClinicalTrials.gov/show/NCT01859442"
1603,"NCT01858896","GLP-1 and Hypoglycemia",,"Active, not recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: Glucagon-Like Peptide- 1 (GLP-1) infusion|Other: Placebo Comparator: Saline Infusion","Change in Plasminogen Activation inhibitor-1 (PAi-1)|Change in Flow mediated dilation (FMD)","University of Maryland","All","18 Years to 45 Years   (Adult)","Early Phase 1","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","HP00055308","July 2013","December 2018","December 2018","May 21, 2013","null","May 7, 2018","University of Maryland, Baltimore, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01858896"
1604,"NCT01858025","Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma",,"Active, not recruiting","No Results Available","Carcinoma of the Anal Canal","Radiation: Pencil Beam scanning Radiation|Drug: 5-fluorouracil|Drug: Mitomycin-C","Feasibility of administration of pencil beam scanning proton beam radiation with chemotherapy for anal cancer|Assessment of Adverse Events|Quality of Life Outcomes|Clinical Complete Response|Radiotherapy treatment time|Local-regional failure|Colostomy Failure and Colostomy-Free Survival|Disease-free Survival|Overall Survival|Correlative Studies|To describe mood in the study population|To measure utilization of health services","Massachusetts General Hospital|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-075","July 2013","July 2017","December 2019","May 20, 2013","null","September 13, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|Roberts Proton Therapy Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01858025"
1605,"NCT01856790","Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes","Device: ePID closed loop system|Drug: liraglutide","peak post-prandial venous glucose levels|the incremental meal-related glucose AUC","Jennifer Sherr|Juvenile Diabetes Research Foundation|Yale University","All","18 Years to 40 Years   (Adult)","Early Phase 1","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1211011156","February 2013","November 2015","November 2015","May 17, 2013","null","April 7, 2016","Yale University School of Medicine, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01856790"
1606,"NCT01856686","Neurocognitive and Neurobiological Improvement in ADHD Children by Modification of Dietary Protein","BrainProtein","Completed","Has Results","ADD|ADHD","Drug: BP22042013|Dietary Supplement: Low carbohydrate diet","Reaction Time at 3 Months|Omission Errors at 3 Months|Comission Errors at 3 Months|Occipital Alpha Brainwaves Amplitudes at 3 Months|Mu Waves-amplitude at 3 Months|Frontal Midline Theta Activity- Amplitude at 3 Months|Occipital Alpha Waves-frequency at 3 Months|Parietal Alpha Waves-frequency at 3 Months|Mu Wave Frequency at 3 Months|Frontal Midline Theta Activity- Frequency at 3 Months|Monastra Ratio at 3 Months|Behavior|Hyperactivity Score|Impulsivity Score|Inattention Score","Spanish Foundation for Neurometrics Development|PronoKal Foundation|Child Health Foundation","All","7 Years to 13 Years   (Child)","Early Phase 1","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","Brain Proteins","December 2013","June 2014","July 2014","May 17, 2013","September 10, 2014","October 16, 2017","Pronokal Foundation, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT01856686"
1607,"NCT01856335","Exercise Education for Adults With Seizure Disorders",,"Completed","No Results Available","Seizures|Epilepsy","Other: Patient Education|Other: exercise: increase physical activity/goal setting","Change in Self-efficacy for exercise score following the E-MOVE intervention.|Change in Outocme Expectations for exercise score following the E-MOVE intervention.|The effect of the E-MOVE intervention on seizure frequency based on seizure calendar self-report, quality of life scores, symptoms of depression and BMI measures.","National Institute of Neurological Disorders and Stroke (NINDS)|National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","130127|13-N-0127","May 10, 2013","January 25, 2017","January 25, 2017","May 17, 2013","null","November 6, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01856335"
1608,"NCT01856179","Supplementation of Land-based Stearidonic Acid (SDA)-Rich Oils in Humans",,"Completed","No Results Available","Hypercholesterolemia|Overweight","Dietary Supplement: Echium oil","eicosapentaenic acid|Lipid mediators derived from AA, EPA and DGLA such as HETE species (5-HETE; 8-HETE, etc.)","University of Jena|German Research Foundation","All","20 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","LSEP H42-KK","March 2011","August 2011","April 2012","May 17, 2013","null","May 17, 2013","Friedrich Schiller University of Jena, Jena, Thuringia, Germany","","https://ClinicalTrials.gov/show/NCT01856179"
1609,"NCT01856140","Treatment of Tendon Injury Using Mesenchymal Stem Cells","ALLO-ASC","Unknown status","No Results Available","Lateral Epicondylitis","Biological: ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection","Change from baseline in Visual analog scale (VAS) at 6 and 12 weeks","Seoul National University Hospital","All","19 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SNUH-RM-SGChung-ASC-01","May 2013","January 2014","April 2014","May 17, 2013","null","November 26, 2013","Seoul National University College of Medicine, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01856140"
1610,"NCT01853449","Inhaled Fentanyl Citrate & Dyspnea",,"Completed","No Results Available","Dyspnea","Drug: Fentanyl Citrate|Other: CWS|Drug: Placebo","Sensory intensity (Borg 0-10 scale) ratings of dyspnea at isotime","McGill University","Male","20 Years to 40 Years   (Adult)","Early Phase 1","14","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A02-M16-13B Fentanyl","June 2013","August 2014","August 2014","May 15, 2013","null","February 14, 2017","Montreal Chest Institute; McGill University Health Center & McGill University, Montreal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT01853449"
1611,"NCT01852864","Degarelix Before Radical Prostatectomy",,"Unknown status","No Results Available","Prostate Cancer","Drug: 240mg degarelix s.c. injection","proliferative index defined by immunohistochemistry for ki67|Gene expression levels measured by microarray","University of Cambridge","Male","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","11/H0311/2","July 2011","July 2015","December 2015","May 14, 2013","null","December 16, 2014","Cambridge University Hopital NHS Trust, Cambridge, Cambridgeshire, United Kingdom","","https://ClinicalTrials.gov/show/NCT01852864"
1612,"NCT01851993","Inhaled Ondansetron & Dyspnea",,"Completed","No Results Available","Dyspnea","Drug: Ondansetron|Drug: Placebo","Sensory Intensity (Borg 0-10 scale) ratings of dyspnea at isotime","McGill University","Male","20 Years to 40 Years   (Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A02-M16-13B Ondansetron","June 2013","September 2014","December 2014","May 13, 2013","null","August 26, 2015","Clinical Exercise & Respiratory Physiology Laboratory (CERPL) of McGill University, Montreal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT01851993"
1613,"NCT01848236","Effects of Vitamin D Insufficiency in Man",,"Suspended","No Results Available","Vitamin D Deficiency","Dietary Supplement: Vitamin D2|Dietary Supplement: Vitamin D3","Change in serum 25D|Change in bone mineral density by biochemistry|Change in muscle strength by exam|Change in muscle strength by questionnaire|Change in bone mineral density by DXA scan|Change in fractional urinary calcium:creatinine excretion ratio|Change in serum 1,25D|Change in serum iPTH|Change in serum bone biomarkers","University of California, Los Angeles","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","300","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Adams VitD 01","August 2010","August 2019","August 2019","May 7, 2013","null","October 11, 2018","UCLA, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01848236"
1614,"NCT01846364","DIM as a Treatment for Thyroid Disease",,"Terminated","No Results Available","Proliferative Thyroid Disease","Dietary Supplement: Diindolylmethane (DIM)","Evidence of objective and quantifiable changes in thyroid size as a resalt of the oral administration of DIM, confirmed by pre- and post- DIM treatment ultrasounds|Evidence of DIM's effect on estrogen metabolites, confirmed by plasma and urine analysis","The New York Eye & Ear Infirmary","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","NYEEI06.33","November 2006","August 2011","September 2011","May 3, 2013","null","May 3, 2013","The New York Eye & Ear Infirmary, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01846364"
1615,"NCT01843881","The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass",,"Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: Exendin 9, 39|Drug: Placebo","Change in Total Disposition Index from Study 1 (Exendin 9,39) to Study 2 (saline)","Adrian Vella|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Center for Research Resources (NCRR)|Mayo Clinic","All","20 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","20","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","11-007667|R01DK082396|UL1RR024150","March 2012","September 2013","December 2013","May 1, 2013","null","December 4, 2013","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01843881"
1616,"NCT01843855","The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass",,"Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: Exendin 9,39|Drug: Placebo","Change in Total Disposition Index from Study 1 (pre-RYGB) to Study 2 (post-RYGB)","Adrian Vella|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Center for Research Resources (NCRR)|Mayo Clinic","All","20 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","12","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","11-000161|R01DK082396|UL1RR024150","June 2011","July 2013","September 2013","May 1, 2013","null","December 4, 2013","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01843855"
1617,"NCT01843634","Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia",,"Completed","No Results Available","Acute Myeloid Leukemia","Drug: ODSH","Safety by incidence of serious events|Efficacy by time to platelet recovery","Cantex Pharmaceuticals","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB 63137","August 2013","April 2015","April 2015","April 30, 2013","null","March 23, 2016","Huntsman Cancer Institute, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01843634"
1618,"NCT01841619","IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus",,"Completed","Has Results","Cutaneous Lupus Erythematosus","Drug: IVIg","Cutaneous Lupus Erythematosus Disease Area and Severity Index - Total Activity Score (CLASI - TAS)|Skindex 29|Mean Percent Change in Physician's Subjective Assessment of Improvement (PSAI)|Mean Percent Change in Physician's Subjective Assessment of Severity (PSAS)|Cutaneous Lupus Erythematosus Disease Area and Severity Index - Total Damage Score (CLASI - TDS)","University of California, Irvine|Grifols Therapeutics LLC","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-9351","March 2013","November 2014","November 2014","April 26, 2013","August 10, 2015","August 10, 2015","The Institute for Clinical and Translational Science (ICTS), Irvine, California, United States|Unversity of California, Irvine Healthcare, Dermatology, Gottschalk Medical Plaza, Irvine, California, United States","","https://ClinicalTrials.gov/show/NCT01841619"
1619,"NCT01836094","Effects of USP Methylene Blue on Cognitive and fMRI Brain Activity",,"Completed","No Results Available","Brain Activity","Drug: Methylene Blue (USP grade, 280mg oral)|Drug: Placebo","Improvement in reaction time assessed by fMRI measurements and PVT measurements|Improvement in memory assessed by fMRI measurements and DMS measurements|Enhanced fMRI responses to visual-motor task","The University of Texas Health Science Center at San Antonio","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","36","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","NS 13-208","August 2013","March 2016","March 2016","April 19, 2013","null","April 11, 2017","Research Imaging Institute, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT01836094"
1620,"NCT01836068","Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals",,"Recruiting","No Results Available","HIV","Drug: Enfuvirtide","Determine the feasibility of maintaining optimal ART in HIV-1 infected patients during allogeneic HSCT|Number of copies of HIV-1 DNA in blood mononuclear cells at baseline|Number of copies of HIV-1 DNA in blood mononuclear cells at 12 weeks|Number of copies of HIV-1 DNA in blood mononuclear cells at 24 weeks|Number of copies of HIV-1 DNA in blood mononuclear cells at 36 weeks|Number of copies of HIV-1 DNA in blood mononuclear cells at 52 weeks|Number of copies of HIV-1 DNA in blood mononuclear cells at 2 years","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","J1331|NA_00083734","July 2013","July 2020","July 2021","April 19, 2013","null","June 25, 2018","The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01836068"
1621,"NCT01835509","Group Intervention to Increase Physical Activity in Childhood Cancer Survivors",,"Completed","No Results Available","Pediatric Cancer","Behavioral: Intervention, Camp plus reunions","Change in level of physical activity|Change in Self efficacy","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","8 Years to 12 Years   (Child)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","J12136","February 2013","February 2014","February 2014","April 19, 2013","null","February 25, 2014","Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01835509"
1622,"NCT01834989","Patellar Tendinopathy - Effect of Training and Enhancement of the Collagen Synthesis by Insulin-like Growth Factor-I","IGF-I","Active, not recruiting","No Results Available","Tendinopathy","Drug: Insulin-like growth factor I|Drug: Placebo","Tendon structure|Tendon Pain","Bispebjerg Hospital|The Danish Medical Research Council","All","18 Years to 50 Years   (Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","H-4-2012-078","April 2013","February 1, 2017","June 2018","April 18, 2013","null","February 9, 2017","Institute of Sports Medicine, Copenhagen, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT01834989"
1623,"NCT01830907","Efficacy of Preoperative Nutritional Support on Postoperative Outcome in Gastric Cancer Patients at Nutritional Risk by NRS-2002",,"Completed","No Results Available","Malnutrition|Gastric Cancer","Dietary Supplement: carbohydrates|Dietary Supplement: vitamins","Infectious complication|Length of hospital stay","First Hospital of Jilin University","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","460","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","First Hospital of JLU","January 2012","February 2013","March 2013","April 12, 2013","null","April 12, 2013","First hospital of Jilin University, Changchun, Jilin, China","","https://ClinicalTrials.gov/show/NCT01830907"
1624,"NCT01827618","Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy",,"Completed","No Results Available","Invasive Bladder Cancer Stage II","Drug: Rapamycin","Tissue pharmacodynamic (PD) response to TORC1 inhibition","The University of Texas Health Science Center at San Antonio","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC20120135H|KL2TR000118-05CTSA","April 2012","April 2014","April 2014","April 9, 2013","null","July 2, 2015","UT Health Science Center San Antonio, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT01827618"
1625,"NCT01827436","Asymmetrical Gait Training After Pediatric Stroke",,"Completed","No Results Available","Stroke|Hemiplegia","Behavioral: Conventional physical therapy|Behavioral: Asymmetrical gait training","Change in walking symmetry|Change in walking speed|Change in excitability of neural motor pathways|Change in patient/parent satisfaction rating|Change in community step activity","Children's Hospital of Philadelphia","All","5 Years to 17 Years   (Child)","Early Phase 1","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-009844","April 2013","December 2016","December 2016","April 9, 2013","null","January 5, 2018","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01827436"
1626,"NCT01827150","The Influence of Energy Drinks on the Blood Oxygenation Concentration of the Optic Nerve",,"Unknown status","No Results Available","Healthy","Drug: Redbull, energy drink","Pupillary dilation|Baseline measurement before the ingestion of either Redbull or an equal amount of water|Ingestion of Redbull/Water|Measurement of major variables|Measurement of minor variables","Université de Montréal","All","18 Years to 30 Years   (Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","13-030-CERES-D","June 2013","December 2013","April 2014","April 9, 2013","null","July 23, 2013","École d'optométrie de l'Université de Montréal, Montréal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT01827150"
1627,"NCT01826708","Breakpoint Analysis of de Novo Apparently Balanced Chromosomal Translocations",,"Unknown status","No Results Available","Balanced Chromosomal Translocation","Biological: Identification of breakpoints","Evaluation of the proportion of cases for which a cause explaining the phenotype is found for patients with a apparently balance de novo translocation","University Hospital, Montpellier","All","Child, Adult, Older Adult","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","UF 8688","October 2011","January 2013","April 2015","April 8, 2013","null","December 31, 2014","Laboratory of Chromosomal Genetics - Universitary Hospital, Montpellier, France","","https://ClinicalTrials.gov/show/NCT01826708"
1628,"NCT01825902","18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma",,"Completed","No Results Available","Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)|Ewing Sarcoma of Bone|Extraosseous Ewing Sarcoma|Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor","Drug: fluorine F 18 fluorothymidine|Radiation: fludeoxyglucose F 18|Procedure: positron emission tomography|Procedure: diffusion-weighted magnetic resonance imaging|Other: laboratory biomarker analysis","18F-FLT PET activity|ADC values from DW-MRI|18F-FDG PET activity|MRI contrast enhancement|Pathologic response|18F-FLT PET and DW-MRI in predicting local control, event-free survival, and overall survival, measured by therapy-induced changes in the scans|Radiotherapy target volume delineation with pre- and post-chemotherapy 18F-FLT PET and DW-MRI|Imaging thresholds|Efficacy of advanced imaging in accurately guiding biopsy, measured by differences in determining target location by contrast enhancement or 18F-FLT PET and DW-MRI|Accuracy in distinguishing between necrosis and non-specific inflammation immediately following treatment|Reduction in acute side effects based on modified RT treatment volumes with pre- and post-chemotherapy 18F-FLT PET and DW-MRI as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Reduction in late side effects based on modified RT treatment volumes with pre- and post-chemotherapy 18F-FLT PET and DW-MRI as assessed by the NCI CTCAE 4.0 version|Automatic image segmentation techniques for 18F-FLT PET and DW-MRI","Mayo Clinic","All","7 Years and older   (Child, Adult, Older Adult)","Early Phase 1","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MC1279|NCI-2013-00707","March 2013","January 2014","November 23, 2015","April 8, 2013","null","November 20, 2017","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01825902"
1629,"NCT01824199","CYP2C19 Genotype Predictor of Gastric Acid Suppression",,"Withdrawn","No Results Available","Esophagitis","Drug: Omeprazole","The correlation specific to CYP2C19 genotype with gastric acid suppression by omeprazole.|To assess patients gastrointestinal symptoms, in patients with EoE by means of standard validated questionnaires","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-008053","March 2013","November 2016","November 2016","April 4, 2013","null","October 11, 2017","Mayo Clinic in Rochester, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01824199"
1630,"NCT01823991","COGNUTRIN in Breast Cancer Survivors",,"Active, not recruiting","No Results Available","Breast Cancer","Drug: VitaBlue™|Other: Placebo|Drug: Lovaza®","Number of Impaired Neuropsychological Tests|Number of Participants with Related Adverse Events (AEs)|Number of Participants With Cognitive Improvement","H. Lee Moffitt Cancer Center and Research Institute","Female","40 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","MCC-17089","February 19, 2014","September 2018","September 2019","April 4, 2013","null","January 11, 2018","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States","","https://ClinicalTrials.gov/show/NCT01823991"
1631,"NCT01822015","Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",,"Active, not recruiting","No Results Available","Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Untreated Adult Acute Myeloid Leukemia","Drug: Sirolimus|Drug: Idarubicin|Drug: Cytarabine","Change in measurement of mTOR activation paired with mTOR target inhibition|Overall survival|Progression free survival|Incidence of toxicities, graded according to National Cancer Institute (NCI) Common Toxicity Criteria (CTC) 4.0 guidelines|Response defined as patients achieving a complete remission (CR), complete response in absence of total platelet recovery (CRp), or partial remission (PR)","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","55","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12D.588|2012-55","March 15, 2013","December 2019","June 2020","April 1, 2013","null","April 24, 2018","Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01822015"
1632,"NCT01821989","Oral Lactoferrin Supplementation for Prevention of Sepsis in Preterm Neonate",,"Unknown status","No Results Available","Neonatal Sepsis","Dietary Supplement: Lactoferrin|Dietary Supplement: Placebo","Blood culture|Complete blood count with differential leucocytic count.","Mooselmokadem","All","up to 28 Days   (Child)","Early Phase 1","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","moos80","June 2013","January 2016","null","April 1, 2013","null","May 12, 2014","Ain Shams University, Cairo, Abassia, Egypt","","https://ClinicalTrials.gov/show/NCT01821989"
1633,"NCT01821612","Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer",,"Completed","No Results Available","Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage II Pancreatic Cancer|Stage III Pancreatic Cancer","Drug: oxaliplatin|Drug: irinotecan|Drug: leucovorin|Drug: 5-fluorouracil|Drug: capecitabine|Radiation: radiation|Procedure: surgery|Drug: gemcitabine","Accrual rate, calculated by total number of patients accrued divided by number of months from the date the study is opened at the fifth site to the evaluation date|Rate of treatment-related toxicity during preoperative therapy assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4|Rate of treatment delay (greater than 4 weeks) during preoperative therapy|Completion rate of all preoperative and operative therapy|Macroscopic (R0/R1) resection rate defined as number of patients achieved R0 or R1 resection during surgery divided by number of evaluable patients|Radiographic response rate defined as number of patients who achieved complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 during pre-operative therapy divided by the number of evaluable patients|Histopathologic response rate defined as number of patients who achieved CR or PR determined according to histopathologic examination during pre-operative therapy divided by the number of evaluable patients|Time to locoregional recurrence|Time to distant recurrence|Overall survival","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","23","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A021101|U10CA031946","May 2013","September 5, 2014","June 15, 2018","April 1, 2013","null","September 3, 2018","UC San Diego Moores Cancer Center, La Jolla, California, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|The James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|University Pointe, West Chester, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|M D Anderson Cancer Center, Houston, Texas, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT01821612"
1634,"NCT01817400","Mediators of Abnormal Reproductive Function in Obesity (MARO)","MARO","Completed","No Results Available","Infertility, Female|Obesity","Other: Microdialysis|Dietary Supplement: Vascepa - Fish Oil|Drug: Aspirin|Drug: Pioglitazone","Area under curve (AUC)- urinary pregnandiol glucuronide (Pdg)|Estradiol|Luteinizing hormone (LH)|Estrone conjugates (E1c)","University of Colorado, Denver|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","18 Years to 60 Years   (Adult)","Early Phase 1","10","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","12-1414|U54HD058155","March 2013","December 2014","December 2014","March 25, 2013","null","March 17, 2015","University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, United States","","https://ClinicalTrials.gov/show/NCT01817400"
1635,"NCT01815775","Predictive Value of Flow MRI in Normal Pressure Hydrocephalus Surgery",,"Completed","No Results Available","Normal Pressure Hydrocephalus","Other: clinical and imaging examinations","CSF stroke volume|Hakim's triad evaluation|Neuropsychological test","Centre Hospitalier Universitaire, Amiens","All","20 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","PI05-PR-LEGARS|2006/0023","March 2006","July 2008","July 2009","March 21, 2013","null","March 21, 2013","CHU Amiens, Amiens, Picardie, France","","https://ClinicalTrials.gov/show/NCT01815775"
1636,"NCT01814410","Interactive Effects of IV Ethanol and IV Nicotine",,"Completed","No Results Available","Healthy","Drug: Intravenous ethanol placebo plus nicotine infusions|Drug: intravenous ethanol 40mg% plus nicotine infusions|Drug: intravenous ethanol 100mg% plus nicotine infusions","Biphasic Alcohol Effects Scale (BAES)|Visual Analog Scales of Mood States|QSU-Brief|Digit Symbol Substitution Task","Yale University|South Central VA Mental Illness Research, Education & Clinical Center","All","21 Years to 50 Years   (Adult)","Early Phase 1","5","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","1209010841","February 22, 2013","June 2014","June 2014","March 20, 2013","null","January 17, 2018","West Haven VA Hospital, West Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01814410"
1637,"NCT01813955","Phosphodiesterase (PDE) Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia",,"Terminated","No Results Available","Schizophrenia|Cognitive Deficits","Drug: Papaverine or placebo","psychophysiology|Hemodynamic changes","University of Copenhagen|Glostrup University Hospital, Copenhagen","Male","18 Years to 60 Years   (Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","Papaverine schizophrenia","June 2011","May 2013","June 2013","March 19, 2013","null","May 28, 2015","Glostrup psychiatric center, Glostrup, Denmark","","https://ClinicalTrials.gov/show/NCT01813955"
1638,"NCT01809626","Proton MRS Study of SSRI-Zolpidem Interactions",,"Completed","No Results Available","Depression","Drug: Zolpidem|Other: Placebo","Change in GABA levels within two specified brain regions (anterior cingulate and thalamus) as measured with proton magnetic resonance spectroscopy|Change in subjective drug effects as measured by self-report questionnaires","Mclean Hospital|Brain & Behavior Research Foundation","All","21 Years to 40 Years   (Adult)","Early Phase 1","14","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","2009-P-001379","May 2010","September 2012","December 2012","March 13, 2013","null","March 13, 2013","McLean Hospital, Belmont, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01809626"
1639,"NCT01808521","A Pilot Study of N-acetylcysteine in Thrombotic Thrombocytopenia Purpura","NACinTTP","Completed","No Results Available","Purpura, Thrombotic Thrombocytopenic|TTP","Drug: N-Acetylcysteine","Changes in platelet count|Laboratory measures of VWF activity|Laboratory measures of ADAMTS13 activity|Laboratory measures of red blood cell (RBC) hemolysis and oxidation|Safety of NAC infusion","Bloodworks|University of Washington","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","N-Acetylcysteine in TTP","May 2013","July 2017","July 2017","March 11, 2013","null","September 20, 2017","Puget Sound Blood Center, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT01808521"
1640,"NCT01807910","ER Stress in NAFLD",,"Withdrawn","No Results Available","Obesity|NAFLD","Drug: methyl-D9-choline","Net hepatic phospholipid production|Kinetics of secretory lipoprotein phospholipids","Vanderbilt University","Female","30 Years to 60 Years   (Adult)","Early Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","ER stress","October 2013","October 2017","April 2018","March 8, 2013","null","October 23, 2013","Vanderbilt University Medical Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT01807910"
1641,"NCT01805505","Comparison of Embryo Transfer in Egg Donation Recipients With Transvaginal and Transabdominal Ultrasound",,"Terminated","No Results Available","Infertility","Procedure: Transvaginal ultrasound-guided embryo transfer|Procedure: Transabdominal ultrasound-guided embryo transfer","Pregnancy rate|Clinical pregnancy rate|Ongoing pregnancy rate|Menstruation-like pain|Discomfort related to vesical distension|Overall discomfort|Difficulty using the assigned technique faced by operators|Catheterization time|Conversion to the opposite technique","IVI Madrid","Female","18 Years to 49 Years   (Adult)","Early Phase 1","346","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MAD-EH-01-2012-01","February 2012","December 2016","December 2016","March 6, 2013","null","March 7, 2017","IVI Madrid, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT01805505"
1642,"NCT01805089","Melatonin Versus Placebo in Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: Melatonin 3 mg","Absolute Plasma Estradiol Levels After 4 Month Course of Melatonin or Placebo|Compliance|Change in Mood, Sleep Quality and Menopausal Symptoms From Baseline to 4 Months","Dana-Farber Cancer Institute","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","95","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","05-305","October 2006","July 2009","July 2009","March 6, 2013","February 23, 2015","March 23, 2015","Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01805089"
1643,"NCT01804777","Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes",,"Terminated","No Results Available","Proteinuria|Hypertension|Type II Diabetes","Drug: Amiloride|Drug: HCTZ","Blood Pressure|Hypertension","University of New Mexico|Dialysis Clinic, Inc.|University of Pittsburgh","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","9","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Health Services Research","13-017","March 2013","December 2014","December 2014","March 5, 2013","null","May 10, 2018","University of New Mexico Hospital; Clinical & Translational Science Center, Albuquerque, New Mexico, United States","","https://ClinicalTrials.gov/show/NCT01804777"
1644,"NCT01804712","Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy",,"Active, not recruiting","No Results Available","Prostate Cancer","Drug: rituximab","Histologic response rate after one cycle of rituximab|Change in prostate-specific antigen (PSA)|Change in peripheral blood B cell number|Change in serum CXCL13 level","Stephen Howell, M.D.|Genentech, Inc.|University of California, San Diego","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","121451","July 2013","April 2018","April 2019","March 5, 2013","null","May 19, 2017","Moores UCSD Cancer Center, La Jolla, California, United States","","https://ClinicalTrials.gov/show/NCT01804712"
1645,"NCT01803451","Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass","GLP-1","Recruiting","No Results Available","Post-bariatric Surgery","Drug: exendin-(9-39)|Drug: exendin -(9-39)","The investigator measure glucose, islet and GI hormonal levels in response to meal ingestion as a composite measure and the percentage of contribution of GLP-1 contribution to postprandial insulin levels will also be calculated","The University of Texas Health Science Center at San Antonio","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Other","HSC20180070H|DK083554","November 2005","December 2020","December 2020","March 4, 2013","null","May 18, 2018","South Texas Veterans Health Care System, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT01803451"
1646,"NCT01801371","68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma","GRGDG","Recruiting","No Results Available","Glioma","Drug: 68Ga-BNOTA-PRGD2","Semiquantitative measurement of standardized uptake values (SUVs) of lesions|Number of participants with adverse events as a measure of safety","Peking Union Medical College Hospital|Beijing Tiantan Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PUMCHNM6","October 2012","December 2017","December 2017","February 28, 2013","null","April 7, 2017","Peking Union Medical College Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT01801371"
1647,"NCT01799135","Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC)",,"Recruiting","No Results Available","Non Small Cell Lung Cancer","Other: DCE-MRI scan|Radiation: Stereotactic Body Radiation Therapy|Other: 4D-CT scan","Change in tumor perfusion from baseline 1-2 days after the first SBRT treatment|Change in tumor perfusion from baseline 1-2 weels after completion of SBRT treatment|Change in tumor perfusion from baseline 3-4 months after completion of SBRT treatment|Acute and subacute radiation-induced lung injury 3 months after completion of SBRT treatment|Feasibility of integrating 4D-CT ventilation imaging with DCE-MRI perfusion imaging in characterizing subacute (3 months) radiation-induced lung injury after SBRT","Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","12-004","April 2012","April 2019","December 2019","February 26, 2013","null","August 15, 2018","Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01799135"
1648,"NCT01798693","Nutritional Supplementation Effects on Rehabilitation Outcomes in Rotator Cuff Pathology",,"Terminated","No Results Available","Rotator Cuff/Shoulder Structure and Function","Dietary Supplement: Placebo (maltodextrin)|Dietary Supplement: Multi-nutrient Blend","Change in shoulder function, pain, strength and range of motion","University of North Carolina, Chapel Hill","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ORB-12-2374","August 2013","August 2014","August 2014","February 26, 2013","null","May 13, 2015","UNC Orthopedics and Exercise and Sport Medicine, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01798693"
1649,"NCT01796951","Low Dose Aspirin Inhibition of COX-2 Derived PGE2 in Male Smokers",,"Completed","No Results Available","Tobacco Use Disorder|Smoking","Drug: Aspirin 325 mg daily|Drug: Celecoxib 200 mg BID","Change in COX-2 dependent urinary PGE-M (ng/mg Cr) production after 16 days of aspirin treatment","Vanderbilt University|Vanderbilt University Medical Center","Male","35 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","VR5137","February 2013","February 2016","February 2016","February 22, 2013","null","April 4, 2017","Vanderbilt University, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT01796951"
1650,"NCT01796041","Intraoperative Imaging of Breast Cancer With Indocyanine Green","ICG","Completed","No Results Available","Invasive Ductal Carcinoma|Invasive Lobular Carcinoma|Ductal Carcinoma","Drug: Indocyanine Green","Identification|Evaluation","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","UPCC 12111|813695","July 2011","November 9, 2016","November 9, 2016","February 21, 2013","null","February 5, 2018","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01796041"
1651,"NCT01794026","Diffusion Weighted Magnetic Resonance Imaging for Preoperative Staging in Gastric Adenocarcinoma Patients",,"Completed","No Results Available","Gastric Adenocarcinoma","Procedure: diffusion weighted magnetic resonance imaging","efficacy of diffusion weighted magnetic resonance imaging to detect benign and malignant lymph nodes","Bezmialem Vakif University","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","DWMRIGASTADENO","March 2013","December 2013","December 2013","February 18, 2013","null","March 1, 2017","Bezmialem Vakif University Faculty of Medicine Dept of General Surgery, Istanbul, Turkey","","https://ClinicalTrials.gov/show/NCT01794026"
1652,"NCT01793948","Metformin Hydrochloride vs. Placebo in Overweight or Obese Patients at Elevated Risk for Breast Cancer",,"Completed","No Results Available","Breast Cancer|Obesity","Drug: metformin hydrochloride|Other: placebo|Other: laboratory biomarker analysis","Changes in the phosphorylation of proteins after metformin exposure|Changes in ordinal level of breast density|Proportion of patients experiencing adverse events assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0","Anna Maria Storniolo|National Cancer Institute (NCI)|Indiana University","Female","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","24","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","IUCRO-0365|NCI-2013-00422|1301010355","April 16, 2013","January 9, 2018","January 9, 2018","February 18, 2013","null","March 30, 2018","Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States","","https://ClinicalTrials.gov/show/NCT01793948"
1653,"NCT01791816","Mechanisms of Vasovagal Syncope",,"Active, not recruiting","No Results Available","Vasovagal Syncope|Postural Tachycardia Syndrome","Drug: Phenylephrine|Drug: L-Ng-monomethyl Arginine (L-NMMA)","Heart rate and blood pressure in response to Lower Body Negative Pressure(LBNP)|Adrenergic neurotransmission as measured by Muscle Sympathetic Nerve Activity(MSNA), doppler ultrasound blood flow, venous Norepinephrine in response to Phenylephrine infusion","New York Medical College","All","14 Years to 29 Years   (Child, Adult)","Early Phase 1","90","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1R01HL112736-01A1","February 2013","February 2019","February 2019","February 15, 2013","null","July 19, 2018","New York Medical College/Bradhurst Building, Hawthorne, New York, United States","","https://ClinicalTrials.gov/show/NCT01791816"
1654,"NCT01788436","A Study to Assess Learning Performance in Patients With Schizophrenia and Young and Elderly Healthy Volunteers",,"Completed","No Results Available","Schizophrenia","Behavioral: Cognitive Test Battery 1|Behavioral: Cognitive Test Battery 2","Measurement of implicit and explicit learning through cognitive testing over a period of 7 days|Incidence of Adverse Events","Janssen Research & Development, LLC","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","51","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","CR100911|NOCOMPOUNDEDI0004","November 2012","May 2014","May 2014","February 11, 2013","null","June 17, 2014","Duffel, Belgium","","https://ClinicalTrials.gov/show/NCT01788436"
1655,"NCT01787318","Effect of the InsuPatch on Automated Closed-loop Glucose Control in Type 1 Diabetes","IPCL","Completed","No Results Available","Type 1 Diabetes","Device: ePID closed loop system|Device: InsuPatch","Peak Post-Prandial Glucose Excursions|Total Area Under Curve of the meal-related glucose excursion over target|Nadir glucose levels following the meals|Mean 24 hour glucose levels|Mean daytime and nighttime glucose levels|Peak post-prandial insulin levels following meals|Area Under Curve meal-related insulin excursion following meals","Yale University","All","12 Years to 40 Years   (Child, Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIC # 1208010682","January 2013","September 2014","December 2015","February 8, 2013","null","April 14, 2016","Yale University School of Medicine, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01787318"
1656,"NCT01784042","Dietary Energy Restriction and Omega-3 Fatty Acids on Mammary Tissue",,"Withdrawn","No Results Available","Breast Cancer","Drug: Placebo|Drug: Lovaza|Other: Dietary energy restriction","Ki67 expression","Milton S. Hershey Medical Center","Female","30 Years to 55 Years   (Adult)","Early Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PSHCI 12-075","March 2013","March 2017","March 2018","February 5, 2013","null","May 9, 2017","Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01784042"
1657,"NCT01783119","Effect of Aloe Vera in the Inflammation of Patients With Mild Ulcerative Colitis","AVIUC","Unknown status","No Results Available","Ulcerative Colitis","Dietary Supplement: Aloe Barbadensis Miller|Dietary Supplement: placebo water","Full Mayo Score|Interleukine - 6","National Institute of Medical Sciences and Nutrition, Salvador Zubiran","All","18 Years to 59 Years   (Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","REF.589","August 2012","December 2013","December 2014","February 4, 2013","null","February 4, 2013","National Institute of Medical Science and Nutrition, Salvador Zubirán, D.f., Tlalpan, Mexico","","https://ClinicalTrials.gov/show/NCT01783119"
1658,"NCT01783054","Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas",,"Terminated","Has Results","Adenocarcinoma Pancreas","Procedure: Surgery|Genetic: Genetic Expression|Drug: Chemotherapy","Tumor Response|Number of Participants With R0 Resection Status.|Estimate Median Time to Recurrence.|Estimate Median Overall Survival|Number of Adverse Events Reported in Subjects Enrolled.","Medical University of South Carolina","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","101826","July 2012","October 2015","null","February 4, 2013","November 9, 2015","March 8, 2016","Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT01783054"
1659,"NCT01782248","Self-consciousness in Dementia",,"Unknown status","No Results Available","Alzheimer Disease|Fronto-temporal Lobar Dementia","Other: Questionnary and IRM","Characterize the deficit in critical components of personal identity in patients with Alzheimer's disease (AD) and fronto-temporal lobar dementia (FTLD), compared to healthy elderly, combining a neuropsychology and multi-podal neuroimaging study.","University Hospital, Strasbourg, France","All","45 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","65","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","5289","February 2013","October 2015","October 2015","February 1, 2013","null","February 1, 2013","Hôpitaux Universitaires de Strasbourg, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT01782248"
1660,"NCT01781741","Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer",,"Active, not recruiting","No Results Available","Recurrent Non-small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer","Combination Product: therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT)|Other: quality-of-life assessment","Portion of patients with grade 3 or greater toxicity assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4|Time until chemotherapy|Incidence of toxicity associated with combining TEMLA with or without minimally invasive surgery stratified by chemotherapy regimens|Overall survival|Quality of life (QoL) scores from European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 and EORTC QLQ Lung Cancer-Specific Module","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 223812|NCI-2013-00055|P30CA016056","March 6, 2013","November 30, 2015","October 15, 2018","February 1, 2013","null","August 3, 2018","Roswell Park Cancer Institute, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT01781741"
1661,"NCT01780337","Oxytocin Effects on Cardiac Electrophysiology",,"Completed","Has Results","Cardiac Arrhythmia","Drug: Oxytocin|Other: Saline","Change in Electrophysiology Measure of AH Interval|Change in Electrophysiology Measure of HV Interval|Change in Electrophysiology Measure of Right Ventricular Refractory Period","William Whang|Columbia University","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AAAC7383","January 2013","May 2016","May 2016","January 31, 2013","June 17, 2016","July 21, 2016","Columbia University Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01780337"
1662,"NCT01779128","PET-CT vs. Integrated MR-PET Scanning of GYN Cancers",,"Unknown status","No Results Available","Cervical Cancer|Endometrial Cancer|Ovarian Cancer","Procedure: PET-CT|Procedure: MR-PET","Evaluate Diagnostic Sensitivity and Specificity of Preoperative MR/PET vs. PET/CT|Evaluate Diagnostic Sensitivity and Specificity of Preoperative MR/PET vs. FDG-PET/CT|Evaluate Additive Diagnostic Value of MRI Fusion|Determine Percentage of Participants in Whom MR/PET (relative to PET/CT) Detects Biopsy Proven Disease","Massachusetts General Hospital","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","12-233","March 2013","March 2015","null","January 30, 2013","null","January 30, 2013","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01779128"
1663,"NCT01778933","Intraoperative Imagery of Renal Nodules With Folate-fluorescein Conjugate(EC17)",,"Completed","No Results Available","Renal Cell Carcinoma","Drug: EC17","The ability of EC17 and the imaging system to detect FRA positive tumors during surgery conducted 2-4 hours post EC-17 administration.|The number of participants that will have an adverse reaction to the EC17","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","EC17 Renal Cell|816726","May 2013","September 2014","September 2014","January 29, 2013","null","July 3, 2018","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01778933"
1664,"NCT01778751","Advanced Comprehensive Diabetes Care for Veterans With Poorly-Controlled Diabetes","ACDC","Completed","Has Results","Diabetes","Behavioral: Home Telehealth with Behavioral Education Component","Diabetes Control|Diabetes Self Care|Self-reported Medication Adherence|Depressive Symptoms","VA Office of Research and Development","All","Child, Adult, Older Adult","Early Phase 1","50","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","RRP 12-458","December 2013","December 2014","December 2014","January 29, 2013","January 25, 2016","January 25, 2016","Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01778751"
1665,"NCT01775020","Dose-response Study of Arginine Supplementation in Severe Sepsis",,"Completed","No Results Available","Sepsis|Septic Shock","Dietary Supplement: L-arginine","Nitric oxide synthesis|hemodynamics|blood parameters|gastric perfusion","Maastricht University Medical Center|Novartis Medical Nutrition","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","MEC03-139.5","October 2003","May 2004","May 2012","January 24, 2013","null","January 29, 2013","","","https://ClinicalTrials.gov/show/NCT01775020"
1666,"NCT01775007","A Pilot Study to Test the Safety and Feasibility of a Brillouin Ocular Analyzer","Brillouin I","Unknown status","No Results Available","Measurement of the Elasticity of the Anterior Eye Segment","Device: Brillouin Ocular Analyser","Number of patients with adverse events|Sensitivity and accuracy of Brillouin modulus measurement.","Massachusetts General Hospital","All","20 Years to 60 Years   (Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2008-P-002176/10","March 2011","January 2014","January 2014","January 24, 2013","null","January 24, 2013","Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01775007"
1667,"NCT01773317","Can Neuromuscular Training Alter Movement Patterns",,"Active, not recruiting","No Results Available","Acute Injury of Anterior Cruciate Ligament","Other: Perturbation|Other: Control","Changes in gait patterns from baseline to completion of intervention (approximately 6 months after surgery), 1 year after anterior cruciate ligament reconstruction and 2 years after anterior cruciate ligament reconstruction|Quadriceps Strength|Patient reported outcomes (Knee Outcomes Survey-Activity of Daily Living Scale, Global Rating Score of Perceived Knee Function, Knee Injury and Osteoarthritis Outcome Score, International Knee Documentation Committee 2000 Subjective Knee Form)|Single-legged hop measures","Lynn Snyder-Mackler|University of Delaware","All","13 Years to 55 Years   (Child, Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","225014-1","November 2011","August 2018","August 2018","January 23, 2013","null","October 25, 2017","University of Delaware, Physical Therapy Department, Newark, Delaware, United States","","https://ClinicalTrials.gov/show/NCT01773317"
1668,"NCT01772303","Safety and Efficacy Study of HO/03/03 10-40 Micro Grams to Treat Hard to Heal Wounds","H2H","Unknown status","No Results Available","Hard to Heal Wounds","Drug: HO/03/03 10-40 µg","Time to Heal|Wound closure","HealOr","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HO-H2H-01-2011","January 2013","August 2013","December 2013","January 21, 2013","null","April 4, 2013","Maccabi Health Services, Wound Clinic, Haifa, Israel","","https://ClinicalTrials.gov/show/NCT01772303"
1669,"NCT01771224","Effect of FAn-7 in UC Activity","FAUC","Unknown status","No Results Available","Inflammatory Bowel Disease|Ulcerative Colitis","Dietary Supplement: Palmitoleic acid","clinical and endoscopic remission|quantification IL-6 in colonic mucosa","National Institute of Medical Sciences and Nutrition, Salvador Zubiran","All","18 Years to 59 Years   (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","REF453","January 2013","December 2013","December 2014","January 18, 2013","null","January 18, 2013","INCMNSZ, DF, Tlalpan, Mexico","","https://ClinicalTrials.gov/show/NCT01771224"
1670,"NCT01770626","A Pilot Study to Determine Nutrition Status in Glioblastoma Multiforme Patients","BEAM","Completed","No Results Available","Brain Cancer","Other: Nutrition","To evaluate the use of Bioelectrical Impedance Analysis as a clinical assessment tool in Glioblastoma Multiforme patients|To compare estimated caloric needs determined by BIA and Harris Benedict Equation to Resting Energy Expenditure from Indirect Calorimetry","University of Alabama at Birmingham","All","19 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","UAB 1106","April 2011","July 2013","June 2014","January 18, 2013","null","October 28, 2014","University of Alabama at Birmingham, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT01770626"
1671,"NCT01768065","Nasal Expiratory Positive Airway Pressure for the Treatment of Pediatric Obstructive Sleep Apnea Syndrome",,"Completed","No Results Available","Organic Pediatric Obstructive Sleep Apnea","Device: Nasal Expiratory Positive Airway Pressure Device|Device: placebo sham","Apnea hypopnea index|Adherence using daily logs","Children's Hospital of Philadelphia","All","5 Years to 16 Years   (Child)","Early Phase 1","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","12-008691","July 2012","April 2013","April 2013","January 15, 2013","null","June 19, 2013","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01768065"
1672,"NCT01766544","Asthma & COPD Guideline Implementation",,"Terminated","No Results Available","Asthma|Chronic Obstructive Pulmonary Disease","Other: Standard Practice Group (SPG)|Other: TISG","Physician Assessment Questionnaire-Asthma|The Physician Practice Assessment Questionnaire","Laval University|GlaxoSmithKline|Canadian Lung Association","All","Child, Adult, Older Adult","Early Phase 1","92","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","GIPC","September 2009","March 2010","March 2010","January 11, 2013","null","January 11, 2013","Institut universitaire de cardiologie et de pneumologie de Québec, Québec, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT01766544"
1673,"NCT01765803","Feasibility of Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells",,"Terminated","Has Results","Healthy Subjects","Drug: Mellaril","CD34+ Progenitor Cell Mobilization|Toxicity","New Mexico Cancer Care Alliance|Oxnard Foundation","All","18 Years to 55 Years   (Adult)","Early Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","INST 1208","June 2013","November 2013","December 2013","January 10, 2013","July 20, 2015","April 14, 2016","University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States","","https://ClinicalTrials.gov/show/NCT01765803"
1674,"NCT01764451","Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins",,"Completed","No Results Available","Cavernous Angioma, Familial|Cerebral Cavernous Malformations|Cerebral Cavernous Hemangioma","Drug: Simvastatin","Change in blood brain barrier permeability over three months for the treatment group compared to the control group.|Correlation of physiologic permeability data with anatomic lesion data","University of New Mexico|National Institute of Neurological Disorders and Stroke (NINDS)|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","BVMC 6205|U54NS065705","March 2012","January 2016","January 2016","January 9, 2013","null","April 11, 2016","University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States","","https://ClinicalTrials.gov/show/NCT01764451"
1675,"NCT01763541","Study of the Effect of Testosterone and Estradiol on NP Responses to Acute and Chronic Salt Loading",,"Withdrawn","No Results Available","Hypertension","Drug: leuprolide acetate|Drug: Anastrozole","NP levels in men with testosterone patch and low-salt diet|NP levels in men with testosterone patch and high-salt diet|NP levels in women with estradiol patch and low-salt diet|NP levels in women with estradiol patch and high-salt diet|NP levels in men with placebo patch and low-salt diet|NP levels in men with placebo patch and high-salt diet|NP levels in women with placebo patch and low-salt diet|NP levels in women with placebo patch and high-salt diet|Plasma Renin Activity (PRA) levels in women on estradiol on low-salt diet|Aldosterone levels in men with testosterone on low-salt diet|Plasma Renin Activity (PRA) levels in women on estradiol on high-salt diet|Plasma Renin Activity (PRA) levels in women on placebo on low-salt diet|Plasma Renin Activity (PRA) levels in women on placebo on high-salt diet|Plasma Renin Activity (PRA) levels in men on testosterone on low-salt diet|Plasma Renin Activity (PRA) levels in men on testosterone on high-salt diet|Plasma Renin Activity (PRA) levels in men on placebo on low-salt diet|Plasma Renin Activity (PRA) levels in men on placebo on high-salt diet|Aldosterone levels in men on testosterone on high-salt diet|Aldosterone levels in men on placebo on high-salt diet|Aldosterone levels in men on placebo on low-salt diet|Aldosterone levels in women on estradiol on high-salt diet|Aldosterone levels in women on estradiol on low-salt diet|Aldosterone levels in women on placebo on high-salt diet|Aldosterone levels in women on placebo on low-salt diet|Urinary sodium concentration in women on estradiol on high-salt diet|Urinary sodium concentration in women on placebo on high-salt diet|Urinary sodium concentration in men on testosterone on high-salt diet|Urinary sodium concentration in men on placebo on high-salt diet","Massachusetts General Hospital","All","18 Years to 40 Years   (Adult)","Early Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","2012P002337","June 2014","February 2016","February 2016","January 9, 2013","null","October 19, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01763541"
1676,"NCT01763437","Intralesional Tetracycline Injection in the Treatment of Chalazia","TET","Withdrawn","No Results Available","Chalazia|Chalazion","Drug: Tetracycline","Lesion size","The Cleveland Clinic","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","TET2013","March 2014","March 2015","March 2015","January 8, 2013","null","January 12, 2017","Cleveland Clinic Cole Eye Institute, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01763437"
1677,"NCT01760226","Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies","DA-EPOCH-R","Completed","No Results Available","Diffuse Large B Cell Lymphoma|Post Transplant Lymphoproliferative Disorder|Primary Mediastinal (Thymic) Large B-cell Lymphoma","Drug: DA-EPOCH-R for DLBCL, PTLD, AND PMBCL|Drug: Methotrexate|Drug: Etoposide|Drug: Doxorubicin|Drug: Vincristine|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Prednisone|Drug: G-CSF","Measure and assess adverse events|Measure and assess immune function","Baylor College of Medicine|National Cancer Institute (NCI)|Texas Children's Hospital","All","up to 21 Years   (Child, Adult)","Early Phase 1","4","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-30759, DA-EPOCH-R|DA-EPOCH-R|5K12CA090433-12","January 2013","August 26, 2016","December 2016","January 4, 2013","null","November 17, 2017","Texas Children's Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01760226"
1678,"NCT01755650","Phase 0 of 18F FPM Using PET/CT in Patients With a Variety of Malignancies",,"Unknown status","No Results Available","Squamous Cell Carcinoma","Radiation: 18F FPM","Safety of D-18F FPM and L-18F FPM administration as measured by occurrence of adverse clinical, biochemical or haematological events following 18F FPM administration|Percentage of injected D-18F FPM and L-18F FPM dose in organs of interest.|Percentage of unmetabolized D-18F FPM and L-18F FPM in plasma and urine after radiotracer administration.|Absorbed organ doses expressed as micro Sv/MBq of administered D-18F FPM and L-18F FPM, and whole body dose expressed as milliSv/200MBq of administered dose","Cooperative Research Centre for Biomedical Imaging Development","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","11/31","October 2011","January 2013","July 2013","December 24, 2012","null","December 24, 2012","Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia","","https://ClinicalTrials.gov/show/NCT01755650"
1679,"NCT01754831","Fluoride Administered and Retained After Topical Fluoride Varnish",,"Completed","No Results Available","Healthy","Device: Fluoride varnish","Urinalysis for fluoride levels","University of Washington","All","12 Months to 15 Months   (Child)","Early Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","41117","December 2011","March 2013","December 2013","December 21, 2012","null","May 7, 2018","UW Center for Pediatric Dentistry, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT01754831"
1680,"NCT01754571","CBT in Patients With Medication Overuse Headache",,"Unknown status","No Results Available","Medication Overuse Headache","Behavioral: Cognitive behavior therapy","","Far Eastern Memorial Hospital","All","20 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","101041-E","July 2012","June 2013","June 2013","December 21, 2012","null","December 21, 2012","Far Eastern Memorial Hospital, New Taipei City, Taiwan","","https://ClinicalTrials.gov/show/NCT01754571"
1681,"NCT01751529","Open-label Pilot Evaluating Renal Lesions w/ Contrast-enhaced US in Patients w/ Renal Cancer",,"Completed","No Results Available","Kidney Cancer","Procedure: Contrast-enhanced Ultrasound|Drug: Perflutren lipid","Feasibility of using contrast-enhanced ultrasound in diagnosing renal malignancy in patients with known renal disease (Cohort 1) and in patients with a risk factor for renal malignancy diagnosed with suspicious or indeterminate lesions (Cohort 2)|Feasibility of comparing the sensitivity and specificity of contrast enhanced ultrasound to traditional imaging techniques (CT and MRI) in detecting renal lesions in patients already diagnosed with a renal malignancy","UNC Lineberger Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","48","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","LCCC 1219","May 2013","November 2015","November 2015","December 18, 2012","null","March 17, 2017","Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01751529"
1682,"NCT01748747","Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery",,"Completed","No Results Available","Recurrent Melanoma|Stage IIA Melanoma|Stage IIB Melanoma|Stage IIC Melanoma|Stage IIIA Melanoma|Stage IIIB Melanoma|Stage IIIC Melanoma|Stage IV Melanoma","Drug: Montanide ISA 51 VG|Biological: MART-1 antigen|Other: laboratory biomarker analysis|Biological: Gag:267-274 peptide vaccine|Drug: resiquimod","Immune response of each vaccination regimen, defined as a 2-fold or more increase from pre-treatment levels in the frequency of vaccine peptide-specific CTL as measured by tetramer staining|Disease-free survival|Incidence of adverse events, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC0972|NCI-2012-01610","October 2012","December 14, 2014","March 30, 2017","December 12, 2012","null","October 8, 2018","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01748747"
1683,"NCT01748149","Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas",,"Active, not recruiting","No Results Available","Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas","Drug: Vemurafenib","Maximum tolerated dose (MTD)/Recommended Phase 2 Dose (RP2D)|Toxicity Profile (dose limiting toxicities)|Concentrations of vemurafenib in the blood found through pharmacokinetic (PK) samples|Objective Response|Intra-tumoral drug concentration Comparison|Progression-free survival","University of California, San Francisco|Genentech, Inc.","All","up to 25 Years   (Child, Adult)","Early Phase 1","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC #120819|NCI-2014-00387","February 2014","January 2019","June 2020","December 12, 2012","null","November 12, 2018","Children's Hospital Los Angeles, Los Angeles, California, United States|Mattel Children's Hospital UCLA, Los Angeles, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|UCSF Medical Center-Mount Zion, San Francisco, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Minnesota/Masonic Children's Hospital, Minneapolis, Minnesota, United States|Saint Louis Children's Hospital, Saint Louis, Missouri, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|Hospital for Sick Children, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01748149"
1684,"NCT01747928","Users Study Of The Caverject Delivery System",,"Completed","Has Results","Healthy","Other: dual-chamber syringe","Delivery System Success Rate (DSSR)|Number of Participants With Categorical Responses to the Participant Assessment Tool (PAT): Instructions Provided Were Useful?|Number of Participants With Categorical Responses to the PAT: Instructions Provided Were Clear?|Number of Participants With Categorical Responses to the PAT: Most Difficult Step?|Number of Participants With Categorical Responses to the PAT: Syringe Easy to Use?|Number of Participants Providing Responses to Any Question on the PAT|Time Required to Perform Segments 1 to 5|Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q1|Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q2|Number of Participants Whom the Observer Had Categorical Responses to in the OAT: Q3|Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q4|Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q5|Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q6|Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q7|Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q8|Number of Participants Whom the Observer Had Categorical Responses to in the OAT: Q9|Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q10|Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q11|Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q12|Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q13|Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q14b|Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q16|Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q17","Pfizer","Male","40 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","48","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)","A6711036","March 2013","March 2013","March 2013","December 12, 2012","May 2, 2014","May 2, 2014","Vince and Associates Clinical Research, Overland Park, Kansas, United States","","https://ClinicalTrials.gov/show/NCT01747928"
1685,"NCT01747590","Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T",,"Unknown status","No Results Available","Psychotropic Drugs Effects","Drug: Zolpidem|Drug: Alprazolam|Drug: Caffeine|Other: Placebo","Change in blood oxygen level-dependent (BOLD) signal as measured with fMRI|Change in subjective drug effects as measured by self-report questionnaires","Mclean Hospital|National Institute on Drug Abuse (NIDA)","All","21 Years to 40 Years   (Adult)","Early Phase 1","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","2011P000058|K01DA023659","July 2011","December 2013","December 2013","December 11, 2012","null","December 11, 2012","McLean Hospital, Belmont, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01747590"
1686,"NCT01744964","Apomorphine Effects on Experimental Pain",,"Completed","No Results Available","Healthy","Drug: Apomorphine","Cold pain tolerance","Rambam Health Care Campus","All","18 Years to 40 Years   (Adult)","Early Phase 1","105","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","0078-09-RBM","July 2009","July 2011","July 2011","December 7, 2012","null","September 16, 2016","Rambam Health Care Campus, Haifa, Israel","","https://ClinicalTrials.gov/show/NCT01744964"
1687,"NCT01743924","Bioavailability of Chemopreventive and Nutritional Compounds in Broccoli",,"Completed","No Results Available","Bioavailability","Other: raw broccoli","Metabolic fate of ITC of the kailan-hybrid broccoli after human comsuption","Universidad Politécnica de Cartagena|Hospital Universitario Reina Sofia de Cordoba","All","22 Years to 50 Years   (Adult)","Early Phase 1","7","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Screening","Broccoli_Bioav.","July 2011","July 2011","July 2011","December 6, 2012","null","December 6, 2012","Hospital General Universitario Reina Sofía, Murcia, Spain","","https://ClinicalTrials.gov/show/NCT01743924"
1688,"NCT01739192","A Novel Anti-Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence",,"Completed","No Results Available","Cocaine Use Disorders","Drug: Bupropion","Reinforcing Effects|Subjective effects|Physiological and side effects.","Craig Rush|National Institute on Drug Abuse (NIDA)|University of Kentucky","All","18 Years to 55 Years   (Adult)","Early Phase 1","34","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Basic Science","R01DA032254","January 2013","December 2017","June 2018","December 3, 2012","null","June 26, 2018","University of Kentucky Medical Center, Lexington, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT01739192"
1689,"NCT01738815","Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer",,"Unknown status","No Results Available","Hematuria|Bladder Cancer","Drug: Valproic Acid","Thrombospondin-1 gene expression|Angiogenesis, proliferation, and histone deacetylase activity markers","State University of New York - Upstate Medical University","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","256549","December 2011","May 2013","May 2013","November 30, 2012","null","December 13, 2012","SUNY Upstate Medical University, Syracuse, New York, United States","","https://ClinicalTrials.gov/show/NCT01738815"
1690,"NCT01737671","Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study",,"Completed","No Results Available","Brain Tumor|Malignant Neoplasm of Fourth Ventricle of Brain","Procedure: Ommaya Reservoir|Drug: Methotrexate|Drug: Leucovorin","Neurological Deficits After Administration of Methotrexate into the Fourth Ventricle of the Brain","M.D. Anderson Cancer Center","All","up to 22 Years   (Child, Adult)","Early Phase 1","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-0823|NCI-2013-00045","December 27, 2012","January 11, 2018","January 11, 2018","November 29, 2012","null","January 19, 2018","Children's Memorial Hermann Hospital, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01737671"
1691,"NCT01737112","99mTc-3PRGD2 SPECT/CT in Lung Cancer Patients","TcRGDLC","Recruiting","No Results Available","Lung Cancer","Drug: 99mTc-3PRGD2","Visual and semiquantitative assessment of lesions and biodistribution|Adverse events collection","Peking Union Medical College Hospital","All","30 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PUMCHNM05","February 2011","December 2017","December 2017","November 29, 2012","null","April 7, 2017","Department of Nuclear Medicine, Peking Union Medical College Hopital, Chinese Academy of Medical Science, Beijing, China","","https://ClinicalTrials.gov/show/NCT01737112"
1692,"NCT01735942","Ingenol Mebutate Compared to Cryotherapy for the Treatment of Skin Lesions",,"Withdrawn","No Results Available","Actinic Keratosis","Drug: Ingenol mebutate|Procedure: cryotherapy","Change from baseline in visual assessment scores at 3 months","Northwestern University","All","18 Years to 89 Years   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","STU68227","October 2012","May 2016","May 2016","November 28, 2012","null","June 28, 2016","","","https://ClinicalTrials.gov/show/NCT01735942"
1693,"NCT01735643","Lifestyle Intervention With an Interactive Video Game for Type 2 Diabetes Patients",,"Completed","No Results Available","Type 2 Diabetes Mellitus","Device: interactive videogame Wii Fit Plus|Other: waiting","HbA1c|weight","West German Center of Diabetes and Health|Novartis Pharmaceuticals|Nintendo of Europe GmbH","All","50 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","220","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Wii study","January 2011","September 2012","September 2012","November 28, 2012","null","November 28, 2012","West German Center of Diabetes and Health, Düsseldorf, Germany","","https://ClinicalTrials.gov/show/NCT01735643"
1694,"NCT01733680","Amiloride Hydrochloride as an Effective Treatment for ADHD",,"Terminated","Has Results","ADHD","Drug: amiloride|Behavioral: Behavioral","Improvement in CGI|AISRS, Adult ADHD Investigator Rating Scale|The Behavior Rating Inventory of Executive Function-Adult (BRIEF-A)","State University of New York - Upstate Medical University","All","18 Years to 55 Years   (Adult)","Early Phase 1","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","320969","September 2012","September 2015","September 2015","November 27, 2012","July 20, 2018","July 20, 2018","SUNY Upstate Medical University, Syracuse, New York, United States","","https://ClinicalTrials.gov/show/NCT01733680"
1695,"NCT01733576","High-definition Transcranial Direct Current Stimulation (HD-tDCS) Verbal Learning",,"Completed","No Results Available","Verbal Learning and Memory","Device: HD-tDCS","Ray Auditory Verbal Learning Test (RAVLT)","The University of New South Wales","All","18 Years to 40 Years   (Adult)","Early Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","CB64","null","March 2014","null","November 27, 2012","null","July 23, 2015","Black Dog Institute, Sydney, New South Wales, Australia","","https://ClinicalTrials.gov/show/NCT01733576"
1696,"NCT01733355","A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807",,"Terminated","No Results Available","Alzheimers Disease|AD","Radiation: [F18] T807","To evaluate the bio-distribution and radiation dosimetry of [F-18]T807 in participants with low probability of Alzheimer's disease (AD) using PET/CT whole body imaging|To evaluate the metabolism of [F-18]T807 in participants with low probability of AD using serial blood samples collected pre- and post-IP administration|To evaluate [F-18]T807 uptake and signal/background information in brain PET/CT imaging of participants with a high probability of currently being positive for AD and age-matched participants with a low probability of currently being positive for AD|To assess the safety of IV administration of [F-18]T807|To begin collection of baseline [F-18]T807 PET/CT imaging data|To gain information to improve the study design for the conduct of future trials","Avid Radiopharmaceuticals","All","55 Years and older   (Adult, Older Adult)","Early Phase 1","11","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","T807000","July 2012","March 2013","March 2013","November 27, 2012","null","July 19, 2013","Research Site, Irvine, California, United States|Research Site, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01733355"
1697,"NCT01732289","Genetic Study of Age Related Hearing Loss","ARHL","Completed","No Results Available","Age-related Hearing Loss|Presbycusis","Genetic: genes","which gene or Single nucleotide polymorphism is related to age related hearing loss|Which environmental factor(s) or systemic diseases are related to age related hearing loss","National Taiwan University Hospital|National Science Council, Taiwan","All","45 Months and older   (Child, Adult, Older Adult)","Early Phase 1","1000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","200806069R|Taiwan NSC 97-2314-B-002-107","August 2008","July 2009","July 2009","November 22, 2012","null","November 22, 2012","National Taiwna University Hospital, Taipei, Taiwan","","https://ClinicalTrials.gov/show/NCT01732289"
1698,"NCT01731834","Pain and Stress Assessment in Children",,"Completed","No Results Available","Acute Respiratory Infections","Other: Vibrocompression and aspiration of secretions","Assess whether there is pain in children when performed randomized technique|Assess whether there is stress in children during the technical run","Federal University of Uberlandia","All","up to 1 Year   (Child)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","11212PSC014|FUUberlandia","September 2011","November 2013","November 2013","November 22, 2012","null","December 2, 2013","FUUberlândia, Uberlândia, Minas Gerais, Brazil","","https://ClinicalTrials.gov/show/NCT01731834"
1699,"NCT01731236","CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease","CARNIVAL","Enrolling by invitation","No Results Available","Dietary Modification","Dietary Supplement: Carnitine|Dietary Supplement: Choline|Drug: Antibiotics|Drug: Choline and Aspirin|Drug: Carnitine and Aspirin","Primary Outcome Measure|Secondary Outcome Measures:","The Cleveland Clinic","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","10-544","July 2010","June 2020","June 2020","November 21, 2012","null","July 17, 2018","Cleveland Clinic, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01731236"
1700,"NCT01730729","Cabergoline in Metastatic Breast Cancer",,"Active, not recruiting","No Results Available","Recurrent Breast Cancer|Stage IV Breast Cancer","Drug: cabergoline","Determining overall response using imaging scans|Survival Rates|Treatment toxicity as measured by adverse events experienced while on treatment|Change in imaging measurements at baseline and after 2 cycles|Change in prolactin receptor expression measurements at baseline and after 1 cycle|Evaluate biomarkers and correlate with response to therapy","Northwestern University|Lynn Sage Foundation","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 12B06|NCI-2012-02039|STU00071477","November 2012","October 2018","August 2019","November 21, 2012","null","January 9, 2018","Northwestern University, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT01730729"
1701,"NCT01730157","Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases",,"Terminated","No Results Available","Ciliary Body and Choroid Melanoma, Medium/Large Size|Ciliary Body and Choroid Melanoma, Small Size|Extraocular Extension Melanoma|Iris Melanoma|Liver Metastases|Metastatic Intraocular Melanoma|Recurrent Intraocular Melanoma|Stage IV Intraocular Melanoma","Biological: ipilimumab|Radiation: yttrium Y 90 glass microspheres|Other: laboratory biomarker analysis","Number of patients that experience grade 3-4 toxicity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)|Number of patients with an overall response of liver metastasis according to Response Evaluation Criteria in Solid Tumors (RECIST)|Overall survival|Progression-free (PFS) survival according to Response Evaluation Criteria in Solid Tumors (RECIST)","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","6","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE1612|NCI-2012-02203","December 2012","February 2016","February 2016","November 21, 2012","null","March 10, 2016","Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01730157"
1702,"NCT01729598","Valproic Acid in Subjects With Intact Cognition - Proof of Concept Study","VPA","Completed","No Results Available","Alzheimer's Disease","Drug: Valproic Acid|Drug: Placebo","Frequency of adverse events|Change in cerebrospinal fluid amyloid levels|Change in cerebrospinal fluid tau levels|Cognitive tests|Change in cerebrospinal fluid clusterin levels","University of Kentucky|Kentucky Alzheimer's Center","All","65 Years to 90 Years   (Older Adult)","Early Phase 1","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","12-0068-F6A","April 2012","October 2014","October 2014","November 20, 2012","null","February 18, 2015","Sander's Brown Center on Aging, Lexington, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT01729598"
1703,"NCT01729026","A Study of Dog Adoption in Veterans With Posttraumatic Stress Disorder (PTSD)","VITAL","Completed","Has Results","Posttraumatic Stress Disorder (PTSD)","Other: Shelter Dog Adoption","Change in PTSD Checklist (PCL-5) Score Between Baseline and 3-month Follow-up|Clinician-Administered PTSD Scale for DSM-5 (CAPS)|Alcohol Use Disorders Identification Test (AUDIT-C)|Beck Depression Inventory - II (BDI-II)|Community Integration Questionnaire (CIQ)|MINI International Neuropsychiatric Inventory (MINI)|Patient Health Questionnaire-9 (PHQ-9)|Physical Activity Questionnaire (PAQ)|Pittsburgh Sleep Quality Inventory With PTSD Addendum (PSQI-A)|Semi-Structured Interview|UCLA Loneliness Scale, Version 3|Veterans RAND 12-item Health Survey (VR-12)|Numeric Rating Scale for Pain Intensity","VA Office of Research and Development|The University of Texas Health Science Center at San Antonio","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","19","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","D0809-P","October 2013","December 2014","March 2015","November 20, 2012","April 27, 2016","April 27, 2016","South Texas Health Care System, San Antonio, TX, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT01729026"
1704,"NCT01728909","Methadone Oxytocin Option","MOO","Completed","No Results Available","Substance Abuse|Opioid Dependence|Methadone Treatment","Drug: Oxytocin|Drug: Saline Nasal Spray","Computerized Social Cognition Tasks|Craving Questionnaires","University of California, San Francisco|San Francisco Veterans Affairs Medical Center","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","64","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11-07691","May 2012","October 2014","October 2014","November 20, 2012","null","October 18, 2018","San Francisco VA Medical Center, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT01728909"
1705,"NCT01727544","Vestibular Function Outcome After Cartilage Cap Occlusion Surgery",,"Withdrawn","No Results Available","Vestibular Dizziness|Superior Semicircular Canal Dehiscence","Procedure: cartilage cap occlusion surgery","objective improvement|ABC Scale|VAS scores","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-001953","August 2012","August 2013","August 2013","November 16, 2012","null","February 12, 2014","","","https://ClinicalTrials.gov/show/NCT01727544"
1706,"NCT01726153","A Pilot Trial of an Individualized Web-Based Condom Use Intervention",,"Unknown status","No Results Available","HIV","Behavioral: Condom-HIM","Change from Baseline in participants self-efficacy in condom use at 2-weeks post-intervention|Change from Baseline in participants intention to use condoms at 2-weeks post-intervention","Centre hospitalier de l'Université de Montréal (CHUM)","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R0018767","November 2012","November 2013","November 2013","November 14, 2012","null","November 14, 2012","Ryerson University, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01726153"
1707,"NCT01725048","Pilot Study to Evaluate Individualized Choice of Antidepressants in Patients With Cancer","NRR","Completed","No Results Available","Major Depressive Disorder|Neoplasms","Drug: Mirtazapine|Drug: Citalopram","Feasibility|Depression Score","UNC Lineberger Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","21","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","LCCC 1021","January 2011","May 2012","October 2013","November 12, 2012","null","March 13, 2017","University of North Carolina Hospital, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01725048"
1708,"NCT01724619","Update and Biodistribution of [F-18]FMDHT pET/CT in Normal Healthy Volunteers and Patients With Metastatic Prostate Cancer - A First in Human Subject Study With [F-18] FMDHT",,"Terminated","No Results Available","Prostate Cancer","Drug: [F-18] fluorinated dihydrotestosterone (FDHT)","To map diffusion and clearance rates of this marker in normal and cancerous tissue.|To determine if [F-18]FMDHT PET/CT uptake in the primary prostate tumor can be differentiated from normal surrounding prostate that will be confirmed with pathologic staining of biopsy or surgical specimens.","Wake Forest University Health Sciences","Male","30 Years and older   (Adult, Older Adult)","Early Phase 1","7","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00015971|CCCWFU 85111","November 2012","March 2013","March 2013","November 12, 2012","null","July 3, 2018","Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01724619"
1709,"NCT01723488","A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808","T808","Terminated","No Results Available","Alzheimers Disease","Radiation: [F18] T808","To monitor and assess the safety of IV administration of [F-18]T808|To begin collection of baseline [F-18]T808 PET/CT imaging data","Avid Radiopharmaceuticals","All","55 Years and older   (Adult, Older Adult)","Early Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","T808000","July 2012","March 2013","March 2013","November 8, 2012","null","July 19, 2013","Research Site, Irvine, California, United States|Research Site, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01723488"
1710,"NCT01722916","Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase",,"Active, not recruiting","No Results Available","Drug Safety","Drug: Hyaluronidase","Dose of hyaluronidase injected until the filler is no longer detectable","Northwestern University","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","STU68166","October 2012","December 2018","December 2018","November 7, 2012","null","April 26, 2018","Northwestern University Department of Dermatology, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT01722916"
1711,"NCT01722669","Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States","PK/PD","Active, not recruiting","No Results Available","Healthy","Drug: isoquercetin or quercetin","Pharmacokinetics profile|pharmacokinetic inhibition of PDI|Thrombin generation","Beth Israel Deaconess Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2012P000022","May 2012","December 2018","December 2019","November 7, 2012","null","August 20, 2018","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01722669"
1712,"NCT01719250","Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",,"Completed","No Results Available","Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Mantle Cell Lymphoma|Transformed Recurrent Non-Hodgkin Lymphoma","Drug: Buparlisib|Other: Laboratory Biomarker Analysis|Other: Questionnaire Administration","Clinical benefit defined as a PR or CR as the objective status at any time or an objective status of SD for a duration of greater than 6 months from registration|Duration of response|Overall response rate estimated by the number of confirmed responses (PR or CR) observed in the trial divided by the total number of evaluable patients|Prognostic factors for aggressive lymphoma|Progression-free survival time|Survival time","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","7","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC1183|NCI-2012-01582|P30CA015083","December 2012","September 16, 2016","March 22, 2017","November 1, 2012","null","October 8, 2018","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01719250"
1713,"NCT01719185","The Effect of Phentermine and B12 on Weight Loss Among Obese Patients",,"Completed","No Results Available","Obesity|Hypertension","Drug: Phentermine and B12|Drug: Phentermine","Weight Change|Blood Pressure|Waist Circumference|Waist to hip ratio","Dr. Michael Lang|East Carolina University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12-001323","September 2012","January 2013","April 2013","November 1, 2012","null","August 13, 2015","Brody Outpatient of Brody Medical Sciences Module D, Greenville, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01719185"
1714,"NCT01718431","Prebiotics as a Means to Modulate Gut Fermentation, Metabolism, Appetite and Cognition",,"Completed","No Results Available","Metabolic Syndrome","Other: test meal|Other: reference meal","Area under the plasma concentration versus time curve (AUC) of the test meal|Cognitive performance|Subjective satiety","Lund University","All","50 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","Dnr2010/457 - 3day","October 2010","March 2013","March 2013","October 31, 2012","null","May 8, 2013","Applied Nutrition and Food Chemistry, Lund University, Lund, Sweden","","https://ClinicalTrials.gov/show/NCT01718431"
1715,"NCT01718418","Role of Colonic Events on Metabolism and Appetite Control: A Synbiotic Approach",,"Completed","No Results Available","Obesity|Metabolic Syndrome","Other: test meal|Other: reference","Differences in concentration of risk markers in blood, measured post-prandial after a breakfast meal.|voluntary energy intake|Subjective satiety|Differences in gut microbiota","Lund University","All","20 Years to 35 Years   (Adult)","Early Phase 1","21","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","Dnr2010/457","September 2012","December 2012","December 2012","October 31, 2012","null","May 8, 2013","Applied Nutrition and Food Chemistry, Lund University, Lund, Sweden","","https://ClinicalTrials.gov/show/NCT01718418"
1716,"NCT01716910","Effect of Synbiotic on Composition of Human Gut Microbiota and Production of Short and Branched-chain Fatty Acids",,"Completed","No Results Available","Synbiotics|Healthy Humans|Composition of Gut Microbiota|Short and Branched-chain Fatty Acids","Dietary Supplement: Combination of Lactobacillus acidophilus NCFM and cellobiose","increase in fecal butyrate concentration|changes in composition of microbiota|changes in short-chain fatty acids","University of Copenhagen","All","18 Years to 50 Years   (Adult)","Early Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","DK-H-4-2010-137","March 2011","June 2011","June 2011","October 30, 2012","null","October 30, 2012","Department of Food Science, Food Microbiology, Faculty of Science, University of Copenhagen, Frederiksberg C, Denmark","","https://ClinicalTrials.gov/show/NCT01716910"
1717,"NCT01715142","Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer","NEOPAX-001","Unknown status","No Results Available","Pancreatic Adenocarcinoma Resectable|Pancreatic Adenocarcinoma Locally Advanced|Pancreatic Adenocarcinoma Metastatic","Drug: Gemcitabine|Drug: Abraxane","Dynamic tumor response rate as defined by a 40% modification of tumoral perfusion and cellular density parameters.|Number of participants with adverse events as assessed by National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Effects (CTCAE) V4.0.","Jean-Luc Van Laethem|Celgene Corporation|Erasme University Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","31","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-003592-19","December 2012","June 2014","September 2015","October 26, 2012","null","October 26, 2012","Antwerp University Hospital (UZA), Edegem, Antwerpen, Belgium|Erasme University Hospital (ULB), Brussels, Belgium","","https://ClinicalTrials.gov/show/NCT01715142"
1718,"NCT01713218","Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer","NEOPACHI-001","Unknown status","No Results Available","Pancreatic Adenocarcinoma Resectable","Drug: gemcitabine|Drug: Vismodegib|Procedure: Neoadjuvant chemotherapy","""Dynamic"" tumor response rate as defined by a 20% modification of tumoral perfusion and cellular density parameters.|Number of participants with adverse events as assessed by National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Effects (CTCAE) V4.0.","Jean-Luc Van Laethem|Roche Pharma AG|Erasme University Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-003516-31","December 2012","June 2014","December 2016","October 24, 2012","null","October 24, 2012","Antwerp University Hospital (UZA), Edegem, Antwerpen, Belgium|Erasme University Hospital (ULB), Brussels, Belgium","","https://ClinicalTrials.gov/show/NCT01713218"
1719,"NCT01705288","Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study",,"Completed","No Results Available","Cervical Cancer|Uterine Endometrial Cancer|Ovarian Cancer","Procedure: Laparotomy|Drug: intravenous narcotics|Drug: standard anesthesia|Drug: regional anesthesia|Drug: Non-steroidal anti-inflammatory drugs","Return to Function|Comparison of Pain Assessment|Comparison of Pain Medications Used","Masonic Cancer Center, University of Minnesota","All","19 Years and older   (Adult, Older Adult)","Early Phase 1","112","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2012LS096","January 1, 2013","August 24, 2016","August 24, 2016","October 12, 2012","null","February 10, 2017","Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01705288"
1720,"NCT01704885","A Cognitive- Behavioral Play Intervention for Siblings of Children Diagnosed With Cancer",,"Terminated","No Results Available","Any Cancer Diagnosis","Behavioral: Play Intervention|Other: Questionnaires","Number of children with increase in coping skills after intervention|Number of children with better psychological adjustment following intervention|Number of parents with decreased parenting stress following intervention","Case Comprehensive Cancer Center","All","4 Years to 10 Years   (Child)","Early Phase 1","5","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","CASE4Z11|CC00130","September 2011","July 2015","July 2015","October 12, 2012","null","August 3, 2015","Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01704885"
1721,"NCT01701180","Neural Correlates of Empathogenic and Affiliative Actions of Oxytocin","ODIS","Completed","No Results Available","Healthy","Drug: Oxytocin|Drug: Placebo","Empathy ratings and their neural correlates|Neural correlates of pair-bonding","University Hospital, Bonn","Male","18 Years to 60 Years   (Adult)","Early Phase 1","23","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","OXT-151/12","August 2012","August 2013","August 2013","October 4, 2012","null","December 3, 2014","Department of Psychiatry, University of Bonn, Bonn, North Rhine-Westphalia, Germany","","https://ClinicalTrials.gov/show/NCT01701180"
1722,"NCT01697345","Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy",,"Completed","Has Results","Breast Cancer|Vaginal Dryness|Dyspareunia|Sexual Health Quality of Life","Drug: Testosterone","Total Female Sexual Function Index (FSFI) Score|FSFI Desire Domain|FSFI Arousal Domain|FSFI Lubrication Domain|FSFI Orgasm Domain|FSFI Satisfaction Domain|FSFI Pain Domain|Number of Participants Who Continued Vaginal Testosterone Upon Completion of the Study","Creighton University","Female","50 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MelissaDahir","February 2013","April 2013","May 2013","October 2, 2012","January 24, 2014","January 24, 2014","Nebraska Cancer Specialists/Midwest Cancer Center - Legacy, Omaha, Nebraska, United States","","https://ClinicalTrials.gov/show/NCT01697345"
1723,"NCT01695525","Influence of Yoga in Patients With Neurocardiogenic Syncope","SYNC - YOGA","Completed","No Results Available","Syncope, Vasovagal","Other: Yoga","Change in frequency of recurrent syncopal spells in patients with Neurocardiogenic syncope (NCS)|Change in Heart Health","Dhanunjaya Lakkireddy, MD, FACC|University of Kansas Medical Center","All","18 Years to 60 Years   (Adult)","Early Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12945","June 2012","March 2015","March 2015","September 28, 2012","null","June 30, 2015","University of Kansas Medical Center, Kansas City, Kansas, United States","","https://ClinicalTrials.gov/show/NCT01695525"
1724,"NCT01694589","A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer",,"Withdrawn","No Results Available","Resectable Pancreatic Cancer","Drug: LDE-225","Changes in mean Gli-1 levels before and after drug|Complications from surgery by time of hospital discharge up to 30 days post-operatively","Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|Novartis Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","071108|0220120066|P30CA072720","November 2012","June 2014","July 2014","September 27, 2012","null","December 12, 2014","Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT01694589"
1725,"NCT01693640","A Pilot Study of the Safety and Efficacy of Abatacept Injections in the Treatment of Behcet's Syndrome",,"Active, not recruiting","No Results Available","Female Patients With Behcet's Syndrome","Drug: Abatacept","ulcers|Genital ulcers|Treatment failures|Oral ulcer pain|Side Effects|MDHAQ|BSAS|BDCAF","New York University School of Medicine|Bristol-Myers Squibb","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-02611","June 2012","December 2018","December 2018","September 26, 2012","null","June 7, 2018","NYU Center for Musculoskeletal Care, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01693640"
1726,"NCT01692990","Study on the Effect of Fish Oil and Appetite",,"Completed","No Results Available","Obesity|Cachexia","Dietary Supplement: Fish oil","Appetite and satiation|Weight change","AAstrup|University of Copenhagen","All","18 Years to 35 Years   (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","LL-spec1","October 2011","November 2011","November 2011","September 26, 2012","null","November 12, 2012","Department of Human Nutrition, Frederiksberg, Denmark","","https://ClinicalTrials.gov/show/NCT01692990"
1727,"NCT01688570","Mechanisms of Neuromuscular Fatigue Post Stroke",,"Completed","No Results Available","Stroke","Drug: duloxetine|Drug: Cyproheptadine|Drug: Placebo","Force generation|Surface electromyography (EMG)of lower leg muscles.","Medical College of Wisconsin","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","27","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","UL1RR031973-02","August 2011","May 2015","May 2015","September 20, 2012","null","November 5, 2015","Medical College of Wisconsin, Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT01688570"
1728,"NCT01688440","ETCare: Safety and Preliminary Efficacy Trial",,"Completed","No Results Available","Respiratory Distress Syndrome, Newborn","Other: #1 Respiratory Care Solution","The incidence of adverse events related to administration.|Feasibility and immediate intolerance","Intermountain Health Care, Inc.|Deseret Foundation","All","Child, Adult, Older Adult","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","05.018","June 2005","September 2005","September 2005","September 19, 2012","null","September 19, 2012","McKay-Dee Hospital Center, Ogden, Utah, United States|LDS Hospital Center, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01688440"
1729,"NCT01687959","Timing of Laparoscopic Cholecystectomy After Endoscopic Retrograde Cholangiography for Acute Biliary Pancreatitis",,"Unknown status","No Results Available","Cholelithiasis Associated With Common Bile Duct Stones","Other: tissue sampling from peritoneum of the gallbladder","measurement of peritoneal fibrinolytic response following endoscopic retrograde cholangiography|surgical outcomes of laparoscopic cholecystectomy following endoscopic retrograde cholangiography","Bezmialem Vakif University","All","Child, Adult, Older Adult","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","BEZM-LC-postERCP","September 2012","June 2015","August 2015","September 19, 2012","null","January 28, 2015","department of general surgery; Bezmialem vakif university, Istanbul, Turkey","","https://ClinicalTrials.gov/show/NCT01687959"
1730,"NCT01685762","Metformin for the Treatment of Endometrial Hyperplasia",,"Active, not recruiting","No Results Available","Endometrial Hyperplasia|Endometrial Hyperplasia Without Atypia","Drug: Metformin","Response Rate|Toxicity evaluation|Patient Compliance|Potential molecular markers in response to treatment with Metformin","UNC Lineberger Comprehensive Cancer Center","Female","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC 1205","January 10, 2013","December 1, 2015","December 2018","September 14, 2012","null","November 8, 2018","The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Southern Pines Women's Health Center, Southern Pines, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01685762"
1731,"NCT01684969","Evidence of Haloperidol Absorption After Topical Administration",,"Withdrawn","No Results Available","Nausea|Vomiting","Drug: Haloperidol|Drug: Placebo","To measure the pharmacokinetics levels of haloperidol after topical administration compared with intravenous administration.","Eric E. Prommer|Mayo Clinic","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","11-005661","March 2012","May 2013","May 2013","September 13, 2012","null","March 17, 2016","","","https://ClinicalTrials.gov/show/NCT01684969"
1732,"NCT01684579","Exercising Our ABC's (African- American Breast Cancer Survivors)",,"Completed","No Results Available","Breast Cancer","Behavioral: Resistance Exercise|Behavioral: Aerobic Exercise|Behavioral: Behavioral Group Counseling","Identify factors contributing to or limiting the success of development of the community-academic partnership.|Number of African-American women that participate, comply, adhere and sustain an aerobic and resistance exercise program.|Change in circulating levels of known cancer promoting cytokines, adipokines and hormones and other measurements of fitness and well-being.","Case Comprehensive Cancer Center","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CASE2111","June 2011","August 2012","March 2013","September 13, 2012","null","March 20, 2013","Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01684579"
1733,"NCT01684306","Pharmacological Cognitive Enhancement","MODREST","Completed","No Results Available","Fluid Inteligence|Modafinil|Healthy Young Subjects|Resting State Networks","Drug: Modafinil|Drug: Placebo","Acute effects of modafinil on brain resting state networks in young healthy subjects","Università degli Studi 'G. d'Annunzio' Chieti e Pescara","Male","25 Years to 35 Years   (Adult)","Early Phase 1","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","MODREST_2011","February 2011","April 2011","January 2012","September 12, 2012","null","September 13, 2012","Department of Neuroscience and Imaging, University ""G. d'Annunzio"", Chieti, Italy","","https://ClinicalTrials.gov/show/NCT01684306"
1734,"NCT01683981","Exercise Capacity and Quality of Life in Patients With PPH Receiving Short Term Oral L-Citrulline Malate",,"Unknown status","No Results Available","Idiopathic Pulmonary Arterial Hypertension|Eisenmenger Syndrome","Drug: L-Citrulline Malate","the change in exercise capacity|changes in mean pulmonary-artery pressure","Masih Daneshvari Hospital","All","15 Years to 70 Years   (Child, Adult, Older Adult)","Early Phase 1","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","f-91-138","August 2012","August 2013","August 2013","September 12, 2012","null","August 12, 2013","MasihDH, Tehran, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT01683981"
1735,"NCT01680926","Metabolic Activation With Almased for Type 2 Diabetes Patients","Almased100","Completed","No Results Available","Type 2 Diabetes Mellitus","Dietary Supplement: Almased","insulin demand per day|HbA1c|body weight","West German Center of Diabetes and Health|Almased Wellness GmbH","All","35 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","22","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Almased100","July 2009","February 2011","October 2011","September 7, 2012","null","September 11, 2012","West German Center of Diabetes and Health, Düsseldorf, Germany","","https://ClinicalTrials.gov/show/NCT01680926"
1736,"NCT01680718","Neuropeptides and Social Behavior",,"Completed","No Results Available","Social Psychology","Drug: Intranasal oxytocin|Drug: Intranasal vasopressin|Drug: Intranasal placebo","Speed in social working memory task|Accuracy of deception detection based on self-report|Self-reported perceptions of trust and threat|Self-reported empathy and altruistic behavior","University of California, Los Angeles","All","18 Years to 50 Years   (Adult)","Early Phase 1","160","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Behavioral Neuropeptides","October 2012","September 2013","September 2013","September 7, 2012","null","May 28, 2015","UCLA Department of Psychology, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01680718"
1737,"NCT01680692","Continuous Femoral and Tibial Nerve Blocks in TKA Patients",,"Terminated","No Results Available","Analgesia in Total Knee Arthroplasty","Drug: Ropivicaine|Device: Continuous Femoral Nerve Catheter|Device: Continuous Tibial Nerve Catheter","Post-Operative Analgesia|Foot Drop","Texas Tech University Health Sciences Center, El Paso|Texas Tech University Health Sciences Center","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E12094","August 2012","March 2014","March 2014","September 7, 2012","null","April 25, 2018","University Medical Center of El Paso, Texas Tech University Health Sciences Center, El Paso, Texas, United States","","https://ClinicalTrials.gov/show/NCT01680692"
1738,"NCT01679236","Pilot Study on Mindfulness for Tobacco and Alcohol in University Students",,"Completed","Has Results","Nicotine Dependence|Alcohol Use","Behavioral: Mindfulness Training for Smokers|Behavioral: Interactive Learning for Smokers","Smoking Abstinence|Alcohol Use in Study Subjects vs Controls","University of Wisconsin, Madison|National Institute on Drug Abuse (NIDA)","All","18 Years to 29 Years   (Adult)","Early Phase 1","55","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-2006-0279|P50DA019706-09","September 2006","September 2007","September 2009","September 5, 2012","June 24, 2014","June 24, 2014","University of Wisconsin School of Medicine and Public Health Center for Tobacco Research and Intervention, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT01679236"
1739,"NCT01678690","An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors",,"Completed","No Results Available","Malignant Tumors","Drug: Gemcitabine HCl Oral Formulation","gemcitabine (dFdC) and difluorodeoxyuridine (dFdU) plasma concentration and gemcitabine triphosphate (dFdCTP) concentration in PBMC|the proportion of subjects experiencing adverse events all grades, change from baseline in clinical laboratory test results, vital sign measurements, and physical examination findings","InnoPharmax Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","HR-11-001","August 2012","April 2014","April 2014","September 5, 2012","null","September 2, 2016","Georgia Regents University- Cancer Center, Augusta, Georgia, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Gabrail Cancer Center Research, Dover, Ohio, United States|National Taiwan University Hospital, Taipei, Taiwan","","https://ClinicalTrials.gov/show/NCT01678690"
1740,"NCT01678352","Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas",,"Active, not recruiting","No Results Available","High Risk WHO Grade II Glioma|Recurrent/Post-Chemotherapy WHO Grade II Glioma","Biological: Tumor Lysate Vaccine|Drug: Imiquimod","Dose limiting toxicity (DLT)|Induction of BTIC Lysate-specific T-cell response","Frank Lieberman|University of Minnesota - Clinical and Translational Science Institute|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","27","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-136","October 2012","November 8, 2017","December 2019","September 5, 2012","null","November 12, 2018","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01678352"
1741,"NCT01676792","SR-T100 Gel Efficacy & Safety Study for Vulva Pre-cancerous Lesions & Cutaneous Condyloma",,"Completed","No Results Available","Vulvar Intraepithelial Neoplasia|Genital Warts","Drug: SR-T100 gel with 2.3% of SM in Solanum undatum plant extract","Patients achieve greater than or equal to 75% lesion size reduction|Total clearance rate|Partial clearance rate","National Cheng-Kung University Hospital|G&E Herbal Biotechnology Co., LTD","All","20 Years and older   (Adult, Older Adult)","Early Phase 1","29","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100CT221","April 2011","April 2013","October 2013","August 31, 2012","null","April 22, 2014","National Cheng Kung University Hospital, Tainan, Taiwan","","https://ClinicalTrials.gov/show/NCT01676792"
1742,"NCT01673802","The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma",,"Completed","Has Results","Cholangiocarcinoma","Drug: CT scan","Number of Subjects Where Hilar Cholangiocarcinomas Could be Visualized Using Gadoxetate Disodium Enhanced Dual Energy CT","University of Alabama at Birmingham|Society of Abdominal Radiology","All","19 Years and older   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R11-153|117354","August 2012","January 2014","January 2014","August 28, 2012","June 20, 2014","June 1, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT01673802"
1743,"NCT01672255","Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)",,"Recruiting","No Results Available","Type 1 Diabetes|Hypoglycemia Associated Autonomic Failure","Drug: Fluoxetine|Drug: Placebo control","Change in Catecholamines","University of Maryland|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 45 Years   (Adult)","Early Phase 1","64","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HP-00044537; SSRI and Exercise","October 2012","December 2018","December 2018","August 24, 2012","null","January 11, 2018","University of Maryland, Baltimore, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01672255"
1744,"NCT01671189","Automated SMS-Based Appointment Validation Tool",,"Unknown status","No Results Available","Diabetes Mellitus Type 2|Adult-onset Diabetes","Other: SMS Reminder Software Tool","Glycemic Control (hemoglobin A1c)|Appointment Adherence Rate","Medic Mobile|San Mateo Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","300","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","SMMC-MCK-2012","October 2012","October 2013","December 2013","August 23, 2012","null","August 23, 2012","San Mateo Medical Center, San Mateo, California, United States","","https://ClinicalTrials.gov/show/NCT01671189"
1745,"NCT01671150","Inflammation-Induced Depressed Mood: The Role of Social Neurocognitive Mechanisms",,"Completed","No Results Available","Depression","Drug: endotoxin","Change in depressed mood from baseline|Neural activity to negative and positive social feedback","University of California, Los Angeles|National Institute of Mental Health (NIMH)","All","18 Years to 50 Years   (Adult)","Early Phase 1","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Endotoxin 2|R01MH091352","March 2011","August 2013","August 2013","August 23, 2012","null","June 18, 2014","UCLA Clinical & Translational Research Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01671150"
1746,"NCT01670799","Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer",,"Active, not recruiting","No Results Available","Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer","Drug: Ketorolac","Measure levels of Ketorolac in peritoneal cavity|Measure effect of IV Ketorolac on ovarian cancer cell adhesion and migration","New Mexico Cancer Care Alliance","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","INST 1115|NCI-2012-00917","March 2012","December 2015","December 2018","August 22, 2012","null","June 4, 2018","University of New Mexico Cancer Center, Albuquerque, New Mexico, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT01670799/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01670799"
1747,"NCT01667237","Feasibility of a Short Home-based Rehabilitation Program for Cancer Patients Waiting for Lung Resection Surgery",,"Completed","No Results Available","Lung Cancer","Behavioral: Home-based pulmonary rehabilitation program","To verify the feasability of a short home-based rehabilitation for cancer patients prior to lung resection surgery program.|To quantify the cycle endurance change induced by a short home-based rehabilitation for cancer patients prior to lung resection surgery program.|To quantify the quadriceps muscle force change induced by a short home-based rehabilitation for cancer patients prior to lung resection surgery program.","Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","All","45 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20525","March 2010","December 2012","December 2012","August 17, 2012","null","January 10, 2013","CRIUCPQ, Québec, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT01667237"
1748,"NCT01666353","PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy",,"Unknown status","No Results Available","Melanoma|Renal Cell Carcinoma (RCC)|Non-small Cell Lung Cancer (NSCLC)","Radiation: PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG)","Compare FDG PET-based qualitative and quantitative tumor response assessment with standard CT immune RECIST criteria|Assess the use of FDG PET as a non-invasive imaging method to detect early evidence of organ inflammation","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","J1208|NA_00049919","April 2012","December 2015","December 2015","August 16, 2012","null","March 18, 2015","Johns Hopkins University, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01666353"
1749,"NCT01665196","18F-FDG PET/CT for IgG4-Related Disease",,"Recruiting","No Results Available","Autoimmune Disease","Drug: 18F-FDG","Visual analysis of organ involvement and treatment response of the IgG4-RD patients.|Semiquantitative measurement of lesion metabolism and treatment response of the IgG4-RD patients.","Peking Union Medical College Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IgG4RD-PET","September 2012","December 2017","December 2017","August 15, 2012","null","April 7, 2017","Peking Union Medical College Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT01665196"
1750,"NCT01661517","Brief Intervention and Referral to Treatment With Substance Use Disorders in the Emergency Room Setting",,"Terminated","No Results Available","Substance Use","Behavioral: Motivational interviewing and referral to treatment","substance use","University of Alabama at Birmingham","All","19 Years and older   (Adult, Older Adult)","Early Phase 1","5271","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","X110829003","September 2011","September 2013","May 2015","August 9, 2012","null","October 18, 2016","University of Alabama Birmingham, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT01661517"
1751,"NCT01661400","Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors","ASCR","Recruiting","No Results Available","Glioma|Neuroectodermal Tumors, Primitive|Wilms Tumor|Rhabdomyosarcoma|Sarcoma, Ewing|Osteosarcoma|Retinoblastoma","Drug: Metronomic Cyclophosphamide|Drug: Thalidomide","Safety|Toxicity|Radiographic marker of neovascularization|Best overall response","Washington University School of Medicine","All","6 Months to 21 Years   (Child, Adult)","Early Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201209088","October 2012","February 2020","February 2022","August 9, 2012","null","May 2, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT01661400"
1752,"NCT01659931","Bioequivalency Study of Montelukast 10 mg Tablets Under Fasted Conditions",,"Completed","No Results Available","Asthma","Drug: Montelukast|Drug: Singulair","bioequivalence determined by statistical comparison Cmax","Roxane Laboratories|West-Ward Pharmaceutical","All","18 Years to 45 Years   (Adult)","Early Phase 1","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MONT-T10-PVFS-1","February 2008","February 2008","February 2008","August 8, 2012","null","January 23, 2018","PRACS Institute, Ltd., Fargo, North Dakota, United States","","https://ClinicalTrials.gov/show/NCT01659931"
1753,"NCT01659918","Bioequivalency Study of Montelukast 10 mg Tablets Under Fed Conditions",,"Completed","No Results Available","Asthma","Drug: Montelukast|Drug: Singulair","bioequivalence determined by statistical comparison Cmax","Roxane Laboratories|West-Ward Pharmaceutical","All","18 Years to 45 Years   (Adult)","Early Phase 1","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MONT-T10-PVFD-1","February 2008","February 2008","February 2008","August 8, 2012","null","January 23, 2018","PRACS Institute, Ltd., Fargo, North Dakota, United States","","https://ClinicalTrials.gov/show/NCT01659918"
1754,"NCT01659905","Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fasted Conditions",,"Completed","No Results Available","Asthma","Drug: Montelukast|Drug: Singulair","bioequivalence determined by statistical comparison Cmax","Roxane Laboratories|West-Ward Pharmaceutical","All","18 Years to 45 Years   (Adult)","Early Phase 1","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MONT-CT5-PVFS-1","August 2008","August 2008","August 2008","August 8, 2012","null","January 23, 2018","PRACS Institute, Ltd., Fargo, North Dakota, United States","","https://ClinicalTrials.gov/show/NCT01659905"
1755,"NCT01659892","Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fed Conditions",,"Completed","No Results Available","Asthma","Drug: Montelukast|Drug: Singulair","bioequivalence determined by statistical comparison Cmax","Roxane Laboratories|West-Ward Pharmaceutical","All","18 Years to 45 Years   (Adult)","Early Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MONT-CT5-PVFD-1","August 2008","August 2008","August 2008","August 8, 2012","null","January 23, 2018","PRACS Institute, Ltd., Fargo, North Dakota, United States","","https://ClinicalTrials.gov/show/NCT01659892"
1756,"NCT01659645","Anti-1-amino-3-[18F]Fluorocyclobutyl-1-carboxylic Acid (Anti-[18F](FACBC)Positron Emission Tomography (PET-CT) of the Breast",,"Completed","No Results Available","Breast Cancer","Drug: FACBC","Presence of FACBC radiotracer in breast carcinoma on FACBC PET scan","Emory University","Female","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00052551|FACBCBr","August 2012","January 2015","January 2015","August 8, 2012","null","October 27, 2016","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01659645"
1757,"NCT01659398","Enhanced External Counterpulsation and Its Effects on Vascular Hemodynamics in Cognitively Impaired Patients",,"Completed","No Results Available","Mild Cognitive Impairment","Device: External Counterpulsation (EECP)","Change in Cognitive Function|Change in Ophthalmic blood flow (OBF)|Change in Blood Viscosity|Cholesterol composition of the blood","Patrick Moriarty, MD, FACP, FACC|University of Kansas Medical Center","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","8","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13106","June 2012","October 2014","October 2014","August 7, 2012","null","January 13, 2016","University of Kansas Medical Center, Kansas City, Kansas, United States","","https://ClinicalTrials.gov/show/NCT01659398"
1758,"NCT01656785","68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Stroke","GRGDS","Unknown status","No Results Available","Stroke","Drug: 68Ga-BNOTA-PRGD2","Visual and semiquantitative assessment (Standardized Uptake Values = SUVs) of cerebral infarction region, SUV ratios (SUVinfarction/SUV contralateral)|Adverse events collection","Peking Union Medical College Hospital","All","30 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PUMCHNM004","February 2012","December 2017","December 2017","August 3, 2012","null","April 7, 2017","Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT01656785"
1759,"NCT01656577","Pexacerfont for Stress-induced Food Craving",,"Terminated","No Results Available","Daily Oral Pexacerfont for 28 Days (300 mg/Day Loading Dose for 7 Days, Followed|Placebo","Drug: Pexacerfont","","National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC)","All","21 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","31","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","999912475|12-DA-N475","June 2012","September 2015","September 2015","August 3, 2012","null","August 18, 2016","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01656577"
1760,"NCT01650480","HELPing Older People With Very Severe Chronic Obstructive Pulmonary Disease Towards the End of Their Lives: Developing, Piloting and Refining a Practical Intervention (HELP-COPD)","HELP-COPD","Completed","No Results Available","Chronic Obstructive Pulmonary Disease (COPD)","Other: HELP-COPD action plan","FACIT|The St George Respiratory Questionnaire (SGRQ)|MRC Dyspnoea score|Dyspnoea 12|COPD Assessment Test (CAT)|The Hospital Anxiety and Depression Scale (HADS)|FACIT Spiritual Well-Being sub-scale (FACIT-Sp)|Palliative care Outcome Scale (POS)|EQ-5D","University of Edinburgh|The Dunhill Medical Trust","All","Child, Adult, Older Adult","Early Phase 1","44","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","2012/R/RES/02|12243","January 2012","September 2013","December 2013","July 26, 2012","null","February 12, 2014","Royal Infirmary of Edinburgh, Edinburgh, City of Edinburgh, United Kingdom","","https://ClinicalTrials.gov/show/NCT01650480"
1761,"NCT01649349","The Feasibility Study of Dual-Section Nasogastric Tube",,"Completed","No Results Available","Stroke|Mouth Neoplasms","Device: two-piece nasogastric tube","Number of Participants with Adverse Events|satisfaction of Dual-Section Nasogastric Tube","Changhua Christian Hospital","All","20 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","110807|TW201010751","May 2012","June 2012","June 2012","July 25, 2012","null","July 25, 2012","","","https://ClinicalTrials.gov/show/NCT01649349"
1762,"NCT01648296","Fatty Acid Radiotracer Comparison Study in Heart Failure Patients",,"Active, not recruiting","No Results Available","Heart Failure|Obesity|Type 2 Diabetes Mellitus|Health Normal Volunteer Subjects","Drug: [18F]FluorbetaOx","The primary endpoint is to determine if PET/CT measurements of myocardial FA metabolism performed with [18F]FluorbetaOx correlated with those performed with [11C]Palmitate and calculation of human dosimetry.|To determine human dosimetry based on the human biodistribution of [18F](+/-)NOS in both normal healthy volunteers and dilated non-ischemic cardiomyopathy patients.","Washington University School of Medicine","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IND113344|IRB#201208087","September 13, 2012","June 4, 2014","June 4, 2018","July 24, 2012","null","February 7, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT01648296"
1763,"NCT01642264","Web-Based Respiratory Education About Tobacco and Health Phase II","WeBREATHe II","Completed","No Results Available","Intervention (Training) Condition|Control (Delayed Training) Condition","Behavioral: WeBREATHe Training Program","Performance of Ask, Advise, Assess, Assist and Arrange Behaviors|Attitudes towards provision of tobacco cessation interventions|Perceived Barriers|Self-Efficacy","Oregon Research Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","217","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","HL083540","March 2008","November 2010","December 2010","July 17, 2012","null","December 11, 2017","","","https://ClinicalTrials.gov/show/NCT01642264"
1764,"NCT01639651","The Acute Effect of a Mobilization With Movement Technique to Improve Internal Rotation of the Shoulder",,"Completed","No Results Available","Disorder of Shoulder|Other Musculoskeletal Disorder|Contracture","Other: Posterior capsule stretching|Other: Mobilization with movement","Analyse the effectiveness of a mobilization with movement technique to improve internal rotation of the shoulder in throwers athletes with GIRD","Federal University of São Paulo","All","15 Years to 18 Years   (Child, Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","02195112.7.0000.5505","June 2012","August 2015","August 2015","July 13, 2012","null","September 2, 2015","Federal University of São Paulo, São Paulo, Brazil","","https://ClinicalTrials.gov/show/NCT01639651"
1765,"NCT01636661","Safety of Transcranial Direct Current Stimulation in Pediatric Hemiparesis","tDCS","Completed","Has Results","Hemiparesis","Device: tDCS","Adverse Events/Safety Assessment.|Hand Function Decline as Measured by Number of Participants","University of Minnesota - Clinical and Translational Science Institute|Minnesota Medical Foundation","All","8 Years to 17 Years   (Child)","Early Phase 1","13","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","1205M13901","July 2012","August 2013","December 2013","July 10, 2012","July 20, 2015","November 9, 2015","University of Minnesota, Minneapolis, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01636661"
1766,"NCT01635192","Effects of Probiotic VSL#3 on Expression of Small Intestinal Renin-angiotensin System",,"Completed","No Results Available","the Local Renin-angiotensin System (RAS) in Small Intestinal Mucosa in Man","Biological: VSL#3|Biological: Placebo","The change in mucosal expression of components of renin-angiotensin (particularly ACE1, AT1-receptor, AT2-receptor)|Changes in epithelial permeability and glucose absorption capacity in vitro|Change in intestinal glucose absorption capacity in-vivo","Göteborg University|Sahlgrenska University Hospital, Sweden","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Basic Science","ProGlucose-1","December 2011","July 2013","July 2013","July 9, 2012","null","May 22, 2014","Dept of Gastrosurgical R&E, Sahlgrenska Universityhospital, Gothenburg, Sweden","","https://ClinicalTrials.gov/show/NCT01635192"
1767,"NCT01634126","Maximizing Yield of the Fecal Immunochemical Test for Colorectal Cancer Screening","MY-FIT","Completed","No Results Available","Colorectal Cancer","Behavioral: 1 FIT kit|Behavioral: 2 FIT kit","FIT Kit adherence","Kaiser Permanente|National Cancer Institute (NCI)","All","50 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","2761","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","5R01CA154982|1R01CA154982","August 2012","April 2016","April 2016","July 6, 2012","null","September 16, 2016","Kaiser Permanente Center for Health Research, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT01634126"
1768,"NCT01633762","Eradication of Gut Microbiota","ERA","Completed","No Results Available","Diabetes|Obesity|Osteoporosis|Inflammation","Drug: meropenem, gentamicin, vancomycin (together)","changes in postprandial GLP-1 secretion|changes in postprandial insulin/c-peptide secretion|changes in postprandial glucose levels|changes in postprandial GLP-2, glucagon, PYY, oxyntomodulin, gastrin, CCK, GIP, leptin, adiponectin and ghrelin secretion|changes in markers of bone formation and resorption|gut microbiome composition|changes in markers of systemic inflammation|changes in glycated hemoglobin (HbA1c)|changes in body weight|changes in basal metabolic rate and respiratory quotient|changes in gastric emptying|changes in gall bladder emptying|appetite, satiety and food intake|changes in ketone metabolism|changes in bile acid deconjugation|changes in plasma lipid levels|microbiome in blood, urine and saliva|adverse effects of the used antibiotics|changes in metabolomic profile","University Hospital, Gentofte, Copenhagen|University of Copenhagen|Steno Diabetes Center|Department of clinical microbiology, Rigshospitalet, Copenhagen","Male","18 Years to 40 Years   (Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ERA 2012","April 2012","April 2013","April 2013","July 4, 2012","null","December 2, 2015","Gentofte University Hospital, Hellerup, Denmark","","https://ClinicalTrials.gov/show/NCT01633762"
1769,"NCT01633008","Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain",,"Completed","No Results Available","Neurofibromatosis","Behavioral: ACT Workshop","Pain improvement|Value of the ACT for future Ph2 trial.|Psychological well-being &amp; stress changes in parents|Explore improvements of pain interference, abilities, coping, anxiety,depression, etc|Relationship between pain and treatment adherence","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","12 Years to 99 Years   (Child, Adult, Older Adult)","Early Phase 1","28","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","120155|12-C-0155","June 15, 2012","May 1, 2014","January 10, 2017","July 4, 2012","null","September 27, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01633008"
1770,"NCT01632696","Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors",,"Terminated","No Results Available","Malignant Solid Tumor","Drug: I-124 PGN650 for PET/CT","To estimate the intensity and distribution in critical and non-critical organs.|The presence of tumor imaging using I-124 PGN650 as a PS-targeting agent.|Demonstrate the safety of tumor imaging in patients with solid cancers.","Peregrine Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","PPHM 1201","June 2012","May 2016","May 2016","July 3, 2012","null","July 11, 2017","Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT01632696"
1771,"NCT01631331","Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)",,"Completed","Has Results","Basal Cell Carcinoma of the Skin|Recurrent Skin Cancer","Drug: vismodegib|Procedure: Mohs surgery","Percent Change in Surgical Defect Area After the Treatment Period Using Calipers and Photographs Was Calculated|Number of Tumors Demonstrating Histologic Cure|Tumor Recurrence Rate of Treated BCCs|Tumor Size Measurements Before and After Short Term Vismodegib Treatment","Stanford University|National Cancer Institute (NCI)|University Hospitals Cleveland Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-24313|NCI-2012-01055|SKIN0012","June 2012","September 17, 2015","May 31, 2016","June 29, 2012","October 2, 2017","December 8, 2017","Stanford University, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT01631331"
1772,"NCT01630993","Milking the Umbilical Cord at Term Cesarean Birth",,"Completed","No Results Available","Anemia","Other: Umbilical Cord Milking","Newborn Hemoglobin and Hematocrit levels|Placental Residual Blood Volume","University of Rhode Island","Female","18 Years to 44 Years   (Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","HU0708-113M","May 2008","April 2009","December 2009","June 28, 2012","null","October 5, 2015","Women & Infants Hospital, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT01630993"
1773,"NCT01630239","MR-Guided Laser Ablation of Hepatic Tumors",,"Completed","No Results Available","Soft Tissue Tumors","Procedure: Laser ablation","MR Images","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-000864","June 2012","March 2015","March 2015","June 28, 2012","null","May 5, 2015","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01630239"
1774,"NCT01629576","Obesity and Financial Incentives","Obesity","Unknown status","No Results Available","Obesity","Other: economic incentive","bodyweight","Rhine-Westphalia Institute for Economic Research","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","010902","March 2010","October 2014","October 2014","June 27, 2012","null","June 27, 2012","Bad Kissingen, Baden-Würrttemberg, Germany","","https://ClinicalTrials.gov/show/NCT01629576"
1775,"NCT01629173","The Analysis and Applications of Dynamic Impression Insole",,"Completed","No Results Available","Metatarsalgia","Procedure: Dynamic impression insole|Procedure: Custom molded insole|Procedure: 9-mm uncompressed Plastazote|Procedure: 7-mm Ethylene Vinyl Acetate (EVA)","Change from baseline in peak plantar pressure value with different insoles|Change from baseline in pain levels using Visual Analog Scales","Taipei Veterans General Hospital, Taiwan","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","97-11-12A","April 2011","June 2012","June 2012","June 27, 2012","null","June 27, 2012","Taipei VGH, Taipei City, Taiwan","","https://ClinicalTrials.gov/show/NCT01629173"
1776,"NCT01626014","Interactive Educational Website for Women With Ovarian Cancer & Caregivers",,"Completed","No Results Available","Stage III Ovarian Cancer|Stage IV Ovarian Cancer|Recurrent Ovarian Cancer|Fallopian Tube Cancer","Behavioral: Usual Care Educational Website|Behavioral: Prototype System","Comparison of Number of Women Who Completed Advanced Directive|Comparison of Number of Women Who Report Appointment with Palliative Care","University of Minnesota - Clinical and Translational Science Institute","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","53","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2012NTLS005","August 2012","December 2014","December 2014","June 22, 2012","null","December 2, 2015","Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01626014"
1777,"NCT01624818","Active With Heart Disease",,"Unknown status","No Results Available","Heart Disease","Behavioral: Cardiac habilitation program","Increased level of physical activity|Increased physical fitness","Oslo University Hospital","All","6 Years to 12 Years   (Child)","Early Phase 1","48","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","268289","March 2013","December 2014","December 2015","June 21, 2012","null","June 21, 2012","Geilomo barnesykehus, Geilo, Buskerud, Norway","","https://ClinicalTrials.gov/show/NCT01624818"
1778,"NCT01620749","Of 18F MEL050 Using PET/CT in Metastatic Melanoma","MEL050","Unknown status","No Results Available","Metastatic Melanoma","Radiation: 18F MEL050","Safety of 18F MEL050 administration as measured by occurrence of adverse clinical, biochemical or haematological events following 18F MEL050 administration.|Percentage of injected 18F MEL050 dose in organs of interest.|Percentage of unmetabolized 18F MEL050 in plasma and urine after radiotracer administration.|Absorbed organ doses and whole body dose expressed as milliSv/200MBq administered dose.","Cooperative Research Centre for Biomedical Imaging Development","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","10/11","June 2010","March 2012","December 2012","June 15, 2012","null","June 15, 2012","Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia","","https://ClinicalTrials.gov/show/NCT01620749"
1779,"NCT01620567","Consumption of Potatoes, Avocados and Chickpeas and Cognitive Function in Older Adults",,"Unknown status","No Results Available","Mild Cognitive Impairment","Dietary Supplement: avocado or chickpeas/potatoes","cognition|inflammation","Tufts University","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","002","August 2012","February 2014","May 2014","June 15, 2012","null","August 19, 2013","Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01620567"
1780,"NCT01620125","Metabolic Control Before and After Supplementation With Lactobacillus Reuteri DSM 17938 in Type 2 Diabetes Patients",,"Unknown status","No Results Available","Type 2 Diabetes|Insulin Resistance","Dietary Supplement: Lactobacillus reuteri DSM 17938","HOMA index|Changes in diabetes medication and hypoglycemia events","Vastra Gotaland Region","All","50 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Lactobacillus reuteri pilot","May 2012","December 2012","December 2012","June 15, 2012","null","June 15, 2012","Gothia Forum, CTC, Gröna Stråket 12, Sahlgrenska University Hospital, Gothenburg, Sweden","","https://ClinicalTrials.gov/show/NCT01620125"
1781,"NCT01616407","Effects of MDMA and Methylphenidate on Social Cognition",,"Completed","No Results Available","Social Cognition","Drug: 3,4-Methylenedioxymethamphetamine|Drug: Methylphenidate|Drug: Placebo","Effects on social cognition (emotion recognition and empathy)|Blood pressure (mmHg) and heart rate (beats per min)|Subjective effects|Neuroendocrine plasma levels|Drug plasma concentration","University Hospital, Basel, Switzerland","All","18 Years to 45 Years   (Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","EK 382/11|2012DR1018","August 2012","December 2012","April 2013","June 11, 2012","null","January 21, 2016","University Hospital Basel, Basel, Switzerland","","https://ClinicalTrials.gov/show/NCT01616407"
1782,"NCT01616368","The Effects of Mindfulness Training on Eating Behaviors and Food Intake",,"Completed","No Results Available","Obesity|Feeding Behavior","Behavioral: Mindful Eating and Living Course","Change in Eating behaviors|Change in Nutrition intake","Seattle Institute for Biomedical and Clinical Research|American College of Gastroenterology","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MIRB 00458","January 2012","January 2013","January 2013","June 11, 2012","null","November 20, 2014","","","https://ClinicalTrials.gov/show/NCT01616368"
1783,"NCT01615055","Fluoxetine Prevention Trial",,"Withdrawn","No Results Available","Cognitive Dysfunction","Drug: Fluoxetine|Other: Placebo","Change from baseline in regional cerebral metabolism|Durability of the protective effect of fluoxetine|Change from baseline in neuropsychological (cognitive, functional) test results|Correlation between cognitive functioning and cerebral metabolism by correlating neuropsychological testing results with PET imaging|Correlation between inflammatory cytokines and cerebral metabolism by correlating blood cytokine marker levels with PET imaging","University of California, Los Angeles|City of Hope Medical Center","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","12-000568","June 2018","October 2020","October 2020","June 8, 2012","null","October 15, 2018","City of Hope, Duarte, California, United States|UCLA Medical Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01615055"
1784,"NCT01614730","User Evaluation in Healthy Volunteers to Verify no Pelvic Floor Contraction is Stimulated When the Modified Neurotech Vital Device is Used Compared to the Neurotech Vital Device","BMR-12-1002","Completed","No Results Available","Contraction of Pelvic Floor Muscle Using EMS","Device: Modified Neurotech Vital Device|Device: Neurotech Vital Device","Using a sonographic/real time ultrasound imaging machine detect if a contraction is stimulated by the 5 minute treatment with the modified Neurotech Device and 5 minute treatment with the Neurotech Vital Device.|Healthy Volunteers feedback questionnaires","Bio-Medical Research, Ltd.","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","BMR-12-1002","June 2012","June 2012","July 2012","June 8, 2012","null","July 9, 2012","","","https://ClinicalTrials.gov/show/NCT01614730"
1785,"NCT01612429","Carbamylation in Renal Disease-modulation With Amino Acid Therapy","CarRAAT","Completed","No Results Available","End Stage Renal Failure on Dialysis","Dietary Supplement: Amino acid supplementation","Change from baseline in plasma carbamylated albumin levels|Number of patients with adverse events","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","23","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-P-000775|IRB# 12-303","January 2013","July 2015","July 2015","June 5, 2012","null","November 10, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01612429"
1786,"NCT01608035","Sciatic Perineural Versus Stump Catheter for Below Knee Amputation",,"Completed","No Results Available","Ischemia|Phantom Limb Pain|Vascular Disease|Chronic Pain","Procedure: Sciatic catheter|Procedure: Stump catheter","Opioid consumption|pain score","University of British Columbia","All","16 Years to 90 Years   (Child, Adult, Older Adult)","Early Phase 1","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H12-00693","September 2012","July 2015","July 2015","May 30, 2012","null","May 20, 2016","Jason Wilson, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT01608035"
1787,"NCT01601210","Dose-Ranging Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Creatine monohydrate or placebo","Brain PCr concentrations","Perry Renshaw|University of Utah","Female","13 Years to 21 Years   (Child, Adult)","Early Phase 1","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00055231","June 2012","May 2014","May 2014","May 17, 2012","null","October 25, 2016","University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01601210"
1788,"NCT01599208","Facilitating Associative Memory Via Deep Transcranial Magnetic Stimulation to the Medial Temporal Lobe",,"Withdrawn","No Results Available","Effect of Deep Transcranial Magnetic Stimulation on Memory","Device: TMS","Change in memory based on the timeframe of the online stimulation","Brainsway","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","TMS-MEMORY-1","August 2012","January 2015","June 2015","May 15, 2012","null","January 25, 2018","","","https://ClinicalTrials.gov/show/NCT01599208"
1789,"NCT01595373","Local Metabolic Effects of Ghrelin in Skeletal Muscle and Adipose Tissue",,"Completed","No Results Available","Healthy","Drug: Acyl ghrelin|Drug: Placebo (Ringer acetate)","Interstitial concentrations of glycerol|Interstitial concentrations of lactate|Interstitial concentrations of glucose","Esben Thyssen Vestergaard|University of Aarhus","Male","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","2012-28512","June 2012","September 2012","January 2013","May 10, 2012","null","January 16, 2013","Aarhus University Hospital, Aarhus, Denmark","","https://ClinicalTrials.gov/show/NCT01595373"
1790,"NCT01595178","Combination SBIRT for Emergency Department Patients Who Drink and Smoke",,"Unknown status","No Results Available","Smoking|Drinking","Behavioral: Combined BNI","Areas in need of help|Barriers and facilitators to accessing care|Counseling satisfaction|Treatment utilization|Reduction of consumption|Quit attempts","Yale University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","1065276 R10701 SAEM","June 2012","June 2013","June 2013","May 9, 2012","null","May 9, 2012","Yale New Haven Hospital Emergency Department, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01595178"
1791,"NCT01594242","Autophagy Induction After Bortezomib for Myeloma",,"Unknown status","No Results Available","Multiple Myeloma","Other: Bortezomib","Number of Adverse Events","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","11","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Treatment","UPCC 05411","April 2012","June 2015","null","May 9, 2012","null","September 26, 2016","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01594242"
1792,"NCT01592526","Autonomic Nervous Activity During the Systemic Inflammatory Response in Trained and Untrained Healthy Volunteers",,"Completed","No Results Available","Systemic Inflammatory Response Syndrome","Other: Endotoxin|Other: Endotoxin + Nicotine","Cytokines|Heart Rate Variability (HRV)","Rigshospitalet, Denmark|Bispebjerg Hospital","Male","18 Years to 35 Years   (Adult)","Early Phase 1","23","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","H-3-2012-011","June 2012","January 2013","December 2015","May 7, 2012","null","January 29, 2016","Center for Inflammation and Metabolism, Rigshospitalet, Copenhagen, Copenhagen OE, Denmark","","https://ClinicalTrials.gov/show/NCT01592526"
1793,"NCT01592019","Clinical Study to Evaluate the Role of Microdialysis for the Comparison of Topical Products",,"Completed","No Results Available","Bioequivalence","Drug: Reference, Patch location thigh, batch 1|Device: Test, Patch location thigh, batch 2|Drug: Reference, Patch location abdomen, batch 1|Device: Test, Patch location abdomen, batch 2","Blood and tissue diclofenac concentrations","University of Florida|Food and Drug Administration (FDA)","All","18 Years to 55 Years   (Adult)","Early Phase 1","6","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","10-223-00277-01","April 2012","November 2012","November 2012","May 4, 2012","null","December 13, 2012","University of Florida, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT01592019"
1794,"NCT01589965","The Impact of Short-term Financial Incentives on Sexual Behavior and HIV Incidence in Lesotho",,"Unknown status","No Results Available","AIDS/HIV PROBLEM|Sexually Transmitted Diseases","Behavioral: Financial incentive through lotteries","HIV prevalence|STI prevalence (Chlamydia, Syphilis, Trichomoniasis)","Bocconi University|World Bank","All","18 Years to 45 Years   (Adult)","Early Phase 1","5000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","100","February 2010","February 2010","June 2012","May 2, 2012","null","May 2, 2012","Lucia Corno, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT01589965"
1795,"NCT01588301","Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention","APACHE-2","Completed","No Results Available","Cervical Cancer|Human Papillomavirus Infection","Behavioral: Attending for cervical cytology|Behavioral: Kit for Self-collected vaginal sample","Comparison of women's attitude according to the arm: participation or not to a whole screening action|Analysis in sub-groups|Identification of the psychological determinants and mechanisms (checks and motivational factors)","University Hospital, Tours","Female","30 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","5998","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Screening","INCA08-KH / APACHE-2","February 2012","December 2012","December 2012","April 30, 2012","null","September 12, 2014","","","https://ClinicalTrials.gov/show/NCT01588301"
1796,"NCT01587820","Intra-arterial Versus Intravenous Cisplatin, Combined With Radiation, for Oral Cavity and Oropharynx Cancer",,"Terminated","No Results Available","Head and Neck Cancer","Drug: Intra-arterial cisplatin|Drug: Intravenous cisplatin","number of enrolled subjects|patient survival|rate of patient morbidity","Southern Illinois University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ROB-SCI 12-001","June 2012","August 2014","August 2014","April 30, 2012","null","December 5, 2014","Southern Illinois University School of Medicine, Springfield, Illinois, United States|Simmons Cancer Institute at SIU School of Medicine, Springfield, Illinois, United States","","https://ClinicalTrials.gov/show/NCT01587820"
1797,"NCT01585012","Usability Study of the Focus Touch™ Conception System: Semen Collection","Ib2C","Completed","No Results Available","Infertility","Device: Cervical cap (Focus Touch™ Conception System)","The primary objective is to determine if the Focus Touch™ Conception System Conceptacle is functionally acceptable and meets the user's needs and expectations when used in the home during sexual intercourse as a semen collection device.","Rinovum Women's Health, Inc.","All","20 Years to 50 Years   (Adult)","Early Phase 1","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","11-045","January 2012","March 2012","March 2012","April 25, 2012","null","May 6, 2015","Forbes Regional Hospital, Monroeville, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01585012"
1798,"NCT01582321","Investigation of the Influence of Gender on Cardiovascular Function",,"Completed","No Results Available","Cardiovascular Function","Biological: Typhoid vaccine|Drug: Cantharidin","Comparison change in blister fluid total and differential leukocyte numbers (Part 1)|Flow-mediated dilatation (Part 2)|Blood pressure (Part 1)|Platelet reactivity (Part 2)|Platelet activation (Part 2)|Arterial stiffness (Part 2)|Inflammatory cell expression (Part 1 and 2)|Blood inflammatory molecule expression (Part 1 and 2)","Queen Mary University of London","All","18 Years to 45 Years   (Adult)","Early Phase 1","56","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","11/LO/2038","March 2012","December 2016","January 2017","April 20, 2012","null","June 14, 2017","William Harvey Heart Centre, Barts & The London Medical School, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT01582321"
1799,"NCT01581645","Mobilaser Study to Help With People Who Are Having Problems With Their Gait",,"Completed","No Results Available","Parkinson's Disease|Parkinsonism","Device: Mobilaser","Improvement in Gait","Mayo Clinic","All","30 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-002978","May 2012","December 2013","December 2013","April 20, 2012","null","December 31, 2015","Mayo Clinic in Florida, Jacksonville, Florida, United States","","https://ClinicalTrials.gov/show/NCT01581645"
1800,"NCT01576159","Serum Cartilage Oligomeric Matrix Protein Levels After 12 Weeks of Different Exercises",,"Completed","Has Results","Osteoarthritis|Articular Cartilage Disorder of Knee|Degenerative Lesion of Articular Cartilage of Knee","Other: Running exercise|Other: Cycling exercise|Other: Swimming Exercise","Changes in Serum COMP Accumulation, Triggered by Acute Exercise, After 12 Weeks of Different Regular Exercises|Physical (Body Mass Index) Changes of Participants|Physiological (Maximum Oxygen Consumption) Changes of Participants","Middle East Technical University","Male","18 Years to 25 Years   (Adult)","Early Phase 1","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","BAPK06K07K03K00K17|107S112","January 2008","June 2008","September 2008","April 12, 2012","June 10, 2015","June 10, 2015","Middle East Technical University, Medical Center and Physical Education and Sports Dep., Ankara, Cankaya, Turkey","","https://ClinicalTrials.gov/show/NCT01576159"
1801,"NCT01576068","Chronic Obstructive Pulmonary Disease Case Finding in Community-pharmacies by Spirometry","FARMAEPOC","Unknown status","No Results Available","Chronic Obstructive Pulmonary Disease","Other: Spirometry","COPD Case Finding","Col·legi de Farmacèutics de la Província de Barcelona|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Hospital Clinic of Barcelona|Spanish Respiratory Society|Catalan Society of Family Medicine","All","40 Years and older   (Adult, Older Adult)","Early Phase 1","3600","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","2008/3128/I","October 2010","July 2012","June 2013","April 12, 2012","null","April 12, 2012","Col·legi Oficial de Farmacèutics de Barcelona, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT01576068"
1802,"NCT01574261","Could the Therapy With Inositol Affect the Cardiovascular Risk in PCOS Women? Results of a Randomized Clinical Trial",,"Unknown status","No Results Available","Polycystic Ovary Syndrome","Drug: Placebo|Drug: Inositol","CD4+ CD28 null T-lymphocyte frequency|insulinaemic area OGTT AUCi, lipid profile, androgen levels","Catholic University of the Sacred Heart","Female","18 Years to 35 Years   (Adult)","Early Phase 1","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","disfunzionale12","March 2012","August 2012","null","April 10, 2012","null","April 10, 2012","Università cattolica S. Cuore, Rome, Italy","","https://ClinicalTrials.gov/show/NCT01574261"
1803,"NCT01573260","Tango for Treatment of Motor and Non-motor Manifestations in Parkinson's Disease.",,"Completed","Has Results","Parkinson's Disease","Other: Argentinean Tango classes|Other: Simple pamphlet about the exercise in PD","Severity of PD (Unified Parkinson Disease Rating Scale - UPDRS, 2008 Version)|MiniBESTest|Number of Participants With a Fall in the Past 3 Months Using the Falls Questionnaire From the Canadian Longitudinal Study of Aging|Freezing of Gait Questionnare (FOG_Q)|The Purdue Pegboard|The Montreal Cognitive Assessment|The Beck Depression Inventory (BDI)|Apathy Evaluation Scale (AES)|The Krupp Fatigue Severity Scale|The Parkinson's Disease Questionnaire is a Quality of Life(PDQ-39)|Adherence to Treatment|Clinical Global Impression of Change|Exit Questionnaire|Adverse Events","McGill University Health Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","33","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEN-11-261","April 2012","April 2013","April 2014","April 9, 2012","February 1, 2016","February 1, 2016","Montreal General Hospital, Montreal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT01573260"
1804,"NCT01571427","Conversations as a Means to Delay the Onset of Alzheimer's Disease","conversation","Completed","No Results Available","Cognitive Impairment","Behavioral: Active social engagement group|Behavioral: Control group","Cognitive functions measured by neuropsychological tests|Psychological well-being|Levels of social engagement","Oregon Health and Science University|National Institute on Aging (NIA)","All","70 Years and older   (Older Adult)","Early Phase 1","96","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","socialengagementR01|R01AG033581","February 2012","September 2013","September 2013","April 5, 2012","null","August 10, 2016","Oregon Health & Science University, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT01571427"
1805,"NCT01568996","Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions",,"Completed","No Results Available","Atypical Nevi|Melanoma","Drug: broccoli sprout extract - sulforaphane (BSE-SFN)","Adverse events associated with oral sulforaphane|Visual changes of atypical nevi: size, border, color.|Cellular changes of the atypical nevi.|Sulforaphane levels in the blood as a result of the 3 doses.|Effects of sulforaphane on STAT1 and STAT3 expression.","John Kirkwood|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","17","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","10-114","August 2012","March 2016","April 2016","April 2, 2012","null","January 9, 2018","UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01568996"
1806,"NCT01568515","Electronic Messaging to Increase Human Papillomavirus Vaccine Utilization and Adherence Among College Students",,"Completed","No Results Available","Patient Compliance|Health Knowledge, Attitudes, Practice","Procedure: Electronic Message","Increase in HPV vaccine uptake among intervention group participants.|Increase knowledge of HPV and HPV vaccine among intervention group participants|Compliance rates among Race/ethnicity and other socio-demographic characteristics.","East Carolina University|Merck Sharp & Dohme Corp.","All","18 Years to 26 Years   (Adult)","Early Phase 1","283","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","MISP-39631","October 2011","August 2014","August 2014","April 2, 2012","null","November 4, 2014","","","https://ClinicalTrials.gov/show/NCT01568515"
1807,"NCT01565291","A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers",,"Completed","Has Results","Alzheimer Disease","Drug: florbetapir F 18","Mean Cortical to Cerebellum SUVR|Precuneus to Cerebellum SUVR","Avid Radiopharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-45-A01","June 2007","January 2008","January 2008","March 28, 2012","May 3, 2012","May 18, 2012","Research Site, Baltimore, Maryland, United States|Research Site, North East, Maryland, United States|Research Site, Long Branch, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT01565291"
1808,"NCT01564433","Effects of Electromechanical Gait Trainer in Patients With Cerebral Palsy",,"Completed","No Results Available","Cerebral Palsy","Procedure: Device: Electromechanical gait trainer|Procedure: Convetional control treatment","Six Minute Walking Test|Ten Meter Walking Test|Wee FIM|Spatio-temporal gait analysis","Universita di Verona","All","10 Years to 16 Years   (Child)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","PCI-GT-2","November 2011","December 2011","January 2012","March 27, 2012","null","June 14, 2012","S.S.O. di Riabilitazione dell'Ospedale Policlinico, Verona, Italy","","https://ClinicalTrials.gov/show/NCT01564433"
1809,"NCT01564160","Assessment of PCSO-524 Relative to a Comparator Product",,"Completed","No Results Available","Healthy","Dietary Supplement: Fish Oil|Dietary Supplement: PCSO-524","Serum Phospholipid|Total Serum Lipid|Serum Free Fatty Acid","Nutrasource Diagnostics Inc.|Pharmalink International Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)","11.0202|176412|12-02-003","April 2012","August 2012","August 2012","March 27, 2012","null","December 3, 2012","Nutrasource Diagnostics Inc, Guelph, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01564160"
1810,"NCT01557686","Health Counseling and Exercise in Patients With Acute Leukemia - Pilot Study","PACE-AL","Completed","No Results Available","Acute Leukemia","Behavioral: Health counseling and exercise","Feasibility - adherence rates|Adverse events|6MWD|Attrition|Timed chair stand|Timed bicep curl|FACT-Anemia|HADS|SF36|MDSAI","Universitetshospitalernes Center for Sygepleje|Novo Nordisk A/S|Lundbeck Foundation","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","H-4-2010-046 Pilot","May 2010","February 2011","February 2011","March 19, 2012","null","March 19, 2012","Copenhagen University Hospital, Copenhagen, Denmark|Herlev Hospital, Herlev, Denmark","","https://ClinicalTrials.gov/show/NCT01557686"
1811,"NCT01555580","A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis",,"Unknown status","No Results Available","Myasthenia Gravis","Drug: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)","Safety of GM-CSF in patients with myasthenia gravis|The change from baseline in the quantitative and functional (suppressive capacity) characterization of circulating regulatory T cells at 30 days post-treatment|The change from baseline in the quantitative and functional (suppressive capacity) characterization of circulating regulatory T cells at 60 days post-treatment|The change from baseline in the quantitative and functional (suppressive capacity) characterization of circulating regulatory T cells at 120 days post-treatment|Change from baseline in the Quantitative Myasthenia Gravis (QMG) score at 60 days|Change from baseline in the Quantitative Myasthenia Gravis (QMG) score at day 120|Change from baseline in the Myasthenia Gravis Composite score at day 60|Change from baseline in the Myasthenia Gravis Composite score at day 120|Change from baseline in Manual Muscle Testing (MMT) score at day 60|Change from baseline in Manual Muscle Testing (MMT) score at day 120|Change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score at day 60|Change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score at day 120|Change from baseline in Quality of Life Assessment (SF-36) at day 60|Change from baseline in Quality of Life Assessment (SF-36) at day 120|Change from baseline in acetylcholine receptor antibody titre level at day 60|Change from baseline in acetylcholine receptor antibody titre level at day 120|Change from baseline in prednisone dose at day 60|Change from baseline in prednisone dose at day 120 Days","Muscular Dystrophy Association","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MDA 2011 MG GM-CSF","April 2012","December 2013","December 2013","March 15, 2012","null","March 15, 2012","University of Illinois at Chicago, Department of Neurology, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT01555580"
1812,"NCT01552252","Evaluation of an Apple Juice Drink With POs-Ca",,"Completed","No Results Available","Food Preferences","Dietary Supplement: apple juice|Dietary Supplement: apple juice with 0.5% POs-Ca|Dietary Supplement: apple juice with 1% POs-Ca|Dietary Supplement: apple juice with 1.5% POs-Ca|Dietary Supplement: apple juice with 2% POs-Ca","Visual Analogue Scale of taste palatability","Hitomi Mita|Tokyo Medical and Dental University","All","18 Years to 25 Years   (Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","POs-Ca02","March 2010","March 2010","March 2012","March 13, 2012","null","March 13, 2012","","","https://ClinicalTrials.gov/show/NCT01552252"
1813,"NCT01550731","Preparing Older Veterans With Serious and Chronic Illness for Decision Making","PREPARE","Completed","No Results Available","Aging","Behavioral: PREPARE website|Behavioral: Advance directive","Advance directive documentation|Engagement in advance care planning behaviors","VA Office of Research and Development","All","60 Years and older   (Adult, Older Adult)","Early Phase 1","414","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","IIR 11-110","July 2012","June 2016","June 2016","March 12, 2012","null","July 27, 2016","San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT01550731"
1814,"NCT01550627","Effect of Intravenous Fluid Supplementation on Serum Bilirubin and Cardiorespiratory Parameters in Preterm Infants During Phototherapy",,"Completed","No Results Available","Hyperbilirubinemia","Other: extra fluid/iv fluid supplementation during phototherapy|Other: Non extra fluid","The maximum total serum bilirubin levels","University of Jena","All","up to 1 Week   (Child)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2127-10/09","November 2007","June 2009","June 2009","March 12, 2012","null","March 12, 2012","University Hospital of Jena, Jena, Germany","","https://ClinicalTrials.gov/show/NCT01550627"
1815,"NCT01550419","Effect of Atorvastatin on the Frequency of Ventilator-associated Pneumonia in Patients With Ischemic Stroke",,"Unknown status","No Results Available","Ventilator-associated Pneumonia|Ischemic Stroke","Drug: Atorvastatin|Drug: Placebo","Cumulative frequency of ventilator-associated pneumonia|Mortality|Ventilation free days|Antibiotic free days|Whether the bacteria of multidrug-resistance can be isolated from the sputum culture|Adverse effects","Shanghai Minhang Central Hospital|Shanghai Jiao Tong University School of Medicine","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","MHC Hospital 01","March 2012","February 2014","February 2014","March 12, 2012","null","February 26, 2013","Shanghai Minhang Central Hospital, Shanghai, China","","https://ClinicalTrials.gov/show/NCT01550419"
1816,"NCT01549457","TB mHealth Study - Use of Cell Phones to Improve Compliance in Patients on LTBI Treatment",,"Unknown status","No Results Available","Latent Tuberculosis Infection","Other: Cell phone text messages","Successful completion of LTBI treatment regimens.","University of British Columbia|British Columbia Cancer Agency","All","19 Years and older   (Adult, Older Adult)","Early Phase 1","350","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","H11-02216","April 2012","October 2016","October 2016","March 9, 2012","null","October 12, 2015","New Westminster TB Control Clinic, New Westminster, British Columbia, Canada|Vancouver Downtown TB Control Clinic, Vancouver, British Columbia, Canada|Vancouver TB Control Clinic (VTC),, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT01549457"
1817,"NCT01545401","Empowering Primary Care Providers and Patients to Improve Chronic Disease Outcomes: The EMPOWER Participatory Action Research (EMPOWER - PAR)",,"Completed","No Results Available","Type 2 Diabetes Mellitus|Hypertension (Without Type 2 Diabetes Mellitus)","Other: EMPOWER-PAR Intervention","Change in the proportion of patients achieving glycaemic and BP control|Change in the proportion of patients achieving clinical targets:|Other secondary outcome measures","Ministry of Health, Malaysia|Ministry of Education, Malaysia|Universiti Teknologi Mara","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","1545","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","NMRR-11-250-8769","January 2012","June 2014","June 2014","March 6, 2012","null","September 19, 2014","Universiti Teknologi MARA, Batu Caves, Selangor, Malaysia","","https://ClinicalTrials.gov/show/NCT01545401"
1818,"NCT01544075","Efficacy of Pain Neurophysiology Education in Combination With Psychologic Inoculation in Chronic Whiplash",,"Unknown status","No Results Available","Pain, Chronic|Whiplash Injury","Behavioral: Pain neurophysiology education (PNE) and psychologic inoculation (PI)|Behavioral: Neck school (NS)","Change in pain pressure thresholds (conditioned pain modulation)|Change in scores on the Neck Disability Index questionnaire|Changes in the scores on the Neurophysiology of Pain Test Questionnaire|Changes in scores on the Tampa Scale Kinesiophobia Questionnaire|Changes in scores on the Pain Catastrophizing Scale Questionnaire|Changes in score on the Pain Coping Inventory Questionnaire|Changes in the Chronic Pain Self Efficacy Questionnaire|Changes in the scores on the Whiplash Associated Disorders Symptom list|Changes in scores on the Short Form 36 questionnaire|Changes in range of movement and pain during the Brachial Plexus Provocation Test|Changes in pain during the Neck Extension Test|Changes is force during the Cranio Cervical Flexion Test|Hospital Anxiety and Depression Scale|Impact of Events Scale","Vrije Universiteit Brussel","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","143201112788","February 2012","September 2015","null","March 5, 2012","null","June 3, 2015","Artesis College Antwerp, Antwerp, Belgium","","https://ClinicalTrials.gov/show/NCT01544075"
1819,"NCT01543009","Use of Local Warming in Children Venipuncture",,"Suspended","No Results Available","Phobia Phlebotomy","Other: Emla + Local Warming","rate of success of peripheral venous cannulation at the first attempt|pain perceived by the child undergone to the cannulation|Difficulty in performing cannulation perceived by Nurse|Time needed to obtain cannulation","University of Florence","All","8 Years to 13 Years   (Child)","Early Phase 1","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","UFI2012WARM","March 2012","October 2015","October 2016","March 2, 2012","null","October 29, 2015","Meyer Children Hospital, Florence, Italy","","https://ClinicalTrials.gov/show/NCT01543009"
1820,"NCT01542073","68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Myocardial Infarction","GRGDMI","Unknown status","No Results Available","Coronary Artery Disease","Drug: 68Ga-BNOTA-PRGD2","Visual and semiquantitative assessment (Standardized Uptake Values = SUVs) of myocardial infarction region and normal left ventricular wall|Number of participants with adverse events","Peking Union Medical College Hospital","All","30 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PUMCHNM003","February 2012","December 2017","December 2017","March 1, 2012","null","April 7, 2017","Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT01542073"
1821,"NCT01541436","Remote Ischemic Preconditioning Mechanism Study",,"Completed","No Results Available","Pain","Device: Remote Ischemic Preconditioning, Capsaicin, UV-B","Areas of hyperalgesia and allodynia to mechanical stimuli.|Pain intensity and unpleasantness to mechanical stimuli|Presence of parathesias where RIPC was used","Wake Forest University Health Sciences","All","18 Years to 55 Years   (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","00019284","March 2012","March 2016","April 30, 2017","March 1, 2012","null","August 10, 2018","WakeForestUBMC, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01541436"
1822,"NCT01539447","Influence of Naproxen on Heterotropic Bone Formation Following Hip Arthroscopy",,"Active, not recruiting","No Results Available","Heterotopic Ossification","Drug: Naproxen|Drug: placebo","Number of participants with documented Heterotopic Ossification (HO) in the Naproxen group vs Placebo group|Number of participants with adverse events in the Naproxen group vs Placebo group.","University of Utah","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","342","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","48961","January 2012","January 2019","January 2019","February 27, 2012","null","June 6, 2018","University of Utah Orthopedics Center, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01539447"
1823,"NCT01537861","Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma",,"Terminated","No Results Available","Multiple Myeloma","Drug: Filgrastim|Drug: Bortezomib|Drug: Carfilzomib|Drug: Dexamethasone|Drug: Cyclophosphamide|Drug: Thalidomide|Drug: Lenalidomide|Drug: Pomalidomide","Safety of the combination of G-CSF and bortezomib-, carfilzomib-, or IMID-based treatment regimens in patients with refractory multiple myeloma.|Effects of G-CSF on bone marrow and bone marrow cytokine and chemokine levels. Including: Quantification of marrow osteoblasts and CAR cells, measurement of SDF-1 (CXCL12), IL-6, BAFF, assessment of myeloma cell proliferation and survival in bone marrow|Response rate as defined by the International Myeloma Working Group (IMWG) criteria|Overall survival duration of patients treated on study|Progression-free survival of patients treated on study|Duration of response of patients treated on study","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201204086","June 2012","February 2014","December 2014","February 23, 2012","null","January 26, 2015","Washington University School of Medicine, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT01537861"
1824,"NCT01536522","Asthma Inflammation Research","AIR","Recruiting","No Results Available","Asthma|Allergic Asthma|Non-allergic Asthma","Dietary Supplement: Nutritional approach for asthma|Dietary Supplement: Low Caloric Shake|Biological: whole lung allergen challenge","Maintaining a tolerance to Medium Chain Triglyceride (MCT) additive for Asthmatics|Improvement of lung function by spirometry testing|Asthma Quality of Life Questionnaire|Asthma Control Test|Gastrointestinal tolerance of a Medium Chain Triglyceride additive to a normal diet in Asthmatics","The Cleveland Clinic","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","10-1049|PAR-09-185","January 2011","June 2021","June 2021","February 22, 2012","null","August 15, 2018","Cleveland Clinic, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01536522"
1825,"NCT01533285","Exploratory Study on the Mood and Cytokine Levels in Female Healthy Participants and Major Depressive Disorder Patients",,"Completed","No Results Available","Major Depressive Disorder","Biological: Placebo|Biological: Salmonella typhi vaccine (Typhim Vi)","Change in Profile of Mood States (POMS) scores from Baseline to Day 1 of Period 1 and Period 2.|Change in Visual Analogue Scale (VAS) scores from Baseline to Day 1 of Period 1 and Period 2.|Change in Snaith-Hamilton Pleasure Scale (SHAPS) scores from Baseline to Day 1 of Period 1 and Period 2.|Change in Montgomery-Asberg Depression Rating Scale (MADRS) scores from Baseline to Day 1 of Period 1 and Period 2.|Change in Cognitive Test Battery performance from Baseline to Day 1 of Period 1 and Period 2.|Changes in levels of hormones and cytokines from Baseline to Day 1 of Period 1 and Period 2.","Janssen Pharmaceutica N.V., Belgium","Female","25 Years and older   (Adult, Older Adult)","Early Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CR100698|NOCOMPOUNDEDI0002|2011-004898-80","May 2012","November 2013","November 2013","February 15, 2012","null","March 28, 2014","Duffel, Belgium|Leuven, Belgium","","https://ClinicalTrials.gov/show/NCT01533285"
1826,"NCT01532596","Mindfulness Meditation in Older Adults","MIND","Completed","No Results Available","Aging","Behavioral: Mindfulness-Based Stress Reduction","Functional Neural Activity|Pro-inflammation|Loneliness|Psychological Distress","University of California, Los Angeles","All","55 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MBSR-Older-00001","January 2008","January 2009","January 2009","February 14, 2012","null","February 14, 2012","Cousins Center for Psychoneuroimmunology, UCLA, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01532596"
1827,"NCT01532024","Exploratory Clinical Study of Neutrophil Activation Probe (NAP) for Optical Molecular Imaging in Human Lungs","NAP","Unknown status","No Results Available","Acute Lung Injury","Other: Microdose of NAP","Image Neutrophil activity|Safety","University of Edinburgh|Medical Research Council","Male","18 Years to 60 Years   (Adult)","Early Phase 1","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NAP|2011-006169-17","October 2014","May 2016","null","February 13, 2012","null","January 20, 2016","Ward 118, Intensive Care, Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom|Wellcome Trust Clinical Research Facility, Edinburgh, United Kingdom|Royal Infirmary of Edinbrugh, Edinburgh, United Kingdom","","https://ClinicalTrials.gov/show/NCT01532024"
1828,"NCT01530490","Cabergoline and Hydroxyethyl Starch in Ovarian Hyperstimulation Syndrome Prevention",,"Completed","No Results Available","Complications Associated With Artificial Fertilization|Disorder of Endocrine Ovary","Drug: Cabergoline and Hydroxyethyl Starch|Drug: Hydroxyethyl Starch","risk of ovarian hyperstimulation syndrome|pregnancy rate","Hospital de Cruces","Female","18 Years to 40 Years   (Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CEIC0754","August 2007","August 2008","September 2010","February 10, 2012","null","February 10, 2012","","","https://ClinicalTrials.gov/show/NCT01530490"
1829,"NCT01527058","68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients","GRGDLC","Unknown status","No Results Available","Lung Cancer","Drug: 68Ga-BNOTA-PRGD2","Visual and semiquantitative assessment of lesions and biodistribution|Blood pressure|Pulse|Respiration frequency|Temperature|Routine blood test|Routine urine test|Serum alanine aminotransferase|Serum albumin|Serum creatinine|Adverse events collection","Peking Union Medical College Hospital","All","30 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PUMCHNM002","December 2011","December 2017","December 2017","February 6, 2012","null","April 7, 2017","Department of Nuclear Medicine, Peking Union Medical College Hopital, Beijing, China","","https://ClinicalTrials.gov/show/NCT01527058"
1830,"NCT01526824","Lovaza's Effect on Clopidogrel in a Neuro Population",,"Unknown status","No Results Available","Ischemic Stroke|Transient Ischemic Attack","Dietary Supplement: omega-3 polyunsaturated fatty acids (Lovaza)","PRU and % inhibition of P2Y12 Assay|Neurologic events in each study|HDL, triglycerides, LDL, or total cholesterol|Bleeding","Millard Fillmore Gates Hospital|Kaleida Health","All","25 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHP1061010A","September 2011","September 2013","September 2013","February 6, 2012","null","February 6, 2012","Millmore Fillmore Gates Hospital, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT01526824"
1831,"NCT01525446","Proton Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer",,"Terminated","No Results Available","Non-small Cell Lung Cancer","Radiation: SBRT with proton beam radiation","Feasibility and safety|Safety and tolerability|Toxicity|Efficacy|Disease Free survival|Overall survival","Massachusetts General Hospital|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","7","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-021","September 2011","December 2015","December 2015","February 3, 2012","null","February 17, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01525446"
1832,"NCT01524185","FamilyLive Feasibility and Effectiveness Study",,"Withdrawn","No Results Available","Mood Lability|PTSD|Anxiety","Behavioral: FamilyLive|Behavioral: Standard Mental Health Treatment","To examine the feasibility of recruiting and conducting the proposed intervention and evaluation procedures on a cohort of children exposed to neglect and their caregivers using a randomized design.|Examine the effects of FL on heart rate variability, behavior, post traumatic stress disorder symptoms, and functioning","Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Substance Abuse and Mental Health Services Administration (SAMHSA)","All","5 Years to 80 Years   (Child, Adult, Older Adult)","Early Phase 1","0","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NA_00022038","February 2009","January 8, 2016","January 8, 2016","February 1, 2012","null","April 9, 2018","Kennedy Krieger Institute, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01524185"
1833,"NCT01524172","Yoga Based Psychotherapy Group Feasibility and Efficacy Study",,"Completed","No Results Available","Emotional Lability|PTSD","Behavioral: Yoga Based Psychotherapy Group|Behavioral: Standard Mental Health Treatment","To examine the feasibility of recruiting and conducting the proposed intervention and evaluation procedures on a cohort of children exposed to neglect and trauma and their caregivers using a randomized design.|Examine the effects of YBMT on heart rate variability, behavior, post traumatic stress disorder symptoms, and functioning.","Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Substance Abuse and Mental Health Services Administration (SAMHSA)","All","8 Years to 12 Years   (Child)","Early Phase 1","20","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NA_00021817","January 2009","August 23, 2017","August 23, 2017","February 1, 2012","null","April 9, 2018","Kennedy Krieger Institute, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01524172"
1834,"NCT01524016","68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia",,"Unknown status","No Results Available","Oncogenic Osteomalacia|Mesenchymal Tumor","Drug: 68Ga-DOTATATE","Number and location of lesions detected by 68GA-DOTATATE PET/CT compared to 99mTc-HYNIC-TOC SPECT/CT and/or 18F-FDG PET/CT|Number of participants and kinds of adverse events as a measure of safety","Peking Union Medical College Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PUMCHNM001","December 2011","December 2017","December 2017","February 1, 2012","null","April 7, 2017","Department of Nuclear Medicine, Peking Union Medical College Hopital, Beijing, China","","https://ClinicalTrials.gov/show/NCT01524016"
1835,"NCT01520441","BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)",,"Withdrawn","No Results Available","Prostate Cancer|Benign Prostatic Hyperplasia|Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)","Drug: BOTOX","Determination the effects of BoNT-A injection on BPH and prostate cancer tissues.|Determination of BOTOX prostate injection on vas deferens tissue","The University of Texas Health Science Center, Houston","Male","50 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","H-25362","March 2011","March 2014","March 2014","January 30, 2012","null","June 3, 2015","University of Texas Houston - Medical School, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01520441"
1836,"NCT01519557","Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders",,"Completed","No Results Available","Schizophrenia|Schizoaffective Disorder","Drug: DAR-100A|Drug: Placebo","Change from Baseline in resting blood flow and neural activity during working memory tasks in the dorsolateral prefrontal cortex (DLPFC)after 5 days study drug administration.|Change from Baseline in cognitive performance after 5 days study drug administration.","New York State Psychiatric Institute","All","18 Years to 55 Years   (Adult)","Early Phase 1","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","#6329|U01MH076544-03","April 2011","August 2013","November 2013","January 27, 2012","null","March 4, 2015","New York State Psychiatric Institute, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01519557"
1837,"NCT01519310","Gut Flora Dependent Metabolism of Dietary Phosphatidylcholine and Cardiovascular Disease","Glory","Completed","No Results Available","Nutrition","Other: Antibiotic (metronidazole and ciprofloxacin)/probiotic","Primary Outcome|Secondary Outcome Measures","The Cleveland Clinic","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","09-988","April 2010","October 2014","October 2014","January 26, 2012","null","March 3, 2016","Cleveland Clinic, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01519310"
1838,"NCT01518478","Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot",,"Completed","No Results Available","Atopic Dermatitis","Drug: Fluzone® Intradermal (Sanofi Pasteur Inc.)","Change from Baseline (Day 0) HAI Antibody Titers|Change from Baseline (Day 0) Influenza-specific T Cell Populations|Change from Baseline (Day 0) Influenza-specific Interferon Gamma and/or Granzyme B Producing Cells|Change from Baseline (Day 0) Microarray Analysis","National Institute of Allergy and Infectious Diseases (NIAID)|Atopic Dermatitis Research Network","All","18 Years to 64 Years   (Adult)","Early Phase 1","40","NIH|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","DAIT ADRN-03","November 2011","February 2012","March 2012","January 26, 2012","null","March 1, 2017","National Jewish Health, Denver, Colorado, United States","","https://ClinicalTrials.gov/show/NCT01518478"
1839,"NCT01518426","Evaluation of Evoked Potentials Recording Modalities in Healthy Volunteer Population","3Electrods","Completed","No Results Available","Attitude to Computers","Device: EEG Recording (Emotiv)","Wilcoxon statistic (Area Under the Curve)","Centre d'Investigation Clinique et Technologique 805|National Research Agency, France","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2011-A00102-39","June 2012","July 2012","July 2012","January 26, 2012","null","May 6, 2014","Raymond Poincaré Hospital, Garches, Paris Area, France","","https://ClinicalTrials.gov/show/NCT01518426"
1840,"NCT01513499","Effect of Intranasal Oxytocin on Appetite and Caloric Intake in Men and Women",,"Completed","No Results Available","Eating Behavior","Drug: Oxytocin|Drug: Placebo","Caloric intake|Appetite|Resting energy expenditure","Massachusetts General Hospital","All","18 Years to 45 Years   (Adult)","Early Phase 1","25","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","MGH1004","January 2012","January 2014","January 2014","January 20, 2012","null","February 16, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01513499"
1841,"NCT01513356","Pharmacodynamic Study of BKM120 in Breast Cancer",,"Completed","No Results Available","Breast Cancer","Drug: BKM120","- To determine the grade of inhibition of PI3K/mTOR pathways, in pre-surgery setting with BKM120|Number, grade and relationship of adverse events with BKM120|Potential predictive biomarkers (PI3K mutation, KRAS, pAkt and RPS6p) for a pathologic complete response relating to BKM120","Sofia Perea, Director Clinical Trials Unit.|Novartis|Grupo Hospital de Madrid","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","CBKM120XES01T","October 2012","February 2014","February 2014","January 20, 2012","null","April 2, 2014","Hospital Madrid Norte Sanchinarro- CIOCC, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT01513356"
1842,"NCT01511991","Sevoflurane's Effect on Mitral Valve Annular Velocity in Cardiac Surgery",,"Completed","No Results Available","Valvular Heart Disease","Drug: Sevoflurane dosage titration","Peak mitral annular velocity during systole (S')|Peak mitral annular velocity during early filling (E')|peak mitral annular velocity during atrial contraction(A')|ejection fraction (EF)|bispectral index (BIS)|peak velocity of mitral inflow during early relaxation (E)|peak velocity of mitral inflow during atrial contraction (A)","Konkuk University Medical Center","All","20 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","KUH1160037","May 2009","May 2014","May 2014","January 19, 2012","null","February 24, 2015","Konkuk University Medical Center, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01511991"
1843,"NCT01511640","Behavioral Effects of Pregabalin and Cannabis",,"Recruiting","No Results Available","Cannabis-use Disorders","Drug: Pregabalin|Drug: Placebo","number of self-administered puffs of smoked cannabis containing active THC concentrations compared to placebo under controlled laboratory conditions","Joshua A. Lile, Ph.D.|University of Kentucky","All","18 Years to 50 Years   (Adult)","Early Phase 1","13","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","R01DA036550","February 1, 2017","June 30, 2019","December 31, 2019","January 18, 2012","null","May 7, 2018","Laboratory of Human Behavioral Pharmacology, Lexington, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT01511640"
1844,"NCT01500629","Study of a Topical Nasal Spray to Ease the Symptoms of Hayfever",,"Completed","Has Results","Rhinitis, Allergic, Seasonal","Device: C-1266-7|Device: C-1266-6 (placebo)","Change From Baseline in the Total Nasal Symptom Score (TNSS) at 15 Minutes After the First Allergan Challenge|Change From Baseline in the Total Nasal Symptom Score (TNSS) at 1 Hour After the First Allergen Challenge|Change From Baseline in the Total Nasal Symptom Score (TNSS) at 15 Minutes After the Second Allergen Challenge|Change From Baseline in the Total Nasal Symptom Score (TNSS) at 1 Hour After the Second Allergen Challenge|Change From Baseline in Number of Sneezes at 15 Minutes After the First Allergen Challenge|Change From Baseline in Number of Sneezes at 1 Hour After the First Allergen Challenge|Change From Baseline in Number of Sneezes at 15 Minutes After the Second Allergen Challenge|Change From Baseline in Number of Sneezes at 1 Hour After the Second Allergen Challenge|Change From Baseline of Individual Nasal Symptoms Score (NSS) for Sneezing at 15 Minutes After the First Allergen Challenge|Change From Baseline of Individual Nasal Symptoms Score (NSS) for Sneezing at 1 Hour After the First Allergen Challenge|Change From Baseline of Individual Nasal Symptoms Score (NSS) for Sneezing at 15 Minutes After the Second Allergen Challenge|Change From Baseline of Individual Nasal Symptoms Score (NSS) for Sneezing at 1 Hour After the Second Allergen Challenge|Change From Baseline of Individual Nasal Symptoms Score (NSS) for Itchy Nose at 15 Minutes After the First Allergen Challenge|Change From Baseline of Individual Nasal Symptoms Score (NSS) for Itchy Nose at 1 Hour After the First Allergen Challenge|Change From Baseline of Individual Nasal Symptoms Score (NSS) for Itchy Nose at 15 Minutes After the Second Allergen Challenge|Change From Baseline of Individual Nasal Symptoms Score (NSS) for Itchy Nose at 1 Hour After the Second Allergen Challenge|Change From Baseline of Individual Nasal Symptoms Score (NSS) for Runny Nose at 15 Minutes After the First Allergen Challenge|Change From Baseline of Individual Nasal Symptoms Score (NSS) for Runny Nose at 1 Hour After the First Allergen Challenge|Change From Baseline of Individual Nasal Symptoms Score (NSS) for Runny Nose at 15 Minutes After the Second Allergen Challenge|Change From Baseline of Individual Nasal Symptoms Score (NSS) for Runny Nose at 1 Hour After the Second Allergen Challenge|Change From Baseline of Individual Nasal Symptoms Score (NSS) for Nasal Congestion at 15 Minutes After the First Allergen Challenge|Change From Baseline of Individual Nasal Symptoms Score (NSS) for Nasal Congestion at 1 Hour After the First Allergen Challenge|Change From Baseline of Individual Nasal Symptoms Score (NSS) for Nasal Congestion at 15 Minutes After the Second Allergen Challenge|Change From Baseline of Individual Nasal Symptoms Score (NSS) for Nasal Congestion at 1 Hour After the Second Allergen Challenge|Total Ocular Symptoms Score (TOSS) at 15 Minutes After the First Allergen Challenge|Total Ocular Symptoms Score (TOSS) at 1 Hour After the First Allergen Challenge|Total Ocular Symptoms Score (TOSS) at 15 Minutes After the Second Allergen Challenge|Total Ocular Symptoms Score (TOSS) at 1 Hour After the Second Allergen Challenge|Change From Baseline of Non Nasal Symptoms Score (NNSS) at 15 Minutes After the First Allergen Challenge|Change From Baseline of Non Nasal Symptoms Score (NNSS) at 1 Hour After the First Allergen Challenge|Change From Baseline of Non Nasal Symptoms Score (NNSS) at 15 Minutes After the Second Allergen Challenge|Change From Baseline of Non Nasal Symptoms Score (NNSS) at 1 Hour After the Second Allergen Challenge|Within Subject Improvement From Placebo in TNSS (Responder) at 15 Minutes After the First Allergen Challenge|Within Subject Improvement From Placebo in TNSS (Responder) at 1 Hour After the First Allergen Challenge|Within Subject Improvement From Placebo in TNSS (Responder) at 15 Minutes After the Second Allergen Challenge|Within Subject Improvement From Placebo in TNSS (Responder) at 1 Hour After the Second Allergen Challenge|Change From Baseline of the Total Score From the Following Nasal Symptoms (TNSSX [Total Nasal Symptom Score Excluding Sneezing]): Itchy Nose, Runny Nose, Nasal Congestion at 15 Minutes After the First Allergen Challenge|Change From Baseline of the Total Score From the Following Nasal Symptoms (TNSSX [Total Nasal Symptom Score Excluding Sneezing]): Itchy Nose, Runny Nose, Nasal Congestion at 1 Hour After the First Allergen Challenge|Change From Baseline of the Total Score From the Following Nasal Symptoms (TNSSX [Total Nasal Symptom Score Excluding Sneezing]): Itchy Nose, Runny Nose, Nasal Congestion at 15 Minutes After the Second Allergen Challenge|Change From Baseline of the Total Score From the Following Nasal Symptoms (TNSSX [Total Nasal Symptom Score Excluding Sneezing]): Itchy Nose, Runny Nose, Nasal Congestion at 1 Hour After the Second Allergen Challenge","McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.|Johnson & Johnson Consumer and Personal Products Worldwide","All","18 Years to 55 Years   (Adult)","Early Phase 1","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)","POCEXP0001","January 2012","December 2012","December 2012","December 28, 2011","May 9, 2014","February 27, 2017","The University of Chicago, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT01500629"
1845,"NCT01498237","Photoacoustic Endoscopy in Endometrial Cancer",,"Withdrawn","No Results Available","Endometrial Cancer|Benign Neoplasm of Body of Uterus","Device: Photoacoustic endoprobe|Procedure: Photoacoustic endoscopy","Feasibility of using the device to image endometrial cancer","Washington University School of Medicine","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201102405","January 2012","December 2012","December 2012","December 23, 2011","null","July 11, 2013","","","https://ClinicalTrials.gov/show/NCT01498237"
1846,"NCT01495403","Treatment of Muscle Cramps in Patients With Liver Cirrhosis",,"Completed","No Results Available","Liver Cirrhosis|Muscle Cramps","Drug: Hydroxychloroquine","frequency and severity of muscle cramps in cirrhotic patients reporting the symptom, based on the modified muscle cramps questionnaire (mMCQ)|safety and efficacy of HCQ for severe cramping using mMCQ, SF-12, and AE inventory.","Mayo Clinic","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","11-002743","December 2011","April 2015","April 2015","December 20, 2011","null","July 30, 2015","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01495403"
1847,"NCT01494844","Comfort Evaluation of Non-Invasive Respiratory Monitor Interfaces",,"Completed","No Results Available","Respiratory Device Comfort","Device: Respiratory monitor patient interface.","Comfort Rating Self-Report Instrument","University of Alabama at Birmingham|Oridion","All","20 Years to 49 Years   (Adult)","Early Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","X110421003|413525","June 2011","September 2011","September 2011","December 19, 2011","null","August 9, 2013","University of Alabama at Birmingham, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT01494844"
1848,"NCT01493791","CDB-2914 for Abnormal Uterine Bleeding in Premenopausal Women",,"Withdrawn","No Results Available","Urogenital Abnormalities","Drug: CDB-2914","Primary outcome parameters will include bleeding symptoms evaluated by Menorrhagia Impact Questionnaire (MIQ), composite bleeding score, endometrial hyperplasia, changes in hemoglobin (g/dL)|Quality of life as measured by surveys.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","25 Years to 50 Years   (Adult)","Early Phase 1","0","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","120015|12-CH-0015","November 8, 2011","July 24, 2013","July 24, 2013","December 16, 2011","null","October 24, 2018","","","https://ClinicalTrials.gov/show/NCT01493791"
1849,"NCT01493609","A Clinical Trial of a New Computer Based Intervention for Children With Autism.","Click-East","Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Click-East app","Autism Diagnostic Observation Schedule - Change (ADOS-C)","University of Edinburgh|NHS Lothian|Newcastle University","All","15 Months to 6 Years   (Child)","Early Phase 1","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2010/C/PMLD/03|NCF/36343","February 2012","June 2013","June 2013","December 16, 2011","null","November 25, 2013","University of Edinburgh, Edinburgh, Midlothian, United Kingdom|Clinical Research Facility, Royal Hospital for Sick Children, Edinburgh, Midlothian, United Kingdom","","https://ClinicalTrials.gov/show/NCT01493609"
1850,"NCT01489982","Treatments for Insomnia in Patients With Parkinson's Disease",,"Completed","No Results Available","Parkinson's Disease|Insomnia","Device: Light box (Litebook company)|Behavioral: CBT and sleep hygiene|Drug: Doxepin and Zopiclone|Device: Light box ( Litebook company)","SCOPA sleep scale|Actigraphy|Daily sleep dairy|Insomnia severity Index (ISI)|Pittsburgh Sleep Quality Index (PSQI)|Parkinson's Disease Sleep Scale (PDSS)|Clinical global impression of change|The Krupp Fatigue Severity Scale|Beck depression index|Adherence to treatment|Severity of motor manifestations (UPDRS)|Quality of life (PDQ-39)|Adverse events|Sleep Hygiene Index|Dysfunctional Beliefs and Attitudes about Sleep, a brief version ( DBAS 16)|Epworth Sleepiness Scale (ESS)","McGill University Health Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","INS-09-10","January 2011","December 2012","December 2012","December 12, 2011","null","April 16, 2015","Montreal General Hospital, Montreal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT01489982"
1851,"NCT01489956","A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)",,"Terminated","Has Results","Autoimmune Disorders","Biological: Immucothel Alone (Part A)|Biological: Immucothel+Montanide (Part A)|Biological: Immucothel Alone or Immucothel+Montanide (Part B)","Participants With a Positive Immune Response to T Cell Stimulation Index (SI) as Measured by 3H-thymidine Incorporation After in Vitro KLH Stimulation of PBMC (Part A)|Participants Demonstrating Tolerance to KLH Using T Cell Stimulation Index (SI) as Measured by 3H-thymidine Incorporation After in Vitro KLH Stimulation of PBMC (Part B)|T Cell Stimulation Index (SI) as Measured by 3H-thymidine Incorporation After in Vitro KLH Stimulation of PBMC (Part A)|Cytokine Secretion Profile of T Cells Stimulated by KLH (Part A)|T Cell Stimulation Index Measured by Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE) Staining After KLH Stimulation (Part A)|Suppression (or Non-activation) of Cytokine Secretion Profile of T Cells Stimulated by KLH Following Oral Feeding (Part B)|Suppression (or Non-activation) of T Cell Stimulation Index Measured by CFSE Staining After KLH Stimulation (Part B)|Other Mechanistic Assessments on Archived Serum Samples Like Anti-KLH Antibodies and Secreted Cytokines (Part B)|Compare the Level of KLH-specific Antibodies in the Serum (Samples From Various Time Points) Between Parts A and B","National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)","All","18 Years to 50 Years   (Adult)","Early Phase 1","19","NIH|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAIT ITN047AI","December 2011","April 2013","April 2013","December 12, 2011","April 12, 2016","April 12, 2016","Mount Sinai Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01489956"
1852,"NCT01484457","Controlled Insulin Delivery: Combining Technology With Treatment",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Device: Closed-loop session","Restoration of Euglycemia|Average percent-of-time-in-range (80 - 180 mg/dL)","Sansum Diabetes Research Institute|Juvenile Diabetes Research Foundation|Schneider Children's Medical Center, Israel","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JDRF 22-2009-796","July 2008","January 2010","January 2010","December 2, 2011","null","June 7, 2012","Sansum Diabetes Research Institute, Santa Barbara, California, United States|Schneider Children's Medical Center of Israel, Petah Tikva, Israel","","https://ClinicalTrials.gov/show/NCT01484457"
1853,"NCT01483677","Comparison Study of the Nintendo Wii Versus Playstation2 in Enhancing Laparoscopic Skills",,"Completed","No Results Available","Laparoscopy Skills","Other: Nintendo Wii|Other: Playstation 2","Difference in the change in box trainer scores between the Wii and Playstation2 groups.|Change between pretest and post test scores in the Wii group.|Change between pretest and posttest scores for the Playstation2 group","Beth Israel Medical Center","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","023-10","November 2010","March 2011","March 2011","December 1, 2011","null","December 1, 2011","Beth Israel Medical Center of The Albert Einstein College of Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01483677"
1854,"NCT01483365","The Need for Luteal Support in NC-FET",,"Unknown status","No Results Available","Abnormal Menstrual Cycle","Drug: Vaginal tablet Endometrin twice a day","Pregnancy rate","Wolfson Medical Center","Female","18 Years to 39 Years   (Adult)","Early Phase 1","100","Other","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","0087-11-WOMC-","December 2011","December 2014","December 2014","December 1, 2011","null","June 17, 2014","Wolfson medical center, Holon, Israel","","https://ClinicalTrials.gov/show/NCT01483365"
1855,"NCT01483287","The Effects of Added Enzyme α-Galactosidase at a Carbohydrate-rich Meal in Irritable Bowel Syndrome (IBS)",,"Completed","No Results Available","Irritable Bowel Syndrome","Dietary Supplement: Alpha-Galactosidase","Change in symptoms|Changes in expiration air","Sahlgrenska University Hospital, Sweden","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Nogasin","November 2011","June 2013","August 2013","December 1, 2011","null","November 18, 2014","Sahlgrenska University Hospital, Gothenburg, Sweden","","https://ClinicalTrials.gov/show/NCT01483287"
1856,"NCT01482728","Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer",,"Completed","No Results Available","Endometrial Cancer","Drug: Dasatinib","Changes in levels of SFK protein activity in a) endometrial tumor tissue and b) blood induced within two different doses of dasatinib treatment.|Changes in levels of SFK protein activity in blood correlates with changes in levels of SFK protein activity in endometrial tumor tissue induced by two different doses of dasatinib treatment.","University of Virginia","Female","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","15809","January 2012","May 2015","December 2015","November 30, 2011","null","May 13, 2016","University of Virginia, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01482728"
1857,"NCT01479348","Imaging Study for FdCyd and THU Cancer Treatment",,"Completed","No Results Available","Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms","Drug: [F-18]-5-FLUORO-2'-DEOXYCYTIDINE|Drug: Tetrahydrouridine (IV)|Drug: Tetrahydrouridine (oral)|Diagnostic Test: PET/CT","Safety of [F-18]-5-fluoro-2'-deoxycytidine (FdCyd) administered intravenously with administration of tetrahydrouridine (THU)|Estimate the radiation dosimetry of [F-18]-FdCyd in humans|To evaluate the pharmacokinetics of [F-18]- FdCyd via PET/CT|To evaluate the distribution of FdCyd in tumorous and nontumoroustissue","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","5","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","120014|12-C-0014","November 1, 2011","August 4, 2017","August 4, 2017","November 24, 2011","null","July 6, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01479348"
1858,"NCT01478230","An Exploratory Study Comparing Two Nicotine Inhalers",,"Completed","No Results Available","Tobacco Dependence","Drug: Nicotine","Maximum Observed Plasma Concentration (Cmax)|Average Concentration (Cav)|Bioavailability [AUCτ]|Minimum Observed Plasma Concentration (Cmin)|Time of Maximum Concentration (Tmax)|Peak Trough Fluctuation (PTF)|Swing|Baseline-corrected Pre-Dosing Plasma Concentration (Cn)|Residual Nicotine|Urges to Smoke|Overall Liking|Ease of Use","McNeil AB|Johnson & Johnson Consumer and Personal Products Worldwide","All","19 Years to 50 Years   (Adult)","Early Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","NICTDP0002|2011-002796-41","November 2011","December 2011","December 2011","November 23, 2011","null","July 10, 2012","McNeil AB Clinical Pharmacology R&D, Lund, Sweden","","https://ClinicalTrials.gov/show/NCT01478230"
1859,"NCT01477398","Improved Patient Recovery After Anesthesia",,"Completed","No Results Available","Recovery From Anesthesia","Device: QED-100","treatment (inspired CO2) caused patients to breath more vigorously|treatment caused the anesthetic vapors to be cleared more rapidly","University of Utah","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","36354","April 2010","April 2011","April 2011","November 22, 2011","null","August 22, 2016","","","https://ClinicalTrials.gov/show/NCT01477398"
1860,"NCT01475435","Oxidative Stress Markers Evaluation Before and After Periodontal Treatment of Diabetics Type 2 Patients",,"Unknown status","No Results Available","Diabetes Mellitus Type 2","Procedure: non- surgical periodontal treatment|Procedure: Prophylaxis","Evaluate level change of oxidative stress biomarkers in crevicular gingival fluid and whole saliva on diabetes type 2 individuals","University of Sao Paulo|Federal University of São Paulo","All","30 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","DMSAL2712","August 2011","December 2011","August 2013","November 21, 2011","null","November 21, 2011","University of São Paulo, São Paulo, SP, Brazil","","https://ClinicalTrials.gov/show/NCT01475435"
1861,"NCT01472406","Feasibility Study Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS)",,"Unknown status","No Results Available","Type 1 Diabetes Mellitus","Device: Sansum Closed-Loop Artificial Pancreas|Device: Insulin infusion pump|Device: Continuous Glucose Monitor|Device: zone-Model Predictive Control algorithm|Device: Safety Health Monitoring System","% of time within zone [80-140] mg/dL except 5 hours post-prandial and during exercise and 3 hours post-exercise|% of time within zone [80-140] mg/dL during night between 12:00 am and 7:00 am|% of time within zone [70-180] mg/dL 5 hours after unannounced evening meal, and breakfast|% of time within zone [70-150] mg/dL during the 30 min exercise|% of time within zone [70-150] mg/dL during the 3 hours following exercise","Sansum Diabetes Research Institute|University of California, Santa Barbara","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DK085628","November 2011","March 2014","March 2014","November 16, 2011","null","May 24, 2013","Sansum Diabetes Research Institute, Santa Barbara, California, United States","","https://ClinicalTrials.gov/show/NCT01472406"
1862,"NCT01472211","Water-based Zinc Intervention Trial in Zinc Deficient Children",,"Terminated","No Results Available","Zinc Deficiency|Diarrhea","Device: zinc enriching filter (LifeStrawFamily)|Device: placebo filter|Other: disinfection tablets","Zinc status|Gut microbiota characterisation|Iron status|Growth rate|Diarrhea prevalence","Swiss Federal Institute of Technology|Université d'Abomey-Calavi","All","2 Years to 5 Years   (Child)","Early Phase 1","317","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LSF_zinc_study","September 2011","December 2011","September 2012","November 16, 2011","null","June 18, 2013","Hopital de Zone, Natitingou, Atacora, Benin","","https://ClinicalTrials.gov/show/NCT01472211"
1863,"NCT01472172","Pleural Cryobiopsies During Semirigid Thoracoscopy: A New Technique",,"Completed","No Results Available","Pleural Effusion|Pleural Diseases","Device: Cryobiopsy (Autoclavable cryoprobe 20416-032)","Number / percent of patients with useful pleural biopsy sample, obtained by cryoprobe|Size of biopsy samples|Quality of the sample|Bleeding","The University Clinic of Pulmonary and Allergic Diseases Golnik","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Endo-0002","February 2010","November 2013","November 2013","November 16, 2011","null","December 5, 2013","University Clinic Golnik, Golnik 36, Golnik, Slovenia","","https://ClinicalTrials.gov/show/NCT01472172"
1864,"NCT01471951","Single Human Embryo Transfer in Assisted Reproduction Programs","SET","Unknown status","No Results Available","Multiple Pregnancies","Other: Single embryo transfer in women at risk of multiple pregnancies","Implantation rate|Morphologic embryo selection|Morphometric embryo selection","Fundacion Para La Investigacion Hospital La Fe","Female","18 Years to 35 Years   (Adult)","Early Phase 1","154","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2011/0329","November 2011","December 2013","June 2014","November 16, 2011","null","November 16, 2011","Hospital Universitari La Fe, Valencia, Spain","","https://ClinicalTrials.gov/show/NCT01471951"
1865,"NCT01468649","Real-Time Near-infrared (NIR) Mapping of Sentinel Lymph Nodes in Breast Cancer",,"Completed","No Results Available","Breast Cancer","Device: NIR Imaging with FLARE and Mini-FLARE Imaging System","Sensitivity of Real-Time Intraoperative NIR Mapping|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Dana-Farber Cancer Institute","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","2007P000431","June 2011","February 2013","December 2013","November 9, 2011","null","March 7, 2017","Dana Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01468649"
1866,"NCT01468298","Global Posture Reeducation (GPR) Compared To Isostretching in Chronic Low Back Pain Patients",,"Unknown status","No Results Available","Low Back Pain","Other: Isostretching|Other: Global Posture Reeducation","functional capacity|Posture|flexibility|muscle strength|heart rate(HR)|peripheral oxygen saturation|systolic blood pressure|diastolic blood pressure|Intensity of Pain","Centro Universitario de Maringa","All","40 Years to 60 Years   (Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","249/2010","August 2010","October 2011","December 2011","November 9, 2011","null","November 9, 2011","Centro Universitário de Maringá, Maringá, Paraná, Brazil","","https://ClinicalTrials.gov/show/NCT01468298"
1867,"NCT01467310","Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212",,"Completed","No Results Available","Breast Cancer","Drug: GSK1120212","the number and type of kinases in participant tissue sample prior to administration of drug compared to post-treatment.|the number and type of kinases that produce a compensatory response to MEK inhibitor|the number of participants with adverse events","UNC Lineberger Comprehensive Cancer Center|GlaxoSmithKline|National Cancer Institute (NCI)|Susan G. Komen Breast Cancer Foundation","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","LCCC 1122|11-1689|CA058223","January 2012","April 2016","April 2016","November 8, 2011","null","March 13, 2017","Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01467310"
1868,"NCT01465113","Vitamin D Supplementation on 15-Prostaglandin Dehydrogenase Expression in Barrett's Esophagus",,"Completed","No Results Available","Short Segment Barrett's Esophagus|Long Segment Barrett's Esophagus","Drug: Omeprazole|Drug: Vitamin D3|Procedure: upper endoscopy|Drug: Metformin","Arm 1(no or low grade dysplasia): 15-Prostaglandin dehydrogenase expression|Arm 2 (high grade dysplasia): 15-Prostaglandin dehydrogenase expression|decreased prostaglandin E2 expression in Barrett's esophagus|effects on cyclooxygenase-2 expression|15-Prostaglandin dehydrogenase expression differences between RT-PCR and immunohistochemistry|effects on levels of Ki-67|effects on levels of caspase|effects on insulin resistance","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","26","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CASE12209","May 2010","February 2016","February 2016","November 4, 2011","null","March 10, 2016","University Hospitals Ahuja Medical Center, Beachwood, Ohio, United States|Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01465113"
1869,"NCT01464528","Safety Study of Use of Hyaluronic Acid Gel To Prevent Intrauterine Adhesions In Hysteroscopic Surgery",,"Unknown status","No Results Available","Tissue Adhesions","Drug: Hyaluronan","Patient satisfaction following gel application","Hadassah Medical Organization","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","HYALOBARRIER- HMO-CTIL","November 2011","March 2012","May 2012","November 3, 2011","null","November 3, 2011","","","https://ClinicalTrials.gov/show/NCT01464528"
1870,"NCT01463852","A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL)",,"Terminated","No Results Available","Chronic Lymphocytic Leukemia (CLL)","Drug: vincristine","c-Jun N-terminal Kinase (JNK) activation","Dartmouth-Hitchcock Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D11199","October 2012","December 2014","December 2014","November 2, 2011","null","May 12, 2015","Dartmouth-Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, New Hampshire, United States","","https://ClinicalTrials.gov/show/NCT01463852"
1871,"NCT01463319","Warm Water and Unsedated Colonoscopy","WW","Completed","No Results Available","Gastrointestinal Diseases|Digestive System Diseases","Other: air insufflation|Other: warm water irrigation","number of patients undergoing complete unsedated or slightly sedated colonoscopy|evaluation of pain and tolerability scores|percentage of caecum intubation|time to reach caecum|Adenoma detection rate","Presidio Ospedaliero Santa Barbara","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","818","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)","ASL07_WW-2011","November 2011","September 2012","September 2012","November 1, 2011","null","February 8, 2013","Servizio Endoscopia Digestiva, Iglesias, Carbonia-Iglesias, Italy|U.O.S.D. Diagnostica e Terapia Endoscopica, San Gavino Monreale, Medio Campidano (VS), Italy","","https://ClinicalTrials.gov/show/NCT01463319"
1872,"NCT01459237","Effects of Hormone Stimulation on Brain Scans for Cushing s Disease",,"Completed","No Results Available","Pituitary Neoplasm","Drug: Acthrel","To determine effect of CRH stimulation on 18F-FDG uptake in high-resolution PET-imaging of ACTH-adenomas in CD.|To determine if CRH stimulation (compared to without CRH stimulation) enhances the detection of ACTH-adenomas as demonstrated on 18F-FDG high-resolution PET-imaging in CD.|To assess the accuracy and sensitivity of 18F-FDG high-resolution PET-imaging detection of ACTH-adenomas in CD compared to MR-imaging.","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","8 Years and older   (Child, Adult, Older Adult)","Early Phase 1","30","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","120007|12-N-0007","October 11, 2011","January 30, 2018","June 12, 2018","October 25, 2011","null","June 14, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01459237"
1873,"NCT01453868","The Effects of Aerobics Training on Balance in Patients With Multiple Sclerosis","NIA","Unknown status","No Results Available","Multiple Sclerosis, Relapsing-Remitting","Other: Non Impact Aerobics|Other: Passive : lecture series","Biodex Scale Balance score: Automated|Pre and post intervention questionaire","Nelson Mandela Metropolitan University","All","20 Years to 60 Years   (Adult)","Early Phase 1","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","H11-HEA-HMS-002","October 2011","March 2012","June 2012","October 18, 2011","null","October 18, 2011","HealthZone Chiropractic Clinic, Gaylord, Michigan, United States","","https://ClinicalTrials.gov/show/NCT01453868"
1874,"NCT01453842","Diet Oil Induced Stimulation of GLP-1",,"Completed","No Results Available","Type 2 Diabetes Mellitus","Dietary Supplement: Diet oil|Dietary Supplement: Olive oil|Dietary Supplement: Carrot","Plasma GLP-1|Plasma insulin|Plasma glucose|Plasma GIP|Plasma glucagon|Plasma PYY|Plasma paracetamol","University of Copenhagen","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","Diet oil","March 2011","December 2011","March 2012","October 18, 2011","null","December 2, 2014","Department of Clinical Physiology, Glostrup, Denmark","","https://ClinicalTrials.gov/show/NCT01453842"
1875,"NCT01453010","Self-directed Upper Limb Training Using a SaeboFlex in Acute Stroke","SaeboFlex","Unknown status","No Results Available","Stroke","Other: Self-directed Upper Limb SaeboFlex Training","Action Research Arm Test (ARAT)|Motricity Index (MI)|Motor Assessment Scale- Upper Limb Section (UL-MAS).|Visual Analogue Scale|Modified Barthel Index (MBI)|Stroke Impact Scale (SIS)|Berg Balance Test|Questionnaire|Adverse effects or events monitoring and recording","Colchester Hospital University NHS Foundation Trust","All","16 Years and older   (Child, Adult, Older Adult)","Early Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11/H0302/8","May 2011","May 2012","null","October 17, 2011","null","October 17, 2011","Colchester Hospital University Foundational NHS Trust, Colchester, Essex, United Kingdom","","https://ClinicalTrials.gov/show/NCT01453010"
1876,"NCT01451697","Cognitive Remediation for Neuropsychological Impairment in Compulsive Hoarding",,"Unknown status","No Results Available","Hoarding Disorder|Attentional Impairment","Behavioral: Cognitive Remediation|Behavioral: Control (Placebo)","Continuous Performance Task (computerized version): change from Baseline in Attentional Functioning at 8 Weeks","Hartford Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DIMA003472HI","July 2011","July 2012","October 2012","October 14, 2011","null","October 14, 2011","Anxiety Disorders Center, Institute of Living/Hartford, Hartford, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01451697"
1877,"NCT01447992","Feasibility Study of a Portable Artificial Pancreas System in Type 1 Diabetes Mellitus (T1DM) - Padova","HomeCTR1_2","Completed","No Results Available","Type 1 Diabetes Mellitus","Device: Portable artificial pancreas system with Control-To-Range","estimation of the failure rates of system components|frequency analysis of lost or inaccurate CGM records|percent time of active CTR","University of Virginia|University of Padova|University Hospital, Montpellier|University of California, Santa Barbara","All","21 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2433P|JDRF 22-2011-649","September 2011","April 2012","April 2012","October 6, 2011","null","June 19, 2014","Azienda Ospedaliera E Universita Degli Study Di Padova, Padova, Veneto, Italy","","https://ClinicalTrials.gov/show/NCT01447992"
1878,"NCT01447979","Feasibility Study of a Portable Artificial Pancreas System in Type 1 Diabetes Mellitus (T1DM) - Montpellier","HomeCTR1_1","Completed","No Results Available","Type 1 Diabetes Mellitus","Device: portable artificial pancreas system with Control-To-Range algorithms","estimation of the failure rates of system components|frequency analysis of lost or inaccurate CGM records|percent time of active CTR","University of Virginia|University Hospital, Montpellier|University of Padova|University of California, Santa Barbara","All","21 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2011-A01096-35|JDRF 22-2011-649","March 2012","April 2012","April 2012","October 6, 2011","null","November 29, 2012","Centre d'Investigation Clinique CHU Montpellier, Montpellier, France","","https://ClinicalTrials.gov/show/NCT01447979"
1879,"NCT01446068","Comparison of Postprandial Inflammation in Lean and Obese Subjects",,"Completed","No Results Available","Nutritional Intervention|Nutritional and Metabolic Diseases|Obesity","Dietary Supplement: High-fat meal","Interleukin-6 (serum)|Glucose (serum)|Triglyceride (serum)|Insulin (serum)|high sensitivity C-Reactive Protein|HDL-cholesterol|Total cholesterol|Total cholesterol / HDL cholesterol|Glucagon-like-protein-1 (serum)|Endotoxin (serum)","Agroscope Liebefeld-Posieux Research Station ALP|University Hospital Inselspital, Berne","Male","25 Years to 50 Years   (Adult)","Early Phase 1","36","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","NUTRICHIP-1","March 2011","June 2012","January 2013","October 4, 2011","null","June 20, 2013","Agroscope Liebefeld-Posieux ALP Research Station, Berne, Switzerland|University Hospital Inselspital, Berne, Berne, Switzerland","","https://ClinicalTrials.gov/show/NCT01446068"
1880,"NCT01445756","Topical Lidocaine for Pain Control With Intrauterine Device (IUD) Insertion",,"Completed","No Results Available","Pain","Drug: Lidocaine|Drug: Placebo","Change in pain level from no Lidocaine administered to after Lidocaine is administered","University of Wisconsin, Madison","Female","18 Years to 35 Years   (Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Health Services Research","H-2010-0062","July 2010","June 2011","June 2011","October 4, 2011","null","August 26, 2014","University Health Services Women's Care Clinic, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT01445756"
1881,"NCT01445054","111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast Cancer",,"Completed","No Results Available","Breast Cancer|Prostate Cancer|Lung Cancer|Colon Cancer","Drug: 111Indium CHX-A","Compare uptake of 111Indium-CHX-A DTPA trastuzumab with HER2/Neu (ErbB2) status of the tumor as determined by IHC|Safety of 111Indium-trastuzumab.|Optimal timing of 111Indium-CHX-A DTPA trastuzumab imaging as a function of HER2/ Neu(ErbB2) status.|Biodistribution of the agent in normal organs|Pharmacokinetic serum clearance of 111Indium-CHXA DTPA trastuzumab|To evaluate the change in 111Indium-CHX-A DTPA trastuzumab uptake in tumors following treatment with a HER2 targeted therapy","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Female","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","13","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","070101|07-C-0101","March 1, 2007","August 20, 2014","August 20, 2014","October 3, 2011","null","July 6, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01445054"
1882,"NCT01441531","Efficacy of Gabapentin in Prevention of Tourniquet Pain and Hypertension",,"Withdrawn","No Results Available","Tourniquet-induced Pain|Tourniquet-induced Hypertension","Drug: gabapentin 600 mg po|Drug: Placebo pill given one hour before surgery","Incidence of tourniquet-induced hypertension|Postoperative pain|Narcotic use","Baylor College of Medicine","All","18 Years to 64 Years   (Adult)","Early Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H-28860","January 2012","June 2014","June 2014","September 27, 2011","null","March 17, 2015","Ben Taub General Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01441531"
1883,"NCT01436188","A Study to Measure CSF Proteins in Elderly Healthy Volunteers and Volunteers With Mild Cognitive Impairment or Alzheimer's Disease",,"Completed","No Results Available","Healthy|Alzheimer Disease","Procedure: Standard CSR sampling procedure|Procedure: Alternate frequency CSR sampling procedure|Procedure: Standard frequent CSR sampling procedure with 800 mg ibuprofen|Procedure: Alternative lower frequency CSR sampling procedure","Measurement of CSF proteins|The number of volunteers with adverse events","Janssen Research & Development, LLC","All","50 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","5","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","CR100658|NOCOMPOUNDEDI0001|2011-003525-94","September 2011","null","June 2013","September 19, 2011","null","March 18, 2014","Antwerp, Belgium|Groningen, Netherlands|Leiden, Netherlands","","https://ClinicalTrials.gov/show/NCT01436188"
1884,"NCT01435837","Interaction of Caffeine and Hydration on Voice",,"Completed","No Results Available","Voice Disorders","Drug: C2 (200mg of caffeine; 1/2 L of water)|Drug: C3(200mg of caffeine; 1 L of water)|Drug: C1 (200mg of caffeine, no water)|Drug: Placebo (no caffeine, no water).","Effect of caffeine and hydration on acoustic measures of voice.|Effect of caffeine and hydration on aerodynamic measures of voice. Effect of caffeine and hydration on aerodynamic measures of voice.","Southern Illinois University Carbondale","All","18 Years to 35 Years   (Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","09433","October 2010","May 2013","May 2013","September 19, 2011","null","June 11, 2013","Southern Illinois University Carbondale, Carbondale, Illinois, United States","","https://ClinicalTrials.gov/show/NCT01435837"
1885,"NCT01434342","Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients",,"Completed","Has Results","Lung Cancer|Tobacco Use Disorder|Breast Cancer|Colorectal Cancer|Prostate Cancer","Drug: Nicotine Replacement Patch","Feasibility of a Smoking Cessation Intervention Among Cancer Patients|Adherence","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","146","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB000019384|U10CA081851|REBACCCWFU 99211","October 2011","June 2014","January 2015","September 14, 2011","June 6, 2017","September 10, 2018","W F Baptist Health, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01434342"
1886,"NCT01432197","Occupational Therapy for Cancer Patients: a Randomised, Controlled Study",,"Completed","No Results Available","HRQOL (Health Related Quality of Life)","Other: ADL intervention","Health related quality of life|Ability to perform activities of daily living","University of Southern Denmark|Naestved Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","116","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","RCT Occup Cancer","March 2010","June 2011","null","September 12, 2011","null","September 12, 2011","Research Unit of General Practice, IST, University of Southern Denmark, Odense, Denmark","","https://ClinicalTrials.gov/show/NCT01432197"
1887,"NCT01427322","Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease",,"Terminated","No Results Available","Epithelial Cancer","Drug: Lapatinib|Radiation: Radiation therapy","TGFalpha","Virginia Commonwealth University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-13711|NCI-2011-02734","September 2011","December 2014","July 2015","September 1, 2011","null","July 8, 2015","Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States|Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01427322"
1888,"NCT01425749","Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI","Mel55","Completed","Has Results","Melanoma","Biological: recMAGE-A3 + AS15 ASCI","Number of Participants With Treatment-related Adverse Events as a Measure of Safety and Tolerability|Enumeration of CD4 and CD8 T Cell Responses to MAGE-A3 Epitopes in the Injection Site-draining Lymph Node (Sentinel Immunized Node, SIN) as a Measure of Immunogenicity.|Enumeration of CD4+ and CD8+ T Cells Reactive to MAGE-A3 Epitopes in Peripheral Blood as a Measure of Immunogenicity.|Identification of Antibody Responses to MAGE-A3 After MAGE-A3 ASCI Administration as a Measure of Immunogenicity.|Characterization of the Maturation and Activation of Dendritic Cell (DC) Populations in the Sentinel Immunized Node (SIN) After Treatment With MAGE-A3 ASCI.|A Preliminary Evaluation of Cellular Components of the Injection Site Microenvironment for Cutaneous Immunization With MAGE-A3 ASCI (Activated T Cells, Th1,Th2, Th17 Infiltrating CD4 Cells, Regulatory T Cells, and Myeloid-derived Suppressor Cells).","Craig L Slingluff, Jr|GlaxoSmithKline|University of Virginia","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSlingluff","June 2011","July 2013","October 2015","August 30, 2011","April 4, 2016","April 4, 2016","University of Virginia, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01425749"
1889,"NCT01423448","Effectiveness of an Online Bulletin Board for Depression: a Longitudinal Randomized Controlled Trial","ShareIT","Withdrawn","No Results Available","Depression","Other: bulletin board","Depressive symptoms: Centre for Epidemiological Studies - Depression Scale (CES-D)","Louise Farrer|Australian National University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","CMHR-123|NHMRC Fellowship ref 525413","null","null","null","August 26, 2011","null","January 14, 2015","Centre for Mental Health Research, The Australian National University, Canberra, Australian Capital Territory, Australia","","https://ClinicalTrials.gov/show/NCT01423448"
1890,"NCT01422733","Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction",,"Withdrawn","No Results Available","Hyperandrogenemia|Obesity|Polycystic Ovary Syndrome","Drug: Hydrocortisone|Drug: dexamethasone|Drug: Cosyntropin|Drug: rhCG","Changes in free testosterone or 17-hydroxyprogesterone levels after ACTH and rhCG administration respectively, before and after hydrocortisone administration for 12 weeks|Changes in adrenal and ovarian steroid precursors after ACTH and rhCG; body composition via air displacement plethysmography, BMI, and glucose tolerance testing results; baseline and after 12 weeks of hydrocortisone administration|Morning cortisol","University of Virginia","Female","7 Years to 16 Years   (Child)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CBS004","June 1, 2018","July 17, 2018","July 17, 2018","August 24, 2011","null","July 19, 2018","University of Virginia Center for Research in Reproduction, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01422733"
1891,"NCT01422707","Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess",,"Withdrawn","No Results Available","Hyperandrogenemia|Obesity|Polycystic Ovary Syndrome","Drug: Hydrocortisone","Changes in free testosterone after ACTH administration before and after hydrocortisone administration for 4 weeks|Changes in adrenal steroid precursors after ACTH, baseline, and after 4 weeks of hydrocortisone administration","University of Virginia","Female","7 Years to 18 Years   (Child, Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CBS003","January 19, 2018","July 17, 2018","July 17, 2018","August 24, 2011","null","July 19, 2018","University of Virginia Center for Research in Reproduction, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01422707"
1892,"NCT01422395","Effect of Oocyte Vitrification on Fertilization Rate, Embryo Quality and Development",,"Completed","No Results Available","Fertility","Procedure: Freezing","fertilization rate|Embryo Quality|Embryo Development","Main Line Fertility Center|Merck Sharp & Dohme Corp.","Female","21 Years to 37 Years   (Adult)","Early Phase 1","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","MLFC-001","August 2011","May 2013","May 2013","August 24, 2011","null","June 4, 2014","Main Line Fertility Center, Bryn Mawr, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01422395"
1893,"NCT01422096","Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess",,"Withdrawn","No Results Available","Hyperandrogenemia|Obesity|Polycystic Ovary Syndrome","Drug: Leuprolide","17 hydroxyprogesterone responses to rhCG before and 4 weeks after depot leuprolide administration|Ovarian hormone precursor responses to rhCG before and 4 weeks after depot leuprolide administration","University of Virginia","Female","7 Years to 18 Years   (Child, Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CBS007","June 1, 2018","July 17, 2018","July 17, 2018","August 23, 2011","null","July 19, 2018","University of Virginia Center for Research in Reproduction, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01422096"
1894,"NCT01421030","Outcomes in Patients and Their Closest Relatives Treated for Congenital Heart Disease With Catheter Based or Surgical Techniques","MEQC","Unknown status","No Results Available","Congenital Heart Defects","Procedure: Percutaneous pulmonary valve implantation or open heart surgery","Quality of life|Clinical outcomes|Are there savings in costs related to the individual and their family and society between the two techniques?","Oslo University Hospital","All","7 Years to 50 Years   (Child, Adult)","Early Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2011/210","September 2011","September 2012","September 2014","August 22, 2011","null","September 25, 2012","The Interventional Centre, Rikshospitalet, Oslo University Hospital, Oslo, Sognsvannsvn 20, Norway","","https://ClinicalTrials.gov/show/NCT01421030"
1895,"NCT01419860","Evaluation of Microcirculation in Colon Wall and Bowel Anastomosis by Laser Induced Fluorescence Video Angiography",,"Unknown status","No Results Available","Colon Cancer|Benign Colon Diseases","Procedure: Elective colon resection","Evaluation of microcirculation in colon wall and bowel anastomosis by laser induced fluorescence video angiography of indocyanine green|Predicting perfusion deficit with laser-induced ICG fluorescence video angiography","Ostfold Hospital Trust","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Microcirculation of colon","January 2010","December 2016","December 2016","August 18, 2011","null","November 1, 2016","Østfold Hospital Trust HF, Fredrikstad, Østfold, Norway","","https://ClinicalTrials.gov/show/NCT01419860"
1896,"NCT01417442","BRAF V600E Mutations In Papillary Thyroid Carcinoma",,"Unknown status","No Results Available","Papillary Thyroid Carcinoma","Genetic: BRAF V600E POSITIVITY","BRAF V600E MUTATION","Bezmialem Vakif University","All","Child, Adult, Older Adult","Early Phase 1","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011/5","July 2011","July 2012","July 2012","August 16, 2011","null","August 16, 2011","Yeliz Emine Ersoy, Istanbul, Turkey","","https://ClinicalTrials.gov/show/NCT01417442"
1897,"NCT01417065","Temsirolimus In Phase 0",,"Completed","No Results Available","Advanced Cancer","Drug: Temsirolimus","Participants' Pharmacodynamic (PD) Responses","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-0259|NCI-2011-02799|2K12CA088084-12","August 2010","June 2014","null","August 16, 2011","null","June 23, 2014","UT MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01417065"
1898,"NCT01414673","HCG Versus Spontaneous LH in Intrauterine Insemination (IUI ) Cycles",,"Completed","No Results Available","Spontaneous Triggering of Ovulation vs. Administration of Human Chorionic Gonadotropin in Patients Undergoing IUI","Drug: HCG","ongoing pregnancy rate","Universitair Ziekenhuis Brussel","Female","18 Years to 36 Years   (Adult)","Early Phase 1","300","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WAS11","April 2009","July 2011","August 2011","August 11, 2011","null","August 11, 2011","Uzbrussel, Brussel, Laarbeeklaan 101, Belgium","","https://ClinicalTrials.gov/show/NCT01414673"
1899,"NCT01414556","GIP Effects at Insulin Induced Hypoglycemia in Patients With Type 2 Diabetes","GIP-HYPO-T2DM","Completed","No Results Available","Type 2 Diabetes Mellitus","Other: Glucose-dependent Insulinotropic polypeptide|Other: saline","glucagon/insulin(c-peptide) absolute, incremental and area under curve values|plasma gut hormones and nutrients","Mikkel Christensen|University Hospital, Gentofte, Copenhagen","Male","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","H-2-2009-078","May 2011","July 2012","November 2012","August 11, 2011","null","April 2, 2013","Gentofte Hospital, Hellerup, Denmark","","https://ClinicalTrials.gov/show/NCT01414556"
1900,"NCT01413659","Evaluation of the Effect of Preoperative Symbiotic Bowel Conditioning on Surgical Site Infection After Elective Colorectal Surgery",,"Unknown status","No Results Available","Postoperative Wound Infection","Biological: Symbiotic","Frequency of post-operative infection after elective colorectal surgery among patients with and without pre-operative symbiotic conditioning.|The incidence of postoperative infection including surgical site infections (SSIs) and distant-site infections after elective colorectal surgery in patients whether or not receiving pre-operative symbiotic conditioning.","Mashhad University of Medical Sciences","All","14 Years and older   (Child, Adult, Older Adult)","Early Phase 1","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","MUMS-89619","September 2011","December 2012","February 2013","August 10, 2011","null","August 25, 2011","","","https://ClinicalTrials.gov/show/NCT01413659"
1901,"NCT01413451","Amatuximab for High Mesothelin Cancers",,"Terminated","No Results Available","Carcinoma, Pancreatic Ductal|Mesothelioma|Ovarian Neoplasms|Carcinoma, Non-Small-Cell Lung","Drug: Amatuximab (MORab-009)","Biodistribution of radiolabelled amatuximab in tumor and nontumor tissues.|Tumor|Background ratio of maximum counts|CTCAE V.4 events|Observation of HACA|PKs|Antibody uptake vs. IHC mesothelin expression","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","7","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","110212|11-C-0212","July 12, 2011","November 15, 2013","November 15, 2013","August 10, 2011","null","November 15, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01413451"
1902,"NCT01411566","Clinical Intervention Psychosis and Addiction","KLIPS","Unknown status","No Results Available","Psychosis|Substance Abuse","Behavioral: Skills trainig for patients with dual diagnosis|Behavioral: regular treatment","Substance use|Change in drug use motivation","University of Cologne","All","18 Years to 60 Years   (Adult)","Early Phase 1","122","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Koeln-Fortune 104/2010","January 2011","November 2011","December 2011","August 8, 2011","null","August 8, 2011","LVR Clinic Cologne - Academic Clinic of the University of Cologne, Cologne, Germany","","https://ClinicalTrials.gov/show/NCT01411566"
1903,"NCT01410760","PERfusion CT in the FOXFIRE Trial to Study Blood Flow to Liver Metastases","PERFORM","Unknown status","No Results Available","Metastatic Colorectal Cancer","Other: Perfusion CT scan","Recruitment rate to this voluntary study and acquisition of sufficient data for perfusion analysis|Correlation between the tumour perfusion pattern on perfusion CT studies at baseline and shortly after the start of therapy and morphological response by RECIST criteria on CT scan 3 months post therapy in both arms of the FOXFIRE trial.","University of Oxford|Oxford University Hospitals NHS Trust|University Hospitals, Leicester","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","10/H0505/95","April 2011","April 2013","null","August 5, 2011","null","June 20, 2012","Oxford Radcliffe Hospitals NHS Trust, Oxford, United Kingdom","","https://ClinicalTrials.gov/show/NCT01410760"
1904,"NCT01405378","Non-invasive Brain Stimulation for People With Stroke",,"Completed","No Results Available","Stroke","Device: Robot therapy and transcranial direct current stimulation","Report change in upper limb function from baseline to 8 weeks and 3 months after treatment|Report change in cortical excitability from baseline to 8 weeks and 3 months after treatment","University of Southampton|University College, London","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","23","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Wessex Innovative Grant P09","October 2011","January 2014","February 2014","July 29, 2011","null","June 23, 2016","Faculty of Health Sciences, University of Southampton, Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT01405378"
1905,"NCT01404468","The Phonophoresis of Lidocaine Gel and Its Effect on Sensory Blockage",,"Completed","No Results Available","Pain|Impairment, Light Touch Sensation","Device: pulsed ultrasound device with lidocaine|Other: off device|Device: continuous ultrasound device with lidocaine","Two-point discrimination,touch and maximum pain thresholds","Shiraz University of Medical Sciences","All","18 Years to 28 Years   (Adult)","Early Phase 1","93","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","84-7.33","March 2006","September 2008","October 2010","July 28, 2011","null","July 28, 2011","Samaneh Ebrahimi, Shiraz, Fars, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT01404468"
1906,"NCT01403103","Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer",,"Withdrawn","No Results Available","Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage I Colon Cancer|Stage I Rectal Cancer","Dietary Supplement: cholecalciferol|Procedure: biopsy|Genetic: protein expression analysis|Other: enzyme-linked immunosorbent assay|Other: laboratory biomarker analysis|Genetic: reverse transcriptase-polymerase chain reaction","Comparison of the expression of 15-PGDH mRNA and protein levels in tumor tissue|Comparison of the expression of 15-PGDH mRNA and protein levels in normal colorectal mucosa|Comparison of the expression of COX-1 and COX-2 mRNA in tumor tissues|Comparison of levels of PGE2 in tumor tissue|Comparison of the expression of COX-1 and COX-2 mRNA in normal colorectal mucosa|Comparison of levels of PGE2 in normal colorectal mucosa|Number of patients with grade 3 related toxicities of a single 100,000 IU dose of 25-OH-vitamin D3","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE2210|NCI-2011-01280","April 2012","January 2014","January 2014","July 27, 2011","null","January 17, 2014","","","https://ClinicalTrials.gov/show/NCT01403103"
1907,"NCT01398280","Effects of Aminocaproic Acid (ACA) on Rosacea-specific Inflammation","ACA","Completed","No Results Available","Rosacea","Drug: Topical aminocaproic acid (ACA) mixed with Vanicream|Drug: Vehicle cream","Cathelicidin protein analysis|KLK5 protease activity","University of California, San Diego","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","100867","July 2011","December 2012","December 2012","July 20, 2011","null","January 15, 2013","University of California, San Diego Perlman Ambulatory Center, La Jolla, California, United States","","https://ClinicalTrials.gov/show/NCT01398280"
1908,"NCT01397487","Effects of Day 3 Blastomere Biopsy on Human Embryos","BB","Unknown status","No Results Available","Blastomere Biopsy Safety","Procedure: Blastomere biopsy","Blastocyst percentage|Number of cells of blastocyst measured by morphometric analysis|Implantation rate","Fundacion Para La Investigacion Hospital La Fe","Female","18 Years to 35 Years   (Adult)","Early Phase 1","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2009/0416","July 2011","January 2012","September 2013","July 19, 2011","null","July 28, 2011","La Fe University Hospital. Department of Obstetrics and Gynecology, Valencia, Spain","","https://ClinicalTrials.gov/show/NCT01397487"
1909,"NCT01396369","Flaxseed Lignan (Brevail)",,"Completed","No Results Available","Polycystic Ovarian Syndrome","Drug: Birth control|Drug: Birth control plus Brevail","Primary outcomes to assess are the changes of testosterone levels and hirsutism.|Secondary outcomes to assess are the lipid profile and estrogen levels.","University of Kansas Medical Center","Female","18 Years to 40 Years   (Adult)","Early Phase 1","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12459","June 2011","December 2013","December 2013","July 18, 2011","null","January 8, 2016","The University of Kansas Medical Center, Kansas City, Kansas, United States","","https://ClinicalTrials.gov/show/NCT01396369"
1910,"NCT01396200","Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine",,"Completed","No Results Available","Myeloma","Drug: Hydroxychloroquine|Drug: Rapamycin","Number of Participants with Adverse Events|Toxicities and response to the regimen","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","UPCC 09411","June 2011","October 2012","October 2012","July 18, 2011","null","February 26, 2013","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01396200"
1911,"NCT01394965","Electrocardiographic Mapping and Imaging",,"Withdrawn","No Results Available","Cardiac Arrhythmia","Procedure: ECG electrodes","Results of ECG Mapping","Mayo Clinic|University of Minnesota - Clinical and Translational Science Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","10-004825","October 2013","October 2013","October 2013","July 15, 2011","null","October 21, 2013","Mayo Clinic in Rochester, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01394965"
1912,"NCT01394861","Endoscopic Submucosal Dissection (ESD)- Master Slave Robotic System - Human Study","ESD","Completed","No Results Available","Endoscopic Submucosal Dissection","Device: ESD using Master Slave Robotic System","Ease of the procedure|Completeness of the Procedure|Immediate Procedure Related Complications|Delayed Procedure Related Complications","Asian Institute of Gastroenterology, India|Nanyang Technological University","All","25 Years to 60 Years   (Adult)","Early Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIG-GI2011-04","June 2011","July 2011","October 2011","July 15, 2011","null","March 6, 2012","Asian Institute Of Gastroenterology India, Hyderabad, Andhra Pradesh, India","","https://ClinicalTrials.gov/show/NCT01394861"
1913,"NCT01394042","Prostate Cancer Imaging With Radioactive Tracer and Ultrasound Detector Compared to MRI and ProstaScint",,"Unknown status","No Results Available","Prostate Cancer","Device: Proxiscan device","Detection of PSMA antibody (ProstaScint)uptake patterns measured by Proxiscan in comparison with anatomic biopsy reports, conventional SPECT and MRI scans within one month of Proxiscan","Radiological Associates of Sacramento Medical Group Inc.|Hybridyne Imaging Technologies","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic","Proxiscan","June 2011","December 2011","March 2012","July 14, 2011","null","July 14, 2011","Roseville PET and Nuclear Imaging Center, Roseville, California, United States","","https://ClinicalTrials.gov/show/NCT01394042"
1914,"NCT01388530","Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder (ADHD)",,"Completed","Has Results","Attention-Deficit/Hyperactivity Disorder","Device: EMS 7500 Digital Muscle Stimulator","ADHD-IV Rating Scale (ADHD-RS)|Clinical Global Impression - Improvement (CGI-I)|Conners Global Index - Parent|Attention Network Task - Incongruent Reaction Time","University of California, Los Angeles|NeuroSigma, Inc.","All","7 Years to 14 Years   (Child)","Early Phase 1","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCLA-TNS/ADHD","July 2011","December 2012","December 2012","July 6, 2011","April 11, 2016","April 11, 2016","UCLA, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01388530"
1915,"NCT01386762","Effect of Intense Multi-modal Training on Bone Health and Quality of Life in Persons With Spinal Cord Injury",,"Unknown status","No Results Available","Spinal Cord Injury|Obesity","Other: Exercise training","Bone mineral density|Body fat","California State University, San Marcos|National Institutes of Health (NIH)","All","18 Years to 45 Years   (Adult)","Early Phase 1","30","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","85756","June 2011","July 2015","July 2015","July 1, 2011","null","July 1, 2011","CSU--San Marcos Human Performance Lab, San Marcos, California, United States","","https://ClinicalTrials.gov/show/NCT01386762"
1916,"NCT01385215","Strategies for Enhancing Mucosal Immunity to Influenza Vaccine",,"Completed","No Results Available","Mucosal Immunity","Drug: Fluzone","Change in hemagglutinin antibody titers from baseline to Day 28 in serum and mucosal secretions.|Number of subjects with adverse events.|Comparison of hemagglutinin antibody titers between intranasal and intramuscular route of administration, from baseline to Day 28.","John Sundy|Duke University","All","18 Years to 50 Years   (Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","Pro00024277","April 2011","June 2011","June 2011","June 30, 2011","null","December 6, 2012","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01385215"
1917,"NCT01384864","Endoscopic Multispectral Imaging for the Early Detection of Barrett's Neoplasia",,"Completed","No Results Available","Barrett's Esophagus|Intraepithelial Neoplasia","Drug: proflavine","to determine whether tissue is neoplastic or non-neoplastic","Anandasabapathy, Sharmila, M.D.|William Marsh Rice University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","GCO# 09-0696 Project 3","August 2011","December 2015","December 2015","June 29, 2011","null","January 11, 2016","Mount Sinai School of Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01384864"
1918,"NCT01384708","Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer",,"Completed","No Results Available","Squamous Cell Cancer","Drug: proflavine","to determine whether or not tissue is neoplastic or non-neoplastic","Anandasabapathy, Sharmila, M.D.|William Marsh Rice University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","70","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","GCO# 10-0982","August 2010","October 2013","October 2013","June 29, 2011","null","January 11, 2016","Mount Sinai Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01384708"
1919,"NCT01384695","A Feasibility Study of Confocal Microendoscopy in the Evaluation of Gastrointestinal Neoplasia -Project 1",,"Terminated","No Results Available","GERD|Barrett's Esophagus","Drug: Fluorescein|Drug: Proflavine hemisulfate","to determine whether tissue is neoplastic or non-neoplastic","Anandasabapathy, Sharmila, M.D.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","67","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","GCO# 09-0696 Project 1","June 2009","February 2014","February 2014","June 29, 2011","null","January 12, 2016","Mount Sinai Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01384695"
1920,"NCT01384240","Evaluation of a Low-Cost High Resolution Microendoscope for the Detection of Lower Gastrointestinal Neoplasia",,"Terminated","No Results Available","Colon Polyps|Colonic Dysplasia|Anal Dysplasia","Drug: Proflavine Hemisulfate","to determine whether tissue in nepoplastic or non-neoplastic","Anandasabapathy, Sharmila, M.D.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","183","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","GCO# 09-1040","April 2010","July 2013","May 2014","June 29, 2011","null","January 12, 2016","Mount Sinai Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01384240"
1921,"NCT01384227","Evaluation of a Miniaturized Microscope Device for the Detection of Barrett's Neoplasia: A Pilot Study",,"Completed","No Results Available","Barrett's Esophagus","Drug: Proflavine Hemisulfate","To determine whether tissue is neoplastic or non-neoplastic","Anandasabapathy, Sharmila, M.D.|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","GCO # 08-1190","February 2009","July 2011","null","June 29, 2011","null","January 12, 2016","Mount Sinai Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01384227"
1922,"NCT01382771","Intraarticular Lumbar Joint Corticosteroid Injection(s) as a Treatment of Chronic Low Back Pain in a Selected Population",,"Completed","No Results Available","Low Back Pain","Drug: Intra-articular corticosteroid injection|Drug: Intra-articular saline injection","Numeric Pain Rating (NPR) or patient estimation of improvement, >80% pain reduction|Numeric Pain Rating (NPR) Daily diary|Oswestry Disability Index (ODI)|Standard Form 36 (SF-36), General Health Survey|Daily Work History Log|Daily Analgesic Use Log|Ancillary Treatment Log","University of Florida","All","45 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","319-2010","October 2010","September 2012","September 2012","June 27, 2011","null","October 14, 2013","UF & Shands Orthopaedics and Sports Medicine Institute, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT01382771"
1923,"NCT01382121","Adolescent Fitness Assessment Program","AFAP","Completed","No Results Available","Diabetes","Behavioral: Peer Modeling|Behavioral: Control","Physiological measure: Aerobic Fitness|Psychological: Self-Efficacy|Changes in variability (standard deviation)","University of Western Ontario, Canada","All","10 Years to 17 Years   (Child)","Early Phase 1","49","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","PeakVO2 PM RCT","September 2010","April 2012","May 2012","June 27, 2011","null","June 26, 2012","Exercise and Health Psychology Laboratory, London, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01382121"
1924,"NCT01380795","Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas","CTC-Poumon","Completed","No Results Available","Non-small Cell Lung Cancer Metastatic","Biological: CTC","search for the mutation of EGFR and Kras in the CTC of the patient|Compare EGFR/ K-ras status between CTC and the primitive tumor|Monitoring of the mutations of EGFR / K-ras in the CTC of the patients during treatment","Centre Georges Francois Leclerc|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","0416-1cobr10","March 2011","February 2013","null","June 27, 2011","null","March 26, 2015","Centre Georges François Leclerc, Dijon, France","","https://ClinicalTrials.gov/show/NCT01380795"
1925,"NCT01380353","Test Uniformity of Transdermal Drug Delivery to Breast Using Diclofenac Epolamine",,"Active, not recruiting","No Results Available","Breast Cancer","Drug: Diclofenac epolamine patch","Compare concentrations of diclofenac epolamine patch when applied to breast vs. abdomen|Determine how the concentrations of the study patch is distributed in the breast.","Northwestern University","Female","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 10B05|STU00042939","June 2011","July 2019","July 2020","June 27, 2011","null","September 14, 2018","Northwestern University, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT01380353"
1926,"NCT01379924","Young Parents Program, Project Connect","YPP ProCon","Unknown status","No Results Available","Parenting Teen Mothers and Fathers|18 and Under When Child Was Born for Mothers|25 and Under When Child Was Born for Fathers|Has a Child Who is Seen at the Young Parents Program for Medical Care","Behavioral: Modules|Other: No intervention","Rapid Repeat Pregnancy|Parenting Skills|Daily Living Skills","Boston Children’s Hospital|Department of Health and Human Services|Boston Public Health Commission","All","13 Years to 25 Years   (Child, Adult)","Early Phase 1","250","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","5 APHPA002033-10-00","September 2007","August 2012","August 2012","June 23, 2011","null","June 27, 2011","Children's Hospital Boston, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01379924"
1927,"NCT01377493","Effects of a Chewing Gum Containing POs-Ca and Fluoride on Enamel",,"Completed","No Results Available","Enamel Subsurface Lesion","Dietary Supplement: chewing gum","Mineral content of enamel","Tokyo Medical and Dental University","All","20 Years to 31 Years   (Adult)","Early Phase 1","36","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1B116","December 2009","February 2010","June 2011","June 21, 2011","null","June 21, 2011","","","https://ClinicalTrials.gov/show/NCT01377493"
1928,"NCT01376011","Modulation of Cerebral Blood Flow Using Quercetin, a Nutritional Supplement","Quercetin","Completed","No Results Available","Stroke|Problem of Aging","Dietary Supplement: quercetin/placebo","Define change from baseline levels of HIF-1 concentration and 3 of its regulated proteins after 6 months of quercetin (versus placebo) dietary intake.|Determine change from baseline brain blood flow after 6 months of quercetin (versus placebo) dietary intake.|Define change from baseline performance in a battery of cognitive tasks after 6 months of quercetin (versus placebo) dietary intake.","Brigham and Women's Hospital|National Institute on Aging (NIA)","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","106","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1 K23AG030967-01A1-2|1K23AG030967-01A1","June 2009","June 2012","December 2014","June 20, 2011","null","January 28, 2015","Brigham and Women's Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01376011"
1929,"NCT01375582","Objective Evaluation of Ocular Surface Lubricants in Two Environments",,"Completed","No Results Available","Dry Eye","Drug: B & L Soothe Lubricant Eye Drops|Drug: Liposic EDO|Drug: OcuFresh Eye Wash","Tear Film Properties","University of Rochester|Bausch & Lomb Incorporated","All","30 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","35809","June 2011","June 2012","June 2012","June 17, 2011","null","December 16, 2013","Flaum Eye Institute at the University of Rochester, Rochester, New York, United States","","https://ClinicalTrials.gov/show/NCT01375582"
1930,"NCT01371240","Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving Pancreatic Tumor Conspicuity",,"Unknown status","No Results Available","Pancreas Cancer","Drug: Secretin Synthetic Human (RG1068)","Increase in pancreatic tumor conspicuity.|Pancreatic tumor conspicuity on MRI|post-injection complications and side effects of secretin","University Hospitals Cleveland Medical Center|Repligen Corporation","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","CC00035","June 2011","December 2011","June 2012","June 10, 2011","null","June 13, 2011","University Hospitals Case Medical Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01371240"
1931,"NCT01365104","Modulation of Cerebral Blood Flow Using Iron Chelators","DFO","Completed","No Results Available","Stroke|Problem of Aging","Drug: desferrioxamine","Define change from baseline cerebral blood flow after receiving DFO infusion.|Determine if DFO changes blood HIF-1 levels from baseline and whether this correlates with changes in cerebrovascular hemodynamics.","Brigham and Women's Hospital|National Institute on Aging (NIA)","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","97","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1K23AG030967-01|1K23AG030967-01A1","March 2008","June 2012","December 2014","June 3, 2011","null","January 28, 2015","Brigham and Women's Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01365104"
1932,"NCT01364454","General Practitioners (GP) Involvement in Colorectal Cancer (CRC) Screening",,"Completed","No Results Available","Colorectal Cancer","Other: Eligible patients' paper-based reminder","Patient's participation to colorectal cancer screening program","Paris 12 Val de Marne University","All","50 Years to 74 Years   (Adult, Older Adult)","Early Phase 1","8140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","DUERMG","June 2010","June 2011","June 2011","June 2, 2011","null","August 19, 2016","Département Universitaire d'Enseignement et de Recherche en Médecine Générale, Créteil, France","","https://ClinicalTrials.gov/show/NCT01364454"
1933,"NCT01362465","Characterization of Interventricular Conduction Measurements","ICM","Completed","No Results Available","Heart Failure","Procedure: Cardiac Resynchronization Therapy","Measure how RV to LV conduction times are altered by pacing site in patients with a CRT system.","Medtronic Cardiac Rhythm and Heart Failure|Medtronic","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TDSICM","June 2011","April 2012","April 2012","May 30, 2011","null","September 20, 2012","","","https://ClinicalTrials.gov/show/NCT01362465"
1934,"NCT01361256","Study of WA-NG Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration",,"Withdrawn","No Results Available","Age Related Macular Degeneration","Device: Telescope prosthesis|Device: WA-NG Telescope Prothesis","Positional Stability|Adverse events","VisionCare, Inc.","All","65 Years and older   (Older Adult)","Early Phase 1","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WA-NG-001","May 2011","April 2015","May 2016","May 26, 2011","null","October 31, 2016","Sheba Medical Center, Tel Hasomer, Israel","","https://ClinicalTrials.gov/show/NCT01361256"
1935,"NCT01358773","The Effect of 1 Year of Multiprofessional Therapy on Obesity",,"Unknown status","No Results Available","Obesity","Other: multidisciplinary intervention","Body composition|visceral and subcutaneous fat were analyzed by ultrasound|Serum analysis|Lung function|Arterial intima-media thickness|Sleep parameters","Ana R. Damaso|Raquel Munhoz da Silveira Campos|Sofia Emanuelle Castro|Ana Claudia Pelissari Kravchychyn|Federal University of São Paulo","All","15 Years to 19 Years   (Child, Adult)","Early Phase 1","150","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#0135/04","February 2004","December 2004","December 2016","May 24, 2011","null","June 30, 2016","CEPE, São Paulo, SP, Brazil","","https://ClinicalTrials.gov/show/NCT01358773"
1936,"NCT01358409","Regression of Myocardial Steatosis by Nebivolol",,"Completed","No Results Available","Cardiac Steatosis and Lipotoxicity","Drug: Nebivolol","Myocardial triglyceride content|Cardiac function|Regression of concentric cardiac remodeling|Regression of steatosis in other non-adipocyte tissue|Regression of subcutaneous fat","Lidia Szczepaniak|Forest Laboratories|Cedars-Sinai Medical Center","All","18 Years to 59 Years   (Adult)","Early Phase 1","31","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MTG_Neb01","April 1, 2011","February 11, 2013","February 11, 2013","May 23, 2011","null","July 14, 2017","Cedars-Sinai Medical Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01358409"
1937,"NCT01355757","Post-Operative Quality of Life Evaluation for Different Anesthesia Techniques for Arthroscopic Shoulder Surgery",,"Completed","No Results Available","Rotator Cuff Injury","Device: Baxter INFUSOR System|Drug: Single Injection of Local Anesthetic","Quality of Life","St. Luke's-Roosevelt Hospital Center|Baxter Healthcare Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","70","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10-142","June 2011","January 2013","January 2013","May 18, 2011","null","May 19, 2014","St. Luke's-Roosevelt Hospital, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01355757"
1938,"NCT01354223","Clinical Evaluation of Stenfilcon A Soft Contact Lens When Compared to Ocufilcon B Soft Contact Lens",,"Completed","Has Results","Myopia","Device: stenfilcon A contact lens|Device: ocufilcon B contact lens","Objective Assessment: Ocular Response - Biomicroscopy|Comparison of Objective Findings - Number of Adverse Events in Unique Eyes|Comparison of Objective Findings for Contact Lens Visual Acuities - Snellen 20/25 VA or Better|Subjective Assessment of Contact Lens Comfort - No Symptoms of Discomfort|Evaluation of Average Lens Wearing Time - Average Daily Hours Worn","Coopervision, Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FC100239","October 2010","March 2011","April 2011","May 16, 2011","March 21, 2014","March 21, 2014","Eric M. White, OD, Inc., San Diego, California, United States|Vision Care Associates, East Lansing, Michigan, United States|Western Reserve Vision Care, Beachwood, Ohio, United States|Primary Eyecare Group, P.C., Brentwood, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT01354223"
1939,"NCT01353014","Genetic Information and Dietary Intake Behaviour",,"Completed","No Results Available","Healthy","Other: Dietary advice with genetic information|Other: General dietary recommendations","Change from Baseline in Dietary Intake at 3 months|Change from Baseline in Dietary Intake at 12 months","University of Toronto|Advance Foods and Materials Network","All","20 Years to 35 Years   (Adult)","Early Phase 1","138","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","AElSohemy","May 2011","December 2011","September 2012","May 12, 2011","null","July 1, 2014","University of Toronto, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01353014"
1940,"NCT01349153","Facebook-based Physical Activity Intervention for Young Adult Cancer Survivors: the FITNET Randomized Pilot Study","FITNET","Completed","No Results Available","Physical Activity","Behavioral: Facebook-based Messages/Website|Behavioral: Facebook-based Self-help Comparison","Primary study outcome measures at the participant level will be minutes of moderate-intensity physical activity per week and exercise in MET-hrs/week.|Quality of life|Psychosocial factors|Utilization of program components/activities|Perceptions of program components/activities|Communication factors","University of North Carolina, Chapel Hill","All","21 Years to 39 Years   (Adult)","Early Phase 1","97","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","10-2150","April 2011","December 2011","December 2011","May 6, 2011","null","December 13, 2011","Lineberger Comprehensive Cancer Center at UNC-CH, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01349153"
1941,"NCT01347125","ImCardia for DHF to Treat Diastolic Heart Failure (DHF) Patient a Pilot Study","ImCardia","Terminated","No Results Available","Heart Failure With Normal Ejection Fraction","Device: ImCardia Device","Safety: Adverse event reporting|Functionality - Successful Device implantation","CorAssist Cadiovascular Ltd.","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","19","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLD 0201","April 2008","April 2011","May 2012","May 4, 2011","null","May 4, 2011","","","https://ClinicalTrials.gov/show/NCT01347125"
1942,"NCT01345994","Brain Plasticity in Carpal Tunnel Syndrome and Its Response to Acupuncture",,"Unknown status","No Results Available","Carpal Tunnel Syndrome","Procedure: electro-acupuncture","Functional MRI brain response","Martinos Center for Biomedical Imaging|National Center for Complementary and Integrative Health (NCCIH)","All","21 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","null","Other|NIH","Interventional","","AT004714|R01AT004714-01","May 2009","May 2013","May 2013","May 2, 2011","null","May 2, 2011","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01345994"
1943,"NCT01343537","Continuous Neurophysiological Monitoring Detection of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage Subjects",,"Terminated","No Results Available","Cerebral Vasospasm|SAH|Aneurysm","Other: Neuro Monitoring","Early detection of cerebral vasospasm after aneurysmal subarachnoid hemorrhage","State University of New York - Upstate Medical University","All","18 Years to 89 Years   (Adult, Older Adult)","Early Phase 1","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5981","December 2010","March 2014","March 2014","April 28, 2011","null","January 1, 2016","SUNY Upstate Medical University, Syracuse, New York, United States","","https://ClinicalTrials.gov/show/NCT01343537"
1944,"NCT01341691","Phosphate Binding of Chitosan Chewing Gum in Patients With Chronic Kidney Disease (CKD)",,"Completed","No Results Available","Chronic Kidney Disease","Other: chewing gum","Total phosphorus bound and entrapped per piece of chewing gum","Denver Nephrologists, P.C.|CM&D Pharma, LTD","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)","CMD 006","March 2011","April 2011","April 2011","April 26, 2011","null","April 26, 2011","Denver Nephrologists, PC, Denver, Colorado, United States","","https://ClinicalTrials.gov/show/NCT01341691"
1945,"NCT01341041","Chlorine Dioxide Versus Saline for Wound Irrigation",,"Completed","No Results Available","Wound - in Medical Care","Biological: chlorine dioxide|Biological: saline","cosmesis","Rhode Island Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","201","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","0334-03","August 2004","December 2007","June 2009","April 25, 2011","null","April 25, 2011","Rhode Island Hospital, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT01341041"
1946,"NCT01341015","Bedside Ultrasound in the Diagnosis of Ankle Fractures in Children",,"Completed","No Results Available","Ankle Fracture","Other: Ultrasound","comparison of ultrasound to xray shows identical read","Rhode Island Hospital","All","2 Years to 18 Years   (Child, Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","0094-10","June 2010","September 2011","December 2011","April 25, 2011","null","December 5, 2012","Hasbro Children's Hospital, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT01341015"
1947,"NCT01339494","Nitric Oxide Production in MELAS Syndrome",,"Completed","No Results Available","MELAS Syndrome","Dietary Supplement: Arginine and citrulline supplementations","Change in nitric oxide production","Baylor College of Medicine","All","3 Years to 65 Years   (Child, Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-24783","July 2009","April 2016","April 2016","April 20, 2011","null","April 5, 2016","Texas Children's Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01339494"
1948,"NCT01337492","Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)",,"Terminated","No Results Available","Carcinoma, Hepatocellular","Drug: Nexavar","Adverse events associated with technical aspects of the operation|Time to progression prior to OLT|Drop Out Rate|Waiting Time","Case Comprehensive Cancer Center|Bayer|Onyx Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","2","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE2209","September 2010","May 2011","January 2012","April 19, 2011","null","March 21, 2012","Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01337492"
1949,"NCT01335854","Promoting Continuous Positive Airway Pressure (CPAP) Adherence",,"Completed","No Results Available","Obstructive Sleep Apnea","Behavioral: Web-based Access to CPAP Data|Behavioral: Web-based Access to CPAP Data with Financial Incentive","Average daily hours of CPAP.|The change in the mean total score on the Functional Outcome of Sleep Questionnaire.|The percentage of days that the CPAP apparatus was used and the average daily hours of CPAP use on days used.|Total scores on the Epworth Sleepiness Scale (ESS) and the Medical Outcomes Study Short-Form-12 (SF-12).","University of Pennsylvania|National Institute on Aging (NIA)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","135","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","812091|RC2AG036592","September 2011","August 2013","August 2013","April 14, 2011","null","May 22, 2014","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01335854"
1950,"NCT01335022","African American Community Health Project on Cardiovascular Disease","AACP-CVD","Completed","No Results Available","Cardiovascular Diseases|Cardiovascular Risk Factor","Behavioral: lecture","Blood pressure|Weight|Body mass index|Waist Circumference|Multiple choice test on cardiovascular disease","Northwestern University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","45","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","STU00035483","October 2010","December 2010","December 2010","April 13, 2011","null","April 13, 2011","Heritage International Christian Church, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT01335022"
1951,"NCT01331616","Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab",,"Unknown status","No Results Available","Glioblastoma|Optic Neuropathy","Drug: Bevacizumab (Avastin)","Measurement of Visual Evoked Potentials (optic nerve function and visual processing) and optic nerve function in 10 patients.|Number of patients diagnosed with optic neuropathy following treatment with chemo and radiation in combination with avastin treatment","West Penn Allegheny Health System","All","Child, Adult, Older Adult","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RC-5148","March 2011","March 2012","July 2012","April 8, 2011","null","April 22, 2011","Allegheny General Neurology Department/Neuro-Oncology, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01331616"
1952,"NCT01331590","Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia",,"Completed","No Results Available","Precursor Cell Lymphoblastic Leukemia-Lymphoma","Drug: G-CSF|Drug: Ifosfamide|Drug: Etoposide|Drug: Dexamethasone|Drug: Mesna","Treatment-related mortality|Delayed hematologic recovery|Complete remission rate cytogenetic complete remission|Overall survival|Disease-free survival|Remission duration|Frequency and severity of adverse events|Interaction of pretreatment disease and patient characteristics on clinical outcomes","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201104323","July 2011","October 2014","November 2015","April 8, 2011","null","September 20, 2016","University of Chicago Medical Center, Chicago, Illinois, United States|Washington University School of Medicine, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT01331590"
1953,"NCT01329718","Specimens for Septin 9 Performance","SPR0012","Completed","No Results Available","Colorectal Cancer","Other: Blood Sample","Effectiveness of the Epi proColon test","Epigenomics, Inc","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","562","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","Epigenomics_SPR0012","May 2011","December 2012","December 2012","April 6, 2011","null","August 4, 2014","","","https://ClinicalTrials.gov/show/NCT01329718"
1954,"NCT01329614","Effects of Nicotine Replacement and Repeated Cue Exposure on Cigarette Craving",,"Completed","No Results Available","Tobacco Use Disorder","Behavioral: Cue Extinction Training|Drug: Nicotine Replacement Therapy|Behavioral: Cue Extinction Therapy|Behavioral: Progressive Muscle Relaxation","Galvanic Skin Response","New York State Psychiatric Institute","All","21 Years to 60 Years   (Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","6001","October 2009","July 2013","July 2013","April 6, 2011","null","July 25, 2013","New York State Psychiatric Institute - Substance Use Research Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01329614"
1955,"NCT01327690","Mental Health in Veterans and Families After Group Therapies",,"Recruiting","No Results Available","Post-Traumatic Stress Disorders","Behavioral: CBT (Cognitive Behavior Therapy)|Behavioral: EFT (Emotional Freedom Techniques)","Change from Baseline PTSD (posttraumatic stress disorder) Symptom Levels","Soul Medicine Institute","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening","SMI-GROUP-12/10/10","December 2010","December 2022","December 2022","April 1, 2011","null","April 25, 2018","Soul Medicine Institute, Santa Rosa, California, United States","","https://ClinicalTrials.gov/show/NCT01327690"
1956,"NCT01325233","The Pilot Clinical Study of PG2 Injection on Hemorrhagic Stroke",,"Completed","No Results Available","Hemorrhagic Stroke","Drug: PG2|Drug: Placebo","Functional Independence Measure (FIM)|Other clinical symptoms including Glasgow outcome scale (GOS), modified rankin scale (MRS), and Barthel Index (BI)|Inflammatory index including C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), S-100 protein, IL-1, IL-6, and TNF-beta levels.","PhytoHealth Corporation","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PH-CP018","March 2011","September 2013","September 2013","March 29, 2011","null","September 10, 2018","China Medical University Hospital, Taichung, Taiwan","","https://ClinicalTrials.gov/show/NCT01325233"
1957,"NCT01318915","Research Study of ATG and Rituximab in Renal Transplantation","RESTARRT","Terminated","Has Results","Renal Transplant Recipients","Drug: ATG|Drug: Rituximab|Drug: Tacrolimus|Drug: Sirolimus|Drug: MMF","Percent of Participants Successfully Withdrawn From Immunosuppression and Remained Off Immunosuppression for at Least 52 Weeks|Percent of Transplanted Participants Who Remain Off Immunosuppression for at Least 52 Weeks Including Those in Whom the 52 Week Biopsy Was Not Performed|Percent of Transplanted Participants Who Remain Off Immunosuppression for the Duration of the Study as Defined as Completion of All Schedules of Events/Followed Through August 25, 2017|Percent of Transplanted Participants Who Achieve Sirolimus Monotherapy Within 52 Weeks Post-transplant|Percent of Transplanted Participants Who Achieve MMF or Mycophenolic Acid Monotherapy Within 52 Weeks Post-transplant in Those Participants Intolerant of Sirolimus|Percent of Transplanted Participants Who Achieve Either Sirolimus Monotherapy or Monotherapy on a Mycophenolic Compound Within 52 Weeks Post-transplant|Immunosuppression-free Duration in Days, Defined as Time From Completion of Immunosuppression Withdrawal to End of Trial Participation or to Time of Restarting Immunosuppression|Time From Completion of Immunosuppression Withdrawal to First Episode of Acute Rejection or Presumed Acute Rejection|Time From Completion of Immunosuppression Withdrawal to First Diagnosis of Chronic T Cell Mediated or Antibody-mediated Rejection|Percent of Transplanted Participants With Graft Loss|Percent of Transplant Participants Who Died|Percent of Transplanted Participants With Acute Rejection or Presumed Acute Rejection|Histological Severity of Biopsies Demonstrating Acute Rejection as Measured by Banff 2007 Grade|Percent of Participants With Chronic T Cell-mediated or Antibody-mediated Rejection|Time From Transplant to the First Episode of Acute Rejection Requiring Treatment|Percent of Participants Requiring Anti-lymphocyte Therapy (OKT3, ATG) for an Acute Rejection Event|Number of Adverse Events, Including Number of Post-transplant Infections, Wound Complications, Lymphocoele, Post-transplant Diabetes Mellitus, and Malignancies|Participant Renal Function as Measured by GFR Using CKD-EPI|Participant Systolic Blood Pressure Over Time|Participant Diastolic Blood Pressure Over Time|Participant Total Cholesterol Over Time|Participant Glucose Level Over Time","National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","10","NIH|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAIT ITN039ST","July 25, 2011","June 17, 2016","August 25, 2017","March 21, 2011","October 4, 2017","October 12, 2018","University of California San Francisco Medical Center, San Francisco, California, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Rogosin Institute/New York Presbyterian-Cornell, New York, New York, United States|Hospital at the University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Wisconsin, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT01318915"
1958,"NCT01317290","Supplementation of Alpha-linolenic Acid (ALA)-Rich Oil in Humans","ALA_KK","Completed","No Results Available","Overweight|Hypercholesterolemia","Dietary Supplement: n-3 PUFA free olive oil|Dietary Supplement: linseed oil","n-3 LC-PUFA in human lipids (EPA)|eicosanoid concentration in plasma","University of Jena|German Research Foundation","All","20 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","H50-11-KK","February 2012","September 2012","May 2013","March 17, 2011","null","November 13, 2013","Friedrich Schiller University of Jena, Jena, Thuringia, Germany","","https://ClinicalTrials.gov/show/NCT01317290"
1959,"NCT01317017","Cell Responses to IFN-gamma",,"Terminated","No Results Available","Plaque Psoriasis","Drug: Actimmune","Function of dendritic cells from IFNg-injected skin|Flow cytometry analysis of circulating leukocyte populations","Rockefeller University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","MLO-0717","July 2010","May 2011","May 2011","March 16, 2011","null","March 5, 2013","Rockefeller University, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01317017"
1960,"NCT01315756","Self-management in Type 2 Diabetes Patients Using the Few Touch Application",,"Completed","No Results Available","Type 2 Diabetes","Device: Use of Few Touch Application (FTA)|Device: Use of FTA and health counseling based on TTM and CBT","Improved glycemic control, HbA1c|Lipids, self-care, lifestyle changes, complications, quality of life.","University Hospital of North Norway|Oslo University College|European Commission|The Research Council of Norway","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","151","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Renewing Health Norway","March 2011","October 2013","October 2013","March 15, 2011","null","December 12, 2014","Norwegian Centre for Integrated Care and Telemedicine (NST ), University Hospital of North- Norway, Tromsø, Troms, Norway|Oslo University College, Oslo, Norway","","https://ClinicalTrials.gov/show/NCT01315756"
1961,"NCT01314742","Study of Biotene OralBalance Gel for Oral Care in Critically-Ill Mechanically Ventilated Neonates",,"Completed","Has Results","Ventilator-associated Pneumonia","Drug: Biotene OralBalance® gel|Other: Sterile Water moisten cotton tipped applicator","Feasibility|Duration of Mechanical Ventilation","Wake Forest University Health Sciences","All","Child, Adult, Older Adult","Early Phase 1","41","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00013036|FMC 2010-100","May 2010","January 2012","July 2012","March 14, 2011","February 4, 2014","September 11, 2018","Forsyth Medical Center, Winston-Salem, North Carolina, United States|Brenner Children's Hospital, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01314742"
1962,"NCT01313923","Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus",,"Terminated","Has Results","Pemphigus","Drug: Sirolimus (formerly known as Rapamycin)","Improvement of ABSIS Score While Reducing Steroid Dosage|Statistical Measures","University of California, Irvine","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-7844","February 2011","October 2014","October 2014","March 14, 2011","March 25, 2016","June 9, 2017","University of California, Irvine, Irvine, California, United States","","https://ClinicalTrials.gov/show/NCT01313923"
1963,"NCT01313910","CCRC: A Project of the Treatment of HIV Enteropathy With ImmunoLin® Supplements",,"Completed","Has Results","HIV","Dietary Supplement: Immunolin®","Number of Bowel Movements Per Day|Frequency of Pro-inflammatory Bacterial Orders|Measures of Gut Permeability|Systemic Immune Activation|Duodenal Immune Reconstitution","University of California, Davis|Proliant Health & Biologicals","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","225193|201118675","March 2011","August 2012","August 2012","March 14, 2011","March 3, 2017","June 15, 2017","UCD CTSC Clinical Research Center (CCRC), Mather, California, United States","","https://ClinicalTrials.gov/show/NCT01313910"
1964,"NCT01313546","A Comparison of Sartorius Vs. Quadriceps Evoked Motor Response for Femoral Nerve to Prevent Secondary Catheter Failure",,"Unknown status","No Results Available","Arthroplasty, Replacement, Knee","Other: Stimulation of quariceps muscle","the number of secondary catheter failures|total morphine consumption","Sunnybrook Health Sciences Centre","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Sunnybrook_Women's","May 2011","May 2012","September 2012","March 11, 2011","null","March 11, 2011","The Holland orthopedic and arthritic centre, TOronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01313546"
1965,"NCT01313039","Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: AZ6244","Increase of ER Protein Expression in ER-Negative/Low Breast Cancer|Changes in ER-regulated Gene Expression in E-negative/Low Breast Cancer|Rate of ER Promoter Methylation in ER-negative/Low Breast Cancer|In Vitro Tamoxifen Response in Tumors","University of Miami","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20100252","February 2011","April 2014","April 2014","March 11, 2011","July 2, 2014","February 7, 2017","University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States","","https://ClinicalTrials.gov/show/NCT01313039"
1966,"NCT01308242","Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease",,"Completed","No Results Available","Chronic Kidney Disease","Drug: Sevelamer Carbonate","Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease","Milton S. Hershey Medical Center|Genzyme, a Sanofi Company","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","33139CS","March 2011","February 27, 2014","February 27, 2014","March 4, 2011","null","May 2, 2018","Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01308242"
1967,"NCT01307904","The Glycemic Indices of Five Common Varieties of Dates in the Tested Among Healthy and Diabetic Subjects","Dates","Completed","No Results Available","Diabetes Mellitus","Other: Glucose|Other: Dates","Dates Glycemic Index","United Arab Emirates University|Abu Dhabi Food Control Authority","All","18 Years to 60 Years   (Adult)","Early Phase 1","23","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)","UAEU Dates GI Study","March 2010","March 2010","July 2010","March 3, 2011","null","March 3, 2011","Internal Medicine Department, FMHS, UAE University, Al Ain, Abu Dhabi, United Arab Emirates","","https://ClinicalTrials.gov/show/NCT01307904"
1968,"NCT01306838","Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy","EMLFO","Completed","No Results Available","Short Bowel Syndrome|Necrotizing Enterocolitis|Small Intestine Perforation","Dietary Supplement: MicroLipid and fish oil|Other: Routine care","Average duration of exposure to PN (including Intralipid, IL) between the initial feeding and bowel reanastomosis|Average weight gain (g/day)from initiating feeding to reanastomosis|Average level of conjugated bilirubin and ostomy output of infants receiving ML/FO to the group receiving usual care between the initial feeding after placement of ostomy and reanastomosis|Dietary fat and protein absorption, from initiating feeding to reanastomosis|Expression of four key genes that play a crucial role in intestinal adaptation|Neurodevelopment outcomes and growth in the infants receiving ML/FO vs. in the infants receiving usual care at the 18-24 month of age.","Wake Forest University|Wake Forest University Health Sciences","All","up to 60 Days   (Child)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00011501","October 2009","October 2014","October 2014","March 2, 2011","null","August 15, 2018","WFUHS Brenner Children's Hospital NICU, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01306838"
1969,"NCT01303484","The Effect of Prebiotic B-GOS on the Immune Function, Metabolism and Gut Microbiota of Elderly People","PRIMES","Completed","No Results Available","Immunosenescence","Dietary Supplement: Bi2muno® GOS|Dietary Supplement: Maltodextrin","Effect of B-GOS on immunity by measuring various inflammatory/immune biomarkers|Effect of B-GOS on the faecal microbiota composition of elderly persons|Effect of aging on body metabolites using NMR|Effect of B-GOS on gut permeability|Weekly assessment of stools and gastrointestinal symptoms","Clasado|University of Reading","All","65 Years to 80 Years   (Older Adult)","Early Phase 1","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Clasado2011","May 2011","November 2012","July 2014","February 24, 2011","null","March 25, 2016","University of Reading, Reading, Berkshire, United Kingdom","","https://ClinicalTrials.gov/show/NCT01303484"
1970,"NCT01302002","The Use of Metformin in Early Breast Cancer Patients Pre-Surgery",,"Withdrawn","No Results Available","Breast Cancer","Drug: Metformin Pre-Surgery","To determine the in situ effects of metformin in women with operable stage I or II breast cancer|To analyse gastrointestinal toxicity|To analyse the blood tests one day before the biopsy and one day before the surgery","Instituto Nacional de Cancer, Brazil","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","INCA113/10","January 2011","February 2016","February 2016","February 23, 2011","null","February 23, 2016","Hospital do Cancer III, Rio de Janeiro, Brazil","","https://ClinicalTrials.gov/show/NCT01302002"
1971,"NCT01298986","Atrial Fibrillation Ablation The Hybrid Approach Versus Traditional Management","AF","Withdrawn","No Results Available","Ablation of Atrial Fibrillation","Procedure: Pulmonary vein isolation ablation procedure for atrial fibrillation|Procedure: Hybrid procedure for ablation of atrial fibrillation|Procedure: The Cox Maze Procedure for Ablation of Atrial Fibrillation|Procedure: Hybrid Procedure for Left Atrium >5 cm but < 6.1 cm","Return to sinus rhythm rate|Post procedure morbidities","Inova Health Care Services","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10.126 Hybrid AF","May 2011","September 2014","September 2014","February 18, 2011","null","March 27, 2015","","","https://ClinicalTrials.gov/show/NCT01298986"
1972,"NCT01298310","A Study to Characterize the Phenotype in Patients With Morton's Neuroma and to Explore the Effect of Local Administration of Xylocaine (Lidocaine)",,"Completed","No Results Available","Morton's Neuroma","Drug: Xylocaine|Drug: Placebo","The baseline phenotypic Quantitative sensory testing (QST) variables (e.g. heat, cold, touch and mechanical pain perception). Sensory tests will be performed to measure pain and skin sensitivity by use of different pressure (mN) and temperature ( C)|The effect of Xylocaine compared to placebo in QST variables. Sensory tests will be performed to measure pain and skin sensitivity by use of different pressure (mN) and temperature ( C)|Frequency/severity of adverse events","AstraZeneca","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","D2285M00032|Eudract no: 2010-024295-26","February 2011","May 2012","May 2012","February 17, 2011","null","May 22, 2012","Research Site, Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT01298310"
1973,"NCT01292733","Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer","OCEDP","Terminated","No Results Available","Ovarian Diseases|Ovarian Neoplasms","Other: Laboratory Tumor Marker Analysis|Other: Transvaginal Ultrasound|Other: Health Status Questionnaire","Measuring for elevated levels of tumor marker CA-125 in the blood over time.|Performing transvaginal ultrasounds to look for any abnormalities over time.|Performing health status questionnaires over time","Swedish Medical Center|Fred Hutchinson Cancer Research Center|The Marsha Rivkin Center for Ovarian Cancer Research","Female","30 Years and older   (Adult, Older Adult)","Early Phase 1","534","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IR 4707|CRC 08108","August 2009","December 2015","December 2015","February 9, 2011","null","January 20, 2016","Marsha Rivkin Center for Ovarian Cancer Research, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT01292733"
1974,"NCT01292070","Safety Evaluation of an Experimental Treatment, Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD), for Cat Allergy",,"Terminated","Has Results","Cat Allergy","Biological: Intradermal Human Fcγ1-Fel d1 fusion protein|Biological: Positive Control - standardized cat hair allergenic extract (CAT)|Biological: Positive Control - Histamine Prick|Biological: Negative Control - Intradermal Diluent","Difference in the Doses of GFD and CAT Required to Elicit a Cutaneous Reaction Demonstrated by a Wheal Greater Than or Equal to 10 mm With Surrounding Erythema","National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|Tunitas Therapeutics, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","4","NIH|Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAIT ITN048AD","March 2011","April 2011","April 2011","February 9, 2011","February 20, 2014","February 20, 2014","Alfred Hospital and Monash University, Melbourne, Victoria, Australia","","https://ClinicalTrials.gov/show/NCT01292070"
1975,"NCT01292005","Pentoxifylline Treatment of Acute Pancreatitis",,"Completed","Has Results","Acute Pancreatitis","Drug: Pentoxifylline|Drug: Placebo","Change in C-Reactive Protein (CRP)|Change in Tumor Necrosis Factor (TNF)-Alpha|Change in Interleukin (IL) IL-6|Changes in Interleukin (IL) IL-8|Number Of Subjects With New Onset Organ Failure During Hospitalization|Number Of Subjects With New Onset Pancreatic Necrosis During Hospitalization|Number of Patients With Lengthy Hospital Stays|Length of Hospital Stay|Length of Intensive Care Unit (ICU) Stay|Number of Subjects Who Needed an Intensive Care Unit Stay","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","08-006648","April 2009","July 2012","July 2012","February 9, 2011","December 13, 2013","October 25, 2016","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01292005"
1976,"NCT01286675","Effect of Eltrombopag Plus Granulocyte Colony-stimulating Factor (G-CSF) on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant (ASCT)",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Eltrombopag","Evaluate the median fold increase in the number of CD34+ cells/kg mobilized at each dose level.|Evaluate the number of apheresis procedures required to obtain at least 2 x 10^6 CD34+ cells/kg at each dose level|Determine the maximum tolerated dose of eltrombopag with granulocyte colony-stimulating factor.|Evaluate the median fold increase in platelet counts at each of the dose levels|Evaluate the median fold increase in hematopoietic colony forming capacity of CD34+ cells at each dose level","Dana-Farber Cancer Institute","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","10-346","March 2011","December 2016","December 2018","January 31, 2011","null","January 19, 2018","Dana Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01286675"
1977,"NCT01282775","Interventions to Control Obesity in Community Colleges (CDC WAY to Health)",,"Completed","No Results Available","Overweight|Obesity","Behavioral: WEB + Environment|Behavioral: WEB + Cash Incentive for Weight Loss","weight change|moderate vigorous physical activity|total calories|percent body fat|fruit/veg intake|absenteeism|quality of life|medical expenditures","University of North Carolina, Chapel Hill|RTI International","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","1029","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","04-0509|DP000102","September 2005","November 2006","March 2007","January 25, 2011","null","January 25, 2011","","","https://ClinicalTrials.gov/show/NCT01282775"
1978,"NCT01276613","Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas",,"Active, not recruiting","No Results Available","Pancreatic Cancer","Drug: Gemcitabine|Drug: Losartan","Intratumoral Gemcitabine Levels in Human Pancreatic Cancer Tissue|Gemcitabine DNA Levels in Human Pancreatic Cancer Tissue|Effect of Losartan on Gemcitabine DNA Incorporation Human Pancreatic Cancer Tissue","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-0371|NCI-2011-00244|RSD1429)|WS#23","January 2011","January 2019","January 2019","January 13, 2011","null","July 13, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01276613"
1979,"NCT01275586","Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas",,"Completed","Has Results","Neurofibromatosis|NF1|Neurofibromas","Drug: Tasigna","Disease Response","Indiana University|Novartis","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1008-06|CAMN107YUS29T","January 2011","July 2016","October 2016","January 12, 2011","April 12, 2017","April 12, 2017","Riley Hospital for Children, Indianapolis, Indiana, United States","","https://ClinicalTrials.gov/show/NCT01275586"
1980,"NCT01275482","Effectiveness of Transverse Friction Massage in Latent Myofascial Trigger Points in Anterior Deltoid Muscle",,"Completed","No Results Available","Myofascial Trigger Points|Myofascial Pain","Procedure: Transverse friction massage (TFM)","Change from Baseline in Pressure pain Threshold (PPT)during treatment.","University of Castilla-La Mancha","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research","deltoid","January 2011","March 2011","March 2011","January 12, 2011","null","April 7, 2011","UCLM, Toledo, Spain","","https://ClinicalTrials.gov/show/NCT01275482"
1981,"NCT01275183","Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of Head and Neck",,"Completed","No Results Available","Head and Neck Cancer","Drug: raltegravir and cisplatin","Gene expression modification|Clinical activity|Clinical toxicity|Progression free survival and overall survival|Metnase expression","New Mexico Cancer Care Alliance|American Cancer Society, Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INST 1012|NCI-2012-00914","December 2010","April 2015","April 2015","January 12, 2011","null","June 18, 2015","University of New Mexico Cancer Center, Albuquerque, New Mexico, United States","","https://ClinicalTrials.gov/show/NCT01275183"
1982,"NCT01274507","A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease",,"Completed","No Results Available","Asthma|Pulmonary Disease, Chronic Obstructive","Other: Medical tests","Asthma Quality of Life Questionnaire (AQLQ) score|Asthma Control Questionnaire (ACQ) score|Forced Expiratory Volume in 1 second (FEV1) value|Forced Vital Capacity (FVC) value|Forced Expiratory Flow (FEF) 25-75 value|Peak Expiratory Flow Rate (PEFR)|Methacholine challenge|Fractional Exhaled Nitric Oxide (FENO)|Induced sputum|Saint George's Respiratory Questionnaire score for Chronic Obstructive Pulmonary Disease (COPD) participants (SGRQ-C)|EXACT-Respiratory Symptoms (E-RS)|Number of participants with adverse events","Janssen Research & Development, LLC","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","328","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CR017362|NOCOMPOUNDASH0001","July 2010","July 2014","July 2014","January 11, 2011","null","December 20, 2016","Birmingham, Alabama, United States|New Haven, Connecticut, United States|Chicago, Illinois, United States|Iowa City, Iowa, United States|Baltimore, Maryland, United States|Chapel Hill, North Carolina, United States|Cleveland, Ohio, United States|Philadelphia, Pennsylvania, United States|Galveston, Texas, United States|Calgary, Alberta, Canada|Vancouver, British Columbia, Canada|Montreal, Quebec, Canada|Sainte Foy, Quebec, Canada|Kobenhavn Nv, Denmark|Bordeaux Pessac N/A, France|Marseille, France|Frankfurt, Germany|Lübeck, Germany|Rotterdam, Netherlands|Bucuresti, Romania|Manchester, United Kingdom","","https://ClinicalTrials.gov/show/NCT01274507"
1983,"NCT01269775","Comparison of Face to Face Lecture, Interactive Internet Based and Computer Based Teaching",,"Completed","No Results Available","3rd Year Medical School's Students","Other: Teaching Methods","","Tehran University of Medical Sciences","All","Child, Adult, Older Adult","Early Phase 1","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)","10764","June 2010","July 2010","July 2010","January 4, 2011","null","January 4, 2011","Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT01269775"
1984,"NCT01269593","PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study",,"Recruiting","No Results Available","Non-Hodgkin's Lymphoma|Myeloma|Active Solid Malignancy","Drug: PET Imaging using 124 IPUH71","To study the pharmacokinetics|To study the metabolism|To study the biodistribution|To study the radiation dosimetry","Memorial Sloan Kettering Cancer Center|Samus Therapeutics","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","67","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","10-139","December 2010","December 2019","December 2019","January 4, 2011","null","January 17, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01269593"
1985,"NCT01269190","Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery",,"Recruiting","No Results Available","Oral Cavity Neoplasm","Procedure: High-Resolution Microendoscopy|Procedure: Multispectral Imaging|Drug: Proflavine","Evaluation of oral mucosa to be used for non-invasive detection and diagnosis with the use of optical imaging after administration of the topical contrast agent proflavine.|Classification of tissue|Percentage of subjects and lesions that can be successfully imaged with wide-field and high-resolution optical microscopes after topical application of contrast dye|Qualitative features within images that differ between pathologically normal, dysplastic, cancerous and inflammatory lesions","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","275","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2008-0613|NCI-2015-01904|P30CA016672","December 30, 2010","December 31, 2018","December 31, 2018","January 4, 2011","null","September 21, 2018","M D Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01269190"
1986,"NCT01268020","Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC","FMH3","Completed","No Results Available","Alzheimer Disease","Drug: [18F]-FMH3","To assess the dynamic uptake and washout of 18F-FMH3","Institute for Neurodegenerative Disorders","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","FMH3-01","December 2010","October 2012","October 2012","December 29, 2010","null","November 11, 2013","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01268020"
1987,"NCT01264757","Steps Toward Adapting Physical Activity Guidelines for the Lower Mississippi Delta Population","STEPS","Completed","No Results Available","Physical Inactivity","Behavioral: Physical Activity Educational Materials|Behavioral: Pedometer","Minutes spent in moderate-to-vigorous physical activity (MVPA)","Pennington Biomedical Research Center|United States Department of Agriculture (USDA)","All","35 Years to 64 Years   (Adult)","Early Phase 1","43","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PBRC 29034","February 2010","June 2010","June 2010","December 22, 2010","null","February 5, 2016","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT01264757"
1988,"NCT01263847","Galactooligosaccharide (GOS) Supplementation and Calcium Absorption in Girls","Friesland","Completed","No Results Available","Osteoporosis","Dietary Supplement: Galactooligosaccharide","Calcium Absorption|Change in fecal microbiota","Purdue University|Friesland Foods","Female","10 Years to 12 Years   (Child)","Early Phase 1","31","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Friesland","June 2009","July 2010","July 2010","December 21, 2010","null","May 9, 2018","Purdue University, West Lafayette, Indiana, United States","","https://ClinicalTrials.gov/show/NCT01263847"
1989,"NCT01263613","Feasibility Study of Biomarkers of Response to Neoadjuvant Paclitaxel in Locally Advanced Breast Cancer",,"Completed","No Results Available","Breast Cancer","Procedure: tumor biopsy and blood draw","Determine feasibility of measuring biomarkers in breast tumors 20 hours after administration of the first dose of paclitaxel chemotherapy.|Measure drug levels in breast tumors 20 hours after administration of paclitaxel|Determine feasibility of correlating drug levels with biomarkers including mitotic index, aneuploidy, and Ki67|Determine feasibility of correlating pathologic response and clinical response with biomarkers including mitotic index, aneuploidy, and Ki67.|Determine the feasibility of obtaining circulating tumor cells (CTCs) for analysis including evaluation for mitosis.|Compare biomarkers from tissue samples obtained 20 hours after administration of paclitaxel with tissue obtained at the time of surgery.","University of Wisconsin, Madison","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","OS10103","December 2010","June 2013","June 2013","December 20, 2010","null","April 8, 2014","University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT01263613"
1990,"NCT01261299","Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer",,"Terminated","No Results Available","Carcinoma, Non-Small-Cell Lung|Urinary Bladder Neoplasms","Drug: Carbon-14-labeled carboplatin","Correlation of carboplatin-DNA monoadducts induced by microdoses of carboplatin with cancer response to carboplatin-based chemotherapy|Determination of the underlying chemoresistance mechanisms to carboplatin","University of California, Davis|Lawrence Livermore National Laboratory|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","21","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCDCC#200|201018146","December 2010","November 2016","November 2016","December 16, 2010","null","January 9, 2018","University of California Los Angeles, Los Angeles, California, United States|University of California, Davis, Sacramento, California, United States","","https://ClinicalTrials.gov/show/NCT01261299"
1991,"NCT01257048","Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler",,"Completed","No Results Available","COPD Method Evaluation|Chronic Obstructive Pulmonary Disease Method Evaluation","Drug: Formoterol Turbuhaler|Drug: Budesonide/Formoterol Turbuhaler","Oxygen enhanced MRI V4|Oxygen enhanced MRI V5|Oxygen enhanced MRI V7|Transferability of OE-MRI technique|OE-MRI variables|Impulse oscillometry parameters V2|Impulse oscillometry parameters V4|Impulse oscillometry parameters V5|Impulse oscillometry parameters V7","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Early Phase 1","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D6256M00046|2010-023751","August 2011","June 2012","June 2012","December 9, 2010","null","September 3, 2012","Research Site, Lund, Sweden|Research Site, Manchester, United Kingdom","","https://ClinicalTrials.gov/show/NCT01257048"
1992,"NCT01256983","Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation","SleepTx-1","Completed","Has Results","Renal Disease|Sleep Disorders","Behavioral: Bright Light Therapy|Behavioral: Wait-list intervention","Bedtime","University of Basel|University Hospital, Basel, Switzerland|University Hospital Inselspital, Berne|University Hospital, Zürich","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","SleepTx-1","October 2010","June 2013","July 2013","December 9, 2010","January 28, 2014","March 3, 2014","","","https://ClinicalTrials.gov/show/NCT01256983"
1993,"NCT01254435","Positioning During Colonoscopy",,"Completed","No Results Available","Colonic Polyps","Procedure: Colonoscopy","Mucosal visualisation|Luminal distension","Sheffield Teaching Hospitals NHS Foundation Trust|Sheffield Teaching Hospitals NHS Foundations Trust","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","41","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","STH14709","May 2009","August 2009","September 2010","December 6, 2010","null","December 6, 2010","Sheffield Teaching Hospitals NHS Trust, Sheffield, South Yorkshire, United Kingdom","","https://ClinicalTrials.gov/show/NCT01254435"
1994,"NCT01253213","BR55 in Prostate Cancer: an Exploratory Clinical Trial",,"Completed","No Results Available","Prostate Cancer","Drug: BR55","BR55 sensitivity assessment|BR55 specificity assessment","Bracco Diagnostics, Inc|Bracco Imaging S.p.A.","Male","40 Years and older   (Adult, Older Adult)","Early Phase 1","26","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","BR55-101","July 2010","December 2012","December 2012","December 3, 2010","null","April 24, 2013","AMC University Amsterdam, Amsterdam, Netherlands","","https://ClinicalTrials.gov/show/NCT01253213"
1995,"NCT01252979","Ketones & Mitochondrial Heteroplasmy",,"Completed","No Results Available","MELAS Syndrome|Mitochondrial Diseases","Dietary Supplement: Medium-Chain Triglycerides","Heteroplasmy","The University of Texas Health Science Center, Houston","All","Child, Adult, Older Adult","Early Phase 1","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC-MS-10-0091","December 2010","December 2011","December 2011","December 3, 2010","null","February 6, 2012","The University of Texas Health Science Center at Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01252979"
1996,"NCT01251497","¡Si, Yo Puedo Control Mi Diabetes!: A Diabetes Self-management Education Program for Hispanic/Latinos","Yo Puedo","Completed","No Results Available","Type 2 Diabetes, Hispanic/Latinos, Diabetes Self-management Education","Behavioral: diabetes self-management education","","Texas AgriLife Extension Service|Texas A&M University","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","null","Other","Interventional","Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care","texn0043","September 2009","October 2010","October 2010","December 2, 2010","null","December 2, 2010","","","https://ClinicalTrials.gov/show/NCT01251497"
1997,"NCT01250431","Gene Expression Correlates of Post-Traumatic Stress Disorder (PTSD) Symptom Change After EFT (Emotional Freedom Techniques)",,"Completed","No Results Available","Stress Disorders, Post-Traumatic","Behavioral: EFT (Emotional Freedom Techniques)","QRT-PCR Assessment of Gene Expression Associated with Psychological Symptoms of Traumatic Stress","Soul Medicine Institute","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","SMI-YOUNT-11/24/10","November 2010","November 2017","November 2017","November 30, 2010","null","April 25, 2018","Soul Medicine Institute, Santa Rosa, California, United States","","https://ClinicalTrials.gov/show/NCT01250431"
1998,"NCT01247298","A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma","RAD 0902","Completed","Has Results","Hepatocellular Carcinoma (HCC)","Combination Product: Stereotactic Body Radiation Therapy (SBRT)","Safety of a Combination Therapy|Median Progression Free Survival (PFS) Treated With a Combination of TACE & SBRT.|Local Recurrence Rate|Percentage of Participants With Overall Survival|Percentage of Participants With Local Failure Patterns","University of Alabama at Birmingham","All","19 Years and older   (Adult, Older Adult)","Early Phase 1","17","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F100708009","October 2010","September 2016","December 2016","November 24, 2010","June 19, 2017","August 21, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT01247298"
1999,"NCT01245660","A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy","LAPAINBLAD","Terminated","No Results Available","Bladder Carcinoma|Infiltrative Bladder Carcinoma|Cystectomy","Drug: LAPATINIB","Effect on egf pathway at a molecular level of 3 weeks treatment by lapatinib.|Lapatinib biological response on key molecules of the egf pathway (EGFR, ERBB2, AKT ERK as well as their phosphorylation status.)|Histological response","University Hospital, Bordeaux","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","CHUBX 2009/04","January 2011","October 2011","October 2011","November 22, 2010","null","January 11, 2013","CHU Bordeaux - Hôpital Saint André - Department of Medical Oncology, Bordeaux, France","","https://ClinicalTrials.gov/show/NCT01245660"
2000,"NCT01245309","Endometrial Scratching Prior to Controlled Ovarian Stimulation (COH) in Women Undergoing In-vitro Fertilization With Previous IVF Failure","ESICOHF","Completed","No Results Available","Infertility","Procedure: scratching|Procedure: A PLACEBO PROCEDURE","live birth rate per woman|ongoing pregnancy rate","Mansoura University","Female","up to 40 Years   (Child, Adult)","Early Phase 1","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AG1001","December 2010","December 2013","December 2013","November 22, 2010","null","January 15, 2014","Mansoura University, Mansoura, Egypt","","https://ClinicalTrials.gov/show/NCT01245309"
2001,"NCT01245075","Deep Brain Stimulation of the Nucleus Accumbens as a Novel Treatment in Severe Opioid Addiction","NASA","Recruiting","No Results Available","Addiction","Other: Deep brain stimulation|Other: Placebo","Reduction of Levomethadone|Drug seeking, goal directed behavior, Craving, Psychological components Laboratory parameters in the urine (parallel consumption of other drugs)","Jens Kuhn|University of Cologne","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","10-090","January 2011","June 2017","December 2017","November 22, 2010","null","December 7, 2016","University of Cologne, Cologne, Germany","","https://ClinicalTrials.gov/show/NCT01245075"
2002,"NCT01241851","Effect of Acute Exercise on Cognitive Functions",,"Unknown status","No Results Available","Cognitive Function in Elderly","Behavioral: Aerobic exercise|Behavioral: Resistance exercise","Level of executive function","Hillel Yaffe Medical Center|The Zinman College for Physical Education and Sport Exercise, Wingate Institute","All","40 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Prevention","0093-10-HYMC","January 2011","July 2011","December 2011","November 16, 2010","null","November 16, 2010","Zinman College, Wingate Institute, Netanya, Israel","","https://ClinicalTrials.gov/show/NCT01241851"
2003,"NCT01240824","Study of BCG + Aminophylline Toxicity When Used in the Treatment of Bladder Cancer","BCG","Completed","No Results Available","Bladder Cancer","Drug: aminophylline","Dose limiting toxicity","University of Virginia","All","40 Years and older   (Adult, Older Adult)","Early Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","14585","July 2010","February 2011","February 2011","November 15, 2010","null","April 14, 2014","University of Virginia Urology Department, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01240824"
2004,"NCT01233024","Satiety Response of Four Dietary Fibers",,"Completed","No Results Available","Healthy","Dietary Supplement: Control|Dietary Supplement: Soluble corn fiber|Dietary Supplement: Resistant starch|Dietary Supplement: Fructooligosaccharide|Dietary Supplement: Inulin","Satiety response using visual analogue scales|Food intake|Breath hydrogen response|Gastrointestinal tolerance using visual analogue scales (VAS)","University of Minnesota - Clinical and Translational Science Institute","Female","18 Years to 40 Years   (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1003E78714","November 2010","February 2012","February 2012","November 2, 2010","null","March 29, 2012","University of Minnesota, Saint Paul, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01233024"
2005,"NCT01232699","Internet Obesity Treatment Enhanced With Motivational Interviewing","iReach2","Completed","No Results Available","Obesity","Behavioral: Internet Obesity Treatment|Behavioral: Internet Obesity Treatment with MI|Behavioral: Contingent MI","Change in Body Weight|Change in body weight|Adherence to Treatment Components|Motivation Measures","University of Vermont|University of Arkansas","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","495","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-124","December 2010","April 2014","April 2014","November 2, 2010","null","May 16, 2014","University of Arkansas for the Medical Sciences, Little Rock, Arkansas, United States|Behavioral Weight Management Program/Univ of Vermont, Burlington, Vermont, United States","","https://ClinicalTrials.gov/show/NCT01232699"
2006,"NCT01231009","The Role of Corticosteroids and Vestibular Exercises in Recovery of Vestibular Neuritis",,"Unknown status","No Results Available","Vestibular Neuritis","Drug: Corticosteroids|Other: Vestibular exercises","clinical recovery of vestibular function|Laboratory recovery of vestibular","Aristotle University Of Thessaloniki","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VN-01-JG","January 2010","January 2012","January 2013","November 1, 2010","null","November 1, 2010","1st ENT Department, AHEPA University Hospital, Thessaloniki, Greece","","https://ClinicalTrials.gov/show/NCT01231009"
2007,"NCT01229163","Automated Prize-based Contingency Management to Increase Counseling Attendance in Opiate-Replacement-Therapy Patients",,"Completed","No Results Available","Opiate-Replacement Therapy","Device: Automated Contingency Management (ACM) software","Participant Feedback; Counselor Feedback; XPMI Performance","National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","25","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","999911464|11-DA-N464","October 3, 2010","April 9, 2012","April 19, 2012","October 27, 2010","null","April 5, 2018","National Institute on Drug Abuse, Biomedical Research Center (BRC), Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01229163"
2008,"NCT01226160","Pilot Randomised Controlled Trial of Posturing Following Surgery for Full-thickness Macular Hole",,"Completed","No Results Available","Full Thickness Macular Hole","Procedure: Postoperative face-down posturing|Procedure: Postoperative non-posturing group","Anatomical closure of the macula hole assessed 6 weeks following surgery by ocular coherence tomography.|Visual acuity assessed 6 weeks following surgery by Snellen charts.","Moorfields Eye Hospital NHS Foundation Trust","All","16 Years and older   (Child, Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","06/Q0603/100/01","January 2005","February 2010","October 2010","October 22, 2010","null","October 22, 2010","Moorfileld's Eye Hospital, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT01226160"
2009,"NCT01225796","Study of Sodium Bicarbonate in Kidney Transplant Recipients",,"Completed","No Results Available","Kidney Transplantation","Drug: Sodium bicarbonate","Urinary transforming growth factor-beta1|urinary ammonia excretion","University of Utah","All","21 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","00044216","November 2010","November 2012","November 2012","October 21, 2010","null","April 6, 2016","University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01225796"
2010,"NCT01221506","Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)",,"Completed","No Results Available","Carcinoma, Renal Cell","Drug: Pazopanib|Device: DCE-MRI and Quantitative Doppler Ultrasound","Evaluate Early Changes in DCE-MRI|Correlating Baseline DCE-MRI and early changes in DCE-MRI with other measures of treatment effectiveness","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 34809","October 2010","June 2015","null","October 15, 2010","null","August 29, 2018","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01221506"
2011,"NCT01218165","Low Grade Inflammation, Gut Microbiota and Barrier Function in Elderly Humans",,"Completed","No Results Available","Aged|Healthy","Dietary Supplement: Probiotic drink|Other: Control Group","Pre/post-intervention change in hsCRP|Intestinal permeability|Stool: Stool: Real-Time-PCR|Blood screening|Muscle function|Physical performance status","Charite University, Berlin, Germany","Male","65 Years to 85 Years   (Older Adult)","Early Phase 1","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","EA1/062/10","May 2010","November 2010","May 2011","October 11, 2010","null","October 28, 2011","Charité - Universitätsmedizin Berlin, Berlin, Germany","","https://ClinicalTrials.gov/show/NCT01218165"
2012,"NCT01217164","Strategy to Minimize In-hospital Malnutrition in Premature Babies","SPN","Completed","No Results Available","Weight Gain Preterm","Dietary Supplement: no intervention","The total of 64 children was followed from birth until discharge or death. The main outcome measured was weight gain during hospitalization or up to a maximum of 43 weeks gestational age when the child remained hospitalized|The difference between score Z (birth weight) and score Z (weight during discharge).","Hospital Universitario Pedro Ernesto","All","up to 43 Weeks   (Child)","Early Phase 1","64","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","DUARTEJLMB-001","October 2008","June 2010","June 2010","October 8, 2010","null","October 8, 2010","Jose Luiz Muniz Bandeira Duarte, Rio de Janeiro, Brazil","","https://ClinicalTrials.gov/show/NCT01217164"
2013,"NCT01217021","Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558","MNI-558","Completed","No Results Available","Alzheimer Disease","Drug: [18F] MNI-558","To evaluate the efficacy safety of MNI-558 positron emission tomography (PET) for detection/exclusion of cerebral amyloid beta in patients with Alzheimer disease (AD) compared to healthy volunteers (HV)|To assess the dynamic uptake of MNI-558, a potential imaging biomarker for B-amyloid burden in brain, using positron emission tomography (PET) in similarly aged Alzheimer (AD) subjects and healthy volunteers (HV|To determine pharmacokinetics pattern of MNI-558 in venous plasma of healthy and AD subjects.|To determine metabolite pattern of MNI-558 in venous plasma of healthy and AD subjects.","Institute for Neurodegenerative Disorders|Molecular NeuroImaging","All","55 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MNI-558-01","September 2010","March 2011","March 2011","October 8, 2010","null","July 25, 2011","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01217021"
2014,"NCT01211561","Colon Cancer Prevention Using Selenium",,"Unknown status","No Results Available","Prevention of Colorectal Cancer","Drug: Selenium, selenomethionine|Drug: placebo","Reduction in ACF biomarkers","University of Illinois at Chicago","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","2008-1122","December 2010","December 2014","December 2016","September 29, 2010","null","September 29, 2010","University of Illinois at Chicago Medical Center, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT01211561"
2015,"NCT01210430","Local Vasoconstriction in Postural Tachycardia Syndrome",,"Completed","No Results Available","Postural Tachycardia Syndrome","Drug: Losartan|Drug: Ascorbic Acid (Vitamin C)|Drug: Normal Saline","Orthostatic tolerance measured by the heart rate and blood pressure response to upright tilt|Sympathetic activation and blood flow measured by sympathetic nerve recordings and Doppler blood flow in the leg","New York Medical College","All","14 Years to 29 Years   (Child, Adult)","Early Phase 1","74","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","2R01HL074873-06A2","July 2010","June 2015","June 2015","September 28, 2010","null","July 20, 2018","New York Medical College/Bradhurst building, Hawthorne, New York, United States","","https://ClinicalTrials.gov/show/NCT01210430"
2016,"NCT01209676","IMCgp100 in Advanced Unresectable Melanoma",,"Completed","No Results Available","Melanoma|Advanced Disease|Unresectable","Drug: IMCgp100 injection","Adverse Events as a Measure of Safety and Tolerability|Adverse events|Vital signs|PE examinations findings|Peripheral blood samples","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 03610","September 2010","March 2013","null","September 27, 2010","null","November 15, 2016","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01209676"
2017,"NCT01209533","Inhaled Iloprost in Mild Asthma",,"Completed","No Results Available","Asthma","Drug: Iloprost","PD20FEV1 methacholine|asthma related symptoms|asthma control|FEV1|Exhaled nitric oxide|Interleukin 17","Vanderbilt University|Actelion","All","18 Years to 60 Years   (Adult)","Early Phase 1","24","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","100637","September 2010","July 2011","July 2011","September 27, 2010","null","August 3, 2011","Vanderbilt University Medical Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT01209533"
2018,"NCT01205672","Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer",,"Completed","No Results Available","Endometrial Cancer","Drug: Metformin","Number of Patients with Increase in s6K Expression","M.D. Anderson Cancer Center|American Cancer Society, Inc.","Female","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009-0927|NCI-2012-01796|CBC 965712","September 16, 2010","May 28, 2017","May 28, 2017","September 20, 2010","null","June 2, 2017","Lyndon B. Johnson General Hospital, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01205672"
2019,"NCT01204554","Microcirculation in Perforator Flaps. Enhancing Tissue Survival",,"Unknown status","No Results Available","Reconstructive Surgery|Microcirculation","Drug: Indocyanine green (ICG)","Mean pixel intensity using dynamic laser-induced-fluorescence-videoangiography","Oslo University Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","08/223b.2008/3837 (REK)","September 2008","December 2010","December 2010","September 17, 2010","null","September 17, 2010","Oslo University Hospital, Oslo, Norway","","https://ClinicalTrials.gov/show/NCT01204554"
2020,"NCT01199445","Efficacy of Vitamin A in Fortified Extruded Rice in School Children",,"Completed","No Results Available","Vitamin A Deficiency","Dietary Supplement: Triple fortified extruded tice (Fe, Zn and vitamin A)","Vitamin A in the entire body|Serum retinol","Swiss Federal Institute of Technology|Mahidol University|University of Wisconsin, Madison","All","8 Years to 12 Years   (Child)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","ETH2010/SP02","August 2010","November 2010","March 2011","September 13, 2010","null","January 6, 2016","Tessaban 3 School, Muang, Satun, Thailand","","https://ClinicalTrials.gov/show/NCT01199445"
2021,"NCT01198197","PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A",,"Completed","No Results Available","Pain|Anxiety|Depression","Drug: NOP-1A","For the PET scans, we will measure the regional densities of NOP receptors as distribution volume (VT). Distribution volume is the ratio at equilibrium of brain uptake to the concentration of parent radioligand in plasma.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)","Early Phase 1","41","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","100204|10-M-0204","September 3, 2010","null","February 28, 2014","September 9, 2010","null","November 14, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01198197"
2022,"NCT01197222","Evaluation of Safety and Efficacy of Using EndoClear-Endoscopic Lens Cleaning Device",,"Completed","No Results Available","Laparoscopic Abdominal Surgery","Device: EndoClear Lens Cleaning Device","","The Oregon Clinic","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","940","March 2009","March 2010","March 2010","September 9, 2010","null","September 9, 2010","Legacy Good Samaritan, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT01197222"
2023,"NCT01192685","Transcranial Magnetic Stimulation in Major Depression With EEG and Near Infrared Spectroscopy (NIRS) Monitoring",,"Terminated","No Results Available","Depression","Procedure: Transcranial Magnetic Stimulation (TMS)|Device: near infrared spectroscopy (NIRS)","The correlations between EEG cordance or task-induced changes in frontal total Hb levels|Changes in MADRAS scores between baseline and the last treatment day","Boston University|Boston Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","H-29098","December 2012","December 2013","December 2013","September 1, 2010","null","April 20, 2017","Boston Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01192685"
2024,"NCT01189643","Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor",,"Active, not recruiting","No Results Available","Sarcoma|Desmoplastic Small Round Cell Tumor (DSRCT)","Drug: irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator","To define the tolerability|To define adverse event profile|To estimate the response rate of two cycles of irinotecan, temozolomide and bevacizumab|To estimate survival|To estimate time to progression|To assess use of 18FDG PET-CT","Memorial Sloan Kettering Cancer Center|Genentech, Inc.","All","1 Year to 29 Years   (Child, Adult)","Early Phase 1","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-091","August 2010","August 2019","August 2019","August 26, 2010","null","September 5, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01189643"
2025,"NCT01187875","Resistant Starch and Satiety",,"Completed","No Results Available","Healthy Adults","Dietary Supplement: Placebo- Fiber free control|Dietary Supplement: Hi-maize resistant starch 9g|Dietary Supplement: Novalose 330 resistant starch 9g|Dietary Supplement: 4.5g Hi-maize resistant starch and 4.5g Novalose 330","Satiety response using visual analogue scales|Satiety response using VAS|Ad libitum food intake|Breath hydrogen response|Gastrointestinal tolerance using visual analogue scales (VAS)","University of Minnesota - Clinical and Translational Science Institute","All","18 Years to 64 Years   (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","806M37445","September 2009","June 2010","June 2011","August 24, 2010","null","March 29, 2012","University of Minnesota, Saint Paul, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01187875"
2026,"NCT01186471","The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic Patients",,"Completed","No Results Available","Schizophrenia|Cognition Disorders","Other: A643 (nicotine)|Drug: placebo","Event related potentials (P50, P300, N100) and measures of standard cognition and social cognition|Nicotine exposure","Janssen Pharmaceutica N.V., Belgium|Agentschap voor Innovatie door Wetenschap en Technologie","All","18 Years to 55 Years   (Adult)","Early Phase 1","32","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","CR017263","May 2010","null","March 2011","August 23, 2010","null","March 20, 2012","","","https://ClinicalTrials.gov/show/NCT01186471"
2027,"NCT01184885","A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy",,"Completed","Has Results","Lymphoid Malignancies (New or Relapsed)|Acute Lymphoblastic Leukemia|Burkitt Lymphoma|Lymphoblastic Lymphoma|Mantle Cell Lymphoma|Adult T-cell Leukemia/Lymphoma","Drug: Hyper-CVAD|Drug: Sirolimus","Number of Participants With Count Recovery That Allows for Starting a Phase II Study to Evaluate Response Rates and Survival|Induction Mortality|Complete Response","Sidney Kimmel Cancer Center at Thomas Jefferson University|American Society of Clinical Oncology|Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09G.474|2009-35","July 2010","March 2011","April 2013","August 19, 2010","January 3, 2014","December 18, 2017","University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01184885"
2028,"NCT01182922","Information About a Doctor or a Possibility of Choosing Doctor's Gender and Attendance to Screening Colonoscopy",,"Completed","No Results Available","Colorectal Cancer|Screening","Behavioral: Invitation letter","Percentage of invitees attending screening colonoscopy in each invitation letter group|Percentage of forms with consent for examination, sent back after invitation letter but before reminding letter. Differences in attendance between men and women depending on type of the invitation.","Maria Sklodowska-Curie Institute - Oncology Center","All","55 Years to 64 Years   (Adult)","Early Phase 1","5100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","CO-I","August 2010","March 2011","August 2011","August 17, 2010","null","November 18, 2011","The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology,, Warsaw, Poland","","https://ClinicalTrials.gov/show/NCT01182922"
2029,"NCT01181934","The Effect of Nicotine on Arousal, Cognition and Social Cognition in Young and Elderly Healthy Subjects.",,"Completed","No Results Available","Schizophrenia|Cognition Disorders","Other: A643 (nicotine)|Drug: placebo","To investigate the effect of nicotine on measures of arousal and event related potentials, especially the P50 auditory evoked potential, as well as standard cognitive tasks and social cognition.|Nicotine exposure","Janssen Pharmaceutica N.V., Belgium|Agentschap voor Innovatie door Wetenschap en Technologie","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","32","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)","CR017251","May 2010","null","February 2011","August 13, 2010","null","March 20, 2012","","","https://ClinicalTrials.gov/show/NCT01181934"
2030,"NCT01179789","New E-Service for a Dietary Approach to the Elderly","RISTOMED","Completed","No Results Available","Aged|Healthy","Behavioral: Optimal Diet|Dietary Supplement: VSL#3®|Dietary Supplement: AISA-5203-L|Dietary Supplement: Argan oil","High-sensitivity C-reactive protein (hs-CRP) as measure of systemic low-grade inflammation (cardiovascular risk)|Inflammageing status as measure of ageing-associated inflammatory processes|Oxidative stress|Gut micobiota|Quality of life (QoL)|Physical performance status|Compliance","Charite University, Berlin, Germany","All","65 Years to 85 Years   (Older Adult)","Early Phase 1","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","EA1/079/09","October 2009","August 2010","June 2011","August 11, 2010","null","October 31, 2011","Charité - Universitätsmedizin Berlin, Berlin, Germany","","https://ClinicalTrials.gov/show/NCT01179789"
2031,"NCT01179503","Vitamin D Supplementation and Physical Function in Older Adults",,"Completed","No Results Available","Physical Function|Vitamin D Insufficiency","Dietary Supplement: calcium|Dietary Supplement: Vitamin D plus calcium","Change in Physical performance|Skeletal muscle gene expression|Change in expanded SPPB balance task time|Change in narrow 4m walk test of balance time|Change in 400m walk test time|Change in knee extensor power","Wake Forest University Health Sciences|National Institute on Aging (NIA)","All","70 Years to 89 Years   (Older Adult)","Early Phase 1","16","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00011371|R01AG029364-03S1","January 2010","May 2011","May 2011","August 11, 2010","null","August 17, 2018","Wake Forest University, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01179503"
2032,"NCT01176994","Safety of Formalin-free Fixatives for In-Vivo Fixation of Skin Lesions.",,"Unknown status","No Results Available","Skin Abnormality","Device: Formulations for in-vivo fixation","Safety|Safety of formulations","Hillel Yaffe Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HYMC-0016-09","December 2010","May 2011","May 2012","August 6, 2010","null","August 6, 2010","Hillel Yaffe Medical Center, Hadera, Israel","","https://ClinicalTrials.gov/show/NCT01176994"
2033,"NCT01175642","Cognitive Remediation and Functional Skills Training in Schizophrenia",,"Completed","No Results Available","Schizophrenia|Schizoaffective Disorder","Behavioral: Cognitive Remediation|Behavioral: FAST","neurocognition|functional competence","National Alliance for Research on Schizophrenia and Depression","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PSYC-085-08","July 2007","August 2010","September 2010","August 5, 2010","null","November 17, 2016","Queen's University, Kingston, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01175642"
2034,"NCT01175577","Feeding the Rainbow to Investigate Endothelial Dysfunction","FRIED","Completed","No Results Available","Dietary Modification|Cardiovascular Disease","Dietary Supplement: Chlorophyll complex, Standard Process|Dietary Supplement: Betatene, sold as ""Full Spectrum Carotenoid Complex""|Other: Small carotenoid-rich meals|Other: Placebo","Change in serum carotenoid fraction concentrations between study arms|Change in oxidized LDL lipoproteins (oxLDL)|Change in serum gamma-glutamyl transferase (GGT)|Change in urinary isoprostanes|Change in serum antioxidant capacity (ORAC)|Change in lipid profile (LDL, HDL, triglycerides)|Change in C-reactive protein (CRP)","Bastyr University|University of Washington","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","SP","October 2009","June 2011","August 2011","August 5, 2010","null","February 3, 2012","Bastyr University Clinical Research Center, Kenmore, Washington, United States|University of Washington Clinical Research Center, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT01175577"
2035,"NCT01174940","Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease",,"Completed","No Results Available","Stem Cell Leukemia of Unclear Lineage|Graft Versus Host Disease","Drug: extracorporeal photopheresis","Presence/absence of grade II-IV acute Graft versus Host Disease (aGVHD)|proportion of patients who develop chronic Graft versus Host Disease (cGVHD) and experience relapse of primary disease.","University of Kansas Medical Center|Mallinckrodt","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","22","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12047","June 2010","August 2014","August 2015","August 4, 2010","null","January 9, 2017","University of Kansas Medical Center, Kansas City, Kansas, United States","","https://ClinicalTrials.gov/show/NCT01174940"
2036,"NCT01174485","Effects of Liposuction and Exercise Training on Metabolism, Lipid Profile and Adiposity in Women",,"Completed","No Results Available","Healthy Subjects","Procedure: exercise","Body composition|Insulin Sensitivity|Total cholesterol, LDL-c, HDL-c, VLDL-c and triacylglycerol plasma levels|Cytokine plasma levels - IL-6, TNF-alpha, IL-10, leptin and adiponectin levels","University of Sao Paulo","Female","20 Years to 36 Years   (Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","EEFEUSP-LIPO","August 2010","April 2011","April 2011","August 3, 2010","null","May 13, 2011","Escola de Educação Física e Esporte da Universidade de São Paulo, São Paulo, SP, Brazil","","https://ClinicalTrials.gov/show/NCT01174485"
2037,"NCT01174056","Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging",,"Completed","No Results Available","Lung Inflammation","Drug: Zileuton|Drug: Pioglitazone placebo|Drug: Zileuton placebo|Drug: Pioglitazone","Ki, measure of FDG uptake|Bronchoalveolar lavage (BAL) fluid cell counts","Washington University School of Medicine|Doris Duke Charitable Foundation","All","19 Years to 44 Years   (Adult)","Early Phase 1","39","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","DDCF-2010060","July 2011","March 2014","March 2014","August 3, 2010","null","April 23, 2014","Washington University / Barnes Jewish Hospital, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT01174056"
2038,"NCT01171092","A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma",,"Completed","No Results Available","Malignant Lymphoma, Stem Cell Type|Autologous Transplant","Drug: bortezomib and G-CSF","Determine the effectiveness of the combination of bortezomib and G-CSF|Assess the safety of the combination of bortezomib and G-CSF","University of Kansas Medical Center|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11803|X05279","September 2010","January 2013","December 2014","July 28, 2010","null","January 11, 2017","University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kansas Medical Center, Westwood Campus, Westwood, Kansas, United States","","https://ClinicalTrials.gov/show/NCT01171092"
2039,"NCT01169480","The Impact of Giving a Massage",,"Completed","No Results Available","Mental State, Reported as Depression, Anxiety or Stress","Behavioral: Give a massage","Perceived, self-reported stress, anxiety and depression|Perceived, self-reported state and trait anxiety","Parker Research Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Massage Study - I","June 2010","September 2010","September 2010","July 26, 2010","null","June 20, 2017","Parker College School of Massage, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT01169480"
2040,"NCT01165632","Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma",,"Active, not recruiting","No Results Available","Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Diffuse Astrocytoma|Adult Ependymoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Myxopapillary Ependymoma|Adult Oligodendroglioma|Adult Pilocytic Astrocytoma|Adult Pineal Gland Astrocytoma|Adult Subependymal Giant Cell Astrocytoma|Adult Subependymoma","Procedure: biopsy|Procedure: computed tomography|Procedure: therapeutic conventional surgery|Radiation: radiation therapy treatment planning/simulation|Radiation: radiation therapy|Procedure: magnetic resonance imaging|Procedure: positron emission tomography|Drug: fluorine F 18 fluorodopa","18F-FDOPA PET activity, MRI contrast enhancement, and high- or low-grade glioma biopsies|18F- FDOPA-PET metabolic imaging information|Concordance of 18F-FDOPA PET and 11C-choline activity, MRI contrast enhancement, and high- or low-grade glioma biopsies|With and without 18F- FDOPA PET, 11C-choline PET metabolic imaging information|18F-FDOPA PET activity, 11C-choline PET activity, MRI contrast enhancement, pMRI, and DTI, with high- or low-grade glioma biopsies","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","24","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MC1078|NCI-2010-01607|10-001904","July 26, 2010","August 26, 2016","July 2019","July 20, 2010","null","October 8, 2018","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01165632"
2041,"NCT01163474","Telemedicine in Cardiac Surgery: A Pilot Study",,"Completed","Has Results","Coronary Artery Disease","Other: Evaluate video clinic visit prior to Face-to-Face usual care visit","Accuracy (FTF Decision on Patient Disposition vs. V-visit Decision on Patient Disposition)|Acceptability|Feasibility","US Department of Veterans Affairs|VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","PPO 10-060","October 2010","June 2011","September 2011","July 15, 2010","January 5, 2015","April 28, 2015","Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01163474"
2042,"NCT01162616","Polyphenols in Sorghum and Iron Absorption",,"Completed","No Results Available","Iron Absorption in Presence of Polyphenols","Dietary Supplement: labeled iron solutions","Iron isotope ratio in blood samples","Swiss Federal Institute of Technology","Female","18 Years to 40 Years   (Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","PP_Fe_Study Sorghum","August 2010","March 2012","April 2012","July 14, 2010","null","July 4, 2012","Swiss Federal Institute of Technology ETH Zurich, Zurich, Switzerland","","https://ClinicalTrials.gov/show/NCT01162616"
2043,"NCT01162473","Milk Oral Immunotherapy in Children to Treat Food Allergy",,"Completed","Has Results","Milk Hypersensitivity","Dietary Supplement: Milk Oral Immunotherapy|Drug: Milk Protein Powder|Other: Food Challenge","Number of Subjects Who Completed Desensitization Protocol","Children's Hospital of Philadelphia","All","6 Years to 17 Years   (Child)","Early Phase 1","25","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","09-007320","June 2010","December 2013","December 2013","July 14, 2010","May 13, 2015","May 13, 2015","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01162473"
2044,"NCT01160302","Curcumin Biomarker Trial in Head and Neck Cancer",,"Completed","No Results Available","Head and Neck Cancer","Drug: Microgranular Curcumin C3 Complex®","Change in tissue biomarkers|Pharmacokinetics of microgranular curcumin|Ease of ingestion","Louisiana State University Health Sciences Center Shreveport|Feist-Weiller Cancer Center at Louisiana State University Health Sciences|National Cancer Institute (NCI)","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","33","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","H08-081|1R21CA137545-01A2|FWCC","June 2010","January 2016","January 2016","July 12, 2010","null","March 2, 2016","LSUHSC-Shreveport and Feist-Weiller Cancer Center, Shreveport, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT01160302"
2045,"NCT01159899","Transplantation of Bone Marrow Stem Cells Stimulated by Proteins Scaffold to Heal Defects Articular Cartilage of the Knee",,"Unknown status","No Results Available","Osteoarthritis|Knee Osteoarthritis|Osteochondritis Dissecans|Osteonecrosis","Procedure: Transplantation of Bone Marrow Stem Cells Activated in Knee Arthrosis","IKS, International Knee Score|KOOS, Knee Injury and Osteoarthritis Outcome Score","Michel Assor, MD|University of Marseille","All","30 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC- AS3","July 2010","December 2014","December 2014","July 12, 2010","null","January 8, 2013","Knee and Lower Limb Institute, Dr Michel Assor, Marseille, France","","https://ClinicalTrials.gov/show/NCT01159899"
2046,"NCT01153646","Gene Transfer for HIV Using Autologous T Cells","Gene Transfer","Terminated","No Results Available","HIV-1 Infection","Genetic: pHIV7-shI-TAR-CCR5RZ treated CD4 cells","Patient Safety|Feasibility|Genetic marking in peripheral blood using vector-specific PCR assay.","City of Hope Medical Center","All","18 Years to 60 Years   (Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","03161|IND #14146","April 2010","January 2011","January 2011","June 30, 2010","null","January 19, 2011","Beckman Research Institute of City of Hope, Duarte, California, United States","","https://ClinicalTrials.gov/show/NCT01153646"
2047,"NCT01151111","Relaxation Guided Imagery for Treatment of Parkinson's Disease",,"Completed","No Results Available","Parkinson's Disease","Behavioral: Relaxation guided imagery","Change from baseline of Unified Parkinson's Disease Rating Scale (UPDRS)|Change from baseline to week 2 in Clinical Global Impression Scale (CGI)|Change from baseline to week 2 in PDQ39|Change from baseline to minutes 30 of Unified Parkinson's Disease Rating Scale (UPDRS) after relaxing music|Change from baseline to week 2 in the number of OFF hours|Change from baseline to month 3 in PDQ39|Change from baseline to month 3 in Clinical Global Impression Scale (CGI)|Change from baseline to week 1 in the number of OFF hours","Rambam Health Care Campus","All","30 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","0457-09-RMB","May 2010","May 2012","May 2014","June 25, 2010","null","May 8, 2014","Ilana Schleainger, Haifa, Israel","","https://ClinicalTrials.gov/show/NCT01151111"
2048,"NCT01150110","Resilient Occlusal and Patients With Temporomandibular Disorder (TMD)",,"Completed","No Results Available","Temporomandibular Disorders","Device: resilient occlusal splints","","Federal University of Uberlandia","All","19 Years to 50 Years   (Adult)","Early Phase 1","null","Other","Interventional","Primary Purpose: Treatment","432","July 2007","null","July 2008","June 24, 2010","null","June 24, 2010","Germana De Villa camargos, Uberlandia, Minas Gerais, Brazil","","https://ClinicalTrials.gov/show/NCT01150110"
2049,"NCT01150084","""Step by Step"": A Feasibility Study of the Promotion of Lunchtime Walking to Increase Physical Activity and Improve Mental Well-being in Sedentary Employees",,"Unknown status","No Results Available","Exercise|Sedentary","Other: 16-week lunchtime walking intervention|Other: delayed treatment","number of steps","University of Birmingham|BUPA Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","75","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","ISRCTN01150084","September 2009","December 2010","March 2011","June 24, 2010","null","June 28, 2010","University of Birmingham, Birmingham, West Midlands, United Kingdom","","https://ClinicalTrials.gov/show/NCT01150084"
2050,"NCT01147601","Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas",,"Terminated","Has Results","Hemangioma|Infant","Drug: topical 0.5% Timolol|Drug: Control (placebo) group","Proportion of Subjects in Treatment Group Compared to Placebo Group With at Least 75% Improvement in the Extent of the Hemangioma as Compared to Baseline Photos.|Compare Treatment Group to Control Group Improvement Assessments","Oregon Health and Science University","All","1 Month to 8 Months   (Child)","Early Phase 1","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6114","March 2010","October 2012","August 2014","June 22, 2010","July 5, 2017","July 5, 2017","Oregon Health & Science University, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT01147601"
2051,"NCT01143558","Searching for Persistence of Infection in Lyme Disease",,"Completed","No Results Available","Lyme Disease|Borrelia Burgdorferi","Procedure: Skin Biopsy|Device: Xenodiagnosis|Procedure: Blood Drawing","Determine whether xenodiagnosis can detect the continued presence of B. burgdorferi in patients with Lyme disease after antibiotic therapy.|Assess the safety of the planned xenodiagnostic procedure in humans.","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","45","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","100139|10-I-0139","August 1, 2010","December 30, 2014","December 30, 2014","June 14, 2010","null","October 23, 2018","Mansfield Family Practice, Storrs, Connecticut, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Tufts University, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01143558"
2052,"NCT01141985","New Disposable Contact Lens Patient Interface For The Lensx Laser",,"Completed","No Results Available","Cataract|Corneal Disease","Device: LenSx Laser modified disposable contact lens","Disposable contact lens successfully applied to the eye|Surgical evaluation of Corneal Incision|Standard Outcomes Measurements|Surgical evaluation of capsulotomy|Surgical evaluation of fragmentation|Standard outcomes measurement","LenSx Lasers Inc.","All","24 Years and older   (Adult, Older Adult)","Early Phase 1","110","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CPT-001h","February 2010","December 2010","December 2010","June 11, 2010","null","October 22, 2014","Slade and Baker Vision Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01141985"
2053,"NCT01139853","Post-Operative Impact of Nasogastric Tubes on Rates of Emesis in Infants Diagnosed With Pyloric Stenosis","POINTS","Completed","No Results Available","Pyloric Stenosis","Device: Nasogastric Tube","Feasibility|post-operative length of stay|rates of post-operative emesis","Hamilton Health Sciences Corporation|McMaster University","All","up to 6 Months   (Child)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","POINTS","January 2010","January 2015","January 2015","June 9, 2010","null","September 28, 2015","McMaster University Medical Center, Hamilton, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01139853"
2054,"NCT01139242","Increasing Colorectal Cancer Screening in Urban African American Communities Via Churches","ACTS","Completed","No Results Available","Colorectal Cancer","Behavioral: Body & Soul nutritional intervention|Behavioral: Experimental: newsletters and peer counseling","Higher incidence of CRC screening, if needed, among experimental participants.","University of North Carolina, Chapel Hill|Centers for Disease Control and Prevention","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","955","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","05-1271|U48DP000059-02S1","February 2008","August 2009","May 2010","June 8, 2010","null","June 8, 2010","","","https://ClinicalTrials.gov/show/NCT01139242"
2055,"NCT01138553","Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer",,"Terminated","No Results Available","Invasive Breast Cancer|Ductal Carcinoma in Situ","Drug: Mifepristone","Change in proliferation by Ki-67 immunohistochemistry.|Tumor size|Expression of related targets following mifepristone exposure","University of California, San Diego","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCSD#100231","June 2010","June 2014","null","June 7, 2010","null","December 2, 2015","Moores UCSD Cancer Center, La Jolla, California, United States","","https://ClinicalTrials.gov/show/NCT01138553"
2056,"NCT01135290","Post Treatment Care After Chemical Peel or Laser Resurfacing",,"Withdrawn","No Results Available","Chemical Peel","Drug: Aquaphor|Drug: HP828-101","Physician and subject evaluation ratings of the signs and symptoms of facial skin during post-operative care.","Healthpoint","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","828-101-09-016","June 2010","October 2010","October 2010","June 2, 2010","null","October 1, 2013","University of Texas Southwestern Medical Center, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT01135290"
2057,"NCT01132014","Autologous OC-DC Vaccine in Ovarian Cancer",,"Completed","No Results Available","Chemotherapy|Tumor|Ovarian Cancer","Biological: OCDC","Safety|Clinical Response|Dose limiting toxicity|Immune Response Immune Response","Abramson Cancer Center of the University of Pennsylvania","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","67","Other","Interventional","Primary Purpose: Treatment","UPCC 19809","May 2010","May 30, 2018","May 30, 2018","May 27, 2010","null","June 11, 2018","Ovarian Cancer Research Center, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01132014"
2058,"NCT01129947","The Use of DHEA in Women With Premature Ovarian Failure",,"Withdrawn","No Results Available","Premature Ovarian Failure","Drug: DHEA","The Use of DHEA in Women With Premature Ovarian Failure","Virginia Center for Reproductive Medicine","Female","18 Years to 40 Years   (Adult)","Early Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VCRM4","May 2010","January 2013","January 2013","May 25, 2010","null","January 29, 2013","Virginia Center for Reproductive Medicine, Reston, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01129947"
2059,"NCT01129830","The Effect of DHEA on Markers of Ovarian Reserve in Women With Diminished Ovarian Reserve",,"Terminated","No Results Available","Infertility","Dietary Supplement: dehydroepiandrosterone","live birth rate|number of oocytes","Virginia Center for Reproductive Medicine","Female","21 Years to 44 Years   (Adult)","Early Phase 1","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VCRM 3","January 2010","September 2014","September 2014","May 25, 2010","null","September 22, 2014","Virginia Center for Reproductive Medicine, Reston, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01129830"
2060,"NCT01129115","Dose Response Study of Aerobic Exercise in Older Adults",,"Completed","Has Results","Alzheimer's Disease","Behavioral: Nonexercise control group|Behavioral: Aerobic Exercise Group 1|Behavioral: Aerobic Exercise Group 2|Behavioral: Aerobic Exercise Group 3","Visuospatial Processing|Change in Maximal Oxygen Consumption|Change in Physical Performance Test|Verbal Memory|Simple Attention|Set Maintenance & Shifting|Reasoning","Jeff Burns, MD|University of Kansas Medical Center","All","65 Years and older   (Older Adult)","Early Phase 1","101","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11883","May 2010","February 2014","April 2014","May 24, 2010","February 15, 2016","February 15, 2016","University of Kansas Medical Center, Kansas City, Kansas, United States","","https://ClinicalTrials.gov/show/NCT01129115"
2061,"NCT01125592","Assessment of the Ability of Ionic Foot Bath (IonCleanse®) to Remove Heavy Metals Through the Feet and Its Potential Impact on Body Burden of Heavy Metals",,"Completed","No Results Available","Healthy","Device: IonCLeanse Footbath","Change in heavy metal content in the water after a 30 minute IonCleanse footbath","The Canadian College of Naturopathic Medicine","All","Child, Adult, Older Adult","Early Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","IonFootbath","May 2010","July 2010","July 2010","May 18, 2010","null","November 15, 2011","Canadian College of Naturopathic Medicine, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01125592"
2062,"NCT01118910","Open-Label Pilot Study of the Efficacy and Safety of Vusion Ointment for the Treatment of Intertrigo",,"Completed","No Results Available","Intertrigo","Drug: Vusion","The number of patients for whom Vusion effectively treated intertrigo","Image Dermatology P.C.","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","W0319-501","April 2010","November 2010","May 2011","May 7, 2010","null","August 4, 2011","Image Dermatology P.C., Montclair, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT01118910"
2063,"NCT01117532","Brief Group Intervention Using EFT (Emotional Freedom Techniques) for Depression in College Students",,"Completed","No Results Available","Depression","Behavioral: EFT (Emotional Freedom Techniques)","Student scores on the Beck Depression Inventory (BDI)","Soul Medicine Institute","All","16 Years to 25 Years   (Child, Adult)","Early Phase 1","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","SMI-DEP-5410","April 2010","May 2010","May 2010","May 5, 2010","null","April 25, 2018","College of Science, University of Santo Tomas, Manila, Philippines","","https://ClinicalTrials.gov/show/NCT01117532"
2064,"NCT01111942","A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer",,"Terminated","No Results Available","Head and Neck Cancer","Other: radiation combined with weekly carboplatin|Procedure: conservation surgery","Rate of pathologic complete response|2 year overall survival|Clinical complete response|2 year disease-free survival|Quality of life|Incidence of HPV and EGFR positivity|K-ras mutational analysis","Southern Illinois University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","ROB-SCCI 10-001-1","February 2010","January 2014","January 2014","April 28, 2010","null","August 5, 2015","Southern Illinois University School of Medicine, Springfield, Illinois, United States","","https://ClinicalTrials.gov/show/NCT01111942"
2065,"NCT01111006","The Effect of Electronic Cleansing Toilet System (Bidet) on Anal Resting Pressure",,"Completed","No Results Available","Anorectal Physiology","Device: Bidet (electronic cleansing toilet system)","The pressure before and after applying the bidet|The temperature of rectum","Seoul National University Hospital|Woongjin Coway Corporation","All","20 Years to 30 Years   (Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","0620092310","September 2009","January 2010","January 2010","April 27, 2010","null","April 27, 2010","Department of Surgery, Seoul National University Hospital, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01111006"
2066,"NCT01109576","Workshops for Veterans With Vision and Hearing Loss","DSLW","Completed","Has Results","Deafness|Blindness","Behavioral: DSL Workshop","Change in Profile of Mood States Total Score.","US Department of Veterans Affairs|Atlanta VA Medical Center|VA Office of Research and Development","All","55 Years and older   (Adult, Older Adult)","Early Phase 1","13","U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","C7460-P","November 2011","July 2012","August 2013","April 23, 2010","September 29, 2015","September 29, 2015","Atlanta VA Medical and Rehab Center, Decatur, Decatur, Georgia, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT01109576"
2067,"NCT01108939","Study of Iron Absorption and Utilization in Asymptomatic Malaria",,"Completed","No Results Available","Malaria, Falciparum","Drug: Antimalarial treatment|Other: Observation","","Swiss Federal Institute of Technology|European Union","Female","16 Years to 35 Years   (Child, Adult)","Early Phase 1","23","Other","Interventional","Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Fe_Malaria_Benin","February 2009","September 2009","April 2010","April 22, 2010","null","June 7, 2013","Hopital de zone de Natitingou, Natitingou, Benin","","https://ClinicalTrials.gov/show/NCT01108939"
2068,"NCT01108523","Evaluation of Effects of HP828-101 for Moisture Associated Skin Damage",,"Terminated","Has Results","Skin Abnormalities","Device: HP828-101","Rating Scores of Skin Erythema, Skin Pallor, Skin Maceration, Skin Denudation at Day 15.|Rating Scores of Skin Erythema, Skin Pallor, Skin Maceration, Skin Denudation at Day 4, 8, and 12. Proportion of Subjects With no Denuded Skin Area at Day 4, 8, 12, and 15. Pre- and Post-Treatment Surveys","Healthpoint","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","7","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","828-101-09-017","April 2010","July 2010","February 2012","April 22, 2010","December 6, 2013","December 6, 2013","Golden Acres, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT01108523"
2069,"NCT01108432","DPBRN Hygienists Internet Quality Improvement in Tobacco Cessation (HiQuit)","HiQuit","Completed","No Results Available","Smoking Cessation","Other: Electronic Referral","Number of smokers referred to tobacco cessation website|Proportion of smokers who go to the tobacco cessation website|Point prevalence smoking cessation","Dental Practice-Based Research Network|University of Alabama at Birmingham|University of Massachusetts, Worcester|HealthPartners Institute","All","19 Years and older   (Adult, Older Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","122286|U01DE016747","April 2010","June 2011","June 2011","April 22, 2010","null","January 25, 2013","University of Alabama at Birmingham, Birmingham, Alabama, United States|Health Partners Research Foundation, Minneapolis, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01108432"
2070,"NCT01105988","Evaluating Tumor Pseudoprogression With FLT-PET and MRI",,"Terminated","No Results Available","Glioblastoma","Other: Radiologic exams","Primary Outcome Measure|Secondary Outcome Measure","Massachusetts General Hospital|Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","2","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","10-008","May 2011","October 2011","October 2011","April 19, 2010","null","January 6, 2012","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01105988"
2071,"NCT01102270","The Effect of Eszopiclone on the Arousal Threshold in Sleep Apnea Syndrome",,"Completed","Has Results","Obstructive Sleep Apnea","Drug: Eszopiclone|Drug: Placebo","Apnea Hypopnea Index|Arousal Threshold|Nadir Overnight Oxygen Saturation|Sleep Duration","Brigham and Women's Hospital|Sunovion|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 64 Years   (Adult)","Early Phase 1","17","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","2008P000818|1P01HL095491-01","January 2009","August 2009","May 2010","April 13, 2010","April 18, 2017","April 18, 2017","Brigham and Women's Hospital, Division of Sleep Medicine, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01102270"
2072,"NCT01102010","Postoperative Blood Transfusion for Frail Elderly With Hip Fracture",,"Completed","No Results Available","Hip Fracture","Biological: Blood transfusion","Functional ability|Mortality|Quality of Life","University of Aarhus","All","65 Years and older   (Older Adult)","Early Phase 1","284","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PBTFEHF","January 2010","October 2013","October 2014","April 12, 2010","null","July 20, 2015","Research Unit, Geriatric Department, Aarhus University Hospital, Aarhus, Central Denmark Region, Denmark","","https://ClinicalTrials.gov/show/NCT01102010"
2073,"NCT01100788","Satiety Response of Short Chain Fructooligosaccharide",,"Completed","No Results Available","Healthy","Dietary Supplement: Short chain fructo-oligosaccharide (scFOS) 5 g|Other: Placebo|Dietary Supplement: Short chain fructooligosaccharide (scFOS) 8 g","Satiety response using visual analogue scales|Ad libitum food intake|Breath hydrogen response|Gastrointestinal tolerance using visual analogue scales (VAS)","University of Minnesota - Clinical and Translational Science Institute","All","18 Years to 64 Years   (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","0806M37444","March 2009","June 2009","June 2009","April 9, 2010","null","April 9, 2010","University of Minnesota, Saint Paul, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01100788"
2074,"NCT01100736","Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3)",,"Completed","No Results Available","Pulmonary Arterial Hypertension|Vasodilation|Vasoconstriction","Drug: Bosentan|Drug: Sitaxsentan|Drug: Placebo|Biological: Endothelin-3","Plasma ET-1 after 7-day administration of bosentan, sitaxsentan and placebo|Responses to ET-3 (maximum vasodilation after ET-3 administration and area under the curve of vasodilation) after bosentan compared with the results from sitaxsentan and placebo.","University of Edinburgh|Encysive Pharmaceuticals","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","2008/W/CRC/01|08/S1102/1","January 2009","September 2009","January 2010","April 9, 2010","null","July 21, 2015","Clinical Research Centre, Western General Hospital, Edinburgh, Scotland, United Kingdom","","https://ClinicalTrials.gov/show/NCT01100736"
2075,"NCT01098955","Smoking Cessation Treatment for Head & Neck Cancer Patients",,"Active, not recruiting","No Results Available","Head and Neck Cancer|Smoking Cessation","Behavioral: Acceptance and Commitment Therapy|Behavioral: Motivational and Behavioral Counseling|Drug: Varenicline","Smoking Abstinence Rate","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","108","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009-0362|NCI-2011-02004|1R01CA120153-01A2","March 2010","March 2019","March 2019","April 5, 2010","null","September 24, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01098955"
2076,"NCT01096901","Choose to Lose for Women-Weight Loss to Reduce Breast Cancer Risk Factors","CTL","Completed","No Results Available","Obesity|Overweight","Behavioral: Behavioral Weight loss","Weight loss for one group|Increased physical activity","California Polytechnic State University-San Luis Obispo","Female","30 Years to 45 Years   (Adult)","Early Phase 1","19","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","CP-CTL|CP-EFI","November 2010","June 2011","June 2011","March 31, 2010","null","October 28, 2015","California Polytechnic State University, San Luis Obispo, California, United States","","https://ClinicalTrials.gov/show/NCT01096901"
2077,"NCT01096888","Fit Moms- an Internet-based Postpartum Weight Loss Program","FM","Completed","No Results Available","Postpartum Weight","Behavioral: Enhanced WIC Program","Enhanced WIC program to instigate weight loss|Baseline characteristics that moderate the efficacy of the intervention.","California Polytechnic State University-San Luis Obispo|Women Infants and Children program WIC","Female","18 Years to 35 Years   (Adult)","Early Phase 1","25","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","CP-FM","June 2010","September 2010","November 2010","March 31, 2010","null","October 28, 2015","California Polytechnic State University, San Luis Obispo, California, United States","","https://ClinicalTrials.gov/show/NCT01096888"
2078,"NCT01093859","An Exploratory Phase 1 Microdose Study of PRX-105",,"Completed","No Results Available","Organophosphate Exposure","Drug: PRX-105","PRX-105 plasma concentration|Cardiovascular monitoring|Neurological examination|Ophthalmic evaluation","Protalix","Male","18 Years to 45 Years   (Adult)","Early Phase 1","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","PB-09-001","March 2010","May 2010","August 2010","March 26, 2010","null","September 5, 2012","Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel","","https://ClinicalTrials.gov/show/NCT01093859"
2079,"NCT01091792","Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)",,"Completed","No Results Available","Glioblastoma Multiforme","Drug: Bevacizumab","Changes in the peripheral blood T-reg profile between pretreatment and 4 weeks after completion of treatment with the addition of bevacizumab to RT and TMZ in patients with glioblastoma|Immunologic shift in the phenotypic T cell, B cell, NK cell and DC repertoire induced by RT-TMZ-BEV comparing pretreatment and 4 weeks after completion of treatment","Dartmouth-Hitchcock Medical Center|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","13","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D0947","March 2010","April 2, 2015","April 2, 2015","March 24, 2010","null","May 25, 2018","Dartmouth Hithcock Medcial Center, Lebanon, New Hampshire, United States","","https://ClinicalTrials.gov/show/NCT01091792"
2080,"NCT01090375","Regulation of Intraarticular and Synovium-related Biomarkers of Osteoarthritis. Effect of Acute Mechanical Joint Loading",,"Completed","No Results Available","Osteoarthritis|Exercise","Other: Exercise|Other: Non Exercise","","Bispebjerg Hospital|The Danish Rheumatism Association|Danish Ministry of Health, Internal Affairs|Danish National Research Council|The Danish Medical Research Council","Female","55 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","null","Other","Interventional","Intervention Model: Parallel Assignment|Primary Purpose: Basic Science","H-KF-306126","August 2008","March 2009","null","March 19, 2010","null","March 19, 2010","","","https://ClinicalTrials.gov/show/NCT01090375"
2081,"NCT01089699","A Trial Testing Professional and Peer-led Support Online Support Groups for Young Canadian Breast Cancer Survivors","CBCRA09","Unknown status","No Results Available","Breast Cancer","Behavioral: online support group|Behavioral: home study support materials","Reduced anxiety","British Columbia Cancer Agency|University of Calgary|McMaster University|University of British Columbia|Tom Baker Cancer Centre|CancerCare Manitoba","Female","18 Years to 45 Years   (Adult)","Early Phase 1","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","H09-03302","April 2010","March 2013","March 2015","March 18, 2010","null","March 18, 2010","","","https://ClinicalTrials.gov/show/NCT01089699"
2082,"NCT01087112","Mother-Infant Psychoanalysis Project of Stockholm (MIPPS)- Follow-up at 4½ Years","MIPPS-02","Unknown status","No Results Available","Mother-child Relationship Disturbances","Behavioral: Mother-Infant Psychoanalytic tmt|Behavioral: Child Health Centre care","Child functioning: Children's Global Assessment Scale|Maternal depression: Edinburgh Postnatal Depression Scale|Maternal distress: Symptom Check List - 90|Maternal stress: Swedish Parental Stress Questionnaire|Child functioning: Ages and Stages Questionnaire:Social Emotional|Child functioning: Strengths and Difficulties Questionnaire|Child cognitive functioning: Wechsler's Preschool and Primary Scales of Intelligence|Child's social and emotional functioning: Story Stem Attachment Profile|Child's social and emotional functioning: Machover Draw-a-Person test","Karolinska Institutet","All","54 Months to 54 Months   (Child)","Early Phase 1","71","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MIPPS-02","December 2009","June 2012","June 2013","March 16, 2010","null","March 16, 2010","Department of Women's and Children's Health, Child and Adolescent Psychiatry Unit, Karolinska Institutet, Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT01087112"
2083,"NCT01086696","A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers",,"Terminated","No Results Available","Breast Cancer|Lung Cancer|Renal Cancer|Adrenal Cancer","Drug: FPAC","Uptake of FPAC in tumors|Safety of FPAC","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","6","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","100078|10-C-0078","March 9, 2010","August 20, 2014","May 11, 2016","March 15, 2010","null","November 9, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01086696"
2084,"NCT01086592","Effects of a Program of Physical Exercise and Electrotherapy on Muscle Strength in Subjects of the Fourth Age",,"Completed","No Results Available","Geriatric Assessment|Muscle Strength|Postural Balance|Body Mass Index","Other: No intervention|Other: Strong progressive strengthening exercises of lower limbs|Other: Electrotherapy|Other: Electrotherapy+weights","Functional Capacity|Strength in lower limbs|Timed standing balance. Side by side, semi tandem, tandem stand and one-leg stand|Maximum Gait Speed. Time to cover a 4 meter distance|Body mass index|Six-minute walking test","Cardenal Herrera University","All","75 Years and older   (Older Adult)","Early Phase 1","118","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","CEU-UCH-87","February 2010","June 2010","June 2010","March 15, 2010","null","July 5, 2010","CEU-Cardenal Herrera University, Moncada, Valencia, Spain","","https://ClinicalTrials.gov/show/NCT01086592"
2085,"NCT01086345","Radiosurgery Plus Bevacizumab in Glioblastoma",,"Terminated","No Results Available","Glioblastoma|Gliosarcoma|Brain Tumor","Radiation: radiosurgery|Biological: bevacizumab|Drug: irinotecan hydrochloride","Overall survival of patients with recurrent GBM treated with bevacizumab, irinotecan and radiosurgery|Treatment-related toxicity|Progression-free survival, defined as the interval from randomization to progression or death, whichever occurs first","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE4309|NCI-2010-00309","February 2010","December 2014","December 2014","March 15, 2010","null","July 3, 2018","Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01086345"
2086,"NCT01085968","Cognitive Rehabilitation in Parkinson's Disease",,"Completed","Has Results","Parkinson's Disease","Behavioral: PC based training","Reaction Time and Variability for Movement Task|Neuropsychological Measures of Cognitive Function, Including Reaction Time and Time to Completion|Task Errors and Variability|Functional Dexterity Test (FDT)|Symbol Digit Modality Test (SDMT)","VA Office of Research and Development|Louisiana State University Health Sciences Center Shreveport","All","55 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","54","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","E7185-R","July 2010","August 2015","August 2015","March 12, 2010","October 11, 2016","October 11, 2016","","","https://ClinicalTrials.gov/show/NCT01085968"
2087,"NCT01083940","Impact of Computerized Decision Support on Racial/Ethnic Disparities in Hypertension Outcomes",,"Unknown status","No Results Available","Hypertension","Other: Computerized reminders on hypertension intensification","Rate of blood pressure control at outcome between study arms|Rate of appropriate intensification of antihypertensive therapy","Brigham and Women's Hospital|Robert Wood Johnson Foundation","All","20 Years and older   (Adult, Older Adult)","Early Phase 1","3600","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","66708","October 2010","October 2011","October 2011","March 10, 2010","null","June 27, 2011","Brigham and Women's Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01083940"
2088,"NCT01083095","Establishment of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers","ChallengeII","Completed","No Results Available","Malaria, Vivax","Biological: Sporozoite Challenge Model for Plasmodium vivax in Humans","Percentage of infected naïve human volunteers after different number of infected mosquito biting|Minimal number of infected mosquitoes required to infect all volunteers with a reproducible prepatent period","Malaria Vaccine and Drug Development Center|Ministerio de la Protección Social, Colombia.","All","18 Years to 50 Years   (Adult)","Early Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","MVDC-2003-003|Reto II","January 2005","March 2005","December 2006","March 9, 2010","null","March 9, 2010","Malaria Vaccine and Drug Testing Center, Cali, Valle, Colombia","","https://ClinicalTrials.gov/show/NCT01083095"
2089,"NCT01082991","Patient Acuity Rating: a Tool to Prevent In-Hospital Cardiac Arrest","PAR","Withdrawn","No Results Available","Heart Arrest","Other: Preemptive Rapid Response Team intervention","Mortality and cardiac arrest rates|Length of stay|Cost|Time to ICU transfer","University of Chicago|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","15723A|1K23HL097157-01","October 2009","December 2013","December 2013","March 9, 2010","null","April 7, 2016","University of Chicago, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT01082991"
2090,"NCT01082497","Mindfulness Training for Staff (MTS)","MTS","Completed","No Results Available","Stress","Behavioral: Mindfulness training","The ability of mindfulness measured by the Five Facet Mindfulness Questionnaire|The amount of work stress and burnout measured with The Maslach Burnout Inventory","University Hospital of North Norway","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","53","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","P REK NORD-134/2008","May 2009","January 2010","January 2011","March 8, 2010","null","April 12, 2012","University Hospital of North-Norway, Tromso, Troms, Norway","","https://ClinicalTrials.gov/show/NCT01082497"
2091,"NCT01073657","Supported Education Pilot","SEd","Completed","Has Results","PTSD","Other: Supported Education|Other: General Peer Support","""Supported Education Process Measure""","US Department of Veterans Affairs|VA Office of Research and Development","All","Child, Adult, Older Adult","Early Phase 1","33","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","PPO 09-254","November 2011","August 2012","August 2012","February 23, 2010","February 18, 2015","April 28, 2015","Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, Bedford, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01073657"
2092,"NCT01066637","iNOS With Positron Emission Tomography (PET) in Cellular Inflammation.","F-NOS","Completed","No Results Available","Patients With Post Orthotopic Heart Transplantation Status","Drug: [18F](+/-)NOS","To demonstrate the feasibility of imaging patients with increased levels of iNOS using [18F](+/-)NOS.|To determine human dosimetry based on the human biodistribution of [18F](+/-)NOS in both normal adult healthy volunteers and heart transplant patients.","Washington University School of Medicine","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","09-0986|201106273","September 2009","June 2017","June 2017","February 10, 2010","null","February 7, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT01066637"
2093,"NCT01066325","Improving Flexibility With a Mindbody Approach",,"Completed","No Results Available","General Low Back Hip and Hamstring Flexibility","Behavioral: Neuro Emotional Technique|Other: Stretching Instruction","Change in Sit-n-Reach Test Scores (cm)|Depression, Anxiety and Stress Scales (DASS) score - change","Parker Research Institute","Female","18 Years to 45 Years   (Adult)","Early Phase 1","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sit-n-Reach Study","March 2010","August 2010","August 2010","February 10, 2010","null","June 20, 2017","Parker Research Institute, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT01066325"
2094,"NCT01064739","Renal Salt Handling in Postural Tachycardia Syndrome Following Dietary Dopa Administration",,"Completed","Has Results","Healthy Participants","Dietary Supplement: Fava beans|Other: Fixed Sodium Diet","Plasma Dopa 1 hr After Breakfast|Urinary Dopa|Urinary Sodium|Plasma Dopa 2 Hrs After Breakfast|Plasma Dopa 4 Hrs After Breakfast|Plasma Dopa 6 Hrs After Breakfast|Plasma Norepinephrine|Plasma Dopamine|Urinary Dopamine|Urinary Norepinephrine|Supine Systolic Blood Pressure|Supine Heart Rate","Vanderbilt University","All","18 Years to 60 Years   (Adult)","Early Phase 1","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","PN 1767","January 2007","September 2012","December 2012","February 8, 2010","July 31, 2013","May 26, 2016","Vanderbilt University Clinical Research Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT01064739"
2095,"NCT01063790","The Effect of an Individualized Education Intervention on Pain Following Inguinal Hernia Repair Surgery","HREI","Completed","No Results Available","Pain","Behavioral: Individualized Education","The primary outcome measure is pain intensity using a 0 to 10 numeric rating scale.|Secondary measures include: quality of pain, pain related interference, analgesic use, prevalence and intensity of adverse effects of analgesics, patient concerns regarding pain management, and adequacy of post-discharge information.","University of Toronto|St. Michael's Hospital, Toronto","Male","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","82","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","24390|09-123c","October 2009","January 2011","July 2012","February 5, 2010","null","July 16, 2012","St. Michael's Hospital, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01063790"
2096,"NCT01062789","Optical Breath-hold Control System for Image-guided Procedures","OBC","Withdrawn","No Results Available","Respiration","Device: Optical breath-hold control system (OBC)","Ability to monitor patient respiration (return of target to same anatomical position)|Needle Placement Time","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","09-004069","February 2010","May 2011","May 2011","February 4, 2010","null","May 17, 2011","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01062789"
2097,"NCT01061307","An Efficacy Trial of Iron, Zinc and Vitamin A Fortified Rice in Children in Satun, Thailand",,"Completed","No Results Available","Vitamin A Deficiency|Iron Deficiency|Zinc Deficiency","Dietary Supplement: fortified extruded rice","serum Zn|Hemoglobin|serum retinol|serum ferritin|ZPP|Anthropometry measures","Swiss Federal Institute of Technology|Mahidol University","All","7 Years to 12 Years   (Child)","Early Phase 1","203","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ETH2010/1","September 2009","March 2010","June 2010","February 3, 2010","null","January 6, 2016","Swiss Federal Institute of Technology Zurich, Zurich, Switzerland|Institute of Nutrition Mahidol University, Phuttamonthon, Nakhon Pathom, Thailand","","https://ClinicalTrials.gov/show/NCT01061307"
2098,"NCT01059487","Bringing Acute and Wellness Care to Underserved Populations Using Traditional Chinese Medicine",,"Unknown status","No Results Available","Pain Management|Traditional Chinese Medicine","Other: Traditional Chinese Medicine","QualityMetric SF36v-2 Quality of Life|QualityMetric PIQ-6","Chicago College of Oriental Medicine|Agency for Healthcare Research and Quality (AHRQ)|QualityMetrics|Inspire Tech Group","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","null","Other|U.S. Fed|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS-10-003 CEG|GRANT10504752","September 2010","August 2012","August 2012","February 1, 2010","null","February 2, 2010","Chicago College of Oriental Medicine, Inc. dba Chicago College of Asian Medicine, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT01059487"
2099,"NCT01055678","To Evaluate the Characteristics of a Breast Cancer",,"Withdrawn","No Results Available","Breast Cancer","Drug: EF5|Procedure: Partial or Total Mastectomy","To evaluate tumor characteristics|Intra and Interpatient correlations with tumor hypoxia","Mark Dewhirst|National Institutes of Health (NIH)|National Cancer Institute (NCI)|Duke University","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Pro00020382|R01CA040355","January 2010","December 2011","December 2011","January 26, 2010","null","December 17, 2012","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01055678"
2100,"NCT01053481","Using Ca-41 Methodology to Assess the Impact of Different Vitamin D Supplementation Levels on Postmenopausal Bone Health",,"Completed","No Results Available","Osteopenia","Dietary Supplement: vitamin D|Behavioral: exercise program (rebounding on a trampoline)","urinary Ca-41/Ca-40 ratio|biomarkers of bone metabolism|urinary iodine","Swiss Federal Institute of Technology|DSM Nutritional Products, Inc.","Female","55 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","2009-04-07-Ca41","March 2010","October 2011","October 2011","January 21, 2010","null","November 25, 2013","Human Nutrition Laboratory, Institute of Food, Nutrition and Health, ETH Zurich, Zurich, Switzerland","","https://ClinicalTrials.gov/show/NCT01053481"
2101,"NCT01052857","Efficacy of Acupuncture on Induction of Labor",,"Completed","No Results Available","Labor|Pregnancy","Procedure: acupuncture","to evaluate the efficacy of acupuncture administered daily from 40 weeks + 4 days of gestation for induction of labor respect with placebo|to evaluate safety of acupuncture","University of Modena and Reggio Emilia","Female","18 Years to 40 Years   (Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","acupuncture","November 2007","May 2008","January 2009","January 20, 2010","null","January 20, 2010","University of Modena and Reggio Emilia, Modena, Mo, Italy|University of Modena and reggio emilia, Modena, Italy","","https://ClinicalTrials.gov/show/NCT01052857"
2102,"NCT01052454","Mindfulness-Based Stress Reduction for Hot Flashes",,"Completed","No Results Available","Vasomotor Symptoms","Behavioral: Mindfulness-based stress reduction","Hot Flash intensity/bother","University of Massachusetts, Worcester","Female","Child, Adult, Older Adult","Early Phase 1","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","AT002910","September 2005","May 2009","null","January 20, 2010","null","January 20, 2010","UMass Medical School, Worcester, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01052454"
2103,"NCT01050842","Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer",,"Completed","No Results Available","Prostate Cancer|Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Stage IV Prostate Cancer","Drug: bicalutamide|Drug: raloxifene|Procedure: quality-of-life assessment","Progression-free survival rate|Adverse events of combined treatment with bicalutamide and raloxifene as measured by CTCAE version 3.0|Quality of life as assessed by Linear Analogue Self Assessment (LASA6) and the Hormonal Domain scale of the Expanded Prostate Cancer Index Composite (EPIC-H) survey|Survival time|Measurable or evaluable disease as assessed by RECIST","Mayo Clinic","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC0851|NCI-2009-01700|07-008912","February 2010","May 2012","October 4, 2012","January 15, 2010","null","March 23, 2017","Mayo Clinic In Arizona, Scottsdale, Arizona, United States","","https://ClinicalTrials.gov/show/NCT01050842"
2104,"NCT01050777","Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis",,"Completed","No Results Available","Cutaneous Leishmaniasis","Drug: Liposomal meglumine antimoniate (Glucantime)|Drug: Liposomal meglumine antimoniate|Drug: Liposomal Paromomycin|Drug: Placebo","Complete cure equal to Complete Re-epithelization of all lesions","Tehran University of Medical Sciences|Mashhad University of Medical Sciences|Center for Research and Training in Skin Diseases and Leprosy","All","12 Years to 60 Years   (Child, Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","86783","March 2011","January 2012","March 2012","January 15, 2010","null","June 20, 2012","Emam Reza Hospital, Mashhad, Khorasan Razavi, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT01050777"
2105,"NCT01049048","The Effect of Vitamin D Statues on Endothelial Function","CVD Cookie","Completed","No Results Available","Cardiovascular Diseases|Vitamin D Deficiency","Dietary Supplement: Vitamin D3|Dietary Supplement: Placebo","The primary outcome measure of this pilot study is change in markers of endothelial function and arterial stiffness with vitamin D3 therapy.","University of Wisconsin, Madison","Female","55 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","H-2008-0190","March 2009","October 2010","October 2010","January 14, 2010","null","October 5, 2015","University of Wisconsin Osteoporosis Clinical and Research Program, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT01049048"
2106,"NCT01042561","Vitamin D Status and Dose Response in Infants",,"Completed","No Results Available","Vitamin D|Prematurity","Dietary Supplement: Vitamin D3|Dietary Supplement: vitamin D3 placebo","serum 25(OH)D levels|serum C-reactive protein (CRP)|serum intact parathyroid hormone (iPTH)","University of Nebraska|Creighton University Medical Center","All","up to 3 Months   (Child)","Early Phase 1","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Diagnostic","281-09","August 2009","August 2010","August 2010","January 5, 2010","null","November 9, 2011","University of Nebraska Medical Center, Omaha, Nebraska, United States","","https://ClinicalTrials.gov/show/NCT01042561"
2107,"NCT01040117","Sensori-motor Integration Training in Multiple Sclerosis",,"Completed","No Results Available","Relapsing-remitting Multiple Sclerosis","Procedure: Sensory-motor Integration Training|Procedure: Conventional neurorehabilitation treatment","Clinical assessment procedures: − Berg Balance Scale (BBS) − Activities-specific Balance Confidence Scale (ABC) Instrumental assessment procedures: − Stabilometric assessment|Clinical evaluation − Walking evaluation − Multiple Sclerosis Quality Of Life-54 (MSQOL-54) - Fatigue Severity Scale (FSS) - Postural Transfers","Universita di Verona","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","FISM-2009|2009/R/27","December 2009","October 2011","January 2012","December 29, 2009","null","March 15, 2012","Section of Clinical Neurology, Department Neurological, Neuropsychological, Morphological and Movement Sciences, University of Verona, Verona, Italy, Verona, Italy|S.S.O. di Riabilitazione dell'Ospedale Policlinico, Verona, Italy","","https://ClinicalTrials.gov/show/NCT01040117"
2108,"NCT01038934","DNA of Oral Cytobrush in Three Means Conservation",,"Completed","No Results Available","Healthy","Procedure: samples collected by buccal cytobrush","","UPECLIN HC FM Botucatu Unesp","All","20 Years to 33 Years   (Adult)","Early Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","upeclin/FOA-Unesp-04","March 2006","December 2009","December 2009","December 24, 2009","null","December 24, 2009","School of Dentistry, Sao Paulo State University, Unesp, Araçatuba/SP, Araçatuba, São Paulo, Brazil","","https://ClinicalTrials.gov/show/NCT01038934"
2109,"NCT01037660","Effects of Lipemia and Metformin on Endothelial Function",,"Completed","No Results Available","Cardiovascular Disease","Drug: Metformin","Brachial artery flow-mediated dilation|blood lipid levels","Boston University","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","139","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","H-23660","September 2005","December 1, 2015","December 1, 2016","December 23, 2009","null","March 10, 2017","Boston Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01037660"
2110,"NCT01037595","Effect of Turmeric on Pruritus in Hemodialysis Patients",,"Completed","No Results Available","End Stage Renal Failure","Drug: turmeric|Drug: placebo","improvement in pruritus","Shiraz University of Medical Sciences","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","3441","September 2010","October 2010","December 2010","December 23, 2009","null","May 14, 2013","Shiraz University Hemodialysis Center, Shiraz, Fars, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT01037595"
2111,"NCT01034514","4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy",,"Terminated","No Results Available","Lung Cancer","Device: Real-time Position Management system|Device: Discovery ST multislice PET/CT scanner|Device: Infinia Hawkeye SPECT/CT gamma camera|Device: Pinnacle3 treatment planning system|Device: SKYLight nuclear camera|Drug: DTPA|Drug: TECHNETIUM TC 99M MAA","The overall correlation between the 4D-CT and the SPECT ventilation images.|The difference between the local ventilation at simulation and during the treatment. Dose-volume or functional dose-volume metrics. The regression coefficient between the regional ventilation and time. The mean dose to the high-functional lung region.","Billy W. Loo Jr.|Stanford University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","LUN0034|SU-04232009-2382","December 2009","June 24, 2014","June 24, 2014","December 17, 2009","null","May 8, 2017","Stanford University School of Medicine, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT01034514"
2112,"NCT01031511","Effect of Cognitive Behavioural Therapy (CBT) for Children With Autistic Spectrum Disorders",,"Unknown status","No Results Available","Autism Spectrum Disorder|Anxiety","Behavioral: Cognitive Behavioural Therapy|Other: Social Recreational","Anxiety level of child|Parent Stress Level","National Healthcare Group, Singapore|Nanyang Technological University|Autism Resource Centre, Singapore","All","9 Years to 16 Years   (Child)","Early Phase 1","73","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","DSRB Ref Code: A/05/091|NMRC/1002/2005|130/2005","June 2005","January 2010","February 2011","December 14, 2009","null","December 14, 2009","Institute of Mental Health, Singapore, Singapore, Singapore","","https://ClinicalTrials.gov/show/NCT01031511"
2113,"NCT01029990","Randomized Controlled Trial to Study Interventions to Increase Participation in Cervical Cancer Screening Program",,"Completed","No Results Available","Cervical Intraepithelial Neoplasia","Other: Telephone arm|Other: Self-test arm","Frequency of testing (cytology in arm A and C and HPV-test in arm B). F|Frequency of further assessment of abnormal tests|Frequency of abnormal smears. (Arm A vs arm C)|Frequency of treated CIN (Arm A vs. arm C)|Number of invasive cancers detected classified by FIGO stadium.|Cost of interventions|Cost per CIN2+ found and treated","Göteborg University|Vastra Gotaland Region|Assar Gabrielsson Cancer Foundation, Sweden","Female","29 Years to 63 Years   (Adult)","Early Phase 1","8800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Screening","OCGbgSw0101","September 2009","February 2010","January 2011","December 10, 2009","null","August 30, 2012","","","https://ClinicalTrials.gov/show/NCT01029990"
2114,"NCT01027390","Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck","VIMS","Completed","No Results Available","Musculoskeletal Disorders","Behavioral: physical training exercise","neck/shoulder pain, selfreported|muscle strength and endurance","University of Southern Denmark|National Research Centre for the Working Environment, Denmark|University of Copenhagen","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","573","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","H-C-2008-103","January 2010","January 2011","February 2011","December 8, 2009","null","December 11, 2012","Rigspolitiet, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT01027390"
2115,"NCT01024660","The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil",,"Completed","No Results Available","Alzheimer's Disease","Drug: Donepezil|Drug: Placebo to match Aricept","CogState Computerized Neurological Test Battery|Neuropsychological Test Battery (NTB)|Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog)|Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)","AstraZeneca","All","55 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","155","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","D2285M00010","December 2009","January 2011","January 2011","December 3, 2009","null","February 8, 2011","Research Site, Ottawa, Ontario, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Reearch Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Callao, Lima, Peru|Research Site, Callao, Peru|Research Site, Lima, Peru|Research Site, Chojnice, Poland|Research Site, Gdansk, Poland|Research Site, Kalisz, Poland|Research Site, Pila, Poland|Research Site, Poznan, Poland|Research Site, Scinawa, Poland|Research Site, Sopot, Poland|Research Site, Warszawa, Poland|Research Site, Cape Town, Western Cape, South Africa|Research Site, Roodepoort, South Africa","","https://ClinicalTrials.gov/show/NCT01024660"
2116,"NCT01022944","Prevalence of Mucosal Biofilm Formations in Adenoidectomy Specimens","BOLERO","Completed","No Results Available","Chronic Serous Otitis Media, Simple or Unspecified","Procedure: With chronic middle ear effusion|Procedure: Without chronic middle ear effusion","Prevalence of mucosal biofilm formations in adenoidectomy specimens analyzed using Confocal Laser Scanning Microscopy with double staining|To build up a tissue bank of human tissue from adenoids and the middle ear for further bacterial identification","Assistance Publique - Hôpitaux de Paris|Ministry of Health, France","All","18 Months to 10 Years   (Child)","Early Phase 1","113","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","P080605","July 2010","May 2012","May 2012","December 1, 2009","null","February 21, 2013","Hôpital ROBERT DEBRE - ORL Pédiatrique, Paris, France","","https://ClinicalTrials.gov/show/NCT01022944"
2117,"NCT01022021","Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine",,"Completed","No Results Available","Lymphoma","Drug: Rituximab|Drug: Bendamustine","To assess the efficacy of G-CSF induced PBSC mobilization after two cycles of rituximab and Bendamustine (BR) as salvage therapy in patients with relapsed non-Hodgkins lymphoma","University of Kansas Medical Center|Cephalon","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","17","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11908","January 2010","April 2014","August 2015","December 1, 2009","null","January 10, 2017","University of Kansas Medical Center, Kansas City, Kansas, United States","","https://ClinicalTrials.gov/show/NCT01022021"
2118,"NCT01021371","The GP's Role in Cancer Rehabilitation: a Randomised, Controlled Study.",,"Completed","No Results Available","HRQOL (Health Related Quality Of Life)","Behavioral: Two step intervention including patient interview followed by an extended information routine to the patients' GP about the patients' rehabilitation needs","Health Related Quality of Life|How the GP act with regard to rehabilitation among cancer patients","University of Southern Denmark|Vejle Hospital|Vejle Kommune","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","959","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","RCT Cancer rehab","May 2008","February 2009","February 2009","November 30, 2009","null","October 27, 2016","Reserch Unit of General Practice, Institute of Public Health, University of Southern Denmark, Odense, Denmark","","https://ClinicalTrials.gov/show/NCT01021371"
2119,"NCT01017796","Contrast Agent-associated Nephrotoxicity in Intensive Care Unit Patients","ICU","Unknown status","No Results Available","Contrast Induced Nephropathy","Drug: N-acetylcysteine and ascorbic acid","Morbidity in the Intensive Care Unit|Incidence of acute nephropathy after administration of radiocontrast agents","University of Thessaly","All","14 Years and older   (Child, Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","KN19201|KIMNEF681264","January 2009","January 2010","June 2010","November 23, 2009","null","November 23, 2009","","","https://ClinicalTrials.gov/show/NCT01017796"
2120,"NCT01015755","Palliation of Thirst in ICU Patients",,"Completed","No Results Available","Thirst","Behavioral: combined therapy treatment","Thirst intensity|Thirst distress","University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","353","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","1R01NR011825-01","January 2010","July 2012","July 2012","November 18, 2009","null","March 8, 2013","University of California San Francisco, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT01015755"
2121,"NCT01015300","Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease",,"Terminated","No Results Available","Hemangioblastomas|Von Hippel Lindau Disease","Drug: Avastin","Radiographic response in the size of the hemangioblastoma on magnetic resonance imaging (MRI)|Changes in VEGF with bevacizumab treatment assist in the predication of radiographic response. Products of the HIF-1A synthesis pathway: plasma VEGF, PDGF, TGF-a and erythropoietin.","Dartmouth-Hitchcock Medical Center|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","1","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D0904","December 2009","October 2011","April 2012","November 18, 2009","null","May 11, 2012","Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States","","https://ClinicalTrials.gov/show/NCT01015300"
2122,"NCT01008644","Do Changes in Plasma Osmolality Influence Ventilation?","OSM","Completed","No Results Available","Hyponatraemia|Hypernatraemia","Other: Water|Other: Saline 3%","pCO2","Vibeke Moen|Kalmar County Hospital","All","18 Years to 45 Years   (Adult)","Early Phase 1","26","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","M-126-09","November 2009","November 2010","November 2010","November 6, 2009","null","October 17, 2012","Department of Anaesthesia and Intensive care, Kalmar County Hospital, Kalmar, Sweden","","https://ClinicalTrials.gov/show/NCT01008644"
2123,"NCT01000870","Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513",,"Terminated","No Results Available","Alzheimer Disease","Drug: MNI-513-01","To evaluate the efficacy and safety of MNI-513 positron emission tomography (PET) for detection/exclusion of cerebral amyloid beta in patients with Alzheimer's disease compared to healthy volunteers","Institute for Neurodegenerative Disorders","All","55 Years and older   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MNI-513-01","October 2009","September 2010","September 2010","October 23, 2009","null","October 6, 2010","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01000870"
2124,"NCT00993642","ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer",,"Withdrawn","No Results Available","Breast Cancer","Drug: Panobinostat (LBH589)","The primary objective of the study is to compare the expression level of ERBB4 pre- and post- treatment with HDACi, Panobinostat (LBH589).","Tulane University Health Sciences Center|Novartis|Board of Regents, State of Louisiana|Tulane University","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CLBH589BUS46T","September 2009","September 2010","December 2010","October 12, 2009","null","March 13, 2017","Tulane Cancer Center, Comprehensive Clinic, CTRC, New Orleans, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT00993642"
2125,"NCT00993057","Efficiency of Two Glucose Sampling Protocols for Maintenance of Euglycemia",,"Completed","No Results Available","Brain Neoplasms|Intracranial Aneurysm","Drug: Insulin","performance of each of glucose sampling and insulin protocols for achieving euglycemia|hypoglycemia|time required to reach euglycemia|relationship of BMI and performance of protocols|relationship of serum biomarkers of insulin resistance and performance of protocols","Northwestern University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU00009023","October 2009","August 2012","August 2012","October 9, 2009","null","September 21, 2018","Dhanesh Gupta, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT00993057"
2126,"NCT00992901","Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery",,"Recruiting","No Results Available","Post Bariatricsurgery|Hypoglycemia","Drug: Exendin-(9-39)|Drug: Atropine|Drug: GLP-1 and GIP","Gut hormones and neural signaling contribution to insulin secretion rate and glucose tolerance","The University of Texas Health Science Center at San Antonio","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","160","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","18-070H|DK083554","October 2009","July 2020","July 2020","October 9, 2009","null","May 18, 2018","South Texas Veterans Health Care System, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT00992901"
2127,"NCT00991978","VEGF Early Imaging for Breast Cancer",,"Completed","No Results Available","Breast Cancer","Other: 89Zr-bevacizumab PET","SUV in tumour and lymph nodes","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","23","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","VEGF early imaging","March 2010","January 2012","January 2012","October 8, 2009","null","March 30, 2012","Universitar Medical Center Groningen, Groningen, Netherlands","","https://ClinicalTrials.gov/show/NCT00991978"
2128,"NCT00986609","MUC1 Vaccine for Triple-negative Breast Cancer",,"Completed","No Results Available","Breast Cancer|Inflammatory Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-negative Breast Cancer","Biological: MUC-1 peptide vaccine|Biological: poly ICLC|Biological: MUC1 peptide-poly-ICLC adjuvant vaccine|Other: laboratory biomarker analysis|Other: enzyme-linked immunosorbent assay|Other: flow cytometry","Proportion of patients showing a positive anti-MUC1 antibody response|Safety and toxicity as assessed by NCI CTC","Joseph Baar, MD, PhD|Case Comprehensive Cancer Center","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","29","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CASE16107|NCI-2009-01318","August 19, 2009","August 29, 2013","January 21, 2016","September 30, 2009","null","July 23, 2018","Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00986609"
2129,"NCT00985933","The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers",,"Completed","No Results Available","Healthy|Memory Impairment","Drug: AZD8529|Drug: Placebo to match AZD8529","fMRI|Ketamine Infusion|Clinician Administered Dissociative States Scale (CADSS)|Positive and Negative Syndrome Scale (PANSS)|Laboratory assessment: electrocardiogram (ECG), physical exam, vital signs, collection of adverse events","AstraZeneca","All","21 Years to 45 Years   (Adult)","Early Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","D2285M00015","February 2010","April 2011","April 2011","September 29, 2009","null","May 4, 2011","Research Site, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT00985933"
2130,"NCT00985816","The Effects of Lactobacillus Reuteri DSM 17938 on Immunomodulation and Gastric Motility in Preterm Newborns",,"Completed","No Results Available","Preterm Birth","Dietary Supplement: Lactobacillus Reuteri|Dietary Supplement: Placebo","Evaluate the effects of L. reuteri in the intestinal motility by measuring the gastric emptying rate in infants before and after 21 consecutive days of administration of L. reuteri|Mechanisms of action of L.reuteri","University of Bari","All","up to 1 Month   (Child)","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","FI-LR2009","October 2009","October 2011","October 2011","September 28, 2009","null","November 8, 2011","Flavia Indrio, Bari, Italy","","https://ClinicalTrials.gov/show/NCT00985816"
2131,"NCT00982410","Managing Chronic Pain in Veterans With Substance Use Disorders",,"Completed","Has Results","Chronic Pain","Behavioral: cognitive-behavioral treatment|Behavioral: educational supportive group","Pain Intensity, as Measured by Average Pain Within the Last Week (NRS-1)|The Impact of Pain on Activities and Functioning: General Activity Score (WHY MPI)|Alcohol Use|Drug Use|Pain Tolerance|Self-efficacy of Pain Management|Self-efficacy of Physical Functioning|As-treated Analysis: Pain Intensity, as Measured by Average Pain Within the Last Week (NRS-1)|As-treated Analysis: The Impact of Pain on Activities and Functioning: General Activity Score (WHY MPI)","US Department of Veterans Affairs|VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","131","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IAC 09-047","April 2010","August 2013","March 2014","September 23, 2009","December 24, 2014","July 13, 2015","VA Ann Arbor Healthcare System, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT00982410"
2132,"NCT00981552","Dosimetric Planning Study Comparing Intensity Modulated Radiotherapy (IMRT) and 4-field Radiotherapy for Definitive Treatment of Cancer of the Cervix",,"Completed","No Results Available","Cervix Cancer","Radiation: IMRT planning|Radiation: 4-Field Radiation Planning","Reduction in dose to organs at risk|Target Coverage","Sunnybrook Health Sciences Centre","Female","Child, Adult, Older Adult","Early Phase 1","55","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMRTCC","December 2008","July 2009","September 2009","September 22, 2009","null","September 22, 2009","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00981552"
2133,"NCT00981396","The Effect of Emotional Freedom Techniques (EFT) in Smokers Failing a Smoking Cessation Program",,"Recruiting","No Results Available","Smoking","Behavioral: EFT (Emotional Freedom Techniques)|Behavioral: CBT (Cognitive Behavioral Therapy)","Quit rate|Psychological symptoms and physiological symptoms","Soul Medicine Institute","All","12 Years and older   (Child, Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SMI-SMO-92509","September 2009","September 2021","December 2021","September 22, 2009","null","April 25, 2018","NHS Central Lancashire Primary Care Trust, Ormskirk, Lancashire, United Kingdom","","https://ClinicalTrials.gov/show/NCT00981396"
2134,"NCT00972972","Effect of Bilberry (European Blueberries) and Grape Polyphenols on Cognition and Blood Parameters","BLUEBERRY","Unknown status","No Results Available","Memory|Gene Expression","Dietary Supplement: bilberry (European blueberries) and red grape juice|Dietary Supplement: placebo juice","neuropsychological test scores and whole blood gene regulation|whole blood gene regulation; parameters in blood|neuropsychological test scores; whole blood gene regulation; parameters in blood|gene expression of stress, repair and maintenance processes measured by whole genome microarray analysis in blood","Ullevaal University Hospital|University of Oslo","Male","67 Years to 77 Years   (Older Adult)","Early Phase 1","61","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","699","December 2006","July 2007","December 2009","September 9, 2009","null","September 15, 2009","Ulleval University Hospital HF, Oslo, Norway","","https://ClinicalTrials.gov/show/NCT00972972"
2135,"NCT00972933","Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma",,"Completed","No Results Available","Melanoma","Drug: ipilimumab","To study the effects of ipilimumab upon the host immune response in nodal metastatic melanoma and in the peripheral blood comparing pre-treatment with post-treatment (baseline, 6 weeks) immunologic features.|To study the effects of ipilimumab upon the host immune response.|To collect pilot data comparing pre-treatment with post-treatment proteomic and genetic features.|To evaluate the clinical efficacy of preoperative neoadjuvant therapy with ipilimumab in high risk clinically and pathologically node-positive melanoma patients (AJCC stage IIIB-C).|To collect safety data and evaluate the safety of neoadjuvant therapy with ipilimumab in high risk clinically and pathologically node-positive melanoma patients (AJCC stage IIIB-C).","Diwakar Davar|Bristol-Myers Squibb|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","59","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08-144","December 2009","July 17, 2013","September 26, 2017","September 9, 2009","null","December 7, 2017","University of Pittsburgh Medical Center/University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00972933"
2136,"NCT00968565","Study Using Citrate to Replace Heparin in Babies Requiring Extracorporeal Membrane Oxygenation (ECMO)",,"Completed","No Results Available","Heart Defects, Congenital|Respiratory Insufficiency","Drug: sodium citrate","anticoagulation of ECMO circuit while maintaining normal coagulation and calcium levels in patient|Maintain normal serum calcium levels in patients","Vanderbilt University","All","up to 1 Year   (Child)","Early Phase 1","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB# 090717","January 2010","June 2015","June 2015","August 31, 2009","null","June 3, 2015","Vanderbilt Children's Hospital, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00968565"
2137,"NCT00968110","Xolair Treatment for Milk Allergic Children",,"Completed","No Results Available","Milk Allergy","Drug: omalizumab","The major goal of this study is to assess the safety of Xolair in young children, and the safety of oral desensitization in patients pretreated with Xolair","Boston Children’s Hospital|Stanford University","All","4 Years to 18 Years   (Child, Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Milk-01","March 2009","April 2017","April 2017","August 28, 2009","null","October 2, 2018","Stanford Uneiversity Medical Center, Stanford, California, United States|Children's Hosptial Boston, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00968110"
2138,"NCT00965016","Induced Hypothermia in Cardiac Arrest Patients Rescued by Extracorporeal Cardiopulmonary Resuscitation.",,"Unknown status","No Results Available","Out-of-Hospital Cardiac Arrest","Procedure: hypothermia","1) ECMO weaning versus nonweaning and 2) survival-to-discharge versus in-hospital death.|Brain injury","Min-Sheng General Hospital","All","16 Years and older   (Child, Adult, Older Adult)","Early Phase 1","45","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSEIRB0980106","January 2009","December 2009","December 2009","August 25, 2009","null","August 25, 2009","Min-sheng General Hospital, Taoyuan, Taiwan","","https://ClinicalTrials.gov/show/NCT00965016"
2139,"NCT00965003","MRI Laryngeal Imaging With a Surface Coil",,"Terminated","No Results Available","Laryngeal Neoplasms|Head and Neck Cancers|Larynx Cancer","Procedure: MRI scan","Tumor stage as determined by HRMRI.|Estimate the precision of HRMRI in discriminating between edema and tumor in patients with prior radiotherapy or chemotherapy.|Tumor stage as determined by histopathology in excised larynges.","Stanford University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","ENT0019|96536|SU-05292009-2661","July 2009","January 2010","January 2010","August 25, 2009","null","October 5, 2017","Stanford University School of Medicine, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT00965003"
2140,"NCT00962845","Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery",,"Completed","No Results Available","Melanoma (Skin)","Drug: hydroxychloroquine","Modulation of markers of autophagy by hydroxychloroquine (HCQ), as measured by p62, Beclin1, LC3, and GRp170 expression|Correlation of steady-state plasma concentration of HCQ with observed trends in induced markers of autophagy|Potential mechanisms of antitumor effect of HCQ, as measured by a reduction in tumor cell proliferation or an increase in apoptosis","Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey","All","18 Years to 120 Years   (Adult, Older Adult)","Early Phase 1","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","090901|P30CA072720|CDR0000648156|NCI-2011-03324","September 2010","May 30, 2013","May 30, 2013","August 20, 2009","null","September 24, 2018","Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT00962845"
2141,"NCT00960817","""Normal Coronary Artery"" With Slow Flow Improved by Adenosine Injection, Dipyridamole Treatment and Clinical Follow-up",,"Unknown status","No Results Available","Coronary Angiography","Drug: Statin, aspirin|Drug: Dipyridamole","Alleviation of chest pain","Hillel Yaffe Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","null","Other","Interventional","","HYMC 02/2009","null","null","null","August 18, 2009","null","August 18, 2009","Hillel Yaffe Medical Center, Hadera, Israel","","https://ClinicalTrials.gov/show/NCT00960817"
2142,"NCT00958932","Telecommunication Enhanced Asthma Management","TEAM","Unknown status","No Results Available","Asthma","Behavioral: Speech recognition","Medication adherence|urgent care visits","National Jewish Health|Kaiser Permanente","All","3 Years to 12 Years   (Child)","Early Phase 1","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","1R01HL084067-01A1","September 2009","May 2012","May 2012","August 14, 2009","null","July 20, 2011","National Jewish Health, Denver, Colorado, United States","","https://ClinicalTrials.gov/show/NCT00958932"
2143,"NCT00958802","Tissue Engineering Microtia Auricular Reconstruction: in Vitro and in Vivo Studies",,"Completed","No Results Available","Microtia","Other: Platelet-rich plasma (PRP)|Other: Chondrocyte culture with FBS medium","The aim of this study was to compare the histological and biochemical character of microtia chondrocytes treated with and without PRP.","Taipei Medical University WanFang Hospital","All","Child, Adult, Older Adult","Early Phase 1","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","98-WF-PHD-05","May 2009","August 2009","September 2009","August 13, 2009","null","November 19, 2010","Taipei Medical University, Wan Fang Hospital, Taipei, Taiwan","","https://ClinicalTrials.gov/show/NCT00958802"
2144,"NCT00956904","Ultrasound-Guided Navigation in Robot-Assisted Laparoscopic Radical Prostatectomy",,"Terminated","No Results Available","Prostate Cancer","Device: 3-D TRUS navigation software during T-RALP","Accuracy of TRUS Robot and 3-D TRUS navigation software.|Safety of T-RALP","Johns Hopkins University","Male","35 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NA_00027540","August 2009","June 2013","June 2013","August 11, 2009","null","June 19, 2013","Johns Hopkins Hospital, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00956904"
2145,"NCT00956826","Continuous Fetal Monitoring During Vacuum Delivery",,"Unknown status","No Results Available","Vacuum Delivery","Device: Agit Vacuum","Quality of fetal heart rate monitoring in both arms","Hadassah Medical Organization","All","up to 1 Day   (Child)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","fetal monitoring vaccum|FMV123","September 2009","April 2010","December 2010","August 11, 2009","null","August 11, 2009","Hadassah Ein Kerem, Jerusalem, Israel","","https://ClinicalTrials.gov/show/NCT00956826"
2146,"NCT00956163","Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer",,"Completed","No Results Available","Bone Metastases|Recurrent Prostate Cancer|Stage I Prostate Cancer|Stage IIA Prostate Cancer|Stage IIB Prostate Cancer|Stage III Prostate Cancer|Stage IV Prostate Cancer","Procedure: magnetic resonance imaging|Radiation: fluorine F 18 sodium fluoride|Procedure: positron emission tomography|Procedure: computed tomography|Radiation: technetium Tc 99m methylene diphosphonate|Other: laboratory biomarker analysis","Uptake of fluorine F 18 sodium fluoride on PET/CT scan|Incidence of focal MRI abnormality","National Cancer Institute (NCI)","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NCI-2011-02972|CDR0000666327|MGH-09364|09-364|8336|P30CA006516|N01CM37120","March 2010","January 2011","May 2014","August 11, 2009","null","July 2, 2014","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00956163"
2147,"NCT00954369","Exploratory and Safety Study of [F-18]W372",,"Completed","No Results Available","Alzheimer's Disease","Drug: [F-18]W372","Safety will be the outcome demonstrated in this clinical trial through analyses of adverse events in subjects who receive study drug.","Siemens Molecular Imaging","All","55 Years and older   (Adult, Older Adult)","Early Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","W372000","August 2009","February 2010","February 2010","August 7, 2009","null","August 22, 2012","University of California, Irvine, Irvine, California, United States","","https://ClinicalTrials.gov/show/NCT00954369"
2148,"NCT00953134","Periconceptional Iron Supplementation in Rural Bangladesh",,"Completed","No Results Available","Anemia","Dietary Supplement: Ferrous fumarate (iron)|Dietary Supplement: folic acid","Hemoglobin|Plasma ferritin","The Hospital for Sick Children","Female","up to 40 Years   (Child, Adult)","Early Phase 1","273","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Periconceptional_Fe","February 2007","February 2008","March 2008","August 6, 2009","null","April 15, 2010","Brac, Dhaka, Dhaka Division, Bangladesh","","https://ClinicalTrials.gov/show/NCT00953134"
2149,"NCT00952666","Transrectal Ultrasound Imaging of the Prostate Gland and Neurovascular Bundles During Robot-Assisted Laparoscopic Radical Prostatectomy",,"Terminated","No Results Available","Prostate Cancer","Device: TRUS-RALRP","","Johns Hopkins University","Male","35 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NA_00014120","November 2008","December 2009","December 2009","August 6, 2009","null","September 13, 2010","Johns Hopkins Hospital, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00952666"
2150,"NCT00952549","Facial Yoga Toning Program - A Pilot Study",,"Withdrawn","No Results Available","Facial Atrophy Related to Age","Procedure: Facial Yoga Toning Program","Efficacy of facial yoga toning program on aesthetic appearance|subject satisfaction with facial yoga toning program","The Cleveland Clinic","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FYTP","August 2009","August 2009","September 2009","August 6, 2009","null","January 26, 2018","","","https://ClinicalTrials.gov/show/NCT00952549"
2151,"NCT00952107","Objective Flap Assessment During Reconstructive Surgery",,"Completed","No Results Available","Cancer","Device: FLARE imaging system","System operation","Beth Israel Deaconess Medical Center","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","2009P-000095/1; BIDMC","June 2009","February 2012","February 2012","August 4, 2009","null","June 13, 2012","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00952107"
2152,"NCT00949845","Cytokine-Associated Depression and Social Pain",,"Completed","No Results Available","Depression","Drug: Endotoxin","","University of California, Los Angeles","All","18 Years to 45 Years   (Adult)","Early Phase 1","null","Other","Interventional","Primary Purpose: Basic Science","Endotoxin","January 2007","null","null","July 30, 2009","null","July 30, 2009","UCLA General Clinical Research Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT00949845"
2153,"NCT00949247","Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases",,"Completed","No Results Available","Breast Cancer","Biological: bevacizumab|Biological: trastuzumab|Drug: carboplatin|Drug: docetaxel|Other: laboratory biomarker analysis","Proportion of patients who have a complete response in bone marrow.|Specific contribution of VEGF and CXCL-12 (SDF-1) signaling to bone marrow support of HER2/neu-positive breast cancer cells|Potential correlation of growth factor and chemokine expression with patient outcome and frequency of tumor cell clusters (mammospheres with tumor stem cell phenotype) in microenvironment supported cultures","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE4108|P30CA043703|CASE4108-CC685","December 2009","January 2013","January 2013","July 30, 2009","null","May 15, 2018","Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|University Hospitals Monarch, Mayfield Heights, Ohio, United States|University Hospitals Chagrin Highlands Medical Center, Orange Village, Ohio, United States|University Hospitals Westlake, Westlake, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00949247"
2154,"NCT00946413","Application and Evaluation of Group Cognitive Intervention for Depressed Adolescents",,"Completed","No Results Available","Community Adolescents at Risk for Depression and Suicide","Behavioral: CBT plus parent education|Behavioral: CBT alone","depressive symptoms, suicidal ideation, cognitive triad, learned resourcefulness (LR), and salivary cortisol","Taipei Medical University Hospital|Department of Health","All","14 Years to 19 Years   (Child, Adult)","Early Phase 1","31","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","DOH95-TD-M-113-058","January 2006","December 2007","December 2007","July 27, 2009","null","July 27, 2009","School of Nursing, Taipei Medical University, Taipei, Taiwan","","https://ClinicalTrials.gov/show/NCT00946413"
2155,"NCT00945607","Guided Relaxation Training for the Reduction of Self-Reported Stress in Individuals With Newly Diagnosed Breast Cancer","09-IM-01","Unknown status","No Results Available","Breast Cancer","Other: GRT (Guided Relaxation Training)","Determining if the use of GRT during treatment in individuals newly diagnosed with breast cancer reduces their perceived stress.|Determining if the use of GRT during treatment in individuals newly diagnosed with breast cancer increases their coping ability.|Determining the effects of GRT on vital signs and self-reported levels of fatigue.|Determining differences of perceived levels of stress among various racial and ethnic groups.","Trinitas Comprehensive Cancer Center|Aptium Oncology Research Network","Female","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","09-IM-01","July 2009","July 2013","null","July 24, 2009","null","July 25, 2011","Trinitas Comprehensive Cancer Center, Elizabeth, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT00945607"
2156,"NCT00943345","Validation of New Tests for Gastrointestinal (GI) Permeability","Permeability","Unknown status","No Results Available","Gastrointestinal Diseases","Drug: indometacin","Comparison of permeability tests (new versus golden standard dual sugar test)|GI permeability","Maastricht University Medical Center|Top Institute Food and Nutrition","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","34","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Diagnostic","MEC 09-3-034","September 2009","February 2012","February 2012","July 22, 2009","null","November 8, 2011","Maastricht University Medical Center, Maastricht, Zuid-Limburg, Netherlands","","https://ClinicalTrials.gov/show/NCT00943345"
2157,"NCT00935051","Matrix Metalloproteinase-1/Tissue Inhibitor of Metalloproteinase-1 (MMP-1/TIMP-1) Ratio and Diabetic Foot Ulcers","DIAB-MMP2","Completed","No Results Available","Diabetic Foot Ulcer","Other: Picture + MMPs and TIMP1 at week 0 and week 4","MMP-1/TIMP-1 ratio at Week 0 assessed by ELISA and percent change in wound area of diabetic foot ulcer between week 0, week 4 and week 12|Evaluation of a MMP-1/TIMP-1 ratio = 0.4 at Week 0 as a predictor of wound healing at week 12|Recognized clinical prognostic factors such as wound duration, wound area, wound depth and other possible confounding factors affecting the validity of the MMP-1/TIMP-1 ratio|Correlation between MMP9, MMP13, MMP9/TIMP1 and MMP13/ TIMP1 ratios and wound healing expressed by the percent change in wound area between week 0, week 4 and week 12.","University Hospital, Grenoble","All","18 Years to 40 Years   (Adult)","Early Phase 1","59","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2008-A00155-50","May 2009","July 2013","November 2013","July 8, 2009","null","December 18, 2013","Diabetology department, Grenoble, Isere, France|Service de Diabétologie du Pr Halimi, CHU Grenoble, Grenoble Cedex 9, France","","https://ClinicalTrials.gov/show/NCT00935051"
2158,"NCT00931021","Smoking Cessation Treatment for Head and Neck Cancer Patients",,"Terminated","No Results Available","Smoking Cessation","Drug: Varenicline (Chantix)|Drug: Nicotine Patch","To develop an effect size estimate for smoking cessation defined as continuous abstinence over the last 4 weeks of treatment for 2 mg varenicline compared to nicotine patch.|To examine tolerability of 2 mg varenicline and the 21 mg nicotine patch in smokers who have been diagnosed with head and neck cancer.|To examine the effects of smoking cessation, varenicline and nicotine patch on markers of inflammation.|To examine the effect of varenicline and nicotine patch on alcohol consumption.","Yale University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","7","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0903004910","July 2009","December 2012","December 2012","July 2, 2009","null","July 15, 2013","Yale University School of Medicine, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT00931021"
2159,"NCT00929045","Growth Hormone and Insulin Growth Factor 1 Deficiencies in Children/Adolescents Following Traumatic Brain Injury: The Impact on Growth and Neuropsychological Development",,"Unknown status","No Results Available","Traumatic Brain Injury","Drug: Growth Hormone Replacement","Neurocognitive changes following moderate/severe TBI","University of Virginia|Commonwealth Neurotrauma Initiative (Commonwealth of Virginia)|National Institutes of Health (NIH)","All","8 Years to 21 Years   (Child, Adult)","Early Phase 1","8","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13239","July 2007","December 2010","December 2010","June 26, 2009","null","April 14, 2010","University of Virginia, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT00929045"
2160,"NCT00929006","Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism","CRM003","Recruiting","No Results Available","Puberty|Hyperandrogenism","Drug: Micronized progesterone suspension|Drug: Placebo","Luteinizing hormone (LH) pulse frequency","University of Virginia|National Institutes of Health (NIH)","Female","10 Years to 17 Years   (Child)","Early Phase 1","36","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","13717","June 2008","December 2024","December 2024","June 26, 2009","null","July 2, 2018","University of Virginia, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT00929006"
2161,"NCT00921427","The Use of Transcranial Direct Current Stimulation (TDCS) to Enhance the Rehabilitative Effect of Vision Restoration Therapy",,"Completed","No Results Available","Hemianopia|Quadrantanopia|Scotoma|Visual Field Loss","Behavioral: Vision Restoration Therapy (VRT)|Device: Transcranial direct current stimulation (tDCS)","Visual Field Gain in Degrees|Visual Field test- Percent accuracy of detection|Functional Questionnaire (Impact of Vision Impairment Profile)|Subjective Drawing of the Visual Field (area of blind field in sq. mm)","Beth Israel Deaconess Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2007-P-000241","November 2007","December 2010","March 2012","June 16, 2009","null","March 21, 2012","","","https://ClinicalTrials.gov/show/NCT00921427"
2162,"NCT00914953","Oxytocin and Social Behavior Over the Lifespan",,"Completed","No Results Available","Social Activity","Drug: oxytocin (Pitocin)","confirm increased social activities in treatment condition compared to control condition via self-report.|Evidence of greater psychological health for treatment condition as compared to control condition.","Claremont Graduate University","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","41","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","CNS-R21AG029871|NIH Grant 1R21AG029871-01A2","February 2010","December 2010","December 2011","June 5, 2009","null","March 2, 2012","Linda Valley Villa, Loma Linda, California, United States","","https://ClinicalTrials.gov/show/NCT00914953"
2163,"NCT00912522","Magnetic Prefrontal Stimulation for Studying the Role of the Cortex in High-level Cognition Processes and Reward System",,"Completed","No Results Available","Healthy Volunteers","Device: TMS","Changes in scoring of different tests and questionnaires|Correlation of different tests and questionnaires","Hadassah Medical Organization|Ben-Gurion University of the Negev","All","18 Years to 60 Years   (Adult)","Early Phase 1","91","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","0116-09-HMO-CTIL","June 2009","June 2014","June 2014","June 3, 2009","null","April 22, 2015","Hadassah medical org, Jerusalem, Israel","","https://ClinicalTrials.gov/show/NCT00912522"
2164,"NCT00910702","The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body",,"Completed","No Results Available","Retinal Detachment","Device: foldable capsular vitreous body(FCVB)","Complete retinal reattach rate at the three years after implantation of the silicone-filled FCVB|visual acuity, intraocular pressure, axial length, ocular inflammatory response, the number of corneal endothelial, anterior chamber angle and ciliary body change, morphological changes of the ocular and FCVB.","GuangZhou WeiShiBo Biotechnology Co., ltd|Sun Yat-sen University","All","10 Years to 65 Years   (Child, Adult, Older Adult)","Early Phase 1","15","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VISBOR-61165995","May 2009","December 2012","March 2013","June 1, 2009","null","April 30, 2013","Zhongshan Ophthalmic Center, Sun Yat-sen University, GuangZhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT00910702"
2165,"NCT00908791","Proof of Principle Trial to Determine if Nutritional Supplement Conjugated Linoleic Acid (CLA) Can Modulate the Lipogenic Pathway in Breast Cancer Tissue",,"Unknown status","No Results Available","Breast Cancer","Drug: Conjugated Linoleic Acid (CLA)","To determine whether CLA consumption suppresses expression of markers of lipogenesis (Spot 14, FASN, LPL, Ki67 and apoptotic index ) in breast cancer tissue in vivo.|To determine whether CLA consumption suppresses expression of lipogenesis markers in adipose tissue.|To measure the baseline and steady state blood/plasma CLA concentrations in breast cancer patients taking CLA, and explore their relationship to the expression of lipogenesis markers in breast tumor tissue and adipocytes.","Dartmouth-Hitchcock Medical Center","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D0906","May 2009","September 2012","December 2012","May 27, 2009","null","June 11, 2012","Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, New Hampshire, United States","","https://ClinicalTrials.gov/show/NCT00908791"
2166,"NCT00906620","Saving and Empowering Young Lives in Europe (Israel)","SEYLE-ISRAEL","Completed","No Results Available","Depression|Suicidality","Other: QPR: question, persuade and refer (SEYLE)","evaluate the efficacy of different preventive programs.|rate of risk taking behavior among adolescents","Rabin Medical Center","All","13 Years to 17 Years   (Child)","Early Phase 1","1247","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","5277","September 2009","January 2012","January 2012","May 21, 2009","null","March 7, 2014","Schnider Children MC, Petach-Tikva, NON, Israel","","https://ClinicalTrials.gov/show/NCT00906620"
2167,"NCT00902759","Fatigue and Pancreas and Bile Duct Cancer Study",,"Completed","No Results Available","Pancreatic Cancer","Other: Walking Program","FACIT (Facit Fatigue Scale) and Medical Outcomes Study Short Form-36 (MOS-SF-36) questionnaires","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","08D.574|2008-37","January 9, 2009","January 7, 2011","April 15, 2015","May 15, 2009","null","August 24, 2017","Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00902759"
2168,"NCT00901706","Multidimensional Assessment and Intervention for Elder Self-Neglect",,"Completed","No Results Available","Self-Neglect|Cognitive Ability, General|Geriatric Disorder","Other: Comprehensive Geriatric Assessment and APS Usual Care|Other: APS usual care","Self-Neglect Severity Scale (SSS)|Functional Status|Kohlman Evaluation of Living Skills (KELS)|Mini-mental State Exam (MMSE)|15-item Geriatric Depression Scale|Physical Performance Test (PPT)|SF-36 Health Survey|The Duke Social Support Index (DSSI)|Client Satisfaction Questionnaire (CSQ-8)|Costs of Social Services and Health Care Utilization and Costs","The University of Texas Health Science Center, Houston|The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston","All","65 Years and older   (Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","HSC-MS-08-0052","August 2009","February 2012","July 2012","May 14, 2009","null","June 18, 2013","The University of Texas Health Science Center at Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00901706"
2169,"NCT00898768","Capsule Endoscopy to Screen for Small Bowel Neoplasia in Lynch Syndrome","CELSIUS","Completed","No Results Available","Lynch Syndrome|Small Bowel Neoplasia","Procedure: Capsule endoscopy","The main outcome measure will be the number of neoplastic small bowel lesions, with determination of size, location and histological characteristics at baseline and at follow-up after 2 years.|The secondary endpoint will be the number of complications following endoscopic procedures: rates of capsule retention and postpolypectomy bleeding and perforation.","University Medical Center Groningen|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Erasmus Medical Center|Leiden University Medical Center|St. Antonius Hospital|The Netherlands Cancer Institute|University Medical Center Nijmegen|Maastricht University Medical Center|Free University Medical Center|Given Imaging Ltd.","All","35 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","200","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","CELSIUS|Dutch Cancer Society 2008-4187","May 2009","December 2014","December 2014","May 12, 2009","null","December 9, 2014","University Medical Center Groningen, Groningen, Netherlands","","https://ClinicalTrials.gov/show/NCT00898768"
2170,"NCT00896792","Nurse Practitioner Hospice Program for Patients With Terminal Metastatic Cancer and Their Families or Caregivers",,"Completed","No Results Available","Hematopoietic/Lymphoid Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Other: counseling intervention|Other: questionnaire administration|Other: survey administration|Procedure: end-of-life treatment/management|Procedure: psychosocial assessment and care","Increased length of enrollment time in hospice care|Effects of incorporating a palliative care advanced registered nurse practitioner liaison program in the late-stage cancer care process|Increased knowledge of hospice services as assessed by a knowledge survey|Patient and family or caregiver psychological stress, as measured by the functional assessment of cancer therapy general (FACT-G) survey","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Older Adult)","Early Phase 1","26","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Other","CDR0000615562|P30CA015083|MC0892|08-002293","October 10, 2008","November 20, 2009","March 17, 2015","May 12, 2009","null","October 8, 2018","Mayo Clinic in Jacksonville, Jacksonville, Florida, United States","","https://ClinicalTrials.gov/show/NCT00896792"
2171,"NCT00894283","A Pilot Study Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients",,"Completed","No Results Available","Deep Venous Thrombosis|Pulmonary Embolism","Drug: Enoxaparin|Drug: Fondaparinux","To estimate the prevalence of asymptomatic deep venous thrombosis and pulmonary emboli in obese patients undergoing bariatric surgery.|To assess the relationship of Anti-factor Xa levels and the occurrence of deep venous thrombosis and pulmonary emboli in bariatric patients receiving standard dose of anticoagulation (enoxaparin/Lovenox or fondaparinux/Arixtra).","Johns Hopkins University|GlaxoSmithKline","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","198","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NA_00025492","June 2009","September 2013","September 2013","May 6, 2009","null","August 7, 2014","Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00894283"
2172,"NCT00890786","A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas",,"Completed","No Results Available","Newly Diagnosed High-Grade Gliomas|Diffuse Intrinsic Pontine Glioma","Drug: Temozolomide|Drug: Bevacizumab|Drug: Irinotecan","To determine the toxicities and feasibility of the proposed treatment regimen in patients with high-grade glioma and diffuse intrinsic brainstem glioma|To determine 1-year EFS, median PFS and median OS in newly diagnosed patients with high-grade glioma treated with radiotherapy and concurrent temozolomide, bevacizumab followed by bevacizumab, irinotecan and temozolomide for 12 courses|To determine the 1-year EFS, median PFS and median OS in newly diagnosed patients with diffuse intrinsic brainstem glioma treated with radiotherapy and concurrent bevacizumab followed by bevacizumab and irinotecan for 12 courses|To estimate blood levels of VEGF in circulating endothelial cells in patients at different time points|To document changes in MR perfusion and diffusion within 24-48 hours after the 2nd dose of bevacizumab during radiotherapy|To correlate functional changes in tumor with responses to treatment using MR diffusion/perfusion imaging|To correlate the results of the biology studies in serum or tumor with PFS|To conduct gene expression profiling, CGH and SNP arrays in patients with high-grade gliomas|To assess telomerase activity, hTert expression, and telomere length in patients with high-grade gliomas|To assess the health-related quality of life of patients by parent report, and when possible, patient report at key points in therapy|To assess functional abilities and level of independence of patients during and following treatment","Children's Hospital Medical Center, Cincinnati|Genentech, Inc.","All","3 Years to 30 Years   (Child, Adult)","Early Phase 1","27","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HGG","May 2009","October 2014","December 2017","April 30, 2009","null","May 2, 2018","Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00890786"
2173,"NCT00884520","An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037","VM4-037","Completed","No Results Available","Lung Cancer|Squamous Cell Carcinoma|Head and Neck Cancer|Hepatic Carcinoma|Renal Cell Carcinoma","Drug: [F-18] VM4-037","Safety will be the outcome demonstrated in this clinical trial through analyses of adverse events in subjects who receive study drug.","Siemens Molecular Imaging","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","DVM4000","April 2009","March 2010","March 2010","April 20, 2009","null","March 16, 2010","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00884520"
2174,"NCT00882193","Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers",,"Terminated","No Results Available","Chronic Hepatitis C|Genotype 1|Relapse","Drug: Betaine|Drug: Peginterferon alpha 2a|Drug: Ribavirin","To examine the safety and efficacy of betaine when combined with standard antiviral therapy in previously teated subjects with chronic hepatitis c genotype 1|The effect on interferon gene signaling in peripheral blood mononuclear cells in the first 12 weeks of treatment and 6 months following the end of therapy.","University of Nebraska","All","19 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","133-09","May 2009","May 2011","May 2011","April 16, 2009","null","August 9, 2011","University of Nebraska Medical Center, Omaha, Nebraska, United States","","https://ClinicalTrials.gov/show/NCT00882193"
2175,"NCT00881907","Tissue Characterization in Teeth Treated With a Regeneration Protocol",,"Completed","No Results Available","Pulp Necrosis","Drug: Triple Antibiotic Paste","The primary outcome measure will be histological identification of mineralized tissue and adherent cells in the apical third of these teeth.|The secondary outcome measure will be conducted by measuring markers of stem cells prior to and after the formation of the blood clot.","The University of Texas Health Science Center at San Antonio","All","10 Years to 60 Years   (Child, Adult)","Early Phase 1","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","HSC20090152H","March 2010","March 2014","March 2014","April 15, 2009","null","February 5, 2016","University of Texas Health Science Center, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT00881907"
2176,"NCT00881556","Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)","RDEB","Unknown status","No Results Available","Epidermolysis Bullosa","Drug: Reduced Intensity Transplant conditioning","To determine the event-free survival (EFS) and overall survival (OS) following RIC consisting of busulfan/fludarabine/alemtuzumab (BFA) and AlloSCT in selected patients with RDEB.|Quantitate the percent of whole blood (CD45), T-cell (CD3), and NK cell (CD56) chimerism following RIC and AlloSCT in selected patients with RDEB|Quantitate the percent of donor skin dermal chimerism following RIC and AlloSCT in selected patients with RDEB.|Compare the gene and protein expression of COL7A1 in the skin pre and post AlloSCT","Columbia University","All","up to 21 Years   (Child, Adult)","Early Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAD5420|CHNY-08-536","March 2009","June 2014","July 2014","April 15, 2009","null","February 15, 2012","The Children's Hospital, Aurora, Colorado, United States|Children's Memorial Hospital, Chicago, Illinois, United States|Morgan Stanley Children's Hospital of NYP, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00881556"
2177,"NCT00881491","Treatment Outcome With a Revascularization Protocol Using the Triple Versus Double Antibiotic Paste",,"Completed","No Results Available","Pulp Necrosis","Drug: Double Antibiotic Paste|Drug: Triple Antibiotic Paste|Drug: Mineral Trioxide Aggregate","The primary outcome measures will be radiographic measurement of root length and dentinal wall thickness.|The secondary outcomes will be lack of clinical symptoms and crown staining.","The University of Texas Health Science Center at San Antonio","All","7 Years to 60 Years   (Child, Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HSC20090181H","April 2009","January 2015","January 2015","April 15, 2009","null","February 5, 2016","University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT00881491"
2178,"NCT00881218","Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson",,"Completed","No Results Available","Ischemic Heart Disease","Drug: Regadenoson","Feasibility of use of regadenoson during cardiac perfusion MRI to visualize regions of myocardial ischemia as demonstrated on SPECT-MPI.","Washington University School of Medicine|Astellas Pharma US, Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","REGADENOSON.MRI.WUSTL","June 2009","December 2011","December 2011","April 15, 2009","null","April 10, 2012","Washington University School of Medicine, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00881218"
2179,"NCT00879164","Stellate Ganglion Nerve Block in Treating Women With Hot Flashes",,"Completed","No Results Available","Hot Flashes","Drug: bupivacaine hydrochloride|Other: questionnaire administration","Difference in hot flash activity between baseline and week 7|Difference in quality of life, toxicity, and self-assessment items between baseline and week 7","Mayo Clinic|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other|NIH","Interventional","Primary Purpose: Supportive Care","CDR0000640197|P30CA015083|MC08C8|08-006796|NCI-2009-01133","April 2009","December 2010","December 2010","April 9, 2009","null","October 17, 2014","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT00879164"
2180,"NCT00877864","Diabetes Exercise and Lifestyle Trial","DEAL","Unknown status","No Results Available","Diabetes Mellitus","Behavioral: High volume combined aerobic/resistance exercise|Behavioral: Low volume combined aerobic/resistance exercise|Behavioral: High volume combined A/R exercise, printouts, pedometers|Behavioral: Low volume combined A/R exercise, printouts, pedometers|Behavioral: Printed PA information, pedometers and step log group|Behavioral: Control","The primary outcome will be A1c at the end of 6 months supervised exercise period.","University of Calgary","All","35 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","26","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","DEAL- 22251|CHREB 22251","February 2010","December 2012","December 2012","April 8, 2009","null","August 5, 2011","University of Calgary, Calgary, Alberta, Canada","","https://ClinicalTrials.gov/show/NCT00877864"
2181,"NCT00874861","HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas",,"Completed","No Results Available","Astrocytoma|Oligoastrocytoma|Oligodendroglioma","Biological: Peptide vaccine + Poly-ICLC","Both immunological and safety data will serve as bases to decide whether a larger follow-up study is warranted.|Clinical response: 6 month and 2-year progression-free survival (PFS) will be evaluated based on serial magnetic resonance imaging (MRI) scans.|Tumor tissues for biological correlates: for patients who develop progression, biopsy/resection will be encouraged and analyzed for GAA expression status and infiltration of GAA-specific T-cells","Ian F. Pollack, M.D.|Musella Foundation|National Cancer Institute (NCI)|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08-135|1R21CA133859","April 2009","May 2012","November 2013","April 3, 2009","null","December 8, 2015","UPMC Hillman Cancer Center (University of Pittsburgh Cancer Institute), Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00874861"
2182,"NCT00874666","Allicin Bioavailability From Garlic Supplements and Garlic Foods",,"Unknown status","No Results Available","Healthy","Other: crushed garlic clove|Dietary Supplement: garlic powder tablet","Breath allyl methyl sulfide","Silliker, Inc.|National Center for Complementary and Integrative Health (NCCIH)","All","18 Years to 72 Years   (Adult, Older Adult)","Early Phase 1","12","Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","R21AT004236|1R21AT004236-01","April 2009","April 2011","April 2011","April 2, 2009","null","November 20, 2009","Silliker, Inc., Orem, Utah, United States","","https://ClinicalTrials.gov/show/NCT00874666"
2183,"NCT00871533","Pilot Study of IFN α2b for Melanoma Patients",,"Terminated","No Results Available","Melanoma","Drug: IFNα2b|Drug: PEG- IFNα2b","To utilize gene-profiling analysis of regional lymph node tissue to molecularly characterize the effect of IFN α2b and PEG IFNα2b on the SLN. Endpoint: mRNA expression by gene array.|Quantitate putative biomarkers differentially expressed in the SLN for each active treatment group and among all active treatment groups combined. Endpoint: mRNA expression by Taqman.|Molecularly characterize the effect of perilesional IFN α2b and PEG IFNα2b administered as close as possible to the primary tumor site on SLNs that are positive vs. negative for tumor micrometastases. Endpoint: mRNA expression by gene array.","University of Pittsburgh|Schering-Plough","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","08-067","September 2009","August 2017","August 2017","March 30, 2009","null","August 4, 2017","UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00871533"
2184,"NCT00870896","The Effects of Tiotropium on the Cough Reflex in Patients With Chronic Obstructive Pulmonary Disease (COPD)",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease|Chronic Bronchitis","Drug: Tiotropium","Number of Coughs Following Capsaicin Inhalation Challenge at Baseline and Following 30 Days of Treatment With Spiriva (Baseline and 30 Days)|Change in FEV1 (in Liters)|Change in FEV1/FVC Ratio","ThomasTruncale|Boehringer Ingelheim|University of South Florida","Male","40 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","5","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P65201|0800000250 V10","February 2008","February 2009","June 2012","March 27, 2009","September 15, 2014","October 1, 2014","James A Haley Veterans' Hospital, Tampa, Florida, United States|University of South Florida (COPH), Tampa, Florida, United States","","https://ClinicalTrials.gov/show/NCT00870896"
2185,"NCT00866450","Effects of a Western-type Diet on Colorectal Inflammation",,"Completed","No Results Available","Colorectal Inflammation","Dietary Supplement: Western style diet (high fat and low in calcium)|Dietary Supplement: Prudent-style diet (low fat and high in calcium)","Inflammation in the rectosigmoid epithelium|Circulating endotoxin levels|Expression profiles of pro- and anti-inflammatory genes in rectosigmoid biopsies|Gut permeability|Inflammatory cytokines in the colorectal mucosa and serum|Luminal and adherent gut microbiota|Fecal calprotectin levels in the stool samples","Rockefeller University","All","50 Years to 72 Years   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","SWP-0658","February 2009","February 2010","February 2010","March 20, 2009","null","January 11, 2012","Rockefeller University, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00866450"
2186,"NCT00864864","Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma",,"Completed","No Results Available","Glioblastoma|Brain Tumor","Drug: Sunitinib","To assess the ability of sunitinib to achieve a target tumor: plasma ration greater than or equal to 0.2 in patients with recurrent GM.|To determine if there is an association between growth factor receptor inhibition and tumor phenotype, tumor: plasma ratio of sunitinib and overall survival.","Massachusetts General Hospital|Brigham and Women's Hospital|Dana-Farber Cancer Institute|Pfizer","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-307","May 2007","May 2011","May 2013","March 19, 2009","null","July 7, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00864864"
2187,"NCT00863265","Phytosterols, Ezetimibe, and Cholesterol Metabolism","Phyteaux-III","Completed","Has Results","Hypercholesterolemia|Coronary Heart Disease","Drug: Ezetimibe|Other: Phytosterols + ezetimibe|Other: Placebo","Cholesterol Excretion|Percent Cholesterol Absorption|LDL Cholesterol","Washington University School of Medicine|Utah State University|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","22","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","CANUSU-phyto3|R01HL050420","June 2009","October 2009","February 2010","March 17, 2009","June 1, 2018","June 1, 2018","Center for Advance Nutrition at Utah State University, Logan, Utah, United States","","https://ClinicalTrials.gov/show/NCT00863265"
2188,"NCT00863122","Concentration and Activity of Lapatinib in Vestibular Schwannomas",,"Unknown status","No Results Available","Vestibular Schwannoma|NF2|Neurofibromatosis 2|Acoustic Neuroma|Auditory Tumor","Drug: lapatinib","To assess steady-state lapatinib plasma concentrations at the time of surgical resection, 10 (+3) days after oral dosing.|To assess whether lapatinib can reach a minimum tumor concentration level of >3uM in VS after oral dosing.|Assess the level of ErbB2 and EGFR phosphorylation and activity of downstream signaling effectors in VS.|Assess markers of tumor proliferation and cell death in VS after exposure to lapatinib.|Explore the difference in the concentration of lapatinib achieved in NF2-related versus idiopathic VS.|Perform NF2 gene mutation analysis via exon scanning and MLPA as well as protein expression in all VS and explore differences between sporadic and NF2 related VS.","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|The Children's Tumor Foundation|GlaxoSmithKline|New York University|Ohio State University|House Research Institute|Washington University School of Medicine|Weill Medical College of Cornell University|Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","26","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","J0867|NA_00020841","June 2009","December 2013","null","March 17, 2009","null","August 7, 2013","House Reserach Institute, Los Angeles, California, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Washington University Medical Center, St. Louis, Missouri, United States|New York University Medical Center, New York, New York, United States|Weil Cornell Medical College, New York Presbyterian Hospital, New York, New York, United States|Ohio State University Medical Center, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00863122"
2189,"NCT00860756","Sleep Disturbance in Deployed Soldiers",,"Unknown status","No Results Available","Sleep Disturbance","Other: Relaxation CD","Actigraph and self report questionnaires|Self report questionnaires","Brooke Army Medical Center","All","18 Years to 50 Years   (Adult)","Early Phase 1","150","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","I2007.242dt","September 2007","July 2009","July 2009","March 12, 2009","null","March 12, 2009","Evans Army Community Hospital, Fort Carson, Colorado, United States|Carl R. Darnall Army Medical Center, Fort Hood, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00860756"
2190,"NCT00860743","Respiratory and Autonomic Plasticity Following Intermittent Hypoxia","RAP-IH","Completed","Has Results","Sleep Apnea Syndromes","Drug: Antioxidant cocktail","Ventilation (Aim 1)|Heart Rate Variability (Aim 2)","VA Office of Research and Development","All","20 Years to 40 Years   (Adult)","Early Phase 1","63","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","PULM-014-08F|GRANT00507547","September 2009","September 2013","September 2013","March 12, 2009","February 25, 2015","November 1, 2017","John D. Dingell VA Medical Center, Detroit, Detroit, Michigan, United States","","https://ClinicalTrials.gov/show/NCT00860743"
2191,"NCT00857740","Influence of Painphysiolgy Education on the Pain Inhibition in Fibromyalgia",,"Completed","No Results Available","Fibromyalgia","Behavioral: Education","Diffuse noxious inhibitory control|pain pressure thresholds","Vrije Universiteit Brussel","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","BUN B14320084324","March 2009","June 2010","June 2010","March 9, 2009","null","July 8, 2010","Vrije Universiteit Brussel, Brussels, Belgium","","https://ClinicalTrials.gov/show/NCT00857740"
2192,"NCT00848705","Adolescent Self-Management of Type 1 Diabetes: an Intervention (Completed)","YourWay","Completed","No Results Available","Adolescent Type 1 Diabetes","Behavioral: YourWay Internet Intervention","Self-management behaviors|Self-management Problem solving","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","13 Years to 17 Years   (Child)","Early Phase 1","72","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","DK70026-01A2","October 2007","January 2009","May 2009","February 20, 2009","null","February 2, 2011","Vanderbilt University Medical Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00848705"
2193,"NCT00848497","Testosterone for Penile Rehabilitation After Radical Prostatectomy",,"Terminated","Has Results","Hypogonadism|Erectile Dysfunction","Drug: Testim®|Other: Placebo Testim®|Drug: Viagra®","Change in SHIM (Sexual Health Inventory for Males) Score at 6 Months After Initial Screening Visit.|Change in the IIEF (International Index of Erectile Function) Score 6 Months After the Initial Screening Visit.|Change in the ADAM (Androgen Deficiency in the Aging Male)Score 6 Months After the Initial Screening Visit.|Change in the EPIC (Expanded Prostate Cancer Index Composite) Score 6 Months After the Initial Screening Visit.","Mohit Khera|Baylor College of Medicine","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","H-21148","November 2007","March 2013","March 2013","February 20, 2009","June 19, 2015","June 19, 2015","Baylor College of Medicine, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00848497"
2194,"NCT00848302","Endothelial Function in Human Arteries",,"Completed","No Results Available","Endothelial Dysfunction","Drug: L-arginine","IVUS mediated assessment of endothelial-dependent (EDR) and endothelial-independent (EIR) vasorelaxation before and after catheter-directed L-arginine delivery in patent arteries.|Local arterial factors including peripheral L-arginine and nitrotyrosine levels via mass spectrometry and morphologic parameters of plaque composition.","The Cleveland Clinic","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","K23HLOBO247","September 2009","January 2011","January 2011","February 20, 2009","null","March 7, 2017","","","https://ClinicalTrials.gov/show/NCT00848302"
2195,"NCT00846664","Short Arc Multifidus Study",,"Unknown status","No Results Available","Multifidus Disuse Atrophy","Procedure: Logan Short Arc Banding","Multifidus cross sectional area","Logan College of Chiropractic","All","18 Years to 54 Years   (Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SR0112080162|396","February 2009","March 2009","March 2009","February 19, 2009","null","February 19, 2009","Logan College of Chiropractic, Chesterfield, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00846664"
2196,"NCT00845494","Efficacy of a Behavioral Based Education Intervention to Decrease Medication History Errors Among Professional Nurses.",,"Unknown status","No Results Available","Medication Errors","Behavioral: cognitive behavioral intervention","Reduction in medication errors on admission medication history form after intervention","Waukesha Memorial Hospital","All","20 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","554","February 2009","February 2010","October 2010","February 18, 2009","null","February 18, 2009","Waukesha Memorial Hospital, Waukesha, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT00845494"
2197,"NCT00844389","Near to Infrared (NIR) Light Neuroprotection in Glaucomatous Optic Neuropathy",,"Unknown status","No Results Available","Open Angle Glaucoma","Device: Near to infrared light retinal stimulation|Device: Green light stimulation","Pattern electroretinogram response|OCT ganglion cell layer average thickness, Visual Field defects","Universidad de Valparaiso|Comisión Nacional de Investigación Científica y Tecnológica","All","40 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ACT45-GLAUC","April 2009","December 2009","March 2010","February 16, 2009","null","October 1, 2009","Servicio de Oftalmología Hospital Van Buren, Valparaiso, Chile","","https://ClinicalTrials.gov/show/NCT00844389"
2198,"NCT00842985","Dronabinol Interactions With Cognitive Enhancing Drug in Humans",,"Completed","Has Results","Cannabis|Marijuana Abuse","Drug: drug condition","CANTAB:CAmbridge Neuropsychological Test Automated Battery RVIP: Rapid Visual Information Processing","Yale University|VA Office of Research and Development|National Institute on Drug Abuse (NIDA)","All","18 Years to 55 Years   (Adult)","Early Phase 1","53","Other|U.S. Fed|NIH","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0702002357|MIRECC 00000000|P50DA009241","September 2008","October 2009","October 2009","February 12, 2009","December 17, 2012","May 30, 2017","Department of Veterans Affairs Hospital, West Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT00842985"
2199,"NCT00842309","D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder","BDD/DCS","Completed","No Results Available","Body Dysmorphic Disorder","Drug: d-cycloserine|Drug: Placebo","Body Dysmorphic Disorder Yale-Brown Obsessive Compulsive Scale (BDD-YBOCS)","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2008P001429","November 2008","December 2017","August 2018","February 12, 2009","null","September 18, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00842309"
2200,"NCT00835679","Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery",,"Terminated","Has Results","Liver Metastases|Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IV Colon Cancer|Stage IV Rectal Cancer","Biological: cetuximab|Drug: dasatinib|Procedure: therapeutic conventional surgery|Other: laboratory biomarker analysis","Patients With a Biologic Response|Patients With Reduction of Biomarkers in Tumor Tissue|Number of Patients With the Given Severity of Adverse Event Within a Specified Duration|Number of Patients With the Given Severity of Post-operative Complications Within the Specified Duration","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","9","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","NCI-2013-00014|VU-VICC-GI-0838|8069|P30CA068485|081338|VICC GI 0838","December 2009","February 2011","August 2011","February 4, 2009","September 7, 2012","May 23, 2014","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00835679"
2201,"NCT00831077","Early Phase I Microdosing Study of ORM-14540 and ORM-12741",,"Completed","No Results Available","Healthy","Drug: ORM-14540|Drug: ORM-12741","Pharmacokinetic variables including: Area under the concentration-time curve (AUC), Maximum observed concentration (Cmax) at the end of infusion, Terminal elimination half-life (t½z), Total clearance (CL)|Safety variables including blood pressure (BP), heart rate (HR), electrocardiograms (ECGs), physical examination, laboratory safety variables (haematology, chemistry, serology and urinalysis) and adverse events (AEs).","Orion Corporation, Orion Pharma","Male","18 Years to 45 Years   (Adult)","Early Phase 1","6","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","3101001","January 2009","April 2009","April 2009","January 28, 2009","null","October 8, 2009","CRST, Turku, Finland","","https://ClinicalTrials.gov/show/NCT00831077"
2202,"NCT00830050","Brain Imaging To Examine The Effect Of Naproxen In Hand Osteoarthritis Patients",,"Completed","No Results Available","Osteoarthritis","Drug: Naproxen|Drug: Placebo","Changes in voxel-wise Blood Oxygen Level Dependent (BOLD) signal throughout the brain and changes in pre-defined brain regions of interest.|Whole brain resting-state distribution of Cerebral Blood Flow|Psychometric measures of pain, namely Daily Pain Diaries and Present Pain Intensity|Pain induced by a grip task measured with a Visual Analogue Scale (VAS), the Short-Form McGill Pain Questionnaire and patient-rated wrist/hand evaluation (PRWHE)","Pfizer|King's College London","Female","50 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","24","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","A9001399","July 2010","December 2010","December 2010","January 27, 2009","null","March 14, 2011","Pfizer Investigational Site, Denmark Hill, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT00830050"
2203,"NCT00829699","Metabolic Causes of Thrombosis in Type 2 Diabetes Mellitus",,"Completed","No Results Available","Type 2 Diabetes","Procedure: euinsulinemic euglycemic glucose clamp|Procedure: euinsulinemic hyperglycemic glucose clamp|Procedure: Hyperinsulinemic euglycemic glucose clamp|Procedure: Hyperinsulinemic hyperglycemic glucose clamp","Percent change in flow mediated dilation of brachial artery|Change in Lipid measures","University of Maryland|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 60 Years   (Adult)","Early Phase 1","31","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","HP-00044874|RFAHL04016","July 2009","June 2013","April 2014","January 27, 2009","null","February 10, 2017","Univerisity of Maryland, Baltimore, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00829699"
2204,"NCT00829608","Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis",,"Withdrawn","No Results Available","Recurrent Respiratory Papillomatosis","Biological: Human Papillomavirus Vaccine","Comparison of the pre-vaccine and post-vaccine RRP scoring assessments, intersurgical intervals, and annualized surgical rates.|The secondary end points will include changes in the RRP scoring assessment, intersurgical intervals and changes in annualized surgical rates.","University of Missouri-Columbia","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1124197","January 2009","December 2009","June 2010","January 27, 2009","null","October 5, 2016","University of Missouri, Columbia, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00829608"
2205,"NCT00829543","Unguided Sacroiliac Injection: Effect on Refractory Buttock Pain in Patients With Spondyloarthropathies",,"Unknown status","No Results Available","Spondylarthropathy","Procedure: guide-free sacroiliac corticosteroid injection","Refractory inflammatory sacroiliac pain|ESR, CRP|Patient's assessment of: pain, sleep disturbance, morning stiffness|Clinician assessment of: SIJ pain, change of finger to floor (cm) and Schober tests (mm)|MRI SIJ inflammatory scoring","Tabriz University","All","16 Years to 50 Years   (Child, Adult)","Early Phase 1","35","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8715","September 2004","January 2007","February 2009","January 27, 2009","null","February 3, 2009","Tabriz Medical University, Rheumatology Department, Tabriz, East Azarbayjan, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT00829543"
2206,"NCT00827749","Swallowing Disorders in Geriatrics Studied With Respiratory Plethysmography by Inductance","PRIOD","Completed","No Results Available","Swallowing Disorders","Device: respiratory plethysmography by inductance","Can we detect with a non-invasive, infra clinical, objective and non-traumatic tool, a patient's deglutitions from an automatic analysis of a recording of his breathing rate?|Can we detect with a non-invasive, infra clinical, objective and non-traumatic tool pathological deglutitions from an automatic analysis of a recording of his breathing rate?|Can we have a test to classify patients into two groups - those without swallowing disorders and those with swallowing disorders - from an analysis of quantitative parameters relating to the analysis of the breathing rate?","University Hospital, Grenoble","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","DCIC 05 22","November 2008","June 2010","June 2010","January 23, 2009","null","July 22, 2010","University Hospital of Grenoble, Grenoble, Cedex 09, France","","https://ClinicalTrials.gov/show/NCT00827749"
2207,"NCT00827476","Improving Human Ovarian Transplantation",,"Unknown status","No Results Available","Fertility Preservation","Procedure: ovarian transplantation","improving folliculogenesis and oocuyte maturation after ovarian transplantation","Hadassah Medical Organization|Israel Science Foundation","Female","5 Years to 40 Years   (Child, Adult)","Early Phase 1","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0530-08-HMO- CTIL","January 2009","January 2012","January 2015","January 22, 2009","null","January 22, 2009","","","https://ClinicalTrials.gov/show/NCT00827476"
2208,"NCT00827294","Home-based Self-delivered Mirror Therapy for Phantom Limb Pain",,"Unknown status","No Results Available","Phantom Limb Pain","Behavioral: Mirror Therapy","Change in phantom pain intensity (from baseline to one month; also measured at 2 months and 3 months to see if treatment gains are sustained). Pain intensity is measured with the Brief Pain Inventory-short form (BPI-sf)at all time points|Outcome will be determined by measuring change in depressive symptoms (using the Center for Epidemiology Depression Scale (CES-D) (comparing baseline levels of depressive symptoms to one month)|Outcome will be determined by measuring changes in pain-related anxiety levels (baseline to one month) as measured by the Pain Anxiety Symptom Scale.|Sleep quality. Outcome for sleep quality will be measured using the Pittsburgh Sleep Quality Index.|Pain Catastrophizing. We will measure outcome for pain catastrophizing with the Pain Catastrophizing Scale.|Pain medication usage. We will measure whether mirror therapy decreases pain medication usage.","Oregon Health and Science University","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4925 Mirror Therapy|5K12HD04348807","January 2009","December 2010","December 2010","January 22, 2009","null","September 14, 2009","Oregon Health & Science University, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT00827294"
2209,"NCT00826488","A Comparison of Breast Tomosynthesis Mammography and Conventional Breast Imaging in the Characterization of Breast Masses",,"Completed","No Results Available","Fibrocystic Disease of Breast|Breast Cancer","Device: Digital Breast Tomosynthesis","It is anticipated that out of 100 subjects recalled for additional breast imaging that 10 women will be recalled for biopsy. By adding 2D & 3D imaging, it is anticipated that 30 subjects out of 100 will have needed no workup.","Washington University School of Medicine","Female","35 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","136","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","DBT11212008","March 2009","December 2014","December 2014","January 22, 2009","null","June 2, 2015","JoAnne Knight Breast Center, Barnes Hospital, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00826488"
2210,"NCT00825591","Biological Clock Dysfunction in Optic Nerve Hypoplasia",,"Unknown status","No Results Available","Biological Clock Dysfunction|Optic Nerve Hypoplasia","Dietary Supplement: Melatonin|Dietary Supplement: Placebo Comparator","Assessment of rest-activity patterns","Yale University|Children's Hospital Los Angeles","All","2 Years to 10 Years   (Child)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","0804003699|TRSH-SAR","October 2008","September 2011","September 2011","January 21, 2009","null","February 8, 2011","Children's Hospital of Los Angeles, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT00825591"
2211,"NCT00823433","Oral Penicillin and Penicillin Levels in Venous Umbilical Cord Blood",,"Terminated","No Results Available","Group B Streptococcus","Drug: oral penicillin V","The level of antibiotics in the umbilical vein cord blood of newborn infants after the administration of penicillin orally while in labor.|Compare levels of penicillin in the umbilical cord blood of women who received oral penicillin to the levels of women who received intravenous penicillin in labor. Comparisons will be done through literature only.","William Beaumont Hospitals","Female","18 Years to 45 Years   (Adult)","Early Phase 1","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2008-183","January 2009","December 2009","December 2009","January 15, 2009","null","November 4, 2016","William Beaumont Hospital, Royal Oak, Michigan, United States","","https://ClinicalTrials.gov/show/NCT00823433"
2212,"NCT00823329","Calorie Balance Monitoring and Analysis of Body Composition and Hydration Status","PCMMS","Suspended","No Results Available","Energy Metabolism|Energy Expenditure|Body Composition|Body Fluids","Device: cardiac stress testing with an exercise machine","Comparison of the measuring function of our prototype devices with that one of commercially available measuring instruments","Ori Diagnostic Instruments LLC","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","ORI-DGI-001","October 2012","October 2012","October 2012","January 15, 2009","null","October 12, 2012","McKee Gym of the Department of Nutrition and Exercise Physiology, Columbia, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00823329"
2213,"NCT00819962","Perioperative Analgesia Using Ultrasound (US) Guided Transversus Abdominis Plane (TAP) Block",,"Unknown status","No Results Available","Postoperative Pain","Drug: Bupivacaine|Other: TAP","Pain relief","King Saud University","All","20 Years to 50 Years   (Adult)","Early Phase 1","42","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","08-652","September 2014","December 2015","December 2016","January 9, 2009","null","September 15, 2015","A Dawlatly, Riyadh, Saudi Arabia|A Dawlatly, Riyadh, Saudi Arabia","","https://ClinicalTrials.gov/show/NCT00819962"
2214,"NCT00816335","Fludeoxyglucose F 18 PET/CT Imaging in Finding Cancer in Patients Undergoing Surgery for Solid Tumors",,"Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Procedure: PET/CT scan|Drug: 18F-FDG Injection|Procedure: Preoperative 18F-FDG PET/CT Scan|Drug: 18F-FDG for patients with Bladder Cancer|Procedure: Surgical Procedure|Procedure: Specimen PET/CT Scan","Determine perioperative PET/CT imaging combined with intraoperative use of handheld gamma probe is feasible during surgical procedure to resect malignancy.|Evaluate if perioperative PET/CT imaging can assist in intraoperatively localizing tumor and verify resection of disease.|Evaluate intraoperative detection of tumor sites using a handheld gamma probe after preoperative injection of 18F-FDG combined with preoperative PET/CT imaging.|Evaluate specimen PET/CT imaging using the preoperative 18F-FDG dose for detecting presence of tumor within the specimen and for assessing surgical margins.|Evaluate specimen MRI imaging for detecting presence of tumor within remnant tissue of appropriately selected resected specimens and for assessing surgical margins.|Evaluate standard pathology sampling with image guided pathology sampling (using specimen PET/CT imaging) in order to determine if sensitivity and accuracy of pathologic evaluation may be improved with PET/CT image guidance.|Compare activity of surgical specimen samples with pathologic findings and tumor burden in order to determine if the concepts in previous two specific aims can be utilized to benefit patients treated at centers without access to PET/CT imaging equipment.","Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","65","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","OSU-08031|NCI-2012-00958","October 2008","August 2011","August 2011","January 1, 2009","null","April 4, 2016","Ohio State University Medical Center, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00816335"
2215,"NCT00815646","Prevention and Treatment of Immersion Pulmonary Edema",,"Completed","No Results Available","Immersion Pulmonary Edema (IPE)|Swimming Induced Pulmonary Edema (SIPE)","Drug: Sildenafil","Pulmonary artery pressure during cold water immersion","Duke University|Divers Alert Network","All","18 Years to 55 Years   (Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Pro00003158","January 2008","December 2015","December 2015","December 30, 2008","null","January 26, 2016","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00815646"
2216,"NCT00813267","Mesenchymal Stem Cell for Osteonecrosis of the Femoral Head",,"Unknown status","No Results Available","Osteochondritis of the Femoral Head","Biological: mesenchymal stem cell infusion|Biological: bone marrow mononuclear cell infusion","The femoral head blood-supply artery angiographies and the areas of femoral head necrosis|Coxa joint paining|Walking distance|Joint functions|Life","Jianming Tan|Fuzhou General Hospital","All","12 Years to 60 Years   (Child, Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","fuzhough1221","December 2009","August 2011","August 2015","December 23, 2008","null","October 10, 2012","Fuzhou General Hospital, Fuzhou, Fujian, China","","https://ClinicalTrials.gov/show/NCT00813267"
2217,"NCT00811122","Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly","11C-PIB PET","Active, not recruiting","No Results Available","Alzheimer's Disease","Radiation: 11C-PIB PET Scan|Radiation: FDG-PET Scan","The agent 11C-PIB has similar biodistribution outside the brain in AD, FTD, and cognitively normal elderly individuals.|Patients with AD scanned with 11C-PIB will have higher standardized uptake values (SUVs) than cognitively normal elderly in brain regions where beta amyloid are expected to be over-expressed.","University of Utah","All","30 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","17991","November 2009","April 2018","April 2018","December 18, 2008","null","May 9, 2017","University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00811122"
2218,"NCT00808574","Screening for Obstructive Sleep Apnea Among Members of an Internet Weight Loss Community",,"Completed","No Results Available","Obstructive Sleep Apnea","Behavioral: Obstructive sleep apnea screening intervention","Online questionnaire asking whether subject has discussed OSA with healthcare provider since enrolling in study|Online questionnaire asking whether subject has plans to discuss OSA with healthcare provider, if not done already|Online questionnaire asking whether subject has undergone testing and treatment for OSA since enrolling in study","The University of Texas Health Science Center, Houston","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","168","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Screening","HSC-MS-08-0346","July 2008","October 2008","October 2008","December 16, 2008","null","December 16, 2008","University of Texas Medical School, Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00808574"
2219,"NCT00802815","Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis",,"Completed","No Results Available","Inclusion Body Myositis","Drug: Etanercept","Change in Quantitative Muscle Testing on 12 proximal and 12 distal muscles","Washington University School of Medicine|Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20031148","April 2005","May 2014","May 2014","December 5, 2008","null","May 29, 2014","Washington University Department of Neurology, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00802815"
2220,"NCT00800098","Effects of an Herbal Topical Cream on Osteoarthritis Symptoms, Biomarkers, and Disease Progression in the Knee",,"Completed","No Results Available","Osteoarthritis","Drug: herbal topical cream","WOMAC|Function|MRI morphology|Blood and urine biomarkers","Stanford University","All","40 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","22","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SU-11252008-1355|Protocol ID:14764","December 2008","September 2009","February 2010","December 1, 2008","null","June 24, 2013","Stanford University School of Medicine, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT00800098"
2221,"NCT00797056","Stem Cell Mobilization by G-CSF to Treat Severe Peripheral Artery Disease","STEMPAD","Completed","No Results Available","Peripheral Vascular Diseases","Drug: G-CSF|Drug: Placebo|Drug: Aspirin|Drug: Clopidogrel","Major limb amputation rate as defined by amputations of the limb that are transmetarsal and higher|Toe pressure index|Ankle-brachial index|Ulcer healing as measured by surface area and depth|Improvement in rest pain as measured by the Vascular Quality of Life Questionnaire","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","07-0043 / 201106083","April 2008","April 2012","April 2012","November 25, 2008","null","April 1, 2015","Washington University School of Medicine, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00797056"
2222,"NCT00795457","Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas",,"Completed","No Results Available","Astrocytoma|Oligo-Astrocytoma|Glioma","Biological: GAA/TT-peptide vaccine and poly-ICLC","Induction of GAA-specific T-cell response|The incidence and severity of adverse events associated with the vaccine regime will be assessed, with an early stopping rule based on the frequency of Regimen Limiting Toxicity (RLT).|Clinical Response: Radiological response will be determined using the standard WHO response criteria. Based on serial magnetic resonance imaging (MRI) scans 2-year progression-free survival (PFS) will be evaluated in an exploratory manner.|Biopsy/resection will be encouraged for patients who develop progression. Whenever post-vaccine tumor tissues are available, they will be analyzed for GAA expression status and infiltration of GAA-specific T-cells.|Influence of RT on induction of GAA-specific immune response: we will compare the rate and magnitude of GAA-specific immune responses in Cohorts 1 and Cohort 2 using IFN-gamma-enzyme-linked immuno-spot (ELISPOT), and tetramer assays.","Ian F. Pollack, M.D.|Oncovir, Inc.|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","13","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-057|R21CA133859-01A1","January 2009","February 2013","July 2015","November 21, 2008","null","July 6, 2017","Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00795457"
2223,"NCT00795405","Cardiovascular Effects of Sporting Events",,"Completed","No Results Available","Coronary Heart Disease","Behavioral: Exposure to sporting events|Behavioral: No exposure to sporting events","Evidence of definite myocardial ischemia confirmed by Holter monitoring|Blood pressure measured by ambulatory blood pressure monitoring|Heart rate variability|Episode of angina|Episode of neurological events|Episode of arrhythmia","Chinese Academy of Medical Sciences, Fuwai Hospital|China National Center for Cardiovascular Diseases","Male","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","38","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","sporting events","August 2008","October 2008","October 2008","November 21, 2008","null","August 6, 2009","","","https://ClinicalTrials.gov/show/NCT00795405"
2224,"NCT00795249","Effects of Chronic Smoking on Circulating Endothelial and Platelet-derived Microparticle",,"Completed","No Results Available","Atherosclerosis","Behavioral: smoking cessation","The number of circulating EMP|FMD","Kurume University","Male","20 Years to 40 Years   (Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","KurumeU-08061","November 2008","November 2010","November 2010","November 21, 2008","null","June 23, 2011","Kurume University Hospital, Kurume, Fukuoka, Japan","","https://ClinicalTrials.gov/show/NCT00795249"
2225,"NCT00794183","A Pilot Study Comparing the Programmed Delay Between the Atrial and Ventricle Interval","BRAVO-CRT","Terminated","No Results Available","Heart Failure","Device: CRT device settings","To assess the effect of CRT atrioventricular delay settings on biochemical markers in blood through 6 months|assess effects of echocardiogram through 6months after CRT on heart failure|assess the effects of minnesota Living with heart failure questionaire through 6 months after CRT on heart failure|assess effects of six minute hall walk through 6 months after CRt on heart failure|assess effects of SDANN through 6 months after CRT on heart failure","University of Minnesota - Clinical and Translational Science Institute|Minnesota Medical Foundation","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","0303M44604","June 2004","May 2010","November 2010","November 19, 2008","null","June 26, 2012","University of Minnesota, Minneapolis, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT00794183"
2226,"NCT00790413","Haploidentical Stem Cell Transplantation in Neuroblastoma",,"Active, not recruiting","No Results Available","Neuroblastoma","Drug: iodine I 131 metaiodobenzylguanidine|Drug: Fludarabine|Drug: Thiotepa|Procedure: T-cell depletion|Procedure: Haploidentical stem cell transplantation|Procedure: Donor Lymphocyte Infusion|Drug: Rituximab|Procedure: Co-transplantation of mesenchymal stem cells","Engraftment rate|Overall survival|Immunological reconstitution|Incidence of acute graft versus host disease","Lund University Hospital","All","6 Months to 21 Years   (Child, Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","385/2005","August 2005","December 2018","null","November 13, 2008","null","March 14, 2017","Lund University Hospital, Department of Pediatric Oncology and Bone Marrow Transplantation, Lund, Sweden","","https://ClinicalTrials.gov/show/NCT00790413"
2227,"NCT00788645","The Use of a Forecasting System for Predicting Exacerbations of COPD",,"Completed","No Results Available","Chronic Obstructive Pulmonary Disease (COPD)","Behavioral: COPD self care advice|Behavioral: Poor weather forecast warning","The incidence and frequency of COPD exacerbations in each of the intervention groups|Electronic diary symptoms using the EXACT instrument|Medication usage and hospital admissions|Changes in the St Georges Respiratory questionaire|Severity and duration of exacerbations assessed using the EXACT instrument","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Early Phase 1","98","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","D6256M00017","August 2008","March 2009","March 2009","November 11, 2008","null","December 2, 2010","Research Site, Exeter, United Kingdom","","https://ClinicalTrials.gov/show/NCT00788645"
2228,"NCT00785746","Improving Balance in Frail Elderly",,"Completed","No Results Available","Elderly|Frail","Other: Core","Berg balance scale|Functional walking capacity 6 minute walk test|Gait speed|Bridge Test|Activities-Specific Balance Confidence Scale (ABC Scale)|International Consultation on Urinary Incontinence Questionnaire- Urinary Incontinence Short Form (ICIQ-UI)","McGill University","All","Child, Adult, Older Adult","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)","SDR-06--010","August 2006","December 2009","December 2009","November 5, 2008","null","February 4, 2013","McGill University-Royal Victoria Hospital Site, Montreal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT00785746"
2229,"NCT00783276","An fMRI Study of SYN115 in Cocaine Dependent Subjects",,"Completed","No Results Available","Cocaine Dependence","Drug: SYN115|Drug: PLACEBO","fMRI Brain Activation","Virginia Commonwealth University|National Institute on Drug Abuse (NIDA)|The University of Texas Health Science Center, Houston","All","18 Years to 50 Years   (Adult)","Early Phase 1","26","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","DA009262-14|P50DA009262|DPMCDA","October 2008","January 2013","January 2013","October 31, 2008","null","July 14, 2016","University of Texas Health Science Center at Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00783276"
2230,"NCT00783042","Exploratory Study of Coronary Flow Reserve Measurements, a Non-Invasive Method for Coronary Function Measurements",,"Completed","No Results Available","Atherosclerosis|Inflammatory Activity in Coronary Arteries","Drug: Rosuvastatin|Drug: Placebo","Change in CFR peak velocity within rosuvastatin group after 1 month of treatment compared to baseline|Comparison of treatment effects on CFR peak velocities between groups after 1 month of treatment|Changes in CFR peak velocity within the rosuvastatin group after 3 months compared to baseline and to 1 month|Changes in other CFR parameters after one month rosuvastatin or placebo treatment; comparisons within groups and between groups|Changes in plasma lipids, lipoproteins and other cardiovascular biomarkers after 1 month of treatment with rosuvastatin or placebo; comparisons within groups and between groups","AstraZeneca","All","45 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","D1840M00006","October 2008","null","May 2009","October 31, 2008","null","June 30, 2009","Research Site, Goteborg, Sweden","","https://ClinicalTrials.gov/show/NCT00783042"
2231,"NCT00781534","A Clinical Trial of Ginseng in Diabetes",,"Completed","No Results Available","Diabetes","Dietary Supplement: Ginseng, ginsenoside Re or placebo|Dietary Supplement: Ginseng|Dietary Supplement: ginsenoside RE|Dietary Supplement: Placebo (sugar pill)","","Washington University School of Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","19","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","03-0824","September 2003","December 2004","September 2008","October 29, 2008","null","February 19, 2010","Washington University School of Medicine, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00781534"
2232,"NCT00780650","Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine",,"Active, not recruiting","No Results Available","Type 1 Diabetes","Drug: Atomoxetine|Drug: Placebo","Change in level of catecholamines in blood from baseline","University of Maryland|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 50 Years   (Adult)","Early Phase 1","56","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HP-00044873","May 2009","December 2019","December 2019","October 27, 2008","null","May 7, 2018","Univerisity of Maryland, Baltimore, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00780650"
2233,"NCT00779961","An Investigation for the Optimal Timing of a Cleft Palate Repair",,"Unknown status","No Results Available","Cleft Palate","Procedure: Palatoplasty","The primary outcome will be determined by the presence/absence of Velopharyngeal Insufficiency (VPI) at 5 years of age.|Surgical Complications: Surgical complications (i.e. fistula and dehiscence) will be evaluated between 6-8 weeks post-operatively and recorded.|Feeding Assessment: A feeding assessment will be conducted pre-surgery (5 months of age) and post surgery (6-8 weeks post-operatively).|Dental and Facial Growth Disturbances measured in patients with isolated secondary plate cleft by analysis of the severity of their malocclusion,and performing a lateral cephalometric analysis","The Hospital for Sick Children","All","up to 5 Months   (Child)","Early Phase 1","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1000010915","April 2008","April 2011","April 2013","October 24, 2008","null","October 24, 2008","The Hospital for Sick Children, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00779961"
2234,"NCT00779909","Dose-dependent Anti-inflammatory Effects of Vitamin D in a Human Gingivitis Model",,"Completed","Has Results","Gingivitis","Drug: vitamin D3|Other: Placebo","Proportion of Sites That Bleed on Probing|Mandibular Modified Gingival Index (MGI) Score|Maxillary Modified Gingival Index (MGI) Score|Mandibular Plaque Index (PI) Score|Maxillary Plaque Index (PI) Score|Gingival Crevicular Fluid (GCF) Volume|Gingival Crevicular Fluid (GCF) Concentrations of TNF-alpha, IL1-beta, IL-2, IL-12|Serum Calcium|Urinary Calcium/Creatinine Ratio","Boston University|National Center for Complementary and Integrative Health (NCCIH)","All","18 Years to 64 Years   (Adult)","Early Phase 1","35","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","H-26461|R21AT003714-01","December 2008","May 2011","September 2011","October 24, 2008","October 2, 2017","October 2, 2017","Boston University Goldman School of Dental Medicine, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00779909"
2235,"NCT00776360","The Effect of Oxytocin on the Gastric Emptying",,"Completed","No Results Available","Postprocedural Delayed Gastric Emptying","Drug: oxytocin","To examine whether oxytocin improves gastric emptying in gastroparesis","Skane University Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","29/2008","December 2008","December 2009","December 2009","October 21, 2008","null","April 7, 2015","","","https://ClinicalTrials.gov/show/NCT00776360"
2236,"NCT00775008","Media Effects Study on Health-Related Content",,"Completed","No Results Available","Processing Health Information","Behavioral: electronic health information","Physiological response|Psychosocial response","University of North Carolina, Chapel Hill","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","07-0430-02","October 2008","October 2008","November 2008","October 17, 2008","null","March 3, 2009","UNC-Chapel Hill, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00775008"
2237,"NCT00772772","Vitamin D Repletion in Chronic Kidney Disease",,"Completed","Has Results","Chronic Kidney Disease","Drug: Vitamin D3","Change in Endotoxin Activity|Blood Pressure|Intestinal Permeability|Nuclear Magnetic Resonance (NMR) Lipoprotein Profile|25-hydroxy Vitamin D (25-OH Vitamin D)|1, 25-OH Vitamin D","Rockefeller University","All","50 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MAP-0626","March 2008","June 2009","October 2009","October 15, 2008","June 13, 2011","January 15, 2015","Rockefeller University, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00772772"
2238,"NCT00769210","The Effect of Simvastatin Therapy on the Expression of Procoagulant and Inflammatory Markers in Heart Failure",,"Completed","No Results Available","Heart Failure","Drug: Simvastatin","Measure the effect of simvastatin treatment on the expression and activity of TF in patients with heart failure.|Determine if polymorphisms in the gene coding for TF affect the impact of simvastatin therapy on tissue factor expression","University of Utah","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2012064|IRB# 00013639","May 2005","July 2008","July 2008","October 9, 2008","null","March 31, 2016","University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00769210"
2239,"NCT00765791","Shoulder Function After Level IIB Neck Dissection: A Randomized Controlled Study","2B/Not 2B","Unknown status","No Results Available","Head and Neck Squamous Cell Carcinoma","Procedure: Selective Neck Dissection Including Level IIB|Procedure: Selective Neck Dissection Excluding Level IIB","Change in Neck Dissection Impairment Index (NDII) score from pre- to post-op.|Shoulder strength, range of motion and electromyographic (EMG)/nerve conduction testing","Peter Dziegielewski|University of Alberta","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","7527","December 2008","February 2014","February 2014","October 3, 2008","null","December 18, 2013","University of Alberta Hospital, Edmonton, Alberta, Canada","","https://ClinicalTrials.gov/show/NCT00765791"
2240,"NCT00765297","Identify Subjects at Risk for Falling Using Acceleration Based Gait Analysis System","stumble","Unknown status","No Results Available","Fall Risk","Device: fall related movement (stumble) detector|Device: fall related movement characteristic (stumble) detector","accelerations and acceleration based movement parameters","Maastricht University Medical Center","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MEC 07-3-045|NL17267.068.07","September 2007","October 2010","October 2010","October 2, 2008","null","July 27, 2010","University Maastricht, Maastricht, Limburg, Netherlands","","https://ClinicalTrials.gov/show/NCT00765297"
2241,"NCT00764218","Cardiovascular Phenotype Study in Patients With Obstructive Sleep Apnea Syndrome","SAS-HTA","Unknown status","No Results Available","Obstructive Sleep Apnea Syndrome|Hypertension","Device: Positive airway pressure treatment|Other: No positive airway pressure treatment","cardiovascular phenotype study in patients with non treated obstructive sleep apnea syndrome|characterization of arterial blood pressure, sympathetic activity, functional and morphological cardiovascular modifications. Effect of a treatment of obstructive sleep apnea syndrome on those different parameters.","University Hospital, Grenoble","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","300","Other","Interventional","Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","DGS2001/0398","March 2001","December 2003","December 2008","October 1, 2008","null","October 1, 2008","Cardiology and hypertension service, Grenoble, Isère, France","","https://ClinicalTrials.gov/show/NCT00764218"
2242,"NCT00763178","Effects of Duloxetine on Fear Conditioning in Posttraumatic Stress Disorder (PTSD)",,"Completed","No Results Available","Posttraumatic Stress Disorder","Drug: Duloxetine","Anxiolytic and antidepressant effects of duloxetine in patients with chronic PTSD","Yale University|VA Connecticut Healthcare System","Male","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","26","Other|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","0612002110|M120627","February 2007","April 2009","December 2009","September 30, 2008","null","April 23, 2015","VA Connecticut Healthcare System, West Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT00763178"
2243,"NCT00763035","Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)",,"Terminated","Has Results","Coronary Artery Disease|Asthma|Chronic Obstructive Pulmonary Disease (COPD)|Angina","Drug: Regadenoson|Drug: Dobutamine","Duration of Procedures|Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare MD Questionnaire|Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare MD Questionnaire (Episodes of Arrhythmias, Bradycardia, and Wheezing)|Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare Tech Questionnaire|Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare Tech Questionnaire (Episodes of Wheezing)|Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare Nurse Questionnaire|Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare Nurse Questionnaire (Episodes of Arrhythmias, Bradycardia, Hypertension, and Wheezing)","Wake Forest University Health Sciences|Astellas Pharma US, Inc.","All","40 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","14","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","IRB00006484","January 2009","December 2010","March 2011","September 30, 2008","September 26, 2018","September 26, 2018","WAKE FOREST UNIVERSITY Baptist Medical Center, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00763035"
2244,"NCT00762814","The Use of Sensory or Motor Cues Using Electrical Stimulation to Reduce Gait Freezing in Patients With Parkinson Disease",,"Terminated","No Results Available","Parkinson Disease","Device: Gait tests with and without the use of a tactile sensory cue (electrical stimulation using a TENS unit)","Timed Up and Go|Time to perform a 360 degree turn while standing in place|Time to complete a figure-eight walking pattern around cones placed anterior and posterior to the subject","Washington University School of Medicine","All","50 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-0890","May 2008","March 2009","June 2009","September 30, 2008","null","May 11, 2018","Washington University Program in Physical Therapy, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00762814"
2245,"NCT00760630","Measurements to Assess Severity of Epicardial Stenoses","MASES","Suspended","No Results Available","Coronary Artery Disease","Device: FFR/CFR and IVUS","to detect ischemic heart disease in patients with abnormal stress tests using MPI with SPECT and to determine the presence of significant epicardial stenosis using coronary angiography with simultaneous physiological pressure and flow measurements|To compare novel measurements, Pressure Drop Coefficient (CDP) & Lesion Flow Coefficient (LFC), against measured current parameters called Fractional flow reserve (FFR) & Coronary flow reserve (CFR).","University of Cincinnati|American Heart Association","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","76","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","UCIRB08031108","December 2009","October 2011","April 2012","September 26, 2008","null","September 6, 2010","University Hospital, Cincinnati, Ohio, United States|Department of Veterans Affairs, Cincinnati, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00760630"
2246,"NCT00758511","Pain Reactivity to Non-Pharmacological Interventions Across Repeated Routine Heel-Sticks in Preterm Infants in a Neonatal Intensive Care Unit","PAMINA","Completed","No Results Available","Preterm Infants","Procedure: 25% Sucrose|Procedure: facilitated tucking|Procedure: Sucrose and facilitated tucking","Pain reaction","University of Basel|University of Pittsburgh|University Hospital, Zürich|University Hospital Inselspital, Berne","All","up to 15 Days   (Child)","Early Phase 1","71","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","3200B1_122676","January 2009","December 2009","December 2009","September 25, 2008","null","November 15, 2013","Institute of Nursing Science Medical Faculty, University of Basel, Basel, Switzerland","","https://ClinicalTrials.gov/show/NCT00758511"
2247,"NCT00757549","3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx",,"Completed","No Results Available","Head and Neck Cancer","Biological: cetuximab|Drug: cisplatin|Genetic: TdT-mediated dUTP nick end labeling assay|Other: 3'-deoxy-3'-[18F]fluorothymidine|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Radiation: fludeoxyglucose F 18|Radiation: radiation therapy","Percent change in the standard uptake value levels calculated for the identified volumes of interest for FLT and FDG PET scans from baseline to after 2 weeks of cetuximab therapy and from baseline to after 20-30 Gy of radiotherapy|Quantified change values (after cetuximab therapy and after 20-30 Gy of radiotherapy) for the FLT and FDG PET scan-based topographic profiles created using the ImQuant software package","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Older Adult)","Early Phase 1","30","Other|NIH","Interventional","Primary Purpose: Diagnostic","MC057M|P30CA015083|08-002166|NCI-2009-01193","September 2008","August 2011","October 25, 2017","September 23, 2008","null","October 31, 2017","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT00757549"
2248,"NCT00757185","Compromised Microcirculation in Women With Polycystic Ovary Syndrome",,"Completed","No Results Available","Polycystic Ovary Syndrome","Drug: ganirelix acetate|Drug: methyl testosterone","Skin blood flow and cutaneous vascular conductance","Yale University|National Heart, Lung, and Blood Institute (NHLBI)","Female","18 Years to 35 Years   (Adult)","Early Phase 1","28","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","0801003437|R21HL093450","February 2008","April 2012","December 2012","September 23, 2008","null","July 4, 2016","John B. Pierce Laboratory, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT00757185"
2249,"NCT00756795","Increasing Physical Activity of Patients With Head and Neck Cancer (I-PAP Study)","I-PAP","Withdrawn","No Results Available","Head and Neck Cancer","Behavioral: Intervention group","Self-report of physical activity behavior (duration, intensity and frequency)|Quality of Life|Depression Score|Fatigue Score|Plasma IL-6 Concentration","University of Nebraska","All","19 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","053-08","April 2008","August 2010","August 2010","September 22, 2008","null","April 11, 2018","University of Nebraska Medical Center, Omaha, Nebraska, United States","","https://ClinicalTrials.gov/show/NCT00756795"
2250,"NCT00755677","Exploring the Health Benefits Associated With Daily Pulse Consumption in Individuals With Peripheral Arterial Disease",,"Completed","No Results Available","Peripheral Arterial Disease","Other: Pulses","Identification of changes in endothelial function in response to dietary modification|Correlation of serum adiponectin levels|Correlation of changes in endothelial cell function with serum isoflavone levels|Genetic Profiling|Analysis of serum and urinary eicosanoids|Serum analysis for fatty acid composition|Descriptive analysis of clinical data: Demographics, medical history,|Physical findings, concomitant medications and adverse events|Qualitative analysis of data collected from semi-structured subject interviews|(Compliance/tolerability/side effects)","St. Boniface General Hospital Research Centre|University of Manitoba","All","40 Years to 82 Years   (Adult, Older Adult)","Early Phase 1","26","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Pulse Study","March 2007","January 2008","July 2008","September 19, 2008","null","March 21, 2012","St. Boniface General Hospital, Winnipeg, Manitoba, Canada","","https://ClinicalTrials.gov/show/NCT00755677"
2251,"NCT00753935","Aspirin Resistance in Coronary Artery Disease",,"Completed","Has Results","Coronary Artery Disease","Drug: enteric-coated aspirin|Drug: Chewable aspirin","Change in Serum Thromboxane B2","Vanderbilt University|National Heart, Lung, and Blood Institute (NHLBI)|Vanderbilt University Medical Center","All","40 Years and older   (Adult, Older Adult)","Early Phase 1","92","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","040065|5P50HL081009-03","June 2006","August 2011","March 2014","September 17, 2008","April 19, 2018","April 19, 2018","Vanderbilt University, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00753935"
2252,"NCT00752154","Curcumin in Rheumatoid Arthritis",,"Unknown status","No Results Available","Rheumatoid Arthritis","Drug: Curcumin (Longvida™)","American College of Rheumatology 20%|Inflammatory cell signaling markers|Safety of curcumin","University of California, Los Angeles","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","07-12-051","January 2010","December 2010","January 2011","September 15, 2008","null","July 2, 2010","Swamy Venuturpualli, M.D., 8737 Beverly Blvd., #203, Beverly Hills, CA, California, United States|UCLA, 1000 Veteran Avenue, Rehab Building, 3rd Floor, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT00752154"
2253,"NCT00748683","Development of an Integrated Health Care Environment for Elderly With RFID Technology",,"Completed","No Results Available","Elderly","Other: RFID","Falling rate of participants","National Taiwan University Hospital","All","65 Years and older   (Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","20080816R","September 2008","February 2009","August 2009","September 8, 2008","null","December 15, 2009","Nursing Home, Bei-Hu Branch, National Taiwan University Hospital, Taipei, Taiwan","","https://ClinicalTrials.gov/show/NCT00748683"
2254,"NCT00747630","Evaluating the Efficacy of a Video Based Intervention to Educate Teen Moms About Fetal Alcohol Syndrome (FAS)",,"Terminated","No Results Available","Fetal Alcohol Syndrome|Teen Pregnancy","Other: An educational video about Fetal Alcohol Syndrome","To determine whether an educational video on FAS increases maternal knowledge on the subject and affects their likelihood to drink alcohol.","Texas Tech University Health Sciences Center","Female","12 Years to 16 Years   (Child)","Early Phase 1","99","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","FAS Study","May 2006","January 2010","January 2010","September 5, 2008","null","December 17, 2012","Grand Expectations, Lubbock, Texas, United States","","https://ClinicalTrials.gov/show/NCT00747630"
2255,"NCT00747370","Dynamic MRI of the Behaviour of Female Pelvic Floor",,"Completed","No Results Available","Stress Urinary Incontinence|Genital Prolapse","Procedure: movement of midurethra, bladder neck, cervix and rectum","The movement of midurethra, bladder neck, cervix and rectum measured by dynamic MRI","Kuopio University Hospital|University of Eastern Finland","Female","Child, Adult, Older Adult","Early Phase 1","74","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","KUH5302421","January 2002","December 2007","June 2008","September 5, 2008","null","September 5, 2008","Department of Gynecology and Radiology, Kuopio University Hospital, Kuopio, Finland","","https://ClinicalTrials.gov/show/NCT00747370"
2256,"NCT00743782","Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism",,"Completed","No Results Available","Hypoparathyroidism|Hypocalcemia","Drug: Synthetic Human Parathyroid Hormone 1-34","Assess the feasability of PTH 1-34 therapy via pump.|This pilot study is being conducted to compare PTH therapy via pump vs. twice daily subcutaneous injections.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","7 Years to 70 Years   (Child, Adult, Older Adult)","Early Phase 1","24","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","080203|08-CH-0203","August 22, 2008","April 7, 2014","April 7, 2014","August 29, 2008","null","November 14, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00743782"
2257,"NCT00743353","Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5","K5","Completed","No Results Available","Sarcoma|Melanoma|Lung Cancer|Breast Cancer|High Grade Gliomas","Drug: F-18 RGD-K5","To collect bio-distribution data to calculate dosimetry values in normals and obtain and evaluate PET images in cancer subjects for resolution of [F-18]RGD-K5","Siemens Molecular Imaging","All","Child, Adult, Older Adult","Early Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","K5-100","August 2008","January 2009","January 2009","August 28, 2008","null","February 2, 2009","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00743353"
2258,"NCT00743314","Single-Photon Emission Computed Tomography, Computed Tomography Lymphoscintigraphy, and Intensity-Modulated Radiation Therapy in Treating Patients Who Have Undergone Surgery for Stage I or Stage II Breast Cancer",,"Completed","No Results Available","Breast Cancer|Lymphedema","Other: screening questionnaire administration|Procedure: computed tomography|Procedure: lymphoscintigraphy|Procedure: single photon emission computed tomography|Radiation: intensity-modulated radiation therapy|Radiation: technetium Tc 99m sulfur colloid","Philips Precedence SPECT/CT® and GE PET/CT Fusion software integration|Dosimetry differences between 3-D conformal radiotherapy with vs without the Philips Precedence SPECT/CT®|Lymph node dosimetry differences between single photon emission computed tomography (SPECT) and computed tomography (CT) with 3-D conformal radiotherapy vs intensity-modulated radiotherapy|Association between radiation exposure and limb volume, circumferential wrist measurements, circumferential forearm measurements, and extra-cellular fluid measurements","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Older Adult)","Early Phase 1","30","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Diagnostic","CDR0000611987|P30CA015083|MC0734|07-008292","September 2008","October 2016","October 2016","August 28, 2008","null","October 8, 2018","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT00743314"
2259,"NCT00743041","The Effect of EFT on Psychological States in a Veterans Population",,"Completed","No Results Available","Stress Disorders, Post-Traumatic","Behavioral: Emotional Freedom Techniques (EFT)","Scores on the PCL-M (PTSD Symptom Checklist-Military)","Soul Medicine Institute","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","SMI-PTSD-82508","December 2008","December 2009","May 2010","August 28, 2008","null","April 25, 2018","Soul Medicine Institute, Santa Rosa, California, United States","","https://ClinicalTrials.gov/show/NCT00743041"
2260,"NCT00741013","Quantifying Airway Inflammation With Radiologic Tests",,"Completed","Has Results","Lung Inflammation","Drug: placebo pill and placebo IV|Drug: Lovastatin pill and placebo IV|Drug: placebo pill and recombinant human activated protein C IV|Biological: Endotoxin","Change in Ki (Measure of [18F]Fluorodeoxyglucose ([18F]FDG) Uptake Determined by Patlak Graphical Analysis) in the Right Lung 24 Hours After LPS Instillation|Number of Total Nucleated Cells From Bronchoalveolar Lavage (BAL) Fluid 24 Hours After Endotoxin Instillation","Washington University School of Medicine|Barnes-Jewish Hospital","All","19 Years to 44 Years   (Adult)","Early Phase 1","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","05-1137","March 2007","March 2008","March 2008","August 25, 2008","May 26, 2014","May 26, 2014","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00741013"
2261,"NCT00739544","Chronic Pain After Operation for Breast Cancer",,"Unknown status","No Results Available","Pain Threshold","Other: 1","Reference values on: Cold and cold detection threshold,Paradoxical heat sensation,Thermal sensory limen procedure,Cold and heat pain threshold,Mechanical detection and pain threshold and sensitivity,Vibration detection threshold,Pressure pain threshold","Rigshospitalet, Denmark|Danish Breast Cancer Cooperative Group|Danish Cancer Society","Female","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","RH2101project.1.2008","August 2008","March 2010","March 2010","August 21, 2008","null","August 21, 2008","Department of Breast Surgery, Centre of Head and Orthopaedics, Rigshospitalet (university of Copenhagen), Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT00739544"
2262,"NCT00737399","Anxiety and Depression Levels in Cancer Patients After Self-Application of EFT (Emotional Freedom Techniques)",,"Recruiting","No Results Available","Depression","Behavioral: Lifestyle Counseling with Emotional Freedom Techniques (EFT)","depression|anxiety|pain|insomnia","Soul Medicine Institute","All","18 Years to 89 Years   (Adult, Older Adult)","Early Phase 1","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","SMI-CHOL-82008","September 2008","April 2021","December 2021","August 19, 2008","null","April 25, 2018","Soul Medicine Institute, Santa Rosa, California, United States","","https://ClinicalTrials.gov/show/NCT00737399"
2263,"NCT00734994","Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer",,"Completed","Has Results","Transitional Cell Carcinoma of Bladder|Superficial Bladder Cancer","Device: Hyperthermia System|Drug: Mitomycin C","Safety and Tolerability|Median Recurrence Free-survival","Mark Dewhirst|Duke University","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00003239","April 2008","February 2011","March 2011","August 14, 2008","August 30, 2011","June 29, 2015","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00734994"
2264,"NCT00734773","Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL",,"Withdrawn","No Results Available","Brain and Central Nervous System Tumors|Lymphoma|Neurotoxicity","Biological: Rituximab|Drug: Cytarabine|Drug: Methotrexate|Drug: Motexafin gadolinium|Drug: Procarbazine hydrochloride|Drug: Vincristine sulfate|Radiation: Radiation therapy","Toxicity of motexafin gadolinium (MGd) and rituximab added to high-dose methotrexate, procarbazine hydrochloride, and vincristine (MPV) chemotherapy|Toxicity of MGd added to whole-brain radiotherapy (WBRT)|Tumor-selective uptake of MGd|Overall response rate (complete remission [CR] and partial remission [CR]) to pre-radiation chemo-immunotherapy (R-MPV with MGd)|Complete response rate to pre-radiation chemo-immunotherapy (R-MPV with MGd)|Overall survival at 1 year|Event-free survival at 1 year|Progression-free survival at 1 year|Neurotoxicity of R-MVP + MGd based on pre- and post-treatment neuropsychologic testing","Northwestern University|Pharmacyclics LLC.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 05H7|STU00002443","November 2008","null","null","August 14, 2008","null","May 18, 2012","","","https://ClinicalTrials.gov/show/NCT00734773"
2265,"NCT00734279","Follicle-Stimulating Hormone (FSH) and the Onset of Puberty",,"Completed","No Results Available","Delayed Puberty|Precocious Puberty","Drug: Leuprolide Acetate - Early Puberty Leuprolide Visit|Drug: Ganirelix - Early Puberty Ganirelix Visit|Drug: Ganirelix - Delayed Puberty Ganirelix Visit|Drug: Leuprolide Acetate- Delayed Puberty Leuprolide Visit","Determine the ability of the GnRH antagonist, ganirelix, to suppress nocturnal gonadotropin secretion in peripubertal boys and girls","University of Utah|University of Michigan|University of Chicago","All","6 Years to 17 Years   (Child)","Early Phase 1","11","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","05-3125|5M01RR000064","March 2006","November 2010","December 2010","August 14, 2008","null","December 26, 2017","Utah Diabetes Center, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00734279"
2266,"NCT00730340","Closure Method Study Following Tonsillectomy in Children",,"Completed","No Results Available","Tonsillectomy|Children","Procedure: Closure of the Tonsillar Fossa|Procedure: Tonsillectomy with open fossa","Decreased morbidity in children with closure of the tonsillar fossae compared with tonsillectomy without closure|The patients will also be examined in the clinic postoperatively to determine if the fossae remained closed or dehisced.","University of Oklahoma","All","5 Years to 10 Years   (Child)","Early Phase 1","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Tonsillar Closure_Berryhill","August 2008","June 2010","June 2010","August 8, 2008","null","June 15, 2010","University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States","","https://ClinicalTrials.gov/show/NCT00730340"
2267,"NCT00729625","Air Muscle and Task Practice in Upper Limb Stroke Rehab",,"Completed","No Results Available","Stroke","Device: robotic device","Wolf Motor Function Test","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","24","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","R21HD045514|7R21HD045514-03","April 2005","March 2007","March 2007","August 7, 2008","null","May 23, 2016","","","https://ClinicalTrials.gov/show/NCT00729625"
2268,"NCT00727948","The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy",,"Unknown status","No Results Available","Breast Cancer|Angiogenesis","Drug: Aspirin","Changes in pro-angiogenic and anti-angiogenic protein levels.","University of Vermont","Female","18 Years to 95 Years   (Adult, Older Adult)","Early Phase 1","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","V0801","July 2008","December 2010","December 2011","August 4, 2008","null","April 22, 2011","University of Vermont, Burlington, Vermont, United States","","https://ClinicalTrials.gov/show/NCT00727948"
2269,"NCT00726947","Ultrasound Elasticity Imaging of Venous Thrombi",,"Completed","No Results Available","Thrombosis","Procedure: Ultrasound","To determine if ultrasound imaging will aid in the diagnosis and classification of venous blood clots|Follow-up with subjects who have been diagnosed with Acute DVT to see if they develop post-thrombotic syndrome (PTS)","University of Michigan|National Institutes of Health (NIH)","All","Child, Adult, Older Adult","Early Phase 1","254","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HUM 0040239|NIH ROI HL 78656-01A1","December 2002","May 2010","June 2011","August 1, 2008","null","May 24, 2016","University of Michigan Health System, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT00726947"
2270,"NCT00725946","Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT",,"Terminated","No Results Available","Breast Cancer|Breast Cancer Early Stage Breast Cancer (Stage 1-3)|Breast Cancer Metastatic Breast Cancer","Drug: Iodine-124|Radiation: PET/CT with Iodine-124","Radioiodide accumulation|Dosimetry","Stanford University","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","BRS0001|98583|SU-03142008-1044|IRB-11927","February 2008","December 2012","December 2012","July 31, 2008","null","October 11, 2017","Stanford University School of Medicine, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT00725946"
2271,"NCT00723541","Breast Lesion Analysis for Tomosynthesis Mammography",,"Recruiting","No Results Available","Breast Cancer|Abnormal Findings on Radiological Examination of Breast","Procedure: Computer aided analysis of breast lesions","Achieve earlier breast cancer detection and characterization","University of Michigan|National Institutes of Health (NIH)","Female","21 Years and older   (Adult, Older Adult)","Early Phase 1","800","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HUM 00003483|NIH","January 2008","December 2020","December 2020","July 28, 2008","null","January 11, 2018","University of Michigan Health System, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT00723541"
2272,"NCT00723463","Determine if Apparent Diffusion Coefficient (ADC) Values Can Differentiate Tumors From Normal Tissue",,"Completed","No Results Available","Brain Cancer|Neck Cancer","Procedure: 3T MRI scan","To determine if ADC values determined at 3T are different between normal tissues and tumors arising from the extracranial head and neck.","University of Michigan|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","200","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HUM 5527","June 2006","June 2016","July 2016","July 28, 2008","null","November 2, 2016","University of Michigan Health System, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT00723463"
2273,"NCT00722163","A Randomized Controlled Trial of Individual Therapy for First Episode Psychosis","PSTEP","Unknown status","No Results Available","Psychosis","Other: Cognitive Behavioural Therapy|Other: befriending","Social Functioning|Positive & negative symptoms|Individual dimensions of psychotic symptoms|Depression|Substance use|Alcohol and Drug Use|Medication adherenceAdaptation to illness|Self Esteem|Coping Skills (MACS)","Ontario Mental Health Foundation|Schizophrenia Society of Ontario","All","16 Years to 35 Years   (Child, Adult)","Early Phase 1","330","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)","195/2006","September 2007","May 2009","March 2013","July 25, 2008","null","July 25, 2008","Centre for Addiction and Mental Health, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00722163"
2274,"NCT00722059","Detection and/or Evaluation of Dense Breast Abnormalities Using Tomosynthesis and Digital Mammography",,"Completed","No Results Available","Breast Neoplasms|Breast Abnormalities","Procedure: Breast Tomosynthesis","Measure of digital tomosynthesis and digital mammography test performance.","University of Michigan","Female","30 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HUM 13236","April 2006","October 2013","October 2013","July 25, 2008","null","February 3, 2014","University of Michigan Health System, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT00722059"
2275,"NCT00721643","Absorption Kinetics of Polyphenols in Angel's Plant (Angelica Keiskei)",,"Completed","No Results Available","Oxidative Stress","Dietary Supplement: angel's plant (Angelica keiskei)|Dietary Supplement: Angel's plant (Angelica keiskei)","Plasma quercetin","Tufts University","All","60 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HNRCA2580|BioGreen 20070301034009","July 2008","March 2009","December 2010","July 24, 2008","null","April 25, 2017","Jean Mayer USDA-Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00721643"
2276,"NCT00720577","Study to Evaluate the Effect of Simvastatin, Losartan and Pioglitazone on Patients With Peripheral Arterial Disease.","LEAP","Completed","No Results Available","Peripheral Arterial Disease","Drug: Simvastatin|Drug: Losartan|Drug: Pioglitazone","Evaluate RNA expression profiles, protein and lipid biomarkers, and gene expression profiling on pts receiving simvastatin, losartan or pioglitazone.|Evaluate plaque characteristics in 3 patient subsets and Left and Right extremity comparisons.","ev3|FoxHollow Technologies|Merck Sharp & Dohme Corp.","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","164","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","FHT-P-05-005","December 2005","July 2007","August 2007","July 23, 2008","null","July 23, 2008","","","https://ClinicalTrials.gov/show/NCT00720577"
2277,"NCT00720239","Taliderm Dressing for Venous Ulcers",,"Completed","No Results Available","Venous Stasis Ulcers|Venous Insufficiency","Other: Taliderm wound healing dressing","wound healing","Medical University of South Carolina","All","45 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","86606","February 2008","September 2009","August 2010","July 22, 2008","null","February 22, 2013","Roper St. Francis Hospitals, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT00720239"
2278,"NCT00719602","Differences in Malaria Infection Levels in HIV-infected Infants and Children Receiving PI- and NNRTI-based HAART",,"Completed","No Results Available","HIV Infections|Malaria","Drug: Lamivudine|Drug: Lopinavir/Ritonavir|Drug: Nevirapine|Drug: Zidovudine","Parasitemia in blood samples|Time of initiation of treatment for clinical malaria requiring conventional anti-malarial therapy|Severity of malarial disease|Measured anti-malaria IgG, protein in plasma, and mRNA transcripts in PBMC of chemokines|IL4-589C/T genotypes","International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Months to 35 Months   (Child)","Early Phase 1","105","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","IMPAACT P1068s|U01AI068632","August 2009","August 2013","August 2013","July 21, 2008","null","September 19, 2016","University of North Carolina Lilongwe (12001), Lilongwe, Malawi|Makerere University - JHU Research Collaboration (30293), Kampala, Uganda|George Clinic CRS (30273), Lusaka, Zambia","","https://ClinicalTrials.gov/show/NCT00719602"
2279,"NCT00718770","A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression",,"Completed","Has Results","Thyroid Cancer","Drug: Bexarotene","Change in Tumor Size","University of Colorado, Denver|American Cancer Society, Inc.|Eisai Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-0727.cc","November 2008","January 2013","February 2013","July 21, 2008","January 17, 2014","January 17, 2014","University of Colorado Cancer Center, Aurora, Colorado, United States","","https://ClinicalTrials.gov/show/NCT00718770"
2280,"NCT00714194","Effect of Daily Interruption of Continuous Sedation on Delirium, Sleep Perception in Intensive Care Unit (ICU) Patients","ICUDelirium","Completed","No Results Available","Delirium|Sleep Perception","Procedure: Normal continuous sedation|Other: Daily interruption of continuous sedation","Delirium and sleep","University of California, San Francisco","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","52","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H41297-32404-01","July 2008","September 2009","September 2009","July 14, 2008","null","May 8, 2015","Trauma Unit University of Puerto Rico Medical Center, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00714194"
2281,"NCT00713921","Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients",,"Withdrawn","No Results Available","Urinary Incontinence|Bladder Dysfunction","Drug: Fesoterodine Oral Product","Develop and quantify methods for evaluating bladder dysfunction in diabetes and stroke. Develop pilot data of medical therapy (Toviaz) in diabetic and stroke bladder dysfunction.","Saint Thomas Health|Pfizer","Female","21 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","051008","September 15, 2009","January 17, 2014","January 17, 2014","July 14, 2008","null","September 11, 2018","Vanderbilt Univiersity, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00713921"
2282,"NCT00708357","Does eNOS Gene Polymorphism Play a Role in the Maintenance of Basal Vascular Tone in the Choroid or Optic Nerve Head?",,"Terminated","No Results Available","Ocular Physiology|Regional Blood Flow","Drug: NG-monomethyl-L-arginine","Genotyping","Medical University of Vienna","Male","19 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","OPHT-311004","May 2005","December 2009","January 2013","July 2, 2008","null","November 17, 2014","Department of Clinical Pharmacology, Vienna, Austria","","https://ClinicalTrials.gov/show/NCT00708357"
2283,"NCT00704691","Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas",,"Terminated","No Results Available","Peripheral T-cell Lymphomas|Adult T-cell Leukemia|Adult T-cell Lymphoma|Peripheral T-cell Lymphoma Unspecified|Angioimmunoblastic T-cell Lymphoma|Anaplastic Large Cell Lymphoma|T/Null Cell Systemic Type|Cutaneous t-Cell Lymphoma With Nodal/Visceral Disease","Drug: Lenalidomide","Response Rate to lenalidomide (CR,PR and unconfirmed complete responses|Toxicity of lenalidomide","University of Alabama at Birmingham","All","19 Years and older   (Adult, Older Adult)","Early Phase 1","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F071108004|UAB 0663","June 2008","July 2009","December 2009","June 25, 2008","null","April 20, 2012","University of Alabama at Birmingham, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT00704691"
2284,"NCT00702130","Pravastatin and Ventilatory Associated Pneumonia","EPRAVAP","Completed","No Results Available","Ventilator Associated Pneumonia","Drug: Pravastatin","Length of hospitalization in the Intensive Care Unit, morbidity in the Intensive Care Unit|Severity of Ventilator Associated Pneumonia","University of Thessaly","All","14 Years and older   (Child, Adult, Older Adult)","Early Phase 1","152","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","310UT","June 2008","April 2010","April 2010","June 20, 2008","null","November 30, 2011","General Hospital Larissa, Larissa, Thessalia, Greece|Zakynthinos E. Dir-University Hospital Larisa, Mezourlo / Larissa, Greece","","https://ClinicalTrials.gov/show/NCT00702130"
2285,"NCT00700791","Efficacy of Natural Vitamin E Tocotrienol on the Treatment of Surgical Scars",,"Active, not recruiting","No Results Available","Scar","Dietary Supplement: Natural Vitamin E Tocotrienol supplement (TCT)|Device: Natural Vitamin E Tocotrienol Cream (TCT)|Other: Placebo|Other: Placebo Cream","1.To determine the efficacy of TCT in improving the appearance of post-surgical scars following oral supplementation 2.To determine the efficacy of TCT in improving the appearance of post-surgical scars following topical application","Chandan K Sen|Ohio State University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","168","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","2008H0001","July 2008","December 2018","December 2019","June 19, 2008","null","January 29, 2018","OSU Plastic Surgery - Knightsbridge, Columbus, Ohio, United States|The Ohio State University, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00700791"
2286,"NCT00696176","STAT3 DECOY in Head and Neck Cancer",,"Completed","No Results Available","Head and Neck Cancer","Drug: STAT 3 DECOY","Evaluate the safety of a single injection.|Evaluate the biological activity by observing the consequences of STAT3 decoy administration on STAT3 activation and target gene expression in the tumor.","University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","07-022","August 2008","August 2011","August 2011","June 12, 2008","null","July 23, 2015","University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00696176"
2287,"NCT00693758","Assessment of Oxygen Changes in the Heart With Cardio-vascular Magnetic Resonance Imaging",,"Completed","No Results Available","Vascular Diseases|Myocardial Ischemia","Drug: adenosine|Other: modified end-tidal forcing system|Other: arm cuff occlusion|Device: Breathing gas|Device: Blood pressure cuff","BOLD-MRI signal intensity changes|Flow changes","University of Calgary","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18798","January 2006","September 2011","September 2011","June 9, 2008","null","October 4, 2011","Stephenson CMR Centre at Foothills Medical Centre, University of Calgary, Calgary, Alberta, Canada","","https://ClinicalTrials.gov/show/NCT00693758"
2288,"NCT00689416","Effects of Crestor on Inflammation of Atherosclerotic Plaques",,"Completed","No Results Available","Atherosclerosis|Inflammatory Activity in Carotid Arteries","Drug: rosuvastatin|Drug: placebo","Comparison between the active and the placebo group regarding changes in MRI contrast enhancement in terms of the transfer constant (Ktrans) for the carotid region|Comparison between the active and the placebo group regarding changes in MRI contrast enhancement measured as fractional plasma volume (Vp) and changes in 18FDG uptake in terms of standardised uptake value (SUV), respectively|Change in carotid MRI contrast enhancement in terms of Ktrans and Vp.|Change in 18FDG uptake in terms of SUV.","AstraZeneca","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","74","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","D4411M00010","December 2007","null","June 2009","June 3, 2008","null","June 30, 2009","Research Site, Uppsala, Sweden","","https://ClinicalTrials.gov/show/NCT00689416"
2289,"NCT00689208","Pharmacological Intervention in Insulin Resistance Targeting Autonomic Nerve Activity",,"Completed","No Results Available","Insulin Resistance","Drug: Atropine|Drug: Physostigmine|Drug: Placebo Sodium","Study the effect of anticholinergic drugs on insulin sensitivity by assessment of glucose infusion rate during hyperinsulinemic euglycemic clamp.|Study the effect of cholinergic stimulation on insulin sensitivity by assessment ofglucose infusion rate during hyperinsulinemic euglycemic clamp.|Study the possible difference in effect of cholinergic (physostigmine) andanticholinergic (atropine) drugs on insulin sensitivity in a lean and abdominal obese subgroup of subjects.","AstraZeneca","All","18 Years to 60 Years   (Adult)","Early Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","D4411M00007","May 2007","October 2008","November 2008","June 3, 2008","null","March 13, 2009","Research Site, Göteborg, Sweden","","https://ClinicalTrials.gov/show/NCT00689208"
2290,"NCT00688961","Effects of Omacor and Aspirin on Platelet Function",,"Completed","No Results Available","Healthy","Drug: Aspirin|Drug: omega-3 acid ethyl esters","Whole blood aggregometry in response to 4 agonists","Sanford Research","All","21 Years to 60 Years   (Adult)","Early Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WSH-001","June 2007","August 2007","August 2007","June 3, 2008","null","June 3, 2008","Sanford Research/USD, Sioux Falls, South Dakota, United States","","https://ClinicalTrials.gov/show/NCT00688961"
2291,"NCT00685555","Healthy Futures Project: A Community Based Obesity Prevention Program","SWITCH","Completed","No Results Available","Overweight|Obesity","Behavioral: Switch active lifestyles brought to you by MediaWise|Behavioral: Switch active lifestyles from MediaWise","Our outcome measure was reduction of screen time|Our secondary outcome measure increase in fruit and vegetable consumption.","National Institute on Media and the Family|Fairview Health Services|Medica|Healthy and Active America Foundation,|Cargill|Spunk Design Machine|Iowa State University|Michigan State University|University of Minnesota - Clinical and Translational Science Institute","All","8 Years to 13 Years   (Child)","Early Phase 1","1300","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NIMF-1300-05","October 2005","December 2006","December 2006","May 28, 2008","null","June 23, 2011","National Institute on Media and the Family, Minneapolis, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT00685555"
2292,"NCT00678834","Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol",,"Completed","Has Results","End Stage Cardiac Failure|Pulmonary Failure|End Stage Liver Disease|Morbid Obesity|Recalcitrant Epilepsy Requiring Surgery|Healthy Subjects","Dietary Supplement: To surgery patients, Tocopherol capsules.|Dietary Supplement: Tocotrienol to healthy subjects.|Dietary Supplement: To surgery patients, Tocotrienol capsules.","The Levels of TCT in the Tissues of ""Non-healthy"" Subjects and in the Tissue of ""Healthy"" Subjects Following Oral Supplementation (200 mg x 2 Per Day for 4-24 Weeks)","Chandan K Sen|Carotech Inc.|Ohio State University","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)","2005C0034","March 2006","June 2012","June 2012","May 16, 2008","September 16, 2014","September 16, 2014","The Ohio State University, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00678834"
2293,"NCT00677911","Immunologic Response to Negative Cognition in Persons With Chronic Pain",,"Completed","No Results Available","Chronic Pain","Behavioral: In-vivo pain catastrophizing induction","Interleukin-6","Oregon Health and Science University|American Pain Society","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","47","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment","OCTRI975","February 2007","December 2007","December 2007","May 15, 2008","null","May 15, 2008","OCTRI; OHSU Mail Code: CHH 13th floor 3303 Bond St., Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT00677911"
2294,"NCT00673283","Early Detection of Lung Cancer Via Bi-plane Correlation Chest Imaging",,"Completed","No Results Available","Lung Cancer|Metastatic Cancer in the Lungs","Device: bi-plane chest radiography","The technique is effective in diagnosing early lung tumors.|The relative performance of BCI with respect to chest radiography and CT for lung cancer detection.","Duke University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","86","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Pro00008644|2485-07-6R6","April 2007","November 2008","November 2008","May 7, 2008","null","August 1, 2014","Duke University Medcal Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00673283"
2295,"NCT00667771","The Effect of Naltrexone on Alcohol Craving and on Brain Activity During Alcohol Infusion",,"Completed","No Results Available","Alcohol Dependence|Alcoholism","Drug: Naltrexone","BOLD response during the ethanol infusion challenge|Self-reported AUQ, PACS, OCDS, POMS and cue-induced craving during the CR session","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","21 Years to 50 Years   (Adult)","Early Phase 1","70","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","080125|08-AA-0125","April 22, 2008","December 27, 2010","April 4, 2011","April 28, 2008","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00667771"
2296,"NCT00663910","Topical Aminolevulinic Acid in Patients With Nonmelanoma Skin Cancer",,"Terminated","No Results Available","Non-melanomatous Skin Cancer","Drug: Aminolevulinic Acid|Procedure: biopsy|Procedure: diagnostic imaging technique|Procedure: therapeutic conventional surgery","Maximum depth of protoporphyrin IX (PpIX) fluorescence within different types of nonmelanoma skin cancers after topical aminolevulinic acid (ALA) administration|In vivo measurements of ALA-induced PpIX formation within different zones of the tumors as measured by fluorescence detection methods|Correlation of the level of PpIX fluorescence detected by non-invasive optical measurements with morphological characteristics of the tumors|Establishment of a skin cancer tissue bank","The Cleveland Clinic|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Older Adult)","Early Phase 1","18","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CASE-9Z07-CC417|P30CA043703|P01CA084203|CC417","March 2008","October 2009","October 2009","April 22, 2008","null","January 2, 2017","","","https://ClinicalTrials.gov/show/NCT00663910"
2297,"NCT00663078","Group Cognitive Behavioral Therapy (CBT) Intervention for Women With Mild to Moderate Depression","BackonTrack","Completed","No Results Available","Depression|Anxiety","Behavioral: Brief CBT Group therapy","PHQ-9 Score","University of Bristol","Female","30 Years to 54 Years   (Adult)","Early Phase 1","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07/H0107/60","August 2007","March 2009","March 2009","April 22, 2008","null","January 14, 2010","Merrywood GP Practice Knowle West,, Bristol, United Kingdom|Wellspring Healthy Living Centre, Bristol, United Kingdom","","https://ClinicalTrials.gov/show/NCT00663078"
2298,"NCT00662389","Application of the Apsara Thermal Wand System",,"Completed","Has Results","Tightening of Skin Laxity","Device: Apsara Thermal Wand System","Serious Adverse Events","Apsara Medical Corporation","All","40 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","4","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NEIRB08-090","April 2008","March 2009","March 2009","April 21, 2008","August 28, 2009","August 28, 2009","Bryant A. Toth, MD, FACS, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT00662389"
2299,"NCT00662233","Combination Chemotherapy in Treating Patients With Sarcoma",,"Completed","No Results Available","Ovarian Cancer|Sarcoma","Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: vincristine sulfate|Procedure: adjuvant therapy|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery|Radiation: brachytherapy|Radiation: intraoperative radiation therapy|Radiation: radiation therapy","Efficacy in terms of long-term disease-free survival|Clinical response of the tumors|Pathologic response of the tumors|Long term disease-free survival","Mayo Clinic|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Early Phase 1","28","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Treatment","CDR0000582271|P30CA015083|919110|542-91|0791","October 1991","October 21, 2013","October 21, 2013","April 21, 2008","null","October 8, 2018","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT00662233"
2300,"NCT00657280","Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure","S-001","Completed","Has Results","Heart Failure, Congestive","Drug: Sitagliptin","Determine the Effects of Sitagliptin on Myocardial Glucose Uptake Measured by Myocardial PET Scan|Determine the Effects of Sitagliptin on Myocardial Glucose Uptake in Patients With Nonischemic Cardiomyopathy|Determine the Effects of Sitagliptin on Microvascular Function in Patients With Nonischemic Cardiomyopathy","Stanford University|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SU-04082008-1088","April 2008","February 2011","February 2012","April 14, 2008","December 5, 2014","December 5, 2014","Stanford University School of Medicine, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT00657280"
2301,"NCT00657202","Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1",,"Completed","No Results Available","Neurofibromatosis Type 1|Cutaneous Neurofibromas","Drug: Ranibizumab","Determine the effect of inhibiting VEGF signaling on tumor volume and tumor interstitial fluid pressure by local injection of ranibizumab into cutaneous neurofibromas.|To identify angiogenic molecules upregulated in neurofibromas treated with ranibizumab.","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-332","March 2008","October 2009","December 2013","April 14, 2008","null","July 7, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00657202"
2302,"NCT00656552","Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation",,"Unknown status","No Results Available","Premature Ejaculation","Drug: Escitalopram","change in geometric mean IELT from baseline to four weeks.|changes in the intercourse satisfaction domain values of IIEF(Arabic version). Assessment of possible side effects","Cairo University","Male","20 Years to 59 Years   (Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EPE100","May 2008","December 2008","null","April 11, 2008","null","April 11, 2008","Kasr el ainy school of medicine , Cairo university, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT00656552"
2303,"NCT00655070","Effect of Timi3 Ultrasound on Myocardial Blow Flow in the Hibernating Myocardium",,"Terminated","No Results Available","Myocardial Ischemia","Device: Timi3 Transthoracic ultrasound","Change in myocardial blood flow from baseline to post ultrasound treatment","University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","H1644-31803-02","April 2008","April 2010","December 2010","April 9, 2008","null","April 4, 2012","UC San Francisco, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT00655070"
2304,"NCT00653471","Micro-stream Capnography in Non-intubated Lean and Obese Patients With and Without Obstructive Sleep Apnea",,"Completed","No Results Available","Obesity|Obstructive Sleep Apnea","Device: Microcapmicro-stream device with Smart CapnoLine Plus|Device: Microcap micro-stream device with CapnoLine|Device: TG-920 main-stream device (Nihon Kohden, Tokyo, Japan).","Difference in endtidal PCO2 and PaCO2","The Cleveland Clinic","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)","Capnography","June 2006","August 2008","September 2008","April 7, 2008","null","July 20, 2016","University of Louisville, Louisville, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT00653471"
2305,"NCT00651976","Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery",,"Terminated","No Results Available","Breast Cancer","Drug: letrozole|Other: Blood Collection|Procedure: biopsy/lumpectomy/mastectomy","Ki67 index measured in hormone receptor-positive breast cancers compared to those that are hormone receptor-negative|In situ apoptotic effect of letrozole|Identification of a recurrence risk biomarker profile using RNA microarray","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","213","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VICC BRE 0776|P50CA098131|P30CA068485|VU-VICC-BRE-0776|VU-VICC-IRB-080064","March 2008","September 2018","September 2018","April 3, 2008","null","October 15, 2018","Emory University, Atlanta, Georgia, United States|Surgical Associates, Inc., Tulsa, Oklahoma, United States|Allegheny Cancer Center, Pittsburgh, Pennsylvania, United States|Vanderbilt-Ingram Cancer Center, One Hundred Oaks, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00651976"
2306,"NCT00650988","Cryotherapy for Barrett's Esophagus and Early Esophageal Cancers",,"Completed","No Results Available","Barretts Esophagus|Esophageal Cancer","Procedure: Cryospray Ablation","Number of patients that achieved successful ablation of dysplasia and neoplasia Barrett's Esophagus.|Number of patients that experience toxicity with cryotherapy|Assess the degree of tumor ablation of inoperable early esophageal cancer","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","37","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE5205|Cleveland Clinic IRB 8270","September 2005","May 2008","December 2008","April 2, 2008","null","December 24, 2012","The Cleveland Clinic, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00650988"
2307,"NCT00649324","Fasting Study of Hydrochlorothiazide Tablets 50 mg to Hydrochlorothiazide Tablets 50 mg",,"Completed","No Results Available","Healthy","Drug: Hydrochlorothiazide Tablets 50 mg|Drug: Hydrochlorothiazide Tablets (50 mg","Bioequivalence","Mylan Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","HCTZ-0588","October 2005","October 2005","October 2005","April 1, 2008","null","April 1, 2008","PRACS Institute, Ltd., Fargo, North Dakota, United States","","https://ClinicalTrials.gov/show/NCT00649324"
2308,"NCT00648193","Fasting Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg",,"Completed","No Results Available","Healthy","Drug: Paroxetine hydrochloride 40 mg tablet|Drug: Paxil® 40 mg Table","Bioequivalence","Mylan Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","PARO-0678","December 2006","December 2006","January 2007","April 1, 2008","null","April 1, 2008","Gateway Medical Research, Inc., St. Charles, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00648193"
2309,"NCT00645489","A Family Intervention for Improving Self-Care of Patients With Heart Failure",,"Completed","No Results Available","Heart Failure, Congestive","Behavioral: psychoeducational|Other: wait list","dietary sodium intake|medication adherence","US Department of Veterans Affairs|VA Office of Research and Development","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","40","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","MIRECC002|01008|0008","March 2008","March 2009","December 2009","March 27, 2008","null","January 6, 2010","VA Medical Center, Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00645489"
2310,"NCT00644137","GABA (Gamma Amino Butyric Acid) Medication for Tobacco",,"Completed","No Results Available","Nicotine Dependence","Drug: pregabalin|Other: cigarettes","We believe this medication will help people to stop smoking","Yale University|National Institute on Drug Abuse (NIDA)|US Department of Veterans Affairs","All","18 Years to 55 Years   (Adult)","Early Phase 1","24","Other|NIH|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","R01DA020752|Yale 0701002184|VA 0023|DPMC","August 2007","February 2010","February 2010","March 26, 2008","null","July 8, 2015","Yale University, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT00644137"
2311,"NCT00643526","A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector",,"Completed","No Results Available","Rheumatoid Arthritis|Psoriatic Arthritis|Ankylosing Spondylitis|Psoriasis","Device: Pre-filled Auto-injector Containing Placebo","To establish that the autoinjector, as designed, meets defined user needs and intended use for self administration by patients with RA, PsA, AS, and psoriasis|•To establish that the specific training, including the instructional video and the Instructions for Use, are appropriate, easy to understand, and able to be followed and implemented by patients with RA, PsA, AS, and psoriasis.","Centocor, Inc.|Quintiles, Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","68","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR014914","December 2007","January 2008","January 2008","March 26, 2008","null","April 10, 2015","Miami, Florida, United States|Duncansville, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00643526"
2312,"NCT00642343","Balance in Children With Cochlear Implants",,"Completed","No Results Available","Severe, Profound Deafness","Behavioral: Evaluation of motor proficiency skills.|Behavioral: Evaluation of motor proficiency|Behavioral: Evaluation of motor proficiency.","The specific aim will be to compare the balance of children with cochlear implants to profoundly deaf children using the BOT2.|To evaluate the differences in balance function between children with bilateral cochlear implants compared to children with unilateral cochlear using implants the BOT2.","University of Oklahoma|American Academy of Otolaryngology-Head and Neck Surgery Foundation","All","4 Years to 18 Years   (Child, Adult)","Early Phase 1","66","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BALANCE W/COCHLEAR_BERRYHILL","March 2008","June 2010","June 2010","March 25, 2008","null","June 15, 2010","University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States","","https://ClinicalTrials.gov/show/NCT00642343"
2313,"NCT00640861","Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer",,"Completed","No Results Available","Breast Cancer","Biological: CpG oligodeoxynucleotide|Biological: HER-2/neu peptide vaccine|Biological: MUC-1 peptide vaccine|Biological: incomplete Freund's adjuvant|Biological: sargramostim|Other: immunoenzyme technique|Other: immunologic technique","Percentage of CD4+ T cells, CD8+ T cells, B cells, monocytes, and dendritic cells in a patient's peripheral blood sample as estimated by flow cytometry with a panel of monoclonal antibodies|Frequency of peptide-specific IFN-gamma producing T cells and peptide-specific IL-5 producing T cells estimated by ELISPOT after in vitro stimulation with peptide-sensitized stimulator cells for MUC1 and HER-2 peptides|Number and severity of hematologic and non-hematologic toxicities reported using the NCI-CTC version 3.0 criteria|Disease-free survival, defined as the time from registration to the documentation of a first failure where a failure is the recurrence of breast cancer or a diagnosis of a second primary cancer|Overall survival, defined as the time from registration to death due to any cause","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Older Adult)","Early Phase 1","45","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000589446|P30CA015083|MC0338|NCI-2009-01342|782-05","August 28, 2008","April 21, 2015","April 21, 2015","March 21, 2008","null","October 31, 2018","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT00640861"
2314,"NCT00640003","Baclofen Treatment of Ataxia Telangiectasia",,"Completed","No Results Available","Ataxia Telangiectasia","Drug: Baclofen|Drug: Placebo","Improvement in the decay constant for velocity storage as assessed by quantitative video examination of eye movement during and after rotation.|Other outcome measures include quantitative measurement of tremor, postural stability and a standard neurologic examination.","Johns Hopkins University","All","12 Years and older   (Child, Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NA_00002180","April 2007","February 2011","February 2011","March 20, 2008","null","December 20, 2017","Johns Hopkins Hospital, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00640003"
2315,"NCT00637299","Osteopathy in Chronic Obstructive Pulmonary Disease (COPD) Rehabilitation Trial",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease","Other: Active osteopathic treatment (OMT+PR): Active Comparator|Other: sham osteopathic treatment (SOT+PR)","Walking Ability|Lung Function Test","Fondazione Salvatore Maugeri","All","45 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","01/2008","January 2008","July 2008","November 2008","March 17, 2008","April 20, 2009","October 24, 2011","Fondazione Salvatore Maugeri, Montescano, Pavia, Italy","","https://ClinicalTrials.gov/show/NCT00637299"
2316,"NCT00636493","Fluocinolone Acetonide Implant for Retinal Vein Occlusion (RVO)",,"Completed","No Results Available","Retinal Vein Occlusion","Device: fluocinolone acetonide (Retisert Implant)","Change from baseline in visual acuity using Early Treatment Diabetic Retinopathy Study (ETDRS) charts|Amount of macular edema on optical coherence tomography and color photos|Elevations in Intraocular Pressure (IOP) requiring anti-glaucoma medication or increase in number of medications required or need for drainage surgery to maintain IOP within clinically satisfactory levels.|Quality of life scores using the Visual Functioning (VF)-25 and SF-36 surveys|Ocular adverse events (vitreous hemorrhage, retinal detachment, cataract, endophthalmitis, drug toxicity)","Glenn Jaffe|Bausch & Lomb Incorporated|Duke University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00010864 (3964)","October 2002","May 2009","May 2009","March 14, 2008","null","December 12, 2012","Duke University Eye Center, Durham,, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00636493"
2317,"NCT00627185","Dental Tobacco Control.Net:Improving Practice","DTC","Completed","No Results Available","Tobacco Use Disorder","Behavioral: Internet-delivered continuing professional development|Other: No intervention arm","Our primary outcome measures are patient-reported provider delivered tobacco screening and tobacco cessation advice.|Point prevalence smoking cessation","University of Alabama at Birmingham","All","19 Years and older   (Adult, Older Adult)","Early Phase 1","190","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","X030814016|R01DA017971","September 2003","June 2008","August 2008","February 29, 2008","null","March 9, 2015","University of Alabama at Birmingham, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT00627185"
2318,"NCT00626171","Role of Cigarette Smoking in Regulating Allergen-induced Early and Late Responses in Mild Asthmatics",,"Completed","No Results Available","Asthma","Procedure: Allergen Challenge","To measure the number of inflammatory cells in induced sputum following allergen challenge in smoking and non-smoking asthmatic subjects.","Hamilton Health Sciences Corporation|McMaster University","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","25","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","ZMsmsp","August 2008","July 2009","July 2009","February 29, 2008","null","April 24, 2013","McMaster University, Hamilton, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00626171"
2319,"NCT00625989","The Effect of Allergen Inhalation on Sputum Myeloid and Plasmacytoid Dendritic Cells in Mild Atopic Asthmatics",,"Completed","Has Results","Asthma","Drug: Aeroallergen","The Primary Outcome Measure for This Study is the Number of Sputum Myeloid Dendritic Cells|The Primary Outcome Measure for This Study is the Number of Sputum Plasmacytoid Dendritic Cells|The Secondary Outcome Measure is the Level of Specific Chemokines Released in the Sputum Supernatant.|The Secondary Outcome Measure is the Level of Specific Chemokines Released in the Sputum Supernatant","Hamilton Health Sciences Corporation|McMaster University","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","sputdend08|BDUA2008","February 2008","November 2008","December 2008","February 29, 2008","May 15, 2015","May 21, 2018","McMaster University, Hamilton, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00625989"
2320,"NCT00625131","Nicotine Patch Pretreatment for Smoking Cessation in PTSD",,"Completed","Has Results","Stress Disorders, Posttraumatic|Tobacco Use Disorder","Drug: Nicotine|Behavioral: Cognitive Behavioral Therapy for Smoking Cessation|Drug: Bupropion Sustained Release (SR)|Drug: Placebo patch","Smoking Abstinence, Self-reported|Carbon Monoxide Monitoring|Smoking Craving","US Department of Veterans Affairs|VA Office of Research and Development","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","87","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NEUA-007-07F","May 2008","March 2013","March 2013","February 28, 2008","November 20, 2014","November 20, 2014","VA Medical Center, Durham, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00625131"
2321,"NCT00624247","Early Versus Delayed Routine HIV Testing in Connecticut Jails","SWAB","Completed","No Results Available","HIV Infections","Other: routine HIV testing","The proportion of individuals in each testing group who are orally swabbed and consented to rapid HIV testing.","Yale University|National Institute on Drug Abuse (NIDA)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","621","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","0705002664","August 2007","April 2008","April 2008","February 27, 2008","null","October 17, 2014","New Haven Community Correctional Center, New Haven, Connecticut, United States|York Correctional Institution, Niantic, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT00624247"
2322,"NCT00620243","Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer.",,"Completed","No Results Available","Ovarian Cancer","Procedure: 1: FDG PET","Partial metabolic response (PMR) - A reduction of a minimum of 15-25% in tumour 18FDG SUV after one cycle of chemotherapy, and greater than 25% after more than one treatment cycle.|Complete metabolic response (CMR) - Complete resolution of 18FDG uptake within the tumour volume so that it was indistinguishable from surrounding normal tissue.|Progressive metabolic disease- increase in 18FDG tumour SUV of greater than 25% within tumour region defined on the baseline scan, visible increase in the extent of 18FDG tumour uptake (>20% in the longest dimension).|Stable metabolic disease (SMD) -An increase in tumour 18FDG SUV of less than 25% or a decrease of less than 15% and no visible increase in extent of 18FDG uptake in tumor (>20% in the longest dimension).","Memorial Sloan Kettering Cancer Center","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","04-064","June 2004","November 2008","November 2008","February 21, 2008","null","January 9, 2012","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00620243"
2323,"NCT00618527","Combination Therapy Using Cellcept and Rebif in RRMS",,"Completed","No Results Available","Multiple Sclerosis","Drug: mycophenolate mofetil (Cellcept)|Drug: human interferon beta 1a (Rebif)","mRNA for MxA gene levels","Aaron Boster|EMD Serono|Pfizer|Ohio State University","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","31","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006H0039","August 2006","May 2012","May 2012","February 20, 2008","null","November 15, 2012","The Ohio State University Multiple Sclerosis Center, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00618527"
2324,"NCT00618215","A Cluster Randomized Controlled Trial in Primary Oral Care",,"Completed","No Results Available","Tooth, Impacted","Behavioral: peer group educational implementation strategy","Number of patients per GDP with assigned recall interval (months) based on individual recall assessment. For high risk children and adolescents <7 months, in case of low risk > 7 months. For adults 9 months or more for low risk profiles, and ≤ than 9 mo|Number of patients per GDP with prescribed individual frequency of BWs (months). For high-risk children and adolescents <24 months frequency, in low risk profiles >36 months. For high-risk adults < 36 months frequency versus low risk >48 months.","Radboud University|The health Care Insurance Board (CVZ)|Department of Preventive and Restorative Dentsitry and Centre of Quality of Care Research (WOK)","All","Child, Adult, Older Adult","Early Phase 1","1161","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Care Provider)|Primary Purpose: Health Services Research","CVZ-538/001/2001/RL000003","September 2006","June 2007","July 2007","February 19, 2008","null","February 19, 2008","University Medical Centre St Radboud, Nijmegen, Gelderland, Netherlands","","https://ClinicalTrials.gov/show/NCT00618215"
2325,"NCT00616746","Interactive Psychopharmacologic Effects of Alcohol and Nicotine in Humans",,"Completed","No Results Available","Alcohol Consumption|Tobacco Use","Drug: Nicotine|Drug: Ethanol","Behavioral and Cognitive Measures","Yale University|VA Connecticut Healthcare System","All","21 Years to 50 Years   (Adult)","Early Phase 1","18","Other|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)","0607001614","January 2007","June 2010","June 2010","February 15, 2008","null","July 8, 2014","VA Connecticut Healthcare System, West Haven Campus, West Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT00616746"
2326,"NCT00612300","Gait Training for Persons With Stroke","GTS","Completed","No Results Available","Stroke|Middle Cerebral Artery Infarction","Behavioral: Lokomat - Physical therapy|Behavioral: Physical therapy - Lokomat","10 meters walking test (gait speed)|Six minutes walking test|Gait symmetry index|Timed Up And Go","University of Aarhus","All","30 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2","June 2007","June 2009","June 2009","February 11, 2008","null","February 17, 2010","Hammel Neurorehabilitation and Research Center, Hammel, Denmark","","https://ClinicalTrials.gov/show/NCT00612300"
2327,"NCT00612274","Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation",,"Completed","No Results Available","Stem Cell Transplantation","Drug: tacrolimus|Drug: Sirolimus|Drug: Methotrexate","Safety/Efficacy of a novel regimen of sirolimus, tacrolimus and methotrexate","Yale University","All","16 Years and older   (Child, Adult, Older Adult)","Early Phase 1","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0703002455","October 2007","October 2014","October 2014","February 11, 2008","null","November 30, 2016","Yale University School of Medicine, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT00612274"
2328,"NCT00609102","Antioxidant Treatment of Type 2 Diabetes",,"Completed","No Results Available","Type 2 Diabetes","Drug: Placebo|Drug: n-aceylcysteine","Blood glucose|HbA1c levels","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","44","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Antioxidant trmt type 2|NIH R01 38325-19","July 2008","September 2013","September 2013","February 6, 2008","null","December 24, 2014","Pacific Northwest Research Institute, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00609102"
2329,"NCT00608751","A Feasibility Study of Adaptive Intensity-Modulated Radiation Therapy","IMRT","Terminated","No Results Available","Head and Neck Cancer","Radiation: IMRT","Feasibility of adaptive radiation therapy in the definitive treatment (MLC-based IMRT or helical tomotherapy)|Measure additional time required by physician and ancillary staff for the process of adaptive IMRT|Identify a subset of patients in whom adaptive IMRT would be recommended|Measure acute and late toxicity|Local, regional, and distant recurrence","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-1210","January 2007","January 2008","January 2008","February 6, 2008","null","May 24, 2013","Washington University School of Medicine, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00608751"
2330,"NCT00607646","Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus",,"Recruiting","No Results Available","Type 1 Diabetes","Drug: Dehydroepiandrosterone|Drug: Placebo","Change in level of catecholamines in blood from baseline","University of Maryland|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 45 Years   (Adult)","Early Phase 1","56","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other","HP-00044672-DHEA|R01DK069803-03","October 2010","December 2018","December 2018","February 6, 2008","null","January 11, 2018","University of Maryland, Baltimore, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00607646"
2331,"NCT00606970","Safety Assessment of Lactobacillus Fermented Extract in Cancer Patients Undergoing Chemotherapy",,"Withdrawn","No Results Available","Cancer","Dietary Supplement: Seigen Alpha EV|Dietary Supplement: Placebo Comparator","Change in self-rated symptoms and assessed signs|Affect on treatment results","New Hope Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Seigen Safety Trial: Cancer|WIRB Study No. 1085894|WIRB Pr. No. 20062258","January 2007","January 2009","December 2009","February 5, 2008","null","May 7, 2013","","","https://ClinicalTrials.gov/show/NCT00606970"
2332,"NCT00606658","Usefulness of Shirodhara for Insomnia",,"Completed","No Results Available","Insomnia","Procedure: Shirodhara Oil Treatment","Insomnia Severity Index|HD-16 Quality of Life Scale","Southern California University of Health Sciences","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCU-07-VINJ002","January 2008","September 2008","September 2008","February 4, 2008","null","September 20, 2012","Southern California University of Health Sciences, Whittier, California, United States","","https://ClinicalTrials.gov/show/NCT00606658"
2333,"NCT00606541","An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)",,"Terminated","No Results Available","Social Anxiety Disorder","Drug: Quetiapine XR|Drug: Placebo","Kaplan Meier survival of Clinical Global Impression of Improvement (CGI-I)|Percentage of CGI-I, BSPS, SPIN","Duke University","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","55","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Pro00002146|eIRB2146|IRUSQUET0452","January 2008","December 2011","November 2012","February 4, 2008","null","August 1, 2014","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00606541"
2334,"NCT00606424","An Exploratory, Open Label, Single Center Study of [F-18]HX4","HX4","Completed","No Results Available","Head and Neck Cancer","Drug: 20 mCi dose for a 50 kg individual of [F-18]HX4","Safety will be the outcome demonstrated in this clinical trial through analyses of adverse events in subjects who receive study drug.","Siemens Molecular Imaging","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","DHX4000","January 2008","January 2009","January 2009","February 4, 2008","null","February 2, 2009","Michael Yu, MD, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00606424"
2335,"NCT00606411","Efficacy and Safety of Topiramate in the Treatment of Sleep-Related Eating Disorder",,"Recruiting","No Results Available","Sleep-Related Eating Disorder","Drug: Topiramate or Placebo","frequency and severity of sleep-related eating episodes|tolerability of topiramate|body weight","Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MGH-2008P000662","January 2008","June 2018","null","February 4, 2008","null","March 21, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00606411"
2336,"NCT00604916","Oral Care Protocol for Preventing Ventilator- Associated Pneumonia","VAP","Completed","No Results Available","Pneumonia","Other: standardized oral care protocol - electronic toothbrush|Other: mimic protocol","the oral hygiene status measured by the oral assessment guide and plague index|The incidence of VAP defined by the Clinical Pulmonary Infection Score","Mackay Memorial Hospital|National Taiwan University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","53","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","MMH-I-S-402","March 2007","November 2007","January 2008","January 30, 2008","null","January 30, 2008","","","https://ClinicalTrials.gov/show/NCT00604916"
2337,"NCT00603655","Effect of Glycemic Load on Body Composition",,"Terminated","No Results Available","Overweight|Obesity","Other: Low glycemic load diet|Other: High glycemic load diet","Reduction of body fat percentage|Reduction of homeostasis model assessment (HOMA)","Universidad Autonoma de Baja California","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","UABC4268|UABC20074268","January 2007","December 2008","December 2008","January 29, 2008","null","December 31, 2008","Facultad de Medicina y Psicología, Tijuana, Baja California, Mexico","","https://ClinicalTrials.gov/show/NCT00603655"
2338,"NCT00602914","A Pilot Study to Assess the Safety, PK and PD of Insulin Injected Via MicronJet or Conventional Needle","MicronJet","Completed","No Results Available","Intradermal Injections","Device: MicronJet","Blood samples for PK and PD will be collected|Feedback from study participants and staff on their overall impression with the MicronJet device, using questionnaires","NanoPass Technologies Ltd","Male","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","23","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","NP-1-001","March 2008","December 2008","July 2009","January 28, 2008","null","May 10, 2013","","","https://ClinicalTrials.gov/show/NCT00602914"
2339,"NCT00601913","Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery",,"Completed","No Results Available","Head and Neck Cancer","Drug: erlotinib hydrochloride|Genetic: protein analysis|Genetic: western blotting|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: liquid chromatography|Other: mass spectrometry|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery","Identify tissue biomarkers of EGFR activation and inhibition for which initial values and changes after treatment with erlotinib hydrochloride would best correlate with the objective response of the tumor measured clinically and radiologically|Objective response|Tumor cell metabolic response measured by PET scan at 4-6 days after beginning of treatment and correlation with tumor response evaluated at the end of treatment by CT scan, PET scan, and direct tumor measurements|Role of PET/CT scan in evaluating response to short-term treatment with erlotinib hydrochloride and comparison with the same response evaluation performed by CT scan|Incidence of risk factors for relapse|Incidence of adverse effects or significant laboratory changes|Any treatment-induced delay of the established date for definitive surgical treatment","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Older Adult)","Early Phase 1","24","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00004038|P30CA012197|CCCWFU-60307","March 2008","October 2014","October 2014","January 28, 2008","null","July 4, 2018","Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00601913"
2340,"NCT00598923","Preventing Epilepsy After Traumatic Brain Injury With Topiramate","PEPTO","Terminated","No Results Available","Traumatic Brain Injury|Epilepsy","Drug: topiramate|Drug: phenytoin","Early and late seizures after traumatic brain injury|Adverse events|Functional recovery after traumatic brain injury","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PR043514","November 2004","February 2009","February 2009","January 23, 2008","null","June 27, 2017","","","https://ClinicalTrials.gov/show/NCT00598923"
2341,"NCT00592189","Study of Donated Amnion, Fetal Placental Membrane, as Skin Substitute for Burn Patients","Amnion","Completed","No Results Available","Wounds","Procedure: blood draw","Safe method of obtaining and processing amnion","The University of Texas Medical Branch, Galveston","Female","16 Years to 65 Years   (Child, Adult, Older Adult)","Early Phase 1","1164","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","1999-209|Clayton","December 1999","June 2014","June 2014","January 11, 2008","null","June 24, 2014","University of Texas Medical Branch, Galveston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00592189"
2342,"NCT00590512","Dietary Salt Intake and Vascular Function",,"Completed","No Results Available","Healthy","Dietary Supplement: High sodium|Dietary Supplement: Low sodium","endothelial function","Brigham and Women's Hospital","Male","18 Years to 35 Years   (Adult)","Early Phase 1","133","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Diagnostic","2004P002705","March 2005","November 2012","November 2012","January 10, 2008","null","August 29, 2013","Brigham and Women's Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00590512"
2343,"NCT00585442","Effects of Vitamin D on Renin Expression in Hypertensive Patients",,"Terminated","No Results Available","Hypertension|Vitamin D Deficiency","Drug: calcitriol|Drug: Placebo","Compare plasma renin activity (PRA) and plasma renin concentration (PRC) in hypertensive patients (JNC VII stage I) following 14 days treatment with calcitriol (1α, 25-[OH]2 vitamin D3) or matched placebo.|Compare mononuclear leukocyte renin transcription (mRNA) between calcitriol and matched placebo.","University of Utah","All","55 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","22714|10151812","May 2007","June 2008","June 2008","January 3, 2008","null","May 27, 2016","University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00585442"
2344,"NCT00585156","The Effects of Celecoxib on Bone Ingrowth",,"Terminated","No Results Available","Bone Ingrowth|Pain","Drug: Celecoxib","Bone Ingrowth|Pain Score","University of Utah|Pfizer","Male","18 Years to 95 Years   (Adult, Older Adult)","Early Phase 1","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","IIR#2005-0300","June 2008","September 2008","September 2008","January 3, 2008","null","March 14, 2016","Veteran Affairs (VA) Medical Center, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00585156"
2345,"NCT00584207","Radiofrequency Ablation of Uterine Fibroids",,"Terminated","No Results Available","Uterine Fibroids","Procedure: radiofrequency ablation","Following the hysterectomy, the study pathologist will perform a histological examination of the treated fibroid specimen to determine the size and volume of the ablation that was created with radiofrequency electrocautery.","University of California, Davis","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200412085","March 2004","March 2007","July 2008","January 2, 2008","null","April 23, 2009","UC Davis Medical Center, Sacramento, California, United States","","https://ClinicalTrials.gov/show/NCT00584207"
2346,"NCT00583869","Role of Pregabalin in Treatment of Post-Op Pain in Fracture Patients","LYRICA","Completed","No Results Available","Post-operative Pain","Drug: Placebo|Drug: Pregabalin","Amount of pain medication in morphine equivalent units used during the hospitalization.|Secondary outcome measures will include Visual Analog Score, timing and frequency of rescue medications, Short-Form 36 Health Survey scores, and adverse events.","University of Alabama at Birmingham|Pfizer","All","19 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","86","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","F061204006","May 2007","August 2009","August 2009","January 2, 2008","null","January 7, 2014","The University of Alabama at Birmingham, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT00583869"
2347,"NCT00583063","Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers",,"Completed","No Results Available","Solid Tumors","Drug: sunitinib|Drug: rapamycin","Pharmacokinetic interactions|Toxicity of the combined drug regimen|Response to drug regimen","University of Chicago|Pfizer","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","23","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15328B","October 2007","April 2008","April 2008","December 31, 2007","null","June 12, 2013","University of Chicago, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT00583063"
2348,"NCT00580788","One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study",,"Completed","Has Results","Osteoporosis|Humoral Hypercalcemia of Malignancy|Hyperparathyroidism","Drug: PTHrP (1-36)","Dose Limiting Toxicity (DLT)|Total Serum Calcium|Ionized Serum Calcium|Serum Phosphorous|1,25 Vitamin D|24 Hour Urine Calcium|Tubular Maximum of Phosphorous (TmP/GFR)|Serum Amino-terminal Telopeptide of Collagen -1 (sNTX)|Serum Carboxy-terminal Telopeptide of Collagen -1 (sCTX)|Amino-terminal Peptides of Procollagen 1 (P1NP)|Bone Specific Alkaline Phosphatase (BSAP)|Parathyroid Hormone (1-84)|Fractional Excretion of Calcium","University of Pittsburgh|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","24 Years to 35 Years   (Adult)","Early Phase 1","14","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)","PRO07040081|R01DK073039","January 2008","December 2009","December 2009","December 27, 2007","February 11, 2016","February 11, 2016","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00580788"
2349,"NCT00580060","Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity",,"Completed","No Results Available","Melanoma","Biological: GM-CSF DNA, NSC 683472 gp100: 209-217(210M), NSC 699048 Tyrosinase: 368-376(370D)","To establish the safety and a recommended dose of subcutaneous human GM-CSF DNA given in conjunction with a multi-epitope peptide vaccine in patients with AJCC stage IIB, IIC, III and IV melanoma who are HLA-A2+.|To evaluate serum pharmacokinetics of GM-CSF after subcutaneous administration of human GM-CSF DNA.|If toxicities are encountered in the dose ranging part of the study, to establish the maximum tolerated dose (MTD) and dose limiting toxicities (DLT).|In the immunological efficacy study, to evaluate the immunogenicity of a multi-epitope peptide vaccine.|A secondary endpoint is to observe the patients for evidence of any anti-tumor response that is generated after vaccination.","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Older Adult","Early Phase 1","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00-142|NCI Protocol #: 5906","December 2003","June 2011","June 2011","December 24, 2007","null","June 10, 2011","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00580060"
2350,"NCT00578656","An Interventional Study of Milk Allergy",,"Completed","No Results Available","Food Hypersensitivity|Milk Hypersensitivity","Dietary Supplement: Baked Milk","Tolerance to heated milk|Development of tolerance to non-heated milk","National Institute of Allergy and Infectious Diseases (NIAID)","All","4 Years to 25 Years   (Child, Adult)","Early Phase 1","220","NIH","Interventional","Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Diagnostic","DAIT P01 AI 144236|GCO#01-1209","June 2004","February 2011","February 2011","December 21, 2007","null","August 1, 2012","Mount Sinai School of Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00578656"
2351,"NCT00577187","Placement of CS/LV Pacing Leads With EnSite NavX Guidance",,"Withdrawn","No Results Available","Heart Failure","Device: EnSite NavX-Guided CRT implant","Fluoroscopy and procedure time","St. Jude Medical","All","Child, Adult, Older Adult","Early Phase 1","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0712.0","June 2008","December 2008","December 2008","December 20, 2007","null","June 12, 2012","University of Nebraska Medical Center, Omaha, Nebraska, United States","","https://ClinicalTrials.gov/show/NCT00577187"
2352,"NCT00574834","Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes",,"Terminated","Has Results","Metabolic Syndrome","Drug: Ramipril|Drug: HCTZ-hydrochlorothiazide|Drug: Ramipril+HCTZ","Changes in Insulin Sensitivity","University of Maryland|King Pharmaceuticals is now a wholly owned subsidiary of Pfizer","All","20 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","17","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","HP-00044872-Ramipril","March 2007","August 2014","August 2014","December 17, 2007","January 15, 2016","March 20, 2017","University of Maryland, Baltimore, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00574834"
2353,"NCT00574639","Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2","Alp Ex","Completed","No Results Available","Type 1 Diabetes","Drug: Alprazolam|Drug: Placebo","Change in Epinephrine Levels","University of Maryland|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 50 Years   (Adult)","Early Phase 1","14","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","HP-00044868|HL056693","July 2007","June 2016","June 2016","December 17, 2007","null","February 10, 2017","University of Maryland, Baltimore, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00574639"
2354,"NCT00574340","Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 4",,"Completed","Has Results","Type 2 Diabetes","Other: Hyperinsulinemic Hypoglycemic Clamp","Percent Changes in Endothelial Function as Measured by Flow Mediated Dilation by 2D Doppler Ultrasound on Day 2","University of Maryland|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 60 Years   (Adult)","Early Phase 1","20","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","HP-00044875-SCCOR-Q4|RFAHL04016","May 2007","April 2011","April 2011","December 17, 2007","September 1, 2014","March 29, 2017","University of Maryland, Baltimore, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00574340"
2355,"NCT00572598","Pilot Study of 18F Fluoropaclitaxel (FPAC)",,"Completed","No Results Available","Breast Cancer","Drug: 4- [F-18] fluoropaclitaxel","Imaging feasibility and dosimetry","Virginia Commonwealth University","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","HM03748","May 2005","March 2008","March 2008","December 13, 2007","null","January 12, 2012","Virginia Commonwealth University, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT00572598"
2356,"NCT00572065","Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis",,"Completed","No Results Available","Myelofibrosis","Drug: arsenic trioxide|Drug: cytarabine","To assess the response rate in patients with advanced MF/LT using criteria of the International Working Group (IWG)|To characterize the safety and tolerability of the regimen in this patient population|To assess overall survival","Weill Medical College of Cornell University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0707009291","February 29, 2008","December 2009","February 8, 2010","December 12, 2007","null","March 3, 2017","Weill Cornell Medical College, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00572065"
2357,"NCT00567866","Methamphetamine-Quetiapine Interactions in Humans",,"Terminated","No Results Available","Methamphetamine Dependence","Drug: Quetiapine","Behavioral Responses to Methamphetamine following predosing with placebo or test article.|Physiological Responses to methamphetamine following predosing of placebo or test article","University of Arkansas","All","18 Years to 50 Years   (Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","72900","January 2008","September 2009","September 2009","December 5, 2007","null","July 13, 2010","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States","","https://ClinicalTrials.gov/show/NCT00567866"
2358,"NCT00565201","Evaluation of BOTOX® With Rehabilitation Therapy for the Treatment of Wrist and Hand Spasticity in Post-Stroke Patients","Botox/Rehab","Completed","No Results Available","Stroke","Drug: Botox and rehab|Drug: Placebo and rehab","Wolf Motor Function Test|Arm Motor Ability Test|Stroke Impact Scale|Modified Ashworth Scale|Upper Extremity range of motion measurements|Caregiver questionnaire","Emory University|Allergan","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","25","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","IRB00002727","October 2007","December 2009","December 2011","November 29, 2007","null","August 13, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00565201"
2359,"NCT00556764","Development of Cognitive Assessment Tools in Parkinson Disease","ANAM","Completed","No Results Available","Parkinson Disease","Drug: [123I] IBVM and SPECT imaging|Drug: Subjects will undergo the 123-I IBVM imaging visit","The overall goal of this proposal is to validate ANAM-PD as an assessment tool for cognitive status in PD","Institute for Neurodegenerative Disorders|United States Department of Defense|University of Oklahoma","All","30 Years and older   (Adult, Older Adult)","Early Phase 1","75","Other|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","ANAM-PD-02|#76,160","July 2007","March 2011","March 2011","November 12, 2007","null","February 9, 2012","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT00556764"
2360,"NCT00555698","Feasibility, Safety and Efficacy of Deep Brain Stimulation for Depression",,"Completed","No Results Available","Depression","Device: Deep Brain Stimulations for Depression","Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton Depression Rating Scale (HDRS)|Inventory for Depressive Symptoms, Self-report (IDS-SR), Clinical Global Impressions (CGI), Patient Global Impressions (PGI), Global Assessment of Functioning (GAF), Social and Occupational Function Assessment Scale (SOFAS), Quality of LIfe Enjoyment and","Ali Rezai, MD|Medtronic|The Cleveland Clinic|Ohio State University","All","18 Years to 55 Years   (Adult)","Early Phase 1","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6577","January 2004","February 2011","February 2011","November 9, 2007","null","March 28, 2017","Cleveland Clinic Foundation, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00555698"
2361,"NCT00543933","Pilot Study of Inhaled Nitric Oxide to Treat Pulmonary Insufficiency in Congenital Heart Disease",,"Terminated","No Results Available","Pulmonary Insufficiency","Drug: iNO administered","pulmonary regurgitant volume and fraction","The Cleveland Clinic","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-491","October 2007","June 2010","June 2010","October 15, 2007","null","January 27, 2017","The Cleveland Clinic, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00543933"
2362,"NCT00542646","Pilot Study to Evaluate the Safety and Preliminary Efficacy of the Peritec Peritoneal Lined Stent and Delivery System",,"Unknown status","No Results Available","Vascular Disease, Peripheral","Procedure: Endovascular Intervention","Efficacy: Primary patency postprocedure and technical success Safety: Composite of major procedural adverse events|Primary Patency Primary Assisted Patency Secondary Patency Clinical Success Major Amputations Target Vessel Revascularization Target Lesion Revascularization","PeriTec Biosciences Ltd.","All","Child, Adult, Older Adult","Early Phase 1","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PB-PLS-2005-001","November 2006","null","November 2010","October 11, 2007","null","November 28, 2007","Pontificia Universidad Catolica de Chile, Santiago, Chile","","https://ClinicalTrials.gov/show/NCT00542646"
2363,"NCT00537160","Diet and Exercise in Overweight Children Postburn",,"Withdrawn","No Results Available","Obesity|Burns","Behavioral: Behavior modification, Nutrition Education, Exercise","BMI|fitness level","Shriners Hospitals for Children","All","10 Years to 18 Years   (Child, Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-04-26-01","April 2006","October 2012","October 2012","September 28, 2007","null","October 29, 2012","","","https://ClinicalTrials.gov/show/NCT00537160"
2364,"NCT00536952","Pilot Study of Pulmozyme (rhDNase) in Patients With Head and Neck Cancers Treated With Radiation Therapy + Chemotherapy",,"Unknown status","No Results Available","Head and Neck Cancer","Drug: Pulmozyme|Drug: Placebo|Radiation: Radiation Therapy","Treatment-related symptoms as assessed daily by the Head and Neck Symptom Inventory Scale (MD Anderson Symptom Inventory)|Quality of life as assessed weekly by the Functional Assessment of Cancer Therapy - Head & Neck Neck questionnaire|Patient comfort and/or disturbance during radiotherapy treatment as assessed daily by Radiation Treatment Disturbance Disturbance Measures questionnaire|Reduction in amount of thick oropharyngeal secretions associated with cancer therapy.|Incidence of mucositis, infections, and aspiration pneumonia","Northwestern University|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","36","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","NU 06N2|STU00001045|GENENTECH-NU-06N2","February 2008","October 2014","December 2016","September 28, 2007","null","June 27, 2013","Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT00536952"
2365,"NCT00536354","Postural Orientation In The Use Of School Backpacks",,"Completed","No Results Available","Backpain|Prevention|Physical Therapy","Other: Postural Orientation","","University of Sao Paulo","All","7 Years to 10 Years   (Child)","Early Phase 1","null","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","SFernandes","August 2005","null","December 2005","September 27, 2007","null","September 27, 2007","University of São Paulo, São Paulo, Brazil","","https://ClinicalTrials.gov/show/NCT00536354"
2366,"NCT00535769","Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use",,"Completed","Has Results","Skin Cancer","Device: Electronic + no text message|Device: Electronic monitor + text messages","Number of Days the Subjects Are Adherent to Using Sunscreen|Usefulness of Text Messaging System|Recalled Frequency of Sunscreen Application","Massachusetts General Hospital|Brigham and Women's Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)","2007-P-001456","September 2007","November 2007","November 2007","September 26, 2007","July 18, 2012","July 20, 2012","Brigham and Women's Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00535769"
2367,"NCT00534755","Prospective & Retrospective Data Collection of Breast Cancer Cases From 2000 to Present",,"Completed","No Results Available","Breast Cancer","Other: Breast Cancer database","Database","King Faisal Specialist Hospital & Research Center","Female","Child, Adult, Older Adult","Early Phase 1","10000","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","RAC#2051-029","June 2005","June 2015","June 2015","September 26, 2007","null","February 25, 2016","KFSH&RC, Riyadh, Saudi Arabia","","https://ClinicalTrials.gov/show/NCT00534755"
2368,"NCT00534612","Diagnostic Accuracy of Fine Needle Aspiration in Parotid Tumors",,"Unknown status","No Results Available","Parotid Gland Neoplasms","Procedure: aspiration biopsy","Diagnosis of malignancy|Specific histopathologic diagnosis","National Institute of Cancerología","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","150","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","006/038/CCI","January 2003","null","December 2007","September 26, 2007","null","September 26, 2007","National Cancer Institute, Mexico, D.f:, Mexico","","https://ClinicalTrials.gov/show/NCT00534612"
2369,"NCT00532753","Evaluating the Hunger Project in Ghana",,"Unknown status","No Results Available","To Better Understand How Epicenter's (Which House Education, Health and Finance Centers in Ghana) Increase Individual's Sense of Empowerment.","Behavioral: Community Empowerment","Increased sense of empowerment|Increased health, education, and consumption outcomes and increase in the number of public goods","University of California, Berkeley|The Robertson Foundation","All","Child, Adult, Older Adult","Early Phase 1","20000","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CPHS Protocol #2007-4-42","August 2007","August 2010","May 2016","September 20, 2007","null","August 4, 2008","Ghana Hunger Project, Several, Eastern, Ghana","","https://ClinicalTrials.gov/show/NCT00532753"
2370,"NCT00532181","Micro-Health Insurance in Cambodia",,"Unknown status","No Results Available","Health Insurance Sale|Health Utilization|Asset Sales, Investment and Saving Behaviors","Behavioral: Savings Behavior and Consumer's Approach to Risk","Better Understand Health Utilization Behavior in Cambodia|Better Understand asset sales, investment and saving behaviors","University of California, Berkeley|French Development Agency|United States Agency for International Development (USAID)","All","Child, Adult, Older Adult","Early Phase 1","null","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","CPHS Protocol 2007-3-48","April 2008","null","December 2011","September 20, 2007","null","September 20, 2007","Sky Health Insurance, Phenom Phen, Cambodia","","https://ClinicalTrials.gov/show/NCT00532181"
2371,"NCT00531869","Safe Water Techniques in Kenya",,"Unknown status","No Results Available","Consumer Willingness to Pay for POU Products|Consumer Preferences and Use of POU Products","Behavioral: biases towards products","Consumer preferences and use of POU products|Consumer willingness to pay for POU products","University of California, Berkeley|Procter and Gamble","All","Child, Adult, Older Adult","Early Phase 1","null","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CPHS Protocol #2007-7-27","May 2008","May 2010","October 2010","September 19, 2007","null","August 4, 2008","Care Kenya, Kisumu, Kenya","","https://ClinicalTrials.gov/show/NCT00531869"
2372,"NCT00530192","Molecular Profiling Protocol (SCRI-CA-001)",,"Completed","No Results Available","Refractory Cancer","Other: Treatment based on Molecular Profiling","To compare progression-free survival using a treatment regimen selected by molecular profiling with progression-free survival for the most recent regimen the patient has progressed on.|To determine the frequency with which molecular profiling of a patient's tumor by IHC/FISH and/or microarray analysis yields a target against which there is a commercially available, approved therapeutic regimen.|To determine the response rate (according to RECIST or disease-specific response criteria) and the percent of patients with non-progression at 4 months in patients with solid tumors whose therapy is selected by molecular profiling.","Scottsdale Healthcare|Translational Genomics Research Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","86","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI-CA-001","September 2006","March 2009","March 2009","September 17, 2007","null","July 10, 2009","Oncology Specialties, Huntsville, Alabama, United States|TGen Clinical Research Services, Scottsdale, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|Tower Oncology, Beverly Hills, California, United States|Louis Warschaw Prostate Cancer Center at Cedars Sinai Medical Center, Los Angeles, California, United States|Central Indiana Cancer Center, Indianapolis, Indiana, United States|Cancer Center of the Carolinas, Greenville, South Carolina, United States|South Texas Oncology Hematology, San Antonio, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States","","https://ClinicalTrials.gov/show/NCT00530192"
2373,"NCT00527293","Partial Breast Radiation Therapy in Treating Women Undergoing Breast-Conserving Therapy for Early Stage Breast Cancer",,"Completed","No Results Available","Breast Cancer","Procedure: adjuvant therapy|Radiation: 3-dimensional conformal radiation therapy|Radiation: brachytherapy","Cosmetic outcome as determined by an established scale employed by the radiation oncologist and the surgeon|Patient satisfaction with partial breast irradiation as measured by a questionnaire|Wound healing and overall complication rate after partial breast irradiation|Determination of which patients are best suited for each individual technique of partial breast irradiation|Ipsilateral breast tumor recurrence rates and tumor bed recurrence rates","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","29","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CASE2104|P30CA043703","June 2007","October 2010","February 2015","September 10, 2007","null","August 25, 2015","Lake/University Ireland Cancer Center, Cleveland, Ohio, United States|Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|UHHS Chagrin Highlands Medical Center, Cleveland, Ohio, United States|UHHS Westlake Medical Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00527293"
2374,"NCT00526500","Effect of Passive Gait Training on the Cortical Activity in Patients With Severe Brain Injury.",,"Unknown status","No Results Available","Craniocerebral Trauma|Traumatic Brain Injury|Subarachnoid Hemorrhage|Anoxic Brain Injury","Behavioral: Tilt Table With Integrated Stepping System","EEG:frequency ratios: Alpha versus delta; alpha and beta versus delta and theta; ERP: latency of P300-component.|EEG: absolute and relative power in every frequency band; median frequency;","University of Aarhus","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HNRC-AAU-07-1","August 2006","May 2009","May 2009","September 10, 2007","null","November 11, 2008","Hammel Neurorehabilitation and Research Centre, Hammel, Denmark","","https://ClinicalTrials.gov/show/NCT00526500"
2375,"NCT00523172","Clinical Assessment of Two Manipulative Protocols in Treatment of Hip Osteoarthritis",,"Unknown status","No Results Available","Osteoarthritis, Hip","Procedure: manual or manipulative therapy|Procedure: Manual / Manipulative Therapy|Procedure: Supportive Care","Recruit a pool of HOA patients from senior centers, the local community, medical and chiropractic clinics, and through advertising in collaboration with other Universities/Colleges or Schools.|Establish protocols for long-term surveillance of OAH in chiropractic patients.|integrate a clinical research program with a teaching clinic system.|Collect and compare protocol outcome data. Primary outcome measure will be: a 6 point Likert scale.","Cleveland Chiropractic College|Durban University of Technology South Africa|Macquarie University, Australia","All","40 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB08102007","October 2007","January 2010","October 2010","August 31, 2007","null","July 19, 2010","Cleveland Chiropractic College Health Center, Los Angeles, California, United States|Macquarie University, Sydney, Australia|Durban University of Technology, Durban, South Africa","","https://ClinicalTrials.gov/show/NCT00523172"
2376,"NCT00517062","Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates",,"Completed","No Results Available","Growth Hormone Deficiency","Drug: Growth hormone (Genotropin)|Drug: Placebo","Changes in insulin sensitivity (from the hyperinsulinemic euglycemic clamp|Changes in fat IGF-I and IGF-I/insulin hybrid receptor density and body composition.","Oregon Health and Science University","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB1844","January 2006","January 2012","January 2012","August 16, 2007","null","May 3, 2012","Oregon Health and Science University, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT00517062"
2377,"NCT00517010","Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration",,"Completed","Has Results","Age-related Macular Degeneration","Drug: Proton beam irradiation and ranibizumab","Incidence and Severity of Ocular Adverse Events|1. Change in BCVA From Baseline","University of California, Davis|University of California, San Francisco|Genentech, Inc.","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200715285|100,481","May 2007","June 2010","June 2010","August 16, 2007","July 11, 2016","July 11, 2016","","","https://ClinicalTrials.gov/show/NCT00517010"
2378,"NCT00515138","A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant",,"Terminated","No Results Available","Lymphoma, B-Cell","Drug: Rituximab, Ifosfamide, Carboplatin, Etoposide, Bortezomib","-Determine the maximum tolerated dose of bortezomib in combination with rituximab, ifosfamide, carboplatin, and etoposide for patients with relapsed or primary refractory aggressive B-cell NHL","University of California, San Francisco","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UC-CC06253","May 2007","November 2011","November 2011","August 13, 2007","null","April 12, 2012","University of California San Francisco, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT00515138"
2379,"NCT00510614","Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study",,"Completed","No Results Available","Bacterial Vaginosis","Drug: tinidazole|Drug: Placebo","Differences in the proportion of women clinically cured at each visit between the two therapy arms will be evaluated using Fisher's-exact test.|Kaplan-Meier product-limit estimation will be used to obtain estimates of the median time to BV recurrence.","University of Pittsburgh|Mission Pharmacal","Female","18 Years to 45 Years   (Adult)","Early Phase 1","37","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","PRO07030019","October 2007","September 2009","September 2009","August 2, 2007","null","February 18, 2011","Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00510614"
2380,"NCT00510601","Treating Congestive Heart Failure Using a Device to Remove Cholesterol",,"Completed","No Results Available","Heart Decompensation","Device: Kaneka Liposorber","Improved Symptoms score on KCCQ|Improved Ejection Fraction on ECHO|Improved distance during 6-minute walk test|Various lab measurements measured pre and post the 1st and last treatment, including blood viscosity","Patrick Moriarty, MD, FACP, FACC|Kaneka Pharma America LLC|University of Kansas Medical Center","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","5","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10282","July 2007","July 2011","July 2011","August 2, 2007","null","January 13, 2016","University of Kansas Medical Center, Kansas City, Kansas, United States","","https://ClinicalTrials.gov/show/NCT00510601"
2381,"NCT00510367","Primary Breast Cancer Occurring Concomitant With Pregnancy",,"Active, not recruiting","No Results Available","Breast Cancer|Pregnancy","Drug: 5-Fluorouracil|Drug: Cyclophosphamide|Drug: Doxorubicin","Response of Multimodality (Chemotherapy, Surgery and Radiation Therapy) Treatment of Primary Breast Cancer in Pregnant Participants|Outcome of Children Exposed to Chemotherapy While in Their Mother's Womb","M.D. Anderson Cancer Center","Female","Child, Adult, Older Adult","Early Phase 1","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ID01-193|NCI-2012-01578","August 2001","August 2019","August 2020","August 2, 2007","null","March 16, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00510367"
2382,"NCT00503542","Management of Vaginal Complaints: A Pilot Study Within a Practice-Based Research Network","VCAT","Completed","No Results Available","Vaginitis","Drug: Terazol or oral fluconazole for candidal vaginitis|Drug: Metronidazole or Clindamycin for Bacterial Vaginosis|Drug: Flagyl for definitively diagnosed vaginal trichomoniasis|Other: Empiric Management","Self-reported improvement in symptoms|Adverse reactions to treatment.|Incidence of STD's|Vaginal Complaints Scale","Agency for Healthcare Research and Quality (AHRQ)","Female","18 Years to 52 Years   (Adult)","Early Phase 1","46","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1R03HS016050-01","February 2007","February 2008","February 2008","July 18, 2007","null","January 8, 2014","Family Health Center, Bronx, New York, United States","","https://ClinicalTrials.gov/show/NCT00503542"
2383,"NCT00494806","Effects of Rocking on Postoperative Ileus Duration Study",,"Completed","Has Results","Abdominal Cancer","Other: Rocking Chair Intervention","Time to First Postoperative Flatus in Days Was the End of Postoperative Ileus (POI) Indicator.","M.D. Anderson Cancer Center","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","2004-0887","July 2005","February 2007","February 2007","July 2, 2007","November 26, 2009","August 7, 2012","U.T.M.D. Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00494806"
2384,"NCT00486421","Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura",,"Completed","No Results Available","Nonneoplastic Condition","Biological: Rituximab|Drug: Prednisone","Failure-free survival at 6 months|Time to platelet recovery|Duration of platelet recovery|Effect of treatment on prevention of spontaneous bleeding events","Mayo Clinic|National Cancer Institute (NCI)","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","22","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000529883|P30CA015083|MC0481|2071-04|U2985s","January 2007","May 2008","November 2008","June 14, 2007","null","October 17, 2014","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT00486421"
2385,"NCT00486239","Emotional Processing and Memory Evaluation in Epilepsy Patients",,"Unknown status","No Results Available","Epilepsy","Behavioral: neuropsychological evaluation","Evaluate the effects of known lateralized neurological dysfunction (Right TLE versus Left TLE) on emotional memory function.|Completion of the pre- and post-surgical study cognitive tests.","University Hospitals Cleveland Medical Center","All","18 Years to 64 Years   (Adult)","Early Phase 1","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","08-06-06","October 2006","null","null","June 14, 2007","null","June 14, 2007","University Hospitals Case Medical Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00486239"
2386,"NCT00484523","Constitution of a Standardized Neural Imaging Database in Healthy Subjects",,"Completed","No Results Available","Healthy","Procedure: SPET, PET and MRI","precise brain morphology","Assistance Publique Hopitaux De Marseille","All","20 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2007/09","July 2007","January 2010","null","June 11, 2007","null","August 28, 2014","CHU Timone, Marseille, France","","https://ClinicalTrials.gov/show/NCT00484523"
2387,"NCT00482404","Effects of Romantic Affection on Blood Chemistry and Immune Parameters",,"Completed","No Results Available","Stress|Hypercholesterolemia","Behavioral: Romantic kissing","","Arizona State University|National Institute of Mental Health (NIMH)","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","null","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","1001 R03 MH075757-01A1","February 2007","null","May 2007","June 5, 2007","null","June 5, 2007","","","https://ClinicalTrials.gov/show/NCT00482404"
2388,"NCT00479960","A Preliminary Study on Effect of Omega-3 on Human Sperm",,"Unknown status","No Results Available","Oligospermia","Behavioral: commercially available omega-3 fatty acids supplementation","sperm count|sperm Lipid phase transition determination","Hadassah Medical Organization|Shaare Zedek Medical Center","Male","Child, Adult, Older Adult","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","022006","June 2007","null","June 2007","May 30, 2007","null","May 30, 2007","Shaare Zedek Medical Center, Jerusalem, Israel","","https://ClinicalTrials.gov/show/NCT00479960"
2389,"NCT00470379","Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery",,"Completed","No Results Available","Melanoma (Skin)","Drug: resiquimod","Number and severity of hematologic and non-hematologic toxicities|Toxicity profile of each dose level|Percent of patients who mount an immune response","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC0578|P30CA015083|169-06","April 2006","October 2011","October 2011","May 7, 2007","null","October 31, 2014","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT00470379"
2390,"NCT00469170","A Safety and Acceptability Study of a Vaginal Ring Microbicide Delivery Method",,"Completed","No Results Available","HIV Infections","Device: intravaginal ring","The primary measure of acceptability will be defined as the proportion of women indicating that they would use the study product if it is found to prevent HIV.|The primary measure of safety will be the proportion of women who have abnormal observations during the pelvic/speculum examinations and the proportion of women who experience adverse events","International Partnership for Microbicides, Inc.","Female","18 Years to 35 Years   (Adult)","Early Phase 1","220","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IPM 011","March 2007","February 2010","February 2010","May 4, 2007","null","November 15, 2010","Reproductive Health & HIV Research Unit - Sheshisani IPM Clinic, Yeoville, Johannesburg, South Africa|South African Medical Research Council, Durban, KwaZulu Natal, South Africa|Desmond Tutu HIV Foundation, Masiphumelele, Cape Town, South Africa|Kilimanjaro Reproductive Health Program, Moshi, Tanzania","","https://ClinicalTrials.gov/show/NCT00469170"
2391,"NCT00468507","The Anti-inflammatory Effects of High-fat Nutrition; Towards a Clinical Application",,"Completed","No Results Available","Trauma","Dietary Supplement: nutritional intervention with Respifor and Diasip","CCK-release","Maastricht University Medical Center","All","45 Years to 55 Years   (Adult)","Early Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","067030","March 2007","February 2010","March 2010","May 2, 2007","null","March 31, 2010","University Maastricht, Maastricht, Limburg, Netherlands","","https://ClinicalTrials.gov/show/NCT00468507"
2392,"NCT00465751","Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism",,"Completed","No Results Available","Metabolic Syndrome|Familial Hypertriglyceridemia|Familial Combined Hyperlipidemia","Drug: chenodeoxycholic acid|Drug: placebo capsules","plasma triglyceride concentrations|hepatic insulin sensitivity|heptic triglyceride content","University Hospital, Basel, Switzerland","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EKBB 211/04 SB","October 2004","null","null","April 25, 2007","null","March 9, 2012","University Hospital Basel, Basel, Switzerland","","https://ClinicalTrials.gov/show/NCT00465751"
2393,"NCT00456976","Efficacy of Selegiline in Negative Symptoms of Schizophrenia",,"Completed","No Results Available","Schizophrenia","Drug: Selegiline","decreasing in negative symptoms in case group","Tabriz University","All","20 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","8514|tums","April 2007","null","September 2007","April 5, 2007","null","July 23, 2008","Razi university hospital, Tabriz, East Azarbaijan, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT00456976"
2394,"NCT00454597","Effect of the Omentectomy on the Hyperglycemia and the Resistance to the Insulin in Patients With Morbid Obesity","omentectomy","Completed","No Results Available","Obesity|Diabetes Mellitus Type 2","Procedure: omentectomy","To compare the Blood levels of of glucose, curve of tolerance wing glucose, hemoglobin glycosylated, insulin, triglyceride, cholesterol, HDL, LDL, leptin and Adiponectin before and after the procedure|To evaluate the metabolic conditions of the subjects of both groups to the 15 days and the month, 6, 12 and 24 months later to the procedure","Universidad de Guanajuato","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","0910-0459|ID :0910-0459","February 2007","March 2007","December 2007","April 2, 2007","null","June 4, 2008","Hospital General Regional de León, Universidad de Guanajuato, Facultad de Medicina de León, Leon, Guanajuato, Mexico","","https://ClinicalTrials.gov/show/NCT00454597"
2395,"NCT00452868","Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain",,"Completed","Has Results","Brain and Central Nervous System Tumors|Cognitive/Functional Effects|Long-term Effects Secondary to Cancer Therapy in Children|Neurotoxicity|Psychosocial Effects of Cancer and Its Treatment|Radiation Toxicity","Drug: Donepezil","Neurocognitive Function as Measured by the Neurocognitive Battery at 24 Weeks","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","8 Years to 17 Years   (Child)","Early Phase 1","14","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CDR0000537049|P30CA012197|CCCWFU-91305|CCCWFU-IRB-00000258","June 2006","February 2010","February 2010","March 28, 2007","February 28, 2013","September 7, 2018","Tufts-NEMC Cancer Center, Boston, Massachusetts, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00452868"
2396,"NCT00446537","Procedural Learning in Participants With ADHD",,"Unknown status","No Results Available","Attention Deficit Hyperactivity Disorder","Procedure: Methylphenidate","","Shaare Zedek Medical Center","All","12 Years to 50 Years   (Child, Adult)","Early Phase 1","null","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double","240446","null","null","null","March 13, 2007","null","March 13, 2007","Neuropediatric Unit, Jerusalem, Israel","","https://ClinicalTrials.gov/show/NCT00446537"
2397,"NCT00443664","External Micropulse Diode Laser Transscleral Trabeculoplasty (EMDLT) for Severe Open Angle Glaucoma","EMDLT","Unknown status","No Results Available","Primary Open Angle Glaucoma","Device: EXTERNAL MICROPULSE DIODE LASER TRANSSCLERAL TRABECULOPLASTY","The amount of pressure lowering after EXTERNAL MICROPULSE DIODE LASER TRANSSCLERAL TRABECULOPLASTY (EMDLT) treatment.|Study of safety of EXTERNAL MICROPULSE DIODE LASER TRANSSCLERAL TRABECULOPLASTY (EMDLT) treatment","National University Hospital, Singapore","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DSRB-A/06/165","June 2006","null","December 2008","March 6, 2007","null","May 15, 2008","National University Hospital, Singapore, Singapore","","https://ClinicalTrials.gov/show/NCT00443664"
2398,"NCT00440570","A Study of Therapeutic Amplitude-modulated Electromagnetic Fields in Advanced Tumors","THBC001","Completed","No Results Available","Cancer|Brain Tumor","Device: Low levels of amplitude-modulated electromagnetic fields|Device: Emitter of low levels of amplitude-modulated electromagnetic fields","Safety of daily administration of amplitude-modulated electromagnetic fields in patients with advanced cancer|Complete blood count, comprehensive chemistry profile, tumor markers|Tumor assessment as per RECIST criteria","Pasche, Boris, M.D.|Barbault, Alexandre, M.S.","All","18 Years to 95 Years   (Adult, Older Adult)","Early Phase 1","2","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","001","October 2004","September 2006","December 2007","February 27, 2007","null","June 29, 2011","Cabinet Médical Avenue de la gare 6, Lausanne, Vaud, Switzerland","","https://ClinicalTrials.gov/show/NCT00440570"
2399,"NCT00437138","Controlled Exposures to Air Pollution in Patients With Coronary Heart Disease",,"Completed","No Results Available","Coronary Heart Disease","Behavioral: Exposure to dilute diesel exhaust (300µg/m3) or filtered air","Exercise induced myocardial ischemia|Vascular vasomotor function|Endogenous fibrinolytic function","University of Edinburgh|Umeå University","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Prevention","RG/05/003 DISARM 2","April 2006","null","June 2006","February 19, 2007","null","February 19, 2007","Umeå University, Umeå, Västerbotten, Sweden","","https://ClinicalTrials.gov/show/NCT00437138"
2400,"NCT00437086","Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders",,"Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia","Drug: PS-341","Number and severity of toxicities as assessed by NCI CTCAE v3.0|Proportion of patients who show treatment success, as defined by anemia, spleen, bone marrow, or constitutional symptoms' response (complete, partial, major, or minor response)|Effects of treatment, in terms of changes in bone marrow cellularity, tryptase-positive mast cells, reticulin fibrosis, osteosclerosis, and angiogenesis, in responding patients","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|NIH","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000529906|P30CA015083|MC0486|695-05|VEL-04-107","September 2005","November 2008","November 2008","February 19, 2007","null","October 17, 2014","Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00437086"
2401,"NCT00436410","Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer",,"Completed","No Results Available","Adrenocortical Carcinoma|Breast Cancer|Colorectal Cancer|Gastrointestinal Cancer|Kidney Cancer|Liver Cancer|Melanoma (Skin)|Ovarian Cancer|Pancreatic Cancer|Sarcoma","Biological: colloidal gold-bound tumor necrosis factor|Other: electron microscopy|Other: pharmacological study|Procedure: conventional surgery","Tumor tissue and normal tissue distribution of colloidal gold-bound tumor necrosis factor|Comparison of the impact of distribution time and histology on accumulation of treatment particles in tumor vs normal tissues|Acute antitumor activity of treatment|Long-term toxicity of treatment as assessed by CTCAE v3.0","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","108","NIH","Interventional","Primary Purpose: Treatment","070043|07-C-0043|NCI-P6066|CYT-NCI-07-C-0043|CDR0000529849","December 2006","null","August 2009","February 19, 2007","null","May 2, 2012","NCI - Center for Cancer Research-Medical Oncology, Bethesda, Maryland, United States|NCI - Surgery Branch, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00436410"
2402,"NCT00435903","Pilot Study of the Feasibility of Palm Pilots in Monitoring Smoking Behavior in Individuals With Chronic Mental Illness",,"Unknown status","No Results Available","Smoking","Device: Palm Pilot","We will compare palm-recordings with paper and pencil recordings to examine how well these correlate.|Correlations will be used to compare the total number of smoked cigarettes reported by the daily ratings (paper and pencil or palm pilot) to participants' report of their weekly totals.|We will measure the frequency at which participants access a screen on the Palm Pilot that presents the ""4 D's,"" which are four strategies for delaying or reducing cigarette use.|Repeated measured t-tests will be used to compare participants' cotinine levels before and after participating in this program.|We will use an independent samples t-test to compare satisfaction scores for the two monitoring methods.|We will assess the degree of compliance with completing the mood rating scale (how many out of 7 were completed in the week) and will compare compliance rates for the Palm and paper-and-pencil versions using an independent samples t-test.|We will assess the amount of training time required to train participants to use either the paper and pencil or Palm Pilot versions of the monitoring form.","North Suffolk Mental Health Association","All","18 Years to 50 Years   (Adult)","Early Phase 1","11","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","CORRC #21-04","June 2005","null","October 2005","February 16, 2007","null","May 18, 2009","Freedom Trail Clinic, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00435903"
2403,"NCT00434239","Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of Myelodysplasia",,"Unknown status","No Results Available","Myelodysplasia","Drug: Lenalidomide + Ancestim","Toxicity as defined by NCI-CTCv3.0|Response|Pharmacodynamics|Change in Biomarkers","Peter MacCallum Cancer Centre, Australia|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06/49","February 2007","May 2011","May 2014","February 13, 2007","null","January 10, 2013","Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia","","https://ClinicalTrials.gov/show/NCT00434239"
2404,"NCT00432887","Experimental Studies of the Effects of Caffeine on Glucose Regulation",,"Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: caffeine administration","postprandial glucose and insulin|fasting glucose and insulin|insulin resistance|glucose tolerance|epinephrine|norepinephrine|cortisol|blood pressure|plasma caffeine concentration","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","150","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","DK67486 (completed)","July 2004","null","February 2007","February 8, 2007","null","March 2, 2010","","","https://ClinicalTrials.gov/show/NCT00432887"
2405,"NCT00431327","Facilitators to Keeping Colonoscopy Appointments",,"Completed","No Results Available","Healthy","Behavioral: Peer coach phone call","Attending the colonoscopy","University of Pennsylvania","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","140","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","705823","February 2005","null","October 2006","February 5, 2007","null","February 5, 2007","University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00431327"
2406,"NCT00430703","Effect of Passive Gait Training on the Cortical Activity in Patients With Severe Traumatic Brain Injury.",,"Completed","No Results Available","Craniocerebral Trauma|Traumatic Brain Injury|""Rehabilitation""","Behavioral: body weight support treadmill training","EEG: difference in the frequency spectrum after training.|EEG: absolute power i every frequency band; median frequency;|frequency ratios: Alpha versus delta;delta and theta versus alpha and beta;|ERP: amplitude of P300-component.|ERP: latency of P300-component.|clinical measure: RLAS (Rancho Los Amigos Scale)","University of Aarhus|Aarhus County, Denmark","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","26","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HNRC-AAU-06-1","August 2006","August 2008","August 2008","February 2, 2007","null","November 6, 2008","Hammel Neurorehabilitation and Research Centre, Hammel, Denmark","","https://ClinicalTrials.gov/show/NCT00430703"
2407,"NCT00427752","Abdominal Exploration Without Incisions",,"Completed","No Results Available","Pancreatic Cancer","Procedure: Transgastric endoscopic peritoneoscopy.","1) That transgastric endoscopic peritoneoscopy is feasible.|That bacterial abdominal contamination is not clinically significant.","Jeffrey Hazey|Stryker Nordic|Ethicon Endo-Surgery|Ohio State University","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","2006H0120","October 2006","January 2012","January 2012","January 29, 2007","null","May 7, 2012","The Ohio State University Center for Minimally Invasive Surgery, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00427752"
2408,"NCT00426517","Donor Stem Cell Transplantation for Congenital Immunodeficiencies",,"Recruiting","No Results Available","Inherited Immune Deficiencies","Drug: Fludarabine|Drug: Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine|Drug: Sirolimus or equivalent based on response|Drug: Granulocyte Colony Stimulating Factor (G-CSF)|Other: hematopoietic progenitor cells","The primary objective for this study is to evaluate the use of immunosuppressive drugs such as Campath -1H or h-ATG, fludarabine, and sirolimus in conjunction with a novel busulfan-based conditioning regimen with or without the addition of radia...|To measure the engraftment rate and the engraftment kinetics using such a regimen|To further elucidate the required dose levels of busulfan as compared to historical controls in conditioning regimens for transplantation in general|To assess the level and kinetics of immune reconstitution when using these conditioning regimens. To further elucidate the factors involved in the development of graft versus host disease.","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","2 Years to 40 Years   (Child, Adult)","Early Phase 1","100","NIH","Interventional","Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","070075|07-I-0075","January 19, 2007","January 8, 2023","January 8, 2026","January 24, 2007","null","November 15, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00426517"
2409,"NCT00425529","Tolerance and Practicality of Module AOX",,"Completed","No Results Available","Gastrointestinal Diseases|Nutrition","Device: Module AOX (attached to Sondalis ISO)","Tolerance: stool outcome (frequency, consistency), diarrhea, faltulence, abdominal pain, amount of feeding according to goal, changes of amount fed, discontinuation of feeding|Practicality: time for connecting the device to the pouch, time needing for mixing content of device with the content of the enteral feding pouch, clotting of theadministration set, product flow,leakage, clarity of instructions of usage|vitamin C, Vitamin E. beta-caroteen, GSH/GSSG, cysteine/cystine, GPx, isoprostane, TAS, Zn, Se, plasma free amino acids, HLADR, TNF soluble receptors (55/75), LBP, BPI, IL-1 IR II, leptin, soluble leptin receptor, IL-6, IL-8, and microciological safety","VU University Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","01.04.CLI","February 2002","null","May 2003","January 23, 2007","null","January 23, 2007","VU Medical Center, Amsterdam, Noord-Holland, Netherlands","","https://ClinicalTrials.gov/show/NCT00425529"
2410,"NCT00424788","A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)",,"Completed","No Results Available","Relapsing Forms of Multiple Sclerosis","Procedure: Plasma exchange|Drug: natalizumab treatment","","Biogen","All","18 Years to 50 Years   (Adult)","Early Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","101MS001","January 2007","October 2007","October 2007","January 22, 2007","null","September 4, 2009","Cleveland Clinic Mellen Center for MS, Cleveland, Ohio, United States|Center for Neurological Disorders, Aurora Health Care, Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT00424788"
2411,"NCT00424242","Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases",,"Active, not recruiting","No Results Available","Brain and Central Nervous System Tumors|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Metastatic Cancer|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous Condition|Secondary Myelofibrosis|Unspecified Adult Solid Tumor, Protocol Specific","Drug: Pemetrexed","Correlation of cerebrospinal fluid levels with plasma levels of different doses of pemetrexed disodium|To determine whether there is any anti-tumor activity against LM with Pemetrexed.|To determine the safety of Pemetrexed in patients with LM.|To assess the role of serum biomarkers in patients with LM.","Northwestern University|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Older Adult)","Early Phase 1","15","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 06C2|STU00004482","January 2007","March 2019","March 2020","January 18, 2007","null","June 14, 2018","Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT00424242"
2412,"NCT00419211","An Intervention Study to Increase Physical Activity and Maternal Well-being During Pregnancy",,"Completed","No Results Available","Pregnancy|Depression","Behavioral: Exercise","Physical Activity Level|Depressed Mood|Health related quality of life|state anxiety|sleep quality|fatigue levels|exercise stage of change|self-efficacy for exercise|social support for exercise","McGill University","Female","18 Years to 40 Years   (Adult)","Early Phase 1","76","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","A06-B25-06A","January 2007","December 2011","null","January 8, 2007","null","May 25, 2012","McGill University Health Centre, Montreal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT00419211"
2413,"NCT00417924","Eye on Diabetes: A Multidisciplinary Patient Education Intervention",,"Completed","No Results Available","Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2","Behavioral: Patient education","Patient knowledge (pre-test, post-test, and 3 month post-test)|Patient satisfaction post-examination","Nova Southeastern University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Educational/Counseling/Training","OPT06170409X","October 2004","null","October 2005","January 4, 2007","null","January 4, 2007","Sanford L. Ziff Health Center, Ft. Lauderdale, Florida, United States","","https://ClinicalTrials.gov/show/NCT00417924"
2414,"NCT00414154","The Importance of Patient Education - A Randomised Controlled Trial",,"Completed","No Results Available","Osteoporosis|Quality of Life|Level of Adherence|Behavior","Behavioral: Group based multidisciplinary patient education programme","Level of compliance to pharmacological treatment|Quality of life,|Level of physical activity,|Daily dietary calcium intake,|registration of fall in and outdoor,|Knowledge on Osteoporosis, BMD","Odense University Hospital","All","45 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","026","May 2002","null","May 2007","December 21, 2006","null","February 24, 2011","Department of Endocrinology, Odense University Hospital, Odense, Denmark","","https://ClinicalTrials.gov/show/NCT00414154"
2415,"NCT00411333","Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy",,"Completed","No Results Available","Diabetic Retinopathy","Drug: triamcinolone acetonide (Kenalog)","Change in retinal vascular density from baseline on fluorescein angiography|Safety","National Eye Institute (NEI)","All","Child, Adult, Older Adult","Early Phase 1","100","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","R01 EY017528-0","July 2006","July 2009","July 2009","December 14, 2006","null","November 11, 2010","Cole Eye Institute, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00411333"
2416,"NCT00405366","Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer","NRR","Completed","No Results Available","Kidney Cancer","Drug: sorafenib tosylate","Number of subjects experiencing adverse events while taking sorafenib prior to nephrectomy|Feasibility of neoadjuvant systemic therapy prior to nephrectomy|Response in primary renal tumors|Effects of sorafenib tosylate therapy on gene expression, protein expression, and metabolic profile","UNC Lineberger Comprehensive Cancer Center|Doris Duke Charitable Foundation|Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC 0603|CDR0000550127","November 2006","June 2009","July 2015","November 30, 2006","null","April 18, 2017","Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00405366"
2417,"NCT00405340","Rituximab in the Treatment of Idiopathic Membranous Nephropathy",,"Completed","No Results Available","Membranous Nephropathy","Drug: Rituximab","Primary endpoint.|Complete and partial remission rates at 6, 9, and 12 months|Pharmacokinetics/bioavailability|Rate of decline in urinary protein|Frequency of relapse after CR|Toxicity","Mayo Clinic|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-004833","October 2006","July 2010","April 2012","November 30, 2006","null","October 27, 2015","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT00405340"
2418,"NCT00402753","Ambulatory Physical Exercise Program in Hematopoietic Stem Cell Transplantation Recipients",,"Completed","No Results Available","Hematopoietic Stem Cell Transplantation","Behavioral: Ambulatory Physical Exercise Program","Musculoskeletal performance|Knee extension strength|Grip Strength|6 minute walk test|15-meter walking speed|and Health Related Quality of Life: (Physical function subscale of the EORTC-QLQ-C30 questionnaire).|Role-,cognitive-,emotional-,social-,symptom scales and the global health and quality of life scale of the EORTC-QLQ-C30 Health Related Quality of Life questionnaire.|Self-reported fatigue|Self-reported and objectively assessed physical activity|Whole body composition|Haemotological values: e.g Hemoglobin","University of Zurich","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","128","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","EK-519","January 2005","December 2009","December 2009","November 22, 2006","null","January 7, 2010","Hogeschool Utrecht, University of Professional Education, Faculty of Health Care, Chair of Lifestyle and Health, Utrecht, Netherlands|Cantonal Hospital Münsterlingen, Münsterlingen, Switzerland|Cantonal Hospital St.Gallen, St.Gallen, Switzerland|University Hospital Zurich, Zurich, Switzerland","","https://ClinicalTrials.gov/show/NCT00402753"
2419,"NCT00397436","Pilot Study of Protein Profiling of the Human Epidermal Cells After Ultraviolet Irradiation",,"Completed","No Results Available","Proteomics","Procedure: UV Irradiation","Ability to quantify protein changes at cytoplasmic and membrane protein levels of epidermal cells in normal vs. irradiated skin|Obtain a profile of membrane integrated and cytoplasmic proteins of epidermal cell populations which will facilitate our understanding of biological responses to UV irradiation.","University of Minnesota - Clinical and Translational Science Institute","Male","18 Years to 30 Years   (Adult)","Early Phase 1","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","0506M70827","February 2007","November 2011","December 2015","November 9, 2006","null","May 17, 2016","University of Minnesota, Minneapolis, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT00397436"
2420,"NCT00395109","PET/CT to Image Hypoxia in Head and Neck Tumours",,"Completed","No Results Available","Head and Neck Cancer","Device: PET/CT","FDG/PET visualization of glycolysis/blood flow in tumors and intra-tumor regions;|Measurement of mRNAs levels encoding hypoxia response genes in tumor samples.","Lawson Health Research Institute","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","17","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","R-06-370|12660","November 8, 2006","November 30, 2009","December 31, 2009","November 2, 2006","null","August 28, 2017","London Health Science Center, London, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00395109"
2421,"NCT00394316","Gene Therapy for Chronic Granulomatous Disease",,"Terminated","No Results Available","Chronic Granulomatous Disease","Drug: Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells","Can conditioning with busulfan improve gene therapy outcomes|1) To evaluate further the safety of gene therapy2) To monitor long-term results of gene therapy with conditioning","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","Male","3 Years to 55 Years   (Child, Adult)","Early Phase 1","3","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","070017|07-I-0017","October 30, 2006","April 8, 2014","April 8, 2014","November 1, 2006","null","July 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00394316"
2422,"NCT00389311","A Pilot Study for Toxicity Evaluation of HIV Rectal Microbicides",,"Completed","No Results Available","HIV Infections","Drug: Normosol-R|Drug: Nonoxynol-9|Procedure: Gastrointestinal instrumentation","Intra-subject comparison of urine and plasma concentrations of 99mTc-DTPA","Johns Hopkins University","Male","21 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","CDC 200-2001-08015-02","April 2007","February 2008","June 2009","October 18, 2006","null","April 1, 2015","The Johns Hopkins Hospital, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00389311"
2423,"NCT00388141","Nursing and Nurturing Premature Infants",,"Completed","No Results Available","Infant Growth|Mothers' Parental Competence","Behavioral: NIDCAP","The mothers' self reported experiences of self esteem and social support|Infant growth|Time of discharge|Days of needing oxygen and respiratory support","University of Aarhus|Aarhus University Hospital|Novo Nordisk A/S","All","up to 32 Weeks   (Child)","Early Phase 1","90","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2005 0149|NIDCAP, HAAG","March 2005","null","June 2007","October 13, 2006","null","December 3, 2007","Faculty of Health Science, University of Aarhus, Aarhus, Jylland, Denmark","","https://ClinicalTrials.gov/show/NCT00388141"
2424,"NCT00382551","The Effect of Beer, Red Wine and Fruit Juice on Blood Vessel Function in Persons With Cardiovascular Disease",,"Completed","No Results Available","Coronary Heart Disease","Behavioral: Moderate daily consumption of Red wine|Behavioral: Moderate daily consumption of beer|Behavioral: Moderate consumption of fruit juice rich in polyphenolics","Changes in flow-mediated vasodilation after 2 weeks intervention compared with baseline|Lipid status after 2 weeks intervention compared with baseline|Effects in Coagulation factors after 2 weeks intervention|Effects on markers of inflammation after 2 weeks intervention|Effects on markers of endothelial function after 2 weeks intervention|Changes in the overall antioxidant activity in plasma after 2 weeks intervention","Aalborg Universitetshospital","All","30 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","49","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","VN-20060043","October 2006","null","null","September 29, 2006","null","January 30, 2009","Department of Cardiology, Aalborg Hospital, Science and Innovation Center, Aalborg, Denmark","","https://ClinicalTrials.gov/show/NCT00382551"
2425,"NCT00379496","Trial of Acupuncture Added to Usual Treatment for Fibromyalgia",,"Completed","No Results Available","Fibromyalgia","Procedure: Antidepressants|Procedure: acupuncture","VAS(Visual Analogical Scale)|SF-36(Short Form 36)|Myalgic Index|Number of tender points|VAS(Visual Analogical Scale)(5 times)|SF-36(Short Form 36)(5 times)|Myalgic Index(5 times)|Number of tender points(5 times)","University of Sao Paulo","Female","20 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","58","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single|Primary Purpose: Treatment","843/99","April 2000","null","May 2002","September 22, 2006","null","September 22, 2006","Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil","","https://ClinicalTrials.gov/show/NCT00379496"
2426,"NCT00378677","Dry Powder Inhalation of Cyclosporine A in Lung Transplant Patients With Bronchiolitis Obliterans Syndrome",,"Unknown status","No Results Available","Lung Transplantation|Bronchiolitis Obliterans","Drug: Cyclosporine A dry powder inhalation (Drug)","Change in Forced Expiratory Volume in 1 second before and after intervention|Amount of lung deposition of cyclosporine A|Systemic uptake of Cyclosporine A|Kidney function (GFR and serum creat)","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","7","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSA-DPI","February 2007","null","null","September 21, 2006","null","February 7, 2007","University Medical Center Groningen, Groningen, Netherlands","","https://ClinicalTrials.gov/show/NCT00378677"
2427,"NCT00377845","Cervix Cytological Screening - Comparison of Tampon Self-Test and the Routine Smear.",,"Completed","No Results Available","Uterine Cervical Dysplasia|Uterine Cervical Neoplasms","Procedure: Regular Tampax used in 3 hours","Sensitivity and specificity of the tampon self-test|The womens socio-demographic relations according to accept the tampon self-test","University of Aarhus","Female","23 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Screening","TP06-2351","September 2006","December 2007","March 2008","September 19, 2006","null","March 27, 2008","Region Hospital Randers, Randers, Denmark","","https://ClinicalTrials.gov/show/NCT00377845"
2428,"NCT00377312","7 Day Continuous Parathyroid Hormone IV Infusion",,"Completed","Has Results","Osteoporosis|Bone Diseases, Endocrine|Hyperparathyroidism","Drug: Parathyroid Hormone (1-34)","Participants With Dose Limiting Toxicity|Total Serum Calcium|Ionized Serum Calcium|Serum Phosphorous|1,25 Vitamin D|Parathyroid Hormone (1-84)|Fractional Excretion of Calcium|24 Hour Urine Calcium|Tubular Maximum for Phosphorous|Serum Amino-terminal of Collagen- (sNTX)|Serum Carboxy-terminal of Collagen- 1(sCTX)|Amino-terminal Peptides of Procollagen- 1(P1NP)|Bone Specific Alkaline Phosphatase (BSAP)","University of Pittsburgh|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","24 Years to 35 Years   (Adult)","Early Phase 1","11","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)","0606127|R01DK073039","September 2006","December 2007","December 2007","September 18, 2006","March 22, 2016","March 22, 2016","University of Pittsburgh Medical Center, Pittsburgh,, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00377312"
2429,"NCT00374569","Dynamic Posturographic Testing and Motor Learning Predictability in Gymnasts",,"Completed","No Results Available","Gymnastics Injury, Motor Learning, Balance","Procedure: Gymnastic Routine","Dynamic Posturography|Blinded expert judging of motor performance in Gymnastics","Carrick Institute for Graduate Studies","All","10 Years to 30 Years   (Child, Adult)","Early Phase 1","300","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CI-05-05","June 2005","July 2006","September 2006","September 11, 2006","null","January 27, 2016","Carrick Institute for Graduate Studies Texas, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT00374569"
2430,"NCT00370799","Effectiveness of Caudal Epidural Injections in Treatment of Chronic Low Back and Lower Extremity Pain",,"Completed","No Results Available","Low Back Pain","Drug: Caudal epidural injection|Drug: Caudal Epidural Injection with generic Celestone|Drug: Caudal Epidural Injection with Celestone|Drug: Caudal Epidural Injection with DepoMedrol","To evaluate for differences between the patients in various groups in the physical function and pain at 1, 3, 6, and 12 months post treatment|To assess adverse events in all four groups.","Pain Management Center of Paducah","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","protocol 10","January 2007","December 2009","March 2010","September 1, 2006","null","August 16, 2013","Ambulatory Surgery Center, Paducah, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT00370799"
2431,"NCT00368511","Fall Prevention Strategies Including Music and Posturography",,"Completed","No Results Available","Fall Prevention","Procedure: Music Listening","Historical Falls Data","Carrick Institute for Graduate Studies","All","60 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CI-09-06-01","August 2006","March 2007","April 2007","August 24, 2006","null","May 7, 2008","Carrick Institute for Graduate Studies-Gouda Netherlands, Gouda, Netherlands","","https://ClinicalTrials.gov/show/NCT00368511"
2432,"NCT00361296","Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes",,"Unknown status","No Results Available","Myelodysplastic Syndromes","Biological: GM-K562 cell vaccine","Safety|Hematologic response, defined as achieving a major response in ≥ 1 lineage as described by an erythroid increase > 2 g/dL, platelet increase of 30,000/mm³, or neutrophil increase by 100%|Cytogenetic response, defined as normalization of pretreatment cytogenetic abnormalities|Immune response to common myeloid antigens (e.g., Wilms' tumor-1 [WT-1], survivin, or proteinase-3) as measured by Elispot assay|Correlation of immune response with clinical response (hematologic response, resolution of cytogenetic abnormalities, or decrease in other parameters, such as WT-1 mRNA levels)","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Older Adult)","Early Phase 1","7","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J05115, CDR0000491987|P30CA006973|JHOC-J05115|NA_00001530","August 2006","December 2016","December 2017","August 8, 2006","null","November 2, 2015","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00361296"
2433,"NCT00361192","Sensitivity and Specificity of Color Doppler Directed Temporal Artery Biopsy as Compared to Standard Random Biopsy in the Diagnosis of Temporal Arteritis",,"Unknown status","No Results Available","Temporal Arteritis|Duplex of Temporal Artery|Biopsy of Temporal Artery","Procedure: biopsy of temporal artery","","Shaare Zedek Medical Center","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","null","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TEMP ARTERITIS 001A","August 2006","null","January 2007","August 8, 2006","null","December 6, 2006","Shaare Zedek Medical Center, Jerusalem, Israel","","https://ClinicalTrials.gov/show/NCT00361192"
2434,"NCT00360919","Assessing the Presence of Casomorphins in Human Plasma After Dairy Ingestion",,"Completed","No Results Available","Food Habits","Behavioral: cheese ingestion","casomorphin quantification","Physicians Committee for Responsible Medicine","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","28","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","WCCR-01","September 2006","December 2010","December 2010","August 7, 2006","null","August 7, 2012","Physicians Committee for Responsible Medicine, Washington, DC, District of Columbia, United States","","https://ClinicalTrials.gov/show/NCT00360919"
2435,"NCT00360152","Testing of Different Methods for Determining Whether Breast Cancer Has Spread to the Lymph Nodes",,"Completed","No Results Available","Breast Neoplasms","Procedure: Fine needle aspiration biopsy (FNAB)|Procedure: Sentinel Lymph Node Biopsy","Determine the sensitivity of AUS and real-time RT-PCR/RT-LAMP to predict the pathologic status of the axilla in breast cancer patients|Determine the feasibility of AUS, FNAB, and RT-PCR/RT-LAMP as an alternative to SLNB for axillary staging of breast cancer patients|Define baseline gene expression levels in lymph nodes by RT-PCR/RT-LAMP in patients with no evidence of malignancy undergoing procedures under general anesthesia","Washington University School of Medicine|Society for Surgical Oncologists|Sysmex America, Inc.","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","06-0530 / 201109077","August 2006","January 2009","April 2013","August 3, 2006","null","July 4, 2013","Washington University School of Medicine, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00360152"
2436,"NCT00350194","The Effects of Omega-3 Fatty Acids on Metabolic Syndrome",,"Unknown status","No Results Available","Metabolic Syndrome X","Dietary Supplement: Omega-3 fatty acids","Change in Carotid IMT|Lipid (apolipoproteins and lipid parameters)|hs-CRP & SAA|Glucose|Insulin|adiponectin|urine microalbumin/creatinine|Serum Fatty Acids","University of Washington|Pfizer|National Institutes of Health (NIH)|Northwest Lipid Research Clinic","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","100","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","28791-D|05-8693-D 03","October 2006","October 2011","June 2012","July 10, 2006","null","March 2, 2012","Northwest Lipid Research Clinic (University of Washington Affiliated), Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00350194"
2437,"NCT00339469","Effect of High-Legume Diet on Colorectal Cancer Risk",,"Completed","No Results Available","Inflammation|Prevention and Control|Colonic Neoplasms|Diet|Insulin","Dietary Supplement: LIFE","Biomarkers of insulin resistance and inflammation|Weight loss","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Male","35 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","65","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","999905215|05-C-N215","August 3, 2005","May 19, 2008","February 13, 2018","June 21, 2006","null","November 15, 2018","Pennsylvania State University, University Park, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00339469"
2438,"NCT00337038","Endothelial Function as a Marker for Blood Pressure Control Among Hypertensive Diabetic Patients",,"Completed","No Results Available","Hypertension|Diabetes Mellitus Type 2","Drug: N-acetylcystein(drug)","endothelial function|blood pressure and glycemic control","Soroka University Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","sor431706ctil","June 2006","July 2010","July 2010","June 15, 2006","null","June 22, 2012","","","https://ClinicalTrials.gov/show/NCT00337038"
2439,"NCT00331630","Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer",,"Active, not recruiting","No Results Available","Breast Cancer","Drug: lapatinib ditosylate|Drug: paclitaxel albumin-stabilized nanoparticle formulation","Clinical response rate as measured by clinical exam and imaging studies|Pathologic complete response rate|Correlation of proliferation (Ki67) with tumor response as measured at baseline and after completion of study treatment|Correlation of apoptosis (cleaved caspase-3) with tumor response as measured at baseline and after completion of study treatment|Correlation of angiogenesis (vW, CD34) markers with tumor response as measured at baseline and after completion of study treatment|Correlation of other studies with tumor response, including epidermal growth factor receptor (EGFR), HER2/neu, matrix metalloproteinases (MMPs), and transforming growth factor (TGF-β) as measured at baseline and after completion of study treatment|Side effects from the combination of Abraxane and Lapatinib|Circulating tumor cell measurement","Northwestern University|GlaxoSmithKline|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 05B2|STU00007257","May 2006","August 2014","August 2020","May 31, 2006","null","February 6, 2018","Northwestern University, Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States|Midwest Center for Hematology/Oncology, Joliet, Illinois, United States|Saint James Hospital and Health Centers Comprehensive Cancer Institute - Olympia Fields, Olympia Fields, Illinois, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States","","https://ClinicalTrials.gov/show/NCT00331630"
2440,"NCT00314743","Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation",,"Completed","No Results Available","Nausea|Vomiting","Drug: Ondansetron|Drug: Dexamethasone|Drug: Aprepitant","To determine the efficacy of aprepitant in preventing acute & delayed chemotherapy induced nausea & vomiting when administered in combination with intravenous or oral ondansetron & intravenous or oral dexamethasone in the autologous transplant setting.|To measure the the severity, frequency, and duration of chemotherapy induced nausea and vomiting in patients receiving aprepitant and compare these results to a control group, not receiving aprepitant.|To measure the need for breakthrough antiemetics in patients receiving aprepitant and compare these results to the control group|To assess the incidence of complications associated with chemotherapy induced nausea and vomiting in patients receiving aprepitant and compare these results to the control group.|To assess the safety of aprepitant in combination with ondansetron and dexamethasone in the autologous transplant setting.","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","03-1192","October 2005","December 2008","December 2008","April 14, 2006","null","May 24, 2013","Washington University School of Medicine, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00314743"
2441,"NCT00301041","Radiation Therapy in Treating Women With Invasive Breast Cancer",,"Completed","No Results Available","Breast Cancer","Other: laboratory biomarker analysis|Procedure: adjuvant therapy|Radiation: radiation therapy","","University of California, San Francisco|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000465214","April 2004","May 2004","May 2004","March 10, 2006","null","August 21, 2013","UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT00301041"
2442,"NCT00278369","Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer",,"Completed","No Results Available","Kidney Cancer","Biological: aldesleukin|Biological: denileukin diftitox","The primary objective is to assess for toxicity|The secondary objectives are to investigate differences in peak and duration of the expansion of CD4+, CD8+, CD4+CD 25+ and CD56+(dim and bright)CD25+ cells|To investigate the effects of denileukin diftitox in combination with IL-2 on plasma TGF-beta levels|To perform TGF-beta promoter and TGF-beta receptor genotyping prior to the start of treatment to search for variants that may be associated with tumor response to therapy.|Overall response rate and time to progression","Northwestern University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 04U1|P30CA060553|NU-04U1|STU00006770","April 2005","June 2009","September 2010","January 18, 2006","null","May 22, 2013","Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT00278369"
2443,"NCT00276835","Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer",,"Completed","No Results Available","Kidney Cancer|Melanoma (Skin)","Biological: High-dose interleukin-2|Dietary Supplement: genistein","Differences in peak and duration of the expansion of circulating CD4+, CD8+, and CD4+, CD25+, and CD56+ cells (dim and bright)|Circulating plasma levels of TGF-beta","Northwestern University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 04V1|NU-04V1|CHIR-NU-04V1|NU-IRB-0310-083","November 2005","July 2007","January 2014","January 13, 2006","null","April 10, 2015","Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT00276835"
2444,"NCT00263809","Safety and Performance of MIRASOL® PRT Treated Platelet Transfusion Products",,"Completed","No Results Available","Thrombocytopenia","Device: Pathogen Reduction Technology","The platelet corrected count increment measured 1 hour post transfusion.|The platelet corrected count increment measured 24 hours post-transfusion.|The number of days between platelet transfusions during the period of the study.|The number of platelet transfusions per subject.|The number of platelets infused per subject.|The number of platelets used.|The frequency of refractoriness to platelet transfusion.|In case of refractoriness, the evidence for neoantigen immunization against test product.|The number of red blood cell transfusions during the study period.|The incidence of serious adverse events in relation to platelet transfusions.|The incidence of any adverse events in relation to platelet transfusions.|The occurrence of bleeding episodes.","Terumo BCTbio","All","16 Years and older   (Child, Adult, Older Adult)","Early Phase 1","118","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTS-0028","December 2005","October 2007","October 2007","December 9, 2005","null","October 7, 2009","Centre Hospitalier Universitaire Jean Minjoz, Besançon, France|EFS Bourgogne - Franche-Comté, Besançon, France|EFS Aquitaine, Bordeaux, France|Centre Hospitalier Univesrsitaire A Michallon, La Tronche, France|EFS Rhône-Alpes (Site de Grenoble), La Tronche, France|EFS Pays de la Loire, Nantes, France|Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France|Centre Hospitalier Universitaire de Bordeaux, Pessac, France|Centre Hospitalier Régional Universitaire Hautepierre, Strasbourg, France|EFS Alsace, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT00263809"
2445,"NCT00263185","High Dose Vit D Musculoskeletal Symptoms & Bone Density in Anastrozole-Treated Breast Cancer With Marginal Vit D Status",,"Completed","No Results Available","Breast Neoplasms","Dietary Supplement: Vitamin D|Dietary Supplement: Calcium carbonate|Drug: Vitamin D|Other: Placebo","To compare the effects of high dose vitamin D versus standard dose vitamin D on musculoskeletal pain in breast cancer patients receiving anastrozole when vitamin D levels are in the insufficient but not deficient range (10 to 29 ng/ml).|To evaluate the prevalence of vitamin D insufficiency/deficiency in post-menopausal women with a history of breast cancer who are treated with anastrozole and have musculoskeletal symptoms versus those who are asymptomatic.|To establish correlations between levels of vitamin D, the levels of PTH, the degree of bone loss and the severity of musculoskeletal symptoms.|To evaluate the effect of standard dose versus high dose Vitamin D replacement on bone density in post-menopausal women with a history of breast cancer who are treated with anastrozole and have musculoskeletal symptoms.","Washington University School of Medicine|AstraZeneca","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","63","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","05-0498 / 201012921","November 2005","November 2009","November 2009","December 7, 2005","null","September 22, 2014","Washington University, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00263185"
2446,"NCT00260546","An-Art Study: Atrioventricular (AV) Node Ablation in Cardiac Resynchronisation Therapy",,"Withdrawn","No Results Available","Congestive Heart Failure","Procedure: AV-node ablation","Percentage of biventricular stimulated heart cycles|Combined endpoint of worsening of heart failure, NYHA class, 6-minute walking distance, and hospitalisation for heart failure, death or heart transplantation","University Hospital, Basel, Switzerland","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","159/05","May 2006","December 2008","December 2008","December 1, 2005","null","September 30, 2011","","","https://ClinicalTrials.gov/show/NCT00260546"
2447,"NCT00257543","SALT: Alternative Donor Bone Marrow and Cord Blood Transplantation for High Risk Sickle Cell Disease",,"Terminated","No Results Available","Sickle Cell Disease","Procedure: Alternative donor bone marrow and cord blood","To determine the frequency of donor engraftment after alternate donor transplantation in children with severe sickle cell disease.","Emory University","All","up to 16 Years   (Child)","Early Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","876-2003","January 2006","August 2012","August 2012","November 23, 2005","null","September 17, 2013","Children's Healthcare of Altanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00257543"
2448,"NCT00253461","11C Topotecan PET Imaging",,"Terminated","No Results Available","Lung Cancer|Metastatic Cancer|Ovarian Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Procedure: computed tomography|Procedure: positron emission tomography|Radiation: 11C topotecan|Radiation: fludeoxyglucose F 18","Pharmacokinetics on day of positron-emission tomography scan|Disease response","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","7","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CWRU6Y02|P30CA043703|CASE-CWRU-6Y02","December 2004","November 2009","November 2009","November 15, 2005","null","March 20, 2012","Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00253461"
2449,"NCT00248677","Sensible Treatment of Obesity in Rural Youth . . .",,"Completed","No Results Available","Obesity","Behavioral: Behavioral Family-Based Intervention|Behavioral: Behavioral Parent-Based Intervention","Change in Child BMI Z-score|Change in parent BMI|Change in child dietary intake|Change in child's physical activity and steps per day","University of Florida|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","8 Years to 13 Years   (Child)","Early Phase 1","93","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DK71555|R34DK071555|1R34DK071555-01","September 2005","August 2008","August 2008","November 4, 2005","null","December 13, 2011","University of Florida, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT00248677"
2450,"NCT00236925","Efficacy Study of Low-Dose Hydrocortisone Treatment for Fibromyalgia",,"Completed","No Results Available","Fibromyalgia","Drug: Low dose Hydrocortisone|Drug: Placebo","Fibromyalgia symptoms|Chronic stress symptoms|Health-related quality of life|Life satisfaction|Infection","Ludwig-Maximilians - University of Munich|University of Zurich","All","18 Years to 60 Years   (Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","348/02","May 2003","May 2007","June 2007","October 12, 2005","null","April 1, 2015","Ludwig-Maximilians University, Muenchen, Bavaria, Germany","","https://ClinicalTrials.gov/show/NCT00236925"
2451,"NCT00226148","Immediate Implant Placement in the Molar Regions",,"Completed","No Results Available","Periodontitis|Dental Caries|Periapical Periodontitis","Procedure: Use of a membrane to cover bonedefects around implant|Device: Use of bonechips to fill up defects around implant|Procedure: Use of membrane and bonechips to manage defects","Digitial radiography of the implants at placement, 3 month, 6 month, at abutmentoperation, at crownplacement, 3 month after crownplacement and 6 month after crownplacement.","University of Aarhus|The Danish Medical Research Council","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","92","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005/0091|22-04-0281","September 2005","September 2009","September 2009","September 26, 2005","null","September 10, 2009","The Royal Dental College of Aarhus, Aarhus, Denmark","","https://ClinicalTrials.gov/show/NCT00226148"
2452,"NCT00221169","Role of PET CT in Determining Target Volumes in Radiation Therapy for Lung Cancer",,"Completed","No Results Available","Non-Small Cell Lung Cancer","Procedure: Surgical resection","Clinical pathological correlation of PET CT with surgically resected NSCLC","Toronto Sunnybrook Regional Cancer Centre|Ontario Cancer Research Network|Ontario Clinical Oncology Group (OCOG)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","31","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","04-may-00142 OCRN|OCRN grant","October 2005","June 2008","January 2009","September 22, 2005","null","February 5, 2009","Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada|Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00221169"
2453,"NCT00218452","Smoking Cessation for Young Adults Who Binge Drink - 1",,"Completed","No Results Available","Adherence|Tobacco Use Cessation|Alcohol & Drug Use|Nicotine Transdermal System","Behavioral: Lifestyle counseling","Treatment attendance","Mayo Clinic|National Institute on Drug Abuse (NIDA)","All","18 Years to 25 Years   (Adult)","Early Phase 1","41","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1996-04|R21DA018106|R21-18106-1|NIDA-18106-1","September 2005","December 2007","April 2008","September 22, 2005","null","April 7, 2015","Mayo Clinic Jacksonville, Jacksonville, Florida, United States|University of North Florida, Jacksonville, Florida, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT00218452"
2454,"NCT00217009","Study to Compare Different Light Therapies (Narrowband Ultraviolet B vs PUVA) for Hand and Foot Skin Diseases.",,"Terminated","No Results Available","Dermatitis|Psoriasis","Procedure: Narrowband Ultraviolet B (TL-01UVB) Therapy|Procedure: Topical Psoralen plus ultraviolet A (PUVA)","Number of treatments required to reach clearance|Change in symptom score (erythema, scaling/hyperkeratosis, papular/vesicular eruption, and fissures)|Change in global score|Number of patients reaching clearance|Adverse effects|Number of days in remission","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","3","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","2435-04","March 2005","November 2008","November 2008","September 22, 2005","null","May 20, 2015","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT00217009"
2455,"NCT00215514","Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma",,"Completed","No Results Available","Stomach Cancer|Gastric Cancer|Gastro-esophageal Junction Cancer","Drug: Epirubicin|Drug: Cisplatin|Drug: 5-Fluorouracil (5-FU)|Procedure: Radiation","To assess patient tolerance and toxicity of postoperative adjuvant regimen using epirubicin, cisplatin, and infusional 5-FU before and after a course of radiotherapy among patients with curatively resected gastric or gastroesophageal adenocarcinoma.","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","00-165","September 2000","November 2003","July 2014","September 22, 2005","null","July 29, 2014","Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00215514"
2456,"NCT00212407","New York Blood Center National Cord Blood Program",,"Terminated","No Results Available","Leukemia|Lymphoma|Genetic Disease|Severe Aplastic Anemia|Myelodysplasia","Biological: Umbilical Cord Blood Transplantation","Engraftment|Treatment Related Mortality|Survival|Graft vs. Host Disease|Relapse","New York Blood Center","All","Child, Adult, Older Adult","Early Phase 1","4476","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","234","February 1993","November 10, 2011","November 10, 2011","September 21, 2005","null","November 2, 2018","New York Blood Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00212407"
2457,"NCT00208780","Effects of Tetrahydrobiopterin on Blood Pressure",,"Completed","No Results Available","Hypertension","Drug: Tetrahydrobiopterin","Evaluate the effects of BH4 on BP|Evaluate the effects of BH4 on vascular function","Emory University|American Heart Association","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0476-2004","December 2004","December 2005","December 2005","September 21, 2005","null","November 18, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00208780"
2458,"NCT00200889","Mapping Auricular Vagus Nerve Circuitry",,"Recruiting","No Results Available","Healthy","Device: active auricular tVNS|Device: inactive auricular tVNS","Brain activity during functional magnetic resonance imaging (fMRI)|Stomach activity during gastric magnetic resonance imaging (MRI)|Electrogastrography (EGG)|Electrocardiography (ECG)|Respiration|Skin Conductance Levels (SCL)","Massachusetts General Hospital|National Institutes of Health (NIH)","All","18 Years to 60 Years   (Adult)","Early Phase 1","60","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2009P002177|3OT2OD023867-01S2","February 1, 2017","May 2019","May 2020","September 20, 2005","null","September 11, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00200889"
2459,"NCT00187941","MPA PK Monitoring Strategy With MMF/FK Based Immunosuppression",,"Completed","No Results Available","Transplantation, Renal|Immunosuppression","Drug: Mycophenolate Mofetil","Proportion of patients whose measured AUC falls within or outside the therapeutic MPA target range (30-60 mg/L/h) at any given follow up interval, as average over the whole time period.|Proportion of patients achieving one or more therapeutic level AUC.|Incidence of acute rejection of transplanted kidney|Incidence of potentially MPA related toxicities|Number of dose changes needed to achieve MPA AUC target within the first month post-transplant|Number of dose changes needed to achieve the individualized MPA trough target levels following the first month.|To obtain 20 to 25 intraindividual correlation estimates (of one type or another) within each patient: trough vs. AUC.","University of Florida|Hoffmann-La Roche","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","22","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CEL470","August 2005","November 2006","November 2006","September 16, 2005","null","June 20, 2012","University of Florida, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT00187941"
2460,"NCT00186784","Transcranial Magnetic Treatment (TMS) in Unipolar Depression",,"Completed","No Results Available","Unipolar Depression","Procedure: Transcranial Magnetic Stimulation (TMS)","Hamilton Depression Rating Scale|Beck Depression Rating Scale|Quantitive Electroencephalographic(QEEG)activity and measures of regional cerebral blood flow","St. Joseph's Healthcare Hamilton|Queen's University, Kingston, Ontario","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","21","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TMS1871","December 2000","July 2011","July 2011","September 16, 2005","null","August 3, 2011","St.Joseph's Healthcare, rTMS Laboratory, Mood Disorders Program, 100 West Fifth Street, Hamilton, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00186784"
2461,"NCT00176059","Immunoregulatory Effects of Immunoglobulin Induction Therapy in Renal Transplant Recipients",,"Completed","No Results Available","Renal Failure, Chronic|Renal Transplantation","Drug: intravenous immunoglobulins (IVIG)|Procedure: kidney transplantation","patient survival|graft survival|acute rejection|chronic allograft nephropathy|graft function|infectious complications|immunoglobulin levels|regulatory autoantibody levels|Th1 and Th2 responses|B-cell/monocyte responses|Expression of adhesion molecules, costimulatory molecules and cytokine receptors|proteinuria (quantitative assessment)","University of Giessen|Heidelberg University|Astellas Pharma Inc|Hoffmann-La Roche|Aventis Pharmaceuticals","All","14 Years and older   (Child, Adult, Older Adult)","Early Phase 1","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NTx-Ig-003","October 2001","null","May 2006","September 15, 2005","null","May 10, 2007","Department of Internal Medicine, University of Giessen, Giessen, Germany","","https://ClinicalTrials.gov/show/NCT00176059"
2462,"NCT00140556","Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer",,"Completed","Has Results","Head and Neck Cancer|Pharynx Cancer","Radiation: Chemoradiotherapy|Drug: Cisplatin|Drug: Bevacizumab|Drug: Erlotinib","Tumor Resolution|Local Regional Control|Failure Free Survival","David M. Brizel, MD|Genentech, Inc.|OSI Pharmaceuticals|Duke University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","28","Other|Industry","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00008840|7077","August 2005","May 2009","April 2010","September 1, 2005","August 31, 2011","January 18, 2013","Department of Radiation Oncology; Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00140556"
2463,"NCT00121693","The Use of Music Therapy in the Prevention of Falls",,"Completed","No Results Available","Accidental Falls|Healthy","Behavioral: Music therapy (listening to specific music)","Pretest and posttest scores will be collected for ten treatment conditions at three post-treatment times (10 minutes, 1 week, and 1 month)","Carrick Institute for Graduate Studies","All","17 Years to 90 Years   (Child, Adult, Older Adult)","Early Phase 1","266","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CI-01-03","December 2003","September 2006","October 2006","July 21, 2005","null","January 27, 2016","Carrick Institute for Graduate Studies, Cape Canaveral, Florida, United States","","https://ClinicalTrials.gov/show/NCT00121693"
2464,"NCT00020670","Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia",,"Terminated","No Results Available","Leukemia","Biological: CD 40","Rate Of Successful Vaccine Preparation","Dana-Farber Cancer Institute|National Cancer Institute (NCI)","All","Child, Adult, Older Adult","Early Phase 1","9","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00-053|P01CA068484|P30CA006516|DFCI-00053|NCI-H01-0074","February 20, 2001","April 1, 2003","July 1, 2003","January 27, 2003","null","June 20, 2017","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00020670"
2465,"NCT00017381","Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Waldenström Macroglobulinemia","Biological: rituximab|Drug: cyclophosphamide|Biological: filgrastim|Radiation: yttrium Y 90 ibritumomab tiuxetan|Procedure: peripheral blood stem cell transplantation","MTD, defined in terms of clinical toxicities graded using the CTC version 2.0","National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","30","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-03156|J0004","April 2001","December 2007","null","January 27, 2003","null","January 9, 2013","Johns Hopkins University, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00017381"
2466,"NCT00047983","Omega-3 Fatty Acids That Affect the Immune System in Kidney Transplant Patients",,"Completed","No Results Available","Kidney Diseases","Dietary Supplement: Canola oil|Dietary Supplement: Arginine|Dietary Supplement: Fish oil emulsion","Increases in omega-3 fatty acid levels in plasma and red blood cell membranes observed in each of the three omega-3 supplements used in this study|Compliance rates observed in each of the three study groups","National Institute of Allergy and Infectious Diseases (NIAID)","All","4 Years and older   (Child, Adult, Older Adult)","Early Phase 1","75","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAIT ID01","null","null","April 2004","October 24, 2002","null","January 11, 2017","Washington Hospital Center, Washington, District of Columbia, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati College of Medicine, Cincinnati, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00047983"
2467,"NCT00043602","Clinician Managed Interpersonal Psychotherapy",,"Completed","No Results Available","Depression|Depression, Postpartum","Behavioral: Standard interpersonal psychotherapy (IPT)|Behavioral: Clinician managed interpersonal psychotherapy (CM-IPT)","Hamilton Rating Scale for Depression","University of Iowa|National Institute of Mental Health (NIMH)","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","140","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R01MH059668|DSIR 83-ATAS","September 2001","December 2007","December 2007","August 13, 2002","null","September 26, 2013","University of Iowa, Iowa City, Iowa, United States","","https://ClinicalTrials.gov/show/NCT00043602"
2468,"NCT00013533","Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies",,"Completed","No Results Available","Hodgkin Lymphoma|Lymphocytic Leukemia|Mixed Cell Leukemia|Myelodysplastic Syndrome|Non Hodgkin's Lymphoma|CML|ALL|AML|Lymphoma","Procedure: Stem cell transplantation","To determine the efficacy and safety of this chemotherapy regimen in facilitating donor engraftment after allogeneic bone marrow transplantation (BMT).|Safety/Efficacy|Toxicity of regimen|To determine the toxicity of this non-myelablative allogeneic BMT regimen.|fludarabine-based induction reducing T-cells|immune suppression|IL-7 levels|cytokine profiles|response rates and DFS|incidence and severity of GVHD|response rates, DFS rates, and incidence and severity ofGVHD following withdrawal of immunosuppression and donorlymphocyte infusions (DLI) for patients who developprogressive disease after day +28 post-transplant","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","4 Years to 20 Years   (Child, Adult)","Early Phase 1","30","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","010125|01-C-0125","March 14, 2001","March 1, 2008","May 7, 2015","March 21, 2001","null","November 15, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00013533"
